<SEC-DOCUMENT>0001047469-16-009501.txt : 20160104
<SEC-HEADER>0001047469-16-009501.hdr.sgml : 20160101
<ACCEPTANCE-DATETIME>20160104064739
ACCESSION NUMBER:		0001047469-16-009501
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		146
FILED AS OF DATE:		20160104
DATE AS OF CHANGE:		20160104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COLLEGIUM PHARMACEUTICAL, INC
		CENTRAL INDEX KEY:			0001267565
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-208641
		FILM NUMBER:		161316412

	BUSINESS ADDRESS:	
		STREET 1:		780 DEDHAM STREET, SUITE 800
		CITY:			CANTON
		STATE:			MA
		ZIP:			02021
		BUSINESS PHONE:		781-713-3699

	MAIL ADDRESS:	
		STREET 1:		780 DEDHAM STREET, SUITE 800
		CITY:			CANTON
		STATE:			MA
		ZIP:			02021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COLLEGIUM PHARMACEUTICAL INC
		DATE OF NAME CHANGE:	20031020
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>a2226986zs-1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg74701_table_of_contents">  TABLE OF CONTENTS</A> <BR>
<A HREF="#fa74701_index_to_financial_statements">  INDEX TO FINANCIAL STATEMENTS</A><BR></font>
</P>

<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;">


<FONT  style="font-size:8pt;line-height:9pt;"><B>As filed with the Securities and Exchange Commission on January&nbsp;4, 2016.

 </B></FONT>

</P>

<P ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>


Registration No. 333-208641

 </B></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> &nbsp;<BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> <div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>


AMENDMENT NO. 1<BR>
TO

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>FORM S-1<BR>  </B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF&nbsp;1933  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Collegium Pharmaceutical,&nbsp;Inc.<BR>  </B></FONT><FONT  style="font-size:8pt;line-height:9pt;">(Exact name of registrant as specified in its charter) </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="31%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="31%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Virginia</B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 2834</B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(Primary Standard Industrial<BR>
Classification Code Number)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B> 03-0416362</B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(I.R.S. Employer<BR>
Identification Number)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Collegium Pharmaceutical,&nbsp;Inc.<BR>
780 Dedham Street<BR>
Suite&nbsp;800<BR>
Canton, MA 02021<BR>
(781)&nbsp;713-3699</B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(Address, including zip code and telephone number, including<BR>
area code, of registrant's principal executive offices) </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Michael T. Heffernan<BR>
President and Chief Executive Officer<BR>
Collegium Pharmaceutical,&nbsp;Inc.<BR>
780 Dedham Street<BR>
Suite&nbsp;800<BR>
Canton, MA 02021<BR>
(781)&nbsp;713-3699</B></FONT><FONT  style="font-size:8pt;line-height:9pt;"><BR>
(Name, address, including zip code and telephone number, including area code, of agent for service) </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="47%" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="47%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Copies to:</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT  style="font-size:8pt;line-height:9pt;"><B>Steven J. Abrams, Esq.<BR>
Shirley R. Kuhlmann, Esq.<BR>
Pepper Hamilton&nbsp;LLP<BR>
19<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">th</font>&nbsp;Floor, High Street Tower<BR>
125 High Street<BR>
Boston, MA 02110<BR>
(617)&nbsp;204-5100</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT  style="font-size:8pt;line-height:9pt;"><B> Peter N. Handrinos, Esq.<BR>
Latham&nbsp;&amp; Watkins&nbsp;LLP<BR>
John Hancock Tower<BR>
200 Clarendon Street<BR>
Boston, MA 02116<BR>
(617)&nbsp;948-6000</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Approximate date of commencement of proposed sale to the public:<BR>
As soon as practicable after the effective date of this registration statement.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933, as
amended (the "Securities Act"), check the following box.&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">If this form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>


<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of
"large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule&nbsp;12b-2 of the Exchange Act. (Check one): </FONT></P>
 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="102pt" style="font-family:arial;"></TD>
<TD WIDTH="12%" style="font-family:arial;"></TD>
<TD WIDTH="78pt" style="font-family:arial;"></TD>
<TD WIDTH="12%" style="font-family:arial;"></TD>
<TD WIDTH="100pt" style="font-family:arial;"></TD>
<TD WIDTH="12%" style="font-family:arial;"></TD>
<TD WIDTH="120pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Large accelerated filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Accelerated filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Non-accelerated filer&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT><BR></FONT> <FONT  style="font-size:8pt;line-height:9pt;">(Do not check if a<BR>
smaller reporting company)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Smaller reporting company&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;">


<FONT  style="font-size:8pt;line-height:9pt;"><B>CALCULATION OF REGISTRATION FEE

  </B></FONT>

</P>




<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="65%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="96" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="96" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:3pt;text-indent:-3pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:arial;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Title of Securities Being Registered</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Proposed Maximum<BR>
Aggregate Offering<BR>
Price<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount of<BR>
Registration Fee<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:arial;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:3pt;text-indent:-3pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B> </B></FONT><FONT  style="font-size:8pt;line-height:9pt;">Common Stock, $0.001 par value per share</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">$86,250,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">$8,686</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:arial;border-bottom:double #000000 2.25pt;"><p style="font-family:arial;margin-left:3pt;text-indent:-3pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<DL compact>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Estimated
solely for purposes of computing the amount of the registration fee pursuant to Rule&nbsp;457(o) under the Securities Act of 1933,
as amended. Includes shares subject to the underwriters' option to purchase additional shares.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">This
fee was previously paid in connection with prior filings of this Registration Statement.


</FONT></DD></DL>

<P ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file&nbsp;a further
amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act, or until the registration statement
shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine.</B></FONT></P>
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT  style="font-size:8pt;line-height:9pt;">
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=376759,FOLIO='blank',FILE='DISK131:[15ZCN1.15ZCN74701]BA74701A.;17',USER='JTAM',CD='30-DEC-2015;18:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_TXTHEX,"" -->


</FONT><FONT COLOR="#FF4040" SIZE=2>The information contained in this preliminary prospectus is not complete and may be changed.
We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </FONT></P>

<P ALIGN="RIGHT" style="font-family:arial;">

<FONT SIZE=2><B>









<!-- COMMAND=ADD_TXTHEX,"" -->


</B></FONT><FONT COLOR="#FF4040" SIZE=2>SUBJECT TO COMPLETION, DATED JANUARY&nbsp;4, 2016


</FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2><B>PRELIMINARY PROSPECTUS

 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>
<IMG SRC="g603081.jpg" ALT="LOGO" WIDTH="307" HEIGHT="66">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=5><B>Collegium Pharmaceutical,&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Common Stock  </B></FONT></P>


<P style="font-family:arial;">


<FONT SIZE=2>We are offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. The offering price is $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share of common stock. Our common stock is listed
on The NASDAQ Global Select Market ("NASDAQ") under the symbol "COLL." The last reported sales price of our common stock on December&nbsp;31, 2015 was $27.50 per share.

 </FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2><B>We are an "emerging growth company" as defined in Section&nbsp;2(a) of the Securities Act of 1933, as amended, or the Securities Act, and are subject to reduced public
company reporting requirements. See "Prospectus Summary&nbsp;&#151; Implications of Being an Emerging Growth Company."</B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Investing in our common stock involves a high degree of risks. Please read "Risk Factors" beginning on page 14 of this prospectus.</B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="8pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="8pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="58pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Per Share </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Public offering price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting discounts and commissions<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds, before expenses, to us</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >




<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">We refer you to "Underwriting" beginning on page 173 of this prospectus for additional information
regarding total underwriter compensation.</FONT>

</DD></DL>


<P style="font-family:arial;"><FONT SIZE=2>Delivery
of the shares of common stock is expected to be made on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016. We
have granted the underwriters an option for a period of 30&nbsp;days to purchase an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. If the underwriters exercise the option in full, the total underwriting discounts and commissions
payable by us will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and the total
proceeds to us, before expenses, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="48%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=5><B>Jefferies</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=5>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=5><B> Piper Jaffray</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><BR><FONT SIZE=4><B>William&nbsp;Blair</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=4><B><BR>&nbsp;</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><BR><FONT SIZE=4><B>Needham&nbsp;&amp;&nbsp;Company</B></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=4><B><BR>
Janney&nbsp;Montgomery&nbsp;Scott<BR> </B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"><font> </FONT> <FONT SIZE=2>
Prospectus dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016 </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=202447,FOLIO='blank',FILE='DISK131:[15ZCN1.15ZCN74701]BC74701A.;51',USER='DSCHWAR',CD='31-DEC-2015;16:13' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="BG74701A_main_toc"></A> </FONT></P>

<A NAME="bg74701_table_of_contents"> </A>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


TABLE OF CONTENTS  </B></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<A NAME="BG74701_TOC"></A> </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->

<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="25pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Page </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ca74701_prospectus_summary"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> PROSPECTUS SUMMARY</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ca74701_prospectus_summary"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#cc74701_the_offering"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>THE OFFERING</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#cc74701_the_offering"><FONT SIZE=2>10</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ce74701_summary_financial_data"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SUMMARY FINANCIAL DATA</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ce74701_summary_financial_data"><FONT SIZE=2>12</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#da74701_risk_factors"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#da74701_risk_factors"><FONT SIZE=2>14</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#dk74701_special_note_regarding_forward-looking_statements"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dk74701_special_note_regarding_forward-looking_statements"><FONT SIZE=2>58</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#dm74701_use_of_proceeds"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dm74701_use_of_proceeds"><FONT SIZE=2>60</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#DM_PR"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PRICE RANGE OF COMMON STOCK</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#DM_PR"><FONT SIZE=2>61</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#dm74701_dividend_policy"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DIVIDEND POLICY</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dm74701_dividend_policy"><FONT SIZE=2>62</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#do74701_capitalization"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CAPITALIZATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#do74701_capitalization"><FONT SIZE=2>63</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#dq74701_selected_financial_data"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SELECTED FINANCIAL DATA</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dq74701_selected_financial_data"><FONT SIZE=2>64</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds74701_management_s_discussion_and_an__man03466"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds74701_management_s_discussion_and_an__man03466"><FONT SIZE=2>65</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#du74701_business"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>BUSINESS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#du74701_business"><FONT SIZE=2>78</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ee74701_management"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MANAGEMENT</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ee74701_management"><FONT SIZE=2>132</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#eg74701_executive_and_director_compensation"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXECUTIVE AND DIRECTOR COMPENSATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#eg74701_executive_and_director_compensation"><FONT SIZE=2>140</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ei74701_certain_relationships_and_related_party_transactions"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ei74701_certain_relationships_and_related_party_transactions"><FONT SIZE=2>153</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ek74701_principal_shareholders"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PRINCIPAL SHAREHOLDERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ek74701_principal_shareholders"><FONT SIZE=2>159</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#em74701_description_of_capital_stock"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#em74701_description_of_capital_stock"><FONT SIZE=2>162</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#eo74701_shares_eligible_for_future_sale"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SHARES ELIGIBLE FOR FUTURE SALE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#eo74701_shares_eligible_for_future_sale"><FONT SIZE=2>167</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#eq74701_material_u.s._federal_income_t__mat03201"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF OUR COMMON
STOCK</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#eq74701_material_u.s._federal_income_t__mat03201"><FONT SIZE=2>169</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#es74701_underwriting"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>UNDERWRITING</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#es74701_underwriting"><FONT SIZE=2>173</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#eu74701_legal_matters"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#eu74701_legal_matters"><FONT SIZE=2>180</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#eu74701_experts"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#eu74701_experts"><FONT SIZE=2>180</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#eu74701_where_you_can_find_more_information"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#eu74701_where_you_can_find_more_information"><FONT SIZE=2>180</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#fa74701_index_to_financial_statements"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INDEX TO FINANCIAL STATEMENTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#fa74701_index_to_financial_statements"><FONT SIZE=2>F-1</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>


<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>Neither
we nor any of the underwriters has authorized anyone to provide you with information different from, or in addition to, that contained in this prospectus or any free writing prospectus
prepared by or on behalf of us or to which we may have referred you in connection with this offering. We take no responsibility for, and can provide no assurance as to the reliability of, any other
information that others may give you. Neither we nor any of the underwriters is making an offer to sell or seeking offers to buy these securities in any jurisdiction where, or to any person to whom,
the offer or sale is not permitted. The information in this prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or
of any sale of shares of our common stock and the information in any free writing prospectus that we may provide you in connection with this offering is accurate only as of the date of that free
writing prospectus. Our business, financial condition, results of operations and future growth prospects may have changed since those dates. </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=109123,FOLIO='blank',FILE='DISK131:[15ZCN1.15ZCN74701]BG74701A.;15',USER='CHE105137',CD='29-DEC-2015;02:29' -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="bg74701_industry_and_market_data"> </A>
<BR></FONT><FONT SIZE=2><B>  INDUSTRY AND MARKET DATA    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We obtained the industry, market and competitive position data in this prospectus from our own internal estimates and research as well as from
industry and general publications and research surveys and studies conducted by third parties. We believe this data is accurate in all material respects as of the date of this prospectus. In addition,
projections, assumptions and estimates of the future performance of the industry in which we operate and our future performance are necessarily subject to a high degree of uncertainty and risk due to
a variety of factors, including those described in "Risk Factors." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="bg74701_trademarks_and_trade_names"> </A>
<BR></FONT><FONT SIZE=2><B>  TRADEMARKS AND TRADE NAMES    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have registered Collegium Pharmaceutical,&nbsp;Inc., DETERx and Xtampza ER as U.S. trademarks. This prospectus contains references to our
trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may
appear without the &reg; or &#153; symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable
law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship
with, or endorsement or sponsorship of us by, any other companies. </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=576097,FOLIO='blank',FILE='DISK131:[15ZCN1.15ZCN74701]BG74701A.;15',USER='CHE105137',CD='29-DEC-2015;02:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ca74701_1_1"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ca74701_prospectus_summary"> </A>
<A NAME="toc_ca74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>This summary highlights certain information about us and this offering contained elsewhere in this prospectus. Because it is
only a summary, it does not contain all of the information that you should consider before investing in shares of our common stock and it is qualified in its entirety by, and should be read in
conjunction with, the more detailed information appearing elsewhere in this prospectus. Before you decide to invest in our common stock, you should read the entire prospectus carefully, including
"Risk Factors," "Special Note Regarding Forward-Looking Statements" and the financial statements and related notes included elsewhere in this prospectus.</I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Unless
the context indicates otherwise, as used in this prospectus, the terms "Collegium," "we," "us," "our," "our company" and "our business" refer to Collegium Pharmaceutical,&nbsp;Inc. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a specialty pharmaceutical company developing and planning to commercialize next-generation abuse-deterrent products that incorporate our
patented DETERx&reg; platform technology for the treatment of chronic pain and other diseases. Our lead product candidate, Xtampza&#153; ER, or Xtampza, is an abuse-deterrent,
extended-release, oral formulation of oxycodone, a widely prescribed opioid medication. On November&nbsp;6, 2015, the U.S. Food and Drug Administration, or FDA, granted tentative approval to the new
drug application, or NDA, for Xtampza for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are
inadequate. The FDA granted tentative approval because Xtampza met the required quality, safety and efficacy standards for approval but remains subject to an automatic stay of up to 30&nbsp;months
as a result of patent litigation filed by Purdue Pharma,&nbsp;L.P., or Purdue, in March 2015. The FDA may grant final regulatory approval upon the earliest to occur of expiration of the automatic
stay, the court invalidating Purdue's patents or issuing an opinion of non-infringement, and expiration of Purdue's listed patents. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
connection with the FDA's tentative approval of our NDA for Xtampza, the FDA tentatively approved a product label, product packaging, post-marketing commitments and a Risk Evaluation and Mitigation
Strategy, or REMS, program, subject to change should new information become available prior to the time that the FDA considers the Xtampza NDA for final regulatory approval. The tentatively approved
Xtampza label, in contrast to the product labels for all currently approved extended-release opioids, does not include a black box warning and related precautions stating that crushing, chewing or
dissolving can cause rapid release and absorption of a potentially fatal dose of the active ingredient. The absence of these warnings is supported by data that is described in the tentatively approved
product label to support the claim that when Xtampza is crushed or chewed, the drug release profile is bioequivalent to taking Xtampza intact, as directed. Furthermore, the tentatively approved
product label contains differentiated abuse-deterrent claims for Xtampza and also states that Xtampza can be taken by
sprinkling the capsule contents on soft foods or into a cup, and then directly into the mouth, or through a gastrostomy or nasogastric feeding tube. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Xtampza
has the same active ingredient as OxyContin&reg; OP, which is the largest selling abuse-deterrent, extended-release opioid in the United States by dollars, with $2.5&nbsp;billion in
U.S. sales in 2014. We conducted a comprehensive preclinical and clinical program for Xtampza consistent with FDA guidance on abuse-deterrence. These studies and clinical trials demonstrated that
chewing, crushing and/or dissolving Xtampza, and then taking it orally or smoking, snorting or injecting it did not meaningfully change its drug release profile or safety characteristics. By contrast,
clinical trials performed by us and others&nbsp;&#151; including a head-to-head clinical trial comparing Xtampza with OxyContin OP&nbsp;&#151; have shown that drug abusers can
achieve rapid release and absorption of the active ingredient by manipulating OxyContin OP using common household tools and methods commonly available on the Internet. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
addition, our preclinical studies and clinical trials have shown that the contents of the Xtampza capsule can be removed from the capsule and sprinkled on food, directly into the mouth or
administered through </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=291527,FOLIO='1',FILE='DISK131:[15ZCN1.15ZCN74701]CA74701A.;24',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_ca74701_1_2"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:arial;"><FONT SIZE=2>feeding
tubes, without compromising their drug release profile, safety or abuse-deterrent characteristics. By contrast, OxyContin OP, which is formulated in hard tablets, has a black box warning
product label stating that crushing, dissolving, or chewing can cause rapid release and absorption of a potentially fatal dose of the active ingredient. We believe that Xtampza, if it ultimately
receives final regulatory approval, can address the pain management needs of the approximately 11&nbsp;million patients in the United States who suffer from chronic pain and have difficulty
swallowing. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our DETERx Platform Technology  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In our proprietary DETERx technology, we combine active ingredients such as oxycodone with fatty acid and waxes to form&nbsp;a molten solution which
is spray-congealed into solid microspheres using a proprietary spinning disk manufacturing process. These solid wax-based microspheres are then filled into capsules. Each individual microsphere is
designed to be extended-release and abuse-deterrent. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition to our Xtampza formulation of oxycodone, DETERx technology is applicable to many other opioid active ingredients, as well as other categories of abuseable drugs, such as amphetamines and
methylphenidate. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Prescription Drug Abuse  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The U.S. Centers for Disease Control and Prevention described abuse of prescription drugs in the United States as a growing and deadly epidemic.
Deaths in the United States from prescription opioid overdose have grown from approximately 4,000 in 1999 to approximately 16,000 in 2013. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
American Journal of Managed Care estimated in a 2013 report that opioid abuse costs public and private healthcare payors over $72&nbsp;billion annually in direct healthcare costs, including
costs of emergency room&nbsp;visits, rehabilitation and associated health problems. In response to widespread prescription opioid abuse, the U.S. government and a number of state legislatures have
introduced, and in some cases have enacted, legislation and regulations intended to encourage the development of abuse-deterrent forms of pain medications, including certain forms of extended-release
opioids. The FDA has stated that addressing prescription drug abuse is a priority, and the development of abuse-deterrent opioids is a key part of that strategy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Extended-release
opioids incorporate a large amount of opioid with a time-release mechanism designed to deliver steady amounts of opioid, typically over 12 to 24&nbsp;hours. Drug abusers find
currently approved extended-release opioid tablets desirable because of the large amount of drug payload, which they attempt to release quickly into the bloodstream to create euphoria. It is difficult
for drug abusers to achieve this rapid release and absorption into the bloodstream by taking multiple intact extended-release opioid tablets or capsules because doing so often causes sleepiness and/or
respiratory distress before euphoria is achieved. Instead, they attempt to defeat the extended-release properties in order to achieve rapid release of the active ingredient. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
2014, there were approximately 29&nbsp;million prescriptions for extended-release and long-acting opioids in the United States. OxyContin OP accounted for approximately $2.5&nbsp;billion in
total U.S. sales from approximately
6&nbsp;million prescriptions. Despite the introduction of OxyContin OP in 2010 as the first FDA-approved, abuse-deterrent, extended-release opioid formulation, abuse of extended-release opioids,
including OxyContin OP, continues to be a major public health issue. OxyContin OP, even with its abuse-deterrent formulation, remains vulnerable to abuse using common household objects, like pill
crushers. Third party studies found that abusers of OxyContin OP use various routes of abuse&nbsp;&#151; including snorting, injection and oral abuse&nbsp;&#151; despite OxyContin
OP's abuse-deterrent features. In a third party study of OxyContin abusers both before and after OxyContin OP was introduced, researchers found that while the non-oral routes of abuse of OxyContin OP
(i.e.,&nbsp;injection, snorting and smoking) were used less after its introduction, oral abuse of OxyContin OP increased from approximately 52% to 75% of OxyContin abusers. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=6,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=588585,FOLIO='2',FILE='DISK131:[15ZCN1.15ZCN74701]CA74701A.;24',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_ca74701_1_3"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ca74701_oxycontin_op_tablet_+_$6.39_pi__oxy02648"> </A>
<A NAME="toc_ca74701_2"> </A>
<BR></FONT><FONT SIZE=2><B><I>OxyContin OP Tablet&nbsp;+&nbsp;$6.39 Pill Crusher&nbsp;= Abuseable Fine Powder in 16 Seconds    <BR>    </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g95987.jpg" ALT="GRAPHIC" WIDTH="438" HEIGHT="157">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Chronic Pain with Dysphagia  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>It is estimated that more than 10% of patients with chronic pain, or approximately 11&nbsp;million patients, have dysphagia, or difficulty in
swallowing, because they have cancer, are elderly, have other medical problems or have difficulty swallowing without a known medical cause. Our preclinical studies and clinical trials have shown, and
our tentatively approved product label states, that the contents of the Xtampza capsules can be taken by sprinkling the capsule contents on soft foods or into a cup, and then directly into the mouth,
or through a gastrostomy or nasogastric feeding tube, without compromising their extended-release properties. By contrast, all other FDA-approved, orally administered, extended-release opioids have a
black box warning product label stating that "crushing, dissolving or chewing can cause rapid release and absorption of a potentially fatal dose of the active drug", making them unsuitable or
unattractive for patients who suffer from chronic pain with dysphagia, or CPD. If Xtampza ultimately receives final regulatory approval, Xtampza could be the only abuse-deterrent extended-release
opioid product with product labeling without such a black box warning. An external marketing study performed for us in 2013 estimated that Xtampza, if it receives final regulatory approval, has a peak
revenue potential for U.S. patients with CPD in excess of $700&nbsp;million annually. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Xtampza  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our lead product candidate, Xtampza, is an abuse-deterrent, extended-release, oral formulation of oxycodone tentatively approved by the FDA for the
management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The active ingredient in Xtampza is
oxycodone, which is approved by the FDA and other regulators around the world in a number of both immediate-release and extended-release drug products. We developed Xtampza using our proprietary,
DETERx abuse-deterrent technology to address common methods of abuse, including chewing, crushing and/or dissolving, and then taking it orally or snorting or injecting Xtampza. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Clinical Development  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In January 2013, the FDA issued a draft guidance document titled "Abuse-Deterrent Opioids&nbsp;&#151; Evaluation and Labeling." Before this
FDA draft guidance was finalized, it was followed by the FDA in the regulatory approval process for abuse-deterrent products. The FDA issued its final guidance in April 2015. Like the draft guidance,
the final guidance specifically defines the studies and clinical trials required to evaluate the abuse-deterrent properties of a formulation and the associated claims that a manufacturer can make
based on the results of those studies and clinical trials. This is meant to inform the development of improved abuse-deterrent products. We believe that all of our studies and clinical trials are
consistent with the final FDA guidance. The Xtampza product label, if finally approved, could be the first
abuse-deterrent opioid to include all three pre-marketing product label claim categories based upon in vitro, pharmacokinetic, or PK, and human abuse potential studies. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=7,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=796297,FOLIO='3',FILE='DISK131:[15ZCN1.15ZCN74701]CA74701A.;24',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_ca74701_1_4"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:arial;"><FONT SIZE=2>We
have completed numerous studies and clinical trials on Xtampza, which have demonstrated:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Safety and effectiveness for treatment of chronic
pain.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In July 2014, we completed a prospective, randomized Phase&nbsp;3 clinical trial that met its primary endpoint, demonstrating that Xtampza, compared to a
placebo, was safe and effective in treating moderate-to-severe chronic lower back pain. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Superior abuse-deterrent properties when compared with
OxyContin OP in a head-to-head oral abuse-deterrence clinical trial.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In an abuse-deterrence clinical trial, we measured the drug release of both OxyContin OP and
Xtampza when intact and when subjected to the most effective method of attempting to defeat their abuse-deterrent properties. This clinical trial showed that crushing OxyContin OP caused the active
ingredient (oxycodone) to be released rapidly, with drug release that was bioequivalent to immediate-release oxycodone. By contrast, this clinical trial showed that the release of oxycodone from
crushed Xtampza was bioequivalent to uncrushed Xtampza. Based on this data, we believe drug abusers may find Xtampza less desirable to abuse orally than OxyContin OP after crushing. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Abuse-deterrent properties in an oral human abuse
potential clinical trial.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Consistent with FDA guidance, we performed a human abuse potential clinical trial using the oral route of administration measuring "drug
liking" in recreational drug users. We measured how well recreational drug users liked intact Xtampza (taken orally as intended) and chewed Xtampza compared with crushed immediate-release oxycodone
taken orally. The clinical trial showed with statistical significance that both chewed and intact Xtampza were "liked" less than immediate-release oxycodone. The clinical trial also showed that
opening our capsules and chewing the microspheres did not change the PK of Xtampza. Our tentatively approved product label includes the PK data from this human abuse potential clinical trial and also
includes data showing that chewed and intact Xtampza was associated with lower drug liking than crushed immediate-release oxycodone. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Abuse-deterrent properties following snorting in a human
abuse potential clinical trial.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Consistent with FDA guidance, we performed a human abuse potential clinical trial using the snorted route of administration. The
clinical trial demonstrated that crushing and snorting Xtampza microspheres resulted in lower blood levels of oxycodone than taking intact Xtampza capsules orally. The clinical trial also demonstrated
with statistical significance that crushed and snorted Xtampza microspheres were "liked" less than both intact Xtampza administered orally and snorted immediate-release oxycodone. Based on this data,
we believe that drug abusers may not find it desirable to snort Xtampza. Our tentatively approved product label includes the PK data from this human abuse potential clinical trial and also includes
data showing that crushed and snorted Xtampza was associated with lower drug liking than both intact Xtampza administered orally and snorted immediate-release oxycodone. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Ability to sprinkle microspheres for patients with
difficulty swallowing.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In clinical trials we performed consistent with FDA guidance, we demonstrated that when Xtampza microspheres were removed from the capsule
and chewed or crushed, or removed from the capsule and sprinkled onto soft food and administered orally, the drug release profile did not significantly change from administering intact Xtampza
capsules. Additionally, in preclinical studies we showed that the drug release profile did not change when the microspheres were administered using various types of feeding tubes. Our tentatively
approved product label states that Xtampza can be taken by sprinkling the capsule contents on soft foods or into a cup, and then directly into the mouth, or through a gastrostomy or nasogastric
feeding tube. </FONT></DD></DL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=8,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=607119,FOLIO='4',FILE='DISK131:[15ZCN1.15ZCN74701]CA74701A.;24',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_ca74701_1_5"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Competitive Abuse-Deterrent Approaches  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To address the potential for abuse, the pharmaceutical industry has created a number of abuse-deterrent products and product candidates, using a
variety of technical strategies that fall under the following categories:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Physical/Chemical
Barriers</I></FONT><FONT SIZE=2>:&nbsp;&nbsp;&nbsp;&nbsp;Physical barriers are formulations designed to prevent chewing, crushing, cutting, grating or grinding for oral or nasal abuse. Physical and chemical
barriers can make it difficult to extract the opioid from the formulation for intravenous abuse using common solvents such as water. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Agonist/Antagonist
Combinations</I></FONT><FONT SIZE=2>:&nbsp;&nbsp;&nbsp;&nbsp;An opioid antagonist can be co-formulated with an active opioid ingredient, or agonist, to interfere with or reduce the euphoria associated with
abuse. Market research studies performed for us have shown that some physicians prefer not to use an abuse-deterrent formulation with an opioid antagonist because such formulations may be less useful
in addressing chronic pain and their antagonist components may precipitate withdrawal. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Prodrug approaches</I></FONT><FONT SIZE=2>:&nbsp;&nbsp;&nbsp;&nbsp;A
prodrug is a drug administered in an inactive, or less active, form designed to enable more effective delivery. The prodrug is then converted by the body into the active ingredient through a normal,
metabolic process. In a prodrug opioid, the active ingredient is designed to be released if the drug is taken orally, but if an abuser or patient takes a large amount of the drug, the prodrug is not
broken down or absorbed rapidly enough to create euphoria. If injected or snorted, the prodrug is not broken down and the active ingredient is not released. To date, the only extended-release product
candidate using the prodrug approach in late-stage clinical development did not achieve its primary endpoint of demonstrating adequate pain relief compared to a placebo in a Phase&nbsp;2 clinical
trial. No opioids using a prodrug approach are currently marketed. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
believe Xtampza represents the best-in-class approach to creating an abuse-deterrent extended-release opioid formulation. Xtampza does not incorporate an opioid antagonist, is not a prodrug, and,
based on the studies and clinical trials we conducted, is resistant to abuse through physical or chemical manipulation. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Patents and Proprietary Technology  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>We regard the protection of patents, designs, trademarks and other proprietary rights that we own or license as critical to our success and
competitive position. Our patent portfolio directed toward Xtampza and our DETERx technology consists of seven issued patents in the United States, two pending applications in the European Union and
one issued patent in each of Canada, Japan and Australia. We also have a Notice of Allowance for a patent in the United States and Canada. In addition, we have six patent applications pending in the
United States, and one pending patent application in Japan. Our issued U.S. patents are projected to expire in 2023 and 2025, and our pending patent applications in the United States, if issued, would
be projected to expire in 2023, 2025 and 2030. In addition, we use a unique and proprietary process to manufacture our products that requires significant know-how, which we currently protect as trade
secrets.

 </FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>Our
technology and products are not in-licensed from any third party, and we own all of the rights to our product candidates. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Patent Litigation Strategy  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We filed the NDA for Xtampza as a 505(b)(2) application, which allows us to reference data from an approved drug listed in the FDA's Approved Drug
Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), in this case OxyContin OP. The 505(b)(2) process requires that we certify to the FDA and notify Purdue as the
holder of the NDA and any other Orange Book-listed patent owners, that we do not infringe any of the patents listed for OxyContin OP in the Orange Book, or that the patents are invalid. We made such
certification and provided such notice on February&nbsp;11, 2015, and such certification documented why Xtampza does not infringe any of the 11 Orange Book-listed patents for </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=9,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=98028,FOLIO='5',FILE='DISK131:[15ZCN1.15ZCN74701]CA74701A.;24',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_ca74701_1_6"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:arial;"><FONT SIZE=2>OxyContin
OP, five of which stand invalidated by the Federal District Court for the Southern District of New York, subject to a pending appeal. Under the Hatch-Waxman Act of 1984, Purdue had the
option to sue us for infringement, and receive a stay of up to 30&nbsp;months before the FDA can issue a final regulatory approval for Xtampza, unless the stay is earlier terminated. Purdue
exercised its option and elected to sue us for infringement in the District of Delaware on March&nbsp;24, 2015 asserting infringement of three of Purdue's Orange Book-listed patents (all of which
stand invalidated, subject to a pending appeal by Purdue) and a non-Orange Book-listed patent, and, accordingly, received a stay of up to 30&nbsp;months before the FDA can issue a final regulatory
approval for Xtampza, unless the stay is earlier terminated. The 30-month stay only applies to the Orange Book-listed patents. On March&nbsp;26, 2015, Purdue filed a second suit against us in the
District of Massachusetts asserting infringement of the same four patents. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


On July&nbsp;23, 2015, Purdue voluntarily dismissed the Massachusetts case and on August&nbsp;6, 2015, Purdue filed another case in Massachusetts asserting the same four patents as in the Delaware
case and the original Massachusetts case. On October&nbsp;7, 2015, the Delaware case was transferred to Massachusetts and on November&nbsp;4, 2015, the two cases pending in Massachusetts were
consolidated. On November&nbsp;9, 2015, we filed a motion for partial judgment on the pleadings in relation to three of the four patents asserted against us, which had been previously invalidated by
the court in the Southern District of New York in Purdue's suit against Teva Pharmaceuticals USA, Inc., or Teva. On the same date, we moved for entry of final judgment and to expedite hearing on our
motions. On November&nbsp;23, 2015, Purdue filed a motion to stay proceedings until resolution of its appeal against Teva. The hearing regarding our motion for partial judgment and entry of judgment
and Purdue's motion to stay was held on December&nbsp;22, 2015. On December&nbsp;23, 2015, the District Court of Massachusetts issued an order staying proceedings in relation to the three Orange
Book-listed patents asserted against us until February&nbsp;25, 2016, which is the date scheduled by the Court for a status conference. The Court reserved the decision to grant our motion for
judgment on the three Orange Book-listed patents to be taken up again at the February&nbsp;25th status conference, at which time the Court indicated it may grant our motion for judgment or may
consider extending the stay. The Court further indicated that it will consider an earlier hearing if the Court of Appeals for the Federal Circuit issues a decision on the appeal of the New York
judgment of invalidity prior to the February&nbsp;25th status conference.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


On November&nbsp;6, 2015, Purdue filed another patent infringement suit against us in Massachusetts asserting infringement of another patent that is a continuation of the three patents previously
asserted by Purdue against us that were invalidated by the court in the Southern District of New York. On December&nbsp;1, 2015, we filed a motion to dismiss for failure to state a claim, arguing
that the patent asserted by Purdue is invalid based on collateral estoppel. Purdue filed its opposition response on December&nbsp;15, 2015. That action has been consolidated into the other
Massachusetts actions, and our motion remains pending.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA's tentative approval of Xtampza means that the product, with its product labeling, is tentatively approved based upon the information available to the FDA at the time of tentative approval.
The FDA can grant final approval following the expiration of the 30-month stay period or termination of the stay. If we receive a court order that the listed patents are invalid or not infringed, or
if we settle the Purdue litigation before the 30-month stay period expires, the FDA could then provide final regulatory approval of Xtampza prior to the expiration of the 30-month period, at which
point the product can be marketed. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


DETERx Pipeline  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have applied our DETERx platform technology to Xtampza as well as other product candidates in our pipeline. We recently completed formulation
development work for our extended-release, abuse-deterrent hydrocodone program. Based upon an assessment of the market opportunity and the potential to differentiate from currently marketed
hydrocodone products as well as programs in development, we are prioritizing our abuse-deterrent hydrocodone program as our second product in development. We filed an IND with the FDA in December 2015
and target initiating a clinical trial in the first quarter of 2016. We also have an extended-release, abuse-deterrent oxymorphone program for the treatment of chronic pain for </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=10,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1035532,FOLIO='6',FILE='DISK131:[15ZCN1.15ZCN74701]CA74701A.;24',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_ca74701_1_7"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:arial;"><FONT SIZE=2>which
we have filed an investigational new drug application, or IND. This program has been granted Fast Track status by the FDA. In addition, we have other extended-release, abuse-deterrent product
candidates that have completed preliminary preclinical studies, including morphine for pain and methylphenidate for the treatment of attention deficit hyperactivity disorder, or ADHD. All of these
product candidates share similar abuse-deterrent qualities as Xtampza and are designed to be suitable for patients with difficulty swallowing. We own all of the rights to our product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g249773.jpg" ALT="GRAPHIC" WIDTH="616" HEIGHT="187">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our Strategy  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our goal is to become the leading marketer of abuse-deterrent extended-release opioids and other commonly abused products. Key elements of our
strategy to achieve this goal are to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Establish our leadership position by obtaining final
regulatory approval to market Xtampza with a best-in-class abuse-deterrent product label.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our tentatively approved product label contains differentiated
abuse-deterrent claims for Xtampza. If Xtampza receives final regulatory approval, this product label may allow us to detail Xtampza to physicians and highlight its unique abuse-deterrent
characteristics. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Commercialize Xtampza in the United States
ourselves.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We are currently building our commercial organization, including our sales force and commercial manufacturing capacity, in preparation for a potential
U.S. commercial launch of Xtampza in the second quarter of 2016, although the timing of a potential commercial launch is subject to whether and when we receive final regulatory approval for Xtampza.
Our management team has extensive experience commercializing pharmaceutical products, and we are in the process of establishing sales, marketing and reimbursement functions to commercialize Xtampza in
the United States. Initially, we plan to detail Xtampza to approximately 11,000 physicians who write approximately 55% of the branded extended-release oral opioid prescriptions in the United States
with a sales team of approximately 120 sales representatives. In addition, we plan to deploy a separate, focused sales team of approximately 25 specialty sales representatives to detail Xtampza to
nursing homes, hospices, and other institutions treating large populations of the elderly and other patients who need chronic pain relief and have difficulty swallowing. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Establish Xtampza as the treatment of choice for
patients with CPD.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Xtampza has been tentatively approved with product labeling for sprinkling Xtampza microspheres on soft foods or into a cup, and then directly
into the mouth, or through a gastrostomy or nasogastric feeding tube. If Xtampza receives final regulatory approval, Xtampza could be the only extended-release oxycodone product designed to be
suitable for this approximately 11&nbsp;million patient segment. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Establish strategic collaborations to accelerate and
maximize the potential of our product candidates worldwide.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We intend to seek strategic collaborations with other pharmaceutical companies to commercialize our
product candidates outside the United States and to develop certain of our product candidates that are outside of our core therapeutic focus. </FONT></DD></DL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=11,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1034464,FOLIO='7',FILE='DISK131:[15ZCN1.15ZCN74701]CA74701A.;24',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_ca74701_1_8"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Advance other product candidates that incorporate our
DETERx platform technology.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We have begun advancing our development program for COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of
chronic pain. We target beginning clinical trials for our second product candidate by the first quarter of 2016. We also have an IND application on file for COL-172, an abuse-deterrent,
extended-release oxymorphone for the treatment of chronic pain, which has been granted Fast Track status by the FDA. In addition, we have COL-171, a proprietary preclinical DETERx extended-release,
abuse-deterrent methylphenidate formulation for the treatment of ADHD. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Acquire additional products and product
candidates.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We may identify and license, co-promote or acquire products or product candidates being developed for pain indications and other complementary products. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risk Factors  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our ability to implement our business strategy is subject to numerous risks and uncertainties. As a clinical-stage biopharmaceutical company, we face
many risks inherent in our business and our industry generally. You should carefully consider all of the information set forth in this prospectus and, in particular, the information under the heading
"Risk Factors" in this prospectus prior to making an investment in our common stock. These risks include, among others, the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our product candidates, including Xtampza, are subject to regulatory approval
processes that are lengthy and unpredictable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may not obtain final regulatory approval for Xtampza or any of our other
product candidates from the FDA or foreign regulatory authorities. Despite receiving tentative approval by the FDA, additional data may emerge that could change the FDA's position on the product
labeling or final regulatory approval of Xtampza; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we are subject to patent infringement litigation relating to Xtampza and may, in
the future, be subject to additional litigation relating to our other product candidates, which may be expensive to defend and delay the commercialization of Xtampza or our other product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we currently generate no commercial revenue, may never become profitable and may
incur substantial and increasing net losses for the foreseeable future as we seek final regulatory approval for, and potentially begin to commercialize, Xtampza; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we currently do not employ sales representatives and, if we are unable to hire
employees to provide the appropriate level of sales support, we may not be successful in commercializing Xtampza if we receive final regulatory approval; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we depend, or will depend in the future, on the performance of third parties for
the supply of the active ingredient used in Xtampza, commercial manufacturing and testing of Xtampza, and the conduct of clinical trials relating to our product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our Corporate Information  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are incorporated in the Commonwealth of Virginia under the name Collegium Pharmaceutical,&nbsp;Inc. Our executive offices are located at 780
Dedham Street, Suite&nbsp;800, Canton, MA 02021 and our telephone number is (781)&nbsp;713-3699. Our website address is www.collegiumpharma.com. The inclusion of our website address above and
elsewhere in this prospectus is, in each case, intended to be an inactive textual reference only and not an active hyperlink to our website. The information contained in, or that can be accessed
through, our website is not part of this prospectus. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=12,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=843109,FOLIO='8',FILE='DISK131:[15ZCN1.15ZCN74701]CA74701A.;24',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_ca74701_1_9"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Implications of Being an Emerging Growth Company  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are an "emerging growth company," as defined in Section&nbsp;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act
of 2012, or the JOBS Act. As such, we are eligible to take advantage of exemptions from various disclosure and reporting requirements that are applicable to other public companies that are not
"emerging growth companies" including, but not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> not being required to comply with the auditor attestation requirements of
Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> being permitted to present only two years of audited financial statements and
only two years of related Management's Discussion and Analysis of Financial Condition and Results of Operations, in each case, instead of three years; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> being permitted to present the same number of years of selected financial data
as the years of audited financial statements presented, instead of five years; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reduced disclosure obligations regarding executive compensation, including no
Compensation Disclosure and Analysis; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> not being required to comply with any requirement that may be adopted by the
Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements;
and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  exemptions from the requirements of holding a non-binding advisory vote on
executive compensation and shareholder approval of any golden parachute payments not previously approved. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
may choose to take advantage of some or all of the available exemptions. We have taken advantage of some of the reduced reporting burdens in this prospectus. Accordingly, the scope of the
information contained herein may be different than the scope of the information you receive from other public companies in which you hold stock. We do not know if some investors will find our shares
less attractive as a result of our utilization of these or other exemptions. The result may be a less active trading market for our shares and our share price may be more volatile. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
addition, Section&nbsp;107 of the JOBS Act also provides that an "emerging growth company" can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the
Securities Act for complying with new or revised accounting standards. In other words, an "emerging growth company" can delay the adoption of certain accounting standards until those standards would
otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new
or revised accounting standards as other public companies that are not "emerging growth companies." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
will remain an "emerging growth company" until the earliest of (i)&nbsp;the last day of the first fiscal year in which our annual gross revenues exceed $1.0&nbsp;billion; (ii)&nbsp;the date
that we become a "large accelerated filer" as defined in Rule&nbsp;12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value of our
shares that are held by non-affiliates exceeds $700&nbsp;million as of the last business day of our most recently completed second fiscal quarter; (iii)&nbsp;the date on which we have issued more
than $1.0&nbsp;billion in nonconvertible debt during the preceding three-year period; and (iv)&nbsp;December&nbsp;31, 2020. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=13,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=330878,FOLIO='9',FILE='DISK131:[15ZCN1.15ZCN74701]CA74701A.;24',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cc74701_1_10"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="cc74701_the_offering"> </A>
<A NAME="toc_cc74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  THE OFFERING    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="233pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Common stock offered by us</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the
underwriters' option to purchase additional shares is exercised in full).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock to be outstanding after this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
(&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters' option to purchase additional shares is exercised in full).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Option to purchase additional shares</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The underwriters have the option to purchase from us up to a maximum
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock. The underwriters can exercise this option at any time within 30&nbsp;days from the date of this
prospectus.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of proceeds</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We estimate that the net proceeds to us from this offering, after deducting estimated underwriting discounts and commissions
and estimated offering expenses payable by us, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, based on
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the last reported sales price of our common stock
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016. We intend to use the net proceeds from this
offering as follows:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>approximately $45.7&nbsp;million for the continued development of our commercial infrastructure, including building our sales, manufacturing, marketing and reimbursement functions and funding the
commercial launch of Xtampza, subject to final regulatory approval;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT FACE="arial" SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>approximately $4.6&nbsp;million to fund research and development efforts of our other product candidates, including clinical development for our hydrocodone program (including Phase&nbsp;1
bioequivalence clinical trials and abuse-deterrence studies and clinical trials); and</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT FACE="arial" SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>the remainder, if any, to fund working capital and general corporate purposes, which may include litigation expenses (including expenses relating to the Purdue litigation) and the acquisition or
licensing of product candidates, technologies, compounds, other assets or complementary businesses.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT FACE="arial" SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>See "Use of Proceeds" for more information.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Market for the common stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Our common stock is listed on NASDAQ under the symbol "COLL."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dividend policy</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We have never paid or declared any cash dividends on our common stock, and we do not anticipate paying any cash dividends on
our common stock in the foreseeable future. See "Dividend Policy."</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<p style="font-family:arial;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT SIZE=2>
</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=14,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=92238,FOLIO='10',FILE='DISK131:[15ZCN1.15ZCN74701]CC74701A.;14',USER='KBLACK',CD=';3-JAN-2016;21:22' -->
<A NAME="page_cc74701_1_11"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="233pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Risk factors</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>You should read the "Risk Factors" section of this prospectus for a discussion of certain factors to consider carefully before deciding to
purchase any shares of our common stock.</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
number of shares of our common stock to be outstanding after this offering is based on 20,687,829 shares of common stock outstanding as of September&nbsp;30, 2015, assumes the issuance by us of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering and excludes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  1,356,246 shares of common stock issuable upon the exercise of outstanding
stock options as September&nbsp;30, 2015, at a weighted-average exercise price of $9.04 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 2,445 shares of common stock issuable upon the exercise of warrants to purchase
common stock as of September&nbsp;30, 2015, at a weighted-average exercise price of $12.27 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  1,337,584 shares of common stock reserved for future issuance under our Amended
and Restated 2014 Stock Incentive Plan as of September&nbsp;30, 2015; and </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  200,000 shares reserved for future issuance under our 2015 Employee Stock
Purchase Plan as of September&nbsp;30, 2015.


</FONT></DD>

</DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Except
as otherwise indicated, all information in this prospectus assumes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> no exercise by the underwriters of the option to purchase up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our existing shareholders will not purchase any shares of our common stock in
this offering. </FONT></DD></DL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=15,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=709334,FOLIO='11',FILE='DISK131:[15ZCN1.15ZCN74701]CC74701A.;14',USER='KBLACK',CD=';3-JAN-2016;21:22' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ce74701_1_12"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ce74701_summary_financial_data"> </A>
<A NAME="toc_ce74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SUMMARY FINANCIAL DATA    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table presents our summary financial data. The following summary of our statement of operations data for the years ended
December&nbsp;31, 2013 and 2014 are derived from our audited financial statements appearing elsewhere in this prospectus. We have derived the summary of our statement of operations data for the nine
months ended September&nbsp;30, 2014 and 2015 and the balance sheet data as of September&nbsp;30, 2015 from our unaudited financial statements appearing elsewhere in this prospectus. Our
historical results are not necessarily indicative of the results that may be expected in the future. The summary financial data presented below should be read in conjunction with "Management's
Discussion and Analysis of Financial Condition and Results of Operations" and our financial statements and the related notes thereto, included elsewhere in this prospectus. The summary financial data
in this section is not intended to replace our financial statements and the related notes thereto. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="73pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Years Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Nine Months Ended<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands, except share<BR>
and per share amounts)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Statement of Operations Data:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14,157</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14,959</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12,652</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6,444</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,885</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,706</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,686</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>11,027 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expense</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>16,042</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>17,665</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14,338</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>17,471 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16,042</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,665</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(14,338</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,471</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense, net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>76</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>252</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>110</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>350</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other expense, net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>79</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(91</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16,197</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,917</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(14,448</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,730</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and diluted net loss per common share<SUP>(1)</SUP>:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4.06</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(22.72</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(18.26</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.94</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average shares used to compute earnings (loss) per common share<SUP>(1)</SUP>:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,697,044</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>933,997</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>926,597</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>11,179,756 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(1)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">See
Note&nbsp;3 to our consolidated financial statements included elsewhere in this prospectus for an explanation of the method used to calculate earnings
(loss) per common share attributable to common shareholders, including the method used to calculate the number of shares used in the computation of the per share amount. </FONT></DD></DL>
 </DIV>

 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=16,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1033805,FOLIO='12',FILE='DISK131:[15ZCN1.15ZCN74701]CE74701A.;17',USER='CGONCE',CD='31-DEC-2015;12:15' -->
<A NAME="page_ce74701_1_13"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=4 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of September&nbsp;30, 2015 </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Actual </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As Adjusted<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font> </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=4 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands)</B></FONT><BR></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance Sheet Data:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>105,460</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Working capital<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>97,726</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>107,050</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other long-term liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,889</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total shareholders' equity (deficit)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>93,561</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
<p style="font-family:arial;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


 </FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(1)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Working
capital is calculated as current assets minus current liabilities.

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(2)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
as adjusted balance sheet data give effect to our issuance and the sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering at an assumed
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the last reported sale price of our common stock on NASDAQ
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016, after deducting the estimated underwriting
discounts and
commissions and estimated offering expenses payable by us. </FONT>

</DD>

</DL>
 </DIV>

 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=17,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=752694,FOLIO='13',FILE='DISK131:[15ZCN1.15ZCN74701]CE74701A.;17',USER='CGONCE',CD='31-DEC-2015;12:15' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_da74701_1_14"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="da74701_risk_factors"> </A>
<A NAME="toc_da74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, together with the other information contained in this
prospectus, including our financial statements and the related notes appearing elsewhere in this prospectus, before making your decision to invest in shares of our common stock. We cannot assure you
that any of the events discussed in the risk factors below will not occur. These risks could have a material and adverse impact on our business, results of operations, financial condition and cash
flows, and our future prospects would likely be materially and adversely affected. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your
investment. You
should understand that it is not possible to predict or identify all such risks. Consequently, you should not consider the following to be a complete discussion of all potential risks or
uncertainties.</I></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to Our Financial Position and Capital Needs  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have incurred significant losses since our inception and anticipate that we will continue to
incur losses in the future.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a clinical-stage pharmaceutical company. To date, we have focused on developing our lead product candidate, Xtampza. Investment in
pharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to gain regulatory approval
or become commercially viable. Since 2010, when we divested our former subsidiary, Onset Therapeutics,&nbsp;LLC, to PreCision Dermatology,&nbsp;Inc., we have not generated any revenue from product
sales as the FDA has not granted final regulatory approval to any of our product candidates, including our tentatively approved product, Xtampza, and we continue to incur significant research,
development and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred losses in each period since January&nbsp;1, 2011. For the year ended
December&nbsp;31, 2014 and for the nine months ended September&nbsp;30, 2015, we reported a net loss of $17.9&nbsp;million and $17.7&nbsp;million, respectively, and we had an accumulated
deficit of $119.5&nbsp;million at September&nbsp;30, 2015. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approvals for, our product candidates,
and begin to commercialize Xtampza, if we receive final regulatory approval for Xtampza. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may
adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If any of our product
candidates fails in clinical trials or does not gain final regulatory approval, or if approved, fails to achieve market acceptance, we may never become profitable. Even if we achieve profitability in
the future, we may not be able to sustain profitability in subsequent periods. Our prior losses and expected future losses have had and will continue to have an adverse effect on our shareholders'
equity and working capital. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We currently generate no revenue from the sale of products and may never become profitable.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As we currently have no products approved for marketing, we are not generating any revenue from product sales. We have not generated any revenue since
we divested our former subsidiary in 2010. Our ability to generate additional revenue and become profitable depends upon our ability to successfully commercialize our existing product candidates,
including our tentatively approved product, Xtampza, or other product candidates that we may in-license or acquire in the future. Even if we are able to successfully achieve regulatory approval for
these product candidates, we do not know when any of these product candidates will generate revenue for us, if at all. Our ability to generate revenue from our current or future product candidates
depends on a number of factors, including our ability to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtain final regulatory approval for, and successfully commercialize, Xtampza; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=18,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=335087,FOLIO='14',FILE='DISK131:[15ZCN1.15ZCN74701]DA74701A.;28',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_da74701_1_15"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  successfully satisfy post-marketing requirements that the FDA will impose if
Xtampza receives final regulatory approval, including studies and clinical trials that have been required for other extended-release/long acting opioid analgesics and individual studies and clinical
trials of Xtampza; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  successfully complete development activities, including the necessary clinical
trials, with respect to other product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  complete and submit NDAs to the FDA and obtain regulatory approval for
indications for which there is a commercial market; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  complete and submit applications to, and obtain regulatory approval from,
foreign regulatory authorities, if we choose to commercialize our product candidates outside the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> set a commercially viable price for our products; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  manufacture commercial quantities of our products at acceptable cost levels; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> develop a commercial organization capable of sales, marketing and distribution
for the products we intend to sell ourselves in the markets in which we have retained commercialization rights; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> find suitable distribution collaborators to help us market, sell and distribute
our products, if approved, in markets outside the United States; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> obtain coverage and adequate reimbursement from third-parties, including
government payors. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, because of the numerous risks and uncertainties associated with product development, including that our product candidates may not advance through development or achieve the safety and
efficacy (including the efficacy of our abuse-deterrent technology) endpoints of applicable clinical trials, we are unable to predict the timing or amount of increased expenses, or when or if we will
be able to achieve or maintain profitability. Furthermore, we anticipate incurring significant costs associated with commercializing these products. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even
if we are able to generate revenues from the sale of our products, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable
or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we require additional capital to fund our operations and we fail to obtain necessary financing,
we may be unable to complete the development and commercialization of our product candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our operations have consumed substantial amounts of cash. We expect to continue to spend substantial amounts to advance the clinical development of
our product candidates and launch and commercialize any product candidates for which we may receive regulatory approval, including building our own commercial organization. We believe that our
existing cash and cash equivalents, including the net proceeds from this offering, will be sufficient to fund our operations into 2018, including the commercialization of Xtampza, if Xtampza receives
final regulatory approval, and the continuation of our development of our other product candidates. However, we may require additional capital for the further development and commercialization of our
product candidates and may also need to raise additional funds sooner in order to accelerate development of our product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
cannot be certain that additional funding will be available on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts, when required or on acceptable terms,
we also could be required to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  significantly delay, scale back or discontinue the development or the
commercialization of our product candidates or one or more of our other research and development initiatives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seek collaborators for one or more of our current or future product candidates
at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  relinquish or license on unfavorable terms our rights to technologies or
product candidates that we otherwise would seek to develop or commercialize ourselves; or </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=19,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=99836,FOLIO='15',FILE='DISK131:[15ZCN1.15ZCN74701]DA74701A.;28',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_da74701_1_16"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  significantly curtail operations. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our
forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual
results could vary as a result of a number of factors, including the factors discussed elsewhere in this "Risk Factors" section. We have based this estimate on assumptions that may prove to be wrong,
and we could utilize our available capital resources sooner than we currently expect. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the ability to obtain abuse-deterrent claims in the product labels for our
product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to successfully satisfy post-marketing requirements that the FDA
will impose if Xtampza receives final regulatory approval, including studies and clinical trials that have been required for other extended-release/long-acting opioid analgesics and individual studies
and clinical trials of Xtampza; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> clinical development plans for our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA's final regulatory approval of inclusion of claims in the product label
for Xtampza that will permit the sprinkling of microspheres on food, directly in the mouth or administered through feeding tubes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the outcome, timing and cost of the regulatory approval process by the FDA and
foreign regulatory authorities, including the potential for regulatory authorities to require that we perform more studies than those that we currently expect; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of filing, prosecuting, defending and enforcing any patent claims and
other intellectual property rights, including defending Purdue's patent infringement claims against us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost and timing of completion of existing or expanded commercial-scale
outsourced manufacturing activities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of establishing sales, marketing and distribution capabilities for
Xtampza and any other product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the initiation, progress, timing, costs and results of clinical trials for our
product candidates and any future product candidates we may in-license. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Raising additional capital may cause dilution to our existing shareholders, restrict our operations
or require us to relinquish rights to our technologies or product candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may seek additional capital through a combination of private and public equity offerings, debt financings, receivables or royalty financings,
strategic collaborations and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest
will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of existing shareholders. Debt, receivables and royalty financings may be coupled with an
equity component, such as warrants to purchase stock, which could also result in dilution of our existing shareholders' ownership. The incurrence of additional indebtedness beyond our existing
indebtedness with Silicon Valley Bank could result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations on our ability to incur further
debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could have a material adverse effect on our ability to conduct our business
and may result in liens being placed on our assets and intellectual property. If we were to default on any of our indebtedness, we could lose such assets and intellectual property. If we raise
additional funds through strategic collaborations and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on
terms that are not favorable to us. If we are unable to raise additional funds through equity or debt financing when needed, we may be required to delay, limit, reduce or terminate our product
development or commercialization efforts or grant rights to develop and market our technologies that we would otherwise prefer to develop and market ourselves. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=20,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=403770,FOLIO='16',FILE='DISK131:[15ZCN1.15ZCN74701]DA74701A.;28',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_da74701_1_17"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have a limited operating history, which may make it difficult for you to evaluate the success of
our business to date and to assess our future viability.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our predecessor was originally incorporated in Delaware in April 2002 under the name Collegium Pharmaceuticals,&nbsp;Inc. In October 2003, our
predecessor changed its name to Collegium Pharmaceutical,&nbsp;Inc. In July 2014, we reincorporated in the Commonwealth of Virginia pursuant to a merger whereby Collegium
Pharmaceutical,&nbsp;Inc., a Delaware corporation, merged with and into Collegium Pharmaceutical,&nbsp;Inc., a Virginia corporation, with the Virginia corporation surviving the merger. From 2002
until 2010, our operations focused primarily on marketing proprietary therapies to the wound care and dermatology
industry through our former subsidiary, Onset Therapeutics,&nbsp;LLC, which was spun off and became a part of PreCision Dermatology,&nbsp;Inc. in 2010. Since 2010, our operations have focused
primarily on developing the DETERx platform technology and identifying and developing product candidates that utilize the DETERx technology, including our lead product candidate, Xtampza. Although the
FDA has given Xtampza a tentative approval, we have not yet obtained final regulatory approval for any of our product candidates or demonstrated an ability to commercialize a product candidate.
Consequently, any predictions about our future success, performance or viability may not be as accurate as they could be if we had a longer operating history or approved products on the market. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our ability to use our net operating loss carryforwards and certain other tax attributes may be
limited.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of December&nbsp;31, 2014, we had net operating loss, or NOL, carryforwards of approximately $78.3&nbsp;million for U.S. federal income tax and
state tax purposes available to offset future taxable income and U.S. federal and state research and development tax credits of $3.1&nbsp;million, prior to consideration of annual limitations that
may be imposed under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, or Section&nbsp;382. These carryforwards begin to expire in 2022. Under Section&nbsp;382, if a corporation
undergoes an "ownership change," generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation's ability to use its pre-change NOLs and
other pre-change tax attributes (such as research and development tax credits) to offset its post-change income may be limited. We may experience ownership changes in the future as a result of shifts
in our stock ownership some of which are outside our control. We have not performed any current analyses under Section&nbsp;382 and cannot forecast or otherwise rely on deriving benefit from our
various federal or state tax attribute carryforwards. As a result, if we earn net taxable income, our ability to use our pre-change NOL carryforwards to offset U.S. federal taxable income may be
subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or
otherwise limited, which could accelerate or permanently increase state taxes owed. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to Clinical Development and Regulatory Approval of Our Product Candidates  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our success depends in large part on the success of our lead product candidate, Xtampza. We cannot
give any assurance that we will receive final regulatory approval for Xtampza, which is necessary before it can be commercialized.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To date, we have invested substantial resources in the development of our lead product candidate, Xtampza, which has been tentatively approved by the
FDA. Our business and future success are substantially dependent on our ability to successfully and timely obtain final regulatory approval for and commercialize this product candidate, which may
never occur. We currently generate no revenues from sales of any drugs and we may never be able to develop or commercialize a marketable drug. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On
November&nbsp;6, 2015, the FDA granted tentative approval to the NDA for Xtampza for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for
which alternative treatment options are inadequate. The FDA granted tentative approval because Xtampza met the required quality, safety and efficacy standards for approval as of the date that the
tentative approval was granted. Because of the ongoing patent litigation brought against us by Purdue in March 2015, final regulatory approval cannot be granted until after an automatic stay of up to
30&nbsp;months expires, the court invalidates </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=21,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=443957,FOLIO='17',FILE='DISK131:[15ZCN1.15ZCN74701]DA74701A.;28',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_da74701_1_18"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Purdue's
patents or issues an opinion of non-infringement, or Purdue's listed patents expire. In addition, the FDA must also be assured that there is no new information that would affect whether final
regulatory approval should be granted. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any
delay or impediment in our ability to obtain final regulatory approval to commercialize Xtampza may cause us to be unable to generate the revenues necessary to continue our research and
development pipeline activities, thereby adversely affecting our business and our prospects for future growth. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even
if we receive final regulatory approval from the FDA, our ability to successfully commercialize Xtampza will depend on many factors, including but not limited
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to successfully satisfy post-marketing requirements that the FDA
will impose, including studies and clinical trials that have been required for other extended-release/long-acting opioid analgesics and individual studies and clinical trials of Xtampza; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the ability to manufacture commercial quantities of Xtampza at reasonable cost
and with sufficient speed to meet commercial demand; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to build a sales and marketing organization to market Xtampza; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our success in educating physicians, patients and caregivers about the benefits,
administration and use of Xtampza; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the availability, perceived advantages, relative cost, relative safety and
relative efficacy of other abuse-deterrent products and treatments for chronic pain and CPD; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to successfully defend any challenges to our intellectual property
relating to Xtampza; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the availability of coverage and adequate reimbursement for Xtampza; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a continued acceptable safety profile of Xtampza following approval. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Many
of these matters are beyond our control and are subject to other risks described elsewhere in this "Risk Factors" section. Accordingly, we cannot assure you that we will be able to successfully
commercialize or generate revenue from Xtampza, even if we receive final regulatory approval. If we cannot do so, or are significantly delayed in doing so, our business will be materially harmed. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Despite receiving tentative approval by the FDA, additional data may emerge that could change the
FDA's position on the product labeling or prevent final regulatory approval of Xtampza. If we fail to obtain final FDA approval of product labeling for sprinkling Xtampza microspheres directly in the
mouth or on food, as well as administering the microspheres through feeding tubes, then our ability to successfully market Xtampza may be adversely affected.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>It is estimated that the U.S. market includes approximately 11&nbsp;million patients with CPD. Our Xtampza microspheres are designed to be removed
from the capsule and sprinkled on food or into a cup, and then directly into the mouth, or administered through feeding tubes, without compromising their extended-release properties. On
November&nbsp;6, 2015, the FDA granted tentative approval for the Xtampza NDA and provided us with a tentative product label. However, we have not yet received final regulatory approval to market
Xtampza and the FDA could change its position on the product labeling or not issue final regulatory approval. If we receive final regulatory approval, but such approval does not permit us to include a
claim in the product label for Xtampza regarding the ability to sprinkle the Xtampza microspheres directly in the mouth, on food or in feeding tubes, or the FDA requires us to have a black box warning
product label stating that "crushing, dissolving or chewing can cause rapid release and absorption of a potentially fatal dose of the active drug," it will limit our ability to differentiate Xtampza
from other abuse-deterrent opioid formulations on the basis of alternative dosing options, and we may not be able to market Xtampza to patients with CPD. As a result, this may have an adverse effect
on our business and our prospects for future growth. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=22,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=505311,FOLIO='18',FILE='DISK131:[15ZCN1.15ZCN74701]DA74701A.;28',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_da74701_1_19"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If the FDA does not conclude that our product candidates in development are sufficiently
bioequivalent, or demonstrate comparable bioavailability to their respective listed drugs, or if the FDA otherwise does not conclude that our product candidates satisfy the requirements for the
Section&nbsp;505(b)(2) approval pathway, the approval pathway for those product candidates will likely take significantly longer, cost significantly more and entail significantly greater
complications and risks than anticipated, and the FDA may not approve those product candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A key element of our strategy is to seek FDA approval for our product candidates through the Section&nbsp;505(b)(2) regulatory pathway.
Section&nbsp;505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or FD&amp;C Act, permits the filing of an NDA that contains full safety and efficacy reports but where at least some of
the information required for approval comes from studies not conducted by or for the applicant, such as the FDA's findings of safety and efficacy in the approval of a similar drug, and for which the
applicant has not obtained a right of reference and/or published literature. Such reliance is typically predicated on a showing of bioequivalence or comparable bioavailability to an approved drug. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
the FDA does not allow us to pursue the Section&nbsp;505(b)(2) approval pathway for our product candidates, or if we cannot demonstrate bioequivalence or comparable bioavailability of our product
candidates to approved products, we may need to conduct additional clinical trials, provide additional data and information, and meet additional standards for regulatory approval. If this were to
occur, the time and financial resources required to obtain FDA approval for these product candidates would increase. Moreover, our inability to pursue the Section&nbsp;505(b)(2) approval pathway
could result in new competitive products reaching the market sooner than our product candidates, which could have a material adverse effect on our competitive position and our business prospects. Even
if we are allowed to pursue the Section&nbsp;505(b)(2) approval pathway, we cannot assure you that our product candidates will receive the requisite approvals for commercialization on a timely
basis, if at all. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, notwithstanding the approval of a number of products by the FDA under Section&nbsp;505(b)(2) over the last few years, pharmaceutical companies and others have objected to the FDA's
interpretation of Section&nbsp;505(b)(2). If the FDA's interpretation of Section&nbsp;505(b)(2) is successfully challenged, the FDA may change its policies and practices with respect to
Section&nbsp;505(b)(2) regulatory approvals, which could delay or even prevent the FDA from approving any NDA that we submit under Section&nbsp;505(b)(2). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even
if our product candidates are approved under Section&nbsp;505(b)(2), the approval may be subject to limitations on the indicated uses for which the products may be marketed or to other
conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the products, including additional preclinical studies and
clinical trials. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our decision to seek approval of our product candidates, including Xtampza, under
Section&nbsp;505(b)(2) increases the risk that a patent infringement suit, like the suits filed by Purdue relating to Xtampza, may be filed against us, which would delay the FDA's final regulatory
approval of such product candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In connection with any NDA that we file under Section&nbsp;505(b)(2), we are required to notify the patent holders of the Section&nbsp;505(b)(2)
listed drug that we have certified to the FDA that any patents listed for the listed drug in the FDA's Orange Book publication are invalid, unenforceable or will not be infringed by the manufacture,
use or sale of our drug. If the patent holder files&nbsp;a patent infringement lawsuit against us within 45&nbsp;days of its receipt of notice of our certification, the FDA is automatically
prevented from approving our Section&nbsp;505(b)(2) NDA until the earliest of 30&nbsp;months, expiration of the patents, settlement of the lawsuit or a court decision in the infringement case that
is favorable to us. Accordingly, we may invest significant time and expense in the development of our product candidates only to be subject to significant delay and expensive and time-consuming patent
litigation before our product candidates may be commercialized. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Purdue, as the sponsor for OxyContin OP, the listed drug for Xtampza, has filed two lawsuits in the District of Massachusetts. In the first case, Purdue has alleged infringement of U.S. Patent
Nos.&nbsp;7,674,799,

</FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=23,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=788298,FOLIO='19',FILE='DISK131:[15ZCN1.15ZCN74701]DA74701A.;28',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_da74701_1_20"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


7,674,800, 7,683,072 and 8,652,497. In the second case, Purdue has alleged infringement of U.S. Patent No.&nbsp;9,073,933, which is a continuation patent of three of the patents asserted in the
first suit. On November&nbsp;9, 2015, we filed a motion requesting partial judgment and a motion requesting expedited hearing of our motion for partial judgment and for final judgment in the
Massachusetts court. Purdue filed its opposition response and a cross-motion for a partial stay on November&nbsp;23, 2015 in the first case. Those motions are fully briefed and the hearing on those
motions was held on December&nbsp;22, 2015. On December&nbsp;23, 2015, the District Court of Massachusetts issued an order staying proceedings in relation to the three Orange Book-listed patents
asserted against us until February&nbsp;25, 2016, which is the date scheduled by the Court for a status conference. The Court reserved the decision to grant our motion for judgment on the three
Orange Book-listed patents to be taken up again at the February&nbsp;25th status conference, at which time the Court indicated it may grant our motion for judgment or may consider extending the
stay. The Court further indicated that it will consider an earlier hearing if the Court of Appeals for the Federal Circuit issues a decision on the appeal of the New York judgment of invalidity prior
to the February&nbsp;25th status conference. On December&nbsp;1, 2015, we filed a motion to dismiss the second case for failure to state a claim and Purdue filed its opposition on
December&nbsp;15, 2015. That action has been consolidated into the other Massachusetts actions, and our motion remains pending. We plan to continue to take all steps necessary to vigorously defend
ourselves against these claims. The strength of our defenses will depend on the patents asserted and the interpretation of these patents. However, we could be unsuccessful in advancing
non-infringement and invalidity arguments in our defense. Purdue need only prove infringement by a preponderance of the evidence, which is a low burden of proof. If before the expiration of the
30-month period, the Court issues a final order that any of the listed patents are valid and have been infringed, final FDA approval of Xtampza, which has been tentatively approved by the FDA, would
be delayed until either a date ordered by the Court or when the Court determines that the patents will expire.


</FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even
if we are found not to infringe or Purdue's, or any other potential plaintiff's, patent claims are found invalid or unenforceable, defending any such infringement claim would be expensive and
time-consuming, and would delay the launch of our product candidates, including Xtampza, and distract management from their normal responsibilities. The Court could decline to hear our summary
judgment motion, could decline to act expeditiously to issue a decision or hold a trial, or could decline to find that all of the listed patents are invalid or non-infringed. If we are unsuccessful in
our defense of non-infringement and unable to prove invalidity of the listed patents, the court could issue an injunction prohibiting the launch of our product candidates, including Xtampza. If we
were to launch any of our product candidates, if we receive final regulatory approval by the FDA, including Xtampza, prior to a full and final determination that the listed patents are invalid or
non-infringed, we could be subject to substantial liability for damages if we do not ultimately prevail on our defenses to a claim of patent infringement. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The regulatory approval processes of the FDA and foreign regulatory authorities are lengthy,
time-consuming and unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The time required to obtain approvals by the FDA and foreign regulatory authorities is unpredictable, but typically takes many years following the
commencement of preclinical studies and clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies,
regulations or the type and amount of clinical data necessary to gain approval varies among jurisdictions and may change during the course of a product candidate's clinical development. Although the
FDA has tentatively approved Xtampza, we have not obtained final regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any future product
candidates that we may in-license, acquire or develop will ever obtain final regulatory approval from the FDA or any foreign regulatory authority. Moreover, even after any product candidate receives
final regulatory approval, the FDA may require, as it will for Xtampza, costly post-marketing requirements. Successful and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=24,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=214110,FOLIO='20',FILE='DISK131:[15ZCN1.15ZCN74701]DA74701A.;28',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_da74701_1_21"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>timely
satisfaction of these post-marketing requirements will be necessary for us to maintain any final regulatory approval that we may receive. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
product candidates could fail to receive regulatory approval from the FDA or a foreign regulatory authority, or we may be required to conduct more extensive studies and clinical trials in order to
receive such approval, for many reasons, including, but not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA and/or foreign regulatory authorities may disagree with or disapprove of
the design or implementation of our clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to demonstrate that a product candidate is safe and effective for its
proposed indication; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to demonstrate that a product candidate is bioequivalent to its listed
drug; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure of clinical trials to meet criteria required for approval; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to demonstrate that a product candidate's clinical and other benefits
outweigh its safety risks; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA or foreign regulatory authorities may disagree with our interpretation
of data from preclinical studies or clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  deficiencies in the manufacturing processes or failure of third-party
manufacturing facilities with whom we contract for clinical and commercial supplies to pass inspection; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the FDA or foreign regulatory authorities may not approve the manufacturing
processes or facilities of third party manufacturers with which we contract for clinical and commercial supplies; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  insufficient data collected from clinical trials of our product candidates or
changes in the approval policies or regulations that render our preclinical and clinical data insufficient to support the submission and filing of an NDA or to obtain regulatory approval. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market our product candidates, which would
harm our business, results of operations and prospects significantly. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, even if we obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve, with respect to
certain foreign regulatory authorities, the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing requirements, or may approve a product
with a product label that does not include the labeling claims necessary or desirable for the successful commercialization of that product. Any of the foregoing scenarios could have a material adverse
effect on our business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA or a foreign regulatory authority may require more information, including additional preclinical or clinical data to support approval, which may delay or prevent approval and our
commercialization plans, or cause us to abandon the development program. Even if we obtain regulatory approval, our product candidates may be approved for fewer or more limited indications than we
request, such approval may be contingent on the performance of costly post-marketing requirements, or we may not be allowed to include the labeling claims necessary or desirable for the successful
commercialization of such product candidate. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
order to market and sell our products outside the United States, we will likely need to obtain separate marketing approvals and comply with numerous and varied regulatory requirements and regimes,
which can involve additional testing, may take substantially longer than the FDA approval process, and still generally includes all of the risks associated with obtaining FDA approval. In addition, in
many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. FDA approval does not ensure
approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by the FDA or regulatory authorities
in other countries or jurisdictions. We may not obtain any regulatory approvals on a timely basis, if at all. We may not be able to file for marketing approvals and may not receive necessary approvals
to commercialize our products in any market. If we are unable to obtain approval of any of our product candidates by regulatory authorities in countries outside the United </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=25,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=576312,FOLIO='21',FILE='DISK131:[15ZCN1.15ZCN74701]DA74701A.;28',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_da74701_1_22"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>States,
the commercial prospects of that product candidate may be significantly diminished and our business prospects could decline. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Development of our product candidates is not complete, and we cannot be certain that our product
candidates will be commercialized.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As we currently have no products approved for marketing, we are not generating any revenues from product sales. To be profitable, we must successfully
research, develop, obtain regulatory approval for, manufacture, launch, market and distribute our product candidates under development. For each product candidate that we intend to commercialize, we
must successfully meet a number of critical developmental milestones, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  selecting and developing a drug delivery platform technology to deliver the
proper dose of drug over the desired period of time; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  determining the appropriate drug dosage that will be tolerated, safe and
effective; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  demonstrating the drug formulation will be stable for commercially reasonable
time periods; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  demonstrating that the drug is safe and effective in patients for the intended
indication; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  completing the manufacturing development and scale-up to permit manufacture of
our product candidates in commercial quantities and at acceptable prices. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
time necessary to achieve these developmental milestones for any individual product candidate is long and uncertain, and we may not successfully complete these milestones for any of our product
candidates in development. We may not be able to finalize the design or formulation of any product candidate. In addition, we may select components, solvents, excipients or other ingredients to
include in our product candidates that have not been previously approved for use in pharmaceutical products, which may require us to perform additional studies and may delay clinical testing and
regulatory approval of our product candidates. Even after we complete the design of a product candidate, the product candidate must still be shown to be bioequivalent to an approved drug or safe and
effective in required clinical trials before approval for commercialization. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are continuing to test and develop our product candidates and may explore possible design or formulation changes to address bioavailability, safety, efficacy, manufacturing efficiency and
performance issues. We may not be able to complete development of any product candidates that will be safe and effective and that will have a commercially reasonable treatment and storage period. If
we are unable to complete development of our product candidates, we will not be able to earn revenue from them. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We anticipate that our product candidates, including Xtampza, will be subject to mandatory REMS
programs, which could increase the cost, burden and liability associated with the commercialization of such product candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The FDA has indicated that extended-release and long-acting opioid drugs formulated with the active ingredients fentanyl, hydromorphone, methadone,
morphine, oxycodone, oxymorphone, and others will be required to have a REMS to ensure that the benefits of the drugs continue to outweigh the risks. The FDA has approved a REMS for extended release,
or ER, and long-acting, or LA, opioids as part of a federal initiative to address prescription drug abuse and misuse, or the ER/LA opioid REMS. The ER/LA opioid REMS introduces new safety measures
designed to reduce risks and improve the safe use of extended-release/long-acting opioids, while continuing to provide access to these medications for patients in pain. The ER/LA opioid REMS applies
to more than 20 companies that manufacture opioid analgesics. Under the ER/LA opioid REMS, companies are required to make education programs available to prescribers based on the FDA Blueprint for
Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics. It is expected that companies will meet this obligation by providing educational grants to continuing education providers,
who will develop and deliver the training. The ER/LA opioid REMS also requires companies to distribute FDA-approved educational materials to prescribers and patients on the safe use of these drugs. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=26,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=428241,FOLIO='22',FILE='DISK131:[15ZCN1.15ZCN74701]DA74701A.;28',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_da74701_1_23"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
companies must perform periodic assessments of the implementation of the ER/LA opioid REMS and the success of the program in meeting its goals. The FDA will review these assessments and may
require additional elements to achieve the goals of the program. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
the FDA determines that a REMS is necessary during review of an application, the drug sponsor must agree to the REMS plan at the time of approval. As part of its tentative approval of the Xtampza
NDA, the FDA has indicated that, if Xtampza receives final regulatory approval, the REMS requirement for ER/LA opioids will apply to Xtampza. The REMS includes a Medication Guide that would be
dispensed with each prescription, physician training based on FDA-identified learning objectives, audits to ensure that the FDA's learning objectives are addressed in the physician trainings, letters
to prescribing physicians, professional organizations and state licensing entities alerting each to the REMS, and the establishment of a call center to provide more information about the REMS. We
anticipate that our future product candidates will also be subject to these REMS requirements. There may be increased cost, administrative burden and potential liability associated with the marketing
and sale of these types of product candidates subject to the ER/LA opioid REMS requirements, which could reduce the commercial benefits to us from the sale of these product candidates. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to obtain the necessary final regulatory approvals, or if such approvals are limited, we
will not be able to commercialize our product candidates, and we will not generate product revenues.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even if we comply with all FDA pre-approval regulatory requirements, the FDA may determine that our product candidates are not safe or effective, and
we may never obtain final regulatory approval for such product candidates. If we fail to obtain final regulatory approval for some or all of our product candidates, we will have fewer commercial
products, if any, and correspondingly lower product revenues, if any. Even if our product candidates receive final regulatory approval, such final regulatory approval may involve limitations on the
indications and conditions of use or marketing claims for our products, or may not include certain of the abuse-deterrence claims or clinical trial data that we have sought, and will seek, to include
in the product label for our DETERx-based product candidates. If we do not receive regulatory approval to include certain abuse-deterrence claims, or certain clinical data, in our product labels, our
ability to successfully commercialize our products may be limited and our financial results may be adversely impacted. Further, later discovery of previously unknown problems or adverse events could
result in additional regulatory restrictions, including withdrawal of products and addition of warnings or other statements on the product label. The FDA is likely to require us to perform lengthy
Phase&nbsp;4 post-approval clinical efficacy or safety trials. As part of the FDA's tentative approval for Xtampza, the FDA identified a number of studies that we will have to conduct if Xtampza
receives final regulatory approval, including required pediatric assessments and the post-marketing studies that have been required for other ER/LA opioid analgesics to estimate the serious risks of
misuse, abuse, addiction, overdose, and death associated with long-term use of these medications for the management of chronic pain. The FDA will also require studies specific to Xtampza, including:
(i)&nbsp;an epidemiologic study to evaluate whether the abuse-deterrent properties of Xtampza actually result in a significant and meaningful decrease in misuse and abuse, and their consequences
with respect to addiction, overdose, and death; (ii)&nbsp;several long-term animal studies to evaluate the mixture of beeswax, carnauba wax, and myristic acid that is representative of Xtampza's
composition; (iii)&nbsp;a study to characterize the levels of lead in Xtampza to inform a proposed release specification to adequately control levels of lead; and (iv)&nbsp;an evaluation of the
beeswax employed in Xtampza's composition for potential residual levels of contaminants. If Xtampza receives final regulatory approval, the FDA will also require us to participate, with other
manufacturers of ER/LA opioid analgesics, in a clinical trial of at least a year in length that would assess the known serious risk of hyperalgesia, or increased sensitivity to pain, with ER/LA opioid
analgesics and the development of tolerance following use of these medications. The FDA may also impose additional post-marketing requirements, which will be very expensive to satisfy. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
jurisdictions outside the United States, we must receive marketing authorizations from the appropriate regulatory authorities before commercializing our product candidates. Regulatory approval
processes outside the United States generally include requirements and risks similar to, and in many cases in excess of, those associated with FDA approval. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=27,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=38458,FOLIO='23',FILE='DISK131:[15ZCN1.15ZCN74701]DA74701A.;28',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dc74701_1_24"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The FDA may not approve product labeling for our product candidates that would permit us to market
and promote our products in the United States by describing their abuse-deterrent features.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have invested substantial time and money conducting Category&nbsp;1, Category&nbsp;2 and Category&nbsp;3 abuse-deterrent studies to ensure
Xtampza's compliance with the FDA's January 2013 draft guidance regarding opioid abuse deterrence, and we believe such studies are consistent with the April 2015 final FDA guidance. The FDA has
tentatively approved a product label for Xtampza with the following features:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> no black box warning or other precautions stating that crushing, chewing or
dissolving can cause rapid release and absorption of a potentially fatal dose of the active ingredient; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> dosage instruction supporting administration of the product as a sprinkle or
administration through gastric or nasogastric feeding tubes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  inclusion of oral and nasal PK data from clinical trials; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  inclusion of oral and nasal human abuse potential clinical trials. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>However,
we have not yet received final regulatory approval to market Xtampza and additional data may emerge that could change the FDA's position on the tentatively approved product label. Our failure
to achieve FDA approval of product labeling containing such information will prevent or substantiality limit our promotion of the abuse-deterrent features of our product candidates in order to
differentiate them from other opioid products containing the same active ingredients. This would make our products less competitive in the market. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Although
we believe that we have conducted all of the preclinical studies and clinical trials that are required to support certain abuse-deterrent claims for Xtampza in our tentatively approved
product label, there can be no assurance that Xtampza, or any of our other product candidates, will receive final FDA-approved product labeling that describes the abuse-deterrent features of such
products. Furthermore, the FDA's April 2015 final guidance on abuse deterrent opioids makes clear that the FDA expects sponsors to compare their formulations against approved abuse-deterrent versions
of the same opioid based on the relevant categories of testing. If a proposed product is less resistant to manipulation than an approved product, the FDA has stated that the proposed product may not
be eligible for product labeling regarding abuse-deterrent properties. If the FDA does not approve product labeling containing abuse-deterrence claims, we will not be able to promote such products
based on their abuse-deterrent features, may not be able to differentiate such products from other opioid products containing the same active ingredients, and may need to lower the price of our
products to the extent that there are competing products with abuse-deterrent claims on their product labels. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because
the FDA closely regulates promotional materials and other promotional activities, even if the FDA initially approves product labeling that includes a description of the abuse-deterrent
characteristics of our product, the FDA may object to our marketing claims and product advertising campaigns. This could lead to the issuance of warning letters or untitled letters, suspension or
withdrawal of our products from the market, recalls, fines, disgorgement of money, operating restrictions, injunctions, and civil or criminal prosecution. Any of these consequences would harm the
commercial success of our products. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even
if Xtampza and any of our other product candidates are approved for marketing with certain abuse-deterrence claims, the April 2015 final FDA guidance on abuse-deterrent opioids is not binding law
and may be superseded or modified at any time. Also, if the FDA determines that our post-marketing data do not demonstrate that the abuse-deterrent properties result in reduction of abuse, or
demonstrate a shift to routes of abuse that present a greater risk, the FDA may find that product labeling revisions are needed, and potentially require the removal of our abuse-deterrence claims. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=28,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=572621,FOLIO='24',FILE='DISK131:[15ZCN1.15ZCN74701]DC74701A.;17',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_dc74701_1_25"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if our product candidates receive regulatory approval, they will be subject to ongoing
regulatory requirements, and we may face regulatory enforcement action if we do not comply with the requirements.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even after a product is approved, we will remain subject to ongoing FDA and other regulatory requirements governing the product labeling, packaging,
storage, distribution, safety surveillance, advertising, promotion, import, export, record-keeping and reporting of safety and other post-market information. The holder of an approved NDA is obligated
to monitor and report adverse events, or AEs, and any failure of a product to meet the specifications in the NDA. In addition, manufacturers of drug products and their facilities are subject to
payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, and other regulations.
If we or a regulatory agency discover problems with a product which were previously unknown, such as adverse events of unanticipated severity or frequency, or problems with the facility where the
product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring product recall, notice to physicians, withdrawal of the
product from the market or suspension of manufacturing, among other things. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with applicable
regulatory requirements, a regulatory agency may:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> issue warning letters or untitled letters; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> mandate modifications to promotional materials or require us to provide
corrective information to healthcare practitioners; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> require us to enter into a consent decree, which can include the imposition of
various fines, reimbursements for inspection costs and penalties for noncompliance, and require due dates for specific actions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seek an injunction or impose civil, criminal and/or administrative penalties,
damages, monetary fines, require disgorgement, consider exclusion from participation in Medicare, Medicaid and other federal healthcare programs and require curtailment or restructuring of our
operations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> suspend or withdraw regulatory approval; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> suspend any ongoing clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> refuse to approve pending applications or supplements to applications filed by
us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> suspend or impose restrictions on operations, including costly new manufacturing
requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seize or detain products, refuse to permit the import or export of products, or
require us to initiate a product recall; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> refuse to allow us to enter into government contracts. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Similar
post-market requirements may apply in foreign jurisdictions in which we may seek approval of our products. Any government investigation of alleged violations of law could require us to expend
significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our products and
generate revenue and may cause a material adverse impact on our financial condition and cash flows. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, the FDA's regulations, policies or guidance may change and new or additional statutes or government regulations in the United States and other jurisdictions may be enacted that could
further restrict or regulate post-approval activities. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from pending or future legislation or
administrative action, either in the United States or abroad. If we are not able to achieve and maintain regulatory compliance, we may not be permitted to market our products and/or product
candidates, which would adversely affect our ability to generate revenue and achieve or maintain profitability. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=29,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=154122,FOLIO='25',FILE='DISK131:[15ZCN1.15ZCN74701]DC74701A.;17',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_dc74701_1_26"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Failure to comply with ongoing governmental regulations for marketing our product candidates could
delay or inhibit our ability to generate revenues from their sale and could also expose us to claims or other sanctions.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Advertising and promotion of any product candidate that obtains approval in the United States will be heavily scrutinized by, among others, the FDA,
the Department of Justice, or the DOJ, the Office of Inspector General of the Department of Health and Human Services, or HHS, state attorneys general, members of Congress and the public. Violations,
including promotion of our product candidates, if approved, for unapproved or off-label uses, are subject to enforcement letters, inquiries and investigations, and civil and
criminal sanctions by the FDA or other government agencies. Additionally, advertising and promotion of any product candidate that obtains approval outside the United States will be heavily scrutinized
by foreign regulatory authorities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the United States, engaging in off-label promotion of Xtampza (or any of our other product candidates), if we receive final regulatory approval, can also subject us to false claims litigation under
federal and state statutes, and other litigation and/or investigation, which can lead to civil and criminal penalties and fines and agreements that materially restrict the manner in which we promote
or distribute our drug products. These false claims statutes include the federal False Claims Act, which allows any individual to bring a lawsuit against a pharmaceutical company on behalf of the
federal government alleging submission of false or fraudulent claims, or causing to present such false or fraudulent claims, for payment by a federal program such as Medicare or Medicaid. If the
government prevails in the lawsuit, the individual will share in any fines or settlement funds. Since 2004, these False Claims Act lawsuits against pharmaceutical companies have increased
significantly in volume and breadth, leading to several substantial civil and criminal settlements based on certain sales practices promoting off-label drug uses. This increasing focus and scrutiny
has increased the risk that a pharmaceutical company will have to defend a false claim action, pay settlement fines or restitution, agree to comply with burdensome reporting and compliance
obligations, and be excluded from the Medicare, Medicaid and other federal and state healthcare programs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged
off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which
specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which
could materially adversely affect our business and financial condition. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, later discovery of previously unknown problems with a product, manufacturer or facility, or our failure to update regulatory files, may result in restrictions, including withdrawal of the
product from the market. Any of the following or other similar events, if they were to occur, could delay or preclude us from further developing, marketing or realizing the full commercial potential
of our product candidates:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to obtain or maintain requisite governmental approvals; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to obtain approvals of product labeling with abuse-deterrent claims; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> FDA required product withdrawals or warnings arising from identification of
serious and unanticipated adverse side effects in our product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our product candidates contain controlled substances, the manufacture, use, sale, importation,
exportation and distribution of which are subject to regulation by state, federal and foreign law enforcement and other regulatory agencies.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our product candidates, including Xtampza, contain, and our future product candidates will likely contain, controlled substances which are subject to
state, federal and foreign laws and regulations regarding their manufacture, use, sale, importation, exportation and distribution. Xtampza's active ingredient, oxycodone, is classified as a controlled
substance under the Controlled Substances Act of 1970, or CSA, and regulations </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=30,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=94972,FOLIO='26',FILE='DISK131:[15ZCN1.15ZCN74701]DC74701A.;17',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_dc74701_1_27"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>of
the U.S. Drug Enforcement Administration, or DEA. A number of states also independently regulate these drugs, including oxycodone, as controlled substances. Controlled substances are classified by
the DEA as Schedule&nbsp;I, II, III, IV or V substances, with Schedule&nbsp;I substances considered to present the highest risk of substance abuse and Schedule&nbsp;V substances the lowest risk.
The active ingredient in our lead product candidate Xtampza, oxycodone, is listed by the DEA as a Schedule&nbsp;II controlled substance under the CSA. For our product candidates containing
controlled substances, we and our suppliers, manufacturers, contractors, customers and distributors are required to obtain and maintain applicable registrations from state, federal and foreign law
enforcement and regulatory agencies and comply with state, federal and foreign laws and regulations regarding the manufacture, use, sale, importation, exportation and distribution of controlled
substances. For example, all Schedule&nbsp;II drug prescriptions must be signed by a physician, physically presented to a pharmacist and may not be refilled without a new prescription. Furthermore,
the amount of Schedule&nbsp;II substances that can be obtained for clinical trials and commercial distribution is limited by the CSA and DEA regulations. We may not be able to obtain sufficient
quantities of these controlled substances in order to complete our clinical trials or meet commercial demand, if our product candidates are approved for marketing. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
addition, controlled substances are also subject to regulations governing manufacturing, labeling, packaging, testing, dispensing, production and procurement quotas, recordkeeping, reporting,
handling, shipment and disposal. These regulations increase the personnel needs and the expense associated with development and commercialization of product candidates that include controlled
substances. The DEA and some states conduct periodic inspections of registered establishments that handle controlled substances. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Failure
to obtain and maintain required registrations or to comply with any applicable regulations could delay or preclude us from developing and commercializing our product candidates that contain
controlled substances and subject us to enforcement action. The DEA may seek civil penalties, refuse to renew necessary registrations or initiate proceedings to revoke those registrations. In some
circumstances, violations could lead to criminal proceedings. Because of their restrictive nature, these regulations could limit commercialization of our product candidates containing controlled
substances. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Clinical development is a lengthy and expensive process with an uncertain outcome, and failure can
occur at any stage of clinical development. If we are unable to design, conduct and complete clinical trials successfully, our product candidates will not be able to receive regulatory approval.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In order to obtain FDA approval for any of our product candidates, we must submit to the FDA an NDA with substantial evidence that demonstrates that
the product candidate is both safe and effective in humans for its intended use. This demonstration requires significant research, preclinical studies and clinical trials. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other
than Xtampza, all of our product candidates are in preclinical development. Clinical trials are time-consuming, expensive and difficult to design and implement, in part because they are subject
to rigorous requirements and their outcomes are inherently uncertain. Clinical testing may take many years to complete, and failure can occur at any time during the clinical trial process, even with
active ingredients that have previously been approved by the FDA as being safe and effective. We could encounter problems that halt our clinical trials or require us to repeat such clinical trials. If
patients participating in clinical trials suffer drug-related adverse reactions during the course of such clinical trials, or if we or the FDA believe that patients are being exposed to unacceptable
health risks, such clinical trials may have to be suspended or terminated. Suspensions, termination or the need to repeat a clinical trial can occur at any stage. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
clinical trial success of each of our product candidates depends on reaching statistically significant changes in patients' symptoms based on clinician-rated scales. There is a lack of consensus
regarding standardized processes for assessing clinical outcomes based on clinician-rated scales. Accordingly, the scores from our clinical trials may not be reliable, useful or acceptable to the FDA
or other regulatory agencies. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=31,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=241141,FOLIO='27',FILE='DISK131:[15ZCN1.15ZCN74701]DC74701A.;17',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_dc74701_1_28"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Changes
in standards related to clinical trial design could have a material adverse effect on our ability to design and conduct clinical trials as planned. For example, we have conducted or will
conduct clinical trials comparing our product candidates to both placebo and other approved drugs, but regulatory authorities may not allow us to compare our product candidates to a placebo in a
particular clinical indication where approved products are
available. In that case, both the cost and the amount of time required to conduct a clinical trial could increase. The FDA may disagree with our trial design and our interpretation of data from
clinical trials, or may change the requirements for approval even after it has reviewed and commented on the design for our clinical trials. The FDA may also approve a product candidate for fewer or
more limited indications than we request, or may grant approval contingent on the performance of costly post-approval clinical trials. In addition, the FDA may not approve the product labeling claims
or removal of certain warnings that we believe are necessary or desirable for the successful commercialization of our product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Approval
may be contingent on a REMS, which could have a material adverse effect on the product labeling, distribution or promotion of a drug product. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Any
of these delays or additional requirements could cause our product candidates to not be approved, or if approved, significantly impact the timing and commercialization of our product candidates
and significantly increase our overall costs of drug development. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Because the results of preclinical studies and early-stage clinical trials are not necessarily
predictive of future results, any product candidate we advance into additional clinical trials may not continue to have favorable results or receive regulatory approval.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other than Xtampza, all of our product candidates are in preclinical development. Success in preclinical studies and early clinical trials does not
ensure that later clinical trials will generate adequate data to demonstrate the efficacy and safety of an investigational drug. Many companies in the pharmaceutical and biotechnology industries,
including those with greater resources and experience, have suffered significant setbacks in clinical trials, even after reporting promising results in earlier clinical trials. Despite the results
reported in preliminary preclinical studies for our other extended-release, abuse-deterrent product candidates, including hydrocodone and oxymorphone for pain, and methylphenidate for the treatment of
ADHD, we do not know whether the clinical trials we may conduct will demonstrate adequate efficacy and safety or otherwise provide adequate information to result in regulatory approval to market any
of our product candidates in any particular jurisdiction. If later-stage clinical trials do not produce favorable results, our ability to achieve regulatory approval for any of our product candidates,
other than Xtampza, may be compromised. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Conducting clinical trials of our product candidates and any future commercial sales of a product
candidate may expose us to expensive product liability claims, and we may not be able to maintain product liability insurance on reasonable terms or at all.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We currently carry product liability insurance with coverage up to approximately $5&nbsp;million, which covers liability relating to our clinical
trials. Even if we successfully commercialize one or more of our product candidates, we may face product liability claims, regardless of FDA approval for commercial
manufacturing and sale. Product liability claims may be brought against us by patients enrolled in our clinical trials, patients, healthcare providers or others using, administering or selling our
products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we could incur substantial liabilities. We may not be able to maintain
insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Regardless of merit or eventual outcome, liability claims may result
in:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  decreased demand for any product candidates or products that we may develop; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  termination of clinical trial sites or entire trial programs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> injury to our reputation and significant negative media attention; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=32,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=969648,FOLIO='28',FILE='DISK131:[15ZCN1.15ZCN74701]DC74701A.;17',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_dc74701_1_29"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  withdrawal of clinical trial participants; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  significant costs to defend the related litigation; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  substantial monetary awards to patients; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> loss of revenue; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  diversion of management and scientific resources from our business operations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the inability to commercialize any products that we may develop; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an increase in product liability insurance premiums or an inability to maintain
product liability insurance coverage. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our
inability to maintain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our
product candidates. Any agreements we may enter into in the future with collaborators in connection with the development or commercialization of our product candidates may entitle us to
indemnification against product liability losses, but such indemnification may not be available or adequate should any claim arise. In addition, several of our agreements require us to indemnify third
parties and these indemnifications obligations may exceed the coverage under our product liability insurance policy. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Xtampza and our other product candidates may be associated with undesirable adverse reactions or
have other properties that could delay or prevent their regulatory approval, limit the commercial profile of their approved product label, or result in significant negative consequences following any
marketing approval.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Undesirable adverse reactions associated with our product candidates could cause us, our IRBs, clinical trial sites or regulatory authorities to
interrupt, delay or halt clinical trials and could result in a restrictive product label or the delay, denial or withdrawal of regulatory approval by the FDA or foreign regulatory authorities. For
example, even though Xtampza has generally been well tolerated by patients in our clinical trials, in some cases there were adverse reactions, one of which was a serious adverse event, moderate in
severity, of gastroesophageal reflux. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
Xtampza or any of our other product candidates receives final regulatory approval, and we or others later identify undesirable adverse events associated with such product, a number of potentially
significant negative consequences could result, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may be forced to suspend marketing of the product; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  regulatory authorities may withdraw their approvals of the product or impose
restrictions on its distribution; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  regulatory authorities may require additional warnings or contradictions in the
product label that could diminish the usage or otherwise limit the commercial success of the product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may be required to conduct additional post-marketing studies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we could be sued and held liable for harm caused to patients; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our reputation may suffer. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Any
of these events could prevent us from achieving or maintaining market acceptance of Xtampza or any of our other product candidates, if approved. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to Intellectual Property  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Unfavorable outcomes in intellectual property litigation could result in costly litigation and
potentially limit our ability to commercialize our products.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our commercial success depends upon our ability to develop product candidates and commercialize future products without infringing the intellectual
property rights of others. Our current or future product candidates or products, or any uses of them, may now or in the future infringe third-party patents or other intellectual property rights. This
is due in part to the considerable uncertainty within the pharmaceutical industry about the validity, scope and enforceability of many issued patents in the United States and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=33,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=818658,FOLIO='29',FILE='DISK131:[15ZCN1.15ZCN74701]DC74701A.;17',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_dc74701_1_30"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>elsewhere
in the world and, to date, there is no consistency regarding the breadth of claims allowed in pharmaceutical patents. We cannot currently determine the ultimate scope and validity of patents
which may be granted to third parties in the future or which patents might be asserted to be infringed by the manufacture, use
and sale of our products. In part as a result of this uncertainty, there has been, and we expect that there will continue to be, significant litigation in the pharmaceutical industry regarding patents
and other intellectual property rights. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Third
parties may assert infringement claims against us, or other parties we have agreed to indemnify, based on existing patents or patents that may be granted in the future. We are aware of
third-party patents and patent applications related to oxycodone, oxymorphone, hydrocodone, morphine, and methylphenidate drugs and formulations, including those listed in the FDA's Orange Book for
oxycodone products. Because of the delay between filing and publication of patent applications, and because applications can take several years to issue, there may be currently pending third-party
patent applications that are unknown to us, which may later result in issued patents. Because of the uncertainty inherent in intellectual property litigation, we could lose, even if the case against
us was weak or flawed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we are found to infringe a third party's intellectual property rights, we could be required to obtain a license from such third party to continue developing or commercializing our product
candidates, products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we are able to obtain a license, it may be
non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or
product. In addition, in any such proceeding or litigation, we could be found liable for monetary damages, including treble damages and attorneys' fees, if we are found to have willfully infringed a
patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
connection with any NDA that we file under Section&nbsp;505(b)(2), including the NDA for Xtampza, we are required to notify the patent holder of the Section&nbsp;505(b)(2) listed drug that we
identify in our NDA, that we have certified to the FDA that any patents listed for the listed drug in the FDA's Orange Book publication are invalid, unenforceable or will not be infringed by the
manufacture, use or sale of our drug. If the patent holder files&nbsp;a patent infringement lawsuit against us within 45&nbsp;days of its receipt of notice of our certification, the FDA is
automatically prevented from approving our Section&nbsp;505(b)(2) NDA until the earliest of 30&nbsp;months after the lawsuit is filed, expiration of the patents, settlement of the lawsuit and a
court decision in the infringement case that is favorable to us. Accordingly, we may invest significant time and expense in the development of our product candidates only to be subject to significant
delay and patent litigation before our product candidates may be commercialized. On March&nbsp;24, 2015, Purdue, as the sponsor for OxyContin OP, the listed drug for Xtampza, brought infringement
claims against us alleging infringement of U.S. Patent Nos.&nbsp;7,674,799, 7,674,800, 7,683,072 and 8,652,497. That case is venued in the District of Massachusetts. On November&nbsp;6, 2015,
Purdue filed another suit in the District of Massachusetts alleging infringement of U.S. Patent No.&nbsp;9,073,933, which is a continuation patent of three of the patents asserted in the first case. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


On November&nbsp;9, 2015, we filed a motion requesting partial judgment and a motion requesting expedited hearing of our motion for partial judgment and for final judgment in the Massachusetts
court. Purdue filed its opposition response and a cross-motion for a partial stay on November&nbsp;23, 2015 in the first case. Those motions are fully briefed and the hearing on those motions was
held on December&nbsp;22, 2015. On December&nbsp;23, 2015, the District Court of Massachusetts issued an order staying proceedings in relation to the three Orange Book-listed patents asserted
against us until February&nbsp;25, 2016, which is the date scheduled by the Court for a status conference. The Court reserved the decision to grant our motion for judgment on the three Orange
Book-listed patents to be taken up again at the February&nbsp;25th status conference, at which time the Court indicated it may grant our motion
for judgment or may consider extending the stay. The Court further indicated that it will consider an earlier hearing if the Court of Appeals for the Federal Circuit issues a decision on the appeal of
the New York judgment of invalidity prior to the

 </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=34,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1000988,FOLIO='30',FILE='DISK131:[15ZCN1.15ZCN74701]DC74701A.;17',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_dc74701_1_31"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


February&nbsp;25th status conference. On December&nbsp;1, 2015, we filed a motion to dismiss the second case for failure to state a claim and Purdue filed its opposition on December&nbsp;15,
2015. That action has been consolidated into the other Massachusetts actions, and our motion remains pending. We plan to continue to take all steps necessary to vigorously defend ourselves against
these claims. The strength of our defenses will depend on the patents asserted and the interpretation of these patents. However, we could be unsuccessful in advancing non-infringement and invalidity
arguments in our defense. Purdue need only prove infringement by a preponderance of the evidence, which is a low burden of proof.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we are found by the court to have infringed a valid patent claim, we could be prevented from using the patented technology or be required to pay Purdue for the right to license the patented
technology. If we decide to pursue a license to use one or more of these patents, we may not be able to obtain a license on commercially reasonable terms, if at all, or the license we obtain may
require us to pay substantial royalties or grant cross licenses to our patent rights. For example, if the relevant patent is owned by a competitor, such as Purdue, that competitor may choose not to
license patent rights to us. If we decide to develop alternative technology, we may not be able to do so in a timely or cost-effective manner, if at all. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Even
if we are found not to infringe or Purdue's, or any other potential plaintiff's, patent claims are found invalid or unenforceable, defending any such infringement claim would be expensive and
time-consuming, and could delay the launch of Xtampza and distract management from their normal responsibilities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Competitors
may sue us as a way of delaying the introduction of our products. Any litigation, including any interference or derivation proceedings to determine priority of inventions, oppositions or
other post-grant review proceedings to patents in the United States or in countries outside the United States, or litigation against our collaborators may be costly and time consuming and could have a
material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. We expect that litigation may be necessary in some
instances to determine the validity and scope of our proprietary rights. Litigation may be necessary in other instances to determine the validity, scope or non-infringement of certain patent rights
claimed by third parties to be pertinent to the manufacture, use or sale of our products. Ultimately, the outcome of such litigation could compromise the validity and scope of our patents or other
proprietary rights or hinder our ability to manufacture and market our products. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to obtain or maintain intellectual property rights for our technology and product
candidates, we may lose valuable assets or experience reduced market share.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We depend on our ability to protect our proprietary technology. We rely on patent and trademark laws, unpatented trade secrets and know-how, and
confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection. Our success depends in large part on our ability to obtain and maintain
patent protection in the United States and other countries with respect to our proprietary technology and product candidates. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
steps we have taken to protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights, both
inside and outside the United States. The rights already granted under any of our currently issued patents and those that may be granted under future issued patents may not provide us with the
proprietary protection or competitive advantages we are seeking. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The patent prosecution process is expensive and time-consuming, and we may not be able to file and
prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of inventions made in the
course of our development and commercialization activities before it is too late to obtain patent protection on them.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Given the amount of time required for the development, testing and regulatory review of product candidates, patents protecting such product candidates
might expire before or shortly after such product candidates are commercialized. If we are unable to obtain and maintain patent protection for our technology and products, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=35,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=111809,FOLIO='31',FILE='DISK131:[15ZCN1.15ZCN74701]DC74701A.;17',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_dc74701_1_32"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>or
if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize technology and products identical, similar or superior to ours, and our ability to
successfully commercialize our technology and products may be adversely affected. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>With
respect to patent rights, our patent applications may not issue into patents, and any issued patents may not provide protection against competitive technologies, may be held invalid or
unenforceable if challenged or may be interpreted in a manner that does not adequately protect our technology, product candidates or future product candidates. Even if our owned patent applications
issue into patents, they may not issue in a form that will
provide us with any meaningful protection, prevent competitors from competing with us, or otherwise provide us with any competitive advantage. The examination process may require us to narrow the
claims in our patents, which may limit the scope of patent protection that may be obtained. Our competitors may design around or otherwise circumvent patents issued to us or licensed by us. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The scope of patent protection in the United States and in foreign jurisdictions is highly
uncertain, and changes in U.S. and foreign patent law have increased that uncertainty and could diminish the value of patents in general, thereby impairing our ability to protect our product
candidates and any future products.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has
in recent years been the subject of much litigation. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our
patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States, and these foreign laws may also be
subject to change. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Publications
of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions typically are not published until
18&nbsp;months after filing or, in some cases, not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our owned or licensed patents or pending patent
applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights, both in
the United States and abroad, are highly uncertain. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Recent
patent reform legislation could increase the uncertainties and costs associated with the prosecution of our patent applications and the enforcement or defense of our issued patents. The
Leahy-Smith America Invents Act, or the Leahy-Smith Act, which was signed into law on September&nbsp;16, 2011, made significant changes to U.S. patent law, including provisions that affect the way
patent applications are prosecuted and litigated. Many of the substantive changes to patent law associated with the Leahy-Smith Act and, in particular, the "first to file" provisions described below,
only became effective on March&nbsp;16, 2013. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the
enforcement or defense of our issued patents. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant
to the Leahy-Smith Act, the United States transitioned to a "first to file" system in which the first inventor to file&nbsp;a patent application will be entitled to the patent. In addition,
third parties are allowed to submit prior art before the issuance of a patent by the U.S. Patent and Trademark Office, or USPTO, and may become involved in opposition, derivation, reexamination, or
inter partes review challenging our patent rights or the patent rights of others. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including
novelty, nonobviousness and enablement. It is possible that prior art of which both we and the patent examiner were unaware during prosecution exists, which could render our patents invalid. Moreover,
there may exist prior art of which we were or are aware, and which we did not or do not consider relevant to our patents, but which could nevertheless be determined to render our patents invalid. An
adverse
determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, which could have a material adverse effect on our competitive position with
respect to third parties. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=36,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=788723,FOLIO='32',FILE='DISK131:[15ZCN1.15ZCN74701]DC74701A.;17',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<A NAME="page_dc74701_1_33"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because
the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, issued patents that we own or license from third parties may be challenged in the courts
or patent offices in the United States and abroad. Such challenges may result in the loss of patent protection, the narrowing of claims in such patents, or the invalidity or unenforceability of such
patents, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection for our technology and
products. Protecting against the unauthorized use of our patented technology, trademarks and other intellectual property rights is expensive, difficult and, may in some cases not be possible. In some
cases, it may be difficult or impossible to detect third party infringement or misappropriation of our intellectual property rights, even in relation to issued patent claims, and proving any such
infringement may be even more difficult. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be forced to litigate to enforce or defend our intellectual property, which could be
expensive, time consuming and unsuccessful, and result in the loss of valuable assets.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may be forced to litigate to enforce or defend our intellectual property rights against infringement and unauthorized use by competitors, and to
protect our trade secrets. To counter infringement or unauthorized use, litigation may be necessary in the future to enforce or defend our intellectual property rights, to protect our trade secrets or
to determine the validity and scope of our own intellectual property rights. In so doing, we may place our intellectual property at risk of being invalidated, rendered unenforceable or limited or
narrowed in scope. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Further,
this can be expensive and time consuming. Many of our current and potential competitors have the ability to dedicate substantially greater resources to defend their intellectual property
rights than we can. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Accordingly,
despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. Litigation could result in substantial costs and
diversion of management resources, which could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial
condition. In addition, an adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by
disclosure during litigation. There could also be public announcements of the results of hearings, motions or other
interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to claims by third parties of ownership of what we regard as our own intellectual
property or obligations to make compensatory payments to employees.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>While it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements
assigning such intellectual property to us, we may be unsuccessful in executing or obtaining such an agreement with each party who, in fact, develops intellectual property that we regard as our own.
In addition, they may breach the assignment agreements or such agreements may not be self-executing, and we may be forced to bring claims against third parties, or defend claims they may bring against
us, to determine the ownership of what we regard as our intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable
intellectual property rights or personnel. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our
technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result in
substantial costs and be a distraction to management. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=37,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=371699,FOLIO='33',FILE='DISK131:[15ZCN1.15ZCN74701]DC74701A.;17',USER='MKEANE',CD='31-DEC-2015;17:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_de74701_1_34"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to protect the confidentiality of our trade secrets, our business and competitive
position would be harmed.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In addition to seeking patents for some of our technology and products, we rely on trade secrets, including unpatented know-how, technology and other
proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have
access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. Despite these efforts, any of
these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim
that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts both within and outside the
United States may be less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently
developed by a competitor, we would have no right to prevent such competitor, or those to whom they communicate them, from using that technology or information to compete with us. If any of our trade
secrets were to be disclosed or independently developed, our competitive position would be harmed. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to protect our intellectual property rights throughout the world.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Filing, prosecuting and defending patents on all of our product candidates throughout the world would be prohibitively expensive. Competitors may use
our technologies in jurisdictions where we have not obtained patent protection to develop and sell their own products and, further, may export otherwise infringing products to territories where we
have patent protection but enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents or our
patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain
developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop
the infringement of our patents or the marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result
in substantial cost and divert our efforts and attention from other aspects of our business. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to claims that our employees have wrongfully used or disclosed alleged trade
secrets of their former employers.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Many of our employees, including our senior management, were previously employed at other biotechnology or pharmaceutical companies, including
potential competitors. These employees typically executed proprietary rights, non-disclosure and non-competition agreements in connection with their previous employment. Although we try to ensure that
our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property,
including trade secrets or other proprietary information, of any such employee's former employer. We are not aware of any threatened or pending claims related to these matters, but in the future
litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or
personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=38,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=864075,FOLIO='34',FILE='DISK131:[15ZCN1.15ZCN74701]DE74701A.;12',USER='CGONCE',CD='31-DEC-2015;12:17' -->
<A NAME="page_de74701_1_35"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Obtaining and maintaining our patent protection depends on compliance with various procedural,
document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar
provisions during the patent application process. In addition, periodic maintenance fees on issued patents are required to be paid to the USPTO and foreign patent agencies in several stages over the
lifetime of the patents. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which
noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that
could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and
failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our product candidates, our competitive position would be adversely
affected. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to the Commercialization of Our Product Candidates  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We currently have limited sales and marketing capabilities and, if we are unable to expand our own
sales and marketing capabilities or enter into strategic alliances with marketing collaborators, we may not be successful in commercializing our product candidates and may be unable to generate any
product revenue.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Although our executive officers have experience marketing pharmaceutical products, we currently have limited sales, marketing or distribution
capabilities. We do not intend to begin to hire field sales representatives until several months prior to receiving final FDA approval of one of our product candidates. Therefore, at the time of our
anticipated commercial launch of Xtampza, assuming resolution of the Purdue litigation and final regulatory approval of the product candidate by the FDA, our sales and marketing team will have worked
together for only a limited period of time. We cannot guarantee that we will be successful in
marketing Xtampza or any of our other product candidates which may be approved in the United States. We may not be able to establish a targeted sales force in a cost-effective manner. In addition, we
will have to compete with other pharmaceutical and biotechnology companies with extensive and well-funded sales and marketing operations to recruit, hire, train and retain sales and marketing
personnel. If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate product revenue and may
not become profitable. Factors that may inhibit our efforts to commercialize our product candidates in the United States include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our inability to recruit and retain adequate numbers of effective sales and
marketing personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the inability of sales personnel to obtain access to or persuade adequate
numbers of physicians to prescribe our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the lack of complementary products to be offered by sales personnel, which may
put us at a competitive disadvantage relative to companies with more extensive product lines; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  unforeseen costs and expenses associated with creating an independent sales and
marketing organization. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>If
we are not successful in recruiting sales and marketing personnel or in building a sales and marketing infrastructure or if we do not successfully enter into appropriate strategic alliances with
marketing collaborators, agreements with contract sales organizations or collaboration arrangements, we will have difficulty commercializing our product candidates. To the extent we commercialize our
product candidates by entering into agreements with third-party collaborators, we may have limited or no control over the sales, marketing and distribution activities of these third parties, in which
case our future revenues would depend heavily on the success of the efforts of these third parties. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=39,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=120233,FOLIO='35',FILE='DISK131:[15ZCN1.15ZCN74701]DE74701A.;12',USER='CGONCE',CD='31-DEC-2015;12:17' -->
<A NAME="page_de74701_1_36"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If physicians, patients, healthcare payors and the medical community do not accept and use our
product candidates, we will not achieve sufficient product revenues and our business will suffer.  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Even if the FDA approves our product candidates, physicians, patients, healthcare payors and the medical community may not accept and use them.
Acceptance and use of our product candidates will depend on a number of factors including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing of market introduction of the product candidates as well as
competitive products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  approved indications, warnings and precautions language that may be less
desirable than anticipated; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  perceptions by members of the healthcare community, including physicians, about
the safety and efficacy of our product candidates, and, in particular, the efficacy of our abuse-deterrent technology in reducing potential risks of unintended use; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  perceptions by physicians regarding the cost benefit of our product candidates
in reducing potential risks of unintended use; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  published studies demonstrating the cost-effectiveness of our product
candidates relative to competing products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the potential and perceived advantages of our product candidates over
alternative treatments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the convenience and ease of administration to patients of our product
candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  availability of coverage and adequate reimbursement for our product candidates
from government or other third-party payors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> any negative publicity related to our or our competitors' products that include
the same active ingredient as our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the prevalence and severity of adverse side effects, including limitations or
warnings contained in a product's FDA approved product labeling; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to implement a REMS prior to the distribution of any product
candidates requiring a REMS; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  effectiveness of marketing and distribution efforts by us and other licensees
and distributors. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>If
our product candidates, including our tentatively approved product, Xtampza, are approved for marketing but fail to achieve an adequate level of acceptance by physicians, healthcare payors,
patients and the medical community, we will not be able to generate significant revenue, and we may not become or remain profitable. Because we expect to rely on sales generated by our current lead
product candidate, if approved, for substantially all of our revenues for the foreseeable future, the failure of any of our product candidates to find market acceptance would harm our business
prospects. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Recently enacted and future legislation may increase the difficulty and cost for us to commercialize
our product candidates and may reduce the prices we are able to obtain for our product candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the
healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities or affect our ability to profitably sell any product
candidates for which we obtain marketing approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, among other things, imposes a significant
annual fee on companies that manufacture or import branded prescription drug products. It also contains substantial new provisions intended to, among other things, broaden access to health insurance,
reduce or constrain the growth of health care spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, and
impose additional health policy reforms, any of which could have a material adverse effect on our business. A significant number of provisions are not yet, or have only recently become, effective, but
the Affordable Care Act is </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=40,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=684245,FOLIO='36',FILE='DISK131:[15ZCN1.15ZCN74701]DE74701A.;12',USER='CGONCE',CD='31-DEC-2015;12:17' -->
<A NAME="page_de74701_1_37"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>likely
to continue the downward pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Other
legislative changes have also been proposed and adopted since the Affordable Care Act was enacted. For example, the Budget Control Act of 2011 resulted in aggregate reductions in Medicare
payments to providers of up to 2% per fiscal year, starting in 2013 and, due to the Bipartisan Budget Act of 2015, will remian in effect through 2025 unless additional action is taken by Congress. In
addition, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several types of providers and increased the statute of limitations period for the
government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could impose additional
financial pressure on our customers, which could in turn diminish demand for our products or result in pricing pressure on us. In addition, drug pricing by pharmaceutical companies has recently come
under close scrutiny. For example, the U.S. House of Representatives recently formed an Affordable Drug Pricing Task Force to advance legislation intended to control pharmaceutical drug costs and
investigate pharmaceutical drug pricing, and the U.S. Senate has requested information from certain pharmaceutical companies in connection with an investigation into pharmaceutical drug pricing
practices. If healthcare policies or reforms intended to curb healthcare costs are adopted, or if we experience negative publicity with respect to pricing of our products or the pricing of
pharmaceutical drugs generally, the prices that we charge for any approved products may be limited, our commercial opportunity may be limited and/or our revenues from sales of our products may be
negatively impacted. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
expect that the Affordable Care Act, as well as other healthcare reform measures that have been and may be adopted in the future, may result in more rigorous coverage criteria, new payment
methodologies and in additional downward pressure on the price that we receive for any approved product, and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or
other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may compromise our ability to
generate revenue, attain profitability or commercialize our products. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, state pharmacy laws may permit pharmacists to substitute generic products for branded products if the products are therapeutic equivalents, or may permit pharmacists and pharmacy benefit
managers to seek prescriber authorization to substitute generics in place of our product candidates, which could significantly diminish demand for them and significantly impact our ability to
successfully commercialize our product candidates and generate revenues. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we are able to commercialize Xtampza and any of our other product candidates, our products
may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could have a material adverse effect on our business.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The regulations that govern marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Current and
future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale
price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription
pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country,
but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods,
which could negatively impact the revenues we are able to generate from the sale of the product in that particular country. Adverse pricing limitations may hinder our ability to recoup our investment
in one or more product candidates even if our product candidates obtain marketing approval. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=41,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=487112,FOLIO='37',FILE='DISK131:[15ZCN1.15ZCN74701]DE74701A.;12',USER='CGONCE',CD='31-DEC-2015;12:17' -->
<A NAME="page_de74701_1_38"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
ability to commercialize any products successfully will also depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available
from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health
maintenance organizations, determine which medications they will cover and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government
authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring
that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that coverage and reimbursement will be
available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be and whether it will be satisfactory. Coverage and reimbursement may impact
the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we
may not be able to successfully commercialize any product candidate for which we obtain marketing approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There
may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or
foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research,
development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may only be temporary. Reimbursement rates
may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing
payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws
that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment
limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved
products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Social issues around the abuse of opioids, including law enforcement concerns over diversion of
opioid and regulatory efforts to combat abuse, could decrease the potential market for our product candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Media stories regarding prescription drug abuse and the diversion of opioids and other controlled substances are commonplace. Law enforcement and
regulatory agencies may apply policies that seek to limit the availability of opioids. Such efforts may inhibit our ability to commercialize our product candidates. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Aggressive
enforcement and unfavorable publicity regarding, for example, the use or misuse of oxycodone or other opioid drugs; the limitations of abuse-resistant formulations; the ability of drug
abusers to discover previously unknown ways to abuse Xtampza; public inquiries and investigations into prescription drug abuse; litigation; or regulatory activity regarding sales, marketing,
distribution or storage of opioid drugs could have a material adverse effect on our reputation. Such negative publicity could reduce the potential size of the market for our product candidates and
decrease the revenues we are able to generate from their sale. Similarly, to the extent opioid abuse becomes less prevalent or less urgent of a public health issue, regulators and third party payers
may not be willing to pay a premium for abuse-deterrent formulations of opioids. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Additionally,
efforts by the FDA and other regulatory bodies to combat abuse of opioids may negatively impact the market for our product candidates. For example, on September&nbsp;10, 2013, the FDA
announced its intention to effect product labeling changes to all approved extended-release/long-acting opioids. In particular, the FDA announced its intention to update the indication for
extended-release/long-acting opioids </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=42,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=557232,FOLIO='38',FILE='DISK131:[15ZCN1.15ZCN74701]DE74701A.;12',USER='CGONCE',CD='31-DEC-2015;12:17' -->
<A NAME="page_de74701_1_39"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>so
that extended-release/long-acting opioids will be indicated only for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative
treatment options are inadequate. On April&nbsp;16, 2014, the FDA updated these indications. It is possible that such changes could reduce the number of prescriptions for opioids written by
physicians and negatively impact the potential market for our product candidates. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If the FDA or other applicable regulatory authorities approve generic products with abuse-deterrent
claims that compete with any of our product candidates, it could reduce our sales of those product candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Once an NDA, including a Section&nbsp;505(b)(2) application, is approved, the product covered thereby becomes a "listed drug" which can, in turn, be
cited by potential competitors in support of approval of an abbreviated NDA, or ANDA. The FD&amp;C Act, FDA regulations and other applicable regulations and policies provide incentives to manufacturers to
create modified, non-infringing versions of a drug to facilitate the approval of an ANDA or other application for generic substitutes. These manufacturers might only be required to conduct a
relatively inexpensive study to show that their product has the same active ingredients, dosage form, strength, route of administration, and conditions of use, or product labeling, as our product
candidate and that the generic product is absorbed in the body at the same rate and to the same extent as, or is bioequivalent to, our product candidate. These generic equivalents would be
significantly less costly than ours to bring to market and companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, after the introduction of a
generic competitor, a significant percentage of the sales of any branded product are typically lost to the generic product. Accordingly, competition from generic equivalents to our product candidates
would substantially limit our ability to generate revenues and therefore to obtain a return on the investments we have made in our product candidates. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Guidelines and recommendations published by various organizations can reduce the use of our
products, if approved.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Government agencies promulgate regulations and guidelines directly applicable to us and to our product candidates. In addition, professional
societies, practice management groups, private health and science foundations and organizations involved in various diseases from time to time may also publish guidelines or recommendations to the
healthcare and patient communities. Recommendations of government agencies or these other groups or organizations may relate to such matters as usage, dosage, route of administration and use of
concomitant therapies. Recommendations or guidelines suggesting the reduced use of our products or the use of competitive or alternative products as the standard of care to be followed by patients and
healthcare providers could result in decreased use of our products. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to Our Dependence on Third Parties  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we encounter difficulties in negotiating a product agreement with the third party manufacturer of
Xtampza or the third-party manufacturer fails to devote sufficient time and resources to Xtampza, or its performance is substandard, our product launch may be delayed and our costs may be higher than
expected and could have a material adverse effect on our business.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We do not own any manufacturing facilities and have limited experience in drug development and commercial manufacturing. We currently have no plans to
build our own clinical or commercial scale manufacturing facility. We lack the resources and expertise to manufacture and test, on a commercial scale, the technical performance of our product
candidates. We currently rely, and expect to continue to rely, on a limited number of experienced personnel and one contract manufacturer, Patheon, as well as other vendors to formulate, test, supply,
store and distribute our product candidates for our clinical trials and FDA registration, and we control only certain aspects of their activities. We are currently negotiating a product agreement with
Patheon and we may not be able to obtain terms that are favorable to us or enter into a product agreement at all. Although we have identified alternate sources for these services, it would be
time-consuming, and require us to incur additional cost, to qualify these sources. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=43,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=689738,FOLIO='39',FILE='DISK131:[15ZCN1.15ZCN74701]DE74701A.;12',USER='CGONCE',CD='31-DEC-2015;12:17' -->
<A NAME="page_de74701_1_40"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
reliance on a limited number of vendors and, in particular, Patheon, as our single manufacturer, exposes us to the following risks, any of which could delay FDA approval of our product candidates
and commercialization of our products, result in higher costs, or deprive us of potential product revenues:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our contract manufacturer, or other third parties we rely on, may encounter
difficulties in achieving the volume of production needed to satisfy commercial demand, may experience technical issues that impact quality or compliance with applicable and strictly enforced
regulations governing the manufacture of pharmaceutical products, and may experience shortages of qualified personnel to adequately staff production operations. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our contract manufacturer could default on its agreement with us to meet our
requirements for commercialization of Xtampza. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the use of alternate manufacturers may be difficult because the number of
potential manufacturers that have the necessary governmental licenses to produce narcotic products is limited. Additionally, the FDA and the DEA must approve any alternative manufacturer of Xtampza
before we may use the alternative manufacturer to produce Xtampza. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> it may be difficult or impossible for us to find a replacement manufacturer on
acceptable terms quickly, or at all. Our contract manufacturer and vendors may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully
produce, store and distribute our products. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> if our contract manufacturer were to terminate our arrangement or fail to meet
our commercial manufacturing demands, we may be forced to delay our development and commercial programs. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our
reliance on third parties reduces our control over our product candidate development and commercialization activities but does not relieve us of our responsibility to ensure compliance with all
required legal, regulatory and scientific standards. The FDA and other regulatory authorities require that our product candidates and any products that we may eventually commercialize be manufactured
according to cGMP and similar foreign standards. Any failure by our third-party manufacturer to comply with cGMP or failure to scale up manufacturing processes, including any failure to deliver
sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates. In addition, such failure could be
the basis for the FDA to issue a warning or untitled letter, withdraw approvals for product candidates previously granted to us, or take other regulatory or legal action, including recall or seizure,
total or partial suspension of production, suspension of ongoing clinical trials, refusal to approve pending applications or supplemental applications, detention or product, refusal to permit the
import or export of products, injunction, imposing civil penalties or pursuing criminal prosecution. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Because we currently rely on a sole supplier to manufacture the active pharmaceutical ingredient of
our lead product candidate, Xtampza, any production problems with our supplier could have a material adverse effect on us.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We presently depend upon a single source as the sole supplier of the active ingredient for Xtampza&nbsp;&#151; oxycodone
base&nbsp;&#151; and we intend to contract with this supplier, as necessary, for commercial supply of our products. Although we have identified an alternate source for oxycodone base, it
would be time-consuming and costly to qualify this source. Since we currently obtain our active ingredient from this manufacturer on a purchase-order basis, either we or our supplier may terminate our
arrangement, without cause, at any time without notice. If our supplier were to terminate our arrangement or fail to meet our supply needs we might incur substantial cost and be forced to delay our
development or commercialization programs. Any such delay could have a material adverse effect on our business. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=44,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=309082,FOLIO='40',FILE='DISK131:[15ZCN1.15ZCN74701]DE74701A.;12',USER='CGONCE',CD='31-DEC-2015;12:17' -->
<A NAME="page_de74701_1_41"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We rely on third parties to conduct our clinical trials. If these third parties do not successfully
carry out their contractual duties or meet expected deadlines, or if they terminate their agreement with us, we may not be able to obtain regulatory approval for or commercialize our product
candidates and our business could suffer a material adverse effect.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have relied upon and plan to continue to rely upon contract research organizations, or CROs, to monitor and manage data for our ongoing preclinical
and clinical programs. We rely on these parties for execution of our clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of
our studies and clinical trials are conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory
responsibilities. We and our CROs are required to comply with federal regulations and current Good Clinical Practices, or GCP, which are international standards meant to protect the rights and health
of patients and to define the roles of clinical trial sponsors, advisors and monitors, enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, or EEA, and
foreign regulatory authorities in the form of International Conference on Harmonization, or ICH, guidelines for all of our product candidates in clinical development. Regulatory authorities enforce
these GCP through periodic inspections of trial sponsors, principal investigators and trial sites. In addition, we and our CROs are required to comply with special regulations regarding the enrollment
of recreational drug abusers in clinical trials. If we or any of our CROs fail to comply with applicable GCP and other regulations, including as a result of any recent changes in such regulations, the
clinical data generated in our clinical trials may be deemed unreliable and the FDA or foreign regulatory authorities may require us to perform additional clinical trials before approving our
marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP
requirements. In addition, our clinical trials must be conducted with product produced under cGMP requirements. While we have agreements governing activities of our CROs, we have limited influence
over their actual performance. Failure to comply with applicable regulations
in the conduct of the clinical trials for our product candidates may require us to repeat preclinical studies and clinical trials, which would delay the regulatory approval process. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our
CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing
clinical and preclinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy
of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or
terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, the commercial prospects for our product candidates would be
harmed, our costs could increase substantially and our ability to generate revenue could be delayed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Switching
or adding additional CROs involves additional cost and requires management time and focus, and there is a limited number of CROs that are equipped and willing to manage clinical trials that
involve recreational drug abusers. Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate
their respective agreements with us if it can be reasonably demonstrated that the safety of the patients participating in our clinical trials warrants such termination, if we make a general assignment
for the benefit of our creditors or if we are liquidated. Identifying, qualifying and managing performance of third-party service providers can be difficult, time-consuming and cause delays in our
development programs. In addition, there is a natural transition period when a new CRO commences work and the new CRO may not provide the same type or level of services as the original provider.
Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a
material adverse impact on our business, financial condition and prospects. If any of our relationships with our CROs terminate, we may not be able to enter into arrangements with </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=45,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=907387,FOLIO='41',FILE='DISK131:[15ZCN1.15ZCN74701]DE74701A.;12',USER='CGONCE',CD='31-DEC-2015;12:17' -->
<A NAME="page_de74701_1_42"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>alternative
CROs or to do so on commercially reasonable terms. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because
we have relied on third parties, our internal capacity to perform these functions is limited. Outsourcing these functions involves risks that third parties may not perform to our standards,
may not produce results in a timely manner or may fail to perform at all. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties,
which could increase the risk that this information will be misappropriated. We currently have a small number of employees, which limits the internal resources we have available to identify and
monitor our third-party providers. To the extent we are unable to identify and successfully manage the performance of third-party service providers in the future, our ability to advance our product
candidates through clinical trials will be compromised. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in
the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


In the future, we may depend on collaborations with third parties for the development and
commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We may not be successful in establishing development and commercialization collaborations which could adversely affect, and potentially prohibit, our
ability to develop or commercialize our product candidates. Collaborations involving our product candidates pose the following risks to us:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators may have significant discretion in determining the efforts and
resources that they will apply to these collaborations. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators may not pursue development and commercialization of our product
candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator's strategic focus or available funding or
external factors such as an acquisition that diverts resources or creates competing priorities. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators may delay clinical trials, provide insufficient funding for a
clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators may conduct clinical trials inappropriately, or may obtain
unfavorable results in their clinical trials, which may have an adverse effect on the development of our own programs. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators could independently develop, or develop with third parties,
products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized
under terms that are more economically attractive than ours. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a collaborator with marketing and distribution rights to one or more products
may not commit sufficient resources to the marketing and distribution of such products. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborators may not properly maintain or defend our intellectual property
rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> disputes may arise between the collaborators and us that result in the delay or
termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we may lose certain valuable rights under circumstances specified in our
collaborations. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborations may be terminated and, if terminated, may result in a need for
additional capital to pursue further development or commercialization of the applicable product candidates. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaboration agreements may not lead to development or commercialization of
product candidates in the most efficient manner or at all. If a future collaborator of ours were to be involved in a business </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=46,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=970693,FOLIO='42',FILE='DISK131:[15ZCN1.15ZCN74701]DE74701A.;12',USER='CGONCE',CD='31-DEC-2015;12:17' -->
<A NAME="page_de74701_1_43"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>combination,
the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated. </FONT></P>

</UL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may rely on collaborators to market and commercialize Xtampza and, if approved, our other product
candidates, who may fail to effectively commercialize our product candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We may utilize strategic collaborators or contract sales forces, where appropriate, to assist in the commercialization of our product candidates, if
approved, including our tentatively approved product, Xtampza. We currently possess limited resources and may not be successful in establishing collaborations or co-promotion arrangements on
acceptable terms, if at all. We also face competition in our search for collaborators and co-promoters. If we enter into strategic collaborations or similar arrangements, we will rely on third parties
for financial resources and for development, commercialization, sales and marketing and regulatory expertise. Our collaborators, if any, may fail to develop or effectively commercialize our product
candidates because they cannot obtain the necessary regulatory approvals, they lack adequate financial or other resources or they decide to focus on other initiatives. Any failure of our third-party
collaborators to successfully market and commercialize our product candidates would diminish our revenues. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Manufacturing issues may arise that could increase product and regulatory approval costs or delay
commercialization.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As we scale up manufacturing of our product candidates and conduct required stability testing, we may encounter product, packaging, equipment and
process-related issues that may require refinement or resolution in order to proceed with our planned clinical trials and obtain regulatory approval for commercial marketing. In the future, we may
identify impurities, which could result in increased scrutiny by regulatory authorities, delays in our clinical programs and regulatory approval, increases in our operating expenses or failure to
obtain or maintain approval for our product candidates. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to Our Business and Strategy  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We face substantial competition from other biotechnology and pharmaceutical companies, which may
result in others discovering, developing or commercializing products before or more successfully than we do.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The biopharmaceutical industry is intensely competitive and subject to rapid and significant technological change. In addition, the competition in the
pain and opioid market is intense. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, biotechnology companies and universities
and other research institutions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
face and will continue to face competition from other companies in the pharmaceutical and medical device industries. Our product candidates, if approved, will compete with currently marketed oral
opioids, transdermal opioids, local anesthetic patches, stimulants and implantable and external infusion pumps that can be used for infusion of opioids and local anesthetics. Products of these types
are marketed by Purdue, Johnson&nbsp;&amp; Johnson, Pfizer, Endo, Mallinckrodt, Pernix, Actavis and others. Some of these current and potential future competitors may be addressing the same therapeutic
areas or indications as we are. Many of our current and potential future competitors have significantly greater research and development capabilities than we do, have substantially more marketing,
manufacturing, financial, technical, human and managerial resources than we do, and have more institutional experience than we do. Mergers and acquisitions in the biotechnology and pharmaceutical
industries may result in even more resources being concentrated in our competitors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
a result of these factors, our competitors may obtain regulatory approval of their products more rapidly than we are able to or may obtain patent protection or other intellectual property rights
that allow them to develop and commercialize their products before us and limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are safer,
more effective, more widely </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=47,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=509508,FOLIO='43',FILE='DISK131:[15ZCN1.15ZCN74701]DE74701A.;12',USER='CGONCE',CD='31-DEC-2015;12:17' -->
<A NAME="page_de74701_1_44"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>used
and less costly than ours, and they may also be more successful than us in manufacturing and marketing their products. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Furthermore,
if the FDA approves a competitor's 505(b)(2) application for a drug candidate before our application for a similar drug candidate and grants the competitor a period of exclusivity, the
FDA may take the position that it cannot approve our NDA for a similar drug candidate. For example, we believe that several competitors are developing extended-release oxycodone products, and if the
FDA approves a competitor's 505(b)(2) application for an extended-release oxycodone product and grants exclusivity before the FDA grants final regulatory approval to Xtampza, we could be subject to a
delay that would dramatically reduce the expected market penetration for Xtampza. Additionally, even if our 505(b)(2) application for Xtampza is approved for marketing first, we may still be subject
to competition from other oxycodone products, including approved products or other approved 505(b)(2) NDAs for different conditions of use that would not be restricted by any grant of exclusivity to
us. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, competitors have developed or are in the process of developing technologies that are, or in the future may be, the basis for competitive products. Some of these products may have an
entirely different approach or means of accomplishing similar therapeutic effects than our product candidates. Our competitors may develop products that are safer, more effective or less costly than
our product candidates and, therefore, present a serious competitive threat to our product offerings. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
widespread acceptance of currently available therapies with which our product candidates will compete may limit market acceptance of our product candidates even if commercialized. Oral medication,
transdermal drug delivery systems, such as drug patches, injectable products and implantable drug delivery devices are currently available treatments for chronic pain, are widely accepted in the
medical community and have a long history of use. These treatments will compete with our product candidates, if approved, and the established use of these competitive products may limit the potential
for our product candidates to receive widespread acceptance if commercialized. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The use of legal and regulatory strategies by competitors with innovator products, including the
filing of citizen petitions, may delay or prevent the introduction or approval of our product candidates, increase our costs associated with the introduction or marketing of our products, or
significantly reduce the profit potential of our product candidates.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Companies with innovator drugs often pursue strategies that may serve to prevent or delay competition from alternatives to their innovator products.
These strategies include, but are not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> filing "citizen petitions" with the FDA that may delay competition by causing
delays of our product approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seeking to establish regulatory and legal obstacles that would make it more
difficult to demonstrate a product's bioequivalence or "sameness" to the related innovator product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> filing suits for patent infringement, like the Purdue litigation, that
automatically delay FDA approval of products seeking approval based on the Section&nbsp;505(b)(2) pathway; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  obtaining extensions of market exclusivity by conducting clinical trials of
innovator drugs in pediatric populations or by other methods; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  persuading the FDA to withdraw the approval of innovator drugs for which the
patents are about to expire, thus allowing the innovator company to develop and launch new patented products serving as substitutes for the withdrawn products; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seeking to obtain new patents on drugs for which patent protection is about to
expire; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  initiating legislative and administrative efforts in various states to limit
the substitution of innovator products by pharmacies. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>These
strategies could delay, reduce or eliminate our entry into the market and our ability to generate revenues associated with our product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=48,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=521465,FOLIO='44',FILE='DISK131:[15ZCN1.15ZCN74701]DE74701A.;12',USER='CGONCE',CD='31-DEC-2015;12:17' -->
<A NAME="page_de74701_1_45"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our future success depends on our ability to retain our key personnel.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are highly dependent upon the services of our key personnel, including our President and Chief Executive Officer, Michael T. Heffernan, and our
Chief Commercial Officer, Barry Duke. Each employee is employed by us at will and is permitted to terminate his employment with us at any time pursuant to the terms of his employment agreement. We do
not maintain "key person" insurance for any of our executives or other employees. The loss of the services of Mr.&nbsp;Heffernan or Mr.&nbsp;Duke could impede the achievement of our development
and commercialization objectives. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to attract and retain highly qualified scientific and technical employees, we may
not be able to grow effectively.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our future growth and success depend on our ability to recruit, retain, manage and motivate our scientific, clinical, manufacturing and commercial
employees. The loss of any member of our senior management team or the inability to hire or retain experienced management personnel could compromise our ability to execute our business plan and harm
our operating results. Because of the specialized scientific nature of our business, we rely heavily on our ability to attract and retain qualified personnel. The competition for qualified personnel
in the pharmaceutical field is intense, and as a result, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable
replacement personnel. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will need to grow the size of our organization, and we may experience difficulties in managing
this growth.  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>As of December&nbsp;31, 2015, we had 46 full-time employees. As our development and commercialization strategies develop, we will need additional
managerial, operational, sales, marketing, financial and other resources. Our management, personnel and systems currently in place may not be adequate to support this future growth. We may not be able
to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and
reduced productivity among remaining employees. Future growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of our
existing or
future product candidates. Future growth would impose significant added responsibilities on members of management, including:</FONT>

</P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  managing the commercialization of any FDA-approved product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  overseeing our ongoing clinical trials effectively; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  identifying, recruiting, maintaining, motivating and integrating additional
employees, including any sales and marketing personnel engaged in connection with the commercialization of any approved product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  managing our internal development efforts effectively while complying with our
contractual obligations to licensors, licensees, contractors and other third parties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  improving our managerial, development, operational and financial systems and
procedures; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  developing our compliance infrastructure and processes to ensure compliance
with regulations applicable to public companies; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  expanding our facilities. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>As
our operations expand, we will need to manage additional relationships with various strategic collaborators, suppliers and other third parties. Our future financial performance and our ability to
commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development
efforts and clinical trials effectively and hire, train and integrate additional management, administrative and sales and marketing personnel. We may not be able to accomplish these tasks, and our
failure to accomplish any of them could prevent us from successfully growing our company. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=49,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=974053,FOLIO='45',FILE='DISK131:[15ZCN1.15ZCN74701]DE74701A.;12',USER='CGONCE',CD='31-DEC-2015;12:17' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dg74701_1_46"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may acquire other assets or businesses, or form collaborations or make investments in other
companies or technologies, that could have a material adverse effect on our operating results, dilute our shareholders' ownership, increase our debt or cause us to incur significant expense.  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>As part of our business strategy, we may pursue acquisitions of assets, including preclinical, clinical or commercial stage products or product
candidates, businesses or strategic alliances and collaborations, to expand our existing technologies and operations. We may not identify or complete these transactions in a timely manner, on a
cost-effective basis, or at all, and we may not realize the anticipated benefits of any such transaction, any of which could have a material adverse effect on our financial condition, results of
operations and cash flows. We have no experience with acquiring other companies, products or product candidates, and limited experience with forming strategic alliances and collaborations. We may not
be able to find suitable acquisition candidates, and if we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business and we may incur additional
debt or assume unknown or
contingent liabilities in connection therewith. Integration of an acquired company or assets may also disrupt ongoing operations, require the hiring of additional personnel and the implementation of
additional internal systems and infrastructure, especially the acquisition of commercial assets, and require management resources that would otherwise focus on developing our existing business. We may
not be able to find suitable strategic alliance or collaborators or identify other investment opportunities, and we may experience losses related to any such investments. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
finance any acquisitions or collaborations, we may choose to issue debt or shares of our common or preferred stock as consideration. Any such issuance of shares would dilute the ownership of our
shareholders. If the price of our common stock is low or volatile, we may not be able to acquire other assets or companies or fund a transaction using our stock as consideration. Alternatively, it may
be necessary for us to raise additional funds for acquisitions through public or private financings. Additional funds may not be available on terms that are favorable to us, or at all. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our employees, independent contractors, principal investigators, CROs, consultants and vendors may
engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in
fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that
violates:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> FDA, DEA or similar regulations of foreign regulatory authorities, including
those laws requiring the reporting of true, complete and accurate information to such authorities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  manufacturing standards; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> federal and state healthcare fraud and abuse laws and regulations and similar
laws and regulations established and enforced by foreign regulatory authorities; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> laws that require the reporting of financial information or data accurately. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive
practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business
arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to
our reputation. We have adopted a Code of Ethics, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent
this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be
in compliance with such laws or regulations. If any such actions are instituted against us, and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=50,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=111369,FOLIO='46',FILE='DISK131:[15ZCN1.15ZCN74701]DG74701A.;14',USER='CGONCE',CD='31-DEC-2015;12:18' -->
<A NAME="page_dg74701_1_47"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>we
are not successful in defending ourselves or asserting our rights, those actions could have a material adverse effect on our business and results of operations, including the imposition of civil,
criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational
harm, diminished profits and future earnings, and curtailment of our operations, any of which could have a material adverse effect on our ability to operate our business and our results of operations. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our relationships with customers and payors will be subject to applicable anti-kickback, fraud and
abuse, transparency, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages,
reputational harm, administrative burdens, and diminished profits and future earnings.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Healthcare providers, physicians and payors play a primary role in the recommendation and prescription of any product candidates for which we may
obtain marketing approval. Our future arrangements with payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the
business or financial arrangements and relationships through which we market, sell and distribute any product candidates for which we may obtain marketing approval. Even though we do not and will not
control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and
patients' rights are and will be applicable to our business. Restrictions under applicable federal, state and foreign
healthcare laws and regulations may affect our ability to operate and expose us to areas of risk, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the federal Anti-Kickback Statute, which prohibits, among other things,
knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the
purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to
have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the federal False Claims Act, which imposes criminal and civil penalties,
including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are
false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items
and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the federal Health Insurance Portability and Accountability Act of 1996, or
HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal
Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute to defraud any healthcare benefit program or specific intent to violate it in order to have committed a
violation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> HIPAA, as amended by the Health Information Technology for Economic and Clinical
Health Act of 2009, or HITECH, and its implementing regulations, which also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as
their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to
safeguarding the privacy, security and transmission of individually identifiable health information; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> federal laws requiring drug manufacturers to report annually information related
to certain payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership or
investment interests held by physicians and their immediate family members, including under the federal Open Payments program, commonly known as the Sunshine Act, as well as other state and foreign
laws regulating </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=51,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=425062,FOLIO='47',FILE='DISK131:[15ZCN1.15ZCN74701]DG74701A.;14',USER='CGONCE',CD='31-DEC-2015;12:18' -->
<A NAME="page_dg74701_1_48"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>marketing
activities and requiring manufacturers to report marketing expenditures, payments and other transfers of value to physicians and other healthcare providers; </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> federal government price reporting laws, which require us to calculate and
report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on our marketed drugs. Participation in these
programs and compliance with the applicable requirements may subject us to potentially significant discounts on our products, increased infrastructure costs, potential liability for the failure to
report such prices in an accurate and timely manner, and potentially limit our ability to offer certain marketplace discounts; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> state and foreign equivalents of each of the above laws, including state
anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private
insurers; state laws which require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal
government or otherwise restricting payments that may be made to healthcare providers; and state and foreign laws governing the privacy and security of health information in certain circumstances,
many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>While
we do not submit claims and our customers will make the ultimate decision on how to submit claims, we may provide reimbursement guidance and support regarding Xtampza, if we receive final
regulatory approval, to our customers and patients. If a government authority were to conclude that we provided improper advice to our
customers and/or encouraged the submission of false claims for reimbursement, we could face action by government authorities. Efforts to ensure that our business arrangements with third parties will
comply with applicable healthcare laws and regulations will involve substantial costs. Nonetheless, it is possible that governmental authorities will conclude that our business practices may not
comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of
these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from
participation in government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to comply with environmental, health and safety laws and regulations, we could become
subject to fines or penalties or incur significant costs.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In connection with our research and development activities and our manufacture of materials and product candidates, we are subject to federal, state
and local laws, rules, regulations and policies governing the use, generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain materials, biological specimens
and wastes. Although we believe that we have complied with the applicable laws, regulations and policies in all material respects and have not been required to correct any material noncompliance, we
may be required to incur significant costs to comply with environmental and health and safety regulations in the future. Current or future laws and regulations may impair our research, development or
production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
research and development involves the use, generation and disposal of hazardous materials, including chemicals, solvents, agents and biohazardous materials. Although we believe that our safety
procedures for storing, handling and disposing of such materials comply with the standards prescribed by state and federal regulations, we cannot completely eliminate the risk of accidental
contamination or injury from these materials. We currently contract with third parties to dispose of these substances that we generate, and we rely on these third parties to properly dispose of these
substances in compliance with applicable laws and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=52,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=407732,FOLIO='48',FILE='DISK131:[15ZCN1.15ZCN74701]DG74701A.;14',USER='CGONCE',CD='31-DEC-2015;12:18' -->
<A NAME="page_dg74701_1_49"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>regulations.
We cannot eliminate the risk of contamination or injury from these materials. If these third parties do not properly dispose of these substances in compliance with applicable laws and
regulations, we may be subject to legal action by governmental agencies or private parties for improper disposal of these substances. The costs of defending such actions and the potential liability
resulting from such actions are often very large. In the event we are subject to such legal action or we otherwise fail to comply with applicable laws and regulations governing the use, generation and
disposal of hazardous materials and chemicals, we could be held liable for any damages that result, and any such liability could exceed our resources. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Although
we maintain workers' compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may
not provide adequate coverage against potential liabilities. We maintain insurance for environmental liability or toxic tort claims, but we may not continue to maintain such insurance in the future,
and such insurance, to the extent maintained, may not be adequate to cover liabilities that may be asserted against us in connection with our storage or disposal of biological, hazardous or
radioactive materials. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our business and operations would suffer in the event of computer system failures, accidents or
security breaches.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Despite the implementation of security measures, our internal computer systems, and those of our CROs, contract manufacturing organization, or CMO,
and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. System
failures, accidents or security breaches could cause interruptions in our operations, and could result in a material disruption of our clinical activities and business operations, in addition to
possibly requiring substantial expenditures of resources to remedy. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug
development programs. For example, the loss of clinical trial data from completed or ongoing clinical trials could result in delays in our regulatory approval efforts and significantly increase our
costs to recover or reproduce the data. To the extent that any disruption or security breach was to result in a loss of or damage to our data or applications, or inappropriate disclosure of
confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to Our Common Stock  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The price of our common stock may be volatile and you may lose all or part of your investment.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The market price of our common stock is highly volatile and may be subject to wide fluctuations in response to various factors, some of which are
beyond our control. In addition to the factors discussed in this prospectus, these factors include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the success of competitive products or technologies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  regulatory actions with respect to our product candidates or our competitors'
products or product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> actual or anticipated changes in our growth rate relative to our competitors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the outcome of any patent infringement or other litigation that may be brought
against us, including the ongoing Purdue litigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  announcements by us or our competitors of significant acquisitions, strategic
collaborations, joint ventures, collaborations or capital commitments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> results of clinical trials of our product candidates or those of our
competitors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  regulatory or legal developments in the United States and other countries; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  developments or disputes concerning patent applications, issued patents or
other proprietary rights; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the recruitment or departure of key personnel; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=53,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=487860,FOLIO='49',FILE='DISK131:[15ZCN1.15ZCN74701]DG74701A.;14',USER='CGONCE',CD='31-DEC-2015;12:18' -->
<A NAME="page_dg74701_1_50"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the level of expenses related to any of our product candidates or clinical
development programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> actual or anticipated variations in our quarterly operating results; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number and characteristics of our efforts to in-license or acquire
additional product candidates or products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  introduction of new products or services by us or our competitors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to meet the estimates and projections of the investment community or
that we may otherwise provide to the public; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> actual or anticipated changes in estimates as to financial results, development
timelines or recommendations by securities analysts; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  variations in our financial results or those of companies that are perceived to
be similar to us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  fluctuations in the valuation of companies perceived by investors to be
comparable to us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> share price and volume fluctuations attributable to inconsistent trading volume
levels of our shares; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  announcement or expectation of additional financing efforts; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> sales of our common stock by us, our insiders or our other shareholders; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes in accounting practices; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  significant lawsuits, including patent or shareholder litigation; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes in the structure of healthcare payment systems; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> market conditions in the pharmaceutical and biotechnology sectors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> general economic, industry and market conditions; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  publication of research reports about us, our competitors or our industry, or
positive or negative recommendations or withdrawal of research coverage by securities or industry analysts; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> other events or factors, many of which are beyond our control. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, the stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or
disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market
price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks stated above could have a material adverse
effect on the market price of our common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
we operate in the pharmaceutical and biotechnology industry, we are especially vulnerable to these factors to the extent that they affect our industry or our products. In the past, securities class
action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management's
attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Sales of a substantial number of shares of our common stock in the public market could cause our
stock price to fall.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market
that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. After this offering, we will have
outstanding&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common
stock based on 20,687,823 shares outstanding as of September&nbsp;30, 2015. This includes the shares that we are selling in this offering, which may be resold in the public market immediately
without restriction, unless purchased by our affiliates. Of the remaining shares, approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million shares are currently restricted as a
result of securities laws or lock-up
agreements entered into in connection with this offering but will be able to be sold as described in the "Shares Eligible for Future Sale" and "Underwriting" sections of this prospectus. The lock-up
agreements pertaining to this offering will expire 90&nbsp;days from the date of this prospectus, following which approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common
stock will be eligible for sale in
the public market, all of which </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=54,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=366581,FOLIO='50',FILE='DISK131:[15ZCN1.15ZCN74701]DG74701A.;14',USER='CGONCE',CD='31-DEC-2015;12:18' -->
<A NAME="page_dg74701_1_51"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>shares
are held by current directors, executive officers, shareholders and other affiliates and may be subject to Rule&nbsp;144 under the Securities Act. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Moreover,
holders of an aggregate of approximately 12.8&nbsp;million shares of our common stock have rights, subject to certain conditions, to require us to file registration statements covering
their shares or to include their shares in registration statements that we may file for ourselves or other shareholders. Once we register these shares, they can be freely sold in the public market,
subject to volume limitations applicable to affiliates and the lock-up arrangements. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Actual or potential sales of our common stock by our directors or employees, including our executive
officers, pursuant to pre-arranged stock trading plans could cause our stock price to fall or prevent it from increasing for numerous reasons, and actual or potential sales by such persons could be
viewed negatively by investors.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In accordance with the guidelines specified under Rule&nbsp;10b5-1 of the Exchange Act and our policies regarding stock transactions, our directors
and employees, including our executive officers, could adopt stock trading plans pursuant to which they may sell shares of our common stock from time to time in the future. Generally, sales under such
plans by our executive officers and directors require public filings. Actual or potential sales of our common stock by such persons could cause our common stock to fall or prevent it from increasing
for numerous reasons. For example, a substantial number of shares of our common stock becoming available (or being perceived to become available) for sale in the public market could cause the market
price of our common stock to fall or prevent it from increasing. Also, actual or potential sales by such persons could be viewed negatively by investors. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Future issuances of our common stock or rights to purchase common stock, including pursuant to our
equity incentive plans, could result in additional dilution of the percentage ownership of our shareholders and could cause our stock price to fall.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We expect that significant additional capital will be needed in the future to continue our planned operations. To raise capital, we may sell
substantial amounts of common stock or securities convertible into or exchangeable for common stock. These future issuances of common stock or common stock-related securities, together with the
exercise of outstanding options and any additional shares issued in connection with acquisitions, if any, may result in material dilution to our investors. Such sales may also result in material
dilution to our existing shareholders, and new investors could gain rights, preferences and privileges senior to those of holders of our common stock, including shares of common stock sold in this
offering. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our principal shareholders and management own a majority of our stock and have the ability to exert
significant control over matters subject to shareholder approval.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of September&nbsp;30, 2015, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates
beneficially owned a majority of our voting stock, including shares subject to outstanding options and warrants, and, upon the closing of this offering, we expect the same group will continue to hold
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding voting stock. As a result, if these shareholders were to choose to act together, they would be able to significantly influence the outcome of all
matters requiring shareholder approval, including the election of directors, amendments of our organizational documents, or approval of any merger, sale of assets or other major corporate transaction.
This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest. The interests of this group of shareholders may not always
coincide with your interests or the interests of other
shareholders and they may act in a manner that advances their best interests and not necessarily those of other shareholders, including seeking a premium value for their common stock, and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=55,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1034439,FOLIO='51',FILE='DISK131:[15ZCN1.15ZCN74701]DG74701A.;14',USER='CGONCE',CD='31-DEC-2015;12:18' -->
<A NAME="page_dg74701_1_52"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>might
affect the prevailing market price for our common stock. Such concentration of ownership control may:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> delay, defer or prevent a change in control; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  entrench our management and/or the board of directors; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> impede a merger, consolidation, takeover or other business combination involving
us that other shareholders may desire. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, persons associated with Longitude Capital Partners,&nbsp;LLC, Skyline Venture Partners V,&nbsp;L.P., Frazier Healthcare VI,&nbsp;L.P., and TPG Biotechnology Partners IV,&nbsp;L.P.
currently serve on our board of directors. The interests of Longitude Capital Partners,&nbsp;LLC, Skyline Venture Partners V,&nbsp;L.P., Frazier Healthcare VI,&nbsp;L.P., and TPG Biotechnology
Partners IV,&nbsp;L.P. may not always coincide with the interests of the other shareholders, and the concentration of control in Longitude Capital Partners,&nbsp;LLC, Skyline Venture Partners
V,&nbsp;L.P., Frazier Healthcare VI,&nbsp;L.P., and TPG Biotechnology Partners IV,&nbsp;L.P. limits other shareholders' ability to influence corporate matters. We may also take actions that our
other shareholders do not view as beneficial, which may adversely affect our results of operations and financial condition and cause a decline in our stock price. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are subject to anti-takeover provisions in our amended and restated articles of incorporation and
amended and restated bylaws and under Virginia law that could delay or prevent an acquisition of our company, even if the acquisition would be beneficial to our shareholders.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Certain provisions of Virginia law, the state in which we are incorporated, and our amended and restated articles of incorporation and amended and
restated bylaws could hamper a third party's acquisition of us, or discourage a third party from attempting to acquire control of us. These provisions include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a provision allowing our board of directors to set the terms of and issue
preferred stock with rights senior to those of the common stock without any vote or action by the holders of our common stock. The issuance of preferred stock could adversely affect the rights and
powers, including voting rights, of the holders of common stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> advance written notice procedures and notice requirements with respect to
shareholder proposals and shareholder nomination of candidates for election as directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a provision that only the board of directors, the chairman of the board of
directors or the president may call a special meeting of the shareholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the application of Virginia law prohibiting us from entering into certain
transactions with the beneficial owner of more than 10&nbsp;percent of our outstanding voting stock for a period of three years after such person first reached that level of stock ownership, unless
certain conditions are met; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a provision dividing our board of directors into three classes, each serving
three-year terms; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the requirement that the authorized number of our directors be changed only by
resolution of our board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a provision that our board of directors shall fill any vacancies on our board of
directors, including vacancies resulting from a board of directors resolution to increase the number of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  limitations on the manner in which shareholders can remove directors from the
board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the lack of cumulative voting in the election of directors; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the prohibition on shareholders acting by less-than-unanimous written consent. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>These
provisions also could limit the price that certain investors might be willing to pay in the future for shares of our common stock. In addition, these provisions make it more difficult for our
shareholders, should they choose to do so, to remove our board of directors or management or elect new directors to our board of directors. See "Description of Capital Stock." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=56,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=915698,FOLIO='52',FILE='DISK131:[15ZCN1.15ZCN74701]DG74701A.;14',USER='CGONCE',CD='31-DEC-2015;12:18' -->
<A NAME="page_dg74701_1_53"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may fail to qualify for continued listing on NASDAQ which could make it more difficult for
investors to sell their shares.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our common stock is listed on NASDAQ. As a NASDAQ listed company, we are required to satisfy the continued listing requirements of NASDAQ for
inclusion in the Global Select Market to maintain such listing, including, among other things, the maintenance of a minimum closing bid price of $1.00 per share and shareholders' equity of at least
$10.0&nbsp;million. There can be no assurance that we will be able to maintain compliance with the continued listing requirements or that our common stock will not be delisted from NASDAQ in the
future. If our common stock is delisted by NASDAQ, we could face significant material adverse consequences, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a limited availability of market quotations for our securities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reduced liquidity with respect to our securities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a determination that our shares are a "penny stock," which will require brokers
trading in our shares to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our shares; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a limited amount of news and analyst coverage for our company; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a decreased ability to issue additional securities or obtain additional
financing in the future. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If securities or industry analysts do not publish research or publish inaccurate or unfavorable
research about our business, our stock price and trading volume could decline.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our
business. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of
these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are an "emerging growth company" and we intend to take advantage of reduced disclosure and
governance requirements applicable to emerging growth companies, which could result in our common stock being less attractive to investors and we cannot be certain if the reduced reporting
requirements applicable to emerging growth companies will make our shares of common stock less attractive to investors.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are an "emerging growth company," as defined in the JOBS Act, and may remain an emerging growth company for up to five years. For so long as we
remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various reporting requirements applicable to other public companies, but not to emerging growth
companies, including, but not limited to, an exemption from the auditor attestation requirement of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure about executive compensation
arrangements pursuant to the rules applicable to smaller reporting companies and no requirement to seek non-binding advisory votes on executive compensation or golden parachute arrangements. We will
remain an emerging growth company until the earliest of (i)&nbsp;December&nbsp;31, 2020, (ii)&nbsp;the first fiscal year after our annual gross revenue are $1.0&nbsp;billion or more,
(iii)&nbsp;the date on which we have, during the previous three-year period, issued more than $1.0&nbsp;billion in non-convertible debt securities or (iv)&nbsp;the end of any fiscal year in
which the market value of our common stock held by non-affiliates exceeded $700&nbsp;million as of the end of the second quarter of that fiscal year. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, Section&nbsp;107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the
Securities Act for complying with new or revised accounting standards. An emerging growth company can therefore delay the adoption of certain accounting standards until those standards would otherwise
apply to private companies. However, we are choosing
to "opt out" of such extended transition period and, as a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=57,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=414006,FOLIO='53',FILE='DISK131:[15ZCN1.15ZCN74701]DG74701A.;14',USER='CGONCE',CD='31-DEC-2015;12:18' -->
<A NAME="page_dg74701_1_54"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>required
for non-emerging growth companies. Section&nbsp;107 of the JOBS Act provides that our decision to opt out of the extended transition period for complying with new or revised accounting
standards is irrevocable. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
cannot predict if investors will find our common stock less attractive as a result of our taking advantage of these exemptions. If some investors find our common stock less attractive as a result
of our choices, there may be a less active trading market for our common stock and our stock price may be more volatile. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>If
investors find our common stock less attractive as a result of our reduced reporting requirements, there may be a less active trading market for our common stock and our stock price may be more
volatile. We may also be unable to raise additional capital as and when we need it. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to maintain an effective system of internal control over financial reporting, we may not
be able to accurately report our financial condition, results of operations or cash flows, which may adversely affect investor confidence in us and, as a result, the value of our common stock.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal control over financial reporting. Commencing with our annual
report on Form&nbsp;10-K for the year ending December&nbsp;31, 2016, we will be required, under Section&nbsp;404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other
things, the effectiveness of our internal control over financial reporting. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal
control over financial reporting. A material weakness is a control deficiency, or combination of control deficiencies, in internal control over financial reporting that results in more than a
reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. Section&nbsp;404 of the Sarbanes-Oxley Act also
generally requires an attestation from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. However, for as long as we remain an
emerging growth company as defined in the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not
emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
compliance with Section&nbsp;404 will require that we incur substantial accounting expense and expend significant management efforts. We currently do not have an internal audit group, and we
will need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge, and compile the system and process documentation necessary to
perform the evaluation needed to comply with Section&nbsp;404. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion, which could potentially
subject us to sanctions or investigations by the Securities and Exchange Commission, or the SEC, or other regulatory authorities. During the evaluation and testing process, if we identify one or more
material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. We cannot assure you that there will
not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely
inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or
if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begin its reviews,
we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations
by NASDAQ, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control
systems required of public companies, could also restrict our future access to the capital markets. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=58,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=822689,FOLIO='54',FILE='DISK131:[15ZCN1.15ZCN74701]DG74701A.;14',USER='CGONCE',CD='31-DEC-2015;12:18' -->
<A NAME="page_dg74701_1_55"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to successfully remediate the existing material weaknesses in our internal control
over financial reporting, the accuracy and timing of our financial reporting may be adversely affected.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our management team is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over
financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally
accepted accounting principles in the United States, or GAAP, and SEC rules and regulations. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial
reporting such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During
the course of preparing our December&nbsp;31, 2014 financial statements, our management team determined that we had the following material weaknesses in our internal control over financial
reporting:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  Adequate controls are not in place to appropriately segregate duties in areas
such as journal entries, cash disbursements, and the calculation, processing and recording of employee compensation and related accounts. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our controls and procedures over the accounting for and reporting of complex
accounting matters were not effectively designed due to a failure to design and implement appropriate policies and procedures to ensure that the accounting and valuation of complex debt and equity
transactions, income taxes and certain other matters is in accordance with GAAP. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our controls were not effectively implemented in the financial statement close
process to ensure that proper cut-off of accrued expenses was achieved at interim periods. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
material weaknesses in our internal control over financial reporting were attributable to our lack of sufficient financial reporting and accounting personnel with appropriate training in GAAP and
SEC rules and regulations. In response to these material weaknesses, we have hired, and plan to continue to hire, additional personnel with public company financial reporting expertise to build our
financial management and reporting infrastructure, and further develop and document our accounting policies and financial reporting procedures. However, we cannot assure you that we will be successful
in pursuing these measures or that these measures will significantly improve or remediate the material weaknesses described above. We also cannot assure you that we have identified all of our existing
material weaknesses, or that we will not in the future have additional material weaknesses. We have not yet remediated our material weaknesses, and the remediation measures that we intend to implement
may be insufficient to address our existing material weaknesses or to identify or prevent additional material weaknesses. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Neither
we nor our independent registered public accounting firm has performed an evaluation of our internal control over financial reporting during any period in accordance with the provisions of the
Sarbanes- Oxley Act. In light of the control deficiencies and the resulting material weaknesses that were identified as a result of the limited procedures performed, we believe that it is possible
that, had we and our independent registered public accounting firm performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act,
additional material weaknesses and significant control deficiencies may have been identified. However, for as long as we remain an "emerging growth company" as defined in the JOBS Act, we intend to
take advantage of the exemption permitting us not to comply with the requirement that our independent registered public accounting firm provide an attestation on the effectiveness of our internal
control over financial reporting. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
we fail to remediate the material weaknesses or to meet the demands that will be placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act, we may be unable to
accurately report our
financial results, or report them within the timeframes required by law or stock exchange regulations. Failure to comply with Section&nbsp;404 of the Sarbanes-Oxley Act could also potentially
subject us to sanctions or investigations by the SEC or other regulatory authorities. There is no assurance that we will be able to remediate these material weaknesses in a timely manner, or at all,
or that in the future, additional material weaknesses will not exist or otherwise be discovered. If our efforts to remediate these </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=59,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=650079,FOLIO='55',FILE='DISK131:[15ZCN1.15ZCN74701]DG74701A.;14',USER='CGONCE',CD='31-DEC-2015;12:18' -->
<A NAME="page_dg74701_1_56"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>material
weaknesses identified are not successful, or if other material weaknesses or other deficiencies occur, our ability to accurately and timely report our financial position could be impaired,
which could result in late filings of our annual and quarterly reports under the Exchange Act, restatements of our financial statements, a decline in our stock price, suspension or delisting of our
common stock from NASDAQ, and could have a material adverse effect on our reputation, results of operations and financial condition. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are subject to the periodic reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure
that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within
the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not
absolute, assurance that the objectives of the control system are met. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>These
inherent limitations reflect the reality that judgments can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the
individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system,
misstatements due to error or fraud may occur and not be detected. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to this Offering  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The exercise of options and warrants and other issuances of shares of common stock or securities
convertible into or exercisable for shares of common stock following this offering will dilute your ownership interests and may adversely affect the future market price of our common stock.  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Sales of our common stock in the public market, either by us or by our current shareholders, or the perception that these sales could occur, could
cause a decline in the market price of our securities. All of the shares of our common stock held by those of our current shareholders who have not entered into lock-up agreements with the
underwriters may be immediately eligible for resale in the open market either in compliance with an exemption under Rule&nbsp;144 promulgated under the Securities Act, or pursuant to an effective
resale registration statement that we have previously filed with the SEC. Such sales, along with any other market transactions, could adversely affect the market price of our common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, as of September&nbsp;30, 2015, there were (a)&nbsp;outstanding options to purchase an aggregate of 1,356,246 shares of our common stock at a weighted average exercise price of $9.04
per share, of which options to purchase 208,438 shares of our common stock were then exercisable, and (b)&nbsp;2,445 shares of common stock issuable upon the exercise of warrants to purchase common
stock at a weighted-average exercise price of $12.27 per share. The exercise of options and warrants at prices below the market price of our common stock could adversely affect the price of shares of
our common stock. Additional dilution may result from the issuance of shares of our common stock in connection with collaborations or manufacturing arrangements or in connection with other financing
efforts. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any
issuance of our common stock that is not made solely to then-existing shareholders proportionate to their interests, such as in the case of a stock dividend or stock split, will result in dilution
to each shareholder by reducing his, her or its percentage ownership of the total outstanding shares. Moreover, if we issue options or warrants to purchase our common stock in the future and those
options or warrants are exercised you may experience further dilution. Holders of shares of our common stock have no preemptive rights that entitle them to purchase their pro rata share of any
offering of shares of any class or series. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


You will suffer immediate and substantial dilution in the securities you purchase.  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of our common stock is substantially higher than the as adjusted net tangible book value per
share of our outstanding shares immediately after this offering. As a </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=60,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=644778,FOLIO='56',FILE='DISK131:[15ZCN1.15ZCN74701]DG74701A.;14',USER='CGONCE',CD='31-DEC-2015;12:18' -->
<A NAME="page_dg74701_1_57"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>



result, investors purchasing securities in this offering will incur immediate and substantial dilution of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock, or
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of
the public offering price, based on an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the last reported sale price of our common stock on NASDAQ
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016.
Accordingly, existing shareholders will benefit disproportionately from this offering. If we raise additional capital through the sale of equity, including convertible securities, your percentage of
ownership will be diluted. You may also experience additional dilution if stock options or warrants to purchase our shares are exercised at less than the offering price. As of September&nbsp;30,
2015, we had reserved 1,337,584 shares of our common stock for issuance under our Amended and Restated 2014 Stock Incentive Plan and 200,000 shares of our common stock for issuance under our 2015
Employee Stock Purchase Plan.

 </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have broad discretion in the use of our cash and cash equivalents, including the net proceeds of
this offering and, despite our efforts, we may use them in a manner that does not increase the value of your investment.  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>We currently anticipate that the net proceeds from the sale of our common stock will be used for the continued development of our commercial
infrastructure, including building our sales, manufacturing, marketing and reimbursement functions, funding the commercial launch of Xtampza, subject to final regulatory approval, funding research and
development efforts of our other product candidates, and funding working capital and general corporate purposes, which may include litigation expenses (including expenses relating to the Purdue
litigation) and the acquisition or licensing of product candidates, technologies, compounds, other assets or complementary businesses. However, we have not determined the specific allocation of the
net proceeds among these potential uses. We have broad discretion in the use of our cash and cash equivalents, including the net proceeds of this offering, and investors must rely on the judgment of
our management regarding the use of our cash and cash equivalents. Our management may not use cash and cash equivalents in ways that ultimately increase the value of your investment. Our failure to
use our cash and cash equivalents effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the
development of our product candidates. Pending their use, we may invest our cash and cash equivalents in short-term or long-term, investment-grade, interest-bearing securities. These investments may
not yield favorable returns. If we do not invest or apply our cash and cash equivalents in ways that enhance shareholder value, we may fail to achieve expected financial results, which could cause the
price of our common stock to decline. Please see the section entitled "Use of Proceeds" on page 60 of this prospectus for further information.


</FONT>

</P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable
future, capital appreciation, if any, will be your sole source of gain.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the
growth and development of our business and do
not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital
appreciation, if any, of our capital stock will be your sole source of gain for the foreseeable future. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=61,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=860587,FOLIO='57',FILE='DISK131:[15ZCN1.15ZCN74701]DG74701A.;14',USER='CGONCE',CD='31-DEC-2015;12:18' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dk74701_1_58"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dk74701_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_dk74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus includes forward-looking statements. The forward-looking statements are contained principally in the sections entitled "Prospectus
Summary," "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Business." These statements relate to future events or to our future financial
performance and involve known and unknown risks, uncertainties and other important factors which may cause our actual results, performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to obtain and maintain regulatory approval of our product
candidates, and any related restrictions, limitations, and/or warnings in the product label of an approved product candidate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our plans to commercialize our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the size and growth potential of the markets for our product candidates, and our
ability to service those markets; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to develop sales and marketing capabilities, whether alone or with
potential future collaborators; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the rate and degree of market acceptance of our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the outcome of any patent infringement or other litigation that may be brought
against us, including the ongoing Purdue litigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to attract collaborators with development, regulatory and
commercialization expertise; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the success, cost and timing of our product development activities, studies and
clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to obtain funding for our operations beyond this offering; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  regulatory developments in the United States and foreign countries; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our expectations regarding our ability to obtain and adequately maintain
sufficient intellectual property protection for our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our ability to operate our business without infringing the intellectual property
rights of others; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the performance of our third-party suppliers and manufacturers; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the success of competing products that are or become available; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the loss of key scientific or management personnel; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our expectations regarding the period during which we qualify as an emerging
growth company under the JOBS Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our use of proceeds from this offering; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the accuracy of our estimates regarding expenses, future revenue, capital
requirements and need for additional financing. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
some cases, you can identify these statements by terms such as "anticipate," "believe," "could," "estimate," "expects," "intend," "may," "plan," "potential," "predict," "project," "should," "will,"
"would" or the negative of those terms, and similar expressions. These forward-looking statements reflect our management's beliefs and views with respect to future events and are based on estimates
and assumptions as of the date of this prospectus and are subject to risks and uncertainties. We discuss many of these risks in greater detail under the heading "Risk Factors." Moreover, we operate in
a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our
business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these
uncertainties, you should not place undue reliance on these forward-looking statements. The Private Securities Litigation Reform Act of 1995 and Section&nbsp;27A of the Securities Act do not protect
any forward-looking statements that we make in connection with this offering. Any forward-looking statements that we make in this prospectus speak only as of the date of such </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=62,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=102071,FOLIO='58',FILE='DISK131:[15ZCN1.15ZCN74701]DK74701A.;16',USER='CHE108234',CD='29-DEC-2015;02:10' -->
<A NAME="page_dk74701_1_59"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>statement,
and we undertake no obligation to update such statements to reflect events or circumstances after the date of this prospectus or to reflect the occurrence of unanticipated events.
Comparisons of results for current
and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>You
should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with
the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus by these cautionary statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Except
as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these
forward-looking statements, even if new information becomes available in the future. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=63,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=41270,FOLIO='59',FILE='DISK131:[15ZCN1.15ZCN74701]DK74701A.;16',USER='CHE108234',CD='29-DEC-2015;02:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dm74701_1_60"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dm74701_use_of_proceeds"> </A>
<A NAME="toc_dm74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>We estimate that our net proceeds from the sale of shares of our common stock in this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million
(or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to purchase additional shares from us in full), based on an assumed offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, which is the last
reported sale price of our common stock on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016, after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each $1.00
increase (decrease) in the assumed offering price would increase (decrease) our net proceeds, assuming that the number of shares of common stock offered by us, as set forth on the cover page of this
prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and offering expenses, by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million.

 </FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>We
intend to use the net proceeds of this offering as follows:</FONT></P>


<UL>
<DL compact>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  approximately $45.7&nbsp;million for the continued development of our
commercial infrastructure, including building our sales, manufacturing, marketing and reimbursement functions and funding the commercial launch of Xtampza, subject to final regulatory approval. If
Xtampza ultimately receives final regulatory approval in the United States, we plan to hire a team of approximately 120 sales representatives for the initial launch. In addition, we expect to deploy a
smaller sales force to detail Xtampza to nursing homes, hospices and other institutions; </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  approximately $4.6&nbsp;million to fund research and development efforts of
our other product candidates, including clinical development for our hydrocodone program (including Phase&nbsp;1 bioequivalence clinical trials and abuse-deterrence studies and clinical trials);
and</FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the remainder, if any, to fund working capital and general corporate purposes,
which may include litigation expenses (including expenses relating to the Purdue litigation) and the acquisition or licensing of product candidates, technologies, compounds, other assets or
complementary businesses. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business
conditions evolve. The amounts and timing of our actual expenditures depend on numerous factors, including final regulatory approval of Xtampza and the progress of our preclinical and clinical
development efforts with respect to our other product candidates. As a result, our management will have broad discretion in applying the net proceeds from this offering. Although we may use a portion
of the net proceeds from this offering for the acquisition or licensing, as the case may be, of product candidates, technologies, compounds, other assets or complementary businesses, we have no
current understandings, agreements or commitments to do so. Pending these uses, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations,
investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Although
it is difficult to predict future liquidity requirements, we believe that the net proceeds from this offering, together with our existing cash resources, will be sufficient to enable us to
fund our operations into 2018, including the commercialization of Xtampza, if it receives final regulatory approval, and the continuation of our development of our other product candidates. We have
based this estimate on assumptions, including with respect to the Purdue litigation, that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>60</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=64,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=84287,FOLIO='60',FILE='DISK131:[15ZCN1.15ZCN74701]DM74701A.;20',USER='DSCHWAR',CD='31-DEC-2015;15:59' -->
<A NAME="page_dm74701_1_61"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> <A NAME="DM_PR"></A>PRICE RANGE OF COMMON STOCK  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our common stock began trading on NASDAQ under the symbol "COLL" on May&nbsp;7, 2015. Prior to that time, there was no public market
for our common stock. The following table sets forth the high and low sale prices per share of our common stock, as reported on NASDAQ, for the periods indicated. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>High </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Low </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Year Ending December&nbsp;31, 2015</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Second Quarter (from May&nbsp;7, 2015)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>20.62</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>11.92</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>24.88</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>12.58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fourth Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>30.58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15.51</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>


On December&nbsp;31, 2015, the last reported sale price of our common stock on NASDAQ was $27.50 per share. As of December&nbsp;31, 2015, we had approximately 60 holders of record of our common
stock. The actual number of shareholders is greater than this number of record holders, and includes shareholders who are beneficial owners but whose shares are held in street name by brokers and
other nominees.

</FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>61</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=65,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1005107,FOLIO='61',FILE='DISK131:[15ZCN1.15ZCN74701]DM74701A.;20',USER='DSCHWAR',CD='31-DEC-2015;15:59' -->
<A NAME="page_dm74701_1_62"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dm74701_dividend_policy"> </A>
<A NAME="toc_dm74701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  DIVIDEND POLICY    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to
support our operations and finance the growth and development of our business and do not intend to declare or pay any cash dividends in the foreseeable future. As a result, you will likely need to
sell your shares of common stock to realize a return on your investment, and you may not be able to sell your shares at or above the price you paid for them. Payment of cash dividends, if any, in the
future will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital
requirements, business prospects and other factors our board of directors may deem relevant. See "Risk Factors&nbsp;&#151; Because we do not anticipate paying any cash dividends on our
capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>62</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=66,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=131403,FOLIO='62',FILE='DISK131:[15ZCN1.15ZCN74701]DM74701A.;20',USER='DSCHWAR',CD='31-DEC-2015;15:59' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_do74701_1_63"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="do74701_capitalization"> </A>
<A NAME="toc_do74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CAPITALIZATION    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth our cash and cash equivalents and our capitalization as of September&nbsp;30, 2015
on:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an actual basis; and</FONT><FONT SIZE=2>


<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an as adjusted basis, giving effect to the sale by us
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of our common stock in this offering at an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which was the last reported sale price of our common stock on NASDAQ
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016,
after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.


</FONT></DD>

</DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>You
should read this table together with our financial statements and the related notes appearing at the end of this prospectus, the sections entitled "Selected Financial Data" and "Management's
Discussion and Analysis of Financial Condition and Results of Operations" and other financial information appearing elsewhere in this prospectus. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of September&nbsp;30, 2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Actual </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As Adjusted </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share<BR>
and&nbsp;per&nbsp;share&nbsp;data)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>105,460</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Undesignated preferred stock, $0.001 par value: 5,000,000 shares authorized and no shares issued or outstanding</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock, par value $0.001 per share; 100,000,000 shares authorized, 20,687,829 shares issued and outstanding, actual;
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, as adjusted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>213,027</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(119,483</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(119,483</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Treasury stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(3</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(3</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total shareholders' equity</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>93,561</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total capitalization</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>93,561</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>The
number of shares of our common stock to be outstanding after this offering is based on 20,687,829 shares of common stock outstanding as of September&nbsp;30, 2015, assumes the issuance by us of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering and excludes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  1,356,246 shares of common stock issuable upon the exercise of outstanding
stock options as September&nbsp;30, 2015, at a weighted-average exercise price of $9.04 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 2,445 shares of common stock issuable upon the exercise of warrants to purchase
common stock as of September&nbsp;30, 2015, at a weighted-average exercise price of $12.27 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  1,337,584 shares of common stock reserved for future issuance under our Amended
and Restated 2014 Stock Incentive Plan as of September&nbsp;30, 2015; and</FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  200,000 shares reserved for future issuance under our 2015 Employee Stock
Purchase Plan as of September&nbsp;30, 2015.

</FONT></DD>

</DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>63</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=67,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=487693,FOLIO='63',FILE='DISK131:[15ZCN1.15ZCN74701]DO74701A.;18',USER='KBLACK',CD=';3-JAN-2016;21:22' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dq74701_1_64"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dq74701_selected_financial_data"> </A>
<A NAME="toc_dq74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SELECTED FINANCIAL DATA    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following selected financial data for the years ended December&nbsp;31, 2013 and 2014 are derived from our audited financial statements,
included elsewhere in this prospectus. The statements of operations data for the nine months ended September&nbsp;30, 2014 and 2015 and the balance sheet data as of September&nbsp;30, 2015 are
derived from our unaudited financial statements included in this prospectus. The unaudited financial statements include, in the opinion of management, all adjustments that management considers
necessary for the fair presentation of the financial information set forth in those statements. Our historical results are not necessarily indicative of results to be expected for the year ending
December&nbsp;31, 2015 or any period in the future. The selected financial data presented below should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and
Results of Operations" and our financial statements and the related notes thereto, included elsewhere in this prospectus. The selected financial data in this section is not intended to replace our
financial statements and the related notes thereto. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="73pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Years Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Nine Months Ended<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands, except share and per share amounts)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Statement of Operations Data:</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14,157</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14,959</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12,652</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6,444</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,885</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,706</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,686</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>11,027 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expense</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>16,042</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>17,665</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14,338</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>17,471 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16,042</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,665</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(14,338</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,471</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense, net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>76</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>252</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>110</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>350</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other expense, net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>79</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(91</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16,197</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,917</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(14,448</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,730</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and diluted net loss per common share<SUP>(1)</SUP>:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4.06</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(22.72</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(18.26</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.94</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average shares used to compute earnings (loss) per common share<SUP>(1)</SUP>:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,697,044</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>933,997</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>926,597</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>11,179,756 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
<p style="font-family:arial;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


 </FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(1)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">See
Note&nbsp;3 to our consolidated financial statements included elsewhere in this prospectus for an explanation of the method used to calculate earnings
(loss) per common share attributable to common shareholders, including the method used to calculate the number of shares used in the computation of the per share amount. </FONT></DD></DL>
 </DIV>

<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="68pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="68pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31,<BR>
2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31,<BR>
2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>September&nbsp;30,<BR>
2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance Sheet Data:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,551</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,634</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>105,460</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Working capital<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,643</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(5,921</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>97,726</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9,034</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5,090</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>107,050</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other long-term liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>834</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,914</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,889</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total shareholders' equity (deficit)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(68,225</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(89,348</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>93,561</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
<p style="font-family:arial;"><font  style="font-size:8pt;line-height:9pt;"></FONT><FONT  style="font-size:8pt;line-height:9pt;">

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


 </FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(1)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Working
capital is calculated as current assets minus current liabilities. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>64</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=68,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1032953,FOLIO='64',FILE='DISK131:[15ZCN1.15ZCN74701]DQ74701A.;20',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ds74701_1_65"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ds74701_management_s_discussion_and_an__man03466"> </A>
<A NAME="toc_ds74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MANAGEMENT'S DISCUSSION AND ANALYSIS OF<BR>  FINANCIAL CONDITION AND RESULTS OF OPERATIONS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I>You should read the following discussion and analysis of our financial condition and results of operations in conjunction with
the "Selected Financial Data" and our financial statements and related notes appearing elsewhere in this prospectus. In addition to historical financial information, the following discussion and
analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results could differ materially from those anticipated by these forward-looking statements
as a result of many factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this prospectus, including those set forth under "Risk Factors"
and "Special Note Regarding Forward-Looking Statements."</I></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a specialty pharmaceutical company developing and planning to commercialize next-generation abuse-deterrent products that incorporate our
patented DETERx&reg; platform technology for the treatment of chronic pain and other diseases. Our lead product candidate, Xtampza, is an abuse-deterrent, extended-release, oral formulation of
oxycodone, a widely prescribed opioid medication. On November&nbsp;6, 2015, the FDA granted tentative approval to the NDA for Xtampza for the management of pain severe enough to require daily,
around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The FDA granted tentative approval because Xtampza met the required quality, safety and
efficacy standards for approval but remains subject to an automatic stay of up to 30&nbsp;months as a result of patent litigation filed by Purdue in March 2015. The FDA may grant final regulatory
approval upon the earliest to occur of expiration of the automatic stay, the court invalidating Purdue's patents or issuing an opinion of non-infringement, and expiration of Purdue's listed patents. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
connection with the FDA's tentative approval of our NDA for Xtampza, the FDA tentatively approved a product label, product packaging, post-marketing commitments and a REMS program, subject to
change should new information become available prior to the time that the FDA considers the Xtampza NDA for final regulatory approval. The tentatively approved Xtampza label, in contrast to the
product labels for all currently approved extended-release opioids, does not include a black box warning and related precautions stating that crushing, chewing or dissolving can cause rapid release
and absorption of a potentially fatal dose of the active ingredient. The absence of these warnings is supported by data that is described in the tentatively approved product label to support the claim
that when Xtampza is crushed or chewed, the drug release profile is bioequivalent to taking Xtampza intact, as directed. Furthermore, the tentatively approved product label contains differentiated
abuse-deterrent claims for Xtampza and also states that Xtampza can be taken by sprinkling the capsule contents on soft foods or into a cup, and then directly into the mouth, or through a gastrostomy
or nasogastric feeding tube. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Xtampza
has the same active ingredient as OxyContin&reg; OP, which is the largest selling abuse-deterrent, extended-release opioid in the United States by dollars, with $2.5&nbsp;billion in
U.S. sales in 2014. We conducted a comprehensive preclinical and clinical program for Xtampza consistent with FDA guidance on abuse-deterrence. These studies and clinical trials demonstrated that
chewing, crushing and/or dissolving Xtampza, and then taking it orally or smoking, snorting or injecting it did not meaningfully change its drug release profile or safety characteristics. By contrast,
clinical trials performed by us and others&nbsp;&#151; including a head-to-head clinical trial comparing Xtampza with OxyContin OP&nbsp;&#151; have shown that drug abusers can
achieve rapid release and absorption of the active ingredient by manipulating OxyContin OP using common household tools and methods commonly available on the Internet. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, our preclinical studies and clinical trials have shown that the contents of the Xtampza capsule can be removed from the capsule and sprinkled on food, directly into the mouth or
administered through feeding tubes, without compromising their drug release profile, safety or abuse-deterrent characteristics. By </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>65</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=69,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=105157,FOLIO='65',FILE='DISK131:[15ZCN1.15ZCN74701]DS74701A.;23',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_ds74701_1_66"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>contrast,
OxyContin OP, which is formulated in hard tablets, has a black box warning product label stating that crushing, dissolving, or chewing can cause rapid release and absorption of a potentially
fatal dose of the active ingredient. We believe that Xtampza, if it ultimately receives final regulatory approval, can address the pain management needs of the approximately 11&nbsp;million patients
in the United States who suffer from chronic pain and have difficulty swallowing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Since
2010, when we divested our former subsidiary, Onset Therapeutics,&nbsp;LLC, to PreCision Dermatology,&nbsp;Inc., we have devoted substantially all of our resources to the development of our
patented DETERx platform technology, the preclinical and clinical advancement of our product candidates, and the creation and protection of related intellectual property. Since 2011, we have not
generated any revenue from product sales as we currently have no approved products, and we continue to incur significant research, development and other expenses related to our ongoing operations.
Prior to our initial public offering of common stock, or IPO, in May 2015, we funded our operations primarily through the private placement of preferred stock, convertible notes and commercial bank
debt. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Outlook  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have never been profitable and have incurred net losses in each year since inception. We incurred net losses of $17.7&nbsp;million and
$14.4&nbsp;million for the nine months ended September&nbsp;30, 2015 and 2014, respectively. As of September&nbsp;30, 2015, we had an accumulated deficit of $119.5&nbsp;million. Substantially
all of our net losses resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to
continue to incur net losses in the foreseeable future as we seek final regulatory approval for, and, if approved, begin to commercialize Xtampza. Our net losses may fluctuate significantly from
quarter to quarter and year to year. We expect our expenses will increase substantially in connection with our ongoing activities as we:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> conduct clinical trials of our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> continue scale-up and improvement of our manufacturing processes; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> continue our research and development efforts; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  manufacture preclinical study and clinical trial materials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  maintain, expand and protect our intellectual property portfolio; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> seek regulatory approvals for our product candidates that successfully complete
clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> hire additional clinical, quality control and technical personnel to conduct our
clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> hire additional scientific personnel to support our product development efforts; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  implement operational, financial and management systems; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> hire additional general and administrative personnel to operate as a public
company. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>If
we obtain final regulatory approval for Xtampza, we expect to incur significant commercialization expenses related to marketing, manufacturing, distribution, product sales and reimbursement
functions. Initially we plan to detail Xtampza to approximately 11,000 physicians who write approximately 55% of the branded extended-release oral opioid prescriptions in the United States with a
sales team of approximately 120 sales representatives. In addition, we plan to deploy a separate, focused sales team of approximately 25 specialty sales representatives to detail Xtampza to nursing
homes, hospices and other institutions treating large populations of the elderly and other patients who need chronic pain relief and have difficulty swallowing. Accordingly, we will seek to fund our
operations through public or private equity or debt financings or other sources. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable
terms or at all. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and ability to develop our product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>66</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=70,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=184994,FOLIO='66',FILE='DISK131:[15ZCN1.15ZCN74701]DS74701A.;23',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_ds74701_1_67"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Financial Operations Overview  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Revenue  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Since 2011, we have not generated any revenue. In the future, we may generate revenue from product sales, marketing and distribution arrangements and
other collaborations, strategic alliances and licensing arrangements, or a combination of these sources. To the extent any of our product candidates are successfully commercialized, we expect that any
revenue we generate will fluctuate from quarter to quarter as a result of the amount and timing of payments that we receive upon the sale of our products, the timing and amount of license fees,
milestone and other payments. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Research and Development Expenses  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Research and development expenses consist of development costs associated with our DETERx platform technology and product candidates programs. These
costs are expensed as incurred and include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  compensation and employee-related costs, including stock-based compensation; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> costs associated with conducting our preclinical, clinical and regulatory
activities, including fees paid to third-party professional consultants and service providers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> costs incurred under clinical trial agreements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> costs for laboratory supplies and laboratory equipment; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  government grants, which are recognized as a reduction of the qualifying cost
being reimbursed; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> costs to acquire, develop and manufacture preclinical study and clinical trial
materials; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  facilities, depreciation and other expenses including allocated expenses for
rent and maintenance of facilities. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our product candidates. At this time,
due to the inherently unpredictable nature of preclinical and clinical development, and given the early stage of our product candidates other than Xtampza, we are unable to estimate with any certainty
the costs we will incur and the timelines we will require in the continued development of our product candidates. Clinical and preclinical development timelines, the probability of success and
development costs can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if
at all, and to what degree such arrangements would affect our development plans and capital requirements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
research and development has been focused primarily on developing our DETERx platform technology and Xtampza. Accordingly, historically we have not tracked research and development costs by
project. In addition, we use our employee and infrastructure resources across multiple research and development projects. We expect to track specific project costs when additional drug candidates
enter clinical trials in humans. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


General and Administrative Expenses  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>General and administrative expenses consist primarily of salaries and employee-related costs, including stock-based compensation and travel expenses
for our employees in executive, finance and administrative functions. Other general and administrative expenses include facility-related costs and professional fees for directors, accounting and legal
services, and expenses associated with obtaining and maintaining patents. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
anticipate that our general and administrative expenses will increase in the future as we increase our administrative headcount to support our continued research and development and the potential
commercialization of our product development programs. We also anticipate increased expenses related to audit, legal, regulatory and tax-related services associated with maintaining compliance with
exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs associated with being a public company. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>67</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=71,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=146410,FOLIO='67',FILE='DISK131:[15ZCN1.15ZCN74701]DS74701A.;23',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_ds74701_1_68"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Other Expense, Net  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Other expense, net consists of interest income, interest expense on convertible bridge notes, a term loan facility and the change in fair value of our
derivative liability. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Critical Accounting Policies and Significant Judgments and Estimates  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our management's discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been
prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and
expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses
and stock-based compensation. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results
of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under
different assumptions or conditions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>While
our significant accounting policies are described in more detail in the notes to our financial statements appearing elsewhere in this prospectus, we believe the following accounting policies to
be most critical to the significant judgments and estimates used in the preparation of our financial statements. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Accrued Expenses  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As part of the process of preparing our financial statements, we are required to estimate our accrued expenses. This process involves reviewing open
contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost
incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when
contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. We
periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees payable
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> clinical research organizations and investigative sites in connection with
clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> vendors in connection with preclinical development activities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> vendors related to product manufacturing, development, and distribution of
clinical materials; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  professional service fees for consulting and related services. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
base our expense accruals related to clinical trials on our estimates of the services received and efforts expended pursuant to our contractual arrangements. The financial terms of these agreements
are subject to negotiation, vary from contract to contract and may result in uneven payment flows and expense recognition. There may be instances in which payments made to our service providers will
exceed the level of services
provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial
milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance
of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly. Our understanding of the status and timing of services performed relative to the actual
status and timing of services performed may vary and may result in our reporting changes in estimates in any particular period. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Although
we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differs from the actual status and
timing of services performed, we may report amounts that are too high or too low in any particular period. To date, there have been no material differences from our estimates to the amount actually
incurred. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>68</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=72,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=464971,FOLIO='68',FILE='DISK131:[15ZCN1.15ZCN74701]DS74701A.;23',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_ds74701_1_69"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Impairment of Long-Lived Assets  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Long-lived assets consist primarily of property and equipment. We test long-lived assets for impairment at year end or whenever events or
circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of
such assets, an impairment loss would be recognized in earnings. The long-lived asset would be written down to the estimated fair value, calculated based on the present value of expected future cash
flows. While our current and historical operating losses and negative cash flows are indicators of impairment, we believe that future cash flows to be received support the carrying value of our
long-lived assets and, accordingly, have not recognized any impairment losses on long-lived assets for the nine months ended September&nbsp;30, 2015 and years ended December&nbsp;31, 2013 and
December&nbsp;31, 2014. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Stock-Based Compensation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We account for grants of stock options and restricted stock to employees based on their grant date fair value and recognize compensation expense over
the vesting periods. We estimate the fair value of stock options as of the date of grant using the Black-Scholes option pricing model, and we estimate the fair value of restricted stock based on the
fair value of the underlying common stock as determined by our board
of directors or the value of the services provided, whichever is more readily determinable. We account for stock options and restricted stock awards to non-employees using the fair value approach.
Stock options and restricted stock awards to non-employees are subject to periodic revaluation over their vesting terms. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Stock-based
compensation expense represents the cost of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards (usually the vesting
period) on a straight-line basis, net of estimated forfeitures. We estimate the fair value of stock option grants using the Black-Scholes option pricing model, which requires the input of highly
subjective assumptions, including (i)&nbsp;the risk-free interest rate, (ii)&nbsp;the expected volatility of our stock, (iii)&nbsp;the expected term of the award and (iv)&nbsp;the expected
dividend yield. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. Treasury securities. Prior to our IPO, there was no public
market for the trading of our common stock. Due to the lack of a public market for the trading of our common stock and a lack of Company-specific historical and implied volatility data, we have based
our estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. For these analyses, we have selected companies with comparable
characteristics to ours, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based
awards. We compute the historical volatility data using the daily closing prices for the selected companies' shares during the equivalent period of the calculated expected term of our stock-based
awards. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available. The expected term represents the
period of time that options are expected to be outstanding. Because there was not enough historical exercise behavior through September&nbsp;30, 2015, we determined the expected life assumption
using the simplified method, which is an average of the contractual term of the option and the vesting period. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>69</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=73,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=328257,FOLIO='69',FILE='DISK131:[15ZCN1.15ZCN74701]DS74701A.;23',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_ds74701_1_70"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>For
employee stock option grants made during the years ended December&nbsp;31, 2013 and 2014 and the nine months ended September&nbsp;30, 2015, the weighted-average assumptions used in the
Black-Scholes option pricing model to determine the fair value of those grants were as follows: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="101pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="100pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=3 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Years Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Nine Months Ended<BR>
September&nbsp;30, 2015 </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.09%&nbsp;&#150;&nbsp;1.22%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.80%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.70%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>87.8%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>77.1%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>77.0%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term (in years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.21</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>We
had no non-employee stock option grants for the years ended December&nbsp;31, 2013 and December&nbsp;31, 2014.  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Fair Value of Common
Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;After our stock began trading on NASDAQ on May&nbsp;7, 2015, the fair value of common stock underlying our options was
determined by the closing price of our common stock on the date of the grant. Prior to the IPO, the fair value of the shares of our common stock underlying our stock options was determined by our
board of directors. Because there was no public market for our common stock, our board of directors determined the fair value of our common stock at the time of grant of the option by considering a
number of objective and subjective factors, including valuations of comparable companies, sales of our convertible preferred stock to unrelated third parties, our operating and financial performance
and general and industry specific economic outlook.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Expected
Term.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The expected term of stock options represents the weighted-average period that the stock options are expected to remain
outstanding. We estimated the expected term using the simplified method, which is an average of the contractual term of the option and the vesting period.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Expected
Volatility.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Since there was limited historical price data for our common stock prior to the IPO and a lack of company-specific historical
volatility, we determined the share price volatility for options granted based on an analysis of the volatility used by a peer group of publicly traded medical device companies. In evaluating
similarity, we consider factors such as industry, stage of life cycle and size.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Risk-free Interest
Rate.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for zero-coupon U.S. Treasury
notes with remaining terms similar to the expected term of the options.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Dividend
Rate.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The expected dividend was assumed to be zero as we have never paid dividends and have no current plans to do so. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I> Expected Forfeiture
Rate.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;We are required to estimate forfeitures at the time of grant, and revise those estimates in subsequent periods if actual
forfeitures differ from those estimates. We use historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest.
To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Warrants  </I></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In connection with execution of an amendment, or Amendment No.&nbsp;1, to our Loan and Security Agreement in January 2014, or the Original Term
Loan, we issued 2,091 warrants to purchase shares of common stock with an exercise price of $0.35 per share to Silicon Valley Bank, or SVB. These warrants expire on </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>70</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=74,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=298370,FOLIO='70',FILE='DISK131:[15ZCN1.15ZCN74701]DS74701A.;23',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_ds74701_1_71"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>January&nbsp;30,
2024. The warrant agreement provides for additional warrants to be issued and immediately exercisable upon additional borrowings by us, which in turn are contingent upon meeting
certain performance measures for Xtampza. We met the performance measures, and in August 2014, the Original Term Loan, as amended by Amendment No.&nbsp;1, was further amended and additional
financing was extended. Based on the terms of the warrant agreement, we issued 12,548 additional warrants to purchase shares of common stock with an exercise price of $0.35 per share to SVB. The fair
value of these warrants was </FONT><FONT SIZE=2><I>de minimis</I></FONT><FONT SIZE=2> as of December&nbsp;31, 2014. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Net Operating Loss Carryforwards  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Utilization of net operating loss, or NOL, and research and development credit carryforwards may be subject to a substantial annual limitation due to
ownership change limitations that have occurred or that could occur in the future, as required by Section&nbsp;382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, as well as
similar state and foreign provisions. These ownership changes may limit the amount of NOL and research and development credit carryforwards that can be utilized annually to offset future taxable
income and tax, respectively. In general, an ownership change, as defined by Section&nbsp;382 of the Code, results from a transaction or series of transactions over a three-year period resulting in
an ownership change of more than 50&nbsp;percentage points of the outstanding stock of a company by certain shareholders. We have not completed a current study to assess whether an ownership change
has occurred or whether there have been multiple ownership changes since our formation. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>At
December&nbsp;31, 2014, we had U.S. federal NOL carryforwards of $78.3&nbsp;million which may be available to offset future taxable income. The U.S. federal NOL carryforwards begin to expire in
2022. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2014 and 2013 and September&nbsp;30, 2015, we have provided a full valuation allowance for deferred tax assets. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Income Taxes  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We record uncertain tax positions on the basis of a two-step process whereby (i)&nbsp;we determine whether it is more likely than not that the tax
positions will be sustained on the basis of the technical merits of the positions and (ii)&nbsp;for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the
largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. We recognize interest and penalties related to unrecognized tax
benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. There were no uncertain tax positions as of December&nbsp;31, 2014 and 2013. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


JOBS Act  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are an "emerging growth company," as defined in Section&nbsp;2(a) of the Securities Act, as modified by the JOBS Act. As such, we are eligible to
take advantage of exemptions from various disclosure and reporting requirements that are applicable to other public companies that are not "emerging growth companies" including, but not limited
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> not being required to comply with the auditor attestation requirements of
Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> being permitted to present only two years of audited financial statements and
only two years of related Management's Discussion and Analysis of Financial Condition and Results of Operations, in each case, instead of three years; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> being permitted to present the same number of years of selected financial data
as the years of audited financial statements presented, instead of five years; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> reduced disclosure obligations regarding executive compensation, including no
Compensation Disclosure and Analysis; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> not being required to comply with any requirement that may be adopted by the
Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements;
and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>71</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=75,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=368904,FOLIO='71',FILE='DISK131:[15ZCN1.15ZCN74701]DS74701A.;23',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_ds74701_1_72"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  exemptions from the requirements of holding a non-binding advisory vote on
executive compensation and shareholder approval of any golden parachute payments not previously approved. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
may choose to take advantage of some or all of the available exemptions. We have taken advantage of some of the reduced reporting burdens in this prospectus. Accordingly, the scope of the
information contained herein may be different than the scope of the information you receive from other public companies in which you hold stock. We do not know if some investors will find our shares
less attractive as a result of our utilization of these or other exemptions. The result may be a less active trading market for our shares and our share price may be more volatile. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, Section&nbsp;107 of the JOBS Act also provides that an "emerging growth company" can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the
Securities Act for complying with new or revised accounting standards. In other words, an "emerging growth company" can delay the adoption of certain
accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards
and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not "emerging growth companies." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
will remain an "emerging growth company" until the earliest of (i)&nbsp;the last day of the first fiscal year in which our annual gross revenues exceed $1&nbsp;billion; (ii)&nbsp;the date
that we become a "large accelerated filer" as defined in Rule&nbsp;12b-2 under the Exchange Act, which would occur if the market value of our shares that are held by non-affiliates exceeds
$700&nbsp;million as of the last business day of our most recently completed second fiscal quarter; (iii)&nbsp;the date on which we have issued more than $1&nbsp;billion in nonconvertible debt
during the preceding three-year period; and (iv)&nbsp;December&nbsp;31, 2020. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Recently Issued Accounting Pronouncements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In May 2014, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No.&nbsp;2014-09, which amends the
guidance for accounting for revenue from contracts with customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification, or ASC, Topic&nbsp;605, Revenue
Recognition, and creates a new Topic&nbsp;606, Revenue from Contracts with Customers. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain
practical expedients permitted; or retrospectively with the cumulative effect of initially adopting the ASU recognized at the date of initial application. On August&nbsp;12, 2015, the FASB issued
ASU No.&nbsp;2015-14, which defers the effective date of ASU No.&nbsp;2014-09 by one year to December&nbsp;15, 2017 for annual reporting periods beginning after that date, including interim
periods within those periods. The FASB also approved permitting early adoption of the standard, but not before the original effective date of December&nbsp;15, 2016. We have not yet determined which
adoption method it will utilize or the effect that the adoption of this guidance will have on its financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
June 2014, the FASB issued ASU 2014-12, </FONT><FONT SIZE=2><I>Compensation&nbsp;&#151; Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award
Provide That a Performance Target Could Be Achieved after the Requisite Service Period</I></FONT><FONT SIZE=2>. ASU 2014-12 applies to all reporting entities that grant their employees share-based
payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. That is the case when an employee is eligible to
retire or otherwise terminate employment before the end of the period in which a performance target (for example, an initial public offering or a profitability target) could be achieved and still be
eligible to vest in the award if and when the performance target is achieved. The standard is required to be adopted by public business entities in annual periods beginning on or after
December&nbsp;15, 2015 and interim periods within those annual periods. We plan to implement this standard in the first quarter of fiscal year 2016 and management is currently evaluating the
potential impact of this new guidance on our financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>72</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=76,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=811502,FOLIO='72',FILE='DISK131:[15ZCN1.15ZCN74701]DS74701A.;23',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_ds74701_1_73"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
August 2014, the FASB issued ASU No.&nbsp;2014-15, </FONT><FONT SIZE=2><I>Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern.</I></FONT><FONT SIZE=2> ASU 2014-15
requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist that raise substantial doubt about an entity's ability to continue as a
going concern within one year after the date the financial statements are issued and provide related disclosures. ASU 2014-15 is effective for annual periods ending after December&nbsp;15, 2016 and
earlier application is permitted. The adoption of ASU 2014-15 is not expected to have a material effect on our financial statements or disclosures. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
July 2015, the FASB issued ASU No.&nbsp;2015-11, which amends existing guidance for measurement of inventory. Current inventory guidance requires an entity to measure inventory at the lower of
cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. The amendments do not apply to inventory that is measured
using last-in, first-out (LIFO) or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out or average cost. An
entity should measure all inventory to which the amendments apply at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of
business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The
amendments in the ASU No.&nbsp;2015-11 more closely align the measurement of inventory pursuant to GAAP with the measurement of inventory pursuant to International Financial Reporting Standards. The
amendments are effective for fiscal years beginning after December&nbsp;15, 2016, and interim periods within fiscal years beginning after December&nbsp;15, 2017. The amendments should be applied
prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. We do not expect the adoption of this guidance to have a material impact on our financial
statements. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Results of Operations  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Comparison of the Nine Months ended September&nbsp;30, 2015 and September&nbsp;30, 2014  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The following table summarizes the results of our operations for the nine months ended September&nbsp;30, 2014 and 2015: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Nine Months Ended<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Change </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>12,652</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,444</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(6,208</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,686</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>11,027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9,341</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other expense, net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>110</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>259</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>149 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(14,448</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(17,730</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,282 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>Research
and development expenses were $12.7&nbsp;million for the nine months ended September&nbsp;30, 2014, or the 2014 Period, compared to $6.4&nbsp;million for the nine months ended
September&nbsp;30, 2015, or the 2015 Period. The $6.2&nbsp;million decrease was primarily related to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a decrease in clinical trial costs of $8.1&nbsp;million due to the completion
of clinical trials for Xtampza during 2014; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an increase in consulting costs of $1.2&nbsp;million mainly due to costs
associated with the FDA Advisory Committee meeting held in September 2015; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an increase in manufacturing costs of $1.0&nbsp;million related to Xtampza. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>73</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=77,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=244014,FOLIO='73',FILE='DISK131:[15ZCN1.15ZCN74701]DS74701A.;23',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_ds74701_1_74"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>General
and administrative expenses were $1.7&nbsp;million for the 2014 Period compared to $11.0&nbsp;million for the 2015 Period. The $9.3&nbsp;million increase was primarily related
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an increase in commercial costs of $3.4&nbsp;million primarily due to
consultant costs related to analytics and strategies for commercialization of Xtampza; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an increase in salaries, wages and benefits of $3.4&nbsp;million primarily due
to headcount, bonuses and stock compensation expense; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an increase in legal and consulting fees of $760,000 primarily due to costs
related to litigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an increase in insurance costs of $491,000 due to directors' and officers'
insurance; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an increase in professional fees of $401,000 primarily due to audit, accounting
and recruitment fees. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Comparison of the Years Ended December&nbsp;31, 2013 and 2014  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The following table summarizes the results of our operations for the years ended December&nbsp;31, 2013 and 2014: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Years Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Change </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>14,157</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>14,959</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>802</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,885</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,706</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>821</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other expense, net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>155</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>252</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>97 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(16,197</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(17,917</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,720 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2><B><I> Research and Development Expenses.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses were $14.2&nbsp;million for the year ended December&nbsp;31, 2013, compared to
$15.0&nbsp;million for the year ended December&nbsp;31, 2014. The $802,000 increase was related primarily to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an increase in consultant costs of $818,000 due to regulatory consulting,
including costs associated with filing the NDA; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an increase of $797,000 in manufacturing costs, due mainly to costs incurred for
pre-validation batches; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an increase of $240,000 in personnel costs, due primarily to increased
headcount. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>These
increases were partially offset by a decrease in clinical trial expenses and other development costs of $1.0&nbsp;million. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> General and Administrative Expenses.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses were $1.9&nbsp;million for the year ended December&nbsp;31, 2013, compared to
$2.7&nbsp;million for the year ended December&nbsp;31, 2014. The $821,000 increase was related primarily to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> An increase in professional fees including legal and audit fees of $832,000, due
mainly to prior year audits, accounting services and recruiting fees. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>This
increase was partially offset by a decrease in market research costs of $129,000. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Other Expense, Net.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Other expense, net was $155,000 for the year ended December&nbsp;31, 2013, compared to $252,000 for the year ended December&nbsp;31, 2014.
The increase in interest expense of $176,000 in </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>74</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=78,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=395315,FOLIO='74',FILE='DISK131:[15ZCN1.15ZCN74701]DS74701A.;23',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_ds74701_1_75"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>2014
was due to larger outstanding balances under our debt agreements, which was partially offset by the decrease to the periodic fair value adjustment of warrant liability of $79,000. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Liquidity and Capital Resources  </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Sources of liquidity  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have incurred net losses and negative cash flows from operations since inception. Since inception, we have funded our operations primarily through
the private placements of our preferred stock, our IPO, convertible notes and commercial bank debt. As of September&nbsp;30, 2015, we had $105.5&nbsp;million in cash and cash equivalents. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
March 2015, we issued 41,666,667 shares of Series&nbsp;D Convertible Preferred Stock in exchange for aggregate consideration of $50.0&nbsp;million, including $45.0&nbsp;million in cash. In
connection with this financing, convertible notes with related parties in the aggregate principal amount of $5.0&nbsp;million automatically converted to an aggregate of 4,166,667 shares of
Series&nbsp;D Preferred Stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
May 2015, we closed our IPO, which resulted in the sale of 6,670,000 shares of our common stock at a public offering price of $12.00 per share, including 870,000 shares of common stock upon the
exercise by the underwriters of their option to purchase additional shares at the public offering price. We received net proceeds from the IPO of approximately $72.0&nbsp;million, after deducting
underwriting discounts, commission and expenses payable by us. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Although
it is difficult to predict future liquidity requirements, we believe that the net proceeds from this offering, together with our existing cash resources, will be sufficient to fund our
operations into 2018, including the commercialization of Xtampza, if it receives final regulatory approval, and the continuation of our development of our other product candidates. We have based this
estimate on assumptions that may prove to be incorrect and we could use our available capital resources sooner than we currently expect. We may never become profitable, or if we do, we may not be able
to sustain profitability on a recurring basis. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Cash flows  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Operating activities.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Cash used was $12.6&nbsp;million in the 2015 Period and $10.4&nbsp;million in the 2014 Period. The increase in cash used in operating
activities was due primarily to the change in net loss partially offset by changes in the working capital accounts. We expect cash used in operating activities to increase for the foreseeable future
as we seek final regulatory approval for, and, prepare to commercialize Xtampza by establishing sales, marketing, manufacturing and distribution capabilities and fund research, development and
clinical activities for additional product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Cash
used in operating activities increased by $1.4&nbsp;million, from $16.5&nbsp;million for the year ended December&nbsp;31, 2013 to $17.9&nbsp;million for the year ended December&nbsp;31,
2014. The increase in cash used in operating activities was driven primarily by an increase in net loss. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Investing activities.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The cash used in the 2015 Period was related to the purchase of property and equipment. There was no cash used for investing activities in the
2014 Period. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Cash
used in investing activities decreased $198,000 from $206,000 for the year ended December&nbsp;31, 2013 to $8,000 for the year ended December&nbsp;31, 2014. The difference was related to
decreased purchases of property and equipment. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Financing activities.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The cash provided by financing activities for the 2015 Period primarily represent net proceeds from the IPO and from the sale of
Series&nbsp;D convertible preferred stock of $72.0&nbsp;million and $44.8&nbsp;million, respectively. The cash provided by financing activities for the 2014 Period primarily reflects the
$7.0&nbsp;million drawdown of a term note payable. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>75</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=79,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=34369,FOLIO='75',FILE='DISK131:[15ZCN1.15ZCN74701]DS74701A.;23',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_ds74701_1_76"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Cash
provided by financing activities decreased $313,000 from $12.4&nbsp;million for the year ended December&nbsp;31, 2013 to $12.0&nbsp;million for the year ended December&nbsp;31, 2014.
During 2013, we issued 8,658,008 shares of Series&nbsp;C Preferred Stock for net proceeds of $12.0&nbsp;million. In January 2014, the Original Term Loan was amended, pursuant to Amendment
No.&nbsp;1, to provide for borrowings of up to $6.0&nbsp;million. In February 2014, we borrowed $2.0&nbsp;million. A portion of the proceeds from the initial borrowing were used to pay down the
original loan balance resulting in us receiving $1.1&nbsp;million. In August 2014, the Original Term Loan, as amended by Amendment No.&nbsp;1, was further amended to provide for borrowing of up to
$8.0&nbsp;million. In August 2014 and September 2014 we drew down $3.0&nbsp;million and $3.0&nbsp;million, respectively under the Original Term Loan, as amended. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Funding requirements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Since 2011, we have not generated any product revenue. We do not know when, or if, we will generate any revenue as we seek final regulatory approval
for, and potentially begin to commercialize, Xtampza. We anticipate that we will continue to incur losses for the next several years, and we expect the losses to increase as we continue the
development of, and seek regulatory final regulatory approval for, Xtampza and our other product candidates, and begin to commercialize any approved products. We are subject to all of the risks common
to the development of new pharmaceutical products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. We
will also incur additional costs associated with operating as a public company. We anticipate that we will need substantial additional funding in connection with our continuing operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Until
we can generate a sufficient amount of revenue from our pharmaceutical products, if ever, we expect to finance future cash needs through public or private equity or debt offerings. Additional
capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale
back or discontinue the development or commercialization of one or more of our product candidates. If we raise additional funds through the issuance of additional debt or equity securities, it could
result in dilution to our existing shareholders, increased fixed payment obligations and the existence of securities with rights that may be senior to those of our common stock. If we incur
indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt,
limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any of these
events could significantly harm our business, financial condition and prospects. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual
results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we
currently expect. The amount and timing of future funding requirements, both near- and long-term, will depend on many factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the design, initiation, progress, size, timing, costs and results of preclinical
studies and clinical trials for our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the outcome, timing and cost of regulatory approvals by the FDA and comparable
foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than, or evaluate clinical endpoints other than
those that we currently expect; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the timing and costs associated with manufacturing Xtampza and our other product
candidates for clinical trials, preclinical studies and, if approved, for commercial sale; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the number and characteristics of product candidates that we pursue; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of patent infringement litigation, including our litigation with Purdue
relating to Xtampza or our other product candidates, which may be expensive to defend and delay the commercialization of Xtampza or our other product candidates; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>76</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=80,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=163965,FOLIO='76',FILE='DISK131:[15ZCN1.15ZCN74701]DS74701A.;23',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_ds74701_1_77"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our need to expand our research and development activities, including our need
and ability to hire additional employees; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> our need to implement additional infrastructure and internal systems and hire
additional employees to operate as a public company; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the effect of competing technological and market developments; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost of establishing sales, marketing and distribution capabilities for any
products for which we may receive regulatory approval. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>If
we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition and results of operations could be
materially adversely affected. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Contractual Obligations and Commitments  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table summarizes our contractual obligations and commitments as of December&nbsp;31, 2014 that will affect our future liquidity: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="46pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Less than<BR>
1&nbsp;year </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>1&nbsp;-&nbsp;3&nbsp;years </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>3&nbsp;-&nbsp;5&nbsp;years </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>More than<BR>
5&nbsp;years </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating lease obligations<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>106</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>227</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-Term Debt<SUP>(2)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>13,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,194</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,806</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>13,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,300</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,033</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Operating
lease obligations represent future minimum lease payments under our non-cancelable operating lease in effect as of
December&nbsp;31, 2014, reflecting remaining lease payments for our current facility in Canton, Massachusetts.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Long-term
debt obligations represent future principal payments under our Original Term Loan, as amended, and our convertible notes as of
December&nbsp;31, 2014. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Off-Balance Sheet Arrangements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Quantitative and Qualitative Disclosures about Market Risks  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are exposed to market risk related to changes in interest rates. As of September&nbsp;30, 2015, we had cash and cash equivalents consisting of
cash and money market funds of $105.5&nbsp;million. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates,
particularly because our money market funds are short-term highly liquid investments. Due to the short-term duration and the low risk profile of our investments, an immediate 10% change in interest
rates would not have a material effect on the fair market value of our portfolio. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>77</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=81,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=370693,FOLIO='77',FILE='DISK131:[15ZCN1.15ZCN74701]DS74701A.;23',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_du74701_1_78"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="du74701_business"> </A>
<A NAME="toc_du74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  BUSINESS    <BR>    </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a specialty pharmaceutical company developing and planning to commercialize next-generation abuse-deterrent products that incorporate our
patented DETERx&reg;
platform technology for the treatment of chronic pain and other diseases. Our lead product candidate, Xtampza&#153; ER, or Xtampza, is an abuse-deterrent, extended-release, oral formulation of
oxycodone, a widely prescribed opioid medication. On November&nbsp;6, 2015, the U.S. Food and Drug Administration, or FDA, granted tentative approval to the new drug application, or NDA, for Xtampza
for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The FDA granted tentative approval
because Xtampza met the required quality, safety and efficacy standards for approval but remains subject to an automatic stay of up to 30&nbsp;months as a result of patent litigation filed by Purdue
Pharma,&nbsp;L.P., or Purdue, in March 2015. The FDA may grant final regulatory approval upon the earliest to occur of expiration of the automatic stay, the court invalidating Purdue's patents or
issuing an opinion of non-infringement, and expiration of Purdue's listed patents. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
connection with the FDA's tentative approval of our NDA for Xtampza, the FDA tentatively approved a product label, product packaging, post-marketing commitments and a Risk Evaluation and Mitigation
Strategy, or REMS, program, subject to change should new information become available prior to the time that the FDA considers the Xtampza NDA for final regulatory approval. The tentatively approved
Xtampza label, in contrast to the product labels for all currently approved extended-release opioids, does not include a black box warning and related precautions stating that crushing, chewing or
dissolving can cause rapid release and absorption of a potentially fatal dose of the active ingredient. The absence of these warnings is supported by data that is described in the tentatively approved
product label to support the claim that when Xtampza is crushed or chewed, the drug release profile is bioequivalent to taking Xtampza intact, as directed. Furthermore, the tentatively approved
product label contains differentiated abuse-deterrent claims for Xtampza and also states that Xtampza can be taken by sprinkling the capsule contents on soft foods or into a cup, and then directly
into the mouth, or through a gastrostomy or nasogastric feeding tube. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Xtampza
has the same active ingredient as OxyContin&reg; OP, which is the largest selling abuse-deterrent, extended-release opioid in the United States by dollars, with $2.5&nbsp;billion in
U.S. sales in 2014. We conducted a comprehensive preclinical and clinical program for Xtampza consistent with FDA guidance on abuse-deterrence. These studies and clinical trials demonstrated that
chewing, crushing and/or dissolving Xtampza, and then taking it orally or smoking, snorting or injecting it did not meaningfully change its drug release profile or safety characteristics. By contrast,
clinical trials performed by us and others&nbsp;&#151; including a head-to-head clinical trial comparing Xtampza with OxyContin OP&nbsp;&#151; have shown that drug abusers can
achieve rapid release and absorption of the active ingredient by manipulating OxyContin OP using common household tools and methods commonly available on the Internet. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, our preclinical studies and clinical trials have shown that the contents of the Xtampza capsule can be removed from the capsule and sprinkled on food, directly into the mouth or
administered through feeding tubes, without compromising their drug release profile, safety or abuse-deterrent characteristics. By contrast, OxyContin OP, which is formulated in hard tablets, has a
black box warning product label stating that crushing, dissolving, or chewing can cause rapid release and absorption of a potentially fatal dose of the active ingredient. We believe that Xtampza, if
it ultimately receives final regulatory approval, can address the pain management needs of the approximately 11&nbsp;million patients in the United States who suffer from chronic pain and have
difficulty swallowing. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>78</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=82,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=788679,FOLIO='78',FILE='DISK131:[15ZCN1.15ZCN74701]DU74701A.;22',USER='CGONCE',CD='31-DEC-2015;12:21' -->
<A NAME="page_du74701_1_79"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Background on Chronic Pain and Opioid Abuse  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Patients Suffering from Chronic Pain  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Chronic pain, typically defined as pain that lasts beyond the healing of an injury or that persists longer than three months, is a worldwide problem
with serious health and economic consequences. According to the National Institutes of Health, or NIH, chronic pain represents a public health crisis of epidemic proportions affecting approximately
100&nbsp;million people in the United States and 20-30% of the population worldwide&nbsp;&#151; more than heart disease, cancer and diabetes combined. Common types of chronic pain include
lower back pain, arthritis, headache, and face and jaw pain. The prevalence of chronic pain is expected to rise in the future, as the incidence of associated illnesses such as diabetes, arthritis and
cancer increases in the aging population. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Chronic
pain leads to over $560&nbsp;billion in healthcare and productivity costs each year according to the Institute of Medicine. Prescription opioids remain the primary treatment for chronic
pain. Chronic pain patients often start treatment with immediate release opioids, but change to extended-release opioids to achieve more convenient dosing with more consistent blood levels of the
active drug. Extended-release opioids incorporate a large amount of opioid with a time-release mechanism designed to deliver steady amounts of opioid, typically over 12 to 24&nbsp;hours. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Annual
sales from extended-release and long-acting opioids represent approximately $6.0&nbsp;billion (29&nbsp;million prescriptions) of the approximately $14&nbsp;billion U.S. opioid market in
2014. OxyContin OP generated U.S. sales of $2.5&nbsp;billion in 2014, which represents approximately a 20% U.S. market share of all extended-release and long-acting opioid prescriptions. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Prescription Opioid Abuse is an Epidemic in the United States  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Abusers tamper with extended-release opioid drugs to achieve the euphoria that results from rapid increases in the blood concentration of the active
ingredient, a potentially fatal activity known as dose dumping. The U.S. Centers for Disease Control and Prevention, or CDC, described abuse of prescription drugs in the United States as a growing and
deadly epidemic. Deaths in the United States from prescription opioid overdose have grown from approximately 4,000 in 1999 to approximately 16,000 in 2013. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>According
to a 2012 study conducted by the CDC, annually there are 144,000 treatment admissions for abuse or misuse of opioids, 560,000 emergency room&nbsp;visits for misuse or abuse of opioids,
over 2.5&nbsp;million individuals who abuse or are dependent on opioids and over 7.3&nbsp;million non-medical users who use opioids without prescriptions or for non-therapeutic effects. The
American Journal of Managed Care estimated in a 2013 report that opioid abuse costs public and private healthcare payors over $72&nbsp;billion annually in direct healthcare costs, including costs of
emergency room&nbsp;visits, rehabilitation and associated health problems. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA has estimated that nearly 35&nbsp;million Americans have used prescription pain relievers, including opioid-containing drugs, for non-prescription purposes at least once in their lifetime. A
2011 research report from the Substance Abuse and Mental Health Services Administration estimated that between 1999 and 2009 there was a 430% increase in substance-abuse treatment facility admissions
resulting from the use of prescription pain relievers. According to a 2011 study by the University of Michigan, one in 12 high school seniors reported non-medical use of Vicodin, a combination of
acetaminophen and hydrocodone, and one in 20 high school seniors reported non-medical use of OxyContin. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Drug
abusers find currently approved extended-release opioids desirable because of the large amount of drug payload, which they attempt to release quickly into the bloodstream to create euphoria. It
is difficult for drug abusers to achieve this rapid release and absorption into the bloodstream by taking multiple intact extended-release opioid tablets or capsules because doing so often causes
sleepiness and/or respiratory distress before euphoria is achieved. Instead, abusers attempt to defeat the extended-release properties in order to achieve rapid release of the active ingredient. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>79</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=83,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=60599,FOLIO='79',FILE='DISK131:[15ZCN1.15ZCN74701]DU74701A.;22',USER='CGONCE',CD='31-DEC-2015;12:21' -->
<A NAME="page_du74701_1_80"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Despite
the introduction of OxyContin OP in 2010 as the first FDA-approved, abuse-deterrent extended-release opioid formulation, abuse of extended-release opioids, including OxyContin OP, continues to
be a major public health issue. OxyContin OP, even with its abuse-deterrent formulation, remains vulnerable to abuse using common household objects, like pill crushers. Third party studies found that
abusers of OxyContin OP use various routes of
abuse&nbsp;&#151; including snorting, injection and oral abuse&nbsp;&#151; despite its abuse-deterrent features. In a third party study of OxyContin abusers both before and after
OxyContin OP was introduced, researchers found that while the non-oral route of administration of abuse of OxyContin OP (i.e.,&nbsp;injection, snorting and smoking) decreased after its introduction,
oral abuse of OxyContin OP increased from approximately 52% to 75% of OxyContin abusers. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="du74701_oxycontin_op_tablet_+_$6.39_pi__oxy02648"> </A>
<A NAME="toc_du74701_2"> </A>
<BR></FONT><FONT SIZE=2><B><I>OxyContin OP Tablet&nbsp;+&nbsp;$6.39 Pill Crusher&nbsp;= Abuseable Fine Powder in 16 Seconds    <BR>    </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g95987.jpg" ALT="GRAPHIC" WIDTH="438" HEIGHT="157">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Legislative and Regulatory Actions  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In response to widespread prescription opioid abuse, the U.S. government and a number of state legislatures have introduced, and in some cases have
enacted, legislation and regulations intended to encourage the development of abuse-deterrent forms of pain medications. The FDA has stated that addressing prescription drug abuse is a priority, and
the development of abuse-deterrent opioids is a key part of that strategy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
2010, Purdue received approval for a new formulation of OxyContin, named OxyContin OP, designed to make it more difficult to abuse. In April 2013, the FDA approved new product labeling for
OxyContin OP, which, for the first time included abuse-deterrent product label claims consistent with the FDA's January 2013 draft abuse-deterrent product label guidance. At the same time, the FDA
withdrew the approval of the original, non-abuse-deterrent OxyContin formulation, thus preventing the commercialization of generic versions of the original OxyContin that did not have abuse-deterrent
properties. This decision by the FDA is consistent with its public statement that the development of abuse-deterrent opioid analgesics is a public health priority. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Recent
actions to address the opioid abuse epidemic include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>STOPP Act:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In July
2012, a bipartisan group of Congressional leaders introduced the STOPP (Stop the Tampering of Prescription Pills) Act. Reintroduced in February 2013, this bill, if approved, would require that
non-abuse-deterrent opioids be removed from the market if an abuse-deterrent formulation of that opioid has already been approved for marketing by the FDA. Since being reintroduced in 2013, this bill
was referred to the U.S. House of Representatives' Subcommittee on Health and there has been no further action taken. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>FDA guidance:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In
January 2013, the FDA introduced draft guidance regarding studies and clinical trials that should be conducted to demonstrate that a given formulation has abuse-deterrent properties, how those studies
and clinical trials will be evaluated, and what product labeling claims may be approved based on the results of those studies and clinical trials. The draft guidance described four categories of
abuse-deterrence studies and clinical trials: Categories&nbsp;1, 2 and 3 consist of pre-marketing studies and clinical trials designed to evaluate a product candidate's potentially abuse-deterrent
properties under controlled conditions, while Category&nbsp;4 post-marketing </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>80</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=84,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=113111,FOLIO='80',FILE='DISK131:[15ZCN1.15ZCN74701]DU74701A.;22',USER='CGONCE',CD='31-DEC-2015;12:21' -->
<A NAME="page_du74701_1_81"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>clinical
trials and studies assess the real-world impact of a potentially abuse-deterrent formulation. These requirements were largely adopted in the April 2015 final FDA guidance, which also provides
examples of product label claims that may be merited based on the results of the corresponding studies and clinical trials. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>48 state and territorial attorneys general support
development of abuse-deterrent opioids:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In March 2013, the National Association of Attorneys General urged the FDA to adopt standards requiring manufacturers and
marketers of prescription opioids to develop abuse-deterrent versions of those products. Their letter, signed by 48 state and territorial attorneys general, commended the FDA for expeditiously
proposing guidance that establishes clear standards for manufacturers who develop and market abuse-resistant opioid products, while considering incentives for undertaking the research and development
necessary to bring such products to market. It also encouraged the FDA to ensure that generic versions of such products are designed with similar abuse-resistant features. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>FDA mandated product label
changes:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;10, 2013, the FDA announced its intention to require product label changes to all approved extended-release and long-acting opioids. In
particular, the FDA announced its intention to update the indications for these opioids so that they will be indicated only for the management of pain severe enough to require daily, around-the-clock,
long-term opioid treatment and for which alternative treatment options are inadequate. On April&nbsp;16, 2014, the FDA updated these indications. The FDA also requires post-marketing studies and
clinical trials for any such opioids. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>29 state and territorial attorneys general speak out
against the approval of non-abuse-deterrent narcotics:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In December 2013, the attorneys general of 29 states and territories urged the FDA to reconsider its approval
of Zohydro&#153; ER, an extended-release hydrocodone formulation with no abuse-deterrent properties, or alternatively to set a rigorous timeline for reformulation of Zohydro ER in an
abuse-deterrent form, with significant limitations on prescriptions of Zohydro ER in the interim. In early 2014, members of Congress from three states introduced a bill to revoke FDA approval of
Zohydro ER and prevent the FDA from approving any new opioids that do not have abuse-deterrent features and the governor of Massachusetts signed an executive order (since overturned by a court) that
attempted to ban the dispensing of Zohydro ER in Massachusetts. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Health Canada Proposed Legislation Requiring Opioids to
be Tamper Resistant Before Sale.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In June 2014, Health Canada issued a Notice of Intent for Interested Parties on Tamper Resistance under the Controlled Drugs and
Substances Act. If approved, the proposed legislation would require that drugs at high risk for abuse, including extended-release oxycodone, have tamper-resistant properties before they can be sold in
Canada. </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Massachusetts and Maine approved laws to mandate that
insurers cover abuse-deterrent opioids:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In August 2014 and June 2015, the governors of Massachusetts and Maine, respectively, signed laws establishing a drug
formulary commission charged with identifying drugs with a heightened public health risk due to their potential for abuse and formulations of abuse-deterrent drugs that may be substituted for these
drugs that have a heightened public health risk. When a prescriber writes a prescription for an opioid identified as having a heightened public health risk, the pharmacist must dispense an
interchangeable abuse-deterrent product from the formulary, if one exists, except when the prescriber indicates "no substitution." The Massachusetts and Maine laws also require insurers to cover
abuse-deterrent opioid drugs on a basis not less favorable than corresponding non-abuse-deterrent drugs. Several other states have enacted or are in the process of introducing similar legislation. </FONT> <FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>FDA held public meeting to discuss
abuse</I></FONT><FONT SIZE=2>-</FONT><FONT SIZE=2><I>deterrent opioid formulations:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In September 2014, the FDA announced a public meeting to discuss the development,
assessment and regulation of opioid medications. In its public notice, the FDA stated that it "looks forward to a future in which all or substantially all opioid medications are less susceptible to
abuse than the conventional formulations that dominate the market today." In October 2014, the FDA held the public meeting with key stakeholders to solicit input regarding three primary topics: how to
make abuse-deterrent opioid </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>81</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=85,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=430487,FOLIO='81',FILE='DISK131:[15ZCN1.15ZCN74701]DU74701A.;22',USER='CGONCE',CD='31-DEC-2015;12:21' -->
<A NAME="page_du74701_1_82"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>formulations
the standard of care, how to best incentivize the pharmaceutical industry to develop next-generation opioid products, and how to ensure that patients have access to affordable
abuse-deterrent opioids by implementing guidance for the release of generic abuse-deterrent opioids. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Industry group letter to the
FDA:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In January 2015, two major trade associations of the drug industry, Biotechnology Industry Organization, or BIO, and Pharmaceutical Research and Manufacturers
of America, or PhRMA, sent a letter to the FDA urging the agency to take two actions: decline to approve generic formulations of opioid medications that lack abuse-deterrent properties comparable to
those of already-approved branded formulations, and remove from the market any generic, non-abuse-deterrent formulations of opioid medications with abuse-deterrent formulations. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Types of Abuse-Deterrent Technologies  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In response to the opioid abuse epidemic, the pharmaceutical industry has created a number of abuse-deterrent products and product candidates, using a
variety of technologies. These strategies generally fall under the following categories:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Physical/Chemical
Barriers:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Physical barriers are formulations designed to prevent chewing, crushing, cutting, grating or grinding for oral or nasal abuse. Physical and chemical
barriers can make it difficult to extract the opioid from the formulation for IV abuse using common solvents such as water. For example, OxyContin OP uses a cured, thermoformed polymer to make the
tablets harder to crush for oral or nasal abuse. When crushed, the product gels in the presence of small injectable volumes of liquid, making it more difficult to draw into a syringe. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Agonist/Antagonist
Combinations:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;An opioid antagonist can be co-formulated with an active opioid ingredient, or agonist, to interfere with or reduce the euphoria associated with
abuse. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The antagonist can be physically sequestered in the tablet
(e.g.,&nbsp;Pfizer's Embeda&reg;). When taken orally as directed, the majority of the encapsulated antagonist is eliminated in the gastrointestinal, or GI, tract and not absorbed into the
bloodstream, allowing the active ingredient to work. However, when crushed or dissolved by an abuser or patient, the antagonist is released with the active ingredient and both are absorbed into the
bloodstream, with the intent of blunting the euphoric effects of the active ingredient. A problem with this approach is that if the tablet is crushed or dissolved, the antagonist can cause the patient
or abuser to experience opioid withdrawal, with potentially serious consequences. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  Alternatively, the antagonist can be co-formulated in a fixed ratio with the
active ingredient (e.g.,&nbsp;Purdue's Targiniq&#153;). When taken orally as directed, most of the antagonist is circulated directly to the liver and rendered ineffective, allowing the active
ingredient to work. However, when snorted or injected, the antagonist is distributed in the bloodstream before it gets to the liver, with the intent of preventing euphoria. A disadvantage with this
approach is that it limits the amount of active ingredient a patient can take, which may make it inadequate to control chronic pain. Further, the presence of the antagonist in the co-formulated drug
may precipitate withdrawal, with potentially serious consequences. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>Market
research studies performed for us have shown that some physicians prefer not to use an abuse-deterrent formulation with an opioid antagonist because such formulations may be less useful in
addressing chronic pain and because their antagonist components may precipitate withdrawal. </FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Prodrug approaches:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;A
prodrug is a drug administered in an inactive, or less active, form designed to enable more effective delivery. The prodrug is then converted by the body into the active ingredient through a normal,
metabolic process. In a prodrug opioid, the active ingredient is designed to be released if the drug is taken orally, but if an abuser or patient takes a large amount of the drug, the prodrug is not
broken down or absorbed rapidly enough to create euphoria. If injected or snorted, the prodrug is not broken down and the active ingredient is not released. To date, the only extended-release product
candidate using the prodrug approach in late-stage clinical development did not achieve its primary endpoint of demonstrating adequate pain relief compared to a placebo, in a Phase&nbsp;2 clinical
trial. No opioids using a prodrug approach are currently marketed. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>82</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=86,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=851915,FOLIO='82',FILE='DISK131:[15ZCN1.15ZCN74701]DU74701A.;22',USER='CGONCE',CD='31-DEC-2015;12:21' -->
<A NAME="page_du74701_1_83"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe Xtampza represents the best-in-class approach to creating an abuse-deterrent extended-release opioid formulation. Xtampza does not incorporate an opioid antagonist, is not a prodrug, and,
based on the studies and clinical trials we conducted, is resistant to abuse through physical or chemical manipulation. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Chronic Pain with Dysphagia  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>It is estimated that more than 10% of patients with chronic pain, or approximately 11&nbsp;million patients, have dysphagia, or difficulty in
swallowing, because they have cancer, are elderly, have other
medical problems or have difficulty swallowing without a known medical cause. The FDA recognized the unmet medical needs of this growing population in issuing draft guidance in December 2013, in which
the FDA cited survey data that suggest that as many as 40% of Americans may have difficulties swallowing tablets and capsules and noted that these difficulties can precipitate a number of adverse
events and noncompliance with treatment regimens. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Currently,
all FDA-approved, orally administered extended-release opioids have a black box warning product label stating that "crushing, dissolving or chewing can cause rapid release and absorption of
a potentially fatal dose of the active drug," making them unsuitable or unattractive for patients who suffer from chronic pain with dysphagia, or CPD. OxyContin OP's product label states that "there
have been post-marketing reports of difficulty in swallowing OxyContin tablets. These reports included choking, gagging, regurgitation and tablets stuck in the throat&#133; Consider use of an
alternative analgesic in patients who have difficulty swallowing." An external marketing study performed for us in 2013 estimated that Xtampza, if finally approved, has a peak revenue potential for
U.S. patients with CPD in excess of $700&nbsp;million annually. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our Solution: The DETERx Platform Technology  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Overview  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>DETERx is a novel, proprietary, patented platform technology that is designed to maintain the extended-release and safety profiles of highly abused
drugs in the face of various methods of abuse and tampering, including chewing, crushing and/or dissolving, and then taking them orally or snorting or injecting them. The DETERx formulation consists
of wax-based microspheres that are filled into a capsule. The microspheres are spherical micron-sized beads that are prepared by combining the active ingredient (oxycodone, in the case of our lead
product candidate, Xtampza) with inactive ingredients. Each microsphere, whether inside or outside the capsule, is designed to be abuse-deterrent and extended-release. The active ingredient is
solubilized and homogenously dispersed in each microsphere. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Xtampza
microspheres have a median particle size of approximately 300 microns and are comprised of the active ingredient (oxycodone), a fatty acid, and wax and surfactant excipients which are all
generally recognized as safe, or GRAS, by the FDA. The microspheres are formulated through a proprietary melt process in which the active ingredient, as a free base, is combined with fatty acid and
wax and surfactant excipients to form&nbsp;a molten solution in which the base is solubilized via an ionic interaction with the fatty acid. The resulting homogenous liquid is spray congealed into
small droplets using a proprietary spinning disk manufacturing process. The droplets rapidly congeal into solid wax-based microspheres, which are then filled into capsules. Differing product strengths
are achieved by varying the weight of the microspheres loaded into a capsule. When administered orally as directed,
the Xtampza formulation is designed to be administered every 12&nbsp;hours and releases oxycodone over an extended period of time in the GI tract by diffusion from the microspheres into
gastrointestinal fluids. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>83</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=87,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=495815,FOLIO='83',FILE='DISK131:[15ZCN1.15ZCN74701]DU74701A.;22',USER='CGONCE',CD='31-DEC-2015;12:21' -->
<A NAME="page_du74701_1_84"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g119546.jpg" ALT="GRAPHIC" WIDTH="600" HEIGHT="339">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because
of our proprietary technology, each individual microsphere has extended-release and abuse-deterrent properties. The microspheres are designed to be administered in capsule form, sprinkled on
food or directly in the mouth, or administered into the stomach via a gastric or nasogastric tube without compromising their abuse-deterrent, extended-release profile. These features may make Xtampza
uniquely suited to address the needs of patients suffering from CPD. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Abuse-Deterrent Features  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Abusers often seek to accelerate the absorption of opioids into the bloodstream by crushing them in order to swallow, snort or smoke the drug, or
dissolving them in order to inject the drug. The wax-based microspheres produced using the DETERx platform technology have physical and chemical barriers that are intended to reduce the potential for
these forms of abuse. We believe that microspheres made using our proprietary technology deter the most common methods of manipulating opioids for abuse because of their features described in the
table below. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>84</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=88,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=549733,FOLIO='84',FILE='DISK131:[15ZCN1.15ZCN74701]DU74701A.;22',USER='CGONCE',CD='31-DEC-2015;12:21' -->
<A NAME="page_du74701_1_85"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="du74701_abuse-deterrent_featur__du702243"> </A>
<A NAME="toc_du74701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Abuse-Deterrent Features of DETERx Platform Technology    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="16%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="171pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="49%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:60pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Method of Abuse

<!-- COMMAND=ADD_SCROPPEDRULE,60pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Abuse-Deterrent Feature: </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Advantages </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>Oral</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><I> Particle Size, Matrix Composition and Fusing Effect</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>The microspheres are small and soft, so chewing or crushing them to further reduce the particle size does not meaningfully reduce the particle size or increase the surface area. The hydrophobic excipient matrix of each
microsphere is composed of soft, fatty, and wax-based inactive ingredients that tend to agglomerate and fuse when crushed.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><BR><FONT SIZE=2>Injection</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2><I> Less Soluble Salt Form</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>We created a novel salt form of the active ingredient, which is less soluble in aqueous solutions (such as water) but readily dissolved in fatty excipients, such as those used in our DETERx formulation.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2><I> Matrix Composition</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>The hydrophobic excipient matrix is designed to trap the active ingredient, making it difficult for abusers to extract the opioid.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2><I> High Melting Point</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>Melting the waxy composition of the microspheres results in quick solidification when heat is removed, clogging a syringe.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><BR><FONT SIZE=2>Snorting</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2><I> Matrix Composition</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>The hydrophobic excipient matrix is designed to trap the active ingredient, preventing the release of the opioid in the nose and causing temporary nasal side effects that make Xtampza undesirable for nasal
abuse.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


DETERx Pipeline  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have applied our DETERx platform technology to Xtampza as well as other product candidates in our pipeline. We recently completed formulation
development work for our extended-release, abuse-deterrent hydrocodone program. Based upon an assessment of the market opportunity and the potential to differentiate from currently marketed
hydrocodone products as well as programs in
development, we are prioritizing our abuse deterrent hydrocodone program as our second product in development. We filed an IND with the FDA in December 2015 and target initiating a clinical trial in
the first quarter of 2016. We also have an extended-release, abuse-deterrent oxymorphone program for the treatment of chronic pain for which we have filed an investigational new drug application, or
IND. This program has been granted Fast Track status by the FDA. In addition, we have other extended-release, abuse-deterrent product candidates that have completed preliminary preclinical studies,
including morphine for pain and methylphenidate for the treatment of attention deficit hyperactivity disorder, or ADHD. All of these product candidates share similar abuse-deterrent qualities as
Xtampza and are designed to be suitable for patients with difficulty swallowing. We own all of the rights to our product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>85</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=89,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=828799,FOLIO='85',FILE='DISK131:[15ZCN1.15ZCN74701]DU74701A.;22',USER='CGONCE',CD='31-DEC-2015;12:21' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dw74701_1_86"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g249773.jpg" ALT="GRAPHIC" WIDTH="616" HEIGHT="187">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Each of our product candidates is being developed to seek FDA approval in accordance with Section&nbsp;505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or FD&amp;C Act.
Section&nbsp;505(b)(2) permits an applicant to file an NDA that relies, in part, on data not developed by or for the applicant and to which the applicant has not received a right of reference, such
as the FDA's findings of safety and efficacy in the approval of a similar drug, or listed drug, or published literature in support of its application. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Xtampza  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Overview  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our lead product candidate, Xtampza, is an abuse-deterrent, extended-release, oral formulation of oxycodone tentatively approved by the FDA for the
management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The active ingredient in Xtampza is
oxycodone, which is approved by the FDA and other regulators around the world in a number of both immediate-release and extended-release drug products. We developed Xtampza using our proprietary,
DETERx abuse-deterrent technology to address common methods of abuse, including chewing, crushing and/or dissolving, and then taking it orally or snorting or injecting Xtampza. On November&nbsp;6,
2015, the FDA granted tentative approval to the NDA for Xtampza for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative
treatment options are inadequate. The FDA granted tentative approval because Xtampza met the required quality, safety and efficacy standards for approval but remains subject to an automatic stay of up
to 30&nbsp;months as a result of patent litigation filed by Purdue in March 2015. The FDA may grant final regulatory approval upon the earliest to occur of expiration of the automatic stay, the
court invalidating Purdue's patents or issuing an opinion of non-infringement, and expiration of Purdue's listed patents. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
sought approval of Xtampza through the FDA's Section&nbsp;505(b)(2) regulatory approval pathway using OxyContin OP as our listed drug, with the goal of obtaining abuse-deterrent claims in our
product label based on three categories of our completed abuse-deterrence studies. In July 2014, we completed our pivotal Phase&nbsp;3 efficacy and safety clinical trial for Xtampza in patients with
moderate-to-severe chronic low back pain, which met efficacy and safety endpoints. We also completed Category&nbsp;1, Category&nbsp;2 and Category&nbsp;3 abuse-deterrent studies and clinical
trials designed to follow the January 2013 FDA draft guidance on abuse-deterrent opioids, and which we believe to be consistent with the April 2015 final FDA guidance, as well as direct guidance
received from the FDA in numerous meetings and written communications, including a pre-NDA meeting in April 2014. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
also conducted an alternative dosing clinical trial to assess the feasibility of administering Xtampza by sprinkling the microspheres onto applesauce. This clinical trial demonstrated that Xtampza
microspheres retain their abuse-deterrent and extended-release properties even after being removed from the capsule and mixed with soft food. If Xtampza ultimately receives final regulatory approval,
Xtampza could be the only abuse-deterrent extended-release oxycodone product with product labeling features targeting patients with </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>86</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=90,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=191342,FOLIO='86',FILE='DISK131:[15ZCN1.15ZCN74701]DW74701A.;22',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_dw74701_1_87"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>CPD.
As part of the FDA's tentative approval of our NDA for Xtampza, we have a tentatively approved product label. The key product label characteristics are summarized below: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="331pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:122pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Section of Tentative Product Label

<!-- COMMAND=ADD_SCROPPEDRULE,122pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Tentative Product Label Characteristics </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><B>Dosage and Administration</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Open capsule and sprinkle microspheres on soft foods or directly into a cup, and then directly into the mouth.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT FACE="arial" SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Administer microspheres through nasogastric and gastrostomy feeding tubes.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT FACE="arial" SIZE=2> </FONT><FONT SIZE=2><B>Pharmacology</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Pharmacokinetic data demonstrating that chewed and crushed Xtampza ER is bioequivalent to intact dosing.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><BR><FONT SIZE=2><B>Black Box Warning and Precautions</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><BR><FONT SIZE=2><B> No warnings or precautions relating to:</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Crushing, chewing or dissolving the drug can cause rapid release and absorption of a potentially fatal dose.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT FACE="arial" SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Difficulty swallowing, risks of IV injection, etc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><BR><FONT SIZE=2><B>Drug Abuse</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2><B> Abuse-deterrent claims</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Category&nbsp;1 in vitro</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT FACE="arial" SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Category&nbsp;2 pharmacokinetic</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT FACE="arial" SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Category&nbsp;3 human abuse potential</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Market Opportunity  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We believe that Xtampza, if it ultimately receives final regulatory approval, can capture a significant share of the $6&nbsp;billion U.S.
extended-release opioid market, including a portion of the existing $2.5&nbsp;billion OxyContin OP market. In addition, we believe that Xtampza can become a market leader for treating patients with
chronic pain who have difficulty swallowing. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


<U>OxyContin OP Extended-Release Market</U>  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Until recently, no product that uses oxycodone as its active ingredient had been approved with product label claims describing the abuse-deterrent
characteristics of its product. Purdue launched OxyContin OP in 2010. In April 2013, the FDA determined that Purdue had been successful in demonstrating OxyContin OP's abuse-deterrent characteristics
and permitted Purdue to amend its product label to include certain abuse-deterrent claims. Since the launch of OxyContin OP, there has been a reduction in the overall abuse of OxyContin, primarily in
the snorted and injected routes of administration. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA also concluded that the benefits of the previously-approved non-abuse-deterrent OxyContin no longer outweighed its risks and removed it from the list of drugs eligible to serve as a reference
product for future generic or Section&nbsp;505(b)(2) approvals. As a result, we expect that all extended-release oxycodone products, including generic products, will now be required to have
abuse-deterrent claims as part of the FDA approval process. We believe this change in FDA policy creates a significant opportunity for Xtampza, if ultimately approved, to capture a portion of the
extended-release oxycodone market. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Despite
OxyContin OP's commercial success, it carries with it a well-documented abuse stigma both for physicians who prescribe it and for patients who use it to treat chronic pain. In a market
research study conducted for us in 2013, 35% of patients surveyed who were taking OxyContin OP indicated concern that their friends or family have a negative perception of OxyContin OP. Of the 1,021
patients surveyed in the study, 11% of chronic pain patients responded that they have had their opioid medication stolen, most often from their home, and 76% indicated an interest in switching to a
pain medication similar to OxyContin OP but that was more abuse-deterrent. A market research study of 30 physicians conducted for us in 2015 concluded that while physicians view OxyContin OP as an
effective and valuable option, one </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>87</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=91,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=168962,FOLIO='87',FILE='DISK131:[15ZCN1.15ZCN74701]DW74701A.;22',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_dw74701_1_88"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>third
reported prescribing it less often than they would like because of patients' reticence to use OxyContin OP because of its reputation for addiction and abuse. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Further,
in a third party study of post-marketing data on misuse and diversion of prescription opioid analgesics, the initial decline in abuse of OxyContin OP by patients who reported abusing the
non-abuse-deterrent OxyContin 30&nbsp;days prior to entering treatment for opioid abuse disorder, plateaued at 25% to 30%, with no further decreases from 2012 to study conclusion in 2014. A
sub-population of participants was surveyed to investigate their continued abuse of OxyContin. Among the 88 participants who abused both non-abuse-deterrent OxyContin and OxyContin OP, their continued
abuse of OxyContin OP was explained by: (i)&nbsp;a transition from non-oral routes of administration to oral use (approximately 43%); (ii)&nbsp;successful efforts to defeat the abuse-deterrent
formulation mechanism leading to a continuation of inhaled or injected use (approximately 34%); and (iii)&nbsp;exclusive use of the oral route independent of formulation type (approximately 23%).
Representative comments of participants who continued to abuse OxyContin OP demonstrated that participants were able to identify methods of circumventing the abuse deterrent properties using the
internet. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


<U>Other Extended-Release Opioids</U>  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>While OxyContin OP is the largest selling extended-release opioid in the United States by dollars in 2014, there are approximately 23&nbsp;million
additional prescriptions for non-abuse-deterrent extended-release opioids annually in the United States. Many of these opioids include active ingredients, such as morphine, that are commonly perceived
as having greater adverse side effects than oxycodone-based formulations. Because of the abuse stigma associated with OxyContin OP and non-abuse-deterrent opioid formulations, we believe that Xtampza
would offer physicians treating chronic pain an attractive alternative to the existing options. Our market research also demonstrates that payors recognize the prevalence of opioid abuse and its
corresponding economic burden. This research indicates that "brand" prices would be acceptable for products that are differentiated. As such, we aim to achieve broad Tier&nbsp;3 payor coverage on
commercial plans and contract with Medicare and Medicaid. In a market research study conducted for us, 83% of disease specialists (such as oncologists and neurologists) and 67% of pain specialists
surveyed indicated that, if approved, they would prescribe Xtampza for patients without dysphagia. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


<U>Chronic Pain with Dysphagia</U>  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In a market research survey conducted for us, of 1,021 patients with chronic pain, 30% of the patients reported that they have trouble swallowing or
do not like to swallow pills, and 65% of the patients did not realize that cutting, crushing or grinding extended-release opioids can change the drug release
profile. None of the currently approved abuse-deterrent opioid drugs has an FDA product label that permits the sprinkling of the product on food, directly in the mouth and administration through
feeding tubes for use by patients with CPD, creating an unmet medical need due to the lack of adequate treatment options. Further, in an effort to make them easier to swallow, some patients with
CPD&nbsp;&#151; and 47 of the 1,021 patients participating in the survey conducted for us&nbsp;&#151; crush their prescribed extended-release opioids and can inadvertently harm
themselves because of the rapid immediate-release of the active ingredient. Because our Xtampza microspheres are designed to be able to be removed from the capsule and still retain their
abuse-deterrent and extended-release properties, we believe that they will be an effective pain-management solution for patients with CPD. An external marketing study performed for us in 2013
estimated that Xtampza, if it ultimately receives final regulatory approval, has a peak revenue potential for U.S. patients with CPD in excess of $700&nbsp;million annually. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Clinical Development  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have completed numerous studies and clinical trials on Xtampza. We submitted an NDA for Xtampza to the FDA on December&nbsp;12, 2014. On
September&nbsp;11, 2015, the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the FDA voted unanimously (23-0) to support the
regulatory approval of Xtampza. Xtampza received tentative FDA approval on November&nbsp;6, 2015. We sought approval of Xtampza through the FDA's Section&nbsp;505(b)(2) regulatory approval pathway
using OxyContin OP as our listed drug with the goal of obtaining abuse-deterrent claims in </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>88</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=92,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=90473,FOLIO='88',FILE='DISK131:[15ZCN1.15ZCN74701]DW74701A.;22',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_dw74701_1_89"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>our
product label based on all three categories of our completed abuse-deterrence studies. To date, we have completed bioequivalence and bioavailability studies, a pivotal Phase&nbsp;3 clinical
trial of Xtampza in patients with moderate-to-severe chronic low back pain, which met safety and efficacy endpoints, as well as Category&nbsp;1, Category&nbsp;2 and Category&nbsp;3 abuse
deterrence studies and clinical trials based on the January 2013 FDA draft guidance regarding abuse-deterrent opioids. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Evaluation of Safety and Efficacy  </I></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


</I></FONT><FONT SIZE=2><U>Phase&nbsp;3 Clinical Trial</U> </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>After
discussions with the FDA, we conducted a single pivotal Phase&nbsp;3 clinical trial designed to show safety and efficacy of Xtampza in a chronic pain population. The
Phase&nbsp;3 clinical trial was a multi-center, prospective, double-blind, enriched enrollment, randomized withdrawal, placebo-controlled clinical trial that examined the safety, tolerability, and
efficacy of Xtampza versus placebo in opioid-experienced and opioid-na&iuml;ve patients with moderate-to-severe chronic low back pain. This study was designed with acetaminophen as the
rescue medication in order to avoid the potential issue of immediate-release opioid rescue medication use confounding the effect of the study drug. The trial design is depicted in the figure below. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g556684.jpg" ALT="GRAPHIC" WIDTH="616" HEIGHT="292">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Of
the 740 patients enrolled in the initial open-label titration portion of the clinical trial, 389 patients met the criteria for randomization, which included stable and effective pain scores,
ability to tolerate the drug at the dose at which effective pain relief was achieved and compliance with all other aspects of the clinical trial protocol. These 389 patients were randomized into a
12-week, double-blind maintenance phase in which they were either maintained on their current dose regimen of Xtampza or were tapered to a placebo. The primary efficacy endpoint of the clinical trial
was the change in average pain intensity from baseline to week 12; pain was measured using an 11-point pain intensity numerical rating scale. Sensitivity analyses were performed to evaluate the
primary endpoint. Secondary endpoints in the clinical trial included evaluation of safety and tolerability, quality of life, physical disability, and global impression of change. The graph below shows
the daily average pain score in the randomized, intent to treat, or ITT, population. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>89</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=93,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=427884,FOLIO='89',FILE='DISK131:[15ZCN1.15ZCN74701]DW74701A.;22',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_dw74701_1_90"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g740367.jpg" ALT="GRAPHIC" WIDTH="585" HEIGHT="460">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
clinical trial demonstrated that the estimated marginal mean change in average pain score from Randomization Baseline to Week 12 was greater for the placebo treatment group (1.85) than for the
Xtampza treatment group (0.29). The clinical trial successfully met the primary efficacy endpoint by showing that the difference between treatment groups in the estimated marginal mean change in
average pain score was statistically significant (p&lt;0.0001). All sensitivity analyses showed statistically significant results (with p values ranging from 0.0002 to &lt;0.0001)
supporting the primary endpoint analysis favoring Xtampza compared to placebo. All secondary endpoints were achieved. The p-value, or probability value, is a measure of statistical significance
reflecting the likelihood that an observed result occurred by chance. Generally, p-values less than or equal to 0.05 are considered to indicate statistical significance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Xtampza
was well-tolerated in this study. No new safety concerns were identified. The most common adverse events, or AEs, (&gt;5%) reported by patients in the Phase&nbsp;3 clinical trial during the
titration phase were nausea, headache, constipation, drowsiness, itching, vomiting and dizziness. Each of these AEs declined in frequency with continued treatment. The most common adverse reactions
(&gt;5%) reported by patients in the Phase&nbsp;3 clinical trial comparing Xtampza with placebo are shown in the table below. One subject was hospitalized for a serious adverse event moderate in
severity of gastroesophageal reflux and subsequently discharged upon resolution of the event. The investigator at the clinical trial site assessed this event as possibly related to study drug, but no
action was taken with the study drug due to this event. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>90</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=94,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=990272,FOLIO='90',FILE='DISK131:[15ZCN1.15ZCN74701]DW74701A.;22',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_dw74701_1_91"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Titration<BR>
Period </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Maintenance Period </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:61pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Adverse Reaction

<!-- COMMAND=ADD_SCROPPEDRULE,61pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Xtampza<BR>
(n&nbsp;= 740)<BR>
(%) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Xtampza<BR>
(n&nbsp;= 193)<BR>
(%) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Placebo<BR>
(n&nbsp;= 196)<BR>
(%) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nausea</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>16.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Headache</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>13.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>11.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Constipation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>13.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Somnolence</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&lt;1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&lt;1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pruritus</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vomiting</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dizziness</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


</I></FONT><FONT SIZE=2><U>Phase&nbsp;1 Clinical Trials</U> </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
performed two Phase&nbsp;1 bioequivalence and bioavailability clinical trials to compare the blood levels obtained after administration of Xtampza versus OxyContin OP.
The first, in which we enrolled 48 patients, compared the pharmacokinetics, or PK, of Xtampza with OxyContin OP in fasted and fed states following single dose administration, with results shown in the
figure below. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g951646.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="264">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
single-dose PK profiles for Xtampza and OxyContin OP were similar. However, in the fasted state, the total amount of absorption, known as area under the curve, or AUC, was lower when compared with
the fed state for Xtampza, suggesting a larger food effect than OxyContin OP. As a result, our tentatively approved product label indicates that Xtampza should be taken with food and should be taken
with approximately the same amount of food with every dose to ensure that consistent plasma levels are achieved. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
performed a second phase&nbsp;1 clinical trial to assess the safety and PK of Xtampza and OxyContin OP in fed and fasted states following multiple-dose administration. In this clinical trial,
which enrolled 45&nbsp;patients, as shown in the figure below, both products were taken with food twice per day for five days, and the PK profiles&nbsp;&#151; which were assessed based on
two variables, peak plasma level of the drug, or C<SUB>max</SUB>, and AUC&nbsp;&#151; were bioequivalent. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>91</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=95,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=664251,FOLIO='91',FILE='DISK131:[15ZCN1.15ZCN74701]DW74701A.;22',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dx74701_1_92"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dx74701_day_5,_all_doses_fed_(cp-oxydet-18)"> </A>
<A NAME="toc_dx74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Day 5, All Doses Fed (CP-OXYDET-18)    <BR>    </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="120pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="114pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>C<font
style="font-size:6pt;position:relative;bottom:-1pt;add_sub:1pt;">max</font> (ng/ml) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>AUC (hr*ng/ml) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Xtampza</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>77.7</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>511</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>OxyContin OP</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>77.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>531</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Xtampza : OxyContin OP % Ratio (90% Confidence Interval)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>99.60 (93.60-105.97)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>95.63 (92.73-98.61)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


<U>Evaluation of Abuse-Deterrence of Xtampza</U>  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Xtampza was developed and evaluated in a manner consistent with recommendations described in the January 2013 draft FDA guidance on the evaluation and
product labeling of abuse-deterrent opioids. We believe our development program is consistent with the April 2015 final FDA guidance. Listed below is an overview of the studies and clinical trials
needed for FDA abuse-deterrent product labeling. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>92</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=96,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=330926,FOLIO='92',FILE='DISK131:[15ZCN1.15ZCN74701]DX74701A.;19',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_dx74701_1_93"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dx74701_fda_guidance_pre_and_post-marketing_study_categories"> </A>
<A NAME="toc_dx74701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  FDA Guidance Pre and Post-marketing Study Categories    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="92pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="25%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="25%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="25%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:30pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Category

<!-- COMMAND=ADD_SCROPPEDRULE,30pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Study Type </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Objective </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Claim Example </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>1 &#151; Pre-market</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Laboratory Manipulation and Extraction Studies</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Evaluate ease with which abuse-deterrent properties of formulation can be defeated or compromised</FONT></TD>
<TD style="font-family:arial;"><FONT FACE="arial" SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Category&nbsp;1: The product is formulated with psychochemical barriers that are expected to deter intravenous abuse.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT FACE="arial" SIZE=2> </FONT><FONT SIZE=2>2 &#151; Pre-market</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PK Studies</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Understand in vivo properties of formulation by comparing PK profiles of manipulated formulation with intact formulation</FONT></TD>
<TD style="font-family:arial;"><FONT FACE="arial" SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Category&nbsp;2: The product is formulated with psychochemical properties that are expected to deter oral and nasal abuse.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT FACE="arial" SIZE=2> </FONT><FONT SIZE=2>3 &#151; Pre-market</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Clinical Human Abuse Potential Clinical Trials (Drug Likability)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Assess impact of the potentially abuse-deterrent formulation on measures that predict how probable it is the formulation will be attractive to abusers ("liked")</FONT></TD>
<TD style="font-family:arial;"><FONT FACE="arial" SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Category&nbsp;3: The results from the oral and intranasal clinical abuse potential studies indicate that the medication has properties expected to deter abuse via oral, intranasal and intravenous
routes.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT FACE="arial" SIZE=2> </FONT><FONT SIZE=2>4&nbsp;&#151; Post-market</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Post-marketing Epidemiologic Studies</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Conduct epidemiologic studies capable of detecting a change in the occurrence of abuse and abuse-related outcomes</FONT></TD>
<TD style="font-family:arial;"><FONT FACE="arial" SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Category&nbsp;4: There was a demonstrated reduction in abuse of this medication in the community setting compared to the levels of abuse, overdose and death that occurred when only formulations of
the same opioid without abuse-deterrent properties were available.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>Our
development program consisted of in vitro studies and clinical trials, the results of which indicate that Xtampza may result in reduced abuse by manipulation followed by oral ingestion, snorting
or attempted intravenous injection. The table below summarizes the abuse deterrence studies and clinical trials we conducted for Xtampza. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>93</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=97,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=122411,FOLIO='93',FILE='DISK131:[15ZCN1.15ZCN74701]DX74701A.;19',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_dx74701_1_94"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dx74701_abuse-deterrent_assessment_strategy"> </A>
<A NAME="toc_dx74701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Abuse-deterrent Assessment Strategy    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="11%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="208pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="47%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Description </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Collegium Studies and Clinical Trials </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><B>Category&nbsp;1</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Laboratory based in vitro manipulation and extraction studies</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Numerous physical, chemical manipulation and route specific studies (IV injection, smoking)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><BR><FONT SIZE=2><B>Category&nbsp;2</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>PK clinical trials</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>Oral Crushed/Chewed PK Clinical Trial (</FONT><FONT SIZE=2><I>CP-OXYDET-17</I></FONT><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Intranasal PK Clinical Trial (</FONT><FONT SIZE=2><I>CP-OXYDET-19</I></FONT><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Comparative Crushing/Tampering PK Clinical Trial (</FONT><FONT SIZE=2><I>CP-OXYDET-25</I></FONT><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Intranasal PK and human abuse potential, or HAP, Clinical Trial (</FONT><FONT SIZE=2><I>CP-OXYDET-21</I></FONT><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Oral Chewed PK and HAP Clinical Trial (</FONT><FONT SIZE=2><I>CP-OXYDET-24</I></FONT><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><BR><FONT SIZE=2><B>Category&nbsp;3</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>Human abuse potential (drug likeability) clinical trials</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><BR><FONT SIZE=2>Intranasal PK and HAP Clinical Trial (</FONT><FONT SIZE=2><I>CP-OXYDET-21</I></FONT><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Oral Chewed PK and HAP Clinical Trial (</FONT><FONT SIZE=2><I>CP-OXYDET-24</I></FONT><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


</I></FONT><FONT SIZE=2><U>Category&nbsp;1: In Vitro Studies</U> </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
demonstrated abuse-deterrent properties of Xtampza in each mode of physical, chemical and route specific manipulations. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Physical Manipulations  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>One of the key objectives of our Category&nbsp;1 studies was to determine the most effective tool to crush Xtampza microspheres and OxyContin OP
tablets as part of a particle size reduction, or PSR, study. The results of this PSR study informed the design of our PK clinical trials. A range of household tools was selected based upon the review
of the literature and researching the internet for common methods used by abusers. Based upon this, 10 tools were selected that cut, broke, ground and crushed the Xtampza microspheres and/or OxyContin
OP tablets. For OxyContin OP, five of these tools were effective in laboratory tests at substantially increasing the rate of drug release, resulting in "dose dumping" of the active ingredient. For
Xtampza, none of these tools was effective at causing dose dumping. A subset of these tools were also applied to the Xtampza microspheres after pre-treatment by freezing or heating, but were still
unable to cause dose dumping. Consistent with FDA guidance, results of the physical manipulation study were replicated by an independent third party analytical laboratory registered with the FDA. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Chemical Extraction  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our chemical extraction studies were completed using the optimal method of crushing for Xtampza and OxyContin OP as identified in the above
Category&nbsp;1 study. We conducted a series of laboratory-based Category&nbsp;1 chemical manipulation studies to investigate simple and complex extraction methods and dissolution of Xtampza and
OxyContin OP in a variety of commonly used beverages, solvents, and soft foods. Results from these studies show that Xtampza microspheres resist extraction of the oxycodone active ingredient into a
usable non-toxic form that could be abused. By contrast, after crushing, the active ingredient was readily extracted from OxyContin OP. Results from these studies show that Xtampza has a greater
resistance to a wide variety of solvents used for extraction than OxyContin OP. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Route Specific&nbsp;&#151; Injection  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>To assess the ability for abusers to inject Xtampza, the microspheres were crushed, suspended in water and the resulting suspension was attempted to
be expelled with needles and syringes. Only negligible amounts of the microspheres were able to pass through any size needle, including an 18 gauge needle (which was the largest needle size tested).
By contrast, crushing OxyContin OP and mixing it in water resulted in a gel </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>94</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=98,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=861068,FOLIO='94',FILE='DISK131:[15ZCN1.15ZCN74701]DX74701A.;19',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_dx74701_1_95"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>where
a substantial amount, up to 54% of the active ingredient, could be passed through an 18 gauge needle, as well as smaller 25 and 27 gauge needles. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Xtampza microspheres were then melted at approximately 75&deg;C and the resulting molten material was attempted to be drawn through a needle into a syringe and then expelled through the
needle. As the liquid was drawn into the syringe, it immediately solidified, making injection impossible. A comparable procedure on OxyContin OP was not performed because a substantial portion of the
crushed and dissolved OxyContin OP mixture, without melting, could be passed through an 18 gauge needle. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Finally,
attempts were made to extract the active drug from Xtampza microspheres and OxyContin OP in injectable amounts of water. Both drugs were subjected to three manipulation techniques prior to
extraction in water, consisting of crushing alone, crushing and heating them on a hot plate, and crushing and microwaving them. For Xtampza, less than 10% of the oxycodone could be extracted for
injection regardless of the manipulation applied. By contrast, the amount of oxycodone extracted from OxyContin OP ranged from 17-84%, depending on the method. Approximately 17% of oxycodone was
extracted when crushed, 68% was extracted when crushed and subjected to pretreatment on a heating plate and 84% was extracted when crushed and subjected to heating in a microwave. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g966126.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="249">
  </B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Route Specific&nbsp;&#151; Smoking  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Studies have shown that less than 5% of OxyContin OP abuse is by smoking. We conducted a study comparing the ability to vaporize Xtampza, OxyContin
OP, and a marketed immediate-release form of oxycodone. The average amount of oxycodone recovered from vapor after 3 minutes, as a percentage of the total available in the smoked capsule or pill, was
approximately 17% for Xtampza, 23% for OxyContin OP and 30% for the marketed immediate-release oxycodone suggesting that Xtampza is unlikely to be abused by smoking more often than existing oxycodone
products. In addition, when Xtampza is heated in order to vaporize the oxycodone, inactive excipients are also vaporized, which may be unpleasant to an abuser. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>95</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=99,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1022234,FOLIO='95',FILE='DISK131:[15ZCN1.15ZCN74701]DX74701A.;19',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_dx74701_1_96"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


 </I></FONT><FONT SIZE=2><U>Category&nbsp;2: Oral PK Clinical Trials</U> </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>To
support oral abuse-deterrent product labeling for Xtampza we performed five separate PK clinical trials, three by the oral route of administration and two by the nasal
route. The oral clinical trials were as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="42%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="21%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="21%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Trial&nbsp;&amp; Category </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Subjects </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Comparator(s) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Key Objective </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><B>Oral Crushed/Chewed PK Clinical Trial</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(CP-OXYDET-17)</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Category&nbsp;2</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>n&nbsp;= 44</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Immediate-release oxycodone solution</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Assess the safety and PK of Xtampza intact, chewed and crushed</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><B>Oral Chewed PK and HAP Clinical Trial</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(CP-OXYDET-24)</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Categories&nbsp;2&nbsp;&amp; 3</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>n&nbsp;= 36</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Crushed immediate-release oxycodone tablets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Assess the PK (Category&nbsp;2) and drug-likeability (Category&nbsp;3) of Xtampza, intact and chewed</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><B>Comparative Crushing/Tampering PK Clinical Trial</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(CP-OXYDET-25)</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Category&nbsp;2</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>n&nbsp;= 36</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>OxyContin OP (intact and crushed) and crushed immediate-release oxycodone tablets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Assess the safety and PK of Xtampza, intact and crushed</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Oral Crushed/Chewed PK Clinical Trial (CP-OXYDET-17)  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our oral crushed/chewed PK clinical trial (CP-OXYDET-17) was an open-label, randomized, active-controlled, crossover clinical trial to evaluate the
effect of tampering (crushing and chewing) on Xtampza microspheres compared with immediate-release oxycodone solution. The clinical trial had seven treatment arms, consisting of three fasted-state
treatment arms and four fed-state treatment arms. Because Xtampza has a food effect, the tentative product label for Xtampza instructs patients to take Xtampza capsules with approximately the same
amount of food for every dose in order to ensure consistent plasma levels are achieved. Accordingly, the graph below provides only the results of the clinical trial for the fed-state treatment arms. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dx74701_mean_concentrations_of_oxycodone"> </A>
<A NAME="toc_dx74701_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean Concentrations of Oxycodone    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g682449.jpg" ALT="GRAPHIC" WIDTH="565" HEIGHT="330">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>96</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=100,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=473044,FOLIO='96',FILE='DISK131:[15ZCN1.15ZCN74701]DX74701A.;19',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_dx74701_1_97"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
demonstrated above, crushing or chewing Xtampza did not increase its C<SUB>max</SUB> as compared to the intact Xtampza capsules. All treatment groups had substantially lower peak plasma levels and
longer time to peak plasma level, or T<SUB>max</SUB>, than the immediate-release oxycodone solution. The absorption of oxycodone, as measured by AUC, was substantially equivalent among the crushed,
chewed and intact Xtampza treatment groups. In all Xtampza treatment groups, the extended-release properties remained intact and there was no evidence of dose dumping. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dx74701_cmax_ratios_relative_t__dx702364"> </A>
<A NAME="toc_dx74701_5"> </A>
<BR></FONT><FONT SIZE=2><B>  C<SUB>max</SUB> Ratios Relative to Xtampza Intact Capsules Baseline    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g387315.jpg" ALT="GRAPHIC" WIDTH="558" HEIGHT="255">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Substantial
early increases in plasma concentrations after crushing or chewing, compared to intact capsules are indicative of dose dumping. As a result, the product labels for all currently available
orally administered extended-release opioids include a black box warning instructing patients that "crushing, dissolving or chewing the tablet can cause rapid release and absorption of a potential
fatal dose" of the respective opioid. The results of the clinical trial shown in the graph below demonstrate that crushing and chewing, two common methods of manipulation used by abusers, did not
increase the early plasma concentration of Xtampza when taken orally. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dx74701_graphical_display_of_mean_oxyc__gra02735"> </A>
<A NAME="toc_dx74701_6"> </A>
<BR></FONT><FONT SIZE=2><B>  Graphical Display of Mean Oxycodone Partial AUC Values from 0.25 to 3.5&nbsp;hours    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g222982.jpg" ALT="GRAPHIC" WIDTH="535" HEIGHT="304">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>97</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=101,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=539142,FOLIO='97',FILE='DISK131:[15ZCN1.15ZCN74701]DX74701A.;19',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dy74701_1_98"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Another measure used to assess the potential "likability" of a drug for abusers is the "abuse quotient," or AQ, which characterizes the rate at which the peak plasma rises after
ingestion and is calculated by dividing C<SUB>max</SUB> by T<SUB>max</SUB>. By manipulating a formulation, an abuser seeks to create euphoria by maximizing AQ. As shown in the graph below, the AQ
values for Xtampza after crushing or chewing were the same as taking the product intact and meaningfully lower than for the immediate-release oxycodone solution. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dy74701_mean_aq_values_for_each_treatment"> </A>
<A NAME="toc_dy74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean AQ Values for Each Treatment    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g625784.jpg" ALT="GRAPHIC" WIDTH="600" HEIGHT="253">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
summary, in this clinical trial, manipulation of Xtampza microspheres by crushing or chewing did not alter the extended-release properties of the Xtampza formulation in the fed-state treatment
arms. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Oral Chewed PK and HAP Clinical Trial (CP-OXYDET-24)  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our oral chewed PK and HAP clinical trial was designed to assess the PK of Xtampza following chewing as compared to taking the product candidate
intact and also as compared to crushing an immediate-release oxycodone tablet. The clinical trial design was consistent with FDA guidance. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>98</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=102,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1006760,FOLIO='98',FILE='DISK131:[15ZCN1.15ZCN74701]DY74701A.;16',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_dy74701_1_99"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
results shown in the figure below indicate that for C<SUB>max</SUB> and AUC, Xtampza intact and Xtampza chewed are bioequivalent with equivalent T<SUB>max</SUB>. These results indicate that
chewing Xtampza does not affect the peak and overall exposure to oxycodone. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dy74701_mean_concentrations_of_oxycodone"> </A>
<A NAME="toc_dy74701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean Concentrations of Oxycodone    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g394314.jpg" ALT="GRAPHIC" WIDTH="601" HEIGHT="349">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
figure below further demonstrates that chewing Xtampza does not affect C<SUB>max</SUB> relative to intact Xtampza capsules. Ratios below 100% indicate chewing does not increase peak plasma
exposure versus baseline (taking Xtampza intact). </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dy74701_cmax_ratios_relative_to_intact_xtampza_capsules"> </A>
<A NAME="toc_dy74701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  C<SUB>max</SUB> Ratios Relative to Intact Xtampza Capsules    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g543307.jpg" ALT="GRAPHIC" WIDTH="538" HEIGHT="267">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
better characterize early plasma exposure, partial area under the curve, or PAUC (which measures cumulative absorption over an initial period, in this case five hours, after dosage), and AQ values
were </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>99</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=103,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=919581,FOLIO='99',FILE='DISK131:[15ZCN1.15ZCN74701]DY74701A.;16',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_dy74701_1_100"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>calculated
for each treatment arm. Over the timeframe of the first sampling time to five hours after dosing, the PAUC values for all Xtampza treatments were substantially lower than the
immediate-release oxycodone crushed solution PAUC values. The small increase in PAUC for the manipulated Xtampza capsules relative to intact capsules was anticipated because the microspheres were
removed from the capsules prior to oral administration and were therefore more rapidly exposed to the gastric environment for absorption. As shown in the figures below, the mean PAUC and AQ values for
all Xtampza treatments were substantially lower than the immediate-release oxycodone crushed solution AQ. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dy74701_graphical_display_of_mean_oxyc__gra03095"> </A>
<A NAME="toc_dy74701_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Graphical Display of Mean Oxycodone Partial AUC Values over the First 5&nbsp;hours    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g321889.jpg" ALT="GRAPHIC" WIDTH="556" HEIGHT="298">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dy74701_mean_aq_values_for_each_treatment_1"> </A>
<A NAME="toc_dy74701_5"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean AQ Values for Each Treatment    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g557825.jpg" ALT="GRAPHIC" WIDTH="616" HEIGHT="219">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
summary, the PK data from this clinical trial indicate that there is no material increase in plasma exposure or dose dumping when Xtampza is administered after chewing, when compared to intact
Xtampza. Similar to our oral crushed/chewed PK clinical trial, our oral chewed PK and HAP clinical trial demonstrated that intact and manipulated Xtampza are bioequivalent to each other. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>100</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=104,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=142669,FOLIO='100',FILE='DISK131:[15ZCN1.15ZCN74701]DY74701A.;16',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_dy74701_1_101"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Comparative Crushing/Tampering PK Clinical Trial (CP-OXYDET-25)  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our comparative crushing/tampering PK clinical trial was an open-label, randomized, active-controlled, cross-over, single-dose clinical trial that
evaluated the effect of crushing Xtampza, OxyContin OP and immediate-release oxycodone tablets. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
figure on the left below indicates that crushing does not materially increase the C<SUB>max</SUB> or materially change the AUC of Xtampza compared with the intact product, which retains its oral
extended-release properties when crushed, confirming observations from our oral crushed/chewed PK clinical trial. By contrast, the OxyContin OP data in the figure on the right below show that
OxyContin OP exhibits&nbsp;a higher C<SUB>max</SUB> and shorter T<SUB>max</SUB> when administered orally in the crushed state, as compared with the intact state, essentially converting OxyContin
OP from an extended-release to an immediate-release formulation. This in vivo observation is consistent with in vitro studies on OxyContin OP, which showed that the amount of drug released in one hour
increased from 17% in the intact state to 77% following crushing. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dy74701_mean_concentrations_of_oxycodone_1"> </A>
<A NAME="toc_dy74701_6"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean Concentrations of Oxycodone    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g216412.jpg" ALT="GRAPHIC" WIDTH="682" HEIGHT="240">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
figure below shows the mean PAUC values from the first sampling time to two hours for all treatments. Over the first two hours after dosing, the PAUC values for intact and crushed Xtampza, as well
as intact OxyContin OP, treatments were substantially lower than the corresponding crushed immediate-release oxycodone values. Over this same timeframe, the PAUC values for crushed OxyContin OP
overlapped with those of crushed immediate-release oxycodone. The small increase in PAUC for the crushed Xtampza treatment relative to intact Xtampza was anticipated because the microspheres were
removed from the capsules prior to oral administration and were therefore more rapidly exposed to the gastric environment for absorption. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>101</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=105,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=217469,FOLIO='101',FILE='DISK131:[15ZCN1.15ZCN74701]DY74701A.;16',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_dy74701_1_102"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dy74701_graphical_display_of_mean_oxyc__gra02765"> </A>
<A NAME="toc_dy74701_7"> </A>
<BR></FONT><FONT SIZE=2><B>  Graphical Display of Mean Oxycodone Partial AUC Values from 0.25 to 2&nbsp;hours    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g967111.jpg" ALT="GRAPHIC" WIDTH="589" HEIGHT="316">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
shown in the figure below, mean AQ values were comparable for crushed and intact Xtampza treatments and substantially lower than crushed immediate-release oxycodone. In contrast to Xtampza,
crushing OxyContin OP compromises its extended-release profile such that the AQ value of crushed OxyContin OP increases by nearly four times and is similar to that of immediate-release oxycodone. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dy74701_graphical_display_of_m__dy702272"> </A>
<A NAME="toc_dy74701_8"> </A>
<BR></FONT><FONT SIZE=2><B>  Graphical Display of Mean (SD) AQ Values for Each Treatment    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g217011.jpg" ALT="GRAPHIC" WIDTH="619" HEIGHT="297">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
summary, crushing Xtampza microspheres does not materially change the extended-release properties of the product. By contrast, crushing OxyContin OP with common household tools causes it to
completely lose its extended-release properties, turning it into an immediate-release and readily abuseable formulation. The data in this clinical trial confirm and extend the findings from previous
studies, demonstrating that crushing or chewing Xtampza should not lead to a potentially fatal rapid release of oxycodone via "dose dumping" should a patient or a drug abuser crush, break or grind
Xtampza. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>102</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=106,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=224020,FOLIO='102',FILE='DISK131:[15ZCN1.15ZCN74701]DY74701A.;16',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dz74701_1_103"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


 </I></FONT><FONT SIZE=2><U>Category&nbsp;2: Intranasal PK Clinical
Trials</U> </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
completed two intranasal PK clinical trials to support abuse-deterrent product labeling for Xtampza. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="34%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="17%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="34%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Trial&nbsp;&amp; Category </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Subjects </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Comparator(s) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Key Objective </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><B>Intranasal PK Clinical Trial</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(CP-OXYDET-19)</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Category&nbsp;2</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>n&nbsp;= 15</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Oxycodone powder</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Compare the safety and PK of crushed and intact Xtampza following intranasal administration.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;"><FONT FACE="arial" SIZE=2> </FONT><FONT SIZE=2><B>Intranasal PK and HAP Clinical Trial</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(CP-OXYDET-21)</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Categories&nbsp;2&nbsp;&amp; 3</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>n&nbsp;= 36</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Crushed immediate-release oxycodone tablets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Evaluate the PK (Category&nbsp;2) and abuse potential (Category&nbsp;3) of crushed and intact Xtampza following snorting and oral administration.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Intranasal PK Clinical Trial (CP-OXYDET-19)  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our intranasal PK clinical trial was a randomized, open-label, active-controlled, cross-over comparison trial. The primary objective was to compare
the safety and PK of crushed and snorted Xtampza, intact Xtampza capsules taken orally, and snorted immediate-release oxycodone powder. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Data
from this clinical trial demonstrated that administration of crushed and snorted Xtampza resulted in a lower C<SUB>max</SUB> than both intact Xtampza taken orally and snorted immediate-release
oxycodone powder; the C<SUB>max</SUB> for crushed and snorted Xtampza was approximately 80% of intact Xtampza taken orally and 60% of snorted immediate-release oxycodone powder. The median
T<SUB>max</SUB> following crushed and snorted Xtampza was equivalent to the median T<SUB>max</SUB> for intact Xtampza taken orally, and both demonstrated longer median T<SUB>max</SUB> values than
snorted immediate-release oxycodone powder. Crushed and snorted Xtampza, intact Xtampza taken orally, and snorted immediate-release oxycodone powder were all bioequivalent with respect to AUC
parameters. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dz74701_mean_concentrations_of_oxycodone"> </A>
<A NAME="toc_dz74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean Concentrations of Oxycodone    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g1037036.jpg" ALT="GRAPHIC" WIDTH="571" HEIGHT="352">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>103</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=107,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=55573,FOLIO='103',FILE='DISK131:[15ZCN1.15ZCN74701]DZ74701A.;15',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_dz74701_1_104"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
figure below shows the mean PAUC values from the first sampling time to two hours for two treatments. Over the first two hours after dosing, the PAUC values for crushed and snorted Xtampza
treatments were substantially lower than the crushed and snorted immediate-release oxycodone powder values. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dz74701_graphical_display_of_mean_oxyc__gra02776"> </A>
<A NAME="toc_dz74701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Graphical Display of Mean Oxycodone Partial AUC Values from 0.1 to 2&nbsp;hours    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g837120.jpg" ALT="GRAPHIC" WIDTH="606" HEIGHT="289">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
shown in the figure below, the mean AQ values for crushed and snorted Xtampza and intact Xtampza taken orally were comparable. In this clinical trial, no increase in AQ was observed with crushed
and snorted Xtampza relative to intact Xtampza taken orally. In contrast, the AQ value for snorted immediate-release oxycodone powder was approximately five-fold higher, on average, than that for
crushed and snorted Xtampza. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dz74701_mean_aq_values_for_each_treatment"> </A>
<A NAME="toc_dz74701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean AQ Values for Each Treatment    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g570433.jpg" ALT="GRAPHIC" WIDTH="672" HEIGHT="232">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
summary, crushed and snorted Xtampza microspheres demonstrated a lower C<SUB>max</SUB> and an equivalent T<SUB>max</SUB> compared to taking the intact product orally as directed. The
C<SUB>max</SUB> of both crushed and snorted Xtampza and intact Xtampza taken orally are substantially lower than the C<SUB>max</SUB> of snorted immediate-release oxycodone powder. Crushing and
snorting Xtampza microspheres did not produce the rapid, high plasma concentrations </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>104</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=108,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=888469,FOLIO='104',FILE='DISK131:[15ZCN1.15ZCN74701]DZ74701A.;15',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_dz74701_1_105"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>that
abusers might seek for euphoria. Additionally, crushed and snorted Xtampza produced a higher percentage of mild respiratory AEs (e.g.,&nbsp;nasal discomfort and congestion) and associated
transient nasal events including burning, and facial pain/pressure compared with the immediate-release comparator. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Intranasal PK and HAP Clinical Trial (CP-OXYDET-21)  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our intranasal PK and HAP clinical trial was a randomized, open-label, active-controlled, cross-over comparison clinical trial. The primary objective
was to compare the safety and PK of crushed and snorted Xtampza, intact Xtampza capsules taken orally, and snorted crushed immediate-release oxycodone tablets. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
PK results from our intranasal PK and HAP clinical trial are similar to those observed in our intranasal PK clinical trial. With respect to AUC, crushed and snorted Xtampza was bioequivalent to
intact Xtampza taken orally. However, crushed and snorted Xtampza microspheres resulted in approximately 70% of the peak exposure of intact Xtampza taken orally and approximately 50% of the peak
exposure of crushed and snorted immediate-release oxycodone. Median T<SUB>max</SUB> was equivalent when comparing crushed and snorted Xtampza relative to intact Xtampza taken orally. Both Xtampza
treatments had substantially longer median T<SUB>max</SUB> values in comparison to crushed and snorted immediate-release oxycodone. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dz74701_mean_concentrations_of_oxycodone_1"> </A>
<A NAME="toc_dz74701_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean Concentrations of Oxycodone    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g535411.jpg" ALT="GRAPHIC" WIDTH="541" HEIGHT="330">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
figure below shows the mean PAUC values from the first sampling time to five hours for all three treatment arms. Over the first five hours after dosing, the PAUC values for intact Xtampza and
crushed and snorted Xtampza treatments were substantially lower than those of the crushed and snorted immediate-release oxycodone treatment. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>105</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=109,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=677902,FOLIO='105',FILE='DISK131:[15ZCN1.15ZCN74701]DZ74701A.;15',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_dz74701_1_106"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dz74701_graphical_display_of_mean_oxyc__gra02768"> </A>
<A NAME="toc_dz74701_5"> </A>
<BR></FONT><FONT SIZE=2><B>  Graphical Display of Mean Oxycodone Partial AUC Values from 0.25 to 5&nbsp;hours    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g681689.jpg" ALT="GRAPHIC" WIDTH="676" HEIGHT="288">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
mean AQ value for crushed and snorted Xtampza was similar to (and slightly lower than) that of intact Xtampza taken orally. By contrast, the mean AQ value for the crushed and snorted
immediate-release oxycodone treatment was approximately 11-fold greater than that of crushed and snorted Xtampza. These data indicate that crushed and snorted Xtampza may potentially be less desirable
to (i.e.,&nbsp;less liked by) drug abusers seeking to achieve a rapid, euphoric effect. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dz74701_mean_aq_values_for_each_treatment_1"> </A>
<A NAME="toc_dz74701_6"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean AQ Values for Each Treatment    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g594336.jpg" ALT="GRAPHIC" WIDTH="678" HEIGHT="261">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
summary, data from our intranasal PK and HAP clinical trial corroborate the findings from our intranasal PK clinical trial. Both clinical trials indicate that crushed and snorted Xtampza
microspheres do not produce the rapid rise in peak plasma drug concentrations that abusers might seek for euphoria when manipulating and administering dosage forms by the nasal route. Additionally,
crushed and snorted Xtampza produced a higher percentage of mild respiratory AEs (e.g.,&nbsp;nasal discomfort, nasal congestion and nose bleeds) and associated transient nasal events including
irritation, burning, and facial pain compared with the immediate-release comparator. The AEs following crushed and snorting Xtampza microspheres, without </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>106</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=110,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=857462,FOLIO='106',FILE='DISK131:[15ZCN1.15ZCN74701]DZ74701A.;15',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_dz74701_1_107"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>the
addition of potentially harmful antagonist or aversive agents, may serve as a nuisance to an abuser who wants to snort Xtampza. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


 </I></FONT><FONT SIZE=2><U>Category&nbsp;3: Human Abuse Potential Clinical
Trials</U> </FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
conducted two clinical trials&nbsp;&#151; our intranasal and oral PK and HAP clinical trial and our oral chewed PK and HAP clinical trial&nbsp;&#151; to
evaluate the HAP of crushed Xtampza microspheres taken orally and snorted, as described in the table below. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Summary of Category&nbsp;3 Human Abuse Potential Clinical Trials  </I></FONT></P>

</UL>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="27%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="13%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="13%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="27%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Trial&nbsp;&amp; Category </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Subjects </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Trial Type </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Comparator(s) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Key Objective </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Intranasal PK and HAP Clinical Trial</B></FONT><BR>
<FONT SIZE=2><B>(CP-OXYDET-21)</B></FONT><BR>
<FONT SIZE=2><I>Category&nbsp;2&nbsp;&amp; 3</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>n&nbsp;= 36</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Intranasal PK and human abuse potential clinical trial</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Crushed immediate-release oxycodone tablets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Evaluate the PK (Category&nbsp;2) and human abuse potential (Category&nbsp;3) of crushed and intact Xtampza following intranasal and oral administration.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT FACE="arial" SIZE=2> </FONT><FONT SIZE=2><B>Oral Chewed PK and HAP Clinical Trial</B></FONT><BR>
<FONT SIZE=2><B>(CP-OXYDET-24)</B></FONT><BR>
<FONT SIZE=2><I>Categories&nbsp;2&nbsp;&amp; 3</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
n&nbsp;= 36</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Oral chewed PK and human abuse potential clinical trial</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Crushed immediate-release oxycodone tablets in solutions</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;text-align:left;"><p align=left style="font-family:arial;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> </FONT><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT><FONT FACE="arial" SIZE=2></font></p> <p align=left
style="font-family:arial;margin-top:0pt;margin-left:18pt;"><font size=2>Assess the PK (Category&nbsp;2) and human abuse potential (Category&nbsp;3) of Xtampza, intact and chewed</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Intranasal PK and HAP Clinical Trial (CP-OXYDET-21)  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our intranasal PK and HAP clinical trial assessed the human abuse potential of crushing and snorting Xtampza compared with taking intact Xtampza
orally and with crushed and snorting immediate-release oxycodone tablets. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>HAP
trials are clinical trials that determine the intrinsic potential for abuse of a drug formulation. These clinical trials are conducted in a non-dependent, recreational drug abuser population and
are designed to predict how probable it is that a particular drug formulation will be attractive to abusers (i.e.,&nbsp;"liked"). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
clinical trial measured drug liking, by which a drug abuser assesses how much he or she likes taking a drug using a visual analogue scale, or VAS, measured from 0 to 100, where 0 means the abuser
significantly dislikes the drug, 50 means neutral, and 100 means the abuser significantly likes the drug. The primary endpoint of this clinical trial was maximum effect, or Drug Liking
E<SUB>max</SUB>, which is the maximum VAS score recorded over the 24-hour period following administration. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Results
of the primary analysis for the Xtampza treatments (crushed and snorted Xtampza compared to intact Xtampza taken orally) were both significantly lower Drug Liking E<SUB>max</SUB> when
compared with the control, crushed and snorted immediate-release oxycodone (p&lt;0.0001 and p=0.0292, respectively). Additionally, a statistically significant reduction in Drug Liking
E<SUB>max</SUB> was also found when comparing crushed and snorted Xtampza microspheres with intact Xtampza capsules taken orally (p=0.037). </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>107</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=111,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=426312,FOLIO='107',FILE='DISK131:[15ZCN1.15ZCN74701]DZ74701A.;15',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<A NAME="page_dz74701_1_108"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dz74701_mean_drug_liking_emax_(peak_effect)"> </A>
<A NAME="toc_dz74701_7"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean Drug Liking E<SUB>max</SUB> (Peak Effect)    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g865624.jpg" ALT="GRAPHIC" WIDTH="654" HEIGHT="292">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
demonstrated in the figure below, analysis of the percentage reduction in Drug Liking E<SUB>max</SUB> score for crushed and snorted Xtampza relative to crushed and snorted immediate-release
oxycodone demonstrated a significant response for individual patients, with approximately 58% of patients showing at least a 50% reduction in Drug Liking E<SUB>max</SUB> and approximately 78% of
patients showing at least a 30% reduction in Drug Liking E<SUB>max</SUB>. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dz74701_percentage_of_subjects_showing__per05680"> </A>
<A NAME="toc_dz74701_8"> </A>
<BR></FONT><FONT SIZE=2><B>  Percentage of Subjects Showing Reduced Drug Liking of Crushed and Snorted Xtampza Relative to Crushed and Snorted Immediate-Release Oxycodone    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g1011221.jpg" ALT="GRAPHIC" WIDTH="516" HEIGHT="282">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>108</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=112,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=632757,FOLIO='108',FILE='DISK131:[15ZCN1.15ZCN74701]DZ74701A.;15',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ea74701_1_109"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In summary, drug abusers liked crushed and snorted Xtampza microspheres significantly less than swallowing intact Xtampza capsules (p=0.037), and they liked swallowing intact
Xtampza capsules significantly less than snorting immediate-release oxycodone powder (p=0.0292). Furthermore, crushing and snorting Xtampza was associated with the increased incidence of mild
respiratory adverse events and associated transient nasal events including irritation, burning, and facial pain among patients who crushed and snorted Xtampza microspheres. These AEs following
snorting Xtampza microspheres, without the addition of potentially harmful antagonist or aversive agents, may serve as a nuisance to an abuser who attempts snorting the drug. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Oral Chewed PK and HAP Clinical Trial (CP-OXYDET-24)  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our oral chewed PK and HAP clinical trial assessed the HAP of chewing Xtampza capsule contents compared with taking the intact Xtampza orally and with
taking crushed immediate-release oxycodone tablets orally. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Similar
to our intranasal and PK and HAP clinical trial, the primary endpoint for this clinical trial was Drug Liking E<SUB>max</SUB> over the 24-hour period after dosing. Results of the primary
analysis demonstrated that chewed Xtampza had significantly lower peak Drug Liking E<SUB>max</SUB> when compared with crushed immediate-release oxycodone (p&lt;0.0001). Similarly, Drug Liking
E<SUB>max</SUB> was significantly lower for intact Xtampza when compared with crushed immediate-release oxycodone (p&lt;0.0001). </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ea74701_mean_drug_liking_emax_(peak_effect)"> </A>
<A NAME="toc_ea74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean Drug Liking E<SUB>max</SUB> (Peak Effect)    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g408147.jpg" ALT="GRAPHIC" WIDTH="592" HEIGHT="307">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
percentage reduction for intact and chewed Xtampza relative to crushed immediate-release oxycodone as measured by Drug Liking E<SUB>max</SUB> is presented below. This figure shows that relative
to crushed immediate-release oxycodone, chewing Xtampza does not markedly impact reduction in Drug Liking E<SUB>max</SUB> compared with swallowing Xtampza intact. For both Xtampza treatments (intact
and chewed), approximately 29-37% of patients showed at least a 50% reduction in Drug Liking E<SUB>max</SUB> relative to crushed immediate-release oxycodone, and approximately 48% of patients showed
at least a 30% reduction in Drug Liking E<SUB>max</SUB> relative to crushed immediate-release oxycodone. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>109</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=113,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=698681,FOLIO='109',FILE='DISK131:[15ZCN1.15ZCN74701]EA74701A.;26',USER='NDEWIND',CD='31-DEC-2015;17:09' -->
<A NAME="page_ea74701_1_110"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ea74701_percentage_reduction_for_xtamp__per04710"> </A>
<A NAME="toc_ea74701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Percentage Reduction for Xtampza Intact and Chewed, Relative to Crushed Immediate-Release Oxycodone for Drug Liking VAS    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g743713.jpg" ALT="GRAPHIC" WIDTH="616" HEIGHT="358">
  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
clinical trial demonstrated that administration of chewed Xtampza resulted in lower Drug Liking E<SUB>max</SUB> than swallowing crushed immediate-release oxycodone. Similarly, swallowing intact
Xtampza resulted in lower Drug Liking E<SUB>max</SUB> than swallowing crushed immediate-release oxycodone. This decrease in Drug Liking E<SUB>max</SUB> for both chewed and intact oral administration
of Xtampza suggests that the relative abuse potential of Xtampza is significantly lower than that of a non-abuse-deterrent formulation of crushed immediate-release oxycodone (p&lt;0.0001). </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
conclusion, data from these Category&nbsp;3 human abuse potential clinical trials demonstrated that Xtampza resulted in reduced Drug Liking when the drug product is chewed prior to oral
administration, or when Xtampza is crushed and snorted, relative to immediate-release oxycodone administered by the same routes. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>110</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=114,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=883762,FOLIO='110',FILE='DISK131:[15ZCN1.15ZCN74701]EA74701A.;26',USER='NDEWIND',CD='31-DEC-2015;17:09' -->
<A NAME="page_ea74701_1_111"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Alternative Dosing PK Clinical Trial (CP-OXYDET-27)  </I></B></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>CP-OXYDET-27 was an open-label, randomized, single-dose, cross-over comparison clinical trial designed to assess the safety and PK profile of Xtampza
administered by sprinkling the Xtampza microspheres onto applesauce compared with administration of intact Xtampza. As shown in the graph below, the
administration of Xtampza microspheres sprinkled onto applesauce did not lead to any change in their PK profile compared to intact Xtampza. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g261394.jpg" ALT="GRAPHIC" WIDTH="595" HEIGHT="312">
  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Manufacturing  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Overview  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our product candidates are manufactured using a proprietary process. This process is reproducible, scalable and cost-efficient, and we believe that
the microsphere formulation&nbsp;&#151; and the related manufacturing process&nbsp;&#151; is unique in the extended-release opioid market. To date, we have manufactured three
registration batches of Xtampza and have 24&nbsp;months of stability data to support a proposed two-year shelf life. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
date, we have produced Xtampza for use in our clinical trials, abuse-deterrence studies and clinical trials, and our preclinical studies at our contract manufacturing organization, Patheon. The
existing Patheon facility has the capacity to support production of commercial quantities of Xtampza during the first several years after commercial launch. We are currently conducting a commercial
validation program in preparation for commercial launch of Xtampza. As needed, we anticipate working with Patheon to build additional and dedicated manufacturing capacity at Patheon's existing
facility. Patheon has an established record of manufacturing products approved in the United States, including controlled substances. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
own all of the intellectual property, including know-how and specialized manufacturing equipment, necessary to be able to replicate the manufacturing equipment currently located at Patheon's
facility at an alternative location (and with an alternative vendor) if necessary. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>111</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=115,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=792731,FOLIO='111',FILE='DISK131:[15ZCN1.15ZCN74701]EA74701A.;26',USER='NDEWIND',CD='31-DEC-2015;17:09' -->
<A NAME="page_ea74701_1_112"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Drug Substances  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The active ingredient used in Xtampza, oxycodone base, is an odorless white crystalline powder. We currently procure this active ingredient pursuant
to a commercial supply agreement with a U.S.-based manufacturer and expect to continue to do so as we scale up production in anticipation of commercialization. If our current supplier is unable to
supply oxycodone base in the quantities and at the times we require it, we are aware of other suppliers who we would expect to be able to satisfy our commercial orders. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Oxycodone
base is classified as a narcotic controlled substance under U.S. federal law. We expect that Xtampza and our other product candidates will be classified by the U.S. Drug Enforcement
Administration, or DEA, as Schedule&nbsp;II controlled substances, meaning that they have a high potential for abuse and dependence among drugs that are recognized as having an accepted medical use.
Consequently, we expect that the manufacturing, shipping, dispensing and storing of our product candidates will be subject to a high degree of regulation, as described in more detail under the caption
"&#151; Governmental Regulation&nbsp;&#151; DEA Regulation." </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Marketing and Commercialization  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We intend to commercialize Xtampza and our other product candidates in the United States, if approved, with a direct sales force. We plan to explore
out-licensing partnerships for Xtampza in other international markets, such as Canada, Australia and Japan, as well as countries in Latin America and Europe. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
members of our management team, who will lead the commercialization of Xtampza, if we receive final regulatory approval, have substantial experience in pharmaceutical sales and marketing. If
Xtampza receives final regulatory approval in the United States, we intend to hire a dedicated field sales force, initially consisting of approximately 120 sales professionals, to target the
approximately 11,000 physicians who write approximately 55% of the branded extended-release oral opioid prescriptions in the United States, with a primary focus on pain specialists. In addition, we
plan to deploy a focused sales force of approximately 25 specialty sales representatives to call on institutions where patients require extended-release opioids, such as skilled nursing or
hospice facilities. In addition, we have employed medical sales liaisons, or MSLs, to respond to clinician inquiries about Xtampza. We have also employed a market-access team to support our formulary
approval and payor contracting. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
are continuing to develop our commercialization strategy with the input of key opinion leaders in the field of pain management, as well as healthcare practitioners. Internally, we have advanced
pre-commercialization activities for Xtampza, such as developing positioning and messaging campaigns, a publication strategy, initiatives with payor organizations, and distribution and national
accounts strategies. Our marketing strategy is expected to include increasing awareness of the differentiated features of Xtampza, the hazards of opioids that are not abuse-deterrent, and increasing
awareness of solutions for patients with CPD who require or would benefit from extended-release opioids. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Intellectual Property  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>We regard the protection of patents, designs, trademarks and other proprietary rights that we own or license as critical to our success and
competitive position. Our patent portfolio directed toward Xtampza and our DETERx technology consists of seven issued patents in the United States (five of which claim compositions of matter, one of
which claims both compositions of matter and methods of use, and one of which claims methods of use), two pending applications in the European Union and one issued patent in each of Canada, Japan and
Australia. In addition, we were granted Notice of Allowances for one patent in the United States and one patent in Canada. Finally, we have six patent applications pending in the United States, and
one pending patent application in Japan. Our issued U.S. patents are projected to expire in 2023 and 2025, and our pending patent applications in the United States, if issued, would be projected to
expire in 2023, 2025 and 2030. In addition, we use a unique and proprietary process to manufacture our products that requires significant know-how, which we currently protect as trade secrets.

</FONT>

</P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>112</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=116,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=971457,FOLIO='112',FILE='DISK131:[15ZCN1.15ZCN74701]EA74701A.;26',USER='NDEWIND',CD='31-DEC-2015;17:09' -->
<A NAME="page_ea74701_1_113"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
policy is to patent the technology, inventions and improvements that we consider important to the development of our business, but only in those cases in which we believe that the costs of
obtaining patent protection is justified by the commercial potential of the technology, and typically only in those jurisdictions that we believe present significant commercial opportunities to us. We
have concluded that some of our technology is best protected as proprietary know-how, rather than through obtaining patents. In some cases, we publish the invention such that it becomes prior art in
order for us to secure freedom to operate and to prevent a third party from patenting the invention before us. Our technology and products are not in-licensed from any third party, and we own all of
the rights to our product candidates. We believe we have freedom to operate in the United States and other countries, but there can be no assurance that other companies, known and unknown, will not
attempt to assert their intellectual property against us. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
also rely on trademarks and trade designs to develop and maintain our competitive position. We have received trademark registration for Collegium Pharmaceutical,&nbsp;Inc., DETERx, and Xtampza ER
in the United States. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
also depend upon the skills, knowledge and experience of our scientific and technical personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary
know-how that is not patentable, we rely on trade secret protection and confidentiality agreements to protect our interests. To this end, we generally require our employees, consultants and advisors
to enter into confidentiality agreements prohibiting the disclosure of confidential information and, in some cases, requiring disclosure and assignment to us of the ideas, developments, discoveries
and inventions important to our business. Additionally, these confidentiality agreements require that our employees, consultants and advisors do not bring to us, or use without proper authorization,
any third party's proprietary technology. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Patent Litigation Strategy  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We filed the NDA for Xtampza as a 505(b)(2) application, which allows us to reference data from an approved drug listed in the FDA's Approved Drug
Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), in this case OxyContin OP. The 505(b)(2) process requires that we certify to the FDA and notify Purdue, as the
holder of the NDA and any other Orange Book-listed patent owners, that we do not infringe any of the patents listed for OxyContin OP in the Orange Book, or that the patents are invalid. We made such
certification and provided such notice on February&nbsp;11, 2015 and such certification documented why Xtampza does not infringe any of the 11 Orange Book listed patents for OxyContin OP, five of
which stand invalidated by the Federal District Court for the Southern District of New York, subject to a pending appeal. Under the Hatch-Waxman Act of 1984, Purdue had the option to sue us for
infringement and receive a stay of up to 30&nbsp;months before the FDA can issue a final regulatory approval for Xtampza, unless the stay is earlier terminated. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Purdue
exercised its option and elected to sue us for infringement in the District of Delaware on March&nbsp;24, 2015 asserting infringement of three of Purdue's Orange Book-listed patents (all of
which stand invalidated subject to a pending appeal by Purdue) and a non-Orange Book-listed patent, and accordingly, received a stay of up to 30&nbsp;months before the FDA can issue a final
regulatory approval for Xtampza, unless the stay is earlier terminated. On March&nbsp;26, 2015, Purdue filed a second suit against us in the District of Massachusetts asserting infringement of the
same four patents. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


On July&nbsp;23, 2015, Purdue voluntarily dismissed the Massachusetts case and on August&nbsp;6, 2015, Purdue filed another case in Massachusetts asserting the same four patents as in the Delaware
case and the original Massachusetts case. On October&nbsp;7, 2015, the Delaware case was transferred to Massachusetts and on November&nbsp;4, 2015, the two cases pending in Massachusetts were
consolidated. On November&nbsp;9, 2015, we filed a motion for partial judgment on the pleadings in relation to three of the four patents asserted against us which, had been previously invalidated by
the court in the Southern District of New York in Purdue's suit against Teva
Pharmaceuticals USA, Inc., or Teva. On the same date, we moved for entry of final judgment and to expedite hearing on our motions. On November&nbsp;23, 2015, Purdue filed a motion to

 </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>113</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=117,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=16795,FOLIO='113',FILE='DISK131:[15ZCN1.15ZCN74701]EA74701A.;26',USER='NDEWIND',CD='31-DEC-2015;17:09' -->
<A NAME="page_ea74701_1_114"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


stay proceedings until resolution of its appeal against Teva. The hearing regarding our motion for partial judgment and entry of judgment and Purdue's motion to stay was held on December&nbsp;22,
2015. On December&nbsp;23, 2015, the District Court of Massachusetts issued an order staying proceedings in relation to the three Orange Book-listed patents asserted against us until
February&nbsp;25, 2016, which is the date scheduled by the Court for a status conference. The Court reserved the decision to grant our motion for judgment on the three Orange Book-listed patents to
be taken up again at the February&nbsp;25th status conference, at which time the Court indicated it may grant our motion for judgment or may consider extending the stay. The Court further indicated
that it will consider an earlier hearing if the Court of Appeals for the Federal Circuit issues a decision on the appeal of the New York judgment of invalidity prior to the February&nbsp;25th status
conference.

</FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


On November&nbsp;6, 2015, Purdue filed another patent infringement suit against us in Massachusetts asserting infringement of another patent that is a continuation of the three patents previously
asserted by Purdue against us that were invalidated by the court in the Southern District of New York. On December&nbsp;1, 2015, we filed a motion to dismiss for failure to state a claim, arguing
that the patent asserted by Purdue is invalid based on collateral estoppel. Purdue filed its opposition response on December&nbsp;15, 2015. That action has been consolidated into the other
Massachusetts actions, and our motion remains pending.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA's tentative approval of Xtampza means that the product, with its product labeling, is tentatively approved based upon the information available to the FDA at the time of tentative approval.
The FDA can grant final approval following the expiration of the 30-month stay period or termination of the stay. If we receive a court order that the listed patents are invalid or not infringed, or
if we settle the Purdue litigation before the 30-month stay period expires, the FDA could then provide final regulatory approval of Xtampza prior to the expiration of the 30-month period, at which
point the product can be marketed. We do not believe we infringe Purdue's patents and intend to vigorously defend the suit. Our certification letter to Purdue and the other Orange Book-listed patent
owners documents why Xtampza does not infringe any of the Orange Book-listed patents for OxyContin OP, or the OxyContin Patents, which fall into three general categories, as
follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>High molecular weight poly(ethylene oxide)/polymer
patents:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Some of the OxyContin Patents describe a formulation containing a significant amount of high molecular weight poly(ethylene oxide) or polyalkalene oxide,
which creates a hard tablet that is difficult to crush. Some of these OxyContin Patents claim specific manufacturing methods and curing conditions that are intended to create hard tablets. The
formulation described in our NDA for Xtampza does not contain any high molecular weight component and is manufactured under different conditions from those claimed by the OxyContin Patents. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Oxycodone HCl or preferential removal of
14-hydroxycodeinione patents:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Some of the OxyContin Patents describe oxycodone compositions, formulations and manufacturing processes that use oxycodone HCl as the
active ingredient and thus require preferential removal of the toxic intermediary 14-hydroxycodeinone. The formulation described in our NDA uses an oxycodone base rather than oxycodone HCl, and does
not require the preferential removal of 14-hydroxycodeinone. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Viscosity-increasing
patents:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Some of the OxyContin Patents describe the addition of viscosity-increasing agents as a method of abuse deterrence. The formulation described in our NDA
does not contain any viscosity-increasing agent and, unlike OxyContin OP, does not form&nbsp;a gel when placed in an aqueous liquid. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our
certification letter to Purdue also noted that five of the 11 Orange Book-listed patents for OxyContin OP stand invalidated by the Federal District Court for the Southern District of New York,
subject to a pending appeal. The oral arguments for the pending appeal in the U.S. Court of Appeals for the Federal Circuit were held on November&nbsp;3, 2015. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Because
we anticipated that Purdue would sue us for patent infringement as a possible means to delay the launch of Xtampza, we have engaged experienced litigation counsel, who worked carefully with us
to construct a strategy to prevail in any litigation that arises as expeditiously as possible. We are now in the process of implementing this litigation strategy and plan to take all steps necessary
to vigorously defend ourselves against these claims. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>114</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=118,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=46389,FOLIO='114',FILE='DISK131:[15ZCN1.15ZCN74701]EA74701A.;26',USER='NDEWIND',CD='31-DEC-2015;17:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_eb74701_1_115"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our Strategy  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our goal is to become the leading marketer of abuse-deterrent extended-release opioids and other commonly abused products. Key elements of our
strategy to achieve this goal are to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Establish our leadership position by obtaining final
regulatory approval to market Xtampza with a best-in-class abuse-deterrent product label.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our tentatively approved product label contains differentiated
abuse-deterrent claims for Xtampza. If Xtampza receives final regulatory approval, this product label may allow us to detail Xtampza to physicians and highlight its unique abuse-deterrent
characteristics. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Commercialize Xtampza in the United States
ourselves.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We are currently building our commercial organization, including our sales force and commercial manufacturing capacity, in preparation for a potential
U.S. commercial launch of Xtampza in the second quarter of 2016, although the timing of a potential commercial launch is subject to whether and when we receive final regulatory approval for Xtampza.
Our management team has extensive experience commercializing pharmaceutical products, and we are in the process of establishing sales, marketing and reimbursement functions to commercialize Xtampza in
the United States. Initially, we plan to detail Xtampza to approximately 11,000 physicians who write approximately 55% of the branded extended-release oral opioid prescriptions in the United States
with a sales team of approximately 120 sales representatives. We believe that this physician group also represents a significant portion of the top prescribers of extended-release and long-acting
opioids (including drugs formulated with fentanyl and methadone) currently used to treat patients with CPD. In addition, we plan to deploy a separate, focused sales team of approximately 25 specialty
sales representatives to detail Xtampza to nursing homes, hospices, and other institutions treating large populations of the elderly and other patients who need chronic pain relief and have difficulty
swallowing. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Establish Xtampza as the treatment of choice for
patients with CPD.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Xtampza has been tentatively approved with product labeling for sprinkling Xtampza microspheres on soft foods or into a cup, and then directly
into the mouth, or through a gastrostomy or nasogastric feeding tube. If Xtampza receives final regulatory approval, Xtampza could be the only extended-release oxycodone product designed to be
suitable for this approximately 11&nbsp;million patient segment. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Establish strategic collaborations to accelerate and
maximize the potential of our product candidates worldwide.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We intend to seek strategic collaborations with other pharmaceutical companies to commercialize our
product candidates outside the United States and to develop certain of our product candidates that are outside of our core therapeutic focus. We believe that we are an attractive collaborator for
pharmaceutical companies due to the strength of our abuse-deterrent technology. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Advance other product candidates that incorporate our
DETERx platform technology.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We have begun advancing our development program for COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of
chronic pain. We target beginning clinical trials for our second product candidate by the first quarter of 2016. We also have an IND application on file for COL-172, an abuse-deterrent,
extended-release oxymorphone for the treatment of chronic pain, which has been granted Fast Track status by the FDA. In addition, we have COL-171, a proprietary preclinical DETERx extended-release,
abuse-deterrent methylphenidate formulation for the treatment of ADHD. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2><I>Acquire additional products and product
candidates.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We may identify and license, co-promote or acquire products or product candidates being developed for pain indications and other complementary products. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
are continuing to develop our commercialization strategy with the input of key opinion leaders in the field of pain management, as well as healthcare practitioners. Internally, we have advanced
pre-commercialization initiatives for Xtampza, such as developing positioning and messaging campaigns, a publication strategy, initiatives with payor organizations, and distribution and national
accounts strategies. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>115</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=119,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=483024,FOLIO='115',FILE='DISK131:[15ZCN1.15ZCN74701]EB74701A.;18',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_eb74701_1_116"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Competition  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face
competition and potential competition from a number of sources, including pharmaceutical and biotechnology companies, generic drug companies, drug delivery companies and academic and research
institutions. Most of the existing and potential competitors have significantly more financial and other resources than we do. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Currently,
the only opioid drugs on the market for chronic pain relief that have an abuse-deterrent product label are OxyContin OP and Hysingla&reg;, both of which are marketed by Purdue, and
Embeda, which is marketed by Pfizer. In addition, there are two other approved extended-release opioids that have abuse-deterrent product labeling, Targiniq from Purdue and MorphaBond&#153; ER
from Inspirion Delivery Technologies,&nbsp;LLC, neither of which is currently on the market. Hysingla is a once a day hydrocodone extended-release product. Embeda is a combination of morphine and
naltrexone, an opioid antagonist that can be
sprinkled on soft food but contains a black box warning product label stating that "crushing, dissolving or chewing can cause rapid release and absorption of a potentially fatal dose of the active
drug." Also, according to the warning labels of OxyContin OP and other extended-release opioids, administration of the active ingredients by injection may result in necrosis, infection and increased
risk of heart disease. Targiniq is a combination of oxycodone and naloxone, an opioid antagonist. MorphaBond ER is a twice daily morphine product formulated with a hard tablet and gelling polymers. In
2014, sales of extended-release opioids in the United States were $6&nbsp;billion, consisting of a number of large and small companies, including Purdue, Pfizer, Actavis, Endo Pharmaceuticals,
Pernix, Janssen Pharmaceuticals, Mallinckrodt and several generic drug companies. A number of other large and small companies are developing abuse-deterrent drugs for chronic pain, including Teva
Pharmaceutical Industries&nbsp;Ltd., Endo Health Solutions&nbsp;Inc., Nektar Therapeutics, Egalet Corporation, and KemPharm,&nbsp;Inc. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe the key competitive factors that will affect the development and commercial success of our product candidates include their degree of abuse deterrence, bioavailability, therapeutic
efficacy, and convenience of dosing and distribution, as well as their safety, cost and tolerability profiles. Xtampza may also face competition from commercially available generic and branded
extended-release and long-acting opioid drugs other than oxycodone, including fentanyl, hydromorphone, oxymorphone and methadone, as well as opioids that are currently in clinical development. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If
it ultimately receives final regulatory approval, Xtampza would compete against all extended-release opioids, including Purdue's OxyContin OP for the treatment of patients experiencing pain severe
enough to require around-the-clock analgesia. Although no generic oxycodone extended-release products are currently commercially available, and although the FDA has not issued guidance on the
regulatory pathway for generic abuse-deterrent products, it is possible that generic forms of OxyContin OP could become available, in which case Xtampza would compete with any such generic oxycodone
extended-release products. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Additionally,
we are aware of companies in late-stage development of abuse-deterrent oxycodone product candidates, including Pain Therapeutics' Remoxy&reg;, a formulation of oxycodone, and
Pfizer's ALO-02, a formulation of oxycodone and naltrexone. If these products are successfully developed and approved for marketing, they could represent significant competition for Xtampza. It is
also possible that a company that has developed an abuse-deterrent technology could initiate an abuse-deterrent oxycodone program at any time. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Government Regulation  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


FDA Approval Process  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The FD&amp;C Act and other federal and state statutes and
regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring
and reporting, sampling, and import and export of pharmaceutical </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>116</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=120,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=961379,FOLIO='116',FILE='DISK131:[15ZCN1.15ZCN74701]EB74701A.;18',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_eb74701_1_117"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>products.
Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as warning or untitled letters, product recalls, product
seizures, total or partial suspension of production or distribution, withdrawal of the product from the market, injunctions, fines, civil penalties, and criminal prosecution. Failure to meet FDA
requirements for approval would also result in a medication not being approved for marketing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
process of developing a pharmaceutical and obtaining FDA approval to market the medication in the United States typically involves:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  completion of preclinical laboratory and animal testing and formulation studies
in compliance with the FDA's good laboratory practices, or GLP, regulation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  submission to the FDA of an IND for human clinical testing, which must become
effective before human clinical trials may begin in the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> approval by an independent institutional review board, or IRB, at each clinical
trial site before each trial may be initiated; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  performance of adequate and well-controlled human clinical trials in accordance
with current good clinical practices, or GCP, to establish the safety and efficacy of the proposed drug product for each indication for which FDA approval is sought; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  satisfactory completion of an FDA pre-approval inspection of the facility or
facilities at which the product is manufactured to assess compliance with the FDA's cGMP regulations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  submission to the FDA of an NDA; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  satisfactory completion of a potential review by an FDA advisory committee, if
applicable; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> FDA review and approval of the NDA. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Satisfaction
of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or
disease. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Preclinical
tests include laboratory evaluation of product chemistry, formulation, stability and toxicity, as well as animal studies to assess the characteristics and potential safety and efficacy of
the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including GLPs. The results of preclinical testing are submitted to the FDA as part of an IND
along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long-term preclinical tests, such as animal tests of
reproductive toxicity and carcinogenicity, may continue after the IND is submitted. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
IND automatically becomes effective 30&nbsp;days after receipt by FDA unless, within the 30-day time period, the FDA raises concerns or questions relating to one or more proposed clinical trials
and places the clinical trial on hold, including concerns that human research subjects will be exposed to unreasonable health risks. In such a case, the IND sponsor and the FDA must resolve any
outstanding concerns before the clinical trial can begin. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Clinical
trials involve the administration of the investigational new drug to healthy volunteers or subjects under the supervision of a qualified investigator. Clinical trials must be conducted:
(i)&nbsp;in compliance with federal regulations, including GCP, an international standard meant to protect the rights, safety and wellbeing of subjects and to define the roles of clinical trial
sponsors, administrators, and monitors; and (ii)&nbsp;under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and any
effectiveness criteria to be evaluated. Each protocol involving testing on U.S. subjects and subsequent protocol amendments must be submitted to the FDA as part of the IND. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>GCP
requirements include that all research subjects provide their informed consent in writing for their participation in any clinical trial. An independent IRB for each site proposing to conduct the
clinical trial must review and approve the informed consent information as well as the clinical trial protocol before the trial commences at that site, and must monitor the study until completed. The
FDA or the IRB may order the temporary or permanent discontinuation of a clinical trial at any time and on various grounds, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>117</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=121,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=520863,FOLIO='117',FILE='DISK131:[15ZCN1.15ZCN74701]EB74701A.;18',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_eb74701_1_118"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>particularly
upon the belief that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial subjects, or impose other
conditions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Clinical
trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap or be combined. In Phase&nbsp;1, the drug is initially
introduced into healthy human subjects or patients, and is tested to assess safety, dose tolerance, absorption, metabolism, PK, pharmacological actions, side effects associated with increasing doses,
and, if possible, early evidence on effectiveness. Phase&nbsp;2 usually involves trials in a limited patient population to determine the effectiveness of the drug for a particular indication, dosage
tolerance, and optimum dosage, and to identify common AEs and safety risks. Multiple Phase&nbsp;2 trials may be conducted by the sponsor to obtain information prior to beginning larger and more
extensive Phase&nbsp;3 clinical trials. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase&nbsp;2 evaluations, Phase&nbsp;3 trials are undertaken to
obtain the additional information about clinical efficacy and safety in a larger number of subjects, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the
overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug. In most cases, the FDA requires two adequate and well controlled Phase&nbsp;3 clinical
trials to demonstrate the efficacy of the drug. A single Phase&nbsp;3 trial with other confirmatory evidence may be sufficient in rare instances where the clinical trial is a large multicenter trial
demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially
serious outcome and confirmation of the result in a second trial would be practically or ethically
impossible. Sponsors of clinical trials generally must register and report key parameters of certain clinical trials at the NIH-maintained website ClinicalTrials.gov. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>After
completion of the required clinical testing, an NDA is prepared and submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in the United States. The
NDA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to the product's pharmacology, chemistry, manufacture, and controls. The cost of
preparing and submitting an NDA is substantial. The submission of most NDAs is additionally subject to a substantial application user fee, currently set at $2,374,200, and the manufacturer and/or
sponsor under an approved new drug application are also subject to annual product and establishment user fees, currently set at $114,450 per product and $585,200 per establishment. These fees are
typically increased annually. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA has 60&nbsp;days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency's threshold determination that it is sufficiently complete to
permit substantive review. Rather than accept an NDA for filing, then FDA may request additional information. In this event, the NDA must be resubmitted with the additional information and may be
subject to payment of additional user fees. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an
in-depth substantive review. The FDA has established certain performance goals for the review of new drug applications. The agency endeavors to review applications for standard review drug products
within 10 to 12&nbsp;months of the acceptance for filing, and aims to review applications for drugs granted priority review, which may apply to drugs that the FDA determines offer major advances in
treatment or provide a treatment where no adequate therapy exists, within six to eight months. The review process for both standard and priority review may be extended by FDA for three additional
months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an advisory committee&nbsp;&#151; typically a panel
that includes clinicians and other experts&nbsp;&#151; for review, evaluation, and a recommendation as to whether the application should be approved and under what conditions. The FDA is not
bound by the recommendation of an advisory committee, but it generally follows such recommendations. In addition, before approving an NDA, the FDA will typically inspect one or more clinical sites to
assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the product </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>118</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=122,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=331505,FOLIO='118',FILE='DISK131:[15ZCN1.15ZCN74701]EB74701A.;18',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_eb74701_1_119"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>unless
compliance with cGMP is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>After
the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter to indicate that the review cycle for an application is complete and
that the application is not
ready for approval. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider
the application. Even with submission of this additional information, the FDA may ultimately decide that an application does not satisfy the regulatory criteria for approval. If, and when, those
deficiencies have been addressed to the FDA's satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six
months depending on the type of information included. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>An
approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. Changes to certain of the conditions established in an approved
application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be
implemented, which may require us to develop additional data or conduct additional preclinical studies and clinical trials. An NDA supplement for a new indication typically requires clinical data
similar to that in the original application, and the FDA uses similar procedures and actions in reviewing NDA supplements as it does in reviewing NDAs. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


REMS  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The FDA has the authority to require a Risk Evaluation and Mitigation Strategy, or REMS, as a condition of the approval of an NDA or after approval to
ensure that the benefits of a drug outweigh its risks. In determining whether a REMS is necessary, the FDA must consider the size of the population likely to use the drug, the seriousness of the
disease or condition to be treated, the expected benefit of the drug, the duration of treatment, the seriousness of known or potential adverse events, and whether the drug is a new molecular entity.
If the FDA determines a REMS is necessary for a new drug, the drug sponsor must submit a proposed REMS plan as part of its NDA prior to approval. The FDA may also impose a REMS requirement on a drug
already on the market if the FDA determines, based on new safety information, that a REMS is necessary to ensure that the drug's benefits continue to outweigh its risks. A REMS can include medication
guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or
dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. In addition, the REMS must include a timetable to periodically assess the strategy, at a
minimum, at 18&nbsp;months, three years, and seven years after the REMS approval. The requirement for a REMS can materially affect the potential market and profitability of a drug. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
February 2009, the FDA informed manufacturers of certain opioid products that it would require a REMS for their opioid drug products. Subsequently, the FDA initiated efforts to develop a new
standardized REMS for these opioid medications to ensure their safe use, and in July 2012, approved a class-wide REMS for extended-release and long-acting opioid products. Extended-release
formulations of oxycodone, morphine, hydrocodone and hydromorphone, for example, are required to have a REMS. Manufacturers subject to this class-wide REMS must work together to implement the REMS as
part of a single shared system to reduce the burden of the REMS on the healthcare system. The central component of the extended release/long acting opioid REMS program is an education program for
prescribers and patients. Specifically, the REMS includes a Medication Guide available for distribution to patients who are dispensed the drug, as well as a number of ETASU. These ETASU include
training for healthcare professionals who prescribe the drug; information provided to prescribers that they can use to educate patients in the safe use, storage, and disposal of opioids; and
information provided to prescribers of the
existence of the REMS and the need to successfully complete the necessary training. Prescriber training required as part of the REMS is conducted by accredited, independent continuing education
providers, without cost to healthcare professionals, under unrestricted grants funded by the opioid analgesic manufacturers. Moreover, REMS assessments must be </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>119</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=123,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=974574,FOLIO='119',FILE='DISK131:[15ZCN1.15ZCN74701]EB74701A.;18',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_eb74701_1_120"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>submitted
on an annual basis to assess the extent to which the ETASU are meeting the goals of the REMS and whether the goals or elements should be modified. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Advertising and Promotion  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The FDA and other federal regulatory agencies closely regulate the marketing and promotion of drugs through, among other things, standards and
regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the Internet. A
product cannot be commercially promoted before it is approved. After approval, product promotion can include only those claims relating to safety and effectiveness that are consistent with the
labeling approved by the FDA. Healthcare providers are permitted to prescribe drugs for "off-label" uses&nbsp;&#151; that is, uses not approved by the FDA and therefore not described in the
drug's labeling&nbsp;&#151; because the FDA does not regulate the practice of medicine. However, FDA regulations impose stringent restrictions on manufacturers' communications regarding
off-label uses. Failure to comply with applicable FDA requirements and restrictions in this area may subject a company to adverse publicity and enforcement action by the FDA, the U.S. Department of
Justice, or the Office of the Inspector General of the U.S. Department of Health and Human Services, or HHS, as well as state authorities. This could subject a company to a range of penalties that
could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Fast Track Designation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The FDA has various programs to facilitate the development and expedite the review of drugs that are intended for the treatment of a serious or
life-threatening condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Under the Fast Track designation program, the
sponsor of a new product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the submission of the IND
for the product candidate. The FDA must determine if the product candidate qualifies for Fast Track designation within 60&nbsp;days after receipt of the sponsor's request. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition to other benefits, such as the ability to have more frequent interactions with the FDA, the FDA may initiate review of sections of a Fast Track product's NDA before the application is
complete. The FDA's time period goal for reviewing a Fast Track application does not begin until the last section of the NDA is submitted. In addition, the Fast Track designation may be withdrawn by
the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Post-Approval Requirements  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Once an NDA is approved, a product will be subject to pervasive and continuing regulation by the FDA, including, among other things, requirements
relating to drug listing and registration, recordkeeping, periodic reporting, product sampling and distribution, adverse event reporting and advertising, marketing and promotion restrictions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Adverse
event reporting and submission of periodic reports is required following FDA approval of an NDA. The FDA also may require post-market testing, known as Phase&nbsp;4 testing, REMS, and
surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control,
drug manufacture, packaging, and labeling procedures must continue to conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their
establishments with FDA and certain state agencies. Registration subjects entities to periodic announced or unannounced inspections by the FDA or these state agencies, during which the agency inspects
manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain
compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following
initial marketing, or if previously unrecognized problems are subsequently discovered. In addition, other regulatory actions may be taken, including, among other things, warning letters, the seizure
of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>120</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=124,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=469898,FOLIO='120',FILE='DISK131:[15ZCN1.15ZCN74701]EB74701A.;18',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_eb74701_1_121"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>products,
injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations, refusal to approve pending applications or supplements to approved applications,
civil penalties, and criminal prosecution. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
part of the sales and marketing process, pharmaceutical companies frequently provide samples of approved drugs to physicians. The Prescription Drug Marketing Act, or PDMA, and associated
regulations, impose certain recordkeeping and reporting requirements and other limitations on the distribution of drug samples to physicians. The PDMA also requires that state licensing of
distributors who distribute prescription drugs meet certain federal guidelines that include minimum standards for storage, handling and record keeping. In addition, the PDMA and a growing majority of
states also impose certain drug pedigree requirements on the sale and distribution of prescription drugs. The PDMA sets forth civil and criminal penalties for violations. In 2010, a statutory
provision was enacted that required manufacturers and authorized distributors of record to report on an annual basis certain information about prescription drug samples they distributed. The FDA
issued a draft compliance policy guide on the reporting requirement. The FDA stated that it would exercise enforcement discretion with regard to companies that have not submitted reports until the FDA
finalizes the reporting requirement and/or provides notice that it is revising its exercise of enforcement discretion. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
FDA may require post-approval studies and clinical trials if the FDA finds that scientific data, including information regarding related drugs, deem it appropriate. The purpose of such studies
would be to assess a known serious risk or signals of serious risk related to the drug or to identify an unexpected serious risk when available data indicate the potential for a serious risk. The FDA
may also require a labeling change if it becomes aware of new safety information that it believes should be included in the labeling of a drug. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


The Hatch-Waxman Amendments  </I></B></FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


<U>Orange Book Listing</U>  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant's product.
Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as
the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated NDA, or ANDA. An ANDA provides for marketing of a drug
product that has the same active ingredient in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed
drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, preclinical or clinical tests to prove the safety or efficacy of their
drug product. Drugs approved in this way are commonly referred to as "generic equivalents" to the listed drug, and can often be substituted by pharmacists under prescriptions written for the original
listed drug. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
ANDA applicant is required to make certain certifications to the FDA concerning any patents listed for the approved product in the FDA's Orange Book. Specifically, the applicant must certify that:
(i)&nbsp;the required patent information has not been filed; (ii)&nbsp;the listed patent has expired; (iii)&nbsp;the listed patent has not expired, but will expire on a particular date and
approval is sought after patent expiration; or (iv)&nbsp;the listed patent is invalid or will not be infringed by the new product. The ANDA applicant may also elect to submit a section&nbsp;viii
statement certifying that its proposed ANDA label does not contain (or carves out) any language regarding the patented method-of-use rather than make certifications concerning a listed method-of-use
patent. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
certification that the new product will not infringe the already approved product's listed patents, or that such patents are invalid, is called a Paragraph&nbsp;IV certification. If the ANDA
applicant has provided a Paragraph&nbsp;IV certification to the FDA, the applicant must also send notice of the Paragraph&nbsp;IV certification to the NDA and patent holders once the ANDA has been
accepted for filing by the FDA. The NDA and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>121</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=125,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=752501,FOLIO='121',FILE='DISK131:[15ZCN1.15ZCN74701]EB74701A.;18',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_eb74701_1_122"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>patent
holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&nbsp;IV certification. The filing of a patent infringement lawsuit within 45&nbsp;days of
the receipt of a Paragraph&nbsp;IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30&nbsp;months, expiration of the patent, settlement of the lawsuit, or
a decision in the infringement case that is favorable to the ANDA applicant. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
ANDA application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the referenced product has expired. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


<U>Exclusivity</U>  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Upon NDA approval of a new chemical entity, or NCE, which is a drug that contains no active moiety that has been approved by FDA in any other NDA,
that drug receives five years of marketing exclusivity during which FDA cannot receive any ANDA seeking approval of a generic version of that drug or any Section&nbsp;505(b)(2) NDA, discussed in
more detail below, that relies on the FDA's findings regarding that drug. A drug may obtain a three-year period of exclusivity for a change to the drug, such as the addition of a new indication to the
labeling or a new formulation, during which FDA cannot approve an ANDA or any Section&nbsp;505(b)(2) NDA, if the supplement includes reports of new clinical trials (other than bioavailability
clinical trials) essential to the approval of the supplement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>An
ANDA may be submitted one year before NCE exclusivity expires if a Paragraph&nbsp;IV certification is filed. If there is no listed patent in the Orange Book, there may not be a
Paragraph&nbsp;IV certification, and, thus, no ANDA may be filed before the expiration of the exclusivity period. </FONT></P>

<UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


<U>Section&nbsp;505(b)(2) NDAs</U>  </I></FONT></P>

</UL>

<P style="font-family:arial;"><FONT SIZE=2>Generally, drug products obtain FDA marketing approval pursuant to an NDA or an ANDA. A third alternative is a Section&nbsp;505(b)(2) NDA, which
enables the applicant to rely, in part, on data not developed by the applicant, such as the FDA's findings of safety and efficacy in the approval of a similar product or published literature in
support of its application. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Section&nbsp;505(b)(2)
NDAs may provide an alternate path to FDA approval for new or improved formulations or new uses of previously approved products. Section&nbsp;505(b)(2) permits the filing of
an NDA where at least some of the information required for approval comes from clinical trials not conducted by, or for, the applicant and for which the applicant has not obtained a right of
reference. If the Section&nbsp;505(b)(2) applicant can establish that reliance on FDA's previous findings of safety and efficacy is scientifically appropriate, it may eliminate the need to conduct
certain preclinical or clinical trials of the new product. The FDA may also require companies to perform additional clinical trials or provide additional materials to support the change from the
approved product. The FDA may then approve the new product candidate for all, or some, of the label indications for which the referenced product has been approved, as well as for any new indication
sought by the Section&nbsp;505(b)(2) applicant. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
the extent that the Section&nbsp;505(b)(2) applicant is relying on the FDA's findings of safety and effectiveness for an already approved product, the applicant is required to certify to the FDA
concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. Thus approval of a Section&nbsp;505(b)(2) NDA can be stalled until all the
listed patents claiming the referenced product have expired; until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the
referenced product has expired; and, in the case of a Paragraph&nbsp;IV certification and subsequent patent infringement suit, until the earlier of 30&nbsp;months, settlement of the lawsuit or a
decision in the infringement case that is favorable to the Section&nbsp;505(b)(2) applicant. In the interim period, the FDA may grant tentative approval. Tentative approval indicates that the FDA
has determined that the applicant meets the standards for approval as of the date that the tentative approval is granted. Final regulatory approval can only be granted if the FDA is assured that there
is no new information that would affect final regulatory approval. As with traditional NDAs, a Section&nbsp;505(b)(2) NDA may be eligible for three-year marketing exclusivity, assuming the NDA
includes reports of new clinical trials (other than bioavailability clinical trials) essential to the approval of the NDA. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>122</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=126,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=753374,FOLIO='122',FILE='DISK131:[15ZCN1.15ZCN74701]EB74701A.;18',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ec74701_1_123"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Disclosure of Clinical Trial Information  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Sponsors of clinical trials of FDA-regulated products, including drugs, are required to register and disclose certain clinical trial information.
Information related to the product, patient population, phase of investigation, clinical trial sites and investigators, and other aspects of the clinical trial is then made public as part of the
registration. Sponsors are also obligated to post certain information regarding the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until
the new product or new indication being studied has been approved. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


DEA Regulation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our lead product candidate, Xtampza, if it ultimately receives final regulatory approval, will be regulated as a "controlled substance" as defined in
the Controlled Substances Act, or CSA, which establishes registration, security, recordkeeping, reporting, storage, distribution, importation, exportation and other requirements administered by the
DEA. The DEA regulates the handling of controlled substances through a closed chain of distribution. This control extends to the equipment and raw materials used in their manufacture and packaging, in
order to prevent loss and diversion into illicit channels of commerce. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
DEA regulates controlled substances as Schedule&nbsp;I, II, III, IV or V substances. Schedule&nbsp;I substances by definition have no established medicinal use, and may not be marketed or sold
in the United States. A pharmaceutical product may be listed as Schedule&nbsp;II, III, IV or V, with Schedule&nbsp;II substances considered to present the highest risk of abuse and
Schedule&nbsp;V substances the lowest relative risk of abuse among such substances. Schedule&nbsp;II drugs are those that meet the following
characteristics:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> high potential for abuse; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  currently accepted medical use in treatment in the United States or a currently
accepted medical use with severe restrictions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> abuse may lead to severe psychological or physical dependence; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> are considered "dangerous." </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
expect that Xtampza, an abuse-deterrent oral formulation of oxycodone, will be listed by the DEA as a Schedule&nbsp;II controlled substance under the CSA. Consequently, the manufacturing,
shipping, storing, selling and using of the products will be subject to a high degree of regulation. Schedule&nbsp;II drugs are subject to the strictest requirements for registration, security,
recordkeeping and reporting. Also, distribution and dispensing of these drugs are highly regulated. For example, all Schedule&nbsp;II drug prescriptions must be signed by a physician, physically
presented to a pharmacist and may not be refilled without a new prescription. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Annual
registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location,
activity and controlled substance schedule. For example, separate registrations are needed for import and manufacturing, and each registration will specify which schedules of controlled substances are
authorized. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
DEA typically inspects a facility to review its security measures prior to issuing a registration. Security requirements vary by controlled substance schedule, with the most stringent requirements
applying to Schedule&nbsp;I and Schedule&nbsp;II substances. Required security measures include background checks on employees and physical control of inventory through measures such as cages,
surveillance cameras and inventory reconciliations. Records must be maintained for the handling of all controlled substances, and periodic reports made to the DEA, for example distribution reports for
Schedule&nbsp;I and II controlled substances, Schedule&nbsp;III substances that are narcotics, and other designated substances. Reports must also be made for thefts or losses of any controlled
substance, and to obtain authorization to destroy any controlled substance. In addition, special permits and notification requirements apply to imports and exports of narcotic drugs. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>123</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=127,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=368143,FOLIO='123',FILE='DISK131:[15ZCN1.15ZCN74701]EC74701A.;22',USER='NDEWIND',CD='31-DEC-2015;17:09' -->
<A NAME="page_ec74701_1_124"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, a DEA quota system controls and limits the availability and production of controlled substances in Schedule&nbsp;I or II. Distributions of any Schedule&nbsp;I or II controlled
substance must also be accompanied by special order forms, with copies provided to the DEA. Because Xtampza is expected to be regulated as a Schedule&nbsp;II controlled substance, it will be subject
to the DEA's production and procurement quota scheme. The DEA establishes annually an aggregate quota for how much oxycodone may be produced in total in the United States based on the DEA's estimate
of the quantity needed to meet legitimate scientific and medicinal needs. The limited aggregate amount of opioids that the DEA allows to be produced in the United States each year is allocated among
individual companies, who must submit applications annually to the DEA for individual production and procurement quotas. We and our contract manufacturers must receive an annual quota from the DEA in
order to produce or procure any Schedule&nbsp;I or Schedule&nbsp;II substance, including oxycodone base for use in manufacturing Xtampza. The DEA may adjust aggregate production quotas and
individual production and procurement quotas from time to time during the year, although the DEA has substantial discretion in whether or not to make such adjustments. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
enforce these requirements, the DEA conducts periodic inspections of registered establishments that handle controlled substances. Failure to maintain compliance with applicable requirements,
particularly as manifested in
loss or diversion, can result in administrative, civil or criminal enforcement action that could have a material adverse effect on our business, results of operations and financial condition. The DEA
may seek civil penalties, refuse to renew necessary registrations or initiate administrative proceedings to revoke those registrations. In certain circumstances, violations could result in criminal
proceedings. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Individual
states also independently regulate controlled substances. We and our contract manufacturers will be subject to state regulation on distribution of these products. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


International Regulation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In addition to regulations in the United States, we will be subject to a variety of foreign regulations regarding safety and efficacy and governing,
among other things, clinical trials and commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain the necessary approvals by the comparable
regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country and can involve
additional product testing and additional review periods, and the time may be longer or shorter than that required to obtain FDA approval and, if applicable, DEA classification. The requirements
governing, among other things, the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country. Regulatory approval in one country does not ensure
regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Many
foreign countries are also signatories to the internal drug control treaties and have implemented regulations of controlled substances similar to those in the United States. Our products will be
subject to such regulation which may impose certain regulatory and reporting requirements and restrict sales of these products in those countries. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Under
European Union regulatory systems, marketing authorizations may be submitted either under a centralized or decentralized procedure. The centralized procedure provides for the grant of a single
marketing authorization that is valid for all European Union member states. The decentralized procedure provides for mutual recognition of national approval decisions. Under this procedure, the holder
of a national marketing authorization may submit an application to the remaining member states. Within 90&nbsp;days of receiving the applications and assessment report, each member state must decide
whether to recognize approval. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition to regulations in Europe and the United States, we will be subject to a variety of foreign regulations governing, among other things, the conduct of clinical trials, pricing and
reimbursement and commercial distribution of our products. If we fail to comply with applicable foreign regulatory </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>124</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=128,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=153703,FOLIO='124',FILE='DISK131:[15ZCN1.15ZCN74701]EC74701A.;22',USER='NDEWIND',CD='31-DEC-2015;17:09' -->
<A NAME="page_ec74701_1_125"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>requirements,
we may be subject to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Other Healthcare Laws and Compliance Requirements  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the United States, the research, manufacturing, distribution, sale and promotion of drug products and medical devices are subject to regulation by
various federal, state and local authorities in addition to the FDA, including the Centers for Medicare&nbsp;&amp; Medicaid Services, other divisions of HHS (e.g.,&nbsp;the Office of Inspector
General), the DOJ, state Attorneys General and other state and local government agencies. For example, sales, marketing and scientific/educational grant programs must comply with fraud and abuse laws
such as the federal Anti-Kickback Statute, the federal False Claims Act, as amended and similar state laws. In order to participate in the Medicaid program, existing federal law requires
pharmaceutical manufacturers to pay rebates to state governments, based on a statutory formula, on covered outpatient drugs reimbursed by the Medicaid program as a condition of having their drugs paid
for by Medicaid. Manufacturers are required to report AMP and best price for each of their covered outpatient drugs to the government on a regular basis. Additionally, some state Medicaid programs
have imposed a requirement for supplemental rebates over and above the formula set forth in federal law, as a condition for coverage. In addition to the Medicaid Rebate Program, federal law also
requires that if a pharmaceutical manufacturer wishes to have its outpatient drugs covered under Medicaid as well as under Medicare Part&nbsp;B, it must sign a "Master Agreement" obligating it to
provide a formulaic discount that results in a federal ceiling price, or maximum price that participating manufacturers may charge for covered drugs sold to the U.S. Departments of Defense (including
the TRICARE retail pharmacy program), Veterans Affairs, the Public Health Service and the Coast Guard, and also provide discounts through a drug pricing agreement meeting the requirements of
Section&nbsp;340B of the Public Health Service Act, for outpatient drugs sold to certain specified eligible health care organizations. The formula for determining the discounted purchase price under
the 340B drug pricing program is defined by statute and is based on the AMP and rebate amount for a particular product as calculated under the Medicaid Drug Rebate Program, discussed above. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
federal Anti-Kickback Statute prohibits any person from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce or reward either the
referral of an individual, or the furnishing, recommending or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid
programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers, on one hand, and prescribers, purchasers, and formulary managers, on the other. The term
"remuneration" is not defined in the federal Anti-Kickback Statute and has been broadly interpreted to include the transfer of anything of value, including for example, gifts, discounts, the
furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payments, ownership interests and providing anything at other than its fair market value. Although there are a
number of statutory exemptions and regulatory safe harbors protecting certain business arrangements from prosecution, the exemptions and safe harbors are drawn narrowly and practices that involve
remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Our practices may not meet all of the
criteria for safe harbor protection from federal Anti-Kickback
Statute liability in all cases. The reach of the federal Anti-Kickback Statute was broadened by the recently enacted Affordable Care Act, which, among other things, amends the intent requirement of
the federal Anti-Kickback Statute such that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In
addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false
or fraudulent claim for purposes of the federal False Claims Act (discussed below) or the civil monetary penalties statute, which imposes fines against any person who is determined to have presented
or caused to be presented claims to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.
Additionally, many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to referral of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>125</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=129,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=711362,FOLIO='125',FILE='DISK131:[15ZCN1.15ZCN74701]EC74701A.;22',USER='NDEWIND',CD='31-DEC-2015;17:09' -->
<A NAME="page_ec74701_1_126"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>patients
for healthcare items or services reimbursed by any third-party payor, not only the Medicare and Medicaid programs in at least some cases, and do not contain safe harbors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
federal False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal
healthcare program. The "</FONT><FONT SIZE=2><I>qui tam</I></FONT><FONT SIZE=2>" provisions of the False Claims Act allow a private individual to bring civil actions on behalf of the federal government
alleging that the defendant has submitted a false claim to the federal government, and to share in any monetary recovery. In recent years, the number of suits brought by private individuals has
increased dramatically. In addition, various states have enacted false claims laws analogous to the False Claims Act. Many of these state laws apply where a claim is submitted to any third-party payor
and not merely a federal healthcare program. There are many potential bases for liability under the False Claims Act. Liability arises, primarily, when an entity knowingly submits, or causes another
to submit, a false claim for reimbursement to the federal government. The False Claims Act has been used to assert liability on the basis of inadequate care, kickbacks and other improper referrals,
improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, improper promotion of off-label uses not expressly approved by FDA in a drug's label, and allegations
as to misrepresentations with respect to the services rendered. To the extent we participate in government healthcare programs, our future activities relating to the reporting of discount and rebate
information and other information affecting federal, state and third party reimbursement of our products, and the sale and marketing of our products and our service arrangements or data purchases,
among other activities, may be subject to scrutiny under these laws. We are unable to predict whether we would be subject to actions under the False Claims Act or a similar state law, or the impact of
such actions. However, the cost of defending such claims, as well as any sanctions imposed, could adversely affect our financial performance. Also, HIPAA created several new federal crimes, including
healthcare fraud and false statements relating to healthcare matters. The healthcare fraud statute prohibits knowingly and willfully executing a scheme to defraud any healthcare benefit program,
including private third-party payors. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or
fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, we may be subject to, or our marketing activities in the future may be limited by, data privacy and security regulation by both the federal government and the states in which we conduct
our business. HIPAA and
its implementing regulations established uniform standards for certain "covered entities," which are healthcare providers, health plans and healthcare clearinghouses, governing the conduct of
specified electronic healthcare transactions and protecting the security and privacy of protected health information. The American Recovery and Reinvestment Act of 2009, commonly referred to as the
economic stimulus package, included expansion of HIPAA's privacy and security standards through HITECH, which became effective on February&nbsp;17, 2010. Among other things, HITECH makes HIPAA's
privacy and security standards directly applicable to "business associates," which are independent contractors or agents of covered entities that receive or obtain protected health information in
connection with providing a service on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly
other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney's fees and costs
associated with pursuing federal civil actions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Additionally,
under the federal Open Payments program, created under Section&nbsp;6002 of the Affordable Care Act and its implementing regulations, manufacturers of drugs for which payment is
available under Medicare, Medicaid or the Children's Health Insurance Program (with certain exceptions) must report information related to "payments or other transfers of value" made or distributed to
physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and manufacturers and applicable group purchasing organizations must report
ownership and investment interests held by physicians (as defined above) and their immediate family members. Such reports are to be </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>126</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=130,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=480714,FOLIO='126',FILE='DISK131:[15ZCN1.15ZCN74701]EC74701A.;22',USER='NDEWIND',CD='31-DEC-2015;17:09' -->
<A NAME="page_ec74701_1_127"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>made
to the Centers for Medicare &amp; Medicaid Services, or CMS, by the 90th day following the end of each subsequent year and CMS subsequently is to publish the reported information on a publicly
available website. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>There
are also an increasing number of state "sunshine" laws that require manufacturers to file reports with states on pricing and marketing information. Many of these laws contain ambiguities as to
what is required to comply with the laws. Several states have enacted legislation requiring pharmaceutical companies to, among other things, establish marketing compliance programs, file periodic
reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities and/or register their sales representatives. Such legislation also prohibits
pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical companies for use in sales and marketing and prohibits certain other sales and marketing
practices. These laws may affect our future sales, marketing and other promotional activities by imposing administrative and compliance burdens on us. In addition, given the lack of clarity with
respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and federal authorities. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Because
of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our business activities could be subject to challenge under one or
more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to
penalties, including criminal and significant civil monetary penalties, damages, fines, imprisonment, exclusion from participation in government healthcare
programs, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, private </FONT><FONT SIZE=2><I>qui
tam</I></FONT><FONT SIZE=2> actions brought by individual whistleblowers in the name of the government or refusal to allow us to enter into supply contracts, including government contracts and the
curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products are
approved and sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety
surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Third-Party Payor Coverage and Reimbursement  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The commercial success of our product candidates, if approved, will depend, in part, upon the availability of coverage and adequate reimbursement from
third-party payors at the federal, state and private levels. Third-party payors include governmental programs such as Medicare or Medicaid, private insurance plans and managed care plans. These
third-party payors may deny coverage or reimbursement for a product or therapy in whole or in part if they determine that the product or therapy was not medically appropriate or necessary. Also,
third-party payors have attempted to control costs by limiting coverage through the use of formularies and other cost-containment mechanisms and the amount of reimbursement for particular procedures
or drug treatments. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
cost of pharmaceuticals and devices continues to generate substantial governmental and third-party payor interest. We expect that the pharmaceutical industry will experience pricing pressures due
to the trend toward managed healthcare, the increasing influence of managed care organizations and additional legislative proposals. Our results of operations and business could be adversely affected
by current and future third-party payor policies as well as healthcare legislative reforms. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Some
third-party payors also require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. While we cannot
predict whether any proposed cost-containment measures will be adopted or otherwise implemented in the future, these requirements or any announcement or adoption of such proposals could have a
material adverse effect on our ability to obtain adequate prices for our product candidates and to operate profitably. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>127</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=131,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=672612,FOLIO='127',FILE='DISK131:[15ZCN1.15ZCN74701]EC74701A.;22',USER='NDEWIND',CD='31-DEC-2015;17:09' -->
<A NAME="page_ec74701_1_128"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Healthcare Reform  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could
affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs. The
Medicare Modernization Act imposed new requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries. Under Part&nbsp;D, Medicare beneficiaries may enroll in
prescription drug plans offered by private entities which will provide coverage of outpatient prescription drugs. Part&nbsp;D plans include both stand-alone prescription drug benefit plans and
prescription drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Part&nbsp;A and B, Part&nbsp;D coverage is not standardized. Part&nbsp;D prescription drug plan sponsors
are not required to pay for all covered Part&nbsp;D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However,
Part&nbsp;D prescription drug formularies must include drugs within each therapeutic category and class of covered Part&nbsp;D drugs, though not necessarily all the drugs in each category or
class. Any formulary used by a Part&nbsp;D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription
drugs may increase demand for our products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part&nbsp;D prescription drug plan will likely be
lower than the prices we might otherwise obtain. Moreover, while the Medicare Modernization Act applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage
policy and payment limitations in setting their own payment rates. Any reduction in payment that results from Medicare Part&nbsp;D may result in a similar reduction in payments from non-governmental
payors. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the effectiveness of different treatments for the same illness. A plan for the research will
be developed by HHS, the Agency for Healthcare Research and Quality and the National Institutes for Health, and periodic reports on the status of the research and related expenditures will be made to
Congress. Although the results of the comparative effectiveness clinical trials are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the
research will have on the sales of any product, if any such product or the condition that it is intended to treat is the subject of a study. It is also possible that comparative effectiveness research
demonstrating benefits in a competitor's product could adversely affect the sales of our product candidates. If third-party payors do not consider our products to be cost-effective compared to other
available therapies, they may not cover our products as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
March 2010, the Affordable Care Act was enacted, which includes measures to significantly change the way healthcare is financed by both governmental and private insurers. Among the provisions of
the Affordable Care Act of importance to the pharmaceutical and biotechnology industry are the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an annual, nondeductible fee on any entity that manufactures or imports certain
branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an increase in the rebates a manufacturer must pay under the Medicaid Drug
Rebate Program to 23.1% and 13% of the average manufacturer price for branded and generic drugs, respectively; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a new Medicare Part&nbsp;D coverage gap discount program, in which
manufacturers must agree to offer 50% point-of-sale discounts to negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the
manufacturer's outpatient drugs to be covered under Medicare Part&nbsp;D; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  extension of manufacturers' Medicaid rebate liability to covered drugs
dispensed to individuals who are enrolled in Medicaid managed care organizations; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>128</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=132,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=449733,FOLIO='128',FILE='DISK131:[15ZCN1.15ZCN74701]EC74701A.;22',USER='NDEWIND',CD='31-DEC-2015;17:09' -->
<A NAME="page_ec74701_1_129"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  expansion of eligibility criteria for Medicaid programs by, among other things,
allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the Federal Poverty
Level, thereby potentially increasing manufacturers' Medicaid rebate liability; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  expansion of the entities eligible for discounts under the Public Health
Service pharmaceutical pricing program; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a licensure framework for follow-on biologic products; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a new Patient-Centered Outcomes Research Institute to oversee, identify
priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a new requirement to annually report drug samples that manufacturers and
distributors provide to physicians; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> creation of the Independent Payment Advisory Board, which has authority to
recommend certain changes to the Medicare program that could result in reduced payments for prescription drugs and those recommendations could have the effect of law even if Congress does not act on
the recommendations (the IPAB has not yet been called upon to act as the annual determinations by the CMS Office of the Actuary have not identified a savings target for implementation in years 2015 or
2016); and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  establishment of a Center for Medicare Innovation at CMS to test innovative
payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending that began on January&nbsp;1, 2011. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. The Budget Control Act of 2011, among other things, created the Joint Select Committee
on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee on Deficit Reduction did not achieve its targeted deficit reduction of at least $1.2 trillion
for the years 2012 through 2021, triggering the
legislation's automatic reductions to several government programs. These reductions include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect
in April 2013 and, due to the Bipartisan Budget Act of 2015, will remain in effect through 2025 unless additional action is taken by Congress. In January 2013, President Obama signed into law the
American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover
overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our
customers and, accordingly, our financial operations. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Other Regulatory Requirements  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are also subject to various laws and regulations regarding laboratory practices, the experimental use of animals, and the use and disposal of
hazardous or potentially hazardous substances in connection with our research. In each of these areas, as above, the FDA has broad regulatory and enforcement powers, including, among other things, the
ability to levy fines and civil penalties, suspend or delay issuance of approvals, seize or recall products, and withdraw approvals, any one or more of which could have a material adverse effect on
us. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Our Corporate Information  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our predecessor was incorporated in Delaware in April 2002 under the name Collegium Pharmaceuticals,&nbsp;Inc. In October 2003, our predecessor
changed its name to Collegium Pharmaceutical,&nbsp;Inc. In 2010, our predecessor divested its former subsidiary, Onset Therapeutics,&nbsp;LLC to PreCision Dermatology,&nbsp;Inc. Since then, we
have devoted substantially all of our resources to the development of our patented DETERx platform technology, the preclinical and clinical advancement of our product candidates and the creation and
protection of related intellectual property. In July 2014, we reincorporated in the Commonwealth of Virginia pursuant to a merger whereby Collegium </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>129</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=133,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=529405,FOLIO='129',FILE='DISK131:[15ZCN1.15ZCN74701]EC74701A.;22',USER='NDEWIND',CD='31-DEC-2015;17:09' -->
<A NAME="page_ec74701_1_130"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pharmaceutical,&nbsp;Inc.,
a Delaware corporation, merged with and into Collegium Pharmaceutical,&nbsp;Inc., a Virginia corporation, with the Virginia corporation surviving the merger. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Legal Proceedings  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>From time to time we face legal claims or actions in the normal course of business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
filed the NDA for Xtampza as a 505(b)(2) application, which allows us to reference data from an approved drug listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations
(commonly known as the Orange Book), in this case OxyContin OP. The 505(b)(2) process requires that we certify to the FDA and notify Purdue, as the holder of the NDA and any other Orange Book-listed
patent owners, that we do not infringe any of the patents listed for OxyContin OP in the Orange Book, or that the patents are invalid. We made such certification and provided such notice on
February&nbsp;11, 2015 and such certification documented why Xtampza does not infringe any of the 11 Orange Book listed patents for OxyContin OP, five of which stand invalidated by the Federal
District Court for the Southern District of New York, subject to a pending appeal. Under the Hatch-Waxman Act of 1984, Purdue had the option to sue us for infringement and receive a stay of up to
30&nbsp;months before the FDA can issue a final regulatory approval for Xtampza, unless the stay is earlier terminated. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Purdue
exercised its option and elected to sue us for infringement in the District of Delaware on March&nbsp;24, 2015 asserting infringement of three of Purdue's Orange Book-listed patents (all of
which stand invalidated subject to a pending appeal by Purdue) and a non-Orange Book-listed patent, and accordingly, received a stay of up to 30&nbsp;months before the FDA can issue a final
regulatory approval for Xtampza, unless the stay is earlier terminated. On March&nbsp;26, 2015, Purdue filed a second suit against us in the District of Massachusetts asserting infringement of the
same four patents. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have engaged experienced litigation counsel who worked carefully with us to construct a strategy to prevail in such litigation as expeditiously as possible. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


On July&nbsp;23, 2015, Purdue voluntarily dismissed the Massachusetts case and on August&nbsp;6, 2015, Purdue filed another case in Massachusetts asserting the same four patents as in the Delaware
case and the original Massachusetts case. On October&nbsp;7, 2015, the Delaware case was transferred to Massachusetts and on November&nbsp;4, 2015, the two cases pending in Massachusetts were
consolidated. On November&nbsp;9, 2015, we filed a motion for partial judgment on the pleadings in relation to three of the four patents asserted against us, which had been previously invalidated by
the court in the Southern District of New York in Purdue's suit against Teva. On the same date, we moved for entry of final judgment and to expedite hearing on our motions. On November&nbsp;23,
2015, Purdue filed a motion to stay proceedings until resolution of its appeal against Teva. The hearing regarding our motion for partial judgment and entry of judgment and Purdue's motion to stay was
held on December&nbsp;22, 2015. On December&nbsp;23, 2015, the District Court of Massachusetts issued an order staying proceedings in relation to the three Orange Book-listed patents asserted
against us until February&nbsp;25, 2016, which is the date scheduled by the Court for a status conference. The Court reserved the decision to grant our motion for judgment on the three Orange
Book-listed patents to be taken up again at the February&nbsp;25th status conference, at which time the Court indicated it may grant our motion for judgment or may consider extending the stay. The
Court further indicated
that it will consider an earlier hearing if the Court of Appeals for the Federal Circuit issues a decision on the appeal of the New York judgment of invalidity prior to the February&nbsp;25th status
conference.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


On November&nbsp;6, 2015, Purdue filed another patent infringement suit against us in Massachusetts asserting infringement of another patent that is a continuation of the three patents previously
asserted by Purdue against us that were invalidated by the court in the Southern District of New York. On December&nbsp;1, 2015, we filed a motion to dismiss for failure to state a claim, arguing
that the patent asserted by Purdue is invalid based on collateral estoppel. Purdue filed its opposition response on December&nbsp;15, 2015. That

 </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>130</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=134,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=269773,FOLIO='130',FILE='DISK131:[15ZCN1.15ZCN74701]EC74701A.;22',USER='NDEWIND',CD='31-DEC-2015;17:09' -->
<A NAME="page_ec74701_1_131"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


action has been consolidated into the other Massachusetts actions, and our motion remains pending. We plan to continue to take all steps necessary to vigorously defend ourselves against these claims.


</FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Facilities  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our corporate headquarters are located in Canton, Massachusetts, where we lease 9,675 square feet of office space (including chemistry and
pilot/formulation laboratories) under a lease agreement that was amended in March 2015 to expand the premises to include an additional 9,660 square feet of space for a total of 19,335 square feet. In
addition, the lease term was extended and now terminates on the date that is five years following August 2015, which is the date that the landlord delivered the expansion space with certain
improvements substantially completed. The lease term may be extended for an additional five-year term at our election. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
believe that our existing facility is adequate for our current and expected future needs. We may seek to negotiate new leases or evaluate additional or alternate space for our operations. We
believe that appropriate alternative space is readily available on commercially reasonable terms. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Employees  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>As of December&nbsp;31, 2015, we had a total of 46 full-time employees. Of these, 11 are engaged in full-time research and development activities.
All of our employees are located in Canton,
Massachusetts. None of our employees are represented by a labor organization or under any collective-bargaining arrangements. We consider our employee relations to be good.

</FONT>

</P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>131</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=135,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=750693,FOLIO='131',FILE='DISK131:[15ZCN1.15ZCN74701]EC74701A.;22',USER='NDEWIND',CD='31-DEC-2015;17:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ee74701_1_132"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ee74701_management"> </A>
<A NAME="toc_ee74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MANAGEMENT    <BR>    </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Executive Officers and Directors  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The following table provides information regarding our executive officers and directors: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="45%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="20pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="45%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Age </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Position(s) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Executive Officers:</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael T. Heffernan, R.Ph.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>51</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Chairman, President and Chief Executive Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Paul Brannelly</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>43</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Executive Vice President and Chief Financial Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Barry S. Duke</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>56</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Executive Vice President and Chief Commercial Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Non-Employee Directors:</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Garen G. Bohlin</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>68</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John G. Freund, M.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>62</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Patrick Heron</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>45</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Hirsch, M.D., Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>45</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Eran Nadav, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>46</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gino Santini</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>59</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


<U>Executive Officers</U>  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Michael T. Heffernan, R.Ph., Chairman, President and Chief Executive Officer.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Heffernan has served as our President and Chief Executive Officer and as a
member of our board of directors since October 2003. Mr.&nbsp;Heffernan has over twenty-five years of experience in the pharmaceutical and related healthcare industries. He was previously the
Founder, President and Chief Executive Officer of Onset Therapeutics,&nbsp;LLC, a dermatology-focused company that developed and commercialized products for the treatment of skin-related illnesses
and was responsible for the spin-off of the business from the Company to create PreCision Dermatology,&nbsp;Inc. Mr.&nbsp;Heffernan has held prior positions as Co-Founder, President and Chief
Executive Officer of Clinical Studies&nbsp;Ltd., a pharmaceutical contract research organization that was sold to PhyMatrix Corp., or PhyMatrix, and as President and Chief Executive Officer of
PhyMatrix. Mr.&nbsp;Heffernan started his career at Eli Lilly and Company, where he served in numerous sales and marketing roles. Since 2012, Mr.&nbsp;Heffernan has served on the board of
directors of Ocata Therapeutics,&nbsp;Inc. (NASDAQ: OCAT) and currently serves as its Chairman. He also serves on the board of directors of Veloxis Pharmaceuticals A/S (CPH: VELO) (March 2015 to
present). Mr.&nbsp;Heffernan previously served on the board of directors of Cornerstone Therapeutics&nbsp;Inc. (now known as Chiesi USA,&nbsp;Inc.) (NASDAQ: CRTX) and two privately held
companies. Mr.&nbsp;Heffernan graduated from the University of Connecticut with a B.S. in Pharmacy in 1987 and is a Registered Pharmacist. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that Mr.&nbsp;Heffernan's perspective and experience as a senior executive in the pharmaceutical industry, as well as the depth of his operations and board experience, provide him with
the qualifications and skills to serve as a director. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Paul Brannelly, Executive Vice President and Chief Financial Officer.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Brannelly has served as our Executive Vice President and Chief Financial Officer
since February 2015. Prior to joining us, Mr.&nbsp;Brannelly served as Senior Vice President, Finance and Administration, and Treasurer of Karyopharm Therapeutics&nbsp;Inc. (NASDAQ: KPTI), or
Karyopharm, from June 2013 to August 2014. From August 2014 to November 2014, Mr.&nbsp;Brannelly served as a consultant to Karyopharm. Prior to joining Karyopharm, Mr.&nbsp;Brannelly served as
Vice President, Finance, Treasurer and Secretary at Verastem,&nbsp;Inc. (NASDAQ: VSTM), or Verastem, from August 2010 to May 2013. From January 2010 to September 2011, Mr.&nbsp;Brannelly held the
position of Chief Financial Officer at the Longwood Fund, a venture capital firm aimed at investing in, managing and building healthcare companies, where he set up the financial and operational
infrastructure following the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>132</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=136,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=679348,FOLIO='132',FILE='DISK131:[15ZCN1.15ZCN74701]EE74701A.;18',USER='KBLACK',CD=';3-JAN-2016;21:25' -->
<A NAME="page_ee74701_1_133"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>closing
of its first fund and eventually served as Chief Financial Officer of its two startup companies, Verastem and OvaScience,&nbsp;Inc. (NASDAQ: OVAS). From November 2005 to September 2009, he
served as Vice President, Finance at Sirtris Pharmaceuticals,&nbsp;Inc., or Sirtris, a biopharmaceutical company which GlaxoSmithKline&nbsp;plc purchased for $720&nbsp;million in 2008, where he
managed the S-1 preparation and due diligence process for Sirtris' initial public offering and managed the company's transition to being a public company. Mr.&nbsp;Brannelly started his
biopharmaceutical career at Dyax Corporation from September 1999 to May 2002, and subsequently moved on to positions of increasing responsibility at CombinatoRx&nbsp;Inc. from May 2002 to November
2005, most recently as Vice President, Finance and Treasurer, where he led Zalicus through the initial public offering process. Mr.&nbsp;Brannelly graduated from the University of Massachusetts at
Amherst with a B.B.A. in Accounting in 1995. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Barry S. Duke, Executive Vice President and Chief Commercial Officer.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Duke has served as our Executive Vice President and Chief Commercial Officer since
March 2015. Prior to joining us, Mr.&nbsp;Duke was Vice President of Sales and Marketing&nbsp;&#151; U.S. Biosurgery at Sanofi,&nbsp;Inc. (formerly Genzyme Corporation), or Sanofi, from
October 2011 to September 2014. From September 2014 to March 2015, Mr.&nbsp;Duke served as a sales and marketing consulting in the biopharmaceutical industry. Mr.&nbsp;Duke joined Sanofi in March
2005 as an area sales director and was promoted to Vice President of Sales&nbsp;&#151; U.S. Biosurgery in November 2007, a position he held until September 2011, when he was promoted to Vice
President of Sales and Marketing&nbsp;&#151; U.S. Biosurgery. Prior to Sanofi, Mr.&nbsp;Duke was Senior Director of National Sales at Enzon Pharmaceuticals,&nbsp;Inc. (NASDAQ: ENZN), or
Enzon, from November 2002 to March 2005. Prior to Enzon, Mr.&nbsp;Duke was Regional Sales Director at &Eacute;lan Corporation,&nbsp;plc (now known as &Eacute;lan
Corporation&nbsp;Ltd) from March 2001 to November 2002. Over the course of his career, Mr.&nbsp;Duke has also held various sales positions at The Liposome Company,&nbsp;Inc., Astra
USA,&nbsp;Inc., Centocor,&nbsp;Inc. and The Upjohn Company. Mr.&nbsp;Duke graduated from University of Virginia with a B.A. in Biology in 1981. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


</I></FONT><FONT SIZE=2><U>Non-Employee Directors</U> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Garen G. Bohlin, Director.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Bohlin has served as a member of our board of directors since January 2015. Mr.&nbsp;Bohlin has almost thirty years'
experience serving in executive roles at several biotechnology companies, including Constellation Pharmaceuticals,&nbsp;Inc., where he served as an Executive Vice President from January 2010 to his
retirement in May 2012. Prior to that, Mr.&nbsp;Bohlin served as Chief Operating Officer at Sirtris Pharmaceuticals,&nbsp;Inc., or Sirtris, which was acquired by GlaxoSmithKline&nbsp;plc. Prior
to joining Sirtris, Mr.&nbsp;Bohlin served as President and Chief Executive Officer of Syntonix Pharmaceuticals,&nbsp;Inc., or Syntonix, which was acquired by Biogen Idec in 2006. Prior to
Syntonix, Mr.&nbsp;Bohlin spent 14&nbsp;years in executive management at Genetics Institute,&nbsp;Inc., or Genetics Institute, which was acquired by Wyeth. Prior to Mr.&nbsp;Bohlin's tenure at
Genetics Institute, he was a partner at Arthur Andersen&nbsp;&amp;&nbsp;Co., where he spent 13&nbsp;years. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Since
his retirement, Mr.&nbsp;Bohlin has served on the boards of directors of several companies. Mr.&nbsp;Bohlin currently serves on the board of directors of Tetraphase
Pharmaceuticals,&nbsp;Inc. (NASDAQ: TTPH) (2010 to Present), Karyopharm Therapeutics,&nbsp;Inc. (NASDAQ GS: KPTI) (2013 to Present), and Proteon Therapeutics,&nbsp;Inc. (NASDAQ: PRTO) (2014 to
Present). Previously, he served on the board of directors of Acusphere,&nbsp;Inc. (OTC: ACUS) (2005 to 2015) and two other privately held companies. Mr.&nbsp;Bohlin graduated from the University
of Illinois with a B.S. in Accounting and Finance in 1970. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>We
believe that Mr.&nbsp;Bohlin's perspective and experience as a senior executive in our industry, as well as his board and audit committee experience with publicly traded and privately held
biotechnology companies, provide him with the qualifications and skills to serve as a director. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> John G. Freund, M.D., Director.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Freund has served as a member of our board of directors since February 2014. Dr.&nbsp;Freund co-founded Skyline
Ventures, or Skyline, in 1997 and has served as Managing Director at Skyline since its founding. Prior to joining Skyline, Dr.&nbsp;Freund served as Managing Director in the private equity group of
Chancellor Capital Management,&nbsp;LLC. In 1995, Dr.&nbsp;Freund co-founded Intuitive Surgical,&nbsp;Inc. and served on its board of directors until 2000. From 1988 to 1994, Dr.&nbsp;Freund
served in </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>133</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=137,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=141630,FOLIO='133',FILE='DISK131:[15ZCN1.15ZCN74701]EE74701A.;18',USER='KBLACK',CD=';3-JAN-2016;21:25' -->
<A NAME="page_ee74701_1_134"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>various
positions at Acuson Corporation, or Acuson, most recently as Executive Vice President. Prior to joining Acuson, Dr.&nbsp;Freund was a General Partner of Morgan Stanley Venture Partners from
1987 to 1988. From 1982 to 1988, Dr.&nbsp;Freund worked at Morgan Stanley&nbsp;&amp;&nbsp;Co., where he co-founded the Healthcare Group in the Corporate Finance Department in 1983. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Dr.&nbsp;Freund
currently serves on the board of directors of XenoPort,&nbsp;Inc. (NASDAQ: XNPT) (1999 to Present), Tetraphase Pharmaceuticals,&nbsp;Inc. (NASDAQ: TTPH) (2012 to Present) and
Proteon Therapeutics,&nbsp;Inc. (NASDAQ GS: PRTO) (2014 to Present). Dr.&nbsp;Freund also serves on the board of directors of two privately held companies and three U.S. registered investment
funds managed by The Capital Group Companies. He also previously served on the board of directors of several publicly traded companies: Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) (2014 to 2015), MAP
Pharmaceuticals,&nbsp;Inc. (NASDAQ: MAPP) (2004 to 2011), and MAKO Surgical Corp. (NASDAQ: MAKO) (2008 to 2013). Dr.&nbsp;Freund is a member of the Advisory Board for the Harvard Business School
Healthcare Initiative. Dr.&nbsp;Freund graduated from Harvard College with a B.A. in History in 1976 and received an M.D. from Harvard Medical School in 1980 and an M.B.A. from Harvard Business
School in 1982. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that Dr.&nbsp;Freund's extensive finance and investment experience, his experience as an executive, and his service on the board of directors of numerous public and privately held
companies in our industry provide him with the qualifications and skills to serve as a director. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Patrick Heron, Director.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Heron has served as a member of our board of directors since September 2008. Mr.&nbsp;Heron is a General Partner of Frazier
Management,&nbsp;LLC, or Frazier, a position he has held since September 1999. Mr.&nbsp;Heron has been active in company formations and initial investments in various biotechnology companies,
including Marcadia Biotech&nbsp;Inc., Calixa Therapeutics,&nbsp;Inc. and VentiRx Pharmaceuticals,&nbsp;Inc. Mr.&nbsp;Heron also led Frazier's involvement in MedPointe&nbsp;Inc. Prior to
joining Frazier, Mr.&nbsp;Heron helped develop McKinsey&nbsp;&amp;&nbsp;Co.'s west coast biotechnology consulting practice. His projects included mergers and acquisitions, product launch, sales
force optimization, corporate partnering and research prioritization. Mr.&nbsp;Heron graduated from the University of North Carolina at Chapel Hill with a B.A. in Political Science in 1992 and
received an M.B.A. from Harvard Business School in 1996. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that Mr.&nbsp;Heron's extensive business experience and his experience in venture capital and the life science industry provide him with the qualifications and skills to serve as a
director. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> David Hirsch, M.D., Ph.D., Director.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Hirsch has served as a member of our board of directors since February 2012. Since 2007, Dr.&nbsp;Hirsch has
served as a Founder and Managing Director at Longitude Capital Management&nbsp;Co.,&nbsp;LLC, or Longitude, where he focuses on investments in biotechnology. From 2005 to 2006,
Dr.&nbsp;Hirsch was Vice President of Pequot Capital Management, or Pequot, where he worked in the life sciences practice. Prior to Pequot, Dr.&nbsp;Hirsch was an Engagement Manager in the
pharmaceutical practice of McKinsey&nbsp;&amp;&nbsp;Co. While at McKinsey&nbsp;&amp;&nbsp;Co., he worked with many large pharmaceutical companies across a range of projects including clinical and
commercial strategies, M&amp;A evaluations, portfolio prioritization and managed care strategy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Dr.&nbsp;Hirsch
currently serves on the board of directors of Rapid Micro Biosystems,&nbsp;Inc. and previously served on Civitas Therapeutics,&nbsp;Inc. and Precision Therapeutics,&nbsp;Inc.
Dr.&nbsp;Hirsch graduated from Johns Hopkins University with a B.S. in Biology in 1991 and, in 2001, received an M.D. from Harvard Medical School as well as a Ph.D. in Biology from Massachusetts
Institute of Technology. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that Dr.&nbsp;Hirsch's perspective and experience as an investor and board member in the life sciences industry, as well as his strong medical and scientific background, provide him with
the qualifications and skills to serve as a director. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Eran Nadav, Ph.D., Director.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Nadav has served as a member of our board of directors since March 2015. Dr.&nbsp;Nadav is a Partner and Managing Director
at TPG Biotech, the life science venture investment arm of TPG, a global private investment firm. Dr.&nbsp;Nadav joined TPG in 2007 with a focus on global </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>134</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=138,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=348398,FOLIO='134',FILE='DISK131:[15ZCN1.15ZCN74701]EE74701A.;18',USER='KBLACK',CD=';3-JAN-2016;21:25' -->
<A NAME="page_ee74701_1_135"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


pharmaceuticals and biotechnology investments. Dr.&nbsp;Nadav has leadership experience in private and public companies in the healthcare sector. Dr.&nbsp;Nadav is currently serving as Chairman of
the Board of Trevi Therapeutics,&nbsp;Inc. and as a board member of ShangPharma Corporation (a China-based CRO) and NovaSom,&nbsp;Inc. Dr.&nbsp;Nadav served as the lead investor and Chairman of
the Board of Ultragenyx Pharmaceutical,&nbsp;Inc. (NASDAQ: RARE) from January 2012 to June 2015. He served on the board of directors of MacroGenics,&nbsp;Inc. (NASDAQ:&nbsp;MGNX) from June 2013
to June 2014, and the board of directors of Eden Springs&nbsp;Ltd., a European provider of drinking water solutions for the workplace, from July 2010 until August 2011.


</FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Prior to TPG, Dr.&nbsp;Nadav served as Business Development Director at Eisai, a pharmaceutical company, from September 2003 to August 2007. He previously worked at Johnson&nbsp;&amp; Johnson
Development Corporation, the venture capital arm of Johnson&nbsp;&amp; Johnson, from November 1999 until July 2002.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Dr.&nbsp;Nadav received a B.Sc. magna cum laude in Life Sciences, an M.Sc. magna cum laude and Ph.D. in Biochemistry, as well as an M.B.A., from Tel Aviv University.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that Dr.&nbsp;Nadav is qualified to serve on our board of directors due to his experience in the venture capital industry and his years of experience in the biopharma business. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I> Gino Santini, Director.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Santini has served as a member of our board of directors since July 2012 and has served as our lead independent director since
May 2015. Since December 2010, Mr.&nbsp;Santini has been a senior advisor providing financing and business consulting services to venture capital, pharmaceutical and biotechnology companies.
Previously, Mr.&nbsp;Santini held various positions at Eli Lilly and Company, or Lilly, from 1983 until his retirement from Lilly in December 2010, most recently as Senior Vice President of
Corporate Strategy and Business Development, a position he held since 2007. Mr.&nbsp;Santini also served as a member of Lilly's Executive Committee from January 2004 to his retirement and as
President of U.S. Operations. He joined Eli Lilly and Company in 1983 as a financial planning associate in Italy. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Mr.&nbsp;Santini
currently serves as chairman of the board of directors of AMAG Pharmaceuticals&nbsp;Inc. (NASDAQ:&nbsp;AMAG) (2012 to Present), and as a member of the board of directors of
Intercept Pharmaceuticals,&nbsp;Inc. (NASDAQ: ICPT) (November 2015 to Present), Horizon Pharma&nbsp;plc (NASDAQ: HZNP) (2012 to Present) and Vitae Pharmaceuticals,&nbsp;Inc. (NASDAQ GS: VTAE)
(2014 to Present), as well as several privately held companies. Previously, Mr.&nbsp;Santini served on the board of directors of Sorin&nbsp;S.p.A., a company traded on the Italian Stock Exchange
(2012 to 2015). He graduated from the University of Bologna, Italy with a B.S. in Mechanical Engineering in 1981 and received an M.B.A. from the Simon School of Business at the University of Rochester
in 1983. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
believe that Mr.&nbsp;Santini's perspective and experience as a senior executive at Lilly, as well as his extensive domestic and international commercial, corporate strategy, business development
and transaction experience, provide him with the qualifications and skills to serve as a director. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Board Composition  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our business and affairs are managed under the direction of our board of directors, which currently consists of seven members. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
amended and restated articles of incorporation and amended bylaws provide that our board of directors consist of a number of directors to be fixed exclusively by resolution of the board of
directors. Under our amended and restated articles of incorporation, our board of directors is divided into three classes, each serving three-year terms and until each director's successors are duly
elected and qualified. The election of the classes is staggered, such that only approximately one third of our board of directors is up for election in any given year. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>135</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=139,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=909876,FOLIO='135',FILE='DISK131:[15ZCN1.15ZCN74701]EE74701A.;18',USER='KBLACK',CD=';3-JAN-2016;21:25' -->
<A NAME="page_ee74701_1_136"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
directors are divided among the three classes as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The Class&nbsp;I directors are Messrs.&nbsp;Freund, Heron and Hirsch, and
their terms will expire at the annual meeting of shareholders to be held in 2016; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The Class&nbsp;II directors are Messrs.&nbsp;Nadav and Santini, and their
terms will expire at the annual meeting of shareholders to be held in 2017; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The Class&nbsp;III directors are Messrs.&nbsp;Heffernan and Bohlin, and
their terms will expire at the annual meeting of shareholders to be held in 2018. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our
amended and restated articles of incorporation do not provide for cumulative voting in the election of directors. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Role of the Board in Risk Oversight  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>One of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors does not have a
standing risk management committee, but rather administers this oversight function directly through the board of directors as a whole, as well as through various standing committees of our board of
directors that address risks inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure and our audit
committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including adopting guidelines
and policies to govern the process by which risk assessment and management is undertaken. The audit committee also monitors compliance with legal and regulatory requirements. Our nominating and
corporate governance committee monitors the effectiveness of our corporate governance practices, including whether they are successful in preventing illegal or improper liability-creating conduct. Our
compensation committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Board Committees  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee. Each
committee operates under a charter that has been approved by our board of directors and is available on our website, www.collegiumpharma.com, under the "Investor Relations" section. The information
contained in, or that can be accessed through, our website is not part of this prospectus. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Audit Committee  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our audit committee consists of Messrs.&nbsp;Bohlin, Freund and Nadav, and is chaired by Mr.&nbsp;Bohlin. The primary purpose of our audit
committee is to assist the board of directors in the oversight of our accounting and financial reporting processes, the audit and integrity of our financial statements, and the qualifications and
independence of our independent auditor and to prepare any reports required of the audit committee under the rules of the SEC. The audit committee has the following responsibilities, among other
things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> hiring our independent registered public accounting firm and pre-approving the
audit and permitted non-audit and tax services to be performed by our independent registered public accounting firm; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing and approving the planned scope of the annual audit and the results
of the annual audit; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing the significant accounting and reporting principles to understand
their impact on our financial statements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing quarterly with management its assessment of the effectiveness and
adequacy of our internal control structure and procedures for financial reporting and reviewing annually with our independent registered public accounting firm the attestation to and report on the
assessment made by management; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>136</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=140,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=60554,FOLIO='136',FILE='DISK131:[15ZCN1.15ZCN74701]EE74701A.;18',USER='KBLACK',CD=';3-JAN-2016;21:25' -->
<A NAME="page_ee74701_1_137"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing with management and our independent registered public accounting
firm, as appropriate, our financial reports, earnings announcements and our compliance with legal and regulatory requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  establishing procedures for the treatment of complaints received by us
regarding accounting, internal accounting controls or auditing matters and confidential submissions by our employees of concerns regarding questionable accounting or auditing matters; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  preparing for adoption by our board of directors a Code of Ethics and
periodically reviewing and recommending appropriate changes thereto; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing and approving related-party transactions; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing and evaluating, at least annually, our audit committee's charter. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Our
audit committee reviews related-party transactions for potential conflicts of interests or other improprieties in accordance with our related party transactions policy. See "Certain Relationships
and Related Party Transactions&nbsp;&#151; Policies and Procedures for Related Party Transactions." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
financial literacy requirements of the SEC require that each member of our audit committee be able to read and understand fundamental financial statements. In addition, our board of directors has
determined that Mr.&nbsp;Bohlin qualifies as an audit committee financial expert, as defined in Item&nbsp;407(d)(5) of Regulation&nbsp;S-K promulgated under the Securities Act, and has financial
sophistication in accordance with the NASDAQ Stock Market Rules. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Both
our independent registered public accounting firm and management periodically meet privately with our audit committee. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Compensation Committee  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our compensation committee consists of Messrs.&nbsp;Heron, Hirsch and Santini, and is chaired by Dr.&nbsp;Hirsch. The primary purpose of our
compensation committee is to review the performance and development of our management in achieving corporate goals and objectives and to assure that our executive officers are compensated effectively
in a manner consistent with the strategy of our company, competitive practice, sound corporate governance principles and shareholder interests. In carrying out these responsibilities, this committee
oversees, reviews and administers all of our compensation, equity and employee benefit plans and programs. The functions of our compensation committee include, among other
things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing and approving the corporate goals and objectives relevant to
executive compensation, evaluating performance in light of those goals and objectives and setting the compensation for our executive officers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing and recommending the terms of employment agreements and other
employment-related arrangements with our executive officers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing and approving our compensation strategy for our employees; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  overseeing and periodically reviewing the operation of all of our employee
benefit plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing and recommending to our board of directors the compensation of our
directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  administering our equity incentive plans and benefit plans and approving the
grant of equity awards to our employees and directors under these plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> when required, reviewing and discussing with management our Compensation
Discussion and Analysis and recommending to the full board its inclusion in our periodic reports and proxy statement to be filed with the SEC; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> when required, preparing the report of the compensation committee to be included
in our annual proxy statement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  engaging compensation consultants or other advisors it deems appropriate to
assist with its duties; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing and evaluating, at least annually, our compensation committee's
charter. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>137</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=141,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=300793,FOLIO='137',FILE='DISK131:[15ZCN1.15ZCN74701]EE74701A.;18',USER='KBLACK',CD=';3-JAN-2016;21:25' -->
<A NAME="page_ee74701_1_138"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Nominating and Corporate Governance Committee  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our nominating and corporate governance committee consists of Messrs.&nbsp;Bohlin, Heffernan and Santini, and is chaired by Mr.&nbsp;Santini. The
primary purpose of our nominating and corporate governance committee is to assist our board of directors by identifying individuals qualified to become members of our board of directors, recommending
a slate of nominees to be proposed by our board of directors to shareholders for election to our board of directors, developing and recommending corporate governance principles and guidelines of our
company and monitoring compliance therewith and to recommend directors to serve on the committees of our board of directors. The functions of our nominating and corporate governance committee include,
among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> assisting our board of directors in identifying prospective director nominees
and recommending nominees for each annual meeting of shareholders to our board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing developments in corporate governance practices and developing and
recommending governance principles applicable to our board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing independence of the board of directors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  evaluating and making recommendations as to the size and composition of the
board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  recommending members for each board committee of our board of directors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  determining qualifications for service on our board; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  developing, as appropriate, a set of corporate governance principles and
guidelines, and reviewing and recommending to our board any changes to such guidelines; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  reviewing the adequacy of our articles of incorporation and bylaws and
recommending to our board of directors, as conditions dictate, amendments for consideration by our shareholders; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  periodically reviewing and evaluating, at least annually, our nominating and
corporate governance committee's charter. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Code of Ethics  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our board of directors has adopted a Code of Ethics applicable to all of our employees, executive officers and directors. The Code of Ethics is
available on our website at www.collegiumpharma.com. Our board of directors is responsible for overseeing the Code of Ethics, and our board of directors or an appropriate committee thereof must
approve any waivers of the Code of Ethics for employees, executive officers or directors. Disclosure regarding any amendments to the Code of Ethics, or any waivers of its requirements, will be
disclosed on our website. The information contained in, or that can be accessed through, our website is not part of this prospectus. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Compensation Committee Interlocks and Insider Participation  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On March&nbsp;30, 2015, our board of directors appointed Messrs.&nbsp;Heron, Hirsch and Santini to be members of the compensation committee. Each
of Messrs.&nbsp;Heron and Hirsch has relationships with us that require disclosure under Item&nbsp;404 of Regulation&nbsp;S-K under the Exchange Act. See "Certain Relationships and Related Party
Transactions" for more information. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>No
member of our compensation committee has ever been an executive officer or employee of ours. None of our officers currently serves, or has served during the last completed year, on the board of
directors, compensation committee or other committee serving an equivalent function, of any other entity that has one or more officers serving as a member of our board of directors or compensation
committee. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Director Independence  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The NASDAQ Stock Market Rules require that each committee of our board of directors has at least one independent director on the listing date of our
common stock, has a majority of independent directors no later than 90&nbsp;days after such date and be fully independent within one year after such date. The composition of our audit, compensation
and nominating and corporate governance committees satisfies </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>138</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=142,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=738008,FOLIO='138',FILE='DISK131:[15ZCN1.15ZCN74701]EE74701A.;18',USER='KBLACK',CD=';3-JAN-2016;21:25' -->
<A NAME="page_ee74701_1_139"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>these
independence requirements in accordance with the phase-in schedule allowed by the NASDAQ Stock Market Rules. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our
board of directors will continue to observe all applicable criteria for independence established by the NASDAQ Stock Market Rules and other governing laws and applicable regulations. No director
will be deemed to be independent unless our board of directors determines that the director has no relationship which would interfere with the exercise of independent judgment in carrying out the
responsibilities of a director. Our board of directors has determined that each of our directors, with the exception of Michael T. Heffernan, is independent as defined under the corporate governance
rules of the NASDAQ Stock Market Rules. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Board Leadership Structure  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Mr.&nbsp;Heffernan serves as Chairman of our board of directors in addition to his role as Chief Executive Officer. In May 2015, our board of
directors appointed Mr.&nbsp;Santini as lead independent director. As lead independent director, Mr.&nbsp;Santini is responsible for, among other
things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> advising the Chairman of the board of directors and of the committees of the
board of directors as to the information needs, agenda, schedule and budgeting of time for meetings, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  collaborating with the Chairman of the board of directors on evaluating and
improving the effectiveness of the board of directors, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> offering counsel to individual directors on the performance of their duties, </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> leading executive sessions of the board of directors' independent directors, and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> serving as principal liaison between the non-employee directors and the Chairman
of the board of directors on significant or sensitive issues. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>We
combine the Chairman and Chief Executive Officer positions because we believe that, at this critical juncture in our development, Mr.&nbsp;Heffernan is best suited to oversee the development and
implementation of our strategic vision, including our planned transition from a development stage entity into a commercial pharmaceutical company. Mr.&nbsp;Heffernan's tenure as Chairman also
reflects our board of directors' confidence in his leadership and vision for us and recognizes his accomplishments since joining us. We believe that by creating a lead independent director position
held by Mr.&nbsp;Santini, we have designed a governance structure that best advances our objectives while maintaining proper checks and balances on senior management, and providing the independent
members of the board of directors with open and transparent communication regarding our strategic planning activities. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>139</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=143,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=87417,FOLIO='139',FILE='DISK131:[15ZCN1.15ZCN74701]EE74701A.;18',USER='KBLACK',CD=';3-JAN-2016;21:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_eg74701_1_140"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="eg74701_executive_and_director_compensation"> </A>
<A NAME="toc_eg74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE AND DIRECTOR COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Summary Compensation Table

  </B></FONT>

</P>

<P style="font-family:arial;">


<FONT SIZE=2>The following table shows the annual compensation paid to or earned by (i)&nbsp;Michael&nbsp;T. Heffernan, our President and Chief Executive
Officer, for the fiscal years ended December&nbsp;31, 2015 and 2014, and (ii)&nbsp;Paul Brannelly, our Executive Vice President and Chief Financial Officer, and Barry&nbsp;S. Duke, our Executive
Vice President and Chief Commercial Officer (together, our "named executive officers"), for the fiscal year ended December&nbsp;31, 2015:


</FONT>

</P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="31pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="15pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="65pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:99pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Name and Principal Position


<!-- COMMAND=ADD_SCROPPEDRULE,99pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Bonus<BR>
($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Stock<BR>
Awards<BR>
($)<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Option<BR>
Awards<BR>
($)<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Non-Equity<BR>
Incentive Plan<BR>
Compensation<BR>
($)<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>All Other<BR>
Compensation<BR>
($)<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Michael&nbsp;T.&nbsp;Heffernan,&nbsp;R.Ph.</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>2015</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>426,242</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>375,000</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><SUP>(5)</SUP></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>633,984</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>1,776,999</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>14,168</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>3,262,393</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President&nbsp;and&nbsp;Chief</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>2014</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>380,380</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>130,851</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><SUP>(6)</SUP></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>7,570</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>518,801</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Executive&nbsp;Officer</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Paul Brannelly</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
2015</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
289,038</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
624,009</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
4,161</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
922,208</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive&nbsp;Vice&nbsp;President and&nbsp;Chief&nbsp;Financial Officer<SUP>(7)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Barry S. Duke</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
2015</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
250,000</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
557,928</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
76,427</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
884,175</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Executive&nbsp;Vice&nbsp;President and&nbsp;Chief&nbsp;Commercial Officer<SUP>(8)</SUP></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >



<DL compact>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
amounts reflect the aggregate grant date fair value of stock awards computed in accordance with FASB ASC Topic 718. Assumptions used in
the calculation of these amounts are included in Note&nbsp;11 to our financial statements.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
amounts reflect the aggregate grant date fair value of option awards computed in accordance with FASB ASC Topic 718. Assumptions used in
the calculation of these amounts are included in Note&nbsp;11 to our financial statements.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Bonuses
for fiscal year 2015 performance of our executive officers have not yet been determined, although information for such bonuses is
described in the section below titled "&#151;&nbsp;Non-Equity Incentive Plan Compensation." We anticipate that bonuses earned for fiscal year 2015 may be determined by the end of January
2016.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">This
amount reflects our contributions to our 401(k) Plan and the amount of life and disability insurance premiums paid by us on behalf of
each named executive officer. Mr.&nbsp;Duke's amount also includes a relocation bonus of&nbsp;$75,000.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Mr.&nbsp;Heffernan
received this bonus in connection with the closing of our Series D Convertible Preferred Stock financing in March 2015.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
annual bonus amount calculated and paid pursuant to Mr.&nbsp;Heffernan's employment agreement. For more information, see
"&#151; Non-Equity Incentive Plan Compensation."


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(7)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Mr.&nbsp;Brannelly
joined our company on February&nbsp;4, 2015.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(8)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Mr.&nbsp;Duke
joined our company on March&nbsp;30, 2015.

 </FONT></DD></DL>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Employment Agreements

 </B></FONT>

</P>

<P style="font-family:arial;">


<FONT SIZE=2>We have employment and other service agreements with all of our named executive officers. The following is a summary of the material terms of each
employment agreement. For complete terms, please see the

</FONT>

</P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>140</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=144,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=943989,FOLIO='140',FILE='DISK131:[15ZCN1.15ZCN74701]EG74701A.;34',USER='KSEAMON',CD=';3-JAN-2016;20:46' -->
<A NAME="page_eg74701_1_141"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


respective employment and service agreements attached as exhibits to the registration statement of which this prospectus forms&nbsp;a part.

 </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;">


<FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Michael T. Heffernan, R.Ph.

 </I></FONT>

</P>

<P style="font-family:arial;">


<FONT SIZE=2>The 2014 data in the table above reflects compensation payable to Michael T. Heffernan, our President and Chief Executive Officer, pursuant to an
amended and restated employment agreement dated June&nbsp;13, 2012 (the "Prior Heffernan Agreement"). The principal compensation terms of the Prior Heffernan Agreement are as
follows:</FONT>

</P>


<UL>
<DL compact>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> base salary of $350,000 per year, subject to annual adjustments; </FONT> <FONT SIZE=2>



<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> annual incentive bonus opportunity in an amount up to 40% of base salary based
upon the achievement of certain bonus eligibility criteria; and </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an award of restricted shares.

 </FONT></DD>

</DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>


On August&nbsp;4, 2015, we entered in a new employment agreement with Mr.&nbsp;Heffernan (the "Heffernan Agreement"), which replaced and superseded the Prior Heffernan Agreement. Pursuant to the
Heffernan Agreement, Mr.&nbsp;Heffernan's base salary was increased to $488,800 per year and his annual incentive bonus opportunity was increased to a target amount of 50% of his base salary.

</FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Upon a termination of Mr.&nbsp;Heffernan's employment by us without cause or by Mr.&nbsp;Heffernan for good reason (each as defined in the Heffernan Agreement) prior to a change in control of our
company, Mr.&nbsp;Heffernan is eligible to receive (i)&nbsp;continuation of his base salary for twelve months (the "Heffernan Severance Period"), (ii)&nbsp;a lump sum payment equal to
Mr.&nbsp;Heffernan's then current target annual bonus, (iii)&nbsp;continuation of his health insurance benefits at our expense for the duration of the Heffernan Severance Period, and
(iv)&nbsp;full vesting with respect to all unvested restricted stock, stock options and other equity incentives awarded to Mr.&nbsp;Heffernan, subject to his execution of and non-revocation of a
general release of claims. Upon a termination of Mr.&nbsp;Heffernan's employment by us without cause or by Mr.&nbsp;Heffernan for good reason within twelve months following a change in control of
our company, Mr.&nbsp;Heffernan is eligible to receive the benefits described in the preceding sentence, except that the Heffernan Severance Period will be "eighteen months" instead of "twelve
months." Upon a termination of
Mr.&nbsp;Heffernan's employment with us due to his death or disability, all unvested restricted stock, stock options and other equity incentives awarded to him by us shall become fully vested.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Mr.&nbsp;Heffernan is entitled to participate in all of our employee benefit plans, subject to the terms and conditions applicable to such plans. Further, the Heffernan Agreement contains customary
non-solicitation and non-competition covenants, which covenants remain in effect for one year following any cessation of employment with respect to Mr.&nbsp;Heffernan.

 </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;">


<FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Paul Brannelly

  </I></FONT>

</P>

<P style="font-family:arial;">


<FONT SIZE=2>On August&nbsp;4, 2015, we entered into an employment agreement with Paul Brannelly, our Executive Vice President and Chief Financial Officer (the
"Brannelly Agreement"). The principal compensation terms of the Brannelly Agreement are as follows:</FONT>

</P>


<UL>
<DL compact>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> base salary of $325,000 per year, subject to annual adjustments; and </FONT> <FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> annual incentive bonus opportunity in an amount up to 35% of base salary based
upon the achievement of certain bonus eligibility criteria.

 </FONT></DD>

</DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>


Additionally, Mr.&nbsp;Brannelly has been granted stock option awards as described below under the heading "&#151;&nbsp;Outstanding Equity Awards at Fiscal Year-End."


</FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Upon a termination of Mr.&nbsp;Brannelly's employment by us without cause or by Mr.&nbsp;Brannelly for good reason (each as defined in the Brannelly Agreement) prior to a change in control of the
Company, Mr.&nbsp;Brannelly is eligible to receive continuation of his base salary and continuation of his health insurance benefits at our expense for nine months, subject to his execution of and
non-revocation of a general release of claims. Upon a termination of Mr.&nbsp;Brannelly's employment by us without cause or by Mr.&nbsp;Brannelly for good reason


</FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>141</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=145,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1042227,FOLIO='141',FILE='DISK131:[15ZCN1.15ZCN74701]EG74701A.;34',USER='KSEAMON',CD=';3-JAN-2016;20:46' -->
<A NAME="page_eg74701_1_142"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


within twelve months following a change in control of our company, Mr.&nbsp;Brannelly is eligible to receive full vesting with respect to all unvested restricted stock, stock options and other
equity incentives awarded to Mr.&nbsp;Brannelly and continuation of his base salary and health insurance benefits at our expense for twelve months, subject to his execution of and non-revocation of
a general release of claims.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Mr.&nbsp;Brannelly is entitled to participate in all of our employee benefit plans, subject to the terms and conditions applicable to such plans. Further, the Brannelly Agreement contains customary
non-solicitation covenants, which covenants remain in effect for nine months following any cessation of employment with respect to Mr.&nbsp;Brannelly.

 </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;">


<FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Barry S. Duke

  </I></FONT>

</P>

<P style="font-family:arial;">


<FONT SIZE=2>On August&nbsp;4, 2015, we entered into an employment agreement with Barry S. Duke, our Executive Vice President and Chief Commercial Officer (the
"Duke Agreement"). The principal compensation terms of the Duke Agreement are as follows:</FONT>

</P>


<UL>
<DL compact>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> base salary of $325,000 per year, subject to annual adjustments; and </FONT> <FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> annual incentive bonus opportunity in an amount up to 40% of base salary based
upon the achievement of certain bonus eligibility criteria.

 </FONT></DD>

</DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>


Additionally, Mr.&nbsp;Duke has been granted stock option awards as described below under the heading "&#151;&nbsp;Outstanding Equity Awards at Fiscal Year-End."


</FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Upon a termination of Mr.&nbsp;Duke's employment by us without cause or by Mr.&nbsp;Duke for good reason (each as defined in the Duke Agreement) prior to a change in control of the Company,
Mr.&nbsp;Duke is eligible to receive continuation of
his base salary and continuation of his health insurance benefits at our expense for nine months, subject to his execution of and non-revocation of a general release of claims. Upon a termination of
Mr.&nbsp;Duke's employment by us without cause or by Mr.&nbsp;Duke for good reason within twelve months following a change in control of our company, Mr.&nbsp;Duke is eligible to receive full
vesting with respect to all unvested restricted stock, stock options and other equity incentives awarded to Mr.&nbsp;Duke and continuation of his base salary and health insurance benefits at our
expense for twelve months, subject to his execution of and non-revocation of a general release of claims.

</FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Mr.&nbsp;Duke is entitled to participate in all of our employee benefit plans, subject to the terms and conditions applicable to such plans. Further, the Duke Agreement contains customary
non-solicitation covenants, which covenants remain in effect for nine months following any cessation of employment with respect to Mr.&nbsp;Duke.

 </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;">


<FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Potential Payments Upon a Termination or Change in Control

  </I></FONT>

</P>

<P style="font-family:arial;">


<FONT SIZE=2>Each of our named executive officers is entitled to severance in the event of a termination by our company without cause or a resignation by such
named executive officer for good reason. The details of such severance arrangements are described above in the section titled "&#151; Employment Agreements."

 </FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>


Additionally, certain unvested equity grants awarded to our named executive officers will become fully vested (and exercisable as applicable) in connection with certain termination of employment
events. The details of such accelerated vesting are described above in the section titled "&#151; Employment Agreements" and below in the section titled "&#151; Outstanding Equity Awards
at Fiscal Year-End."

 </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;">


<FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Non-Equity Incentive Plan Compensation

 </I></FONT>

</P>

<P style="font-family:arial;">


<FONT SIZE=2>Each named executive officer's target bonus opportunity is expressed as a percentage of base salary, as described above. For the fiscal year ended
December&nbsp;31, 2015, Mr.&nbsp;Heffernan's target bonus opportunity was 50% of base salary and the target bonus opportunities for Messrs.&nbsp;Brannelly and Duke were 35% and 40%,
respectively. Bonuses for fiscal 2015 performance of our executive officers have not been determined. We anticipate that bonuses earned for fiscal year 2015 may be determined by the end of January
2016. For the fiscal year ended December&nbsp;31, 2014, Mr.&nbsp;Heffernan was eligible to earn a cash bonus, of which 70% of such bonus was determined based on achievement of corporate
performance goals and 30% of such bonus was determined based on achievement of certain individual performance goals. The target amount of

 </FONT>

</P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>142</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=146,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=673916,FOLIO='142',FILE='DISK131:[15ZCN1.15ZCN74701]EG74701A.;34',USER='KSEAMON',CD=';3-JAN-2016;20:46' -->
<A NAME="page_eg74701_1_143"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


the annual bonus for Mr.&nbsp;Heffernan was 40% of base salary. The applicable corporate performance goals were achieved at 86% of target with the applicable individual performance goals for
Mr.&nbsp;Heffernan achieved at 86% of target. Thus, Mr.&nbsp;Heffernan earned an annual bonus at 86% of target. The amount shown above for Mr.&nbsp;Heffernan in the column titled "&#151;
Non-Equity Incentive Plan Compensation" represents the actual annual performance bonuses payable for the fiscal year ended December&nbsp;31, 2014 to Mr.&nbsp;Heffernan.

 </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;">


<FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Equity Awards During Fiscal Years Ended December&nbsp;31, 2015 and 2014

  </I></FONT>

</P>

<P style="font-family:arial;">


<FONT SIZE=2>On March&nbsp;19, 2015, we awarded Mr.&nbsp;Brannelly stock options to purchase 102,070 shares of our common stock, with an aggregate grant date
fair value computed in accordance with FASB ASC Topic 718 equal to $400,347. The options have an exercise price of $5.73. On March&nbsp;19, 2015, Mr.&nbsp;Brannelly exercised options to purchase
72,463 shares of common stock in exchange for $415,212.99. The remaining options are subject to time-based vesting conditions as described below in the section titled "&#151; Outstanding Equity
Awards at Fiscal Year-End."

 </FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>


On March&nbsp;30, 2015, we awarded Messrs.&nbsp;Heffernan and Duke stock options to purchase 275,463 and 72,463 shares of our common stock, respectively, with an aggregate grant date fair value
computed in accordance with FASB ASC Topic 718 equal to $1,076,993 and $283,313, respectively. The options have an exercise price of $5.73 and are subject to time-based vesting conditions as described
below in the section titled "&#151; Outstanding Equity Awards at Fiscal Year-End."

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


On April&nbsp;2, 2015, we granted Mr.&nbsp;Heffernan restricted stock awards equal to 194,694 shares of our common stock, with an aggregate grant date fair value computed in accordance with FASB
ASC Topic 718 equal to $633,984. The restricted stock is subject to time-based vesting conditions as described below in the section titled "&#151; Outstanding Equity Awards at Fiscal Year-End."

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


On May&nbsp;14, 2015, we awarded Messrs.&nbsp;Heffernan, Brannelly and Duke stock options to purchase 70,193, 22,929 and 27,537 shares of our common stock, respectively, with an aggregate grant
date fair value computed in accordance with FASB ASC Topic 718 equal to $700,005, $228,661 and $274,615, respectively. The options have an exercise price of $14.90 and are subject to time-based
vesting conditions as described below in the section titled "&#151; Outstanding Equity Awards at Fiscal Year-End."


</FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>143</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=147,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=424469,FOLIO='143',FILE='DISK131:[15ZCN1.15ZCN74701]EG74701A.;34',USER='KSEAMON',CD=';3-JAN-2016;20:46' -->
<A NAME="page_eg74701_1_144"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Outstanding Equity Awards at Fiscal Year-End

  </B></FONT>

</P>

<P style="font-family:arial;">


<FONT SIZE=2>The following table provides information regarding equity awards held by each of our named executive officers that were outstanding as of
December&nbsp;31, 2015. The market value of stock awards is based on the closing market price of our common stock of $27.50 per share on December&nbsp;31, 2015.

</FONT>

</P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="82pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="34pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Option Awards </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Stock Awards </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:17pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,17pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
(Exercisable) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
(Unexercisable) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Equity Incentive Plan<BR>
Awards: Number of<BR>
Securities Underlying<BR>
Unexercised<BR>
Unearned<BR>
Options (#) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Option<BR>
Exercise<BR>
Price ($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
Shares or Units<BR>
of Stock That<BR>
Have Not<BR>
Vested (#) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Market Value<BR>
of Shares or<BR>
Units of Stock<BR>
That Have Not<BR>
Vested ($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Michael T. Heffernan, R.Ph.</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
9,673</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3.31</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">11/11/2020</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,027</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,917</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">0.48</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">01/30/2023</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Executive Officer</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">21,578</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">14,755</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5.73</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">03/30/2025</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">44,839</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">194,291</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5.73</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">03/30/2025</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">70,193</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">14.90</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">05/14/2025</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">113,571</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,123,203</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Paul Brannelly</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
5,553</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
24,054</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
<!-- -->
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
5.73</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
03/19/2025</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:6pt;text-indent:-0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Executive Vice President</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(7)</font></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">22,929</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(7)</font></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">14.90</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">05/14/2025</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:6pt;text-indent:-0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">and Chief Financial Officer</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:8pt;margin-left:6pt;text-indent:-6pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Barry S. Duke</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(8)</font></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
72,463</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(8)</font></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
<!-- -->
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
5.73</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
03/30/2025</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:6pt;text-indent:-0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Executive Vice President</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(9)</font></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">27,537</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(9)</font></FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">14.90</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">05/14/2025</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:6pt;text-indent:-0pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 and Chief Commercial Officer</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >



<DL compact>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">A
stock option to purchase 28,984 shares of our common stock was granted to Mr.&nbsp;Heffernan on January&nbsp;24, 2013. The option was
adjusted to an option to purchase 14,492 shares our common stock in connection with the December&nbsp;4, 2013 reverse stock split. The option was initially for 14,492 shares and the option was
exercised as to 7,458 shares. As of December&nbsp;31, 2015, 3,917 option shares were not exercisable. The option vests and becomes exercisable monthly over the four-year period following the grant
date. Pursuant to Mr.&nbsp;Heffernan's employment agreement, the option will immediately become fully vested and exercisable upon a termination of Mr.&nbsp;Heffernan's employment without cause or
due to Mr.&nbsp;Heffernan's death or disability, or upon a resignation by Mr.&nbsp;Heffernan for good reason.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">A
stock option to purchase 36,333 shares of our common stock was granted to Mr.&nbsp;Heffernan on March&nbsp;30, 2015. As of
December&nbsp;31, 2015, 14,755 option shares were not exercisable. On March&nbsp;30, 2015, 50% of the option vested and became exercisable, and the remaining 50% of the option vests and becomes
exercisable monthly over the four-year period commencing on March&nbsp;30, 2015. Pursuant to Mr.&nbsp;Heffernan's employment agreement, the option will immediately become fully vested and
exercisable upon a termination of Mr.&nbsp;Heffernan's employment without cause or due to Mr.&nbsp;Heffernan's death or disability, or upon a resignation by Mr.&nbsp;Heffernan for good reason.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">A
stock option to purchase 239,130 shares of our common stock was granted to Mr.&nbsp;Heffernan on March&nbsp;30, 2015. As of
December&nbsp;31, 2015, 194,291 option shares were not exercisable. The option vests and becomes exercisable monthly over the four-year period following the grant date. Pursuant to
Mr.&nbsp;Heffernan's employment agreement, the option will immediately become fully vested and exercisable upon a termination of Mr.&nbsp;Heffernan's employment without cause or due to
Mr.&nbsp;Heffernan's death or disability, or upon a resignation by Mr.&nbsp;Heffernan for good reason.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">A
stock option to purchase 70,193 shares of our common stock was granted to Mr.&nbsp;Heffernan on May&nbsp;14, 2015. As of
December&nbsp;31, 2015, 70,193 option shares were not exercisable. The option vests and becomes exercisable over the four-year period following the grant date, with 25% of the option becoming vested
and exercisable on May&nbsp;14, 2016 and the remaining shares underlying the option vesting in monthly installments over the remaining three years of the four-year period. Pursuant to
Mr.&nbsp;Heffernan's employment agreement, the option will immediately become fully vested and exercisable upon a termination of Mr.&nbsp;Heffernan's employment without cause or due to
Mr.&nbsp;Heffernan's death or disability, or upon a resignation by Mr.&nbsp;Heffernan for good reason.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Mr.&nbsp;Heffernan
was awarded 194,694 shares of restricted common stock in April 2015. Pursuant to the grant, 97,347 of the shares of
restricted common stock vested upon grant while the remaining 97,347 shares of restricted common stock vest in monthly installments over a three-year period commencing as of the date of the grant.
Pursuant to Mr.&nbsp;Heffernan's employment agreement, the shares will immediately become fully vested upon a termination of Mr.&nbsp;Heffernan's employment without cause or due to
Mr.&nbsp;Heffernan's death or disability, or upon a resignation by Mr.&nbsp;Heffernan for good reason. Additionally, pursuant to Mr.&nbsp;Heffernan's employment agreement, the shares will
immediately become fully vested upon the occurrence of a change of control.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">A
stock option to purchase 29,607 shares of our common stock was granted to Mr.&nbsp;Brannelly on March&nbsp;19, 2015. As of
December&nbsp;31, 2015, 24,054 option shares were not exercisable. The option vests and becomes exercisable monthly over the four-year period following the grant date. Pursuant to
Mr.&nbsp;Brannelly's employment agreement, the option will immediately become fully vested and exercisable upon a termination of Mr.&nbsp;Brannelly's employment without cause or upon a resignation
by Mr.&nbsp;Brannelly for good reason within twelve months of the occurrence of a change of control.

</FONT></DD>

</DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>144</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=148,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=362101,FOLIO='144',FILE='DISK131:[15ZCN1.15ZCN74701]EG74701A.;34',USER='KSEAMON',CD=';3-JAN-2016;20:46' -->
<A NAME="page_eg74701_1_145"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>


<DL compact>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(7)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">A
stock option to purchase 22,929 shares of our common stock was granted to Mr.&nbsp;Brannelly on May&nbsp;14, 2015. As of
December&nbsp;31, 2015, 22,929 option shares were not exercisable. The option vests and becomes exercisable over the four-year period following the grant date, with 25% of the option becoming vested
and exercisable on May&nbsp;14, 2016 and the remaining shares underlying the option vesting in monthly installments over the remaining three years of the four-year period. Pursuant to
Mr.&nbsp;Brannelly's employment agreement, the option will immediately become fully vested and exercisable upon a termination of Mr.&nbsp;Brannelly's employment without cause or upon a resignation
by Mr.&nbsp;Brannelly for good reason within twelve months of the occurrence of a change of control.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(8)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">A
stock option to purchase 72,463 shares of our common stock was granted to Mr.&nbsp;Duke on March&nbsp;30, 2015. As of
December&nbsp;31, 2015, 72,463 option shares were not exercisable. The option vests and becomes exercisable over the four-year period following the grant date, with 25% of the option becoming vested
and exercisable on March&nbsp;30, 2016 and the remaining shares underlying the option vesting in monthly installments over the remaining three years of the four-year period. Pursuant to
Mr.&nbsp;Duke's employment agreement, the option will immediately become fully vested and exercisable upon a termination of Mr.&nbsp;Duke's employment without cause or upon a resignation by
Mr.&nbsp;Duke for good reason within twelve months of the occurrence of a change of control.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(9)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">A
stock option to purchase 27,537 shares of our common stock was granted to Mr.&nbsp;Duke on May&nbsp;14, 2015. As of December&nbsp;31,
2015, 27,537 option shares were not exercisable. The option vests and becomes exercisable over the four-year period following the grant date, with 25% of the option becoming vested and exercisable on
May&nbsp;14, 2016 and the remaining shares underlying the option vesting in monthly installments over the remaining three years of the four-year period. Pursuant to Mr.&nbsp;Duke's employment
agreement, the option will immediately become fully vested and exercisable upon a termination of Mr.&nbsp;Duke's employment without cause or upon a resignation by Mr.&nbsp;Duke for good reason
within twelve months of the occurrence of a change of control.

 </FONT></DD></DL>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Equity Incentive Plans  </B></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Amended and Restated 2014 Stock Incentive Plan  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>All of our outstanding equity awards are governed by the Collegium Pharmaceutical,&nbsp;Inc. Amended and Restated 2014 Stock Incentive Plan, or the
Plan. We adopted the Plan, as amended and restated, on April&nbsp;23, 2015, and it became effective immediately prior to the closing of the IPO. The Plan was adopted to enhance our ability to
attract, retain and motivate persons who make important contributions to us and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to
better align the interests of such persons with those of our shareholders. The material terms of the Plan are described below. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
Plan permits the grant of (i)&nbsp;options, (ii)&nbsp;restricted stock awards, (iii)&nbsp;restricted stock units, or RSUs and (iv)&nbsp;performance awards, which we refer to collectively
as Awards, as more fully described below. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Prior
to the IPO, options to purchase common stock and awards of restricted stock were granted to various participants under the Plan. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>All
Awards granted under the Plan are governed by award agreements, between us and the participants. No Awards may be granted after the tenth anniversary of the Plan's adoption by our shareholders,
although Awards granted before that time will remain valid in accordance with their terms. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
compensation committee of our board of directors administers the Plan. The compensation committee will designate each eligible individual to whom an Award is to be granted. Any of our employees,
consultants, officers or other service providers, or those of our affiliates, are eligible to participate in the Plan if selected by the compensation committee. In its discretion, the compensation
committee may delegate all or part of its authority and duties with respect to granting Awards to one or more individuals, provided applicable law so permits. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Subject
to certain adjustments, the maximum number of shares of common stock that may be issued under the Plan in connection with Awards is (i)&nbsp;2,700,000 shares, plus (ii)&nbsp;an annual
increase to be added on the first day of each fiscal year beginning with the fiscal year ending December&nbsp;31, 2016, and on each anniversary thereof until the expiration of the Plan equal to 4%
of the outstanding shares of our common stock on December&nbsp;31<SUP>st</SUP>&nbsp;of the immediately preceding fiscal year (or such lesser number of shares of common stock as determined by
the board of directors). In the event of any stock dividend, recapitalization, forward stock split or reverse stock split, reorganization, division, merger, consolidation, spin-off, combination,
repurchase or share exchange, extraordinary or unusual cash distribution or other similar corporate transaction or event that affects our common stock, the compensation committee shall make
appropriate adjustment in the number and kind of shares authorized by the Plan and covered under outstanding Awards as it determines appropriate and equitable. Shares of our common stock subject to </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>145</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=149,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=819411,FOLIO='145',FILE='DISK131:[15ZCN1.15ZCN74701]EG74701A.;34',USER='KSEAMON',CD=';3-JAN-2016;20:46' -->
<A NAME="page_eg74701_1_146"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Awards
under the Plan that expire unexercised or are otherwise forfeited shall again be available for Awards under the Plan. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>An
option entitles the holder to purchase from us a stated number of shares of common stock. An incentive stock option, or ISO, may only be granted to an employee of ours or our affiliates (provided
applicable law so permits). The aggregate maximum number of shares that may be issued pursuant to the exercise of ISOs will be 8,100,000 shares. The compensation committee will specify the number of
shares of common stock subject to each option and the exercise price for such option, provided that the exercise price may not be less than the fair market value of a share of common stock on the date
the option is granted. Notwithstanding the foregoing, if ISOs are granted to any 10% shareholder, the exercise price shall not be less than 110% of the fair market value of common stock on the date
the option is granted. Generally, all or part of the exercise price may be paid (i)&nbsp;in cash, (ii)&nbsp;with the proceeds received from a broker-dealer whom the holder has authorized to sell
all or a portion of the common stock covered by the option, (iii)&nbsp;with the consent of the compensation committee, in whole or in part in common stock held by the holder and valued at fair
market value on the date of exercise, or (iv)&nbsp;by any combination of such methods. The compensation committee may, in its sole discretion, permit payment of the exercise price of an option in
the form of previously acquired shares based on the fair market value of the shares on the date the option is exercised or through means of "net settlement." </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>All
options shall be exercisable in accordance with the terms of the applicable award agreement. The maximum term of an option shall be determined by the compensation committee on the date of grant
but shall not exceed 10&nbsp;years (5&nbsp;years in the case of ISOs granted to any 10% shareholder). In the case of ISOs, the aggregate fair market value (determined as of the date of grant) of
common stock with respect to which such ISOs become exercisable for the first time during any calendar year cannot exceed $100,000. ISOs granted in excess of this limitation will be treated as NQOs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Unless
otherwise provided in an award agreement, if a participant terminates employment with us (or our affiliates) due to death or disability, the participant's unexercised options may be exercised,
to the extent they were exercisable on the termination date, for a period of twelve months from the termination date or until the expiration of the original option term, if shorter. If the participant
terminates employment with us (or our affiliates) for cause (as defined in the Plan), all unexercised options (whether vested or unvested) shall terminate and be forfeited on the termination date. If
the participant's employment terminates for any other reason, any vested but unexercised options may be exercised by the participant, to the extent exercisable at the time of termination, for a period
of ninety days from the termination date (or such time as specified by the compensation committee at the time of grant) or until the expiration of the original option term, whichever period is
shorter. Unless otherwise provided by the compensation committee, any options that are not exercisable at the time of termination of employment shall terminate and be forfeited on the termination
date. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
restricted stock award is a grant of shares of common stock, which may or may not be subject to forfeiture restrictions during a restriction period. The compensation committee will determine the
price, if any, to be paid by
the participant for each share of common stock subject to a restricted stock award. The compensation committee may condition the expiration of the restriction period, if any, upon: (i)&nbsp;the
participant's continued service over a period of time with us or our affiliates; (ii)&nbsp;the achievement by the participant, us or our affiliates of any other performance goals set by the
compensation committee; or (iii)&nbsp;any combination of the above conditions as specified in the award agreement. If the specified conditions are not attained, the participant will forfeit the
portion of the restricted stock award with respect to which those conditions are not attained, and the underlying common stock will be forfeited to us. At the end of the restriction period, if the
conditions, if any, have been satisfied, the restrictions imposed will lapse with respect to the applicable number of shares. During the restriction period, a participant will have the right to vote
the shares underlying the restricted stock, however, unless otherwise provided by the compensation committee, all dividends will remain subject to restriction until the stock with respect to which the
dividend was issued lapses. The compensation committee may, in its discretion, accelerate the vesting and delivery of shares of restricted stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>146</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=150,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=941121,FOLIO='146',FILE='DISK131:[15ZCN1.15ZCN74701]EG74701A.;34',USER='KSEAMON',CD=';3-JAN-2016;20:46' -->
<A NAME="page_eg74701_1_147"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>RSUs
are granted in reference to a specified number of shares of common stock and entitle the holder to receive, on achievement of specific performance goals established by the compensation committee,
after a period of continued service or any combination of the above as set forth in the applicable award agreement, one share of common stock for each such share of common stock covered by the RSU.
The compensation committee may, in its discretion, accelerate the vesting of RSUs. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
compensation committee may grant performance awards in accordance with the Plan. Performance awards may be denominated as a number of shares or specified number of other Awards (such as restricted
stock or RSUs), which may be earned upon achievement or satisfaction of such performance goals as may be specified by the compensation committee. Performance goals may be linked to a variety of
factors including the participant's completion of a specified period of employment or service with us or an affiliated company. Additionally, performance goals can include objectives stated with
respect to us, an affiliated company or a business unit and are limited to one or more of the following: (i)&nbsp;specified levels of or increases in pre-tax earnings, return on capital, equity
measures/ratios (on a gross, net, pre-tax or post tax basis), including basic earnings per share, diluted earnings per share, total earnings (including total earnings as adjusted by the compensation
committee at the time of the Award), operating earnings, earnings growth, earnings before interest and taxes, or EBIT, and earnings before interest, taxes, depreciation and amortization, or EBITDA
(including EBIT or EBITDA as adjusted by the Committee at the time of the Award); (ii)&nbsp;total sales or sales growth; (iii)&nbsp;gross margin; (iv)&nbsp;customer service levels;
(v)&nbsp;employee recruiting and development; (vi)&nbsp;advertising effectiveness; (vii)&nbsp;development of new markets; (viii)&nbsp;financial ratios; (ix)&nbsp;strategic initiatives;
(x)&nbsp;improvement in or attainment of operating expense levels; (xi)&nbsp;improvement in or attainment of capital expense levels; (xii)&nbsp;the attainment of certain target levels of, or a
specified increase in, operational cash flow; (xiii)&nbsp;the achievement of a certain level of, reduction of, or other specified objectives with regard to limiting the level of increase in, all or
a portion of, our bank debt or other long-term or short-term public or private debt or other similar financial obligations of ours, which may be calculated net of such cash balances and/or other
specified offsets; (xiv)&nbsp;appreciation in and/or maintenance of certain target levels in the fair market value; (xv)&nbsp;the attainment of a certain level of, reduction of, or other specified
objectives with regard to limiting the level of or rate of increase in all or a portion of specified expenses (xvi)&nbsp;individual objectives; and (xvii)&nbsp;any combination of the foregoing. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
compensation committee may impose restrictions on the grant, exercise or payment of an Award as it determines appropriate. Generally, Awards granted under the Plan shall be nontransferable except
by will or by the laws of descent and distribution. No participant shall have any rights as a shareholder with respect to shares covered by options or RSUs, unless and until such Awards are settled in
shares of common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>No
option shall be exercisable, no shares of common stock shall be issued, no certificates for shares of common stock shall be delivered and no payment shall be made under the Plan except in
compliance with all applicable laws. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
board of directors may amend, suspend or terminate the Plan and the compensation committee may amend any outstanding Award at any time; provided, however, that no such amendment or termination may
adversely affect Awards then outstanding without the holder's permission. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the event of a change in control (as defined in the Plan), the compensation committee may, on a participant-by-participant basis: (i)&nbsp;cause any or all outstanding Awards to become vested and
immediately exercisable (as applicable), in whole or in part; (ii)&nbsp;cause any outstanding option to become fully vested and immediately exercisable for a reasonable period in advance of the
change in control and, to the extent not exercised prior to that change in control, cancel that option upon closing of the change in control; (iii)&nbsp;cancel any unvested Award or unvested portion
thereof, with or without consideration; (iv)&nbsp;cancel any Award in exchange for a substitute award; (v)&nbsp;redeem any restricted stock or RSU for cash and/or other substitute consideration
with value equal to fair market value of an unrestricted share on the date of the change in control; (vi)&nbsp;cancel any outstanding options with respect to all common stock for which the Award
remains unexercised for a cash payment equal to the excess (if any) of the fair market value of the shares </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>147</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=151,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=365639,FOLIO='147',FILE='DISK131:[15ZCN1.15ZCN74701]EG74701A.;34',USER='KSEAMON',CD=';3-JAN-2016;20:46' -->
<A NAME="page_eg74701_1_148"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>subject
to the option over the exercise price of the option; (vii)&nbsp;take such other action as the compensation committee shall determine to be reasonable under the circumstances; and/or
(viii)&nbsp;in the case of any Award subject to Section&nbsp;409A of the Code, such Award shall vest and be distributed only in accordance with the terms of the applicable award agreement and the
compensation committee shall only be permitted to use discretion to the extent that such discretion would be permitted under Section&nbsp;409A of the Code. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Neither
the board of directors nor the compensation committee may, without obtaining prior approval of our shareholders: (i)&nbsp;implement any cancellation/re-grant program pursuant to which
outstanding options under the Plan are cancelled and new options are granted in replacement with a lower exercise per share, (ii)&nbsp;cancel outstanding options under the Plan with an exercise
price per share in excess of the then current fair market value per share for consideration payable in our equity securities or (iii)&nbsp;otherwise directly reduce the exercise price in effect for
outstanding options under the Plan. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


2015 Employee Stock Purchase Plan  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On April&nbsp;23, 2015, we adopted the 2015 Employee Stock Purchase Plan, or the 2015 ESPP, which became effective immediately prior to the closing
of the IPO. The 2015 ESPP is administered by our board of directors or by a committee appointed by our board of directors. The 2015 ESPP initially provides participating employees with the opportunity
to purchase an aggregate of 200,000 shares of our common stock. The number of shares of our common stock reserved for issuance under the 2015 ESPP will automatically increase on the first day of each
fiscal year, commencing on January&nbsp;1, 2016 and ending on December&nbsp;31, 2025, in an amount equal to the least of (i)&nbsp;400,000 shares of our common stock, (ii)&nbsp;1.0% of the
total number of shares of our common stock outstanding on the first day of the applicable year, and (iii)&nbsp;an amount determined by our board of directors. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>All
of our employees are eligible to participate in the 2015 ESPP, provided that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> such person is customarily employed by us for more than 20&nbsp;hours a week
and for more than five months in a calendar year; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> such person has been employed by us or by a designated subsidiary for at least
21&nbsp;days prior to enrolling in the 2015 ESPP; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> such person was our employee on the first day of the applicable offering period
under the 2015 ESPP. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>No
employee may purchase shares of our common stock under the 2015 ESPP and any of our other employee stock purchase plans in excess of $25,000 of the fair market value of our common stock (as of the
date of the option grant) in any calendar year. In addition, no employee may purchase shares of our common stock under the 2015 ESPP that would result in the employee owning 5% or more of the total
combined voting power or value of our stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
expect to make one or more offerings to our eligible employees to purchase stock under the 2015 ESPP beginning at such time as our board of directors may determine. Each offering will consist of a
six-month offering period during which payroll deductions will be made and held for the purchase of our common stock at the end of the offering period. Our board of directors may, at its discretion,
choose a different period of not more than 12&nbsp;months for offerings. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On
the commencement date of each offering period, each eligible employee may authorize up to a maximum of 15% of his or her compensation to be deducted by us during the offering period. Each employee
who continues to be a participant in the 2015 ESPP on the last business day of the offering period will be deemed to have exercised an option to purchase from us the number of whole shares of our
common stock that his or her accumulated payroll deductions on such date will pay for, not in excess of the maximum numbers set forth above. Under the terms of the 2015 ESPP, the purchase price shall
be determined by our board of directors or compensation committee for each offering period and will be at least 85% of the applicable closing price of our common stock. If our board of directors does
not make a determination of the purchase price, the purchase price will be 85% of the lesser of the closing price of our </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>148</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=152,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=496571,FOLIO='148',FILE='DISK131:[15ZCN1.15ZCN74701]EG74701A.;34',USER='KSEAMON',CD=';3-JAN-2016;20:46' -->
<A NAME="page_eg74701_1_149"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>common
stock on the first business day of the offering period or on the last business day of the offering period. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>An
employee may for any reason withdraw from participation in an offering no later than 21&nbsp;days prior to the end of an offering period and permanently draw out the balance accumulated in the
employee's account. If an employee elects to discontinue his or her payroll deductions during an offering period but does not elect to withdraw his or her funds, funds previously deducted will be
applied to the purchase of common stock at the end of the offering period. If a participating employee's employment ends before the last business day of an offering period, no additional payroll
deductions will be made and the balance in the employee's account will be paid to the employee. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
will be required to make equitable adjustments to the number and class of securities available under the 2015 ESPP, the share limitations under the 2015 ESPP and the purchase price for an offering
period under the 2015 ESPP to reflect stock splits, reverse stock splits, stock dividends, recapitalizations, combinations of shares, reclassifications of shares, spin-offs and other similar changes
in capitalization or events or any dividends or distributions to holders of our common stock other than ordinary cash dividends. The number of shares of common stock available for any offerings under
the 2015 ESPP shall be adjusted if the number of our outstanding shares is increased or reduced by split up, reclassification, stock dividend or the like. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
board of directors may at any time, and from time to time, terminate, amend or suspend the 2015 ESPP or any portion thereof. We will obtain shareholder approval for any amendment if such approval
is required by
Section&nbsp;423 of the Code. The 2015 ESPP will also terminate upon the occurrence of a change in control (defined with reference to the Plan). Upon termination, we will refund all amounts in the
accounts of participating employees. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Non-Equity Incentive Compensation  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Performance Bonus Plan  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On April&nbsp;23, 2015, we adopted the Performance Bonus Plan, which became effective immediately prior to the closing of the IPO. The Performance
Bonus Plan is administered by the compensation committee. The purpose of the Performance Bonus Plan is to benefit and advance our interests, by rewarding selected employees of ours and our affiliates
for their contributions to our success and thereby motivate them to continue to make such contributions in the future by granting performance-based awards. The material terms of such plan are
summarized below. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Background.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors believes that it is in our best interests and those of our shareholders to enhance our ability to attract and retain qualified
personnel through performance based incentives, while at the same time obtaining the highest level of deductibility of compensation paid to employees. Section&nbsp;162(m) of the Code disallows a
deduction to us for any compensation paid to certain executive officers in excess of $1.0&nbsp;million per year, subject to certain exceptions. Among other exceptions, the deduction limit does not
apply to compensation that meets the specified requirements for "performance-based compensation." In general, those requirements include the establishment of objective performance goals for the
payment of such compensation by a committee of the board of directors composed solely of two or more outside directors, shareholder approval of the material terms of such compensation, and
certification by the compensation committee that the performance goals for the payment of such compensation have been achieved. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Administration.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to the other provisions of the Performance Bonus Plan, the compensation committee has the authority to administer and interpret the
Performance Bonus Plan, including the authority to select the employees (including employees who are directors) to participate in the Performance Bonus Plan, to establish the performance goals, to
determine the amount of incentive compensation bonus payable to any participant, to determine the terms and conditions of any such incentive opportunity; to </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>149</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=153,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1028945,FOLIO='149',FILE='DISK131:[15ZCN1.15ZCN74701]EG74701A.;34',USER='KSEAMON',CD=';3-JAN-2016;20:46' -->
<A NAME="page_eg74701_1_150"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>make
all determinations and take all other actions necessary or appropriate for proper administration and operation of the Performance Bonus Plan and to establish and amend rules and regulations
relating to the Performance Bonus Plan. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
compensation committee may also delegate to one or more of our executive officers the authority to administer the Performance Bonus Plan with respect to any participants who are not subject to
Section&nbsp;162(m) of the Code. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Eligibility.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The named executive officers and such other of our employees as selected by the compensation committee are eligible to participate in the Performance
Bonus Plan. The maximum amount of the incentive compensation bonuses payable to any participant under the Performance Bonus Plan in, or in respect of, any single fiscal year shall not exceed
$5.0&nbsp;million. All incentive compensation bonuses paid pursuant to the Performance Bonus Plan will be paid in cash. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Bonus Opportunity and Performance Goals.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Bonuses may be payable to a participant as a result of the satisfaction of performance goals in respect of any performance
period determined by the compensation committee; provided that, to the extent a participant would be subject to Section&nbsp;162(m) of the Code, the performance goals will be set in accordance with
the regulations under Section&nbsp;162(m) of the Code. Performance goals, which may vary among and between participants, may include objectives stated with respect to us, an affiliated company or a
business unit and such objectives are limited to one or more of the following: (i)&nbsp;specified levels of or increases in pre-tax earnings, return on capital, equity measures/ratios (on a gross,
net, pre-tax or post tax basis), including basic earnings per share, diluted earnings per share, total earnings (including total earnings as adjusted by the compensation committee at the time of the
Award), operating earnings, earnings growth, EBIT and EBITDA (including EBIT or EBITDA as adjusted by the compensation committee at the time of the Award); (ii)&nbsp;total sales or sales growth;
(iii)&nbsp;gross margin; (iv)&nbsp;customer service levels; (v)&nbsp;employee recruiting and development; (vi)&nbsp;advertising effectiveness; (vii)&nbsp;development of new markets;
(viii)&nbsp;financial ratios; (ix)&nbsp;strategic initiatives; (x)&nbsp;improvement in or attainment of operating expense levels; (xi)&nbsp;improvement in or attainment of capital expense
levels; (xii)&nbsp;the attainment of certain target levels of, or a specified increase in, operational cash flow; (xiii)&nbsp;the achievement of a certain level of, reduction of, or other
specified objectives with regard to limiting the level of increase in, all or a portion of, the Company's bank debt or other long-term or short-term public or private debt or other similar financial
obligations of the Company, which may be calculated net of such cash balances and/or other specified offsets; (xiv)&nbsp;appreciation in and/or maintenance of certain target levels in the fair
market value; (xv)&nbsp;the attainment of a certain level of, reduction of, or other specified objectives with regard to limiting the level of or rate of increase in all or a portion of specified
expenses (xvi)&nbsp;individual objectives; and (xvii)&nbsp;any combination of the foregoing. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
compensation committee shall provide a threshold level of performance below which no incentive compensation bonus will be paid, as well as a maximum level of performance above which no additional
incentive compensation bonus will be paid. It also may provide for the payment of differing amounts for different levels of performance, determined with regard either to a fixed monetary amount or a
percentage of the participant's base salary. The compensation committee shall make such adjustments, to the extent it deems appropriate, to established performance goals and performance thresholds to
compensate for, or to reflect, any material changes which may have occurred due to an "extraordinary event"; provided, however, that no such adjustment may be made unless such adjustment would be
permissible under Section&nbsp;162(m) of the Code. An "extraordinary event" under the Performance Bonus Plan is defined as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> material changes in accounting practices, tax laws, other laws or regulations, </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> material changes in our financial structure, </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an acquisition or disposition of one of our subsidiaries or divisions, or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> unusual circumstances outside of our management's control which, in the sole
judgment of the compensation committee, alters or affects the computation of such established performance goals and performance thresholds, our performance or the performance of a relevant subsidiary
or division. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>150</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=154,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=861945,FOLIO='150',FILE='DISK131:[15ZCN1.15ZCN74701]EG74701A.;34',USER='KSEAMON',CD=';3-JAN-2016;20:46' -->
<A NAME="page_eg74701_1_151"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
soon as practicable after the end of each performance period, but before any incentive compensation bonuses are paid to the participants under the Performance Bonus Plan, the compensation committee
will certify in writing (i)&nbsp;whether the performance goal(s) were attained and (ii)&nbsp;the amount of the incentive compensation bonus payable to each participant based upon the attainment of
such specified performance goals. The compensation committee
also may reduce, eliminate, or, with respect only to participants who are not subject to Section&nbsp;162(m) of the Code, increase the amount of any incentive compensation bonus of any participant
at any time prior to payment thereof, based on such criteria as the compensation committee shall determine, including but not limited to individual merit and attainment of, or the failure to attain,
specified personal goals established by the compensation committee. Under no circumstances, however, may the compensation committee, with respect solely to a participant who is subject to
Section&nbsp;162(m) of the Code, (i)&nbsp;increase the amount of the incentive compensation otherwise payable to such participant beyond the amount originally established by the compensation
committee, (ii)&nbsp;waive the attainment of the performance goals established and applicable to such participant's incentive compensation or (iii)&nbsp;otherwise exercise its discretion so as to
cause any incentive compensation bonus payable to such participant to not qualify as "performance-based compensation" under Section&nbsp;162(m) of the Code. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>All
amounts due under the Performance Bonus Plan shall be paid within two and one-half months of the end of the year in which such incentive compensation is no longer subject to a risk of forfeiture.
The compensation committee, without the consent of any participant, may amend or terminate the Performance Bonus Plan at any time. However, no amendment that would require the consent of the
shareholders pursuant to Section&nbsp;162(m) of the Code shall be effective without such consent. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Retirement Benefits  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>We maintain a section&nbsp;401(k) retirement plan for all employees after three months of consecutive employment who are 21&nbsp;years of age or
older. Employees can contribute up to 100% of their eligible pay, subject to maximum amounts allowed under law. The Company provides matching and profit sharing contributions under the 401(k)
retirement plan. The total amount of Company matching contributions under the 401(k) retirement plan for 2014 and 2015 was $35,000 and $44,095, respectively.


</FONT>

</P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Compensation of Non-Employee Directors

 </B></FONT>

</P>

<P style="font-family:arial;">


<FONT SIZE=2>The following table sets forth in summary form information concerning the compensation that we paid or awarded during the fiscal year ended
December&nbsp;31, 2015 to our non-employee directors.

</FONT>

</P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="75pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="51pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="51pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Fees earned or<BR>
paid in cash ($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Stock<BR>
awards ($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Option<BR>
Awards ($)<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font> </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total ($) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Garen G. Bohlin</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>29,815</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>113,687</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>143,512</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John G. Freund, M.D.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,938</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>139,202</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>146,640</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Patrick Heron</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,047</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>139,202</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>146,249</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Hirsch, M.D., Ph.D.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,830</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>139,202</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>147,032</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Eran Nadav, Ph.D.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,438</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>139,202</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>146,640</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gino Santini</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>31,957</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>139,202</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>171,159</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >




<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Amounts
represent the grant date fair value of stock options granted during 2015, as calculated in accordance with ASC Topic 718. See
Note&nbsp;11 of the financial statements included in this prospectus for assumptions used in calculating this amount. As of December&nbsp;31, 2015, the aggregate number of shares underlying stock
options held by each non-employee director were as follows; Mr.&nbsp;Bohlin: 28,985 (of which, 6,644 were exercisable as of December&nbsp;31, 2015); Dr.&nbsp;Freund: 15,000; Mr.&nbsp;Heron:
15,000; Dr.&nbsp;Hirsch: 15,000; Dr.&nbsp;Nadav: 15,000; and Mr.&nbsp;Santini: 15,000.

 </FONT></DD></DL>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>151</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=155,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=344091,FOLIO='151',FILE='DISK131:[15ZCN1.15ZCN74701]EG74701A.;34',USER='KSEAMON',CD=';3-JAN-2016;20:46' -->
<A NAME="page_eg74701_1_152"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;">


<FONT SIZE=2>The compensation earned by Mr.&nbsp;Heffernan, as President and Chief Executive Officer, for fiscal year 2015 is included in the "&#151; Summary
Compensation Table" and his outstanding stock and option awards are included under "&#151; Outstanding Equity Awards at Fiscal Year-End" above.

 </FONT>

</P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Non-Employee Director Compensation

  </B></FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>On August&nbsp;4, 2015, our board of directors approved a non-employee director compensation policy, which established the following compensation
guidelines:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each non-employee director will receive an annual retainer of $40,000; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> upon joining the board of directors, each non-employee director will receive an
initial grant of options to purchase 15,000 shares of common stock, which will vest over a four-year period with 25% of the grant vesting on the one-year anniversary of the initial grant date and the
remainder vesting ratably each month thereafter in equal installments over a three-year period, subject to continued service as a director; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each non-employee director will be granted options to purchase 8,700 shares of
common stock at each annual meeting of shareholders, which will vest in full on the one-year anniversary of the initial grant date, subject to continued service as a director; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each non-employee director who serves as chairperson of a committee of the board
will receive additional compensation as follows:</FONT><FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the chairperson of the audit committee will receive an annual retainer of
$15,000; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the chairperson of the compensation committee will receive an annual retainer of
$10,000; and </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the chairperson of the nominating and corporate governance committee will
receive an annual retainer of $7,500; and </FONT><FONT SIZE=2>

<BR><BR></FONT></DD></DL>
</DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each non-employee director who serves as a non-chair member of a committee of
the board will receive additional compensation as follows:</FONT><FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the members of the audit committee will receive annual retainers of $7,500; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the members of the compensation committee will receive annual retainers of
$5,000; and </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the members of the nominating and corporate governance committee will receive
annual retainers of $3,750.

</FONT></DD></DL>
</DD>

</DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>152</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=156,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=610821,FOLIO='152',FILE='DISK131:[15ZCN1.15ZCN74701]EG74701A.;34',USER='KSEAMON',CD=';3-JAN-2016;20:46' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ei74701_1_153"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ei74701_certain_relationships_and_related_party_transactions"> </A>
<A NAME="toc_ei74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following includes a summary of transactions since January&nbsp;1, 2012 to which we have been a party, in which the amount involved in the
transaction exceeded $120,000, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family
of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are
described under "Executive and Director Compensation." </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Participation in Initial Public Offering  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In our IPO, certain of our 5% shareholders and their affiliates purchased an aggregate of 1,300,000 shares of our common stock. Each of those
purchases was made through the underwriters at the initial public offering price. The following table set forth the aggregate number of shares of our common stock that these 5% shareholders and their
affiliates purchased in our IPO: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="72pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:35pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Purchaser

<!-- COMMAND=ADD_SCROPPEDRULE,35pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares of<BR>
Common Stock </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Frazier Healthcare VI,&nbsp;L.P.<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>150,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Longitude Capital Partners,&nbsp;LLC<SUP>(2)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>200,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Skyline Venture Partners V,&nbsp;L.P.<SUP>(3)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>150,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>TPG Biotechnology Partners IV,&nbsp;L.P.<SUP>(4)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>100,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RA Capital Healthcare Fund,&nbsp;LP<SUP>(5)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>700,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
general partner of Frazier Healthcare VI,&nbsp;L.P. is a limited partnership, the general partner of which is FHM VI,&nbsp;LLC.
Patrick Heron, a member of our board of directors, is a member of FHM VI,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
shares held, in the aggregate, by Longitude Venture Partners,&nbsp;L.P. and Longitude Capital Associates,&nbsp;L.P. or,
collectively, the Longitude Funds. Longitude Capital Partners,&nbsp;LLC is the general partner of the Longitude Funds. David Hirsch, a member of our board of directors, is a member of Longitude
Capital Partners,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
general partner of Skyline Venture Partners V,&nbsp;L.P. is Skyline Venture Management V,&nbsp;LLC. John G. Freund, a member of our
board of directors, is a manager of Skyline Venture Management V,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
general partner of TPG Biotechnology Partners IV,&nbsp;L.P. is TPG Biotechnology GenPar IV,&nbsp;L.P., a Delaware limited partnership,
whose general partner is TPG Biotechnology GenPar IV Advisors,&nbsp;LLC, a Delaware limited liability company, whose sole member is TPG Holdings I,&nbsp;L.P., a Delaware limited partnership, whose
general partner is TPG Holdings I-A,&nbsp;LLC, a Delaware limited liability company, whose sole member is TPG Group Holdings (SBS),&nbsp;L.P., a Delaware limited partnership, whose general partner
is TPG Group Holdings (SBS) Advisors,&nbsp;Inc., or Group Advisors, a Delaware corporation. Messrs.&nbsp;David Bonderman and James G. Coulter are officers and the sole shareholders of Group
Advisors and may therefore be deemed to be the beneficial owners of the shares held by TPG Biotechnology Partners IV,&nbsp;L.P. Each of Messrs.&nbsp;Bonderman and Coulter expressly disclaims
beneficial ownership of the securities listed above except to the extent of any pecuniary interest therein. Eran Nadav, Ph.D., a member of our board of directors, is a partner of TPG
Global,&nbsp;LLC. The address for Messrs.&nbsp;Bonderman, Coulter, Nadav and TPG Biotechnology Partners IV,&nbsp;L.P. is c/o TPG Global,&nbsp;LLC, 301 Commerce Street, Suite&nbsp;3300, Fort
Worth, TX 76102.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
investment adviser and sole general partner of RA Capital Healthcare Fund,&nbsp;LP is RA Capital Management,&nbsp;LLC. Peter
Kolchinsky is the sole managing member of RA Capital Management,&nbsp;LLC and has the power to vote or dispose of the shares held by RA Capital Healthcare Fund,&nbsp;LP. The address for
Dr.&nbsp;Kolchinsky and RA Capital Healthcare Fund,&nbsp;LP is 20 Park Plaza, Suite&nbsp;1200, Boston, MA 02116. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>153</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=157,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=738841,FOLIO='153',FILE='DISK131:[15ZCN1.15ZCN74701]EI74701A.;26',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_ei74701_1_154"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Series&nbsp;D Convertible Preferred Stock Financing  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In March 2015, we entered into a Series&nbsp;D Convertible Preferred Stock Purchase Agreement pursuant to which we issued and sold to investors an
aggregate of 41,666,667 shares of our Series&nbsp;D Convertible Preferred Stock at a purchase price of $1.20 per share, for aggregate consideration of $50.0&nbsp;million. This financing was led by
TPG Biotechnology Partners IV,&nbsp;L.P., which was joined by RA Capital Management, Adage Capital Management, Rock Springs Capital, EcoR1 Capital, Eventide Asset Management and Aperture Venture
Partners. Entities affiliated with Longitude Capital Partners,&nbsp;LLC, Skyline Ventures Partners V,&nbsp;L.P., Frazier Healthcare VI,&nbsp;L.P. and Boston Millennia Partners also participated
in the financing. In connection with the Series&nbsp;D Convertible Preferred Stock financing, convertible notes with related parties in the aggregate principal amount of $5&nbsp;million
automatically converted to an aggregate of 4,166,667 shares of Series&nbsp;D Convertible Preferred Stock. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Series&nbsp;C Convertible Preferred Stock Financing  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In August 2013, we entered into a Series&nbsp;C Convertible Preferred Stock Purchase Agreement, or the Series&nbsp;C Purchase Agreement, pursuant
to which we issued and sold to investors an aggregate of 2,220,670 shares of our Series&nbsp;C Convertible Preferred Stock at a purchase price of $1.386 per share, for aggregate consideration of
$3.1&nbsp;million. In September 2013, at an additional closing pursuant to the Series&nbsp;C Purchase Agreement, we issued and sold to investors an aggregate of 665,334 shares of our
Series&nbsp;C Convertible Preferred Stock at a purchase price of $1.386 per share, for aggregate consideration of $922,000. In December 2013, those investors who participated in the closings in
August and September 2013 exercised their option under the Series&nbsp;C Purchase Agreement to purchase an additional pro rata portion of an aggregate of 5,772,004 shares of our Series&nbsp;C
Convertible Preferred Stock at a purchase price of $1.386 per share, for aggregate consideration of $8.0&nbsp;million. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Series&nbsp;B Convertible Preferred Stock Financing  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In February 2012, we entered into a Series&nbsp;B Convertible Preferred Stock Purchase Agreement, pursuant to which we issued and sold to investors
an aggregate of 27,324,237 shares of our Series&nbsp;B Convertible Preferred Stock at a purchase price of $0.84 per share, for aggregate consideration of $23.0&nbsp;million. In connection with the
Series&nbsp;B Convertible Preferred Stock financing, all issued and outstanding shares of previously issued Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock, Series&nbsp;C
Preferred Stock, Series&nbsp;C-2 Preferred Stock and Series&nbsp;D-1 Preferred Stock were converted into 18,464,674 shares of Series&nbsp;A Convertible Preferred Stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>All
outstanding convertible preferred stock converted into common stock upon the closing of the IPO. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>154</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=158,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=127865,FOLIO='154',FILE='DISK131:[15ZCN1.15ZCN74701]EI74701A.;26',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_ei74701_1_155"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
participants in the convertible preferred stock financings described above included the following directors, executive officers and/or holders of more than 5% of our capital stock or entities
affiliated with them. The following table presents the number of shares issued to these related parties in these financings: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="20pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="64pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="58pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:43pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Participants<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font>

<!-- COMMAND=ADD_SCROPPEDRULE,43pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares of<BR>
Series&nbsp;A<BR>
Convertible<BR>
Preferred<BR>
Stock </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Series&nbsp;A<BR>
Convertible<BR>
Preferred<BR>
Stock<BR>
Aggregate<BR>
Purchase<BR>
Price </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares of<BR>
Series&nbsp;B<BR>
Convertible<BR>
Preferred<BR>
Stock </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Series&nbsp;B<BR>
Convertible<BR>
Preferred&nbsp;Stock<BR>
Aggregate<BR>
Purchase Price </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares of<BR>
Series&nbsp;C<BR>
Convertible<BR>
Preferred<BR>
Stock </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Series&nbsp;C<BR>
Convertible<BR>
Preferred<BR>
Stock<BR>
Aggregate<BR>
Purchase<BR>
Price </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares of<BR>
Series&nbsp;D<BR>
Convertible<BR>
Preferred<BR>
Stock </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Series&nbsp;D<BR>
Convertible<BR>
Preferred<BR>
Stock<BR>
Aggregate<BR>
Purchase<BR>
Price </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>5% or greater shareholders</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Entities affiliated with Boston Millennia Partners<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">4,881,801</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(8)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,988,017</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,862,481</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,564,484</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">712,357</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">854,828</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Frazier Healthcare VI,&nbsp;L.P.<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">4,019,183</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(8)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">4,929,930</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,533,399</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,288,055</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,705,585</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,749,941</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,676,078</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">4,411,294</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Entities affiliated with Longitude Capital Partners, LLC<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">13,095,238</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">11,000,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,224,261</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">4,468,826</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,146,509</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">6,175,811</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Skyline Venture Partners V,&nbsp;L.P.<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10,714,286</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">9,000,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,638,030</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,656,310</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,881,724</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">7,058,068</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">TPG Biotechnology Partners IV, L.P.<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">8,333,333</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10,000,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">RA Capital Healthcare Fund,&nbsp;LP<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(7)</font></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,833,333</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">7,000,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Additional
details regarding these shareholders and their equity holdings are provided in "Principal Shareholders."
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
shares held, in the aggregate, by Boston Millennia Partners II Limited Partnership, Boston Millennia Partners II-A Limited
Partnership, Boston Millennia Partners&nbsp;GmbH and&nbsp;Co. KG ("BMP KG"), Boston Millennia Associates II Partnership, and Strategic Advisors Fund Limited Partnership, or collectively, the
Boston Millennia Funds. Robert Jevon, a former member of our board of directors, is an affiliate of Glen Partners II Limited Partnership, which is the special limited partner of BMP KG, and the
general partner of the other Boston Millennia Funds.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
general partner of Frazier Healthcare VI,&nbsp;L.P. is a limited partnership, the general partner of which is FHM VI,&nbsp;LLC.
Patrick Heron, a member of our board of directors, is a member of FHM VI,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
shares held, in the aggregate, by Longitude Venture Partners,&nbsp;L.P. and Longitude Capital Associates,&nbsp;L.P. or,
collectively, the Longitude Funds. Longitude Capital Partners,&nbsp;LLC is the general partner of the Longitude Funds. David Hirsch, a member of our board of directors, is a member of Longitude
Capital Partners,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
general partner of Skyline Venture Partners V,&nbsp;L.P. is Skyline Venture Management V,&nbsp;LLC. John G. Freund, a member of our
board of directors, is a manager of Skyline Venture Management V,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
general partner of TPG Biotechnology Partners IV,&nbsp;L.P. is TPG Biotechnology GenPar IV,&nbsp;L.P., a Delaware limited partnership,
whose general partner is TPG Biotechnology GenPar IV Advisors,&nbsp;LLC, a Delaware limited liability company, whose sole member is TPG Holdings&nbsp;I,&nbsp;L.P., a Delaware limited
partnership, whose general partner is TPG Holdings I-A,&nbsp;LLC, a Delaware limited liability company, whose sole member is TPG Group Holdings (SBS),&nbsp;L.P., a Delaware limited partnership,
whose general partner is TPG Group Holdings (SBS) Advisors,&nbsp;Inc., or Group Advisors, a Delaware corporation. Messrs.&nbsp;David Bonderman and James G. Coulter are officers and the sole
shareholders of Group Advisors and may therefore be deemed to be the beneficial owners of the shares held by TPG Biotechnology Partners&nbsp;IV,&nbsp;L.P. Each of Messrs.&nbsp;Bonderman and
Coulter expressly disclaims beneficial ownership of the securities listed above except to the extent of any pecuniary interest therein. Eran Nadav, Ph.D., a member of our board of directors, is a
partner of TPG Global,&nbsp;LLC. The address for Messrs.&nbsp;Bonderman, Coulter, Nadav and TPG Biotechnology Partners IV,&nbsp;L.P. is c/o TPG Global,&nbsp;LLC, 301 Commerce Street,
Suite&nbsp;3300, Fort Worth, TX 76102.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(7)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
investment adviser and sole general partner of RA Capital Healthcare Fund,&nbsp;LP is RA Capital Management,&nbsp;LLC. Peter
Kolchinsky is the sole managing member of RA Capital Management,&nbsp;LLC and has the power to vote or dispose of the shares held by RA Capital Healthcare Fund,&nbsp;LP. The address for
Dr.&nbsp;Kolchinsky and RA Capital Healthcare Fund,&nbsp;LP is 20 Park Plaza, Suite&nbsp;1200, Boston, MA 02116
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(8)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">These
amounts reflect the December 2013 reverse stock split pursuant to which every two issued and outstanding shares of Series&nbsp;A
Convertible Preferred Stock were reclassified and combined into one share of Series&nbsp;A Convertible Preferred Stock. </FONT></DD></DL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Convertible Note Financing  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November and December 2014, we entered into a Convertible Note Purchase Agreement, pursuant to which we issued and sold to investors convertible promissory notes in the aggregate principal amount
of $5&nbsp;million, or the 2014 Convertible Note Financing. Pursuant to the Convertible Note Purchase Agreement, the convertible notes bore interest at a rate per annum of 6.0% and mature on the
earlier of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>155</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=159,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=697415,FOLIO='155',FILE='DISK131:[15ZCN1.15ZCN74701]EI74701A.;26',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_ei74701_1_156"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>(i)&nbsp;November&nbsp;14,
2015, (ii)&nbsp;immediately prior to a liquidation of the company, or (iii)&nbsp;upon an event of default. In connection with the Series&nbsp;D Convertible
Preferred Stock financing, the notes automatically converted into an aggregate of 4,166,667 shares of Series&nbsp;D Convertible Preferred Stock. The participants in the 2014 Convertible Notes
Financing included the following directors, executive officers and/or holders of more than 5% of our capital stock or entities affiliated with them. The following table presents the amount of the
notes issued to these related parties in this financing: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="79pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:49pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Participants<font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font>

<!-- COMMAND=ADD_SCROPPEDRULE,49pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount of<BR>
Notes Purchased </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>5% or greater shareholders</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Boston Millennia Partners<SUP>(2)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>754,829</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Frazier Healthcare VI,&nbsp;L.P.<SUP>(3)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>924,264</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Longitude Capital Partners,&nbsp;LLC<SUP>(4)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,826,499</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Skyline Venture Partners V,&nbsp;L.P.<SUP>(5)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,494,408</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Additional
details regarding these shareholders and their equity holdings are provided in "Principal Shareholders."
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
shares held, in the aggregate, by the Boston Millennia Funds. Robert Jevon, a former member of our board of directors, is an
affiliate of Glen Partners II Limited Partnership, which is the special limited partner of BMP KG, and the general partner of the other Boston Millennia Funds.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
general partner of Frazier Healthcare VI,&nbsp;L.P. is a limited partnership, the general partner of which is FHM VI,&nbsp;LLC.
Patrick Heron, a member of our board of directors, is a member of FHM VI,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
shares held, in the aggregate, by the Longitude Funds. Longitude Capital Partners,&nbsp;LLC is the general partner of the
Longitude Funds. David Hirsch, a member of our board of directors, is a member of Longitude Capital Partners,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
general partner of Skyline Venture Partners V,&nbsp;L.P. is Skyline Venture Management V,&nbsp;LLC. John G. Freund, a member of our
board of directors, is a manager of Skyline Venture Management V,&nbsp;LLC. </FONT></DD></DL>
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>In
connection with the 2014 Convertible Note Financing, we entered into a Preferred Shareholder Agreement with the Boston Millennia Funds, the Longitude Funds, Skyline Venture Partners V,&nbsp;L.P.
and Frazier Healthcare VI,&nbsp;L.P., pursuant to which the Longitude Funds, Skyline Venture Partners V,&nbsp;L.P. and Frazier Healthcare VI,&nbsp;L.P. agreed to vote their shares to waive, with
respect to the Boston Millennia Funds, application of a mandatory conversion provision in our Articles of Incorporation, as amended, and other similar conversion provisions or other devices or
mechanisms that may be adopted that are intended to incentivize the continued investment in the Company by existing holders of our preferred stock, subject to certain conditions described in the
Preferred Shareholder Agreement. The Preferred Shareholder Agreement terminated by its terms upon the closing of the Series&nbsp;D Convertible Preferred Stock financing. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Seventh Amended and Restated Stockholders Agreement  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In connection with the Series&nbsp;D Convertible Preferred Stock financing in March 2015, we entered into the Seventh Amended and Restated
Stockholders Agreement, or the Stockholders Agreement, with certain of our shareholders, including Island View Investors,&nbsp;LLC, a limited liability company of which our President and Chief
Executive Officer, Michael T. Heffernan, is the sole member, the Longitude Funds, the Boston Millennia Funds, Frazier Healthcare VI,&nbsp;L.P., Skyline Venture Partners V,&nbsp;L.P., TPG
Biotechnology Partners&nbsp;IV,&nbsp;L.P. and RA Capital Healthcare Fund,&nbsp;LP. The Stockholders Agreement, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> imposes restrictions on the transfer of capital stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> grants holders of our outstanding convertible preferred stock certain rights of
first refusal, co-sale and put rights with respect to certain proposed transfers of our securities by shareholders other than holders of Series&nbsp;D Convertible Preferred Stock; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>156</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=160,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=128296,FOLIO='156',FILE='DISK131:[15ZCN1.15ZCN74701]EI74701A.;26',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_ei74701_1_157"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> grants us certain rights of first refusal with respect to certain proposed
transfers of our securities by shareholders other than holders of Series&nbsp;D Convertible Preferred Stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> imposes "drag along" obligations on our shareholders, and permits "tag along" by
holders of our preferred stock in certain sale transactions that are approved by our board of directors and certain of our preferred shareholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> sets forth voting obligations with respect to the constituency and size of our
board of directors, and provides for the designation of our directors by certain of our preferred shareholders; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> requires shareholders to enter into a 180-day lock-up period upon an initial
public offering. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
Stockholders Agreement terminated automatically upon completion of the IPO. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Eighth Amended and Restated Investor Rights Agreement  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In connection with the Series&nbsp;D Convertible Preferred Stock financing in March 2015, we entered into the Eighth Amended and Restated Investor
Rights Agreement, or the Investor Right Agreement, with certain of our investors, including the Longitude Funds, the Boston Millennia Funds, Frazier Healthcare VI,&nbsp;L.P., Skyline Venture
Partners V,&nbsp;L.P., TPG Biotechnology Partners IV,&nbsp;L.P. and RA Capital Healthcare Fund,&nbsp;LP The Investor Rights Agreement, among other
things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> imposes restrictions on the transfer of capital stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> grants holders of our outstanding convertible preferred stock certain
registration rights following an initial public offering; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> grants holders of our outstanding convertible preferred stock certain
pre-emptive rights with respect to certain issuances of our securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> imposes certain affirmative and negative covenants on us, including an
obligation for us to deliver periodic financial statements and budgets to any holder of at least 1&nbsp;million shares of our preferred stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> grants board observer rights to the Longitude Funds, Skyline Venture Partners
V,&nbsp;L.P., Boston Millennia Partners and TPG Biotechnology Partners IV,&nbsp;L.P. so long as such investors hold at least 2&nbsp;million shares of our preferred stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> requires us to prepare and submit to the SEC a registration statement on
Form&nbsp;S-1 for an initial public offering of our common stock and to use our best efforts to cause the registration statement to be declared effective; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> requires shareholders to enter into a 180-day lock-up period upon an initial
public offering. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>The
provisions in the Investor Rights Agreement granting certain pre-emptive rights terminated automatically upon closing of the IPO. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Management Rights Letters  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We entered into management rights letters with certain of our shareholders, including the Boston Millennia Funds, the Longitude Funds, Frazier
Healthcare VI,&nbsp;L.P., Skyline Venture Partners V,&nbsp;L.P. and Aperture Venture Partners III,&nbsp;L.P. The management rights letters grant certain management rights in the event that such
shareholder is not represented on our Board of Directors, as well as certain inspection rights. The management rights letters terminated automatically upon completion of the IPO. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Employment Agreements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have entered into employment agreements with certain of our named executive officers that provide for salary, bonus and severance compensation. For
more information regarding these employment agreements, see "Executive and Director Compensation&nbsp;&#151; Employment Agreements" and "Executive and Director
Compensation&nbsp;&#151; Potential Payments Upon a Termination or Change of Control." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>157</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=161,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=789061,FOLIO='157',FILE='DISK131:[15ZCN1.15ZCN74701]EI74701A.;26',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_ei74701_1_158"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Equity Issued to Executive Officers and Directors  </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>We have granted common stock and/or stock options to our named executive officers and directors, as more fully described in "Executive and Director
Compensation&nbsp;&#151; Employment Agreements," "Executive and Director Compensation&nbsp;&#151; Equity Awards During Fiscal Years Ended December&nbsp;31, 2015 and 2014" and
"Executive and Director Compensation&nbsp;&#151; Compensation of Non-Employee Directors."

 </FONT>

</P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Indemnification Agreements with our Directors and Officers  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have entered into, and intend to continue to enter into, indemnification agreements with our directors and executive officers, in addition to the
indemnification provided for in our amended and restated articles of incorporation and our amended and restated bylaws. These agreements, among other things, require us to indemnify our directors and
executive officers for certain expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of their
services as one of our directors and/or executive officers or any other company or enterprise to which the person provides services at our request. We believe that these charter and bylaw provisions
and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
limitation of liability and indemnification provisions in our amended and restated articles of incorporation and amended and restated bylaws may discourage shareholders from bringing a lawsuit
against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit
us and our shareholders. A shareholder's investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification
provisions. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Policies and Procedures for Transactions with Related Persons  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our board of directors has adopted a related party transactions policy for us. Pursuant to the related party transactions policy, we will review all
transactions with a dollar value in excess of $120,000 involving us in which any of our directors, director nominees, significant shareholders and executive officers and their immediate family members
will be participants, to determine whether such person has a direct or indirect material interest in the transaction. This policy was not in effect when we entered into the transactions described
above. All directors, director nominees and executive officers will be required to promptly notify our chief financial officer of any proposed transaction involving us in which such person has a
direct or indirect material interest. Such proposed transaction will then be reviewed by the audit committee to determine whether the proposed transaction is a related party transaction under our
policy. In reviewing any related party transaction, the audit committee will determine whether or not to approve or ratify the transaction based on all relevant facts and circumstances, including the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the materiality and character of the related person's interest in the
transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the commercial reasonableness of the terms of the transaction; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the benefit and perceived benefit, or lack thereof, to us; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the opportunity costs of alternate transactions; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the actual or apparent conflict of interest of the related person. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
the event that any member of the audit committee is not a disinterested member with respect to the related person transaction under review, that member will be excluded from the review and approval
or rejection of such related party transaction and another director may be designated to join the committee for purposes of such review. Whenever practicable, the reporting, review and approval will
occur prior to entering into the transaction. If advance review and approval is not practicable, the audit committee will review and may, in its discretion, ratify the related party transaction. After
any such review, the audit committee will approve or ratify the transaction only if it determines that the transaction is in, or not inconsistent with, the best interests of us and our shareholders.
Our related party transaction policy is available on our website, www.collegiumpharma.com, under the "Investor Relations" section. The information contained in, or that can be accessed through, our
website is not part of this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>158</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=162,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=30104,FOLIO='158',FILE='DISK131:[15ZCN1.15ZCN74701]EI74701A.;26',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ek74701_1_159"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ek74701_principal_shareholders"> </A>
<A NAME="toc_ek74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PRINCIPAL SHAREHOLDERS    <BR>    </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>The following table sets forth certain information regarding the beneficial ownership of our capital stock outstanding as of December&nbsp;31, 2015
by:</FONT>

</P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each person, or group of affiliated persons, known by us to beneficially own
more than 5% of our shares of common stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each of our directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> each of our named executive officers; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> all of our directors and executive officers as a group. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>


The percentage ownership information under the column entitled "Before offering" is based on 20,739,351 shares of common stock outstanding as of December&nbsp;31, 2015. The percentage ownership
information under the column entitled "After offering" is based on the sale of shares of common stock to be outstanding after this offering.

 </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Information
with respect to beneficial ownership has been furnished by each director, officer or beneficial owner of more than 5% of our common stock. We have determined beneficial ownership in
accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those
securities. The table below assumes that the underwriters do not exercise their option to purchase additional shares from us. In addition, the rules attribute beneficial ownership of securities as of
a particular date to persons who hold options or warrants to purchase shares of common stock and that are exercisable within 60&nbsp;days of such date. These shares are deemed to be outstanding and
beneficially owned by the person holding those options or warrants for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of
computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares
shown as beneficially owned by them, subject to applicable community property laws. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Except
as otherwise noted below, the address for each person or entity listed in the table is c/o&nbsp;Collegium Pharmaceutical,&nbsp;Inc., 780 Dedham Street, Suite&nbsp;800, Canton, MA 02021.
The table below does not reflect any shares of our common stock that our directors, executive officers, 5% shareholders or their affiliated </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>159</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=163,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=207684,FOLIO='159',FILE='DISK131:[15ZCN1.15ZCN74701]EK74701A.;27',USER='ABEAULI',CD='31-DEC-2015;18:29' -->
<A NAME="page_ek74701_1_160"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>entities
may purchase in this offering, including any of the reserved shares, as described in the "Underwriting" section of this prospectus. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="37pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="37pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Percentage of<BR>
shares beneficially<BR>
owned </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
shares<BR>
beneficially<BR>
owned </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:139pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Name and Address of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,139pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Before<BR>
offering </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>After<BR>
offering </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>5% or greater shareholders:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Longitude Capital Partners,&nbsp;LLC<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,321,842</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>16.02</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Skyline Venture Partners V,&nbsp;L.P.<SUP>(2)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,949,916</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>14.22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Frazier Healthcare VI,&nbsp;L.P.<SUP>(3)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,887,332</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RA Capital Healthcare Fund,&nbsp;L.P.<SUP>(4)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,545,410</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7.45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>TPG Biotechnology Partners IV,&nbsp;L.P.<SUP>(5)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,325,263</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.39</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Boston Millennia Partners<SUP>(6)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,082,160</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5.22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Directors and Named Executive Officers:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael T. Heffernan, R. Ph.<SUP>(7)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>609,174</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.92</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Paul Brannelly<SUP>(8)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>79,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Barry S. Duke</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Garen G. Bohlin<SUP>(9)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7,852</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John G. Freund, M.D.<SUP>(10)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,949,916</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>14.22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Patrick Heron<SUP>(11)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,887,332</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>9.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Hirsch, M.D., Ph.D.<SUP>(12)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,321,842</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>16.02</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Eran Nadav, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gino Santini</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>23,188</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>All current executive officers and directors as a group (9&nbsp;persons)<SUP>(13)</SUP></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8,878,554</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>42.59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">*</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
beneficial ownership of less than one percent (1%) of the outstanding shares of our common stock.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Includes
(a)&nbsp;3,256,572 shares of common stock held by Longitude Venture Partners,&nbsp;L.P. and (b)&nbsp;65,270 shares of common
stock held by Longitude Capital Associates,&nbsp;L.P. Longitude Capital Partners,&nbsp;LLC is the general partner of the Longitude Funds and may be deemed to have sole voting investment and
dispositive power over the shares held by the Longitude Funds. Patrick G. Enright and Juliet Tammenoms Bakker are managing members and in their capacity as such, may be deemed to exercise shared
voting and investment power over the shares held by the reporting persons. David Hirsch, a member of our board of directors, is a member of Longitude Capital Partners,&nbsp;LLC. Each of these
individuals disclaims beneficial ownership of such shares except to the extent of his or her pecuniary interest therein.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(2)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
general partner of Skyline Venture Partners V,&nbsp;L.P. is Skyline Venture Management V,&nbsp;LLC. John G. Freund and Yasunori Kaneko
are managers of Skyline Venture Management V,&nbsp;LLC. These individuals share voting and investment power over the shares held by Skyline Venture Management,&nbsp;LLC. Each of these individuals
disclaims beneficial ownership of all the shares held by Skyline Venture Partners V,&nbsp;L.P. except to the extent of his proportionate pecuniary interest therein.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(3)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
general partner of Frazier Healthcare VI,&nbsp;L.P. is a limited partnership, the general partner of which is FHM VI,&nbsp;LLC. The
members of FHM VI,&nbsp;LLC are Dr.&nbsp;Nathan Every, Alan Frazier, Nader Naini, Patrick Heron, a member of our board of directors, and Dr.&nbsp;James Topper. These individuals share voting and
investment power over the shares held by Frazier Healthcare VI,&nbsp;L.P. Each of these individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(4)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
investment adviser and sole general partner of RA Capital Healthcare Fund,&nbsp;LP is RA Capital Management,&nbsp;LLC. Peter
Kolchinsky is the sole managing member of RA Capital Management,&nbsp;LLC and has the power to vote or dispose of the shares held by RA Capital Healthcare Fund,&nbsp;LP. The address for
Dr.&nbsp;Kolchinsky and RA Capital Healthcare Fund,&nbsp;LP is 20 Park Plaza, Suite&nbsp;1200, Boston, MA 02116 </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>160</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=164,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1004478,FOLIO='160',FILE='DISK131:[15ZCN1.15ZCN74701]EK74701A.;27',USER='ABEAULI',CD='31-DEC-2015;18:29' -->
<A NAME="page_ek74701_1_161"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(5)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">The
general partner of TPG Biotechnology Partners IV,&nbsp;L.P. is TPG Biotechnology GenPar IV,&nbsp;L.P., a Delaware limited partnership,
whose general partner is TPG Biotechnology GenPar IV Advisors,&nbsp;LLC, a Delaware limited liability company, whose sole member is TPG Holdings I,&nbsp;L.P., a Delaware limited partnership, whose
general partner is TPG Holdings I-A,&nbsp;LLC, a Delaware limited liability company, whose sole member is TPG Group Holdings (SBS),&nbsp;L.P., a Delaware limited partnership, whose general partner
is TPG Group Holdings (SBS) Advisors,&nbsp;Inc., or Group Advisors, a Delaware corporation. Messrs.&nbsp;David Bonderman and James G. Coulter are officers and the sole shareholders of Group
Advisors and may therefore be deemed to be the beneficial owners of the shares held by TPG Biotechnology Partners IV,&nbsp;L.P. Each of Messrs.&nbsp;Bonderman and Coulter expressly disclaims
beneficial ownership of the securities listed above except to the extent of any pecuniary interest therein. The address for Messrs.&nbsp;Bonderman and Coulter and TPG Biotechnology Partners
IV,&nbsp;L.P. is c/o&nbsp;TPG Global,&nbsp;LLC, 301&nbsp;Commerce Street, Suite&nbsp;3300, Fort Worth, TX 76102.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(6)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Represents
shares held, in the aggregate, by the Boston Millennia Funds. Robert Jevon, a former member of our board of directors, is an
affiliate of Glen Partners II Limited Partnership which is the special limited partner of BMP KG, and the general partner of the other Boston Millennia Funds. A. Dana Callow Jr., Martin J. Hernon, and
Robert S. Sherman are general partners of Glen Partners II Limited Partnership, exercise shared voting and investment power over the shares held by the Boston Millennia Funds, and may be deemed to
have beneficial ownership of these shares.

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(7)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Includes
90,822 shares of our common stock subject to options exercisable within 60&nbsp;days of December&nbsp;31, 2015 and 163,043 shares
of common stock held by Island View Investors&nbsp;LLC, of which Mr.&nbsp;Heffernan, our President and Chief Executive Officer, is the sole member.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(8)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Includes
6,787 shares of our common stock subject to options exercisable within 60&nbsp;days of December&nbsp;31, 2015.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(9)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Includes
7,852 shares of our common stock subject to options exercisable within 60&nbsp;days of December&nbsp;31, 2015.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(10)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Dr.&nbsp;Freund
is a member of a group of persons who exercise voting and investment power over the shares of common stock beneficially
owned by Skyline Venture Partners V,&nbsp;L.P. and may be deemed to beneficially own the shares held by Skyline Venture Partners V,&nbsp;L.P. Dr.&nbsp;Freund's address is c/o&nbsp;Skyline
Venture Partners V,&nbsp;L.P., 525 University Ave., Palo Alto, CA&nbsp;94301.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(11)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Mr.&nbsp;Heron
is a member of a group of persons who exercise voting and investment power over the shares of common stock beneficially
owned by Frazier Healthcare VI,&nbsp;L.P. and may be deemed to beneficially own the shares held by Frazier Healthcare VI,&nbsp;L.P. Mr.&nbsp;Heron's address is c/o&nbsp;Frazier Healthcare
VI,&nbsp;L.P., 601 Union Street, Suite&nbsp;3200, Seattle, WA&nbsp;98101.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(12)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Dr.&nbsp;Hirsch
is a member of a group of persons who exercise voting and investment power over the shares of common stock beneficially
owned by the Longitude Funds and may be deemed to beneficially own the shares held by the Longitude Funds. Dr.&nbsp;Hirsch disclaims beneficial ownership of such shares except to the extent of his
pecuniary interest therein. Dr.&nbsp;Hirsch's address is c/o&nbsp;Longitude Capital Partners,&nbsp;LLC, 800 El Camino Real, Ste. 220, Menlo Park, CA&nbsp;94024.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(13)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Includes
105,461 shares of common stock which the directors and current executive officers (i.e.,&nbsp;Messrs.&nbsp;Heffernan, Brannelly
and Duke) have the right to acquire upon the exercise of stock options that were exercisable as of December&nbsp;31, 2015, or that will become exercisable within 60&nbsp;days after that date. </FONT>

</DD>

</DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>161</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=165,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=365469,FOLIO='161',FILE='DISK131:[15ZCN1.15ZCN74701]EK74701A.;27',USER='ABEAULI',CD='31-DEC-2015;18:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_em74701_1_162"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="em74701_description_of_capital_stock"> </A>
<A NAME="toc_em74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF CAPITAL STOCK    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following description summarizes information about our capital stock. This information does not purport to be complete and is subject to, and
qualified in its entirety by reference to, the terms of our amended and restated articles of incorporation and amended and restated bylaws, which are included as exhibits to the registration statement
of which this prospectus forms a part, and the applicable provisions of Virginia law, the state in which we are incorporated. You are encouraged to read our amended and restated articles of
incorporation and amended and restated bylaws for greater detail with respect to these provisions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>



As of December&nbsp;31, 2015 our capital stock was held of record by 60 shareholders. Our authorized capital stock consists of 105,000,000 shares, 100,000,000 of which are designated as common stock
with a par value of $0.001 per share and 5,000,000 of which are designated as preferred stock with a par value of $0.001.

 </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Common Stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Shares of our common stock have the following rights, preferences and privileges: </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Voting Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the shareholders. With
certain exceptions, a majority of the votes cast at a shareholder meeting at which a quorum is present must approve all shareholder matters. Our amended and restated articles of incorporation provide
that an amendment to our amended and restated articles of incorporation, a merger, share exchange, domestication, entity conversion, sale of assets that requires shareholder approval or our
dissolution must be approved by a majority of all the votes entitled to be cast at a shareholder meeting. Our amended and restated articles of incorporation provide that an amendment to our bylaws by
the shareholders must be approved by more than two thirds of all the votes entitled to be cast. Our amended and restated bylaws also provide that our directors are elected by a plurality of the votes
cast. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> Dividends.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to the preferences applicable to any shares of preferred stock outstanding at any time, holders of our common stock are entitled to receive
dividends when and as declared by our board of directors from assets or funds legally available therefor. The timing, declaration, amount and payment of future dividends will depend on our financial
condition, earnings, capital requirements and debt service obligations, as well as legal requirements, regulatory constraints, industry practice and other factors that our board of directors deems
relevant. Our board of directors will make all decisions regarding our payment of dividends from time to time in accordance with applicable law. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> Liquidation.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to any preferential liquidation rights of holders of preferred stock that may be outstanding, upon our dissolution, the holders of our common
stock will be entitled to share ratably in our assets legally available for distribution to our shareholders. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> No Preemptive or Similar Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The holders of our common stock do not have any preemptive rights or
preferential rights to subscribe for shares of our capital stock or any other securities. Our common stock is not subject to any redemption or sinking fund provisions. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Preferred Stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Immediately prior to the consummation of our IPO, all outstanding shares of preferred stock converted into an aggregate of 12,591,456 shares of common
stock. Under our amended and restated articles of incorporation, our board of directors may issue preferred stock in one or more series, with preferences, limitations and rights as authorized by our
board of directors, to the extent permitted by Virginia law. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>162</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=166,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=58163,FOLIO='162',FILE='DISK131:[15ZCN1.15ZCN74701]EM74701A.;16',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_em74701_1_163"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Stock Options  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of September&nbsp;30, 2015, we had outstanding options to purchase 1,356,246 shares of our common stock at a weighted-average price of $9.04 per
share, pursuant to the Plan. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Restricted Common Stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As of September&nbsp;30, 2015, we had 153,589 shares of restricted common stock issued and outstanding. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Warrants  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In October 2010, we issued a warrant to Comerica Bank, which warrant was immediately exercisable for 33,746 shares of our then outstanding
Series&nbsp;D-1 Convertible Preferred Stock. In connection with the Series&nbsp;B Convertible Preferred Stock financing, all issued and outstanding shares of previously issued preferred stock,
including Series&nbsp;D-1 Preferred Stock, were converted into shares of Series&nbsp;A Convertible Preferred Stock. Additionally, pursuant to the December 2013 reverse stock split, the number of
shares underlying the warrant was adjusted to 16,873 shares of Series&nbsp;A Preferred Stock. Upon the completion of our IPO, the warrant converted into a warrant to purchase 2,445 shares of common
stock at an exercise price of $12.27. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Registration Rights  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Pursuant to the Investor Rights Agreement, certain holders of shares of our common stock have registration rights as further described below. After
registration of these shares of common stock pursuant to these rights, these shares will become freely tradable without restriction under the Securities Act. These holders may also be able to sell
shares without registration pursuant to Rule&nbsp;144 as described in this prospectus. See "Shares Eligible for Future Sale&nbsp;&#151;&nbsp;Rule&nbsp;144." </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Demand Registration Rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Subject to specified limitations set forth in the Investor Rights Agreement, (i)&nbsp;holders holding a majority of the registrable shares issued or
issuable upon the conversion of Series&nbsp;D Convertible Preferred Stock, (ii)&nbsp;holders holding a majority of the registrable shares issued or issuable upon the conversion of Preferred Stock,
or (iii)&nbsp;a lesser percentage of holders of registrable shares if the anticipated aggregate offering price to the public, net of underwriting discounts and commissions, is not less than
$10&nbsp;million, may demand in writing that we register all or a portion of the registrable shares under the Securities Act pursuant to the filing of a Registration Statement on Form&nbsp;S-1. We
are not obligated to file&nbsp;a registration statement pursuant to this provision on more than two occasions in any 12-month period, provided, however, that such obligation shall be deemed
satisfied only when (i)&nbsp;a registration statement covering no less than 70% of the number of registrable shares specified in a notice received for sale in accordance with the method of
disposition specified by the requesting holders shall have become effective or if such registration statement has been withdrawn prior to the consummation of the offering at the request of the holders
of a majority of the registrable shares requested to be included in the offering, and (ii)&nbsp;if such method of disposition is a firm commitment, underwritten public offering, all such shares were
sold pursuant thereto. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, subject to specified limitations set forth in the Investor Rights Agreement, at any time after we become eligible to file&nbsp;a registration statement on Form&nbsp;S-3, a holder or
holders of the registrable shares then outstanding may request that we register their registrable securities on Form&nbsp;S-3 for purposes of a public offering if the total shares registered have an
aggregate offering price of at least $1&nbsp;million. We are not obligated to file&nbsp;a registration statement pursuant to this provision on more than two occasions in any 12-month period. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Piggyback Registration Rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If, at any time, we propose to file&nbsp;a registration statement to register any of our securities under the Securities Act, either for our own
account or for the account of any of our shareholders, the holders of our registrable securities are entitled to notice of registration and, subject to specified exceptions, we will be </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>163</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=167,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1046109,FOLIO='163',FILE='DISK131:[15ZCN1.15ZCN74701]EM74701A.;16',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_em74701_1_164"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>required
upon the holder's request to use our best efforts to register their then-held registrable securities. The underwriters of any underwritten offering will have the right to limit the number of
shares having registration rights to be included in the registration statement, but not below 30% of the total amount of securities included in such registration. In addition, pursuant to the Investor
Rights Agreement, in no event will shares of any other selling shareholder be included in such registration that would reduce the number of shares which may be included by holders without the written
consent of holders of at least 60% of the registrable shares held by all holders. All investors entitled to piggyback registration rights have waived such rights in connection with this offering. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Other Provisions  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We will pay registration expenses other than the underwriting discount, selling commissions and the fees and expenses of the selling shareholders' own
counsel (other than the counsel selected to represent all of the selling shareholders), related to any demand registration. The Investor Rights Agreement contains customary cross-indemnification
provisions, pursuant to which we are obligated to indemnify the selling shareholders in the event of material misstatements or omissions in the registration statement attributable to us, and they are
obligated to indemnify us for material misstatements or omissions in the registration statement attributable to them. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Anti-Takeover Effects of Provisions of our Articles of Incorporation, our Bylaws and Virginia Law  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Various provisions contained in our amended and restated articles of incorporation, our amended and restated bylaws and Virginia law could delay,
deter or discourage some transactions involving an actual or potential change in control of the Company. Provisions in our amended and restated articles of incorporation and our amended and restated
bylaws include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a provision allowing our board of directors to establish one or more series or
classes of undesignated preferred stock, the terms of which can be determined by the board of directors at the time of issuance; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> advance written notice procedures and notice requirements with respect to
shareholder proposals and shareholder nomination of candidates for election as directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a provision that only the board of directors, the chairman of the board of
directors or the president may call a special meeting of the shareholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a provision dividing our board of directors into three classes, each serving
three-year terms; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the requirement that the authorized number of our directors be changed only by
resolution of our board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a provision that our board of directors shall fill any vacancies on our board of
directors, including vacancies resulting from a board of directors resolution to increase the number of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  limitations on the manner in which shareholders can remove directors from the
board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the lack of cumulative voting in the election of directors; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a prohibition on shareholders acting by less-than-unanimous written consent. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Articles of Incorporation and Bylaws  </I></B></FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Preferred stock  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our amended and restated articles of incorporation authorize our board of directors to establish one or more series of preferred stock and to
determine, with respect to any series of preferred stock, the preferences, rights and other terms of such series. See "&#151;&nbsp;Preferred Stock" for additional information. Under this
authority, our board of directors could create and issue a series of preferred stock with rights, preferences or restrictions that have the effect of discriminating against an existing or prospective
holder of our capital stock as a result of such holder beneficially owning or commencing a tender or exchange offer for a substantial amount of our common stock. One of the effects of authorized but
unissued and unreserved shares of preferred stock may be to render it more difficult for, or to discourage an attempt by, a potential acquiror to obtain control of us by means of a merger, tender or
exchange offer, proxy contest or otherwise, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>164</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=168,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=480343,FOLIO='164',FILE='DISK131:[15ZCN1.15ZCN74701]EM74701A.;16',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_em74701_1_165"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>and
thereby protect the continuity of our management. The issuance of shares of preferred stock may have the effect of delaying, deferring or preventing a change in control of our Company without any
action by our shareholders. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Qualification and election of directors  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our amended and restated bylaws provide that to be eligible to be nominated by a shareholder for election to our board of directors, a person must
submit a written questionnaire regarding his or her background and qualifications and must agree to other representations as set forth in our amended and restated bylaws. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Under
our amended and restated articles of incorporation, our board of directors is divided into three classes, each serving three-year terms and until each director's successors are duly elected and
qualified. The election of the classes is staggered, such that only approximately one third of our board of directors is up for election in any given year. Our amended and restated articles of
incorporation do not provide for cumulative voting in the election of directors. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Board vacancies; removal  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our amended and restated articles of incorporation provide that any vacancy occurring on our board of directors will be filled by a majority of
directors then in office, even if less than a quorum. Our amended and restated articles of incorporation also provide that our directors can only be removed for cause upon the vote of more than two
thirds of the votes entitled to be cast by holders of common stock. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Special meetings of shareholders  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our amended and restated articles of incorporation provide that only the board of directors, the chairman of the board of directors or the president
may call a special meeting of the shareholders. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Advance notification of shareholder nominations and proposals  </I></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our amended and restated bylaws establish advance notice procedures with respect to shareholder proposals and the nomination of persons for election
as directors, other than nominations made by or at the direction of our board of directors. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Virginia Anti-Takeover Statutes  </I></B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Affiliated transactions statute  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Virginia law contains provisions governing certain material transactions, or affiliated transactions, between the Company and any holder of more than
10% of any class of its outstanding voting shares, or an interested shareholder. In general, these provisions prohibit a Virginia corporation from engaging in an affiliated transaction with an
interested shareholder for a period of three years following the date such person became an interested shareholder, unless (i)&nbsp;a majority of the disinterested directors and the holders of at
least two-thirds of the voting shares, other than those beneficially owned by the interested shareholder, approved the affiliated transaction, or (ii)&nbsp;before the date that the person became an
interested shareholder, a majority of the disinterested directors approved the transaction that resulted in the person becoming an interested shareholder. After three years, any such transaction must
be at a "fair price," as statutorily defined, or must be approved by the holders of at least two-thirds of the voting shares, other than those beneficially owned by the interested shareholder.
Affiliated transactions subject to this approval requirement include mergers, share exchanges, material dispositions of corporate assets not in the ordinary course of business, the sale of shares of
the corporation or any of its subsidiaries to an interested shareholder having an aggregate fair market value of greater than 5% of the aggregate fair market value of the corporation's outstanding
shares, any dissolution of the Company proposed by or on behalf of an interested shareholder or any reclassification, including reverse stock splits, recapitalization or merger of the Company with its
subsidiaries, if any, that increases the percentage of voting shares beneficially owned by an interested shareholder by more than 5%. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
shareholders of a Virginia corporation may adopt an amendment to the corporation's articles of incorporation or bylaws opting out of the provisions of Virginia law governing affiliated
transactions but such amendment shall not be effective until 18&nbsp;months after its adoption. Neither our amended and restated </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>165</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=169,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=413599,FOLIO='165',FILE='DISK131:[15ZCN1.15ZCN74701]EM74701A.;16',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_em74701_1_166"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>articles
of incorporation nor our amended and restated bylaws contain a provision opting out of the provisions of Virginia law governing affiliated transactions. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Control share acquisitions statute  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Virginia law also contains provisions relating to control share acquisitions, which are transactions causing the voting strength of any person
acquiring beneficial ownership of shares of a Virginia public corporation to meet or exceed certain threshold percentages (20%, 33<SUP>1</SUP>/<SMALL>3</SMALL>% or 50%) of the total votes entitled to be
cast for the election of directors. Shares acquired in a control share acquisition have no voting rights unless (i)&nbsp;the voting rights are granted by a majority vote of all outstanding shares
other than those held by the acquiring person or any officer or employee director of the corporation or (ii)&nbsp;the articles of incorporation or bylaws of the corporation provide that these
Virginia law provisions do not apply to acquisitions of its shares. The acquiring person may require that a special meeting of the shareholders be held to consider the grant of voting rights to the
shares acquired in the control share acquisition. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
permitted by Virginia law, our amended and restated articles of incorporation contain a provision opting out of the Virginia anti-takeover law regulating control share acquisitions. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Indemnification and limitation of directors' and officers' liability  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a Virginia corporation. As permitted by Virginia law, our amended and restated articles of incorporation provide that no director or officer
shall be liable in any proceeding brought by or in the right of us or our shareholders for monetary damages arising out of any transaction, occurrence or other course of conduct, except for liability
resulting from willful misconduct or a knowing violation of criminal law or of any federal or state securities laws. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our
amended and restated articles of incorporation require us to indemnify any director or officer who was or is a party to a proceeding, including a proceeding brought by or in the right of the
Company, due to his or her status as our director or officer unless he or she engaged in willful misconduct or a knowing violation of criminal law. Our amended and restated articles of incorporation
also require us to advance expenses to such person prior to the final disposition of any such proceeding. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have obtained policies that insure our directors and officers against certain liabilities they may incur in their capacity as directors and officers. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have entered into indemnification agreements with our directors and executive officers. These agreements contain provisions that may require us, among other things, to advance expenses to and
indemnify these directors and officers against certain liabilities that may arise because of their status or service as directors or officers of us. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Transfer Agent and Registrar  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Listing  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our common stock is listed on NASDAQ under the symbol "COLL." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>166</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=170,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=541008,FOLIO='166',FILE='DISK131:[15ZCN1.15ZCN74701]EM74701A.;16',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_eo74701_1_167"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="eo74701_shares_eligible_for_future_sale"> </A>
<A NAME="toc_eo74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SHARES ELIGIBLE FOR FUTURE SALE    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Future sales of substantial amounts of common stock in the public market could adversely affect prevailing market prices. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Based
on the number of shares of common stock outstanding as of September&nbsp;30, 2015, upon the closing of this offering,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock will be outstanding,
assuming no
exercise of the underwriters' option to purchase additional shares from us and no exercise of options or warrants. All of the shares sold in this offering will be freely tradable unless held by an
affiliate of ours. Except as set forth below, the remaining shares of common stock outstanding after this offering will be restricted as a result of securities laws or lock-up
agreements. These remaining shares will be eligible for sale under Rule&nbsp;144 or Rule&nbsp;701 of the Securities Act upon expiration of lock-up agreements at least 90&nbsp;days after the date
of this offering. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Rule&nbsp;144  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In general, under Rule&nbsp;144 of the Securities Act, any person who is not an affiliate of ours and has held their shares for at least six months,
including the holding period of any prior owner other than one of our affiliates, may sell shares without restriction, provided current public information about us is available. In addition, under
Rule&nbsp;144, any person who is not an affiliate of ours and has held their shares for at least one year, including the holding period of any prior owner other than one of our affiliates, would be
entitled to sell an unlimited number of shares immediately upon the closing of this offering without regard to whether current public information about us is available. A person who is an affiliate of
ours and who has beneficially owned restricted securities for at least six months, including the holding period of any prior owner other than one of our affiliates, is entitled to sell a number of
restricted shares within any three-month period that does not exceed the greater of:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 1% of the number of shares of our common stock then outstanding, which will
equal approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares immediately after this offering; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the average weekly trading volume of our common stock on NASDAQ during the four
calendar weeks preceding the filing of a notice on Form&nbsp;144 pursuant to Rule&nbsp;144 with respect to the sale. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>Sales
of restricted shares under Rule&nbsp;144 held by our affiliates are also subject to requirements regarding the manner of sale, notice and the availability of current public information about
us. Rule&nbsp;144 also provides that affiliates relying on Rule&nbsp;144 to sell shares of our common stock that are not restricted shares must nonetheless comply with the same restrictions
applicable to restricted shares, other than the holding period requirement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Notwithstanding
the availability of Rule&nbsp;144, our directors and executive officers have entered into lock-up agreements as described below and their restricted shares will become eligible for
sale at the expiration of the restrictions set forth in those agreements. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Rule&nbsp;701  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In general, under Rule&nbsp;701 of the Securities Act, any of our employees, directors, officers, consultants or advisors who acquired common stock
from us in connection with a written compensatory stock or option plan or other written agreement in compliance with Rule&nbsp;701 before the IPO is entitled to rely on Rule&nbsp;701 to resell
such shares in reliance on Rule&nbsp;144, but without compliance with the holding period requirements contained in Rule&nbsp;144. Accordingly, subject to any applicable lock-up agreements, under
Rule&nbsp;701 persons who are not our "affiliates," as defined in Rule&nbsp;144, may resell those shares without complying with the minimum holding period or public information requirements of
Rule&nbsp;144, and persons who are our "affiliates" may resell those shares without compliance with Rule&nbsp;144's minimum holding period requirements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>167</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=171,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=11512,FOLIO='167',FILE='DISK131:[15ZCN1.15ZCN74701]EO74701A.;14',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_eo74701_1_168"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Lock-Up Agreements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We, along with our directors, executive officers and certain of our shareholders have agreed that for a period of 90 days after the date of this
prospectus, subject to specified exceptions, we or they will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any shares of our common stock or securities
convertible into or exchangeable or exercisable for any shares of our common stock. Upon expiration of the "lock-up" period, certain of our shareholders will have the right to require us to register
their shares under the Securities Act. See "&#151;&nbsp;Registration Rights" below. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Registration Rights  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The holders of 12.8&nbsp;million shares of our common stock are entitled to rights with respect to the registration of their shares under the
Securities Act, subject to the lock-up arrangement described above. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under
the Securities Act, except for shares purchased by affiliates, immediately upon the effectiveness of the registration. Any sales of securities by these shareholders could have a material adverse
effect on the trading price of our common stock. See "Description of Capital Stock&nbsp;&#151;&nbsp;Registration Rights." </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Equity Incentive Plans  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have filed with the SEC a registration statement on Form&nbsp;S-8 under the Securities Act covering the shares of common stock reserved for
issuance under the Amended and Restated 2014 Stock Incentive Plan and 2015 Employee Stock Purchase Plan. Accordingly, shares registered under the registration statement are available for sale in the
open market, subject to Rule&nbsp;144 volume limitations and the lock-up agreements described above, if applicable. See "Executive and Director Compensation." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>168</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=172,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=130794,FOLIO='168',FILE='DISK131:[15ZCN1.15ZCN74701]EO74701A.;14',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_eq74701_1_169"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="eq74701_material_u.s._federal_income_t__mat03201"> </A>
<A NAME="toc_eq74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES<BR>  TO NON-U.S. HOLDERS OF OUR COMMON STOCK    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following is a general discussion of material U.S. federal income and estate tax considerations relating to the ownership and disposition of our
common stock by a non-U.S. holder. For purposes of this discussion, the term "non-U.S. holder" means a beneficial owner of our common stock that is not and is not treated as, for U.S. federal income
tax purposes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an individual who is a citizen or resident of the United States; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a corporation, or other entity treated as a corporation for U.S. federal income
tax purposes, created or organized in or under the laws of the United States or of any political subdivision of the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an estate the income of which is subject to U.S. federal income taxation
regardless of its source; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a trust, if (i)&nbsp;a U.S. court is able to exercise primary supervision over
the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of the trust or (ii)&nbsp;if the trust has a valid election to be treated as a U.S.
person under applicable U.S. Treasury Regulations. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>An
individual may be treated as a resident instead of a nonresident of the United States in any calendar year for U.S. federal income tax purposes if the individual was present in the United States
for at least 31&nbsp;days in that calendar year and for an aggregate of at least 183&nbsp;days during the three-year period ending with that calendar year. For purposes of this calculation, all of
the days present in the tested year, one-third of the days present in the immediately preceding year and one-sixth of the days present in the second preceding year are counted. Residents are taxed for
U.S. federal income tax purposes as if they were U.S. citizens. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
discussion is based on current provisions of the Code, existing and proposed U.S. Treasury Regulations promulgated thereunder, current administrative rulings and judicial decisions, all as in
effect as of the date of this prospectus and all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any change or differing interpretation could alter the
tax consequences to non-U.S. holders described in this prospectus. In addition, the Internal Revenue Service, or the IRS, could challenge one or more of the tax consequences described in this
discussion. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
assume in this discussion that each non-U.S. holder holds shares of our common stock as a capital asset within the meaning of the Code (generally, property held for investment). This discussion
does not address all aspects of U.S. federal income and estate taxation that may be relevant to a particular non-U.S. holder in light of that non-U.S. holder's individual circumstances nor does it
address any aspects of state, local or non-U.S. taxes.
This discussion also does not consider any specific facts or circumstances that may apply to a non-U.S. holder, including the alternative minimum tax and the Medicare contribution tax on net
investment income, and does not address the special tax rules applicable to particular non-U.S. holders, such as:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  insurance companies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  tax-exempt organizations or tax-qualified retirement plans; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  governmental organizations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> financial institutions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> brokers, dealers or traders in securities or currencies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> real estate investment trusts or regulated investment companies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> pension plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  controlled foreign corporations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> passive foreign investment companies; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>169</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=173,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=447525,FOLIO='169',FILE='DISK131:[15ZCN1.15ZCN74701]EQ74701A.;14',USER='LSMITH',CD=';3-JAN-2016;14:56' -->
<A NAME="page_eq74701_1_170"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> persons deemed to sell our common stock under the constructive sale provisions
of the Code; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> persons who hold or receive our common stock pursuant to the exercise of any
employee stock option or otherwise as compensation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> owners that hold our common stock as part of a straddle, hedge, conversion
transaction, synthetic security or other integrated investment; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> certain U.S. expatriates. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>In
addition, this discussion does not address the tax treatment of partnerships or persons who hold their common stock through partnerships or other entities that are pass-through entities for U.S.
federal income tax purposes. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>This summary is general information only. It is not tax advice. We urge each prospective non-U.S. Holder to consult their tax advisor concerning the particular U.S. federal,
state, local and non-U.S. income, estate and other tax consequences of the purchase, ownership and disposition of our common stock.</B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Dividends  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If we pay distributions on our common stock, those distributions generally will constitute dividends for U.S. federal income tax purposes to the
extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits,
the excess will be treated as a tax-free return of the non-U.S. holder's investment, up to such non-U.S. holder's tax basis in the common stock. Any remaining excess will be treated as capital gain,
subject to the tax treatment described in this prospectus under the heading "&#151; Gain on Disposition of Common Stock." Any such distribution will also be subject to the discussion in this
prospectus under the heading "&#151; Withholding and Information Reporting Requirements&nbsp;&#151; FATCA." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Dividends
paid to a non-U.S. holder generally will be subject to withholding of U.S. federal income tax on the gross amount of the dividends at a 30.0% rate or such lower rate as may be specified by
an applicable income tax treaty between the United States and such holder's country of residence. If we determine, at a time reasonably close to the date of payment of a distribution on our common
stock, that the distribution will not constitute a dividend because we do not anticipate having current or accumulated earnings and profits, we may elect not to withhold U.S. federal income tax from
such distribution as permitted by U.S. Treasury Regulations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
non-U.S. holder of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder's country of residence will generally be required to provide a
properly executed IRS Form&nbsp;W-8BEN or W-8BEN-E (or successor form) and satisfy applicable certification and other requirements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
non-U.S. holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing an appropriate
claim with the IRS. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Dividends
that are treated as effectively connected with a trade or business conducted by a non-U.S. holder within the United States, and, if an applicable income tax treaty so provides, that are
attributable to a permanent establishment or a fixed base maintained by the non-U.S. holder within the United States, are generally exempt from the 30.0% withholding tax if the non-U.S. holder
provides a properly executed IRS Form&nbsp;W-8ECI (or successor form). However, such U.S. effectively connected income, net of specified deductions and credits, is
taxed at the same graduated U.S. federal income tax rates applicable to "United States persons" (within the meaning of the Code). Any U.S. effectively connected income received by a non-U.S. holder
that is a corporation may also, under certain circumstances, be subject to an additional "branch profits tax" at a 30.0% rate or such lower rate as may be specified by an applicable income tax treaty
between the United States and such non-U.S. holder's country of residence. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>170</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=174,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=821516,FOLIO='170',FILE='DISK131:[15ZCN1.15ZCN74701]EQ74701A.;14',USER='LSMITH',CD=';3-JAN-2016;14:56' -->
<A NAME="page_eq74701_1_171"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Gain on Disposition of Common Stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Subject to the discussion below regarding backup withholding and the Foreign Account Tax Compliance Act, or FATCA, a non-U.S. holder generally will
not be subject to U.S. federal income tax on gain recognized on a disposition of our common stock unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the gain is effectively connected with the non-U.S. holder's conduct of a trade
or business in the United States, and, if an applicable income tax treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by the non-U.S. holder in the
United States; in this case, the non-U.S. holder will be taxed on a net income basis at the regular graduated rates and in the manner applicable to United States persons, and, if the non-U.S. holder
is a foreign corporation, an additional branch profits tax at a rate of 30.0%, or a lower rate as may be specified by an applicable income tax treaty, may also apply; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the non-U.S. holder is an individual present in the United States for
183&nbsp;days or more in the taxable year of the disposition and certain other requirements are met (in which case the non-U.S. holder will be subject to a 30.0% tax, or such lower rate as may be
specified by an applicable income tax treaty, on the net gain derived from the disposition, which may be offset by U.S.-source capital losses of the non-U.S. holder, if any); or </FONT> <FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we are or have been, at any time during the five-year period preceding such
disposition (or the non-U.S. holder's holding period, if shorter) a "United States real property holding corporation" within the meaning of the Code, unless during such applicable period our common
stock is regularly traded on an established securities market and the non-U.S. holder held no more than 5.0% of our outstanding common stock, actually or constructively. Generally, a corporation is a
"United States real property holding corporation" if the fair market value of its "United States real property interests" equals or exceeds 50.0% of the sum of the fair market value of its worldwide
real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we believe that we are not currently, and we do not anticipate becoming,
a "United States real property holding corporation" for U.S. federal income tax purposes. No assurance can be provided that our common stock will be regularly traded on an established securities
market for purposes of the rule described above. If the foregoing exception does not apply, and if we are or were to become a "United States real property holding corporation", a purchaser may be
required to withhold 15% of the proceeds payable to a non-U.S. holder from a sale of our common stock and such non-U.S. holder generally will be taxed on its net gain derived from the disposition at
the graduated U.S. federal income tax rates applicable to U.S. persons (as defined in the Code).

 </FONT></DD></DL>
</UL>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Information Reporting and Backup Withholding  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The gross amount of the distributions on our common stock paid to each non-U.S. holder and the tax withheld, if any, with respect to such
distributions must be reported annually to the IRS. Non-U.S. holders may have to comply with specific certification procedures to establish that they are not "United States persons" (within the
meaning of the Code) in order to avoid backup withholding at the applicable rate, currently 28.0%, with respect to dividends on our common stock. Generally, a non-U.S. holder will comply with such
procedures if it provides a properly executed IRS Form&nbsp;W-8BEN, W-8BEN-E or W-8ECI or otherwise meets documentary evidence requirements for establishing that it is a non-U.S. holder, or
otherwise establishes an exemption. Dividends paid to non-U.S. holders subject to withholding of U.S. federal income tax, as described above under the heading "Dividends," will generally be exempt
from backup withholding. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Information
reporting and backup withholding generally will apply to the proceeds of a disposition of our common stock by a non-U.S. holder effected by or through a U.S. office of any broker, United
States or foreign, unless the holder certifies its status as a non-U.S. holder (such as by providing a valid IRS Form&nbsp;W-8BEN, W-8BEN-E or W-8ECI) and satisfies certain other requirements, or
otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>171</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=175,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=397948,FOLIO='171',FILE='DISK131:[15ZCN1.15ZCN74701]EQ74701A.;14',USER='LSMITH',CD=';3-JAN-2016;14:56' -->
<A NAME="page_eq74701_1_172"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>disposition
proceeds to a non-U.S. holder where the transaction is effected outside the United States through a non-U.S. office of a broker. However, for information reporting purposes, dispositions
effected through a non-U.S.
office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Copies
of information returns may be made available to the tax authorities of the country in which the non-U.S. holder resides or is incorporated under the provisions of a specific treaty or
agreement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Backup
withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a non-U.S. holder can be refunded or credited against the non-U.S. holder's U.S.
federal income tax liability, if any, provided that an appropriate claim is timely filed with the IRS. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Withholding and Information Reporting Requirements&nbsp;&#151; FATCA  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Legislation known as the Foreign Account Tax Compliance Act, or FATCA, imposes U.S. federal withholding tax of 30.0% on payments of dividends on, and
(to the extent described below) on gross proceeds from the sale or disposition of, our common stock if paid to a foreign entity unless (i)&nbsp;in the case of a foreign entity that is a "foreign
financial institution" (within the meaning of the Code), the foreign entity undertakes certain due diligence, reporting, withholding and certification obligations, (ii)&nbsp;in the case of a foreign
entity that is not a foreign financial institution, the foreign entity either certifies it does not have any "substantial United States owners" (as defined in the Code) or identifies each substantial
United States owner or (iii)&nbsp;the foreign entity is otherwise exempt under FATCA. Withholding under FATCA will only apply (1)&nbsp;to payments of dividends on our common stock and
(2)&nbsp;to payments of gross proceeds from a sale or other disposition of our common stock made after December&nbsp;31, 2018. Under certain circumstances, a non-U.S. holder may be eligible for
refunds or credits of such taxes. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Federal Estate Tax  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Common stock owned or treated as owned by an individual (including by reason of holding interests in certain entities) who is not a citizen or
resident of the United States (as specially determined for U.S. federal estate tax purposes) at the time of death will be included in the individual's gross estate for U.S. federal estate tax purposes
and, therefore, may be subject to U.S. federal estate tax, unless an applicable estate tax or other treaty provides otherwise. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>THE PRECEDING DISCUSSION OF MATERIAL U.S. FEDERAL INCOME AND ESTATE TAX CONSIDERATIONS IS FOR GENERAL INFORMATION ONLY. IT IS NOT TAX ADVICE. PROSPECTIVE INVESTORS SHOULD
CONSULT
THEIR TAX ADVISORS REGARDING THE PARTICULAR U.S. FEDERAL, STATE, LOCAL AND NON-U.S. TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK (DIRECTLY OR THROUGH ENTITIES), INCLUDING
THE CONSEQUENCES OF ANY PROPOSED CHANGES IN APPLICABLE LAWS.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>172</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=176,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=906386,FOLIO='172',FILE='DISK131:[15ZCN1.15ZCN74701]EQ74701A.;14',USER='LSMITH',CD=';3-JAN-2016;14:56' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_es74701_1_173"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="es74701_underwriting"> </A>
<A NAME="toc_es74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  UNDERWRITING    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Subject to the terms and conditions set forth in the underwriting agreement, among us and Jefferies&nbsp;LLC and Piper Jaffray&nbsp;&amp;&nbsp;Co.,
as the representatives of the underwriters named below and the joint book-running managers of this offering, we have agreed to sell to the underwriters, and each of the underwriters has agreed,
severally and not jointly, to purchase from us, the respective number of shares of common stock shown opposite its name below: </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="84pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:41pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Underwriter

<!-- COMMAND=ADD_SCROPPEDRULE,41pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of Shares </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jefferies&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Piper Jaffray&nbsp;&amp;&nbsp;Co.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William Blair &amp; Company, L.L.C.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Needham&nbsp;&amp; Company,&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Janney Montgomery Scott LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>The
underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters of officers' certificates and
legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the shares of common stock if any of them are
purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be
terminated. We have agreed to indemnify the underwriters and certain of their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to
payments that the underwriters may be required to make in respect of those liabilities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the common stock as permitted by applicable laws and regulations. However,
the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no assurance can be
given as to the liquidity of the trading market for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you receive when
you sell will be favorable. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
underwriters are offering the shares of common stock subject to their acceptance of the shares of common stock from us and subject to prior sale. The underwriters reserve the right to withdraw,
cancel or modify offers to the public and to reject orders in whole or in part. In addition, the underwriters have advised us that they do not intend to confirm sales to any account over which they
exercise discretionary authority. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Commission and Expenses  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The underwriters have advised us that they propose to offer the shares of common stock to the public at the public offering price set forth on the
cover page of this prospectus and to certain dealers, which may include the underwriters, at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common
stock. The underwriters
may allow, and certain dealers may reallow, a discount from the concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock to certain brokers and dealers. After the
offering, the public
offering price, concession and reallowance to dealers may be reduced by the representatives. No such </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>173</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=177,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=613216,FOLIO='173',FILE='DISK131:[15ZCN1.15ZCN74701]ES74701A.;15',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_es74701_1_174"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>reduction
will change the amount of proceeds to be received by us as set forth on the cover page of this prospectus. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following table shows the public offering price, the underwriting discounts and commissions that we are to pay the underwriters and the proceeds, before expenses, to us in connection with this
offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters' option to purchase additional shares. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="82pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="82pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="82pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="82pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Per Share </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Without Option<BR>
to Purchase<BR>
Additional Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>With Option<BR>
to Purchase<BR>
Additional Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Without Option<BR>
to Purchase<BR>
Additional Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>With Option<BR>
to Purchase<BR>
Additional Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Public offering price</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting discounts and commissions paid by us</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds to us, before expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2>We
estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have also
agreed to reimburse the underwriters for certain of their expenses in an amount up to $50,000, incurred in connection with review by the Financial Industry Regulatory Authority,&nbsp;Inc. of the
terms of this offering, as set forth in the underwriting agreement. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Listing  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Our common stock is listed on NASDAQ under the trading symbol "COLL." </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Stamp Taxes  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>If you purchase shares of common stock offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws and
practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Option to Purchase Additional Shares  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have granted to the underwriters an option, exercisable for 30&nbsp;days from the date of this prospectus, to purchase, from time to time, in
whole or in part, up to an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares from us at the public offering
price set forth on the cover page of this prospectus, less underwriting discounts and commissions. If the
underwriters exercise this option, each underwriter will be obligated, subject to specified conditions, to purchase a number of additional shares proportionate to that underwriter's initial purchase
commitment as indicated in the table above. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


No Sales of Similar Securities  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We, our officers, directors and certain holders of our outstanding capital stock and other securities have agreed, subject to specified exceptions,
not to directly or indirectly:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> sell, offer, contract or grant any option to sell (including any short sale),
pledge, transfer, establish an open "put equivalent position" within the meaning of Rule&nbsp;16a-l(h) under the Exchange Act, or </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>174</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=178,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=200483,FOLIO='174',FILE='DISK131:[15ZCN1.15ZCN74701]ES74701A.;15',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_es74701_1_175"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>  otherwise dispose of any shares of common stock, options or warrants to acquire
shares of common stock, or securities exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record or beneficially, or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> publicly announce an intention to do any of the foregoing for a period of
90&nbsp;days after the date of this prospectus without the prior written consent of Jefferies&nbsp;LLC and Piper Jaffray&nbsp;&amp;&nbsp;Co. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>This
restriction terminates after the close of trading of the common stock on and including the 90<SUP>th</SUP>&nbsp;day after the date of this prospectus. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Jefferies&nbsp;LLC
and Piper Jaffray&nbsp;&amp;&nbsp;Co. may, in their sole discretion and at any time or from time to time before the termination of the 90-day period release all or any portion of
the securities subject to lock-up agreements. There are no existing agreements between the underwriters and any of our shareholders who will execute a lock-up agreement, providing consent to the sale
of shares prior to the expiration of the lock-up period. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Stabilization  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The underwriters have advised us that they, pursuant to Regulation&nbsp;M under the Exchange Act, certain persons participating in the offering may
engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering. These activities may have the effect of
stabilizing or maintaining the market price of the common stock at a level
above that which might otherwise prevail in the open market. Establishing short sales positions may involve either "covered" short sales or "naked" short sales. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>"Covered"
short sales are sales made in an amount not greater than the underwriters' option to purchase additional shares of our common stock in this offering. The underwriters may close out any
covered short position by either exercising their option to purchase additional shares of our common stock or purchasing shares of our common stock in the open market. In determining the source of
shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they
may purchase shares through the option to purchase additional shares. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>"Naked"
short sales are sales in excess of the option to purchase additional shares of our common stock. The underwriters must close out any naked short position by purchasing shares in the open
market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the shares of our common stock in the open market
after pricing that could adversely affect investors who purchase in this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
stabilizing bid is a bid for the purchase of shares of common stock on behalf of the underwriters for the purpose of fixing or maintaining the price of the common stock. A syndicate covering
transaction is the bid for or the purchase of shares of common stock on behalf of the underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to
other purchase transactions, the underwriter's purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or preventing or
retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. A penalty bid is an
arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the common stock originally sold by such syndicate
member are purchased in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Neither
we, nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common
stock. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at any time. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>175</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=179,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=346435,FOLIO='175',FILE='DISK131:[15ZCN1.15ZCN74701]ES74701A.;15',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_es74701_1_176"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Electronic Distribution  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A prospectus in electronic format may be made available by e-mail or on the web sites or through online services maintained by one or more of the
underwriters or their affiliates. In those cases, prospective investors may view offering terms online and may be allowed to place orders online. The underwriters may agree with us to allocate a
specific number of shares of common stock for sale to online brokerage account holders. Any such allocation for online distributions will be made by the underwriters on the same basis as other
allocations. Other than the prospectus in electronic format, the information on the underwriters' web sites and any information contained in any other web site maintained by any of the underwriters is
not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Other Activities and Relationships  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The underwriter and certain of its affiliates are full service financial institutions engaged in various activities, which may include securities
trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriter and
certain of its affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for
which they received or will receive customary fees and expenses. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
the ordinary course of their various business activities, the underwriter and certain of its affiliates may make or hold a broad array of investments and actively trade debt and equity securities
(or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may
involve securities and/or instruments issued by us and our affiliates. If the underwriters or their respective affiliates have a lending relationship with us, they routinely hedge their credit
exposure to us consistent with their customary risk management policies. The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of either
the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the common stock offered hereby. Any such short
positions could adversely affect future trading prices of the common stock offered hereby. The underwriters and certain of their respective affiliates may also communicate independent investment
recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that
they acquire, long and/or short positions in such securities and instruments. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Disclaimers About Non-U.S. Jurisdictions  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Australia  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus is not a disclosure document for the purposes of Australia's Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not
been lodged with the Australian Securities&nbsp;&amp; Investments Commission and is only directed to the categories of exempt persons set out below. Accordingly, if you receive this prospectus in
Australia: </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You
confirm and warrant that you are either:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a "sophisticated investor" under section&nbsp;708(8)(a) or (b)&nbsp;of the
Corporations Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a "sophisticated investor" under section&nbsp;708(8)(c) or (d)&nbsp;of the
Corporations Act and that you have provided an accountant's certificate to the Company which complies with the requirements of section&nbsp;708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and
related regulations before the offer has been made; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a person associated with the Company under Section&nbsp;708(12) of the
Corporations Act; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a "professional investor" within the meaning of section&nbsp;708(11)(a) or
(b)&nbsp;of the Corporations Act. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>176</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=180,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=245023,FOLIO='176',FILE='DISK131:[15ZCN1.15ZCN74701]ES74701A.;15',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_es74701_1_177"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>To
the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor under the Corporations Act any offer made to you under
this prospectus is void and incapable of acceptance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>You
warrant and agree that you will not offer any of the securities issued to you pursuant to this prospectus for resale in Australia within 12&nbsp;months of those securities being issued unless
any such resale offer is exempt from the requirement to issue a disclosure document under section&nbsp;708 of the Corporations Act. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


European Economic Area  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In relation to each member state of the European Economic Area which has implemented the Prospectus Directive (each, a "Relevant Member State"), an
offer to the public of any common stock which is the subject of the offering contemplated by this prospectus may not be made in that Relevant Member State except that an offer to the public in that
Relevant Member State of any common stock may be made at any time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member
State:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to any legal entity which is a "qualified investor" as defined in the Prospectus
Directive; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to fewer than 100 or, if the Relevant Member State has implemented the relevant
provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject
to obtaining the prior consent of the underwriters or the underwriters nominated by us for any such offer; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> in any other circumstances falling within Article&nbsp;3(2) of the Prospectus
Directive, </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>provided
that no such offer of common stock shall require us or any of the underwriters to publish a prospectus pursuant to Article&nbsp;3 of the Prospectus Directive or supplement a prospectus
pursuant to Article&nbsp;16 of the Prospectus Directive. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
the purposes of this provision, the expression an "offer common stock to the public" in relation to the common stock in any Relevant Member State means the communication in any form and by any
means of sufficient information on the terms of the offer and the common stock to be offered so as to enable an investor to decide to purchase or subscribe to the common stock, as the same may be
varied in that Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State and the expression "Prospectus Directive" means Directive 2003/71/EC (and
amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State and
the expression "2010 PD Amending Directive" means Directive 2010/73/EU. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Hong Kong  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>No securities have been offered or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose
ordinary business is to buy or sell shares or debentures, whether as principal or agent; or to "professional investors" as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong
("SFO") and any rules made under that Ordinance; or in other circumstances which do not result in the document being a "prospectus" as defined in the Companies Ordinance (Cap. 32)&nbsp;of Hong Kong
("CO") or which do not constitute an offer or invitation to the public for the purpose of the CO or the SFO. No document, invitation or advertisement relating to the securities has been issued or may
be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed
or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons
outside Hong Kong or only to "professional investors" as defined in the SFO and any rules made under that Ordinance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
prospectus has not been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong Kong, and the securities may not
be offered </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>177</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=181,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=745000,FOLIO='177',FILE='DISK131:[15ZCN1.15ZCN74701]ES74701A.;15',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_es74701_1_178"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>for
subscription to members of the public in Hong Kong. Each person acquiring the securities will be required, and is deemed by the acquisition of the securities, to confirm that he, she or it is
aware of the restriction on offers of the securities described in this prospectus and the relevant offering documents and that he, she or it is not acquiring, and has not been offered any securities
in circumstances that contravene any such restrictions. </FONT></P>


<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Japan  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The offering has not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948 of Japan, as
amended), or FIEL, and the underwriters will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any
person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to, or for the
benefit of, any resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws, regulations and
ministerial guidelines of Japan. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Singapore  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this
prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares
be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor
under Section&nbsp;274 of the Securities and Futures Act, Chapter&nbsp;289 of Singapore (the "SFA"), (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to
Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other
applicable provision of the SFA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Where
the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a corporation (which is not an accredited investor (as defined in
Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a trust (where the trustee is not an accredited investor) whose sole purpose is
to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>securities
(as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within six months
after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to an institutional investor or to a relevant person defined in
Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> where no consideration is or will be given for the transfer; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> where the transfer is by operation of law; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> as specified in Section&nbsp;276(7) of the SFA; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> as specified in Regulation&nbsp;32 of the Securities and Futures (Offers of
Investments) (Shares and Debentures) Regulations&nbsp;2005 of Singapore. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Switzerland  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange ("SIX") or on any other stock exchange or
regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of
Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in
Switzerland. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>178</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=182,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=339480,FOLIO='178',FILE='DISK131:[15ZCN1.15ZCN74701]ES74701A.;15',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<A NAME="page_es74701_1_179"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Neither
this prospectus nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Neither
this prospectus nor any other offering or marketing material relating to the offering, the Company or the securities have been or will be filed with or approved by any Swiss regulatory
authority. In particular, this prospectus will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of
securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes ("CISA"). The investor protection afforded to acquirers of interests in collective
investment schemes under the CISA does not extend to acquirers of securities. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


United Kingdom  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This prospectus is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors within the meaning
of Article&nbsp;2(1)(e) of the Prospectus Directive that are also (i)&nbsp;investment professionals falling within Article&nbsp;19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended (the "Order") and/or (ii)&nbsp;high net worth entities falling within
Article&nbsp;49(2)(a) to (d)&nbsp;of the Order and other persons to whom it may lawfully be communicated (each such person being referred to as a "relevant person"). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any
person in the United Kingdom that is not a relevant person should not act or rely on this document or any of its contents. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>179</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=183,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=968457,FOLIO='179',FILE='DISK131:[15ZCN1.15ZCN74701]ES74701A.;15',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_eu74701_1_180"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="eu74701_legal_matters"> </A>
<A NAME="toc_eu74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The validity of the shares of common stock being offered by this prospectus will be passed upon for us by Pepper Hamilton&nbsp;LLP. Latham&nbsp;&amp;
Watkins&nbsp;LLP is counsel for the underwriters in connection with this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="eu74701_experts"> </A>
<A NAME="toc_eu74701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The annual audited financial statements of Collegium Pharmaceutical,&nbsp;Inc. included in this prospectus and elsewhere in the registration
statement have been so included in reliance upon the report of Grant Thornton&nbsp;LLP, independent registered public accountants, upon the authority of said firm as experts in accounting and
auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="eu74701_where_you_can_find_more_information"> </A>
<A NAME="toc_eu74701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have filed with the SEC a registration statement on Form&nbsp;S-1 under the Securities Act, with respect to the shares of common stock being
offered by this prospectus. This prospectus does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and the common stock
offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to
are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified
in all respects by this reference. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, over the Internet at the SEC's
website at www.sec.gov. You may also read and copy any document we file with the SEC at its public reference facilities at 100&nbsp;F Street, NE, Washington, DC 20549. You may also obtain copies of
these documents at prescribed rates by writing to the Public Reference Section of the SEC at 100&nbsp;F Street, NE, Washington, DC 20549. Please call the SEC at 1-800-SEC-0330 for further
information on the operation of the public reference facilities. You may also request a copy of these filings, at no cost, by writing us at 780 Dedham Street, Suite&nbsp;800, Canton, MA 02021 or
telephoning us at (781)&nbsp;713-3699. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
also maintain a website at www.collegiumpharma.com, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished
to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>180</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=184,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=971278,FOLIO='180',FILE='DISK131:[15ZCN1.15ZCN74701]EU74701A.;12',USER='CHE108236',CD='29-DEC-2015;02:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fa74701_1_1"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<A NAME="fa74701_index_to_financial_statements"> </A>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


COLLEGIUM PHARMACEUTICAL,&nbsp;INC.<BR>
Index to Financial Statements  </B></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<A NAME="FA74701_TOC2"></A> </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="30pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:105pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Audited Financial Statements

<!-- COMMAND=ADD_SCROPPEDRULE,105pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Pages </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#FC_RE"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Report of Independent Registered Public Accounting Firm</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#FC_RE"><FONT SIZE=2>F-2</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#FE_BS"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance Sheets as of December&nbsp;31, 2013 and 2014</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#FE_BS"><FONT SIZE=2>F-3</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#FG_SO"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Operations for the Years Ended December&nbsp;31, 2013 and 2014</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#FG_SO"><FONT SIZE=2>F-4</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#FI_SD"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Convertible Redeemable Preferred Stock and Shareholders' Deficit for the Years Ended December&nbsp;31, 2013
and 2014</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#FI_SD"><FONT SIZE=2>F-5</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#FK_CF"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Cash Flows for the Years Ended December&nbsp;31, 2013 and 2014</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#FK_CF"><FONT SIZE=2>F-6</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#fm74701_collegium_pharmaceutical,_inc.__col04039"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes to Financial Statements</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#fm74701_collegium_pharmaceutical,_inc.__col04039"><FONT SIZE=2>F-7</FONT></A></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>

<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<A NAME="FA74701_TOC"></A> </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="30pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:114pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Unaudited Financial Statements

<!-- COMMAND=ADD_SCROPPEDRULE,114pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Pages </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#GA_CBS"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unaudited Balance Sheets as of December&nbsp;31, 2014 and September&nbsp;30, 2015</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#GA_CBS"><FONT SIZE=2>F-30</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#GC_CSO"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unaudited Statements of Operations for the nine months ended September&nbsp;30, 2014 and 2015</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#GC_CSO"><FONT SIZE=2>F-31</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#GE_CFS"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unaudited Statements of Cash Flows for the nine months ended September&nbsp;30, 2014 and 2015</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#GE_CFS"><FONT SIZE=2>F-32</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#GG_FS"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes to Unaudited Interim Financial Statements</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#GG_FS"><FONT SIZE=2>F-33</FONT></A></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-1</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=185,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=345140,FOLIO='F-1',FILE='DISK131:[15ZCN1.15ZCN74701]FA74701A.;8',USER='CHE108236',CD='29-DEC-2015;02:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fc74701_1_2"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


<A NAME="FC_RE"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Board
of Directors and Shareholders<BR>
Collegium Pharmaceutical,&nbsp;Inc. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have audited the accompanying balance sheets of Collegium Pharmaceutical,&nbsp;Inc. (a Virginia corporation) (the "Company") as of December&nbsp;31, 2013 and 2014, and the related statements of
operations, convertible redeemable preferred stock and shareholders' deficit, and cash flows for each of the two years in the period ended December&nbsp;31, 2014. These financial statements are the
responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company's internal control over financial reporting. Our
audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an
opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our opinion. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Collegium Pharmaceutical,&nbsp;Inc. as of December&nbsp;31, 2013 and
2014, and the results of its operations and its cash flows for each of the two years in the period ended December&nbsp;31, 2014 in conformity with accounting principles generally accepted in the
United States of America. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>/s/
Grant Thornton&nbsp;LLP </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Boston,
Massachusetts<BR>
April&nbsp;27, 2015 </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-2</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=186,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=991801,FOLIO='F-2',FILE='DISK131:[15ZCN1.15ZCN74701]FC74701A.;6',USER='CHE108236',CD='29-DEC-2015;02:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fe74701_1_3"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<A NAME="FE_BS"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC.<BR>
BALANCE SHEETS<BR>
(In thousands, except share and per share data)  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="54pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>ASSETS</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Current assets:</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Cash and cash equivalents</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">7,551</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,634</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Refundable PDUFA fee</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,335</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">710</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">527 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total current assets</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">8,261</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">4,496</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Property and equipment, net</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">693</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">514</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Restricted cash</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">80</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">80 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total assets</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">9,034</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,090 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>LIABILITIES, CONVERTIBLE REDEEMABLE PREFERRED STOCK AND SHAREHOLDERS' DEFICIT</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Current liabilities:</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Accounts payable</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,217</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,208</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Accrued expenses</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,013</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,956</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Current portion of deferred rent and lease note payable</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">55</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">59</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Current portion of term loan payable</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">333</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,194</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Convertible bridge notes with related parties</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,000 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total current liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,618</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10,417</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Deferred rent and lease note payable, long-term</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">59</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Lease incentive obligation</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">135</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">101</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Term loan payable, long-term</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">640</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">6,813 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,452</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">17,331 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Commitments and contingencies (See Note&nbsp;7)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:9pt;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Convertible redeemable preferred stock (See Note&nbsp;10):</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Series&nbsp;A convertible redeemable preferred stock, $0.001 par value; authorized shares&nbsp;&#151; 18,498,419 at December&nbsp;31, 2013 and
December&nbsp;31, 2014; issued and outstanding shares&nbsp;&#151; 9,232,334 at December&nbsp;31, 2013 and December&nbsp;31, 2014; liquidation preference of $12,277 at December&nbsp;31, 2013 and $12,781 at December&nbsp;31, 2014</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,277</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,781</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Series&nbsp;B convertible redeemable preferred stock, $0.001 par value; authorized shares&nbsp;&#151; 27,324,237 at December&nbsp;31, 2013 and
December&nbsp;31, 2014; issued and outstanding shares&nbsp;&#151; 27,324,237 at December&nbsp;31, 2013 and December&nbsp;31, 2014; liquidation preference of $49,376 at December&nbsp;31, 2013 and $51,212 at December&nbsp;31, 2014</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">49,376</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">51,212</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Series&nbsp;C convertible redeemable preferred stock, $0.001 par value; authorized shares&nbsp;&#151; 8,658,344 at December&nbsp;31, 2013 and
December&nbsp;31, 2014; issued and outstanding shares&nbsp;&#151; 8,658,008 at December&nbsp;31, 2013 and December&nbsp;31, 2014; liquidation preference of $12,154 at December&nbsp;31, 2013 and $13,114 at December&nbsp;31, 2014</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,154</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">13,114</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Shareholders' deficit:</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Common stock, $0.001 par value; authorized shares&nbsp;&#151; 72,000,000 at December&nbsp;31, 2013 and December&nbsp;31, 2014; issued and outstanding
shares&nbsp;&#151; 962,960 at December&nbsp;31, 2013 and 1,006,219 at December&nbsp;31, 2014</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Additional paid-in capital</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,313</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,407</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Accumulated deficit</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(80,536</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(101,753</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Treasury stock</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total shareholders' deficit</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(68,225</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(89,348</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total liabilities, convertible redeemable preferred stock and shareholders' deficit</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">9,034</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,090 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"> <FONT SIZE=2>
The accompanying notes are an integral part of these financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-3</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=187,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=275189,FOLIO='F-3',FILE='DISK131:[15ZCN1.15ZCN74701]FE74701A.;5',USER='CHE108236',CD='29-DEC-2015;02:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fg74701_1_4"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<A NAME="FG_SO"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC.<BR>
STATEMENTS OF OPERATIONS<BR>
(In thousands, except share and per share data)  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="73pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="73pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14,157</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14,959</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,885</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,706 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>16,042</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>17,665 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16,042</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,665</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other expense:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense, net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>76</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>252</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of derivative liability</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>79</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other expense, net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>155</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>252 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16,197</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,917</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and diluted net loss per common share (See Note&nbsp;3)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4.06</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(22.72</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share (See Note&nbsp;3)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,697,044</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>933,997 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss per common share, basic and diluted (unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2.84</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average shares used to compute pro forma net loss per common share (unaudited)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,471,303 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"> <FONT SIZE=2>
The accompanying notes are an integral part of these financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-4</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=188,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1037858,FOLIO='F-4',FILE='DISK131:[15ZCN1.15ZCN74701]FG74701A.;5',USER='CHE108236',CD='29-DEC-2015;02:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fi74701_1_5"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<!-- COMMAND=ROTATED_TABLE WIDTH="150%" -->

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="99%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="99%" ALIGN="CENTER" >


<P style="font-family:arial;"><FONT SIZE=2><A
NAME="FI_SD"></A></FONT><FONT SIZE=2><B>COLLEGIUM PHARMACEUTICAL,&nbsp;INC.<BR>
STATEMENTS OF CONVERTIBLE REDEEMABLE PREFERRED STOCK AND SHAREHOLDERS' DEFICIT<BR>
(In thousands, except share data)  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="45pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="41pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="50pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="34pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="44pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="36pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=3 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Series&nbsp;A<BR>
Convertible<BR>
Redeemable<BR>
Preferred Stock </B></FONT></TH>
<TH ROWSPAN=3 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=3 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Series&nbsp;B<BR>
Convertible<BR>
Redeemable<BR>
Preferred Stock </B></FONT></TH>
<TH ROWSPAN=3 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=3 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Series&nbsp;C<BR>
Convertible<BR>
Redeemable<BR>
Preferred Stock </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Common Stock </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Additional Paid- In Capital </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Treasury Stock,<BR>
at cost </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Accumulated Deficit </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total<BR>
Shareholders'<BR>
Deficit </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Balance at January&nbsp;1, 2013</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">18,464,674</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">23,546</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">27,324,237</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">47,540</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,924,845</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">11</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(61,414</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(61,404</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Issuance of new Series&nbsp;C convertible redeemable preferred stock, net of issuance costs of $45</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">8,658,008</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,034</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Accruals of dividends and accretion to redemption value</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">970</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,836</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">120</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2,925</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(2,926</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Performance Adjustment of Series&nbsp;A</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(9,232,340</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(12,239</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(962,962</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(1</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,240</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,239</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Stock-based compensation expense</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">62</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">62</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Exercise of common stock options</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,077</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(16,197</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(16,197</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Balance at December&nbsp;31, 2013</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">9,232,334</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,277</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">27,324,237</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">49,376</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">8,658,008</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,154</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">962,960</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,313</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(80,536</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(68,225</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Accruals of dividends and accretion to redemption value</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">504</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,836</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">960</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3,300</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3,300</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Issuance of restricted stock awards to employees</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10,869</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Exercise of common stock options&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">32,390</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">72</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">72</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Stock-based compensation expense</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">22</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">22</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:14pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(17,917</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(17,917</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:7pt;text-indent:-7pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Balance at December&nbsp;31, 2014</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">9,232,334</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,781</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">27,324,237</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">51,212</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">8,658,008</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">13,114</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,006,219</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,407</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(101,753</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(89,348</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="99%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="99%" ALIGN="CENTER" >


<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>The
accompanying notes are an integral part of these financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-5</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=189,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=71076,FOLIO='F-5',FILE='DISK131:[15ZCN1.15ZCN74701]FI74701A.;9',USER='CHE108236',CD='29-DEC-2015;02:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fk74701_1_6"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<A NAME="FK_CF"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC.<BR>
STATEMENTS OF CASH FLOWS<BR>
(In thousands)  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Years Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CASH FLOWS FROM OPERATING ACTIVITIES:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16,197</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,917</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustments to reconcile net loss to net cash used in operating activities:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>169</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>187</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lease incentive</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(34</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(34</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock-based compensation</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>62</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>22</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non cash interest expense</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrual of back end fees related to note payable</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>13</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of derivative liability</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>79</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in operating assets and liabilities:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:31pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(11</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>183</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:31pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Refundable PDUFA fee</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,335</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:31pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(822</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>990</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:31pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>199</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>943 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in operating activities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16,530</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,947</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CASH FLOWS FROM INVESTING ACTIVITIES:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchases of property and equipment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(206</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(8</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in investing activities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(206</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(8</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CASH FLOWS FROM FINANCING ACTIVITIES:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from issuance of convertible bridge note</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from notes payable, net of original note payoff</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>500</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,056</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from issuance of Series&nbsp;C preferred stock, net of issuance costs of $45</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>11,955</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Repayment of term note borrowings</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(43</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(28</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Repayment of lease note payable</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(62</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(62</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from the exercise of common stock options</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>72 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by financing activities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12,351</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12,038 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net decrease in cash and cash equivalents</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4,385</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(5,917</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents&nbsp;&#151; Beginning of period</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>11,936</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,551 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents&nbsp;&#151; End of period</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,551</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,634 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Supplemental disclosure of noncash activities</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accruals of dividends and accretion to redemption value</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,926</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3,300 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Performance Adjustment to Series&nbsp;A and common shares</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12,239</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Repayment of term note with proceeds of notes payable</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>944 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash paid for interest</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>73</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>181 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash paid for taxes</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"> <FONT SIZE=2>
The accompanying notes are an integral part of these financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-6</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=190,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=903685,FOLIO='F-6',FILE='DISK131:[15ZCN1.15ZCN74701]FK74701A.;6',USER='CHE108236',CD='29-DEC-2015;02:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fm74701_1_7"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><A
NAME="fm74701_collegium_pharmaceutical,_inc.__col04039"> </A>
<A NAME="toc_fm74701_1"> </A></FONT> <FONT SIZE=2><B><BR>  COLLEGIUM PHARMACEUTICAL,&nbsp;INC.    <BR>    <BR>    NOTES TO FINANCIAL STATEMENTS    <BR>    <BR>    (in thousands, except share and per share data)    <BR>    </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


1. NATURE OF BUSINESS  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Organization  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Collegium Pharmaceutical,&nbsp;Inc. (the "Company") was incorporated in Delaware in April 2002 and then reincorporated in Virginia in July 2014. The
Company has its principal operations in Canton, Massachusetts. The Company is a specialty pharmaceutical company developing and planning to commercialize next-generation abuse-deterrent products that
incorporate the Company's patented DETERx&reg; platform technology for the treatment of chronic pain and other diseases. The Company's lead product candidate, Xtampza&#153; ER, or
Xtampza, is an abuse-deterrent, extended-release, oral formulation of oxycodone, a widely prescribed opioid medication. Xtampza has received Fast Track status from the U.S. Food and Drug
Administration ("FDA"). The Company's new drug application ("NDA") filing for Xtampza was accepted by the FDA on February&nbsp;10, 2015. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company's operations are subject to certain risks and uncertainties. The risks include negative outcome of clinical trials, inability or delay in completing clinical trials or obtaining regulatory
approvals, changing market conditions for products being developed by the Company, the need to retain key personnel and protect intellectual property, patent infringement litigation and the
availability of additional capital financing on terms acceptable to the Company. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Basis of Accounting  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The financial statements include the accounts of the Company and are prepared in conformity with accounting principles generally accepted in the
United States of America. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Liquidity  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company has experienced net losses and negative cash flows from operating activities since its inception, and as of December&nbsp;31, 2013 and
December&nbsp;31, 2014, had a deficit accumulated of $80,536 and $101,753, respectively. The Company expects to continue to incur net losses in the foreseeable future. A successful transition to
attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company's cost structure. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>On
March&nbsp;6, 2015, the Company received aggregate consideration of $50,000 from the issuance of Series&nbsp;D preferred stock, comprised of $45,000 in cash and $5,000 in convertible notes from
related parties. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company expects to continue to incur losses for the foreseeable future. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise
additional cash. Management intends to fund future operations through additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic
partners or from other sources. The Company believes that it will have sufficient cash to fund operations and future growth initiatives through December&nbsp;31, 2015; however, there can be no
assurance that the Company will be successful in achieving its projections, reducing costs, or raising additional funds with terms acceptable to the Company. If the Company is unable to obtain
financing or increase profitability, the related lack of liquidity will have a material adverse effect on the Company's operations and future prospects. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-7</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=191,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=178511,FOLIO='F-7',FILE='DISK131:[15ZCN1.15ZCN74701]FM74701A.;10',USER='NDEWIND',CD='30-DEC-2015;17:57' -->
<A NAME="page_fm74701_1_8"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Use of Estimates  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The preparation of the Company's financial statements requires it to make estimates and assumptions that impact the reported amounts of assets,
liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company's financial statements and accompanying notes. The most significant estimates in the Company's
financial statements relate to the valuation of equity awards, fair value estimates of warrants, estimated useful lives of fixed assets, asset retirement obligations and accruals related to clinical
trials. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its
estimates and assumptions on an ongoing basis. The Company's actual results may differ from these estimates under different assumptions or conditions. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Unaudited Pro Forma Net Loss per Share Information

  </B></FONT>

</P>

<P style="font-family:arial;"><FONT SIZE=2>Unaudited pro forma net loss per share applicable to common shareholders is computed using the weighted-average number of common shares outstanding
after giving effect to the conversion of all the outstanding convertible redeemable preferred stock into shares of common stock as if such conversion had occurred at the beginning of the period
presented, or the date of original issuance, if later, and excludes the gain on extinguishment of preferred stock and the accretion of dividends. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Fair Value Measurements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Disclosures of fair value information about financial instruments are required, whether or not recognized in the balance sheet, for financial
instruments with respect to which it is practicable to estimate that value. The carrying amounts reported in the Company's financial statements for cash and cash equivalents, accounts payable and
accrued liabilities approximate their respective fair values because of the short-term nature of these accounts. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Fair
Value Measurements and Disclosures describes the fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used
to measure fair value, as follows: </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> Level&nbsp;1</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. The
Company's Level&nbsp;1 assets and liabilities consist of money market investments. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> Level&nbsp;2</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration
with observable market data. Level&nbsp;2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security. The Company does not have
Level&nbsp;2 assets or liabilities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> Level&nbsp;3</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pricing inputs are unobservable for the assets or liabilities, that is, inputs that reflect the reporting entity's own assumptions about the
assumptions market participants would use in pricing the assets. Level&nbsp;3 includes private investments that are supported by little or no market activity. The Company does not have
Level&nbsp;3 assets or liabilities. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Transfers
are calculated on values as of the transfer date. There were no transfers between Levels&nbsp;1, 2 and 3 during the years ended December&nbsp;31, 2013 and 2014. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-8</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=192,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=600701,FOLIO='F-8',FILE='DISK131:[15ZCN1.15ZCN74701]FM74701A.;10',USER='NDEWIND',CD='30-DEC-2015;17:57' -->
<A NAME="page_fm74701_1_9"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Concentration of Credit Risk  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash and cash
equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and
management believes that the Company is not exposed to significant credit risk due to the financial position of the financial institutions in which those deposits are held. The Company has no
financial instruments with off-balance sheet risk of loss. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Cash and Cash Equivalents  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Cash and cash equivalents include cash in readily available checking and savings accounts and money market funds. The Company considers all highly
liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
Company's cash equivalents, which consist of money market funds, are measured at fair value on a recurring basis. As of December&nbsp;31, 2013 and 2014, the carrying amount of cash and cash
equivalents was $7,551 and $1,634, respectively, which approximates fair value and was determined based upon Level&nbsp;1 inputs. Money market funds are valued using quoted market prices with no
valuation adjustments applied. Accordingly, these securities are categorized as Level&nbsp;1. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Property and Equipment  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Property and equipment are recorded at historical cost. Maintenance and repair costs are expensed as incurred. Costs which materially improve or
extend the lives of existing assets are
capitalized. The Company provides for depreciation and amortization using the straight-line method over the estimated useful lives of the assets, which are as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="40%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="40%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Asset Category </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Estimated Useful Life </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>Machinery and equipment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>5&nbsp;years</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>Computers and office equipment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>5&nbsp;years</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>Furniture and fixtures</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>7&nbsp;years</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>Leasehold improvements</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>5&nbsp;years</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>Upon
retirement or sale, the cost of assets disposed and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recorded in the statements of operations. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Impairment of Long-Lived Assets  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Long-lived assets consist of property and equipment. When impairment indicators exist, the Company's management evaluates long-lived assets for
potential impairment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those
assets are less than the carrying amount of those assets. While the Company's current and historical operating losses and negative cash flows are indicators of impairment, management believes that
future cash flows to be received support the carrying value of its long-lived assets and, accordingly, has not recognized any impairment losses since inception. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-9</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=193,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=262988,FOLIO='F-9',FILE='DISK131:[15ZCN1.15ZCN74701]FM74701A.;10',USER='NDEWIND',CD='30-DEC-2015;17:57' -->
<A NAME="page_fm74701_1_10"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Impairment
losses, if any, are recognized in earnings. An impairment loss would be recognized in an amount equal to the excess of the carrying amount over the undiscounted expected future cash flows. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Initial Public Offering Costs  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company defers direct incremental costs attributable to the initial public offering ("IPO") of its common stock. These costs represent legal,
accounting and other direct costs related to the Company's efforts to raise capital through a public sale of its common stock. Future costs will be deferred until the completion of the IPO, at which
time they will be reclassified to additional paid-in capital as a reduction of the IPO proceeds. If the Company terminates its plan for an IPO or delays such plan for more than 90&nbsp;days, any
costs deferred will be expensed immediately. As of December&nbsp;31, 2014, IPO costs were $233 and are included in prepaid expenses and other assets in the balance sheet. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Restricted Cash  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Restricted cash represents cash held in a depository account at a financial institution to collateralize a conditional stand-by letter of credit
related to the Company's Canton, Massachusetts facility lease agreement. Restricted cash is reported as non-current unless the restrictions are expected to be released in the next twelve months. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Deferred Rent  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis for the facilities the
Company occupies. The Company's lease for its facility provides for fixed increases in minimum annual rental payments and for additional rent in the form of maintenance and operating costs during the
lease term. The total amount of rental payments due over the lease term is being charged to rent expense ratably over the life of the lease. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Convertible Redeemable Preferred Stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company classifies convertible redeemable preferred stock that is redeemable outside of the Company's control outside of permanent equity. The
Company recorded such redeemable preferred stock at fair value upon issuance, net of any issuance costs or discounts, and the carrying value is being increased by periodic accretion to its redemption
value at each balance sheet date as if the redeemable preferred stock was redeemable at that date. In the absence of retained earnings these accretion charges are recorded against additional paid-in
capital, if any, and then to accumulated deficit. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Research and Development Costs  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Research and development costs are charged to expense as incurred and consist of costs incurred to further the Company's research and development
activities including salaries and employee related costs, costs associated with market research and design, costs associated with conducting preclinical, clinical and regulatory activities including
fees paid to third-party professional consultants and service providers, costs incurred under clinical trial agreements, costs for laboratory supplies and laboratory equipment, costs to acquire,
develop and manufacture preclinical study and clinical trial materials, facilities, depreciation and other expenses including allocated expenses for rent and maintenance of facilities. Government
grants are recognized as a reduction of the qualifying cost being reimbursed. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-10</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=194,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=536471,FOLIO='F-10',FILE='DISK131:[15ZCN1.15ZCN74701]FM74701A.;10',USER='NDEWIND',CD='30-DEC-2015;17:57' -->
<A NAME="page_fm74701_1_11"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Patent Costs  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Costs related to filing and pursuing patent applications are recorded as general and administrative expense as incurred since the recoverability of
such expenditures is uncertain. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Stock-Based Compensation  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company accounts for grants of stock options and restricted stock to employees based on their grant date fair value and recognizes compensation
expense over their vesting period. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the fair
value of the underlying common stock as determined by management or the value of the services provided, whichever is more readily determinable. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Stock-based
compensation expense represents the cost of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards (usually the vesting
period) on a straight-line basis, net of estimated forfeitures. The expense is adjusted for actual forfeitures at year end. Stock-based compensation expense recognized in the financial statements is
based on awards that are ultimately expected to vest. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>For
stock option grants with performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable or the
performance condition has been achieved. For stock option grants with both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when
the achievement of the performance-based milestone is probable or the performance condition has been achieved. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company accounts for stock options and restricted stock awards to non-employees using the fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic
revaluation over their vesting terms. There were no non-employee grants in 2013 and 2014. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Income Taxes  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company accounts for income taxes under the liability method, which requires the recognition of deferred tax assets and liabilities for the
expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences
between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the years in which the differences are expected to reverse. The effect of a change in tax
rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all
available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent
operations. If management determines that the Company would be able to realize its deferred tax assets in the future, in excess of its net recorded amount, management would make an adjustment to the
deferred tax asset valuation allowance, which would reduce the provision for income taxes. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-11</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=195,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=156738,FOLIO='F-11',FILE='DISK131:[15ZCN1.15ZCN74701]FM74701A.;10',USER='NDEWIND',CD='30-DEC-2015;17:57' -->
<A NAME="page_fm74701_1_12"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company records uncertain tax positions on the basis of a two-step process whereby (i)&nbsp;management determines whether it is more likely than not that the tax positions will be sustained on
the basis of the technical merits of the position and (ii)&nbsp;for those tax positions that meet the more likely than not recognition threshold, management recognizes the largest amount of tax
benefit that is more than 50&nbsp;percent likely to be realized upon ultimate settlement with the related tax authority. The Company will recognize interest and penalties related to uncertain tax
positions within income tax expense. Any accrued interest and penalties will be included within the related tax liability. As of December&nbsp;31, 2013 and 2014, the Company had no accrued interest
or penalties related to uncertain tax positions and no amounts have been recognized in the Company's statements of operations. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Net loss per Common Share  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Basic net loss per common share is calculated by dividing the net loss attributable to common shareholders by the weighted-average number of shares of
common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common
shareholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock
options, warrants, redeemable convertible preferred stock and unvested restricted stock are considered potentially dilutive securities. Because the Company has reported a net loss for the twelve
months ended December&nbsp;31, 2013 and 2014, diluted net loss per common share is the same as basic net loss per common share for those periods. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Diluted
earnings per share is computed using the more dilutive of (i)&nbsp;the two-class method, or (ii)&nbsp;the if-converted method. The Company allocates earnings first to preferred
shareholders based on dividend rights and then to common and preferred shareholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted
earnings (loss) gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants, convertible redeemable preferred stock and the
potential issuance of stock upon the conversion of the Company's convertible notes. Common stock equivalent shares are excluded from the computation of diluted earnings (loss) per share if their
effect is antidilutive. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Recently Issued Accounting Pronouncements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In July 2013, the Financial Accounting Standards Board ("FASB") issued ASU No.&nbsp;2013-11, </FONT><FONT SIZE=2><I>Presentation of an Unrecognized
Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exist.</I></FONT><FONT SIZE=2> ASU&nbsp;2013-11 amends the presentation requirements of
ASC&nbsp;740 and requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, similar tax loss, or a
tax credit carryforward. To the extent the tax benefit is not available at the reporting date under the governing tax law or if the entity does not intend to use the deferred tax asset for such
purpose, the unrecognized tax benefit should be presented as a liability and not combined with deferred tax assets. This ASU is effective for annual periods, and interim periods within those years,
beginning after December&nbsp;15, 2013, which is fiscal 2014 for the Company. The amendments are to be applied to all unrecognized tax benefits that exist as of the effective date and may be applied
retrospectively to each prior reporting period presented. The adoption of ASU&nbsp;2013-11 did not have a material impact on the Company's financial position or results of operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-12</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=196,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=605504,FOLIO='F-12',FILE='DISK131:[15ZCN1.15ZCN74701]FM74701A.;10',USER='NDEWIND',CD='30-DEC-2015;17:57' -->
<A NAME="page_fm74701_1_13"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
May 2014, the FASB issued ASU No.&nbsp;2014-09, </FONT><FONT SIZE=2><I>Revenue from Contracts with Customers.</I></FONT><FONT SIZE=2> This ASU is a comprehensive new revenue recognition model that
requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or
services. This ASU is effective for annual reporting periods beginning after December&nbsp;15, 2016 and early adoption is not permitted. Accordingly, the Company will adopt this ASU on
January&nbsp;1, 2017. Management does not believe the adoption of this ASU will have a material impact on the Company's financial condition, results of operations or cash flows. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
June 2014, the FASB issued ASU No.&nbsp;2014-12, </FONT><FONT SIZE=2><I>Compensation&nbsp;&#151; Stock Compensation (Topic&nbsp;718): Accounting for Share-Based Payments When the Terms
of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period</I></FONT><FONT SIZE=2>. ASU&nbsp;2014-12 applies to all reporting entities that grant their
employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. That is the case when an
employee is eligible to retire or otherwise terminate employment before the end of the period in which a performance target (for example, an initial public offering or a profitability target) could be
achieved and still be eligible to vest in the award if and when the performance target is achieved. The standard is required to be adopted by public business entities in annual periods beginning on or
after December&nbsp;15, 2015 and interim periods within those annual periods. The
Company plans to implement this standard in the first quarter of fiscal year 2016 and is currently evaluating the potential impact of this new guidance on its financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
August 2014, the FASB issued ASU No.&nbsp;2014-15, </FONT><FONT SIZE=2><I>Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern.</I></FONT><FONT SIZE=2>
ASU&nbsp;2014-15 requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist that raise substantial doubt about an entity's ability
to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU&nbsp;2014-15 is effective for annual periods ending after
December&nbsp;15, 2016 and earlier application is permitted. The adoption of ASU&nbsp;2014-15 is not expected to have a material effect on the Company's financial statements or disclosures. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November 2014, the FASB issued ASU No.&nbsp;2014-16, </FONT><FONT SIZE=2><I>Derivatives and Hedging (Topic&nbsp;815)&nbsp;&#151; Determining Whether the Host Contract in a Hybrid
Financial Instrument Issued in the Form of a Share is More Akin to Debt or to Equity</I></FONT><FONT SIZE=2>. This ASU was issued to clarify how current U.S. generally accepted accounting principles
should be interpreted in evaluating the economic characteristics and risk of a host contract in a hybrid financial instrument that is issued in the form of a share. In addition, this ASU was issued to
clarify that in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (that is, the relative strength of the debt-like or equity-like terms
and features given the facts and circumstances) when considering how to weight those terms and features. The effects of initially adopting this ASU should be applied on a modified retrospective basis
to existing hybrid financial instruments issued in a form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all
relevant prior periods. This ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December&nbsp;15, 2015. Early adoption in an interim period is
permitted. The Company is currently evaluating the impact of the adoption of this ASU on its financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-13</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=197,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=770235,FOLIO='F-13',FILE='DISK131:[15ZCN1.15ZCN74701]FM74701A.;10',USER='NDEWIND',CD='30-DEC-2015;17:57' -->
<A NAME="page_fm74701_1_14"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


3. NET LOSS PER COMMON SHARE  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the
net loss attributable to common shareholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. Stock options, warrants,
convertible preferred stock and unvested restricted stock are considered to be potentially dilutive securities and are only included in the calculation of diluted net loss per share when their effect
is dilutive. For the twelve months ended December&nbsp;31, 2013 and December&nbsp;31, 2014, these securities were anti-dilutive due to the net losses in those periods and, therefore, the number of
shares used to compute basic and diluted earnings per share are the same for of those periods. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following table presents the computations of basic and dilutive net loss per share: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Years Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16,197</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,917</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Performance Adjustment of Series&nbsp;A</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12,239</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accruals of dividends and accretion to redemption value of preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,925</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(3,300</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss attributable to common shareholders&nbsp;&#151; basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(6,883</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(21,217</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average shares used in computing basic and diluted net loss per common share</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,697,044</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>933,997 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Basic and diluted net loss per common share</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(4.06</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(22.72</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact
due to losses reported (in common stock equivalent shares): </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Years Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock Options</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>229,791</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>281,029</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrants</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,170</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>18,809</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Redeemable convertible preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,552,820</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,552,820</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unvested restricted stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>55,298</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15,387</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-14</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=198,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=1030094,FOLIO='F-14',FILE='DISK131:[15ZCN1.15ZCN74701]FM74701A.;10',USER='NDEWIND',CD='30-DEC-2015;17:57' -->
<A NAME="page_fm74701_1_15"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


4. PREPAID EXPENSES AND OTHER CURRENT ASSETS  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
Prepaid expenses and other current assets consisted of the following: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other current assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>253</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Initial public offering costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>233</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Employee advances</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>33</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>33</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid development costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>656</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>710</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>527 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


5. PROPERTY AND EQUIPMENT  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
Property and equipment consisted of the following: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Machinery and equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>741</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>741</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Computers and office equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Furniture and fixtures</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>36</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>44</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leasehold improvements</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>606</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>606 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total property and equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,409</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,417</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less: accumulated deprecation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(716</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(903</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property and equipment, net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>693</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>514 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>Depreciation
expense related to property and equipment amounted to $169 and $187 for the years ended December&nbsp;31, 2013 and 2014, respectively. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


6. ACCRUED EXPENSES  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
Accrued expenses consisted of the following: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued development costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>520</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>970</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued compensation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>449</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>635</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued audit and legal</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>12</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>249</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued interest</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>71</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>32</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>31 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total accrued expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,956 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-15</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=199,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=847781,FOLIO='F-15',FILE='DISK131:[15ZCN1.15ZCN74701]FM74701A.;10',USER='NDEWIND',CD='30-DEC-2015;17:57' -->
<A NAME="page_fm74701_1_16"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. COMMITMENTS AND CONTINGENCIES  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Legal Proceedings  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>From time to time the Company may face legal claims or actions in the normal course of business. The Company is not currently a party to any
litigation and, accordingly, does not have any amounts recorded for any litigation related matters. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company's NDA filing for Xtampza is a 505(b)(2) application, which allows the Company to reference data from an approved drug listed in the FDA's Approved Drug Products with Therapeutic
Equivalence Evaluations (commonly known as the "Orange Book"), in this case OxyContin OP. In connection with the 505(b)(2) process, the Company certified to the FDA and notified Purdue
Pharma,&nbsp;L.P. ("Purdue"), as the holder of the NDA and any other Orange Book-listed patent owners, that the Company does not infringe any of the patents listed for OxyContin OP in the Orange
Book. Under the Hatch-Waxman Act of 1984 (the "Hatch-Waxman Act"), Purdue can elect to sue the Company for infringement, and if they do, receive a stay of up to 30&nbsp;months before the FDA can
issue a final approval for Xtampza, unless the stay is earlier terminated. Purdue has not yet brought such litigation, but it is possible that they will do so. At this time the Company is unable to
provide meaningful quantification of how this potential litigation may impact its future financial condition, results of operations, or cash flows. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Operating Leases  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company leases its office and research facility under a non-cancellable operating lease, which expires in December 2017. Terms of the agreement
provide for an initial two-month rent-free period and future rent escalation, and provide that in addition to minimum lease rental payments, the Company is responsible for a pro-rata share of
operating expenses and taxes. Aggregate minimum annual lease commitments of the Company under its non-cancellable operating lease as of December&nbsp;31, 2014 are as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="31pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:95pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Year Ending December&nbsp;31,

<!-- COMMAND=ADD_SCROPPEDRULE,95pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>106</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>111</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>116 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total minimum lease payments</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>333 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>Rent
expense under the operating lease agreement amounted to approximately $69 for the years ended December&nbsp;31, 2013 and 2014, respectively. In addition, the Company maintained a stand-by
letter of credit in connection with the Canton facility lease of $80 at December&nbsp;31, 2013 and December&nbsp;31, 2014. This amount is classified as restricted cash in the balance sheets. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
an inducement to enter into its Canton facility lease, the lessor agreed to provide the Company with an improvement allowance of up to $174 towards leasehold improvements. In addition the lessor
provided the Company with a reimbursable allowance of $164 which is to be amortized and repaid by the Company at an 8% interest rate over the initial term of 36&nbsp;months. Amounts provided by the
lessor related to tenant improvements are considered inducements to enter into the lease. The Company has recorded these costs in the balance sheet as leasehold improvements, with the corresponding
liabilities as deferred lease incentive and lease note payable. These liabilities are amortized on a straight-line basis over the term of the lease. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-16</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=200,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=920184,FOLIO='F-16',FILE='DISK131:[15ZCN1.15ZCN74701]FM74701A.;10',USER='NDEWIND',CD='30-DEC-2015;17:57' -->
<A NAME="page_fm74701_1_17"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. DEBT  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
On August&nbsp;28, 2012, the Company entered into a loan agreement ("Original Term Loan") with Silicon Valley Bank ("SVB") to borrow up to a maximum amount of $1,000. In August 2012, October 2012
and February 2013, the Company borrowed $250, $250 and $500, respectively. The Original Term Loan bore interest at a rate per annum of 2.25% above the prime rate fixed at the time of advance of the
Original Term Loan (5.50%). The Original Term Loan provided for interest-only payments for the first 12&nbsp;months based on the date of each borrowing, and, thereafter, 36&nbsp;monthly payments
of principal and interest. In connection with the Original Term Loan, the Company granted SVB a warrant to purchase 23,810 shares of common stock at an exercise price of $0.07 per share (See
Note&nbsp;9). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
January 2014, the Original Term Loan was amended ("Amendment No.&nbsp;1") to provide for the following; borrowings of up to $6,000, repayment in full of the Original Term Loan balance
outstanding, and an adjustment of the variable interest rate from 2.25% above the prime rate to 1.75% above the prime rate. In February 2014, the Company borrowed $2,000. The proceeds from the initial
borrowing were used to pay down the Original Term Loan balance outstanding resulting in the Company receiving $1,056. Borrowings under Amendment No.&nbsp;1 bore interest at a rate of 5.0%. Amendment
No.&nbsp;1 provided for interest-only payments for the first 12&nbsp;months based on the date of each borrowing, and thereafter, 36&nbsp;monthly payments of principal and interest. In connection
with Amendment No.&nbsp;1, the Company granted to SVB a warrant to purchase 14,430 shares of common stock with an exercise price of $0.05 per share (See Note&nbsp;9). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
August 2014 the Original Term Loan was further amended ("Amendment No.&nbsp;2") to provide for total borrowings of up to $8,000. In August 2014 and September 2014 the Company drew down $3,000 and
$3,000, respectively. Pursuant to Amendment No.&nbsp;2, interest-only payments are to be made for the first 12&nbsp;months based on the date of each borrowing; thereafter, 36&nbsp;monthly
payments of principal and interest are to be made.
Borrowings under Amendment 2 bear interest at the rate of 5.0%. The warrant agreement contains a performance clause that the Company met, resulting in additional financing extended and issuance of a
warrant to purchase 86,580 additional shares of common stock with an exercise price of $0.05 per share (See Note&nbsp;9). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
September 2014, the Original Term Loan was further amended ("Amendment No.&nbsp;3") to extend the loan draw period through the earlier to occur of September&nbsp;30, 2014 and an Event of
Default. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company capitalized deferred financing costs of approximately $38 in entering into the Original Term Loan, of which approximately $16 was repaid at the time of Amendment No.&nbsp;1 with the
remaining approximately $22 being amortized to interest expense over the term of the debt. The balance of deferred financing costs was approximately $15 and $7 at December&nbsp;31, 2013 and
December&nbsp;31, 2014 respectively. The total outstanding amount of the loans was $958 and $8,000 at December&nbsp;31, 2013 and December&nbsp;31, 2014 respectively. Interest expense on these
notes payable totaled $62 and $208 or the years ended December&nbsp;31, 2013 and December&nbsp;31, 2014. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
November and December of 2014 the Company entered into a Note Purchase Agreement (the "Bridge Notes") allowing for the issuance of $5,000 of convertible promissory notes to a group of investors
(the "Holders") bearing interest at a rate per annum of 6.0%. The Holders are related parties of the Company. All notes become due and payable at the earlier to occur of a qualified financing, a
deemed liquidation event and November 2015. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-17</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=201,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=995640,FOLIO='F-17',FILE='DISK131:[15ZCN1.15ZCN74701]FM74701A.;10',USER='NDEWIND',CD='30-DEC-2015;17:57' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_fo74701_1_18"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data)  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. DEBT (Continued)  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2014, future payments under the Company's debt agreements are as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2015</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6,194</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2016</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,667</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,667</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2018</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,479 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance as of December&nbsp;31, 2014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>13,007 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. WARRANTS  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
In November 2010, the Company issued to Comerica Bank a warrant to purchase 33,746 shares of a series of then outstanding preferred stock with an exercise price of $1.778 per share through
October&nbsp;28, 2017. In February 2012, all outstanding shares of Preferred Stock were converted to shares of Series&nbsp;A Preferred Stock. As such the warrant was amended to be exercisable into
33,746 shares of Series&nbsp;A Preferred Stock. In December 2013, a Performance Adjustment (See Note&nbsp;10) occurred, pursuant to which the Series&nbsp;A Preferred Stock and common stock were
subject to modification such that every two shares of issued and outstanding Series&nbsp;A Preferred Stock and common stock became one share of each class respectively, resulting in the warrant
being adjusted to represent the right to purchase 16,873 shares of Series&nbsp;A Preferred Stock. The shares of Series&nbsp;A Preferred Stock have certain mandatorily redeemable features resulting
in the warrant being recorded as a liability and re-measured at each period at fair value. The fair value of the warrant was </FONT><FONT SIZE=2><I>de minimis</I></FONT><FONT SIZE=2> at
December&nbsp;31, 2013 and December&nbsp;31, 2014. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
connection with the issuance of the Original Term Loan (See Note&nbsp;8), in August 2012, the Company issued to SVB a warrant to purchase 3,450 shares of common stock with an exercise price of
$0.48 per share through August&nbsp;27, 2022. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>This
Performance Adjustment resulted in the number of common shares issuable upon exercise of the warrant being adjusted to 1,725. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
connection with the execution of Amendment No.&nbsp;1 to the Original Term Loan in January 2014, the Company issued an additional warrant to the lending financial institution. In January 2014,
the Company issued a warrant to purchase 2,091 shares of common stock with an exercise price of $0.35 per share through January&nbsp;31, 2024. The warrant agreement provides for additional warrant
shares to be issued and immediately exercisable upon additional borrowings by the Company. Additional borrowings are contingent upon meeting certain performance measures for the Company's lead product
candidate. The Company met the performance measures and in August 2014 additional financing was extended. Based on the terms of the warrant agreement an additional 12,548 shares were granted. The fair
value of these warrants was </FONT><FONT SIZE=2><I>de&nbsp;minimis</I></FONT><FONT SIZE=2> at December&nbsp;31, 2013 and December&nbsp;31, 2014. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. EQUITY  </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>
As of December&nbsp;31, 2013, the authorized capital stock of the Company included 72,000,000 shares of common stock, par value $0.001 per share, 962,960 of which were issued and outstanding. As of
December&nbsp;31, 2013, 54,481,000 shares of preferred stock were authorized, designated as Series&nbsp;A, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-18</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=202,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=100958,FOLIO='F-18',FILE='DISK131:[15ZCN1.15ZCN74701]FO74701A.;11',USER='CHE108236',CD='29-DEC-2015;02:10' -->
<A NAME="page_fo74701_1_19"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. EQUITY (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Series&nbsp;B
and Series&nbsp;C Preferred Stock of which 9,232,334, 27,324,237 and 8,658,008 were issued and outstanding, respectively. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2014, the authorized capital stock of the Company included 72,000,000 shares of common stock, par value $0.001 per share, 1,006,219 of which were issued and outstanding. As
of December&nbsp;31, 2014, 54,481,000 shares of preferred stock were authorized, designated as Series&nbsp;A, Series&nbsp;B and Series&nbsp;C Preferred Stock of which 9,232,334, 27,324,237 and
8,658,008 were issued and outstanding, respectively. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Common Stock  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


General  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The voting, dividend and liquidation rights of the holders of shares of common stock are subject to and qualified by the rights, powers and
preferences of the holders of shares of preferred stock. Common stock has the characteristics described herein. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Voting  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The holders of shares of common stock are entitled to one vote for each share of common stock held, may act by written consent in lieu of
shareholder's meetings in accordance with the Company's articles of incorporation, and shall be entitled to notice of shareholder's meetings. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Dividends  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company shall not declare, pay or set aside any dividends on shares of common stock (other than dividends on shares of common stock payable in
shares of common stock) unless in addition to obtaining any consents required by law and/or the Company's articles of incorporation, the holders of Series&nbsp;A, Series&nbsp;B and Series&nbsp;C
Preferred Stock then outstanding receive a dividend payment as specified in the Company's articles of incorporation. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Liquidation  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>After payment of all preferential amounts required to be paid to the holders of shares of Preferred Stock, the remaining assets of the Company
available for distribution to the shareholders shall be distributed among the holders of shares of Preferred Stock and common stock pro rata based on the number of shares held by each such holder,
treating for this purpose all such securities as if they had been converted to common stock pursuant to the terms of the Company's articles of incorporation immediately prior to such dissolution,
liquidation or winding up or deemed liquidation event of the Company. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Reserved for future issuance  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company has reserved for future issuance the following number of shares of common stock: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="96pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of<BR>
December&nbsp;31, 2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Conversion of Series&nbsp;A Preferred</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>18,498,419</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Conversion of Series&nbsp;B Preferred</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>27,324,237</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Conversion of Series&nbsp;C Preferred</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8,658,344</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options to purchase common stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,412,685 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>57,893,685 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-19</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=203,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=724202,FOLIO='F-19',FILE='DISK131:[15ZCN1.15ZCN74701]FO74701A.;11',USER='CHE108236',CD='29-DEC-2015;02:10' -->
<A NAME="page_fo74701_1_20"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. EQUITY (Continued) </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Convertible Redeemable Preferred Stock  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Series&nbsp;A, B and Series&nbsp;C Redeemable Convertible Preferred Stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In February 2012, the Company exchanged all previously outstanding preferred stock into 18,464,674 shares of Series&nbsp;A Preferred Stock
("Series&nbsp;A"), par value $0.001. On the same date, the Company issued 27,324,237 shares of Series&nbsp;B Preferred Stock ("Series&nbsp;B"), par value $0.001 for $0.84 per share, which
resulted in gross proceeds of $20,050. Closing costs associated with the issuance of the Series&nbsp;B amounted to $147. These costs were recorded as a reduction of the carrying amount of the
Series&nbsp;B and are being accreted to the carrying value of the applicable preferred stock. During 2013, the Company issued 8,658,008 shares of Series&nbsp;C Preferred Stock ("Series&nbsp;C")
in exchange for $12,000 in a series of tranches. Costs incurred in connection with the issuance of Series&nbsp;C amounted to $45 and have been recorded as a reduction to the carrying amount of
Series&nbsp;C and were accreted to the carrying value of the applicable preferred stock. In accordance with the terms of the Series&nbsp;C Preferred Stock Purchase Agreement, the Company
authorized the sale and issuance of up to 8,658,008 shares of Series&nbsp;C for total gross proceeds of $12,000. Closing costs associated with the issuance of Series&nbsp;C amounted to $45. The
Series&nbsp;C financing was structured to close in two tranches. The Company determined the right of the investors to purchase shares of Series&nbsp;C in a future tranche met the definition of a
freestanding financial instrument and was recognized as a liability at fair value. The Company adjusted the carrying value of the tranche obligations to its estimated fair value at each reporting date
and upon closing of the second tranche in December 2013. Increases or decreases in the fair value of the tranche obligations were recorded as other expense, net, in the statements of operations. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
first tranche closed in August and September 2013 and resulted in the issuance of 2,886,004 shares of Series&nbsp;C for gross cash proceeds of $4,000. Upon the first tranche closing, the Company
recognized a liability of $266 for the fair value of the future tranche obligations. The fair value of the freestanding instrument tranche obligations was determined using Black-Scholes option-pricing
models on the date of the issuance using the
following assumptions: fair value of Series&nbsp;C of $1.30, expected life of 0.35 to 0.43&nbsp;years and expected volatility of 53% to 60%. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
liability related to the tranche obligations was remeasured at fair value up to the date of the closing of the second tranche in December 2013. Upon the closing of the second tranche, the Company
derecognized the tranche obligation, which resulted in a net increase in the proceeds allocated to the Series&nbsp;C shares of $345. The fair value of the freestanding instrument tranche obligations
was determined using Black-Scholes option-pricing models on the date of the issuance using the following assumptions: fair value of Series&nbsp;C of $1.27, expected life of 0.16&nbsp;years and
expected volatility of 52%. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-20</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=204,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=770706,FOLIO='F-20',FILE='DISK131:[15ZCN1.15ZCN74701]FO74701A.;11',USER='CHE108236',CD='29-DEC-2015;02:10' -->
<A NAME="page_fo74701_1_21"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. EQUITY (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
valuation of the tranche obligation liability was determined to be a Level&nbsp;3 valuation based upon the use of unobservable inputs. A roll-forward of the recurring fair value measurements of
the tranche liability categorized with Level&nbsp;3 inputs are as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance&nbsp;&#151; December&nbsp;31, 2012</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tranche liability upon issuance</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>266</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>79</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tranche liability upon close of tranche</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(345</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance&nbsp;&#151; December&nbsp;31, 2013</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
closing of the second tranche of Series&nbsp;C in December 2013 triggered the Performance Adjustment (described below) of the outstanding shares of Series&nbsp;A and common stock to which the
Series&nbsp;A and common stock were subject to modification in which every two shares of issued and outstanding Series&nbsp;A and common shares became one share of each class respectively. In
connection with the Performance Adjustment, the Company adjusted the carrying value of the outstanding shares of Series&nbsp;A to its redemption amount by recording a decrease of $12,239. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2014, the holders of Series&nbsp;A, Series&nbsp;B and Series&nbsp;C Preferred Stock had rights, preferences, privileges and restrictions as follows: </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Voting  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The holders of shares of Preferred Stock are entitled to the number of votes equal to the number of whole shares of common stock into which the shares
of the applicable series of Preferred Stock held by such holder are convertible as of the record date. Except as provided by law or otherwise, the holders of shares of Preferred Stock vote together
with the holders of shares of common stock as a single class. The holders of record of Series&nbsp;A exclusively and as a separate class are entitled to elect two directors of the Company. The
holders of record of Series&nbsp;B and Series&nbsp;C exclusively and as a separate class are entitled to elect one director, respectively, of the Company. The Company cannot amend, alter or repeal
the preferences, special rights or other powers of the Series&nbsp;A, Series&nbsp;B or Series&nbsp;C without the written consent or affirmative vote of not less than 66% of the then outstanding
shares of the respective class. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Dividends  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>From and after the issuance of any shares of Series&nbsp;A, Series&nbsp;B and Series&nbsp;C cumulative non-compounding stock, dividends will
accrue at a rate of 4.5%, 8.0% and 8.0% per annum respectively per share. In the event a dividend is declared on common stock, Series&nbsp;A, Series&nbsp;B and Series&nbsp;C will receive a
dividend equal to the equivalent number of common shares multiplied by the dividend payable on each class of stock. The Company has recorded cumulative accrued dividends for Series&nbsp;A,
Series&nbsp;B and Series&nbsp;C of $2,371, $5,307 and $1,114, respectively, as of December&nbsp;31, 2013 and 2014. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Conversion  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Each share of Series&nbsp;A, Series&nbsp;B and Series&nbsp;C is convertible at the option of the holder at any time into such number of fully
paid and nonassessable shares of common stock as is determined by dividing the original issue price of each Series by its conversion price of $8.46, $5.80 and $9.59 per share, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-21</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=205,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=286830,FOLIO='F-21',FILE='DISK131:[15ZCN1.15ZCN74701]FO74701A.;11',USER='CHE108236',CD='29-DEC-2015;02:10' -->
<A NAME="page_fo74701_1_22"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. EQUITY (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Conversion
is mandatory for all Series upon an IPO with gross proceeds in excess of $50,000 and a price per share of at least $20.70. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Special Mandatory Conversion  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any holder of at least 1,000,000 shares of Preferred Stock who does not participate in a Qualified Financing by purchasing such holder's applicable
portion of the shares of each Preferred Stock, within the time period specified by the Company, are automatically converted into shares of Common Stock at the applicable Conversion Price to that
series of Preferred Stock concurrently with the Qualified Financing. A Qualified Financing is a financing or series of financings after the issuance date of the Series&nbsp;C involving the sale of
additional shares of common stock (including pursuant to the conversion of debt) with gross proceeds of more than $1,000. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Liquidation Rights  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the affairs of the Company or a Deemed Liquidation Event, the
holders of Series&nbsp;B are entitled to be paid out an amount per share equal to two times the Series&nbsp;B original issue price of $5.80 plus unpaid accrued dividends. The holders of
Series&nbsp;A and Series&nbsp;C are entitled to be paid out an amount per share equal to one times the original issue price of $8.46 and $9.59, respectively, plus any unpaid accrued dividends.
After the payment of all preferential amounts required to be paid to the holders of the Preferred Stock, all the remaining assets of the Company shall be distributed among the holders of the common
and Preferred Stock pro rata based on the number of shares held. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Participation  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In the event of liquidation, payment to the holders of Series&nbsp;C shall precede payment to the holders of Series&nbsp;B, which shall precede
payment to the holders of Series&nbsp;A. Holders of Series&nbsp;C shall be paid at their Original Issuance Price plus any unpaid accrued dividends. In the event that the amount to be distributed
to the shareholders is in excess of the Series&nbsp;A, Series&nbsp;B and Series&nbsp;C liquidation preferences, the preferred holders shall participate on an as-converted basis with the common
stock holders in the distribution of the remaining assets. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Redemption  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company shall require a redemption of Series&nbsp;A, Series&nbsp;B and Series&nbsp;C in the event of a deemed liquidation event, including
(i)&nbsp;merger or consolidation, (ii)&nbsp;sale or transfer of substantially all of the Company's assets or (iii)&nbsp;sale or exchange or transfer by the Company's shareholders of a majority
of the voting power of the Company unless the requisite holders (as defined in the Company's articles of incorporation) elect otherwise. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>There
is an optional redemption feature on or after August&nbsp;27, 2019 for all series of Preferred Stock, upon a vote of at least 60% of the holders of the Preferred Stock voting as a single
class. The payment is equal to the original issuance price for Series&nbsp;A and Series&nbsp;C and two (2)&nbsp;times the original issuance price for Series&nbsp;B, plus unpaid accrued
dividends on the date of the redemption. Optional redemption shall be paid in three installments. </FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Protective Provision  </I></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>At any time when there are shares of Series&nbsp;B and Series&nbsp;C outstanding the Company will not engage in certain activities (including
enter into a liquidating event) without written consent of a majority of the Series&nbsp;B and Series&nbsp;C holders. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-22</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=206,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=267780,FOLIO='F-22',FILE='DISK131:[15ZCN1.15ZCN74701]FO74701A.;11',USER='CHE108236',CD='29-DEC-2015;02:10' -->
<A NAME="page_fo74701_1_23"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. EQUITY (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Performance Adjustment  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company's articles of incorporation provided that if the Company raised additional capital in excess of $4,000 after the initial closing of the
Series&nbsp;C financing, that such additional financing would trigger a one-time modification of the Series&nbsp;A and common stock shares (the "Performance Adjustment"), such that every two
shares of issued and outstanding Series&nbsp;A and common stock became one share of each class, respectively. The Performance Adjustment occurred in December 2013. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. STOCK-BASED COMPENSATION  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Restricted Stock Awards and Stock Options  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In July 2014, the Company adopted the 2014 Stock Incentive Plan (the "Plan"), under which 525,700 shares of common stock are authorized for issuance
to employees, officers, directors, consultants and advisors of the Company. As of December&nbsp;31, 2014, 281,029 of the shares of common stock authorized for issuance pursuant to the Plan were
outstanding. In connection with the Company's reincorporation into Virginia in July 2014, each outstanding option to purchase shares of common stock under the 2012 Stock Incentive Plan and 2002 Stock
Plan, was automatically terminated and replaced with an option to purchase shares of common stock under the Plan having the same vesting terms and exercise price as the option that was replaced. The
Plan provides for granting of both Internal Revenue Service qualified incentive stock options ("ISOs") and non-qualified options ("NQs"), restricted stock awards ("RSAs") and restricted stock units
("RSUs"). Stock options generally vest over a four year period of service; however, certain options contain performance conditions. The options generally have a ten year contractual life and, upon
termination, vested options are generally exercisable between one and three months following the termination date, while unvested options are forfeited immediately. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
determining the exercise prices for options granted, the board of directors considered the fair value of the common stock as of the measurement date. The fair value of the common stock was
determined by the board of directors based on a variety of factors, including valuations prepared by third parties, Company's financial position, the status of development efforts within the Company,
the composition and ability of the current scientific and management teams, the current climate in the marketplace, the illiquid nature of the Company's common stock, arm's length sales of the
Company's preferred stock, the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event, among others. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
connection with the Performance Adjustment which occurred on December&nbsp;4, 2013 (See Note&nbsp;10) the Company adjusted previously granted and then outstanding options such that for each
option exercised, the option holder would receive one share of common stock for every two shares of common stock underlying the grant. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-23</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=207,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=900766,FOLIO='F-23',FILE='DISK131:[15ZCN1.15ZCN74701]FO74701A.;11',USER='CHE108236',CD='29-DEC-2015;02:10' -->
<A NAME="page_fo74701_1_24"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. STOCK-BASED COMPENSATION (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Stock
option activity under the Plan is summarized as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="55pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="47pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number<BR>
of Options </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Weighted-<BR>
Average<BR>
Exercise<BR>
Price </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Weighted-<BR>
Average<BR>
Remaining<BR>
Contractual<BR>
Term<BR>
(in years) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Aggregate<BR>
Intrinsic<BR>
Value </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding at December&nbsp;31, 2012</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>323,488</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.73</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.94</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>146,730</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.48</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(1,077</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.62</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cancelled</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(9,559</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.76</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Modification</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(229,791</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding at December&nbsp;31, 2013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>229,791</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7.02</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>117</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>89,641</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(32,390</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2.21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cancelled</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(6,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4.42</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding at December&nbsp;31, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>281,029</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.69</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>7.49</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,505 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested and expected to vest at December&nbsp;31, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>247,139</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,293</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercisable at December&nbsp;31, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>121,304</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>570</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2013 and 2014, the unrecognized compensation cost related to outstanding options was $40 and $215, respectively, and is expected to be recognized as expense over
approximately 1.1&nbsp;years and 1.0&nbsp;years, respectively. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2014, the weighted average fair value of vested options was $1.93. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Additional
information about the Company's stock option activity is as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average grant date fair value per share of employee option grants</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.28</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.76</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-24</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=208,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=727691,FOLIO='F-24',FILE='DISK131:[15ZCN1.15ZCN74701]FO74701A.;11',USER='CHE108236',CD='29-DEC-2015;02:10' -->
<A NAME="page_fo74701_1_25"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. STOCK-BASED COMPENSATION (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Restricted
stock awards under the Plan are summarized as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="51pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="82pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Number of<BR>
Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Weighted-Average<BR>
Grant Date<BR>
Fair Value </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unvested at December&nbsp;31, 2012</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>203,342</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.62</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vesting of restricted stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(89,308</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.55</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Performance Adjustment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(58,736</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.62 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unvested at December&nbsp;31, 2013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>55,298</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.69</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Grant of restricted stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10,869</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.24</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vesting of restricted stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(50,780</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.62 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unvested at December&nbsp;31, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15,387</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.69 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2013 and 2014, the unrecognized compensation cost related to restricted stock awards was $73 and $26, respectively, and is expected to be recognized as expense over
approximately 1.2&nbsp;years and 0.2&nbsp;years, respectively. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Stock-Based Compensation Expense  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company granted stock options to employees for the years ended December&nbsp;31, 2013 and 2014. The Company estimates the fair value of stock
options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the fair value of the award. Stock options and restricted stock issued to non-board member,
non-employees are accounted for using the fair value approach and are subject to periodic revaluation over their vesting terms. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Stock-based
compensation for all stock options and restricted stock awards are reported within: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Years Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>24</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>12</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stock-based compensation expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>62</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>22 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="97pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="39pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=4 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Years Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.09%&nbsp;&#150; 1.22%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.80</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>87.8%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>77.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term (in years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.0%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-25</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=209,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=346569,FOLIO='F-25',FILE='DISK131:[15ZCN1.15ZCN74701]FO74701A.;11',USER='CHE108236',CD='29-DEC-2015;02:10' -->
<A NAME="page_fo74701_1_26"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. STOCK-BASED COMPENSATION (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Risk-free Interest Rate.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the stock option grants. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><I> Expected Volatility.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Due to the Company's limited operating history and lack of company-specific historical or
implied volatility, the expected volatility assumption is based on historical volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed
based on companies in the biotechnology and medical device industries. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Expected Term.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise
behavior, through December&nbsp;31, 2014 it determined the expected life assumption using the simplified method, which is an average of the contractual term of the option and its vesting period. In
2013, some of the stock option grants were in-the-money, based on the retrospective fair value determinations, so the Company determined the expected life using a risk-adjusted method, which adjusts
the average of the contractual term of the option and its vesting period for risk, thereby reducing the expected life. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><I> Expected Dividend Yield.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The expected dividend yield assumption is based on the fact that the Company has never paid cash dividends and has no present intention to
pay cash dividends. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


12. INCOME TAXES  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
For the years ended December&nbsp;31, 2014 and 2013, the Company did not record a current or deferred income tax expense or (benefit) due to current and historical losses incurred by the Company.
The Company's losses before income taxes consist solely of domestic losses. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A
reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="42pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Federal income tax (benefit) at statutory rate</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>34.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>34.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>(Increase) decrease income tax (benefit) resulting from:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expiration of state net operating losses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> (12.11</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Permanent items</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(0.01</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> (0.17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and experimental credits</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4.19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3.74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in valuation allowance</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> (26.07</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2> (37.57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Income tax expense (benefit)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-26</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=210,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=949382,FOLIO='F-26',FILE='DISK131:[15ZCN1.15ZCN74701]FO74701A.;11',USER='CHE108236',CD='29-DEC-2015;02:10' -->
<A NAME="page_fo74701_1_27"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


12. INCOME TAXES (Continued) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Deferred
taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company's
deferred tax assets and liabilities are comprised of the following: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2013 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax assets:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net operating loss carryforwards</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>21,392</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>28,419</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and amortization</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>36</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research Credits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>3,070 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax assets before valuation allowance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>23,792</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>31,525</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Valuation allowance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(23,788</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(31,525</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax liabilities:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and amortization</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net deferred tax assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. As of December&nbsp;31, 2014 and 2013, based on the Company's history of
operating losses, the Company has concluded that it is not more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation
allowance for deferred tax assets as of December&nbsp;31, 2014 and 2013. The valuation allowance increased $7,737 during the year ended December&nbsp;31, 2014, due primarily to net operating
losses generated. The valuation allowance increased by $5,081 during the year ended December&nbsp;31, 2013, due primarily to net operating losses generated. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>As
of December&nbsp;31, 2014 and 2013, the Company had U.S. federal net operating loss carryforwards of $78,276 and $60,380, respectively, which may be available to offset future income tax
liabilities and expire at various dates through 2034. As of December&nbsp;31, 2014 and 2013, the Company also had U.S. state net operating loss carryforwards of $34,184 and $16,354, respectively,
which may be available to offset future income tax liabilities and expire at various dates through 2034. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Utilization
of the NOL and research and development credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that have occurred or that could occur in
the future, as required by Section&nbsp;382 and Section&nbsp;383 of the Internal Revenue Code of 1986, as amended (the "Code"), as well as similar state and foreign provisions. These ownership
changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an
"ownership change" as defined by Section&nbsp;382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than
50&nbsp;percentage points of the outstanding stock of a company by certain shareholders. The Company has not completed a study to assess whether an ownership change has occurred or whether there
have been multiple ownership changes since its formation. The Company has not recorded net operating losses that, as a result of these restrictions, will expire unused. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-27</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=211,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=949558,FOLIO='F-27',FILE='DISK131:[15ZCN1.15ZCN74701]FO74701A.;11',USER='CHE108236',CD='29-DEC-2015;02:10' -->
<A NAME="page_fo74701_1_28"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


12. INCOME TAXES (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company files income tax returns in the United States and Massachusetts. The federal and Massachusetts income tax returns are generally subject to tax examinations for the tax years ended
December&nbsp;31, 2011 through December&nbsp;31, 2013. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon
examination by the Internal Revenue Service and state tax authorities to the extent utilized in a future period. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


13. EMPLOYEE BENEFITS  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
The Company has a retirement savings plan, which is qualified under section&nbsp;401(k) of the Code, for its employees. The plan allows eligible employees to defer, at the employee's discretion,
pretax compensation up to the Internal Revenue Service annual limits. Employees become eligible to participate after completing 3&nbsp;months of service. The Company is not required to contribute to
this plan. Total expense for contributions made by the Company was $31 for the year ended December&nbsp;31, 2013 and $35 for the year ended December&nbsp;31, 2014. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


14. SUBSEQUENT EVENTS  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
The Company has completed an evaluation of all subsequent events through April&nbsp;27, 2015, the date these financial statements are available to be issued. The Company has concluded that no
subsequent event has occurred that requires disclosure, except as noted below: </FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>In
March 2015, the Company sold 41,666,667 shares of Series&nbsp;D convertible preferred stock for aggregate consideration of $50,000, comprised of
$45,000 in cash and conversion of $5,000 in convertible notes with related parties. The convertible notes converted into 4,166,667 shares of Series&nbsp;D convertible preferred stock. The accrued
interest on the convertible notes was waived. In this financing, the mandatory conversion for all series of preferred stock was modified so as to occur upon an initial public offering with gross
proceeds in excess of $50,000.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>On
March&nbsp;24, 2015, Purdue sued the Company in the District of Delaware asserting infringement of four patents. On March&nbsp;26, 2015, Purdue filed
a second suit against the Company in the District of Massachusetts asserting infringement of the same four patents.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>In
March 2015, the Company granted a total of 638,095 stock options under the Plan to employees. The stock options were granted at fair market value on the
date of grant, vest over approximately four years and expire ten years from the date of grant.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(d)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>In
March 2015, the Plan was amended to increase the maximum number authorized for issuance pursuant to the Plan to 1,087,005 shares.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(e)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>In
March 2015, the Company amended its lease to include an additional 9,660 square feet of space for a total of 19,335 square feet. In addition, the lease
term was extended and now terminates on the date that is 5&nbsp;years following the date, which has not yet been determined, on which the landlord delivers the expansion space with certain
improvements substantially completed. At the Company's election, the lease term may be extended for an additional 5-year term. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-28</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=212,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=201056,FOLIO='F-28',FILE='DISK131:[15ZCN1.15ZCN74701]FO74701A.;11',USER='CHE108236',CD='29-DEC-2015;02:10' -->
<A NAME="page_fo74701_1_29"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (in thousands, except share and per share data) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


14. SUBSEQUENT EVENTS (Continued) </B></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(f)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>In
April 2015, the Company granted 194,694 shares of restricted stock to an employee. Pursuant to the grant, 97,347 shares vested upon grant, while the
remaining 97,347 shares of restricted stock vest in monthly installments over a three-year period commencing as of the date of grant.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>(g)</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2>In
April 2015, the Company's board of directors and shareholders approved a one-for-6.9 reverse split of the Company's common stock. All common stock share
and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse split of our common stock, including reclassifying an amount
equal to the reduction in par value to additional paid-in capital. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-29</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=213,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=414331,FOLIO='F-29',FILE='DISK131:[15ZCN1.15ZCN74701]FO74701A.;11',USER='CHE108236',CD='29-DEC-2015;02:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ga74701_1_30"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<A NAME="GA_CBS"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC.<BR>
CONDENSED BALANCE SHEETS<BR>
(unaudited)<BR>
(in thousands, except share and per share amounts)  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="68pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31,<BR>
2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>September&nbsp;30,<BR>
2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>Assets</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Current assets:</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Cash and cash equivalents</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,634</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">105,460</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Refundable PDUFA fee</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,335</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">527</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">866 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total current assets</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">4,496</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">106,326</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Property and equipment, net</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">514</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">627</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Restricted cash</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">80</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">97 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total assets</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,090</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">107,050 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>Liabilities, convertible redeemable preferred stock and shareholders' equity (deficit)</B></FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Current liabilities:</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Accounts payable</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,208</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">3,237</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Accrued expenses</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,956</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,681</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Current portion of deferred rent and lease note payable</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">59</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">15</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Current portion of term loan payable</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1,194</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">2,667</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Convertible bridge notes with related parties</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,000</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total current liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">10,417</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">8,600</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Lease incentive obligation</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">101</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">76</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Term loan payable, long-term</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">6,813</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">4,813 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total liabilities</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">17,331</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">13,489 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Commitments and contingencies (See Note&nbsp;9)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:9pt;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Series&nbsp;A convertible redeemable preferred stock, $0.001 par value; authorized shares&nbsp;&#151; 18,498,419 at December&nbsp;31, 2014
and none at September&nbsp;30, 2015; issued and outstanding shares&nbsp;&#151; 9,232,334 at December&nbsp;31, 2014 and none at September&nbsp;30, 2015; liquidation preference of $12,781 at December&nbsp;31, 2014 and none at September&nbsp;30,
2015</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
12,781</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><BR>
&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Series&nbsp;B convertible redeemable preferred stock, $0.001 par value; authorized shares&nbsp;&#151; 27,324,237 at December&nbsp;31, 2014 and none at
September&nbsp;30, 2015; issued and outstanding shares&nbsp;&#151; 27,324,237 at December&nbsp;31, 2014 and none at September&nbsp;30, 2015; liquidation preference of $51,212 at December&nbsp;31, 2014 and none at September&nbsp;30, 2015</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">51,212</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Series&nbsp;C convertible redeemable preferred stock, $0.001 par value; authorized shares&nbsp;&#151; 8,658,344 at December&nbsp;31, 2014 and none at
September&nbsp;30, 2015; issued and outstanding shares&nbsp;&#151; 8,658,008 at December&nbsp;31, 2014 and none at September&nbsp;30, 2015; liquidation preference of $13,114 at December&nbsp;31, 2014 and none at September&nbsp;30, 2015</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">13,114</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Series&nbsp;D convertible redeemable preferred stock, $0.001 par value; authorized shares&nbsp;&#151; none at December&nbsp;31, 2014 and
September&nbsp;30, 2015; issued and outstanding shares&nbsp;&#151; none at December&nbsp;31, 2014, September&nbsp;30, 2015; liquidation preference of none at December&nbsp;31, 2014 and September&nbsp;30, 2015</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Shareholders' equity (deficit):</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Common stock, $0.001 par value; authorized shares&nbsp;&#151; 72,000,000 at December&nbsp;31, 2014 and 100,000,000 at September&nbsp;30, 2015; issued and
outstanding shares&nbsp;&#151; 1,006,219 at December&nbsp;31, 2014, 20,687,829 at September&nbsp;30, 2015</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">1</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">20</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Additional paid-in capital</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">12,407</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">213,027</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Accumulated deficit</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(101,753</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(119,483</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Treasury stock</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(3</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total shareholders' equity (deficit)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">(89,348</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">93,561 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:12pt;text-indent:-12pt;"><FONT  style="font-size:8pt;line-height:9pt;"> </FONT><FONT  style="font-size:8pt;line-height:9pt;">Total liabilities, convertible redeemable preferred stock and shareholders' equity (deficit)</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">5,090</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">107,050 </FONT></TD>
<TD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"> <FONT SIZE=2>
See accompanying notes to the unaudited condensed financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-30</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=214,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=881938,FOLIO='F-30',FILE='DISK131:[15ZCN1.15ZCN74701]GA74701A.;8',USER='CHE105137',CD='29-DEC-2015;02:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_gc74701_1_31"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<A NAME="GC_CSO"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC.<BR>
CONDENSED STATEMENTS OF OPERATIONS<BR>
(unaudited)<BR>
(in thousands, except share and per share amounts)  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="63pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="73pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Nine months ended<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>12,652</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6,444</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,686</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>11,027 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>14,338</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>17,471 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(14,338</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,471</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other expense:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense, net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>110</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>350</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gain on extinguishment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(91</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other expense, net</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>110</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>259 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(14,448</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,730</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share&nbsp;&#151; basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(18.26</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.94</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average number of common shares used in net loss per share-basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>926,597</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>11,179,756 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"> <FONT SIZE=2>
See accompanying notes to the unaudited condensed financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-31</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=215,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=578231,FOLIO='F-31',FILE='DISK131:[15ZCN1.15ZCN74701]GC74701A.;8',USER='CHE105137',CD='29-DEC-2015;02:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ge74701_1_32"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<A NAME="GE_CFS"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC.<BR>
CONDENSED STATEMENTS OF CASH FLOWS<BR>
(unaudited)<BR>
(in thousands)  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Nine months ended<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Operating activities</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(14,448</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,730</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustments to reconcile net loss to net cash used in operating activities:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and amortization</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>141</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>130</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lease incentive</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(25</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(25</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock-based compensation expense</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>16</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,217</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non cash interest expense</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>6</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrual of back end fees related to note payable</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(12</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in operating assets and liabilities:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:31pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(139</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(338</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:31pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Refundable PDUFA fee</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,335</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:31pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,563</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>962</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:31pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,518</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>815 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in operating activities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(10,380</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(12,628</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Investing activities</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchases of property and equipment</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(175</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in investing activities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(175</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Financing activities</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from issuance of common stock, net of issuance costs of $2,408&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>72,029</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from issuance of Series&nbsp;D convertible redeemable preferred stock, net of issuance costs of $193</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>44,807</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>(Repayment of) borrowing from term note</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,044</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(619</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Repayment of lease note payable</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(46</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(44</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Restricted cash</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from the exercise of stock options</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>472 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by financing activities</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,007</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>116,629 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net increase (decrease) in cash and cash equivalents</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(3,373</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>103,826</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents at beginning of period</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7,551</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,634 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents at end of period</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,178</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>105,460 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:13pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Supplemental disclosure of non-cash activities</B></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Preferred stock conversion to common stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>120,302 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accruals of dividends and accretion to redemption value</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2,469</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>24,572 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Conversion of bridge note to preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5,000 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash paid for interest</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>46</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>260 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash paid for taxes</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:22pt;text-indent:-13pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Repayment of term note with proceeds of notes payable</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>944</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"> <FONT SIZE=2>
See accompanying notes to the unaudited condensed financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-32</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=216,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=86110,FOLIO='F-32',FILE='DISK131:[15ZCN1.15ZCN74701]GE74701A.;7',USER='CHE105137',CD='29-DEC-2015;02:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_gg74701_1_33"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="GG_FS"></A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO CONDENSED FINANCIAL STATEMENTS  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (unaudited, in thousands, except share and per share amounts)  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


1. NATURE OF BUSINESS  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
Collegium Pharmaceutical,&nbsp;Inc. (the "Company") was incorporated in Delaware in April 2002 and then reincorporated in Virginia in July 2014. The Company has its principal operations in Canton,
Massachusetts. The Company is a specialty pharmaceutical company developing and planning to commercialize next-generation abuse-deterrent products that incorporate the Company's patented
DETERx&reg; platform technology for the treatment of chronic pain and other diseases. The Company's lead product candidate, Xtampza&#153; ER, or Xtampza, is an abuse-deterrent,
extended-release, oral formulation of oxycodone, a widely prescribed opioid medication. Xtampza has received Fast Track status from the U.S. Food and Drug Administration ("FDA"). The Company's new
drug application ("NDA") filing for Xtampza was accepted by the FDA on February&nbsp;10, 2015. On February&nbsp;25, 2015, the FDA set a Prescription Drug User Fee Act, or PDUFA, goal date of
October&nbsp;12, 2015 for completion of its review of the Xtampza NDA. On November&nbsp;6, 2015, the FDA granted tentative approval to the Xtampza NDA for the management of pain severe enough to
require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. With a tentative approval, the FDA has determined that Xtampza meets the
required quality, safety and efficacy standards for approval but that it is subject to an automatic stay of up to 30&nbsp;months as a result of patent litigation filed by Purdue Pharma, L.P (Purdue)
in March 2015. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
Company's operations are subject to certain risks and uncertainties. The principal risks include negative outcome of clinical trials, inability or delay in completing clinical trials or obtaining
regulatory approvals, changing market conditions for products being developed by the Company, the need to retain key personnel and protect intellectual property, patent infringement litigation and the
availability of additional capital financing on terms acceptable to the Company. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Basis of presentation  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally
accepted in the United States ("GAAP") for interim financial reporting and as required by Regulation&nbsp;S-X, Rule&nbsp;10-01. Accordingly, they do not include all of the information and
footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair
presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the
reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating
results for the interim periods ended September&nbsp;30, 2015 and 2014 are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The
condensed interim financial statements should be read in conjunction with the audited financial statements and notes as of and for the year ended December&nbsp;31, 2014. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Initial Public Offering  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In May 2015, the Company closed an initial public offering ("IPO") of its common stock, which resulted in the sale of 6,670,000 shares of its common
stock at a public offering price of $12.00 per share, including 870,000 shares of common stock upon the exercise by the underwriters of their option to purchase additional shares at the public
offering price. The Company received proceeds from the IPO of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-33</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=217,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=479843,FOLIO='F-33',FILE='DISK131:[15ZCN1.15ZCN74701]GG74701A.;9',USER='CHE105137',CD='29-DEC-2015;02:10' -->
<A NAME="page_gg74701_1_34"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO CONDENSED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (unaudited, in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>approximately
$72,029, after deducting underwriting discounts, commissions and expenses payable by the Company. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
connection with preparing for the IPO, the Company's Board of Directors and shareholders approved a one-for-6.9 reverse stock split of the Company's common stock. The reverse stock split became
effective in April 2015. All share and per share amounts in the condensed interim financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to
this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. In connection with the closing of the IPO, all of the
Company's outstanding convertible preferred stock automatically converted to common stock in May 2015, resulting in an additional 12,591,456 shares of common stock of the Company becoming outstanding.
The significant increase in common stock outstanding in May 2015 is expected to impact the year-over-year comparability of the Company's net loss per share calculations in future periods. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Subsequent Events  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide
additional evidence relative to certain estimates or to identify matters that require additional disclosure. Through November&nbsp;12, 2015, the Company has concluded that no subsequent events have
occurred that require disclosure, except as described in Note&nbsp;9. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Critical Accounting Policies  </B></FONT></P>

<P style="font-family:arial;;margin-left:9.0pt;text-indent:-9.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->


Earnings (Loss) per Common Share  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Earnings (loss) per common share is calculated using the two-class method, which is an earnings allocation formula that determines earnings (loss) per
share for the holders of the Company's common shares and participating securities. All series of preferred stock contain participation rights in any dividend paid by the Company and are deemed to be
participating securities. Earnings available to common shareholders and participating convertible redeemable preferred shares is allocated first to the preferred stock based upon the distribution
criteria in the Company's Articles of Incorporation then the remainder to the common shareholders. The participating securities do not include a contractual obligation to share in losses of the
Company and are not included in the calculation of net loss per share in the periods that have a net loss. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Diluted
earnings per share is computed using the more dilutive of (a)&nbsp;the two-class method, or (b)&nbsp;the if-converted method. The Company allocates earnings first to preferred shareholders
based on dividend rights and then to common and preferred shareholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted earnings (loss)
gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants, convertible redeemable preferred stock and the potential issuance of stock upon the
conversion of the Company's convertible notes. Common stock equivalent shares are excluded from the computation of diluted earnings (loss) per share if their effect is antidilutive. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Recent Accounting Pronouncements  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In May 2014, the Financial Accounting Standards Board ("FASB"), issued Accounting Standards Update ("ASU"), No.&nbsp;2014-09, which amends the
guidance for accounting for revenue from contracts with </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-34</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=218,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=405017,FOLIO='F-34',FILE='DISK131:[15ZCN1.15ZCN74701]GG74701A.;9',USER='CHE105137',CD='29-DEC-2015;02:10' -->
<A NAME="page_gg74701_1_35"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO CONDENSED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (unaudited, in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>customers.
This ASU supersedes the revenue recognition requirements in Accounting Standards Codification ("ASC"), Topic 605, Revenue Recognition, and creates a new Topic 606, Revenue from Contracts
with Customers. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain practical expedients permitted; or retrospectively with the cumulative effect
of initially adopting the ASU recognized at the date of initial application. On August&nbsp;12, 2015, the FASB issued ASU No.&nbsp;2015-14, which defers the effective date of ASU
No.&nbsp;2014-09 by one year to December&nbsp;15, 2017 for annual reporting periods beginning after that date, including interim periods within those periods. The FASB also approved permitting
early adoption of the
standard, but not before the original effective date of December&nbsp;15, 2016. The Company has not yet determined which adoption method it will utilize or the effect that the adoption of this
guidance will have on its financial statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
July 2015, the FASB issued ASU No.&nbsp;2015-11, which amends existing guidance for measurement of inventory. Current inventory guidance requires an entity to measure inventory at the lower of
cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. The amendments do not apply to inventory that is measured
using last-in, first-out (LIFO) or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out or average cost. An
entity should measure all inventory to which the amendments apply at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of
business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The
amendments in the ASU No.&nbsp;2015-11 more closely align the measurement of inventory pursuant to GAAP with the measurement of inventory pursuant to International Financial Reporting Standards. The
amendments are effective for fiscal years beginning after December&nbsp;15, 2016, and interim periods within fiscal years beginning after December&nbsp;15, 2017. The amendments should be applied
prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company does not expect the adoption of this guidance to have a material impact on
its condensed financial statements. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


3. NET LOSS PER COMMON SHARE  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="73pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Nine months ended<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(14,448</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(17,730</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Extinguishment of preferred stock&nbsp;&#151; see note&nbsp;7</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>31,806</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion of prior preferred stock&nbsp;&#151; see note&nbsp;7</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(2,469</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(23,327</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accretion and dividends of Series&nbsp;D preferred stock</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(1,245</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss attributable to common shareholders&nbsp;&#151; basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(16,917</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(10,496</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average number of common shares used in net loss per share&nbsp;&#151; basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>926,597</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>11,179,756 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share&nbsp;&#151; basic and diluted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(18.26</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(0.94</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-35</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=219,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=771727,FOLIO='F-35',FILE='DISK131:[15ZCN1.15ZCN74701]GG74701A.;9',USER='CHE105137',CD='29-DEC-2015;02:10' -->
<A NAME="page_gg74701_1_36"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO CONDENSED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (unaudited, in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


3. NET LOSS PER COMMON SHARE (Continued) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>The
following potentially dilutive securities, which represent all outstanding potentially dilutive securities, were excluded from the calculation of diluted net loss per share due to their
anti-dilutive effect (in common stock equivalent shares): </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Nine months ended<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding stock options</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>311,365</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,356,246</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrants</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>18,810</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,445</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Redeemable convertible preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6,552,820</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unvested restricted stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>28,536</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>153,589</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


4. FAIR VALUE OF FINANCIAL INSTRUMENTS  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair
value hierarchy is now established that prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining
the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs: </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Level&nbsp;1 inputs&nbsp;&nbsp;&nbsp;&nbsp;Quoted prices in active markets for identical assets or liabilities </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Level&nbsp;2 inputs&nbsp;&nbsp;&nbsp;&nbsp;Inputs other than quoted prices included within Level&nbsp;1 that are observable for the asset or liability, either directly or indirectly </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Level&nbsp;3 inputs&nbsp;&nbsp;&nbsp;&nbsp;Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or
liability </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
following tables present the Company's financial instruments carried at fair value using the lowest level input applicable to each financial instrument at December&nbsp;31, 2014 and
September&nbsp;30, 2015. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="56pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="67pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="51pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="61pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:40pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Description

<!-- COMMAND=ADD_SCROPPEDRULE,40pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Total </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Quoted Prices<BR>
in active<BR>
markets<BR>
(Level&nbsp;1) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Significant<BR>
other<BR>
observable<BR>
inputs<BR>
(Level&nbsp;2) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Significant<BR>
unobservable<BR>
inputs<BR>
(Level&nbsp;3) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>December&nbsp;31, 2014</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Money market funds, included in cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>457</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>457</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>September&nbsp;30, 2015</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Money market funds, included in cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>104,911</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>104,911</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>The
Company's cash equivalents are comprised of money market funds that are measured on a recurring basis based on quoted market prices. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-36</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=220,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=66873,FOLIO='F-36',FILE='DISK131:[15ZCN1.15ZCN74701]GG74701A.;9',USER='CHE105137',CD='29-DEC-2015;02:10' -->
<A NAME="page_gg74701_1_37"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO CONDENSED FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B> (unaudited, in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


5. ACCRUED EXPENSES  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
Accrued expenses consisted of the following: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="68pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="70pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>December&nbsp;31,<BR>
2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>September&nbsp;30,<BR>
2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued compensation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>635</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,169</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued development costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>970</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>597</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued marketing</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>685</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued audit and legal</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>249</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>109</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued interest</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>71</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>90 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total accrued expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,956</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>2,681 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


6. CONVERTIBLE BRIDGE NOTE WITH RELATED PARTY  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
In November and December 2014, the Company entered into a Note Purchase Agreement (the "Bridge Notes") allowing for the issuance of $5,000 of convertible promissory notes to a group of investors (the
"Holders") bearing interest at a rate per annum of 6.0%. The Holders are related parties of the Company. In connection with the Series&nbsp;D convertible preferred stock financing (see
note&nbsp;7), the Bridge Notes converted into Series&nbsp;D convertible preferred stock. Upon the conversion, the Company recognized a gain on extinguishment of $91. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. CONVERTIBLE PREFERRED STOCK  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
In March 2015, the Company issued and sold an aggregate of 41,666,667 shares of Series&nbsp;D convertible preferred stock for aggregate consideration of $50,000, comprised of $45,000 in cash and
conversion of $5,000 in Bridge Notes. The accrued interest on the convertible notes was waived. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Concurrently
with the issuance of the Series&nbsp;D Preferred Stock, the Company amended and restated its Articles of Incorporation (the "Amended Articles"). The Company made certain amendments to
the terms of the Series&nbsp;A, Series&nbsp;B, and Series&nbsp;C Preferred Stock (together, the "Prior Preferred Stock"). Prior to the adoption of the Amended Articles, the Series&nbsp;A,
Series&nbsp;B, and Series&nbsp;C Preferred Stock accrued dividends at a rate of 4.5%, 8.0% and 8.0% per annum, respectively, per share. All accrued and unpaid dividends on the Prior Preferred
Stock were automatically cancelled and forfeited and the Prior Preferred Stock no longer accrued dividends. Prior to the cancellation and forfeiture of accrued dividends, the Prior Preferred Stock had
accrued dividends of $622 during 2015. The holders of outstanding shares of Prior Preferred Stock were entitled to receive dividends, when, as and if declared by the Board of Directors. The mandatory
conversion for all series of Prior Preferred Stock was modified so as to occur upon an initial public offering with gross proceeds in excess of $50,000. The amendments to the Prior Preferred Stock
were treated as an extinguishment which resulted in a gain on extinguishment of $31,806. The gain on extinguishment was added to net loss to arrive at income available to common shareholders in the
calculation of earnings per share. During the nine months ended September&nbsp;30, 2015, total accrued dividends and accretion for preferred stock was $24,572. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-37</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=221,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=921438,FOLIO='F-37',FILE='DISK131:[15ZCN1.15ZCN74701]GG74701A.;9',USER='CHE105137',CD='29-DEC-2015;02:10' -->
<A NAME="page_gg74701_1_38"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO CONDENSED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (unaudited, in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. CONVERTIBLE PREFERRED STOCK (Continued) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
connection with the closing of the IPO, all of the Company's outstanding convertible preferred stock automatically converted to common stock in May 2015, resulting in an additional 12,591,456
shares of common stock of the Company becoming outstanding. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. STOCK-BASED COMPENSATION  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
In July 2014, the Company adopted the 2014 Stock Incentive Plan (the "Plan"), under which 525,700 shares of common stock are authorized for issuance to employees, officers, directors, consultants and
advisors of the Company. In connection with the Company's reincorporation into Virginia in July 2014, each outstanding option to purchase shares of common stock under the Company's 2012 Stock
Incentive Plan and 2002 Stock Plan, was automatically terminated and replaced with an option to purchase shares of common stock under the Plan having the same vesting terms and exercise price as the
option that was replaced. The Plan provides for granting of both Internal Revenue Service qualified incentive stock options ("ISOs") and non-qualified options ("NQs"), restricted stock awards ("RSAs")
and restricted stock units ("RSUs"). Stock options generally vest over a four year period of service; however, certain options contain performance conditions. The options generally have a ten year
contractual life and, upon termination, vested options are generally exercisable between one and three months following the termination date, while unvested options are forfeited immediately. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>In
April 2015, the Plan was amended to increase the maximum number of shares of common stock that may be issued to 2,700,000 shares. In addition, an "evergreen provision" was added to the Plan that
allows for an annual increase in the number of shares of common stock available for issuance under the Plan. The annual increase will be added on the first day of each fiscal year beginning with the
fiscal year ending December&nbsp;31, 2016, and on each anniversary thereof until the expiration of the Plan equal to 4% of the outstanding shares of our common stock on
December&nbsp;31st&nbsp;of the immediately preceding fiscal year (or such lesser number of shares of common stock as determined by the board of directors). </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Restricted common stock  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A summary of the Company's restricted stock activity for the nine months ended September&nbsp;30, 2015 and related information is as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="53pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="82pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Weighted average<BR>
purchase price<BR>
per share </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unvested at December&nbsp;31, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15,387</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>0.69</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>194,694</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5.73</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>(128,955</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5.13 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unvested at September&nbsp;30, 2015<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>81,126</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>5.73 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Excludes
72,463 shares of unvested restricted stock remaining from the early exercise of stock options as of September&nbsp;30, 2015. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-38</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=222,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=92675,FOLIO='F-38',FILE='DISK131:[15ZCN1.15ZCN74701]GG74701A.;9',USER='CHE105137',CD='29-DEC-2015;02:10' -->
<A NAME="page_gg74701_1_39"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO CONDENSED FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B> (unaudited, in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. STOCK-BASED COMPENSATION (Continued) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Stock options  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>A summary of the Company's stock option activity and related information follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="59pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="65pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="54pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="49pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Shares </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Weighted-<BR>
average<BR>
exercise price<BR>
per share </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Weighted-<BR>
average<BR>
remaining<BR>
contractual<BR>
term<BR>
(years) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Aggregate<BR>
Intrinsic<BR>
Value </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding at December&nbsp;31, 2014</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>281,029</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.69</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,197,452</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.47</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(121,729</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.89</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cancelled</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>(506</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2.06</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding at September&nbsp;30, 2015</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,356,246</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9.04</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9.2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>17,722 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercisable at September&nbsp;30, 2015</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>208,438</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2.65</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>7.9</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4,056 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested and expected to vest at September&nbsp;30, 2015</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1,341,543</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9.13</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9.2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>18,595 </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

<P style="font-family:arial;"><FONT SIZE=2>The
fair value of each stock option is estimated on the grant date using the Black-Scholes option-pricing model using the following assumptions: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="24pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Nine months<BR>
ended<BR>
September&nbsp;30, </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2014 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2015 </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>77</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>77</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term (years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>6.21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. COMMITMENTS AND CONTINGENCIES  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
The Company's NDA filing for Xtampza is a 505(b)(2) application, which allows the Company to reference data from an approved drug listed in the FDA's Approved Drug Products with Therapeutic
Equivalence Evaluations (commonly known as the "Orange Book"), in this case OxyContin OP. In connection with the 505(b)(2) process, the Company certified to the FDA and notified Purdue
Pharma,&nbsp;L.P. ("Purdue"), as the holder of the NDA and any other Orange Book-listed patent owners, that the Company does not infringe any of the patents listed for OxyContin OP in the Orange
Book. Under the Hatch-Waxman Act of 1984 (the "Hatch-Waxman Act"), Purdue can elect to sue the Company for infringement, and if they do, receive a stay of up to 30&nbsp;months before the FDA can
issue a final approval for Xtampza, unless the stay is earlier terminated. On March&nbsp;24, 2015, Purdue sued the Company in the District of Delaware asserting infringement of four patents. On
March&nbsp;26, 2015, Purdue filed a
second suit against the Company in the District of Massachusetts asserting infringement of the same four patents. On July&nbsp;23, 2015, Purdue voluntarily dismissed the Massachusetts suit. On
August&nbsp;6, 2015, the Delaware court dismissed the suit in </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-39</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=223,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=420317,FOLIO='F-39',FILE='DISK131:[15ZCN1.15ZCN74701]GG74701A.;9',USER='CHE105137',CD='29-DEC-2015;02:10' -->
<A NAME="page_gg74701_1_40"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B><BR>
COLLEGIUM PHARMACEUTICAL,&nbsp;INC. </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> NOTES TO CONDENSED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B> (unaudited, in thousands, except share and per share amounts) </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. COMMITMENTS AND CONTINGENCIES (Continued) </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Delaware
and issued a memorandum opinion finding the Delaware court lacks personal jurisdiction over the Company Following the dismissal in Delaware, on August&nbsp;6, 2015, the Company filed a
complaint in the Southern District of New York asserting an action to obtain patent certainty, and requesting that the New York court find that Xtampza will not infringe any valid patent claim of the
patents asserted by Purdue in the Delaware action. Also on August&nbsp;6, 2015, Purdue sued the Company in the District of Massachusetts asserting the same claims as the prior suit. On
August&nbsp;7, 2015, Purdue filed a motion in the Delaware court requesting reconsideration of the August&nbsp;6, 2015 order that dismissed the case. In the motion requesting reconsideration,
Purdue asked that the Delaware court find that it does have personal jurisdiction over the Company and then transfer the case to the District of Massachusetts. On October&nbsp;7, 2015, the Delaware
court transferred the case to the District of Massachusetts. On November&nbsp;9, 2015, the Company filed a motion for summary judgment, for which it requested expedited hearing in Massachusetts. At
this time the Company is unable to provide meaningful quantification of how this litigation may impact its future financial condition, results of operations, or cash flows. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>In
March 2015, the Company amended its lease to include an additional 9,660 square feet of space for a total of 19,335 square feet. In addition, the lease term was extended and now terminates on the
date that is 5&nbsp;years following August 2015 which is the date that the landlord delivered the expansion space with certain improvements substantially completed. At the Company's election, the
lease term may be extended for an additional 5-year term. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>F-40</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=224,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=922488,FOLIO='F-40',FILE='DISK131:[15ZCN1.15ZCN74701]GG74701A.;9',USER='CHE105137',CD='29-DEC-2015;02:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>
<IMG SRC="g603081.jpg" ALT="LOGO" WIDTH="307" HEIGHT="66">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=5><B>Collegium Pharmaceutical,&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Common Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="28%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="28%" ALIGN="CENTER" >


 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B>PRELIMINARY PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=3><B>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="28%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="28%" ALIGN="CENTER" >


  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>Jefferies  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B> Piper Jaffray  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>William Blair  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B> Needham&nbsp;&amp; Company  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B> Janney Montgomery Scott  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016 </FONT></P>
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P style="font-family:arial;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=225,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=126605,FOLIO='blank',FILE='DISK131:[15ZCN1.15ZCN74701]HO74701A.;8',USER='CHE108234',CD='29-DEC-2015;02:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ja74701_1_1"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ja74701_part_ii_information_not_required_in_prospectus"> </A>
<A NAME="toc_ja74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PART II<BR>  INFORMATION NOT REQUIRED IN PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="ja74701_item_13._other_expense__ja701992"> </A>
<A NAME="toc_ja74701_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and Distribution.    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The following table sets forth all expenses, other than underwriting discounts and commissions, paid or payable by us in connection with this
offering. All amounts shown are estimates except for the SEC registration fee, the Financial Industry Regulatory Authority, or FINRA, filing fee and NASDAQ listing fee. </FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="CENTER" >
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="61pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Amount Paid<BR>
or to be Paid </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> SEC registration fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>8,686</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FINRA filing fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>13,438</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>NASDAQ listing fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Blue sky qualification fees and expenses, if any</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Printing and engraving expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounting fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Transfer agent and registrar fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Miscellaneous expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">

<DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">*</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">To
be completed by amendment. </FONT>


</DD></DL>


 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2><A
NAME="ja74701_item_14._indemnification_of_directors_and_officers."> </A>
<A NAME="toc_ja74701_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers.    <BR>    </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Virginia Stock Corporation Act  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We are a Virginia corporation. The Virginia Stock Corporation Act, or the VSCA, permits indemnification of a corporation's directors and officers in a
variety of circumstances, which may include indemnification for liabilities under the Securities Act. Sections&nbsp;13.1-696 and 13.1-704 of the VSCA generally authorize a Virginia corporation to
indemnify its directors and officers in civil or criminal actions if they acted in good faith and believed their conduct to be in the best interests of the corporation if acting in their official
capacity with the corporation or, in all other cases, at least not opposed to its best interests, and, in the case of criminal actions, had no reasonable cause to believe that the conduct was
unlawful. Additionally, Section&nbsp;13.1-704 of the VSCA provides that a Virginia corporation has the power to make any further indemnity to any director or officer, including in a proceeding
brought by or in the right of the corporation, if authorized by its articles of incorporation or any bylaw or resolution adopted by the shareholders, except an indemnity against his or her willful
misconduct or a knowing violation of the criminal law. Our amended and restated articles of incorporation require us to indemnify our directors and officers to the full extent permitted by the VSCA. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>Our
amended and restated articles of incorporation also provide that, to the full extent that the VSCA permits the limitation or elimination of the liability of directors and officers, no director or
officer of the Company shall be liable in any proceeding brought by or on behalf of the Company or its shareholders for monetary damages arising out of any transaction, occurrence or course of
conduct. Section&nbsp;13.1-692.1 of the VSCA permits the elimination of liability of directors and officers in any proceeding brought by or in the right of a corporation or brought by or on behalf
of shareholders of a corporation, except for liability resulting from such persons having engaged in willful misconduct or a knowing violation of the criminal law </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-1</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=226,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=512142,FOLIO='II-1',FILE='DISK131:[15ZCN1.15ZCN74701]JA74701A.;19',USER='CGONCE',CD='31-DEC-2015;12:26' -->
<A NAME="page_ja74701_1_2"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>or
any federal or state securities law, including, without limitation, any unlawful insider trading or manipulation of the market for any security. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
have entered into indemnification agreements with each of our directors and executive officers pursuant to which we agree to indemnify, including advancing expenses to, each of them against any
liabilities that he or she may incur as a result of his or her service as a director or officer of the Company to the fullest extent permitted by Virginia law and our amended and restated articles of
incorporation. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We
carry insurance on behalf of directors, officers, employees or agents that may cover liabilities under the Securities Act. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
form of underwriting agreement attached hereto as Exhibit&nbsp;1.1 provides for indemnification by the underwriters named in this registration statement of our executive officers, directors and
us, and by us of the underwriters named in the registration statement, for certain liabilities, including liabilities arising under the Securities Act, in connection with matters specifically provided
in writing for inclusion in this registration statement.  </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="ja74701_item_15._recent_sales_of_unregistered_securities."> </A>
<A NAME="toc_ja74701_4"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;Recent Sales of Unregistered Securities.    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>During the three years preceding the filing of this registration statement, we (since our reincorporation in Virginia in July 2014) and our
predecessor Delaware corporation (prior to such reincorporation), issued unregistered securities in the following transactions. None of these transactions involved underwriters, underwriting discounts
or commissions, or any public offering, and we believe that each transaction was exempt from the registration requirements of the Securities Act, as described below. </FONT></P>

<UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;(i)&nbsp;&nbsp;Issuances
of Common Stock </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> From May&nbsp;12, 2015 to September&nbsp;30, 2015, 6,170 shares of common
stock were acquired through the exercise of stock option awards granted prior to the completion of our initial public offering in May&nbsp;2015 under our equity incentive plan by certain employees,
prior to the effectiveness of our Registration Statement on Form&nbsp;S-8 filed on November&nbsp;2, 2015. The exercise price for the options ranged from $0.90 to $3.38, and the gross proceeds from
the exercises was approximately $13,000. These transactions were exempt from the registration requirements of the Securities Act in reliance upon Rule&nbsp;701 promulgated under the Securities Act. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In April 2015, we issued 194,694 shares of restricted common stock to Michael T.
Heffernan. Pursuant to the grant, 97,347 of the shares of restricted common stock vested upon grant while the remaining 97,347 shares of restricted common stock vest in monthly installments over a
three-year period commencing as of the date of the grant; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In connection with our reincorporation into Virginia in July 2014, each
outstanding share of common stock was converted into one share of common stock of the new Virginia corporation. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In connection with the closing of the second tranche of our Series&nbsp;C
Convertible Preferred Stock financing in December 2013, every two issued and outstanding shares of common stock were reclassified and combined into one share of common stock. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On June&nbsp;13, 2012, we issued 247,437 restricted shares of common stock,
which have since vested, to Michael T. Heffernan under the 2012 Stock Incentive Plan. </FONT></DD></DL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;(ii)&nbsp;&nbsp;Issuances
of Preferred Stock </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In March 2015, we issued 41,666,667 shares of our Series&nbsp;D Convertible
Preferred Stock to TPG Biotechnology Partners IV,&nbsp;L.P., RA Capital Healthcare Fund,&nbsp;LP, the Longitude Funds, Skyline Venture Partners V,&nbsp;L.P., Frazier Healthcare VI,&nbsp;L.P.,
the Boston Millennia Funds and certain other investors, at a purchase price of $1.20 per share, for an aggregate purchase price of approximately $50.0&nbsp;million. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-2</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=227,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=670101,FOLIO='II-2',FILE='DISK131:[15ZCN1.15ZCN74701]JA74701A.;19',USER='CGONCE',CD='31-DEC-2015;12:26' -->
<A NAME="page_ja74701_1_3"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In connection with our reincorporation into Virginia in July 2014, each
outstanding share of Series&nbsp;A Convertible Preferred Stock, Series&nbsp;B Convertible Preferred Stock and Series&nbsp;C Convertible Preferred Stock was converted into one share of
Series&nbsp;A Convertible Preferred Stock, Series&nbsp;B Convertible Preferred Stock and Series&nbsp;C Convertible Preferred Stock, respectively, of the new Virginia corporation. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In connection with the closing of the second tranche of our Series&nbsp;C
Convertible Preferred Stock financing in December 2013, every two issued and outstanding shares of Series&nbsp;A Convertible Preferred Stock were reclassified and combined into one share of
Series&nbsp;A Convertible Preferred Stock. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In December 2013, those investors who participated in the closings in August and
September 2013 exercised their option to purchase an additional pro rata portion of an aggregate of 5,772,004 shares of our Series&nbsp;C Convertible Preferred Stock, at a purchase price of $1.386
per share, for an aggregate purchase price of approximately $8&nbsp;million. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On August&nbsp;27, 2013, we issued 2,220,670 shares of our Series&nbsp;C
Convertible Preferred Stock to the Longitude Funds, Skyline Venture Partners V,&nbsp;L.P., Frazier Healthcare VI,&nbsp;L.P. and certain other existing investors in the Company, at a purchase price
of $1.386 per share, for an aggregate purchase price of approximately $3.1&nbsp;million, or the Initial Tranche&nbsp;1 Closing. On September&nbsp;25, 2013, we issued and sold an additional
665,334 shares of Series&nbsp;C Convertible Preferred Stock to certain of our investors, some of whom did not participate in the Initial Tranche&nbsp;1 Closing and who qualified as "accredited
investors" under Regulation&nbsp;D of the Securities Act, at a purchase price of $1.386 per share, for an aggregate purchase price of approximately $922,000, or the Additional Tranche&nbsp;1
Closing. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On February&nbsp;10, 2012, we issued an aggregate of 27,324,237 shares of
Series&nbsp;B Convertible Preferred Stock to the Longitude Funds, Skyline Venture Partners V,&nbsp;L.P., Frazier Healthcare&nbsp;VI,&nbsp;L.P., the Boston Millennia Funds and certain other
investors, at a purchase price of $0.84 per share, for an aggregate purchase price of approximately $23.0&nbsp;million. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On February&nbsp;10, 2012, in connection with our Series&nbsp;B Convertible
Preferred Stock financing, all issued and outstanding shares of previously issued Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock, Series&nbsp;C Preferred Stock, Series&nbsp;C-2
Preferred Stock and Series&nbsp;D-1 Preferred Stock were converted into shares of Series&nbsp;A Convertible Preferred Stock. In connection with this financing, we issued an aggregate of 18,464,674
shares of Series&nbsp;A Convertible Preferred Stock. </FONT></DD></DL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>(iii)&nbsp;&nbsp;Issuance
of Convertible Notes </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In November and December 2014, we entered into a Convertible Note Purchase
Agreement, pursuant to which we issued and sold to investors convertible promissory notes in the aggregate principal amount of $5&nbsp;million. The participants in the convertible note financing
described above included the Longitude Funds, Skyline Venture Partners V,&nbsp;L.P., Frazier Healthcare VI,&nbsp;L.P. and the Boston Millennia Funds. In connection with the Series&nbsp;D
Convertible Stock financing, convertible notes in the aggregate principal amount of $5&nbsp;million automatically converted to an aggregate of 4,166,667 shares of Series&nbsp;D Convertible
Preferred Stock. </FONT></DD></DL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;(iv)&nbsp;&nbsp;Stock
Option Grants </FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In March 2015, we granted options to purchase an aggregate of 638,095 shares of
our common stock with an exercise price of $5.73 per share to 24 employees and 1 director. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In connection with our reincorporation into Virginia in July 2014, each
outstanding option to purchase shares of common stock under the 2012 Stock Incentive Plan, as amended, and the Amended and Restated 2002 Stock Option Plan, as amended, was automatically terminated and
replaced with an option to purchase shares of common stock under the 2014 Stock Incentive Plan having the same vesting terms and exercise price as the option that was replaced. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-3</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=228,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=721674,FOLIO='II-3',FILE='DISK131:[15ZCN1.15ZCN74701]JA74701A.;19',USER='CGONCE',CD='31-DEC-2015;12:26' -->
<A NAME="page_ja74701_1_4"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On March&nbsp;5, 2014, we granted options to purchase an aggregate of 89,641
shares of our common stock with an exercise price of $0.28 per share to 16 employees. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On May&nbsp;30, 2013, we granted options to purchase an aggregate of 79,778
shares of our common stock with an exercise price of $0.48 per share to 2 employees. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On January&nbsp;24, 2013, we granted options to purchase an aggregate of
66,952 shares of our common stock with an exercise price of $0.48 per share to 14 employees. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On December&nbsp;20, 2012, we granted options to purchase an aggregate of 724
shares of our common stock with an exercise price of $0.48 per share to 1 employee. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On August&nbsp;16, 2012, we granted options to purchase 72,462 shares of our
common stock with an exercise price of $0.48 per share to 1 employee. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On May&nbsp;10, 2012, we granted options to purchase an aggregate of 39,275
shares of our common stock with an exercise price of $0.48 per share to 9 employees. </FONT></DD></DL>
<UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;(v)&nbsp;&nbsp;Warrants
</FONT></P>

</UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In connection with our reincorporation into Virginia in July 2014, each warrant
to purchase shares of Series&nbsp;A Convertible Preferred Stock and each warrant to purchase shares of our common stock was assumed by the new Virginia corporation. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT FACE="WINGDINGS" SIZE=2>&sect;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> On August&nbsp;28, 2012, in connection with the closing of the Original Term
Loan, we issued the First SVB Warrant, which warrant was immediately exercisable for 3,450 shares of our common stock at an exercise price of $0.48 per share. Pursuant to the December 2013 reverse
stock split, the number of shares underlying the First SVB Warrant was adjusted to 1,725 shares of common stock. On January&nbsp;31, 2014, in connection with the closing of Amendment No.&nbsp;1 to
the Original Term Loan, we issued the Second SVB Warrant, which warrant was immediately exercisable for 2,091 shares of our common stock at an exercise price of $0.35 per share. Pursuant to an
adjustment mechanism included in the Second SVB Warrant, the Second SVB Warrant automatically became exercisable for an additional 12,548 shares of our common stock. </FONT></DD></DL>

<P style="font-family:arial;"><FONT SIZE=2>We
believe these transactions, including the issuance of new securities in connection with our reincorporation in Virginia, were exempt from registration under the Securities Act in reliance upon
Section&nbsp;4(a)(2) of the Securities Act, or Regulation&nbsp;D promulgated thereunder, or Rule&nbsp;701 promulgated under Section&nbsp;3(b) of the Securities Act as transactions by an issuer
not involving any public offering or pursuant to benefit plans and contracts relating to compensation as provided under Rule&nbsp;701. The recipients of the securities in each of these transactions
represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the
stock certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about Collegium.  </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="ja74701_item_16._exhibits_and_financial_statement_schedules."> </A>
<A NAME="toc_ja74701_5"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits and Financial Statement Schedules.    <BR>    </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B>(a)&nbsp;&nbsp;&nbsp;Exhibits.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>See the Index to Exhibits attached to this registration statement, which is incorporated by reference herein. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><B>(b)&nbsp;&nbsp;&nbsp;Financial statement schedule.  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or notes. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="ja74701_item_17._undertakings."> </A>
<A NAME="toc_ja74701_6"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;17.&nbsp;&nbsp;&nbsp;&nbsp;Undertakings.    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of
the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-4</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=229,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=923103,FOLIO='II-4',FILE='DISK131:[15ZCN1.15ZCN74701]JA74701A.;19',USER='CGONCE',CD='31-DEC-2015;12:26' -->
<A NAME="page_ja74701_1_5"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>such
indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment
by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director,
officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit
to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>The
undersigned registrant hereby undertakes that: </FONT></P>

<UL>

<P style="font-family:arial;"><FONT SIZE=2>(1)&nbsp;&nbsp;For
purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in
reliance upon Rule&nbsp;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be
part of this registration statement as of the time it was declared effective. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>(2)&nbsp;&nbsp;For
the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </FONT><FONT SIZE=2><I>bona
fide</I></FONT><FONT SIZE=2> offering thereof. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-5</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=230,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=460959,FOLIO='II-5',FILE='DISK131:[15ZCN1.15ZCN74701]JA74701A.;19',USER='CGONCE',CD='31-DEC-2015;12:26' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_jc74701_1_6"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="jc74701_signatures"> </A>
<A NAME="toc_jc74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SIGNATURES    <BR>    </B></FONT></P>

<P style="font-family:arial;">


<FONT SIZE=2>Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Amendment No.&nbsp;1 to this Registration Statement
to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Canton, Commonwealth of Massachusetts, on the 4<SUP>th</SUP>&nbsp;day of January,&nbsp;2016.

 </FONT>

</P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="49%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="20pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="46%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:arial;"><FONT SIZE=2><B> COLLEGIUM PHARMACEUTICAL,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><BR><FONT SIZE=2>/s/&nbsp;MICHAEL T. HEFFERNAN, R.PH.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Michael T. Heffernan, R.Ph.<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>


Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment No.&nbsp;1 to this Registration Statement has been signed by the following persons in the capacities and on the
dates indicated below:

</FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="40pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="29%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="29%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="122pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:34pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,34pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:16pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Title


<!-- COMMAND=ADD_SCROPPEDRULE,16pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:17pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,17pt -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>/s/&nbsp;MICHAEL T. HEFFERNAN, R.PH.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Michael T. Heffernan, R.Ph.</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>President, Chief Executive Officer (Principal Executive Officer) and Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>January&nbsp;4, 2016</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>
*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Paul Brannelly</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>January&nbsp;4, 2016</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=5 ALIGN="CENTER" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Garen G. Bohlin</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>January&nbsp;4, 2016</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=5 ALIGN="CENTER" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> John G. Freund, M.D.</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>January&nbsp;4, 2016</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=5 ALIGN="CENTER" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Patrick Heron</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>January&nbsp;4, 2016</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=5 ALIGN="CENTER" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> David Hirsch, M.D., Ph.D.</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>January&nbsp;4, 2016</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=5 ALIGN="CENTER" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Eran Nadav, Ph.D.</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>January&nbsp;4, 2016</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-6</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=231,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=202838,FOLIO='II-6',FILE='DISK131:[15ZCN1.15ZCN74701]JC74701A.;13',USER='ALOEW',CD='29-DEC-2015;04:22' -->
<A NAME="page_jc74701_1_7"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="28pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="40pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="29%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="29%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="122pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD COLSPAN=5 ALIGN="CENTER" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>
*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Gino Santini</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>January&nbsp;4, 2016</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2> *</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:arial;"><BR><FONT SIZE=2>/s/&nbsp;MICHAEL T. HEFFERNAN, R.PH.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
<TD style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Name:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Michael T. Heffernan, R.Ph.</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Title:</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2><I> Attorney-in-Fact</I></FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-7</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=232,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=159020,FOLIO='II-7',FILE='DISK131:[15ZCN1.15ZCN74701]JC74701A.;13',USER='ALOEW',CD='29-DEC-2015;04:22' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ka74701_1_8"> </A>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ka74701_index_to_exhibits"> </A>
<A NAME="toc_ka74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  INDEX TO EXHIBITS    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="82pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Exhibit Number </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Exhibit Description </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 1.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Underwriting Agreement.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Agreement and Plan of Merger, dated July&nbsp;10, 2014, by and between Collegium Pharmaceutical,&nbsp;Inc., a Delaware corporation, and Collegium Pharmaceutical,&nbsp;Inc., a Virginia corporation.<SUP>(1)
</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Second Amended and Restated Articles of Incorporation of Collegium Pharmaceutical,&nbsp;Inc.<SUP>(2)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Amended and Restated Bylaws of Collegium Pharmaceutical,&nbsp;Inc.<SUP>(2)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Eighth Amended and Restated Investor Rights Agreement, dated March&nbsp;6, 2015, by and among Collegium Pharmaceutical,&nbsp;Inc. and certain of its shareholders.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Warrant to Purchase Stock, dated October&nbsp;28, 2010, issued by Collegium Pharmaceutical,&nbsp;Inc. to Comerica Bank.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Opinion of Pepper Hamilton&nbsp;LLP.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Office Lease Agreement, dated August&nbsp;28, 2012, by and between 780 Dedham Street Holdings,&nbsp;LLC and Collegium Pharmaceutical,&nbsp;Inc.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Loan and Security Agreement, dated August&nbsp;28, 2012, by and between Silicon Valley Bank and Collegium Pharmaceutical,&nbsp;Inc.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>First Amendment to Loan and Security Agreement, dated January&nbsp;31, 2014, by and between Silicon Valley Bank and Collegium Pharmaceutical,&nbsp;Inc.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Assumption and Second Amendment to Loan and Security Agreement, dated August&nbsp;12, 2014, by and between Silicon Valley Bank and Collegium Pharmaceutical,&nbsp;Inc.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Third Amendment to Loan and Security Agreement, dated September&nbsp;25, 2014, by and between Silicon Valley Bank and Collegium Pharmaceutical,&nbsp;Inc.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.6</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Fourth Amendment to Loan and Security Agreement, dated October&nbsp;31, 2014, by and between Silicon Valley Bank and Collegium Pharmaceutical,&nbsp;Inc.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.7</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Subordination Agreement, dated November&nbsp;14, 2014, by and among Collegium Pharmaceutical,&nbsp;Inc., Silicon Valley Bank and the creditors named therein.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.8</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Subordination Agreement, dated December&nbsp;2, 2014, by and among Collegium Pharmaceutical,&nbsp;Inc., Silicon Valley Bank and the creditors named therein.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.9</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Restricted Stock Award Agreement, dated June&nbsp;13, 2012, by and between Collegium Pharmaceutical,&nbsp;Inc. and Michael T. Heffernan.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.10</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Restricted Stock Award Agreement, dated July&nbsp;18, 2012, by and between Collegium Pharmaceutical,&nbsp;Inc. and Gino Santini.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.11</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Restricted Stock Award Agreement, dated March&nbsp;5, 2014, by and between Collegium Pharmaceutical,&nbsp;Inc. and Gino Santini.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.12</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Confidentiality and Inventions Agreement.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.13</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Offer Letter, dated January&nbsp;29, 2015, by and between Collegium Pharmaceutical,&nbsp;Inc. and Garen Bohlin.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.14</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Series&nbsp;D Convertible Preferred Stock Purchase Agreement, dated March&nbsp;6, 2015, by and among Collegium Pharmaceutical,&nbsp;Inc. and the purchasers thereto.<SUP>(1)</SUP></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-8</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=233,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=322432,FOLIO='II-8',FILE='DISK131:[15ZCN1.15ZCN74701]KA74701A.;15',USER='CGONCE',CD='31-DEC-2015;12:30' -->
<A NAME="page_ka74701_1_9"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:arial;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="82pt" style="font-family:arial;"></TD>
<TD WIDTH="18pt" style="font-family:arial;"></TD>
<TD WIDTH="" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Exhibit Number </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Exhibit Description </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2> 10.15</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>First Amendment to Lease, dated March&nbsp;24, 2015, by and between Park at 95,&nbsp;LLC (as successor in interest to 780 Dedham Street Holdings,&nbsp;LLC) and Collegium Pharmaceutical,&nbsp;Inc.<SUP>(1)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.16</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>2015 Employee Stock Purchase Plan.<SUP>(3)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.17</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Performance Bonus Plan.<SUP>(4)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.18(a)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Amended and Restated 2014 Stock Incentive Plan.<SUP>(3)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.18(b)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Incentive Stock Option Agreement under the Amended and Restated 2014 Stock Incentive Plan.<SUP>(3)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.18(c)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Non-Qualified Stock Option Agreement under the Amended and Restated 2014 Stock Incentive Plan.<SUP>(3)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.18(d)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Restricted Stock Award Agreement under the Amended and Restated 2014 Stock Incentive Plan.<SUP>(3)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.19</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Restricted Stock Award Agreement, dated April&nbsp;2, 2015, by and between Collegium Pharmaceutical,&nbsp;Inc. and Michael T. Heffernan.<SUP>(4)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.20</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Form of Indemnification Agreement.<SUP>(4)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.21</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Employment Agreement, dated August&nbsp;4, 2015, by and between Michael Heffernan and Collegium Pharmaceutical,&nbsp;Inc.<SUP>(5)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.22</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Employment Agreement, dated August&nbsp;4, 2015, by and between Paul Brannelly and Collegium Pharmaceutical,&nbsp;Inc.<SUP>(5)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.23</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Employment Agreement, dated August&nbsp;4, 2015, by and between Barry S. Duke and Collegium Pharmaceutical,&nbsp;Inc.<SUP>(6)</SUP></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.24</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Employment Agreement, dated August&nbsp;4, 2015, by and between Ernest&nbsp;A. Kopecky,&nbsp;Ph.D. and Collegium Pharmaceutical,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>10.25</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Employment Agreement, dated August&nbsp;4, 2015, by and between Douglas&nbsp;R. Carlson and Collegium Pharmaceutical,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>21.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Subsidiaries of Collegium Pharmaceutical, Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>23.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Consent of Grant Thornton&nbsp;LLP.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>23.2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Consent of Pepper Hamilton&nbsp;LLP (included in Exhibit&nbsp;5.1).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>24.1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>Power of Attorney (included on signature page of the Registration Statement (File No.&nbsp;333-208641) initially filed with the Commission on December&nbsp;18, 2015)<SUP>(7)</SUP></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>101.INS XBRL</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>Instance Document</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>101.SCH XBRL</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>Schema Document</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>101.CAL XBRL</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>Calculation Linkbase Document</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>101.LAB XBRL</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>Labels Linkbase Document</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>101.PRE XBRL</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>Presentation Linkbase Document</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>101.DEF XBRL</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>Definition Linkbase Document</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">&#134;</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Previously
filed.

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">+</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Indicates
management contract or compensatory plan.


<BR><BR></FONT></DD>



<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">*</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">To
be filed by amendment.

</FONT></DD>

</DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-9</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=234,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=140267,FOLIO='II-9',FILE='DISK131:[15ZCN1.15ZCN74701]KA74701A.;15',USER='CGONCE',CD='31-DEC-2015;12:30' -->
<A NAME="page_ka74701_1_10"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg74701a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(1)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Previously
filed as an exhibit to the registrant's Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-203208) filed with the Commission on
April&nbsp;2, 2015.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(2)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Previously
filed as an exhibit to the registrant's Current Report on Form&nbsp;8-K filed with the Commission on May&nbsp;12, 2015.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(3)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Previously
filed as an exhibit to the registrant's Registration Statement on Form&nbsp;S-8 (File No.&nbsp;333-207744) filed with the Commission on
November&nbsp;2, 2015.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(4)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Previously
filed as an exhibit to the registrant's Registration Statement on Form&nbsp;S-1/A (File No.&nbsp;333-203208) filed with the Commission on
April&nbsp;27, 2015.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(5)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Previously
filed as an exhibit to the registrant's Current Report on Form&nbsp;8-K filed with the Commission on August&nbsp;10, 2015.
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(6)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Previously
filed as an exhibit to the registrant's Quarterly Report on Form&nbsp;10-Q for the quarterly period ended June&nbsp;30, 2015 filed with the
Commission on August&nbsp;12, 2015.

<BR><BR></FONT></DD>

<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;">(7)</FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">Previously
filed as an exhibit to the registrant's Registration Statement on Form S-1 (File No. 333-208641) filed with the Commission on December&nbsp;18,
2015. </FONT>

</DD>

</DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>II-10</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=235,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="1",CHK=759174,FOLIO='II-10',FILE='DISK131:[15ZCN1.15ZCN74701]KA74701A.;15',USER='CGONCE',CD='31-DEC-2015;12:30' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>2
<FILENAME>a2226986zex-10_24.htm
<DESCRIPTION>EX-10.24
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.24</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">EMPLOYMENT AGREEMENT</font></u></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">THIS EMPLOYMENT AGREEMENT (the &#147;Agreement&#148;) is made by and between COLLEGIUM PHARMACEUTICAL,&nbsp;INC. (the &#147;<u>Company</u>&#148;) and Ernest Kopecky (the &#147;<u>Executive</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, the Company desires to continue to employ Executive on at at-will basis, and the Executives wishes to continue to be employed by the Company on at-will basis, on the terms and conditions set forth herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, the Company and the Executive are parties to an Employment Agreement dated May&nbsp;30, 2012 (the &#147;<u>Existing Agreement</u>&#148;); and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, the parties wish to enter into this Agreement to memorialize the terms of Executive&#146;s continued employment by the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW, THEREFORE, in consideration of the foregoing and intending to be bound hereby, the parties agree as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:37.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Duration of Agreement</u>.&#160; This Agreement is effective on the date it is fully executed (the &#147;<u>Effective Date</u>&#148;) and has no specific expiration date.&#160; Unless terminated by agreement of the parties, this Agreement will govern Executive&#146;s continued employment by the Company until that employment ceases.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Title; Duties</u>.&#160; Executive will be employed as the Company&#146;s Vice President, Clinical Development and Head, Neuroscience.&#160; Executive will devote his best efforts and substantially all of his business time and services to the Company and its affiliates to perform such duties as may be customarily incident to his position and as may reasonably be assigned to him from time to time.&#160; Executive shall report to such individual as designated by the Company.&#160; Executive will not, in any capacity, engage in other business activities or perform services for any other individual, firm or corporation without the prior written consent of the Company; <i>provided, however</i>, that without such consent, Executive may engage in charitable, non-profit and public service activities, so long as such activities do not in any respect interfere or conflict with Executive&#146;s performance of his duties and obligations to the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:37.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Place of Performance</u>.&#160; Executive will perform his services hereunder at the principal executive offices of the Company in Canton, Massachusetts; <i>provided, however,</i> that Executive may be required to travel from time to time for business purposes.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:37.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Compensation and Indemnification</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Base Salary</u>.&#160; Executive&#146;s annual salary will be $299,027 (the &#147;<u>Base Salary</u>&#148;), paid in accordance with the Company&#146;s payroll practices as in effect from time to time.&#160; The Base Salary will be reviewed annually by the Compensation Committee of the Company&#146;s Board of Directors (the &#147;<u>Committee</u>&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Annual Bonuses</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>For each fiscal year ending during his employment, Executive will be eligible to earn an annual bonus.&#160; The target amount of that bonus will be 30% percent of Executive&#146;s Base Salary for the applicable fiscal year.&#160; The actual bonus payable with respect to a particular year will be determined by the Committee, based on the achievement of corporate and /or individual performance objectives established by the Committee.&#160; Any bonus payable under this paragraph will be paid during the calendar year immediately following the fiscal year in respect of which the bonus is payable and, except</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=590162,FOLIO='',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KI_ZCN74702.CHC",USER="VSTEFAN",CD='Jan  1 04:06 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">as otherwise provided in <u>Section&nbsp;5.1.1</u>, will only be paid if Executive remains continuously employed by the Company through the actual bonus payment date.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>For purposes of determining any bonus payable to Executive, the measurement of corporate and individual performance will be performed by the Committee in good faith.&#160; From time to time, the Committee may, in its sole discretion, make adjustments to corporate or individual performance goals, so that required departures from the Company&#146;s operating budget, changes in accounting principles, acquisitions, dispositions, mergers, consolidations and other corporate transactions, and other factors influencing the achievement or calculation of such goals do not affect the operation of this provision in a manner inconsistent with its intended purposes.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Employee Benefits</u>.&#160; During Executive&#146;s employment, Executive will be eligible to participate in all employee benefit plans and programs made available by the Company from time to time to employees generally, subject to applicable plan terms and policies.&#160; The Company periodically reviews its benefits, policies, benefits providers and practices and may terminate, alter or change them at its discretion from time to time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Reimbursement of Expenses</u>.&#160; The Executive will be reimbursed by the Company for all reasonable business expenses incurred by Executive in accordance with the Company&#146;s customary expense reimbursement policies as in effect from time to time.&#160; Notwithstanding anything herein to the contrary, to the extent any expense, reimbursement or in-kind benefit provided to the Executive constitutes a &#147;deferral of compensation&#148; within the meaning of Section&nbsp;409A of the Internal Revenue Code (the &#147;<u>Code</u>&#148;) (i)&nbsp;the amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive must be incurred during the Executive&#146;s term of employment; (ii)&nbsp;the amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive in any other calendar year, (iii)&nbsp;the reimbursements for expenses for which the Executive is entitled to be reimbursed shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred and (iv)&nbsp;the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination</u>.&#160; Executive&#146;s employment with the Company may be terminated by the Company or Executive at any time and for any reason.&#160; Upon any cessation of his employment with the Company, Executive will be entitled only to such compensation and benefits as described in this <u>Section&nbsp;5</u>.&#160; Upon any cessation of his employment for any reason, unless otherwise requested by the Company, Executive agrees to resign immediately from all officer and director positions he then holds with the Company and its affiliates.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination without Cause or for Good Reason</u>.&#160; If Executive&#146;s employment by the Company ceases due to a termination by the Company without Cause (as defined below) or a resignation by Executive for Good Reason (as defined below), Executive will be entitled to:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>payment of any annual bonus otherwise payable (but for the cessation of Executive&#146;s employment) with respect to a year ended prior to the cessation of Executive&#146;s employment;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>continuation of Executive&#146;s Base Salary for a period equal to 6 months, payable in accordance with the Company&#146;s standard payroll practices; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="20747-2-KI_PB_2_234452_3701"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=107737,FOLIO='2',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KI_ZCN74702.CHC",USER="VSTEFAN",CD='Jan  1 04:06 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>waiver of the applicable premium otherwise payable for COBRA continuation coverage for Executive (and, to the extent covered immediately prior to the date of such cessation, his eligible dependents) for a period equal to 6 months.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except as otherwise provided in this <u>Section&nbsp;5.1</u>, and except for payment of all (i)&nbsp;accrued and unpaid Base Salary through the date of such cessation, (ii)&nbsp;any expense reimbursements to be paid in accordance with Company policy and (iii)&nbsp;payments for any accrued but unused paid time off in accordance with the Company&#146;s policies and applicable law, all compensation and benefits will cease at the time of such cessation and the Company will have no further liability or obligation by reason of such cessation.&#160; The payments and benefits described in this <u>Section&nbsp;5.1</u> are in lieu of, and not in addition to, any other severance arrangement maintained by the Company.&#160; Notwithstanding any provision of this Agreement, the payments and benefits described in <u>Section&nbsp;5.1</u> are conditioned on: (a)&nbsp;the Executive&#146;s execution and delivery to the Company and the expiration of all applicable statutory revocation periods, by the 45th day following the effective date of his cessation of employment, of a general release of claims against the Company and its affiliates in a form reasonably prescribed by the Company (the &#147;<u>Release</u>&#148;); and (b)&nbsp;the Executive&#146;s continued compliance with the Restrictive Covenants (as defined below).&#160; Subject to <u>Section&nbsp;5.4</u>, below, the benefits described in <u>Section&nbsp;5.1</u> will be paid or provided (or begin to be paid or provided) as soon as administratively practicable (or determinable in the case of the benefits described in <u>Section&nbsp;5.1.1</u>) after the Release becomes irrevocable, provided that if the 45 day period described above begins in one taxable year and ends in a second taxable year such payments or benefits shall not commence until the second taxable year.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination Following a Change in Control</u>.&#160; For cessations of employment described in <u>Section&nbsp;5.1</u> that occur during the twelve (12) month period immediately following the occurrence of a Change in Control (as defined below), the Executive will receive the payments and benefits described in <u>Section&nbsp;5.1</u> above, subject to the following modifications:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the references in <u>Sections 5.1.2 and 5.1.3</u> to &#147;6 months&#148; will each be replaced with a reference to &#147;9 months&#148;; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>all unvested restricted stock, stock options and other equity incentives awarded to Executive by the Company will become immediately and automatically fully vested and exercisable (as applicable).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Other Terminations</u>.&#160; If Executive&#146;s employment with the Company ceases for any reason other than as described in <u>Section&nbsp;5.1</u>, above (including but not limited to termination (i)&nbsp;by the Company for Cause, (ii)&nbsp;as a result of Executive&#146;s death, (iii)&nbsp;as a result of Executive&#146;s Disability or (d)&nbsp;by Executive without Good Reason, then the Company&#146;s obligation to Executive will be limited solely to (a)&nbsp;accrued and unpaid Base Salary through the date of such cessation, (b)&nbsp;any expense reimbursements to be paid in accordance with Company policy and (c)&nbsp;payments for any accrued but unused paid time off in accordance with the Company&#146;s policies and applicable law.&#160; All compensation and benefits will cease at the time of such cessation and, except as otherwise provided by COBRA or this <u>Section&nbsp;5.3</u>, the Company will have no further liability or obligation by reason of such termination.&#160; The foregoing will not be construed to limit Executive&#146;s right to payment or reimbursement for claims incurred prior to the date of such termination under any insurance contract funding an employee benefit plan, policy or arrangement of the Company in accordance with the terms of such insurance contract.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Compliance with Section&nbsp;409A</u>.&#160; If the termination giving rise to the payments described in <u>Section&nbsp;5.1</u> is not a &#147;Separation from Service&#148; within the meaning of Treas. Reg. &#167; 1.409A-1(h)(1)&nbsp;(or any successor provision), then the amounts otherwise payable pursuant to that section will instead be deferred without interest and will not be paid until Executive experiences a Separation from</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="20747-2-KI_PB_3_234507_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=42843,FOLIO='3',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KI_ZCN74702.CHC",USER="VSTEFAN",CD='Jan  1 04:06 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Service.&#160; To the maximum extent permitted under Section&nbsp;409A of the Code and its corresponding regulations, the cash severance benefits payable under this Agreement are intended to meet the requirements of the short-term deferral exemption under Section&nbsp;409A of the Code and the &#147;separation pay exception&#148; under Treas. Reg. &#167;1.409A-1(b)(9)(iii).&#160; To the extent compliance with the requirements of Treas. Reg. &#167; 1.409A-3(i)(2)&nbsp;(or any successor provision) is necessary to avoid the application of an additional tax under Section&nbsp;409A of the Internal Revenue Code to payments due to Executive upon or following his Separation from Service, then notwithstanding any other provision of this Agreement (or any otherwise applicable plan, policy, agreement or arrangement), any such payments that are otherwise due within six months following Executive&#146;s Separation from Service (taking into account the preceding sentence of this paragraph) will be deferred without interest and paid to Executive in a lump sum immediately following that six month period.&#160; For purposes of the application of Treas. Reg. &#167; 1.409A-1(b)(4)(or any successor provision), each payment in a series of payments will be deemed a separate payment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>PPACA</u>.&#160; Notwithstanding anything in this Agreement to the contrary, the waiver in respect of COBRA premiums pursuant to this <u>Sections 5.1</u> and <u>5.2</u> shall cease to the extent required to avoid adverse consequences to the Company under the Patient Protection and Affordable Care Act of 2010 and regulations thereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Section&nbsp;280G</u>.&#160; If any payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise pursuant to or by reason of any other agreement, policy, plan, program or arrangement or the lapse or termination of any restriction on or the vesting or exercisability of any payment or benefit (each a &#147;<u>Payment</u>&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code (or any successor provision thereto) or to any similar tax imposed by state or local law (such tax or taxes are hereafter collectively referred to as the &#147;<u>Excise Tax</u>&#148;), then the aggregate amount of Payments payable to Executive shall be reduced to the aggregate amount of Payments that may be made to the Executive without incurring an excise tax (the &#147;<u>Safe-Harbor Amount</u>&#148;) in accordance with the immediately following sentence; <i>provided that</i> such reduction shall only be imposed if the aggregate after-tax value of the Payments retained by Executive (after giving effect to such reduction) is equal to or greater than the aggregate after-tax value (after giving effect to the Excise Tax) of the Payments to Executive without any such reduction.&#160; Any such reduction shall be made in the following order: (i)&nbsp;first, any future cash payments (if any) shall be reduced (if necessary, to zero); (ii)&nbsp;second, any current cash payments shall be reduced (if necessary, to zero); (iii)&nbsp;third, all non-cash payments (other than equity or equity derivative related payments) shall be reduced (if necessary, to zero); and (iv)&nbsp;fourth, all equity or equity derivative payments shall be reduced.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Definitions</u>.&#160; For purposes of this Agreement:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.7.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Cause</u>&#148; means (a)&nbsp;commission or conviction of any felony or any crime involving dishonesty; (b)&nbsp;commission of any fraud against the Company; (c)&nbsp;intentional and material damage to any material property of the Company; (d)&nbsp;Executive&#146;s material breach of any agreement with or duty owed to the Company or any of its affiliates (including, without limitation, Executive&#146;s material breach of any of the Restrictive Covenants, as defined below); or (e)&nbsp;refusal to perform the lawful, reasonable and material directives of the Company&#146;s Board of Directors (the &#147;<u>Board</u>&#148;) or the Company&#146;s Chief Executive Officer.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.7.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Change in Control</u>&#148; means the first to occur of any of the events described in Section&nbsp;1(g)&nbsp;of the Company&#146;s Amended and Restated 2014 Stock Incentive Plan (or any successor provision).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="20747-2-KI_PB_4_234548_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=614647,FOLIO='4',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KI_ZCN74702.CHC",USER="VSTEFAN",CD='Jan  1 04:06 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.7.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Disability</u>&#148; means a condition entitling the Executive to benefits under the Company&#146;s long term disability plan, policy or arrangement; <i>provided, however</i>, that if no such plan, policy or arrangement is then maintained by the Company and applicable to the Executive, &#147;<u>Disability</u>&#148; will mean the Executive&#146;s inability to perform his duties under this Agreement due to a mental or physical condition that can be expected to result in death or that can be expected to last (or has already lasted) for a continuous period of 90 days or more, or for 120 days in any 180 consecutive day period.&#160; Termination as a result of a Disability will not be construed as a termination by the Company &#147;without Cause.&#148;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.7.4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Good Reason</u>&#148; means any of the following, without the Executive&#146;s prior consent: (a)&nbsp;a diminution of the Executive&#146;s title below the rank of Vice President; (b)&nbsp;a reduction in Base Salary; or (c)&nbsp;the relocation of the Executive&#146;s primary place of employment to a location that is (i)&nbsp;more than 50 miles from the location of the Executive&#146;s permanent primary place of employment prior to such relocation and (ii)&nbsp;more than 50 miles from the location of the Executive&#146;s residence. However, none of the foregoing events or conditions will constitute Good Reason unless the Executive provides the Company with written objection to the event or condition within 30 days following the occurrence thereof, the Company does not reverse or otherwise cure the event or condition within 30 days of receiving that written objection, and the Executive resigns Executive&#146;s employment within 30 days following the expiration of that cure period. Notwithstanding the foregoing and for the avoidance of doubt, a diminution of the Executive&#146;s title as a result of Change in Control shall not constitute Good Reason.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:37.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Restrictive Covenants</u>.&#160; To induce the Company to enter into this Agreement and in recognition of the compensation to be paid to the Executive pursuant to <u>Sections 4 and 5</u> of this Agreement, the Executive agrees to be bound by the provisions of this <u>Section&nbsp;6</u> (the &#147;<u>Restrictive Covenants</u>&#148;). These Restrictive Covenants will apply without regard to whether any termination or cessation of the Executive&#146;s employment is initiated by the Company or the Executive, and without regard to the reason for that termination or cessation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Covenant Not To Compete</u>.&#160; The Executive covenants that, during his employment by the Company and for a period of 6 months following immediately thereafter (the &#147;<b>Restricted Period</b>&#148;), the Executive will not (except in his capacity as an employee or director of the Company) do any of the following, directly or indirectly:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>engage or participate in any Competing Business (as defined below) wherever the Company or its affiliates do business, do or plan to do business or sell or market their products or services;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>become interested in (as owner, stockholder, lender, partner, co-venturer, director, officer, employee, agent or consultant) any person, firm, corporation, association or other entity engaged in a Competing Business.&#160; Notwithstanding the foregoing, the Executive may hold up to 1% of the outstanding securities of any class of any publicly-traded securities of any company;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>influence or attempt to influence any employee, consultant, supplier, licensor, licensee, contractor, agent, strategic partner, distributor, customer or other person to terminate or modify any written or oral agreement, arrangement or course of dealing with the Company or any of its affiliates; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1.4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>solicit for employment or retention as an independent contractor (or arrange to have any other person or entity solicit for employment or retention) any person employed or retained by the Company or any of its affiliates.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="20747-2-KI_PB_5_234558_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=885258,FOLIO='5',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KI_ZCN74702.CHC",USER="VSTEFAN",CD='Jan  1 04:06 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Confidentiality</u>.&#160; The Executive recognizes and acknowledges that the Proprietary Information (as defined in below) is a valuable, special and unique asset of the business of the Company and its affiliates.&#160; As a result, both during the Term and thereafter, the Executive will not, without the prior written consent of the Company, for any reason divulge to any third-party or use for his own benefit, or for any purpose other than the exclusive benefit of the Company and its affiliates, any Proprietary Information.&#160; Notwithstanding the foregoing, if the Executive is compelled to disclose Proprietary Information by court order or other legal or regulatory process, to the extent permitted by applicable law, he shall promptly so notify the Company so that it may seek a protective order or other assurance that confidential treatment of such Proprietary Information shall be afforded, and the Executive shall reasonably cooperate with the Company and its affiliates in connection therewith.&#160; If the Executive is so obligated by court order or other legal process to disclose Proprietary Information it will disclose only the minimum amount of such Proprietary Information as is necessary for the Executive to comply with such court order or other legal process.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Property of the Company</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.3.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Proprietary Information</u>. All right, title and interest in and to Proprietary Information will be and remain the sole and exclusive property of the Company and its affiliates.&#160; The Executive will not remove from the Company&#146;s or its affiliates&#146; offices or premises any documents, records, notebooks, files, correspondence, reports, memoranda or similar materials of or containing Proprietary Information, or other materials or property of any kind belonging to the Company or its affiliates unless necessary or appropriate in the performance of his duties to the Company and its affiliates.&#160; If the Executive removes such materials or property in the performance of his duties, he will return such materials or property promptly after the removal has served its purpose.&#160; The Executive will not make, retain, remove and/or distribute any copies of any such materials or property, or divulge to any third person the nature of and/or contents of such materials or property, except to the extent necessary to satisfy contractual obligations of the Company or its affiliates or to perform his duties on behalf of the Company and its affiliates.&#160; Upon termination of the Executive&#146;s employment with the Company, he will leave with the Company and its affiliates or promptly return to the Company and its affiliates all originals and copies of such materials or property then in his possession.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.3.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Intellectual Property</u>.&#160; The Executive agrees that all the Intellectual Property (as defined below) will be considered &#147;works made for hire&#148; as that term is defined in Section&nbsp;101 of the Copyright Act (17 U.S.C. &#167; 101) and that all right, title and interest in such Intellectual Property will be the sole and exclusive property of the Company and its affiliates.&#160; To the extent that any of the Intellectual Property may not by law be considered a work made for hire, or to the extent that, notwithstanding the foregoing, the Executive retains any interest in the Intellectual Property, the Executive hereby irrevocably assigns and transfers to the Company and its affiliates any and all right, title, or interest that the Executive may now or in the future have in the Intellectual Property under patent, copyright, trade secret, trademark&#160; or other law, in perpetuity or for the longest period otherwise permitted by law, without the necessity of further consideration.&#160; The Company and its affiliates will be entitled to obtain and hold in its own name all copyrights, patents, trade secrets, trademarks and other similar registrations with respect to such Intellectual Property.&#160; The Executive further agrees to execute any and all documents and provide any further cooperation or assistance reasonably required by the Company, at the Company&#146;s expense,&#160; to perfect, maintain or otherwise protect its rights in the Intellectual Property.&#160; If the Company or its affiliates, as applicable, are unable after reasonable efforts to secure the Executive&#146;s signature, cooperation or assistance in accordance with the preceding sentence, whether because of the Executive&#146;s incapacity or any other reason whatsoever, the Executive hereby designates and appoints the Company, the appropriate affiliate, or their respective designee as the Executive&#146;s agent and attorney-in-fact, to act on his behalf, to execute and file documents and to do all other lawfully permitted acts necessary or desirable to perfect, maintain or otherwise protect the Company&#146;s or its affiliates&#146; rights</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="20747-2-KI_PB_6_234610_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=769269,FOLIO='6',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KI_ZCN74702.CHC",USER="VSTEFAN",CD='Jan  1 04:06 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">in the Intellectual Property.&#160; The Executive acknowledges and agrees that such appointment is coupled with an interest and is therefore irrevocable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Definitions</u>.&#160; For purposes of this Agreement:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.4.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Competing Business</u>&#148; means any person, firm, corporation, partnership, association or other entity engaged in developing, manufacturing, marketing, distributing or selling, directly or indirectly, pharmaceutical abuse-deterrent products or any other product for pain indications that directly competes with a product developed, manufactured, marketed, distributed or sold by the Company.&#160; A division, subsidiary or similar business unit of an entity that does not engage in the business activities described in this definition will not be considered a Competing Business even if another separate division, subsidiary or similar business unit does engage in such activities.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.4.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Intellectual Property</u>&#148; means (a)&nbsp;all inventions (whether patentable or unpatentable and whether or not reduced to practice), all improvements thereto, and all patents and patent applications claiming such inventions, (b)&nbsp;all trademarks, service marks, trade dress, logos, trade names, fictitious names, brand names, brand marks and corporate names, together with all translations, adaptations, derivations, and combinations thereof and including all goodwill associated therewith, and all applications, registrations, and renewals in connection therewith, (c)&nbsp;all copyrightable works, all copyrights, and all applications, registrations, and renewals in connection therewith, (d)&nbsp;all mask works and all applications, registrations, and renewals in connection therewith, (e)&nbsp;all trade secrets (including research and development, know-how, formulas, compositions, manufacturing and production processes and techniques, methodologies, technical data, designs, drawings and specifications), (f)&nbsp;all computer software (including data, source and object codes and related documentation), (g)&nbsp;all other proprietary rights, (h)&nbsp;all copies and tangible embodiments thereof (in whatever form or medium), or (i)&nbsp;similar intangible personal property which have been or are developed or created in whole or in part by the Executive (1)&nbsp;at any time and at any place while the Executive is employed by Company and which, in the case of any or all of the foregoing, are related to and used in connection with the business of the Company or its affiliates, or (2)&nbsp;as a result of tasks assigned to the Executive by the Company or its affiliates.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.4.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Proprietary Information</u>&#148; means any and all proprietary information developed or acquired by the Company or any of its subsidiaries or affiliates that has not been specifically authorized to be disclosed.&#160; Such Proprietary Information shall include, but shall not be limited to, the following items and information relating to the following items: (a)&nbsp;all intellectual property and proprietary rights of the Company (including, without limitation, the Intellectual Property), (b) computer codes and instructions, processing systems and techniques, inputs and outputs (regardless of the media on which stored or located) and hardware and software configurations, designs, architecture and interfaces, (c) business research, studies, procedures and costs, (d) financial data, (e) distribution methods, (f) marketing data, methods, plans and efforts, (g) the identities of actual and prospective suppliers, (h) the terms of contracts and agreements with, the needs and requirements of, and the Company&#146;s or its affiliates&#146; course of dealing with, actual or prospective suppliers, (i) personnel information, (j)&nbsp;customer and vendor credit information, and (k) information received from third parties subject to obligations of non-disclosure or non-use.&#160; Failure by the Company or its affiliates to mark any of the Proprietary Information as confidential or proprietary shall not affect its status as Proprietary Information.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Acknowledgements</u>.&#160; The Executive acknowledges that the Restrictive Covenants are reasonable and necessary to protect the legitimate interests of the Company and its affiliates, that the duration and geographic scope of the Restrictive Covenants are reasonable given the nature of this Agreement and the position the Executive holds within the Company, and that the Company would not</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="20747-2-KI_PB_7_234620_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=982539,FOLIO='7',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KI_ZCN74702.CHC",USER="VSTEFAN",CD='Jan  1 04:06 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">enter into this Agreement or otherwise employ or continue to employ the Executive unless the Executive agrees to be bound by the Restrictive Covenants set forth in this <u>Section&nbsp;6</u>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Remedies and Enforcement Upon Breach</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.6.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Specific Enforcement</u>. The Executive acknowledges that any breach by him, willfully or otherwise, of the Restrictive Covenants will cause continuing and irreparable injury to the Company or its affiliates for which monetary damages would not be an adequate remedy.&#160; The Executive shall not, in any action or proceeding to enforce any of the provisions of this Agreement, assert the claim or defense that such an adequate remedy at law exists.&#160; In the event of any such breach or threatened breach by the Executive of any of the Restrictive Covenants, the Company or its affiliates, as applicable, shall be entitled to injunctive or other similar equitable relief in any court, without any requirement that a bond or other security be posted, and this Agreement shall not in any way limit remedies of law or in equity otherwise available to the Company and its affiliates.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.6.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Judicial Modification</u>.&#160; If any court determines that any of the Restrictive Covenants, or any part thereof, is unenforceable because of the duration or geographical scope of such provision, such court shall have the power to modify such provision and, in its modified form, such provision shall then be enforceable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.6.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Enforceability</u>.&#160; If any court holds the Restrictive Covenants unenforceable by reason of their breadth or scope or otherwise, it is the intention of the parties hereto that such determination not bar or in any way affect the right of the Company and its affiliates to the relief provided above in the courts of any other jurisdiction within the geographic scope of such Restrictive Covenants.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.6.4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Disclosure of Restrictive Covenants</u>.&#160; The Executive agrees to disclose the existence and terms of the Restrictive Covenants to any employer that the Executive may work for during the Restricted Period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.6.5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Extension of Restricted Period</u>.&#160; If the Executive breaches <u>Section&nbsp;6.1 </u>in any respect, the restrictions contained in that section will be extended for a period equal to the period that the Executive was in breach.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:36.7pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Miscellaneous</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Other Agreements</u>.&#160; Executive represents and warrants to the Company that there are no restrictions, agreements or understandings whatsoever to which he is a party that would prevent or make unlawful his execution of this Agreement, that would be inconsistent or in conflict with this Agreement or Executive&#146;s obligations hereunder, or that would otherwise prevent, limit or impair the performance by Executive of his duties under this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Successors and Assigns</u>.&#160; The Company may assign this Agreement to any successor to its assets and business by means of liquidation, dissolution, sale of assets or otherwise.&#160; The duties of Executive hereunder are personal to Executive and may not be assigned by him.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Governing Law and Enforcement</u>.&#160; This Agreement will be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, without regard to the principles of conflicts of laws.&#160; Any legal proceeding arising out of or relating to this Agreement will be instituted in a state or federal court in the Commonwealth of Massachusetts, and Executive and the Company hereby consent to the personal and exclusive jurisdiction of such court(s)&nbsp;and hereby waive any</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="20747-2-KI_PB_8_234630_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=168533,FOLIO='8',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KI_ZCN74702.CHC",USER="VSTEFAN",CD='Jan  1 04:06 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">objection(s)&nbsp;that they may have to personal jurisdiction, the laying of venue of any such proceeding and any claim or defense of inconvenient forum.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Waivers</u>.&#160; The waiver by either party of any right hereunder or of any breach by the other party will not be deemed a waiver of any other right hereunder or of any other breach by the other party.&#160; No waiver will be deemed to have occurred unless set forth in a writing.&#160; No waiver will constitute a continuing waiver unless specifically stated, and any waiver will operate only as to the specific term or condition waived.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Severability</u>.&#160; Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law.&#160; However, if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provision, and this Agreement will be reformed, construed and enforced as though the invalid, illegal or unenforceable provision had never been herein contained.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Survival</u>.&#160; This Agreement will survive the cessation of Executive&#146;s employment to the extent necessary to fulfill the purposes and intent the Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notices</u>.&#160; Any notice or communication required or permitted under this Agreement will be made in writing and (a)&nbsp;sent by overnight courier, (b)&nbsp;mailed by overnight U.S. express mail, return receipt requested or (c)&nbsp;sent by telecopier.&#160; Any notice or communication to Executive will be sent to the address contained in his personnel file.&#160; Any notice or communication to the Company will be sent to the Company&#146;s principal executive offices, to the attention of its Chief Executive Officer.&#160; Notwithstanding the foregoing, either party may change the address for notices or communications hereunder by providing written notice to the other in the manner specified in this paragraph.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Entire Agreement; Amendments</u>.&#160; This Agreement contains the entire agreement and understanding of the parties hereto relating to the subject matter hereof, and merges and supersedes all prior and contemporaneous discussions, agreements and understandings of every nature relating to that subject matter (including, without limitation, the Existing Agreement).&#160; This Agreement may not be changed or modified, except by an agreement in writing signed by each of the parties hereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Withholding</u>.&#160; All payments (or transfers of property) to Executive will be subject to tax withholding to the extent required by applicable law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.10.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Section&nbsp;Headings</u>.&#160; The headings of sections and paragraphs of this Agreement are inserted for convenience only and will not in any way affect the meaning or construction of any provision of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.11.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Counterparts; Facsimile</u>.&#160; This Agreement may be executed in multiple counterparts (including by facsimile signature), each of which will be deemed to be an original, but all of which together will constitute but one and the same instrument. &#160;Counterparts may be delivered via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&lt;<b><i style="font-weight:bold;">remainder of page&nbsp;intentionally left blank; signature page&nbsp;follows</i></b>&gt;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="20747-2-KI_PB_9_234645_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=267352,FOLIO='9',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KI_ZCN74702.CHC",USER="VSTEFAN",CD='Jan  1 04:06 2016' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer, and Executive has executed this Agreement, on the date(s)&nbsp;indicated below.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COLLEGIUM   PHARMACEUTICAL,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: </font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Paul Brannelly</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: </font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Paul Brannelly</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title: </font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Financial Officer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: </font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">August&nbsp;4, 2015</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ERNEST   KOPECKY</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Ernest Kopecky</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: </font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">August&nbsp;3, 2015</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Signature Page to Employment Agreement</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="2",CHK=714349,FOLIO='',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KI_ZCN74702.CHC",USER="VSTEFAN",CD='Jan  1 04:06 2016' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>3
<FILENAME>a2226986zex-10_25.htm
<DESCRIPTION>EX-10.25
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.25</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">EMPLOYMENT AGREEMENT</font></u></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">THIS EMPLOYMENT AGREEMENT (the &#147;Agreement&#148;) is made by and between COLLEGIUM PHARMACEUTICAL,&nbsp;INC. (the &#147;<u>Company</u>&#148;) and Douglas Carlson (the &#147;<u>Executive</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, the Company desires to continue to employ Executive on at at-will basis, and the Executives wishes to continue to be employed by the Company on at-will basis, on the terms and conditions set forth herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, the Company and the Executive are parties to an Employment Agreement dated March&nbsp;13, 2013 (the &#147;<u>Existing Agreement</u>&#148;); and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, the parties wish to enter into this Agreement to memorialize the terms of Executive&#146;s continued employment by the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW, THEREFORE, in consideration of the foregoing and intending to be bound hereby, the parties agree as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:37.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Duration of Agreement</u>.&#160; This Agreement is effective on the date it is fully executed (the &#147;<u>Effective Date</u>&#148;) and has no specific expiration date.&#160; Unless terminated by agreement of the parties, this Agreement will govern Executive&#146;s continued employment by the Company until that employment ceases.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Title; Duties</u>.&#160; Executive will be employed as the Company&#146;s Vice President, Corporate Development.&#160; Executive will devote his best efforts and substantially all of his business time and services to the Company and its affiliates to perform such duties as may be customarily incident to his position and as may reasonably be assigned to him from time to time.&#160; Executive shall report to such individual as designated by the Company.&#160; Executive will not, in any capacity, engage in other business activities or perform services for any other individual, firm or corporation without the prior written consent of the Company; <i>provided, however</i>, that without such consent, Executive may engage in charitable, non-profit and public service activities, so long as such activities do not in any respect interfere or conflict with Executive&#146;s performance of his duties and obligations to the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:37.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Place of Performance</u>.&#160; Executive will perform his services hereunder at the principal executive offices of the Company in Canton, Massachusetts; <i>provided, however,</i> that Executive may be required to travel from time to time for business purposes.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:37.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Compensation and Indemnification</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Base Salary</u>.&#160; Executive&#146;s annual salary will be $241,000 (the &#147;<u>Base Salary</u>&#148;), paid in accordance with the Company&#146;s payroll practices as in effect from time to time.&#160; The Base Salary will be reviewed annually by the Compensation Committee of the Company&#146;s Board of Directors (the &#147;<u>Committee</u>&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Annual Bonuses</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>For each fiscal year ending during his employment, Executive will be eligible to earn an annual bonus.&#160; The target amount of that bonus will be 30% percent of Executive&#146;s Base Salary for the applicable fiscal year.&#160; The actual bonus payable with respect to a particular year will be determined by the Committee, based on the achievement of corporate and /or individual performance objectives established by the Committee.&#160; Any bonus payable under this paragraph will be paid during the calendar year immediately following the fiscal year in respect of which the bonus is payable and, except</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="3",CHK=340039,FOLIO='',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KK_ZCN74702.CHC",USER="VSTEFAN",CD='Jan  1 04:08 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">as otherwise provided in <u>Section&nbsp;5.1.1</u>, will only be paid if Executive remains continuously employed by the Company through the actual bonus payment date.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>For purposes of determining any bonus payable to Executive, the measurement of corporate and individual performance will be performed by the Committee in good faith.&#160; From time to time, the Committee may, in its sole discretion, make adjustments to corporate or individual performance goals, so that required departures from the Company&#146;s operating budget, changes in accounting principles, acquisitions, dispositions, mergers, consolidations and other corporate transactions, and other factors influencing the achievement or calculation of such goals do not affect the operation of this provision in a manner inconsistent with its intended purposes.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Employee Benefits</u>.&#160; During Executive&#146;s employment, Executive will be eligible to participate in all employee benefit plans and programs made available by the Company from time to time to employees generally, subject to applicable plan terms and policies.&#160; The Company periodically reviews its benefits, policies, benefits providers and practices and may terminate, alter or change them at its discretion from time to time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Reimbursement of Expenses</u>.&#160; The Executive will be reimbursed by the Company for all reasonable business expenses incurred by Executive in accordance with the Company&#146;s customary expense reimbursement policies as in effect from time to time.&#160; Notwithstanding anything herein to the contrary, to the extent any expense, reimbursement or in-kind benefit provided to the Executive constitutes a &#147;deferral of compensation&#148; within the meaning of Section&nbsp;409A of the Internal Revenue Code (the &#147;<u>Code</u>&#148;) (i)&nbsp;the amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive must be incurred during the Executive&#146;s term of employment; (ii)&nbsp;the amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive in any other calendar year, (iii)&nbsp;the reimbursements for expenses for which the Executive is entitled to be reimbursed shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred and (iv)&nbsp;the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination</u>.&#160; Executive&#146;s employment with the Company may be terminated by the Company or Executive at any time and for any reason.&#160; Upon any cessation of his employment with the Company, Executive will be entitled only to such compensation and benefits as described in this <u>Section&nbsp;5</u>.&#160; Upon any cessation of his employment for any reason, unless otherwise requested by the Company, Executive agrees to resign immediately from all officer and director positions he then holds with the Company and its affiliates.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination without Cause or for Good Reason</u>.&#160; If Executive&#146;s employment by the Company ceases due to a termination by the Company without Cause (as defined below) or a resignation by Executive for Good Reason (as defined below), Executive will be entitled to:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>payment of any annual bonus otherwise payable (but for the cessation of Executive&#146;s employment) with respect to a year ended prior to the cessation of Executive&#146;s employment;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>continuation of Executive&#146;s Base Salary for a period equal to 6 months, payable in accordance with the Company&#146;s standard payroll practices; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="20747-2-KK_PB_2_021452_9864"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="3",CHK=107737,FOLIO='2',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KK_ZCN74702.CHC",USER="VSTEFAN",CD='Jan  1 04:08 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>waiver of the applicable premium otherwise payable for COBRA continuation coverage for Executive (and, to the extent covered immediately prior to the date of such cessation, his eligible dependents) for a period equal to 6 months.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except as otherwise provided in this <u>Section&nbsp;5.1</u>, and except for payment of all (i)&nbsp;accrued and unpaid Base Salary through the date of such cessation, (ii)&nbsp;any expense reimbursements to be paid in accordance with Company policy and (iii)&nbsp;payments for any accrued but unused paid time off in accordance with the Company&#146;s policies and applicable law, all compensation and benefits will cease at the time of such cessation and the Company will have no further liability or obligation by reason of such cessation.&#160; The payments and benefits described in this <u>Section&nbsp;5.1</u> are in lieu of, and not in addition to, any other severance arrangement maintained by the Company.&#160; Notwithstanding any provision of this Agreement, the payments and benefits described in <u>Section&nbsp;5.1</u> are conditioned on: (a)&nbsp;the Executive&#146;s execution and delivery to the Company and the expiration of all applicable statutory revocation periods, by the 45th day following the effective date of his cessation of employment, of a general release of claims against the Company and its affiliates in a form reasonably prescribed by the Company (the &#147;<u>Release</u>&#148;); and (b)&nbsp;the Executive&#146;s continued compliance with the Restrictive Covenants (as defined below).&#160; Subject to <u>Section&nbsp;5.4</u>, below, the benefits described in <u>Section&nbsp;5.1</u> will be paid or provided (or begin to be paid or provided) as soon as administratively practicable (or determinable in the case of the benefits described in <u>Section&nbsp;5.1.1</u>) after the Release becomes irrevocable, provided that if the 45 day period described above begins in one taxable year and ends in a second taxable year such payments or benefits shall not commence until the second taxable year.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination Following a Change in Control</u>.&#160; For cessations of employment described in <u>Section&nbsp;5.1</u> that occur during the twelve (12) month period immediately following the occurrence of a Change in Control (as defined below), the Executive will receive the payments and benefits described in <u>Section&nbsp;5.1</u> above, subject to the following modifications:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the references in <u>Sections 5.1.2 and 5.1.3</u> to &#147;6 months&#148; will each be replaced with a reference to &#147;9 months&#148;; and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>all unvested restricted stock, stock options and other equity incentives awarded to Executive by the Company will become immediately and automatically fully vested and exercisable (as applicable).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Other Terminations</u>.&#160; If Executive&#146;s employment with the Company ceases for any reason other than as described in <u>Section&nbsp;5.1</u>, above (including but not limited to termination (i)&nbsp;by the Company for Cause, (ii)&nbsp;as a result of Executive&#146;s death, (iii)&nbsp;as a result of Executive&#146;s Disability or (d)&nbsp;by Executive without Good Reason, then the Company&#146;s obligation to Executive will be limited solely to (a)&nbsp;accrued and unpaid Base Salary through the date of such cessation, (b)&nbsp;any expense reimbursements to be paid in accordance with Company policy and (c)&nbsp;payments for any accrued but unused paid time off in accordance with the Company&#146;s policies and applicable law.&#160; All compensation and benefits will cease at the time of such cessation and, except as otherwise provided by COBRA or this <u>Section&nbsp;5.3</u>, the Company will have no further liability or obligation by reason of such termination.&#160; The foregoing will not be construed to limit Executive&#146;s right to payment or reimbursement for claims incurred prior to the date of such termination under any insurance contract funding an employee benefit plan, policy or arrangement of the Company in accordance with the terms of such insurance contract.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Compliance with Section&nbsp;409A</u>.&#160; If the termination giving rise to the payments described in <u>Section&nbsp;5.1</u> is not a &#147;Separation from Service&#148; within the meaning of Treas. Reg. &#167; 1.409A-1(h)(1)&nbsp;(or any successor provision), then the amounts otherwise payable pursuant to that section will instead be deferred without interest and will not be paid until Executive experiences a Separation from</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="20747-2-KK_PB_3_021502_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="3",CHK=42843,FOLIO='3',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KK_ZCN74702.CHC",USER="VSTEFAN",CD='Jan  1 04:08 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Service.&#160; To the maximum extent permitted under Section&nbsp;409A of the Code and its corresponding regulations, the cash severance benefits payable under this Agreement are intended to meet the requirements of the short-term deferral exemption under Section&nbsp;409A of the Code and the &#147;separation pay exception&#148; under Treas. Reg. &#167;1.409A-1(b)(9)(iii).&#160; To the extent compliance with the requirements of Treas. Reg. &#167; 1.409A-3(i)(2)&nbsp;(or any successor provision) is necessary to avoid the application of an additional tax under Section&nbsp;409A of the Internal Revenue Code to payments due to Executive upon or following his Separation from Service, then notwithstanding any other provision of this Agreement (or any otherwise applicable plan, policy, agreement or arrangement), any such payments that are otherwise due within six months following Executive&#146;s Separation from Service (taking into account the preceding sentence of this paragraph) will be deferred without interest and paid to Executive in a lump sum immediately following that six month period.&#160; For purposes of the application of Treas. Reg. &#167; 1.409A-1(b)(4)(or any successor provision), each payment in a series of payments will be deemed a separate payment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>PPACA</u>.&#160; Notwithstanding anything in this Agreement to the contrary, the waiver in respect of COBRA premiums pursuant to this <u>Sections 5.1</u> and <u>5.2</u> shall cease to the extent required to avoid adverse consequences to the Company under the Patient Protection and Affordable Care Act of 2010 and regulations thereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Section&nbsp;280G</u>.&#160; If any payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise pursuant to or by reason of any other agreement, policy, plan, program or arrangement or the lapse or termination of any restriction on or the vesting or exercisability of any payment or benefit (each a &#147;<u>Payment</u>&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code (or any successor provision thereto) or to any similar tax imposed by state or local law (such tax or taxes are hereafter collectively referred to as the &#147;<u>Excise Tax</u>&#148;), then the aggregate amount of Payments payable to Executive shall be reduced to the aggregate amount of Payments that may be made to the Executive without incurring an excise tax (the &#147;<u>Safe-Harbor Amount</u>&#148;) in accordance with the immediately following sentence; <i>provided that</i> such reduction shall only be imposed if the aggregate after-tax value of the Payments retained by Executive (after giving effect to such reduction) is equal to or greater than the aggregate after-tax value (after giving effect to the Excise Tax) of the Payments to Executive without any such reduction.&#160; Any such reduction shall be made in the following order: (i)&nbsp;first, any future cash payments (if any) shall be reduced (if necessary, to zero); (ii)&nbsp;second, any current cash payments shall be reduced (if necessary, to zero); (iii)&nbsp;third, all non-cash payments (other than equity or equity derivative related payments) shall be reduced (if necessary, to zero); and (iv)&nbsp;fourth, all equity or equity derivative payments shall be reduced.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Definitions</u>.&#160; For purposes of this Agreement:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.7.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Cause</u>&#148; means (a) commission or conviction of any felony or any crime involving dishonesty; (b) commission of any fraud against the Company; (c)&nbsp;intentional and material damage to any material property of the Company; (d) Executive&#146;s material breach of any agreement with or duty owed to the Company or any of its affiliates (including, without limitation, Executive&#146;s material breach of any of the Restrictive Covenants, as defined below); or (e) refusal to perform the lawful, reasonable and material directives of the Company&#146;s Board of Directors (the &#147;<u>Board</u>&#148;) or the Company&#146;s Chief Executive Officer.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.7.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Change in Control</u>&#148; means the first to occur of any of the events described in Section&nbsp;1(g)&nbsp;of the Company&#146;s Amended and Restated 2014 Stock Incentive Plan (or any successor provision).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="20747-2-KK_PB_4_021511_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="3",CHK=986787,FOLIO='4',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KK_ZCN74702.CHC",USER="VSTEFAN",CD='Jan  1 04:08 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.7.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Disability</u>&#148; means a condition entitling the Executive to benefits under the Company&#146;s long term disability plan, policy or arrangement; <i>provided, however</i>, that if no such plan, policy or arrangement is then maintained by the Company and applicable to the Executive, &#147;<u>Disability</u>&#148; will mean the Executive&#146;s inability to perform his duties under this Agreement due to a mental or physical condition that can be expected to result in death or that can be expected to last (or has already lasted) for a continuous period of 90 days or more, or for 120 days in any 180 consecutive day period.&#160; Termination as a result of a Disability will not be construed as a termination by the Company &#147;without Cause.&#148;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.7.4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Good Reason</u>&#148; means any of the following, without the Executive&#146;s prior consent: (a)&nbsp;a diminution of the Executive&#146;s title below the rank of Vice President; (b)&nbsp;a reduction in Base Salary; or (c)&nbsp;the relocation of the Executive&#146;s primary place of employment to a location that is (i)&nbsp;more than 50 miles from the location of the Executive&#146;s permanent primary place of employment prior to such relocation and (ii)&nbsp;more than 50 miles from the location of the Executive&#146;s residence. However, none of the foregoing events or conditions will constitute Good Reason unless the Executive provides the Company with written objection to the event or condition within 30 days following the occurrence thereof, the Company does not reverse or otherwise cure the event or condition within 30 days of receiving that written objection, and the Executive resigns Executive&#146;s employment within 30 days following the expiration of that cure period. Notwithstanding the foregoing and for the avoidance of doubt, a diminution of the Executive&#146;s title as a result of Change in Control shall not constitute Good Reason.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:37.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Restrictive Covenants</u>.&#160; To induce the Company to enter into this Agreement and in recognition of the compensation to be paid to the Executive pursuant to <u>Sections 4 and 5</u> of this Agreement, the Executive agrees to be bound by the provisions of this <u>Section&nbsp;6</u> (the &#147;<u>Restrictive Covenants</u>&#148;). These Restrictive Covenants will apply without regard to whether any termination or cessation of the Executive&#146;s employment is initiated by the Company or the Executive, and without regard to the reason for that termination or cessation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Covenant Not To Compete</u>.&#160; The Executive covenants that, during his employment by the Company and for a period of 6 months following immediately thereafter (the &#147;<b>Restricted Period</b>&#148;), the Executive will not (except in his capacity as an employee or director of the Company) do any of the following, directly or indirectly:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>engage or participate in any Competing Business (as defined below) wherever the Company or its affiliates do business, do or plan to do business or sell or market their products or services;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>become interested in (as owner, stockholder, lender, partner, co-venturer, director, officer, employee, agent or consultant) any person, firm, corporation, association or other entity engaged in a Competing Business.&#160; Notwithstanding the foregoing, the Executive may hold up to 1% of the outstanding securities of any class of any publicly-traded securities of any company;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>influence or attempt to influence any employee, consultant, supplier, licensor, licensee, contractor, agent, strategic partner, distributor, customer or other person to terminate or modify any written or oral agreement, arrangement or course of dealing with the Company or any of its affiliates; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1.4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>solicit for employment or retention as an independent contractor (or arrange to have any other person or entity solicit for employment or retention) any person employed or retained by the Company or any of its affiliates.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="20747-2-KK_PB_5_021531_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="3",CHK=885258,FOLIO='5',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KK_ZCN74702.CHC",USER="VSTEFAN",CD='Jan  1 04:08 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Confidentiality</u>.&#160; The Executive recognizes and acknowledges that the Proprietary Information (as defined in below) is a valuable, special and unique asset of the business of the Company and its affiliates.&#160; As a result, both during the Term and thereafter, the Executive will not, without the prior written consent of the Company, for any reason divulge to any third-party or use for his own benefit, or for any purpose other than the exclusive benefit of the Company and its affiliates, any Proprietary Information.&#160; Notwithstanding the foregoing, if the Executive is compelled to disclose Proprietary Information by court order or other legal or regulatory process, to the extent permitted by applicable law, he shall promptly so notify the Company so that it may seek a protective order or other assurance that confidential treatment of such Proprietary Information shall be afforded, and the Executive shall reasonably cooperate with the Company and its affiliates in connection therewith.&#160; If the Executive is so obligated by court order or other legal process to disclose Proprietary Information it will disclose only the minimum amount of such Proprietary Information as is necessary for the Executive to comply with such court order or other legal process.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Property of the Company</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.3.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Proprietary Information</u>. All right, title and interest in and to Proprietary Information will be and remain the sole and exclusive property of the Company and its affiliates.&#160; The Executive will not remove from the Company&#146;s or its affiliates&#146; offices or premises any documents, records, notebooks, files, correspondence, reports, memoranda or similar materials of or containing Proprietary Information, or other materials or property of any kind belonging to the Company or its affiliates unless necessary or appropriate in the performance of his duties to the Company and its affiliates.&#160; If the Executive removes such materials or property in the performance of his duties, he will return such materials or property promptly after the removal has served its purpose.&#160; The Executive will not make, retain, remove and/or distribute any copies of any such materials or property, or divulge to any third person the nature of and/or contents of such materials or property, except to the extent necessary to satisfy contractual obligations of the Company or its affiliates or to perform his duties on behalf of the Company and its affiliates.&#160; Upon termination of the Executive&#146;s employment with the Company, he will leave with the Company and its affiliates or promptly return to the Company and its affiliates all originals and copies of such materials or property then in his possession.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.3.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Intellectual Property</u>.&#160; The Executive agrees that all the Intellectual Property (as defined below) will be considered &#147;works made for hire&#148; as that term is defined in Section&nbsp;101 of the Copyright Act (17 U.S.C. &#167; 101) and that all right, title and interest in such Intellectual Property will be the sole and exclusive property of the Company and its affiliates.&#160; To the extent that any of the Intellectual Property may not by law be considered a work made for hire, or to the extent that, notwithstanding the foregoing, the Executive retains any interest in the Intellectual Property, the Executive hereby irrevocably assigns and transfers to the Company and its affiliates any and all right, title, or interest that the Executive may now or in the future have in the Intellectual Property under patent, copyright, trade secret, trademark&#160; or other law, in perpetuity or for the longest period otherwise permitted by law, without the necessity of further consideration.&#160; The Company and its affiliates will be entitled to obtain and hold in its own name all copyrights, patents, trade secrets, trademarks and other similar registrations with respect to such Intellectual Property.&#160; The Executive further agrees to execute any and all documents and provide any further cooperation or assistance reasonably required by the Company, at the Company&#146;s expense,&#160; to perfect, maintain or otherwise protect its rights in the Intellectual Property.&#160; If the Company or its affiliates, as applicable, are unable after reasonable efforts to secure the Executive&#146;s signature, cooperation or assistance in accordance with the preceding sentence, whether because of the Executive&#146;s incapacity or any other reason whatsoever, the Executive hereby designates and appoints the Company, the appropriate affiliate, or their respective designee as the Executive&#146;s agent and attorney-in-fact, to act on his behalf, to execute and file documents and to do all other lawfully permitted acts necessary or desirable to perfect, maintain or otherwise protect the Company&#146;s or its affiliates&#146; rights</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="20747-2-KK_PB_6_021542_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="3",CHK=769269,FOLIO='6',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KK_ZCN74702.CHC",USER="VSTEFAN",CD='Jan  1 04:08 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">in the Intellectual Property.&#160; The Executive acknowledges and agrees that such appointment is coupled with an interest and is therefore irrevocable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Definitions</u>.&#160; For purposes of this Agreement:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.4.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Competing Business</u>&#148; means any person, firm, corporation, partnership, association or other entity engaged in developing, manufacturing, marketing, distributing or selling, directly or indirectly, pharmaceutical abuse-deterrent products or any other product for pain indications that directly competes with a product developed, manufactured, marketed, distributed or sold by the Company.&#160; A division, subsidiary or similar business unit of an entity that does not engage in the business activities described in this definition will not be considered a Competing Business even if another separate division, subsidiary or similar business unit does engage in such activities.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.4.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Intellectual Property</u>&#148; means (a)&nbsp;all inventions (whether patentable or unpatentable and whether or not reduced to practice), all improvements thereto, and all patents and patent applications claiming such inventions, (b)&nbsp;all trademarks, service marks, trade dress, logos, trade names, fictitious names, brand names, brand marks and corporate names, together with all translations, adaptations, derivations, and combinations thereof and including all goodwill associated therewith, and all applications, registrations, and renewals in connection therewith, (c)&nbsp;all copyrightable works, all copyrights, and all applications, registrations, and renewals in connection therewith, (d)&nbsp;all mask works and all applications, registrations, and renewals in connection therewith, (e)&nbsp;all trade secrets (including research and development, know-how, formulas, compositions, manufacturing and production processes and techniques, methodologies, technical data, designs, drawings and specifications), (f)&nbsp;all computer software (including data, source and object codes and related documentation), (g)&nbsp;all other proprietary rights, (h)&nbsp;all copies and tangible embodiments thereof (in whatever form or medium), or (i)&nbsp;similar intangible personal property which have been or are developed or created in whole or in part by the Executive (1)&nbsp;at any time and at any place while the Executive is employed by Company and which, in the case of any or all of the foregoing, are related to and used in connection with the business of the Company or its affiliates, or (2)&nbsp;as a result of tasks assigned to the Executive by the Company or its affiliates.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.4.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#147;<u>Proprietary Information</u>&#148; means any and all proprietary information developed or acquired by the Company or any of its subsidiaries or affiliates that has not been specifically authorized to be disclosed.&#160; Such Proprietary Information shall include, but shall not be limited to, the following items and information relating to the following items: (a)&nbsp;all intellectual property and proprietary rights of the Company (including, without limitation, the Intellectual Property), (b) computer codes and instructions, processing systems and techniques, inputs and outputs (regardless of the media on which stored or located) and hardware and software configurations, designs, architecture and interfaces, (c) business research, studies, procedures and costs, (d) financial data, (e) distribution methods, (f)&nbsp;marketing data, methods, plans and efforts, (g) the identities of actual and prospective suppliers, (h) the terms of contracts and agreements with, the needs and requirements of, and the Company&#146;s or its affiliates&#146; course of dealing with, actual or prospective suppliers, (i)&nbsp;personnel information, (j)&nbsp;customer and vendor credit information, and (k)&nbsp;information received from third parties subject to obligations of non-disclosure or non-use.&#160; Failure by the Company or its affiliates to mark any of the Proprietary Information as confidential or proprietary shall not affect its status as Proprietary Information.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Acknowledgements</u>.&#160; The Executive acknowledges that the Restrictive Covenants are reasonable and necessary to protect the legitimate interests of the Company and its affiliates, that the duration and geographic scope of the Restrictive Covenants are reasonable given the nature of this Agreement and the position the Executive holds within the Company, and that the Company would not</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="20747-2-KK_PB_7_021555_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="3",CHK=203385,FOLIO='7',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KK_ZCN74702.CHC",USER="VSTEFAN",CD='Jan  1 04:08 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">enter into this Agreement or otherwise employ or continue to employ the Executive unless the Executive agrees to be bound by the Restrictive Covenants set forth in this <u>Section&nbsp;6</u>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Remedies and Enforcement Upon Breach</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.6.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Specific Enforcement</u>. The Executive acknowledges that any breach by him, willfully or otherwise, of the Restrictive Covenants will cause continuing and irreparable injury to the Company or its affiliates for which monetary damages would not be an adequate remedy.&#160; The Executive shall not, in any action or proceeding to enforce any of the provisions of this Agreement, assert the claim or defense that such an adequate remedy at law exists.&#160; In the event of any such breach or threatened breach by the Executive of any of the Restrictive Covenants, the Company or its affiliates, as applicable, shall be entitled to injunctive or other similar equitable relief in any court, without any requirement that a bond or other security be posted, and this Agreement shall not in any way limit remedies of law or in equity otherwise available to the Company and its affiliates.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.6.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Judicial Modification</u>.&#160; If any court determines that any of the Restrictive Covenants, or any part thereof, is unenforceable because of the duration or geographical scope of such provision, such court shall have the power to modify such provision and, in its modified form, such provision shall then be enforceable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.6.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Enforceability</u>.&#160; If any court holds the Restrictive Covenants unenforceable by reason of their breadth or scope or otherwise, it is the intention of the parties hereto that such determination not bar or in any way affect the right of the Company and its affiliates to the relief provided above in the courts of any other jurisdiction within the geographic scope of such Restrictive Covenants.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.6.4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Disclosure of Restrictive Covenants</u>.&#160; The Executive agrees to disclose the existence and terms of the Restrictive Covenants to any employer that the Executive may work for during the Restricted Period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.6.5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Extension of Restricted Period</u>.&#160; If the Executive breaches <u>Section&nbsp;6.1 </u>in any respect, the restrictions contained in that section will be extended for a period equal to the period that the Executive was in breach.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:36.7pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Miscellaneous</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Other Agreements</u>.&#160; Executive represents and warrants to the Company that there are no restrictions, agreements or understandings whatsoever to which he is a party that would prevent or make unlawful his execution of this Agreement, that would be inconsistent or in conflict with this Agreement or Executive&#146;s obligations hereunder, or that would otherwise prevent, limit or impair the performance by Executive of his duties under this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Successors and Assigns</u>.&#160; The Company may assign this Agreement to any successor to its assets and business by means of liquidation, dissolution, sale of assets or otherwise.&#160; The duties of Executive hereunder are personal to Executive and may not be assigned by him.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Governing Law and Enforcement</u>.&#160; This Agreement will be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, without regard to the principles of conflicts of laws.&#160; Any legal proceeding arising out of or relating to this Agreement will be instituted in a state or federal court in the Commonwealth of Massachusetts, and Executive and the Company hereby consent to the personal and exclusive jurisdiction of such court(s)&nbsp;and hereby waive any</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="20747-2-KK_PB_8_021609_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="3",CHK=168533,FOLIO='8',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KK_ZCN74702.CHC",USER="VSTEFAN",CD='Jan  1 04:08 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">objection(s)&nbsp;that they may have to personal jurisdiction, the laying of venue of any such proceeding and any claim or defense of inconvenient forum.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Waivers</u>.&#160; The waiver by either party of any right hereunder or of any breach by the other party will not be deemed a waiver of any other right hereunder or of any other breach by the other party.&#160; No waiver will be deemed to have occurred unless set forth in a writing.&#160; No waiver will constitute a continuing waiver unless specifically stated, and any waiver will operate only as to the specific term or condition waived.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Severability</u>.&#160; Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law.&#160; However, if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provision, and this Agreement will be reformed, construed and enforced as though the invalid, illegal or unenforceable provision had never been herein contained.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Survival</u>.&#160; This Agreement will survive the cessation of Executive&#146;s employment to the extent necessary to fulfill the purposes and intent the Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notices</u>.&#160; Any notice or communication required or permitted under this Agreement will be made in writing and (a)&nbsp;sent by overnight courier, (b)&nbsp;mailed by overnight U.S. express mail, return receipt requested or (c)&nbsp;sent by telecopier.&#160; Any notice or communication to Executive will be sent to the address contained in his personnel file.&#160; Any notice or communication to the Company will be sent to the Company&#146;s principal executive offices, to the attention of its Chief Executive Officer.&#160; Notwithstanding the foregoing, either party may change the address for notices or communications hereunder by providing written notice to the other in the manner specified in this paragraph.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Entire Agreement; Amendments</u>.&#160; This Agreement contains the entire agreement and understanding of the parties hereto relating to the subject matter hereof, and merges and supersedes all prior and contemporaneous discussions, agreements and understandings of every nature relating to that subject matter (including, without limitation, the Existing Agreement).&#160; This Agreement may not be changed or modified, except by an agreement in writing signed by each of the parties hereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Withholding</u>.&#160; All payments (or transfers of property) to Executive will be subject to tax withholding to the extent required by applicable law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.10.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Section&nbsp;Headings</u>.&#160; The headings of sections and paragraphs of this Agreement are inserted for convenience only and will not in any way affect the meaning or construction of any provision of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.11.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Counterparts; Facsimile</u>.&#160; This Agreement may be executed in multiple counterparts (including by facsimile signature), each of which will be deemed to be an original, but all of which together will constitute but one and the same instrument.&#160; Counterparts may be delivered via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&lt;<b><i style="font-weight:bold;">remainder of page&nbsp;intentionally left blank; signature page&nbsp;follows</i></b>&gt;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="20747-2-KK_PB_9_021618_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="3",CHK=31333,FOLIO='9',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KK_ZCN74702.CHC",USER="VSTEFAN",CD='Jan  1 04:08 2016' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer, and Executive has executed this Agreement, on the date(s)&nbsp;indicated below.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">COLLEGIUM   PHARMACEUTICAL,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By: </font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Paul Brannelly</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: </font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Paul Brannelly</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title: </font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Financial Officer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: </font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">August&nbsp;4, 2015</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DOUGLAS   CARLSON</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Douglas Carlson</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="7%" valign="top" style="padding:0in 0in 0in 0in;width:7.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: </font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">August&nbsp;3, 2015</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Signature Page to Employment Agreement</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="3",CHK=555674,FOLIO='',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KK_ZCN74702.CHC",USER="VSTEFAN",CD='Jan  1 04:08 2016' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>a2226986zex-21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;21.1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SUBSIDIARIES</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.76%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="72%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:72.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Subsidiary</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="20%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Jurisdiction&nbsp;of<br>   Incorporation</font></b></p>    </td>   </tr>
<tr>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>
<td width="1%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="72%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:72.08%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;">Collegium Securities   Corporation</p>    </td>
<td width="2%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Massachusetts</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="4",CHK=612438,FOLIO='',FILE="DISK132:[15ZCN2.15ZCN74702]20747-2-KM_ZCN74702.CHC",USER="VSTEFAN",CD='Dec 31 05:30 2015' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>a2226986zex-23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#15ZCN74701_5">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:arial;"><FONT SIZE=2>

<!-- COMMAND=ADD_POSTPROCESS_EXTRA,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_HTMLFIX,"0915" -->




<!-- COMMAND=ADD_POSTPROCESS_JUSTIFYPARAGRAPH,"0915" -->




<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><A
NAME="kg74701_exhibit_23.1"> </A>
<A NAME="toc_kg74701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit 23.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="kg74701_consent_of_independent__kg702321"> </A>
<A NAME="toc_kg74701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>We have issued our report dated April&nbsp;27, 2015, with respect to the financial statements of Collegium Pharmaceutical,&nbsp;Inc. contained in
the Registration Statement and Prospectus. We consent to the use of the aforementioned report in the Registration Statement and Prospectus, and to the use of our name as it appears under the caption
"Experts." </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>/s/
GRANT THORNTON&nbsp;LLP </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>


Boston, Massachusetts<BR>
January&nbsp;4, 2016

</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="5",CHK=182324,FOLIO='blank',FILE='DISK131:[15ZCN1.15ZCN74701]KG74701A.;6',USER='JTAM',CD='30-DEC-2015;18:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="15ZCN74701_5">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:arial;"><A HREF="#toc_kg74701_1">Exhibit 23.1</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:arial;"><A HREF="#toc_kg74701_2">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</A></FONT><BR>

<!-- SEQ=,FILE='QUICKLINK',USER=VSTEFAN,SEQ=,EFW="2226986",CP="COLLEGIUM PHARMACEUTICAL",DN="5" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>coll-20160104.xml
<DESCRIPTION>EX-101.INS
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:coll="http://www.collegiumpharma.com/20160104" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:schemaRef xlink:type="simple" xlink:href="coll-20160104.xsd" />
  <xbrli:context id="I2013-09-30_us-gaap-ClassOfWarrantOrRightAxis_coll-StockPurchaseRightMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">coll:StockPurchaseRightMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coll:SeriesCPreferredStockFinancing2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012-02-29_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012-02-29_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-12-04_2013-12-04_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coll:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-12-04</xbrli:startDate>
      <xbrli:endDate>2013-12-04</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-12-01_2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-12-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_us-gaap-RedeemableConvertiblePreferredStockMember_us-gaap-StatementScenarioAxis_coll-ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">coll:ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012-02-29_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesBPreferredStockFinancingFebruary2012Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coll:SeriesBPreferredStockFinancingFebruary2012Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-ClassOfWarrantOrRightAxis_coll-StockPurchaseRightMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">coll:StockPurchaseRightMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coll:SeriesCPreferredStockFinancing2013TrancheTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-09-30_us-gaap-ClassOfWarrantOrRightAxis_coll-StockPurchaseRightMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">coll:StockPurchaseRightMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coll:SeriesCPreferredStockFinancing2013TrancheTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012-01-01_2012-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coll:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-PlanNameAxis_coll-StockIncentivePlan2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">coll:StockIncentivePlan2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coll:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_coll-NonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coll:NonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_coll-NonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coll:NonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-03-31_us-gaap-PlanNameAxis_coll-StockIncentivePlan2014Member_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">coll:StockIncentivePlan2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-07-31_us-gaap-PlanNameAxis_coll-StockIncentivePlan2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">coll:StockIncentivePlan2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-RangeAxis_us-gaap-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-RangeAxis_us-gaap-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-04-01_2015-04-30_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember_us-gaap-VestingAxis_us-gaap-ShareBasedCompensationAwardTrancheOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-04-01_2015-04-30_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember_us-gaap-TitleOfIndividualAxis_coll-NonemployeeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">coll:NonemployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember_us-gaap-TitleOfIndividualAxis_coll-NonemployeeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">coll:NonemployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-04-01_2015-04-30_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember_us-gaap-VestingAxis_us-gaap-ShareBasedCompensationAwardTrancheTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-01_2015-03-31_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-InvestmentTypeAxis_us-gaap-StandbyLettersOfCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-InvestmentTypeAxis_us-gaap-StandbyLettersOfCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-11-01_2014-12-31_us-gaap-DebtInstrumentAxis_coll-ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_us-gaap-RelatedPartyTransactionAxis_coll-NotePurchaseAgreementConvertiblePromissoryNotesMember_us-gaap-RelatedPartyTransactionsByRelatedPartyAxis_us-gaap-InvestorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:ConvertiblePromissoryNotes6.0PercentDueNovember2015Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">coll:NotePurchaseAgreementConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-11-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-MachineryAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_coll-ComputerEquipmentAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">coll:ComputerEquipmentAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-MachineryAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_coll-ComputerEquipmentAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">coll:ComputerEquipmentAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-MachineryAndEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_coll-ComputerEquipmentAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">coll:ComputerEquipmentAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-09-01_2014-09-30_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-09-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-02-01_2013-02-28_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreement28August2012Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-02-01</xbrli:startDate>
      <xbrli:endDate>2013-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012-10-01_2012-10-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreement28August2012Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-01</xbrli:startDate>
      <xbrli:endDate>2012-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012-08-01_2012-08-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreement28August2012Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-08-01</xbrli:startDate>
      <xbrli:endDate>2012-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_us-gaap-RedeemableConvertiblePreferredStockMember_us-gaap-StatementScenarioAxis_coll-ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">coll:ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_us-gaap-RedeemableConvertiblePreferredStockMember_us-gaap-StatementScenarioAxis_coll-ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">coll:ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-01-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreement28August2012Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-IncomeTaxAuthorityAxis_us-gaap-StateAndLocalJurisdictionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-IncomeTaxAuthorityNameAxis_us-gaap-InternalRevenueServiceIRSMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-IncomeTaxAuthorityAxis_us-gaap-StateAndLocalJurisdictionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-IncomeTaxAuthorityNameAxis_us-gaap-InternalRevenueServiceIRSMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-26_2015-03-26_us-gaap-LitigationCaseAxis_coll-PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">coll:PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-26</xbrli:startDate>
      <xbrli:endDate>2015-03-26</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-24_2015-03-24_us-gaap-LitigationCaseAxis_coll-PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">coll:PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-24</xbrli:startDate>
      <xbrli:endDate>2015-03-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-08-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember_us-gaap-VariableRateAxis_us-gaap-PrimeRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-02-28_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember_us-gaap-VariableRateAxis_us-gaap-PrimeRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012-08-28_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember_us-gaap-VariableRateAxis_us-gaap-PrimeRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreement28August2012Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-08-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-08-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-01-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012-08-28">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-08-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-01_2015-03-31_us-gaap-LeaseArrangementTypeAxis_coll-OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_us-gaap-StatementScenarioAxis_coll-DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">coll:OfficeAndResearchFacilityOperatingLeaseAsAmendedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">coll:DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-01_2015-03-31_us-gaap-LeaseArrangementTypeAxis_coll-OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">coll:OfficeAndResearchFacilityOperatingLeaseAsAmendedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreement28August2012Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreement28August2012Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-12-01_2013-12-31_us-gaap-ClassOfWarrantOrRightAxis_coll-StockPurchaseRightMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">coll:StockPurchaseRightMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coll:SeriesCPreferredStockFinancing2013TrancheTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-12-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-08-01_2013-09-30_us-gaap-ClassOfWarrantOrRightAxis_coll-StockPurchaseRightMember_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">coll:StockPurchaseRightMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coll:SeriesCPreferredStockFinancing2013TrancheTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-08-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-08-01_2013-09-30_us-gaap-ClassOfWarrantOrRightAxis_coll-StockPurchaseRightMember_us-gaap-RangeAxis_us-gaap-MaximumMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">coll:StockPurchaseRightMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coll:SeriesCPreferredStockFinancing2013TrancheTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-08-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coll:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coll:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-StatementScenarioAxis_us-gaap-ProFormaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ProFormaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-BalanceSheetLocationAxis_us-gaap-PrepaidExpensesAndOtherCurrentAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-01-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreement28August2012Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012-08-28_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreement28August2012Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-08-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-DebtInstrumentAxis_coll-CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-01-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember_us-gaap-VariableRateAxis_us-gaap-PrimeRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreement28August2012Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreement28August2012Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember_us-gaap-VariableRateAxis_us-gaap-PrimeRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreement28August2012Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember_us-gaap-VariableRateAxis_us-gaap-PrimeRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreement28August2012Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-06_2015-03-06_us-gaap-DebtConversionByUniqueDescriptionAxis_coll-ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_us-gaap-RelatedPartyTransactionAxis_coll-ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember_us-gaap-RelatedPartyTransactionsByRelatedPartyAxis_us-gaap-InvestorMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">coll:ConvertiblePromissoryNotes6.0PercentDueNovember2015Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">coll:ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-06</xbrli:startDate>
      <xbrli:endDate>2015-03-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-06_2015-03-06_us-gaap-DebtConversionByUniqueDescriptionAxis_coll-ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_us-gaap-RelatedPartyTransactionAxis_coll-ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember_us-gaap-RelatedPartyTransactionsByRelatedPartyAxis_us-gaap-InvestorMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">coll:ConvertiblePromissoryNotes6.0PercentDueNovember2015Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">coll:ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-06</xbrli:startDate>
      <xbrli:endDate>2015-03-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012-02-01_2012-02-29_us-gaap-ConversionOfStockByUniqueDescriptionAxis_coll-ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">coll:ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-02-01</xbrli:startDate>
      <xbrli:endDate>2012-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-ConversionOfStockByUniqueDescriptionAxis_coll-ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">coll:ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-ConversionOfStockByUniqueDescriptionAxis_coll-ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">coll:ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-ConversionOfStockByUniqueDescriptionAxis_coll-ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">coll:ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-08-31_us-gaap-ClassOfWarrantOrRightAxis_coll-CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_us-gaap-StatementScenarioAxis_us-gaap-ProFormaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">coll:CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ProFormaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-ClassOfWarrantOrRightAxis_coll-CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member_us-gaap-StatementScenarioAxis_us-gaap-ProFormaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">coll:CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ProFormaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-ClassOfWarrantOrRightAxis_coll-SeriesaPreferredStockWarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">coll:SeriesaPreferredStockWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012-02-29_us-gaap-ClassOfWarrantOrRightAxis_coll-SeriesaPreferredStockWarrantMember_us-gaap-ConversionOfStockByUniqueDescriptionAxis_coll-ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">coll:SeriesaPreferredStockWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">coll:ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-08-31_us-gaap-ClassOfWarrantOrRightAxis_coll-CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">coll:CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-02-28_us-gaap-ClassOfWarrantOrRightAxis_coll-CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">coll:CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-01-31_us-gaap-ClassOfWarrantOrRightAxis_coll-CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_us-gaap-StatementScenarioAxis_us-gaap-ProFormaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">coll:CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ProFormaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012-08-28_us-gaap-ClassOfWarrantOrRightAxis_coll-CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member_us-gaap-StatementScenarioAxis_us-gaap-ProFormaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">coll:CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ProFormaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-08-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012-08-28_us-gaap-ClassOfWarrantOrRightAxis_coll-CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">coll:CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-08-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010-11-30_us-gaap-ClassOfWarrantOrRightAxis_coll-PreferredStockWarrantsIssuedNovember2010Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">coll:PreferredStockWarrantsIssuedNovember2010Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-FairValueByMeasurementBasisAxis_us-gaap-CarryingReportedAmountFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-FairValueByMeasurementBasisAxis_us-gaap-CarryingReportedAmountFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-03-31_us-gaap-LeaseArrangementTypeAxis_coll-OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">coll:OfficeAndResearchFacilityOperatingLeaseAsAmendedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-03-31_us-gaap-LeaseArrangementTypeAxis_coll-AmendmentToOfficeAndResearchFacilityOperatingLeaseMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">coll:AmendmentToOfficeAndResearchFacilityOperatingLeaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-RestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-RedeemableConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_coll-EmployeeAndNonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">coll:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-RestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-RedeemableConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_coll-EmployeeAndNonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">coll:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-IncomeStatementLocationAxis_us-gaap-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-IncomeStatementLocationAxis_us-gaap-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-IncomeStatementLocationAxis_us-gaap-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-IncomeStatementLocationAxis_us-gaap-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-06_2015-03-06_us-gaap-RelatedPartyTransactionAxis_us-gaap-PrivatePlacementMember_us-gaap-RelatedPartyTransactionsByRelatedPartyAxis_us-gaap-InvestorMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-06</xbrli:startDate>
      <xbrli:endDate>2015-03-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-08-01_2013-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coll:SeriesCPreferredStockFinancing2013TrancheOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-08-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012-02-01_2012-02-29_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesBPreferredStockFinancingFebruary2012Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coll:SeriesBPreferredStockFinancingFebruary2012Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-02-01</xbrli:startDate>
      <xbrli:endDate>2012-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-12-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-12-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_us-gaap-RedeemableConvertiblePreferredStockMember_us-gaap-StatementScenarioAxis_coll-ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">coll:ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-RedeemableConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_us-gaap-RedeemableConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coll:SeriesCPreferredStockFinancing2013TrancheTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coll:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coll:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember_us-gaap-RangeAxis_us-gaap-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coll:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember_us-gaap-RangeAxis_us-gaap-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coll:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coll:SeriesCPreferredStockFinancing2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-RangeAxis_us-gaap-MaximumMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">coll:SeriesCPreferredStockFinancing2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-DebtInstrumentAxis_coll-CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-LossContingenciesByNatureOfContingencyAxis_coll-HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember_us-gaap-RangeAxis_us-gaap-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">coll:HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-RangeAxis_us-gaap-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-08-01_2014-08-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-08-01</xbrli:startDate>
      <xbrli:endDate>2014-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-02-01_2014-02-28_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-02-01</xbrli:startDate>
      <xbrli:endDate>2014-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012-08-28_2012-08-28_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:SiliconValleyBankLoanAgreement28August2012Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-08-28</xbrli:startDate>
      <xbrli:endDate>2012-08-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013-01-01_2013-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_2015-02-28_us-gaap-StatementClassOfStockAxis_coll-SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coll:SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-05-01_2015-05-31_us-gaap-SubsidiarySaleOfStockAxis_us-gaap-OverAllotmentOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-05-01</xbrli:startDate>
      <xbrli:endDate>2015-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-04-01_2015-04-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-05-31_us-gaap-SubsidiarySaleOfStockAxis_us-gaap-IPOMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-04-30_us-gaap-PlanNameAxis_coll-StockIncentivePlan2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">coll:StockIncentivePlan2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_2015-09-30_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coll:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-05-01_2015-05-31_us-gaap-SubsidiarySaleOfStockAxis_us-gaap-IPOMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-05-01</xbrli:startDate>
      <xbrli:endDate>2015-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-01_2015-03-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-01_2015-03-31_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_coll-SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember_us-gaap-StatementScenarioAxis_coll-ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coll:SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">coll:ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_2015-02-28_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_2015-02-28_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_2015-02-28_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_2015-09-30_us-gaap-StatementClassOfStockAxis_coll-CommonStockNoClassMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coll:CommonStockNoClassMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-26_2015-03-26_us-gaap-LitigationCaseAxis_coll-PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">coll:PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-26</xbrli:startDate>
      <xbrli:endDate>2015-03-26</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-24_2015-03-24_us-gaap-LitigationCaseAxis_coll-PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">coll:PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-24</xbrli:startDate>
      <xbrli:endDate>2015-03-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-01_2015-03-31_us-gaap-LeaseArrangementTypeAxis_coll-OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_us-gaap-StatementScenarioAxis_coll-DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">coll:OfficeAndResearchFacilityOperatingLeaseAsAmendedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">coll:DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-01_2015-03-31_us-gaap-LeaseArrangementTypeAxis_coll-OfficeAndResearchFacilityOperatingLeaseAsAmendedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">coll:OfficeAndResearchFacilityOperatingLeaseAsAmendedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-01_2015-03-31_us-gaap-DebtInstrumentAxis_coll-ConvertiblePromissoryNotes6.0PercentDueNovember2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">coll:ConvertiblePromissoryNotes6.0PercentDueNovember2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-01_2015-03-31_us-gaap-DebtConversionByUniqueDescriptionAxis_coll-ConvertiblePromissoryNotes6.0PercentDueNovember2015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">coll:ConvertiblePromissoryNotes6.0PercentDueNovember2015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-05-01_2015-05-31_us-gaap-ConversionOfStockByUniqueDescriptionAxis_coll-ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember_us-gaap-StatementClassOfStockAxis_us-gaap-RedeemableConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">coll:ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-05-01</xbrli:startDate>
      <xbrli:endDate>2015-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_2015-09-30_us-gaap-ConversionOfStockByUniqueDescriptionAxis_coll-ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember_us-gaap-StatementClassOfStockAxis_us-gaap-RedeemableConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">coll:ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_us-gaap-CashAndCashEquivalentsAxis_us-gaap-MoneyMarketFundsMember_us-gaap-FairValueByFairValueHierarchyLevelAxis_us-gaap-FairValueInputsLevel1Member_us-gaap-FairValueByMeasurementBasisAxis_us-gaap-EstimateOfFairValueFairValueDisclosureMember_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_us-gaap-CashAndCashEquivalentsAxis_us-gaap-MoneyMarketFundsMember_us-gaap-FairValueByMeasurementBasisAxis_us-gaap-EstimateOfFairValueFairValueDisclosureMember_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-CashAndCashEquivalentsAxis_us-gaap-MoneyMarketFundsMember_us-gaap-FairValueByFairValueHierarchyLevelAxis_us-gaap-FairValueInputsLevel1Member_us-gaap-FairValueByMeasurementBasisAxis_us-gaap-EstimateOfFairValueFairValueDisclosureMember_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_us-gaap-CashAndCashEquivalentsAxis_us-gaap-MoneyMarketFundsMember_us-gaap-FairValueByMeasurementBasisAxis_us-gaap-EstimateOfFairValueFairValueDisclosureMember_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-03-31_us-gaap-LeaseArrangementTypeAxis_coll-OfficeAndResearchFacilityOperatingLeaseAsAmendedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">coll:OfficeAndResearchFacilityOperatingLeaseAsAmendedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-03-31_us-gaap-LeaseArrangementTypeAxis_coll-AmendmentToOfficeAndResearchFacilityOperatingLeaseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">coll:AmendmentToOfficeAndResearchFacilityOperatingLeaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_2015-09-30_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_2015-09-30_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-RestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_2015-09-30_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_coll-EmployeeAndNonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">coll:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-09-30_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-09-30_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-RestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-09-30_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-RedeemableConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-09-30_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_coll-EmployeeAndNonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">coll:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-01_2015-03-31_us-gaap-StatementClassOfStockAxis_coll-SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coll:SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_2015-09-30_us-gaap-StatementClassOfStockAxis_coll-SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coll:SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-09-30_us-gaap-StatementClassOfStockAxis_coll-SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">coll:SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_2015-09-30_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember_us-gaap-RangeAxis_us-gaap-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coll:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_2015-09-30_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember_us-gaap-RangeAxis_us-gaap-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">coll:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-04-01_2015-04-30_us-gaap-PlanNameAxis_coll-StockIncentivePlan2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">coll:StockIncentivePlan2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-03-01_2015-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_2015-09-30_us-gaap-LossContingenciesByNatureOfContingencyAxis_coll-HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember_us-gaap-RangeAxis_us-gaap-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">coll:HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_2015-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_2014-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="coll-patent">
    <xbrli:measure>coll:patent</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="utr-sqft">
    <xbrli:measure>utr:sqft</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="coll-director">
    <xbrli:measure>coll:director</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="coll-installment">
    <xbrli:measure>coll:installment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-USD_xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="coll-tranche">
    <xbrli:measure>coll:tranche</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="coll-Vote">
    <xbrli:measure>coll:Vote</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <us-gaap:WarrantsAndRightsOutstanding id="Fact-fb950329-eef7-4f57-b06d-d4843608d317_20151231" decimals="-3" contextRef="I2013-09-30_us-gaap-ClassOfWarrantOrRightAxis_coll-StockPurchaseRightMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013Member" unitRef="iso4217-USD">266000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="Fact-e89fda0f-2b16-44ff-a6d3-545ed9645812_20151231" decimals="INF" contextRef="I2012-02-29_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="Fact-1de46a98-ff6b-45cf-a5b0-8b8e7ec69e75_20151231" decimals="INF" contextRef="I2012-02-29_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Fact-df82464e-49e5-4ecd-b6f1-b744ac719820_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="iso4217-USD">12154000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="Fact-c4236c03-ca80-478d-b234-00979de3240f_20151231" decimals="INF" contextRef="I2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="Fact-9349d78c-4e57-451b-8156-710685e95222_20151231" decimals="INF" contextRef="I2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="xbrli-shares">8658344</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="Fact-fc3ced97-6e20-4bfc-9406-3baa3468ad07_20151231" decimals="INF" contextRef="I2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="xbrli-shares">8658008</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="Fact-7c0cf3d1-a106-461a-903d-371273e23f86_20151231" decimals="INF" contextRef="I2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="xbrli-shares">8658008</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Fact-8a6ae08d-476a-4afe-947f-61cbf6fb0334_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="iso4217-USD">49376000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="Fact-f41d8214-bf2a-43ef-9b69-4af8e0eb0fb6_20151231" decimals="INF" contextRef="I2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="Fact-6b555cb0-a19b-4bc2-bed4-ff2b82ac7fcf_20151231" decimals="INF" contextRef="I2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="xbrli-shares">27324237</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="Fact-94953fa2-52a5-453a-b3bb-83cf4872450b_20151231" decimals="INF" contextRef="I2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="xbrli-shares">27324237</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="Fact-ab66ad37-c15f-4d3b-873f-f7d031ae5938_20151231" decimals="INF" contextRef="I2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="xbrli-shares">27324237</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Fact-57a17214-8c95-41a2-aafb-5076c7a2631c_20151231" decimals="-3" contextRef="I2012-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="iso4217-USD">47540000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquitySharesIssued id="Fact-d5e2b6b0-df97-48b9-a7cf-f266f643d2f0_20151231" decimals="INF" contextRef="I2012-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="xbrli-shares">27324237</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Fact-5bdddb50-8f87-48b5-9d4f-98fdb906c926_20151231" decimals="-3" contextRef="I2012-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="iso4217-USD">23546000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquitySharesIssued id="Fact-b5d6ad88-16df-4d5d-96f6-0c3e3f4b24c2_20151231" decimals="INF" contextRef="I2012-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="xbrli-shares">18464674</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross id="Fact-3f4927ed-7511-42c0-9cec-fe2d99bf89fc_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="xbrli-shares">10869</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Fact-a976ad8f-8f48-4e7e-871a-115bda0ac3d5_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="xbrli-shares">32390</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="Fact-189619cc-1f42-4da4-99dc-3564ca149cc6_20151231" decimals="1" contextRef="D2013-12-04_2013-12-04_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="xbrli-pure">0.5</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="Fact-f348ddd0-b625-42ba-9a60-e0978f3ad73e_20151231" decimals="1" contextRef="D2013-12-01_2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="xbrli-pure">0.5</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:StockholdersEquity id="Fact-cf620d4a-0ba4-4f9f-af0c-d1e65af3a477_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-TreasuryStockMember" unitRef="iso4217-USD">-3000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Fact-31bf3630-8879-42e1-86d0-3453d407f3a7_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD">-101753000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Fact-e147fc5e-12c9-4a9a-9135-f4dfaea0f87b_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">12407000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Fact-725d29e6-7b6c-4667-9fe9-13da8340d752_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-TreasuryStockMember" unitRef="iso4217-USD">-3000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Fact-ea7dfb75-be17-4e41-a88d-ba6a3bc95372_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD">-80536000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Fact-42ab235c-1863-4ce7-b7ea-5348bb052335_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">12313000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Fact-7a5945a0-5a2d-479a-b485-ac778c1e20c0_20151231" decimals="-3" contextRef="I2012-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-TreasuryStockMember" unitRef="iso4217-USD">-3000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Fact-809fdf25-b56c-4558-83ff-e2935bf47d66_20151231" decimals="-3" contextRef="I2012-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD">-61414000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Fact-1d8dd82e-fb5f-4d5f-a336-13dcd75747b5_20151231" decimals="-3" contextRef="I2012-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">11000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="Fact-090ffba9-e505-422c-9cab-02e2c6bfda5d_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="xbrli-shares">1006219</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Fact-1845ef84-2176-47a6-a114-53a72bc81015_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD">1000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="Fact-d6680a28-0081-4e18-82b5-22d2aeeeeef9_20151231" decimals="INF" contextRef="I2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="xbrli-shares">962960</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Fact-29458137-e5a1-42b6-bdc0-3fa2bb0f9fe9_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD">1000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="Fact-b866f377-3963-4263-9e4f-9f81c5f89669_20151231" decimals="INF" contextRef="I2012-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="xbrli-shares">1924845</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="Fact-df914a27-f5ee-4b48-83ec-2df9904bfe2e_20151231" decimals="-3" contextRef="I2012-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD">2000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssuedPricePerShare id="Fact-a19dfb9c-e20a-4d09-8187-3c9066d36d0a_20151231" decimals="2" contextRef="I2014-12-31_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_us-gaap-RedeemableConvertiblePreferredStockMember_us-gaap-StatementScenarioAxis_coll-ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" unitRef="iso4217-USD_xbrli-shares">20.70</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare id="Fact-83d8ea1b-fc38-403f-a128-4b5e11a2dfcd_20151231" decimals="2" contextRef="I2012-02-29_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesBPreferredStockFinancingFebruary2012Member" unitRef="iso4217-USD_xbrli-shares">0.84</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharePrice id="Fact-1b6588dd-c834-4385-aadc-69502bfd0132_20151231" decimals="2" contextRef="I2013-12-31_us-gaap-ClassOfWarrantOrRightAxis_coll-StockPurchaseRightMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheTwoMember" unitRef="iso4217-USD_xbrli-shares">1.27</us-gaap:SharePrice>
  <us-gaap:SharePrice id="Fact-dab2cc83-a754-4886-8036-5b122155e00b_20151231" decimals="2" contextRef="I2013-09-30_us-gaap-ClassOfWarrantOrRightAxis_coll-StockPurchaseRightMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheTwoMember" unitRef="iso4217-USD_xbrli-shares">1.30</us-gaap:SharePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Fact-4d28eb86-9d0b-49c2-9507-2da60f80ab74_20151231" contextRef="D2012-01-01_2012-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember">P6Y11M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Fact-9acd0b9a-3e78-4544-a831-737e797511c5_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-PlanNameAxis_coll-StockIncentivePlan2014Member" unitRef="xbrli-shares">281029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="Fact-bf2a0f28-76e9-4522-addb-37f6f0c6a526_20151231" decimals="-3" contextRef="I2012-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="iso4217-USD">8000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Fact-c6be16f8-6fb8-4482-b8b0-6947fdafcb1d_20151231" decimals="INF" contextRef="I2012-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="xbrli-shares">323488</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Fact-6706889a-a08a-4a11-9626-71c68ab9ca57_20151231" decimals="2" contextRef="I2012-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="iso4217-USD_xbrli-shares">1.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Fact-3e53b8ab-3ff8-41b3-bfaf-2ae38a31e544_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_coll-NonemployeeStockOptionsMember" unitRef="xbrli-shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Fact-444d2f5a-14cc-4e1a-9bd5-72cc69065c5b_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_coll-NonemployeeStockOptionsMember" unitRef="xbrli-shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="Fact-e8dcca0b-a4fc-4419-b4bc-f369bbcff276_20151231" decimals="INF" contextRef="I2015-03-31_us-gaap-PlanNameAxis_coll-StockIncentivePlan2014Member_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="xbrli-shares">1087005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="Fact-e24d28fa-c98d-4bc6-ab4d-221317c13587_20151231" decimals="INF" contextRef="I2014-07-31_us-gaap-PlanNameAxis_coll-StockIncentivePlan2014Member" unitRef="xbrli-shares">525700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Fact-3e68ae99-b320-4242-bbf8-d1c5105acf32_20151231" decimals="4" contextRef="D2013-01-01_2013-12-31_us-gaap-RangeAxis_us-gaap-MinimumMember" unitRef="xbrli-pure">0.0109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Fact-cfd16605-b670-4461-ab6a-2d563bd8fc4c_20151231" decimals="4" contextRef="D2013-01-01_2013-12-31_us-gaap-RangeAxis_us-gaap-MaximumMember" unitRef="xbrli-pure">0.0122</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="Fact-753a1931-5527-4423-b7fd-ea7835abe98e_20151231" decimals="INF" contextRef="I2012-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember" unitRef="xbrli-shares">203342</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="Fact-91854a3e-964a-4c7f-b233-9cec968fdbf6_20151231" decimals="2" contextRef="I2012-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember" unitRef="iso4217-USD_xbrli-shares">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="Fact-eff16963-75af-46b4-ac21-03cb6dd27ac7_20151231" decimals="INF" contextRef="D2015-04-01_2015-04-30_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember_us-gaap-VestingAxis_us-gaap-ShareBasedCompensationAwardTrancheOneMember" unitRef="xbrli-shares">97347</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="Fact-383b5fe4-b338-4003-9352-fd5fed46832e_20151231" decimals="INF" contextRef="D2015-04-01_2015-04-30_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="xbrli-shares">194694</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="Fact-0e27b8ce-c3fe-4efb-bca8-fd562f4f3e40_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember_us-gaap-TitleOfIndividualAxis_coll-NonemployeeMember" unitRef="xbrli-shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="Fact-1ac81603-9803-4863-ade7-0fc61db0115a_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember_us-gaap-TitleOfIndividualAxis_coll-NonemployeeMember" unitRef="xbrli-shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Fact-704ef60f-0e50-4e29-b6e4-74c2b652dc05_20151231" contextRef="D2015-04-01_2015-04-30_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember_us-gaap-VestingAxis_us-gaap-ShareBasedCompensationAwardTrancheTwoMember">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="Fact-4ae6cdf0-39da-4124-9d88-c665368dbabd_20151231" decimals="INF" contextRef="D2015-04-01_2015-04-30_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember_us-gaap-VestingAxis_us-gaap-ShareBasedCompensationAwardTrancheTwoMember" unitRef="xbrli-shares">97347</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Fact-0b139ae5-4dbb-41a6-9fb7-4ce9d73c0c61_20151231" contextRef="D2015-03-01_2015-03-31_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="Fact-a26bd053-c5fc-471f-bde2-f21f8bcbc5bf_20151231" contextRef="D2015-03-01_2015-03-31_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Fact-b3b9665e-acb8-4d39-beec-36932d08150d_20151231" decimals="INF" contextRef="D2015-03-01_2015-03-31_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="xbrli-shares">638095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="Fact-f3f3209e-4fa4-405e-97c9-88cbdfdf23b5_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-InvestmentTypeAxis_us-gaap-StandbyLettersOfCreditMember" unitRef="iso4217-USD">80000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="Fact-4438c871-e313-4345-b2fa-37da27eaa063_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-InvestmentTypeAxis_us-gaap-StandbyLettersOfCreditMember" unitRef="iso4217-USD">80000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction id="Fact-0c620509-72b6-483d-ad5e-3f5a68a76830_20151231" decimals="-3" contextRef="D2014-11-01_2014-12-31_us-gaap-DebtInstrumentAxis_coll-ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_us-gaap-RelatedPartyTransactionAxis_coll-NotePurchaseAgreementConvertiblePromissoryNotesMember_us-gaap-RelatedPartyTransactionsByRelatedPartyAxis_us-gaap-InvestorMember" unitRef="iso4217-USD">5000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionRate id="Fact-c3eca7a0-862d-4560-a7c3-18f1f89d67a5_20151231" decimals="INF" contextRef="D2014-11-01_2014-12-31_us-gaap-DebtInstrumentAxis_coll-ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_us-gaap-RelatedPartyTransactionAxis_coll-NotePurchaseAgreementConvertiblePromissoryNotesMember_us-gaap-RelatedPartyTransactionsByRelatedPartyAxis_us-gaap-InvestorMember" unitRef="xbrli-pure">0.06</us-gaap:RelatedPartyTransactionRate>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="Fact-2e8afec1-db18-434d-b76b-70a13a1a0370_20151231" contextRef="D2014-01-01_2014-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-MachineryAndEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="Fact-e74572ef-c964-446c-ab57-ca4ce2198d99_20151231" contextRef="D2014-01-01_2014-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-LeaseholdImprovementsMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="Fact-46075020-333b-4125-a4ab-19c89d207927_20151231" contextRef="D2014-01-01_2014-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-FurnitureAndFixturesMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="Fact-822b17b3-902d-4c1b-8f5b-60058322d887_20151231" contextRef="D2014-01-01_2014-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_coll-ComputerEquipmentAndOfficeEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentGross id="Fact-d3757003-88d4-48dd-94c0-f6214bf0ccdc_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-MachineryAndEquipmentMember" unitRef="iso4217-USD">741000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Fact-dfc5809d-c45f-4d5c-9be5-ee0eab67569e_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-LeaseholdImprovementsMember" unitRef="iso4217-USD">606000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Fact-f4f9b4ed-ffa3-4d7d-abe2-6e79af18ebed_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-FurnitureAndFixturesMember" unitRef="iso4217-USD">44000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Fact-e445950f-e7da-425c-8d14-2369b7bae6d4_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_coll-ComputerEquipmentAndOfficeEquipmentMember" unitRef="iso4217-USD">26000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Fact-7de57179-f7e6-4c4f-8404-8f0ede7b7518_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-MachineryAndEquipmentMember" unitRef="iso4217-USD">741000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Fact-389203fd-c216-439e-aec8-2014d4d350af_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-LeaseholdImprovementsMember" unitRef="iso4217-USD">606000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Fact-8d04ac2f-ec05-46b4-8011-03c78c432140_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_us-gaap-FurnitureAndFixturesMember" unitRef="iso4217-USD">36000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="Fact-77dbc3d9-8682-4475-9fbb-591f4ba55fb4_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-PropertyPlantAndEquipmentByTypeAxis_coll-ComputerEquipmentAndOfficeEquipmentMember" unitRef="iso4217-USD">26000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt id="Fact-4776cd15-6964-4492-9ce5-7233666e5441_20151231" decimals="-3" contextRef="D2014-09-01_2014-09-30_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember" unitRef="iso4217-USD">3000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt id="Fact-1207a702-e736-4628-ac22-925c56196c02_20151231" decimals="-3" contextRef="D2013-02-01_2013-02-28_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember" unitRef="iso4217-USD">500000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt id="Fact-71f06929-8ea1-4b24-8ed6-224bbd772efe_20151231" decimals="-3" contextRef="D2012-10-01_2012-10-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember" unitRef="iso4217-USD">250000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt id="Fact-13c0cc83-3e6f-46c7-a9c0-39a0a0a6a7b2_20151231" decimals="-3" contextRef="D2012-08-01_2012-08-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember" unitRef="iso4217-USD">250000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="Fact-2f2dff26-af3e-47b5-9b04-e9ad3ed189ad_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_us-gaap-RedeemableConvertiblePreferredStockMember_us-gaap-StatementScenarioAxis_coll-ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" unitRef="iso4217-USD">50000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="Fact-84ead4f0-0604-44b1-8645-2c5931f864d9_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_us-gaap-RedeemableConvertiblePreferredStockMember_us-gaap-StatementScenarioAxis_coll-ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember" unitRef="iso4217-USD">1000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:PaymentsOfFinancingCosts id="Fact-5e02a320-141f-4b3e-b1a9-4217a814e178_20151231" decimals="-3" contextRef="D2014-01-01_2014-01-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember" unitRef="iso4217-USD">16000</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:OperatingLossCarryforwards id="Fact-2d9c341a-a743-4c06-832f-8588f8f843a8_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-IncomeTaxAuthorityAxis_us-gaap-StateAndLocalJurisdictionMember" unitRef="iso4217-USD">34184000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="Fact-b8ff0512-dd6c-4587-9e88-4e385c5d1bd6_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-IncomeTaxAuthorityNameAxis_us-gaap-InternalRevenueServiceIRSMember" unitRef="iso4217-USD">78276000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="Fact-ac44bf52-04d9-4458-aa3f-622ec6e13981_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-IncomeTaxAuthorityAxis_us-gaap-StateAndLocalJurisdictionMember" unitRef="iso4217-USD">16354000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="Fact-6739c6f9-fb19-4997-afff-d348749a00fa_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-IncomeTaxAuthorityNameAxis_us-gaap-InternalRevenueServiceIRSMember" unitRef="iso4217-USD">60380000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber id="Fact-f77bcdad-1549-41b3-87fb-92d17495f1ee_20151231" decimals="INF" contextRef="D2015-03-26_2015-03-26_us-gaap-LitigationCaseAxis_coll-PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="coll-patent">4</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
  <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber id="Fact-8c511b28-5373-4773-8c6c-bb37ccb395e8_20151231" decimals="INF" contextRef="D2015-03-24_2015-03-24_us-gaap-LitigationCaseAxis_coll-PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="coll-patent">4</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
  <us-gaap:LongTermDebtPercentageBearingVariableInterestRate id="Fact-0c41e1d6-ee35-4fac-890d-0094ce36986e_20151231" decimals="4" contextRef="I2014-08-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember_us-gaap-VariableRateAxis_us-gaap-PrimeRateMember" unitRef="xbrli-pure">0.0500</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
  <us-gaap:LongTermDebtPercentageBearingVariableInterestRate id="Fact-61cc171a-5240-4b30-bbb6-8f6415dbaf7e_20151231" decimals="4" contextRef="I2014-02-28_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember_us-gaap-VariableRateAxis_us-gaap-PrimeRateMember" unitRef="xbrli-pure">0.0500</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
  <us-gaap:LongTermDebtPercentageBearingVariableInterestRate id="Fact-2ed1b06b-c3dc-420e-983e-9eacc0e37c6c_20151231" decimals="4" contextRef="I2012-08-28_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember_us-gaap-VariableRateAxis_us-gaap-PrimeRateMember" unitRef="xbrli-pure">0.0550</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity id="Fact-aaa274f1-8c62-4806-a945-e93ad2cdc7b9_20151231" decimals="-3" contextRef="I2014-08-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember" unitRef="iso4217-USD">8000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity id="Fact-57b769e1-c7f1-497e-ac14-336016d1377f_20151231" decimals="-3" contextRef="I2014-01-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember" unitRef="iso4217-USD">6000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity id="Fact-957c14bc-f983-400a-9478-d0de01c3beab_20151231" decimals="-3" contextRef="I2012-08-28" unitRef="iso4217-USD">1000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract id="Fact-f612fc55-1aa3-4219-9581-e5caae0fe671_20151231" contextRef="D2015-03-01_2015-03-31_us-gaap-LeaseArrangementTypeAxis_coll-OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_us-gaap-StatementScenarioAxis_coll-DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">P5Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm id="Fact-af20d0c7-af2c-45e8-a2b8-4f5f35ea0d30_20151231" contextRef="D2015-03-01_2015-03-31_us-gaap-LeaseArrangementTypeAxis_coll-OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember">P5Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm>
  <us-gaap:InterestExpenseDebt id="Fact-a8a6ad5e-c5bc-4cb7-81dd-0e7c1c87c699_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember" unitRef="iso4217-USD">208000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt id="Fact-69782157-cbff-4e64-9019-8b22bb00b192_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember" unitRef="iso4217-USD">62000</us-gaap:InterestExpenseDebt>
  <us-gaap:FairValueAssumptionsExpectedTerm id="Fact-f25f4f6e-92be-46a9-83e5-3f52e530e7b0_20151231" contextRef="D2013-12-01_2013-12-31_us-gaap-ClassOfWarrantOrRightAxis_coll-StockPurchaseRightMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheTwoMember">P1M28D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="Fact-b977e08d-3d39-459e-b0bc-1958d90e8371_20151231" decimals="2" contextRef="D2013-12-01_2013-12-31_us-gaap-ClassOfWarrantOrRightAxis_coll-StockPurchaseRightMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheTwoMember" unitRef="xbrli-pure">0.52</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings id="Fact-0dff700f-4e41-4116-9e1c-8a8c0f51b135_20151231" decimals="-3" contextRef="D2013-12-01_2013-12-31_us-gaap-ClassOfWarrantOrRightAxis_coll-StockPurchaseRightMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheTwoMember" unitRef="iso4217-USD">79000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues id="Fact-66340934-c348-48cd-84a7-cbc88be17423_20151231" decimals="-3" contextRef="D2013-12-01_2013-12-31_us-gaap-ClassOfWarrantOrRightAxis_coll-StockPurchaseRightMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheTwoMember" unitRef="iso4217-USD">266000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales id="Fact-c62c766b-a547-4e54-a7c6-5c60eef91050_20151231" decimals="-3" contextRef="D2013-12-01_2013-12-31_us-gaap-ClassOfWarrantOrRightAxis_coll-StockPurchaseRightMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheTwoMember" unitRef="iso4217-USD">345000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
  <us-gaap:FairValueAssumptionsExpectedTerm id="Fact-3e7bfdd8-e21a-46b7-9408-d2fc7b856bcb_20151231" contextRef="D2013-08-01_2013-09-30_us-gaap-ClassOfWarrantOrRightAxis_coll-StockPurchaseRightMember_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheTwoMember">P4M6D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="Fact-9a032048-66d8-4fa2-a272-f990f2c5d3a1_20151231" decimals="2" contextRef="D2013-08-01_2013-09-30_us-gaap-ClassOfWarrantOrRightAxis_coll-StockPurchaseRightMember_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheTwoMember" unitRef="xbrli-pure">0.53</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedTerm id="Fact-e27c20ff-6c68-4bb7-b2bb-fd91e6474db1_20151231" contextRef="D2013-08-01_2013-09-30_us-gaap-ClassOfWarrantOrRightAxis_coll-StockPurchaseRightMember_us-gaap-RangeAxis_us-gaap-MaximumMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheTwoMember">P5M5D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="Fact-b77f1c75-12b7-489c-9789-d006ae24fa68_20151231" decimals="2" contextRef="D2013-08-01_2013-09-30_us-gaap-ClassOfWarrantOrRightAxis_coll-StockPurchaseRightMember_us-gaap-RangeAxis_us-gaap-MaximumMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheTwoMember" unitRef="xbrli-pure">0.60</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="Fact-a3959973-0020-44b7-a290-aa50d28aaaaa_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="iso4217-USD">40000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="Fact-e77e7786-2307-4b80-b4a0-6509c4321d9a_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="iso4217-USD">117000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Fact-4eea2d93-6960-41b0-a117-fba86ff20b1c_20151231" decimals="INF" contextRef="I2013-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="xbrli-shares">229791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Fact-bf679f84-4843-4655-8f31-158c83beb58b_20151231" decimals="2" contextRef="I2013-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="iso4217-USD_xbrli-shares">1.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions id="Fact-4ecc7fcb-b2f3-45b8-ad53-22a932c1a05b_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember" unitRef="iso4217-USD">26000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="Fact-5f569eee-cddf-4129-beb6-af246cf7546b_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember" unitRef="xbrli-shares">15387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="Fact-46547a87-45dc-41bd-a9ca-d70d54c6e710_20151231" decimals="2" contextRef="I2014-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember" unitRef="iso4217-USD_xbrli-shares">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions id="Fact-c60ea30c-7a09-42ac-ad4c-8fa3ccde329f_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember" unitRef="iso4217-USD">73000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="Fact-d203b5b7-a663-465b-99c7-f655cf689ea0_20151231" decimals="INF" contextRef="I2013-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember" unitRef="xbrli-shares">55298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="Fact-119f566e-3bf1-4157-8a64-1e4eaf561e5e_20151231" decimals="2" contextRef="I2013-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember" unitRef="iso4217-USD_xbrli-shares">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="Fact-02336475-12e3-40ea-acd3-45806f1cefed_20151231" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember">P2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="Fact-691e24a3-9e89-4a58-a715-46acda5afe4e_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember" unitRef="xbrli-shares">10869</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="Fact-c99b826a-9d84-47b3-ac7d-74934a437ac5_20151231" decimals="2" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember" unitRef="iso4217-USD_xbrli-shares">1.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="Fact-a0245a91-e499-494f-a78d-7336840a56a9_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember" unitRef="xbrli-shares">50780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue id="Fact-664311ea-1110-4f47-be26-64768e9e7e5f_20151231" decimals="2" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember" unitRef="iso4217-USD_xbrli-shares">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="Fact-88741ebb-be97-497d-b6f7-d0fed8b94446_20151231" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Fact-8da15654-c394-477b-8d6c-d69abe01f0f4_20151231" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="Fact-966bfaa1-14db-4f95-a99f-2c177b7f1668_20151231" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="Fact-4cba7809-d2eb-4fa7-aae1-c744d7d174b9_20151231" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember">P4Y3M22D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod id="Fact-be2d04e1-c195-46bb-b74a-098ea8800fbf_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="xbrli-shares">6013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice id="Fact-2a34f69d-a9ee-4e58-a978-6886699e7588_20151231" decimals="2" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="iso4217-USD_xbrli-shares">4.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Fact-12d28779-63f4-40d2-be37-fb20dec71487_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="xbrli-shares">89641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Fact-44c098a1-7031-4fa6-a87d-63d67ddec267_20151231" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember">P7Y5M27D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 id="Fact-4174b2dd-c9f9-4709-b634-01002eb8ef01_20151231" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember">P4Y3M22D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="Fact-bac7629c-b1d7-4a00-874b-e4ef8c00b6dd_20151231" decimals="2" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="iso4217-USD_xbrli-shares">2.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Fact-7cc34116-d894-4f8a-91cb-be5406bbcbec_20151231" decimals="2" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="iso4217-USD_xbrli-shares">0.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Fact-913f0a4c-80dd-49c4-a7a5-19415e3db613_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="xbrli-shares">32390</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Fact-af3b4c92-8d9e-434b-b7bd-5c871f875e12_20151231" decimals="2" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementScenarioAxis_us-gaap-ProFormaMember" unitRef="iso4217-USD_xbrli-shares">-2.84</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Fact-37e58af8-3d04-4137-bca4-9e3816995bd7_20151231" decimals="0" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementScenarioAxis_us-gaap-ProFormaMember" unitRef="xbrli-shares">7471303</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:DeferredOfferingCosts id="Fact-ca05b220-f786-438a-9e0b-8b385d281bac_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-BalanceSheetLocationAxis_us-gaap-PrepaidExpensesAndOtherCurrentAssetsMember" unitRef="iso4217-USD">233000</us-gaap:DeferredOfferingCosts>
  <us-gaap:DeferredFinanceCostsGross id="Fact-df9df2e2-e286-4fee-b60d-da0da6b71955_20151231" decimals="-3" contextRef="I2014-01-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember" unitRef="iso4217-USD">22000</us-gaap:DeferredFinanceCostsGross>
  <us-gaap:DeferredFinanceCostsGross id="Fact-eab17a6f-f0fd-40c7-8a6a-f64386979eea_20151231" decimals="-3" contextRef="I2012-08-28_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember" unitRef="iso4217-USD">38000</us-gaap:DeferredFinanceCostsGross>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity id="Fact-d5118daa-5e66-4a05-9e38-516b7ad53d9e_20151231" decimals="-3" contextRef="I2012-08-28_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember" unitRef="iso4217-USD">1000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:DebtInstrumentTerm id="Fact-659b171d-5165-479a-8235-ee2085ce595c_20151231" contextRef="D2014-01-01_2014-12-31_us-gaap-DebtInstrumentAxis_coll-CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember">P36M</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis id="Fact-fb9f1b35-bc23-4d00-90fd-e7e8a7f4402f_20151231" contextRef="D2014-01-01_2014-01-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember_us-gaap-VariableRateAxis_us-gaap-PrimeRateMember">1.75%</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
  <us-gaap:DebtInstrumentCarryingAmount id="Fact-df423f2e-0ce0-4f21-a8c1-549ee788ca80_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember" unitRef="iso4217-USD">8000000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DeferredFinanceCostsNet id="Fact-b60fea25-d858-4354-8861-dd5cb7d4a84d_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember" unitRef="iso4217-USD">7000</us-gaap:DeferredFinanceCostsNet>
  <us-gaap:DebtInstrumentCarryingAmount id="Fact-af96e9a6-b7ad-41e3-87c7-df296cae5d1a_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember" unitRef="iso4217-USD">958000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DeferredFinanceCostsNet id="Fact-a492314d-9ac7-42c3-81cd-734fd841a200_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember" unitRef="iso4217-USD">15000</us-gaap:DeferredFinanceCostsNet>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="Fact-a93e9a27-16a7-4d65-a3c2-0ee9c3551b60_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember_us-gaap-VariableRateAxis_us-gaap-PrimeRateMember" unitRef="xbrli-pure">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="Fact-15c7b850-cd05-4ac2-bf02-6d0e3dd3514f_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember_us-gaap-VariableRateAxis_us-gaap-PrimeRateMember" unitRef="xbrli-pure">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:DebtConversionOriginalDebtAmount1 id="Fact-36327290-42b0-4a35-8212-ecd153555bdd_20151231" decimals="-3" contextRef="D2015-03-06_2015-03-06_us-gaap-DebtConversionByUniqueDescriptionAxis_coll-ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_us-gaap-RelatedPartyTransactionAxis_coll-ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember_us-gaap-RelatedPartyTransactionsByRelatedPartyAxis_us-gaap-InvestorMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="iso4217-USD">5000000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="Fact-c1ad7102-5818-447d-9458-314dc536f7df_20151231" decimals="INF" contextRef="D2015-03-06_2015-03-06_us-gaap-DebtConversionByUniqueDescriptionAxis_coll-ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_us-gaap-RelatedPartyTransactionAxis_coll-ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember_us-gaap-RelatedPartyTransactionsByRelatedPartyAxis_us-gaap-InvestorMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="xbrli-shares">4166667</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:ConversionOfStockSharesIssued1 id="Fact-a6c9b72c-ba3c-4832-98b6-d4ec36e1b2c1_20151231" decimals="INF" contextRef="D2012-02-01_2012-02-29_us-gaap-ConversionOfStockByUniqueDescriptionAxis_coll-ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="xbrli-shares">18464674</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="Fact-57318526-42b9-48f6-8e81-7b077c403c82_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-ConversionOfStockByUniqueDescriptionAxis_coll-ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="xbrli-shares">8658344</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="Fact-a0ed7356-5395-4c7d-b08a-d082aaa54816_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-ConversionOfStockByUniqueDescriptionAxis_coll-ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="xbrli-shares">27324237</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="Fact-be8f1131-29a5-4c6b-be59-91f6527ee549_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-ConversionOfStockByUniqueDescriptionAxis_coll-ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="xbrli-shares">18498419</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="Fact-ae8d2fb4-a5af-4933-ada6-3c2abe30d9a7_20151231" decimals="INF" contextRef="I2014-08-31_us-gaap-ClassOfWarrantOrRightAxis_coll-CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_us-gaap-StatementScenarioAxis_us-gaap-ProFormaMember" unitRef="xbrli-shares">12548</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="Fact-c40bcea8-3b07-4163-8303-54924ba6d60d_20151231" decimals="INF" contextRef="I2013-12-31_us-gaap-ClassOfWarrantOrRightAxis_coll-CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member_us-gaap-StatementScenarioAxis_us-gaap-ProFormaMember" unitRef="xbrli-shares">1725</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="Fact-9a625ab9-7caa-4dea-a34f-d6442047902b_20151231" decimals="INF" contextRef="I2013-12-31_us-gaap-ClassOfWarrantOrRightAxis_coll-SeriesaPreferredStockWarrantMember" unitRef="xbrli-shares">16873</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="Fact-cbbaf15a-e845-4566-88f7-28a3883d4a06_20151231" decimals="INF" contextRef="I2012-02-29_us-gaap-ClassOfWarrantOrRightAxis_coll-SeriesaPreferredStockWarrantMember_us-gaap-ConversionOfStockByUniqueDescriptionAxis_coll-ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember" unitRef="xbrli-shares">33746</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Fact-cd901226-24fa-4250-b21f-dfc07a838afb_20151231" decimals="2" contextRef="I2014-08-31_us-gaap-ClassOfWarrantOrRightAxis_coll-CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" unitRef="iso4217-USD_xbrli-shares">0.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="Fact-a2e075f0-ee6c-458b-8cfa-b0a04e7c1e9d_20151231" decimals="INF" contextRef="I2014-08-31_us-gaap-ClassOfWarrantOrRightAxis_coll-CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" unitRef="xbrli-shares">86580</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Fact-fa33de8e-bfe8-4ecb-ada6-eca16c064b99_20151231" decimals="2" contextRef="I2014-02-28_us-gaap-ClassOfWarrantOrRightAxis_coll-CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" unitRef="iso4217-USD_xbrli-shares">0.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="Fact-c946d874-1571-4d54-96a3-f19744fb052c_20151231" decimals="INF" contextRef="I2014-02-28_us-gaap-ClassOfWarrantOrRightAxis_coll-CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" unitRef="xbrli-shares">14430</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Fact-465efa42-de85-46ff-87b1-4f26ac1b906b_20151231" decimals="2" contextRef="I2014-01-31_us-gaap-ClassOfWarrantOrRightAxis_coll-CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_us-gaap-StatementScenarioAxis_us-gaap-ProFormaMember" unitRef="iso4217-USD_xbrli-shares">0.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="Fact-0ffecf2a-f009-4520-9211-a924f06c94b2_20151231" decimals="INF" contextRef="I2014-01-31_us-gaap-ClassOfWarrantOrRightAxis_coll-CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_us-gaap-StatementScenarioAxis_us-gaap-ProFormaMember" unitRef="xbrli-shares">2091</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Fact-f49e53b8-76e7-460e-8125-9baaed49357f_20151231" decimals="2" contextRef="I2012-08-28_us-gaap-ClassOfWarrantOrRightAxis_coll-CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member_us-gaap-StatementScenarioAxis_us-gaap-ProFormaMember" unitRef="iso4217-USD_xbrli-shares">0.48</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="Fact-cfb5ce3f-a10e-4e45-bfad-5e957a114995_20151231" decimals="INF" contextRef="I2012-08-28_us-gaap-ClassOfWarrantOrRightAxis_coll-CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member_us-gaap-StatementScenarioAxis_us-gaap-ProFormaMember" unitRef="xbrli-shares">3450</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Fact-92a96236-2e30-419d-a7c4-5b259d9a4df9_20151231" decimals="2" contextRef="I2012-08-28_us-gaap-ClassOfWarrantOrRightAxis_coll-CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" unitRef="iso4217-USD_xbrli-shares">0.07</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="Fact-712babee-5796-44bf-bb78-6b6aed89d4d1_20151231" decimals="INF" contextRef="I2012-08-28_us-gaap-ClassOfWarrantOrRightAxis_coll-CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" unitRef="xbrli-shares">23810</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Fact-b1368be0-9041-4c4e-96b4-c99df76290f4_20151231" decimals="3" contextRef="I2010-11-30_us-gaap-ClassOfWarrantOrRightAxis_coll-PreferredStockWarrantsIssuedNovember2010Member" unitRef="iso4217-USD_xbrli-shares">1.778</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="Fact-3266fb65-6f14-4252-9e04-c86bff6c8e36_20151231" decimals="INF" contextRef="I2010-11-30_us-gaap-ClassOfWarrantOrRightAxis_coll-PreferredStockWarrantsIssuedNovember2010Member" unitRef="xbrli-shares">33746</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="Fact-2c83a115-f30c-42f4-a30b-7dd9fc4d94f8_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-FairValueByMeasurementBasisAxis_us-gaap-CarryingReportedAmountFairValueDisclosureMember" unitRef="iso4217-USD">1634000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="Fact-c9aeb0b5-3c0d-4e36-9f24-d9db349920c5_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-FairValueByMeasurementBasisAxis_us-gaap-CarryingReportedAmountFairValueDisclosureMember" unitRef="iso4217-USD">7551000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Fact-9735a3f1-655c-4a0c-ae7b-4f35c7088a43_20151231" decimals="-3" contextRef="I2012-12-31" unitRef="iso4217-USD">11936000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity id="Fact-6282990e-e17e-42bf-a7a9-ff80a1ded45d_20151231" decimals="-3" contextRef="I2012-12-31" unitRef="iso4217-USD">-61404000</us-gaap:StockholdersEquity>
  <us-gaap:AreaOfRealEstateProperty id="Fact-3dea1f7f-246f-429e-9c89-61eeff2068bb_20151231" decimals="0" contextRef="I2015-03-31_us-gaap-LeaseArrangementTypeAxis_coll-OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="utr-sqft">19335</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:AreaOfRealEstateProperty id="Fact-d873b4fb-2161-4480-8bf4-9a26403a3afa_20151231" decimals="0" contextRef="I2015-03-31_us-gaap-LeaseArrangementTypeAxis_coll-AmendmentToOfficeAndResearchFacilityOperatingLeaseMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="utr-sqft">9660</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Fact-a87bf124-a4c1-4290-98d6-d1ff612c89e4_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-WarrantMember" unitRef="xbrli-shares">18809</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Fact-9c179583-d585-46c6-962f-8cd223711a05_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-RestrictedStockMember" unitRef="xbrli-shares">15387</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Fact-bca17e53-f189-44ce-b57f-e4fd83e2424c_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-RedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">6552820</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Fact-18a86629-424a-4dfa-830e-7f329ae1f8ff_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="xbrli-shares">281029</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Fact-1faaf353-9172-4e72-b9cc-ddfba3a54c67_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-WarrantMember" unitRef="xbrli-shares">4170</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Fact-e9eaa07d-9d6b-4e87-ba72-f96726427dcc_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-RestrictedStockMember" unitRef="xbrli-shares">55298</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Fact-d32626fd-aad8-4853-83e3-6fe33a4d7edd_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-RedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">6552820</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Fact-77f4eb3d-4b01-45b1-9900-0650e6adc663_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="xbrli-shares">229791</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Fact-e0f414a5-ce92-4ad1-9ab9-01a47fc311a7_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31_us-gaap-IncomeStatementLocationAxis_us-gaap-ResearchAndDevelopmentExpenseMember" unitRef="iso4217-USD">12000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Fact-e00ecc7e-91df-4b0f-aa89-c550e04eebc9_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31_us-gaap-IncomeStatementLocationAxis_us-gaap-GeneralAndAdministrativeExpenseMember" unitRef="iso4217-USD">10000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Fact-217f8e8f-d0c4-40cb-b0b3-8708da29f539_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-IncomeStatementLocationAxis_us-gaap-ResearchAndDevelopmentExpenseMember" unitRef="iso4217-USD">24000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Fact-f3487a6e-babf-4af6-aa84-14f34f0041e7_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-IncomeStatementLocationAxis_us-gaap-GeneralAndAdministrativeExpenseMember" unitRef="iso4217-USD">38000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Fact-4bbceebe-6ef0-49f0-9a3d-273db3d5c3eb_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">22000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Fact-d1220758-719b-4c18-a169-482d77e0e663_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">72000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <coll:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="Fact-30784529-22ac-4b7a-90d2-59b44d5d954c_20151231" decimals="INF" contextRef="D2015-03-06_2015-03-06_us-gaap-RelatedPartyTransactionAxis_us-gaap-PrivatePlacementMember_us-gaap-RelatedPartyTransactionsByRelatedPartyAxis_us-gaap-InvestorMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="xbrli-shares">41666667</coll:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock id="Fact-ad942448-c76d-4dc4-8090-8b6ab46316cc_20151231" decimals="-3" contextRef="D2015-03-06_2015-03-06_us-gaap-RelatedPartyTransactionAxis_us-gaap-PrivatePlacementMember_us-gaap-RelatedPartyTransactionsByRelatedPartyAxis_us-gaap-InvestorMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="iso4217-USD">45000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="Fact-49be0c46-1652-4cd4-ae7d-bc0a6fc1af9b_20151231" decimals="-3" contextRef="D2015-03-06_2015-03-06_us-gaap-RelatedPartyTransactionAxis_us-gaap-PrivatePlacementMember_us-gaap-RelatedPartyTransactionsByRelatedPartyAxis_us-gaap-InvestorMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember_us-gaap-SubsequentEventTypeAxis_us-gaap-SubsequentEventMember" unitRef="iso4217-USD">50000000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <coll:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="Fact-312d57b6-fbe3-4405-9c4f-9cd0e036deda_20151231" decimals="INF" contextRef="D2013-08-01_2013-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheOneMember" unitRef="xbrli-shares">2886004</coll:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock id="Fact-621ee7a4-e5fa-406d-970c-d7cec60e194d_20151231" decimals="-3" contextRef="D2013-08-01_2013-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheOneMember" unitRef="iso4217-USD">4000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
  <coll:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="Fact-58d568d3-a8b6-4168-aac5-e991da097bf6_20151231" decimals="INF" contextRef="D2012-02-01_2012-02-29_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesBPreferredStockFinancingFebruary2012Member" unitRef="xbrli-shares">27324237</coll:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <coll:TemporaryEquityStockIssuedIssuanceCosts id="Fact-28df6f5b-7a5f-4773-be31-4b328fbce8a7_20151231" decimals="-3" contextRef="D2012-02-01_2012-02-29_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesBPreferredStockFinancingFebruary2012Member" unitRef="iso4217-USD">147000</coll:TemporaryEquityStockIssuedIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock id="Fact-ecf9c354-07a0-4d86-9c9f-44edea00a149_20151231" decimals="-3" contextRef="D2012-02-01_2012-02-29_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesBPreferredStockFinancingFebruary2012Member" unitRef="iso4217-USD">20050000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
  <coll:TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue id="Fact-e1219edb-35f9-465d-a32f-26d1b76bcacc_20151231" decimals="-3" contextRef="D2013-12-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="iso4217-USD">12239000</coll:TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="Fact-9cb8efcf-e164-4b39-9079-5cb4ee5ed514_20151231" decimals="1" contextRef="D2013-12-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="xbrli-pure">0.5</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <coll:TemporaryEquityShareholderSharesOwned id="Fact-0f061cba-4347-4dfb-8e1f-80220c1946f9_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_us-gaap-RedeemableConvertiblePreferredStockMember_us-gaap-StatementScenarioAxis_coll-ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember" unitRef="xbrli-shares">1000000</coll:TemporaryEquityShareholderSharesOwned>
  <coll:TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments id="Fact-f1fbaa59-ceba-4ff1-8db6-ddcc2fc31745_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-RedeemableConvertiblePreferredStockMember" unitRef="coll-installment">3</coll:TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments>
  <coll:TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage id="Fact-768b0ea0-29cb-450c-98f5-43000a1a407f_20151231" decimals="2" contextRef="D2014-01-01_2014-12-31_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_us-gaap-RedeemableConvertiblePreferredStockMember" unitRef="xbrli-pure">0.60</coll:TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage>
  <us-gaap:TemporaryEquityLiquidationPreference id="Fact-85d82d41-95e7-4bb4-ae70-1654094a2655_20150930" decimals="-3" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="iso4217-USD">13114000</us-gaap:TemporaryEquityLiquidationPreference>
  <coll:TemporaryEquityCumulativeAccretionOfDividends id="Fact-ac8aa794-36dc-403c-a973-e0e3cc338a28_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="iso4217-USD">1114000</coll:TemporaryEquityCumulativeAccretionOfDividends>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Fact-60897bc5-535c-4e5c-a357-ba9983b5ffdb_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="iso4217-USD">13114000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="Fact-f078f7da-4c71-4496-9843-2a91604b59d5_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="Fact-06773823-b67f-4aa2-ba55-e3df457f83a4_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="xbrli-shares">8658344</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="Fact-8eb4aaf9-bbd4-4f76-a349-ebcec77284f8_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="xbrli-shares">8658008</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="Fact-6d99ebb9-3129-4cea-8cce-c9377892a2f3_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="xbrli-shares">8658008</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityLiquidationPreference id="Fact-455f6c53-d44a-4f7e-a32e-31b3f65bb74e_20150930" decimals="-3" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="iso4217-USD">51212000</us-gaap:TemporaryEquityLiquidationPreference>
  <coll:TemporaryEquityCumulativeAccretionOfDividends id="Fact-2996e610-d2a5-4fc9-82ee-568aa38a92df_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="iso4217-USD">5307000</coll:TemporaryEquityCumulativeAccretionOfDividends>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Fact-3cf89584-7e9b-4308-bfef-7730ce075605_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="iso4217-USD">51212000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="Fact-951a6adb-7e01-4146-8e40-f8727346604c_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="Fact-b92971a1-6f16-43f6-823a-2abf03779bec_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="xbrli-shares">27324237</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="Fact-20995936-144a-4d6b-a2c9-b10a35985fb5_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="xbrli-shares">27324237</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="Fact-ecd3112d-98e5-4447-aeb2-957c03b9be38_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="xbrli-shares">27324237</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityLiquidationPreference id="Fact-faea6319-bf12-4d97-915c-dc53b1e6e4a8_20150930" decimals="-3" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="iso4217-USD">12781000</us-gaap:TemporaryEquityLiquidationPreference>
  <coll:TemporaryEquityCumulativeAccretionOfDividends id="Fact-6fea89cf-9097-4229-acfa-e30897781afd_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="iso4217-USD">2371000</coll:TemporaryEquityCumulativeAccretionOfDividends>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Fact-7c9f2415-179b-4554-9146-261e8f08c64f_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="iso4217-USD">12781000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="Fact-26a60d85-18f6-4d66-8860-8b35d7c1b62a_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="Fact-5c63a397-c831-4697-9b28-c8815ec5dedc_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="xbrli-shares">18498419</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="Fact-94783dcf-2286-42ba-9d1e-617f07eec3ca_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="xbrli-shares">9232334</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="Fact-079967cc-ec5b-4487-b7a6-c77ca34b4ba1_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="xbrli-shares">9232334</us-gaap:TemporaryEquitySharesOutstanding>
  <coll:TemporaryEquityCumulativeAccretionOfDividends id="Fact-3015d9b7-a0b9-473b-8402-b5e08e79bc5c_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="iso4217-USD">2371000</coll:TemporaryEquityCumulativeAccretionOfDividends>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Fact-c4c2ce1e-85c4-4fc0-b2db-033ad8d4e1df_20151231" decimals="-3" contextRef="I2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="iso4217-USD">12277000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="Fact-75e814ae-acaa-4828-b97d-bd2c5bdba6e8_20151231" decimals="INF" contextRef="I2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="Fact-b4fcda13-9965-4752-a93b-addda44ed4eb_20151231" decimals="INF" contextRef="I2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="xbrli-shares">18498419</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="Fact-9eca71f5-c068-45a3-9118-59cc053873ad_20151231" decimals="INF" contextRef="I2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="xbrli-shares">9232334</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="Fact-42b0aef5-f0b6-4613-af10-db938f8ec242_20151231" decimals="INF" contextRef="I2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="xbrli-shares">9232334</us-gaap:TemporaryEquitySharesOutstanding>
  <coll:TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage id="Fact-3af0fe6e-1005-4794-8dc2-a1529ec180af_20151231" decimals="2" contextRef="D2014-01-01_2014-12-31_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="xbrli-pure">0.66</coll:TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage>
  <coll:TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage id="Fact-366c684b-4bbc-48c1-865f-e10052ec8396_20151231" decimals="2" contextRef="D2014-01-01_2014-12-31_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="xbrli-pure">0.66</coll:TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage>
  <coll:TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage id="Fact-b551ad3a-1196-4092-afec-db11dc9202a3_20151231" decimals="2" contextRef="D2014-01-01_2014-12-31_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="xbrli-pure">0.66</coll:TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage>
  <coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue id="Fact-615ae2c2-abfa-4b65-940c-50eff936b5b2_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="iso4217-USD">960000</coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue>
  <coll:TemporaryEquityConvertibleConversionPrice id="Fact-535d645e-8bac-4533-95eb-42752e435934_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="iso4217-USD_xbrli-shares">9.59</coll:TemporaryEquityConvertibleConversionPrice>
  <coll:TemporaryEquityLiquidationRightsOriginalIssuePricePerShare id="Fact-597f1a8e-e047-42e9-85f7-e4adc562e76a_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="iso4217-USD_xbrli-shares">9.59</coll:TemporaryEquityLiquidationRightsOriginalIssuePricePerShare>
  <coll:TemporaryEquityLiquidationRightsPerShareIssuePriceRatio id="Fact-52567d16-d7e2-412b-bd89-d87c69525ad6_20151231" decimals="0" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="xbrli-pure">1</coll:TemporaryEquityLiquidationRightsPerShareIssuePriceRatio>
  <coll:TemporaryEquityRightsToElectDirectorsNumberOfDirectors id="Fact-7a438cd4-2628-4ce3-bd71-c81baf8484a7_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="coll-director">1</coll:TemporaryEquityRightsToElectDirectorsNumberOfDirectors>
  <us-gaap:PreferredStockDividendRatePercentage id="Fact-82a56a50-a45e-4dfc-adaa-fef3a4604bcc_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="xbrli-pure">0.08</us-gaap:PreferredStockDividendRatePercentage>
  <coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue id="Fact-3b994458-abb5-4b1d-b028-36f6a4781598_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="iso4217-USD">1836000</coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue>
  <coll:TemporaryEquityConvertibleConversionPrice id="Fact-6a1fbab5-338b-44b6-9339-bd3abc79de69_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="iso4217-USD_xbrli-shares">5.80</coll:TemporaryEquityConvertibleConversionPrice>
  <coll:TemporaryEquityLiquidationRightsOriginalIssuePricePerShare id="Fact-50549593-7879-4d1d-b091-b04bf27ce780_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="iso4217-USD_xbrli-shares">5.80</coll:TemporaryEquityLiquidationRightsOriginalIssuePricePerShare>
  <coll:TemporaryEquityLiquidationRightsPerShareIssuePriceRatio id="Fact-ce75f7b1-8e86-4db4-adf2-5914198930be_20151231" decimals="0" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="xbrli-pure">2</coll:TemporaryEquityLiquidationRightsPerShareIssuePriceRatio>
  <coll:TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio id="Fact-7a6a85ed-ddf8-413c-b2ef-047c32dfbb7b_20151231" decimals="0" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="xbrli-pure">2</coll:TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio>
  <coll:TemporaryEquityRightsToElectDirectorsNumberOfDirectors id="Fact-5c592efb-8512-4e7a-9b52-e2597f3d1c2e_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="coll-director">1</coll:TemporaryEquityRightsToElectDirectorsNumberOfDirectors>
  <us-gaap:PreferredStockDividendRatePercentage id="Fact-49624588-1b55-4fda-9b12-4d2a75caedd6_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="xbrli-pure">0.08</us-gaap:PreferredStockDividendRatePercentage>
  <coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue id="Fact-c0519fd7-3884-42b2-bb13-37d8352d8769_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="iso4217-USD">504000</coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue>
  <coll:TemporaryEquityConvertibleConversionPrice id="Fact-b71a265d-3c6f-4a4c-b377-d54068b9e61a_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="iso4217-USD_xbrli-shares">8.46</coll:TemporaryEquityConvertibleConversionPrice>
  <coll:TemporaryEquityLiquidationRightsOriginalIssuePricePerShare id="Fact-db56e251-270a-4548-bcc6-97cb65a84db4_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="iso4217-USD_xbrli-shares">8.46</coll:TemporaryEquityLiquidationRightsOriginalIssuePricePerShare>
  <coll:TemporaryEquityLiquidationRightsPerShareIssuePriceRatio id="Fact-90a094dc-35f7-42f2-b7b1-62c7f35dff15_20151231" decimals="0" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="xbrli-pure">1</coll:TemporaryEquityLiquidationRightsPerShareIssuePriceRatio>
  <coll:TemporaryEquityRightsToElectDirectorsNumberOfDirectors id="Fact-8e03a7f8-094c-4dc3-a775-4a91b2d10edb_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="coll-director">2</coll:TemporaryEquityRightsToElectDirectorsNumberOfDirectors>
  <us-gaap:PreferredStockDividendRatePercentage id="Fact-624fbb31-8650-4316-82ee-2105a781f6f0_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="xbrli-pure">0.045</us-gaap:PreferredStockDividendRatePercentage>
  <coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue id="Fact-b65f591e-ead5-4003-9ac1-b12c8529778f_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="iso4217-USD">120000</coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue>
  <coll:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="Fact-c6f350e3-a5d0-4a60-855c-4d99b7effda4_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="xbrli-shares">8658008</coll:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:PaymentsOfStockIssuanceCosts id="Fact-ee25c0f4-8c9f-4d6d-8705-f13cfeacc1dc_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="iso4217-USD">45000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="Fact-fd1627d8-257a-43d5-afcb-76a161ac795c_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="iso4217-USD">12034000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue id="Fact-7cd1e8f7-e14d-45f8-b490-a7f6691f1579_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="iso4217-USD">1836000</coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue>
  <coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue id="Fact-42324c2b-3068-445b-b2fe-1322ad16aef4_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="iso4217-USD">970000</coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue>
  <coll:TemporaryEquityRedemptionValueModificationAdjustment id="Fact-8594fa53-85d6-4e5b-8ba0-3fdf0c1a0aad_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="iso4217-USD">12239000</coll:TemporaryEquityRedemptionValueModificationAdjustment>
  <coll:TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue id="Fact-2b972484-4308-4440-8201-b508f9fb68e6_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="iso4217-USD">12239000</coll:TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue>
  <coll:TemporaryEquityStockIssuedAndOutstandingModificationShares id="Fact-668334c8-df73-489b-8150-bd5ae278394e_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="xbrli-shares">9232340</coll:TemporaryEquityStockIssuedAndOutstandingModificationShares>
  <coll:StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold id="Fact-887f39af-3118-4954-bd1c-d9c9d02890f2_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013TrancheTwoMember" unitRef="iso4217-USD">4000000</coll:StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold>
  <coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding id="Fact-48ffe584-76f8-4fac-a50d-fbf493344b69_20151231" decimals="2" contextRef="I2014-12-31_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember" unitRef="iso4217-USD_xbrli-shares">0.76</coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding>
  <coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding id="Fact-80f1e8a0-b282-4bbf-a803-04fc42670ddc_20151231" decimals="2" contextRef="I2013-12-31_us-gaap-AwardTypeAxis_us-gaap-EmployeeStockOptionMember" unitRef="iso4217-USD_xbrli-shares">0.28</coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding>
  <coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue id="Fact-1a18dccd-13f2-4f16-a814-523b80d427f3_20151231" decimals="2" contextRef="I2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="iso4217-USD_xbrli-shares">1.93</coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="Fact-5440786a-d930-43d9-8e07-10dd69797846_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="xbrli-shares">3412685</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="Fact-a392f040-2844-4437-99eb-5a3c3b664d6f_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="iso4217-USD">215000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="Fact-69be2c08-c788-452a-9806-252c185dbc0c_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="iso4217-USD">570000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="Fact-90875d74-b110-4f95-8994-77adb7928c47_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="xbrli-shares">121304</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="Fact-44b5f2b4-642c-4102-913c-e7a8e737799e_20151231" decimals="2" contextRef="I2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="iso4217-USD_xbrli-shares">1.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="Fact-c9096282-0096-415f-ac5b-8acaf9c8a9c0_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="iso4217-USD">1505000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Fact-7f1a6fd4-14a6-41bf-ac56-104979519734_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="xbrli-shares">281029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Fact-1dfc8e6a-14c0-4509-b65f-e1e4ff12f1ad_20151231" decimals="2" contextRef="I2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="iso4217-USD_xbrli-shares">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="Fact-38aa77f1-5896-4c66-9c28-c4807dd9ac59_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="iso4217-USD">1293000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="Fact-aaa02343-16de-4da2-9a29-4a4d22b37249_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="xbrli-shares">247139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice id="Fact-c692d5c2-9e56-4b93-9e62-1c90b7cd70ef_20151231" decimals="2" contextRef="I2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="iso4217-USD_xbrli-shares">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
  <coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification id="Fact-de5e9754-13d1-42fb-aebb-77b070051fe4_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="xbrli-shares">-229791</coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification>
  <coll:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice id="Fact-d69e0331-a6fa-4eac-9c9a-4f7c09e8cf56_20151231" decimals="2" contextRef="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="iso4217-USD_xbrli-shares">1.17</coll:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="Fact-1661331e-0d6b-4852-87a9-a6476d1ce2c3_20151231" contextRef="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember">P1Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod id="Fact-fa3f0ef5-7217-49cc-a20e-1c991033f85b_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="xbrli-shares">9559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice id="Fact-9b0b76dc-34ca-4f1b-8678-c355cf72cf64_20151231" decimals="2" contextRef="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="iso4217-USD_xbrli-shares">2.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Fact-6d71064e-6138-41c2-b7e3-29b24d9a6ddf_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="xbrli-shares">146730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Fact-23015e01-4969-44af-9540-d8abc1161956_20151231" contextRef="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember">P7Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="Fact-41153520-cbc6-499f-bde7-eda05d0c1b2e_20151231" decimals="2" contextRef="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="iso4217-USD_xbrli-shares">0.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Fact-38f6d9d5-62b8-482c-8d42-22d5b79ee149_20151231" decimals="2" contextRef="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="iso4217-USD_xbrli-shares">0.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Fact-12102e09-ab6b-4542-8a66-4716403d0a95_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="xbrli-shares">1077</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification id="Fact-2fe61ffc-611a-4ae2-8e47-afa527cb2e24_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember" unitRef="xbrli-shares">-58736</coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification>
  <coll:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue id="Fact-e60177de-d766-4c26-a28b-7ea934080709_20151231" decimals="2" contextRef="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember" unitRef="iso4217-USD_xbrli-shares">0.62</coll:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="Fact-1e545d1b-6436-4d20-8642-56ac0b708d0a_20151231" contextRef="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="Fact-8689ccbb-3332-49bc-8da7-66a0f5935358_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember" unitRef="xbrli-shares">89308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue id="Fact-1dfd914c-ca1c-4dc0-a4f6-82020dbf2133_20151231" decimals="2" contextRef="D2013-01-01_2013-12-31_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember" unitRef="iso4217-USD_xbrli-shares">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate id="Fact-58cc4929-6d8a-4af7-b6e1-3a7fe652ba98_20151231" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember_us-gaap-RangeAxis_us-gaap-MinimumMember">P1M</coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate>
  <coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate id="Fact-e6626836-5900-469e-a88e-58ec63771302_20151231" contextRef="D2014-01-01_2014-12-31_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember_us-gaap-RangeAxis_us-gaap-MaximumMember">P3M</coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate>
  <coll:SaleOfStockNumberOfTranches id="Fact-a4a68363-79d9-456b-8208-66f2e6f565da_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013Member" unitRef="coll-tranche">2</coll:SaleOfStockNumberOfTranches>
  <coll:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues id="Fact-a0684918-1c6d-4563-b2fe-ebe761140828_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013Member" unitRef="xbrli-shares">8658008</coll:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <coll:TemporaryEquityStockIssuedIssuanceCosts id="Fact-693d2a23-25f2-4073-a810-96b3e1fdaf6a_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013Member" unitRef="iso4217-USD">45000</coll:TemporaryEquityStockIssuedIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock id="Fact-1028fcb9-329c-432a-b591-c64ba9861ab6_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013Member" unitRef="iso4217-USD">12000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
  <coll:SaleOfStockAuthorizedAmount id="Fact-d5610dfd-7c2c-42af-9a05-88af4e5e3314_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-RangeAxis_us-gaap-MaximumMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013Member" unitRef="iso4217-USD">12000000</coll:SaleOfStockAuthorizedAmount>
  <coll:SaleOfStockNumberOfSharesAuthorizedToBeSold id="Fact-1073bb5e-9584-4934-8636-a36bfa90cf25_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31_us-gaap-RangeAxis_us-gaap-MaximumMember_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember_us-gaap-SubsidiarySaleOfStockAxis_coll-SeriesCPreferredStockFinancing2013Member" unitRef="xbrli-shares">8658008</coll:SaleOfStockNumberOfSharesAuthorizedToBeSold>
  <coll:ReimbursableIncentiveFromLessorGross id="Fact-072417c4-f51e-4a59-832b-d52450190673_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-DebtInstrumentAxis_coll-CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember" unitRef="iso4217-USD">164000</coll:ReimbursableIncentiveFromLessorGross>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="Fact-387d6e46-62fa-47e2-b37a-84bcdb7f2a53_20151231" decimals="INF" contextRef="I2014-12-31_us-gaap-DebtInstrumentAxis_coll-CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember" unitRef="xbrli-pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <coll:LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected id="Fact-f3e07d6c-2857-45a5-921d-9abf635cc2b8_20151231" contextRef="D2014-01-01_2014-12-31_us-gaap-LossContingenciesByNatureOfContingencyAxis_coll-HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember_us-gaap-RangeAxis_us-gaap-MaximumMember">P30M</coll:LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected>
  <coll:IncentiveFromLessorGross id="Fact-5cba6a07-5834-4339-9e01-ca2ec9873ec5_20151231" decimals="-3" contextRef="I2014-12-31_us-gaap-RangeAxis_us-gaap-MaximumMember" unitRef="iso4217-USD">174000</coll:IncentiveFromLessorGross>
  <coll:DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod id="Fact-7011b8c9-960a-42a2-972b-b20027f1463e_20151231" contextRef="D2014-08-01_2014-08-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">P36M</coll:DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod>
  <coll:DebtInstrumentPeriodicPaymentInterestOnlyPeriod id="Fact-7c997aef-6542-44dd-b662-dc6f6a4449e1_20151231" contextRef="D2014-08-01_2014-08-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">P12M</coll:DebtInstrumentPeriodicPaymentInterestOnlyPeriod>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt id="Fact-33a0ca49-f918-48e7-8689-4c64871680ad_20151231" decimals="-3" contextRef="D2014-08-01_2014-08-31_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember" unitRef="iso4217-USD">3000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <coll:DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod id="Fact-36766712-ab46-4a84-888e-6646ef88a4f7_20151231" contextRef="D2014-02-01_2014-02-28_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">P36M</coll:DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod>
  <coll:DebtInstrumentPeriodicPaymentInterestOnlyPeriod id="Fact-677e4830-5311-4e5f-918a-1d60d4457cf0_20151231" contextRef="D2014-02-01_2014-02-28_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">P12M</coll:DebtInstrumentPeriodicPaymentInterestOnlyPeriod>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt id="Fact-49e4599f-6548-4951-979d-b4f9421e78d0_20151231" decimals="-3" contextRef="D2014-02-01_2014-02-28_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember" unitRef="iso4217-USD">2000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ProceedsFromRepaymentsOfNotesPayable id="Fact-2a7c4be4-2413-4d46-b861-8e86eedba52d_20151231" decimals="-3" contextRef="D2014-02-01_2014-02-28_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember" unitRef="iso4217-USD">1056000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
  <coll:DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod id="Fact-f98a61c9-5354-44da-a170-df0af8c2d821_20151231" contextRef="D2012-08-28_2012-08-28_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">P36M</coll:DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod>
  <coll:DebtInstrumentPeriodicPaymentInterestOnlyPeriod id="Fact-a882ccec-9108-4189-a6c4-f2d742cf90b9_20151231" contextRef="D2012-08-28_2012-08-28_us-gaap-DebtInstrumentAxis_coll-SiliconValleyBankLoanAgreement28August2012Member_us-gaap-LongtermDebtTypeAxis_us-gaap-NotesPayableToBanksMember">P12M</coll:DebtInstrumentPeriodicPaymentInterestOnlyPeriod>
  <coll:AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified id="Fact-69170250-3ea2-4f64-99eb-75058d0518c4_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="iso4217-USD">-1000</coll:AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified>
  <coll:CommonStockIssuedAndOutstandingModificationShares id="Fact-c2c9d286-58ef-4be0-bf59-4c142a029f8c_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="xbrli-shares">962962</coll:CommonStockIssuedAndOutstandingModificationShares>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Fact-5e866ea4-60de-4446-9a60-0f3c8547a56c_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-CommonStockMember" unitRef="xbrli-shares">1077</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <coll:AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock id="Fact-611b6a3e-ede5-4b48-9ecf-fdc7a8da4927_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD">3300000</coll:AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock>
  <us-gaap:NetIncomeLoss id="Fact-63d5a5eb-6bc4-45c0-b7f7-7f282974aff4_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD">-17917000</us-gaap:NetIncomeLoss>
  <coll:AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock id="Fact-84c72526-7243-486d-9714-501f0bc36ce7_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">3300000</coll:AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock>
  <coll:AmortizationOfIncentiveFromLessor id="Fact-4766ee7b-9299-4027-a23e-61ed62821b50_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">34000</coll:AmortizationOfIncentiveFromLessor>
  <coll:CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock id="Fact-38c6e247-12fc-4d96-b5af-46fd15befa9b_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="96"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;As of&lt;br /&gt;
December&amp;#160;31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Conversion of Series&amp;#160;A Preferred&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18,498,419&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Conversion of Series&amp;#160;B Preferred&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;27,324,237&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Conversion of Series&amp;#160;C Preferred&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;8,658,344&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Options to purchase common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;3,412,685&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;57,893,685&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</coll:CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock>
  <coll:CommonStockVotingRightsNumber id="Fact-973a1d62-7cbd-4c33-bc77-4e3645b6b125_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31" unitRef="coll-Vote">1</coll:CommonStockVotingRightsNumber>
  <coll:ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock id="Fact-49f8a2bf-26f7-4e40-a3a3-56779ecc079b_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Unaudited Pro Forma Net Loss per Share Information&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Unaudited pro forma net loss per share applicable to common shareholders is computed using the weighted-average number of common shares outstanding after giving effect to the conversion of all the outstanding convertible redeemable preferred stock into shares of common stock as if such conversion had occurred at the beginning of the period presented, or the date of original issuance, if later, and excludes the gain on extinguishment of preferred stock and the accretion of dividends.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</coll:ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock>
  <coll:DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan id="Fact-e2e13853-8f7d-4e70-992e-032c00db80fb_20151231" contextRef="D2014-01-01_2014-12-31">P3M</coll:DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan>
  <coll:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent id="Fact-3112e062-2802-4cad-a035-53d7f09e1588_20151231" decimals="4" contextRef="D2014-01-01_2014-12-31" unitRef="xbrli-pure">0.0000</coll:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent>
  <coll:InitialPublicOfferingCostsPolicyPolicyTextBlock id="Fact-70b952bc-05de-4df4-b1f2-c2c5f8bbbec5_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Initial Public Offering Costs&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company defers direct incremental costs attributable to the initial public offering ("IPO") of its common stock. These costs represent legal, accounting and other direct costs related to the Company's efforts to raise capital through a public sale of its common stock. Future costs will be deferred until the completion of the IPO, at which time they will be reclassified to additional paid-in capital as a reduction of the IPO proceeds. If the Company terminates its plan for an IPO or delays such plan for more than 90&amp;#160;days, any costs deferred will be expensed immediately. As of December&amp;#160;31, 2014, IPO costs were $233 and are included in prepaid expenses and other assets in the balance sheet.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</coll:InitialPublicOfferingCostsPolicyPolicyTextBlock>
  <coll:LesseeLeasingArrangementsOperatingLeasesRentFreeTerm id="Fact-1a7a6eb9-6f4d-49ee-87df-4ed7713995c4_20151231" contextRef="D2014-01-01_2014-12-31">P2M</coll:LesseeLeasingArrangementsOperatingLeasesRentFreeTerm>
  <coll:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted id="Fact-caf3af93-f7db-4e42-b2f4-388fb2e8d5dd_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">-21217000</coll:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
  <coll:PatentCostsIncurredPolicyPolicyTextBlock id="Fact-a4b38d12-2dab-438f-a1fc-99e36e0a2106_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Patent Costs&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expense as incurred since the recoverability of such expenditures is uncertain.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</coll:PatentCostsIncurredPolicyPolicyTextBlock>
  <coll:PrepaidExpensesAndOtherCurrentAssetsTextBlock id="Fact-ae5e75b2-0f62-4481-ae86-2655b0251248_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;4. PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Prepaid expenses and other current assets consisted of the following:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="42"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="42"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;As of December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Other current assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;253&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Initial public offering costs&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;233&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Employee advances&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;21&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;33&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Prepaid expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;33&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;8&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Prepaid development costs&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;656&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Prepaid expenses and other current assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;710&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;527&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</coll:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
  <coll:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock id="Fact-bb59f4fd-c875-483a-ab61-f0a67122b53b_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" width="40%" align="center"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="40%" align="center"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Asset Category&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Estimated Useful Life&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;Machinery and equipment&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;5&amp;#160;years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;Computers and office equipment&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;5&amp;#160;years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;Furniture and fixtures&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;7&amp;#160;years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;5&amp;#160;years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</coll:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock>
  <coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue id="Fact-5937a3ff-b3e6-4024-bb2d-a4b3998c9a6f_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">3300000</coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue>
  <coll:TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock id="Fact-6f696c1b-c8be-4aca-8a82-8f1d1fc90add_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;10. EQUITY&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;As of December&amp;#160;31, 2013, the authorized capital stock of the Company included 72,000,000 shares of common stock, par value $0.001 per share, 962,960 of which were issued and outstanding. As of December&amp;#160;31, 2013, 54,481,000 shares of preferred stock were authorized, designated as Series&amp;#160;A, Series&amp;#160;B and Series&amp;#160;C Preferred Stock of which 9,232,334, 27,324,237 and 8,658,008 were issued and outstanding, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;As of December&amp;#160;31, 2014, the authorized capital stock of the Company included 72,000,000 shares of common stock, par value $0.001 per share, 1,006,219 of which were issued and outstanding. As of December&amp;#160;31, 2014, 54,481,000 shares of preferred stock were authorized, designated as Series&amp;#160;A, Series&amp;#160;B and Series&amp;#160;C Preferred Stock of which 9,232,334, 27,324,237 and 8,658,008 were issued and outstanding, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Common Stock&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;&lt;i&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" --&gt;General&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The voting, dividend and liquidation rights of the holders of shares of common stock are subject to and qualified by the rights, powers and preferences of the holders of shares of preferred stock. Common stock has the characteristics described herein.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;&lt;i&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" --&gt;Voting&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The holders of shares of common stock are entitled to one vote for each share of common stock held, may act by written consent in lieu of shareholder's meetings in accordance with the Company's articles of incorporation, and shall be entitled to notice of shareholder's meetings.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;&lt;i&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" --&gt;Dividends&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company shall not declare, pay or set aside any dividends on shares of common stock (other than dividends on shares of common stock payable in shares of common stock) unless in addition to obtaining any consents required by law and/or the Company's articles of incorporation, the holders of Series&amp;#160;A, Series&amp;#160;B and Series&amp;#160;C Preferred Stock then outstanding receive a dividend payment as specified in the Company's articles of incorporation.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;&lt;i&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" --&gt;Liquidation&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;After payment of all preferential amounts required to be paid to the holders of shares of Preferred Stock, the remaining assets of the Company available for distribution to the shareholders shall be distributed among the holders of shares of Preferred Stock and common stock pro rata based on the number of shares held by each such holder, treating for this purpose all such securities as if they had been converted to common stock pursuant to the terms of the Company's articles of incorporation immediately prior to such dissolution, liquidation or winding up or deemed liquidation event of the Company.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;&lt;i&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" --&gt;Reserved for future issuance&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company has reserved for future issuance the following number of shares of common stock:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="96"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;As of&lt;br /&gt;
December&amp;#160;31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Conversion of Series&amp;#160;A Preferred&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18,498,419&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Conversion of Series&amp;#160;B Preferred&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;27,324,237&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Conversion of Series&amp;#160;C Preferred&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;8,658,344&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Options to purchase common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;3,412,685&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;57,893,685&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Convertible Redeemable Preferred Stock&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Series&amp;#160;A, B and Series&amp;#160;C Redeemable Convertible Preferred Stock&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In February 2012, the Company exchanged all previously outstanding preferred stock into 18,464,674 shares of Series&amp;#160;A Preferred Stock ("Series&amp;#160;A"), par value $0.001. On the same date, the Company issued 27,324,237 shares of Series&amp;#160;B Preferred Stock ("Series&amp;#160;B"), par value $0.001 for $0.84 per share, which resulted in gross proceeds of $20,050. Closing costs associated with the issuance of the Series&amp;#160;B amounted to $147. These costs were recorded as a reduction of the carrying amount of the Series&amp;#160;B and are being accreted to the carrying value of the applicable preferred stock. During 2013, the Company issued 8,658,008 shares of Series&amp;#160;C Preferred Stock ("Series&amp;#160;C") in exchange for $12,000 in a series of tranches. Costs incurred in connection with the issuance of Series&amp;#160;C amounted to $45 and have been recorded as a reduction to the carrying amount of Series&amp;#160;C and were accreted to the carrying value of the applicable preferred stock. In accordance with the terms of the Series&amp;#160;C Preferred Stock Purchase Agreement, the Company authorized the sale and issuance of up to 8,658,008 shares of Series&amp;#160;C for total gross proceeds of $12,000. Closing costs associated with the issuance of Series&amp;#160;C amounted to $45. The Series&amp;#160;C financing was structured to close in two tranches. The Company determined the right of the investors to purchase shares of Series&amp;#160;C in a future tranche met the definition of a freestanding financial instrument and was recognized as a liability at fair value. The Company adjusted the carrying value of the tranche obligations to its estimated fair value at each reporting date and upon closing of the second tranche in December 2013. Increases or decreases in the fair value of the tranche obligations were recorded as other expense, net, in the statements of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The first tranche closed in August and September 2013 and resulted in the issuance of 2,886,004 shares of Series&amp;#160;C for gross cash proceeds of $4,000. Upon the first tranche closing, the Company recognized a liability of $266 for the fair value of the future tranche obligations. The fair value of the freestanding instrument tranche obligations was determined using Black-Scholes option-pricing models on the date of the issuance using the following assumptions: fair value of Series&amp;#160;C of $1.30, expected life of 0.35 to 0.43&amp;#160;years and expected volatility of 53% to 60%.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The liability related to the tranche obligations was remeasured at fair value up to the date of the closing of the second tranche in December 2013. Upon the closing of the second tranche, the Company derecognized the tranche obligation, which resulted in a net increase in the proceeds allocated to the Series&amp;#160;C shares of $345. The fair value of the freestanding instrument tranche obligations was determined using Black-Scholes option-pricing models on the date of the issuance using the following assumptions: fair value of Series&amp;#160;C of $1.27, expected life of 0.16&amp;#160;years and expected volatility of 52%.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The valuation of the tranche obligation liability was determined to be a Level&amp;#160;3 valuation based upon the use of unobservable inputs. A roll-forward of the recurring fair value measurements of the tranche liability categorized with Level&amp;#160;3 inputs are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="35"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Balance&amp;#160;&amp;#8212; December&amp;#160;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Tranche liability upon issuance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;266&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Change in fair value&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;79&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Tranche liability upon close of tranche&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(345&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Balance&amp;#160;&amp;#8212; December&amp;#160;31, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The closing of the second tranche of Series&amp;#160;C in December 2013 triggered the Performance Adjustment (described below) of the outstanding shares of Series&amp;#160;A and common stock to which the Series&amp;#160;A and common stock were subject to modification in which every two shares of issued and outstanding Series&amp;#160;A and common shares became one share of each class respectively. In connection with the Performance Adjustment, the Company adjusted the carrying value of the outstanding shares of Series&amp;#160;A to its redemption amount by recording a decrease of $12,239.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;As of December&amp;#160;31, 2014, the holders of Series&amp;#160;A, Series&amp;#160;B and Series&amp;#160;C Preferred Stock had rights, preferences, privileges and restrictions as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;&lt;i&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" --&gt;Voting&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The holders of shares of Preferred Stock are entitled to the number of votes equal to the number of whole shares of common stock into which the shares of the applicable series of Preferred Stock held by such holder are convertible as of the record date. Except as provided by law or otherwise, the holders of shares of Preferred Stock vote together with the holders of shares of common stock as a single class. The holders of record of Series&amp;#160;A exclusively and as a separate class are entitled to elect two directors of the Company. The holders of record of Series&amp;#160;B and Series&amp;#160;C exclusively and as a separate class are entitled to elect one director, respectively, of the Company. The Company cannot amend, alter or repeal the preferences, special rights or other powers of the Series&amp;#160;A, Series&amp;#160;B or Series&amp;#160;C without the written consent or affirmative vote of not less than 66% of the then outstanding shares of the respective class.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;&lt;i&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" --&gt;Dividends&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;From and after the issuance of any shares of Series&amp;#160;A, Series&amp;#160;B and Series&amp;#160;C cumulative non-compounding stock, dividends will accrue at a rate of 4.5%, 8.0% and 8.0% per annum respectively per share. In the event a dividend is declared on common stock, Series&amp;#160;A, Series&amp;#160;B and Series&amp;#160;C will receive a dividend equal to the equivalent number of common shares multiplied by the dividend payable on each class of stock. The Company has recorded cumulative accrued dividends for Series&amp;#160;A, Series&amp;#160;B and Series&amp;#160;C of $2,371, $5,307 and $1,114, respectively, as of December&amp;#160;31, 2013 and 2014.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;&lt;i&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" --&gt;Conversion&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Each share of Series&amp;#160;A, Series&amp;#160;B and Series&amp;#160;C is convertible at the option of the holder at any time into such number of fully paid and nonassessable shares of common stock as is determined by dividing the original issue price of each Series by its conversion price of $8.46, $5.80 and $9.59 per share, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Conversion is mandatory for all Series upon an IPO with gross proceeds in excess of $50,000 and a price per share of at least $20.70.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;&lt;i&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" --&gt;Special Mandatory Conversion&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Any holder of at least 1,000,000 shares of Preferred Stock who does not participate in a Qualified Financing by purchasing such holder's applicable portion of the shares of each Preferred Stock, within the time period specified by the Company, are automatically converted into shares of Common Stock at the applicable Conversion Price to that series of Preferred Stock concurrently with the Qualified Financing. A Qualified Financing is a financing or series of financings after the issuance date of the Series&amp;#160;C involving the sale of additional shares of common stock (including pursuant to the conversion of debt) with gross proceeds of more than $1,000.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;&lt;i&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" --&gt;Liquidation Rights&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the affairs of the Company or a Deemed Liquidation Event, the holders of Series&amp;#160;B are entitled to be paid out an amount per share equal to two times the Series&amp;#160;B original issue price of $5.80 plus unpaid accrued dividends. The holders of Series&amp;#160;A and Series&amp;#160;C are entitled to be paid out an amount per share equal to one times the original issue price of $8.46 and $9.59, respectively, plus any unpaid accrued dividends. After the payment of all preferential amounts required to be paid to the holders of the Preferred Stock, all the remaining assets of the Company shall be distributed among the holders of the common and Preferred Stock pro rata based on the number of shares held.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;&lt;i&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" --&gt;Participation&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In the event of liquidation, payment to the holders of Series&amp;#160;C shall precede payment to the holders of Series&amp;#160;B, which shall precede payment to the holders of Series&amp;#160;A. Holders of Series&amp;#160;C shall be paid at their Original Issuance Price plus any unpaid accrued dividends. In the event that the amount to be distributed to the shareholders is in excess of the Series&amp;#160;A, Series&amp;#160;B and Series&amp;#160;C liquidation preferences, the preferred holders shall participate on an as-converted basis with the common stock holders in the distribution of the remaining assets.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;&lt;i&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" --&gt;Redemption&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company shall require a redemption of Series&amp;#160;A, Series&amp;#160;B and Series&amp;#160;C in the event of a deemed liquidation event, including (i)&amp;#160;merger or consolidation, (ii)&amp;#160;sale or transfer of substantially all of the Company's assets or (iii)&amp;#160;sale or exchange or transfer by the Company's shareholders of a majority of the voting power of the Company unless the requisite holders (as defined in the Company's articles of incorporation) elect otherwise.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;There is an optional redemption feature on or after August&amp;#160;27, 2019 for all series of Preferred Stock, upon a vote of at least 60% of the holders of the Preferred Stock voting as a single class. The payment is equal to the original issuance price for Series&amp;#160;A and Series&amp;#160;C and two (2)&amp;#160;times the original issuance price for Series&amp;#160;B, plus unpaid accrued dividends on the date of the redemption. Optional redemption shall be paid in three installments.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;&lt;i&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" --&gt;Protective Provision&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;At any time when there are shares of Series&amp;#160;B and Series&amp;#160;C outstanding the Company will not engage in certain activities (including enter into a liquidating event) without written consent of a majority of the Series&amp;#160;B and Series&amp;#160;C holders.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;&lt;i&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" --&gt;Performance Adjustment&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company's articles of incorporation provided that if the Company raised additional capital in excess of $4,000 after the initial closing of the Series&amp;#160;C financing, that such additional financing would trigger a one-time modification of the Series&amp;#160;A and common stock shares (the "Performance Adjustment"), such that every two shares of issued and outstanding Series&amp;#160;A and common stock became one share of each class, respectively. The Performance Adjustment occurred in December 2013.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</coll:TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock>
  <coll:TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment id="Fact-a51cce12-c928-4a1a-9a72-24a332398d99_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">3300000</coll:TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment>
  <coll:TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock id="Fact-7b321fc9-2cc8-44f2-864c-8cf099cec1d7_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Convertible Redeemable Preferred Stock&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company classifies convertible redeemable preferred stock that is redeemable outside of the Company's control outside of permanent equity. The Company recorded such redeemable preferred stock at fair value upon issuance, net of any issuance costs or discounts, and the carrying value is being increased by periodic accretion to its redemption value at each balance sheet date as if the redeemable preferred stock was redeemable at that date. In the absence of retained earnings these accretion charges are recorded against additional paid-in capital, if any, and then to accumulated deficit.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</coll:TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock>
  <coll:WarrantsDisclosureTextBlock id="Fact-e597d3b4-c02c-4596-9394-0d4a7f15fe01_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;9. WARRANTS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In November 2010, the Company issued to Comerica Bank a warrant to purchase 33,746 shares of a series of then outstanding preferred stock with an exercise price of $1.778 per share through October&amp;#160;28, 2017. In February 2012, all outstanding shares of Preferred Stock were converted to shares of Series&amp;#160;A Preferred Stock. As such the warrant was amended to be exercisable into 33,746 shares of Series&amp;#160;A Preferred Stock. In December 2013, a Performance Adjustment (See Note&amp;#160;10) occurred, pursuant to which the Series&amp;#160;A Preferred Stock and common stock were subject to modification such that every two shares of issued and outstanding Series&amp;#160;A Preferred Stock and common stock became one share of each class respectively, resulting in the warrant being adjusted to represent the right to purchase 16,873 shares of Series&amp;#160;A Preferred Stock. The shares of Series&amp;#160;A Preferred Stock have certain mandatorily redeemable features resulting in the warrant being recorded as a liability and re-measured at each period at fair value. The fair value of the warrant was&lt;/font&gt; &lt;font size="2"&gt;&lt;i&gt;de minimis&lt;/i&gt;&lt;/font&gt; &lt;font size="2"&gt;at December&amp;#160;31, 2013 and December&amp;#160;31, 2014.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In connection with the issuance of the Original Term Loan (See Note&amp;#160;8), in August 2012, the Company issued to SVB a warrant to purchase 3,450 shares of common stock with an exercise price of $0.48 per share through August&amp;#160;27, 2022.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;This Performance Adjustment resulted in the number of common shares issuable upon exercise of the warrant being adjusted to 1,725.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In connection with the execution of Amendment No.&amp;#160;1 to the Original Term Loan in January 2014, the Company issued an additional warrant to the lending financial institution. In January 2014, the Company issued a warrant to purchase 2,091 shares of common stock with an exercise price of $0.35 per share through January&amp;#160;31, 2024. The warrant agreement provides for additional warrant shares to be issued and immediately exercisable upon additional borrowings by the Company. Additional borrowings are contingent upon meeting certain performance measures for the Company's lead product candidate. The Company met the performance measures and in August 2014 additional financing was extended. Based on the terms of the warrant agreement an additional 12,548 shares were granted. The fair value of these warrants was&lt;/font&gt; &lt;font size="2"&gt;&lt;i&gt;de&amp;#160;minimis&lt;/i&gt;&lt;/font&gt; &lt;font size="2"&gt;at December&amp;#160;31, 2013 and December&amp;#160;31, 2014.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</coll:WarrantsDisclosureTextBlock>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock id="Fact-429d397a-ea1e-4532-8216-e012b4c0a07a_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;6. ACCRUED EXPENSES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Accrued expenses consisted of the following:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="42"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="42"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;As of December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued development costs&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;520&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;970&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued compensation&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;449&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;635&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued audit and legal&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;12&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;249&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued interest&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;71&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued other&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;32&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;31&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Total accrued expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,013&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,956&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Fact-670f1292-ed82-47e0-ad2e-e2768ad32e50_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">22000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Fact-a8523149-2410-4092-a6cf-df2ae3fba05b_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">22000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="Fact-26c72ada-77bb-4ab8-8494-a85fb87a1450_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">7000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy id="Fact-2e8636de-8414-4094-9bd2-a9ec646f4ace_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Restricted Cash&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Restricted cash represents cash held in a depository account at a financial institution to collateralize a conditional stand-by letter of credit related to the Company's Canton, Massachusetts facility lease agreement. Restricted cash is reported as non-current unless the restrictions are expected to be released in the next twelve months.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy id="Fact-33676ccf-eddb-4dce-87a2-2c942ec416b7_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Cash and cash equivalents include cash in readily available checking and savings accounts and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company's cash equivalents, which consist of money market funds, are measured at fair value on a recurring basis. As of December&amp;#160;31, 2013 and 2014, the carrying amount of cash and cash equivalents was $7,551 and $1,634, respectively, which approximates fair value and was determined based upon Level&amp;#160;1 inputs. Money market funds are valued using quoted market prices with no valuation adjustments applied. Accordingly, these securities are categorized as Level&amp;#160;1.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:ConcentrationRiskCreditRisk id="Fact-9cdc94af-d079-4220-b1f1-4ad9d9e15452_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Concentration of Credit Risk&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the financial institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:DebtDisclosureTextBlock id="Fact-3f8b29e3-2891-4dd1-8a82-c3f883a2417a_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;8. DEBT&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;On August&amp;#160;28, 2012, the Company entered into a loan agreement ("Original Term Loan") with Silicon Valley Bank ("SVB") to borrow up to a maximum amount of $1,000. In August 2012, October 2012 and February 2013, the Company borrowed $250, $250 and $500, respectively. The Original Term Loan bore interest at a rate per annum of 2.25% above the prime rate fixed at the time of advance of the Original Term Loan (5.50%). The Original Term Loan provided for interest-only payments for the first 12&amp;#160;months based on the date of each borrowing, and, thereafter, 36&amp;#160;monthly payments of principal and interest. In connection with the Original Term Loan, the Company granted SVB a warrant to purchase 23,810 shares of common stock at an exercise price of $0.07 per share (See Note&amp;#160;9).&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In January 2014, the Original Term Loan was amended ("Amendment No.&amp;#160;1") to provide for the following; borrowings of up to $6,000, repayment in full of the Original Term Loan balance outstanding, and an adjustment of the variable interest rate from 2.25% above the prime rate to 1.75% above the prime rate. In February 2014, the Company borrowed $2,000. The proceeds from the initial borrowing were used to pay down the Original Term Loan balance outstanding resulting in the Company receiving $1,056. Borrowings under Amendment No.&amp;#160;1 bore interest at a rate of 5.0%. Amendment No.&amp;#160;1 provided for interest-only payments for the first 12&amp;#160;months based on the date of each borrowing, and thereafter, 36&amp;#160;monthly payments of principal and interest. In connection with Amendment No.&amp;#160;1, the Company granted to SVB a warrant to purchase 14,430 shares of common stock with an exercise price of $0.05 per share (See Note&amp;#160;9).&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In August 2014 the Original Term Loan was further amended ("Amendment No.&amp;#160;2") to provide for total borrowings of up to $8,000. In August 2014 and September 2014 the Company drew down $3,000 and $3,000, respectively. Pursuant to Amendment No.&amp;#160;2, interest-only payments are to be made for the first 12&amp;#160;months based on the date of each borrowing; thereafter, 36&amp;#160;monthly payments of principal and interest are to be made. Borrowings under Amendment 2 bear interest at the rate of 5.0%. The warrant agreement contains a performance clause that the Company met, resulting in additional financing extended and issuance of a warrant to purchase 86,580 additional shares of common stock with an exercise price of $0.05 per share (See Note&amp;#160;9).&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In September 2014, the Original Term Loan was further amended ("Amendment No.&amp;#160;3") to extend the loan draw period through the earlier to occur of September&amp;#160;30, 2014 and an Event of Default.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company capitalized deferred financing costs of approximately $38 in entering into the Original Term Loan, of which approximately $16 was repaid at the time of Amendment No.&amp;#160;1 with the remaining approximately $22 being amortized to interest expense over the term of the debt. The balance of deferred financing costs was approximately $15 and $7 at December&amp;#160;31, 2013 and December&amp;#160;31, 2014 respectively. The total outstanding amount of the loans was $958 and $8,000 at December&amp;#160;31, 2013 and December&amp;#160;31, 2014 respectively. Interest expense on these notes payable totaled $62 and $208 or the years ended December&amp;#160;31, 2013 and December&amp;#160;31, 2014.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In November and December of 2014 the Company entered into a Note Purchase Agreement (the "Bridge Notes") allowing for the issuance of $5,000 of convertible promissory notes to a group of investors (the "Holders") bearing interest at a rate per annum of 6.0%. The Holders are related parties of the Company. All notes become due and payable at the earlier to occur of a qualified financing, a deemed liquidation event and November 2015.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;As of December&amp;#160;31, 2014, future payments under the Company's debt agreements are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 75%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 12%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="49"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;6,194&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;2016&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;2,667&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;2017&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;2,667&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;2018&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;1,479&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Balance as of December&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;13,007&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction id="Fact-37267fe4-4724-4586-a901-608f0ad38502_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">7000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
  <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock id="Fact-ddefae9e-937f-4c0c-9933-0f54df156e6f_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="42"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="42"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;As of December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Other current assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;253&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Initial public offering costs&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;233&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Employee advances&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;21&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;33&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Prepaid expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;33&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;8&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Prepaid development costs&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;656&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Prepaid expenses and other current assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;710&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;527&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
  <us-gaap:DefinedContributionPlanCostRecognized id="Fact-419f63b8-eed6-4075-ae79-d076d790ce48_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">35000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:DepreciationAndAmortization id="Fact-d40b579e-c247-4c6d-a63e-e5e89729c05e_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">187000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="Fact-b704c7bc-f920-4849-9881-80fd6a16593d_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;11. STOCK-BASED COMPENSATION&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Restricted Stock Awards and Stock Options&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In July 2014, the Company adopted the 2014 Stock Incentive Plan (the "Plan"), under which 525,700 shares of common stock are authorized for issuance to employees, officers, directors, consultants and advisors of the Company. As of December&amp;#160;31, 2014, 281,029 of the shares of common stock authorized for issuance pursuant to the Plan were outstanding. In connection with the Company's reincorporation into Virginia in July 2014, each outstanding option to purchase shares of common stock under the 2012 Stock Incentive Plan and 2002 Stock Plan, was automatically terminated and replaced with an option to purchase shares of common stock under the Plan having the same vesting terms and exercise price as the option that was replaced. The Plan provides for granting of both Internal Revenue Service qualified incentive stock options ("ISOs") and non-qualified options ("NQs"), restricted stock awards ("RSAs") and restricted stock units ("RSUs"). Stock options generally vest over a four year period of service; however, certain options contain performance conditions. The options generally have a ten year contractual life and, upon termination, vested options are generally exercisable between one and three months following the termination date, while unvested options are forfeited immediately.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In determining the exercise prices for options granted, the board of directors considered the fair value of the common stock as of the measurement date. The fair value of the common stock was determined by the board of directors based on a variety of factors, including valuations prepared by third parties, Company's financial position, the status of development efforts within the Company, the composition and ability of the current scientific and management teams, the current climate in the marketplace, the illiquid nature of the Company's common stock, arm's length sales of the Company's preferred stock, the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event, among others.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In connection with the Performance Adjustment which occurred on December&amp;#160;4, 2013 (See Note&amp;#160;10) the Company adjusted previously granted and then outstanding options such that for each option exercised, the option holder would receive one share of common stock for every two shares of common stock underlying the grant.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Stock option activity under the Plan is summarized as follows:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="53"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="47"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="55"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="47"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Number&lt;br /&gt;
of Options&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
Average&lt;br /&gt;
Exercise&lt;br /&gt;
Price&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
Average&lt;br /&gt;
Remaining&lt;br /&gt;
Contractual&lt;br /&gt;
Term&lt;br /&gt;
(in years)&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
Intrinsic&lt;br /&gt;
Value&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Outstanding at December&amp;#160;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;323,488&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1.73&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6.94&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;8&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;146,730&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.48&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(1,077&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.62&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Cancelled&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(9,559&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2.76&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Modification&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(229,791&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1.17&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Outstanding at December&amp;#160;31, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;229,791&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1.17&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;7.02&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;117&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;89,641&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.28&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(32,390&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2.21&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Cancelled&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(6,013&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4.42&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Outstanding at December&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;281,029&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.69&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;7.49&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,505&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Vested and expected to vest at December&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;247,139&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.83&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4.31&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,293&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Exercisable at December&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;121,304&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1.38&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4.31&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;570&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;As of December&amp;#160;31, 2013 and 2014, the unrecognized compensation cost related to outstanding options was $40 and $215, respectively, and is expected to be recognized as expense over approximately 1.1&amp;#160;years and 1.0&amp;#160;years, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;As of December&amp;#160;31, 2014, the weighted average fair value of vested options was $1.93.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Additional information about the Company's stock option activity is as follows:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="35"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="35"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;As of&lt;br /&gt;
December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Weighted-average grant date fair value per share of employee option grants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;0.28&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;0.76&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Restricted stock awards under the Plan are summarized as follows:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="51"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="82"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Number of&lt;br /&gt;
Shares&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Weighted-Average&lt;br /&gt;
Grant Date&lt;br /&gt;
Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Unvested at December&amp;#160;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;203,342&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.62&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Vesting of restricted stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(89,308&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.55&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Performance Adjustment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(58,736&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.62&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Unvested at December&amp;#160;31, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;55,298&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.69&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Grant of restricted stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;10,869&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1.24&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Vesting of restricted stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(50,780&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.62&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Unvested at December&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;15,387&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.69&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;As of December&amp;#160;31, 2013 and 2014, the unrecognized compensation cost related to restricted stock awards was $73 and $26, respectively, and is expected to be recognized as expense over approximately 1.2&amp;#160;years and 0.2&amp;#160;years, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Stock-Based Compensation Expense&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company granted stock options to employees for the years ended December&amp;#160;31, 2013 and 2014. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the fair value of the award. Stock options and restricted stock issued to non-board member, non-employees are accounted for using the fair value approach and are subject to periodic revaluation over their vesting terms.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Stock-based compensation for all stock options and restricted stock awards are reported within:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="28"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="28"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Years Ended December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Research and development&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;24&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;12&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;38&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;10&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;62&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;22&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="97" align="center"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="39"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="4" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Years Ended December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="center"&gt;&lt;font size="2"&gt;1.09%&amp;#160;&amp;#8211; 1.22%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1.80&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="center"&gt;&lt;font size="2"&gt;87.8%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;77.1&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Expected term (in years)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="center"&gt;&lt;font size="2"&gt;6.25&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6.25&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="center"&gt;&lt;font size="2"&gt;0.0%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;i&gt;Risk-free Interest Rate.&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the stock option grants.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;i&gt;Expected Volatility.&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Due to the Company's limited operating history and lack of company-specific historical or implied volatility, the expected volatility assumption is based on historical volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology and medical device industries.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;i&gt;Expected Term.&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, through December&amp;#160;31, 2014 it determined the expected life assumption using the simplified method, which is an average of the contractual term of the option and its vesting period. In 2013, some of the stock option grants were in-the-money, based on the retrospective fair value determinations, so the Company determined the expected life using a risk-adjusted method, which adjusts the average of the contractual term of the option and its vesting period for risk, thereby reducing the expected life.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;i&gt;Expected Dividend Yield.&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The expected dividend yield assumption is based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock id="Fact-7d54d684-c485-4032-bfe1-4c771c54474d_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Net loss per Common Share&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock options, warrants, redeemable convertible preferred stock and unvested restricted stock are considered potentially dilutive securities. Because the Company has reported a net loss for the twelve months ended December&amp;#160;31, 2013 and 2014, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Diluted earnings per share is computed using the more dilutive of (i)&amp;#160;the two-class method, or (ii)&amp;#160;the if-converted method. The Company allocates earnings first to preferred shareholders based on dividend rights and then to common and preferred shareholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted earnings (loss) gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants, convertible redeemable preferred stock and the potential issuance of stock upon the conversion of the Company's convertible notes. Common stock equivalent shares are excluded from the computation of diluted earnings (loss) per share if their effect is antidilutive.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="Fact-46ab5d99-b264-4f03-bfb1-718cf70d08df_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;3. NET LOSS PER COMMON SHARE&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. Stock options, warrants, convertible preferred stock and unvested restricted stock are considered to be potentially dilutive securities and are only included in the calculation of diluted net loss per share when their effect is dilutive. For the twelve months ended December&amp;#160;31, 2013 and December&amp;#160;31, 2014, these securities were anti-dilutive due to the net losses in those periods and, therefore, the number of shares used to compute basic and diluted earnings per share are the same for of those periods.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The following table presents the computations of basic and dilutive net loss per share:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="67"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="56"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Years Ended December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Net loss&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(16,197&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(17,917&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Performance Adjustment of Series&amp;#160;A&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;12,239&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accruals of dividends and accretion to redemption value of preferred stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(2,925&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(3,300&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Loss attributable to common shareholders&amp;#160;&amp;#8212; basic and diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(6,883&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(21,217&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Weighted-average shares used in computing basic and diluted net loss per common share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;1,697,044&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;933,997&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Basic and diluted net loss per common share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(4.06&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(22.72&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares):&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="59"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="59"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Years Ended December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Stock Options&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;229,791&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;281,029&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4,170&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18,809&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6,552,820&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6,552,820&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Unvested restricted stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;55,298&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;15,387&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="Fact-5df8e987-6629-48b5-9565-3b6e9edd90e6_20151231" decimals="4" contextRef="D2014-01-01_2014-12-31" unitRef="xbrli-pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="Fact-7fa7b897-0189-4b7d-aca5-55a8946a60d1_20151231" decimals="INF" contextRef="D2014-01-01_2014-12-31" unitRef="xbrli-pure">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="Fact-7c445b70-6698-428d-aad5-5ccb4761f37e_20151231" decimals="4" contextRef="D2014-01-01_2014-12-31" unitRef="xbrli-pure">0.3757</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense id="Fact-4c613e27-6834-41c0-9165-007238d62be0_20151231" decimals="4" contextRef="D2014-01-01_2014-12-31" unitRef="xbrli-pure">0.0017</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="Fact-5cb68418-7f1e-4839-a6ee-f8336bf9e409_20151231" decimals="4" contextRef="D2014-01-01_2014-12-31" unitRef="xbrli-pure">0.0374</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock id="Fact-001ef151-51b0-4f97-bd11-f4dc2cd24eae_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="35"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Balance&amp;#160;&amp;#8212; December&amp;#160;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Tranche liability upon issuance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;266&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Change in fair value&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;79&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Tranche liability upon close of tranche&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(345&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Balance&amp;#160;&amp;#8212; December&amp;#160;31, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet id="Fact-23c3b96a-feef-4b4d-9475-19c538ead38b_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="Fact-d440e82b-5aec-4a33-8b82-761af2e8129c_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Disclosures of fair value information about financial instruments are required, whether or not recognized in the balance sheet, for financial instruments with respect to which it is practicable to estimate that value. The carrying amounts reported in the Company's financial statements for cash and cash equivalents, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these accounts.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Fair Value Measurements and Disclosures describes the fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;b&gt;Level&amp;#160;1&lt;/b&gt;&lt;/font&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. The Company's Level&amp;#160;1 assets and liabilities consist of money market investments.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;b&gt;Level&amp;#160;2&lt;/b&gt;&lt;/font&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level&amp;#160;2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security. The Company does not have Level&amp;#160;2 assets or liabilities.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;b&gt;Level&amp;#160;3&lt;/b&gt;&lt;/font&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Pricing inputs are unobservable for the assets or liabilities, that is, inputs that reflect the reporting entity's own assumptions about the assumptions market participants would use in pricing the assets. Level&amp;#160;3 includes private investments that are supported by little or no market activity. The Company does not have Level&amp;#160;3 assets or liabilities.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Transfers are calculated on values as of the transfer date. There were no transfers between Levels&amp;#160;1, 2 and 3 during the years ended December&amp;#160;31, 2013 and 2014.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:IncomeTaxDisclosureTextBlock id="Fact-6a10202c-f2bf-455d-858e-927ee2847474_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;12. INCOME TAXES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;For the years ended December&amp;#160;31, 2014 and 2013, the Company did not record a current or deferred income tax expense or (benefit) due to current and historical losses incurred by the Company. The Company's losses before income taxes consist solely of domestic losses.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;A reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="42"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="42"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;As of December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Federal income tax (benefit) at statutory rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;34.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;34.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;(Increase) decrease income tax (benefit) resulting from:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Expiration of state net operating losses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(12.11&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Permanent items&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.01&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.17&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Research and experimental credits&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4.19&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;3.74&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(26.07&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(37.57&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Income tax expense (benefit)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company's deferred tax assets and liabilities are comprised of the following:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="53"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="53"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;As of December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Deferred tax assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;21,392&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;28,419&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Depreciation and amortization&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;36&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Research Credits&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,400&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;3,070&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Deferred tax assets before valuation allowance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;23,792&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;31,525&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Valuation allowance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(23,788&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(31,525&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Depreciation and amortization&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(4&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(4&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Net deferred tax assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. As of December&amp;#160;31, 2014 and 2013, based on the Company's history of operating losses, the Company has concluded that it is not more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December&amp;#160;31, 2014 and 2013. The valuation allowance increased $7,737 during the year ended December&amp;#160;31, 2014, due primarily to net operating losses generated. The valuation allowance increased by $5,081 during the year ended December&amp;#160;31, 2013, due primarily to net operating losses generated.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;As of December&amp;#160;31, 2014 and 2013, the Company had U.S. federal net operating loss carryforwards of $78,276 and $60,380, respectively, which may be available to offset future income tax liabilities and expire at various dates through 2034. As of December&amp;#160;31, 2014 and 2013, the Company also had U.S. state net operating loss carryforwards of $34,184 and $16,354, respectively, which may be available to offset future income tax liabilities and expire at various dates through 2034.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Utilization of the NOL and research and development credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that have occurred or that could occur in the future, as required by Section&amp;#160;382 and Section&amp;#160;383 of the Internal Revenue Code of 1986, as amended (the "Code"), as well as similar state and foreign provisions. These ownership changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an "ownership change" as defined by Section&amp;#160;382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50&amp;#160;percentage points of the outstanding stock of a company by certain shareholders. The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since its formation. The Company has not recorded net operating losses that, as a result of these restrictions, will expire unused.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company files income tax returns in the United States and Massachusetts. The federal and Massachusetts income tax returns are generally subject to tax examinations for the tax years ended December&amp;#160;31, 2011 through December&amp;#160;31, 2013. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax authorities to the extent utilized in a future period.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock id="Fact-0d6434f9-9488-43dc-abf8-a4f4db6bdf24_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company accounts for income taxes under the liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the years in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future, in excess of its net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (i)&amp;#160;management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii)&amp;#160;for those tax positions that meet the more likely than not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50&amp;#160;percent likely to be realized upon ultimate settlement with the related tax authority. The Company will recognize interest and penalties related to uncertain tax positions within income tax expense. Any accrued interest and penalties will be included within the related tax liability. As of December&amp;#160;31, 2013 and 2014, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company's statements of operations.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="Fact-19d9468f-756b-4afa-95c5-e8df16c70ffd_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">990000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="Fact-a1f19adf-3bfe-483f-a5b1-adb9ff7af486_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">943000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInDepositsOutstanding id="Fact-de487fc3-4a58-4e8d-9ede-6ebbed40682c_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">2335000</us-gaap:IncreaseDecreaseInDepositsOutstanding>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Fact-0f05ae46-62c2-463b-aea6-3728e6d0548d_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">-183000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestPaid id="Fact-208f0679-3689-4359-9ae2-5bb3da99c878_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">181000</us-gaap:InterestPaid>
  <us-gaap:LeasePolicyTextBlock id="Fact-45338639-3f93-46b9-aa19-768e4a8aef2a_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Deferred Rent&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis for the facilities the Company occupies. The Company's lease for its facility provides for fixed increases in minimum annual rental payments and for additional rent in the form of maintenance and operating costs during the lease term. The total amount of rental payments due over the lease term is being charged to rent expense ratably over the life of the lease.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:LeasePolicyTextBlock>
  <us-gaap:MaturitiesOfSeniorDebt id="Fact-86155304-16ee-4271-bd92-64c3197afd34_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">28000</us-gaap:MaturitiesOfSeniorDebt>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations id="Fact-476da8b2-4957-4fa9-9b41-48a26f653406_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">-5917000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Fact-785cd2d6-e926-43b0-a8e0-f771eb679aa2_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">12038000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Fact-71fbe9fb-b0f4-4a16-9869-da546cd417c3_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">-8000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Fact-89615118-5b06-4f68-9d23-b98c2438526f_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">-17947000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="Fact-b9ef6af8-2dbc-4d18-a080-42fbe98964a3_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In July 2013, the Financial Accounting Standards Board ("FASB") issued ASU No.&amp;#160;2013-11,&lt;/font&gt; &lt;font size="2"&gt;&lt;i&gt;Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exist.&lt;/i&gt;&lt;/font&gt; &lt;font size="2"&gt;ASU&amp;#160;2013-11 amends the presentation requirements of ASC&amp;#160;740 and requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, similar tax loss, or a tax credit carryforward. To the extent the tax benefit is not available at the reporting date under the governing tax law or if the entity does not intend to use the deferred tax asset for such purpose, the unrecognized tax benefit should be presented as a liability and not combined with deferred tax assets. This ASU is effective for annual periods, and interim periods within those years, beginning after December&amp;#160;15, 2013, which is fiscal 2014 for the Company. The amendments are to be applied to all unrecognized tax benefits that exist as of the effective date and may be applied retrospectively to each prior reporting period presented. The adoption of ASU&amp;#160;2013-11 did not have a material impact on the Company's financial position or results of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In May 2014, the FASB issued ASU No.&amp;#160;2014-09,&lt;/font&gt; &lt;font size="2"&gt;&lt;i&gt;Revenue from Contracts with Customers.&lt;/i&gt;&lt;/font&gt; &lt;font size="2"&gt;This ASU is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This ASU is effective for annual reporting periods beginning after December&amp;#160;15, 2016 and early adoption is not permitted. Accordingly, the Company will adopt this ASU on January&amp;#160;1, 2017. Management does not believe the adoption of this ASU will have a material impact on the Company's financial condition, results of operations or cash flows.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In June 2014, the FASB issued ASU No.&amp;#160;2014-12,&lt;/font&gt; &lt;font size="2"&gt;&lt;i&gt;Compensation&amp;#160;&amp;#8212; Stock Compensation (Topic&amp;#160;718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period&lt;/i&gt;&lt;/font&gt;&lt;font size="2"&gt;. ASU&amp;#160;2014-12 applies to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. That is the case when an employee is eligible to retire or otherwise terminate employment before the end of the period in which a performance target (for example, an initial public offering or a profitability target) could be achieved and still be eligible to vest in the award if and when the performance target is achieved. The standard is required to be adopted by public business entities in annual periods beginning on or after December&amp;#160;15, 2015 and interim periods within those annual periods. The Company plans to implement this standard in the first quarter of fiscal year 2016 and is currently evaluating the potential impact of this new guidance on its financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In August 2014, the FASB issued ASU No.&amp;#160;2014-15,&lt;/font&gt; &lt;font size="2"&gt;&lt;i&gt;Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern.&lt;/i&gt;&lt;/font&gt; &lt;font size="2"&gt;ASU&amp;#160;2014-15 requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU&amp;#160;2014-15 is effective for annual periods ending after December&amp;#160;15, 2016 and earlier application is permitted. The adoption of ASU&amp;#160;2014-15 is not expected to have a material effect on the Company's financial statements or disclosures.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In November 2014, the FASB issued ASU No.&amp;#160;2014-16,&lt;/font&gt; &lt;font size="2"&gt;&lt;i&gt;Derivatives and Hedging (Topic&amp;#160;815)&amp;#160;&amp;#8212; Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share is More Akin to Debt or to Equity&lt;/i&gt;&lt;/font&gt;&lt;font size="2"&gt;. This ASU was issued to clarify how current U.S. generally accepted accounting principles should be interpreted in evaluating the economic characteristics and risk of a host contract in a hybrid financial instrument that is issued in the form of a share. In addition, this ASU was issued to clarify that in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (that is, the relative strength of the debt-like or equity-like terms and features given the facts and circumstances) when considering how to weight those terms and features. The effects of initially adopting this ASU should be applied on a modified retrospective basis to existing hybrid financial instruments issued in a form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods. This ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December&amp;#160;15, 2015. Early adoption in an interim period is permitted. The Company is currently evaluating the impact of the adoption of this ASU on its financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock id="Fact-cdfa4219-3ca7-4faf-979c-cf10ff2685fe_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="51"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="82"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Number of&lt;br /&gt;
Shares&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Weighted-Average&lt;br /&gt;
Grant Date&lt;br /&gt;
Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Unvested at December&amp;#160;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;203,342&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.62&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Vesting of restricted stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(89,308&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.55&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Performance Adjustment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(58,736&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.62&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Unvested at December&amp;#160;31, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;55,298&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.69&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Grant of restricted stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;10,869&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1.24&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Vesting of restricted stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(50,780&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.62&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Unvested at December&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;15,387&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.69&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
  <us-gaap:NotesReduction id="Fact-7066abec-ae9f-4b1b-8d6c-1e16bbc31518_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">944000</us-gaap:NotesReduction>
  <us-gaap:OperatingLeasesRentExpenseNet id="Fact-f93c27e9-6288-4d8e-83a3-034313184474_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">69000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="Fact-0e448f2f-9070-44db-9bb1-472cabebf208_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;1. NATURE OF BUSINESS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Organization&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Collegium Pharmaceutical,&amp;#160;Inc. (the "Company") was incorporated in Delaware in April 2002 and then reincorporated in Virginia in July 2014. The Company has its principal operations in Canton, Massachusetts. The Company is a specialty pharmaceutical company developing and planning to commercialize next-generation abuse-deterrent products that incorporate the Company's patented DETERx&amp;#174; platform technology for the treatment of chronic pain and other diseases. The Company's lead product candidate, Xtampza&amp;#8482; ER, or Xtampza, is an abuse-deterrent, extended-release, oral formulation of oxycodone, a widely prescribed opioid medication. Xtampza has received Fast Track status from the U.S. Food and Drug Administration ("FDA"). The Company's new drug application ("NDA") filing for Xtampza was accepted by the FDA on February&amp;#160;10, 2015.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company's operations are subject to certain risks and uncertainties. The risks include negative outcome of clinical trials, inability or delay in completing clinical trials or obtaining regulatory approvals, changing market conditions for products being developed by the Company, the need to retain key personnel and protect intellectual property, patent infringement litigation and the availability of additional capital financing on terms acceptable to the Company.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Basis of Accounting&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The financial statements include the accounts of the Company and are prepared in conformity with accounting principles generally accepted in the United States of America.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Liquidity&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company has experienced net losses and negative cash flows from operating activities since its inception, and as of December&amp;#160;31, 2013 and December&amp;#160;31, 2014, had a deficit accumulated of $80,536 and $101,753, respectively. The Company expects to continue to incur net losses in the foreseeable future. A successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company's cost structure.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;On March&amp;#160;6, 2015, the Company received aggregate consideration of $50,000 from the issuance of Series&amp;#160;D preferred stock, comprised of $45,000 in cash and $5,000 in convertible notes from related parties.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company expects to continue to incur losses for the foreseeable future. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic partners or from other sources. The Company believes that it will have sufficient cash to fund operations and future growth initiatives through December&amp;#160;31, 2015; however, there can be no assurance that the Company will be successful in achieving its projections, reducing costs, or raising additional funds with terms acceptable to the Company. If the Company is unable to obtain financing or increase profitability, the related lack of liquidity will have a material adverse effect on the Company's operations and future prospects.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Fact-56cd1b20-1630-4b64-b7cd-2e976ab7cfc2_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">8000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock id="Fact-c18a66a8-9058-4b30-b27a-1bb9703bae0d_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;13. EMPLOYEE BENEFITS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company has a retirement savings plan, which is qualified under section&amp;#160;401(k) of the Code, for its employees. The plan allows eligible employees to defer, at the employee's discretion, pretax compensation up to the Internal Revenue Service annual limits. Employees become eligible to participate after completing 3&amp;#160;months of service. The Company is not required to contribute to this plan. Total expense for contributions made by the Company was $31 for the year ended December&amp;#160;31, 2013 and $35 for the year ended December&amp;#160;31, 2014.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:ProceedsFromRepaymentsOfNotesPayable id="Fact-be2e8a90-5d54-454e-98b9-51c73db58130_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">7056000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
  <us-gaap:ProceedsFromShortTermDebt id="Fact-9ccc7288-39d3-4c63-9b3f-de94a454fc4c_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">5000000</us-gaap:ProceedsFromShortTermDebt>
  <us-gaap:ProceedsFromStockOptionsExercised id="Fact-2f6db0db-6bc8-4508-a359-9ce4e31ca8bd_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">72000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="Fact-3a1c27a6-f59e-4a03-9e17-e338d3970102_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;5. PROPERTY AND EQUIPMENT&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Property and equipment consisted of the following:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="42"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="42"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;As of December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Machinery and equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;741&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;741&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Computers and office equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;26&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;26&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Furniture and fixtures&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;36&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;44&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;606&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;606&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Total property and equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,409&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,417&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Less: accumulated deprecation&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(716&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(903&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Property and equipment, net&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;693&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;514&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Depreciation expense related to property and equipment amounted to $169 and $187 for the years ended December&amp;#160;31, 2013 and 2014, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentImpairment id="Fact-9b4a39ef-74cb-4335-bf08-8b3aa631e94c_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Impairment of Long-Lived Assets&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Long-lived assets consist of property and equipment. When impairment indicators exist, the Company's management evaluates long-lived assets for potential impairment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. While the Company's current and historical operating losses and negative cash flows are indicators of impairment, management believes that future cash flows to be received support the carrying value of its long-lived assets and, accordingly, has not recognized any impairment losses since inception.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Impairment losses, if any, are recognized in earnings. An impairment loss would be recognized in an amount equal to the excess of the carrying amount over the undiscounted expected future cash flows.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentImpairment>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="Fact-9c97d151-9468-45b1-a4d0-de54e6ed680c_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Property and equipment are recorded at historical cost. Maintenance and repair costs are expensed as incurred. Costs which materially improve or extend the lives of existing assets are capitalized. The Company provides for depreciation and amortization using the straight-line method over the estimated useful lives of the assets, which are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" width="40%" align="center"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="40%" align="center"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Asset Category&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Estimated Useful Life&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;Machinery and equipment&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;5&amp;#160;years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;Computers and office equipment&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;5&amp;#160;years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;Furniture and fixtures&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;7&amp;#160;years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;5&amp;#160;years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Upon retirement or sale, the cost of assets disposed and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recorded in the statements of operations.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="Fact-12ab1f59-8fa3-4852-b32a-05c310276c57_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="42"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="42"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;As of December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Machinery and equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;741&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;741&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Computers and office equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;26&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;26&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Furniture and fixtures&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;36&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;44&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;606&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;606&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Total property and equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,409&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,417&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Less: accumulated deprecation&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(716&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(903&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Property and equipment, net&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;693&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;514&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:RepaymentsOfLongtermLoansFromVendors id="Fact-3375c24e-5114-4b32-8fe0-e73e720fe568_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">62000</us-gaap:RepaymentsOfLongtermLoansFromVendors>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="Fact-5cf93065-a405-4c0a-91e2-b7eda9b42f2f_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Research and Development Costs&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Research and development costs are charged to expense as incurred and consist of costs incurred to further the Company's research and development activities including salaries and employee related costs, costs associated with market research and design, costs associated with conducting preclinical, clinical and regulatory activities including fees paid to third-party professional consultants and service providers, costs incurred under clinical trial agreements, costs for laboratory supplies and laboratory equipment, costs to acquire, develop and manufacture preclinical study and clinical trial materials, facilities, depreciation and other expenses including allocated expenses for rent and maintenance of facilities. Government grants are recognized as a reduction of the qualifying cost being reimbursed.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="Fact-3c1c8af1-c098-4b11-afff-41189535f22c_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="42"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="42"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;As of December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued development costs&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;520&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;970&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued compensation&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;449&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;635&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued audit and legal&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;12&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;249&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued interest&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;71&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued other&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;32&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;31&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Total accrued expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,013&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,956&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="Fact-2f0287e7-f9d2-4d5a-bedb-8d63e9d585d7_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="59"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="59"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Years Ended December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Stock Options&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;229,791&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;281,029&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4,170&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18,809&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6,552,820&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6,552,820&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Unvested restricted stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;55,298&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;15,387&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="Fact-acfc4acb-f9e2-4ca3-b9e5-13f4ef4ecd8f_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="53"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="53"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;As of December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Deferred tax assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;21,392&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;28,419&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Depreciation and amortization&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;36&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Research Credits&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,400&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;3,070&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Deferred tax assets before valuation allowance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;23,792&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;31,525&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Valuation allowance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(23,788&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(31,525&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Depreciation and amortization&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(4&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(4&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Net deferred tax assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="Fact-f35efd42-3f84-4145-b9c3-dc3b387d4f72_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="67"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="56"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Years Ended December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Net loss&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(16,197&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(17,917&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Performance Adjustment of Series&amp;#160;A&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;12,239&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accruals of dividends and accretion to redemption value of preferred stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(2,925&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(3,300&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Loss attributable to common shareholders&amp;#160;&amp;#8212; basic and diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(6,883&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(21,217&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Weighted-average shares used in computing basic and diluted net loss per common share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;1,697,044&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;933,997&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Basic and diluted net loss per common share&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(4.06&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(22.72&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="Fact-bf35cc97-e626-4cef-a21a-2a081832005d_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="42"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="42"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;As of December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Federal income tax (benefit) at statutory rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;34.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;34.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;(Increase) decrease income tax (benefit) resulting from:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Expiration of state net operating losses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(12.11&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Permanent items&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.01&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(0.17&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Research and experimental credits&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4.19&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;3.74&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(26.07&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(37.57&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Income tax expense (benefit)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="Fact-7ef831cf-3182-4b4d-9963-3be8d477adb6_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="28"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="28"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Years Ended December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Research and development&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;24&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;12&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;38&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;10&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;62&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;22&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock id="Fact-aa5e8a97-a733-4b45-9b7a-a5dfb3e17908_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Aggregate minimum annual lease commitments of the Company under its non-cancellable operating lease as of December&amp;#160;31, 2014 are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="31"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" nowrap="nowrap" align="left"&gt;
&lt;div style="MARGIN-BOTTOM: 0pt; WIDTH: 95pt; BORDER-BOTTOM: #000000 1pt solid;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Year Ending December&amp;#160;31, &lt;!-- COMMAND=ADD_SCROPPEDRULE,95pt --&gt;&lt;/b&gt;&lt;/font&gt;&lt;/div&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;106&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;2016&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;111&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;2017&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;116&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Total minimum lease payments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;333&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock id="Fact-675c51d8-2b0d-40a7-b99f-abdb6372faca_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;As of December&amp;#160;31, 2014, future payments under the Company's debt agreements are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 75%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 12%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="49"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;6,194&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;2016&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;2,667&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;2017&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;2,667&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;2018&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;1,479&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Balance as of December&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;13,007&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="Fact-0ad0c6df-70a3-4e70-9844-079ed84dd620_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="53"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="47"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="55"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="47"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Number&lt;br /&gt;
of Options&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
Average&lt;br /&gt;
Exercise&lt;br /&gt;
Price&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
Average&lt;br /&gt;
Remaining&lt;br /&gt;
Contractual&lt;br /&gt;
Term&lt;br /&gt;
(in years)&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
Intrinsic&lt;br /&gt;
Value&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Outstanding at December&amp;#160;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;323,488&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1.73&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6.94&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;8&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;146,730&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.48&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(1,077&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.62&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Cancelled&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(9,559&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2.76&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Modification&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(229,791&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1.17&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Outstanding at December&amp;#160;31, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;229,791&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1.17&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;7.02&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;117&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;89,641&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.28&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(32,390&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2.21&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Cancelled&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(6,013&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4.42&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Outstanding at December&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;281,029&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.69&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;7.49&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,505&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Vested and expected to vest at December&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;247,139&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.83&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4.31&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,293&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Exercisable at December&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;121,304&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1.38&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;4.31&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;570&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="Fact-19adb688-18ec-4a05-8319-9083fcd3e942_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="97" align="center"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="39"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="4" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Years Ended December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="center"&gt;&lt;font size="2"&gt;1.09%&amp;#160;&amp;#8211; 1.22%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1.80&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="center"&gt;&lt;font size="2"&gt;87.8%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;77.1&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Expected term (in years)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="center"&gt;&lt;font size="2"&gt;6.25&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6.25&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="center"&gt;&lt;font size="2"&gt;0.0%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensation id="Fact-b573fe39-1625-47b5-8a27-d78b72517760_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">22000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Fact-dafa4a04-8d25-47d9-8f7d-b8e84110ecfa_20151231" decimals="4" contextRef="D2014-01-01_2014-12-31" unitRef="xbrli-pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Fact-753629a9-c8d6-43ca-8394-7a0d251dbd75_20151231" contextRef="D2014-01-01_2014-12-31">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Fact-97514695-8cb9-4f11-b25d-4793f27b202e_20151231" decimals="4" contextRef="D2014-01-01_2014-12-31" unitRef="xbrli-pure">0.7710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Fact-c34cd044-9c2f-4783-ae38-046f3e4147d8_20151231" decimals="4" contextRef="D2014-01-01_2014-12-31" unitRef="xbrli-pure">0.0180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock id="Fact-3d97ee28-af9e-40cd-9cf5-8ce1cffb1465_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="35"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="35"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;As of&lt;br /&gt;
December&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Weighted-average grant date fair value per share of employee option grants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;0.28&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;0.76&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="Fact-d256f6ea-f7d8-4f81-be09-6500b7d9a280_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company accounts for grants of stock options and restricted stock to employees based on their grant date fair value and recognizes compensation expense over their vesting period. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the fair value of the underlying common stock as determined by management or the value of the services provided, whichever is more readily determinable.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Stock-based compensation expense represents the cost of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of estimated forfeitures. The expense is adjusted for actual forfeitures at year end. Stock-based compensation expense recognized in the financial statements is based on awards that are ultimately expected to vest.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;For stock option grants with performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable or the performance condition has been achieved. For stock option grants with both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company accounts for stock options and restricted stock awards to non-employees using the fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic revaluation over their vesting terms. There were no non-employee grants in 2013 and 2014.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="Fact-37a7daff-f45f-4d3a-b146-faf23487067a_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Use of Estimates&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The preparation of the Company's financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company's financial statements and accompanying notes. The most significant estimates in the Company's financial statements relate to the valuation of equity awards, fair value estimates of warrants, estimated useful lives of fixed assets, asset retirement obligations and accruals related to clinical trials. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company's actual results may differ from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Unaudited Pro Forma Net Loss per Share Information&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Unaudited pro forma net loss per share applicable to common shareholders is computed using the weighted-average number of common shares outstanding after giving effect to the conversion of all the outstanding convertible redeemable preferred stock into shares of common stock as if such conversion had occurred at the beginning of the period presented, or the date of original issuance, if later, and excludes the gain on extinguishment of preferred stock and the accretion of dividends.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Fair Value Measurements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Disclosures of fair value information about financial instruments are required, whether or not recognized in the balance sheet, for financial instruments with respect to which it is practicable to estimate that value. The carrying amounts reported in the Company's financial statements for cash and cash equivalents, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these accounts.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Fair Value Measurements and Disclosures describes the fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;b&gt;Level&amp;#160;1&lt;/b&gt;&lt;/font&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. The Company's Level&amp;#160;1 assets and liabilities consist of money market investments.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;b&gt;Level&amp;#160;2&lt;/b&gt;&lt;/font&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level&amp;#160;2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security. The Company does not have Level&amp;#160;2 assets or liabilities.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;b&gt;Level&amp;#160;3&lt;/b&gt;&lt;/font&gt;&lt;font size="2"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Pricing inputs are unobservable for the assets or liabilities, that is, inputs that reflect the reporting entity's own assumptions about the assumptions market participants would use in pricing the assets. Level&amp;#160;3 includes private investments that are supported by little or no market activity. The Company does not have Level&amp;#160;3 assets or liabilities.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Transfers are calculated on values as of the transfer date. There were no transfers between Levels&amp;#160;1, 2 and 3 during the years ended December&amp;#160;31, 2013 and 2014.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Concentration of Credit Risk&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the financial institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Cash and cash equivalents include cash in readily available checking and savings accounts and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company's cash equivalents, which consist of money market funds, are measured at fair value on a recurring basis. As of December&amp;#160;31, 2013 and 2014, the carrying amount of cash and cash equivalents was $7,551 and $1,634, respectively, which approximates fair value and was determined based upon Level&amp;#160;1 inputs. Money market funds are valued using quoted market prices with no valuation adjustments applied. Accordingly, these securities are categorized as Level&amp;#160;1.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Property and Equipment&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Property and equipment are recorded at historical cost. Maintenance and repair costs are expensed as incurred. Costs which materially improve or extend the lives of existing assets are capitalized. The Company provides for depreciation and amortization using the straight-line method over the estimated useful lives of the assets, which are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left;" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" width="40%" align="center"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="40%" align="center"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Asset Category&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Estimated Useful Life&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;Machinery and equipment&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;5&amp;#160;years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;Computers and office equipment&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;5&amp;#160;years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;Furniture and fixtures&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;7&amp;#160;years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="center"&gt;&lt;font size="2"&gt;5&amp;#160;years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Upon retirement or sale, the cost of assets disposed and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recorded in the statements of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Impairment of Long-Lived Assets&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Long-lived assets consist of property and equipment. When impairment indicators exist, the Company's management evaluates long-lived assets for potential impairment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. While the Company's current and historical operating losses and negative cash flows are indicators of impairment, management believes that future cash flows to be received support the carrying value of its long-lived assets and, accordingly, has not recognized any impairment losses since inception.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Impairment losses, if any, are recognized in earnings. An impairment loss would be recognized in an amount equal to the excess of the carrying amount over the undiscounted expected future cash flows.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Initial Public Offering Costs&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company defers direct incremental costs attributable to the initial public offering ("IPO") of its common stock. These costs represent legal, accounting and other direct costs related to the Company's efforts to raise capital through a public sale of its common stock. Future costs will be deferred until the completion of the IPO, at which time they will be reclassified to additional paid-in capital as a reduction of the IPO proceeds. If the Company terminates its plan for an IPO or delays such plan for more than 90&amp;#160;days, any costs deferred will be expensed immediately. As of December&amp;#160;31, 2014, IPO costs were $233 and are included in prepaid expenses and other assets in the balance sheet.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Restricted Cash&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Restricted cash represents cash held in a depository account at a financial institution to collateralize a conditional stand-by letter of credit related to the Company's Canton, Massachusetts facility lease agreement. Restricted cash is reported as non-current unless the restrictions are expected to be released in the next twelve months.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Deferred Rent&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis for the facilities the Company occupies. The Company's lease for its facility provides for fixed increases in minimum annual rental payments and for additional rent in the form of maintenance and operating costs during the lease term. The total amount of rental payments due over the lease term is being charged to rent expense ratably over the life of the lease.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Convertible Redeemable Preferred Stock&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company classifies convertible redeemable preferred stock that is redeemable outside of the Company's control outside of permanent equity. The Company recorded such redeemable preferred stock at fair value upon issuance, net of any issuance costs or discounts, and the carrying value is being increased by periodic accretion to its redemption value at each balance sheet date as if the redeemable preferred stock was redeemable at that date. In the absence of retained earnings these accretion charges are recorded against additional paid-in capital, if any, and then to accumulated deficit.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Research and Development Costs&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Research and development costs are charged to expense as incurred and consist of costs incurred to further the Company's research and development activities including salaries and employee related costs, costs associated with market research and design, costs associated with conducting preclinical, clinical and regulatory activities including fees paid to third-party professional consultants and service providers, costs incurred under clinical trial agreements, costs for laboratory supplies and laboratory equipment, costs to acquire, develop and manufacture preclinical study and clinical trial materials, facilities, depreciation and other expenses including allocated expenses for rent and maintenance of facilities. Government grants are recognized as a reduction of the qualifying cost being reimbursed.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Patent Costs&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expense as incurred since the recoverability of such expenditures is uncertain.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Stock-Based Compensation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company accounts for grants of stock options and restricted stock to employees based on their grant date fair value and recognizes compensation expense over their vesting period. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the fair value of the underlying common stock as determined by management or the value of the services provided, whichever is more readily determinable.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Stock-based compensation expense represents the cost of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of estimated forfeitures. The expense is adjusted for actual forfeitures at year end. Stock-based compensation expense recognized in the financial statements is based on awards that are ultimately expected to vest.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;For stock option grants with performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable or the performance condition has been achieved. For stock option grants with both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company accounts for stock options and restricted stock awards to non-employees using the fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic revaluation over their vesting terms. There were no non-employee grants in 2013 and 2014.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Income Taxes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company accounts for income taxes under the liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the years in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future, in excess of its net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (i)&amp;#160;management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii)&amp;#160;for those tax positions that meet the more likely than not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50&amp;#160;percent likely to be realized upon ultimate settlement with the related tax authority. The Company will recognize interest and penalties related to uncertain tax positions within income tax expense. Any accrued interest and penalties will be included within the related tax liability. As of December&amp;#160;31, 2013 and 2014, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company's statements of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Net loss per Common Share&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock options, warrants, redeemable convertible preferred stock and unvested restricted stock are considered potentially dilutive securities. Because the Company has reported a net loss for the twelve months ended December&amp;#160;31, 2013 and 2014, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Diluted earnings per share is computed using the more dilutive of (i)&amp;#160;the two-class method, or (ii)&amp;#160;the if-converted method. The Company allocates earnings first to preferred shareholders based on dividend rights and then to common and preferred shareholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted earnings (loss) gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants, convertible redeemable preferred stock and the potential issuance of stock upon the conversion of the Company's convertible notes. Common stock equivalent shares are excluded from the computation of diluted earnings (loss) per share if their effect is antidilutive.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In July 2013, the Financial Accounting Standards Board ("FASB") issued ASU No.&amp;#160;2013-11,&lt;/font&gt; &lt;font size="2"&gt;&lt;i&gt;Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exist.&lt;/i&gt;&lt;/font&gt; &lt;font size="2"&gt;ASU&amp;#160;2013-11 amends the presentation requirements of ASC&amp;#160;740 and requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, similar tax loss, or a tax credit carryforward. To the extent the tax benefit is not available at the reporting date under the governing tax law or if the entity does not intend to use the deferred tax asset for such purpose, the unrecognized tax benefit should be presented as a liability and not combined with deferred tax assets. This ASU is effective for annual periods, and interim periods within those years, beginning after December&amp;#160;15, 2013, which is fiscal 2014 for the Company. The amendments are to be applied to all unrecognized tax benefits that exist as of the effective date and may be applied retrospectively to each prior reporting period presented. The adoption of ASU&amp;#160;2013-11 did not have a material impact on the Company's financial position or results of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In May 2014, the FASB issued ASU No.&amp;#160;2014-09,&lt;/font&gt; &lt;font size="2"&gt;&lt;i&gt;Revenue from Contracts with Customers.&lt;/i&gt;&lt;/font&gt; &lt;font size="2"&gt;This ASU is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This ASU is effective for annual reporting periods beginning after December&amp;#160;15, 2016 and early adoption is not permitted. Accordingly, the Company will adopt this ASU on January&amp;#160;1, 2017. Management does not believe the adoption of this ASU will have a material impact on the Company's financial condition, results of operations or cash flows.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In June 2014, the FASB issued ASU No.&amp;#160;2014-12,&lt;/font&gt; &lt;font size="2"&gt;&lt;i&gt;Compensation&amp;#160;&amp;#8212; Stock Compensation (Topic&amp;#160;718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period&lt;/i&gt;&lt;/font&gt;&lt;font size="2"&gt;. ASU&amp;#160;2014-12 applies to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. That is the case when an employee is eligible to retire or otherwise terminate employment before the end of the period in which a performance target (for example, an initial public offering or a profitability target) could be achieved and still be eligible to vest in the award if and when the performance target is achieved. The standard is required to be adopted by public business entities in annual periods beginning on or after December&amp;#160;15, 2015 and interim periods within those annual periods. The Company plans to implement this standard in the first quarter of fiscal year 2016 and is currently evaluating the potential impact of this new guidance on its financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In August 2014, the FASB issued ASU No.&amp;#160;2014-15,&lt;/font&gt; &lt;font size="2"&gt;&lt;i&gt;Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern.&lt;/i&gt;&lt;/font&gt; &lt;font size="2"&gt;ASU&amp;#160;2014-15 requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU&amp;#160;2014-15 is effective for annual periods ending after December&amp;#160;15, 2016 and earlier application is permitted. The adoption of ASU&amp;#160;2014-15 is not expected to have a material effect on the Company's financial statements or disclosures.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In November 2014, the FASB issued ASU No.&amp;#160;2014-16,&lt;/font&gt; &lt;font size="2"&gt;&lt;i&gt;Derivatives and Hedging (Topic&amp;#160;815)&amp;#160;&amp;#8212; Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share is More Akin to Debt or to Equity&lt;/i&gt;&lt;/font&gt;&lt;font size="2"&gt;. This ASU was issued to clarify how current U.S. generally accepted accounting principles should be interpreted in evaluating the economic characteristics and risk of a host contract in a hybrid financial instrument that is issued in the form of a share. In addition, this ASU was issued to clarify that in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (that is, the relative strength of the debt-like or equity-like terms and features given the facts and circumstances) when considering how to weight those terms and features. The effects of initially adopting this ASU should be applied on a modified retrospective basis to existing hybrid financial instruments issued in a form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods. This ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December&amp;#160;15, 2015. Early adoption in an interim period is permitted. The Company is currently evaluating the impact of the adoption of this ASU on its financial statements.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Fact-1f89517d-59d2-48fa-9c49-133dcf971caa_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">72000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:SubsequentEventsTextBlock id="Fact-826b8ff1-cc0c-485f-b474-b0f529ca8a62_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;14. SUBSEQUENT EVENTS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company has completed an evaluation of all subsequent events through April&amp;#160;27, 2015, the date these financial statements are available to be issued. The Company has concluded that no subsequent event has occurred that requires disclosure, except as noted below:&lt;/font&gt;&lt;/p&gt;
&lt;dl compact="compact"&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;(a)&lt;/font&gt;&lt;/dt&gt;
&lt;dd style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In March 2015, the Company sold 41,666,667 shares of Series&amp;#160;D convertible preferred stock for aggregate consideration of $50,000, comprised of $45,000 in cash and conversion of $5,000 in convertible notes with related parties. The convertible notes converted into 4,166,667 shares of Series&amp;#160;D convertible preferred stock. The accrued interest on the convertible notes was waived. In this financing, the mandatory conversion for all series of preferred stock was modified so as to occur upon an initial public offering with gross proceeds in excess of $50,000.&lt;br /&gt;
&lt;br /&gt;&lt;/font&gt;&lt;/dd&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;(b)&lt;/font&gt;&lt;/dt&gt;
&lt;dd style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;On March&amp;#160;24, 2015, Purdue sued the Company in the District of Delaware asserting infringement of four patents. On March&amp;#160;26, 2015, Purdue filed a second suit against the Company in the District of Massachusetts asserting infringement of the same four patents.&lt;br /&gt;
&lt;br /&gt;&lt;/font&gt;&lt;/dd&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;(c)&lt;/font&gt;&lt;/dt&gt;
&lt;dd style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In March 2015, the Company granted a total of 638,095 stock options under the Plan to employees. The stock options were granted at fair market value on the date of grant, vest over approximately four years and expire ten years from the date of grant.&lt;br /&gt;
&lt;br /&gt;&lt;/font&gt;&lt;/dd&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;(d)&lt;/font&gt;&lt;/dt&gt;
&lt;dd style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In March 2015, the Plan was amended to increase the maximum number authorized for issuance pursuant to the Plan to 1,087,005 shares.&lt;br /&gt;
&lt;br /&gt;&lt;/font&gt;&lt;/dd&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;(e)&lt;/font&gt;&lt;/dt&gt;
&lt;dd style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In March 2015, the Company amended its lease to include an additional 9,660 square feet of space for a total of 19,335 square feet. In addition, the lease term was extended and now terminates on the date that is 5&amp;#160;years following the date, which has not yet been determined, on which the landlord delivers the expansion space with certain improvements substantially completed. At the Company's election, the lease term may be extended for an additional 5-year term.&lt;/font&gt;&lt;/dd&gt;&lt;/dl&gt;
&lt;dl compact="compact"&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;(f)&lt;/font&gt;&lt;/dt&gt;
&lt;dd style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In April 2015, the Company granted 194,694 shares of restricted stock to an employee. Pursuant to the grant, 97,347 shares vested upon grant, while the remaining 97,347 shares of restricted stock vest in monthly installments over a three-year period commencing as of the date of grant.&lt;br /&gt;
&lt;br /&gt;&lt;/font&gt;&lt;/dd&gt;
&lt;dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;(g)&lt;/font&gt;&lt;/dt&gt;
&lt;dd style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In April 2015, the Company's board of directors and shareholders approved a one-for-6.9 reverse split of the Company's common stock. All common stock share and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse split of our common stock, including reclassifying an amount equal to the reduction in par value to additional paid-in capital.&lt;/font&gt;&lt;/dd&gt;&lt;/dl&gt;
&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:UseOfEstimates id="Fact-155e5a50-e18c-47ef-b8ac-bf35f887d622_20151231" contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The preparation of the Company's financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company's financial statements and accompanying notes. The most significant estimates in the Company's financial statements relate to the valuation of equity awards, fair value estimates of warrants, estimated useful lives of fixed assets, asset retirement obligations and accruals related to clinical trials. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company's actual results may differ from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="Fact-302ef187-8780-481b-9947-040cdd270e8b_20151231" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">7737000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Fact-db201c5e-94f9-4a67-9a16-276bcac649ec_20150930" decimals="2" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD_xbrli-shares">-18.26</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:GeneralAndAdministrativeExpense id="Fact-1842c4dd-fb17-4b9b-b2ed-7701ea8e3194_20150930" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">1686000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:InterestIncomeExpenseNonoperatingNet id="Fact-c1153645-d0d1-4747-903b-9272bb406a33_20150930" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">-110000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:NetIncomeLoss id="Fact-5ba467fc-8e34-4b3b-88bd-8acf795d5c30_20150930" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">-14448000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses id="Fact-4ef3a5cc-d242-486a-8313-21b4a62578ad_20150930" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">14338000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="Fact-bbd82674-db6e-4941-9ac9-0ce606184505_20150930" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">-14338000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncomeExpense id="Fact-e000d607-ab78-4d80-9185-89847e362d9d_20150930" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">-110000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Fact-a247979d-9bf6-4f71-92c1-c572f7bf7380_20150930" decimals="-3" contextRef="D2014-01-01_2014-12-31" unitRef="iso4217-USD">12652000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Fact-0d2e798c-9c84-44f7-ba41-bf576505c2ff_20150930" decimals="0" contextRef="D2014-01-01_2014-12-31" unitRef="xbrli-shares">926597</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <coll:AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock id="Fact-ca7d985e-100d-41c9-b842-2c839761cda3_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD">2925000</coll:AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock>
  <us-gaap:NetIncomeLoss id="Fact-09614d43-5bc0-4430-bf7a-58bf204c9f2d_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-RetainedEarningsMember" unitRef="iso4217-USD">-16197000</us-gaap:NetIncomeLoss>
  <coll:AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock id="Fact-5b18fdbd-6416-4e59-9aba-f970dab94440_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">1000</coll:AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock>
  <coll:AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified id="Fact-00c465b4-30b4-45d7-8265-bc5a8e06c9bc_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">12240000</coll:AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Fact-565e65ea-9d03-4214-b3b5-837942e62a21_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">62000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Fact-ac99a802-8054-4653-ad80-2333f87f004c_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31_us-gaap-StatementEquityComponentsAxis_us-gaap-AdditionalPaidInCapitalMember" unitRef="iso4217-USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <coll:AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock id="Fact-877c31bb-cf2a-4a2d-aab2-21002bca4416_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">2926000</coll:AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock>
  <coll:AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified id="Fact-cb1bbc79-a3ea-4622-8571-a38b3a6a0033_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">12239000</coll:AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified>
  <coll:AmortizationOfIncentiveFromLessor id="Fact-116e8c74-7586-4c10-86a5-87e8147311ec_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">34000</coll:AmortizationOfIncentiveFromLessor>
  <coll:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent id="Fact-86d5a39e-241d-4a17-a443-8e8f7aa02616_20151231" decimals="4" contextRef="D2013-01-01_2013-12-31" unitRef="xbrli-pure">0.1211</coll:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent>
  <coll:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted id="Fact-c0feafbe-bebf-4dda-ae97-c76b26abee53_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">-6883000</coll:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
  <coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue id="Fact-3b931952-5c55-4414-87da-5b54e85fafb2_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">2926000</coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue>
  <coll:TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment id="Fact-7d1d9821-fdcd-44e0-8f0a-6e9b2afca22f_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">2925000</coll:TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Fact-fc159ed5-fc8c-4a71-8505-f6b3d13342d5_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">62000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Fact-4572fd4f-d3a3-458b-9ffa-138cac5d2451_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">62000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="Fact-585b7c87-cb80-4f00-a736-6ffa59e80096_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">12000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction id="Fact-6d73e80c-42bb-4aed-9c41-56e39a93c73c_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">13000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
  <us-gaap:DefinedContributionPlanCostRecognized id="Fact-63cdc5c7-e3dd-4be6-922a-14d2ee76e484_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">31000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:DepreciationAndAmortization id="Fact-c3695926-4c23-46ea-834f-2fd13994956a_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">169000</us-gaap:DepreciationAndAmortization>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Fact-51291126-baae-4158-8fc3-641edb72d8e6_20151231" decimals="2" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD_xbrli-shares">-4.06</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="Fact-842a5c24-4e1b-403f-ad8d-7e0b16c33eab_20151231" decimals="4" contextRef="D2013-01-01_2013-12-31" unitRef="xbrli-pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="Fact-400239ef-b4e5-4050-a612-2cdd930db342_20151231" decimals="INF" contextRef="D2013-01-01_2013-12-31" unitRef="xbrli-pure">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="Fact-24d89555-257d-4042-b62b-f8dd33df8046_20151231" decimals="4" contextRef="D2013-01-01_2013-12-31" unitRef="xbrli-pure">0.2607</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense id="Fact-a79de3d6-2f26-4c6e-80d6-e6a35a14afce_20151231" decimals="4" contextRef="D2013-01-01_2013-12-31" unitRef="xbrli-pure">0.0001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="Fact-ac689b55-1933-4145-8b01-9872b62866dc_20151231" decimals="4" contextRef="D2013-01-01_2013-12-31" unitRef="xbrli-pure">0.0419</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet id="Fact-8b03d367-bd40-46be-a05a-5170a7d1f2fd_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
  <us-gaap:GeneralAndAdministrativeExpense id="Fact-71aa784c-ba51-4e21-955f-6a0ceeb20766_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">1885000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxesPaid id="Fact-de57b843-ac6d-4a3e-bfb8-3902c6230f46_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">14000</us-gaap:IncomeTaxesPaid>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="Fact-1ba44e15-75ec-4d0e-bc54-1bfbc0012f42_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">-822000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="Fact-4ba05e5c-5f20-450e-b9d5-8e6265847d96_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">199000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Fact-52723f12-7aa6-4d64-a878-d4aa1e95eca0_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">11000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestIncomeExpenseNonoperatingNet id="Fact-5bc709dd-36aa-4d35-8385-7487bc2363bb_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">-76000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InterestPaid id="Fact-c55b6e34-a0e3-4dc8-9f08-eb6c88b82ad9_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">73000</us-gaap:InterestPaid>
  <us-gaap:MaturitiesOfSeniorDebt id="Fact-4c9b8425-ff76-4740-aa64-6bafaa593cc9_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">43000</us-gaap:MaturitiesOfSeniorDebt>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations id="Fact-44283c72-b688-4d31-b7d1-73c53e981a2b_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">-4385000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Fact-0a17503a-1871-42c6-a97d-3b144a896235_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">12351000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Fact-8db2e52e-ed54-468d-b925-1e1f156b42a7_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">-206000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Fact-832e54cc-e735-4b3c-8b73-9a4192267401_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">-16530000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetIncomeLoss id="Fact-cd7f760f-d312-4ed3-8fb9-049f98118d9a_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">-16197000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses id="Fact-0f6b6386-3db0-4ce5-a2dd-16108df952bd_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">16042000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="Fact-ec2aa9db-9f82-48f7-aa57-9c2eff292119_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">-16042000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeasesRentExpenseNet id="Fact-4aafffcd-b12f-4806-a4f5-bac15fadc916_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">69000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OtherNonoperatingIncomeExpense id="Fact-d3974164-7673-42f3-8f8f-ad5fe1565695_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">-155000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Fact-091bdf76-b186-4d56-be58-2d34af8f5a73_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">206000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromRepaymentsOfNotesPayable id="Fact-f4e6f15a-30bc-476a-9990-4987ea8f7b82_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">500000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
  <us-gaap:ProceedsFromStockOptionsExercised id="Fact-b4ed2849-931c-4df1-abb9-12c5422648a5_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">1000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:RepaymentsOfLongtermLoansFromVendors id="Fact-d31b7056-33d7-47d9-91d0-21f29d101f49_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">62000</us-gaap:RepaymentsOfLongtermLoansFromVendors>
  <us-gaap:ResearchAndDevelopmentExpense id="Fact-80bfcfaf-5d5b-4ee3-9db9-d0d28d690f2e_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">14157000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction id="Fact-9d9ae6c2-1f2a-4c2c-bdc6-30db3d33cb9a_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">11955000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:ShareBasedCompensation id="Fact-92aded8f-b4f0-4d9d-98d8-16d364aa9d6c_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">62000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Fact-29333fb2-2398-4761-ac6e-a53bf8987e51_20151231" decimals="4" contextRef="D2013-01-01_2013-12-31" unitRef="xbrli-pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Fact-d48544b9-48c9-4010-82b5-b3c944190f12_20151231" contextRef="D2013-01-01_2013-12-31">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Fact-a02772bf-d782-4cbb-b11f-91637d2c5dad_20151231" decimals="4" contextRef="D2013-01-01_2013-12-31" unitRef="xbrli-pure">0.8780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="Fact-85fa35e1-2ddd-4945-a31c-7c9b77717b18_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:UnrealizedGainLossOnDerivatives id="Fact-54cb2d3f-2d30-4cc6-93a5-7f9a20580ba2_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">-79000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="Fact-ca42e6a8-9969-4755-a56c-164194e0b67f_20151231" decimals="-3" contextRef="D2013-01-01_2013-12-31" unitRef="iso4217-USD">5081000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Fact-4c5e0814-9dde-4940-a8ca-cce5fe2abc00_20151231" decimals="0" contextRef="D2013-01-01_2013-12-31" unitRef="xbrli-shares">1697044</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="Fact-8ad798b3-80a3-44e3-a709-2853392f5486_20150930" decimals="INF" contextRef="I2014-12-31" unitRef="xbrli-shares">15387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="Fact-ba7e74b8-65ff-4fb6-867c-c41fc8f89762_20150930" decimals="2" contextRef="I2014-12-31" unitRef="iso4217-USD_xbrli-shares">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Fact-218e0c4d-d37b-4521-a4c8-4e9aa6f3f0a0_20150930" decimals="INF" contextRef="I2014-12-31" unitRef="xbrli-shares">281029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Fact-39bea600-c326-434e-b5c2-5db406e897cb_20150930" decimals="2" contextRef="I2014-12-31" unitRef="iso4217-USD_xbrli-shares">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="Fact-5fcc3a86-835d-4792-a007-f511bfb18f2f_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">903000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="Fact-ad49ed3c-4d42-4aed-9f58-1e07869e6e73_20151231" decimals="INF" contextRef="I2014-12-31" unitRef="xbrli-shares">57893685</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:DebtCurrent id="Fact-cde662fc-7f78-45c1-b856-b0837b301438_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">6194000</us-gaap:DebtCurrent>
  <us-gaap:DebtLongtermAndShorttermCombinedAmount id="Fact-61999d06-fdcd-4d5a-8cc3-ae1066955f13_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">13007000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
  <us-gaap:DeferredOfferingCosts id="Fact-a7ee4d63-c215-4d6a-abe1-893c587283fd_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">233000</us-gaap:DeferredOfferingCosts>
  <us-gaap:DeferredTaxAssetsGross id="Fact-2d78a51c-dbe6-42c7-9f21-03d3c63f1172_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">31525000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="Fact-aa77d2ff-92ac-4002-850f-90b29a00820f_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">28419000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment id="Fact-f6fc947b-32a5-4b49-9b54-72d312d876ce_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">36000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="Fact-85f5b82a-4432-4bad-9d0b-566719c409f6_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">3070000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="Fact-83493742-488b-43be-b09d-1402adf01e03_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">31525000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DueFromEmployeesCurrent id="Fact-c0647820-0319-4cf2-85ef-ea07611a78a2_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">33000</us-gaap:DueFromEmployeesCurrent>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount id="Fact-22e5425d-2eae-4912-a572-3b53ed73daf7_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount id="Fact-43e86ebb-a3fd-46d4-865c-67e74bb3951a_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset id="Fact-671bb79a-89a8-4417-89f6-417c0f4acd6e_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">0</us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset>
  <us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountLiability id="Fact-9088f163-ab40-4e5f-b2c2-751ed4b25bf4_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">0</us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountLiability>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour id="Fact-2ed6f3df-b458-4d1d-aeb0-5b5fa91aa1e7_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">1479000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree id="Fact-b4f71ccd-e3c9-4f3c-9715-ca4d8ecc91ec_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">2667000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo id="Fact-938c37ee-c86d-4246-9826-842a81b2c986_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">2667000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue id="Fact-9d8c507c-cdcb-4e2d-9c9d-89865c5c5f10_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">333000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="Fact-4b0065b1-e1a4-448a-acf5-971b992e6299_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">106000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears id="Fact-6b18d25b-a171-47c6-817f-50ea381e1e25_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">116000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears id="Fact-a7fa7988-f59a-49c2-92c7-0ff470a1e292_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">111000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OtherAssetsCurrent id="Fact-a5f93ca8-9f76-443d-ab45-0457bea2b890_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">253000</us-gaap:OtherAssetsCurrent>
  <us-gaap:PrepaidExpenseCurrent id="Fact-a110ddf5-59e9-4e5a-8667-5c66e654557b_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">8000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PropertyPlantAndEquipmentGross id="Fact-fa2f3da4-5426-465b-88a1-bd96abaa213f_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">1417000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:TemporaryEquitySharesAuthorized id="Fact-244f16c1-e7b1-40df-9b4b-81cab3529bf9_20151231" decimals="INF" contextRef="I2014-12-31" unitRef="xbrli-shares">54481000</us-gaap:TemporaryEquitySharesAuthorized>
  <coll:AccruedResearchAndDevelopmentCostsCurrent id="Fact-1295e9cb-4cb2-47cf-a93c-a693dce36486_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">970000</coll:AccruedResearchAndDevelopmentCostsCurrent>
  <coll:DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent id="Fact-4fa02214-589c-4b9c-80fa-0a268e622745_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">59000</coll:DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent>
  <us-gaap:AccountsPayableCurrent id="Fact-5050ae8f-5e87-4856-892a-7f63d8ed2887_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">2208000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Fact-2ac3d424-69fa-4e6a-b2d8-330722df1a72_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">1956000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="Fact-1e3c35af-936f-4cee-a072-6518cbbcda3c_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">249000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AdditionalPaidInCapital id="Fact-ddf4dbf4-8316-424e-9446-908a56fa6eba_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">12407000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:Assets id="Fact-cfeb0a9e-ea53-4472-9adf-fdc099b7bf8d_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">5090000</us-gaap:Assets>
  <us-gaap:AssetsCurrent id="Fact-52f1a669-bf7e-44be-8a8f-b667a00bb479_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">4496000</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Fact-b363a869-4ad6-44b2-8308-572fa68e648a_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">1634000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommitmentsAndContingencies id="Fact-33e4f914-357a-43d7-9e05-0bd77783299f_20151231" xsi:nil="true" contextRef="I2014-12-31" unitRef="iso4217-USD" />
  <us-gaap:CommonStockParOrStatedValuePerShare id="Fact-17c08efd-0396-4c53-b278-5e29b1bcdc6c_20151231" decimals="INF" contextRef="I2014-12-31" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="Fact-bd3c0fa4-40a2-40e3-8170-0d59b2f278e4_20151231" decimals="INF" contextRef="I2014-12-31" unitRef="xbrli-shares">72000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="Fact-b03f0239-ef3f-4a22-8c48-b778343b98ed_20151231" decimals="INF" contextRef="I2014-12-31" unitRef="xbrli-shares">1006219</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="Fact-060f7010-b6fb-400b-88f9-4200096b7926_20151231" decimals="INF" contextRef="I2014-12-31" unitRef="xbrli-shares">1006219</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue id="Fact-b5abfef6-a3a9-471d-8cc2-c7cf09ca37e3_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">1000</us-gaap:CommonStockValue>
  <us-gaap:DepositsAssetsCurrent id="Fact-59928b04-f6d4-4eb1-86d1-79d5f6d6aef3_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">2335000</us-gaap:DepositsAssetsCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="Fact-4b0eb717-44e4-4e87-9d31-b6686ae4260a_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">635000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:IncentiveFromLessor id="Fact-24328e30-3a42-4cfd-8d36-fdf25e372548_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">101000</us-gaap:IncentiveFromLessor>
  <us-gaap:InterestPayableCurrent id="Fact-12f689dc-a2ec-40bf-b97c-665ed89446e3_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">71000</us-gaap:InterestPayableCurrent>
  <us-gaap:Liabilities id="Fact-1dbaa0f1-f1de-4b13-8e4b-38f049edc132_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">17331000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Fact-691dca3a-8b01-4fa4-bd99-f0eff2308c0d_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">5090000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent id="Fact-351ce02d-3b9a-4049-bcee-ae56077c2d9b_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">10417000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LoansPayableCurrent id="Fact-ad4a033b-535a-4d0e-bf0c-5667b45a6dde_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">1194000</us-gaap:LoansPayableCurrent>
  <us-gaap:LongTermLoansPayable id="Fact-9ffb7bab-d597-4977-bfd0-2c81ee73ffb5_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">6813000</us-gaap:LongTermLoansPayable>
  <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent id="Fact-4745220b-e13a-4baf-85d9-1b99b4fe152e_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">5000000</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="Fact-d95e63d4-5c53-413d-aa5d-abe761fe8f9a_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">31000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Fact-02709bf1-6e53-4c5e-b300-e61cc6e11818_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">527000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="Fact-f5e61508-51af-47f7-875a-da1957497c01_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">514000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="Fact-10f7e84d-c783-4eed-88dd-d0519d0e6817_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">80000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="Fact-4c5d723b-e7ce-4801-92ee-8c6a6375b832_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">-101753000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="Fact-6975e480-f972-4c46-a0ff-5951c72ad680_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">-89348000</us-gaap:StockholdersEquity>
  <us-gaap:TreasuryStockCarryingBasis id="Fact-3d622446-8b8f-4c1c-80bb-8c074c310ec7_20151231" decimals="-3" contextRef="I2014-12-31" unitRef="iso4217-USD">3000</us-gaap:TreasuryStockCarryingBasis>
  <coll:AccruedResearchAndDevelopmentCostsCurrent id="Fact-12a2a678-315b-4678-99bb-936f7776d111_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">520000</coll:AccruedResearchAndDevelopmentCostsCurrent>
  <coll:DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent id="Fact-ed7c9d92-26f3-4354-ad34-4b907120979b_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">55000</coll:DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent>
  <coll:PrepaidDevelopmentCosts id="Fact-5f9b58c3-efc0-4217-ad1e-c8942f190243_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">656000</coll:PrepaidDevelopmentCosts>
  <us-gaap:AccountsPayableCurrent id="Fact-a1717f64-a153-4cf1-abd6-b7a10b5571c6_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">1217000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Fact-afd420d7-9883-4a3d-a6de-de97536d3548_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">1013000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="Fact-17d62858-3896-4d15-8b3b-3fa32c8eb9d8_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">12000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="Fact-703af272-2b19-4d61-a8b3-1d5605a92a2e_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">716000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapital id="Fact-6b07b1e2-e820-42f2-b4e0-b7718071c3eb_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">12313000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:Assets id="Fact-4153b977-935e-41e6-bb61-9a02062ee19d_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">9034000</us-gaap:Assets>
  <us-gaap:AssetsCurrent id="Fact-81ff74b5-9f3c-44ab-8d8a-92e41eb7c759_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">8261000</us-gaap:AssetsCurrent>
  <us-gaap:CommitmentsAndContingencies id="Fact-dc32792e-106b-4da1-9684-58c3e4109c9d_20151231" xsi:nil="true" contextRef="I2013-12-31" unitRef="iso4217-USD" />
  <us-gaap:CommonStockParOrStatedValuePerShare id="Fact-ab4d36ea-d4b5-4513-a5f6-f3d4686f3b4a_20151231" decimals="INF" contextRef="I2013-12-31" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="Fact-75a4397c-9290-42c2-a3f9-a23596d2ea0b_20151231" decimals="INF" contextRef="I2013-12-31" unitRef="xbrli-shares">72000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="Fact-ada301f5-4dff-43b2-8198-ba06eb7d73a2_20151231" decimals="INF" contextRef="I2013-12-31" unitRef="xbrli-shares">962960</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="Fact-bf9f6f48-61f5-4bea-a341-b6c075090ec4_20151231" decimals="INF" contextRef="I2013-12-31" unitRef="xbrli-shares">962960</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue id="Fact-8668de2c-3872-4bc7-adb5-be025b9597e6_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">1000</us-gaap:CommonStockValue>
  <us-gaap:DeferredIncomeTaxLiabilities id="Fact-da769b85-4e3f-4445-8725-53bbecbefd71_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">4000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredTaxAssetsGross id="Fact-08f5b011-578e-4e1a-a406-e5acbe3aa72d_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">23792000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsNet id="Fact-391f3278-ee0c-407f-bc68-7dac8ae5f7d9_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">4000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="Fact-a9d79c20-daae-46eb-87e3-a53024acfae1_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">21392000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="Fact-e3324d54-7a98-4994-81fc-ce07349c540b_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">2400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="Fact-cd2fb7d7-a9bc-4c95-96a1-0ad42601966a_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">23788000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment id="Fact-d6972fc2-9350-4ab9-8495-96a759d5b3d2_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">4000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <us-gaap:DueFromEmployeesCurrent id="Fact-510aa773-491b-4282-bab9-5f1c1899c71f_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">21000</us-gaap:DueFromEmployeesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="Fact-18aecad2-6728-4359-ad61-2ebf952fd459_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">449000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount id="Fact-9970c980-0c34-4c46-bee2-4e0ae231e4e9_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount id="Fact-96ae398a-d0ec-4726-a444-3e6dbac351ef_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:IncentiveFromLessor id="Fact-9c4a2805-0151-4409-b380-8d003259a319_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">135000</us-gaap:IncentiveFromLessor>
  <us-gaap:Liabilities id="Fact-72a8543d-bea5-4298-9616-fe35925ad2f3_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">3452000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Fact-b9cd148a-6700-4260-ad3c-729092348d69_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">9034000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent id="Fact-a39a38df-e2de-4814-9d23-3e3d539961de_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">2618000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LoansPayableCurrent id="Fact-dc9d6fe1-3fb0-4bc6-be05-2f711a8b5bfc_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">333000</us-gaap:LoansPayableCurrent>
  <us-gaap:LongTermLoansPayable id="Fact-447793b3-eb6b-4bd7-bd88-c99cd50ce2a4_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">640000</us-gaap:LongTermLoansPayable>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="Fact-1bc57743-4af7-4bc0-b2cb-b3cbb62fc4dd_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">32000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Fact-16521f21-cf92-4e7f-ad8e-fd674c164833_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">710000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseCurrent id="Fact-3073fc33-947d-4ad2-84ea-d9b61153593f_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">33000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PropertyPlantAndEquipmentGross id="Fact-1a65a691-429c-4f5b-81f8-39554c68b2ab_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">1409000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet id="Fact-3ac6b272-b5bc-4928-bdd9-2eb86f33fe6b_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">693000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="Fact-4062b1d5-5d95-45c4-a30d-622364ae6873_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">80000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="Fact-c99e164d-af54-4b94-b4df-7a5a035e8d63_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">-80536000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="Fact-9421fe4f-9a2e-483f-81fa-6143fd0b5aff_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">-68225000</us-gaap:StockholdersEquity>
  <us-gaap:TemporaryEquitySharesAuthorized id="Fact-a1fcb6cc-13e9-4797-83bc-0e8ad9ad14ec_20151231" decimals="INF" contextRef="I2013-12-31" unitRef="xbrli-shares">54481000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TreasuryStockCarryingBasis id="Fact-911ca715-ea87-4145-b71d-b728959c9ed8_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">3000</us-gaap:TreasuryStockCarryingBasis>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Fact-fca856bc-61fe-4f8b-bd0e-c1a8b0cccfaf_20151231" decimals="-3" contextRef="I2013-12-31" unitRef="iso4217-USD">7551000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:TemporaryEquityLiquidationPreference id="Fact-22e781a8-2051-489e-8aab-e2193aeef912_20150930" decimals="-3" contextRef="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember" unitRef="iso4217-USD">0</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="Fact-9d3e591b-e9be-4164-b6dc-d2e7cb2bb6cb_20150930" decimals="INF" contextRef="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="Fact-8931b6ab-8e1e-4bfb-902a-23625d8af307_20150930" decimals="INF" contextRef="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="Fact-9d164cab-3ee8-4ef8-afed-6a3bf1e1c4ab_20150930" decimals="INF" contextRef="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="Fact-1fec154f-7252-4386-8c66-4de54058e00f_20150930" decimals="INF" contextRef="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityLiquidationPreference id="Fact-2db2078e-b063-41f1-aee8-d719cdbc7f57_20150930" decimals="-3" contextRef="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="iso4217-USD">0</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="Fact-b2997ebe-5592-4c27-bd96-5066e60b0881_20150930" decimals="INF" contextRef="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="Fact-9b696e5e-5be4-4dac-bc2b-ab911e34ee47_20150930" decimals="INF" contextRef="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="Fact-4ff2c232-716a-41b9-833e-b7ddf59c70a7_20150930" decimals="INF" contextRef="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="Fact-afb66987-7fb5-434d-a494-bceb3fede485_20150930" decimals="INF" contextRef="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityLiquidationPreference id="Fact-d66cfcc9-b0e5-4e18-90bb-ec1d7130ab15_20150930" decimals="-3" contextRef="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="iso4217-USD">0</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="Fact-c0be0581-4869-48bd-a7f5-8cfa5debabca_20150930" decimals="INF" contextRef="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="Fact-f55e9a8a-c5ba-41ca-b9ea-e90fddcf4ba1_20150930" decimals="INF" contextRef="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="Fact-9aed1df5-29be-4f3b-9149-de316e3a9fc7_20150930" decimals="INF" contextRef="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="Fact-913c356b-55f5-43ff-a086-534f9450507f_20150930" decimals="INF" contextRef="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityLiquidationPreference id="Fact-fa1b0013-7a4d-4fc3-999c-d037bbc0cd42_20150930" decimals="-3" contextRef="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="iso4217-USD">0</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="Fact-87941cff-c91d-48fa-b3aa-e8b3a6586182_20150930" decimals="INF" contextRef="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="Fact-b1b59f4a-24aa-4e42-864c-27ab00517704_20150930" decimals="INF" contextRef="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="Fact-9cd588a4-975d-4122-96cd-61987872e8b6_20150930" decimals="INF" contextRef="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="Fact-5dadc64a-21a6-4f97-968b-8982d7f2eb69_20150930" decimals="INF" contextRef="I2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityLiquidationPreference id="Fact-dd20ae10-8922-431b-8599-8ddc94a9e23c_20150930" decimals="-3" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember" unitRef="iso4217-USD">0</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="Fact-34df2d1e-d0c9-4cbe-9d08-22e000e53cbb_20150930" decimals="INF" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="Fact-55fa7065-e4b4-4416-8120-8bb55b563011_20150930" decimals="INF" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="Fact-119ac122-832d-4bed-ade1-807d26e22370_20150930" decimals="INF" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="Fact-9f2597f1-47ff-490b-8374-4a2952f6543b_20150930" decimals="INF" contextRef="I2014-12-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityAccretionOfDividends id="Fact-22264f2e-9c5e-4999-bfd5-dffff3a38037_20150930" decimals="-3" contextRef="D2015-01-01_2015-02-28_us-gaap-StatementClassOfStockAxis_coll-SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD">622000</us-gaap:TemporaryEquityAccretionOfDividends>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Fact-f3fbfa83-11dd-44e1-b083-bbcb17d3dacf_20150930" decimals="INF" contextRef="D2015-05-01_2015-05-31_us-gaap-SubsidiarySaleOfStockAxis_us-gaap-OverAllotmentOptionMember" unitRef="xbrli-shares">870000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="Fact-983e2781-24e5-46e8-8395-caba108dfde5_20150930" decimals="9" contextRef="D2015-04-01_2015-04-30" unitRef="xbrli-pure">0.144927536</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:SharesIssuedPricePerShare id="Fact-6e130aab-3324-47b8-99f4-8735f00f53f4_20150930" decimals="2" contextRef="I2015-05-31_us-gaap-SubsidiarySaleOfStockAxis_us-gaap-IPOMember" unitRef="iso4217-USD_xbrli-shares">12.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="Fact-d4a8e496-0203-42b5-b7fc-ff37320c7765_20150930" decimals="INF" contextRef="I2015-04-30_us-gaap-PlanNameAxis_coll-StockIncentivePlan2014Member" unitRef="xbrli-shares">2700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Fact-729c6b88-b267-48ac-af79-65eb692f5542_20150930" contextRef="D2015-01-01_2015-09-30_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="Fact-57cdc12c-d3eb-44e7-8d1b-868c61630263_20150930" contextRef="D2015-01-01_2015-09-30_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction id="Fact-3977af09-574e-4a60-b6f6-50632fe5be0c_20150930" decimals="-5" contextRef="D2015-05-01_2015-05-31_us-gaap-SubsidiarySaleOfStockAxis_us-gaap-IPOMember" unitRef="iso4217-USD">72000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Fact-d8609596-da57-4d46-a9f5-85d5dd21fa5c_20150930" decimals="INF" contextRef="D2015-05-01_2015-05-31_us-gaap-SubsidiarySaleOfStockAxis_us-gaap-IPOMember" unitRef="xbrli-shares">6670000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock id="Fact-63c313f4-303a-4227-aea6-18e45439c8a1_20150930" decimals="-3" contextRef="D2015-03-01_2015-03-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember" unitRef="iso4217-USD">45000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Fact-75c0df87-5e76-4cb8-9c01-966edaef9cf9_20150930" decimals="INF" contextRef="D2015-03-01_2015-03-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember" unitRef="xbrli-shares">41666667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="Fact-1b9de044-99de-4956-a428-855ef7cd332f_20150930" decimals="-3" contextRef="D2015-03-01_2015-03-31_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember" unitRef="iso4217-USD">50000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="Fact-91875418-bccd-407f-a417-3fdb3455a0bc_20150930" decimals="-3" contextRef="D2015-03-01_2015-03-31_us-gaap-RangeAxis_us-gaap-MinimumMember_us-gaap-StatementClassOfStockAxis_coll-SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember_us-gaap-StatementScenarioAxis_coll-ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" unitRef="iso4217-USD">50000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:PreferredStockDividendRatePercentage id="Fact-757fa5b3-139f-41b6-a05d-a9074424ba3b_20150930" decimals="INF" contextRef="D2015-01-01_2015-02-28_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesCPreferredStockMember" unitRef="xbrli-pure">0.08</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:PreferredStockDividendRatePercentage id="Fact-7889f217-fa29-4395-8ab5-8f67c32fddae_20150930" decimals="INF" contextRef="D2015-01-01_2015-02-28_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesBPreferredStockMember" unitRef="xbrli-pure">0.08</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:PreferredStockDividendRatePercentage id="Fact-3e0f4b7c-954b-4b72-9aa1-c75c1b2f8221_20150930" decimals="INF" contextRef="D2015-01-01_2015-02-28_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember" unitRef="xbrli-pure">0.045</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:PaymentsOfStockIssuanceCosts id="Fact-1755980f-1672-47c3-9134-d66df8ee4596_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30_us-gaap-StatementClassOfStockAxis_coll-CommonStockNoClassMember" unitRef="iso4217-USD">2408000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction id="Fact-0cc00dd1-a24e-4841-8a78-d35ba58287f2_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30_us-gaap-StatementClassOfStockAxis_coll-CommonStockNoClassMember" unitRef="iso4217-USD">72029000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber id="Fact-f6bf0ade-eba4-4793-bc22-20425aed67dc_20150930" decimals="INF" contextRef="D2015-03-26_2015-03-26_us-gaap-LitigationCaseAxis_coll-PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" unitRef="coll-patent">4</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
  <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber id="Fact-de43eda0-d30c-431f-a12c-ddbc4967b822_20150930" decimals="INF" contextRef="D2015-03-24_2015-03-24_us-gaap-LitigationCaseAxis_coll-PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" unitRef="coll-patent">4</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract id="Fact-bff9bec7-901e-4185-b0c5-724e18df20c7_20150930" contextRef="D2015-03-01_2015-03-31_us-gaap-LeaseArrangementTypeAxis_coll-OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_us-gaap-StatementScenarioAxis_coll-DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember">P5Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm id="Fact-2ba90b6d-a79e-4110-9795-3338e1c3e3e6_20150930" contextRef="D2015-03-01_2015-03-31_us-gaap-LeaseArrangementTypeAxis_coll-OfficeAndResearchFacilityOperatingLeaseAsAmendedMember">P5Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="Fact-9dfc2d42-0a24-458a-ae1d-afb2e043aff7_20150930" decimals="-3" contextRef="D2015-03-01_2015-03-31_us-gaap-DebtInstrumentAxis_coll-ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" unitRef="iso4217-USD">91000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:DebtConversionOriginalDebtAmount1 id="Fact-eed7e35c-5ecc-4a16-a973-98e37cb34413_20150930" decimals="-3" contextRef="D2015-03-01_2015-03-31_us-gaap-DebtConversionByUniqueDescriptionAxis_coll-ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" unitRef="iso4217-USD">5000000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:ConversionOfStockSharesIssued1 id="Fact-3457a580-4f9c-4ae8-9e2a-d55ef5549dbf_20150930" decimals="INF" contextRef="D2015-05-01_2015-05-31_us-gaap-ConversionOfStockByUniqueDescriptionAxis_coll-ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember_us-gaap-StatementClassOfStockAxis_us-gaap-RedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">12591456</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:ConversionOfStockAmountConverted1 id="Fact-99b11c44-54aa-4982-8e04-3a08969bde81_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30_us-gaap-ConversionOfStockByUniqueDescriptionAxis_coll-ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember_us-gaap-StatementClassOfStockAxis_us-gaap-RedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD">120302000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="Fact-dc9934d2-aef8-4db8-ade1-4ae0bcace19f_20150930" decimals="-3" contextRef="I2015-09-30_us-gaap-CashAndCashEquivalentsAxis_us-gaap-MoneyMarketFundsMember_us-gaap-FairValueByFairValueHierarchyLevelAxis_us-gaap-FairValueInputsLevel1Member_us-gaap-FairValueByMeasurementBasisAxis_us-gaap-EstimateOfFairValueFairValueDisclosureMember_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember" unitRef="iso4217-USD">104911000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="Fact-1d682467-fbfb-41a6-b769-9c17c25eff19_20150930" decimals="-3" contextRef="I2015-09-30_us-gaap-CashAndCashEquivalentsAxis_us-gaap-MoneyMarketFundsMember_us-gaap-FairValueByMeasurementBasisAxis_us-gaap-EstimateOfFairValueFairValueDisclosureMember_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember" unitRef="iso4217-USD">104911000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="Fact-a9e18b51-70cc-4194-a46d-12255fec1337_20150930" decimals="-3" contextRef="I2014-12-31_us-gaap-CashAndCashEquivalentsAxis_us-gaap-MoneyMarketFundsMember_us-gaap-FairValueByFairValueHierarchyLevelAxis_us-gaap-FairValueInputsLevel1Member_us-gaap-FairValueByMeasurementBasisAxis_us-gaap-EstimateOfFairValueFairValueDisclosureMember_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember" unitRef="iso4217-USD">457000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="Fact-de72f904-2b71-4e74-a60f-ccad9b96deaf_20150930" decimals="-3" contextRef="I2014-12-31_us-gaap-CashAndCashEquivalentsAxis_us-gaap-MoneyMarketFundsMember_us-gaap-FairValueByMeasurementBasisAxis_us-gaap-EstimateOfFairValueFairValueDisclosureMember_us-gaap-FairValueByMeasurementFrequencyAxis_us-gaap-FairValueMeasurementsRecurringMember" unitRef="iso4217-USD">457000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Fact-e61ca83a-09d3-4283-a6d3-9d8a9c554a56_20150930" decimals="-3" contextRef="I2014-09-30" unitRef="iso4217-USD">4178000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AreaOfRealEstateProperty id="Fact-6190533c-f451-49ca-a15e-ad83460d6cf5_20150930" decimals="0" contextRef="I2015-03-31_us-gaap-LeaseArrangementTypeAxis_coll-OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" unitRef="utr-sqft">19335</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:AreaOfRealEstateProperty id="Fact-be608933-7e8d-4e97-aefa-3b009e5af21c_20150930" decimals="0" contextRef="I2015-03-31_us-gaap-LeaseArrangementTypeAxis_coll-AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" unitRef="utr-sqft">9660</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Fact-07fb97ed-ca64-4121-af15-137ba733a847_20150930" decimals="INF" contextRef="D2015-01-01_2015-09-30_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-WarrantMember" unitRef="xbrli-shares">2445</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Fact-555663fe-e183-421d-a3e2-9cb4803d9614_20150930" decimals="INF" contextRef="D2015-01-01_2015-09-30_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-RestrictedStockMember" unitRef="xbrli-shares">153589</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Fact-5b27d377-304a-4d64-9b98-5983cfdc1b28_20150930" decimals="INF" contextRef="D2015-01-01_2015-09-30_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="xbrli-shares">1356246</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Fact-de78cc05-b34f-4721-99db-8b0572537ca2_20150930" decimals="INF" contextRef="D2014-01-01_2014-09-30_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-WarrantMember" unitRef="xbrli-shares">18810</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Fact-1e1bc5ec-39d4-406e-8eb9-76bb518977d5_20150930" decimals="INF" contextRef="D2014-01-01_2014-09-30_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-RestrictedStockMember" unitRef="xbrli-shares">28536</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Fact-ea4a464c-a989-475c-9dcb-b7b4404fe43d_20150930" decimals="INF" contextRef="D2014-01-01_2014-09-30_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap-RedeemableConvertiblePreferredStockMember" unitRef="xbrli-shares">6552820</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Fact-6c6c8930-1bd8-42f9-9d94-11526e23842b_20150930" decimals="INF" contextRef="D2014-01-01_2014-09-30_us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_coll-EmployeeAndNonemployeeStockOptionsMember" unitRef="xbrli-shares">311365</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <coll:TemporaryEquityGainLossOnExtinguishment id="Fact-cb5ae5b0-078e-4557-888d-bf9a2ea26a50_20150930" decimals="-3" contextRef="D2015-03-01_2015-03-31_us-gaap-StatementClassOfStockAxis_coll-SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD">31806000</coll:TemporaryEquityGainLossOnExtinguishment>
  <coll:TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment id="Fact-c39e1d5c-a55f-46b0-b893-b22d545ed92d_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30_us-gaap-StatementClassOfStockAxis_coll-SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD">23327000</coll:TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment>
  <coll:TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment id="Fact-cd14db23-9707-41c6-ac68-c6302af67840_20150930" decimals="-3" contextRef="D2014-01-01_2014-09-30_us-gaap-StatementClassOfStockAxis_coll-SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" unitRef="iso4217-USD">2469000</coll:TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment>
  <coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue id="Fact-6787cae5-80df-413c-b75f-4e8cac336c29_20150930" decimals="-2" contextRef="D2015-01-01_2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember" unitRef="iso4217-USD">24572000</coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue>
  <coll:TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment id="Fact-00dfac63-2360-4f68-8d39-1ba619b7766d_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember" unitRef="iso4217-USD">1245000</coll:TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment>
  <us-gaap:PaymentsOfStockIssuanceCosts id="Fact-c1a7f33a-2ad8-44a7-afae-8df36a9650f7_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember" unitRef="iso4217-USD">193000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction id="Fact-e3dc77e2-cd8b-4328-b2ab-bae44fcb6c58_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesDPreferredStockMember" unitRef="iso4217-USD">44807000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber id="Fact-ed63686a-a15e-4ccb-9ecb-87cc33382538_20150930" decimals="INF" contextRef="I2015-09-30_us-gaap-AwardTypeAxis_us-gaap-RestrictedStockMember" unitRef="xbrli-shares">72463</coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber>
  <coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate id="Fact-82f31866-db51-49b4-a600-a4212804e8c6_20150930" contextRef="D2015-01-01_2015-09-30_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember_us-gaap-RangeAxis_us-gaap-MinimumMember">P1M</coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate>
  <coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate id="Fact-f228ab70-c093-4f70-9655-140878c4ba15_20150930" contextRef="D2015-01-01_2015-09-30_us-gaap-AwardTypeAxis_coll-EmployeeAndNonemployeeStockOptionsMember_us-gaap-RangeAxis_us-gaap-MaximumMember">P3M</coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate>
  <coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares id="Fact-a07e430a-05a6-44ad-973d-8c3d1b700ceb_20150930" decimals="INF" contextRef="D2015-04-01_2015-04-30_us-gaap-PlanNameAxis_coll-StockIncentivePlan2014Member" unitRef="xbrli-pure">0.04</coll:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares>
  <coll:MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation id="Fact-568b3004-e3a1-4072-839d-f2c00f15954e_20150930" contextRef="D2015-03-01_2015-03-31">P30M</coll:MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation>
  <coll:LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected id="Fact-e4a38e7a-6c6b-4c73-857d-f6bcd7d5f578_20150930" contextRef="D2015-01-01_2015-09-30_us-gaap-LossContingenciesByNatureOfContingencyAxis_coll-HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember_us-gaap-RangeAxis_us-gaap-MaximumMember">P30M</coll:LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected>
  <coll:AmortizationOfIncentiveFromLessor id="Fact-07165ef6-a6bd-4724-81c8-80472521b849_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">25000</coll:AmortizationOfIncentiveFromLessor>
  <coll:InitialPublicOfferingCostsPolicyPolicyTextBlock id="Fact-bd683548-d3eb-44da-a78c-c7ed65c20580_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Initial Public Offering&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In May 2015, the Company closed an initial public offering ("IPO") of its common stock, which resulted in the sale of 6,670,000 shares of its common stock at a public offering price of $12.00 per share, including 870,000 shares of common stock upon the exercise by the underwriters of their option to purchase additional shares at the public offering price. The Company received proceeds from the IPO of approximately $72,029, after deducting underwriting discounts, commissions and expenses payable by the Company.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In connection with preparing for the IPO, the Company's Board of Directors and shareholders approved a one-for-6.9 reverse stock split of the Company's common stock. The reverse stock split became effective in April 2015. All share and per share amounts in the condensed interim financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. In connection with the closing of the IPO, all of the Company's outstanding convertible preferred stock automatically converted to common stock in May 2015, resulting in an additional 12,591,456 shares of common stock of the Company becoming outstanding. The significant increase in common stock outstanding in May 2015 is expected to impact the year-over-year comparability of the Company's net loss per share calculations in future periods.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</coll:InitialPublicOfferingCostsPolicyPolicyTextBlock>
  <coll:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted id="Fact-feafa448-4a92-46f6-a004-4d70bed17b50_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">-10496000</coll:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
  <coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue id="Fact-d4a267bb-9a80-46e7-b2e1-46f25e88c13f_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">24572000</coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue>
  <coll:TemporaryEquityGainLossOnExtinguishment id="Fact-d9413dcd-4681-4180-9e72-29e2348e474a_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">31806000</coll:TemporaryEquityGainLossOnExtinguishment>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock id="Fact-2fb102a0-b112-48f2-86ff-16df37d1eb3c_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;5. ACCRUED EXPENSES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Accrued expenses consisted of the following:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="68"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="70"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;December&amp;#160;31,&lt;br /&gt;
2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;September&amp;#160;30,&lt;br /&gt;
2015&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued compensation&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;635&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,169&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued development costs&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;970&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;597&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued marketing&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;685&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued audit and legal&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;249&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;109&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued interest&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;71&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;31&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued other&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;31&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;90&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Total accrued expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,956&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,681&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="Fact-8bafb125-a9a3-4a32-bd76-7f0d4de36c5f_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">6000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="Fact-3554c539-bdfc-4dfb-9933-96bc33f50d90_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Basis of presentation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial reporting and as required by Regulation&amp;#160;S-X, Rule&amp;#160;10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the interim periods ended September&amp;#160;30, 2015 and 2014 are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The condensed interim financial statements should be read in conjunction with the audited financial statements and notes as of and for the year ended December&amp;#160;31, 2014.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="Fact-5d56bcb0-0f19-448d-853b-ed088135edd5_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;9. COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company's NDA filing for Xtampza is a 505(b)(2) application, which allows the Company to reference data from an approved drug listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the "Orange Book"), in this case OxyContin OP. In connection with the 505(b)(2) process, the Company certified to the FDA and notified Purdue Pharma,&amp;#160;L.P. ("Purdue"), as the holder of the NDA and any other Orange Book-listed patent owners, that the Company does not infringe any of the patents listed for OxyContin OP in the Orange Book. Under the Hatch-Waxman Act of 1984 (the "Hatch-Waxman Act"), Purdue can elect to sue the Company for infringement, and if they do, receive a stay of up to 30&amp;#160;months before the FDA can issue a final approval for Xtampza, unless the stay is earlier terminated. On March&amp;#160;24, 2015, Purdue sued the Company in the District of Delaware asserting infringement of four patents. On March&amp;#160;26, 2015, Purdue filed a second suit against the Company in the District of Massachusetts asserting infringement of the same four patents. On July&amp;#160;23, 2015, Purdue voluntarily dismissed the Massachusetts suit. On August&amp;#160;6, 2015, the Delaware court dismissed the suit in Delaware and issued a memorandum opinion finding the Delaware court lacks personal jurisdiction over the Company Following the dismissal in Delaware, on August&amp;#160;6, 2015, the Company filed a complaint in the Southern District of New York asserting an action to obtain patent certainty, and requesting that the New York court find that Xtampza will not infringe any valid patent claim of the patents asserted by Purdue in the Delaware action. Also on August&amp;#160;6, 2015, Purdue sued the Company in the District of Massachusetts asserting the same claims as the prior suit. On August&amp;#160;7, 2015, Purdue filed a motion in the Delaware court requesting reconsideration of the August&amp;#160;6, 2015 order that dismissed the case. In the motion requesting reconsideration, Purdue asked that the Delaware court find that it does have personal jurisdiction over the Company and then transfer the case to the District of Massachusetts. On October&amp;#160;7, 2015, the Delaware court transferred the case to the District of Massachusetts. On November&amp;#160;9, 2015, the Company filed a motion for summary judgment, for which it requested expedited hearing in Massachusetts. At this time the Company is unable to provide meaningful quantification of how this litigation may impact its future financial condition, results of operations, or cash flows.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In March 2015, the Company amended its lease to include an additional 9,660 square feet of space for a total of 19,335 square feet. In addition, the lease term was extended and now terminates on the date that is 5&amp;#160;years following August 2015 which is the date that the landlord delivered the expansion space with certain improvements substantially completed. At the Company's election, the lease term may be extended for an additional 5-year term.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:DebtConversionOriginalDebtAmount1 id="Fact-3ed72023-e5b3-41c3-85cf-b706591b9dba_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">5000000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:Depreciation id="Fact-d0c5831c-73d2-45e1-a1d0-8738168bc44f_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">130000</us-gaap:Depreciation>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="Fact-ea0f9a90-fb8b-460d-853b-9b7a6251da19_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;8. STOCK-BASED COMPENSATION&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In July 2014, the Company adopted the 2014 Stock Incentive Plan (the "Plan"), under which 525,700 shares of common stock are authorized for issuance to employees, officers, directors, consultants and advisors of the Company. In connection with the Company's reincorporation into Virginia in July 2014, each outstanding option to purchase shares of common stock under the Company's 2012 Stock Incentive Plan and 2002 Stock Plan, was automatically terminated and replaced with an option to purchase shares of common stock under the Plan having the same vesting terms and exercise price as the option that was replaced. The Plan provides for granting of both Internal Revenue Service qualified incentive stock options ("ISOs") and non-qualified options ("NQs"), restricted stock awards ("RSAs") and restricted stock units ("RSUs"). Stock options generally vest over a four year period of service; however, certain options contain performance conditions. The options generally have a ten year contractual life and, upon termination, vested options are generally exercisable between one and three months following the termination date, while unvested options are forfeited immediately.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In April 2015, the Plan was amended to increase the maximum number of shares of common stock that may be issued to 2,700,000 shares. In addition, an "evergreen provision" was added to the Plan that allows for an annual increase in the number of shares of common stock available for issuance under the Plan. The annual increase will be added on the first day of each fiscal year beginning with the fiscal year ending December&amp;#160;31, 2016, and on each anniversary thereof until the expiration of the Plan equal to 4% of the outstanding shares of our common stock on December&amp;#160;31st&amp;#160;of the immediately preceding fiscal year (or such lesser number of shares of common stock as determined by the board of directors).&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Restricted common stock&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;A summary of the Company's restricted stock activity for the nine months ended September&amp;#160;30, 2015 and related information is as follows:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="53"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="82"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Weighted average&lt;br /&gt;
purchase price&lt;br /&gt;
per share&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Unvested at December&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;15,387&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.69&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;194,694&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;5.73&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Vested&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(128,955&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;5.13&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Unvested at September&amp;#160;30, 2015&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;81,126&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;5.73&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" --&gt;
&lt;hr style="COLOR: #000000;" align="left" size="1" width="26%" noshade="noshade" /&gt;&lt;/div&gt;
&lt;div style="POSITION: relative; PADDING-BOTTOM: 0pt; TEXT-ALIGN: left; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;dl compact="compact"&gt;
&lt;dt style="MARGIN-BOTTOM: -9pt; FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;font style="FONT-SIZE: 6pt; POSITION: relative; TOP: -2pt; add_sup: 2pt;"&gt;(1)&lt;/font&gt;&lt;/font&gt;&lt;/dt&gt;
&lt;dd style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;Excludes 72,463 shares of unvested restricted stock remaining from the early exercise of stock options as of September&amp;#160;30, 2015.&lt;/font&gt;&lt;/dd&gt;&lt;/dl&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Stock options&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;A summary of the Company's stock option activity and related information follows:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="59"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="65"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="54"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="49"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
average&lt;br /&gt;
exercise price&lt;br /&gt;
per share&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
average&lt;br /&gt;
remaining&lt;br /&gt;
contractual&lt;br /&gt;
term&lt;br /&gt;
(years)&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
Intrinsic&lt;br /&gt;
Value&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Outstanding at December&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;281,029&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;0.69&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;1,197,452&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;10.47&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(121,729&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;3.89&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Cancelled&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(506&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;2.06&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Outstanding at September&amp;#160;30, 2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;1,356,246&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;9.04&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;9.2&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;17,722&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Exercisable at September&amp;#160;30, 2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;208,438&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;2.65&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;7.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;4,056&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Vested and expected to vest at September&amp;#160;30, 2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;1,341,543&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;9.13&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;9.2&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;18,595&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The fair value of each stock option is estimated on the grant date using the Black-Scholes option-pricing model using the following assumptions:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="28"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="24"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="28"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Nine months&lt;br /&gt;
ended&lt;br /&gt;
September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1.8&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1.7&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;77&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;77&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Expected term (years)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6.25&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6.21&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Fact-72c003b6-40db-4c5b-83ec-68869da0a9ed_20150930" decimals="2" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD_xbrli-shares">-0.94</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock id="Fact-5ee28a12-de2d-432e-9e46-06cf791683e5_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;&lt;i&gt;Earnings (Loss) per Common Share&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Earnings (loss) per common share is calculated using the two-class method, which is an earnings allocation formula that determines earnings (loss) per share for the holders of the Company's common shares and participating securities. All series of preferred stock contain participation rights in any dividend paid by the Company and are deemed to be participating securities. Earnings available to common shareholders and participating convertible redeemable preferred shares is allocated first to the preferred stock based upon the distribution criteria in the Company's Articles of Incorporation then the remainder to the common shareholders. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods that have a net loss.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Diluted earnings per share is computed using the more dilutive of (a)&amp;#160;the two-class method, or (b)&amp;#160;the if-converted method. The Company allocates earnings first to preferred shareholders based on dividend rights and then to common and preferred shareholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted earnings (loss) gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants, convertible redeemable preferred stock and the potential issuance of stock upon the conversion of the Company's convertible notes. Common stock equivalent shares are excluded from the computation of diluted earnings (loss) per share if their effect is antidilutive.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="Fact-b7f71f0d-30ef-4f5c-99c4-1413e7536aa7_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;3. NET LOSS PER COMMON SHARE&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="56"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="73"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Nine months ended&lt;br /&gt;
September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Net loss&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(14,448&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(17,730&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Extinguishment of preferred stock&amp;#160;&amp;#8212; see note&amp;#160;7&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;31,806&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accretion of prior preferred stock&amp;#160;&amp;#8212; see note&amp;#160;7&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(2,469&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(23,327&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accretion and dividends of Series&amp;#160;D preferred stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(1,245&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Loss attributable to common shareholders&amp;#160;&amp;#8212; basic and diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(16,917&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(10,496&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Weighted-average number of common shares used in net loss per share&amp;#160;&amp;#8212; basic and diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;926,597&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;11,179,756&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Net loss per share&amp;#160;&amp;#8212; basic and diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(18.26&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(0.94&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The following potentially dilutive securities, which represent all outstanding potentially dilutive securities, were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in common stock equivalent shares):&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="59"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="59"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Nine months ended&lt;br /&gt;
September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Outstanding stock options&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;311,365&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,356,246&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18,810&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,445&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6,552,820&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Unvested restricted stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;28,536&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;153,589&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock id="Fact-6f14dbd8-eb77-4b73-a8fa-cf6689b5c189_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="56"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="67"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="51"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="61"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" nowrap="nowrap" align="left"&gt;
&lt;div style="MARGIN-BOTTOM: 0pt; WIDTH: 40pt; BORDER-BOTTOM: #000000 1pt solid;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Description &lt;!-- COMMAND=ADD_SCROPPEDRULE,40pt --&gt;&lt;/b&gt;&lt;/font&gt;&lt;/div&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Quoted Prices&lt;br /&gt;
in active&lt;br /&gt;
markets&lt;br /&gt;
(Level&amp;#160;1)&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Significant&lt;br /&gt;
other&lt;br /&gt;
observable&lt;br /&gt;
inputs&lt;br /&gt;
(Level&amp;#160;2)&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Significant&lt;br /&gt;
unobservable&lt;br /&gt;
inputs&lt;br /&gt;
(Level&amp;#160;3)&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;December&amp;#160;31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Money market funds, included in cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;457&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;457&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; MARGIN-TOP: 12pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;September&amp;#160;30, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;br /&gt;
&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;br /&gt;
&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;br /&gt;
&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;br /&gt;
&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Money market funds, included in cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;104,911&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;104,911&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="Fact-10518897-913e-4d51-85f5-d9233f657d9c_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;4. FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy is now established that prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Level&amp;#160;1 inputs&amp;#160;&amp;#160;&amp;#160;&amp;#160;Quoted prices in active markets for identical assets or liabilities&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Level&amp;#160;2 inputs&amp;#160;&amp;#160;&amp;#160;&amp;#160;Inputs other than quoted prices included within Level&amp;#160;1 that are observable for the asset or liability, either directly or indirectly&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Level&amp;#160;3 inputs&amp;#160;&amp;#160;&amp;#160;&amp;#160;Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The following tables present the Company's financial instruments carried at fair value using the lowest level input applicable to each financial instrument at December&amp;#160;31, 2014 and September&amp;#160;30, 2015.&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="56"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="67"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="51"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="61"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" nowrap="nowrap" align="left"&gt;
&lt;div style="MARGIN-BOTTOM: 0pt; WIDTH: 40pt; BORDER-BOTTOM: #000000 1pt solid;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Description &lt;!-- COMMAND=ADD_SCROPPEDRULE,40pt --&gt;&lt;/b&gt;&lt;/font&gt;&lt;/div&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Quoted Prices&lt;br /&gt;
in active&lt;br /&gt;
markets&lt;br /&gt;
(Level&amp;#160;1)&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Significant&lt;br /&gt;
other&lt;br /&gt;
observable&lt;br /&gt;
inputs&lt;br /&gt;
(Level&amp;#160;2)&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Significant&lt;br /&gt;
unobservable&lt;br /&gt;
inputs&lt;br /&gt;
(Level&amp;#160;3)&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;December&amp;#160;31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Money market funds, included in cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;457&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;457&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; MARGIN-TOP: 12pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;September&amp;#160;30, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;br /&gt;
&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;br /&gt;
&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;br /&gt;
&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&lt;br /&gt;
&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Money market funds, included in cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;104,911&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;104,911&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company's cash equivalents are comprised of money market funds that are measured on a recurring basis based on quoted market prices.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="Fact-db634f60-9b4c-427d-bebd-d1d34fc642ff_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">91000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:GeneralAndAdministrativeExpense id="Fact-2e2427e4-b566-421a-afb1-c7a6dcdb9be1_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">11027000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxesPaid id="Fact-1c7f76c1-4e5b-4dad-932e-10d0bb46d985_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">4000</us-gaap:IncomeTaxesPaid>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="Fact-1b4ca0c9-d3ef-46e2-9b2a-c7f1d985efe3_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">962000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="Fact-5b471e92-96c2-486e-afc0-e2fa57252d81_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">815000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInDepositsOutstanding id="Fact-cda8a5d3-80a1-45be-9047-140f23cb00dd_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">-2335000</us-gaap:IncreaseDecreaseInDepositsOutstanding>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Fact-41d883de-4166-4c81-a81a-6f52f7c44650_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">338000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseInRestrictedCash id="Fact-3d3b4abc-b1ae-4d16-93b4-e6ddf8eebd27_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">16000</us-gaap:IncreaseInRestrictedCash>
  <us-gaap:InterestIncomeExpenseNonoperatingNet id="Fact-aa5d6c2e-4bc2-4ac1-882b-b5abc0085d43_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">-350000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InterestPaid id="Fact-9bfd3dca-3bd7-4b5e-81bd-54b08ed46011_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">260000</us-gaap:InterestPaid>
  <us-gaap:MaturitiesOfSeniorDebt id="Fact-77871e21-7828-4063-b530-8a906a229762_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">619000</us-gaap:MaturitiesOfSeniorDebt>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations id="Fact-2c0af140-b44e-452d-993c-52fd9975e400_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">103826000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Fact-badfba43-a5a9-4b9a-ae58-1c4367d70edf_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">116629000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Fact-562bd95b-8475-4664-ae22-2e32514c9e6a_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">-175000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Fact-0c8cf339-2558-47e3-a564-c16692b3861d_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">-12628000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetIncomeLoss id="Fact-0c60db50-b13e-4ab6-8dcc-18b227cec6aa_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">-17730000</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="Fact-eaee9176-89cd-40af-b91d-8a53a8f391f6_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In May 2014, the Financial Accounting Standards Board ("FASB"), issued Accounting Standards Update ("ASU"), No.&amp;#160;2014-09, which amends the guidance for accounting for revenue from contracts with customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification ("ASC"), Topic 605, Revenue Recognition, and creates a new Topic 606, Revenue from Contracts with Customers. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain practical expedients permitted; or retrospectively with the cumulative effect of initially adopting the ASU recognized at the date of initial application. On August&amp;#160;12, 2015, the FASB issued ASU No.&amp;#160;2015-14, which defers the effective date of ASU No.&amp;#160;2014-09 by one year to December&amp;#160;15, 2017 for annual reporting periods beginning after that date, including interim periods within those periods. The FASB also approved permitting early adoption of the standard, but not before the original effective date of December&amp;#160;15, 2016. The Company has not yet determined which adoption method it will utilize or the effect that the adoption of this guidance will have on its financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In July 2015, the FASB issued ASU No.&amp;#160;2015-11, which amends existing guidance for measurement of inventory. Current inventory guidance requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. The amendments do not apply to inventory that is measured using last-in, first-out (LIFO) or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out or average cost. An entity should measure all inventory to which the amendments apply at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The amendments in the ASU No.&amp;#160;2015-11 more closely align the measurement of inventory pursuant to GAAP with the measurement of inventory pursuant to International Financial Reporting Standards. The amendments are effective for fiscal years beginning after December&amp;#160;15, 2016, and interim periods within fiscal years beginning after December&amp;#160;15, 2017. The amendments should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company does not expect the adoption of this guidance to have a material impact on its condensed financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock id="Fact-8d15f23b-c329-4a10-a626-e89da8e157b7_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="53"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="82"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Weighted average&lt;br /&gt;
purchase price&lt;br /&gt;
per share&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Unvested at December&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;15,387&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;0.69&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;194,694&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;5.73&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Vested&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;(128,955&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;5.13&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Unvested at September&amp;#160;30, 2015&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;81,126&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;5.73&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" --&gt;
&lt;hr style="COLOR: #000000;" align="left" size="1" width="26%" noshade="noshade" /&gt;&lt;/div&gt;
&lt;div style="POSITION: relative; PADDING-BOTTOM: 0pt; TEXT-ALIGN: left; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;dl compact="compact"&gt;
&lt;dt style="MARGIN-BOTTOM: -9pt; FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;font style="FONT-SIZE: 6pt; POSITION: relative; TOP: -2pt; add_sup: 2pt;"&gt;(1)&lt;/font&gt;&lt;/font&gt;&lt;/dt&gt;
&lt;dd style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;Excludes 72,463 shares of unvested restricted stock remaining from the early exercise of stock options as of September&amp;#160;30, 2015.&lt;/font&gt;&lt;/dd&gt;&lt;/dl&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
  <us-gaap:OperatingExpenses id="Fact-cbddaddc-301f-4a93-8254-25d385678c34_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">17471000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="Fact-48a95c48-8023-4934-b40d-5da72b65a901_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">-17471000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="Fact-13725c49-f0db-44bd-a16a-e42899c1ce64_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;1. NATURE OF BUSINESS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Collegium Pharmaceutical,&amp;#160;Inc. (the "Company") was incorporated in Delaware in April 2002 and then reincorporated in Virginia in July 2014. The Company has its principal operations in Canton, Massachusetts. The Company is a specialty pharmaceutical company developing and planning to commercialize next-generation abuse-deterrent products that incorporate the Company's patented DETERx&amp;#174; platform technology for the treatment of chronic pain and other diseases. The Company's lead product candidate, Xtampza&amp;#8482; ER, or Xtampza, is an abuse-deterrent, extended-release, oral formulation of oxycodone, a widely prescribed opioid medication. Xtampza has received Fast Track status from the U.S. Food and Drug Administration ("FDA"). The Company's new drug application ("NDA") filing for Xtampza was accepted by the FDA on February&amp;#160;10, 2015. On February&amp;#160;25, 2015, the FDA set a Prescription Drug User Fee Act, or PDUFA, goal date of October&amp;#160;12, 2015 for completion of its review of the Xtampza NDA. On November&amp;#160;6, 2015, the FDA granted tentative approval to the Xtampza NDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. With a tentative approval, the FDA has determined that Xtampza meets the required quality, safety and efficacy standards for approval but that it is subject to an automatic stay of up to 30&amp;#160;months as a result of patent litigation filed by Purdue Pharma, L.P (Purdue) in March 2015.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company's operations are subject to certain risks and uncertainties. The principal risks include negative outcome of clinical trials, inability or delay in completing clinical trials or obtaining regulatory approvals, changing market conditions for products being developed by the Company, the need to retain key personnel and protect intellectual property, patent infringement litigation and the availability of additional capital financing on terms acceptable to the Company.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:OtherNonoperatingIncomeExpense id="Fact-76f229c2-8252-4567-bbe3-ebf4860a3611_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">-259000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Fact-5b40f146-7900-4884-b60c-36d5a4bd98a3_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">175000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PreferredStockTextBlock id="Fact-97492017-a69e-4558-b514-0dd552b4a38e_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;7. CONVERTIBLE PREFERRED STOCK&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In March 2015, the Company issued and sold an aggregate of 41,666,667 shares of Series&amp;#160;D convertible preferred stock for aggregate consideration of $50,000, comprised of $45,000 in cash and conversion of $5,000 in Bridge Notes. The accrued interest on the convertible notes was waived.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Concurrently with the issuance of the Series&amp;#160;D Preferred Stock, the Company amended and restated its Articles of Incorporation (the "Amended Articles"). The Company made certain amendments to the terms of the Series&amp;#160;A, Series&amp;#160;B, and Series&amp;#160;C Preferred Stock (together, the "Prior Preferred Stock"). Prior to the adoption of the Amended Articles, the Series&amp;#160;A, Series&amp;#160;B, and Series&amp;#160;C Preferred Stock accrued dividends at a rate of 4.5%, 8.0% and 8.0% per annum, respectively, per share. All accrued and unpaid dividends on the Prior Preferred Stock were automatically cancelled and forfeited and the Prior Preferred Stock no longer accrued dividends. Prior to the cancellation and forfeiture of accrued dividends, the Prior Preferred Stock had accrued dividends of $622 during 2015. The holders of outstanding shares of Prior Preferred Stock were entitled to receive dividends, when, as and if declared by the Board of Directors. The mandatory conversion for all series of Prior Preferred Stock was modified so as to occur upon an initial public offering with gross proceeds in excess of $50,000. The amendments to the Prior Preferred Stock were treated as an extinguishment which resulted in a gain on extinguishment of $31,806. The gain on extinguishment was added to net loss to arrive at income available to common shareholders in the calculation of earnings per share. During the nine months ended September&amp;#160;30, 2015, total accrued dividends and accretion for preferred stock was $24,572.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In connection with the closing of the IPO, all of the Company's outstanding convertible preferred stock automatically converted to common stock in May 2015, resulting in an additional 12,591,456 shares of common stock of the Company becoming outstanding.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:PreferredStockTextBlock>
  <us-gaap:ProceedsFromStockOptionsExercised id="Fact-10bfeb02-0e15-471f-8dc7-fd7494efa87b_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">472000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:RepaymentsOfLongtermLoansFromVendors id="Fact-9c008483-5e8e-44dd-9dd6-7873a9f95371_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">44000</us-gaap:RepaymentsOfLongtermLoansFromVendors>
  <us-gaap:ResearchAndDevelopmentExpense id="Fact-edc2652d-931f-405b-9612-4465065b7063_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">6444000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="Fact-d0ae1e09-383e-4abe-a119-43fa44695eb9_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="68"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="70"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;December&amp;#160;31,&lt;br /&gt;
2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;September&amp;#160;30,&lt;br /&gt;
2015&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued compensation&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;635&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,169&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued development costs&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;970&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;597&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued marketing&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;685&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued audit and legal&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;249&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;109&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued interest&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;71&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;31&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accrued other&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;31&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;90&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Total accrued expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,956&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,681&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="Fact-296637bd-691a-42de-bb59-216618c5c102_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="59"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="59"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Nine months ended&lt;br /&gt;
September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Outstanding stock options&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;311,365&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1,356,246&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Warrants&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;18,810&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;2,445&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6,552,820&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Unvested restricted stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;28,536&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;153,589&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="Fact-c008fa79-5dec-46a2-8b21-c379f4d1a0b4_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="56"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="73"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Nine months ended&lt;br /&gt;
September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Net loss&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(14,448&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(17,730&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Extinguishment of preferred stock&amp;#160;&amp;#8212; see note&amp;#160;7&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;31,806&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accretion of prior preferred stock&amp;#160;&amp;#8212; see note&amp;#160;7&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(2,469&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(23,327&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Accretion and dividends of Series&amp;#160;D preferred stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(1,245&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Loss attributable to common shareholders&amp;#160;&amp;#8212; basic and diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(16,917&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(10,496&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Weighted-average number of common shares used in net loss per share&amp;#160;&amp;#8212; basic and diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;926,597&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;11,179,756&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Net loss per share&amp;#160;&amp;#8212; basic and diluted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(18.26&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(0.94&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="Fact-9a4894ce-ce9b-416b-861d-f4dd8e0d493f_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="59"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="65"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="54"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="49"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
average&lt;br /&gt;
exercise price&lt;br /&gt;
per share&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
average&lt;br /&gt;
remaining&lt;br /&gt;
contractual&lt;br /&gt;
term&lt;br /&gt;
(years)&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
Intrinsic&lt;br /&gt;
Value&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Outstanding at December&amp;#160;31, 2014&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;281,029&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;0.69&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;1,197,452&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;10.47&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(121,729&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;3.89&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Cancelled&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;(506&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;2.06&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Outstanding at September&amp;#160;30, 2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;1,356,246&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;9.04&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;9.2&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;17,722&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Exercisable at September&amp;#160;30, 2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;208,438&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;2.65&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;7.9&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;4,056&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Vested and expected to vest at September&amp;#160;30, 2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;1,341,543&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;9.13&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;9.2&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" align="right"&gt;&lt;font size="2"&gt;18,595&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="bottom"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="Fact-340e9298-9c49-4390-b5d3-44a44cbc0cf4_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="28"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="24"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="28"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Nine months&lt;br /&gt;
ended&lt;br /&gt;
September&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" align="left"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1.8&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;1.7&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;77&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;77&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Expected term (years)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6.25&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;6.21&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensation id="Fact-c1a8cdc9-1fbd-4ac8-b2e4-e9d3fd892708_20150930" decimals="-3" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD">1217000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="Fact-22310f4c-c017-4834-a564-948432add1df_20150930" decimals="INF" contextRef="D2015-01-01_2015-09-30" unitRef="xbrli-shares">194694</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="Fact-7d9654a6-99f5-44fe-aa53-35dbe4403d31_20150930" decimals="2" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD_xbrli-shares">5.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="Fact-24ad2e99-f938-4c2b-ad97-8f32af5a12e8_20150930" decimals="INF" contextRef="D2015-01-01_2015-09-30" unitRef="xbrli-shares">128955</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue id="Fact-91ed768f-7249-45a0-a403-c636c010eb78_20150930" decimals="2" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD_xbrli-shares">5.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Fact-f7525d4d-761b-4903-85aa-a9488d1034e7_20150930" contextRef="D2015-01-01_2015-09-30">P6Y2M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Fact-4b4fdd18-1db0-454b-bc04-86b35038df6c_20150930" decimals="2" contextRef="D2015-01-01_2015-09-30" unitRef="xbrli-pure">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Fact-6d9e247f-ba9f-42dc-b5b1-c10ddf4fb3c0_20150930" decimals="3" contextRef="D2015-01-01_2015-09-30" unitRef="xbrli-pure">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="Fact-3ede7ddb-0529-417b-b579-2cc0e299f9c3_20150930" contextRef="D2015-01-01_2015-09-30">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod id="Fact-f1ae1a04-b953-4311-abd2-07c6a740c8f7_20150930" decimals="INF" contextRef="D2015-01-01_2015-09-30" unitRef="xbrli-shares">506</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice id="Fact-fc148dd4-13e1-4763-952f-65106f8251d3_20150930" decimals="2" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD_xbrli-shares">2.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Fact-ecfcbcbe-b3f9-4e30-9f17-720cdc0d9701_20150930" decimals="INF" contextRef="D2015-01-01_2015-09-30" unitRef="xbrli-shares">1197452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Fact-6824fe19-1b58-4ab7-9a9d-a1c859adb168_20150930" contextRef="D2015-01-01_2015-09-30">P9Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 id="Fact-48322594-d421-42ce-878a-e38d9cd582c0_20150930" contextRef="D2015-01-01_2015-09-30">P9Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="Fact-b34bd065-8c07-4482-af02-981283528b4b_20150930" decimals="2" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD_xbrli-shares">3.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Fact-7eb71f1d-e454-4aac-b1cd-28963f9aa1ff_20150930" decimals="2" contextRef="D2015-01-01_2015-09-30" unitRef="iso4217-USD_xbrli-shares">10.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShortTermDebtTextBlock id="Fact-b3afcf91-bd55-491f-8a2f-d9c287e6396d_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;6. CONVERTIBLE BRIDGE NOTE WITH RELATED PARTY&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In November and December 2014, the Company entered into a Note Purchase Agreement (the "Bridge Notes") allowing for the issuance of $5,000 of convertible promissory notes to a group of investors (the "Holders") bearing interest at a rate per annum of 6.0%. The Holders are related parties of the Company. In connection with the Series&amp;#160;D convertible preferred stock financing (see note&amp;#160;7), the Bridge Notes converted into Series&amp;#160;D convertible preferred stock. Upon the conversion, the Company recognized a gain on extinguishment of $91.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:ShortTermDebtTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="Fact-927eeb79-c9c9-4d56-95b5-77d0585e185e_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Basis of presentation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial reporting and as required by Regulation&amp;#160;S-X, Rule&amp;#160;10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the interim periods ended September&amp;#160;30, 2015 and 2014 are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The condensed interim financial statements should be read in conjunction with the audited financial statements and notes as of and for the year ended December&amp;#160;31, 2014.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Initial Public Offering&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In May 2015, the Company closed an initial public offering ("IPO") of its common stock, which resulted in the sale of 6,670,000 shares of its common stock at a public offering price of $12.00 per share, including 870,000 shares of common stock upon the exercise by the underwriters of their option to purchase additional shares at the public offering price. The Company received proceeds from the IPO of approximately $72,029, after deducting underwriting discounts, commissions and expenses payable by the Company.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In connection with preparing for the IPO, the Company's Board of Directors and shareholders approved a one-for-6.9 reverse stock split of the Company's common stock. The reverse stock split became effective in April 2015. All share and per share amounts in the condensed interim financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. In connection with the closing of the IPO, all of the Company's outstanding convertible preferred stock automatically converted to common stock in May 2015, resulting in an additional 12,591,456 shares of common stock of the Company becoming outstanding. The significant increase in common stock outstanding in May 2015 is expected to impact the year-over-year comparability of the Company's net loss per share calculations in future periods.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Subsequent Events&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Through November&amp;#160;12, 2015, the Company has concluded that no subsequent events have occurred that require disclosure, except as described in Note&amp;#160;9.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Critical Accounting Policies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;&lt;i&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" --&gt;Earnings (Loss) per Common Share&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Earnings (loss) per common share is calculated using the two-class method, which is an earnings allocation formula that determines earnings (loss) per share for the holders of the Company's common shares and participating securities. All series of preferred stock contain participation rights in any dividend paid by the Company and are deemed to be participating securities. Earnings available to common shareholders and participating convertible redeemable preferred shares is allocated first to the preferred stock based upon the distribution criteria in the Company's Articles of Incorporation then the remainder to the common shareholders. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods that have a net loss.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Diluted earnings per share is computed using the more dilutive of (a)&amp;#160;the two-class method, or (b)&amp;#160;the if-converted method. The Company allocates earnings first to preferred shareholders based on dividend rights and then to common and preferred shareholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted earnings (loss) gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants, convertible redeemable preferred stock and the potential issuance of stock upon the conversion of the Company's convertible notes. Common stock equivalent shares are excluded from the computation of diluted earnings (loss) per share if their effect is antidilutive.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In May 2014, the Financial Accounting Standards Board ("FASB"), issued Accounting Standards Update ("ASU"), No.&amp;#160;2014-09, which amends the guidance for accounting for revenue from contracts with customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification ("ASC"), Topic 605, Revenue Recognition, and creates a new Topic 606, Revenue from Contracts with Customers. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain practical expedients permitted; or retrospectively with the cumulative effect of initially adopting the ASU recognized at the date of initial application. On August&amp;#160;12, 2015, the FASB issued ASU No.&amp;#160;2015-14, which defers the effective date of ASU No.&amp;#160;2014-09 by one year to December&amp;#160;15, 2017 for annual reporting periods beginning after that date, including interim periods within those periods. The FASB also approved permitting early adoption of the standard, but not before the original effective date of December&amp;#160;15, 2016. The Company has not yet determined which adoption method it will utilize or the effect that the adoption of this guidance will have on its financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;In July 2015, the FASB issued ASU No.&amp;#160;2015-11, which amends existing guidance for measurement of inventory. Current inventory guidance requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. The amendments do not apply to inventory that is measured using last-in, first-out (LIFO) or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out or average cost. An entity should measure all inventory to which the amendments apply at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The amendments in the ASU No.&amp;#160;2015-11 more closely align the measurement of inventory pursuant to GAAP with the measurement of inventory pursuant to International Financial Reporting Standards. The amendments are effective for fiscal years beginning after December&amp;#160;15, 2016, and interim periods within fiscal years beginning after December&amp;#160;15, 2017. The amendments should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company does not expect the adoption of this guidance to have a material impact on its condensed financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Fact-d9a9ac49-8e1c-49f7-83fe-682a336af16d_20150930" decimals="INF" contextRef="D2015-01-01_2015-09-30" unitRef="xbrli-shares">121729</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:SubsequentEventsPolicyPolicyTextBlock id="Fact-25a6f734-f368-4d1c-8932-03d845f57780_20150930" contextRef="D2015-01-01_2015-09-30">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;Subsequent Events&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Through November&amp;#160;12, 2015, the Company has concluded that no subsequent events have occurred that require disclosure, except as described in Note&amp;#160;9.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Fact-0be94e6e-8293-43e8-a190-d42275269255_20150930" decimals="0" contextRef="D2015-01-01_2015-09-30" unitRef="xbrli-shares">11179756</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <coll:AmortizationOfIncentiveFromLessor id="Fact-cc4afacf-2465-487e-b8b3-14ce102bddcd_20150930" decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">25000</coll:AmortizationOfIncentiveFromLessor>
  <coll:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted id="Fact-894cdd34-1963-4c61-8506-d609ffc0b968_20150930" decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">-16917000</coll:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
  <coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue id="Fact-5a27ef85-8135-4f3e-b7f6-dd183111df79_20150930" decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">2469000</coll:TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="Fact-2ed49307-40f3-4797-98c6-b47ff0f64dd2_20150930" decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">6000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction id="Fact-af80a994-f52b-4675-ad48-65ac071b7b3e_20150930" decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">-12000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
  <us-gaap:Depreciation id="Fact-dbdaa0db-9e38-4533-9b43-2491381a4667_20150930" decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">141000</us-gaap:Depreciation>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Fact-58f9745a-0b93-4ed5-be14-a76d1f71be6a_20150930" decimals="2" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD_xbrli-shares">-18.26</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="Fact-ff9a96ea-87bf-4a5e-9bfd-4ecb85545e7a_20150930" decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">1563000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="Fact-af7eedb9-3daa-4989-a4fa-879e02e7f1fb_20150930" decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">2518000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Fact-fcd6238b-9288-471a-9672-0548a593e5a6_20150930" decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">139000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestPaid id="Fact-3688d62b-883a-4684-86b4-ff7f68035f42_20150930" decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">46000</us-gaap:InterestPaid>
  <us-gaap:MaturitiesOfSeniorDebt id="Fact-006f35a1-758d-489c-802e-d8451e2be7da_20150930" decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">-7044000</us-gaap:MaturitiesOfSeniorDebt>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations id="Fact-f7f7f6c9-ea5b-428e-8671-dfe3caa6e061_20150930" decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">-3373000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Fact-b4e2394d-c7d3-4d50-9453-140a55598bf9_20150930" decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">7007000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Fact-aa0f44b6-2ef5-4a17-9bae-dce8b4fe74eb_20150930" decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">-10380000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetIncomeLoss id="Fact-f0abfd29-67ce-47f7-afdb-656ac7800f9c_20150930" decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">-14448000</us-gaap:NetIncomeLoss>
  <us-gaap:NotesReduction id="Fact-1dc5b107-ac3c-457d-845c-47b5bb06eb6f_20150930" decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">944000</us-gaap:NotesReduction>
  <us-gaap:ProceedsFromStockOptionsExercised id="Fact-435ad77e-22d0-40af-a641-f248f812b597_20150930" decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">9000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:RepaymentsOfLongtermLoansFromVendors id="Fact-505f5d2c-a2b0-4d16-8520-cbd419106555_20150930" decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">46000</us-gaap:RepaymentsOfLongtermLoansFromVendors>
  <us-gaap:ShareBasedCompensation id="Fact-1e21b57b-fcb0-491a-bde9-6eee586451bd_20150930" decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">16000</us-gaap:ShareBasedCompensation>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Fact-e14c0cbd-82d6-482e-8483-103ee3859024_20150930" contextRef="D2014-01-01_2014-09-30">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Fact-d6f7d034-f552-467f-82e9-3302e3367d82_20150930" decimals="2" contextRef="D2014-01-01_2014-09-30" unitRef="xbrli-pure">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Fact-c3ea2a02-b2ab-49ae-aa1b-abe71ce82e66_20150930" decimals="3" contextRef="D2014-01-01_2014-09-30" unitRef="xbrli-pure">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Fact-b15c33d4-3577-40ac-82c1-e39cd879eafb_20150930" decimals="0" contextRef="D2014-01-01_2014-09-30" unitRef="xbrli-shares">926597</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <coll:AccruedResearchAndDevelopmentCostsCurrent id="Fact-35be2206-7600-41f1-83ff-f2b49cea7be8_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">597000</coll:AccruedResearchAndDevelopmentCostsCurrent>
  <coll:DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent id="Fact-465cb964-9193-483c-959a-790c5c8e85b5_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">15000</coll:DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent>
  <us-gaap:AccountsPayableCurrent id="Fact-4cd55f47-d52d-4e7e-adc4-63354dc59dc1_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">3237000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Fact-c2f802d8-3dea-438c-a5f2-6a389da6ba56_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">2681000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedMarketingCostsCurrent id="Fact-96a5ea99-9a30-4ccf-ae67-506e9bdb6727_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">685000</us-gaap:AccruedMarketingCostsCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="Fact-524e94ca-16a4-4b58-80a9-7552a1665d82_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">109000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AdditionalPaidInCapital id="Fact-1ad20519-b96a-4ebb-87d0-32a626acfb39_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">213027000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:Assets id="Fact-c60254b6-1a24-416c-8846-63b5be4deb98_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">107050000</us-gaap:Assets>
  <us-gaap:AssetsCurrent id="Fact-59fd7c7c-2f90-4878-8686-c170bf48dd31_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">106326000</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Fact-dc7fc696-8a31-4f8e-a1e8-3144699522c9_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">105460000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommitmentsAndContingencies id="Fact-18e42721-f991-48a6-bc7c-b5dd6558a328_20150930" xsi:nil="true" contextRef="I2015-09-30" unitRef="iso4217-USD" />
  <us-gaap:CommonStockParOrStatedValuePerShare id="Fact-c2c04e70-0fa7-4a33-b242-62945e47090a_20150930" decimals="INF" contextRef="I2015-09-30" unitRef="iso4217-USD_xbrli-shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="Fact-28ce6f02-0601-44bc-ae47-69f73783922a_20150930" decimals="INF" contextRef="I2015-09-30" unitRef="xbrli-shares">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="Fact-c927863f-5521-4534-b817-a537c3358d50_20150930" decimals="INF" contextRef="I2015-09-30" unitRef="xbrli-shares">20687829</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="Fact-b383dc5d-9adb-4250-8392-be3c22f5367d_20150930" decimals="INF" contextRef="I2015-09-30" unitRef="xbrli-shares">1006219</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue id="Fact-773d3805-0c3d-4d0f-96b4-eef0def2cf73_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">20000</us-gaap:CommonStockValue>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="Fact-3453c330-2cf5-4c2a-91f1-7a9537d8c81b_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">1169000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:IncentiveFromLessor id="Fact-9af703ef-744d-431a-bd5c-4c1d58098d81_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">76000</us-gaap:IncentiveFromLessor>
  <us-gaap:InterestPayableCurrent id="Fact-730ca2ec-60d4-4bea-b82f-3a976965ac0c_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">31000</us-gaap:InterestPayableCurrent>
  <us-gaap:Liabilities id="Fact-24477617-fd74-463b-89f1-cce41bc099bf_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">13489000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Fact-64823709-7387-45c8-8719-4ae0c6edfae7_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">107050000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent id="Fact-53b74a99-8b2b-4c7e-97d9-6421d9d412cd_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">8600000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LoansPayableCurrent id="Fact-10318e55-e2be-4cb2-a9f3-a3f3f250ff64_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">2667000</us-gaap:LoansPayableCurrent>
  <us-gaap:LongTermLoansPayable id="Fact-a1e950c2-2847-4a3e-aad5-076d42bdf7ee_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">4813000</us-gaap:LongTermLoansPayable>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="Fact-5dadfbf2-17f5-4c21-92c5-e246bb744ff3_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">90000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Fact-42142147-656c-4219-a005-34457bac678c_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">866000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="Fact-90862d33-715e-4216-8960-56b3edb0111d_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">627000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="Fact-fe84df1b-0144-466c-ae1b-3939d1490266_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">97000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="Fact-aaa80b49-f8cc-4e1e-ae60-69a72b643788_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">-119483000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="Fact-f80693d3-e670-4a9d-bf5d-0e9b879d1295_20150930" decimals="INF" contextRef="I2015-09-30" unitRef="xbrli-shares">81126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="Fact-1f17873a-27d5-43bb-ab7b-6227e31033a1_20150930" decimals="2" contextRef="I2015-09-30" unitRef="iso4217-USD_xbrli-shares">5.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="Fact-6182f431-4df4-4de8-b57b-f340fa0a7aa6_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">4056000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="Fact-51f36716-4264-40e7-9dd8-f7f69ca576b2_20150930" decimals="INF" contextRef="I2015-09-30" unitRef="xbrli-shares">208438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="Fact-f14f008a-bb12-4706-8b48-97f2278b3f86_20150930" decimals="2" contextRef="I2015-09-30" unitRef="iso4217-USD_xbrli-shares">2.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="Fact-d86adbad-6be6-45c6-8755-1e89450bdff3_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">17722000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Fact-67d84838-0f8c-4787-a4fd-ebb109f1c13a_20150930" decimals="INF" contextRef="I2015-09-30" unitRef="xbrli-shares">1356246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Fact-04bc94e5-ab59-4c26-a7b5-657503379cfc_20150930" decimals="2" contextRef="I2015-09-30" unitRef="iso4217-USD_xbrli-shares">9.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="Fact-c21ec3ac-5e87-46f5-ba2f-052d8e4bfc6e_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">18595000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="Fact-f8ab3189-123a-4b63-b3c7-262e08113178_20150930" decimals="INF" contextRef="I2015-09-30" unitRef="xbrli-shares">1341543</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice id="Fact-067efefd-d0c6-4adb-b330-c045288ad56b_20150930" decimals="2" contextRef="I2015-09-30" unitRef="iso4217-USD_xbrli-shares">9.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
  <us-gaap:StockholdersEquity id="Fact-ed8942b9-4ecd-4ce2-a0d3-58dcb98007e7_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">93561000</us-gaap:StockholdersEquity>
  <us-gaap:TreasuryStockCarryingBasis id="Fact-99cc60ee-7eb0-4fc6-bc20-cec0a05db2e6_20150930" decimals="-3" contextRef="I2015-09-30" unitRef="iso4217-USD">3000</us-gaap:TreasuryStockCarryingBasis>
  <dei:EntityRegistrantName contextRef="D2015-01-01_2015-09-30">COLLEGIUM PHARMACEUTICAL, INC</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey contextRef="D2015-01-01_2015-09-30">0001267565</dei:EntityCentralIndexKey>
  <dei:DocumentType contextRef="D2015-01-01_2015-09-30">S-1</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="D2015-01-01_2015-09-30">2015-09-30</dei:DocumentPeriodEndDate>
  <dei:AmendmentFlag contextRef="D2015-01-01_2015-09-30">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="D2015-01-01_2015-09-30">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:CurrentFiscalYearEndDate contextRef="D2015-01-01_2015-09-30">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:ResearchAndDevelopmentExpense decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">12652000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">1686000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingIncomeLoss decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">-14338000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestIncomeExpenseNonoperatingNet decimals="-3" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">-110000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:OtherNonoperatingIncomeExpense decimals="0" contextRef="D2014-01-01_2014-09-30" unitRef="iso4217-USD">-110000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="D2014-01-01_2014-12-31">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;7. COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Legal Proceedings&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;From time to time the Company may face legal claims or actions in the normal course of business. The Company is not currently a party to any litigation and, accordingly, does not have any amounts recorded for any litigation related matters.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company's NDA filing for Xtampza is a 505(b)(2) application, which allows the Company to reference data from an approved drug listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the "Orange Book"), in this case OxyContin OP. In connection with the 505(b)(2) process, the Company certified to the FDA and notified Purdue Pharma,&amp;#160;L.P. ("Purdue"), as the holder of the NDA and any other Orange Book-listed patent owners, that the Company does not infringe any of the patents listed for OxyContin OP in the Orange Book. Under the Hatch-Waxman Act of 1984 (the "Hatch-Waxman Act"), Purdue can elect to sue the Company for infringement, and if they do, receive a stay of up to 30&amp;#160;months before the FDA can issue a final approval for Xtampza, unless the stay is earlier terminated. Purdue has not yet brought such litigation, but it is possible that they will do so. At this time the Company is unable to provide meaningful quantification of how this potential litigation may impact its future financial condition, results of operations, or cash flows.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"&gt;&lt;font size="2"&gt;&lt;b&gt;&lt;!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" --&gt;Operating Leases&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;The Company leases its office and research facility under a non-cancellable operating lease, which expires in December 2017. Terms of the agreement provide for an initial two-month rent-free period and future rent escalation, and provide that in addition to minimum lease rental payments, the Company is responsible for a pro-rata share of operating expenses and taxes. Aggregate minimum annual lease commitments of the Company under its non-cancellable operating lease as of December&amp;#160;31, 2014 are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;"&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_TABLEWIDTH,"100%" --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;!-- User-specified TAGGED TABLE --&gt;
&lt;div align="center"&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;"&gt;

&lt;tr style="padding:0;"&gt;&lt;!-- TABLE COLUMN WIDTHS SET --&gt;
&lt;td style="FONT-FAMILY: arial;" align="left"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="7" align="right"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="31"&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" width="12"&gt;&lt;/td&gt;&lt;!-- TABLE COLUMN WIDTHS END --&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" valign="bottom"&gt;
&lt;th style="FONT-FAMILY: arial;" nowrap="nowrap" align="left"&gt;
&lt;div style="MARGIN-BOTTOM: 0pt; WIDTH: 95pt; BORDER-BOTTOM: #000000 1pt solid;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&lt;b&gt;Year Ending December&amp;#160;31, &lt;!-- COMMAND=ADD_SCROPPEDRULE,95pt --&gt;&lt;/b&gt;&lt;/font&gt;&lt;/div&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;" colspan="2" align="center"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/th&gt;
&lt;th style="FONT-FAMILY: arial;"&gt;&lt;font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/th&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;106&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;2016&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;111&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#CCEEFF" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;2017&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;116&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="white" valign="top"&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;
&lt;p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"&gt;&lt;font size="2"&gt;Total minimum lease payments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- --&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom" align="right"&gt;&lt;font size="2"&gt;333&lt;/font&gt;&lt;/td&gt;
&lt;td style="FONT-FAMILY: arial;" valign="bottom"&gt;&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;" bgcolor="#ffffff" valign="top"&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&lt;font size="2"&gt;&lt;!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --&gt;&lt;!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --&gt;&lt;/font&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right"&gt;&amp;#8203; &lt;!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --&gt;&lt;/td&gt;
&lt;td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"&gt;&amp;#8203;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;!-- end of user-specified TAGGED TABLE --&gt;&lt;/div&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;Rent expense under the operating lease agreement amounted to approximately $69 for the years ended December&amp;#160;31, 2013 and 2014, respectively. In addition, the Company maintained a stand-by letter of credit in connection with the Canton facility lease of $80 at December&amp;#160;31, 2013 and December&amp;#160;31, 2014. This amount is classified as restricted cash in the balance sheets.&lt;/font&gt;&lt;/p&gt;
&lt;p style="FONT-FAMILY: arial;"&gt;&lt;font size="2"&gt;As an inducement to enter into its Canton facility lease, the lessor agreed to provide the Company with an improvement allowance of up to $174 towards leasehold improvements. In addition the lessor provided the Company with a reimbursable allowance of $164 which is to be amortized and repaid by the Company at an 8% interest rate over the initial term of 36&amp;#160;months. Amounts provided by the lessor related to tenant improvements are considered inducements to enter into the lease. The Company has recorded these costs in the balance sheet as leasehold improvements, with the corresponding liabilities as deferred lease incentive and lease note payable. These liabilities are amortized on a straight-line basis over the term of the lease.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>coll-20160104.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<xsd:schema targetNamespace="http://www.collegiumpharma.com/20160104" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:coll="http://www.collegiumpharma.com/20160104" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-roles="http://fasb.org/us-roles/2015-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="coll-20160104_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="coll-20160104_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="coll-20160104_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="coll-20160104_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.collegiumpharma.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>100100 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/StatementStatementsOfOperations" id="StatementStatementsOfOperations">
        <link:definition>100200 - Statement - STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>100500 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails2" id="DisclosureNetLossPerCommonShareDetails2">
        <link:definition>140302 - Disclosure - NET LOSS PER COMMON SHARE (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>140401 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosurePropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentDetails">
        <link:definition>140501 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>140601 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetails2" id="DisclosureCommitmentsAndContingenciesDetails2">
        <link:definition>140702 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureDebtDetails3" id="DisclosureDebtDetails3">
        <link:definition>140803 - Disclosure - DEBT (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>141201 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureIncomeTaxesDetails2" id="DisclosureIncomeTaxesDetails2">
        <link:definition>141202 - Disclosure - INCOME TAXES (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>100105 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/StatementConvertibleRedeemablePreferredStock" id="StatementConvertibleRedeemablePreferredStock">
        <link:definition>100300 - Statement - CONVERTIBLE REDEEMABLE PREFERRED STOCK</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/StatementConvertibleRedeemablePreferredStockParenthetical" id="StatementConvertibleRedeemablePreferredStockParenthetical">
        <link:definition>100305 - Statement - CONVERTIBLE REDEEMABLE PREFERRED STOCK (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/StatementShareholdersDeficit" id="StatementShareholdersDeficit">
        <link:definition>100400 - Statement - SHAREHOLDERS' DEFICIT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlowsParenthetical" id="StatementStatementsOfCashFlowsParenthetical">
        <link:definition>100505 - Statement - STATEMENTS OF CASH FLOWS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureNatureOfBusiness" id="DisclosureNatureOfBusiness">
        <link:definition>110101 - Disclosure - NATURE OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>110201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShare" id="DisclosureNetLossPerCommonShare">
        <link:definition>110301 - Disclosure - NET LOSS PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" id="DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>110401 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>110501 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>110601 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>110701 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>110801 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureWarrants" id="DisclosureWarrants">
        <link:definition>110901 - Disclosure - WARRANTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureEquity" id="DisclosureEquity">
        <link:definition>111001 - Disclosure - EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>111101 - Disclosure - STOCK BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>111201 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureEmployeeBenefits" id="DisclosureEmployeeBenefits">
        <link:definition>111301 - Disclosure - EMPLOYEE BENEFITS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>111401 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>120202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>130203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareTables" id="DisclosureNetLossPerCommonShareTables">
        <link:definition>130303 - Disclosure - NET LOSS PER COMMON SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>130403 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>130503 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>130603 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>130703 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>130803 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureEquityTables" id="DisclosureEquityTables">
        <link:definition>131003 - Disclosure - EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>131103 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>131203 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureNatureOfBusinessDetails" id="DisclosureNatureOfBusinessDetails">
        <link:definition>140101 - Disclosure - NATURE OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureNatureOfBusinessDetails2" id="DisclosureNatureOfBusinessDetails2">
        <link:definition>140102 - Disclosure - NATURE OF BUSINESS (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>140201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails2">
        <link:definition>140202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails3" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails3">
        <link:definition>140203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails4" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails4">
        <link:definition>140204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails5" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails5">
        <link:definition>140205 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 5)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails" id="DisclosureNetLossPerCommonShareDetails">
        <link:definition>140301 - Disclosure - NET LOSS PER COMMON SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails3" id="DisclosureNetLossPerCommonShareDetails3">
        <link:definition>140303 - Disclosure - NET LOSS PER COMMON SHARE (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>140701 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureDebtDetails" id="DisclosureDebtDetails">
        <link:definition>140801 - Disclosure - DEBT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureDebtDetails2" id="DisclosureDebtDetails2">
        <link:definition>140802 - Disclosure - DEBT (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureWarrantsDetails" id="DisclosureWarrantsDetails">
        <link:definition>140901 - Disclosure - WARRANTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureEquityDetails" id="DisclosureEquityDetails">
        <link:definition>141001 - Disclosure - EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureEquityDetails2" id="DisclosureEquityDetails2">
        <link:definition>141002 - Disclosure - EQUITY (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureEquityDetails3" id="DisclosureEquityDetails3">
        <link:definition>141003 - Disclosure - EQUITY (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails" id="DisclosureStockBasedCompensationDetails">
        <link:definition>141101 - Disclosure - STOCK-BASED COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails2" id="DisclosureStockBasedCompensationDetails2">
        <link:definition>141102 - Disclosure - STOCK-BASED COMPENSATION (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails3" id="DisclosureStockBasedCompensationDetails3">
        <link:definition>141103 - Disclosure - STOCK-BASED COMPENSATION (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails4" id="DisclosureStockBasedCompensationDetails4">
        <link:definition>141104 - Disclosure - STOCK-BASED COMPENSATION (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails5" id="DisclosureStockBasedCompensationDetails5">
        <link:definition>141105 - Disclosure - STOCK-BASED COMPENSATION (Details 5)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureIncomeTaxesDetails3" id="DisclosureIncomeTaxesDetails3">
        <link:definition>141203 - Disclosure - INCOME TAXES (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureEmployeeBenefitsDetails" id="DisclosureEmployeeBenefitsDetails">
        <link:definition>141301 - Disclosure - EMPLOYEE BENEFITS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureSubsequentEventsUnauditedDetails" id="DisclosureSubsequentEventsUnauditedDetails">
        <link:definition>141401 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/StatementBalanceSheetsQuarterEnd" id="StatementBalanceSheetsQuarterEnd">
        <link:definition>200100 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/StatementStatementsOfOperationsQuarterEnd" id="StatementStatementsOfOperationsQuarterEnd">
        <link:definition>200200 - Statement - STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlowsQuarterEnd" id="StatementStatementsOfCashFlowsQuarterEnd">
        <link:definition>200300 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetailsQuarterEnd" id="DisclosureNetLossPerCommonShareDetailsQuarterEnd">
        <link:definition>240301 - Disclosure - Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureAccruedExpensesDetailsQuarterEnd" id="DisclosureAccruedExpensesDetailsQuarterEnd">
        <link:definition>240501 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/StatementBalanceSheetsParentheticalQuarterEnd" id="StatementBalanceSheetsParentheticalQuarterEnd">
        <link:definition>200105 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlowsParentheticalQuarterEnd" id="StatementStatementsOfCashFlowsParentheticalQuarterEnd">
        <link:definition>200305 - Statement - STATEMENTS OF CASH FLOWS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureNatureOfBusinessQuarterEnd" id="DisclosureNatureOfBusinessQuarterEnd">
        <link:definition>210101 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesQuarterEnd" id="DisclosureSummaryOfSignificantAccountingPoliciesQuarterEnd">
        <link:definition>210201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareQuarterEnd" id="DisclosureNetLossPerCommonShareQuarterEnd">
        <link:definition>210301 - Disclosure - Net Loss per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureFairValueOfFinancialInstrumentsQuarterEnd" id="DisclosureFairValueOfFinancialInstrumentsQuarterEnd">
        <link:definition>210401 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureAccruedExpensesQuarterEnd" id="DisclosureAccruedExpensesQuarterEnd">
        <link:definition>210501 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureConvertibleBridgeNoteWithRelatedPartyQuarterEnd" id="DisclosureConvertibleBridgeNoteWithRelatedPartyQuarterEnd">
        <link:definition>210601 - Disclosure - Convertible Bridge Note with Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureConvertiblePreferredStockQuarterEnd" id="DisclosureConvertiblePreferredStockQuarterEnd">
        <link:definition>210701 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationQuarterEnd" id="DisclosureStockBasedCompensationQuarterEnd">
        <link:definition>210801 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesQuarterEnd" id="DisclosureCommitmentsAndContingenciesQuarterEnd">
        <link:definition>210901 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesQuarterEnd" id="DisclosureSummaryOfSignificantAccountingPoliciesPoliciesQuarterEnd">
        <link:definition>220202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareTablesQuarterEnd" id="DisclosureNetLossPerCommonShareTablesQuarterEnd">
        <link:definition>230303 - Disclosure - Net Loss per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTablesQuarterEnd" id="DisclosureFairValueOfFinancialInstrumentsTablesQuarterEnd">
        <link:definition>230403 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureAccruedExpensesTablesQuarterEnd" id="DisclosureAccruedExpensesTablesQuarterEnd">
        <link:definition>230503 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationTablesQuarterEnd" id="DisclosureStockBasedCompensationTablesQuarterEnd">
        <link:definition>230803 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureNatureOfBusinessDetailsQuarterEnd" id="DisclosureNatureOfBusinessDetailsQuarterEnd">
        <link:definition>240101 - Disclosure - Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailsQuarterEnd" id="DisclosureSummaryOfSignificantAccountingPoliciesDetailsQuarterEnd">
        <link:definition>240201 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2QuarterEnd" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails2QuarterEnd">
        <link:definition>240202 - Disclosure - Summary of Significant Accounting Policies (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails2QuarterEnd" id="DisclosureNetLossPerCommonShareDetails2QuarterEnd">
        <link:definition>240302 - Disclosure - Net Loss Per Common Share (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureFairValueOfFinancialInstrumentsDetailsQuarterEnd" id="DisclosureFairValueOfFinancialInstrumentsDetailsQuarterEnd">
        <link:definition>240401 - Disclosure - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureConvertibleBridgeNoteWithRelatedPartyDetailsQuarterEnd" id="DisclosureConvertibleBridgeNoteWithRelatedPartyDetailsQuarterEnd">
        <link:definition>240601 - Disclosure - Convertible Bridge Note with Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureConvertiblePreferredStockDetailsQuarterEnd" id="DisclosureConvertiblePreferredStockDetailsQuarterEnd">
        <link:definition>240701 - Disclosure - Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetailsQuarterEnd" id="DisclosureStockBasedCompensationDetailsQuarterEnd">
        <link:definition>240801 - Disclosure - Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails2QuarterEnd" id="DisclosureStockBasedCompensationDetails2QuarterEnd">
        <link:definition>240802 - Disclosure - Stock-based Compensation (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails3QuarterEnd" id="DisclosureStockBasedCompensationDetails3QuarterEnd">
        <link:definition>240803 - Disclosure - Stock-based Compensation (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails4QuarterEnd" id="DisclosureStockBasedCompensationDetails4QuarterEnd">
        <link:definition>240804 - Disclosure - Stock-based Compensation (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetailsQuarterEnd" id="DisclosureCommitmentsAndContingenciesDetailsQuarterEnd">
        <link:definition>240901 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetails2QuarterEnd" id="DisclosureCommitmentsAndContingenciesDetails2QuarterEnd">
        <link:definition>240902 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="coll_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeAndNonemployeeStockOptionsMember" id="coll_EmployeeAndNonemployeeStockOptionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmortizationOfIncentiveFromLessor" id="coll_AmortizationOfIncentiveFromLessor" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" id="coll_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" id="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedResearchAndDevelopmentCostsCurrent" id="coll_AccruedResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="StockIncentivePlan2014Member" id="coll_StockIncentivePlan2014Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate" id="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding" id="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="SiliconValleyBankLoanAgreement28August2012Member" id="coll_SiliconValleyBankLoanAgreement28August2012Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" id="coll_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" id="coll_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentPeriodicPaymentInterestOnlyPeriod" id="coll_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod" id="coll_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NotePurchaseAgreementConvertiblePromissoryNotesMember" id="coll_NotePurchaseAgreementConvertiblePromissoryNotesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockVotingRightsNumber" id="coll_CommonStockVotingRightsNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember" id="coll_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityRightsToElectDirectorsNumberOfDirectors" id="coll_TemporaryEquityRightsToElectDirectorsNumberOfDirectors" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage" id="coll_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityCumulativeAccretionOfDividends" id="coll_TemporaryEquityCumulativeAccretionOfDividends" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="TemporaryEquityConvertibleConversionPrice" id="coll_TemporaryEquityConvertibleConversionPrice" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" id="coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityShareholderSharesOwned" id="coll_TemporaryEquityShareholderSharesOwned" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember" id="coll_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityLiquidationRightsPerShareIssuePriceRatio" id="coll_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage" id="coll_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio" id="coll_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments" id="coll_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" id="coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" id="coll_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember" id="coll_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" id="coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" id="coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected" id="coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember" id="coll_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" id="coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" id="coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" id="coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember" id="coll_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan" id="coll_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent" id="coll_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification" id="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice" id="coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue" id="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification" id="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue" id="coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock" id="coll_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock" id="coll_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock" id="coll_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PatentCostsIncurredPolicyPolicyTextBlock" id="coll_PatentCostsIncurredPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="InitialPublicOfferingCostsPolicyPolicyTextBlock" id="coll_InitialPublicOfferingCostsPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ComputerEquipmentAndOfficeEquipmentMember" id="coll_ComputerEquipmentAndOfficeEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NonemployeeStockOptionsMember" id="coll_NonemployeeStockOptionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NonemployeeMember" id="coll_NonemployeeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityRedemptionValueModificationAdjustment" id="coll_TemporaryEquityRedemptionValueModificationAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" id="coll_PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PrepaidDevelopmentCosts" id="coll_PrepaidDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="coll_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LesseeLeasingArrangementsOperatingLeasesRentFreeTerm" id="coll_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncentiveFromLessorGross" id="coll_IncentiveFromLessorGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ReimbursableIncentiveFromLessorGross" id="coll_ReimbursableIncentiveFromLessorGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember" id="coll_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" id="coll_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" id="coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" id="coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="WarrantsDisclosureTextBlock" id="coll_WarrantsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PreferredStockWarrantsIssuedNovember2010Member" id="coll_PreferredStockWarrantsIssuedNovember2010Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesaPreferredStockWarrantMember" id="coll_SeriesaPreferredStockWarrantMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember" id="coll_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember" id="coll_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesBPreferredStockFinancingFebruary2012Member" id="coll_SeriesBPreferredStockFinancingFebruary2012Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesCPreferredStockFinancing2013Member" id="coll_SeriesCPreferredStockFinancing2013Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesCPreferredStockFinancing2013TrancheOneMember" id="coll_SeriesCPreferredStockFinancing2013TrancheOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesCPreferredStockFinancing2013TrancheTwoMember" id="coll_SeriesCPreferredStockFinancing2013TrancheTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityStockIssuedIssuanceCosts" id="coll_TemporaryEquityStockIssuedIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityLiquidationRightsOriginalIssuePricePerShare" id="coll_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" id="coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="StatementOfTemporaryEquityAbstract" id="coll_StatementOfTemporaryEquityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityStockIssuedAndOutstandingModificationShares" id="coll_TemporaryEquityStockIssuedAndOutstandingModificationShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock" id="coll_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified" id="coll_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="CommonStockIssuedAndOutstandingModificationShares" id="coll_CommonStockIssuedAndOutstandingModificationShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SaleOfStockAuthorizedAmount" id="coll_SaleOfStockAuthorizedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="SaleOfStockNumberOfSharesAuthorizedToBeSold" id="coll_SaleOfStockNumberOfSharesAuthorizedToBeSold" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SaleOfStockNumberOfTranches" id="coll_SaleOfStockNumberOfTranches" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockPurchaseRightMember" id="coll_StockPurchaseRightMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockModificationAbstract" id="coll_StockModificationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" id="coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold" id="coll_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="MaturitiesOfDebtAbstract" id="coll_MaturitiesOfDebtAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SubsequentEventsUnauditedAbstract" id="coll_SubsequentEventsUnauditedAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" id="coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares" id="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" id="coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber" id="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" id="coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TemporaryEquityGainLossOnExtinguishment" id="coll_TemporaryEquityGainLossOnExtinguishment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="CommonStockNoClassMember" id="coll_CommonStockNoClassMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation" id="coll_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>coll-20160104_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementStatementsOfOperations" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementStatementsOfOperations" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlows" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementStatementsOfCashFlows" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails2" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNetLossPerCommonShareDetails2" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosurePropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureCommitmentsAndContingenciesDetails2" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureDebtDetails3" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureDebtDetails3" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureIncomeTaxesDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureIncomeTaxesDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureIncomeTaxesDetails2" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureIncomeTaxesDetails2" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementBalanceSheetsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementBalanceSheetsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementStatementsOfOperationsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementStatementsOfOperationsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlowsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementStatementsOfCashFlowsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetailsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNetLossPerCommonShareDetailsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureAccruedExpensesDetailsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureAccruedExpensesDetailsQuarterEnd" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_635858824697066517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_635858824697066517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_635858824697066517" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_635858824697066517" use="optional" priority="4" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_635858824697066517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_635858824697066517" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_635858824697066517" use="optional" priority="2" order="2.0" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858824697066517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635858824697066517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858824697066517" xlink:to="us-gaap_NetIncomeLoss_635858824697066517" use="optional" priority="2" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AmortizationOfIncentiveFromLessor" xlink:label="coll_AmortizationOfIncentiveFromLessor_635858824697066517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858824697066517" xlink:to="coll_AmortizationOfIncentiveFromLessor_635858824697066517" use="optional" priority="3" order="2.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_635858824697066517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858824697066517" xlink:to="us-gaap_ShareBasedCompensation_635858824697066517" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_635858824697066517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858824697066517" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_635858824697066517" use="optional" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_635858824697066517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858824697066517" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_635858824697066517" use="optional" priority="2" order="5.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_635858824697066517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858824697066517" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_635858824697066517" use="optional" priority="3" order="6.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635858824697066517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858824697066517" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635858824697066517" use="optional" priority="3" order="7.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding_635858824697066517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858824697066517" xlink:to="us-gaap_IncreaseDecreaseInDepositsOutstanding_635858824697066517" use="optional" priority="2" order="8.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_635858824697066517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858824697066517" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_635858824697066517" use="optional" priority="2" order="9.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_635858824697066517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858824697066517" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_635858824697066517" use="optional" priority="2" order="10.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635858824697076517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt_635858824697076517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635858824697076517" xlink:to="us-gaap_ProceedsFromShortTermDebt_635858824697076517" use="optional" priority="2" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_635858824697076517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635858824697076517" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_635858824697076517" use="optional" priority="3" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_635858824697076517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635858824697076517" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_635858824697076517" use="optional" priority="2" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaturitiesOfSeniorDebt" xlink:label="us-gaap_MaturitiesOfSeniorDebt_635858824697076517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635858824697076517" xlink:to="us-gaap_MaturitiesOfSeniorDebt_635858824697076517" use="optional" priority="2" order="4.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLongtermLoansFromVendors" xlink:label="us-gaap_RepaymentsOfLongtermLoansFromVendors_635858824697076517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635858824697076517" xlink:to="us-gaap_RepaymentsOfLongtermLoansFromVendors_635858824697076517" use="optional" priority="2" order="5.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_635858824697076517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635858824697076517" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_635858824697076517" use="optional" priority="3" order="6.0" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635858824697076517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss_635858824697076517" use="optional" priority="2" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityRedemptionValueModificationAdjustment" xlink:label="coll_TemporaryEquityRedemptionValueModificationAdjustment_635858824697076517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="coll_TemporaryEquityRedemptionValueModificationAdjustment_635858824697076517" use="optional" priority="2" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" xlink:label="coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_635858824697076517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_635858824697076517" use="optional" priority="2" order="3.0" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_635858824697076517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_635858824697076517" use="optional" priority="2" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts_635858824697076517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DeferredOfferingCosts_635858824697076517" use="optional" priority="2" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueFromEmployeesCurrent" xlink:label="us-gaap_DueFromEmployeesCurrent_635858824697076517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DueFromEmployeesCurrent_635858824697076517" use="optional" priority="2" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_635858824697076517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_635858824697076517" use="optional" priority="2" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_PrepaidDevelopmentCosts" xlink:label="coll_PrepaidDevelopmentCosts_635858824697076517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="coll_PrepaidDevelopmentCosts_635858824697076517" use="optional" priority="2" order="5.0" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosurePropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_635858824697086517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_635858824697086517" use="optional" priority="2" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_635858824697086517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_635858824697086517" use="optional" priority="2" order="2.0" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_635858824697086517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_635858824697086517" use="optional" priority="2" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_635858824697086517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_635858824697086517" use="optional" priority="2" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_635858824697086517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_635858824697086517" use="optional" priority="2" order="3.0" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureDebtDetails3">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_635858824697086517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_635858824697086517" use="optional" priority="2" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_635858824697086517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_635858824697086517" use="optional" priority="2" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_635858824697086517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_635858824697086517" use="optional" priority="2" order="3.0" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_635858824697086517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_635858824697086517" use="optional" priority="2" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent" xlink:label="coll_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent_635858824697086517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="coll_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent_635858824697086517" use="optional" priority="3" order="2.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_635858824697086517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_635858824697086517" use="optional" priority="3" order="3.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_635858824697086517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_635858824697086517" use="optional" priority="2" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_635858824697086517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_635858824697086517" use="optional" priority="3" order="5.0" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureIncomeTaxesDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_635858824697096517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_635858824697096517" use="optional" priority="2" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_635858824697096517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_635858824697096517" xlink:to="us-gaap_DeferredTaxAssetsGross_635858824697096517" use="optional" priority="2" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_635858824697096517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_635858824697096517" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_635858824697096517" use="optional" priority="2" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_635858824697096517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_635858824697096517" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_635858824697096517" use="optional" priority="2" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_635858824697096517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_635858824697096517" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_635858824697096517" use="optional" priority="2" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_635858824697096517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_635858824697096517" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_635858824697096517" use="optional" priority="2" order="2.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_635858824697096517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_635858824697096517" use="optional" priority="2" order="2.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_635858824697096517" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_635858824697096517" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_635858824697096517" use="optional" priority="2" order="1.0" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementBalanceSheetsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_635858815104830549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_635858815104830549" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_635858815104830549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_635858815104830549" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_635858815104830549" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent_635858815104830549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_635858815104830549" xlink:to="us-gaap_DepositsAssetsCurrent_635858815104830549" use="optional" priority="2" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635858815104830549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_635858815104830549" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635858815104830549" use="optional" priority="2" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_635858815104830549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_635858815104830549" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_635858815104830549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_635858815104830549" use="optional" priority="2" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_635858815104830549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_635858815104830549" use="optional" priority="2" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_635858815104830549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_635858815104830549" xlink:to="us-gaap_LiabilitiesCurrent_635858815104830549" use="optional" priority="1" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_635858815104830549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_635858815104830549" xlink:to="us-gaap_AccountsPayableCurrent_635858815104830549" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_635858815104830549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_635858815104830549" xlink:to="us-gaap_AccruedLiabilitiesCurrent_635858815104830549" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" xlink:label="coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent_635858815104830549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_635858815104830549" xlink:to="coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent_635858815104830549" use="optional" priority="2" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent_635858815104830549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_635858815104830549" xlink:to="us-gaap_LoansPayableCurrent_635858815104830549" use="optional" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_635858815104830549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_635858815104830549" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_635858815104830549" use="optional" priority="2" order="5.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncentiveFromLessor" xlink:label="us-gaap_IncentiveFromLessor_635858815104830549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_635858815104830549" xlink:to="us-gaap_IncentiveFromLessor_635858815104830549" use="optional" priority="3" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable_635858815104830549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_635858815104830549" xlink:to="us-gaap_LongTermLoansPayable_635858815104830549" use="optional" priority="1" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_635858815104840550" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_635858815104840550" use="optional" priority="2" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_635858815104840550" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_635858815104840550" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_635858815104840550" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635858815104840550" xlink:to="us-gaap_CommonStockValue_635858815104840550" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_635858815104840550" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635858815104840550" xlink:to="us-gaap_AdditionalPaidInCapital_635858815104840550" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_635858815104840550" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635858815104840550" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_635858815104840550" use="optional" priority="2" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockCarryingBasis" xlink:label="us-gaap_TreasuryStockCarryingBasis_635858815104840550" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635858815104840550" xlink:to="us-gaap_TreasuryStockCarryingBasis_635858815104840550" use="optional" priority="2" order="4.0" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementStatementsOfOperationsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_635858815104840550" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_635858815104840550" use="optional" priority="2" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_635858815104840550" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_635858815104840550" xlink:to="us-gaap_OperatingExpenses_635858815104840550" use="optional" priority="2" order="1.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_635858815104840550" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_635858815104840550" xlink:to="us-gaap_ResearchAndDevelopmentExpense_635858815104840550" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_635858815104840550" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_635858815104840550" xlink:to="us-gaap_GeneralAndAdministrativeExpense_635858815104840550" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_635858815104840550" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_635858815104840550" use="optional" priority="2" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_635858815104840550" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_635858815104840550" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_635858815104840550" use="optional" priority="4" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_635858815104840550" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_635858815104840550" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_635858815104840550" use="optional" priority="2" order="2.0" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlowsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858815104850551" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858815104850551" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635858815104850551" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858815104850551" xlink:to="us-gaap_NetIncomeLoss_635858815104850551" use="optional" priority="2" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AmortizationOfIncentiveFromLessor" xlink:label="coll_AmortizationOfIncentiveFromLessor_635858815104850551" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858815104850551" xlink:to="coll_AmortizationOfIncentiveFromLessor_635858815104850551" use="optional" priority="3" order="3.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_635858815104850551" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858815104850551" xlink:to="us-gaap_ShareBasedCompensation_635858815104850551" use="optional" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_635858815104850551" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858815104850551" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_635858815104850551" use="optional" order="5.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_635858815104850551" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858815104850551" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_635858815104850551" use="optional" priority="2" order="6.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635858815104850551" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858815104850551" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635858815104850551" use="optional" priority="3" order="7.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding_635858815104850551" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858815104850551" xlink:to="us-gaap_IncreaseDecreaseInDepositsOutstanding_635858815104850551" use="optional" priority="2" order="8.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_635858815104850551" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858815104850551" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_635858815104850551" use="optional" priority="2" order="9.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_635858815104850551" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858815104850551" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_635858815104850551" use="optional" priority="2" order="10.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_635858815104850551" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858815104850551" xlink:to="us-gaap_Depreciation_635858815104850551" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635858815104850551" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635858815104850551" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635858815104850551" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635858815104850551" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635858815104850551" use="optional" order="1.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635858815104850551" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635858815104850551" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_635858815104850551" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635858815104850551" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_635858815104850551" use="optional" priority="2" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaturitiesOfSeniorDebt" xlink:label="us-gaap_MaturitiesOfSeniorDebt_635858815104850551" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635858815104850551" xlink:to="us-gaap_MaturitiesOfSeniorDebt_635858815104850551" use="optional" priority="2" order="2.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLongtermLoansFromVendors" xlink:label="us-gaap_RepaymentsOfLongtermLoansFromVendors_635858815104860552" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635858815104850551" xlink:to="us-gaap_RepaymentsOfLongtermLoansFromVendors_635858815104860552" use="optional" priority="2" order="3.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_635858815104860552" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635858815104850551" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_635858815104860552" use="optional" priority="3" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseInRestrictedCash" xlink:label="us-gaap_IncreaseInRestrictedCash_635858815104860552" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635858815104850551" xlink:to="us-gaap_IncreaseInRestrictedCash_635858815104860552" use="optional" priority="3" order="5.0" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_635828440980266910" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635858815104860552" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_635828440980266910" xlink:to="us-gaap_NetIncomeLoss_635858815104860552" use="optional" priority="2" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityGainLossOnExtinguishment" xlink:label="coll_TemporaryEquityGainLossOnExtinguishment_635858815104860552" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_635828440980266910" xlink:to="coll_TemporaryEquityGainLossOnExtinguishment_635858815104860552" use="optional" priority="3" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" xlink:label="coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_635858815104860552" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_635828440980266910" xlink:to="coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_635858815104860552" use="optional" priority="2" order="3.0" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureAccruedExpensesDetailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="coll_AccruedResearchAndDevelopmentCostsCurrent_635858815104870553" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="coll_AccruedResearchAndDevelopmentCostsCurrent_635858815104870553" use="optional" priority="2" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_635858815104870553" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_635858815104870553" use="optional" priority="2" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="us-gaap_AccruedMarketingCostsCurrent_635858815104870553" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedMarketingCostsCurrent_635858815104870553" use="optional" priority="2" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_635858815104870553" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_635858815104870553" use="optional" priority="2" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_635858815104870553" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent_635858815104870553" use="optional" priority="2" order="5.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_635858815104870553" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_635858815104870553" use="optional" order="6.0" weight="1" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>coll-20160104_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="AccruedResearchAndDevelopmentCostsCurrent" xlink:title="AccruedResearchAndDevelopmentCostsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccruedResearchAndDevelopmentCostsCurrent" xml:lang="en-US" id="label_AccruedResearchAndDevelopmentCostsCurrent">Accrued development costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentCostsCurrent" xlink:to="label_AccruedResearchAndDevelopmentCostsCurrent" xlink:title="label_AccruedResearchAndDevelopmentCostsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccruedResearchAndDevelopmentCostsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccruedResearchAndDevelopmentCostsCurrent_1" xml:lang="en-US" id="label_AccruedResearchAndDevelopmentCostsCurrent_1">Accrued Research and Development Costs, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentCostsCurrent" xlink:to="label_AccruedResearchAndDevelopmentCostsCurrent_1" xlink:title="label_AccruedResearchAndDevelopmentCostsCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_AccruedResearchAndDevelopmentCostsCurrent_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AccruedResearchAndDevelopmentCostsCurrent_2" xml:lang="en-US" id="label_AccruedResearchAndDevelopmentCostsCurrent_2">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentCostsCurrent" xlink:to="label_AccruedResearchAndDevelopmentCostsCurrent_2" xlink:title="label_AccruedResearchAndDevelopmentCostsCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:title="AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock">Accruals of dividends and accretion to redemption value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock_1" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock_1">Adjustments to Additional Paid in Capital and Retained Earnings, Increase in Carrying Amount of Redeemable Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock_1" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock_1" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock_2" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock_2">Amount of decrease (increase) in additional paid in capital (APIC) and adjustment to retained earnings for the increase in carrying amount of redeemable preferred stock that is classified as temporary equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock_2" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified" xlink:label="AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified" xlink:title="AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified">Performance Adjustment of Series A</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified_1" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified_1">Performance Adjustment to Series A and common shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified_1" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified_1" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified_2" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified_2">Adjustments to Additional Paid in Capital, Decrease in Carrying Amount of Redeemable Preferred Stock and Common Stock, Value of Stock Modified</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified_2" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified_2" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified_3" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified_3">Amount of increase in additional paid in capital (APIC) for the decrease in carrying amount of redeemable preferred stock that is classified as temporary equity and common stock and the (decrease) in common stock value as a result of a share modification.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified_3" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified_3" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" xlink:label="AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" xlink:title="AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" />
    <link:label xlink:type="resource" xlink:label="label_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" xml:lang="en-US" id="label_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember">Amendment to office and research facility operating lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" xlink:to="label_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" xlink:title="label_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" />
    <link:label xlink:type="resource" xlink:label="label_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember_1" xml:lang="en-US" id="label_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember_1">Amendment To Office And Research Facility Operating Lease [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" xlink:to="label_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember_1" xlink:title="label_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember_1" />
    <link:label xlink:type="resource" xlink:label="label_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember_2" xml:lang="en-US" id="label_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember_2">Represents information pertaining to the terms of an amendment to an existing office and research facility operating lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" xlink:to="label_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember_2" xlink:title="label_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AmortizationOfIncentiveFromLessor" xlink:label="AmortizationOfIncentiveFromLessor" xlink:title="AmortizationOfIncentiveFromLessor" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfIncentiveFromLessor" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_AmortizationOfIncentiveFromLessor" xml:lang="en-US" id="label_AmortizationOfIncentiveFromLessor">Lease incentive</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIncentiveFromLessor" xlink:to="label_AmortizationOfIncentiveFromLessor" xlink:title="label_AmortizationOfIncentiveFromLessor" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfIncentiveFromLessor_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmortizationOfIncentiveFromLessor_1" xml:lang="en-US" id="label_AmortizationOfIncentiveFromLessor_1">Amortization of Incentive from Lessor</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIncentiveFromLessor" xlink:to="label_AmortizationOfIncentiveFromLessor_1" xlink:title="label_AmortizationOfIncentiveFromLessor_1" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfIncentiveFromLessor_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AmortizationOfIncentiveFromLessor_2" xml:lang="en-US" id="label_AmortizationOfIncentiveFromLessor_2">This element represents the amortization of the deferred credit for an incentive or inducement received by a lessee from a lessor, in order to motivate the lessee to enter the lease agreement, amortized over the term of the lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIncentiveFromLessor" xlink:to="label_AmortizationOfIncentiveFromLessor_2" xlink:title="label_AmortizationOfIncentiveFromLessor_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember" xlink:label="CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember" xlink:title="CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember" />
    <link:label xlink:type="resource" xlink:label="label_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember" xml:lang="en-US" id="label_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember">Canton facility lease reimbursable allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember" xlink:to="label_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember" xlink:title="label_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember" />
    <link:label xlink:type="resource" xlink:label="label_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember_1" xml:lang="en-US" id="label_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember_1">Canton Facility Operating Lease Obligation Reimbursable Tenant Allowance [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember" xlink:to="label_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember_1" xlink:title="label_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember_1" />
    <link:label xlink:type="resource" xlink:label="label_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember_2" xml:lang="en-US" id="label_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember_2">A borrowing recorded for a reimbursable tenant allowance received by a lessee from a lessor, in order to motivate the lessee to enter the lease agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember" xlink:to="label_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember_2" xlink:title="label_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:title="CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xml:lang="en-US" id="label_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock">Schedule of shares of common stock reserved for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:to="label_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:title="label_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_1" xml:lang="en-US" id="label_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_1">Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:to="label_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_1" xlink:title="label_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_2" xml:lang="en-US" id="label_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_2">Tabular disclosure of the aggregate number of common shares reserved for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:to="label_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_2" xlink:title="label_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockIssuedAndOutstandingModificationShares" xlink:label="CommonStockIssuedAndOutstandingModificationShares" xlink:title="CommonStockIssuedAndOutstandingModificationShares" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockIssuedAndOutstandingModificationShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_CommonStockIssuedAndOutstandingModificationShares" xml:lang="en-US" id="label_CommonStockIssuedAndOutstandingModificationShares">Performance Adjustment of Series A (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockIssuedAndOutstandingModificationShares" xlink:to="label_CommonStockIssuedAndOutstandingModificationShares" xlink:title="label_CommonStockIssuedAndOutstandingModificationShares" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockIssuedAndOutstandingModificationShares_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockIssuedAndOutstandingModificationShares_1" xml:lang="en-US" id="label_CommonStockIssuedAndOutstandingModificationShares_1">Common Stock Issued and Outstanding Modification, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockIssuedAndOutstandingModificationShares" xlink:to="label_CommonStockIssuedAndOutstandingModificationShares_1" xlink:title="label_CommonStockIssuedAndOutstandingModificationShares_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockIssuedAndOutstandingModificationShares_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_CommonStockIssuedAndOutstandingModificationShares_2" xml:lang="en-US" id="label_CommonStockIssuedAndOutstandingModificationShares_2">Decrease in the number of shares of issued and outstanding common stock during the period as a result of a modification.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockIssuedAndOutstandingModificationShares" xlink:to="label_CommonStockIssuedAndOutstandingModificationShares_2" xlink:title="label_CommonStockIssuedAndOutstandingModificationShares_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockNoClassMember" xlink:label="CommonStockNoClassMember" xlink:title="CommonStockNoClassMember" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockNoClassMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockNoClassMember" xml:lang="en-US" id="label_CommonStockNoClassMember">Common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNoClassMember" xlink:to="label_CommonStockNoClassMember" xlink:title="label_CommonStockNoClassMember" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockNoClassMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockNoClassMember_1" xml:lang="en-US" id="label_CommonStockNoClassMember_1">Common Stock No Class [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNoClassMember" xlink:to="label_CommonStockNoClassMember_1" xlink:title="label_CommonStockNoClassMember_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockNoClassMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_CommonStockNoClassMember_2" xml:lang="en-US" id="label_CommonStockNoClassMember_2">Stock that is subordinate to all other stock of the issuer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNoClassMember" xlink:to="label_CommonStockNoClassMember_2" xlink:title="label_CommonStockNoClassMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockVotingRightsNumber" xlink:label="CommonStockVotingRightsNumber" xlink:title="CommonStockVotingRightsNumber" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockVotingRightsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockVotingRightsNumber" xml:lang="en-US" id="label_CommonStockVotingRightsNumber">Number of votes each share of common stock held is entitled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockVotingRightsNumber" xlink:to="label_CommonStockVotingRightsNumber" xlink:title="label_CommonStockVotingRightsNumber" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockVotingRightsNumber_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockVotingRightsNumber_1" xml:lang="en-US" id="label_CommonStockVotingRightsNumber_1">Common Stock Voting Rights Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockVotingRightsNumber" xlink:to="label_CommonStockVotingRightsNumber_1" xlink:title="label_CommonStockVotingRightsNumber_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockVotingRightsNumber_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_CommonStockVotingRightsNumber_2" xml:lang="en-US" id="label_CommonStockVotingRightsNumber_2">Represents the number of votes a share of common stock is entitled.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockVotingRightsNumber" xlink:to="label_CommonStockVotingRightsNumber_2" xlink:title="label_CommonStockVotingRightsNumber_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" xlink:label="CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" xlink:title="CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" xml:lang="en-US" id="label_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member">Common stock warrant, Silicon Valley Bank, Original Term Loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" xlink:to="label_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" xlink:title="label_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member_1" xml:lang="en-US" id="label_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member_1">Common Stock Warrant Silicon Valley Bank Loan Agreement28 August2012 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" xlink:to="label_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member_1" xlink:title="label_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member_2" xml:lang="en-US" id="label_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member_2">Security that gives the holder the right to purchase shares of common stock in accordance with the terms of the instrument, usually upon payment of a specified amount, issued in connection with the loan agreement (Original Term Loan) with Silicon Valley Bank (SVB) entered into on August 28, 2012.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" xlink:to="label_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member_2" xlink:title="label_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xlink:label="CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xlink:title="CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xml:lang="en-US" id="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member">Common stock warrant, Silicon Valley Bank, Term Loan, Amendment No. 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xlink:to="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xlink:title="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_1" xml:lang="en-US" id="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_1">Common Stock Warrant Silicon Valley Bank Loan Agreement Amendment Number1 January2014 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xlink:to="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_1" xlink:title="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_2" xml:lang="en-US" id="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_2">Security that gives the holder the right to purchase shares of common stock in accordance with the terms of the instrument, usually upon payment of a specified amount, issued in connection with Amendment No. 1 to the loan agreement with Silicon Valley Bank (SVB) entered into in January 2014.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xlink:to="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_2" xlink:title="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xlink:label="CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xlink:title="CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xml:lang="en-US" id="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member">Common stock warrant, Silicon Valley Bank, Term Loan, Amendment No. 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xlink:to="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xlink:title="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_1" xml:lang="en-US" id="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_1">Common Stock Warrant Silicon Valley Bank Loan Agreement Amendment Number2 August2014 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xlink:to="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_1" xlink:title="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_2" xml:lang="en-US" id="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_2">Security that gives the holder the right to purchase shares of common stock in accordance with the terms of the instrument, usually upon payment of a specified amount, issued in connection with Amendment No. 2 to the loan agreement with Silicon Valley Bank (SVB) entered into in August 2014.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xlink:to="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_2" xlink:title="label_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ComputerEquipmentAndOfficeEquipmentMember" xlink:label="ComputerEquipmentAndOfficeEquipmentMember" xlink:title="ComputerEquipmentAndOfficeEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_ComputerEquipmentAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ComputerEquipmentAndOfficeEquipmentMember" xml:lang="en-US" id="label_ComputerEquipmentAndOfficeEquipmentMember">Computers and office equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerEquipmentAndOfficeEquipmentMember" xlink:to="label_ComputerEquipmentAndOfficeEquipmentMember" xlink:title="label_ComputerEquipmentAndOfficeEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_ComputerEquipmentAndOfficeEquipmentMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ComputerEquipmentAndOfficeEquipmentMember_1" xml:lang="en-US" id="label_ComputerEquipmentAndOfficeEquipmentMember_1">Computer Equipment And Office Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerEquipmentAndOfficeEquipmentMember" xlink:to="label_ComputerEquipmentAndOfficeEquipmentMember_1" xlink:title="label_ComputerEquipmentAndOfficeEquipmentMember_1" />
    <link:label xlink:type="resource" xlink:label="label_ComputerEquipmentAndOfficeEquipmentMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ComputerEquipmentAndOfficeEquipmentMember_2" xml:lang="en-US" id="label_ComputerEquipmentAndOfficeEquipmentMember_2">Represents combined information pertaining to long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and tangible personal property used in an office setting.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerEquipmentAndOfficeEquipmentMember" xlink:to="label_ComputerEquipmentAndOfficeEquipmentMember_2" xlink:title="label_ComputerEquipmentAndOfficeEquipmentMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember" xlink:label="ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember" xlink:title="ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember" xml:lang="en-US" id="label_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember">Conversion of convertible notes into convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember" xlink:to="label_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember" xlink:title="label_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember_1" xml:lang="en-US" id="label_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember_1">Conversion Of Convertible Promissory Notes Into Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember" xlink:to="label_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember_1" xlink:title="label_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember_1" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember_2" xml:lang="en-US" id="label_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember_2">Represents the conversion of convertible promissory notes into redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember" xlink:to="label_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember_2" xlink:title="label_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember" xlink:label="ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember" xlink:title="ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember" xml:lang="en-US" id="label_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember">Conversion of convertible redeemable preferred stock into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember" xlink:to="label_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember" xlink:title="label_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember_1" xml:lang="en-US" id="label_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember_1">Conversion Of Convertible Redeemable Preferred Stock Into Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember" xlink:to="label_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember_1" xlink:title="label_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember_1" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember_2" xml:lang="en-US" id="label_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember_2">Represents the conversion of shares of convertible redeemable preferred stock into shares of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember" xlink:to="label_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember_2" xlink:title="label_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember" xlink:label="ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember" xlink:title="ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember" xml:lang="en-US" id="label_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember">Conversion of preferred stock into Series A Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember" xlink:to="label_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember" xlink:title="label_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember_1" xml:lang="en-US" id="label_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember_1">Conversion Of Stock Preferred Stock Into Seriesa Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember" xlink:to="label_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember_1" xlink:title="label_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember_1" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember_2" xml:lang="en-US" id="label_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember_2">Represents the conversion of preferred stock into Series A preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember" xlink:to="label_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember_2" xlink:title="label_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember" xlink:label="ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember" xlink:title="ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember" xml:lang="en-US" id="label_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember">Conversion of preferred stock warrant into Series A Preferred Stock warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember" xlink:to="label_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember" xlink:title="label_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember_1" xml:lang="en-US" id="label_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember_1">Conversion Of Stock Preferred Stock Warrant Into Seriesa Preferred Stock Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember" xlink:to="label_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember_1" xlink:title="label_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember_1" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember_2" xml:lang="en-US" id="label_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember_2">Represents the conversion of a warrant to purchase preferred stock into a warrant to purchase Series A preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember" xlink:to="label_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember_2" xlink:title="label_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" xlink:label="ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" xlink:title="ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" xml:lang="en-US" id="label_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember">Conversion of redeemable convertible preferred stock into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" xlink:to="label_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" xlink:title="label_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember_1" xml:lang="en-US" id="label_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember_1">Conversion Of Stock Redeemable Convertible Preferred Stock Into Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" xlink:to="label_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember_1" xlink:title="label_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember_1" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember_2" xml:lang="en-US" id="label_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember_2">Represents the conversion of redeemable convertible preferred stock into common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" xlink:to="label_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember_2" xlink:title="label_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember" xlink:label="ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember" xlink:title="ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember" xml:lang="en-US" id="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember">Automatic conversion concurrently with Qualified Financing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember" xlink:to="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember" xlink:title="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember_1" xml:lang="en-US" id="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember_1">Convertible Financial Instrument Automatic Conversion Provision Completion Of Qualified Financing [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember" xlink:to="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember_1" xlink:title="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember_1" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember_2" xml:lang="en-US" id="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember_2">Represents information pertaining to a convertible financial instrument which provides for automatic conversion upon the completion of a Qualified Financing, as defined in the agreement to the financial instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember" xlink:to="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember_2" xlink:title="label_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" xlink:label="ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" xlink:title="ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" xml:lang="en-US" id="label_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember">Mandatory conversion, initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" xlink:to="label_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" xlink:title="label_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember_1" xml:lang="en-US" id="label_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember_1">Convertible Financial Instrument Mandatory Conversion Completion Of Initial Public Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" xlink:to="label_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember_1" xlink:title="label_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember_1" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember_2" xml:lang="en-US" id="label_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember_2">Represents information pertaining to a convertible financial instrument which provides for mandatory conversion upon the completion of an initial public offering if certain conditions are met as defined in the agreement to the financial instrument. Such conditions may include, but are not limited to, the amount of gross proceeds received and the price per share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" xlink:to="label_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember_2" xlink:title="label_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" xlink:label="ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" xlink:title="ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" />
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" xml:lang="en-US" id="label_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member">6.0% Convertible promissory notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" xlink:to="label_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" xlink:title="label_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" />
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_1" xml:lang="en-US" id="label_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_1">Convertible Promissory Notes6.0 Percent Due November2015 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" xlink:to="label_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_1" xlink:title="label_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_1" />
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_2" xml:lang="en-US" id="label_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_2">Written promise to pay a note which can be exchanged for a specified quantity of securities at the option of the issuer or the holder pursuant to the terms of the Note Purchase Agreement, bearing interest at 6.0 percent and due and payable at the earlier to occur of certain events as, defined, and November 2015.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" xlink:to="label_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_2" xlink:title="label_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock" xlink:label="ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock" xlink:title="ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock" xml:lang="en-US" id="label_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock">Unaudited Pro Forma Balance Sheet and Net Loss per Share Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock" xlink:to="label_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock" xlink:title="label_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock_1" xml:lang="en-US" id="label_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock_1">Convertible Redeemable Preferred Stock, Pro Forma Balance Sheet and Net Income (Loss) per Share [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock" xlink:to="label_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock_1" xlink:title="label_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock_2" xml:lang="en-US" id="label_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock_2">Disclosure of accounting policy for pro forma balance sheet and net income (loss) per share information with respect to assumed conversion of all outstanding shares of convertible redeemable preferred stock into shares of common stock and methodology for calculation of pro form weighted-average number of common shares outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock" xlink:to="label_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock_2" xlink:title="label_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod" xlink:label="DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod" xlink:title="DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod" xml:lang="en-US" id="label_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod">Subsequent period of principal and interest payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod" xlink:to="label_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod" xlink:title="label_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod_1" xml:lang="en-US" id="label_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod_1">Debt Instrument, Periodic Payment, Interest and Principal Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod" xlink:to="label_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod_1" xlink:title="label_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod_2" xml:lang="en-US" id="label_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod_2">Period of time after the end of the interest only period to maturity of each borrowing, the required periodic payments include both interest and principal payments, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod" xlink:to="label_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod_2" xlink:title="label_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" xlink:label="DebtInstrumentPeriodicPaymentInterestOnlyPeriod" xlink:title="DebtInstrumentPeriodicPaymentInterestOnlyPeriod" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" xml:lang="en-US" id="label_DebtInstrumentPeriodicPaymentInterestOnlyPeriod">Initial period of interest only payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentInterestOnlyPeriod" xlink:to="label_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" xlink:title="label_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_1" xml:lang="en-US" id="label_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_1">Debt Instrument, Periodic Payment, Interest Only Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentInterestOnlyPeriod" xlink:to="label_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_1" xlink:title="label_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_2" xml:lang="en-US" id="label_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_2">Period of time from the date of each borrowing the required periodic payments are applied to interest only, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentInterestOnlyPeriod" xlink:to="label_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_2" xlink:title="label_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" xlink:label="DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" xlink:title="DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" xml:lang="en-US" id="label_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent">Current portion of deferred rent and lease note payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" xlink:to="label_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" xlink:title="label_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent_1" xml:lang="en-US" id="label_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent_1">Deferred Rent Credit, and Reimbursable Incentive from Lessor, Net, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" xlink:to="label_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent_1" xlink:title="label_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent_2" xml:lang="en-US" id="label_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent_2">For a classified balance sheet, the combined amount of cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date and the current portion of the net carrying amount of the reimbursable incentive or inducement received by a lessee from a lessor, in order to motivate the lessee to enter the lease agreement, which incentive or inducement is to be repaid over the lease term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" xlink:to="label_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent_2" xlink:title="label_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan" xlink:label="DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan" xlink:title="DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan" />
    <link:label xlink:type="resource" xlink:label="label_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan" xml:lang="en-US" id="label_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan">Requisite service period of employees to be eligible to participate in the 401(k) plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan" xlink:to="label_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan" xlink:title="label_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan" />
    <link:label xlink:type="resource" xlink:label="label_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan_1" xml:lang="en-US" id="label_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan_1">Defined Contribution Plan, Requisite Service Period for Eligibility to Participate in Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan" xlink:to="label_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan_1" xlink:title="label_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan_1" />
    <link:label xlink:type="resource" xlink:label="label_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan_2" xml:lang="en-US" id="label_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan_2">Represents the period that the employee is required to perform services from the date of employment, or anniversary thereof, in order to be eligible to participate in the defined contribution plan, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan" xlink:to="label_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan_2" xlink:title="label_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember" xlink:label="DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember" xlink:title="DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="label_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember" xml:lang="en-US" id="label_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember">Delivery of expansion space with substantial completion of certain improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember" xlink:to="label_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember" xlink:title="label_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="label_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember_1" xml:lang="en-US" id="label_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember_1">Delivery Of Expansion Space With Substantial Completion Of Certain Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember" xlink:to="label_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember_1" xlink:title="label_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember_1" />
    <link:label xlink:type="resource" xlink:label="label_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember_2" xml:lang="en-US" id="label_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember_2">Represents the scenario of delivery of expansion space with certain improvements substantially completed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember" xlink:to="label_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember_2" xlink:title="label_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentAndEntityInformationAbstract" xml:lang="en-US" id="label_DocumentAndEntityInformationAbstract">Document and Entity Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="label_DocumentAndEntityInformationAbstract" xlink:title="label_DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent" xlink:label="EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent" xlink:title="EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent" />
    <link:label xlink:type="resource" xlink:label="label_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent" xml:lang="en-US" id="label_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent">Expiration of state net operating losses (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent" xlink:to="label_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent" xlink:title="label_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent" />
    <link:label xlink:type="resource" xlink:label="label_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent_1" xml:lang="en-US" id="label_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent_1">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Expiration of State Net Operating Losses, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent" xlink:to="label_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent_1" xlink:title="label_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent_1" />
    <link:label xlink:type="resource" xlink:label="label_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent_2" xml:lang="en-US" id="label_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent_2">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense for the expiration of state net operating losses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent" xlink:to="label_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent_2" xlink:title="label_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_EmployeeAndNonemployeeStockOptionsMember" xlink:label="EmployeeAndNonemployeeStockOptionsMember" xlink:title="EmployeeAndNonemployeeStockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeAndNonemployeeStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeAndNonemployeeStockOptionsMember" xml:lang="en-US" id="label_EmployeeAndNonemployeeStockOptionsMember">Stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeAndNonemployeeStockOptionsMember" xlink:to="label_EmployeeAndNonemployeeStockOptionsMember" xlink:title="label_EmployeeAndNonemployeeStockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeAndNonemployeeStockOptionsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeAndNonemployeeStockOptionsMember_1" xml:lang="en-US" id="label_EmployeeAndNonemployeeStockOptionsMember_1">Employee And Nonemployee Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeAndNonemployeeStockOptionsMember" xlink:to="label_EmployeeAndNonemployeeStockOptionsMember_1" xlink:title="label_EmployeeAndNonemployeeStockOptionsMember_1" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeAndNonemployeeStockOptionsMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_EmployeeAndNonemployeeStockOptionsMember_2" xml:lang="en-US" id="label_EmployeeAndNonemployeeStockOptionsMember_2">An arrangement whereby an employee or nonemployee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Nonemployees may include, but are not limited to, consultants and outside members of the board of directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeAndNonemployeeStockOptionsMember" xlink:to="label_EmployeeAndNonemployeeStockOptionsMember_2" xlink:title="label_EmployeeAndNonemployeeStockOptionsMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember" xlink:label="HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember" xlink:title="HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember" />
    <link:label xlink:type="resource" xlink:label="label_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember" xml:lang="en-US" id="label_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember">Hatch-Waxman Act of 1984 election to sue for patent infringement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember" xlink:to="label_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember" xlink:title="label_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember" />
    <link:label xlink:type="resource" xlink:label="label_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember_1" xml:lang="en-US" id="label_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember_1">Hatch Waxman Act Of1984 Available Election To Sue For Patent Infringement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember" xlink:to="label_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember_1" xlink:title="label_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember_1" />
    <link:label xlink:type="resource" xlink:label="label_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember_2" xml:lang="en-US" id="label_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember_2">Represents the election available to a patent owner under the Hatch-Waxman Act of 1984 to sue for patent infringement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember" xlink:to="label_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember_2" xlink:title="label_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_IncentiveFromLessorGross" xlink:label="IncentiveFromLessorGross" xlink:title="IncentiveFromLessorGross" />
    <link:label xlink:type="resource" xlink:label="label_IncentiveFromLessorGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncentiveFromLessorGross" xml:lang="en-US" id="label_IncentiveFromLessorGross">Leasehold improvement allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncentiveFromLessorGross" xlink:to="label_IncentiveFromLessorGross" xlink:title="label_IncentiveFromLessorGross" />
    <link:label xlink:type="resource" xlink:label="label_IncentiveFromLessorGross_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncentiveFromLessorGross_1" xml:lang="en-US" id="label_IncentiveFromLessorGross_1">Incentive from Lessor, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncentiveFromLessorGross" xlink:to="label_IncentiveFromLessorGross_1" xlink:title="label_IncentiveFromLessorGross_1" />
    <link:label xlink:type="resource" xlink:label="label_IncentiveFromLessorGross_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_IncentiveFromLessorGross_2" xml:lang="en-US" id="label_IncentiveFromLessorGross_2">This item represents the gross deferred credit for an incentive or inducement received by a lessee from a lessor, before considering accumulated amortization, in order to motivate the lessee to enter the lease agreement, which incentive or inducement is to be recognized as a reduction of rental expense over the lease term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncentiveFromLessorGross" xlink:to="label_IncentiveFromLessorGross_2" xlink:title="label_IncentiveFromLessorGross_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_InitialPublicOfferingCostsPolicyPolicyTextBlock" xlink:label="InitialPublicOfferingCostsPolicyPolicyTextBlock" xlink:title="InitialPublicOfferingCostsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_InitialPublicOfferingCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_InitialPublicOfferingCostsPolicyPolicyTextBlock" xml:lang="en-US" id="label_InitialPublicOfferingCostsPolicyPolicyTextBlock">Initial Public Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialPublicOfferingCostsPolicyPolicyTextBlock" xlink:to="label_InitialPublicOfferingCostsPolicyPolicyTextBlock" xlink:title="label_InitialPublicOfferingCostsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_InitialPublicOfferingCostsPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InitialPublicOfferingCostsPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_InitialPublicOfferingCostsPolicyPolicyTextBlock_1">Initial Public Offering Costs, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialPublicOfferingCostsPolicyPolicyTextBlock" xlink:to="label_InitialPublicOfferingCostsPolicyPolicyTextBlock_1" xlink:title="label_InitialPublicOfferingCostsPolicyPolicyTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_InitialPublicOfferingCostsPolicyPolicyTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InitialPublicOfferingCostsPolicyPolicyTextBlock_2" xml:lang="en-US" id="label_InitialPublicOfferingCostsPolicyPolicyTextBlock_2">Initial Public Offering Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialPublicOfferingCostsPolicyPolicyTextBlock" xlink:to="label_InitialPublicOfferingCostsPolicyPolicyTextBlock_2" xlink:title="label_InitialPublicOfferingCostsPolicyPolicyTextBlock_2" />
    <link:label xlink:type="resource" xlink:label="label_InitialPublicOfferingCostsPolicyPolicyTextBlock_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_InitialPublicOfferingCostsPolicyPolicyTextBlock_3" xml:lang="en-US" id="label_InitialPublicOfferingCostsPolicyPolicyTextBlock_3">Disclosure of accounting policy for legal, accounting and other direct costs incurred related to efforts to raise capital through a public sale of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialPublicOfferingCostsPolicyPolicyTextBlock" xlink:to="label_InitialPublicOfferingCostsPolicyPolicyTextBlock_3" xlink:title="label_InitialPublicOfferingCostsPolicyPolicyTextBlock_3" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm" xlink:label="LesseeLeasingArrangementsOperatingLeasesRentFreeTerm" xlink:title="LesseeLeasingArrangementsOperatingLeasesRentFreeTerm" />
    <link:label xlink:type="resource" xlink:label="label_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm" xml:lang="en-US" id="label_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm">Rent-free term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeasingArrangementsOperatingLeasesRentFreeTerm" xlink:to="label_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm" xlink:title="label_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm" />
    <link:label xlink:type="resource" xlink:label="label_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm_1" xml:lang="en-US" id="label_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm_1">Lessee Leasing Arrangements, Operating Leases, Rent Free Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeasingArrangementsOperatingLeasesRentFreeTerm" xlink:to="label_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm_1" xlink:title="label_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm_1" />
    <link:label xlink:type="resource" xlink:label="label_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm_2" xml:lang="en-US" id="label_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm_2">Rent-free portion of the term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeasingArrangementsOperatingLeasesRentFreeTerm" xlink:to="label_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm_2" xlink:title="label_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected" xlink:label="LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected" xlink:title="LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected" />
    <link:label xlink:type="resource" xlink:label="label_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected" xml:lang="en-US" id="label_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected">Stay period before FDA can issue a final approval if patent litigation is elected</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected" xlink:to="label_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected" xlink:title="label_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected" />
    <link:label xlink:type="resource" xlink:label="label_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected_1" xml:lang="en-US" id="label_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected_1">Loss Contingency, Stay Period before Final Federal Drug Administration Approval can be Issued if Patent Infringement Litigation Elected</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected" xlink:to="label_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected_1" xlink:title="label_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected_1" />
    <link:label xlink:type="resource" xlink:label="label_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected_2" xml:lang="en-US" id="label_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected_2">Represents the stay period before the Federal Drug Administration (FDA) can issue final approval if patent infringement litigation is elected.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected" xlink:to="label_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected_2" xlink:title="label_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_MaturitiesOfDebtAbstract" xlink:label="MaturitiesOfDebtAbstract" xlink:title="MaturitiesOfDebtAbstract" />
    <link:label xlink:type="resource" xlink:label="label_MaturitiesOfDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MaturitiesOfDebtAbstract" xml:lang="en-US" id="label_MaturitiesOfDebtAbstract">Future payments under debt agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaturitiesOfDebtAbstract" xlink:to="label_MaturitiesOfDebtAbstract" xlink:title="label_MaturitiesOfDebtAbstract" />
    <link:label xlink:type="resource" xlink:label="label_MaturitiesOfDebtAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MaturitiesOfDebtAbstract_1" xml:lang="en-US" id="label_MaturitiesOfDebtAbstract_1">Maturities of Debt [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaturitiesOfDebtAbstract" xlink:to="label_MaturitiesOfDebtAbstract_1" xlink:title="label_MaturitiesOfDebtAbstract_1" />
    <link:label xlink:type="resource" xlink:label="label_MaturitiesOfDebtAbstract_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_MaturitiesOfDebtAbstract_2" xml:lang="en-US" id="label_MaturitiesOfDebtAbstract_2">No definition available.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaturitiesOfDebtAbstract" xlink:to="label_MaturitiesOfDebtAbstract_2" xlink:title="label_MaturitiesOfDebtAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation" xlink:label="MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation" xlink:title="MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation" />
    <link:label xlink:type="resource" xlink:label="label_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation" xml:lang="en-US" id="label_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation">Maximum period automatic stay in effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation" xlink:to="label_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation" xlink:title="label_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation" />
    <link:label xlink:type="resource" xlink:label="label_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation_1" xml:lang="en-US" id="label_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation_1">Maximum Period Automatic Stay In Effect As Result Of Patent Litigation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation" xlink:to="label_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation_1" xlink:title="label_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation_1" />
    <link:label xlink:type="resource" xlink:label="label_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation_2" xml:lang="en-US" id="label_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation_2">Maximum period of time a product has automatic stay as a result of patent litigation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation" xlink:to="label_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation_2" xlink:title="label_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted">Loss attributable to common stockholders - basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_1" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_1">Net Income Loss Available To Common Stockholders Basic And Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_1" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_1" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_2" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_2">Loss attributable to common stockholders - basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_2" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_2" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_3" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_3">Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that basic and dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_3" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_3" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_NonemployeeMember" xlink:label="NonemployeeMember" xlink:title="NonemployeeMember" />
    <link:label xlink:type="resource" xlink:label="label_NonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NonemployeeMember" xml:lang="en-US" id="label_NonemployeeMember">Non-employee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonemployeeMember" xlink:to="label_NonemployeeMember" xlink:title="label_NonemployeeMember" />
    <link:label xlink:type="resource" xlink:label="label_NonemployeeMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NonemployeeMember_1" xml:lang="en-US" id="label_NonemployeeMember_1">Nonemployee [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonemployeeMember" xlink:to="label_NonemployeeMember_1" xlink:title="label_NonemployeeMember_1" />
    <link:label xlink:type="resource" xlink:label="label_NonemployeeMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NonemployeeMember_2" xml:lang="en-US" id="label_NonemployeeMember_2">Represents an individual other than an employee.  Nonemployees may include, but are not limited to, outside members of the board of directors, consultants and advisors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonemployeeMember" xlink:to="label_NonemployeeMember_2" xlink:title="label_NonemployeeMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_NonemployeeStockOptionsMember" xlink:label="NonemployeeStockOptionsMember" xlink:title="NonemployeeStockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="label_NonemployeeStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NonemployeeStockOptionsMember" xml:lang="en-US" id="label_NonemployeeStockOptionsMember">Non-employee stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonemployeeStockOptionsMember" xlink:to="label_NonemployeeStockOptionsMember" xlink:title="label_NonemployeeStockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="label_NonemployeeStockOptionsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NonemployeeStockOptionsMember_1" xml:lang="en-US" id="label_NonemployeeStockOptionsMember_1">Nonemployee Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonemployeeStockOptionsMember" xlink:to="label_NonemployeeStockOptionsMember_1" xlink:title="label_NonemployeeStockOptionsMember_1" />
    <link:label xlink:type="resource" xlink:label="label_NonemployeeStockOptionsMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NonemployeeStockOptionsMember_2" xml:lang="en-US" id="label_NonemployeeStockOptionsMember_2">An arrangement whereby an individual other than an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Nonemployees may include, but are not limited to, outside members of the board of directors, consultants and advisors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonemployeeStockOptionsMember" xlink:to="label_NonemployeeStockOptionsMember_2" xlink:title="label_NonemployeeStockOptionsMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_NotePurchaseAgreementConvertiblePromissoryNotesMember" xlink:label="NotePurchaseAgreementConvertiblePromissoryNotesMember" xlink:title="NotePurchaseAgreementConvertiblePromissoryNotesMember" />
    <link:label xlink:type="resource" xlink:label="label_NotePurchaseAgreementConvertiblePromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NotePurchaseAgreementConvertiblePromissoryNotesMember" xml:lang="en-US" id="label_NotePurchaseAgreementConvertiblePromissoryNotesMember">Bridge Notes Purchase Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotePurchaseAgreementConvertiblePromissoryNotesMember" xlink:to="label_NotePurchaseAgreementConvertiblePromissoryNotesMember" xlink:title="label_NotePurchaseAgreementConvertiblePromissoryNotesMember" />
    <link:label xlink:type="resource" xlink:label="label_NotePurchaseAgreementConvertiblePromissoryNotesMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NotePurchaseAgreementConvertiblePromissoryNotesMember_1" xml:lang="en-US" id="label_NotePurchaseAgreementConvertiblePromissoryNotesMember_1">Note Purchase Agreement Convertible Promissory Notes [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotePurchaseAgreementConvertiblePromissoryNotesMember" xlink:to="label_NotePurchaseAgreementConvertiblePromissoryNotesMember_1" xlink:title="label_NotePurchaseAgreementConvertiblePromissoryNotesMember_1" />
    <link:label xlink:type="resource" xlink:label="label_NotePurchaseAgreementConvertiblePromissoryNotesMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NotePurchaseAgreementConvertiblePromissoryNotesMember_2" xml:lang="en-US" id="label_NotePurchaseAgreementConvertiblePromissoryNotesMember_2">Represents the Note Purchase Agreement (Bridge Notes) allowing for the issuance of convertible promissory notes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotePurchaseAgreementConvertiblePromissoryNotesMember" xlink:to="label_NotePurchaseAgreementConvertiblePromissoryNotesMember_2" xlink:title="label_NotePurchaseAgreementConvertiblePromissoryNotesMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" xlink:label="OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" xlink:title="OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" />
    <link:label xlink:type="resource" xlink:label="label_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" xml:lang="en-US" id="label_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember">Office and research facility operating lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" xlink:to="label_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" xlink:title="label_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" />
    <link:label xlink:type="resource" xlink:label="label_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_1" xml:lang="en-US" id="label_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_1">Office And Research Facility Operating Lease As Amended [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" xlink:to="label_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_1" xlink:title="label_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_1" />
    <link:label xlink:type="resource" xlink:label="label_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_2" xml:lang="en-US" id="label_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_2">Represents information pertaining to an office and research facility operating lease, as amended.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" xlink:to="label_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_2" xlink:title="label_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_PatentCostsIncurredPolicyPolicyTextBlock" xlink:label="PatentCostsIncurredPolicyPolicyTextBlock" xlink:title="PatentCostsIncurredPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PatentCostsIncurredPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PatentCostsIncurredPolicyPolicyTextBlock" xml:lang="en-US" id="label_PatentCostsIncurredPolicyPolicyTextBlock">Patent Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PatentCostsIncurredPolicyPolicyTextBlock" xlink:to="label_PatentCostsIncurredPolicyPolicyTextBlock" xlink:title="label_PatentCostsIncurredPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PatentCostsIncurredPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PatentCostsIncurredPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_PatentCostsIncurredPolicyPolicyTextBlock_1">Patent Costs Incurred, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PatentCostsIncurredPolicyPolicyTextBlock" xlink:to="label_PatentCostsIncurredPolicyPolicyTextBlock_1" xlink:title="label_PatentCostsIncurredPolicyPolicyTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_PatentCostsIncurredPolicyPolicyTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PatentCostsIncurredPolicyPolicyTextBlock_2" xml:lang="en-US" id="label_PatentCostsIncurredPolicyPolicyTextBlock_2">Disclosure of accounting policy for costs incurred related to filing and pursuing patent applications.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PatentCostsIncurredPolicyPolicyTextBlock" xlink:to="label_PatentCostsIncurredPolicyPolicyTextBlock_2" xlink:title="label_PatentCostsIncurredPolicyPolicyTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_PreferredStockWarrantsIssuedNovember2010Member" xlink:label="PreferredStockWarrantsIssuedNovember2010Member" xlink:title="PreferredStockWarrantsIssuedNovember2010Member" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockWarrantsIssuedNovember2010Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockWarrantsIssuedNovember2010Member" xml:lang="en-US" id="label_PreferredStockWarrantsIssuedNovember2010Member">Preferred stock warrant issued November 2010</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockWarrantsIssuedNovember2010Member" xlink:to="label_PreferredStockWarrantsIssuedNovember2010Member" xlink:title="label_PreferredStockWarrantsIssuedNovember2010Member" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockWarrantsIssuedNovember2010Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockWarrantsIssuedNovember2010Member_1" xml:lang="en-US" id="label_PreferredStockWarrantsIssuedNovember2010Member_1">Preferred Stock Warrants Issued November2010 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockWarrantsIssuedNovember2010Member" xlink:to="label_PreferredStockWarrantsIssuedNovember2010Member_1" xlink:title="label_PreferredStockWarrantsIssuedNovember2010Member_1" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockWarrantsIssuedNovember2010Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PreferredStockWarrantsIssuedNovember2010Member_2" xml:lang="en-US" id="label_PreferredStockWarrantsIssuedNovember2010Member_2">Security that gives the holder the right to purchase shares of preferred stock in accordance with the terms of the instrument, usually upon payment of a specified amount, issued in November 2010.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockWarrantsIssuedNovember2010Member" xlink:to="label_PreferredStockWarrantsIssuedNovember2010Member_2" xlink:title="label_PreferredStockWarrantsIssuedNovember2010Member_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_PrepaidDevelopmentCosts" xlink:label="PrepaidDevelopmentCosts" xlink:title="PrepaidDevelopmentCosts" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PrepaidDevelopmentCosts" xml:lang="en-US" id="label_PrepaidDevelopmentCosts">Prepaid development costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidDevelopmentCosts" xlink:to="label_PrepaidDevelopmentCosts" xlink:title="label_PrepaidDevelopmentCosts" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidDevelopmentCosts_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidDevelopmentCosts_1" xml:lang="en-US" id="label_PrepaidDevelopmentCosts_1">Prepaid Development Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidDevelopmentCosts" xlink:to="label_PrepaidDevelopmentCosts_1" xlink:title="label_PrepaidDevelopmentCosts_1" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidDevelopmentCosts_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PrepaidDevelopmentCosts_2" xml:lang="en-US" id="label_PrepaidDevelopmentCosts_2">Amount of asset related to consideration paid in advance for costs of product development that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidDevelopmentCosts" xlink:to="label_PrepaidDevelopmentCosts_2" xlink:title="label_PrepaidDevelopmentCosts_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:title="PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xml:lang="en-US" id="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:title="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock_1" xml:lang="en-US" id="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock_1">Prepaid Expenses and Other Current Assets [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock_1" xlink:title="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock_2" xml:lang="en-US" id="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock_2">The entire disclosure for prepaid expenses and other current assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock_2" xlink:title="label_PrepaidExpensesAndOtherCurrentAssetsTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" xlink:label="PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" xlink:title="PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" />
    <link:label xlink:type="resource" xlink:label="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" xml:lang="en-US" id="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember">Purdue Pharma, L. P. patent infringement suit, District of Delaware</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" xlink:to="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" xlink:title="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" />
    <link:label xlink:type="resource" xlink:label="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember_1" xml:lang="en-US" id="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember_1">Purdue Pharma Limited Partnership Patent Infringement District Of Delaware [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" xlink:to="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember_1" xlink:title="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember_1" />
    <link:label xlink:type="resource" xlink:label="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember_2" xml:lang="en-US" id="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember_2">Represents the suit filed against the entity by Purdue Pharma, L.P. in the District of Delaware asserting patent infringement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" xlink:to="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember_2" xlink:title="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" xlink:label="PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" xlink:title="PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" />
    <link:label xlink:type="resource" xlink:label="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" xml:lang="en-US" id="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember">Purdue Pharma, L. P., patent infringement suit, District of Massachusetts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" xlink:to="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" xlink:title="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" />
    <link:label xlink:type="resource" xlink:label="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember_1" xml:lang="en-US" id="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember_1">Purdue Pharma Limited Partnership Patent Infringement District Of Massachusetts [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" xlink:to="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember_1" xlink:title="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember_1" />
    <link:label xlink:type="resource" xlink:label="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember_2" xml:lang="en-US" id="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember_2">Represents the suit filed against the entity by Purdue Pharma, L.P. in the District of Massachusetts asserting patent infringement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" xlink:to="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember_2" xlink:title="label_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ReimbursableIncentiveFromLessorGross" xlink:label="ReimbursableIncentiveFromLessorGross" xlink:title="ReimbursableIncentiveFromLessorGross" />
    <link:label xlink:type="resource" xlink:label="label_ReimbursableIncentiveFromLessorGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ReimbursableIncentiveFromLessorGross" xml:lang="en-US" id="label_ReimbursableIncentiveFromLessorGross">Reimbursable improvement allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReimbursableIncentiveFromLessorGross" xlink:to="label_ReimbursableIncentiveFromLessorGross" xlink:title="label_ReimbursableIncentiveFromLessorGross" />
    <link:label xlink:type="resource" xlink:label="label_ReimbursableIncentiveFromLessorGross_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ReimbursableIncentiveFromLessorGross_1" xml:lang="en-US" id="label_ReimbursableIncentiveFromLessorGross_1">Reimbursable Incentive from Lessor, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReimbursableIncentiveFromLessorGross" xlink:to="label_ReimbursableIncentiveFromLessorGross_1" xlink:title="label_ReimbursableIncentiveFromLessorGross_1" />
    <link:label xlink:type="resource" xlink:label="label_ReimbursableIncentiveFromLessorGross_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ReimbursableIncentiveFromLessorGross_2" xml:lang="en-US" id="label_ReimbursableIncentiveFromLessorGross_2">This item represents the gross reimbursable incentive or inducement received by a lessee from a lessor, before amortization, in order to motivate the lessee to enter the lease agreement, which incentive or inducement is to be repaid over the lease term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReimbursableIncentiveFromLessorGross" xlink:to="label_ReimbursableIncentiveFromLessorGross_2" xlink:title="label_ReimbursableIncentiveFromLessorGross_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SaleOfStockAuthorizedAmount" xlink:label="SaleOfStockAuthorizedAmount" xlink:title="SaleOfStockAuthorizedAmount" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SaleOfStockAuthorizedAmount" xml:lang="en-US" id="label_SaleOfStockAuthorizedAmount">Amount authorized for sale and issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockAuthorizedAmount" xlink:to="label_SaleOfStockAuthorizedAmount" xlink:title="label_SaleOfStockAuthorizedAmount" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockAuthorizedAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SaleOfStockAuthorizedAmount_1" xml:lang="en-US" id="label_SaleOfStockAuthorizedAmount_1">Sale of Stock, Authorized Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockAuthorizedAmount" xlink:to="label_SaleOfStockAuthorizedAmount_1" xlink:title="label_SaleOfStockAuthorizedAmount_1" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockAuthorizedAmount_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SaleOfStockAuthorizedAmount_2" xml:lang="en-US" id="label_SaleOfStockAuthorizedAmount_2">Authorized amount of consideration that can be received in exchange for shares of stock issued or sold pursuant to a stock purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockAuthorizedAmount" xlink:to="label_SaleOfStockAuthorizedAmount_2" xlink:title="label_SaleOfStockAuthorizedAmount_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SaleOfStockNumberOfSharesAuthorizedToBeSold" xlink:label="SaleOfStockNumberOfSharesAuthorizedToBeSold" xlink:title="SaleOfStockNumberOfSharesAuthorizedToBeSold" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockNumberOfSharesAuthorizedToBeSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SaleOfStockNumberOfSharesAuthorizedToBeSold" xml:lang="en-US" id="label_SaleOfStockNumberOfSharesAuthorizedToBeSold">Shares authorized for sale and issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNumberOfSharesAuthorizedToBeSold" xlink:to="label_SaleOfStockNumberOfSharesAuthorizedToBeSold" xlink:title="label_SaleOfStockNumberOfSharesAuthorizedToBeSold" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockNumberOfSharesAuthorizedToBeSold_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SaleOfStockNumberOfSharesAuthorizedToBeSold_1" xml:lang="en-US" id="label_SaleOfStockNumberOfSharesAuthorizedToBeSold_1">Sale of Stock, Number of Shares Authorized to be Sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNumberOfSharesAuthorizedToBeSold" xlink:to="label_SaleOfStockNumberOfSharesAuthorizedToBeSold_1" xlink:title="label_SaleOfStockNumberOfSharesAuthorizedToBeSold_1" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockNumberOfSharesAuthorizedToBeSold_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SaleOfStockNumberOfSharesAuthorizedToBeSold_2" xml:lang="en-US" id="label_SaleOfStockNumberOfSharesAuthorizedToBeSold_2">The number of shares authorized to be issued or sold pursuant to a stock purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNumberOfSharesAuthorizedToBeSold" xlink:to="label_SaleOfStockNumberOfSharesAuthorizedToBeSold_2" xlink:title="label_SaleOfStockNumberOfSharesAuthorizedToBeSold_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SaleOfStockNumberOfTranches" xlink:label="SaleOfStockNumberOfTranches" xlink:title="SaleOfStockNumberOfTranches" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SaleOfStockNumberOfTranches" xml:lang="en-US" id="label_SaleOfStockNumberOfTranches">Number of tranches into which financing was structured</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNumberOfTranches" xlink:to="label_SaleOfStockNumberOfTranches" xlink:title="label_SaleOfStockNumberOfTranches" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockNumberOfTranches_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SaleOfStockNumberOfTranches_1" xml:lang="en-US" id="label_SaleOfStockNumberOfTranches_1">Sale of Stock, Number of Tranches</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNumberOfTranches" xlink:to="label_SaleOfStockNumberOfTranches_1" xlink:title="label_SaleOfStockNumberOfTranches_1" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockNumberOfTranches_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SaleOfStockNumberOfTranches_2" xml:lang="en-US" id="label_SaleOfStockNumberOfTranches_2">The number of tranches in which shares may be issued or sold pursuant to a stock purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNumberOfTranches" xlink:to="label_SaleOfStockNumberOfTranches_2" xlink:title="label_SaleOfStockNumberOfTranches_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:title="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xml:lang="en-US" id="label_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock">Schedule of estimated useful lives of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="label_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:title="label_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_1" xml:lang="en-US" id="label_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_1">Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="label_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_1" xlink:title="label_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_2" xml:lang="en-US" id="label_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_2">Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="label_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_2" xlink:title="label_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesaPreferredStockWarrantMember" xlink:label="SeriesaPreferredStockWarrantMember" xlink:title="SeriesaPreferredStockWarrantMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesaPreferredStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesaPreferredStockWarrantMember" xml:lang="en-US" id="label_SeriesaPreferredStockWarrantMember">Series A preferred stock warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesaPreferredStockWarrantMember" xlink:to="label_SeriesaPreferredStockWarrantMember" xlink:title="label_SeriesaPreferredStockWarrantMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesaPreferredStockWarrantMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesaPreferredStockWarrantMember_1" xml:lang="en-US" id="label_SeriesaPreferredStockWarrantMember_1">Seriesa Preferred Stock Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesaPreferredStockWarrantMember" xlink:to="label_SeriesaPreferredStockWarrantMember_1" xlink:title="label_SeriesaPreferredStockWarrantMember_1" />
    <link:label xlink:type="resource" xlink:label="label_SeriesaPreferredStockWarrantMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeriesaPreferredStockWarrantMember_2" xml:lang="en-US" id="label_SeriesaPreferredStockWarrantMember_2">Security that gives the holder the right to purchase shares of Series A preferred stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesaPreferredStockWarrantMember" xlink:to="label_SeriesaPreferredStockWarrantMember_2" xlink:title="label_SeriesaPreferredStockWarrantMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesBPreferredStockFinancingFebruary2012Member" xlink:label="SeriesBPreferredStockFinancingFebruary2012Member" xlink:title="SeriesBPreferredStockFinancingFebruary2012Member" />
    <link:label xlink:type="resource" xlink:label="label_SeriesBPreferredStockFinancingFebruary2012Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesBPreferredStockFinancingFebruary2012Member" xml:lang="en-US" id="label_SeriesBPreferredStockFinancingFebruary2012Member">Series B Preferred Stock financing February 2012</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockFinancingFebruary2012Member" xlink:to="label_SeriesBPreferredStockFinancingFebruary2012Member" xlink:title="label_SeriesBPreferredStockFinancingFebruary2012Member" />
    <link:label xlink:type="resource" xlink:label="label_SeriesBPreferredStockFinancingFebruary2012Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesBPreferredStockFinancingFebruary2012Member_1" xml:lang="en-US" id="label_SeriesBPreferredStockFinancingFebruary2012Member_1">Series B Preferred Stock Financing February2012 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockFinancingFebruary2012Member" xlink:to="label_SeriesBPreferredStockFinancingFebruary2012Member_1" xlink:title="label_SeriesBPreferredStockFinancingFebruary2012Member_1" />
    <link:label xlink:type="resource" xlink:label="label_SeriesBPreferredStockFinancingFebruary2012Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeriesBPreferredStockFinancingFebruary2012Member_2" xml:lang="en-US" id="label_SeriesBPreferredStockFinancingFebruary2012Member_2">Represents the sale of the entity's series B preferred stock in February 2012.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockFinancingFebruary2012Member" xlink:to="label_SeriesBPreferredStockFinancingFebruary2012Member_2" xlink:title="label_SeriesBPreferredStockFinancingFebruary2012Member_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesCPreferredStockFinancing2013Member" xlink:label="SeriesCPreferredStockFinancing2013Member" xlink:title="SeriesCPreferredStockFinancing2013Member" />
    <link:label xlink:type="resource" xlink:label="label_SeriesCPreferredStockFinancing2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesCPreferredStockFinancing2013Member" xml:lang="en-US" id="label_SeriesCPreferredStockFinancing2013Member">Series C Preferred Stock financing 2013</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesCPreferredStockFinancing2013Member" xlink:to="label_SeriesCPreferredStockFinancing2013Member" xlink:title="label_SeriesCPreferredStockFinancing2013Member" />
    <link:label xlink:type="resource" xlink:label="label_SeriesCPreferredStockFinancing2013Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesCPreferredStockFinancing2013Member_1" xml:lang="en-US" id="label_SeriesCPreferredStockFinancing2013Member_1">Series C Preferred Stock Financing2013 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesCPreferredStockFinancing2013Member" xlink:to="label_SeriesCPreferredStockFinancing2013Member_1" xlink:title="label_SeriesCPreferredStockFinancing2013Member_1" />
    <link:label xlink:type="resource" xlink:label="label_SeriesCPreferredStockFinancing2013Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeriesCPreferredStockFinancing2013Member_2" xml:lang="en-US" id="label_SeriesCPreferredStockFinancing2013Member_2">Represents the sale of the entity's series C preferred stock in 2013.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesCPreferredStockFinancing2013Member" xlink:to="label_SeriesCPreferredStockFinancing2013Member_2" xlink:title="label_SeriesCPreferredStockFinancing2013Member_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesCPreferredStockFinancing2013TrancheOneMember" xlink:label="SeriesCPreferredStockFinancing2013TrancheOneMember" xlink:title="SeriesCPreferredStockFinancing2013TrancheOneMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesCPreferredStockFinancing2013TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesCPreferredStockFinancing2013TrancheOneMember" xml:lang="en-US" id="label_SeriesCPreferredStockFinancing2013TrancheOneMember">Series C Preferred Stock financing 2013, first tranche</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesCPreferredStockFinancing2013TrancheOneMember" xlink:to="label_SeriesCPreferredStockFinancing2013TrancheOneMember" xlink:title="label_SeriesCPreferredStockFinancing2013TrancheOneMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesCPreferredStockFinancing2013TrancheOneMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesCPreferredStockFinancing2013TrancheOneMember_1" xml:lang="en-US" id="label_SeriesCPreferredStockFinancing2013TrancheOneMember_1">Series C Preferred Stock Financing2013 Tranche One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesCPreferredStockFinancing2013TrancheOneMember" xlink:to="label_SeriesCPreferredStockFinancing2013TrancheOneMember_1" xlink:title="label_SeriesCPreferredStockFinancing2013TrancheOneMember_1" />
    <link:label xlink:type="resource" xlink:label="label_SeriesCPreferredStockFinancing2013TrancheOneMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeriesCPreferredStockFinancing2013TrancheOneMember_2" xml:lang="en-US" id="label_SeriesCPreferredStockFinancing2013TrancheOneMember_2">Represents the first tranche of the sale of the entity's series C preferred stock in 2013.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesCPreferredStockFinancing2013TrancheOneMember" xlink:to="label_SeriesCPreferredStockFinancing2013TrancheOneMember_2" xlink:title="label_SeriesCPreferredStockFinancing2013TrancheOneMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesCPreferredStockFinancing2013TrancheTwoMember" xlink:label="SeriesCPreferredStockFinancing2013TrancheTwoMember" xlink:title="SeriesCPreferredStockFinancing2013TrancheTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesCPreferredStockFinancing2013TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesCPreferredStockFinancing2013TrancheTwoMember" xml:lang="en-US" id="label_SeriesCPreferredStockFinancing2013TrancheTwoMember">Series C Preferred Stock financing 2013, second tranche</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesCPreferredStockFinancing2013TrancheTwoMember" xlink:to="label_SeriesCPreferredStockFinancing2013TrancheTwoMember" xlink:title="label_SeriesCPreferredStockFinancing2013TrancheTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesCPreferredStockFinancing2013TrancheTwoMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesCPreferredStockFinancing2013TrancheTwoMember_1" xml:lang="en-US" id="label_SeriesCPreferredStockFinancing2013TrancheTwoMember_1">Series C Preferred Stock Financing2013 Tranche Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesCPreferredStockFinancing2013TrancheTwoMember" xlink:to="label_SeriesCPreferredStockFinancing2013TrancheTwoMember_1" xlink:title="label_SeriesCPreferredStockFinancing2013TrancheTwoMember_1" />
    <link:label xlink:type="resource" xlink:label="label_SeriesCPreferredStockFinancing2013TrancheTwoMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeriesCPreferredStockFinancing2013TrancheTwoMember_2" xml:lang="en-US" id="label_SeriesCPreferredStockFinancing2013TrancheTwoMember_2">Represents the second tranche of the sale of the entity's series C preferred stock in 2013.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesCPreferredStockFinancing2013TrancheTwoMember" xlink:to="label_SeriesCPreferredStockFinancing2013TrancheTwoMember_2" xlink:title="label_SeriesCPreferredStockFinancing2013TrancheTwoMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" xlink:label="SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" xlink:title="SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" xml:lang="en-US" id="label_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember">Series A, Series B and Series C convertible redeemable preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" xlink:to="label_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" xlink:title="label_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember_1" xml:lang="en-US" id="label_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember_1">Series Series B And Series C Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" xlink:to="label_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember_1" xlink:title="label_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember_1" />
    <link:label xlink:type="resource" xlink:label="label_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember_2" xml:lang="en-US" id="label_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember_2">Represents combined information about outstanding Series A, Series B and Series C redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" xlink:to="label_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember_2" xlink:title="label_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares">Increase in number of authorized shares on the first day of each fiscal year, as a percentage of outstanding common stock (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares_1">Share Based Compensation Arrangement by Share Based Payment Award, Annual Additional Shares Authorized as Percentage of Outstanding Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares_2">Represents the additional shares that may be authorized for issuance annually under an established share-based compensation plan, expressed as a percentage of the entity's outstanding shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate">Period following termination date vested options are exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate_1">Share-based Compensation Arrangement by Share-based Payment Award, Award Exercise Period after Expiration Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate_2">Period after the date the vested equity-based award expires during which an employee continues to have the right to exercise an award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber">Unvested remaining from the early exercise of stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Early Exercise of Stock Options, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber_2">The number of non-vested equity-based payment instruments, issued in connection with the early exercise of stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification">Performance Adjustment (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Other Increases (Decreases) in Period, Modification</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification_2">The addition or reduction in the number of equity-based payment instruments, excluding stock (or unit) options, attributable to a modification during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification">Modification (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period, Modification</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification_2">The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to a modification during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue">Weighted average fair value of vested options (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue_2">As of the balance sheet date, the weighted-average fair value for outstanding stock options that are fully vested.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding">Weighted-average grant date fair value per share of employee option grants (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Grant Date Fair Value, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding_2">Weighted average grant-date fair value of options outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue">Performance Adjustment (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue_1">Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Other Share Increase (Decrease) in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue_1" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue_2">Weighted average fair value as of the grant date of of equity-based award plans other than stock (unit) option plans with respect to a change in nonvested shares attributable to a modification.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue_2" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice">Modification (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Other Share Increase (Decrease) in Period, Modification, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice_1" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice_2">Weighted average price at which grantees could acquire or could have acquired the underlying shares with respect to a change in shares reserved for issuance attributable to a modification.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice_2" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SiliconValleyBankLoanAgreement28August2012Member" xlink:label="SiliconValleyBankLoanAgreement28August2012Member" xlink:title="SiliconValleyBankLoanAgreement28August2012Member" />
    <link:label xlink:type="resource" xlink:label="label_SiliconValleyBankLoanAgreement28August2012Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SiliconValleyBankLoanAgreement28August2012Member" xml:lang="en-US" id="label_SiliconValleyBankLoanAgreement28August2012Member">Silicon Valley Bank loan agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SiliconValleyBankLoanAgreement28August2012Member" xlink:to="label_SiliconValleyBankLoanAgreement28August2012Member" xlink:title="label_SiliconValleyBankLoanAgreement28August2012Member" />
    <link:label xlink:type="resource" xlink:label="label_SiliconValleyBankLoanAgreement28August2012Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SiliconValleyBankLoanAgreement28August2012Member_1" xml:lang="en-US" id="label_SiliconValleyBankLoanAgreement28August2012Member_1">Silicon Valley Bank Loan Agreement28 August2012 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SiliconValleyBankLoanAgreement28August2012Member" xlink:to="label_SiliconValleyBankLoanAgreement28August2012Member_1" xlink:title="label_SiliconValleyBankLoanAgreement28August2012Member_1" />
    <link:label xlink:type="resource" xlink:label="label_SiliconValleyBankLoanAgreement28August2012Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SiliconValleyBankLoanAgreement28August2012Member_2" xml:lang="en-US" id="label_SiliconValleyBankLoanAgreement28August2012Member_2">Represents the loan agreement with Silicon Valley Bank (SVB) entered into on August 28, 2012.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SiliconValleyBankLoanAgreement28August2012Member" xlink:to="label_SiliconValleyBankLoanAgreement28August2012Member_2" xlink:title="label_SiliconValleyBankLoanAgreement28August2012Member_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xlink:label="SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xlink:title="SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" />
    <link:label xlink:type="resource" xlink:label="label_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xml:lang="en-US" id="label_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member">Silicon Valley Bank loan agreement, Amendment No. 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xlink:to="label_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xlink:title="label_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" />
    <link:label xlink:type="resource" xlink:label="label_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_1" xml:lang="en-US" id="label_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_1">Silicon Valley Bank Loan Agreement Amendment Number1 January2014 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xlink:to="label_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_1" xlink:title="label_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_1" />
    <link:label xlink:type="resource" xlink:label="label_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_2" xml:lang="en-US" id="label_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_2">Represents Amendment No. 1 to the loan agreement with Silicon Valley Bank (SVB) entered into in January 2014.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xlink:to="label_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_2" xlink:title="label_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xlink:label="SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xlink:title="SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" />
    <link:label xlink:type="resource" xlink:label="label_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xml:lang="en-US" id="label_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member">Silicon Valley Bank loan agreement Amendment No. 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xlink:to="label_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xlink:title="label_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" />
    <link:label xlink:type="resource" xlink:label="label_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_1" xml:lang="en-US" id="label_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_1">Silicon Valley Bank Loan Agreement Amendment Number2 August2014 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xlink:to="label_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_1" xlink:title="label_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_1" />
    <link:label xlink:type="resource" xlink:label="label_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_2" xml:lang="en-US" id="label_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_2">Represents Amendment No. 2 to the loan agreement with Silicon Valley Bank (SVB) entered into in August 2014.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xlink:to="label_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_2" xlink:title="label_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StatementOfTemporaryEquityAbstract" xlink:label="StatementOfTemporaryEquityAbstract" xlink:title="StatementOfTemporaryEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfTemporaryEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfTemporaryEquityAbstract" xml:lang="en-US" id="label_StatementOfTemporaryEquityAbstract">STATEMENTS OF CONVERTIBLE REDEEMABLE PREFERRED STOCK</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfTemporaryEquityAbstract" xlink:to="label_StatementOfTemporaryEquityAbstract" xlink:title="label_StatementOfTemporaryEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfTemporaryEquityAbstract_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StatementOfTemporaryEquityAbstract_1" xml:lang="en-US" id="label_StatementOfTemporaryEquityAbstract_1">No definition available.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfTemporaryEquityAbstract" xlink:to="label_StatementOfTemporaryEquityAbstract_1" xlink:title="label_StatementOfTemporaryEquityAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StockIncentivePlan2014Member" xlink:label="StockIncentivePlan2014Member" xlink:title="StockIncentivePlan2014Member" />
    <link:label xlink:type="resource" xlink:label="label_StockIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIncentivePlan2014Member" xml:lang="en-US" id="label_StockIncentivePlan2014Member">2014 Stock Incentive Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIncentivePlan2014Member" xlink:to="label_StockIncentivePlan2014Member" xlink:title="label_StockIncentivePlan2014Member" />
    <link:label xlink:type="resource" xlink:label="label_StockIncentivePlan2014Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIncentivePlan2014Member_1" xml:lang="en-US" id="label_StockIncentivePlan2014Member_1">Stock Incentive Plan2014 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIncentivePlan2014Member" xlink:to="label_StockIncentivePlan2014Member_1" xlink:title="label_StockIncentivePlan2014Member_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIncentivePlan2014Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIncentivePlan2014Member_2" xml:lang="en-US" id="label_StockIncentivePlan2014Member_2">Represents the 2014 Stock Incentive Plan  (the Plan), as amended.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIncentivePlan2014Member" xlink:to="label_StockIncentivePlan2014Member_2" xlink:title="label_StockIncentivePlan2014Member_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold" xlink:label="StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold" xlink:title="StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold" xml:lang="en-US" id="label_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold">Threshold of additional capital raised to trigger Performance Adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold" xlink:to="label_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold" xlink:title="label_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold_1" xml:lang="en-US" id="label_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold_1">Stock Issued and Outstanding Modification, Sale of Stock, Consideration Received on Transaction Threshold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold" xlink:to="label_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold_1" xlink:title="label_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold_2" xml:lang="en-US" id="label_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold_2">The threshold of cash received on a stock transaction to trigger a modification of issued and outstanding shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold" xlink:to="label_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold_2" xlink:title="label_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StockModificationAbstract" xlink:label="StockModificationAbstract" xlink:title="StockModificationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StockModificationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockModificationAbstract" xml:lang="en-US" id="label_StockModificationAbstract">Performance Adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockModificationAbstract" xlink:to="label_StockModificationAbstract" xlink:title="label_StockModificationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StockModificationAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockModificationAbstract_1" xml:lang="en-US" id="label_StockModificationAbstract_1">Stock Modification [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockModificationAbstract" xlink:to="label_StockModificationAbstract_1" xlink:title="label_StockModificationAbstract_1" />
    <link:label xlink:type="resource" xlink:label="label_StockModificationAbstract_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockModificationAbstract_2" xml:lang="en-US" id="label_StockModificationAbstract_2">No definition available.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockModificationAbstract" xlink:to="label_StockModificationAbstract_2" xlink:title="label_StockModificationAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StockPurchaseRightMember" xlink:label="StockPurchaseRightMember" xlink:title="StockPurchaseRightMember" />
    <link:label xlink:type="resource" xlink:label="label_StockPurchaseRightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockPurchaseRightMember" xml:lang="en-US" id="label_StockPurchaseRightMember">Stock purchase right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockPurchaseRightMember" xlink:to="label_StockPurchaseRightMember" xlink:title="label_StockPurchaseRightMember" />
    <link:label xlink:type="resource" xlink:label="label_StockPurchaseRightMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockPurchaseRightMember_1" xml:lang="en-US" id="label_StockPurchaseRightMember_1">Stock Purchase Right [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockPurchaseRightMember" xlink:to="label_StockPurchaseRightMember_1" xlink:title="label_StockPurchaseRightMember_1" />
    <link:label xlink:type="resource" xlink:label="label_StockPurchaseRightMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockPurchaseRightMember_2" xml:lang="en-US" id="label_StockPurchaseRightMember_2">A financial instrument that gives an investor the right to purchase shares of stock in a future transaction in accordance with the terms of a stock purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockPurchaseRightMember" xlink:to="label_StockPurchaseRightMember_2" xlink:title="label_StockPurchaseRightMember_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SubsequentEventsUnauditedAbstract" xlink:label="SubsequentEventsUnauditedAbstract" xlink:title="SubsequentEventsUnauditedAbstract" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsUnauditedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventsUnauditedAbstract" xml:lang="en-US" id="label_SubsequentEventsUnauditedAbstract">SUBSEQUENT EVENTS (Unaudited)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsUnauditedAbstract" xlink:to="label_SubsequentEventsUnauditedAbstract" xlink:title="label_SubsequentEventsUnauditedAbstract" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsUnauditedAbstract_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SubsequentEventsUnauditedAbstract_1" xml:lang="en-US" id="label_SubsequentEventsUnauditedAbstract_1">n/a</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsUnauditedAbstract" xlink:to="label_SubsequentEventsUnauditedAbstract_1" xlink:title="label_SubsequentEventsUnauditedAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" xlink:label="TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" xlink:title="TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" xml:lang="en-US" id="label_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue">Accruals of dividends and accretion to redemption value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" xlink:to="label_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" xlink:title="label_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue_1" xml:lang="en-US" id="label_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue_1">Temporary Equity, Accretion of Dividends and Accretion to Redemption Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" xlink:to="label_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue_1" xlink:title="label_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue_2" xml:lang="en-US" id="label_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue_2">Represents the combined value of accretion of temporary equity during the period due to unpaid dividends and accretion of temporary equity to its redemption value during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" xlink:to="label_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue_2" xlink:title="label_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock" xlink:label="TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock" xlink:title="TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US" id="label_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock">EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock" xlink:to="label_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock" xlink:title="label_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock_1" xml:lang="en-US" id="label_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock_1">Temporary Equity and Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock" xlink:to="label_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock_1" xlink:title="label_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock_2" xml:lang="en-US" id="label_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock_2">Combined disclosure for securities with redemption features that are outside the control of the issuer and shareholders' equity which may include, for temporary equity, a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable; and for stockholders' equity, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock" xlink:to="label_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock_2" xlink:title="label_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage" xlink:label="TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage" xlink:title="TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage" xml:lang="en-US" id="label_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage">Written consent or affirmative vote of outstanding shares to amend, alter or repeal the preferences, special rights or other powers (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage" xlink:to="label_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage" xlink:title="label_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage_1" xml:lang="en-US" id="label_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage_1">Temporary Equity, Change in Features, Written Consent or Affirmative Vote of Outstanding Shares Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage" xlink:to="label_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage_1" xlink:title="label_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage_2" xml:lang="en-US" id="label_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage_2">Represents the required percentage of written consent or affirmative vote of all shares outstanding of securities classified as temporary equity to amend, alter or repeal the preferences, special rights or other powers of such securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage" xlink:to="label_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage_2" xlink:title="label_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityConvertibleConversionPrice" xlink:label="TemporaryEquityConvertibleConversionPrice" xlink:title="TemporaryEquityConvertibleConversionPrice" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityConvertibleConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityConvertibleConversionPrice" xml:lang="en-US" id="label_TemporaryEquityConvertibleConversionPrice">Conversion price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityConvertibleConversionPrice" xlink:to="label_TemporaryEquityConvertibleConversionPrice" xlink:title="label_TemporaryEquityConvertibleConversionPrice" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityConvertibleConversionPrice_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityConvertibleConversionPrice_1" xml:lang="en-US" id="label_TemporaryEquityConvertibleConversionPrice_1">Temporary Equity, Convertible, Conversion Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityConvertibleConversionPrice" xlink:to="label_TemporaryEquityConvertibleConversionPrice_1" xlink:title="label_TemporaryEquityConvertibleConversionPrice_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityConvertibleConversionPrice_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityConvertibleConversionPrice_2" xml:lang="en-US" id="label_TemporaryEquityConvertibleConversionPrice_2">The per share conversion price of stock classified as temporary equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityConvertibleConversionPrice" xlink:to="label_TemporaryEquityConvertibleConversionPrice_2" xlink:title="label_TemporaryEquityConvertibleConversionPrice_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityCumulativeAccretionOfDividends" xlink:label="TemporaryEquityCumulativeAccretionOfDividends" xlink:title="TemporaryEquityCumulativeAccretionOfDividends" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityCumulativeAccretionOfDividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityCumulativeAccretionOfDividends" xml:lang="en-US" id="label_TemporaryEquityCumulativeAccretionOfDividends">Cumulative accrued dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCumulativeAccretionOfDividends" xlink:to="label_TemporaryEquityCumulativeAccretionOfDividends" xlink:title="label_TemporaryEquityCumulativeAccretionOfDividends" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityCumulativeAccretionOfDividends_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityCumulativeAccretionOfDividends_1" xml:lang="en-US" id="label_TemporaryEquityCumulativeAccretionOfDividends_1">Temporary Equity, Cumulative Accretion of Dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCumulativeAccretionOfDividends" xlink:to="label_TemporaryEquityCumulativeAccretionOfDividends_1" xlink:title="label_TemporaryEquityCumulativeAccretionOfDividends_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityCumulativeAccretionOfDividends_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityCumulativeAccretionOfDividends_2" xml:lang="en-US" id="label_TemporaryEquityCumulativeAccretionOfDividends_2">Cumulative value of accretion of temporary equity due to unpaid dividends.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCumulativeAccretionOfDividends" xlink:to="label_TemporaryEquityCumulativeAccretionOfDividends_2" xlink:title="label_TemporaryEquityCumulativeAccretionOfDividends_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" xlink:label="TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" xlink:title="TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" xml:lang="en-US" id="label_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment">Accretion and dividends of preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" xlink:to="label_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" xlink:title="label_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_1" xml:lang="en-US" id="label_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_1">Temporary Equity, Dividends, Adjustment and Accretion to Redemption Value, Adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" xlink:to="label_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_1" xlink:title="label_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:title="label_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_2" xml:lang="en-US" id="label_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_2">Accruals of dividends and accretion to redemption value of preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" xlink:to="label_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_2" xlink:title="label_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_2" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_3" xml:lang="en-US" id="label_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_3">Represents the combined amount of accretion of temporary equity during the period due to cash, stock, and in-kind dividends and decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" xlink:to="label_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_3" xlink:title="label_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_3" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityGainLossOnExtinguishment" xlink:label="TemporaryEquityGainLossOnExtinguishment" xlink:title="TemporaryEquityGainLossOnExtinguishment" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityGainLossOnExtinguishment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_TemporaryEquityGainLossOnExtinguishment" xml:lang="en-US" id="label_TemporaryEquityGainLossOnExtinguishment">Extinguishment of preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityGainLossOnExtinguishment" xlink:to="label_TemporaryEquityGainLossOnExtinguishment" xlink:title="label_TemporaryEquityGainLossOnExtinguishment" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityGainLossOnExtinguishment_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityGainLossOnExtinguishment_1" xml:lang="en-US" id="label_TemporaryEquityGainLossOnExtinguishment_1">Gain on extinguishment for amendment to dividend terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityGainLossOnExtinguishment" xlink:to="label_TemporaryEquityGainLossOnExtinguishment_1" xlink:title="label_TemporaryEquityGainLossOnExtinguishment_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityGainLossOnExtinguishment_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityGainLossOnExtinguishment_2" xml:lang="en-US" id="label_TemporaryEquityGainLossOnExtinguishment_2">Temporary Equity, Gain (Loss) on Extinguishment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityGainLossOnExtinguishment" xlink:to="label_TemporaryEquityGainLossOnExtinguishment_2" xlink:title="label_TemporaryEquityGainLossOnExtinguishment_2" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityGainLossOnExtinguishment_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityGainLossOnExtinguishment_3" xml:lang="en-US" id="label_TemporaryEquityGainLossOnExtinguishment_3">Amount of gain (loss) due to an amendment to the dividend terms of temporary equity which is accounted for as an extinguishment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityGainLossOnExtinguishment" xlink:to="label_TemporaryEquityGainLossOnExtinguishment_3" xlink:title="label_TemporaryEquityGainLossOnExtinguishment_3" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare" xlink:label="TemporaryEquityLiquidationRightsOriginalIssuePricePerShare" xlink:title="TemporaryEquityLiquidationRightsOriginalIssuePricePerShare" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare" xml:lang="en-US" id="label_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare">Liquidation rights, original issue price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityLiquidationRightsOriginalIssuePricePerShare" xlink:to="label_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare" xlink:title="label_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare_1" xml:lang="en-US" id="label_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare_1">Temporary Equity, Liquidation Rights, Original Issue Price Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityLiquidationRightsOriginalIssuePricePerShare" xlink:to="label_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare_1" xlink:title="label_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare_2" xml:lang="en-US" id="label_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare_2">Represents the original issue price per share of stock classified as temporary equity that has liquidation preference in the event of any voluntary or involuntary liquidation, dissolution or winding-up of the affairs of the entity or a Deemed Liquidation Event, as defined in the agreement to the financial instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityLiquidationRightsOriginalIssuePricePerShare" xlink:to="label_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare_2" xlink:title="label_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio" xlink:label="TemporaryEquityLiquidationRightsPerShareIssuePriceRatio" xlink:title="TemporaryEquityLiquidationRightsPerShareIssuePriceRatio" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio" xml:lang="en-US" id="label_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio">Liquidation rights, ratio applied to original issue price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityLiquidationRightsPerShareIssuePriceRatio" xlink:to="label_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio" xlink:title="label_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio_1" xml:lang="en-US" id="label_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio_1">Temporary Equity, Liquidation Rights, Per Share Issue Price, Ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityLiquidationRightsPerShareIssuePriceRatio" xlink:to="label_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio_1" xlink:title="label_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio_2" xml:lang="en-US" id="label_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio_2">Ratio applied to the original issue price of stock classified as temporary equity that has liquidation preference in the event of any voluntary or involuntary liquidation, dissolution or winding-up of the affairs of the entity or a Deemed Liquidation Event, as defined in the agreement to the financial instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityLiquidationRightsPerShareIssuePriceRatio" xlink:to="label_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio_2" xlink:title="label_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage" xlink:label="TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage" xlink:title="TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage" xml:lang="en-US" id="label_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage">Affirmative vote of outstanding shares for optional redemption (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage" xlink:to="label_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage" xlink:title="label_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage_1" xml:lang="en-US" id="label_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage_1">Temporary Equity, Optional Redemption Feature, Affirmative Vote of Outstanding Shares Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage" xlink:to="label_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage_1" xlink:title="label_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage_2" xml:lang="en-US" id="label_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage_2">Represents the required percentage of affirmative vote of all shares outstanding of securities classified as temporary equity to exercise for the holders to exercise the optional redemption feature on or after the date specified in the agreement to the financial instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage" xlink:to="label_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage_2" xlink:title="label_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments" xlink:label="TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments" xlink:title="TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments" xml:lang="en-US" id="label_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments">Optional redemption feature, number of installment payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments" xlink:to="label_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments" xlink:title="label_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments_1" xml:lang="en-US" id="label_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments_1">Temporary Equity, Optional Redemption Feature, Number of Installment Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments" xlink:to="label_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments_1" xlink:title="label_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments_2" xml:lang="en-US" id="label_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments_2">The number of installments in which an optional redemption of stock classified as temporary equity is to be paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments" xlink:to="label_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments_2" xlink:title="label_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio" xlink:label="TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio" xlink:title="TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio" xml:lang="en-US" id="label_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio">Optional redemption feature, ratio applied to original price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio" xlink:to="label_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio" xlink:title="label_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio_1" xml:lang="en-US" id="label_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio_1">Temporary Equity, Optional Redemption Feature, Per Share Issue Price, Ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio" xlink:to="label_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio_1" xlink:title="label_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio_2" xml:lang="en-US" id="label_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio_2">Ratio applied to the original issue price of stock classified as temporary equity in an optional redemption, as defined in the agreement to the financial instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio" xlink:to="label_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio_2" xlink:title="label_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock" xlink:label="TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock" xlink:title="TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock" xml:lang="en-US" id="label_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock">Convertible Redeemable Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock" xlink:to="label_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock" xlink:title="label_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock_1" xml:lang="en-US" id="label_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock_1">Temporary Equity, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock" xlink:to="label_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock_1" xlink:title="label_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock_2" xml:lang="en-US" id="label_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock_2">Disclosure of accounting policy for redeemable preferred stock issued which is not included within permanent equity. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock" xlink:to="label_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock_2" xlink:title="label_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityRedemptionValueModificationAdjustment" xlink:label="TemporaryEquityRedemptionValueModificationAdjustment" xlink:title="TemporaryEquityRedemptionValueModificationAdjustment" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityRedemptionValueModificationAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityRedemptionValueModificationAdjustment" xml:lang="en-US" id="label_TemporaryEquityRedemptionValueModificationAdjustment">Performance Adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityRedemptionValueModificationAdjustment" xlink:to="label_TemporaryEquityRedemptionValueModificationAdjustment" xlink:title="label_TemporaryEquityRedemptionValueModificationAdjustment" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityRedemptionValueModificationAdjustment_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityRedemptionValueModificationAdjustment_1" xml:lang="en-US" id="label_TemporaryEquityRedemptionValueModificationAdjustment_1">Temporary Equity, Redemption Value, Modification Adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityRedemptionValueModificationAdjustment" xlink:to="label_TemporaryEquityRedemptionValueModificationAdjustment_1" xlink:title="label_TemporaryEquityRedemptionValueModificationAdjustment_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityRedemptionValueModificationAdjustment_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityRedemptionValueModificationAdjustment_2" xml:lang="en-US" id="label_TemporaryEquityRedemptionValueModificationAdjustment_2">Amount of increase (decrease) to net income to adjust temporary equity to its redemption value due to a modification of the number of issued and outstanding shares of temporary equity outstanding during the period, as defined by the entity's articles of incorporation. This item is an increase (decrease) to net income necessary to derive net income apportioned to common stockholders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityRedemptionValueModificationAdjustment" xlink:to="label_TemporaryEquityRedemptionValueModificationAdjustment_2" xlink:title="label_TemporaryEquityRedemptionValueModificationAdjustment_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityRightsToElectDirectorsNumberOfDirectors" xlink:label="TemporaryEquityRightsToElectDirectorsNumberOfDirectors" xlink:title="TemporaryEquityRightsToElectDirectorsNumberOfDirectors" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityRightsToElectDirectorsNumberOfDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityRightsToElectDirectorsNumberOfDirectors" xml:lang="en-US" id="label_TemporaryEquityRightsToElectDirectorsNumberOfDirectors">Number of directors holders of record are entitled to elect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityRightsToElectDirectorsNumberOfDirectors" xlink:to="label_TemporaryEquityRightsToElectDirectorsNumberOfDirectors" xlink:title="label_TemporaryEquityRightsToElectDirectorsNumberOfDirectors" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityRightsToElectDirectorsNumberOfDirectors_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityRightsToElectDirectorsNumberOfDirectors_1" xml:lang="en-US" id="label_TemporaryEquityRightsToElectDirectorsNumberOfDirectors_1">Temporary Equity, Rights to Elect Directors, Number of Directors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityRightsToElectDirectorsNumberOfDirectors" xlink:to="label_TemporaryEquityRightsToElectDirectorsNumberOfDirectors_1" xlink:title="label_TemporaryEquityRightsToElectDirectorsNumberOfDirectors_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityRightsToElectDirectorsNumberOfDirectors_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityRightsToElectDirectorsNumberOfDirectors_2" xml:lang="en-US" id="label_TemporaryEquityRightsToElectDirectorsNumberOfDirectors_2">Represents the number of directors the holders of record of securities classified as temporary equity are entitled to elect.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityRightsToElectDirectorsNumberOfDirectors" xlink:to="label_TemporaryEquityRightsToElectDirectorsNumberOfDirectors_2" xlink:title="label_TemporaryEquityRightsToElectDirectorsNumberOfDirectors_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityShareholderSharesOwned" xlink:label="TemporaryEquityShareholderSharesOwned" xlink:title="TemporaryEquityShareholderSharesOwned" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityShareholderSharesOwned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityShareholderSharesOwned" xml:lang="en-US" id="label_TemporaryEquityShareholderSharesOwned">Shares owned by a shareholder (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityShareholderSharesOwned" xlink:to="label_TemporaryEquityShareholderSharesOwned" xlink:title="label_TemporaryEquityShareholderSharesOwned" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityShareholderSharesOwned_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityShareholderSharesOwned_1" xml:lang="en-US" id="label_TemporaryEquityShareholderSharesOwned_1">Temporary Equity, Shareholder, Shares Owned</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityShareholderSharesOwned" xlink:to="label_TemporaryEquityShareholderSharesOwned_1" xlink:title="label_TemporaryEquityShareholderSharesOwned_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityShareholderSharesOwned_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityShareholderSharesOwned_2" xml:lang="en-US" id="label_TemporaryEquityShareholderSharesOwned_2">The number of the entity's securities classified as temporary equity that are owned by a shareholder.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityShareholderSharesOwned" xlink:to="label_TemporaryEquityShareholderSharesOwned_2" xlink:title="label_TemporaryEquityShareholderSharesOwned_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" xlink:label="TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" xlink:title="TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" xml:lang="en-US" id="label_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue">Performance Adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" xlink:to="label_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" xlink:title="label_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_1" xml:lang="en-US" id="label_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_1">Performance Adjustment of Series A</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" xlink:to="label_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_1" xlink:title="label_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_2" xml:lang="en-US" id="label_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_2">Temporary Equity, Stock Issued and Outstanding Modification, Adjustment to Redemption Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" xlink:to="label_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_2" xlink:title="label_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_2" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_3" xml:lang="en-US" id="label_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_3">Value of decrease to temporary equity to its redemption value during the period for a modification of shares issued and outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" xlink:to="label_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_3" xlink:title="label_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_3" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedAndOutstandingModificationShares" xlink:label="TemporaryEquityStockIssuedAndOutstandingModificationShares" xlink:title="TemporaryEquityStockIssuedAndOutstandingModificationShares" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityStockIssuedAndOutstandingModificationShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_TemporaryEquityStockIssuedAndOutstandingModificationShares" xml:lang="en-US" id="label_TemporaryEquityStockIssuedAndOutstandingModificationShares">Performance Adjustment of Series A (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityStockIssuedAndOutstandingModificationShares" xlink:to="label_TemporaryEquityStockIssuedAndOutstandingModificationShares" xlink:title="label_TemporaryEquityStockIssuedAndOutstandingModificationShares" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityStockIssuedAndOutstandingModificationShares_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityStockIssuedAndOutstandingModificationShares_1" xml:lang="en-US" id="label_TemporaryEquityStockIssuedAndOutstandingModificationShares_1">Temporary Equity, Stock Issued and Outstanding Modification, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityStockIssuedAndOutstandingModificationShares" xlink:to="label_TemporaryEquityStockIssuedAndOutstandingModificationShares_1" xlink:title="label_TemporaryEquityStockIssuedAndOutstandingModificationShares_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityStockIssuedAndOutstandingModificationShares_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityStockIssuedAndOutstandingModificationShares_2" xml:lang="en-US" id="label_TemporaryEquityStockIssuedAndOutstandingModificationShares_2">Decrease in the number of shares of issued and outstanding temporary equity during the period as a result of a modification.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityStockIssuedAndOutstandingModificationShares" xlink:to="label_TemporaryEquityStockIssuedAndOutstandingModificationShares_2" xlink:title="label_TemporaryEquityStockIssuedAndOutstandingModificationShares_2" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:title="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="label_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">Issuance of new Series C convertible redeemable preferred stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="label_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:title="label_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US" id="label_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_1">Issuance of stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="label_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_1" xlink:title="label_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2" xml:lang="en-US" id="label_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="label_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2" xlink:title="label_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_2" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_3" xml:lang="en-US" id="label_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_3">Number of shares of temporary equity issued during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="label_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_3" xlink:title="label_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_3" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedIssuanceCosts" xlink:label="TemporaryEquityStockIssuedIssuanceCosts" xlink:title="TemporaryEquityStockIssuedIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_TemporaryEquityStockIssuedIssuanceCosts" xml:lang="en-US" id="label_TemporaryEquityStockIssuedIssuanceCosts">Closing costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityStockIssuedIssuanceCosts" xlink:to="label_TemporaryEquityStockIssuedIssuanceCosts" xlink:title="label_TemporaryEquityStockIssuedIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityStockIssuedIssuanceCosts_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityStockIssuedIssuanceCosts_1" xml:lang="en-US" id="label_TemporaryEquityStockIssuedIssuanceCosts_1">Issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityStockIssuedIssuanceCosts" xlink:to="label_TemporaryEquityStockIssuedIssuanceCosts_1" xlink:title="label_TemporaryEquityStockIssuedIssuanceCosts_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityStockIssuedIssuanceCosts_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityStockIssuedIssuanceCosts_2" xml:lang="en-US" id="label_TemporaryEquityStockIssuedIssuanceCosts_2">Temporary Equity, Stock Issued, Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityStockIssuedIssuanceCosts" xlink:to="label_TemporaryEquityStockIssuedIssuanceCosts_2" xlink:title="label_TemporaryEquityStockIssuedIssuanceCosts_2" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityStockIssuedIssuanceCosts_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TemporaryEquityStockIssuedIssuanceCosts_3" xml:lang="en-US" id="label_TemporaryEquityStockIssuedIssuanceCosts_3">Amount of decrease to temporary equity resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityStockIssuedIssuanceCosts" xlink:to="label_TemporaryEquityStockIssuedIssuanceCosts_3" xlink:title="label_TemporaryEquityStockIssuedIssuanceCosts_3" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_WarrantsDisclosureTextBlock" xlink:label="WarrantsDisclosureTextBlock" xlink:title="WarrantsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantsDisclosureTextBlock" xml:lang="en-US" id="label_WarrantsDisclosureTextBlock">WARRANTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsDisclosureTextBlock" xlink:to="label_WarrantsDisclosureTextBlock" xlink:title="label_WarrantsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantsDisclosureTextBlock_1" xml:lang="en-US" id="label_WarrantsDisclosureTextBlock_1">Warrants Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsDisclosureTextBlock" xlink:to="label_WarrantsDisclosureTextBlock_1" xlink:title="label_WarrantsDisclosureTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_WarrantsDisclosureTextBlock_2" xml:lang="en-US" id="label_WarrantsDisclosureTextBlock_2">The entire disclosure for information about warrants or rights issued, which may include the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsDisclosureTextBlock" xlink:to="label_WarrantsDisclosureTextBlock_2" xlink:title="label_WarrantsDisclosureTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountingPoliciesAbstract" xml:lang="en-US" id="label_AccountingPoliciesAbstract">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="label_AccountingPoliciesAbstract" xlink:title="label_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US" id="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1" xml:lang="en-US" id="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1">ACCRUED EXPENSES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1" xlink:title="label_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountsPayableCurrent" xml:lang="en-US" id="label_AccountsPayableCurrent">Accounts Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="label_AccountsPayableCurrent" xlink:title="label_AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccountsPayableCurrent_1" xml:lang="en-US" id="label_AccountsPayableCurrent_1">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="label_AccountsPayableCurrent_1" xlink:title="label_AccountsPayableCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xml:lang="en-US" id="label_AccruedLiabilitiesAndOtherLiabilitiesAbstract">ACCRUED EXPENSES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="label_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="label_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccruedLiabilitiesCurrent" xml:lang="en-US" id="label_AccruedLiabilitiesCurrent">Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="label_AccruedLiabilitiesCurrent" xlink:title="label_AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccruedLiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccruedLiabilitiesCurrent_1" xml:lang="en-US" id="label_AccruedLiabilitiesCurrent_1">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="label_AccruedLiabilitiesCurrent_1" xlink:title="label_AccruedLiabilitiesCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_AccruedLiabilitiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_AccruedLiabilitiesCurrent_2" xml:lang="en-US" id="label_AccruedLiabilitiesCurrent_2">Total accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="label_AccruedLiabilitiesCurrent_2" xlink:title="label_AccruedLiabilitiesCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="AccruedMarketingCostsCurrent" xlink:title="AccruedMarketingCostsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccruedMarketingCostsCurrent" xml:lang="en-US" id="label_AccruedMarketingCostsCurrent">Accrued Marketing Costs, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedMarketingCostsCurrent" xlink:to="label_AccruedMarketingCostsCurrent" xlink:title="label_AccruedMarketingCostsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccruedMarketingCostsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccruedMarketingCostsCurrent_1" xml:lang="en-US" id="label_AccruedMarketingCostsCurrent_1">Accrued marketing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedMarketingCostsCurrent" xlink:to="label_AccruedMarketingCostsCurrent_1" xlink:title="label_AccruedMarketingCostsCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccruedProfessionalFeesCurrent" xml:lang="en-US" id="label_AccruedProfessionalFeesCurrent">Accrued Professional Fees, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedProfessionalFeesCurrent" xlink:to="label_AccruedProfessionalFeesCurrent" xlink:title="label_AccruedProfessionalFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccruedProfessionalFeesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccruedProfessionalFeesCurrent_1" xml:lang="en-US" id="label_AccruedProfessionalFeesCurrent_1">Accrued audit and legal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedProfessionalFeesCurrent" xlink:to="label_AccruedProfessionalFeesCurrent_1" xlink:title="label_AccruedProfessionalFeesCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US" id="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xml:lang="en-US" id="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1">Less: accumulated deprecation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xlink:title="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdditionalPaidInCapital" xml:lang="en-US" id="label_AdditionalPaidInCapital">Additional Paid in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="label_AdditionalPaidInCapital" xlink:title="label_AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapital_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdditionalPaidInCapital_1" xml:lang="en-US" id="label_AdditionalPaidInCapital_1">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="label_AdditionalPaidInCapital_1" xlink:title="label_AdditionalPaidInCapital_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdditionalPaidInCapitalMember" xml:lang="en-US" id="label_AdditionalPaidInCapitalMember">Additional Paid In Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="label_AdditionalPaidInCapitalMember" xlink:title="label_AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapitalMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdditionalPaidInCapitalMember_1" xml:lang="en-US" id="label_AdditionalPaidInCapitalMember_1">Additional Paid-In Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="label_AdditionalPaidInCapitalMember_1" xlink:title="label_AdditionalPaidInCapitalMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US" id="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:title="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xml:lang="en-US" id="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2">Changes in operating assets and liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:title="label_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="label_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AllocatedShareBasedCompensationExpense" xml:lang="en-US" id="label_AllocatedShareBasedCompensationExpense">Allocated Share-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="label_AllocatedShareBasedCompensationExpense" xlink:title="label_AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="label_AllocatedShareBasedCompensationExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AllocatedShareBasedCompensationExpense_1" xml:lang="en-US" id="label_AllocatedShareBasedCompensationExpense_1">Total stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="label_AllocatedShareBasedCompensationExpense_1" xlink:title="label_AllocatedShareBasedCompensationExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US" id="label_AmortizationOfFinancingCostsAndDiscounts">Amortization of Financing Costs and Discounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfFinancingCostsAndDiscounts" xlink:to="label_AmortizationOfFinancingCostsAndDiscounts" xlink:title="label_AmortizationOfFinancingCostsAndDiscounts" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfFinancingCostsAndDiscounts_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AmortizationOfFinancingCostsAndDiscounts_1" xml:lang="en-US" id="label_AmortizationOfFinancingCostsAndDiscounts_1">Non cash interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfFinancingCostsAndDiscounts" xlink:to="label_AmortizationOfFinancingCostsAndDiscounts_1" xlink:title="label_AmortizationOfFinancingCostsAndDiscounts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1">Potentially dilutive securities outstanding excluded from the computations of diluted weighted-average shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1">Anti-dilutive securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AntidilutiveSecuritiesNameDomain" xml:lang="en-US" id="label_AntidilutiveSecuritiesNameDomain">Antidilutive Securities Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="label_AntidilutiveSecuritiesNameDomain" xlink:title="label_AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesNameDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AntidilutiveSecuritiesNameDomain_1" xml:lang="en-US" id="label_AntidilutiveSecuritiesNameDomain_1">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="label_AntidilutiveSecuritiesNameDomain_1" xlink:title="label_AntidilutiveSecuritiesNameDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="AreaOfRealEstateProperty" xlink:title="AreaOfRealEstateProperty" />
    <link:label xlink:type="resource" xlink:label="label_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AreaOfRealEstateProperty" xml:lang="en-US" id="label_AreaOfRealEstateProperty">Area of Real Estate Property</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AreaOfRealEstateProperty" xlink:to="label_AreaOfRealEstateProperty" xlink:title="label_AreaOfRealEstateProperty" />
    <link:label xlink:type="resource" xlink:label="label_AreaOfRealEstateProperty_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AreaOfRealEstateProperty_1" xml:lang="en-US" id="label_AreaOfRealEstateProperty_1">Square of feet of space</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AreaOfRealEstateProperty" xlink:to="label_AreaOfRealEstateProperty_1" xlink:title="label_AreaOfRealEstateProperty_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="label_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Assets" xml:lang="en-US" id="label_Assets">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="label_Assets" xlink:title="label_Assets" />
    <link:label xlink:type="resource" xlink:label="label_Assets_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_Assets_1" xml:lang="en-US" id="label_Assets_1">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="label_Assets_1" xlink:title="label_Assets_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsAbstract" xml:lang="en-US" id="label_AssetsAbstract">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="label_AssetsAbstract" xlink:title="label_AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AssetsAbstract_1" xml:lang="en-US" id="label_AssetsAbstract_1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="label_AssetsAbstract_1" xlink:title="label_AssetsAbstract_1" />
    <link:label xlink:type="resource" xlink:label="label_AssetsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_AssetsAbstract_2" xml:lang="en-US" id="label_AssetsAbstract_2">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="label_AssetsAbstract_2" xlink:title="label_AssetsAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsCurrent" xml:lang="en-US" id="label_AssetsCurrent">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="label_AssetsCurrent" xlink:title="label_AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_AssetsCurrent_1" xml:lang="en-US" id="label_AssetsCurrent_1">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="label_AssetsCurrent_1" xlink:title="label_AssetsCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsCurrentAbstract" xml:lang="en-US" id="label_AssetsCurrentAbstract">Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="label_AssetsCurrentAbstract" xlink:title="label_AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AssetsCurrentAbstract_1" xml:lang="en-US" id="label_AssetsCurrentAbstract_1">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="label_AssetsCurrentAbstract_1" xlink:title="label_AssetsCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AwardTypeAxis" xml:lang="en-US" id="label_AwardTypeAxis">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="label_AwardTypeAxis" xlink:title="label_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="BalanceSheetLocationAxis" xlink:title="BalanceSheetLocationAxis" />
    <link:label xlink:type="resource" xlink:label="label_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BalanceSheetLocationAxis" xml:lang="en-US" id="label_BalanceSheetLocationAxis">Balance Sheet Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BalanceSheetLocationAxis" xlink:to="label_BalanceSheetLocationAxis" xlink:title="label_BalanceSheetLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="BalanceSheetLocationDomain" xlink:title="BalanceSheetLocationDomain" />
    <link:label xlink:type="resource" xlink:label="label_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BalanceSheetLocationDomain" xml:lang="en-US" id="label_BalanceSheetLocationDomain">Balance Sheet Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BalanceSheetLocationDomain" xlink:to="label_BalanceSheetLocationDomain" xlink:title="label_BalanceSheetLocationDomain" />
    <link:label xlink:type="resource" xlink:label="label_BalanceSheetLocationDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BalanceSheetLocationDomain_1" xml:lang="en-US" id="label_BalanceSheetLocationDomain_1">Balance Sheet Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BalanceSheetLocationDomain" xlink:to="label_BalanceSheetLocationDomain_1" xlink:title="label_BalanceSheetLocationDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US" id="label_BasisOfAccountingPolicyPolicyTextBlock">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="label_BasisOfAccountingPolicyPolicyTextBlock" xlink:title="label_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_BasisOfAccountingPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BasisOfAccountingPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_BasisOfAccountingPolicyPolicyTextBlock_1">Basis of presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="label_BasisOfAccountingPolicyPolicyTextBlock_1" xlink:title="label_BasisOfAccountingPolicyPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="CarryingReportedAmountFairValueDisclosureMember" xlink:title="CarryingReportedAmountFairValueDisclosureMember" />
    <link:label xlink:type="resource" xlink:label="label_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CarryingReportedAmountFairValueDisclosureMember" xml:lang="en-US" id="label_CarryingReportedAmountFairValueDisclosureMember">Carrying Reported Amount Fair Value Disclosure [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CarryingReportedAmountFairValueDisclosureMember" xlink:to="label_CarryingReportedAmountFairValueDisclosureMember" xlink:title="label_CarryingReportedAmountFairValueDisclosureMember" />
    <link:label xlink:type="resource" xlink:label="label_CarryingReportedAmountFairValueDisclosureMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CarryingReportedAmountFairValueDisclosureMember_1" xml:lang="en-US" id="label_CarryingReportedAmountFairValueDisclosureMember_1">Carrying amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CarryingReportedAmountFairValueDisclosureMember" xlink:to="label_CarryingReportedAmountFairValueDisclosureMember_1" xlink:title="label_CarryingReportedAmountFairValueDisclosureMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="CashAndCashEquivalentsAbstract" xlink:title="CashAndCashEquivalentsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAndCashEquivalentsAbstract" xml:lang="en-US" id="label_CashAndCashEquivalentsAbstract">Cash and Cash Equivalents [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="label_CashAndCashEquivalentsAbstract" xlink:title="label_CashAndCashEquivalentsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashAndCashEquivalentsAbstract_1" xml:lang="en-US" id="label_CashAndCashEquivalentsAbstract_1">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="label_CashAndCashEquivalentsAbstract_1" xlink:title="label_CashAndCashEquivalentsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_1">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_1" xlink:title="label_CashAndCashEquivalentsAtCarryingValue_1" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue_2" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_2">Cash and cash equivalents at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_2" xlink:title="label_CashAndCashEquivalentsAtCarryingValue_2" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue_3" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_3">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_3" xlink:title="label_CashAndCashEquivalentsAtCarryingValue_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="CashAndCashEquivalentsAxis" xlink:title="CashAndCashEquivalentsAxis" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAndCashEquivalentsAxis" xml:lang="en-US" id="label_CashAndCashEquivalentsAxis">Cash and Cash Equivalents [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAxis" xlink:to="label_CashAndCashEquivalentsAxis" xlink:title="label_CashAndCashEquivalentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US" id="label_CashAndCashEquivalentsFairValueDisclosure">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsFairValueDisclosure" xlink:to="label_CashAndCashEquivalentsFairValueDisclosure" xlink:title="label_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsFairValueDisclosure_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CashAndCashEquivalentsFairValueDisclosure_1" xml:lang="en-US" id="label_CashAndCashEquivalentsFairValueDisclosure_1">Cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsFairValueDisclosure" xlink:to="label_CashAndCashEquivalentsFairValueDisclosure_1" xlink:title="label_CashAndCashEquivalentsFairValueDisclosure_1" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsFairValueDisclosure_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashAndCashEquivalentsFairValueDisclosure_2" xml:lang="en-US" id="label_CashAndCashEquivalentsFairValueDisclosure_2">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsFairValueDisclosure" xlink:to="label_CashAndCashEquivalentsFairValueDisclosure_2" xlink:title="label_CashAndCashEquivalentsFairValueDisclosure_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:title="CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US" id="label_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="label_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:title="label_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1" xml:lang="en-US" id="label_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1">Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="label_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1" xlink:title="label_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:label="CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:title="CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US" id="label_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="label_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:title="label_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_1" xml:lang="en-US" id="label_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_1">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="label_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_1" xlink:title="label_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfStockDomain" xml:lang="en-US" id="label_ClassOfStockDomain">Class Of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="label_ClassOfStockDomain" xlink:title="label_ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfStockDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfStockDomain_1" xml:lang="en-US" id="label_ClassOfStockDomain_1">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="label_ClassOfStockDomain_1" xlink:title="label_ClassOfStockDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfStockLineItems" xml:lang="en-US" id="label_ClassOfStockLineItems">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="label_ClassOfStockLineItems" xlink:title="label_ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfStockLineItems_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ClassOfStockLineItems_1" xml:lang="en-US" id="label_ClassOfStockLineItems_1">Preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="label_ClassOfStockLineItems_1" xlink:title="label_ClassOfStockLineItems_1" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfStockLineItems_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfStockLineItems_2" xml:lang="en-US" id="label_ClassOfStockLineItems_2">Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="label_ClassOfStockLineItems_2" xlink:title="label_ClassOfStockLineItems_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightAxis" xml:lang="en-US" id="label_ClassOfWarrantOrRightAxis">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="label_ClassOfWarrantOrRightAxis" xlink:title="label_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightDomain" xml:lang="en-US" id="label_ClassOfWarrantOrRightDomain">Class Of Warrant Or Right [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="label_ClassOfWarrantOrRightDomain" xlink:title="label_ClassOfWarrantOrRightDomain" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfWarrantOrRightDomain_1" xml:lang="en-US" id="label_ClassOfWarrantOrRightDomain_1">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="label_ClassOfWarrantOrRightDomain_1" xlink:title="label_ClassOfWarrantOrRightDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US" id="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xml:lang="en-US" id="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1">Exercise price of warrant (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xlink:title="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US" id="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1" xml:lang="en-US" id="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1">Common stock that may be purchased upon exercise of warrant (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1" xlink:title="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2" xml:lang="en-US" id="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2">Stock that may be purchased upon exercise of warrant (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2" xlink:title="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommitmentsAndContingencies" xml:lang="en-US" id="label_CommitmentsAndContingencies">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="label_CommitmentsAndContingencies" xlink:title="label_CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingencies_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CommitmentsAndContingencies_1" xml:lang="en-US" id="label_CommitmentsAndContingencies_1">Commitments and contingencies (See Note 9)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="label_CommitmentsAndContingencies_1" xlink:title="label_CommitmentsAndContingencies_1" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingencies_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommitmentsAndContingencies_2" xml:lang="en-US" id="label_CommitmentsAndContingencies_2">Commitments and contingencies (See note 7)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="label_CommitmentsAndContingencies_2" xlink:title="label_CommitmentsAndContingencies_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US" id="label_CommitmentsAndContingenciesDisclosureAbstract">COMMITMENTS AND CONTINGENCIES.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="label_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="label_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US" id="label_CommitmentsAndContingenciesDisclosureTextBlock">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="label_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="label_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingenciesDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CommitmentsAndContingenciesDisclosureTextBlock_1" xml:lang="en-US" id="label_CommitmentsAndContingenciesDisclosureTextBlock_1">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="label_CommitmentsAndContingenciesDisclosureTextBlock_1" xlink:title="label_CommitmentsAndContingenciesDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US" id="label_CommonStockCapitalSharesReservedForFutureIssuance">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="label_CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="label_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockCapitalSharesReservedForFutureIssuance_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockCapitalSharesReservedForFutureIssuance_1" xml:lang="en-US" id="label_CommonStockCapitalSharesReservedForFutureIssuance_1">Common stock reserved for future issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="label_CommonStockCapitalSharesReservedForFutureIssuance_1" xlink:title="label_CommonStockCapitalSharesReservedForFutureIssuance_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockMember" xml:lang="en-US" id="label_CommonStockMember">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="label_CommonStockMember" xlink:title="label_CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockMember_1" xml:lang="en-US" id="label_CommonStockMember_1">Common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="label_CommonStockMember_1" xlink:title="label_CommonStockMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="label_CommonStockParOrStatedValuePerShare">Common Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="label_CommonStockParOrStatedValuePerShare" xlink:title="label_CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockParOrStatedValuePerShare_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US" id="label_CommonStockParOrStatedValuePerShare_1">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="label_CommonStockParOrStatedValuePerShare_1" xlink:title="label_CommonStockParOrStatedValuePerShare_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockParOrStatedValuePerShare_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockParOrStatedValuePerShare_2" xml:lang="en-US" id="label_CommonStockParOrStatedValuePerShare_2">Par value of common stock (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="label_CommonStockParOrStatedValuePerShare_2" xlink:title="label_CommonStockParOrStatedValuePerShare_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesAuthorized" xml:lang="en-US" id="label_CommonStockSharesAuthorized">Common Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="label_CommonStockSharesAuthorized" xlink:title="label_CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesAuthorized_1" xml:lang="en-US" id="label_CommonStockSharesAuthorized_1">Common stock, authorized shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="label_CommonStockSharesAuthorized_1" xlink:title="label_CommonStockSharesAuthorized_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesAuthorized_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CommonStockSharesAuthorized_2" xml:lang="en-US" id="label_CommonStockSharesAuthorized_2">Authorized common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="label_CommonStockSharesAuthorized_2" xlink:title="label_CommonStockSharesAuthorized_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesIssued" xml:lang="en-US" id="label_CommonStockSharesIssued">Common Stock, Shares, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="label_CommonStockSharesIssued" xlink:title="label_CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesIssued_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesIssued_1" xml:lang="en-US" id="label_CommonStockSharesIssued_1">Common stock, issued shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="label_CommonStockSharesIssued_1" xlink:title="label_CommonStockSharesIssued_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesIssued_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CommonStockSharesIssued_2" xml:lang="en-US" id="label_CommonStockSharesIssued_2">Common stock issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="label_CommonStockSharesIssued_2" xlink:title="label_CommonStockSharesIssued_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesOutstanding" xml:lang="en-US" id="label_CommonStockSharesOutstanding">Common Stock, Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="label_CommonStockSharesOutstanding" xlink:title="label_CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesOutstanding_1" xml:lang="en-US" id="label_CommonStockSharesOutstanding_1">Common stock, outstanding shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="label_CommonStockSharesOutstanding_1" xlink:title="label_CommonStockSharesOutstanding_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CommonStockSharesOutstanding_2" xml:lang="en-US" id="label_CommonStockSharesOutstanding_2">Common stock outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="label_CommonStockSharesOutstanding_2" xlink:title="label_CommonStockSharesOutstanding_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockValue" xml:lang="en-US" id="label_CommonStockValue">Common Stock, Value, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="label_CommonStockValue" xlink:title="label_CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockValue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockValue_1" xml:lang="en-US" id="label_CommonStockValue_1">Common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="label_CommonStockValue_1" xlink:title="label_CommonStockValue_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockValue_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CommonStockValue_2" xml:lang="en-US" id="label_CommonStockValue_2">Common stock, $0.001 par value; authorized shares - 72,000,000 at December 31, 2013, December 31, 2014 and at December 31, 2014 pro forma (unaudited); issued and outstanding shares - 962,960 at December 31, 2013, 1,006,219 at December 31, 2014; and 7,559,035 at December 31, 2014 pro forma (unaudited)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="label_CommonStockValue_2" xlink:title="label_CommonStockValue_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="ComponentsOfDeferredTaxAssetsAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US" id="label_ComponentsOfDeferredTaxAssetsAbstract">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="label_ComponentsOfDeferredTaxAssetsAbstract" xlink:title="label_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ComponentsOfDeferredTaxAssetsAbstract_1" xml:lang="en-US" id="label_ComponentsOfDeferredTaxAssetsAbstract_1">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="label_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:title="label_ComponentsOfDeferredTaxAssetsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US" id="label_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="label_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:title="label_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" xml:lang="en-US" id="label_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1">Significant components of deferred tax assets and liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="label_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" xlink:title="label_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:title="ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ComponentsOfDeferredTaxLiabilitiesAbstract" xml:lang="en-US" id="label_ComponentsOfDeferredTaxLiabilitiesAbstract">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="label_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:title="label_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ComponentsOfDeferredTaxLiabilitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ComponentsOfDeferredTaxLiabilitiesAbstract_1" xml:lang="en-US" id="label_ComponentsOfDeferredTaxLiabilitiesAbstract_1">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="label_ComponentsOfDeferredTaxLiabilitiesAbstract_1" xlink:title="label_ComponentsOfDeferredTaxLiabilitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:label xlink:type="resource" xlink:label="label_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConcentrationRiskCreditRisk" xml:lang="en-US" id="label_ConcentrationRiskCreditRisk">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="label_ConcentrationRiskCreditRisk" xlink:title="label_ConcentrationRiskCreditRisk" />
    <link:label xlink:type="resource" xlink:label="label_ConcentrationRiskCreditRisk_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConcentrationRiskCreditRisk_1" xml:lang="en-US" id="label_ConcentrationRiskCreditRisk_1">Concentration of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="label_ConcentrationRiskCreditRisk_1" xlink:title="label_ConcentrationRiskCreditRisk_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="ConversionOfStockAmountConverted1" xlink:title="ConversionOfStockAmountConverted1" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfStockAmountConverted1" xml:lang="en-US" id="label_ConversionOfStockAmountConverted1">Conversion of Stock, Amount Converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockAmountConverted1" xlink:to="label_ConversionOfStockAmountConverted1" xlink:title="label_ConversionOfStockAmountConverted1" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockAmountConverted1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConversionOfStockAmountConverted1_1" xml:lang="en-US" id="label_ConversionOfStockAmountConverted1_1">Preferred stock conversion to common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockAmountConverted1" xlink:to="label_ConversionOfStockAmountConverted1_1" xlink:title="label_ConversionOfStockAmountConverted1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="ConversionOfStockByUniqueDescriptionAxis" xlink:title="ConversionOfStockByUniqueDescriptionAxis" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfStockByUniqueDescriptionAxis" xml:lang="en-US" id="label_ConversionOfStockByUniqueDescriptionAxis">Stock Conversion Description [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockByUniqueDescriptionAxis" xlink:to="label_ConversionOfStockByUniqueDescriptionAxis" xlink:title="label_ConversionOfStockByUniqueDescriptionAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="ConversionOfStockLineItems" xlink:title="ConversionOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfStockLineItems" xml:lang="en-US" id="label_ConversionOfStockLineItems">Conversion of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockLineItems" xlink:to="label_ConversionOfStockLineItems" xlink:title="label_ConversionOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockLineItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConversionOfStockLineItems_1" xml:lang="en-US" id="label_ConversionOfStockLineItems_1">Conversion of stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockLineItems" xlink:to="label_ConversionOfStockLineItems_1" xlink:title="label_ConversionOfStockLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="ConversionOfStockNameDomain" xlink:title="ConversionOfStockNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfStockNameDomain" xml:lang="en-US" id="label_ConversionOfStockNameDomain">Conversion Of Stock Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockNameDomain" xlink:to="label_ConversionOfStockNameDomain" xlink:title="label_ConversionOfStockNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockNameDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConversionOfStockNameDomain_1" xml:lang="en-US" id="label_ConversionOfStockNameDomain_1">Conversion of Stock, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockNameDomain" xlink:to="label_ConversionOfStockNameDomain_1" xlink:title="label_ConversionOfStockNameDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="ConversionOfStockSharesIssued1" xlink:title="ConversionOfStockSharesIssued1" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfStockSharesIssued1" xml:lang="en-US" id="label_ConversionOfStockSharesIssued1">Conversion of Stock, Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockSharesIssued1" xlink:to="label_ConversionOfStockSharesIssued1" xlink:title="label_ConversionOfStockSharesIssued1" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockSharesIssued1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConversionOfStockSharesIssued1_1" xml:lang="en-US" id="label_ConversionOfStockSharesIssued1_1">Number of shares of common stock into which convertible preferred stock was converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockSharesIssued1" xlink:to="label_ConversionOfStockSharesIssued1_1" xlink:title="label_ConversionOfStockSharesIssued1_1" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockSharesIssued1_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ConversionOfStockSharesIssued1_2" xml:lang="en-US" id="label_ConversionOfStockSharesIssued1_2">Number of shares issued in exchange for previously outstanding stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockSharesIssued1" xlink:to="label_ConversionOfStockSharesIssued1_2" xlink:title="label_ConversionOfStockSharesIssued1_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="ConversionOfStockTable" xlink:title="ConversionOfStockTable" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfStockTable" xml:lang="en-US" id="label_ConversionOfStockTable">Conversion of Stock [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockTable" xlink:to="label_ConversionOfStockTable" xlink:title="label_ConversionOfStockTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="DebtConversionByUniqueDescriptionAxis" xlink:title="DebtConversionByUniqueDescriptionAxis" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtConversionByUniqueDescriptionAxis" xml:lang="en-US" id="label_DebtConversionByUniqueDescriptionAxis">Debt Conversion Description [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="label_DebtConversionByUniqueDescriptionAxis" xlink:title="label_DebtConversionByUniqueDescriptionAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US" id="label_DebtConversionConvertedInstrumentSharesIssued1">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionConvertedInstrumentSharesIssued1" xlink:to="label_DebtConversionConvertedInstrumentSharesIssued1" xlink:title="label_DebtConversionConvertedInstrumentSharesIssued1" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionConvertedInstrumentSharesIssued1_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_DebtConversionConvertedInstrumentSharesIssued1_1" xml:lang="en-US" id="label_DebtConversionConvertedInstrumentSharesIssued1_1">Number of shares of stock into which debt was converted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionConvertedInstrumentSharesIssued1" xlink:to="label_DebtConversionConvertedInstrumentSharesIssued1_1" xlink:title="label_DebtConversionConvertedInstrumentSharesIssued1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain" xlink:title="DebtConversionNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtConversionNameDomain" xml:lang="en-US" id="label_DebtConversionNameDomain">Debt Conversion Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionNameDomain" xlink:to="label_DebtConversionNameDomain" xlink:title="label_DebtConversionNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionNameDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtConversionNameDomain_1" xml:lang="en-US" id="label_DebtConversionNameDomain_1">Debt Conversion, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionNameDomain" xlink:to="label_DebtConversionNameDomain_1" xlink:title="label_DebtConversionNameDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="DebtConversionOriginalDebtAmount1" xlink:title="DebtConversionOriginalDebtAmount1" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtConversionOriginalDebtAmount1" xml:lang="en-US" id="label_DebtConversionOriginalDebtAmount1">Debt Conversion, Original Debt, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionOriginalDebtAmount1" xlink:to="label_DebtConversionOriginalDebtAmount1" xlink:title="label_DebtConversionOriginalDebtAmount1" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionOriginalDebtAmount1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtConversionOriginalDebtAmount1_1" xml:lang="en-US" id="label_DebtConversionOriginalDebtAmount1_1">Principal amount converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionOriginalDebtAmount1" xlink:to="label_DebtConversionOriginalDebtAmount1_1" xlink:title="label_DebtConversionOriginalDebtAmount1_1" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionOriginalDebtAmount1_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_DebtConversionOriginalDebtAmount1_2" xml:lang="en-US" id="label_DebtConversionOriginalDebtAmount1_2">Conversion of bridge note to preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionOriginalDebtAmount1" xlink:to="label_DebtConversionOriginalDebtAmount1_2" xlink:title="label_DebtConversionOriginalDebtAmount1_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtCurrent" xlink:label="DebtCurrent" xlink:title="DebtCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtCurrent" xml:lang="en-US" id="label_DebtCurrent">Debt, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtCurrent" xlink:to="label_DebtCurrent" xlink:title="label_DebtCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DebtCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtCurrent_1" xml:lang="en-US" id="label_DebtCurrent_1">2015</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtCurrent" xlink:to="label_DebtCurrent_1" xlink:title="label_DebtCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtDisclosureAbstract" xml:lang="en-US" id="label_DebtDisclosureAbstract">DEBT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureAbstract" xlink:to="label_DebtDisclosureAbstract" xlink:title="label_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtDisclosureTextBlock" xml:lang="en-US" id="label_DebtDisclosureTextBlock">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="label_DebtDisclosureTextBlock" xlink:title="label_DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DebtDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtDisclosureTextBlock_1" xml:lang="en-US" id="label_DebtDisclosureTextBlock_1">DEBT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="label_DebtDisclosureTextBlock_1" xlink:title="label_DebtDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentAxis" xml:lang="en-US" id="label_DebtInstrumentAxis">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAxis" xlink:to="label_DebtInstrumentAxis" xlink:title="label_DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentBasisSpreadOnVariableRate1" xml:lang="en-US" id="label_DebtInstrumentBasisSpreadOnVariableRate1">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="label_DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="label_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentBasisSpreadOnVariableRate1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentBasisSpreadOnVariableRate1_1" xml:lang="en-US" id="label_DebtInstrumentBasisSpreadOnVariableRate1_1">Variable interest rate margin (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="label_DebtInstrumentBasisSpreadOnVariableRate1_1" xlink:title="label_DebtInstrumentBasisSpreadOnVariableRate1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentCarryingAmount" xml:lang="en-US" id="label_DebtInstrumentCarryingAmount">Long-term Debt, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentCarryingAmount" xlink:to="label_DebtInstrumentCarryingAmount" xlink:title="label_DebtInstrumentCarryingAmount" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentCarryingAmount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentCarryingAmount_1" xml:lang="en-US" id="label_DebtInstrumentCarryingAmount_1">Outstanding amount of loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentCarryingAmount" xlink:to="label_DebtInstrumentCarryingAmount_1" xlink:title="label_DebtInstrumentCarryingAmount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="DebtInstrumentDescriptionOfVariableRateBasis" xlink:title="DebtInstrumentDescriptionOfVariableRateBasis" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentDescriptionOfVariableRateBasis" xml:lang="en-US" id="label_DebtInstrumentDescriptionOfVariableRateBasis">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="label_DebtInstrumentDescriptionOfVariableRateBasis" xlink:title="label_DebtInstrumentDescriptionOfVariableRateBasis" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentDescriptionOfVariableRateBasis_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentDescriptionOfVariableRateBasis_1" xml:lang="en-US" id="label_DebtInstrumentDescriptionOfVariableRateBasis_1">Variable rate basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="label_DebtInstrumentDescriptionOfVariableRateBasis_1" xlink:title="label_DebtInstrumentDescriptionOfVariableRateBasis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US" id="label_DebtInstrumentInterestRateStatedPercentage">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="label_DebtInstrumentInterestRateStatedPercentage" xlink:title="label_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentInterestRateStatedPercentage_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentInterestRateStatedPercentage_1" xml:lang="en-US" id="label_DebtInstrumentInterestRateStatedPercentage_1">Interest rate (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="label_DebtInstrumentInterestRateStatedPercentage_1" xlink:title="label_DebtInstrumentInterestRateStatedPercentage_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentLineItems" xml:lang="en-US" id="label_DebtInstrumentLineItems">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="label_DebtInstrumentLineItems" xlink:title="label_DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentLineItems_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_DebtInstrumentLineItems_1" xml:lang="en-US" id="label_DebtInstrumentLineItems_1">Loan and Security Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="label_DebtInstrumentLineItems_1" xlink:title="label_DebtInstrumentLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentNameDomain" xml:lang="en-US" id="label_DebtInstrumentNameDomain">Debt Instrument Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="label_DebtInstrumentNameDomain" xlink:title="label_DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentNameDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentNameDomain_1" xml:lang="en-US" id="label_DebtInstrumentNameDomain_1">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="label_DebtInstrumentNameDomain_1" xlink:title="label_DebtInstrumentNameDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentTable" xml:lang="en-US" id="label_DebtInstrumentTable">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTable" xlink:to="label_DebtInstrumentTable" xlink:title="label_DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentTerm" xml:lang="en-US" id="label_DebtInstrumentTerm">Debt Instrument, Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTerm" xlink:to="label_DebtInstrumentTerm" xlink:title="label_DebtInstrumentTerm" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentTerm_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentTerm_1" xml:lang="en-US" id="label_DebtInstrumentTerm_1">Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTerm" xlink:to="label_DebtInstrumentTerm_1" xlink:title="label_DebtInstrumentTerm_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:title="DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
    <link:label xlink:type="resource" xlink:label="label_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xml:lang="en-US" id="label_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="label_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:title="label_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
    <link:label xlink:type="resource" xlink:label="label_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_1" xml:lang="en-US" id="label_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_1">Accrual of back end fees related to note payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="label_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_1" xlink:title="label_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="DebtLongtermAndShorttermCombinedAmount" xlink:title="DebtLongtermAndShorttermCombinedAmount" />
    <link:label xlink:type="resource" xlink:label="label_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtLongtermAndShorttermCombinedAmount" xml:lang="en-US" id="label_DebtLongtermAndShorttermCombinedAmount">Debt, Long-term and Short-term, Combined Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtLongtermAndShorttermCombinedAmount" xlink:to="label_DebtLongtermAndShorttermCombinedAmount" xlink:title="label_DebtLongtermAndShorttermCombinedAmount" />
    <link:label xlink:type="resource" xlink:label="label_DebtLongtermAndShorttermCombinedAmount_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_DebtLongtermAndShorttermCombinedAmount_1" xml:lang="en-US" id="label_DebtLongtermAndShorttermCombinedAmount_1">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtLongtermAndShorttermCombinedAmount" xlink:to="label_DebtLongtermAndShorttermCombinedAmount_1" xlink:title="label_DebtLongtermAndShorttermCombinedAmount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:title="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xml:lang="en-US" id="label_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="label_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:title="label_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1" xml:lang="en-US" id="label_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1">Schedule of components of prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="label_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1" xlink:title="label_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="DeferredFinanceCostsGross" xlink:title="DeferredFinanceCostsGross" />
    <link:label xlink:type="resource" xlink:label="label_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredFinanceCostsGross" xml:lang="en-US" id="label_DeferredFinanceCostsGross">Deferred Finance Costs, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFinanceCostsGross" xlink:to="label_DeferredFinanceCostsGross" xlink:title="label_DeferredFinanceCostsGross" />
    <link:label xlink:type="resource" xlink:label="label_DeferredFinanceCostsGross_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredFinanceCostsGross_1" xml:lang="en-US" id="label_DeferredFinanceCostsGross_1">Deferred financing costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFinanceCostsGross" xlink:to="label_DeferredFinanceCostsGross_1" xlink:title="label_DeferredFinanceCostsGross_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="DeferredFinanceCostsNet" xlink:title="DeferredFinanceCostsNet" />
    <link:label xlink:type="resource" xlink:label="label_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredFinanceCostsNet" xml:lang="en-US" id="label_DeferredFinanceCostsNet">Deferred Finance Costs, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFinanceCostsNet" xlink:to="label_DeferredFinanceCostsNet" xlink:title="label_DeferredFinanceCostsNet" />
    <link:label xlink:type="resource" xlink:label="label_DeferredFinanceCostsNet_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredFinanceCostsNet_1" xml:lang="en-US" id="label_DeferredFinanceCostsNet_1">Deferred financing costs, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFinanceCostsNet" xlink:to="label_DeferredFinanceCostsNet_1" xlink:title="label_DeferredFinanceCostsNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="DeferredIncomeTaxLiabilities" xlink:title="DeferredIncomeTaxLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredIncomeTaxLiabilities" xml:lang="en-US" id="label_DeferredIncomeTaxLiabilities">Deferred Tax Liabilities, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxLiabilities" xlink:to="label_DeferredIncomeTaxLiabilities" xlink:title="label_DeferredIncomeTaxLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_DeferredIncomeTaxLiabilities_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_DeferredIncomeTaxLiabilities_1" xml:lang="en-US" id="label_DeferredIncomeTaxLiabilities_1">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxLiabilities" xlink:to="label_DeferredIncomeTaxLiabilities_1" xlink:title="label_DeferredIncomeTaxLiabilities_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="DeferredOfferingCosts" xlink:title="DeferredOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredOfferingCosts" xml:lang="en-US" id="label_DeferredOfferingCosts">Deferred Offering Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredOfferingCosts" xlink:to="label_DeferredOfferingCosts" xlink:title="label_DeferredOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_DeferredOfferingCosts_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredOfferingCosts_1" xml:lang="en-US" id="label_DeferredOfferingCosts_1">Deferred IPO costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredOfferingCosts" xlink:to="label_DeferredOfferingCosts_1" xlink:title="label_DeferredOfferingCosts_1" />
    <link:label xlink:type="resource" xlink:label="label_DeferredOfferingCosts_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_DeferredOfferingCosts_2" xml:lang="en-US" id="label_DeferredOfferingCosts_2">Initial public offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredOfferingCosts" xlink:to="label_DeferredOfferingCosts_2" xlink:title="label_DeferredOfferingCosts_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueAndCreditsAbstract" xlink:label="DeferredRevenueAndCreditsAbstract" xlink:title="DeferredRevenueAndCreditsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DeferredRevenueAndCreditsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredRevenueAndCreditsAbstract" xml:lang="en-US" id="label_DeferredRevenueAndCreditsAbstract">Deferred Revenue and Credits [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueAndCreditsAbstract" xlink:to="label_DeferredRevenueAndCreditsAbstract" xlink:title="label_DeferredRevenueAndCreditsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DeferredRevenueAndCreditsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredRevenueAndCreditsAbstract_1" xml:lang="en-US" id="label_DeferredRevenueAndCreditsAbstract_1">Lease inducements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueAndCreditsAbstract" xlink:to="label_DeferredRevenueAndCreditsAbstract_1" xlink:title="label_DeferredRevenueAndCreditsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredTaxAssetsGross" xml:lang="en-US" id="label_DeferredTaxAssetsGross">Deferred Tax Assets, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGross" xlink:to="label_DeferredTaxAssetsGross" xlink:title="label_DeferredTaxAssetsGross" />
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsGross_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_DeferredTaxAssetsGross_1" xml:lang="en-US" id="label_DeferredTaxAssetsGross_1">Deferred tax assets before valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGross" xlink:to="label_DeferredTaxAssetsGross_1" xlink:title="label_DeferredTaxAssetsGross_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US" id="label_DeferredTaxAssetsLiabilitiesNet">Deferred Tax Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="label_DeferredTaxAssetsLiabilitiesNet" xlink:title="label_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsLiabilitiesNet_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_DeferredTaxAssetsLiabilitiesNet_1" xml:lang="en-US" id="label_DeferredTaxAssetsLiabilitiesNet_1">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="label_DeferredTaxAssetsLiabilitiesNet_1" xlink:title="label_DeferredTaxAssetsLiabilitiesNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredTaxAssetsNet" xml:lang="en-US" id="label_DeferredTaxAssetsNet">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNet" xlink:to="label_DeferredTaxAssetsNet" xlink:title="label_DeferredTaxAssetsNet" />
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsNet_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_DeferredTaxAssetsNet_1" xml:lang="en-US" id="label_DeferredTaxAssetsNet_1">Deferred tax assets net of valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNet" xlink:to="label_DeferredTaxAssetsNet_1" xlink:title="label_DeferredTaxAssetsNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US" id="label_DeferredTaxAssetsOperatingLossCarryforwards">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="label_DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="label_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsOperatingLossCarryforwards_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredTaxAssetsOperatingLossCarryforwards_1" xml:lang="en-US" id="label_DeferredTaxAssetsOperatingLossCarryforwards_1">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="label_DeferredTaxAssetsOperatingLossCarryforwards_1" xlink:title="label_DeferredTaxAssetsOperatingLossCarryforwards_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="DeferredTaxAssetsPropertyPlantAndEquipment" xlink:title="DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredTaxAssetsPropertyPlantAndEquipment" xml:lang="en-US" id="label_DeferredTaxAssetsPropertyPlantAndEquipment">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="label_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:title="label_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsPropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredTaxAssetsPropertyPlantAndEquipment_1" xml:lang="en-US" id="label_DeferredTaxAssetsPropertyPlantAndEquipment_1">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="label_DeferredTaxAssetsPropertyPlantAndEquipment_1" xlink:title="label_DeferredTaxAssetsPropertyPlantAndEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US" id="label_DeferredTaxAssetsTaxCreditCarryforwardsResearch">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="label_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="label_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1" xml:lang="en-US" id="label_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1">Research Credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="label_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1" xlink:title="label_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredTaxAssetsValuationAllowance" xml:lang="en-US" id="label_DeferredTaxAssetsValuationAllowance">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowance" xlink:to="label_DeferredTaxAssetsValuationAllowance" xlink:title="label_DeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsValuationAllowance_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_DeferredTaxAssetsValuationAllowance_1" xml:lang="en-US" id="label_DeferredTaxAssetsValuationAllowance_1">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowance" xlink:to="label_DeferredTaxAssetsValuationAllowance_1" xlink:title="label_DeferredTaxAssetsValuationAllowance_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:title="DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US" id="label_DeferredTaxLiabilitiesPropertyPlantAndEquipment">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="label_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:title="label_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1" xml:lang="en-US" id="label_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="label_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1" xlink:title="label_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:title="DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xml:lang="en-US" id="label_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract">EMPLOYEE BENEFITS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="label_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:title="label_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="DefinedContributionPlanCostRecognized" xlink:title="DefinedContributionPlanCostRecognized" />
    <link:label xlink:type="resource" xlink:label="label_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DefinedContributionPlanCostRecognized" xml:lang="en-US" id="label_DefinedContributionPlanCostRecognized">Defined Contribution Plan, Cost Recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanCostRecognized" xlink:to="label_DefinedContributionPlanCostRecognized" xlink:title="label_DefinedContributionPlanCostRecognized" />
    <link:label xlink:type="resource" xlink:label="label_DefinedContributionPlanCostRecognized_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DefinedContributionPlanCostRecognized_1" xml:lang="en-US" id="label_DefinedContributionPlanCostRecognized_1">Total expense for contributions made to 401(k) plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanCostRecognized" xlink:to="label_DefinedContributionPlanCostRecognized_1" xlink:title="label_DefinedContributionPlanCostRecognized_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="DepositsAssetsCurrent" xlink:title="DepositsAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DepositsAssetsCurrent" xml:lang="en-US" id="label_DepositsAssetsCurrent">Deposits Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAssetsCurrent" xlink:to="label_DepositsAssetsCurrent" xlink:title="label_DepositsAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DepositsAssetsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DepositsAssetsCurrent_1" xml:lang="en-US" id="label_DepositsAssetsCurrent_1">Refundable PDUFA fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAssetsCurrent" xlink:to="label_DepositsAssetsCurrent_1" xlink:title="label_DepositsAssetsCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:label xlink:type="resource" xlink:label="label_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Depreciation" xml:lang="en-US" id="label_Depreciation">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="label_Depreciation" xlink:title="label_Depreciation" />
    <link:label xlink:type="resource" xlink:label="label_Depreciation_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_Depreciation_1" xml:lang="en-US" id="label_Depreciation_1">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="label_Depreciation_1" xlink:title="label_Depreciation_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:label xlink:type="resource" xlink:label="label_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DepreciationAndAmortization" xml:lang="en-US" id="label_DepreciationAndAmortization">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationAndAmortization" xlink:to="label_DepreciationAndAmortization" xlink:title="label_DepreciationAndAmortization" />
    <link:label xlink:type="resource" xlink:label="label_DepreciationAndAmortization_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DepreciationAndAmortization_1" xml:lang="en-US" id="label_DepreciationAndAmortization_1">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationAndAmortization" xlink:to="label_DepreciationAndAmortization_1" xlink:title="label_DepreciationAndAmortization_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US" id="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">STOCK BASED COMPENSATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US" id="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" xml:lang="en-US" id="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1">STOCK BASED COMPENSATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" xlink:title="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueFromEmployeesCurrent" xlink:label="DueFromEmployeesCurrent" xlink:title="DueFromEmployeesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DueFromEmployeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DueFromEmployeesCurrent" xml:lang="en-US" id="label_DueFromEmployeesCurrent">Due from Employees, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DueFromEmployeesCurrent" xlink:to="label_DueFromEmployeesCurrent" xlink:title="label_DueFromEmployeesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DueFromEmployeesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DueFromEmployeesCurrent_1" xml:lang="en-US" id="label_DueFromEmployeesCurrent_1">Employee advances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DueFromEmployeesCurrent" xlink:to="label_DueFromEmployeesCurrent_1" xlink:title="label_DueFromEmployeesCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareAbstract" xml:lang="en-US" id="label_EarningsPerShareAbstract">NET LOSS PER COMMON SHARE</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="label_EarningsPerShareAbstract" xlink:title="label_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareBasicAndDiluted" xml:lang="en-US" id="label_EarningsPerShareBasicAndDiluted">Earnings Per Share, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="label_EarningsPerShareBasicAndDiluted" xlink:title="label_EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasicAndDiluted_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarningsPerShareBasicAndDiluted_1" xml:lang="en-US" id="label_EarningsPerShareBasicAndDiluted_1">Net loss per share - basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="label_EarningsPerShareBasicAndDiluted_1" xlink:title="label_EarningsPerShareBasicAndDiluted_1" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasicAndDiluted_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_EarningsPerShareBasicAndDiluted_2" xml:lang="en-US" id="label_EarningsPerShareBasicAndDiluted_2">Basic and diluted net loss per common share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="label_EarningsPerShareBasicAndDiluted_2" xlink:title="label_EarningsPerShareBasicAndDiluted_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="EarningsPerShareBasicLineItems" xlink:title="EarningsPerShareBasicLineItems" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareBasicLineItems" xml:lang="en-US" id="label_EarningsPerShareBasicLineItems">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicLineItems" xlink:to="label_EarningsPerShareBasicLineItems" xlink:title="label_EarningsPerShareBasicLineItems" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasicLineItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarningsPerShareBasicLineItems_1" xml:lang="en-US" id="label_EarningsPerShareBasicLineItems_1">Net loss per common share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicLineItems" xlink:to="label_EarningsPerShareBasicLineItems_1" xlink:title="label_EarningsPerShareBasicLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerSharePolicyTextBlock" xml:lang="en-US" id="label_EarningsPerSharePolicyTextBlock">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="label_EarningsPerSharePolicyTextBlock" xlink:title="label_EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerSharePolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarningsPerSharePolicyTextBlock_1" xml:lang="en-US" id="label_EarningsPerSharePolicyTextBlock_1">Earnings (Loss) per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="label_EarningsPerSharePolicyTextBlock_1" xlink:title="label_EarningsPerSharePolicyTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerSharePolicyTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_EarningsPerSharePolicyTextBlock_2" xml:lang="en-US" id="label_EarningsPerSharePolicyTextBlock_2">Net loss per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="label_EarningsPerSharePolicyTextBlock_2" xlink:title="label_EarningsPerSharePolicyTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="EarningsPerShareTextBlock" xlink:title="EarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareTextBlock" xml:lang="en-US" id="label_EarningsPerShareTextBlock">Earnings Per Share [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareTextBlock" xlink:to="label_EarningsPerShareTextBlock" xlink:title="label_EarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_EarningsPerShareTextBlock_1" xml:lang="en-US" id="label_EarningsPerShareTextBlock_1">NET LOSS PER COMMON SHARE</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareTextBlock" xlink:to="label_EarningsPerShareTextBlock_1" xlink:title="label_EarningsPerShareTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US" id="label_EffectiveIncomeTaxRateContinuingOperations">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="label_EffectiveIncomeTaxRateContinuingOperations" xlink:title="label_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_EffectiveIncomeTaxRateContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_EffectiveIncomeTaxRateContinuingOperations_1" xml:lang="en-US" id="label_EffectiveIncomeTaxRateContinuingOperations_1">Income tax expense (benefit) (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="label_EffectiveIncomeTaxRateContinuingOperations_1" xlink:title="label_EffectiveIncomeTaxRateContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US" id="label_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="label_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="label_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1" xml:lang="en-US" id="label_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1">Reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="label_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1" xlink:title="label_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="label_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US" id="label_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="label_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="label_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="label_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xml:lang="en-US" id="label_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1">Federal income tax (benefit) at statutory rate (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="label_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xlink:title="label_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="label_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US" id="label_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="label_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="label_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="label_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1" xml:lang="en-US" id="label_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1">Change in valuation allowance (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="label_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1" xlink:title="label_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:label xlink:type="resource" xlink:label="label_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xml:lang="en-US" id="label_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="label_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:title="label_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:label xlink:type="resource" xlink:label="label_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_1" xml:lang="en-US" id="label_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_1">Permanent items (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="label_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_1" xlink:title="label_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:label xlink:type="resource" xlink:label="label_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xml:lang="en-US" id="label_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="label_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:title="label_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:label xlink:type="resource" xlink:label="label_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_1" xml:lang="en-US" id="label_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_1">Research and experimental credits (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="label_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_1" xlink:title="label_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US" id="label_EmployeeRelatedLiabilitiesCurrent">Employee-related Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeRelatedLiabilitiesCurrent" xlink:to="label_EmployeeRelatedLiabilitiesCurrent" xlink:title="label_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeRelatedLiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeRelatedLiabilitiesCurrent_1" xml:lang="en-US" id="label_EmployeeRelatedLiabilitiesCurrent_1">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeRelatedLiabilitiesCurrent" xlink:to="label_EmployeeRelatedLiabilitiesCurrent_1" xlink:title="label_EmployeeRelatedLiabilitiesCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1">Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1" xlink:title="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_1" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_1">Unrecognized compensation cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_1" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1">Period over which unrecognized compensation cost is expected to be recognized as expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1">Unrecognized stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1">Unrecognized compensation cost related to outstanding options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeStockOptionMember" xml:lang="en-US" id="label_EmployeeStockOptionMember">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="label_EmployeeStockOptionMember" xlink:title="label_EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeStockOptionMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeStockOptionMember_1" xml:lang="en-US" id="label_EmployeeStockOptionMember_1">Employee stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="label_EmployeeStockOptionMember_1" xlink:title="label_EmployeeStockOptionMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquityAbstract" xml:lang="en-US" id="label_EquityAbstract">EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityAbstract" xlink:to="label_EquityAbstract" xlink:title="label_EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="label_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquityComponentDomain" xml:lang="en-US" id="label_EquityComponentDomain">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="label_EquityComponentDomain" xlink:title="label_EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="label_EquityComponentDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EquityComponentDomain_1" xml:lang="en-US" id="label_EquityComponentDomain_1">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="label_EquityComponentDomain_1" xlink:title="label_EquityComponentDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="EstimateOfFairValueFairValueDisclosureMember" xlink:title="EstimateOfFairValueFairValueDisclosureMember" />
    <link:label xlink:type="resource" xlink:label="label_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EstimateOfFairValueFairValueDisclosureMember" xml:lang="en-US" id="label_EstimateOfFairValueFairValueDisclosureMember">Estimate Of Fair Value Fair Value Disclosure [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimateOfFairValueFairValueDisclosureMember" xlink:to="label_EstimateOfFairValueFairValueDisclosureMember" xlink:title="label_EstimateOfFairValueFairValueDisclosureMember" />
    <link:label xlink:type="resource" xlink:label="label_EstimateOfFairValueFairValueDisclosureMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EstimateOfFairValueFairValueDisclosureMember_1" xml:lang="en-US" id="label_EstimateOfFairValueFairValueDisclosureMember_1">Measured at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimateOfFairValueFairValueDisclosureMember" xlink:to="label_EstimateOfFairValueFairValueDisclosureMember_1" xlink:title="label_EstimateOfFairValueFairValueDisclosureMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xml:lang="en-US" id="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1" xml:lang="en-US" id="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1">Fair value measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US" id="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:title="FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssetsLevel1ToLevel2TransfersAmount" xml:lang="en-US" id="label_FairValueAssetsLevel1ToLevel2TransfersAmount">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="label_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:title="label_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsLevel1ToLevel2TransfersAmount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssetsLevel1ToLevel2TransfersAmount_1" xml:lang="en-US" id="label_FairValueAssetsLevel1ToLevel2TransfersAmount_1">Asset transfers out of Level 1 into Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="label_FairValueAssetsLevel1ToLevel2TransfersAmount_1" xlink:title="label_FairValueAssetsLevel1ToLevel2TransfersAmount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:title="FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssetsLevel2ToLevel1TransfersAmount" xml:lang="en-US" id="label_FairValueAssetsLevel2ToLevel1TransfersAmount">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="label_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:title="label_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsLevel2ToLevel1TransfersAmount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssetsLevel2ToLevel1TransfersAmount_1" xml:lang="en-US" id="label_FairValueAssetsLevel2ToLevel1TransfersAmount_1">Asset transfers out of Level 2 into Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="label_FairValueAssetsLevel2ToLevel1TransfersAmount_1" xlink:title="label_FairValueAssetsLevel2ToLevel1TransfersAmount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:title="FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US" id="label_FairValueAssetsMeasuredOnRecurringBasisTextBlock">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="label_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:title="label_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsMeasuredOnRecurringBasisTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssetsMeasuredOnRecurringBasisTextBlock_1" xml:lang="en-US" id="label_FairValueAssetsMeasuredOnRecurringBasisTextBlock_1">Schedule of financial instruments measured at fair value by level within fair value hierarchy</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="label_FairValueAssetsMeasuredOnRecurringBasisTextBlock_1" xlink:title="label_FairValueAssetsMeasuredOnRecurringBasisTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:title="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xml:lang="en-US" id="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract">Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:title="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_1" xml:lang="en-US" id="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_1">Fair value assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_1" xlink:title="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="FairValueAssumptionsExpectedTerm" xlink:title="FairValueAssumptionsExpectedTerm" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssumptionsExpectedTerm" xml:lang="en-US" id="label_FairValueAssumptionsExpectedTerm">Fair Value Assumptions, Expected Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedTerm" xlink:to="label_FairValueAssumptionsExpectedTerm" xlink:title="label_FairValueAssumptionsExpectedTerm" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsExpectedTerm_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssumptionsExpectedTerm_1" xml:lang="en-US" id="label_FairValueAssumptionsExpectedTerm_1">Expected life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedTerm" xlink:to="label_FairValueAssumptionsExpectedTerm_1" xlink:title="label_FairValueAssumptionsExpectedTerm_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="FairValueAssumptionsExpectedVolatilityRate" xlink:title="FairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US" id="label_FairValueAssumptionsExpectedVolatilityRate">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedVolatilityRate" xlink:to="label_FairValueAssumptionsExpectedVolatilityRate" xlink:title="label_FairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsExpectedVolatilityRate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssumptionsExpectedVolatilityRate_1" xml:lang="en-US" id="label_FairValueAssumptionsExpectedVolatilityRate_1">Volatility (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedVolatilityRate" xlink:to="label_FairValueAssumptionsExpectedVolatilityRate_1" xlink:title="label_FairValueAssumptionsExpectedVolatilityRate_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:title="FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xml:lang="en-US" id="label_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="label_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:title="label_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_1" xml:lang="en-US" id="label_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_1">Fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="label_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_1" xlink:title="label_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="FairValueByBalanceSheetGroupingTable" xlink:title="FairValueByBalanceSheetGroupingTable" />
    <link:label xlink:type="resource" xlink:label="label_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueByBalanceSheetGroupingTable" xml:lang="en-US" id="label_FairValueByBalanceSheetGroupingTable">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByBalanceSheetGroupingTable" xlink:to="label_FairValueByBalanceSheetGroupingTable" xlink:title="label_FairValueByBalanceSheetGroupingTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:label xlink:type="resource" xlink:label="label_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US" id="label_FairValueByFairValueHierarchyLevelAxis">Fair Value, Hierarchy [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="label_FairValueByFairValueHierarchyLevelAxis" xlink:title="label_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="FairValueByMeasurementBasisAxis" xlink:title="FairValueByMeasurementBasisAxis" />
    <link:label xlink:type="resource" xlink:label="label_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueByMeasurementBasisAxis" xml:lang="en-US" id="label_FairValueByMeasurementBasisAxis">Measurement Basis [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByMeasurementBasisAxis" xlink:to="label_FairValueByMeasurementBasisAxis" xlink:title="label_FairValueByMeasurementBasisAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:label xlink:type="resource" xlink:label="label_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueByMeasurementFrequencyAxis" xml:lang="en-US" id="label_FairValueByMeasurementFrequencyAxis">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="label_FairValueByMeasurementFrequencyAxis" xlink:title="label_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="FairValueDisclosureItemAmountsDomain" xlink:title="FairValueDisclosureItemAmountsDomain" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueDisclosureItemAmountsDomain" xml:lang="en-US" id="label_FairValueDisclosureItemAmountsDomain">Fair Value Disclosure Item Amounts [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosureItemAmountsDomain" xlink:to="label_FairValueDisclosureItemAmountsDomain" xlink:title="label_FairValueDisclosureItemAmountsDomain" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosureItemAmountsDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueDisclosureItemAmountsDomain_1" xml:lang="en-US" id="label_FairValueDisclosureItemAmountsDomain_1">Fair Value Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosureItemAmountsDomain" xlink:to="label_FairValueDisclosureItemAmountsDomain_1" xlink:title="label_FairValueDisclosureItemAmountsDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:label="FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:title="FairValueDisclosureOffbalanceSheetRisksAmountAsset" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xml:lang="en-US" id="label_FairValueDisclosureOffbalanceSheetRisksAmountAsset">Fair Value Disclosure, Off-balance Sheet Risks, Amount, Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:to="label_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:title="label_FairValueDisclosureOffbalanceSheetRisksAmountAsset" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosureOffbalanceSheetRisksAmountAsset_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueDisclosureOffbalanceSheetRisksAmountAsset_1" xml:lang="en-US" id="label_FairValueDisclosureOffbalanceSheetRisksAmountAsset_1">Financial instruments with off balance sheet risk of loss, assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:to="label_FairValueDisclosureOffbalanceSheetRisksAmountAsset_1" xlink:title="label_FairValueDisclosureOffbalanceSheetRisksAmountAsset_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountLiability" xlink:label="FairValueDisclosureOffbalanceSheetRisksAmountLiability" xlink:title="FairValueDisclosureOffbalanceSheetRisksAmountLiability" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosureOffbalanceSheetRisksAmountLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueDisclosureOffbalanceSheetRisksAmountLiability" xml:lang="en-US" id="label_FairValueDisclosureOffbalanceSheetRisksAmountLiability">Fair Value Disclosure, Off-balance Sheet Risks, Amount, Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosureOffbalanceSheetRisksAmountLiability" xlink:to="label_FairValueDisclosureOffbalanceSheetRisksAmountLiability" xlink:title="label_FairValueDisclosureOffbalanceSheetRisksAmountLiability" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosureOffbalanceSheetRisksAmountLiability_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueDisclosureOffbalanceSheetRisksAmountLiability_1" xml:lang="en-US" id="label_FairValueDisclosureOffbalanceSheetRisksAmountLiability_1">Financial instruments with off balance sheet risk of loss, liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosureOffbalanceSheetRisksAmountLiability" xlink:to="label_FairValueDisclosureOffbalanceSheetRisksAmountLiability_1" xlink:title="label_FairValueDisclosureOffbalanceSheetRisksAmountLiability_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueDisclosuresAbstract" xml:lang="en-US" id="label_FairValueDisclosuresAbstract">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresAbstract" xlink:to="label_FairValueDisclosuresAbstract" xlink:title="label_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueDisclosuresTextBlock" xml:lang="en-US" id="label_FairValueDisclosuresTextBlock">Fair Value Disclosures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="label_FairValueDisclosuresTextBlock" xlink:title="label_FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosuresTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_FairValueDisclosuresTextBlock_1" xml:lang="en-US" id="label_FairValueDisclosuresTextBlock_1">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="label_FairValueDisclosuresTextBlock_1" xlink:title="label_FairValueDisclosuresTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueInputsLevel1Member" xml:lang="en-US" id="label_FairValueInputsLevel1Member">Fair Value Inputs Level1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="label_FairValueInputsLevel1Member" xlink:title="label_FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel1Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueInputsLevel1Member_1" xml:lang="en-US" id="label_FairValueInputsLevel1Member_1">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="label_FairValueInputsLevel1Member_1" xlink:title="label_FairValueInputsLevel1Member_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1">Roll forward of the recurring fair value measurements of the tranche liability categorized with Level 3 inputs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1">Schedule of roll-forward of recurring fair value measurements of tranche liability categorized with Level 3 inputs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementFrequencyDomain" xml:lang="en-US" id="label_FairValueMeasurementFrequencyDomain">Fair Value Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="label_FairValueMeasurementFrequencyDomain" xlink:title="label_FairValueMeasurementFrequencyDomain" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementFrequencyDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueMeasurementFrequencyDomain_1" xml:lang="en-US" id="label_FairValueMeasurementFrequencyDomain_1">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="label_FairValueMeasurementFrequencyDomain_1" xlink:title="label_FairValueMeasurementFrequencyDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US" id="label_FairValueMeasurementsFairValueHierarchyDomain">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="label_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="label_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueMeasurementsFairValueHierarchyDomain_1" xml:lang="en-US" id="label_FairValueMeasurementsFairValueHierarchyDomain_1">Fair Value Hierarchy [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="label_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="label_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementsRecurringMember" xml:lang="en-US" id="label_FairValueMeasurementsRecurringMember">Fair Value Measurements Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="label_FairValueMeasurementsRecurringMember" xlink:title="label_FairValueMeasurementsRecurringMember" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsRecurringMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueMeasurementsRecurringMember_1" xml:lang="en-US" id="label_FairValueMeasurementsRecurringMember_1">Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="label_FairValueMeasurementsRecurringMember_1" xlink:title="label_FairValueMeasurementsRecurringMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_1" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_1">Asset transfers into (out of) Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_1" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1">Change in fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_1" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_1">Tranche liability upon issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_1" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_1" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_1">Tranche liability upon close of tranche</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_1" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US" id="label_FairValueOfFinancialInstrumentsPolicy">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="label_FairValueOfFinancialInstrumentsPolicy" xlink:title="label_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOfFinancialInstrumentsPolicy_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueOfFinancialInstrumentsPolicy_1" xml:lang="en-US" id="label_FairValueOfFinancialInstrumentsPolicy_1">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="label_FairValueOfFinancialInstrumentsPolicy_1" xlink:title="label_FairValueOfFinancialInstrumentsPolicy_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="label_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FurnitureAndFixturesMember" xml:lang="en-US" id="label_FurnitureAndFixturesMember">Furniture And Fixtures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FurnitureAndFixturesMember" xlink:to="label_FurnitureAndFixturesMember" xlink:title="label_FurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="label_FurnitureAndFixturesMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FurnitureAndFixturesMember_1" xml:lang="en-US" id="label_FurnitureAndFixturesMember_1">Furniture and fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FurnitureAndFixturesMember" xlink:to="label_FurnitureAndFixturesMember_1" xlink:title="label_FurnitureAndFixturesMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:label xlink:type="resource" xlink:label="label_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US" id="label_GainsLossesOnExtinguishmentOfDebt">Gains (Losses) on Extinguishment of Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExtinguishmentOfDebt" xlink:to="label_GainsLossesOnExtinguishmentOfDebt" xlink:title="label_GainsLossesOnExtinguishmentOfDebt" />
    <link:label xlink:type="resource" xlink:label="label_GainsLossesOnExtinguishmentOfDebt_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_GainsLossesOnExtinguishmentOfDebt_1" xml:lang="en-US" id="label_GainsLossesOnExtinguishmentOfDebt_1">Gain on extinguishment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExtinguishmentOfDebt" xlink:to="label_GainsLossesOnExtinguishmentOfDebt_1" xlink:title="label_GainsLossesOnExtinguishmentOfDebt_1" />
    <link:label xlink:type="resource" xlink:label="label_GainsLossesOnExtinguishmentOfDebt_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GainsLossesOnExtinguishmentOfDebt_2" xml:lang="en-US" id="label_GainsLossesOnExtinguishmentOfDebt_2">Gain on extinguishment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExtinguishmentOfDebt" xlink:to="label_GainsLossesOnExtinguishmentOfDebt_2" xlink:title="label_GainsLossesOnExtinguishmentOfDebt_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GeneralAndAdministrativeExpense" xml:lang="en-US" id="label_GeneralAndAdministrativeExpense">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="label_GeneralAndAdministrativeExpense" xlink:title="label_GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GeneralAndAdministrativeExpense_1" xml:lang="en-US" id="label_GeneralAndAdministrativeExpense_1">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="label_GeneralAndAdministrativeExpense_1" xlink:title="label_GeneralAndAdministrativeExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GeneralAndAdministrativeExpenseMember" xml:lang="en-US" id="label_GeneralAndAdministrativeExpenseMember">General And Administrative Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="label_GeneralAndAdministrativeExpenseMember" xlink:title="label_GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpenseMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GeneralAndAdministrativeExpenseMember_1" xml:lang="en-US" id="label_GeneralAndAdministrativeExpenseMember_1">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="label_GeneralAndAdministrativeExpenseMember_1" xlink:title="label_GeneralAndAdministrativeExpenseMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GuaranteesAbstract" xlink:label="GuaranteesAbstract" xlink:title="GuaranteesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_GuaranteesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GuaranteesAbstract" xml:lang="en-US" id="label_GuaranteesAbstract">Guarantees [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GuaranteesAbstract" xlink:to="label_GuaranteesAbstract" xlink:title="label_GuaranteesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_GuaranteesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GuaranteesAbstract_1" xml:lang="en-US" id="label_GuaranteesAbstract_1">Guarantees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GuaranteesAbstract" xlink:to="label_GuaranteesAbstract_1" xlink:title="label_GuaranteesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncentiveFromLessor" xlink:label="IncentiveFromLessor" xlink:title="IncentiveFromLessor" />
    <link:label xlink:type="resource" xlink:label="label_IncentiveFromLessor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncentiveFromLessor" xml:lang="en-US" id="label_IncentiveFromLessor">Incentive from Lessor</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncentiveFromLessor" xlink:to="label_IncentiveFromLessor" xlink:title="label_IncentiveFromLessor" />
    <link:label xlink:type="resource" xlink:label="label_IncentiveFromLessor_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncentiveFromLessor_1" xml:lang="en-US" id="label_IncentiveFromLessor_1">Lease incentive obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncentiveFromLessor" xlink:to="label_IncentiveFromLessor_1" xlink:title="label_IncentiveFromLessor_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeStatementAbstract" xml:lang="en-US" id="label_IncomeStatementAbstract">CONDENSED STATEMENTS OF OPERATIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="label_IncomeStatementAbstract" xlink:title="label_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="label_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeStatementLocationAxis" xml:lang="en-US" id="label_IncomeStatementLocationAxis">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="label_IncomeStatementLocationAxis" xlink:title="label_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="label_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeStatementLocationDomain" xml:lang="en-US" id="label_IncomeStatementLocationDomain">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="label_IncomeStatementLocationDomain" xlink:title="label_IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="label_IncomeStatementLocationDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncomeStatementLocationDomain_1" xml:lang="en-US" id="label_IncomeStatementLocationDomain_1">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="label_IncomeStatementLocationDomain_1" xlink:title="label_IncomeStatementLocationDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxAuthorityAxis" xml:lang="en-US" id="label_IncomeTaxAuthorityAxis">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityAxis" xlink:to="label_IncomeTaxAuthorityAxis" xlink:title="label_IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxAuthorityDomain" xml:lang="en-US" id="label_IncomeTaxAuthorityDomain">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityDomain" xlink:to="label_IncomeTaxAuthorityDomain" xlink:title="label_IncomeTaxAuthorityDomain" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxAuthorityDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncomeTaxAuthorityDomain_1" xml:lang="en-US" id="label_IncomeTaxAuthorityDomain_1">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityDomain" xlink:to="label_IncomeTaxAuthorityDomain_1" xlink:title="label_IncomeTaxAuthorityDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="IncomeTaxAuthorityNameAxis" xlink:title="IncomeTaxAuthorityNameAxis" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxAuthorityNameAxis" xml:lang="en-US" id="label_IncomeTaxAuthorityNameAxis">Income Tax Authority, Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityNameAxis" xlink:to="label_IncomeTaxAuthorityNameAxis" xlink:title="label_IncomeTaxAuthorityNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="IncomeTaxAuthorityNameDomain" xlink:title="IncomeTaxAuthorityNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxAuthorityNameDomain" xml:lang="en-US" id="label_IncomeTaxAuthorityNameDomain">Income Tax Authority Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityNameDomain" xlink:to="label_IncomeTaxAuthorityNameDomain" xlink:title="label_IncomeTaxAuthorityNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxAuthorityNameDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncomeTaxAuthorityNameDomain_1" xml:lang="en-US" id="label_IncomeTaxAuthorityNameDomain_1">Income Tax Authority, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityNameDomain" xlink:to="label_IncomeTaxAuthorityNameDomain_1" xlink:title="label_IncomeTaxAuthorityNameDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxDisclosureAbstract" xml:lang="en-US" id="label_IncomeTaxDisclosureAbstract">INCOME TAXES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="label_IncomeTaxDisclosureAbstract" xlink:title="label_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxDisclosureTextBlock" xml:lang="en-US" id="label_IncomeTaxDisclosureTextBlock">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="label_IncomeTaxDisclosureTextBlock" xlink:title="label_IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_IncomeTaxDisclosureTextBlock_1" xml:lang="en-US" id="label_IncomeTaxDisclosureTextBlock_1">INCOME TAXES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="label_IncomeTaxDisclosureTextBlock_1" xlink:title="label_IncomeTaxDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="IncomeTaxesPaid" xlink:title="IncomeTaxesPaid" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxesPaid" xml:lang="en-US" id="label_IncomeTaxesPaid">Income Taxes Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxesPaid" xlink:to="label_IncomeTaxesPaid" xlink:title="label_IncomeTaxesPaid" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxesPaid_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncomeTaxesPaid_1" xml:lang="en-US" id="label_IncomeTaxesPaid_1">Cash paid for taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxesPaid" xlink:to="label_IncomeTaxesPaid_1" xlink:title="label_IncomeTaxesPaid_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxPolicyTextBlock" xml:lang="en-US" id="label_IncomeTaxPolicyTextBlock">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="label_IncomeTaxPolicyTextBlock" xlink:title="label_IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncomeTaxPolicyTextBlock_1" xml:lang="en-US" id="label_IncomeTaxPolicyTextBlock_1">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="label_IncomeTaxPolicyTextBlock_1" xlink:title="label_IncomeTaxPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInAccountsPayable" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsPayable">Increase (Decrease) in Accounts Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="label_IncreaseDecreaseInAccountsPayable" xlink:title="label_IncreaseDecreaseInAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsPayable_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInAccountsPayable_1" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsPayable_1">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="label_IncreaseDecreaseInAccountsPayable_1" xlink:title="label_IncreaseDecreaseInAccountsPayable_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US" id="label_IncreaseDecreaseInAccruedLiabilities">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilities" xlink:to="label_IncreaseDecreaseInAccruedLiabilities" xlink:title="label_IncreaseDecreaseInAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccruedLiabilities_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInAccruedLiabilities_1" xml:lang="en-US" id="label_IncreaseDecreaseInAccruedLiabilities_1">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilities" xlink:to="label_IncreaseDecreaseInAccruedLiabilities_1" xlink:title="label_IncreaseDecreaseInAccruedLiabilities_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:label="IncreaseDecreaseInDepositsOutstanding" xlink:title="IncreaseDecreaseInDepositsOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInDepositsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInDepositsOutstanding" xml:lang="en-US" id="label_IncreaseDecreaseInDepositsOutstanding">Increase (Decrease) in Deposits Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDepositsOutstanding" xlink:to="label_IncreaseDecreaseInDepositsOutstanding" xlink:title="label_IncreaseDecreaseInDepositsOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInDepositsOutstanding_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncreaseDecreaseInDepositsOutstanding_1" xml:lang="en-US" id="label_IncreaseDecreaseInDepositsOutstanding_1">Refundable PDUFA fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDepositsOutstanding" xlink:to="label_IncreaseDecreaseInDepositsOutstanding_1" xlink:title="label_IncreaseDecreaseInDepositsOutstanding_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="label_IncreaseDecreaseInOperatingCapitalAbstract">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="label_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOperatingCapitalAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInOperatingCapitalAbstract_1" xml:lang="en-US" id="label_IncreaseDecreaseInOperatingCapitalAbstract_1">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_IncreaseDecreaseInOperatingCapitalAbstract_1" xlink:title="label_IncreaseDecreaseInOperatingCapitalAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xml:lang="en-US" id="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US" id="label_IncreaseDecreaseInStockholdersEquityRollForward">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="label_IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="label_IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInStockholdersEquityRollForward_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInStockholdersEquityRollForward_1" xml:lang="en-US" id="label_IncreaseDecreaseInStockholdersEquityRollForward_1">Increase (decrease) in stockholders' equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="label_IncreaseDecreaseInStockholdersEquityRollForward_1" xlink:title="label_IncreaseDecreaseInStockholdersEquityRollForward_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="IncreaseDecreaseInTemporaryEquityRollForward" xlink:title="IncreaseDecreaseInTemporaryEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInTemporaryEquityRollForward" xml:lang="en-US" id="label_IncreaseDecreaseInTemporaryEquityRollForward">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="label_IncreaseDecreaseInTemporaryEquityRollForward" xlink:title="label_IncreaseDecreaseInTemporaryEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInTemporaryEquityRollForward_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInTemporaryEquityRollForward_1" xml:lang="en-US" id="label_IncreaseDecreaseInTemporaryEquityRollForward_1">Increase (decrease) in convertible redeemable preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="label_IncreaseDecreaseInTemporaryEquityRollForward_1" xlink:title="label_IncreaseDecreaseInTemporaryEquityRollForward_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseInRestrictedCash" xlink:label="IncreaseInRestrictedCash" xlink:title="IncreaseInRestrictedCash" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseInRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseInRestrictedCash" xml:lang="en-US" id="label_IncreaseInRestrictedCash">Increase in Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseInRestrictedCash" xlink:to="label_IncreaseInRestrictedCash" xlink:title="label_IncreaseInRestrictedCash" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseInRestrictedCash_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncreaseInRestrictedCash_1" xml:lang="en-US" id="label_IncreaseInRestrictedCash_1">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseInRestrictedCash" xlink:to="label_IncreaseInRestrictedCash_1" xlink:title="label_IncreaseInRestrictedCash_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="InterestExpenseDebt" xlink:title="InterestExpenseDebt" />
    <link:label xlink:type="resource" xlink:label="label_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestExpenseDebt" xml:lang="en-US" id="label_InterestExpenseDebt">Interest Expense, Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseDebt" xlink:to="label_InterestExpenseDebt" xlink:title="label_InterestExpenseDebt" />
    <link:label xlink:type="resource" xlink:label="label_InterestExpenseDebt_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InterestExpenseDebt_1" xml:lang="en-US" id="label_InterestExpenseDebt_1">Interest expense on notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseDebt" xlink:to="label_InterestExpenseDebt_1" xlink:title="label_InterestExpenseDebt_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="InterestIncomeExpenseNonoperatingNet" xlink:title="InterestIncomeExpenseNonoperatingNet" />
    <link:label xlink:type="resource" xlink:label="label_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestIncomeExpenseNonoperatingNet" xml:lang="en-US" id="label_InterestIncomeExpenseNonoperatingNet">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncomeExpenseNonoperatingNet" xlink:to="label_InterestIncomeExpenseNonoperatingNet" xlink:title="label_InterestIncomeExpenseNonoperatingNet" />
    <link:label xlink:type="resource" xlink:label="label_InterestIncomeExpenseNonoperatingNet_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_InterestIncomeExpenseNonoperatingNet_1" xml:lang="en-US" id="label_InterestIncomeExpenseNonoperatingNet_1">Interest expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncomeExpenseNonoperatingNet" xlink:to="label_InterestIncomeExpenseNonoperatingNet_1" xlink:title="label_InterestIncomeExpenseNonoperatingNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="InterestPaid" xlink:title="InterestPaid" />
    <link:label xlink:type="resource" xlink:label="label_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestPaid" xml:lang="en-US" id="label_InterestPaid">Interest Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaid" xlink:to="label_InterestPaid" xlink:title="label_InterestPaid" />
    <link:label xlink:type="resource" xlink:label="label_InterestPaid_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InterestPaid_1" xml:lang="en-US" id="label_InterestPaid_1">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaid" xlink:to="label_InterestPaid_1" xlink:title="label_InterestPaid_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestPayableCurrent" xml:lang="en-US" id="label_InterestPayableCurrent">Interest Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPayableCurrent" xlink:to="label_InterestPayableCurrent" xlink:title="label_InterestPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_InterestPayableCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InterestPayableCurrent_1" xml:lang="en-US" id="label_InterestPayableCurrent_1">Accrued interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPayableCurrent" xlink:to="label_InterestPayableCurrent_1" xlink:title="label_InterestPayableCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="InternalRevenueServiceIRSMember" xlink:title="InternalRevenueServiceIRSMember" />
    <link:label xlink:type="resource" xlink:label="label_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InternalRevenueServiceIRSMember" xml:lang="en-US" id="label_InternalRevenueServiceIRSMember">Internal Revenue Service I R S [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InternalRevenueServiceIRSMember" xlink:to="label_InternalRevenueServiceIRSMember" xlink:title="label_InternalRevenueServiceIRSMember" />
    <link:label xlink:type="resource" xlink:label="label_InternalRevenueServiceIRSMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InternalRevenueServiceIRSMember_1" xml:lang="en-US" id="label_InternalRevenueServiceIRSMember_1">U.S. federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InternalRevenueServiceIRSMember" xlink:to="label_InternalRevenueServiceIRSMember_1" xlink:title="label_InternalRevenueServiceIRSMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="InvestmentTypeAxis" xlink:title="InvestmentTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InvestmentTypeAxis" xml:lang="en-US" id="label_InvestmentTypeAxis">Investment Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentTypeAxis" xlink:to="label_InvestmentTypeAxis" xlink:title="label_InvestmentTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember" xlink:title="InvestmentTypeCategorizationMember" />
    <link:label xlink:type="resource" xlink:label="label_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InvestmentTypeCategorizationMember" xml:lang="en-US" id="label_InvestmentTypeCategorizationMember">Investment Type Categorization [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentTypeCategorizationMember" xlink:to="label_InvestmentTypeCategorizationMember" xlink:title="label_InvestmentTypeCategorizationMember" />
    <link:label xlink:type="resource" xlink:label="label_InvestmentTypeCategorizationMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InvestmentTypeCategorizationMember_1" xml:lang="en-US" id="label_InvestmentTypeCategorizationMember_1">Investments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentTypeCategorizationMember" xlink:to="label_InvestmentTypeCategorizationMember_1" xlink:title="label_InvestmentTypeCategorizationMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestorMember" xlink:label="InvestorMember" xlink:title="InvestorMember" />
    <link:label xlink:type="resource" xlink:label="label_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InvestorMember" xml:lang="en-US" id="label_InvestorMember">Investor [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorMember" xlink:to="label_InvestorMember" xlink:title="label_InvestorMember" />
    <link:label xlink:type="resource" xlink:label="label_InvestorMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InvestorMember_1" xml:lang="en-US" id="label_InvestorMember_1">Investors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorMember" xlink:to="label_InvestorMember_1" xlink:title="label_InvestorMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IPOMember" xlink:label="IPOMember" xlink:title="IPOMember" />
    <link:label xlink:type="resource" xlink:label="label_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IPOMember" xml:lang="en-US" id="label_IPOMember">I P O [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IPOMember" xlink:to="label_IPOMember" xlink:title="label_IPOMember" />
    <link:label xlink:type="resource" xlink:label="label_IPOMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IPOMember_1" xml:lang="en-US" id="label_IPOMember_1">Initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IPOMember" xlink:to="label_IPOMember_1" xlink:title="label_IPOMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="LeaseArrangementTypeAxis" xlink:title="LeaseArrangementTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_LeaseArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LeaseArrangementTypeAxis" xml:lang="en-US" id="label_LeaseArrangementTypeAxis">Lease Arrangement, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseArrangementTypeAxis" xlink:to="label_LeaseArrangementTypeAxis" xlink:title="label_LeaseArrangementTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="LeaseArrangementTypeDomain" xlink:title="LeaseArrangementTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_LeaseArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LeaseArrangementTypeDomain" xml:lang="en-US" id="label_LeaseArrangementTypeDomain">Lease Arrangement Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseArrangementTypeDomain" xlink:to="label_LeaseArrangementTypeDomain" xlink:title="label_LeaseArrangementTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_LeaseArrangementTypeDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LeaseArrangementTypeDomain_1" xml:lang="en-US" id="label_LeaseArrangementTypeDomain_1">Lease Arrangement, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseArrangementTypeDomain" xlink:to="label_LeaseArrangementTypeDomain_1" xlink:title="label_LeaseArrangementTypeDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="label_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LeaseholdImprovementsMember" xml:lang="en-US" id="label_LeaseholdImprovementsMember">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseholdImprovementsMember" xlink:to="label_LeaseholdImprovementsMember" xlink:title="label_LeaseholdImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="label_LeaseholdImprovementsMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LeaseholdImprovementsMember_1" xml:lang="en-US" id="label_LeaseholdImprovementsMember_1">Leasehold improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseholdImprovementsMember" xlink:to="label_LeaseholdImprovementsMember_1" xlink:title="label_LeaseholdImprovementsMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="LeasePolicyTextBlock" xlink:title="LeasePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_LeasePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LeasePolicyTextBlock" xml:lang="en-US" id="label_LeasePolicyTextBlock">Lease, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasePolicyTextBlock" xlink:to="label_LeasePolicyTextBlock" xlink:title="label_LeasePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_LeasePolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LeasePolicyTextBlock_1" xml:lang="en-US" id="label_LeasePolicyTextBlock_1">Deferred Rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasePolicyTextBlock" xlink:to="label_LeasePolicyTextBlock_1" xlink:title="label_LeasePolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="LeasesOperatingAbstract" xlink:title="LeasesOperatingAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LeasesOperatingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LeasesOperatingAbstract" xml:lang="en-US" id="label_LeasesOperatingAbstract">Leases, Operating [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasesOperatingAbstract" xlink:to="label_LeasesOperatingAbstract" xlink:title="label_LeasesOperatingAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LeasesOperatingAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LeasesOperatingAbstract_1" xml:lang="en-US" id="label_LeasesOperatingAbstract_1">Lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasesOperatingAbstract" xlink:to="label_LeasesOperatingAbstract_1" xlink:title="label_LeasesOperatingAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:title="LesseeLeasingArrangementsOperatingLeasesRenewalTerm" />
    <link:label xlink:type="resource" xlink:label="label_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xml:lang="en-US" id="label_LesseeLeasingArrangementsOperatingLeasesRenewalTerm">Lessee Leasing Arrangements, Operating Leases, Renewal Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:to="label_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:title="label_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" />
    <link:label xlink:type="resource" xlink:label="label_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_1" xml:lang="en-US" id="label_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_1">Term of lease extension option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:to="label_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_1" xlink:title="label_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:title="LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <link:label xlink:type="resource" xlink:label="label_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xml:lang="en-US" id="label_LesseeLeasingArrangementsOperatingLeasesTermOfContract">Lessee Leasing Arrangements, Operating Leases, Term of Contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:to="label_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:title="label_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <link:label xlink:type="resource" xlink:label="label_LesseeLeasingArrangementsOperatingLeasesTermOfContract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LesseeLeasingArrangementsOperatingLeasesTermOfContract_1" xml:lang="en-US" id="label_LesseeLeasingArrangementsOperatingLeasesTermOfContract_1">Lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:to="label_LesseeLeasingArrangementsOperatingLeasesTermOfContract_1" xlink:title="label_LesseeLeasingArrangementsOperatingLeasesTermOfContract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="label_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Liabilities" xml:lang="en-US" id="label_Liabilities">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="label_Liabilities" xlink:title="label_Liabilities" />
    <link:label xlink:type="resource" xlink:label="label_Liabilities_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_Liabilities_1" xml:lang="en-US" id="label_Liabilities_1">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="label_Liabilities_1" xlink:title="label_Liabilities_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquity">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="label_LiabilitiesAndStockholdersEquity" xlink:title="label_LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquity_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquity_1">Total liabilities, convertible redeemable preferred stock and shareholders' equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="label_LiabilitiesAndStockholdersEquity_1" xlink:title="label_LiabilitiesAndStockholdersEquity_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquityAbstract">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_LiabilitiesAndStockholdersEquityAbstract" xlink:title="label_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquityAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiabilitiesAndStockholdersEquityAbstract_1" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquityAbstract_1">Liabilities, convertible redeemable preferred stock and shareholders' equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_LiabilitiesAndStockholdersEquityAbstract_1" xlink:title="label_LiabilitiesAndStockholdersEquityAbstract_1" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquityAbstract_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_LiabilitiesAndStockholdersEquityAbstract_2" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquityAbstract_2">LIABILITIES, CONVERTIBLE REDEEMABLE PREFERRED STOCK AND SHAREHOLDERS' DEFICIT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_LiabilitiesAndStockholdersEquityAbstract_2" xlink:title="label_LiabilitiesAndStockholdersEquityAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesCurrent" xml:lang="en-US" id="label_LiabilitiesCurrent">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="label_LiabilitiesCurrent" xlink:title="label_LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LiabilitiesCurrent_1" xml:lang="en-US" id="label_LiabilitiesCurrent_1">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="label_LiabilitiesCurrent_1" xlink:title="label_LiabilitiesCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesCurrentAbstract" xml:lang="en-US" id="label_LiabilitiesCurrentAbstract">Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="label_LiabilitiesCurrentAbstract" xlink:title="label_LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiabilitiesCurrentAbstract_1" xml:lang="en-US" id="label_LiabilitiesCurrentAbstract_1">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="label_LiabilitiesCurrentAbstract_1" xlink:title="label_LiabilitiesCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xlink:type="resource" xlink:label="label_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US" id="label_LineOfCreditFacilityMaximumBorrowingCapacity">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="label_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="label_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xlink:type="resource" xlink:label="label_LineOfCreditFacilityMaximumBorrowingCapacity_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LineOfCreditFacilityMaximumBorrowingCapacity_1" xml:lang="en-US" id="label_LineOfCreditFacilityMaximumBorrowingCapacity_1">Maximum borrowing capacity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="label_LineOfCreditFacilityMaximumBorrowingCapacity_1" xlink:title="label_LineOfCreditFacilityMaximumBorrowingCapacity_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="LitigationCaseAxis" xlink:title="LitigationCaseAxis" />
    <link:label xlink:type="resource" xlink:label="label_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LitigationCaseAxis" xml:lang="en-US" id="label_LitigationCaseAxis">Litigation Case [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LitigationCaseAxis" xlink:to="label_LitigationCaseAxis" xlink:title="label_LitigationCaseAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="LitigationCaseTypeDomain" xlink:title="LitigationCaseTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LitigationCaseTypeDomain" xml:lang="en-US" id="label_LitigationCaseTypeDomain">Litigation Case Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LitigationCaseTypeDomain" xlink:to="label_LitigationCaseTypeDomain" xlink:title="label_LitigationCaseTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_LitigationCaseTypeDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LitigationCaseTypeDomain_1" xml:lang="en-US" id="label_LitigationCaseTypeDomain_1">Litigation Case [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LitigationCaseTypeDomain" xlink:to="label_LitigationCaseTypeDomain_1" xlink:title="label_LitigationCaseTypeDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="LoansPayableCurrent" xlink:title="LoansPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LoansPayableCurrent" xml:lang="en-US" id="label_LoansPayableCurrent">Loans Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoansPayableCurrent" xlink:to="label_LoansPayableCurrent" xlink:title="label_LoansPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LoansPayableCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LoansPayableCurrent_1" xml:lang="en-US" id="label_LoansPayableCurrent_1">Current portion of term loan payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoansPayableCurrent" xlink:to="label_LoansPayableCurrent_1" xlink:title="label_LoansPayableCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebt" xml:lang="en-US" id="label_LongTermDebt">Long-term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebt" xlink:to="label_LongTermDebt" xlink:title="label_LongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebt_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LongTermDebt_1" xml:lang="en-US" id="label_LongTermDebt_1">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebt" xlink:to="label_LongTermDebt_1" xlink:title="label_LongTermDebt_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="LongTermDebtByMaturityAbstract" xlink:title="LongTermDebtByMaturityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtByMaturityAbstract" xml:lang="en-US" id="label_LongTermDebtByMaturityAbstract">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtByMaturityAbstract" xlink:to="label_LongTermDebtByMaturityAbstract" xlink:title="label_LongTermDebtByMaturityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtByMaturityAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtByMaturityAbstract_1" xml:lang="en-US" id="label_LongTermDebtByMaturityAbstract_1">Future payments under debt agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtByMaturityAbstract" xlink:to="label_LongTermDebtByMaturityAbstract_1" xlink:title="label_LongTermDebtByMaturityAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1">2018</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1">2017</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1">2016</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="LongTermDebtPercentageBearingVariableInterestRate" xlink:title="LongTermDebtPercentageBearingVariableInterestRate" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtPercentageBearingVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtPercentageBearingVariableInterestRate" xml:lang="en-US" id="label_LongTermDebtPercentageBearingVariableInterestRate">Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtPercentageBearingVariableInterestRate" xlink:to="label_LongTermDebtPercentageBearingVariableInterestRate" xlink:title="label_LongTermDebtPercentageBearingVariableInterestRate" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtPercentageBearingVariableInterestRate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtPercentageBearingVariableInterestRate_1" xml:lang="en-US" id="label_LongTermDebtPercentageBearingVariableInterestRate_1">Interest rate (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtPercentageBearingVariableInterestRate" xlink:to="label_LongTermDebtPercentageBearingVariableInterestRate_1" xlink:title="label_LongTermDebtPercentageBearingVariableInterestRate_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongtermDebtTypeAxis" xml:lang="en-US" id="label_LongtermDebtTypeAxis">Long-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtTypeAxis" xlink:to="label_LongtermDebtTypeAxis" xlink:title="label_LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongtermDebtTypeDomain" xml:lang="en-US" id="label_LongtermDebtTypeDomain">Longterm Debt Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtTypeDomain" xlink:to="label_LongtermDebtTypeDomain" xlink:title="label_LongtermDebtTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_LongtermDebtTypeDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongtermDebtTypeDomain_1" xml:lang="en-US" id="label_LongtermDebtTypeDomain_1">Long-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtTypeDomain" xlink:to="label_LongtermDebtTypeDomain_1" xlink:title="label_LongtermDebtTypeDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="LongTermLoansPayable" xlink:title="LongTermLoansPayable" />
    <link:label xlink:type="resource" xlink:label="label_LongTermLoansPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermLoansPayable" xml:lang="en-US" id="label_LongTermLoansPayable">Loans Payable, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermLoansPayable" xlink:to="label_LongTermLoansPayable" xlink:title="label_LongTermLoansPayable" />
    <link:label xlink:type="resource" xlink:label="label_LongTermLoansPayable_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermLoansPayable_1" xml:lang="en-US" id="label_LongTermLoansPayable_1">Term loan payable, long-term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermLoansPayable" xlink:to="label_LongTermLoansPayable_1" xlink:title="label_LongTermLoansPayable_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="LossContingenciesByNatureOfContingencyAxis" xlink:title="LossContingenciesByNatureOfContingencyAxis" />
    <link:label xlink:type="resource" xlink:label="label_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LossContingenciesByNatureOfContingencyAxis" xml:lang="en-US" id="label_LossContingenciesByNatureOfContingencyAxis">Loss Contingency Nature [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingenciesByNatureOfContingencyAxis" xlink:to="label_LossContingenciesByNatureOfContingencyAxis" xlink:title="label_LossContingenciesByNatureOfContingencyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:label xlink:type="resource" xlink:label="label_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LossContingenciesLineItems" xml:lang="en-US" id="label_LossContingenciesLineItems">Loss Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingenciesLineItems" xlink:to="label_LossContingenciesLineItems" xlink:title="label_LossContingenciesLineItems" />
    <link:label xlink:type="resource" xlink:label="label_LossContingenciesLineItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LossContingenciesLineItems_1" xml:lang="en-US" id="label_LossContingenciesLineItems_1">Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingenciesLineItems" xlink:to="label_LossContingenciesLineItems_1" xlink:title="label_LossContingenciesLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:label xlink:type="resource" xlink:label="label_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LossContingenciesTable" xml:lang="en-US" id="label_LossContingenciesTable">Loss Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingenciesTable" xlink:to="label_LossContingenciesTable" xlink:title="label_LossContingenciesTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="LossContingencyInformationAboutLitigationMattersAbstract" xlink:title="LossContingencyInformationAboutLitigationMattersAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LossContingencyInformationAboutLitigationMattersAbstract" xml:lang="en-US" id="label_LossContingencyInformationAboutLitigationMattersAbstract">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyInformationAboutLitigationMattersAbstract" xlink:to="label_LossContingencyInformationAboutLitigationMattersAbstract" xlink:title="label_LossContingencyInformationAboutLitigationMattersAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LossContingencyInformationAboutLitigationMattersAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LossContingencyInformationAboutLitigationMattersAbstract_1" xml:lang="en-US" id="label_LossContingencyInformationAboutLitigationMattersAbstract_1">Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyInformationAboutLitigationMattersAbstract" xlink:to="label_LossContingencyInformationAboutLitigationMattersAbstract_1" xlink:title="label_LossContingencyInformationAboutLitigationMattersAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="LossContingencyNatureDomain" xlink:title="LossContingencyNatureDomain" />
    <link:label xlink:type="resource" xlink:label="label_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LossContingencyNatureDomain" xml:lang="en-US" id="label_LossContingencyNatureDomain">Loss Contingency Nature [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyNatureDomain" xlink:to="label_LossContingencyNatureDomain" xlink:title="label_LossContingencyNatureDomain" />
    <link:label xlink:type="resource" xlink:label="label_LossContingencyNatureDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LossContingencyNatureDomain_1" xml:lang="en-US" id="label_LossContingencyNatureDomain_1">Loss Contingency, Nature [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyNatureDomain" xlink:to="label_LossContingencyNatureDomain_1" xlink:title="label_LossContingencyNatureDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:label="LossContingencyPatentsAllegedlyInfringedNumber" xlink:title="LossContingencyPatentsAllegedlyInfringedNumber" />
    <link:label xlink:type="resource" xlink:label="label_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LossContingencyPatentsAllegedlyInfringedNumber" xml:lang="en-US" id="label_LossContingencyPatentsAllegedlyInfringedNumber">Loss Contingency, Patents Allegedly Infringed, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyPatentsAllegedlyInfringedNumber" xlink:to="label_LossContingencyPatentsAllegedlyInfringedNumber" xlink:title="label_LossContingencyPatentsAllegedlyInfringedNumber" />
    <link:label xlink:type="resource" xlink:label="label_LossContingencyPatentsAllegedlyInfringedNumber_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LossContingencyPatentsAllegedlyInfringedNumber_1" xml:lang="en-US" id="label_LossContingencyPatentsAllegedlyInfringedNumber_1">Number of patents asserted to have been infringed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyPatentsAllegedlyInfringedNumber" xlink:to="label_LossContingencyPatentsAllegedlyInfringedNumber_1" xlink:title="label_LossContingencyPatentsAllegedlyInfringedNumber_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="MachineryAndEquipmentMember" xlink:title="MachineryAndEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MachineryAndEquipmentMember" xml:lang="en-US" id="label_MachineryAndEquipmentMember">Machinery And Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MachineryAndEquipmentMember" xlink:to="label_MachineryAndEquipmentMember" xlink:title="label_MachineryAndEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_MachineryAndEquipmentMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MachineryAndEquipmentMember_1" xml:lang="en-US" id="label_MachineryAndEquipmentMember_1">Machinery and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MachineryAndEquipmentMember" xlink:to="label_MachineryAndEquipmentMember_1" xlink:title="label_MachineryAndEquipmentMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaturitiesOfSeniorDebt" xlink:label="MaturitiesOfSeniorDebt" xlink:title="MaturitiesOfSeniorDebt" />
    <link:label xlink:type="resource" xlink:label="label_MaturitiesOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MaturitiesOfSeniorDebt" xml:lang="en-US" id="label_MaturitiesOfSeniorDebt">Maturities of Senior Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaturitiesOfSeniorDebt" xlink:to="label_MaturitiesOfSeniorDebt" xlink:title="label_MaturitiesOfSeniorDebt" />
    <link:label xlink:type="resource" xlink:label="label_MaturitiesOfSeniorDebt_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_MaturitiesOfSeniorDebt_1" xml:lang="en-US" id="label_MaturitiesOfSeniorDebt_1">(Repayment of) borrowing from term note</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaturitiesOfSeniorDebt" xlink:to="label_MaturitiesOfSeniorDebt_1" xlink:title="label_MaturitiesOfSeniorDebt_1" />
    <link:label xlink:type="resource" xlink:label="label_MaturitiesOfSeniorDebt_2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:title="label_MaturitiesOfSeniorDebt_2" xml:lang="en-US" id="label_MaturitiesOfSeniorDebt_2">Repayment of term note borrowings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaturitiesOfSeniorDebt" xlink:to="label_MaturitiesOfSeniorDebt_2" xlink:title="label_MaturitiesOfSeniorDebt_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="label_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MaximumMember" xml:lang="en-US" id="label_MaximumMember">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="label_MaximumMember" xlink:title="label_MaximumMember" />
    <link:label xlink:type="resource" xlink:label="label_MaximumMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MaximumMember_1" xml:lang="en-US" id="label_MaximumMember_1">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="label_MaximumMember_1" xlink:title="label_MaximumMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="label_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MinimumMember" xml:lang="en-US" id="label_MinimumMember">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="label_MinimumMember" xlink:title="label_MinimumMember" />
    <link:label xlink:type="resource" xlink:label="label_MinimumMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MinimumMember_1" xml:lang="en-US" id="label_MinimumMember_1">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="label_MinimumMember_1" xlink:title="label_MinimumMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="MoneyMarketFundsMember" xlink:title="MoneyMarketFundsMember" />
    <link:label xlink:type="resource" xlink:label="label_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MoneyMarketFundsMember" xml:lang="en-US" id="label_MoneyMarketFundsMember">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MoneyMarketFundsMember" xlink:to="label_MoneyMarketFundsMember" xlink:title="label_MoneyMarketFundsMember" />
    <link:label xlink:type="resource" xlink:label="label_MoneyMarketFundsMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MoneyMarketFundsMember_1" xml:lang="en-US" id="label_MoneyMarketFundsMember_1">Money market funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MoneyMarketFundsMember" xlink:to="label_MoneyMarketFundsMember_1" xlink:title="label_MoneyMarketFundsMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="NetCashProvidedByUsedInContinuingOperations" xlink:title="NetCashProvidedByUsedInContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInContinuingOperations">Net Cash Provided by (Used in) Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="label_NetCashProvidedByUsedInContinuingOperations" xlink:title="label_NetCashProvidedByUsedInContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInContinuingOperations_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInContinuingOperations_1">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="label_NetCashProvidedByUsedInContinuingOperations_1" xlink:title="label_NetCashProvidedByUsedInContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1">Financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1">Investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2">CASH FLOWS INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1">Operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetIncomeLoss" xml:lang="en-US" id="label_NetIncomeLoss">Net Income (Loss) Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="label_NetIncomeLoss" xlink:title="label_NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLoss_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetIncomeLoss_1" xml:lang="en-US" id="label_NetIncomeLoss_1">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="label_NetIncomeLoss_1" xlink:title="label_NetIncomeLoss_1" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLoss_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetIncomeLoss_2" xml:lang="en-US" id="label_NetIncomeLoss_2">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="label_NetIncomeLoss_2" xlink:title="label_NetIncomeLoss_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasic">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasic_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasic_1" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasic_1">Loss attributable to common stockholders - basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasic_1" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasic_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US" id="label_NewAccountingPronouncementsPolicyPolicyTextBlock">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="label_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="label_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_NewAccountingPronouncementsPolicyPolicyTextBlock_1">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="label_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xlink:title="label_NewAccountingPronouncementsPolicyPolicyTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_NewAccountingPronouncementsPolicyPolicyTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_NewAccountingPronouncementsPolicyPolicyTextBlock_2" xml:lang="en-US" id="label_NewAccountingPronouncementsPolicyPolicyTextBlock_2">Recently Issued Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="label_NewAccountingPronouncementsPolicyPolicyTextBlock_2" xlink:title="label_NewAccountingPronouncementsPolicyPolicyTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="NoncashInvestingAndFinancingItemsAbstract" xlink:title="NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US" id="label_NoncashInvestingAndFinancingItemsAbstract">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="label_NoncashInvestingAndFinancingItemsAbstract" xlink:title="label_NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NoncashInvestingAndFinancingItemsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NoncashInvestingAndFinancingItemsAbstract_1" xml:lang="en-US" id="label_NoncashInvestingAndFinancingItemsAbstract_1">Supplemental disclosure of noncash activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="label_NoncashInvestingAndFinancingItemsAbstract_1" xlink:title="label_NoncashInvestingAndFinancingItemsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:title="NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NonvestedRestrictedStockSharesActivityTableTextBlock" xml:lang="en-US" id="label_NonvestedRestrictedStockSharesActivityTableTextBlock">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="label_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:title="label_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_NonvestedRestrictedStockSharesActivityTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NonvestedRestrictedStockSharesActivityTableTextBlock_1" xml:lang="en-US" id="label_NonvestedRestrictedStockSharesActivityTableTextBlock_1">Summary of restricted stock awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="label_NonvestedRestrictedStockSharesActivityTableTextBlock_1" xlink:title="label_NonvestedRestrictedStockSharesActivityTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="NotesPayableRelatedPartiesClassifiedCurrent" xlink:title="NotesPayableRelatedPartiesClassifiedCurrent" />
    <link:label xlink:type="resource" xlink:label="label_NotesPayableRelatedPartiesClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NotesPayableRelatedPartiesClassifiedCurrent" xml:lang="en-US" id="label_NotesPayableRelatedPartiesClassifiedCurrent">Notes Payable, Related Parties, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="label_NotesPayableRelatedPartiesClassifiedCurrent" xlink:title="label_NotesPayableRelatedPartiesClassifiedCurrent" />
    <link:label xlink:type="resource" xlink:label="label_NotesPayableRelatedPartiesClassifiedCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NotesPayableRelatedPartiesClassifiedCurrent_1" xml:lang="en-US" id="label_NotesPayableRelatedPartiesClassifiedCurrent_1">Convertible bridge notes with related parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="label_NotesPayableRelatedPartiesClassifiedCurrent_1" xlink:title="label_NotesPayableRelatedPartiesClassifiedCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableToBanksMember" xlink:label="NotesPayableToBanksMember" xlink:title="NotesPayableToBanksMember" />
    <link:label xlink:type="resource" xlink:label="label_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NotesPayableToBanksMember" xml:lang="en-US" id="label_NotesPayableToBanksMember">Notes Payable To Banks [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesPayableToBanksMember" xlink:to="label_NotesPayableToBanksMember" xlink:title="label_NotesPayableToBanksMember" />
    <link:label xlink:type="resource" xlink:label="label_NotesPayableToBanksMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NotesPayableToBanksMember_1" xml:lang="en-US" id="label_NotesPayableToBanksMember_1">Term loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesPayableToBanksMember" xlink:to="label_NotesPayableToBanksMember_1" xlink:title="label_NotesPayableToBanksMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesReduction" xlink:label="NotesReduction" xlink:title="NotesReduction" />
    <link:label xlink:type="resource" xlink:label="label_NotesReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NotesReduction" xml:lang="en-US" id="label_NotesReduction">Notes Reduction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesReduction" xlink:to="label_NotesReduction" xlink:title="label_NotesReduction" />
    <link:label xlink:type="resource" xlink:label="label_NotesReduction_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NotesReduction_1" xml:lang="en-US" id="label_NotesReduction_1">Repayment of term note with proceeds of notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesReduction" xlink:to="label_NotesReduction_1" xlink:title="label_NotesReduction_1" />
    <link:label xlink:type="resource" xlink:label="label_NotesReduction_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_NotesReduction_2" xml:lang="en-US" id="label_NotesReduction_2">Repayment of term note with proceeds of note payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesReduction" xlink:to="label_NotesReduction_2" xlink:title="label_NotesReduction_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="label_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingExpenses" xml:lang="en-US" id="label_OperatingExpenses">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="label_OperatingExpenses" xlink:title="label_OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="label_OperatingExpenses_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_OperatingExpenses_1" xml:lang="en-US" id="label_OperatingExpenses_1">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="label_OperatingExpenses_1" xlink:title="label_OperatingExpenses_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingExpensesAbstract" xml:lang="en-US" id="label_OperatingExpensesAbstract">Operating Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="label_OperatingExpensesAbstract" xlink:title="label_OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OperatingExpensesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingExpensesAbstract_1" xml:lang="en-US" id="label_OperatingExpensesAbstract_1">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="label_OperatingExpensesAbstract_1" xlink:title="label_OperatingExpensesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingIncomeLoss" xml:lang="en-US" id="label_OperatingIncomeLoss">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="label_OperatingIncomeLoss" xlink:title="label_OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_OperatingIncomeLoss_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingIncomeLoss_1" xml:lang="en-US" id="label_OperatingIncomeLoss_1">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="label_OperatingIncomeLoss_1" xlink:title="label_OperatingIncomeLoss_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="OperatingLeasesFutureMinimumPaymentsDue" xlink:title="OperatingLeasesFutureMinimumPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDue" xml:lang="en-US" id="label_OperatingLeasesFutureMinimumPaymentsDue">Operating Leases, Future Minimum Payments Due</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDue" xlink:to="label_OperatingLeasesFutureMinimumPaymentsDue" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesFutureMinimumPaymentsDue_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDue_1" xml:lang="en-US" id="label_OperatingLeasesFutureMinimumPaymentsDue_1">Total minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDue" xlink:to="label_OperatingLeasesFutureMinimumPaymentsDue_1" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:title="OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueAbstract" xml:lang="en-US" id="label_OperatingLeasesFutureMinimumPaymentsDueAbstract">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="label_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xml:lang="en-US" id="label_OperatingLeasesFutureMinimumPaymentsDueAbstract_1">Aggregate minimum annual lease commitments under non cancellable operating lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="label_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US" id="label_OperatingLeasesFutureMinimumPaymentsDueCurrent">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="label_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesFutureMinimumPaymentsDueCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueCurrent_1" xml:lang="en-US" id="label_OperatingLeasesFutureMinimumPaymentsDueCurrent_1">2015</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="label_OperatingLeasesFutureMinimumPaymentsDueCurrent_1" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US" id="label_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="label_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1" xml:lang="en-US" id="label_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1">2017</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="label_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US" id="label_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="label_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1" xml:lang="en-US" id="label_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1">2016</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="label_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseAbstract" xlink:label="OperatingLeasesRentExpenseAbstract" xlink:title="OperatingLeasesRentExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesRentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLeasesRentExpenseAbstract" xml:lang="en-US" id="label_OperatingLeasesRentExpenseAbstract">Operating Leases, Rent Expense, Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesRentExpenseAbstract" xlink:to="label_OperatingLeasesRentExpenseAbstract" xlink:title="label_OperatingLeasesRentExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesRentExpenseAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLeasesRentExpenseAbstract_1" xml:lang="en-US" id="label_OperatingLeasesRentExpenseAbstract_1">Rent expense under operating lease agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesRentExpenseAbstract" xlink:to="label_OperatingLeasesRentExpenseAbstract_1" xlink:title="label_OperatingLeasesRentExpenseAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="OperatingLeasesRentExpenseNet" xlink:title="OperatingLeasesRentExpenseNet" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLeasesRentExpenseNet" xml:lang="en-US" id="label_OperatingLeasesRentExpenseNet">Operating Leases, Rent Expense, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesRentExpenseNet" xlink:to="label_OperatingLeasesRentExpenseNet" xlink:title="label_OperatingLeasesRentExpenseNet" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesRentExpenseNet_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLeasesRentExpenseNet_1" xml:lang="en-US" id="label_OperatingLeasesRentExpenseNet_1">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesRentExpenseNet" xlink:to="label_OperatingLeasesRentExpenseNet_1" xlink:title="label_OperatingLeasesRentExpenseNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLossCarryforwards" xml:lang="en-US" id="label_OperatingLossCarryforwards">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwards" xlink:to="label_OperatingLossCarryforwards" xlink:title="label_OperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLossCarryforwards_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLossCarryforwards_1" xml:lang="en-US" id="label_OperatingLossCarryforwards_1">Available net operating loss carryforwards as of the end of the year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwards" xlink:to="label_OperatingLossCarryforwards_1" xlink:title="label_OperatingLossCarryforwards_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLossCarryforwardsLineItems" xml:lang="en-US" id="label_OperatingLossCarryforwardsLineItems">Operating Loss Carryforwards [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="label_OperatingLossCarryforwardsLineItems" xlink:title="label_OperatingLossCarryforwardsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLossCarryforwardsLineItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLossCarryforwardsLineItems_1" xml:lang="en-US" id="label_OperatingLossCarryforwardsLineItems_1">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="label_OperatingLossCarryforwardsLineItems_1" xlink:title="label_OperatingLossCarryforwardsLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLossCarryforwardsTable" xml:lang="en-US" id="label_OperatingLossCarryforwardsTable">Operating Loss Carryforwards [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsTable" xlink:to="label_OperatingLossCarryforwardsTable" xlink:title="label_OperatingLossCarryforwardsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US" id="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">NATURE OF BUSINESS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US" id="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" xml:lang="en-US" id="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1">NATURE OF BUSINESS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherAccruedLiabilitiesCurrent" xml:lang="en-US" id="label_OtherAccruedLiabilitiesCurrent">Other Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAccruedLiabilitiesCurrent" xlink:to="label_OtherAccruedLiabilitiesCurrent" xlink:title="label_OtherAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherAccruedLiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherAccruedLiabilitiesCurrent_1" xml:lang="en-US" id="label_OtherAccruedLiabilitiesCurrent_1">Accrued other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAccruedLiabilitiesCurrent" xlink:to="label_OtherAccruedLiabilitiesCurrent_1" xlink:title="label_OtherAccruedLiabilitiesCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="OtherAssetsCurrent" xlink:title="OtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherAssetsCurrent" xml:lang="en-US" id="label_OtherAssetsCurrent">Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsCurrent" xlink:to="label_OtherAssetsCurrent" xlink:title="label_OtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherAssetsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherAssetsCurrent_1" xml:lang="en-US" id="label_OtherAssetsCurrent_1">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsCurrent" xlink:to="label_OtherAssetsCurrent_1" xlink:title="label_OtherAssetsCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="OtherCommitmentsLineItems" xlink:title="OtherCommitmentsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherCommitmentsLineItems" xml:lang="en-US" id="label_OtherCommitmentsLineItems">Other Commitments [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsLineItems" xlink:to="label_OtherCommitmentsLineItems" xlink:title="label_OtherCommitmentsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_OtherCommitmentsLineItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherCommitmentsLineItems_1" xml:lang="en-US" id="label_OtherCommitmentsLineItems_1">Commitments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsLineItems" xlink:to="label_OtherCommitmentsLineItems_1" xlink:title="label_OtherCommitmentsLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="OtherCommitmentsTable" xlink:title="OtherCommitmentsTable" />
    <link:label xlink:type="resource" xlink:label="label_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherCommitmentsTable" xml:lang="en-US" id="label_OtherCommitmentsTable">Other Commitments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsTable" xlink:to="label_OtherCommitmentsTable" xlink:title="label_OtherCommitmentsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="OtherExpensesAbstract" xlink:title="OtherExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OtherExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherExpensesAbstract" xml:lang="en-US" id="label_OtherExpensesAbstract">Other Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherExpensesAbstract" xlink:to="label_OtherExpensesAbstract" xlink:title="label_OtherExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OtherExpensesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherExpensesAbstract_1" xml:lang="en-US" id="label_OtherExpensesAbstract_1">Other expense:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherExpensesAbstract" xlink:to="label_OtherExpensesAbstract_1" xlink:title="label_OtherExpensesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherNonoperatingIncomeExpense" xml:lang="en-US" id="label_OtherNonoperatingIncomeExpense">Other Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="label_OtherNonoperatingIncomeExpense" xlink:title="label_OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_OtherNonoperatingIncomeExpense_1" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:title="label_OtherNonoperatingIncomeExpense_1" xml:lang="en-US" id="label_OtherNonoperatingIncomeExpense_1">Total other expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="label_OtherNonoperatingIncomeExpense_1" xlink:title="label_OtherNonoperatingIncomeExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="OverAllotmentOptionMember" xlink:title="OverAllotmentOptionMember" />
    <link:label xlink:type="resource" xlink:label="label_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OverAllotmentOptionMember" xml:lang="en-US" id="label_OverAllotmentOptionMember">Over Allotment Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OverAllotmentOptionMember" xlink:to="label_OverAllotmentOptionMember" xlink:title="label_OverAllotmentOptionMember" />
    <link:label xlink:type="resource" xlink:label="label_OverAllotmentOptionMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OverAllotmentOptionMember_1" xml:lang="en-US" id="label_OverAllotmentOptionMember_1">Underwriters over-allotment option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OverAllotmentOptionMember" xlink:to="label_OverAllotmentOptionMember_1" xlink:title="label_OverAllotmentOptionMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="PaymentsOfFinancingCosts" xlink:title="PaymentsOfFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsOfFinancingCosts" xml:lang="en-US" id="label_PaymentsOfFinancingCosts">Payments of Financing Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfFinancingCosts" xlink:to="label_PaymentsOfFinancingCosts" xlink:title="label_PaymentsOfFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsOfFinancingCosts_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PaymentsOfFinancingCosts_1" xml:lang="en-US" id="label_PaymentsOfFinancingCosts_1">Financing costs repaid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfFinancingCosts" xlink:to="label_PaymentsOfFinancingCosts_1" xlink:title="label_PaymentsOfFinancingCosts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsOfStockIssuanceCosts" xml:lang="en-US" id="label_PaymentsOfStockIssuanceCosts">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfStockIssuanceCosts" xlink:to="label_PaymentsOfStockIssuanceCosts" xlink:title="label_PaymentsOfStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsOfStockIssuanceCosts_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PaymentsOfStockIssuanceCosts_1" xml:lang="en-US" id="label_PaymentsOfStockIssuanceCosts_1">Stock issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfStockIssuanceCosts" xlink:to="label_PaymentsOfStockIssuanceCosts_1" xlink:title="label_PaymentsOfStockIssuanceCosts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US" id="label_PaymentsToAcquirePropertyPlantAndEquipment">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="label_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquirePropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US" id="label_PaymentsToAcquirePropertyPlantAndEquipment_1">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_PaymentsToAcquirePropertyPlantAndEquipment_1" xlink:title="label_PaymentsToAcquirePropertyPlantAndEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US" id="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1" xml:lang="en-US" id="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1">EMPLOYEE BENEFITS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1" xlink:title="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="label_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PlanNameAxis" xml:lang="en-US" id="label_PlanNameAxis">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="label_PlanNameAxis" xlink:title="label_PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PlanNameDomain" xml:lang="en-US" id="label_PlanNameDomain">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="label_PlanNameDomain" xlink:title="label_PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_PlanNameDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PlanNameDomain_1" xml:lang="en-US" id="label_PlanNameDomain_1">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="label_PlanNameDomain_1" xlink:title="label_PlanNameDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="PortionAtFairValueFairValueDisclosureMember" xlink:title="PortionAtFairValueFairValueDisclosureMember" />
    <link:label xlink:type="resource" xlink:label="label_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PortionAtFairValueFairValueDisclosureMember" xml:lang="en-US" id="label_PortionAtFairValueFairValueDisclosureMember">Portion At Fair Value Fair Value Disclosure [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PortionAtFairValueFairValueDisclosureMember" xlink:to="label_PortionAtFairValueFairValueDisclosureMember" xlink:title="label_PortionAtFairValueFairValueDisclosureMember" />
    <link:label xlink:type="resource" xlink:label="label_PortionAtFairValueFairValueDisclosureMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PortionAtFairValueFairValueDisclosureMember_1" xml:lang="en-US" id="label_PortionAtFairValueFairValueDisclosureMember_1">Portion at Fair Value Measurement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PortionAtFairValueFairValueDisclosureMember" xlink:to="label_PortionAtFairValueFairValueDisclosureMember_1" xlink:title="label_PortionAtFairValueFairValueDisclosureMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="PreferredStockDividendRatePercentage" xlink:title="PreferredStockDividendRatePercentage" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockDividendRatePercentage" xml:lang="en-US" id="label_PreferredStockDividendRatePercentage">Preferred Stock, Dividend Rate, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendRatePercentage" xlink:to="label_PreferredStockDividendRatePercentage" xlink:title="label_PreferredStockDividendRatePercentage" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockDividendRatePercentage_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockDividendRatePercentage_1" xml:lang="en-US" id="label_PreferredStockDividendRatePercentage_1">Dividend rate (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendRatePercentage" xlink:to="label_PreferredStockDividendRatePercentage_1" xlink:title="label_PreferredStockDividendRatePercentage_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="PreferredStockTextBlock" xlink:title="PreferredStockTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockTextBlock" xml:lang="en-US" id="label_PreferredStockTextBlock">Preferred Stock [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockTextBlock" xlink:to="label_PreferredStockTextBlock" xlink:title="label_PreferredStockTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockTextBlock_1" xml:lang="en-US" id="label_PreferredStockTextBlock_1">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockTextBlock" xlink:to="label_PreferredStockTextBlock_1" xlink:title="label_PreferredStockTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrent">Prepaid Expense and Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent_1" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrent_1">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrent_1" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrent_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent_2" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrent_2">Total prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrent_2" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrentAbstract" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrentAbstract">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="PrepaidExpenseCurrent" xlink:title="PrepaidExpenseCurrent" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidExpenseCurrent" xml:lang="en-US" id="label_PrepaidExpenseCurrent">Prepaid Expense, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseCurrent" xlink:to="label_PrepaidExpenseCurrent" xlink:title="label_PrepaidExpenseCurrent" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PrepaidExpenseCurrent_1" xml:lang="en-US" id="label_PrepaidExpenseCurrent_1">Prepaid expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseCurrent" xlink:to="label_PrepaidExpenseCurrent_1" xlink:title="label_PrepaidExpenseCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="PrepaidExpensesAndOtherCurrentAssetsMember" xlink:title="PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidExpensesAndOtherCurrentAssetsMember" xml:lang="en-US" id="label_PrepaidExpensesAndOtherCurrentAssetsMember">Prepaid Expenses And Other Current Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="label_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:title="label_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpensesAndOtherCurrentAssetsMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PrepaidExpensesAndOtherCurrentAssetsMember_1" xml:lang="en-US" id="label_PrepaidExpensesAndOtherCurrentAssetsMember_1">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="label_PrepaidExpensesAndOtherCurrentAssetsMember_1" xlink:title="label_PrepaidExpensesAndOtherCurrentAssetsMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="PrimeRateMember" xlink:title="PrimeRateMember" />
    <link:label xlink:type="resource" xlink:label="label_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrimeRateMember" xml:lang="en-US" id="label_PrimeRateMember">Prime Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrimeRateMember" xlink:to="label_PrimeRateMember" xlink:title="label_PrimeRateMember" />
    <link:label xlink:type="resource" xlink:label="label_PrimeRateMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PrimeRateMember_1" xml:lang="en-US" id="label_PrimeRateMember_1">Prime</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrimeRateMember" xlink:to="label_PrimeRateMember_1" xlink:title="label_PrimeRateMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="PrivatePlacementMember" xlink:title="PrivatePlacementMember" />
    <link:label xlink:type="resource" xlink:label="label_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrivatePlacementMember" xml:lang="en-US" id="label_PrivatePlacementMember">Private Placement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrivatePlacementMember" xlink:to="label_PrivatePlacementMember" xlink:title="label_PrivatePlacementMember" />
    <link:label xlink:type="resource" xlink:label="label_PrivatePlacementMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PrivatePlacementMember_1" xml:lang="en-US" id="label_PrivatePlacementMember_1">Private Placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrivatePlacementMember" xlink:to="label_PrivatePlacementMember_1" xlink:title="label_PrivatePlacementMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US" id="label_ProceedsFromIssuanceOfCommonStock">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="label_ProceedsFromIssuanceOfCommonStock" xlink:title="label_ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfCommonStock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US" id="label_ProceedsFromIssuanceOfCommonStock_1">Gross proceeds from sale of stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="label_ProceedsFromIssuanceOfCommonStock_1" xlink:title="label_ProceedsFromIssuanceOfCommonStock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="ProceedsFromIssuanceOfLongTermDebt" xlink:title="ProceedsFromIssuanceOfLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceOfLongTermDebt" xml:lang="en-US" id="label_ProceedsFromIssuanceOfLongTermDebt">Proceeds from Issuance of Long-term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfLongTermDebt" xlink:to="label_ProceedsFromIssuanceOfLongTermDebt" xlink:title="label_ProceedsFromIssuanceOfLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfLongTermDebt_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ProceedsFromIssuanceOfLongTermDebt_1" xml:lang="en-US" id="label_ProceedsFromIssuanceOfLongTermDebt_1">Amount borrowed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfLongTermDebt" xlink:to="label_ProceedsFromIssuanceOfLongTermDebt_1" xlink:title="label_ProceedsFromIssuanceOfLongTermDebt_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:title="ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xml:lang="en-US" id="label_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">Proceeds from Issuance of Redeemable Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="label_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:title="label_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_1" xml:lang="en-US" id="label_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_1">Cash consideration from issuance of preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="label_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_1" xlink:title="label_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_1" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_2" xml:lang="en-US" id="label_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_2">Gross proceeds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="label_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_2" xlink:title="label_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="ProceedsFromRepaymentsOfNotesPayable" xlink:title="ProceedsFromRepaymentsOfNotesPayable" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromRepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromRepaymentsOfNotesPayable" xml:lang="en-US" id="label_ProceedsFromRepaymentsOfNotesPayable">Proceeds from (Repayments of) Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromRepaymentsOfNotesPayable" xlink:to="label_ProceedsFromRepaymentsOfNotesPayable" xlink:title="label_ProceedsFromRepaymentsOfNotesPayable" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromRepaymentsOfNotesPayable_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ProceedsFromRepaymentsOfNotesPayable_1" xml:lang="en-US" id="label_ProceedsFromRepaymentsOfNotesPayable_1">Proceeds from notes payable, net of original note payoff</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromRepaymentsOfNotesPayable" xlink:to="label_ProceedsFromRepaymentsOfNotesPayable_1" xlink:title="label_ProceedsFromRepaymentsOfNotesPayable_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="ProceedsFromShortTermDebt" xlink:title="ProceedsFromShortTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromShortTermDebt" xml:lang="en-US" id="label_ProceedsFromShortTermDebt">Proceeds from Short-term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromShortTermDebt" xlink:to="label_ProceedsFromShortTermDebt" xlink:title="label_ProceedsFromShortTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromShortTermDebt_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromShortTermDebt_1" xml:lang="en-US" id="label_ProceedsFromShortTermDebt_1">Proceeds from issuance of convertible bridge note</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromShortTermDebt" xlink:to="label_ProceedsFromShortTermDebt_1" xlink:title="label_ProceedsFromShortTermDebt_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromStockOptionsExercised" xml:lang="en-US" id="label_ProceedsFromStockOptionsExercised">Proceeds from Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="label_ProceedsFromStockOptionsExercised" xlink:title="label_ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromStockOptionsExercised_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromStockOptionsExercised_1" xml:lang="en-US" id="label_ProceedsFromStockOptionsExercised_1">Proceeds from the exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="label_ProceedsFromStockOptionsExercised_1" xlink:title="label_ProceedsFromStockOptionsExercised_1" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromStockOptionsExercised_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ProceedsFromStockOptionsExercised_2" xml:lang="en-US" id="label_ProceedsFromStockOptionsExercised_2">Proceeds from the exercise of common stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="label_ProceedsFromStockOptionsExercised_2" xlink:title="label_ProceedsFromStockOptionsExercised_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProFormaMember" xlink:label="ProFormaMember" xlink:title="ProFormaMember" />
    <link:label xlink:type="resource" xlink:label="label_ProFormaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProFormaMember" xml:lang="en-US" id="label_ProFormaMember">Pro Forma [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProFormaMember" xlink:to="label_ProFormaMember" xlink:title="label_ProFormaMember" />
    <link:label xlink:type="resource" xlink:label="label_ProFormaMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProFormaMember_1" xml:lang="en-US" id="label_ProFormaMember_1">Pro Forma</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProFormaMember" xlink:to="label_ProFormaMember_1" xlink:title="label_ProFormaMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentAbstract" xml:lang="en-US" id="label_PropertyPlantAndEquipmentAbstract">PROPERTY AND EQUIPMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="label_PropertyPlantAndEquipmentAbstract" xlink:title="label_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US" id="label_PropertyPlantAndEquipmentByTypeAxis">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="label_PropertyPlantAndEquipmentByTypeAxis" xlink:title="label_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US" id="label_PropertyPlantAndEquipmentDisclosureTextBlock">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="label_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="label_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentDisclosureTextBlock_1" xml:lang="en-US" id="label_PropertyPlantAndEquipmentDisclosureTextBlock_1">PROPERTY AND EQUIPMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="label_PropertyPlantAndEquipmentDisclosureTextBlock_1" xlink:title="label_PropertyPlantAndEquipmentDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentGross" xml:lang="en-US" id="label_PropertyPlantAndEquipmentGross">Property, Plant and Equipment, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="label_PropertyPlantAndEquipmentGross" xlink:title="label_PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentGross_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_PropertyPlantAndEquipmentGross_1" xml:lang="en-US" id="label_PropertyPlantAndEquipmentGross_1">Total property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="label_PropertyPlantAndEquipmentGross_1" xlink:title="label_PropertyPlantAndEquipmentGross_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="PropertyPlantAndEquipmentImpairment" xlink:title="PropertyPlantAndEquipmentImpairment" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentImpairment" xml:lang="en-US" id="label_PropertyPlantAndEquipmentImpairment">Property, Plant and Equipment, Impairment [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentImpairment" xlink:to="label_PropertyPlantAndEquipmentImpairment" xlink:title="label_PropertyPlantAndEquipmentImpairment" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentImpairment_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentImpairment_1" xml:lang="en-US" id="label_PropertyPlantAndEquipmentImpairment_1">Impairment of Long Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentImpairment" xlink:to="label_PropertyPlantAndEquipmentImpairment_1" xlink:title="label_PropertyPlantAndEquipmentImpairment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentLineItems" xml:lang="en-US" id="label_PropertyPlantAndEquipmentLineItems">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="label_PropertyPlantAndEquipmentLineItems" xlink:title="label_PropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentLineItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentLineItems_1" xml:lang="en-US" id="label_PropertyPlantAndEquipmentLineItems_1">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="label_PropertyPlantAndEquipmentLineItems_1" xlink:title="label_PropertyPlantAndEquipmentLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="label_PropertyPlantAndEquipmentNet">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="label_PropertyPlantAndEquipmentNet" xlink:title="label_PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentNet_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentNet_1" xml:lang="en-US" id="label_PropertyPlantAndEquipmentNet_1">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="label_PropertyPlantAndEquipmentNet_1" xlink:title="label_PropertyPlantAndEquipmentNet_1" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentNet_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_PropertyPlantAndEquipmentNet_2" xml:lang="en-US" id="label_PropertyPlantAndEquipmentNet_2">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="label_PropertyPlantAndEquipmentNet_2" xlink:title="label_PropertyPlantAndEquipmentNet_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US" id="label_PropertyPlantAndEquipmentPolicyTextBlock">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="label_PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="label_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentPolicyTextBlock_1" xml:lang="en-US" id="label_PropertyPlantAndEquipmentPolicyTextBlock_1">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="label_PropertyPlantAndEquipmentPolicyTextBlock_1" xlink:title="label_PropertyPlantAndEquipmentPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US" id="label_PropertyPlantAndEquipmentTextBlock">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="label_PropertyPlantAndEquipmentTextBlock" xlink:title="label_PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentTextBlock_1" xml:lang="en-US" id="label_PropertyPlantAndEquipmentTextBlock_1">Schedule of components of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="label_PropertyPlantAndEquipmentTextBlock_1" xlink:title="label_PropertyPlantAndEquipmentTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US" id="label_PropertyPlantAndEquipmentTypeDomain">Property Plant And Equipment Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="label_PropertyPlantAndEquipmentTypeDomain" xlink:title="label_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentTypeDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentTypeDomain_1" xml:lang="en-US" id="label_PropertyPlantAndEquipmentTypeDomain_1">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="label_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="label_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US" id="label_PropertyPlantAndEquipmentUsefulLife">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="label_PropertyPlantAndEquipmentUsefulLife" xlink:title="label_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentUsefulLife_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentUsefulLife_1" xml:lang="en-US" id="label_PropertyPlantAndEquipmentUsefulLife_1">Estimate Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="label_PropertyPlantAndEquipmentUsefulLife_1" xlink:title="label_PropertyPlantAndEquipmentUsefulLife_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="label_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RangeAxis" xml:lang="en-US" id="label_RangeAxis">Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="label_RangeAxis" xlink:title="label_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="label_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RangeMember" xml:lang="en-US" id="label_RangeMember">Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="label_RangeMember" xlink:title="label_RangeMember" />
    <link:label xlink:type="resource" xlink:label="label_RangeMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RangeMember_1" xml:lang="en-US" id="label_RangeMember_1">Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="label_RangeMember_1" xlink:title="label_RangeMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="RedeemableConvertiblePreferredStockMember" xlink:title="RedeemableConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_RedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RedeemableConvertiblePreferredStockMember" xml:lang="en-US" id="label_RedeemableConvertiblePreferredStockMember">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RedeemableConvertiblePreferredStockMember" xlink:to="label_RedeemableConvertiblePreferredStockMember" xlink:title="label_RedeemableConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_RedeemableConvertiblePreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RedeemableConvertiblePreferredStockMember_1" xml:lang="en-US" id="label_RedeemableConvertiblePreferredStockMember_1">Redeemable Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RedeemableConvertiblePreferredStockMember" xlink:to="label_RedeemableConvertiblePreferredStockMember_1" xlink:title="label_RedeemableConvertiblePreferredStockMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyDomain" xml:lang="en-US" id="label_RelatedPartyDomain">Related Party [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyDomain" xlink:to="label_RelatedPartyDomain" xlink:title="label_RelatedPartyDomain" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RelatedPartyDomain_1" xml:lang="en-US" id="label_RelatedPartyDomain_1">Related Party [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyDomain" xlink:to="label_RelatedPartyDomain_1" xlink:title="label_RelatedPartyDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="RelatedPartyTransactionAmountsOfTransaction" xlink:title="RelatedPartyTransactionAmountsOfTransaction" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US" id="label_RelatedPartyTransactionAmountsOfTransaction">Related Party Transaction, Amounts of Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionAmountsOfTransaction" xlink:to="label_RelatedPartyTransactionAmountsOfTransaction" xlink:title="label_RelatedPartyTransactionAmountsOfTransaction" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionAmountsOfTransaction_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RelatedPartyTransactionAmountsOfTransaction_1" xml:lang="en-US" id="label_RelatedPartyTransactionAmountsOfTransaction_1">Amount issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionAmountsOfTransaction" xlink:to="label_RelatedPartyTransactionAmountsOfTransaction_1" xlink:title="label_RelatedPartyTransactionAmountsOfTransaction_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionAxis" xml:lang="en-US" id="label_RelatedPartyTransactionAxis">Related Party Transaction [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionAxis" xlink:to="label_RelatedPartyTransactionAxis" xlink:title="label_RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionDomain" xml:lang="en-US" id="label_RelatedPartyTransactionDomain">Related Party Transaction [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionDomain" xlink:to="label_RelatedPartyTransactionDomain" xlink:title="label_RelatedPartyTransactionDomain" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RelatedPartyTransactionDomain_1" xml:lang="en-US" id="label_RelatedPartyTransactionDomain_1">Related Party Transaction [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionDomain" xlink:to="label_RelatedPartyTransactionDomain_1" xlink:title="label_RelatedPartyTransactionDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionLineItems" xml:lang="en-US" id="label_RelatedPartyTransactionLineItems">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionLineItems" xlink:to="label_RelatedPartyTransactionLineItems" xlink:title="label_RelatedPartyTransactionLineItems" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionLineItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RelatedPartyTransactionLineItems_1" xml:lang="en-US" id="label_RelatedPartyTransactionLineItems_1">Related party transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionLineItems" xlink:to="label_RelatedPartyTransactionLineItems_1" xlink:title="label_RelatedPartyTransactionLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="RelatedPartyTransactionRate" xlink:title="RelatedPartyTransactionRate" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionRate" xml:lang="en-US" id="label_RelatedPartyTransactionRate">Related Party Transaction, Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionRate" xlink:to="label_RelatedPartyTransactionRate" xlink:title="label_RelatedPartyTransactionRate" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionRate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RelatedPartyTransactionRate_1" xml:lang="en-US" id="label_RelatedPartyTransactionRate_1">Stated interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionRate" xlink:to="label_RelatedPartyTransactionRate_1" xlink:title="label_RelatedPartyTransactionRate_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US" id="label_RelatedPartyTransactionsByRelatedPartyAxis">Related Party [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="label_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="label_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLongtermLoansFromVendors" xlink:label="RepaymentsOfLongtermLoansFromVendors" xlink:title="RepaymentsOfLongtermLoansFromVendors" />
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfLongtermLoansFromVendors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RepaymentsOfLongtermLoansFromVendors" xml:lang="en-US" id="label_RepaymentsOfLongtermLoansFromVendors">Repayments of Long-term Loans from Vendors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongtermLoansFromVendors" xlink:to="label_RepaymentsOfLongtermLoansFromVendors" xlink:title="label_RepaymentsOfLongtermLoansFromVendors" />
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfLongtermLoansFromVendors_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_RepaymentsOfLongtermLoansFromVendors_1" xml:lang="en-US" id="label_RepaymentsOfLongtermLoansFromVendors_1">Repayment of lease note payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongtermLoansFromVendors" xlink:to="label_RepaymentsOfLongtermLoansFromVendors_1" xlink:title="label_RepaymentsOfLongtermLoansFromVendors_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchAndDevelopmentExpense" xml:lang="en-US" id="label_ResearchAndDevelopmentExpense">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="label_ResearchAndDevelopmentExpense" xlink:title="label_ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ResearchAndDevelopmentExpense_1" xml:lang="en-US" id="label_ResearchAndDevelopmentExpense_1">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="label_ResearchAndDevelopmentExpense_1" xlink:title="label_ResearchAndDevelopmentExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchAndDevelopmentExpenseMember" xml:lang="en-US" id="label_ResearchAndDevelopmentExpenseMember">Research And Development Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="label_ResearchAndDevelopmentExpenseMember" xlink:title="label_ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpenseMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ResearchAndDevelopmentExpenseMember_1" xml:lang="en-US" id="label_ResearchAndDevelopmentExpenseMember_1">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="label_ResearchAndDevelopmentExpenseMember_1" xlink:title="label_ResearchAndDevelopmentExpenseMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US" id="label_ResearchAndDevelopmentExpensePolicy">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="label_ResearchAndDevelopmentExpensePolicy" xlink:title="label_ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpensePolicy_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ResearchAndDevelopmentExpensePolicy_1" xml:lang="en-US" id="label_ResearchAndDevelopmentExpensePolicy_1">Research and Development Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="label_ResearchAndDevelopmentExpensePolicy_1" xlink:title="label_ResearchAndDevelopmentExpensePolicy_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xlink:type="resource" xlink:label="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US" id="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xlink:type="resource" xlink:label="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xml:lang="en-US" id="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1">Cash and Cash Equivalents [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="label_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="RestrictedCashAndCashEquivalentsNoncurrent" xlink:title="RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RestrictedCashAndCashEquivalentsNoncurrent" xml:lang="en-US" id="label_RestrictedCashAndCashEquivalentsNoncurrent">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="label_RestrictedCashAndCashEquivalentsNoncurrent" xlink:title="label_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_RestrictedCashAndCashEquivalentsNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RestrictedCashAndCashEquivalentsNoncurrent_1" xml:lang="en-US" id="label_RestrictedCashAndCashEquivalentsNoncurrent_1">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="label_RestrictedCashAndCashEquivalentsNoncurrent_1" xlink:title="label_RestrictedCashAndCashEquivalentsNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:label xlink:type="resource" xlink:label="label_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RestrictedStockMember" xml:lang="en-US" id="label_RestrictedStockMember">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockMember" xlink:to="label_RestrictedStockMember" xlink:title="label_RestrictedStockMember" />
    <link:label xlink:type="resource" xlink:label="label_RestrictedStockMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RestrictedStockMember_1" xml:lang="en-US" id="label_RestrictedStockMember_1">Restricted stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockMember" xlink:to="label_RestrictedStockMember_1" xlink:title="label_RestrictedStockMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RetainedEarningsAccumulatedDeficit" xml:lang="en-US" id="label_RetainedEarningsAccumulatedDeficit">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="label_RetainedEarningsAccumulatedDeficit" xlink:title="label_RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsAccumulatedDeficit_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_RetainedEarningsAccumulatedDeficit_1" xml:lang="en-US" id="label_RetainedEarningsAccumulatedDeficit_1">Deficit accumulated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="label_RetainedEarningsAccumulatedDeficit_1" xlink:title="label_RetainedEarningsAccumulatedDeficit_1" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsAccumulatedDeficit_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RetainedEarningsAccumulatedDeficit_2" xml:lang="en-US" id="label_RetainedEarningsAccumulatedDeficit_2">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="label_RetainedEarningsAccumulatedDeficit_2" xlink:title="label_RetainedEarningsAccumulatedDeficit_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficitAbstract" xlink:label="RetainedEarningsAccumulatedDeficitAbstract" xlink:title="RetainedEarningsAccumulatedDeficitAbstract" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsAccumulatedDeficitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RetainedEarningsAccumulatedDeficitAbstract" xml:lang="en-US" id="label_RetainedEarningsAccumulatedDeficitAbstract">Retained Earnings (Accumulated Deficit) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficitAbstract" xlink:to="label_RetainedEarningsAccumulatedDeficitAbstract" xlink:title="label_RetainedEarningsAccumulatedDeficitAbstract" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsAccumulatedDeficitAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RetainedEarningsAccumulatedDeficitAbstract_1" xml:lang="en-US" id="label_RetainedEarningsAccumulatedDeficitAbstract_1">Deficit accumulated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficitAbstract" xlink:to="label_RetainedEarningsAccumulatedDeficitAbstract_1" xlink:title="label_RetainedEarningsAccumulatedDeficitAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RetainedEarningsMember" xml:lang="en-US" id="label_RetainedEarningsMember">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="label_RetainedEarningsMember" xlink:title="label_RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RetainedEarningsMember_1" xml:lang="en-US" id="label_RetainedEarningsMember_1">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="label_RetainedEarningsMember_1" xlink:title="label_RetainedEarningsMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="SaleOfStockConsiderationReceivedOnTransaction" xlink:title="SaleOfStockConsiderationReceivedOnTransaction" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US" id="label_SaleOfStockConsiderationReceivedOnTransaction">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockConsiderationReceivedOnTransaction" xlink:to="label_SaleOfStockConsiderationReceivedOnTransaction" xlink:title="label_SaleOfStockConsiderationReceivedOnTransaction" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockConsiderationReceivedOnTransaction_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SaleOfStockConsiderationReceivedOnTransaction_1" xml:lang="en-US" id="label_SaleOfStockConsiderationReceivedOnTransaction_1">Proceeds from the offering, after deducting underwriting discounts and commissions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockConsiderationReceivedOnTransaction" xlink:to="label_SaleOfStockConsiderationReceivedOnTransaction_1" xlink:title="label_SaleOfStockConsiderationReceivedOnTransaction_1" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockConsiderationReceivedOnTransaction_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_SaleOfStockConsiderationReceivedOnTransaction_2" xml:lang="en-US" id="label_SaleOfStockConsiderationReceivedOnTransaction_2">Proceeds from issuance of stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockConsiderationReceivedOnTransaction" xlink:to="label_SaleOfStockConsiderationReceivedOnTransaction_2" xlink:title="label_SaleOfStockConsiderationReceivedOnTransaction_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SaleOfStockNameOfTransactionDomain" xml:lang="en-US" id="label_SaleOfStockNameOfTransactionDomain">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="label_SaleOfStockNameOfTransactionDomain" xlink:title="label_SaleOfStockNameOfTransactionDomain" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockNameOfTransactionDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SaleOfStockNameOfTransactionDomain_1" xml:lang="en-US" id="label_SaleOfStockNameOfTransactionDomain_1">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="label_SaleOfStockNameOfTransactionDomain_1" xlink:title="label_SaleOfStockNameOfTransactionDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:label xlink:type="resource" xlink:label="label_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScenarioUnspecifiedDomain" xml:lang="en-US" id="label_ScenarioUnspecifiedDomain">Scenario Unspecified [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioUnspecifiedDomain" xlink:to="label_ScenarioUnspecifiedDomain" xlink:title="label_ScenarioUnspecifiedDomain" />
    <link:label xlink:type="resource" xlink:label="label_ScenarioUnspecifiedDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScenarioUnspecifiedDomain_1" xml:lang="en-US" id="label_ScenarioUnspecifiedDomain_1">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioUnspecifiedDomain" xlink:to="label_ScenarioUnspecifiedDomain_1" xlink:title="label_ScenarioUnspecifiedDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US" id="label_ScheduleOfAccruedLiabilitiesTableTextBlock">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="label_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="label_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfAccruedLiabilitiesTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfAccruedLiabilitiesTableTextBlock_1" xml:lang="en-US" id="label_ScheduleOfAccruedLiabilitiesTableTextBlock_1">Schedule of components of accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="label_ScheduleOfAccruedLiabilitiesTableTextBlock_1" xlink:title="label_ScheduleOfAccruedLiabilitiesTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US" id="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US" id="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" xml:lang="en-US" id="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1">Schedule of potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" xlink:title="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US" id="label_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="label_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="label_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xml:lang="en-US" id="label_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1">Schedule of significant components of deferred tax assets and liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="label_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xlink:title="label_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US" id="label_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="label_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="label_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" xml:lang="en-US" id="label_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1">Schedule of computations of basic and diluted net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="label_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" xlink:title="label_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:title="ScheduleOfEarningsPerShareBasicByCommonClassTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfEarningsPerShareBasicByCommonClassTable" xml:lang="en-US" id="label_ScheduleOfEarningsPerShareBasicByCommonClassTable">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="label_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:title="label_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US" id="label_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="label_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="label_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1" xml:lang="en-US" id="label_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1">Schedule of reconciliation of income tax expense (benefit) at statutory federal income tax rate to income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="label_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1" xlink:title="label_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US" id="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US" id="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xml:lang="en-US" id="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1">Schedule of stock-based compensation for all stock options and restricted stock awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xlink:title="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:title="ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US" id="label_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="label_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:title="label_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1" xml:lang="en-US" id="label_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1">Schedule of aggregate minimum annual lease commitments under non-cancellable operating lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="label_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1" xlink:title="label_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:title="ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US" id="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:title="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1" xml:lang="en-US" id="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1">Schedule of future payments under debt agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1" xlink:title="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US" id="label_ScheduleOfPropertyPlantAndEquipmentTable">Property, Plant and Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="label_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="label_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US" id="label_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="label_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="label_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US" id="label_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="label_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="label_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US" id="label_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="label_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="label_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xml:lang="en-US" id="label_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1">Summary of stock option activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="label_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xlink:title="label_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US" id="label_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="label_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="label_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xml:lang="en-US" id="label_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1">Schedule of weighted-average assumptions used in Black-Scholes option-pricing model</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="label_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xlink:title="label_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfStockByClassTable" xml:lang="en-US" id="label_ScheduleOfStockByClassTable">Schedule of Stock by Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockByClassTable" xlink:to="label_ScheduleOfStockByClassTable" xlink:title="label_ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesAPreferredStockMember" xml:lang="en-US" id="label_SeriesAPreferredStockMember">Series A Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAPreferredStockMember" xlink:to="label_SeriesAPreferredStockMember" xlink:title="label_SeriesAPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesAPreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesAPreferredStockMember_1" xml:lang="en-US" id="label_SeriesAPreferredStockMember_1">Series A convertible redeemable preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAPreferredStockMember" xlink:to="label_SeriesAPreferredStockMember_1" xlink:title="label_SeriesAPreferredStockMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="SeriesBPreferredStockMember" xlink:title="SeriesBPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesBPreferredStockMember" xml:lang="en-US" id="label_SeriesBPreferredStockMember">Series B Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockMember" xlink:to="label_SeriesBPreferredStockMember" xlink:title="label_SeriesBPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesBPreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesBPreferredStockMember_1" xml:lang="en-US" id="label_SeriesBPreferredStockMember_1">Series B convertible redeemable preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBPreferredStockMember" xlink:to="label_SeriesBPreferredStockMember_1" xlink:title="label_SeriesBPreferredStockMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="SeriesCPreferredStockMember" xlink:title="SeriesCPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesCPreferredStockMember" xml:lang="en-US" id="label_SeriesCPreferredStockMember">Series C Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesCPreferredStockMember" xlink:to="label_SeriesCPreferredStockMember" xlink:title="label_SeriesCPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesCPreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesCPreferredStockMember_1" xml:lang="en-US" id="label_SeriesCPreferredStockMember_1">Series C convertible redeemable preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesCPreferredStockMember" xlink:to="label_SeriesCPreferredStockMember_1" xlink:title="label_SeriesCPreferredStockMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="SeriesDPreferredStockMember" xlink:title="SeriesDPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesDPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesDPreferredStockMember" xml:lang="en-US" id="label_SeriesDPreferredStockMember">Series D Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesDPreferredStockMember" xlink:to="label_SeriesDPreferredStockMember" xlink:title="label_SeriesDPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesDPreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesDPreferredStockMember_1" xml:lang="en-US" id="label_SeriesDPreferredStockMember_1">Series D convertible redeemable preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesDPreferredStockMember" xlink:to="label_SeriesDPreferredStockMember_1" xlink:title="label_SeriesDPreferredStockMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:title="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xml:lang="en-US" id="label_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">Share-based Arrangements with Employees and Nonemployees [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="label_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:title="label_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_1" xml:lang="en-US" id="label_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_1">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="label_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_1" xlink:title="label_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensation" xml:lang="en-US" id="label_ShareBasedCompensation">Share-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="label_ShareBasedCompensation" xlink:title="label_ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensation_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensation_1" xml:lang="en-US" id="label_ShareBasedCompensation_1">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="label_ShareBasedCompensation_1" xlink:title="label_ShareBasedCompensation_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1">Vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2">Restricted stock granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1">Unvested at end of year (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2">Unvested at beginning of year (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1">Restricted stock awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1">Unvested at end of year (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2">Unvested at beginning of year (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1">Weighted-average purchase price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2">Weighted-Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1">Vested (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1">Vested (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1">Contractual life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2">Period from grant date to expiration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1">Weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1">Expected dividend yield (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2">Expected term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2">Volatility (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2">Risk-free interest rate (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1">Shares of common stock authorized for issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2">Maximum number of shares authorized for issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1">Stock option activity, additional information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1">Exercisable at end of period, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2">Exercisable at end of period, Aggregate intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1">Exercisable at end of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1">Exercisable at end of period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1">Exercisable at end of period, Weighted-average remaining contractual term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1">Cancelled (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1">Cancelled (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2">Options granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1">Schedule of additional information about stock option activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1">Outstanding at end of period, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2">Outstanding at end of period, Aggregate intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1">Outstanding at end of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2">Outstanding at beginning of year (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3">Shares of common stock authorized for issuance outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1">Stock option activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1">Outstanding at end of period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2">Outstanding at beginning of year (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1">Weighted average exercise price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1">Outstanding at end of period, Weighted-average remaining contractual term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1">Vested and expected to vest at end of period, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2">Vested and expected to vest at end of period, Aggregate intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1">Vested and expected to vest at end of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1">Vested and expected to vest at end of period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1">Vested and expected to vest at end of period, weighted-average remaining contractual term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1">Equity Award [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1">Exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="ShareBasedCompensationAwardTrancheOneMember" xlink:title="ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US" id="label_ShareBasedCompensationAwardTrancheOneMember">Share Based Compensation Award Tranche One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAwardTrancheOneMember" xlink:to="label_ShareBasedCompensationAwardTrancheOneMember" xlink:title="label_ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationAwardTrancheOneMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationAwardTrancheOneMember_1" xml:lang="en-US" id="label_ShareBasedCompensationAwardTrancheOneMember_1">Vested upon grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAwardTrancheOneMember" xlink:to="label_ShareBasedCompensationAwardTrancheOneMember_1" xlink:title="label_ShareBasedCompensationAwardTrancheOneMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="ShareBasedCompensationAwardTrancheTwoMember" xlink:title="ShareBasedCompensationAwardTrancheTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US" id="label_ShareBasedCompensationAwardTrancheTwoMember">Share Based Compensation Award Tranche Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAwardTrancheTwoMember" xlink:to="label_ShareBasedCompensationAwardTrancheTwoMember" xlink:title="label_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationAwardTrancheTwoMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationAwardTrancheTwoMember_1" xml:lang="en-US" id="label_ShareBasedCompensationAwardTrancheTwoMember_1">Vesting in monthly installments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAwardTrancheTwoMember" xlink:to="label_ShareBasedCompensationAwardTrancheTwoMember_1" xlink:title="label_ShareBasedCompensationAwardTrancheTwoMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US" id="label_ShareBasedCompensationOptionAndIncentivePlansPolicy">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="label_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="label_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xml:lang="en-US" id="label_ShareBasedCompensationOptionAndIncentivePlansPolicy_1">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="label_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xlink:title="label_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:label xlink:type="resource" xlink:label="label_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharePrice" xml:lang="en-US" id="label_SharePrice">Share Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="label_SharePrice" xlink:title="label_SharePrice" />
    <link:label xlink:type="resource" xlink:label="label_SharePrice_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharePrice_1" xml:lang="en-US" id="label_SharePrice_1">Fair value of stock (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="label_SharePrice_1" xlink:title="label_SharePrice_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="SharesIssuedPricePerShare" xlink:title="SharesIssuedPricePerShare" />
    <link:label xlink:type="resource" xlink:label="label_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharesIssuedPricePerShare" xml:lang="en-US" id="label_SharesIssuedPricePerShare">Shares Issued, Price Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedPricePerShare" xlink:to="label_SharesIssuedPricePerShare" xlink:title="label_SharesIssuedPricePerShare" />
    <link:label xlink:type="resource" xlink:label="label_SharesIssuedPricePerShare_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_SharesIssuedPricePerShare_1" xml:lang="en-US" id="label_SharesIssuedPricePerShare_1">Offering price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedPricePerShare" xlink:to="label_SharesIssuedPricePerShare_1" xlink:title="label_SharesIssuedPricePerShare_1" />
    <link:label xlink:type="resource" xlink:label="label_SharesIssuedPricePerShare_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharesIssuedPricePerShare_2" xml:lang="en-US" id="label_SharesIssuedPricePerShare_2">Issue price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedPricePerShare" xlink:to="label_SharesIssuedPricePerShare_2" xlink:title="label_SharesIssuedPricePerShare_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharesOutstanding" xml:lang="en-US" id="label_SharesOutstanding">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="label_SharesOutstanding" xlink:title="label_SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_SharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_SharesOutstanding_1" xml:lang="en-US" id="label_SharesOutstanding_1">Balance at end of year (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="label_SharesOutstanding_1" xlink:title="label_SharesOutstanding_1" />
    <link:label xlink:type="resource" xlink:label="label_SharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_SharesOutstanding_2" xml:lang="en-US" id="label_SharesOutstanding_2">Balance at beginning of year (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="label_SharesOutstanding_2" xlink:title="label_SharesOutstanding_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermDebtOtherDisclosuresAbstract" xlink:label="ShortTermDebtOtherDisclosuresAbstract" xlink:title="ShortTermDebtOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ShortTermDebtOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShortTermDebtOtherDisclosuresAbstract" xml:lang="en-US" id="label_ShortTermDebtOtherDisclosuresAbstract">Convertible Bridge Note with Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermDebtOtherDisclosuresAbstract" xlink:to="label_ShortTermDebtOtherDisclosuresAbstract" xlink:title="label_ShortTermDebtOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="ShortTermDebtTextBlock" xlink:title="ShortTermDebtTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ShortTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShortTermDebtTextBlock" xml:lang="en-US" id="label_ShortTermDebtTextBlock">Short-term Debt [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermDebtTextBlock" xlink:to="label_ShortTermDebtTextBlock" xlink:title="label_ShortTermDebtTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ShortTermDebtTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShortTermDebtTextBlock_1" xml:lang="en-US" id="label_ShortTermDebtTextBlock_1">Convertible Bridge Note with Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermDebtTextBlock" xlink:to="label_ShortTermDebtTextBlock_1" xlink:title="label_ShortTermDebtTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="label_SignificantAccountingPoliciesTextBlock">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="label_SignificantAccountingPoliciesTextBlock" xlink:title="label_SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SignificantAccountingPoliciesTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_SignificantAccountingPoliciesTextBlock_1" xml:lang="en-US" id="label_SignificantAccountingPoliciesTextBlock_1">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="label_SignificantAccountingPoliciesTextBlock_1" xlink:title="label_SignificantAccountingPoliciesTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="StandbyLettersOfCreditMember" xlink:title="StandbyLettersOfCreditMember" />
    <link:label xlink:type="resource" xlink:label="label_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StandbyLettersOfCreditMember" xml:lang="en-US" id="label_StandbyLettersOfCreditMember">Standby Letters Of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StandbyLettersOfCreditMember" xlink:to="label_StandbyLettersOfCreditMember" xlink:title="label_StandbyLettersOfCreditMember" />
    <link:label xlink:type="resource" xlink:label="label_StandbyLettersOfCreditMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StandbyLettersOfCreditMember_1" xml:lang="en-US" id="label_StandbyLettersOfCreditMember_1">Stand-by letter of credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StandbyLettersOfCreditMember" xlink:to="label_StandbyLettersOfCreditMember_1" xlink:title="label_StandbyLettersOfCreditMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:label xlink:type="resource" xlink:label="label_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StateAndLocalJurisdictionMember" xml:lang="en-US" id="label_StateAndLocalJurisdictionMember">State And Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StateAndLocalJurisdictionMember" xlink:to="label_StateAndLocalJurisdictionMember" xlink:title="label_StateAndLocalJurisdictionMember" />
    <link:label xlink:type="resource" xlink:label="label_StateAndLocalJurisdictionMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StateAndLocalJurisdictionMember_1" xml:lang="en-US" id="label_StateAndLocalJurisdictionMember_1">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StateAndLocalJurisdictionMember" xlink:to="label_StateAndLocalJurisdictionMember_1" xlink:title="label_StateAndLocalJurisdictionMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="label_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementClassOfStockAxis" xml:lang="en-US" id="label_StatementClassOfStockAxis">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="label_StatementClassOfStockAxis" xlink:title="label_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="label_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementEquityComponentsAxis" xml:lang="en-US" id="label_StatementEquityComponentsAxis">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="label_StatementEquityComponentsAxis" xlink:title="label_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="label_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementLineItems" xml:lang="en-US" id="label_StatementLineItems">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="label_StatementLineItems" xlink:title="label_StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="label_StatementLineItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StatementLineItems_1" xml:lang="en-US" id="label_StatementLineItems_1">Statement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="label_StatementLineItems_1" xlink:title="label_StatementLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfCashFlowsAbstract" xml:lang="en-US" id="label_StatementOfCashFlowsAbstract">CONDENSED STATEMENTS OF CASH FLOWS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="label_StatementOfCashFlowsAbstract" xlink:title="label_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfFinancialPositionAbstract" xml:lang="en-US" id="label_StatementOfFinancialPositionAbstract">BALANCE SHEETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="label_StatementOfFinancialPositionAbstract" xlink:title="label_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfStockholdersEquityAbstract" xml:lang="en-US" id="label_StatementOfStockholdersEquityAbstract">STATEMENTS OF SHAREHOLDERS' DEFICIT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="label_StatementOfStockholdersEquityAbstract" xlink:title="label_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:label xlink:type="resource" xlink:label="label_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementScenarioAxis" xml:lang="en-US" id="label_StatementScenarioAxis">Scenario [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementScenarioAxis" xlink:to="label_StatementScenarioAxis" xlink:title="label_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="label_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementTable" xml:lang="en-US" id="label_StatementTable">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="label_StatementTable" xlink:title="label_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquity" xml:lang="en-US" id="label_StockholdersEquity">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity" xlink:title="label_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_StockholdersEquity_1" xml:lang="en-US" id="label_StockholdersEquity_1">Total shareholders' equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity_1" xlink:title="label_StockholdersEquity_1" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity_2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_StockholdersEquity_2" xml:lang="en-US" id="label_StockholdersEquity_2">Balance at end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity_2" xlink:title="label_StockholdersEquity_2" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity_3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_StockholdersEquity_3" xml:lang="en-US" id="label_StockholdersEquity_3">Balance at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity_3" xlink:title="label_StockholdersEquity_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityAbstract" xml:lang="en-US" id="label_StockholdersEquityAbstract">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="label_StockholdersEquityAbstract" xlink:title="label_StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityAbstract_1" xml:lang="en-US" id="label_StockholdersEquityAbstract_1">Shareholders' equity (deficit):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="label_StockholdersEquityAbstract_1" xlink:title="label_StockholdersEquityAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityNoteAbstract" xml:lang="en-US" id="label_StockholdersEquityNoteAbstract">Stockholders' Equity Note [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteAbstract" xlink:to="label_StockholdersEquityNoteAbstract" xlink:title="label_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US" id="label_StockholdersEquityNoteStockSplitConversionRatio1">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="label_StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="label_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteStockSplitConversionRatio1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityNoteStockSplitConversionRatio1_1" xml:lang="en-US" id="label_StockholdersEquityNoteStockSplitConversionRatio1_1">Common stock split ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="label_StockholdersEquityNoteStockSplitConversionRatio1_1" xlink:title="label_StockholdersEquityNoteStockSplitConversionRatio1_1" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteStockSplitConversionRatio1_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_StockholdersEquityNoteStockSplitConversionRatio1_2" xml:lang="en-US" id="label_StockholdersEquityNoteStockSplitConversionRatio1_2">Performance adjustment ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="label_StockholdersEquityNoteStockSplitConversionRatio1_2" xlink:title="label_StockholdersEquityNoteStockSplitConversionRatio1_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesNewIssues">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_StockIssuedDuringPeriodSharesNewIssues" xlink:title="label_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesNewIssues_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesNewIssues_1">Issuance of stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_StockIssuedDuringPeriodSharesNewIssues_1" xlink:title="label_StockIssuedDuringPeriodSharesNewIssues_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesNewIssues_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_StockIssuedDuringPeriodSharesNewIssues_2" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesNewIssues_2">Common stock sold (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_StockIssuedDuringPeriodSharesNewIssues_2" xlink:title="label_StockIssuedDuringPeriodSharesNewIssues_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="label_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="label_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_1">Issuance of restricted stock awards to employees (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="label_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_1" xlink:title="label_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesStockOptionsExercised">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="label_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesStockOptionsExercised_1">Exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xlink:title="label_StockIssuedDuringPeriodSharesStockOptionsExercised_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesStockOptionsExercised_2">Exercise of common stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xlink:title="label_StockIssuedDuringPeriodSharesStockOptionsExercised_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueNewIssues">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="label_StockIssuedDuringPeriodValueNewIssues" xlink:title="label_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueNewIssues_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueNewIssues_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueNewIssues_1">Aggregate consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="label_StockIssuedDuringPeriodValueNewIssues_1" xlink:title="label_StockIssuedDuringPeriodValueNewIssues_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueStockOptionsExercised">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="label_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="label_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueStockOptionsExercised_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueStockOptionsExercised_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueStockOptionsExercised_1">Exercise of common stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="label_StockIssuedDuringPeriodValueStockOptionsExercised_1" xlink:title="label_StockIssuedDuringPeriodValueStockOptionsExercised_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventLineItems" xml:lang="en-US" id="label_SubsequentEventLineItems">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventLineItems" xlink:to="label_SubsequentEventLineItems" xlink:title="label_SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventLineItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SubsequentEventLineItems_1" xml:lang="en-US" id="label_SubsequentEventLineItems_1">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventLineItems" xlink:to="label_SubsequentEventLineItems_1" xlink:title="label_SubsequentEventLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventMember" xml:lang="en-US" id="label_SubsequentEventMember">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="label_SubsequentEventMember" xlink:title="label_SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SubsequentEventMember_1" xml:lang="en-US" id="label_SubsequentEventMember_1">Subsequent events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="label_SubsequentEventMember_1" xlink:title="label_SubsequentEventMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventsAbstract" xml:lang="en-US" id="label_SubsequentEventsAbstract">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsAbstract" xlink:to="label_SubsequentEventsAbstract" xlink:title="label_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="SubsequentEventsPolicyPolicyTextBlock" xlink:title="SubsequentEventsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US" id="label_SubsequentEventsPolicyPolicyTextBlock">Subsequent Events, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsPolicyPolicyTextBlock" xlink:to="label_SubsequentEventsPolicyPolicyTextBlock" xlink:title="label_SubsequentEventsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SubsequentEventsPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_SubsequentEventsPolicyPolicyTextBlock_1">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsPolicyPolicyTextBlock" xlink:to="label_SubsequentEventsPolicyPolicyTextBlock_1" xlink:title="label_SubsequentEventsPolicyPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventsTextBlock" xml:lang="en-US" id="label_SubsequentEventsTextBlock">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="label_SubsequentEventsTextBlock" xlink:title="label_SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_SubsequentEventsTextBlock_1" xml:lang="en-US" id="label_SubsequentEventsTextBlock_1">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="label_SubsequentEventsTextBlock_1" xlink:title="label_SubsequentEventsTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventTable" xml:lang="en-US" id="label_SubsequentEventTable">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTable" xlink:to="label_SubsequentEventTable" xlink:title="label_SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventTypeAxis" xml:lang="en-US" id="label_SubsequentEventTypeAxis">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeAxis" xlink:to="label_SubsequentEventTypeAxis" xlink:title="label_SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventTypeDomain" xml:lang="en-US" id="label_SubsequentEventTypeDomain">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="label_SubsequentEventTypeDomain" xlink:title="label_SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventTypeDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SubsequentEventTypeDomain_1" xml:lang="en-US" id="label_SubsequentEventTypeDomain_1">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="label_SubsequentEventTypeDomain_1" xlink:title="label_SubsequentEventTypeDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:label xlink:type="resource" xlink:label="label_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xml:lang="en-US" id="label_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="label_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="label_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="label_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsidiarySaleOfStockAxis" xml:lang="en-US" id="label_SubsidiarySaleOfStockAxis">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="label_SubsidiarySaleOfStockAxis" xlink:title="label_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="SubsidiarySaleOfStockLineItems" xlink:title="SubsidiarySaleOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="label_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsidiarySaleOfStockLineItems" xml:lang="en-US" id="label_SubsidiarySaleOfStockLineItems">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="label_SubsidiarySaleOfStockLineItems" xlink:title="label_SubsidiarySaleOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="label_SubsidiarySaleOfStockLineItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SubsidiarySaleOfStockLineItems_1" xml:lang="en-US" id="label_SubsidiarySaleOfStockLineItems_1">Sale of stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="label_SubsidiarySaleOfStockLineItems_1" xlink:title="label_SubsidiarySaleOfStockLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="TemporaryEquityAbstract" xlink:title="TemporaryEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityAbstract" xml:lang="en-US" id="label_TemporaryEquityAbstract">Temporary Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityAbstract" xlink:to="label_TemporaryEquityAbstract" xlink:title="label_TemporaryEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityAbstract_1" xml:lang="en-US" id="label_TemporaryEquityAbstract_1">Convertible redeemable preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityAbstract" xlink:to="label_TemporaryEquityAbstract_1" xlink:title="label_TemporaryEquityAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends" xlink:label="TemporaryEquityAccretionOfDividends" xlink:title="TemporaryEquityAccretionOfDividends" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityAccretionOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityAccretionOfDividends" xml:lang="en-US" id="label_TemporaryEquityAccretionOfDividends">Temporary Equity, Accretion of Dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityAccretionOfDividends" xlink:to="label_TemporaryEquityAccretionOfDividends" xlink:title="label_TemporaryEquityAccretionOfDividends" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityAccretionOfDividends_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityAccretionOfDividends_1" xml:lang="en-US" id="label_TemporaryEquityAccretionOfDividends_1">Accrued dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityAccretionOfDividends" xlink:to="label_TemporaryEquityAccretionOfDividends_1" xlink:title="label_TemporaryEquityAccretionOfDividends_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US" id="label_TemporaryEquityCarryingAmountAttributableToParent">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCarryingAmountAttributableToParent" xlink:to="label_TemporaryEquityCarryingAmountAttributableToParent" xlink:title="label_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityCarryingAmountAttributableToParent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityCarryingAmountAttributableToParent_1" xml:lang="en-US" id="label_TemporaryEquityCarryingAmountAttributableToParent_1">Convertible redeemable preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCarryingAmountAttributableToParent" xlink:to="label_TemporaryEquityCarryingAmountAttributableToParent_1" xlink:title="label_TemporaryEquityCarryingAmountAttributableToParent_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityCarryingAmountAttributableToParent_2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_TemporaryEquityCarryingAmountAttributableToParent_2" xml:lang="en-US" id="label_TemporaryEquityCarryingAmountAttributableToParent_2">Balance at end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCarryingAmountAttributableToParent" xlink:to="label_TemporaryEquityCarryingAmountAttributableToParent_2" xlink:title="label_TemporaryEquityCarryingAmountAttributableToParent_2" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityCarryingAmountAttributableToParent_3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_TemporaryEquityCarryingAmountAttributableToParent_3" xml:lang="en-US" id="label_TemporaryEquityCarryingAmountAttributableToParent_3">Balance at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCarryingAmountAttributableToParent" xlink:to="label_TemporaryEquityCarryingAmountAttributableToParent_3" xlink:title="label_TemporaryEquityCarryingAmountAttributableToParent_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="TemporaryEquityDisclosureAbstract" xlink:title="TemporaryEquityDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityDisclosureAbstract" xml:lang="en-US" id="label_TemporaryEquityDisclosureAbstract">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityDisclosureAbstract" xlink:to="label_TemporaryEquityDisclosureAbstract" xlink:title="label_TemporaryEquityDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="TemporaryEquityLiquidationPreference" xlink:title="TemporaryEquityLiquidationPreference" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityLiquidationPreference" xml:lang="en-US" id="label_TemporaryEquityLiquidationPreference">Temporary Equity, Liquidation Preference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityLiquidationPreference" xlink:to="label_TemporaryEquityLiquidationPreference" xlink:title="label_TemporaryEquityLiquidationPreference" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityLiquidationPreference_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityLiquidationPreference_1" xml:lang="en-US" id="label_TemporaryEquityLiquidationPreference_1">Convertible redeemable preferred stock, liquidation preference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityLiquidationPreference" xlink:to="label_TemporaryEquityLiquidationPreference_1" xlink:title="label_TemporaryEquityLiquidationPreference_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="TemporaryEquityParOrStatedValuePerShare" xlink:title="TemporaryEquityParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US" id="label_TemporaryEquityParOrStatedValuePerShare">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityParOrStatedValuePerShare" xlink:to="label_TemporaryEquityParOrStatedValuePerShare" xlink:title="label_TemporaryEquityParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityParOrStatedValuePerShare_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityParOrStatedValuePerShare_1" xml:lang="en-US" id="label_TemporaryEquityParOrStatedValuePerShare_1">Convertible redeemable preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityParOrStatedValuePerShare" xlink:to="label_TemporaryEquityParOrStatedValuePerShare_1" xlink:title="label_TemporaryEquityParOrStatedValuePerShare_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="TemporaryEquitySharesAuthorized" xlink:title="TemporaryEquitySharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquitySharesAuthorized" xml:lang="en-US" id="label_TemporaryEquitySharesAuthorized">Temporary Equity, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesAuthorized" xlink:to="label_TemporaryEquitySharesAuthorized" xlink:title="label_TemporaryEquitySharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquitySharesAuthorized_1" xml:lang="en-US" id="label_TemporaryEquitySharesAuthorized_1">Convertible redeemable preferred stock, authorized shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesAuthorized" xlink:to="label_TemporaryEquitySharesAuthorized_1" xlink:title="label_TemporaryEquitySharesAuthorized_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesAuthorized_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_TemporaryEquitySharesAuthorized_2" xml:lang="en-US" id="label_TemporaryEquitySharesAuthorized_2">Authorized preferred stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesAuthorized" xlink:to="label_TemporaryEquitySharesAuthorized_2" xlink:title="label_TemporaryEquitySharesAuthorized_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="TemporaryEquitySharesIssued" xlink:title="TemporaryEquitySharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquitySharesIssued" xml:lang="en-US" id="label_TemporaryEquitySharesIssued">Temporary Equity, Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesIssued" xlink:to="label_TemporaryEquitySharesIssued" xlink:title="label_TemporaryEquitySharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesIssued_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquitySharesIssued_1" xml:lang="en-US" id="label_TemporaryEquitySharesIssued_1">Convertible redeemable preferred stock, issued shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesIssued" xlink:to="label_TemporaryEquitySharesIssued_1" xlink:title="label_TemporaryEquitySharesIssued_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesIssued_2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_TemporaryEquitySharesIssued_2" xml:lang="en-US" id="label_TemporaryEquitySharesIssued_2">Balance at end of year (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesIssued" xlink:to="label_TemporaryEquitySharesIssued_2" xlink:title="label_TemporaryEquitySharesIssued_2" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesIssued_3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_TemporaryEquitySharesIssued_3" xml:lang="en-US" id="label_TemporaryEquitySharesIssued_3">Balance at beginning of year (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesIssued" xlink:to="label_TemporaryEquitySharesIssued_3" xlink:title="label_TemporaryEquitySharesIssued_3" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesIssued_4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_TemporaryEquitySharesIssued_4" xml:lang="en-US" id="label_TemporaryEquitySharesIssued_4">Preferred stock issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesIssued" xlink:to="label_TemporaryEquitySharesIssued_4" xlink:title="label_TemporaryEquitySharesIssued_4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="TemporaryEquitySharesOutstanding" xlink:title="TemporaryEquitySharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquitySharesOutstanding" xml:lang="en-US" id="label_TemporaryEquitySharesOutstanding">Temporary Equity, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesOutstanding" xlink:to="label_TemporaryEquitySharesOutstanding" xlink:title="label_TemporaryEquitySharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquitySharesOutstanding_1" xml:lang="en-US" id="label_TemporaryEquitySharesOutstanding_1">Convertible redeemable preferred stock, outstanding shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesOutstanding" xlink:to="label_TemporaryEquitySharesOutstanding_1" xlink:title="label_TemporaryEquitySharesOutstanding_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_TemporaryEquitySharesOutstanding_2" xml:lang="en-US" id="label_TemporaryEquitySharesOutstanding_2">Preferred stock outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesOutstanding" xlink:to="label_TemporaryEquitySharesOutstanding_2" xlink:title="label_TemporaryEquitySharesOutstanding_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:title="TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xml:lang="en-US" id="label_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="label_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:title="label_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_1" xml:lang="en-US" id="label_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_1">Aggregate consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="label_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_1" xlink:title="label_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_1" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_2" xml:lang="en-US" id="label_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_2">Issuance of new Series C convertible redeemable preferred stock, net of issuance costs of $45</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="label_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_2" xlink:title="label_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:label xlink:type="resource" xlink:label="label_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TitleOfIndividualAxis" xml:lang="en-US" id="label_TitleOfIndividualAxis">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualAxis" xlink:to="label_TitleOfIndividualAxis" xlink:title="label_TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xlink:type="resource" xlink:label="label_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US" id="label_TitleOfIndividualWithRelationshipToEntityDomain">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="label_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="label_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xlink:type="resource" xlink:label="label_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TitleOfIndividualWithRelationshipToEntityDomain_1" xml:lang="en-US" id="label_TitleOfIndividualWithRelationshipToEntityDomain_1">Relationship to Entity [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="label_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="label_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockCarryingBasis" xlink:label="TreasuryStockCarryingBasis" xlink:title="TreasuryStockCarryingBasis" />
    <link:label xlink:type="resource" xlink:label="label_TreasuryStockCarryingBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TreasuryStockCarryingBasis" xml:lang="en-US" id="label_TreasuryStockCarryingBasis">Treasury Stock, Carrying Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockCarryingBasis" xlink:to="label_TreasuryStockCarryingBasis" xlink:title="label_TreasuryStockCarryingBasis" />
    <link:label xlink:type="resource" xlink:label="label_TreasuryStockCarryingBasis_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_TreasuryStockCarryingBasis_1" xml:lang="en-US" id="label_TreasuryStockCarryingBasis_1">Treasury stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockCarryingBasis" xlink:to="label_TreasuryStockCarryingBasis_1" xlink:title="label_TreasuryStockCarryingBasis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="TreasuryStockMember" xlink:title="TreasuryStockMember" />
    <link:label xlink:type="resource" xlink:label="label_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TreasuryStockMember" xml:lang="en-US" id="label_TreasuryStockMember">Treasury Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockMember" xlink:to="label_TreasuryStockMember" xlink:title="label_TreasuryStockMember" />
    <link:label xlink:type="resource" xlink:label="label_TreasuryStockMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TreasuryStockMember_1" xml:lang="en-US" id="label_TreasuryStockMember_1">Treasury Stock, at cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TreasuryStockMember" xlink:to="label_TreasuryStockMember_1" xlink:title="label_TreasuryStockMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="UnrealizedGainLossOnDerivatives" xlink:title="UnrealizedGainLossOnDerivatives" />
    <link:label xlink:type="resource" xlink:label="label_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_UnrealizedGainLossOnDerivatives" xml:lang="en-US" id="label_UnrealizedGainLossOnDerivatives">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrealizedGainLossOnDerivatives" xlink:to="label_UnrealizedGainLossOnDerivatives" xlink:title="label_UnrealizedGainLossOnDerivatives" />
    <link:label xlink:type="resource" xlink:label="label_UnrealizedGainLossOnDerivatives_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_UnrealizedGainLossOnDerivatives_1" xml:lang="en-US" id="label_UnrealizedGainLossOnDerivatives_1">Change in fair value of derivative liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrealizedGainLossOnDerivatives" xlink:to="label_UnrealizedGainLossOnDerivatives_1" xlink:title="label_UnrealizedGainLossOnDerivatives_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="label_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_UseOfEstimates" xml:lang="en-US" id="label_UseOfEstimates">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="label_UseOfEstimates" xlink:title="label_UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="label_UseOfEstimates_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_UseOfEstimates_1" xml:lang="en-US" id="label_UseOfEstimates_1">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="label_UseOfEstimates_1" xlink:title="label_UseOfEstimates_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowanceAbstract" xlink:label="ValuationAllowanceAbstract" xlink:title="ValuationAllowanceAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ValuationAllowanceAbstract" xml:lang="en-US" id="label_ValuationAllowanceAbstract">Valuation Allowance [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowanceAbstract" xlink:to="label_ValuationAllowanceAbstract" xlink:title="label_ValuationAllowanceAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ValuationAllowanceAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ValuationAllowanceAbstract_1" xml:lang="en-US" id="label_ValuationAllowanceAbstract_1">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowanceAbstract" xlink:to="label_ValuationAllowanceAbstract_1" xlink:title="label_ValuationAllowanceAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xlink:type="resource" xlink:label="label_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US" id="label_ValuationAllowanceDeferredTaxAssetChangeInAmount">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="label_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="label_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xlink:type="resource" xlink:label="label_ValuationAllowanceDeferredTaxAssetChangeInAmount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ValuationAllowanceDeferredTaxAssetChangeInAmount_1" xml:lang="en-US" id="label_ValuationAllowanceDeferredTaxAssetChangeInAmount_1">Deferred tax asset valuation allowance increase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="label_ValuationAllowanceDeferredTaxAssetChangeInAmount_1" xlink:title="label_ValuationAllowanceDeferredTaxAssetChangeInAmount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:label xlink:type="resource" xlink:label="label_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_VariableRateAxis" xml:lang="en-US" id="label_VariableRateAxis">Variable Rate [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableRateAxis" xlink:to="label_VariableRateAxis" xlink:title="label_VariableRateAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:label xlink:type="resource" xlink:label="label_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_VariableRateDomain" xml:lang="en-US" id="label_VariableRateDomain">Variable Rate [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableRateDomain" xlink:to="label_VariableRateDomain" xlink:title="label_VariableRateDomain" />
    <link:label xlink:type="resource" xlink:label="label_VariableRateDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_VariableRateDomain_1" xml:lang="en-US" id="label_VariableRateDomain_1">Variable Rate [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableRateDomain" xlink:to="label_VariableRateDomain_1" xlink:title="label_VariableRateDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:label xlink:type="resource" xlink:label="label_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_VestingAxis" xml:lang="en-US" id="label_VestingAxis">Vesting [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingAxis" xlink:to="label_VestingAxis" xlink:title="label_VestingAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:label xlink:type="resource" xlink:label="label_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_VestingDomain" xml:lang="en-US" id="label_VestingDomain">Vesting [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingDomain" xlink:to="label_VestingDomain" xlink:title="label_VestingDomain" />
    <link:label xlink:type="resource" xlink:label="label_VestingDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_VestingDomain_1" xml:lang="en-US" id="label_VestingDomain_1">Vesting [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingDomain" xlink:to="label_VestingDomain_1" xlink:title="label_VestingDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="label_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantMember" xml:lang="en-US" id="label_WarrantMember">Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="label_WarrantMember" xlink:title="label_WarrantMember" />
    <link:label xlink:type="resource" xlink:label="label_WarrantMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantMember_1" xml:lang="en-US" id="label_WarrantMember_1">Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="label_WarrantMember_1" xlink:title="label_WarrantMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" xlink:title="WarrantsAndRightsNoteDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsAndRightsNoteDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantsAndRightsNoteDisclosureAbstract" xml:lang="en-US" id="label_WarrantsAndRightsNoteDisclosureAbstract">WARRANTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="label_WarrantsAndRightsNoteDisclosureAbstract" xlink:title="label_WarrantsAndRightsNoteDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantsAndRightsOutstanding" xml:lang="en-US" id="label_WarrantsAndRightsOutstanding">Warrants and Rights Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstanding" xlink:to="label_WarrantsAndRightsOutstanding" xlink:title="label_WarrantsAndRightsOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsAndRightsOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantsAndRightsOutstanding_1" xml:lang="en-US" id="label_WarrantsAndRightsOutstanding_1">Stock purchase right liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstanding" xlink:to="label_WarrantsAndRightsOutstanding_1" xlink:title="label_WarrantsAndRightsOutstanding_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US" id="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xml:lang="en-US" id="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1">Weighted-average number of common shares used in net loss per share-basic and diluted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xlink:title="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2" xml:lang="en-US" id="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2">Weighted-average shares used in computing basic and diluted net loss per common share (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2" xlink:title="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="label_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmendmentFlag" xml:lang="en-US" id="label_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="label_AmendmentFlag" xlink:title="label_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="label_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CurrentFiscalYearEndDate" xml:lang="en-US" id="label_CurrentFiscalYearEndDate">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="label_CurrentFiscalYearEndDate" xlink:title="label_CurrentFiscalYearEndDate" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="label_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentFiscalPeriodFocus" xml:lang="en-US" id="label_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="label_DocumentFiscalPeriodFocus" xlink:title="label_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="label_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentFiscalYearFocus" xml:lang="en-US" id="label_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="label_DocumentFiscalYearFocus" xlink:title="label_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="label_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentPeriodEndDate" xml:lang="en-US" id="label_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="label_DocumentPeriodEndDate" xlink:title="label_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="label_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentType" xml:lang="en-US" id="label_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="label_DocumentType" xlink:title="label_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="label_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCentralIndexKey" xml:lang="en-US" id="label_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="label_EntityCentralIndexKey" xlink:title="label_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCommonStockSharesOutstanding" xml:lang="en-US" id="label_EntityCommonStockSharesOutstanding">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="label_EntityCommonStockSharesOutstanding" xlink:title="label_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="label_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCurrentReportingStatus" xml:lang="en-US" id="label_EntityCurrentReportingStatus">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="label_EntityCurrentReportingStatus" xlink:title="label_EntityCurrentReportingStatus" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="label_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityFilerCategory" xml:lang="en-US" id="label_EntityFilerCategory">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="label_EntityFilerCategory" xlink:title="label_EntityFilerCategory" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:label xlink:type="resource" xlink:label="label_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityPublicFloat" xml:lang="en-US" id="label_EntityPublicFloat">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityPublicFloat" xlink:to="label_EntityPublicFloat" xlink:title="label_EntityPublicFloat" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="label_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityRegistrantName" xml:lang="en-US" id="label_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="label_EntityRegistrantName" xlink:title="label_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="label_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityVoluntaryFilers" xml:lang="en-US" id="label_EntityVoluntaryFilers">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityVoluntaryFilers" xlink:to="label_EntityVoluntaryFilers" xlink:title="label_EntityVoluntaryFilers" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="label_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityWellKnownSeasonedIssuer" xml:lang="en-US" id="label_EntityWellKnownSeasonedIssuer">Entity Well Known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityWellKnownSeasonedIssuer" xlink:to="label_EntityWellKnownSeasonedIssuer" xlink:title="label_EntityWellKnownSeasonedIssuer" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>coll-20160104_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="coll-20160104.xsd#DocumentDocumentAndEntityInformation" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementBalanceSheets" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementBalanceSheets" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementBalanceSheetsParenthetical" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementStatementsOfOperations" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementStatementsOfOperations" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementConvertibleRedeemablePreferredStock" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementConvertibleRedeemablePreferredStock" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementConvertibleRedeemablePreferredStockParenthetical" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementConvertibleRedeemablePreferredStockParenthetical" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementShareholdersDeficit" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementShareholdersDeficit" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlows" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementStatementsOfCashFlows" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlowsParenthetical" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementStatementsOfCashFlowsParenthetical" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNatureOfBusiness" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNatureOfBusiness" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShare" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNetLossPerCommonShare" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssets" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosurePropertyAndEquipment" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosurePropertyAndEquipment" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureAccruedExpenses" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureAccruedExpenses" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureDebt" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureDebt" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureWarrants" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureWarrants" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureEquity" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureEquity" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensation" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureStockBasedCompensation" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureIncomeTaxes" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureIncomeTaxes" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureEmployeeBenefits" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureEmployeeBenefits" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSubsequentEvents" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSubsequentEvents" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareTables" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNetLossPerCommonShareTables" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosurePropertyAndEquipmentTables" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosurePropertyAndEquipmentTables" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureAccruedExpensesTables" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureAccruedExpensesTables" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureCommitmentsAndContingenciesTables" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureDebtTables" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureDebtTables" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureEquityTables" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureEquityTables" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationTables" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureStockBasedCompensationTables" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureIncomeTaxesTables" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureIncomeTaxesTables" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNatureOfBusinessDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNatureOfBusinessDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNatureOfBusinessDetails2" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNatureOfBusinessDetails2" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails2" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails3" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails3" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails4" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails4" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails5" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails5" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNetLossPerCommonShareDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails2" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNetLossPerCommonShareDetails2" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails3" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNetLossPerCommonShareDetails3" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosurePropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureAccruedExpensesDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureAccruedExpensesDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureCommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureCommitmentsAndContingenciesDetails2" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureDebtDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureDebtDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureDebtDetails2" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureDebtDetails2" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureDebtDetails3" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureDebtDetails3" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureWarrantsDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureWarrantsDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureEquityDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureEquityDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureEquityDetails2" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureEquityDetails2" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureEquityDetails3" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureEquityDetails3" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureStockBasedCompensationDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails2" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureStockBasedCompensationDetails2" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails3" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureStockBasedCompensationDetails3" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails4" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureStockBasedCompensationDetails4" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails5" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureStockBasedCompensationDetails5" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureIncomeTaxesDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureIncomeTaxesDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureIncomeTaxesDetails2" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureIncomeTaxesDetails2" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureIncomeTaxesDetails3" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureIncomeTaxesDetails3" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureEmployeeBenefitsDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureEmployeeBenefitsDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSubsequentEventsUnauditedDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSubsequentEventsUnauditedDetails" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementBalanceSheetsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementBalanceSheetsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementBalanceSheetsParentheticalQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementBalanceSheetsParentheticalQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementStatementsOfOperationsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementStatementsOfOperationsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlowsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementStatementsOfCashFlowsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlowsParentheticalQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementStatementsOfCashFlowsParentheticalQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNatureOfBusinessQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNatureOfBusinessQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSummaryOfSignificantAccountingPoliciesQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNetLossPerCommonShareQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureFairValueOfFinancialInstrumentsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureFairValueOfFinancialInstrumentsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureAccruedExpensesQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureAccruedExpensesQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureConvertibleBridgeNoteWithRelatedPartyQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureConvertibleBridgeNoteWithRelatedPartyQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureConvertiblePreferredStockQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureConvertiblePreferredStockQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureStockBasedCompensationQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureCommitmentsAndContingenciesQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPoliciesQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareTablesQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNetLossPerCommonShareTablesQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTablesQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureFairValueOfFinancialInstrumentsTablesQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureAccruedExpensesTablesQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureAccruedExpensesTablesQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationTablesQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureStockBasedCompensationTablesQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNatureOfBusinessDetailsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNatureOfBusinessDetailsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetailsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2QuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails2QuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetailsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNetLossPerCommonShareDetailsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails2QuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNetLossPerCommonShareDetails2QuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureFairValueOfFinancialInstrumentsDetailsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureFairValueOfFinancialInstrumentsDetailsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureAccruedExpensesDetailsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureAccruedExpensesDetailsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureConvertibleBridgeNoteWithRelatedPartyDetailsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureConvertibleBridgeNoteWithRelatedPartyDetailsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureConvertiblePreferredStockDetailsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureConvertiblePreferredStockDetailsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetailsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureStockBasedCompensationDetailsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails2QuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureStockBasedCompensationDetails2QuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails3QuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureStockBasedCompensationDetails3QuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails4QuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureStockBasedCompensationDetails4QuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetailsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureCommitmentsAndContingenciesDetailsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetails2QuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureCommitmentsAndContingenciesDetails2QuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingencies" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureCommitmentsAndContingencies" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DocumentAndEntityInformationAbstract" xlink:label="coll_DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_635858824698296517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_635858824698296517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_635858824698306517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_635858824698306517" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_635858824698306517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_635858824698306517" xlink:title="presentation:  to " use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_635858824698306517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_635858824698306517" xlink:title="presentation:  to " use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_635858824698306517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_635858824698306517" xlink:title="presentation:  to " use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_635858824698306517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate_635858824698306517" xlink:title="presentation:  to " use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_635858824698306517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus_635858824698306517" xlink:title="presentation:  to " use="optional" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_635858824698306517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory_635858824698306517" xlink:title="presentation:  to " use="optional" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_635858824698306517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat_635858824698306517" xlink:title="presentation:  to " use="optional" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_635858824698306517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_635858824698306517" xlink:title="presentation:  to " use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_635858824698306517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus_635858824698306517" xlink:title="presentation:  to " use="optional" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_635858824698306517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_635858824698306517" xlink:title="presentation:  to " use="optional" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_DocumentAndEntityInformationAbstract" xlink:to="EntityVoluntaryFilers" xlink:title="presentation:  to EntityVoluntaryFilers" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_DocumentAndEntityInformationAbstract" xlink:to="EntityWellKnownSeasonedIssuer" xlink:title="presentation:  to EntityWellKnownSeasonedIssuer" order="14.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNatureOfBusiness">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_635858824698406517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_635858824698406517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNatureOfBusinessQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_635858815105470613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_635858815105470613" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNatureOfBusinessDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficitAbstract" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficitAbstract_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficitAbstract_635858824698446517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficitAbstract_635858824698446517" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_635858824698446517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNatureOfBusinessDetailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficitAbstract" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficitAbstract_635858815105500616" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficitAbstract_635858815105500616" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_635858815105500616" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficitAbstract_635858815105500616" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_635858815105500616" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation" xlink:label="coll_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation_635858815105500616" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="coll_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation_635858815105500616" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_635858824698406517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_635858824698406517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_635858815105470613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_635858815105470613" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_635793774048713473" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_635858824698416517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635793774048713473" xlink:to="us-gaap_UseOfEstimates_635858824698416517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock" xlink:label="coll_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock_635858824698416517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635793774048713473" xlink:to="coll_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock_635858824698416517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_635858824698416517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635793774048713473" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_635858824698416517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_635858824698416517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635793774048713473" xlink:to="us-gaap_ConcentrationRiskCreditRisk_635858824698416517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_635858824698416517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635793774048713473" xlink:to="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_635858824698416517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_635858824698416517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635793774048713473" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_635858824698416517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment_635858824698416517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635793774048713473" xlink:to="us-gaap_PropertyPlantAndEquipmentImpairment_635858824698416517" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_InitialPublicOfferingCostsPolicyPolicyTextBlock" xlink:label="coll_InitialPublicOfferingCostsPolicyPolicyTextBlock_635858824698416517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635793774048713473" xlink:to="coll_InitialPublicOfferingCostsPolicyPolicyTextBlock_635858824698416517" xlink:title="presentation:  to " use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_635858824698416517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635793774048713473" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_635858824698416517" xlink:title="presentation:  to " use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="us-gaap_LeasePolicyTextBlock_635858824698426517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635793774048713473" xlink:to="us-gaap_LeasePolicyTextBlock_635858824698426517" xlink:title="presentation:  to " use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock" xlink:label="coll_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock_635858824698426517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635793774048713473" xlink:to="coll_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock_635858824698426517" xlink:title="presentation:  to " use="optional" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_635858824698426517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635793774048713473" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_635858824698426517" xlink:title="presentation:  to " use="optional" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_PatentCostsIncurredPolicyPolicyTextBlock" xlink:label="coll_PatentCostsIncurredPolicyPolicyTextBlock_635858824698426517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635793774048713473" xlink:to="coll_PatentCostsIncurredPolicyPolicyTextBlock_635858824698426517" xlink:title="presentation:  to " use="optional" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_635858824698426517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635793774048713473" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_635858824698426517" xlink:title="presentation:  to " use="optional" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_635858824698426517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635793774048713473" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_635858824698426517" xlink:title="presentation:  to " use="optional" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_635858824698426517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635793774048713473" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_635858824698426517" xlink:title="presentation:  to " use="optional" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_635858824698426517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635793774048713473" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_635858824698426517" xlink:title="presentation:  to " use="optional" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_InitialPublicOfferingCostsPolicyPolicyTextBlock" xlink:label="coll_InitialPublicOfferingCostsPolicyPolicyTextBlock_635858815105490615" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="coll_InitialPublicOfferingCostsPolicyPolicyTextBlock_635858815105490615" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_635858815105490615" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_635858815105490615" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_635858815105490615" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_635858815105490615" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_635858815105490615" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_635858815105490615" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_635858815105490615" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_635858815105490615" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="coll_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_635858824698426517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="coll_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_635858824698426517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_635858824698456517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_635858824698456517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_635858824698456517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_635858824698456517" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_635858824698456517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_635858824698456517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_635858824698456517" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_635858824698456517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_635858824698456517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_635858824698456517" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_635858824698456517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_635858824698456517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_635858824698456517" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_635858824698456517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountLiability" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountLiability_635858824698456517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_635858824698456517" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountLiability_635858824698456517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails3QuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635858815105580624" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_635858815105580624" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635858815105580624" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_635858815105580624" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6358588151055806241" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635858815105580624" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6358588151055806241" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_635858815105580624" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635858815105580624" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_635858815105580624" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_635858815105580624" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635858815105580624" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_635858815105580624" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_635858815105580624" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635858815105580624" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_635858815105580624" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_635858815105580624" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635858815105580624" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_635858815105580624" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_635858815105580624" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635858815105580624" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_635858815105580624" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635858815105580624" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_635858815105580624" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635858815105580624" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_635858815105580624" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_635858815105590625" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635858815105580624" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_635858815105590625" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_635858815105580624" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635858815105580624" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_635858815105580624" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_635858815105580624" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635858815105580624" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_635858815105580624" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_635858815105590625" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635858815105580624" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_635858815105590625" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_635858815105590625" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635858815105580624" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_635858815105590625" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_635858815105590625" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635858815105580624" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_635858815105590625" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635858815105590625" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_635858815105590625" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635858815105590625" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_635858815105590625" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_635858815105590625" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635858815105590625" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_635858815105590625" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_635858815105590625" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635858815105590625" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_635858815105590625" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_635858815105590625" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635858815105590625" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_635858815105590625" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_635858815105590625" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635858815105590625" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_635858815105590625" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_635858815105590625" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635858815105590625" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_635858815105590625" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635858815105580624" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635858815105580624" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635858815105590625" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails4QuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635858815105590625" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_635858815105590625" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635858815105590625" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_635858815105590625" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_635858815105590625" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635858815105590625" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_635858815105590625" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_635858815105590625" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635858815105590625" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_635858815105590625" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635858815105590625" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShare">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_635858824698406517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_635858824698406517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_635858815105470613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_635858815105470613" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_635858824698426517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_635858824698426517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_635858824698426517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_635858824698426517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareTablesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_635858815105490615" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_635858815105490615" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_635858815105490615" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_635858815105490615" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_635858824698476517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_635858824698476517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="coll_PrepaidExpensesAndOtherCurrentAssetsTextBlock_635858824698406517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="coll_PrepaidExpensesAndOtherCurrentAssetsTextBlock_635858824698406517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_635790567363388416" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_635858824698426517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_635790567363388416" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_635858824698426517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosurePropertyAndEquipment">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_635858824698406517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_635858824698406517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosurePropertyAndEquipmentTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_635858824698426517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_635858824698426517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureAccruedExpenses">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_635858824698406517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_635858824698406517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureAccruedExpensesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_635858815105480614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_635858815105480614" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureAccruedExpensesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_635858824698436517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_635858824698436517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureAccruedExpensesTablesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_635858815105500616" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_635858815105500616" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureAccruedExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="coll_AccruedResearchAndDevelopmentCostsCurrent_635858824698496517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="coll_AccruedResearchAndDevelopmentCostsCurrent_635858824698496517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_635858824698496517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_635858824698496517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_635858824698496517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_635858824698496517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_635858824698496517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_InterestPayableCurrent_635858824698496517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_635858824698496517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_635858824698496517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_635858824698496517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_635858824698496517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureDebt">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_635858824698406517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_635858824698406517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureDebtTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_635858824698436517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_635858824698436517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureWarrants">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_WarrantsDisclosureTextBlock" xlink:label="coll_WarrantsDisclosureTextBlock_635858824698406517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="coll_WarrantsDisclosureTextBlock_635858824698406517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock" xlink:label="coll_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock_635858824698406517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="coll_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock_635858824698406517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureEquityTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="coll_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_635858824698436517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="coll_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_635858824698436517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_635858824698436517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_635858824698436517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensation">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_635858824698416517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_635858824698416517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_635858815105480614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_635858815105480614" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_635858824698436517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_635858824698436517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_635858824698436517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_635858824698436517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_635858824698436517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_635858824698436517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_635858824698436517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_635858824698436517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_635858824698436517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_635858824698436517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationTablesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_635858815105500616" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_635858815105500616" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_635858815105500616" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_635858815105500616" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_635858815105500616" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_635858815105500616" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureIncomeTaxes">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_635858824698416517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_635858824698416517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_635858824698436517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_635858824698436517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_635858824698436517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_635858824698436517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureEmployeeBenefits">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_635858824698416517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_635858824698416517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureEmployeeBenefitsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan" xlink:label="coll_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan_635858824698766517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="coll_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan_635858824698766517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_635858824698766517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_635858824698766517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSubsequentEvents">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_635858824698416517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_635858824698416517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_635858824698436517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_635858824698436517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_635858815105480614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_635858815105480614" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureConvertibleBridgeNoteWithRelatedPartyQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermDebtOtherDisclosuresAbstract" xlink:label="us-gaap_ShortTermDebtOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock_635858815105480614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtOtherDisclosuresAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock_635858815105480614" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureFairValueOfFinancialInstrumentsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_635858815105480614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_635858815105480614" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTablesQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_635858815105490615" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_635858815105490615" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureConvertiblePreferredStockQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock_635858815105480614" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_PreferredStockTextBlock_635858815105480614" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementStatementsOfOperationsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_635858815105400606" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_635858815105400606" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_635858815105400606" xlink:to="us-gaap_ResearchAndDevelopmentExpense_635858815105400606" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_635858815105400606" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_635858815105400606" xlink:to="us-gaap_GeneralAndAdministrativeExpense_635858815105400606" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_635858815105400606" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_635858815105400606" xlink:to="us-gaap_OperatingExpenses_635858815105400606" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="us-gaap_OtherExpensesAbstract_635858815105400606" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_635858815105400606" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_635858815105400606" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_635858815105400606" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_635858815105400606" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_635858815105400606" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_635858815105400606" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_635858815105400606" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_635858815105400606" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_635858815105400606" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_635858815105400606" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_635858815105400606" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_635858815105400606" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherExpensesAbstract_635858815105400606" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635858815105410607" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_635858815105410607" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_635858815105410607" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_635858815105410607" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_635858815105410607" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_635858815105410607" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureDebtDetails3">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_635785189025066740" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_MaturitiesOfDebtAbstract" xlink:label="coll_MaturitiesOfDebtAbstract_635858824698586517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_635785189025066740" xlink:to="coll_MaturitiesOfDebtAbstract_635858824698586517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent_635858824698586517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_MaturitiesOfDebtAbstract_635858824698586517" xlink:to="us-gaap_DebtCurrent_635858824698586517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_635858824698586517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_MaturitiesOfDebtAbstract_635858824698586517" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_635858824698586517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_635858824698586517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_MaturitiesOfDebtAbstract_635858824698586517" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_635858824698586517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_635858824698586517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_MaturitiesOfDebtAbstract_635858824698586517" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_635858824698586517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_635858824698586517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_MaturitiesOfDebtAbstract_635858824698586517" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount_635858824698586517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_635858824698586517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_635785189025066740" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_635858824698586517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_635858824698586517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_635858824698586517" xlink:to="us-gaap_LongTermDebt_635858824698586517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_635858824698746517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_635858824698746517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_635858824698746517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_635858824698746517" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_635858824698746517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent" xlink:label="coll_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent_635858824698746517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_635858824698746517" xlink:to="coll_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent_635858824698746517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_635858824698746517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_635858824698746517" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_635858824698746517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_635858824698756517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_635858824698746517" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_635858824698756517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_635858824698756517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_635858824698746517" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_635858824698756517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_635858824698756517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_635858824698746517" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_635858824698756517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureIncomeTaxesDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_635858824698756517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_635858824698756517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_635858824698756517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_635858824698756517" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_635858824698756517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_635858824698756517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_635858824698756517" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_635858824698756517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_635858824698756517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_635858824698756517" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_635858824698756517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_635858824698756517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_635858824698756517" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_635858824698756517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_635858824698756517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_635858824698756517" xlink:to="us-gaap_DeferredTaxAssetsGross_635858824698756517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_635858824698756517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_635858824698756517" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_635858824698756517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_635858824698756517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_635858824698756517" xlink:to="us-gaap_DeferredTaxAssetsNet_635858824698756517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_635858824698756517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_635858824698756517" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_635858824698756517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_635858824698756517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_635858824698756517" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_635858824698756517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_635858824698756517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_635858824698756517" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_635858824698756517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_635858824698756517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_635858824698756517" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_635858824698756517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowanceAbstract" xlink:label="us-gaap_ValuationAllowanceAbstract_635858824698756517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceAbstract_635858824698756517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_635858824698756517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract_635858824698756517" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_635858824698756517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent_635858824698486517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredOfferingCosts_635858824698486517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueFromEmployeesCurrent" xlink:label="us-gaap_DueFromEmployeesCurrent_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DueFromEmployeesCurrent_635858824698486517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent_635858824698486517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_PrepaidDevelopmentCosts" xlink:label="coll_PrepaidDevelopmentCosts_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="coll_PrepaidDevelopmentCosts_635858824698486517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635858824698486517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureAccruedExpensesDetailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_635785186058410745" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="coll_AccruedResearchAndDevelopmentCostsCurrent_635858815105530619" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_635785186058410745" xlink:to="coll_AccruedResearchAndDevelopmentCostsCurrent_635858815105530619" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_635858815105530619" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_635785186058410745" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_635858815105530619" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_635858815105540620" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_635785186058410745" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_635858815105540620" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_635858815105540620" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_635785186058410745" xlink:to="us-gaap_InterestPayableCurrent_635858815105540620" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_635858815105540620" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_635785186058410745" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_635858815105540620" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_635858815105540620" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_635785186058410745" xlink:to="us-gaap_AccruedLiabilitiesCurrent_635858815105540620" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="us-gaap_AccruedMarketingCostsCurrent_635858815105530619" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_635785186058410745" xlink:to="us-gaap_AccruedMarketingCostsCurrent_635858815105530619" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635858824698376517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635858824698376517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635858824698376517" xlink:to="us-gaap_NetIncomeLoss_635858824698376517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635858824698376517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635858824698376517" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635858824698376517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_635858824698376517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635858824698376517" xlink:to="us-gaap_DepreciationAndAmortization_635858824698376517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AmortizationOfIncentiveFromLessor" xlink:label="coll_AmortizationOfIncentiveFromLessor_635858824698376517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635858824698376517" xlink:to="coll_AmortizationOfIncentiveFromLessor_635858824698376517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_635858824698376517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635858824698376517" xlink:to="us-gaap_ShareBasedCompensation_635858824698376517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_635858824698376517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635858824698376517" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_635858824698376517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_635858824698386517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635858824698376517" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_635858824698386517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_635858824698386517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635858824698376517" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_635858824698386517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635858824698386517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635858824698376517" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635858824698386517" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635858824698386517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635858824698386517" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635858824698386517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding_635858824698386517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635858824698386517" xlink:to="us-gaap_IncreaseDecreaseInDepositsOutstanding_635858824698386517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_635858824698386517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635858824698386517" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_635858824698386517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_635858824698386517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635858824698386517" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_635858824698386517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858824698386517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635858824698376517" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858824698386517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635858824698386517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635858824698386517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635858824698386517" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635858824698386517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635858824698386517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635858824698386517" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635858824698386517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635858824698386517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt_635858824698386517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635858824698386517" xlink:to="us-gaap_ProceedsFromShortTermDebt_635858824698386517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_635858824698386517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635858824698386517" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_635858824698386517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_635858824698386517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635858824698386517" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_635858824698386517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaturitiesOfSeniorDebt" xlink:label="us-gaap_MaturitiesOfSeniorDebt_635858824698386517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635858824698386517" xlink:to="us-gaap_MaturitiesOfSeniorDebt_635858824698386517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLongtermLoansFromVendors" xlink:label="us-gaap_RepaymentsOfLongtermLoansFromVendors_635858824698386517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635858824698386517" xlink:to="us-gaap_RepaymentsOfLongtermLoansFromVendors_635858824698386517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_635858824698386517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635858824698386517" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_635858824698386517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635858824698386517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635858824698386517" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635858824698386517" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_635858824698396517" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" xlink:label="coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue_635858824698396517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_635858824698396517" xlink:to="coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue_635858824698396517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified" xlink:label="coll_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified_635858824698396517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_635858824698396517" xlink:to="coll_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified_635858824698396517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesReduction" xlink:label="us-gaap_NotesReduction_635858824698396517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_635858824698396517" xlink:to="us-gaap_NotesReduction_635858824698396517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid_635858824698396517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_635858824698396517" xlink:to="us-gaap_InterestPaid_635858824698396517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid_635858824698396517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_635858824698396517" xlink:to="us-gaap_IncomeTaxesPaid_635858824698396517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635858824698376517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635858824698386517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635858824698386517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations_635858824698386517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInContinuingOperations_635858824698386517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_635858824698396517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_635858824698396517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6358588246983965171" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6358588246983965171" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_635858824698396517" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635858824698316517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858824698316517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635858824698316517" xlink:to="us-gaap_ClassOfStockDomain_635858824698316517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_635858824698316517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698316517" xlink:to="us-gaap_SeriesAPreferredStockMember_635858824698316517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_635858824698316517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698316517" xlink:to="us-gaap_SeriesBPreferredStockMember_635858824698316517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember_635858824698316517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698316517" xlink:to="us-gaap_SeriesCPreferredStockMember_635858824698316517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_635858824698316517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858824698316517" xlink:to="us-gaap_StatementClassOfStockAxis_635858824698316517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_635858824698316517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858824698316517" xlink:to="us-gaap_StatementLineItems_635858824698316517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_635858824698316517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698316517" xlink:to="us-gaap_AssetsAbstract_635858824698316517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_635858824698326517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635858824698316517" xlink:to="us-gaap_AssetsCurrentAbstract_635858824698326517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_635858824698326517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635858824698326517" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_635858824698326517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent_635858824698326517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635858824698326517" xlink:to="us-gaap_DepositsAssetsCurrent_635858824698326517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635858824698326517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635858824698326517" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635858824698326517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_635858824698326517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635858824698326517" xlink:to="us-gaap_AssetsCurrent_635858824698326517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_635858824698326517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635858824698316517" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_635858824698326517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_635858824698326517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635858824698316517" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_635858824698326517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_635858824698326517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635858824698316517" xlink:to="us-gaap_Assets_635858824698326517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635858824698326517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698316517" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635858824698326517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_635858824698326517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635858824698326517" xlink:to="us-gaap_LiabilitiesCurrentAbstract_635858824698326517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_635858824698326517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635858824698326517" xlink:to="us-gaap_AccountsPayableCurrent_635858824698326517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_635858824698326517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635858824698326517" xlink:to="us-gaap_AccruedLiabilitiesCurrent_635858824698326517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" xlink:label="coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent_635858824698326517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635858824698326517" xlink:to="coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent_635858824698326517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent_635858824698326517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635858824698326517" xlink:to="us-gaap_LoansPayableCurrent_635858824698326517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_635858824698326517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635858824698326517" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_635858824698326517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_635858824698326517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635858824698326517" xlink:to="us-gaap_LiabilitiesCurrent_635858824698326517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncentiveFromLessor" xlink:label="us-gaap_IncentiveFromLessor_635858824698326517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635858824698326517" xlink:to="us-gaap_IncentiveFromLessor_635858824698326517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable_635858824698326517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635858824698326517" xlink:to="us-gaap_LongTermLoansPayable_635858824698326517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_635858824698326517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635858824698326517" xlink:to="us-gaap_Liabilities_635858824698326517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_635858824698336517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635858824698326517" xlink:to="us-gaap_CommitmentsAndContingencies_635858824698336517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract_635858824698336517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635858824698326517" xlink:to="us-gaap_TemporaryEquityAbstract_635858824698336517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_635858824698336517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityAbstract_635858824698336517" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_635858824698336517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_635858824698336517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635858824698326517" xlink:to="us-gaap_StockholdersEquityAbstract_635858824698336517" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_635858824698336517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635858824698336517" xlink:to="us-gaap_CommonStockValue_635858824698336517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_635858824698336517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635858824698336517" xlink:to="us-gaap_AdditionalPaidInCapital_635858824698336517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_635858824698336517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635858824698336517" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_635858824698336517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockCarryingBasis" xlink:label="us-gaap_TreasuryStockCarryingBasis_635858824698336517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635858824698336517" xlink:to="us-gaap_TreasuryStockCarryingBasis_635858824698336517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_635858824698336517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635858824698336517" xlink:to="us-gaap_StockholdersEquity_635858824698336517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_635858824698336517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635858824698326517" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_635858824698336517" xlink:title="presentation:  to " use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_635858824698316517" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635858824698336517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635858824698336517" xlink:to="us-gaap_ClassOfStockDomain_635858824698346517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698346517" xlink:to="us-gaap_SeriesAPreferredStockMember_635858824698346517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698346517" xlink:to="us-gaap_SeriesBPreferredStockMember_635858824698346517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698346517" xlink:to="us-gaap_SeriesCPreferredStockMember_635858824698346517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_635858824698336517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858824698336517" xlink:to="us-gaap_StatementClassOfStockAxis_635858824698336517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858824698336517" xlink:to="us-gaap_StatementLineItems_635858824698346517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698346517" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_635858824698346517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698346517" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_635858824698346517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698346517" xlink:to="us-gaap_TemporaryEquitySharesIssued_635858824698346517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698346517" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_635858824698346517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698346517" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_635858824698346517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698346517" xlink:to="us-gaap_CommonStockSharesAuthorized_635858824698346517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698346517" xlink:to="us-gaap_CommonStockSharesIssued_635858824698346517" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698346517" xlink:to="us-gaap_CommonStockSharesOutstanding_635858824698346517" xlink:title="presentation:  to " use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_635858824698336517" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis_635858824698346517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis_635858824698346517" xlink:to="us-gaap_ScenarioUnspecifiedDomain_635858824698346517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProFormaMember" xlink:label="us-gaap_ProFormaMember_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain_635858824698346517" xlink:to="us-gaap_ProFormaMember_635858824698346517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_635858824698346517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858824698346517" xlink:to="us-gaap_StatementLineItems_635858824698346517" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698346517" xlink:to="us-gaap_OperatingExpensesAbstract_635858824698346517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_635858824698346517" xlink:to="us-gaap_ResearchAndDevelopmentExpense_635858824698346517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_635858824698346517" xlink:to="us-gaap_GeneralAndAdministrativeExpense_635858824698346517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_635858824698346517" xlink:to="us-gaap_OperatingExpenses_635858824698346517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698346517" xlink:to="us-gaap_OperatingIncomeLoss_635858824698346517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="us-gaap_OtherExpensesAbstract_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698346517" xlink:to="us-gaap_OtherExpensesAbstract_635858824698346517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_635858824698346517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_635858824698346517" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_635858824698346517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_635858824698356517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_635858824698346517" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_635858824698356517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_635858824698356517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_635858824698346517" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_635858824698356517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635858824698356517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698346517" xlink:to="us-gaap_NetIncomeLoss_635858824698356517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_635858824698356517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698346517" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_635858824698356517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_635858824698356517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698346517" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_635858824698356517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858824698346517" xlink:to="us-gaap_StatementScenarioAxis_635858824698346517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable_635858824698346517" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementConvertibleRedeemablePreferredStock">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635858824698356517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858824698356517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635858824698356517" xlink:to="us-gaap_ClassOfStockDomain_635858824698356517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_635858824698356517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698356517" xlink:to="us-gaap_SeriesAPreferredStockMember_635858824698356517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_635858824698356517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698356517" xlink:to="us-gaap_SeriesBPreferredStockMember_635858824698356517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember_635858824698356517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698356517" xlink:to="us-gaap_SeriesCPreferredStockMember_635858824698356517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_635858824698356517" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_635858824698356517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_635858824698356517" xlink:to="coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_635858824698356517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" xlink:label="coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_635858824698356517" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedAndOutstandingModificationShares" xlink:label="coll_TemporaryEquityStockIssuedAndOutstandingModificationShares_635858824698356517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_635858824698356517" xlink:to="coll_TemporaryEquityStockIssuedAndOutstandingModificationShares_635858824698356517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_635858824698356517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858824698356517" xlink:to="us-gaap_StatementClassOfStockAxis_635858824698356517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_635858824698356517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858824698356517" xlink:to="us-gaap_StatementLineItems_635858824698356517" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_635858824698356517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698356517" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_635858824698356517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_635858824698356517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_635858824698356517" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_635858824698356517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6358588246983565171" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_635858824698356517" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6358588246983565171" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_635858824698356517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_635858824698356517" xlink:to="us-gaap_TemporaryEquitySharesIssued_635858824698356517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_635858824698366517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_635858824698356517" xlink:to="us-gaap_TemporaryEquitySharesIssued_635858824698366517" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_635858824698356517" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_635858824698356517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" xlink:label="coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue_635858824698356517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_635858824698356517" xlink:to="coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue_635858824698356517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_635858824698356517" xlink:to="coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_635858824698356517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StatementOfTemporaryEquityAbstract" xlink:label="coll_StatementOfTemporaryEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_StatementOfTemporaryEquityAbstract" xlink:to="us-gaap_StatementTable_635858824698356517" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementShareholdersDeficit">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_635858824698366517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_635858824698366517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_635858824698366517" xlink:to="us-gaap_CommonStockMember_635858824698366517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_635858824698366517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_635858824698366517" xlink:to="us-gaap_AdditionalPaidInCapitalMember_635858824698366517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember_635858824698366517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_635858824698366517" xlink:to="us-gaap_TreasuryStockMember_635858824698366517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_635858824698366517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_635858824698366517" xlink:to="us-gaap_RetainedEarningsMember_635858824698366517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_635858824698366517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_635858824698366517" xlink:to="us-gaap_EquityComponentDomain_635858824698366517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_635858824698366517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_635858824698366517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858824698366517" xlink:to="us-gaap_StatementLineItems_635858824698366517" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635858824698366517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698366517" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635858824698366517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_635858824698366517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635858824698366517" xlink:to="us-gaap_StockholdersEquity_635858824698366517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_635858824698376517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635858824698366517" xlink:to="us-gaap_StockholdersEquity_635858824698376517" xlink:title="presentation:  to " use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_635858824698366517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635858824698366517" xlink:to="us-gaap_SharesOutstanding_635858824698366517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_635858824698376517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635858824698366517" xlink:to="us-gaap_SharesOutstanding_635858824698376517" xlink:title="presentation:  to " use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="coll_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock_635858824698366517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635858824698366517" xlink:to="coll_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock_635858824698366517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified" xlink:label="coll_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified_635858824698376517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635858824698366517" xlink:to="coll_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified_635858824698376517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockIssuedAndOutstandingModificationShares" xlink:label="coll_CommonStockIssuedAndOutstandingModificationShares_635858824698376517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified_635858824698376517" xlink:to="coll_CommonStockIssuedAndOutstandingModificationShares_635858824698376517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_635858824698376517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635858824698366517" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_635858824698376517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_635858824698376517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635858824698366517" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_635858824698376517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_635858824698376517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635858824698366517" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_635858824698376517" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_635858824698376517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_635858824698376517" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_635858824698376517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635858824698376517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_635858824698366517" xlink:to="us-gaap_NetIncomeLoss_635858824698376517" xlink:title="presentation:  to " use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858824698366517" xlink:to="us-gaap_StatementEquityComponentsAxis_635858824698366517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_635858824698366517" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635858824698596517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858824698596517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635858824698596517" xlink:to="us-gaap_ClassOfStockDomain_635858824698596517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_635858824698596517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698596517" xlink:to="us-gaap_SeriesAPreferredStockMember_635858824698596517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_635858824698596517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_635858824698596517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis_635858824698596517" xlink:to="us-gaap_ConversionOfStockNameDomain_635858824698596517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember" xlink:label="coll_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember_635858824698596517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockNameDomain_635858824698596517" xlink:to="coll_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember_635858824698596517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_635858824698596517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_635858824698596517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_635858824698596517" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_635858824698596517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" xlink:label="coll_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member_635858824698596517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_635858824698596517" xlink:to="coll_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member_635858824698596517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xlink:label="coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_635858824698596517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_635858824698596517" xlink:to="coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_635858824698596517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xlink:label="coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_635858824698596517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_635858824698596517" xlink:to="coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_635858824698596517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_PreferredStockWarrantsIssuedNovember2010Member" xlink:label="coll_PreferredStockWarrantsIssuedNovember2010Member_635858824698596517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_635858824698596517" xlink:to="coll_PreferredStockWarrantsIssuedNovember2010Member_635858824698596517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesaPreferredStockWarrantMember" xlink:label="coll_SeriesaPreferredStockWarrantMember_635858824698596517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_635858824698596517" xlink:to="coll_SeriesaPreferredStockWarrantMember_635858824698596517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_635858824698596517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_635858824698596517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_635858824698596517" xlink:to="us-gaap_EquityComponentDomain_635858824698596517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_635858824698596517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_635858824698596517" xlink:to="us-gaap_CommonStockMember_635858824698596517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis_635858824698596517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_635858824698596517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis_635858824698596517" xlink:to="us-gaap_ScenarioUnspecifiedDomain_635858824698596517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProFormaMember" xlink:label="us-gaap_ProFormaMember_635858824698596517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain_635858824698596517" xlink:to="us-gaap_ProFormaMember_635858824698596517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_635858824698596517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_StatementTable_635858824698596517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858824698596517" xlink:to="us-gaap_StatementClassOfStockAxis_635858824698596517" xlink:title="presentation:  to " use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_635858824698606517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858824698596517" xlink:to="us-gaap_StatementLineItems_635858824698606517" xlink:title="presentation:  to " use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_635858824698606517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698606517" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_635858824698606517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_635858824698606517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698606517" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_635858824698606517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_635858824698606517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858824698606517" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_635858824698606517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858824698596517" xlink:to="us-gaap_StatementScenarioAxis_635858824698596517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858824698596517" xlink:to="us-gaap_StatementEquityComponentsAxis_635858824698596517" xlink:title="presentation:  to " use="optional" order="5.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858824698596517" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis_635858824698596517" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858824698596517" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_635858824698596517" xlink:title="presentation:  to " use="optional" order="3.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementBalanceSheetsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635858815105340600" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858815105340600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635858815105340600" xlink:to="us-gaap_ClassOfStockDomain_635858815105340600" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_635858815105340600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105340600" xlink:to="us-gaap_SeriesAPreferredStockMember_635858815105340600" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_635858815105340600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105340600" xlink:to="us-gaap_SeriesBPreferredStockMember_635858815105340600" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember_635858815105340600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105340600" xlink:to="us-gaap_SeriesCPreferredStockMember_635858815105340600" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_635858815105340600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858815105340600" xlink:to="us-gaap_StatementClassOfStockAxis_635858815105340600" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_635858815105340600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858815105340600" xlink:to="us-gaap_StatementLineItems_635858815105340600" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_635858815105340600" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858815105340600" xlink:to="us-gaap_AssetsAbstract_635858815105340600" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_635858815105350601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635858815105340600" xlink:to="us-gaap_AssetsCurrentAbstract_635858815105350601" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_635858815105350601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635858815105350601" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_635858815105350601" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent_635858815105350601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635858815105350601" xlink:to="us-gaap_DepositsAssetsCurrent_635858815105350601" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635858815105350601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635858815105350601" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635858815105350601" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_635858815105350601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635858815105350601" xlink:to="us-gaap_AssetsCurrent_635858815105350601" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_635858815105350601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635858815105340600" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_635858815105350601" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_635858815105350601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635858815105340600" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_635858815105350601" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_635858815105350601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635858815105340600" xlink:to="us-gaap_Assets_635858815105350601" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635858815105350601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858815105340600" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635858815105350601" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_635858815105350601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635858815105350601" xlink:to="us-gaap_LiabilitiesCurrentAbstract_635858815105350601" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_635858815105350601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635858815105350601" xlink:to="us-gaap_AccountsPayableCurrent_635858815105350601" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_635858815105350601" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635858815105350601" xlink:to="us-gaap_AccruedLiabilitiesCurrent_635858815105350601" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" xlink:label="coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent_635858815105360602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635858815105350601" xlink:to="coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent_635858815105360602" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent_635858815105360602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635858815105350601" xlink:to="us-gaap_LoansPayableCurrent_635858815105360602" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_635858815105360602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635858815105350601" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_635858815105360602" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_635858815105360602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635858815105350601" xlink:to="us-gaap_LiabilitiesCurrent_635858815105360602" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncentiveFromLessor" xlink:label="us-gaap_IncentiveFromLessor_635858815105360602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635858815105350601" xlink:to="us-gaap_IncentiveFromLessor_635858815105360602" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable_635858815105360602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635858815105350601" xlink:to="us-gaap_LongTermLoansPayable_635858815105360602" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_635858815105360602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635858815105350601" xlink:to="us-gaap_Liabilities_635858815105360602" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_635858815105360602" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635858815105350601" xlink:to="us-gaap_CommitmentsAndContingencies_635858815105360602" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract_635858815105370603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635858815105350601" xlink:to="us-gaap_TemporaryEquityAbstract_635858815105370603" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_635858815105370603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityAbstract_635858815105370603" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_635858815105370603" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_635858815105370603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635858815105350601" xlink:to="us-gaap_StockholdersEquityAbstract_635858815105370603" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_635858815105370603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635858815105370603" xlink:to="us-gaap_CommonStockValue_635858815105370603" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_635858815105370603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635858815105370603" xlink:to="us-gaap_AdditionalPaidInCapital_635858815105370603" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_635858815105370603" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635858815105370603" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_635858815105370603" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockCarryingBasis" xlink:label="us-gaap_TreasuryStockCarryingBasis_635858815105380604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635858815105370603" xlink:to="us-gaap_TreasuryStockCarryingBasis_635858815105380604" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_635858815105380604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635858815105370603" xlink:to="us-gaap_StockholdersEquity_635858815105380604" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_635858815105380604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635858815105350601" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_635858815105380604" xlink:title="presentation:  to " use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_635858815105340600" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementBalanceSheetsParentheticalQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635858815105380604" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858815105390605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635858815105380604" xlink:to="us-gaap_ClassOfStockDomain_635858815105390605" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_635858815105390605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105390605" xlink:to="us-gaap_SeriesAPreferredStockMember_635858815105390605" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_635858815105390605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105390605" xlink:to="us-gaap_SeriesBPreferredStockMember_635858815105390605" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember_635858815105390605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105390605" xlink:to="us-gaap_SeriesCPreferredStockMember_635858815105390605" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember_635858815105390605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105390605" xlink:to="us-gaap_SeriesDPreferredStockMember_635858815105390605" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis_635858815105380604" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_635858815105380604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis_635858815105380604" xlink:to="us-gaap_ScenarioUnspecifiedDomain_635858815105380604" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProFormaMember" xlink:label="us-gaap_ProFormaMember_635858815105380604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain_635858815105380604" xlink:to="us-gaap_ProFormaMember_635858815105380604" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_635858815105380604" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858815105380604" xlink:to="us-gaap_StatementClassOfStockAxis_635858815105380604" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_635858815105390605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858815105380604" xlink:to="us-gaap_StatementLineItems_635858815105390605" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_635858815105390605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858815105390605" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_635858815105390605" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_635858815105390605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858815105390605" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_635858815105390605" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_635858815105390605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858815105390605" xlink:to="us-gaap_TemporaryEquitySharesIssued_635858815105390605" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_635858815105390605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858815105390605" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_635858815105390605" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_635858815105390605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858815105390605" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_635858815105390605" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_635858815105390605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858815105390605" xlink:to="us-gaap_CommonStockSharesAuthorized_635858815105390605" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_635858815105400606" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858815105390605" xlink:to="us-gaap_CommonStockSharesIssued_635858815105400606" xlink:title="presentation:  to " use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_635858815105400606" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858815105390605" xlink:to="us-gaap_CommonStockSharesOutstanding_635858815105400606" xlink:title="presentation:  to " use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_635858815105390605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858815105390605" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_635858815105390605" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858815105380604" xlink:to="us-gaap_StatementScenarioAxis_635858815105380604" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_635858815105380604" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlowsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635858815105410607" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858815105410607" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635858815105410607" xlink:to="us-gaap_ClassOfStockDomain_635858815105410607" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember_635858815105410607" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105410607" xlink:to="us-gaap_SeriesDPreferredStockMember_635858815105410607" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_635858815105410607" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105410607" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_635858815105410607" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockNoClassMember" xlink:label="coll_CommonStockNoClassMember_635858815105410607" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105410607" xlink:to="coll_CommonStockNoClassMember_635858815105410607" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_635858815105410607" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_635858815105410607" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis_635858815105410607" xlink:to="us-gaap_ConversionOfStockNameDomain_635858815105410607" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" xlink:label="coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember_635858815105410607" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockNameDomain_635858815105410607" xlink:to="coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember_635858815105410607" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_635858815105410607" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858815105410607" xlink:to="us-gaap_StatementClassOfStockAxis_635858815105410607" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_635858815105420608" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858815105410607" xlink:to="us-gaap_StatementLineItems_635858815105420608" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635858815105420608" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858815105420608" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635858815105420608" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635858815105420608" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635858815105420608" xlink:to="us-gaap_NetIncomeLoss_635858815105420608" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635858815105420608" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635858815105420608" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635858815105420608" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AmortizationOfIncentiveFromLessor" xlink:label="coll_AmortizationOfIncentiveFromLessor_635858815105420608" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635858815105420608" xlink:to="coll_AmortizationOfIncentiveFromLessor_635858815105420608" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_635858815105420608" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635858815105420608" xlink:to="us-gaap_ShareBasedCompensation_635858815105420608" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_635858815105420608" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635858815105420608" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_635858815105420608" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_635858815105420608" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635858815105420608" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_635858815105420608" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635858815105420608" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635858815105420608" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635858815105420608" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635858815105420608" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635858815105420608" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635858815105420608" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding_635858815105430609" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635858815105420608" xlink:to="us-gaap_IncreaseDecreaseInDepositsOutstanding_635858815105430609" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_635858815105430609" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635858815105420608" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_635858815105430609" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_635858815105430609" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635858815105420608" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_635858815105430609" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_635858815105420608" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635858815105420608" xlink:to="us-gaap_Depreciation_635858815105420608" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858815105430609" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635858815105420608" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635858815105430609" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635858815105430609" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858815105420608" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635858815105430609" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635858815105430609" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635858815105430609" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635858815105430609" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635858815105430609" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635858815105430609" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635858815105430609" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635858815105430609" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858815105420608" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635858815105430609" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_635858815105440610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635858815105430609" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_635858815105440610" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaturitiesOfSeniorDebt" xlink:label="us-gaap_MaturitiesOfSeniorDebt_635858815105440610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635858815105430609" xlink:to="us-gaap_MaturitiesOfSeniorDebt_635858815105440610" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLongtermLoansFromVendors" xlink:label="us-gaap_RepaymentsOfLongtermLoansFromVendors_635858815105440610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635858815105430609" xlink:to="us-gaap_RepaymentsOfLongtermLoansFromVendors_635858815105440610" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_635858815105440610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635858815105430609" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_635858815105440610" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635858815105440610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635858815105430609" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635858815105440610" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseInRestrictedCash" xlink:label="us-gaap_IncreaseInRestrictedCash_635858815105440610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635858815105430609" xlink:to="us-gaap_IncreaseInRestrictedCash_635858815105440610" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations_635858815105440610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858815105420608" xlink:to="us-gaap_NetCashProvidedByUsedInContinuingOperations_635858815105440610" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_635858815105450611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858815105420608" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_635858815105450611" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6358588151054506111" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858815105420608" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6358588151054506111" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_635858815105450611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858815105420608" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_635858815105450611" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" xlink:label="coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue_635858815105450611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_635858815105450611" xlink:to="coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue_635858815105450611" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesReduction" xlink:label="us-gaap_NotesReduction_635858815105460612" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_635858815105450611" xlink:to="us-gaap_NotesReduction_635858815105460612" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid_635858815105460612" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_635858815105450611" xlink:to="us-gaap_InterestPaid_635858815105460612" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid_635858815105460612" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_635858815105450611" xlink:to="us-gaap_IncomeTaxesPaid_635858815105460612" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1_635858815105450611" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_635858815105450611" xlink:to="us-gaap_ConversionOfStockAmountConverted1_635858815105450611" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_635858815105460612" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_635858815105450611" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_635858815105460612" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_635858815105410607" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis_635858815105410607" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable_635858815105410607" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureFairValueOfFinancialInstrumentsDetailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_635858815105530619" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_635858815105530619" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_635858815105530619" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_635858815105530619" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_635858815105530619" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain_635858815105530619" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_635858815105530619" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_635858815105530619" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_635858815105530619" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_635858815105530619" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_635858815105530619" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635858815105530619" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635858815105530619" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635858815105530619" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_635858815105530619" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_635858815105530619" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635858815105530619" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_635858815105530619" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_635858815105530619" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_635858815105530619" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_635858815105530619" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_635858815105530619" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_635858815105530619" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_635858815105530619" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_635858815105530619" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635858815105530619" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_635858815105530619" xlink:title="presentation:  to " use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635858815105530619" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_635858815105530619" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635858815105530619" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_635858815105530619" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635858815105530619" xlink:to="us-gaap_FairValueInputsLevel1Member_635858815105530619" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_635858815105530619" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635858815105530619" xlink:to="us-gaap_CashAndCashEquivalentsAxis_635858815105530619" xlink:title="presentation:  to " use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_635858815105530619" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_635858815105530619" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_635858815105530619" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_635858815105530619" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_635858815105530619" xlink:to="us-gaap_MoneyMarketFundsMember_635858815105530619" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635858815105530619" xlink:to="us-gaap_StatementLineItems_635858815105530619" xlink:title="presentation:  to " use="optional" order="5.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementConvertibleRedeemablePreferredStockParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635858824698366517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858824698366517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635858824698366517" xlink:to="us-gaap_ClassOfStockDomain_635858824698366517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember_635858824698366517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698366517" xlink:to="us-gaap_SeriesCPreferredStockMember_635858824698366517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_635858824698366517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_635858824698366517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_635858824698366517" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_635858824698366517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesCPreferredStockFinancing2013Member" xlink:label="coll_SeriesCPreferredStockFinancing2013Member_635858824698366517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_635858824698366517" xlink:to="coll_SeriesCPreferredStockFinancing2013Member_635858824698366517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_635858824698366517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_635858824698366517" xlink:to="us-gaap_StatementClassOfStockAxis_635858824698366517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_635858824698366517" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_635858824698366517" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_635858824698366517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_635858824698366517" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_635858824698366517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedIssuanceCosts" xlink:label="coll_TemporaryEquityStockIssuedIssuanceCosts_635858824698366517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_635858824698366517" xlink:to="coll_TemporaryEquityStockIssuedIssuanceCosts_635858824698366517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StatementOfTemporaryEquityAbstract" xlink:label="coll_StatementOfTemporaryEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_StatementOfTemporaryEquityAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_635858824698366517" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlowsParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_635858824698396517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635858824698396517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698396517" xlink:to="us-gaap_StatementClassOfStockAxis_635858824698396517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858824698396517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635858824698396517" xlink:to="us-gaap_ClassOfStockDomain_635858824698396517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember_635858824698396517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698396517" xlink:to="us-gaap_SeriesCPreferredStockMember_635858824698396517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_635858824698396517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698396517" xlink:to="us-gaap_ClassOfStockLineItems_635858824698396517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_635858824698396517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698396517" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_635858824698396517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_635858824698396517" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNatureOfBusinessDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_635858824698446517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698446517" xlink:to="us-gaap_StatementClassOfStockAxis_635858824698446517" xlink:title="presentation:  to " use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635858824698446517" xlink:to="us-gaap_ClassOfStockDomain_635858824698446517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698446517" xlink:to="us-gaap_SeriesDPreferredStockMember_635858824698446517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698446517" xlink:to="us-gaap_ClassOfStockLineItems_635858824698446517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698446517" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_635858824698446517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698446517" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_635858824698446517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_635858824698456517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698446517" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_635858824698456517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698446517" xlink:to="us-gaap_SubsequentEventTypeAxis_635858824698446517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_635858824698446517" xlink:to="us-gaap_SubsequentEventTypeDomain_635858824698446517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_635858824698446517" xlink:to="us-gaap_SubsequentEventMember_635858824698446517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698446517" xlink:to="us-gaap_RelatedPartyTransactionAxis_635858824698446517" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_635858824698446517" xlink:to="us-gaap_RelatedPartyTransactionDomain_635858824698446517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_635858824698446517" xlink:to="us-gaap_PrivatePlacementMember_635858824698446517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember" xlink:label="coll_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_635858824698446517" xlink:to="coll_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember_635858824698446517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698446517" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_635858824698446517" xlink:title="presentation:  to " use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_635858824698446517" xlink:to="us-gaap_RelatedPartyDomain_635858824698446517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_635858824698446517" xlink:to="us-gaap_InvestorMember_635858824698446517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698446517" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis_635858824698446517" xlink:title="presentation:  to " use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis_635858824698446517" xlink:to="us-gaap_DebtConversionNameDomain_635858824698446517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" xlink:label="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_635858824698446517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionNameDomain_635858824698446517" xlink:to="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_635858824698446517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635858824698476517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858824698476517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635858824698476517" xlink:to="us-gaap_ClassOfStockDomain_635858824698476517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_635858824698476517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698476517" xlink:to="us-gaap_SeriesAPreferredStockMember_635858824698476517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis_635858824698476517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_635858824698476517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis_635858824698476517" xlink:to="us-gaap_ScenarioUnspecifiedDomain_635858824698476517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProFormaMember" xlink:label="us-gaap_ProFormaMember_635858824698476517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain_635858824698476517" xlink:to="us-gaap_ProFormaMember_635858824698476517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_635858824698476517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_635858824698476517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_635858824698476517" xlink:to="us-gaap_StatementScenarioAxis_635858824698476517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_635858824698476517" xlink:to="us-gaap_StatementClassOfStockAxis_635858824698476517" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems_635858824698476517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_635858824698476517" xlink:to="us-gaap_EarningsPerShareBasicLineItems_635858824698476517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635858824698476517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_635858824698476517" xlink:to="us-gaap_NetIncomeLoss_635858824698476517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityRedemptionValueModificationAdjustment" xlink:label="coll_TemporaryEquityRedemptionValueModificationAdjustment_635858824698476517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_635858824698476517" xlink:to="coll_TemporaryEquityRedemptionValueModificationAdjustment_635858824698476517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" xlink:label="coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_635858824698476517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_635858824698476517" xlink:to="coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_635858824698476517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_635858824698476517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_635858824698476517" xlink:to="coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_635858824698476517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_635858824698476517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_635858824698476517" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_635858824698476517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_635858824698476517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_635858824698476517" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_635858824698476517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_635858824698476517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_635858824698476517" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_635858824698476517" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureEquityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_635858824698606517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635858824698606517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698606517" xlink:to="us-gaap_StatementClassOfStockAxis_635858824698606517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858824698606517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635858824698606517" xlink:to="us-gaap_ClassOfStockDomain_635858824698606517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_635858824698606517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698606517" xlink:to="us-gaap_SeriesAPreferredStockMember_635858824698606517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_635858824698606517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698606517" xlink:to="us-gaap_SeriesBPreferredStockMember_635858824698606517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember_635858824698606517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698606517" xlink:to="us-gaap_SeriesCPreferredStockMember_635858824698606517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_635858824698606517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698606517" xlink:to="us-gaap_ClassOfStockLineItems_635858824698606517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_635858824698606517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698606517" xlink:to="us-gaap_CommonStockSharesAuthorized_635858824698606517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_635858824698606517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698606517" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_635858824698606517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_635858824698616517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698606517" xlink:to="us-gaap_CommonStockSharesIssued_635858824698616517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_635858824698616517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698606517" xlink:to="us-gaap_CommonStockSharesOutstanding_635858824698616517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_635858824698616517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698606517" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_635858824698616517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_635858824698616517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698606517" xlink:to="us-gaap_TemporaryEquitySharesIssued_635858824698616517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_635858824698616517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698606517" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_635858824698616517" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockVotingRightsNumber" xlink:label="coll_CommonStockVotingRightsNumber_635858824698616517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698606517" xlink:to="coll_CommonStockVotingRightsNumber_635858824698616517" xlink:title="presentation:  to " use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_635858824698616517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698606517" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_635858824698616517" xlink:title="presentation:  to " use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_635858824698606517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698606517" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis_635858824698606517" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_635858824698606517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis_635858824698606517" xlink:to="us-gaap_ConversionOfStockNameDomain_635858824698606517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember" xlink:label="coll_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember_635858824698606517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockNameDomain_635858824698606517" xlink:to="coll_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember_635858824698606517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_635858824698606517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698606517" xlink:to="us-gaap_AwardTypeAxis_635858824698606517" xlink:title="presentation:  to " use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698606517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_635858824698606517" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698606517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_EmployeeAndNonemployeeStockOptionsMember" xlink:label="coll_EmployeeAndNonemployeeStockOptionsMember_635858824698606517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698606517" xlink:to="coll_EmployeeAndNonemployeeStockOptionsMember_635858824698606517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_635858824698606517" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureEquityDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_635858824698616517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635858824698626517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698616517" xlink:to="us-gaap_StatementClassOfStockAxis_635858824698626517" xlink:title="presentation:  to " use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858824698626517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635858824698626517" xlink:to="us-gaap_ClassOfStockDomain_635858824698626517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_635858824698626517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698626517" xlink:to="us-gaap_SeriesAPreferredStockMember_635858824698626517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_635858824698626517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698626517" xlink:to="us-gaap_SeriesBPreferredStockMember_635858824698626517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember_635858824698626517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698626517" xlink:to="us-gaap_SeriesCPreferredStockMember_635858824698626517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_635858824698626517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698616517" xlink:to="us-gaap_ClassOfStockLineItems_635858824698626517" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_635858824698636517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698626517" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_635858824698636517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_635858824698626517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698626517" xlink:to="us-gaap_ConversionOfStockSharesIssued1_635858824698626517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_635858824698626517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698626517" xlink:to="coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_635858824698626517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_635858824698636517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698626517" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_635858824698636517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_635858824698636517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698626517" xlink:to="us-gaap_SharesIssuedPricePerShare_635858824698636517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedIssuanceCosts" xlink:label="coll_TemporaryEquityStockIssuedIssuanceCosts_635858824698636517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698626517" xlink:to="coll_TemporaryEquityStockIssuedIssuanceCosts_635858824698636517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SaleOfStockNumberOfSharesAuthorizedToBeSold" xlink:label="coll_SaleOfStockNumberOfSharesAuthorizedToBeSold_635858824698636517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698626517" xlink:to="coll_SaleOfStockNumberOfSharesAuthorizedToBeSold_635858824698636517" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SaleOfStockAuthorizedAmount" xlink:label="coll_SaleOfStockAuthorizedAmount_635858824698636517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698626517" xlink:to="coll_SaleOfStockAuthorizedAmount_635858824698636517" xlink:title="presentation:  to " use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SaleOfStockNumberOfTranches" xlink:label="coll_SaleOfStockNumberOfTranches_635858824698636517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698626517" xlink:to="coll_SaleOfStockNumberOfTranches_635858824698636517" xlink:title="presentation:  to " use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_635858824698636517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698626517" xlink:to="us-gaap_WarrantsAndRightsOutstanding_635858824698636517" xlink:title="presentation:  to " use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_635858824698636517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698626517" xlink:to="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_635858824698636517" xlink:title="presentation:  to " use="optional" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_635858824698636517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_635858824698636517" xlink:to="us-gaap_SharePrice_635858824698636517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_635858824698636517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_635858824698636517" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_635858824698636517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_635858824698636517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_635858824698636517" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_635858824698636517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_635858824698646517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698626517" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_635858824698646517" xlink:title="presentation:  to " use="optional" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_635858824698646517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_635858824698646517" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_635858824698646517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_635858824698646517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_635858824698646517" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_635858824698646517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_635858824698646517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_635858824698646517" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_635858824698646517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StockModificationAbstract" xlink:label="coll_StockModificationAbstract_635858824698646517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698626517" xlink:to="coll_StockModificationAbstract_635858824698646517" xlink:title="presentation:  to " use="optional" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_635858824698646517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_StockModificationAbstract_635858824698646517" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_635858824698646517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" xlink:label="coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_635858824698646517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_StockModificationAbstract_635858824698646517" xlink:to="coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_635858824698646517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_635858824698616517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698616517" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis_635858824698616517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_635858824698616517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis_635858824698616517" xlink:to="us-gaap_ConversionOfStockNameDomain_635858824698616517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember" xlink:label="coll_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember_635858824698616517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockNameDomain_635858824698616517" xlink:to="coll_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember_635858824698616517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_635858824698616517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698616517" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_635858824698616517" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_635858824698616517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_635858824698616517" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_635858824698616517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesCPreferredStockFinancing2013Member" xlink:label="coll_SeriesCPreferredStockFinancing2013Member_635858824698616517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_635858824698616517" xlink:to="coll_SeriesCPreferredStockFinancing2013Member_635858824698616517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesCPreferredStockFinancing2013TrancheOneMember" xlink:label="coll_SeriesCPreferredStockFinancing2013TrancheOneMember_635858824698616517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_SeriesCPreferredStockFinancing2013Member_635858824698616517" xlink:to="coll_SeriesCPreferredStockFinancing2013TrancheOneMember_635858824698616517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesCPreferredStockFinancing2013TrancheTwoMember" xlink:label="coll_SeriesCPreferredStockFinancing2013TrancheTwoMember_635858824698616517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_SeriesCPreferredStockFinancing2013Member_635858824698616517" xlink:to="coll_SeriesCPreferredStockFinancing2013TrancheTwoMember_635858824698616517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesBPreferredStockFinancingFebruary2012Member" xlink:label="coll_SeriesBPreferredStockFinancingFebruary2012Member_635858824698616517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_635858824698616517" xlink:to="coll_SeriesBPreferredStockFinancingFebruary2012Member_635858824698616517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_635858824698626517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698616517" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_635858824698626517" xlink:title="presentation:  to " use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_635858824698626517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_635858824698626517" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_635858824698626517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StockPurchaseRightMember" xlink:label="coll_StockPurchaseRightMember_635858824698626517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_635858824698626517" xlink:to="coll_StockPurchaseRightMember_635858824698626517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_635858824698626517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698616517" xlink:to="us-gaap_StatementEquityComponentsAxis_635858824698626517" xlink:title="presentation:  to " use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_635858824698626517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_635858824698626517" xlink:to="us-gaap_EquityComponentDomain_635858824698626517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_635858824698626517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_635858824698626517" xlink:to="us-gaap_CommonStockMember_635858824698626517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_635858824698626517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698616517" xlink:to="us-gaap_RangeAxis_635858824698626517" xlink:title="presentation:  to " use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635858824698626517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_635858824698626517" xlink:to="us-gaap_RangeMember_635858824698626517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_635858824698626517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635858824698626517" xlink:to="us-gaap_MaximumMember_635858824698626517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_635858824698626517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635858824698626517" xlink:to="us-gaap_MinimumMember_635858824698626517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_635858824698616517" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureEquityDetails3">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_635858824698656517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698656517" xlink:to="us-gaap_StatementClassOfStockAxis_635858824698656517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635858824698656517" xlink:to="us-gaap_ClassOfStockDomain_635858824698656517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698656517" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_635858824698656517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember_635858824698656517" xlink:to="us-gaap_SeriesAPreferredStockMember_635858824698656517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember_635858824698656517" xlink:to="us-gaap_SeriesBPreferredStockMember_635858824698656517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember_635858824698656517" xlink:to="us-gaap_SeriesCPreferredStockMember_635858824698656517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698656517" xlink:to="us-gaap_ClassOfStockLineItems_635858824698656517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_635858824698666517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698656517" xlink:to="us-gaap_SharesIssuedPricePerShare_635858824698666517" xlink:title="presentation:  to " use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StockModificationAbstract" xlink:label="coll_StockModificationAbstract_635858824698676517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698656517" xlink:to="coll_StockModificationAbstract_635858824698676517" xlink:title="presentation:  to " use="optional" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_635858824698686517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_StockModificationAbstract_635858824698676517" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_635858824698686517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" xlink:label="coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_635858824698686517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_StockModificationAbstract_635858824698676517" xlink:to="coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue_635858824698686517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold" xlink:label="coll_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold_635858824698686517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_StockModificationAbstract_635858824698676517" xlink:to="coll_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold_635858824698686517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityRightsToElectDirectorsNumberOfDirectors" xlink:label="coll_TemporaryEquityRightsToElectDirectorsNumberOfDirectors_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698656517" xlink:to="coll_TemporaryEquityRightsToElectDirectorsNumberOfDirectors_635858824698656517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage" xlink:label="coll_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage_635858824698666517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698656517" xlink:to="coll_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage_635858824698666517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_635858824698666517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698656517" xlink:to="us-gaap_PreferredStockDividendRatePercentage_635858824698666517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityCumulativeAccretionOfDividends" xlink:label="coll_TemporaryEquityCumulativeAccretionOfDividends_635858824698666517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698656517" xlink:to="coll_TemporaryEquityCumulativeAccretionOfDividends_635858824698666517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityConvertibleConversionPrice" xlink:label="coll_TemporaryEquityConvertibleConversionPrice_635858824698666517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698656517" xlink:to="coll_TemporaryEquityConvertibleConversionPrice_635858824698666517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityShareholderSharesOwned" xlink:label="coll_TemporaryEquityShareholderSharesOwned_635858824698666517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698656517" xlink:to="coll_TemporaryEquityShareholderSharesOwned_635858824698666517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_635858824698666517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698656517" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_635858824698666517" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio" xlink:label="coll_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio_635858824698666517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698656517" xlink:to="coll_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio_635858824698666517" xlink:title="presentation:  to " use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare" xlink:label="coll_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare_635858824698676517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698656517" xlink:to="coll_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare_635858824698676517" xlink:title="presentation:  to " use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage" xlink:label="coll_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage_635858824698676517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698656517" xlink:to="coll_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage_635858824698676517" xlink:title="presentation:  to " use="optional" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio" xlink:label="coll_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio_635858824698676517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698656517" xlink:to="coll_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio_635858824698676517" xlink:title="presentation:  to " use="optional" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments" xlink:label="coll_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments_635858824698676517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858824698656517" xlink:to="coll_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments_635858824698676517" xlink:title="presentation:  to " use="optional" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698656517" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_635858824698656517" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_635858824698656517" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_635858824698656517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesCPreferredStockFinancing2013TrancheTwoMember" xlink:label="coll_SeriesCPreferredStockFinancing2013TrancheTwoMember_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_635858824698656517" xlink:to="coll_SeriesCPreferredStockFinancing2013TrancheTwoMember_635858824698656517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698656517" xlink:to="us-gaap_StatementEquityComponentsAxis_635858824698656517" xlink:title="presentation:  to " use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_635858824698656517" xlink:to="us-gaap_EquityComponentDomain_635858824698656517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_635858824698656517" xlink:to="us-gaap_CommonStockMember_635858824698656517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698656517" xlink:to="us-gaap_RangeAxis_635858824698656517" xlink:title="presentation:  to " use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_635858824698656517" xlink:to="us-gaap_RangeMember_635858824698656517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635858824698656517" xlink:to="us-gaap_MinimumMember_635858824698656517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858824698656517" xlink:to="us-gaap_StatementScenarioAxis_635858824698656517" xlink:title="presentation:  to " use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis_635858824698656517" xlink:to="us-gaap_ScenarioUnspecifiedDomain_635858824698656517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" xlink:label="coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain_635858824698656517" xlink:to="coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember_635858824698656517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember" xlink:label="coll_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember_635858824698656517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain_635858824698656517" xlink:to="coll_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember_635858824698656517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_635858824698656517" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSubsequentEventsUnauditedDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635858824698776517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858824698776517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635858824698776517" xlink:to="us-gaap_ClassOfStockDomain_635858824698776517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_635858824698776517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858824698776517" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_635858824698776517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember_635858824698776517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember_635858824698776517" xlink:to="us-gaap_SeriesDPreferredStockMember_635858824698776517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_635858824698766517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_635858824698766517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_635858824698766517" xlink:to="us-gaap_SubsequentEventTypeDomain_635858824698766517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_635858824698766517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_635858824698766517" xlink:to="us-gaap_SubsequentEventMember_635858824698766517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_635858824698766517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_635858824698766517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_635858824698766517" xlink:to="us-gaap_RelatedPartyTransactionDomain_635858824698766517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_635858824698766517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_635858824698766517" xlink:to="us-gaap_PrivatePlacementMember_635858824698766517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember" xlink:label="coll_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember_635858824698766517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_635858824698766517" xlink:to="coll_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember_635858824698766517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_635858824698776517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_635858824698776517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_635858824698776517" xlink:to="us-gaap_RelatedPartyDomain_635858824698776517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember_635858824698776517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_635858824698776517" xlink:to="us-gaap_InvestorMember_635858824698776517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_635858824698776517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain_635858824698776517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis_635858824698776517" xlink:to="us-gaap_DebtConversionNameDomain_635858824698776517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" xlink:label="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_635858824698776517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionNameDomain_635858824698776517" xlink:to="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_635858824698776517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_635858824698776517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698776517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_635858824698776517" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698776517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_635858824698786517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698776517" xlink:to="us-gaap_RestrictedStockMember_635858824698786517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_635858824698776517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698776517" xlink:to="us-gaap_EmployeeStockOptionMember_635858824698776517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_635858824698766517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_635858824698766517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_635858824698766517" xlink:to="us-gaap_EquityComponentDomain_635858824698766517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_635858824698766517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_635858824698766517" xlink:to="us-gaap_CommonStockMember_635858824698766517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_635858824698796517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635858824698796517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_635858824698796517" xlink:to="us-gaap_RangeMember_635858824698796517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_635858824698796517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635858824698796517" xlink:to="us-gaap_MinimumMember_635858824698796517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis_635858824698786517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_635858824698786517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis_635858824698786517" xlink:to="us-gaap_ScenarioUnspecifiedDomain_635858824698786517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" xlink:label="coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember_635858824698786517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain_635858824698786517" xlink:to="coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember_635858824698786517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember" xlink:label="coll_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember_635858824698786517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain_635858824698786517" xlink:to="coll_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember_635858824698786517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_635858824698786517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_635858824698786517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_635858824698786517" xlink:to="us-gaap_PlanNameDomain_635858824698786517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StockIncentivePlan2014Member" xlink:label="coll_StockIncentivePlan2014Member_635858824698786517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_635858824698786517" xlink:to="coll_StockIncentivePlan2014Member_635858824698786517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract_635858824698816517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_635858824698816517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_635858824698816517" xlink:to="us-gaap_AreaOfRealEstateProperty_635858824698816517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_635858824698816517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_635858824698816517" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_635858824698816517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_635858824698816517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_635858824698816517" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_635858824698816517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis_635858824698786517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain_635858824698786517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis_635858824698786517" xlink:to="us-gaap_LeaseArrangementTypeDomain_635858824698786517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" xlink:label="coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_635858824698786517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain_635858824698786517" xlink:to="coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_635858824698786517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" xlink:label="coll_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember_635858824698786517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_635858824698786517" xlink:to="coll_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember_635858824698786517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis_635858824698776517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain_635858824698776517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseAxis_635858824698776517" xlink:to="us-gaap_LitigationCaseTypeDomain_635858824698776517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" xlink:label="coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember_635858824698776517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseTypeDomain_635858824698776517" xlink:to="coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember_635858824698776517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" xlink:label="coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember_635858824698776517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseTypeDomain_635858824698776517" xlink:to="coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember_635858824698776517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SubsequentEventsUnauditedAbstract" xlink:label="coll_SubsequentEventsUnauditedAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_635858824698766517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_SubsequentEventsUnauditedAbstract" xlink:to="us-gaap_SubsequentEventTable_635858824698766517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_635858824698766517" xlink:to="us-gaap_SubsequentEventTypeAxis_635858824698766517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_635858824698766517" xlink:to="us-gaap_StatementEquityComponentsAxis_635858824698766517" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_635858824698766517" xlink:to="us-gaap_RelatedPartyTransactionAxis_635858824698766517" xlink:title="presentation:  to " use="optional" order="3.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_635858824698766517" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_635858824698776517" xlink:title="presentation:  to " use="optional" order="4.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_635858824698766517" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis_635858824698776517" xlink:title="presentation:  to " use="optional" order="5.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_635858824698766517" xlink:to="us-gaap_StatementClassOfStockAxis_635858824698776517" xlink:title="presentation:  to " use="optional" order="6.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_635858824698766517" xlink:to="us-gaap_LitigationCaseAxis_635858824698776517" xlink:title="presentation:  to " use="optional" order="7.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_635858824698766517" xlink:to="us-gaap_AwardTypeAxis_635858824698776517" xlink:title="presentation:  to " use="optional" order="8.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_635858824698766517" xlink:to="us-gaap_PlanNameAxis_635858824698786517" xlink:title="presentation:  to " use="optional" order="9.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_635858824698766517" xlink:to="us-gaap_LeaseArrangementTypeAxis_635858824698786517" xlink:title="presentation:  to " use="optional" order="10.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_635858824698766517" xlink:to="us-gaap_StatementScenarioAxis_635858824698786517" xlink:title="presentation:  to " use="optional" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_635858824698796517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_635858824698766517" xlink:to="us-gaap_VestingAxis_635858824698796517" xlink:title="presentation:  to " use="optional" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_635858824698796517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_635858824698796517" xlink:to="us-gaap_VestingDomain_635858824698796517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_635858824698796517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_635858824698796517" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_635858824698796517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_635858824698796517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_635858824698796517" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_635858824698796517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_635858824698766517" xlink:to="us-gaap_RangeAxis_635858824698796517" xlink:title="presentation:  to " use="optional" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_635858824698796517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_635858824698766517" xlink:to="us-gaap_SubsequentEventLineItems_635858824698796517" xlink:title="presentation:  to " use="optional" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_635858824698796517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_635858824698796517" xlink:to="coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_635858824698796517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_635858824698796517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_635858824698796517" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_635858824698796517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_635858824698806517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_635858824698796517" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_635858824698806517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_635858824698806517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_635858824698796517" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_635858824698806517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_635858824698806517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_635858824698796517" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_635858824698806517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_635858824698806517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_635858824698796517" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_635858824698806517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_635858824698806517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_635858824698796517" xlink:to="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_635858824698806517" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:label="us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_635858824698806517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_635858824698806517" xlink:to="us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_635858824698806517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_635858824698806517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_635858824698796517" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_635858824698806517" xlink:title="presentation:  to " use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_635858824698806517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_635858824698806517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_635858824698806517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_635858824698816517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_635858824698806517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_635858824698816517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_635858824698816517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_635858824698806517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_635858824698816517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_635858824698816517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_635858824698806517" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_635858824698816517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_635858824698816517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_635858824698806517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_635858824698816517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_635858824698796517" xlink:to="us-gaap_LeasesOperatingAbstract_635858824698816517" xlink:title="presentation:  to " use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_635858824698826517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_635858824698796517" xlink:to="us-gaap_StockholdersEquityNoteAbstract_635858824698826517" xlink:title="presentation:  to " use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_635858824698826517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_635858824698826517" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_635858824698826517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlowsParentheticalQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_635858815105470613" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635858815105470613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858815105470613" xlink:to="us-gaap_StatementClassOfStockAxis_635858815105470613" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858815105470613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635858815105470613" xlink:to="us-gaap_ClassOfStockDomain_635858815105470613" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember_635858815105470613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105470613" xlink:to="us-gaap_SeriesDPreferredStockMember_635858815105470613" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockNoClassMember" xlink:label="coll_CommonStockNoClassMember_635858815105470613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105470613" xlink:to="coll_CommonStockNoClassMember_635858815105470613" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_635858815105470613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858815105470613" xlink:to="us-gaap_ClassOfStockLineItems_635858815105470613" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_635858815105470613" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858815105470613" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_635858815105470613" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_635858815105470613" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2QuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635858815105510617" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858815105510617" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635858815105510617" xlink:to="us-gaap_ClassOfStockDomain_635858815105510617" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_635858815105510617" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105510617" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_635858815105510617" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_635858815105510617" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_635858815105510617" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis_635858815105510617" xlink:to="us-gaap_ConversionOfStockNameDomain_635858815105510617" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" xlink:label="coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember_635858815105510617" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockNameDomain_635858815105510617" xlink:to="coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember_635858815105510617" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_635785181795773401" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="us-gaap_ConversionOfStockTable_635858815105510617" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635785181795773401" xlink:to="us-gaap_ConversionOfStockTable_635858815105510617" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockTable_635858815105510617" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis_635858815105510617" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockTable_635858815105510617" xlink:to="us-gaap_StatementClassOfStockAxis_635858815105510617" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="us-gaap_ConversionOfStockLineItems_635858815105510617" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockTable_635858815105510617" xlink:to="us-gaap_ConversionOfStockLineItems_635858815105510617" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_635858815105520618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockLineItems_635858815105510617" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_635858815105520618" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_635858815105520618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockLineItems_635858815105510617" xlink:to="us-gaap_ConversionOfStockSharesIssued1_635858815105520618" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635858815105520618" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858815105520618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635858815105520618" xlink:to="us-gaap_ClassOfStockDomain_635858815105520618" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember_635858815105520618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105520618" xlink:to="us-gaap_SeriesDPreferredStockMember_635858815105520618" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" xlink:label="coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember_635858815105520618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105520618" xlink:to="coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember_635858815105520618" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_635785183135073401" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_635858815105520618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_635785183135073401" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_635858815105520618" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_635858815105520618" xlink:to="us-gaap_StatementClassOfStockAxis_635858815105520618" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems_635858815105520618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_635858815105520618" xlink:to="us-gaap_EarningsPerShareBasicLineItems_635858815105520618" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635858815105520618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_635858815105520618" xlink:to="us-gaap_NetIncomeLoss_635858815105520618" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" xlink:label="coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_635858815105520618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_635858815105520618" xlink:to="coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment_635858815105520618" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_635858815105520618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_635858815105520618" xlink:to="coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_635858815105520618" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_635858815105520618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_635858815105520618" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_635858815105520618" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_635858815105520618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_635858815105520618" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_635858815105520618" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityGainLossOnExtinguishment" xlink:label="coll_TemporaryEquityGainLossOnExtinguishment_635858815105520618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_635858815105520618" xlink:to="coll_TemporaryEquityGainLossOnExtinguishment_635858815105520618" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureConvertiblePreferredStockDetailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_635858815105540620" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_635858815105540620" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858815105540620" xlink:to="us-gaap_StatementClassOfStockAxis_635858815105540620" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858815105540620" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_635858815105540620" xlink:to="us-gaap_ClassOfStockDomain_635858815105540620" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105540620" xlink:to="us-gaap_SeriesAPreferredStockMember_635858815105550621" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105540620" xlink:to="us-gaap_SeriesBPreferredStockMember_635858815105550621" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105540620" xlink:to="us-gaap_SeriesCPreferredStockMember_635858815105550621" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105540620" xlink:to="us-gaap_SeriesDPreferredStockMember_635858815105550621" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105540620" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_635858815105550621" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" xlink:label="coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_635858815105540620" xlink:to="coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember_635858815105550621" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858815105540620" xlink:to="us-gaap_ClassOfStockLineItems_635858815105550621" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_635858815105560622" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858815105550621" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_635858815105560622" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_635858815105560622" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858815105550621" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_635858815105560622" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_635858815105560622" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858815105550621" xlink:to="us-gaap_ConversionOfStockSharesIssued1_635858815105560622" xlink:title="presentation:  to " use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_635858815105560622" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858815105550621" xlink:to="us-gaap_PreferredStockDividendRatePercentage_635858815105560622" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_635858815105560622" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858815105550621" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_635858815105560622" xlink:title="presentation:  to " use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858815105550621" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_635858815105550621" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858815105550621" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_635858815105550621" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends_635858815105560622" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858815105550621" xlink:to="us-gaap_TemporaryEquityAccretionOfDividends_635858815105560622" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" xlink:label="coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue_635858815105560622" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858815105550621" xlink:to="coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue_635858815105560622" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityGainLossOnExtinguishment" xlink:label="coll_TemporaryEquityGainLossOnExtinguishment_635858815105560622" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_635858815105550621" xlink:to="coll_TemporaryEquityGainLossOnExtinguishment_635858815105560622" xlink:title="presentation:  to " use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858815105540620" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis_635858815105550621" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis_635858815105550621" xlink:to="us-gaap_DebtConversionNameDomain_635858815105550621" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" xlink:label="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionNameDomain_635858815105550621" xlink:to="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_635858815105550621" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858815105540620" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis_635858815105550621" xlink:title="presentation:  to " use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis_635858815105550621" xlink:to="us-gaap_ConversionOfStockNameDomain_635858815105550621" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" xlink:label="coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockNameDomain_635858815105550621" xlink:to="coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember_635858815105550621" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858815105540620" xlink:to="us-gaap_RangeAxis_635858815105550621" xlink:title="presentation:  to " use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_635858815105550621" xlink:to="us-gaap_RangeMember_635858815105550621" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635858815105550621" xlink:to="us-gaap_MinimumMember_635858815105550621" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_635858815105540620" xlink:to="us-gaap_StatementScenarioAxis_635858815105550621" xlink:title="presentation:  to " use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis_635858815105550621" xlink:to="us-gaap_ScenarioUnspecifiedDomain_635858815105550621" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" xlink:label="coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember_635858815105550621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain_635858815105550621" xlink:to="coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember_635858815105550621" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_635858815105540620" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetails2QuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis_635858815105610627" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_635858815105610627" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis_635858815105610627" xlink:to="us-gaap_ScenarioUnspecifiedDomain_635858815105610627" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember" xlink:label="coll_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember_635858815105610627" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain_635858815105610627" xlink:to="coll_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember_635858815105610627" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_635785187300845594" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_635858815105610627" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_635785187300845594" xlink:to="us-gaap_OtherCommitmentsTable_635858815105610627" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_635858815105610627" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_635858815105610627" xlink:to="us-gaap_OtherCommitmentsLineItems_635858815105610627" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract_635858815105610627" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_635858815105610627" xlink:to="us-gaap_LeasesOperatingAbstract_635858815105610627" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_635858815105610627" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_635858815105610627" xlink:to="us-gaap_AreaOfRealEstateProperty_635858815105610627" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_635858815105610627" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_635858815105610627" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_635858815105610627" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_635858815105610627" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_635858815105610627" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_635858815105610627" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_635858815105610627" xlink:to="us-gaap_StatementScenarioAxis_635858815105610627" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis_635858815105610627" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_635858815105610627" xlink:to="us-gaap_LeaseArrangementTypeAxis_635858815105610627" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain_635858815105610627" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis_635858815105610627" xlink:to="us-gaap_LeaseArrangementTypeDomain_635858815105610627" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" xlink:label="coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_635858815105610627" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain_635858815105610627" xlink:to="coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_635858815105610627" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" xlink:label="coll_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember_635858815105610627" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember_635858815105610627" xlink:to="coll_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember_635858815105610627" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureDebtDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_635858824698556517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_635858824698556517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_635858824698556517" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_635858824698556517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" xlink:label="coll_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member_635858824698556517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_635858824698556517" xlink:to="coll_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member_635858824698556517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xlink:label="coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_635858824698556517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_635858824698556517" xlink:to="coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_635858824698556517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xlink:label="coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_635858824698556517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_635858824698556517" xlink:to="coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_635858824698556517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_635792058133771926" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_635858824698556517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_635792058133771926" xlink:to="us-gaap_DebtInstrumentTable_635858824698556517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_635858824698556517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_635858824698556517" xlink:to="us-gaap_LongtermDebtTypeAxis_635858824698556517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_635858824698556517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_635858824698556517" xlink:to="us-gaap_LongtermDebtTypeDomain_635858824698556517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableToBanksMember" xlink:label="us-gaap_NotesPayableToBanksMember_635858824698556517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_635858824698556517" xlink:to="us-gaap_NotesPayableToBanksMember_635858824698556517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_635858824698556517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_635858824698556517" xlink:to="us-gaap_DebtInstrumentAxis_635858824698556517" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_635858824698556517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_635858824698556517" xlink:to="us-gaap_DebtInstrumentNameDomain_635858824698556517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SiliconValleyBankLoanAgreement28August2012Member" xlink:label="coll_SiliconValleyBankLoanAgreement28August2012Member_635858824698556517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_635858824698556517" xlink:to="coll_SiliconValleyBankLoanAgreement28August2012Member_635858824698556517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xlink:label="coll_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_635858824698556517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_SiliconValleyBankLoanAgreement28August2012Member_635858824698556517" xlink:to="coll_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member_635858824698556517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xlink:label="coll_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_635858824698556517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="coll_SiliconValleyBankLoanAgreement28August2012Member_635858824698556517" xlink:to="coll_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member_635858824698556517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_635858824698556517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_635858824698556517" xlink:to="us-gaap_VariableRateAxis_635858824698556517" xlink:title="presentation:  to " use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_635858824698556517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_635858824698556517" xlink:to="us-gaap_VariableRateDomain_635858824698556517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember_635858824698556517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_635858824698556517" xlink:to="us-gaap_PrimeRateMember_635858824698556517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_635858824698556517" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_635858824698556517" xlink:title="presentation:  to " use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_635858824698556517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_635858824698556517" xlink:to="us-gaap_DebtInstrumentLineItems_635858824698556517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_635858824698556517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635858824698556517" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_635858824698556517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_635858824698566517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635858824698556517" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_635858824698566517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_635858824698566517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635858824698556517" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_635858824698566517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_635858824698566517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635858824698556517" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_635858824698566517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_635858824698566517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635858824698556517" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_635858824698566517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_635858824698566517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635858824698556517" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_635858824698566517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" xlink:label="coll_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_635858824698566517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635858824698556517" xlink:to="coll_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_635858824698566517" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod" xlink:label="coll_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod_635858824698566517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635858824698556517" xlink:to="coll_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod_635858824698566517" xlink:title="presentation:  to " use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_635858824698566517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635858824698556517" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_635858824698566517" xlink:title="presentation:  to " use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_635858824698566517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635858824698556517" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_635858824698566517" xlink:title="presentation:  to " use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross_635858824698566517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635858824698556517" xlink:to="us-gaap_DeferredFinanceCostsGross_635858824698566517" xlink:title="presentation:  to " use="optional" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_635858824698566517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635858824698556517" xlink:to="us-gaap_PaymentsOfFinancingCosts_635858824698566517" xlink:title="presentation:  to " use="optional" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_635858824698566517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635858824698556517" xlink:to="us-gaap_DeferredFinanceCostsNet_635858824698566517" xlink:title="presentation:  to " use="optional" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_635858824698566517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635858824698556517" xlink:to="us-gaap_DebtInstrumentCarryingAmount_635858824698566517" xlink:title="presentation:  to " use="optional" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_635858824698566517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635858824698556517" xlink:to="us-gaap_InterestExpenseDebt_635858824698566517" xlink:title="presentation:  to " use="optional" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_635858824698456517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_635858824698456517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_635858824698456517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_635858824698456517" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_635858824698456517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="FairValueDisclosureItemAmountsDomain" xlink:title="FairValueDisclosureItemAmountsDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_635858824698456517" xlink:to="FairValueDisclosureItemAmountsDomain" xlink:title="presentation: FairValueByMeasurementBasisAxis to FairValueDisclosureItemAmountsDomain" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="CarryingReportedAmountFairValueDisclosureMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosureItemAmountsDomain" xlink:to="CarryingReportedAmountFairValueDisclosureMember" xlink:title="presentation: FairValueDisclosureItemAmountsDomain to CarryingReportedAmountFairValueDisclosureMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_635858824698456517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_635858824698456517" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_635858824698456517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_635858824698456517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_635858824698456517" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_635858824698456517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_635858824698456517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract_635858824698456517" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_635858824698456517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails4">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_635858824698466517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_635858824698466517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_635858824698466517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_635858824698466517" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_635858824698466517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts_635858824698466517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_635858824698466517" xlink:to="us-gaap_DeferredOfferingCosts_635858824698466517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_635858824698466517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_635858824698466517" xlink:to="us-gaap_BalanceSheetLocationAxis_635858824698466517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_635858824698466517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_635858824698466517" xlink:to="us-gaap_BalanceSheetLocationDomain_635858824698466517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_635858824698466517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_635858824698466517" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_635858824698466517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_635858815105500616" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_635858815105500616" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_635858815105500616" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_635858815105500616" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_635858815105510617" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_635858815105500616" xlink:to="us-gaap_IPOMember_635858815105510617" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_635858815105510617" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IPOMember_635858815105510617" xlink:to="us-gaap_OverAllotmentOptionMember_635858815105510617" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_635785181209273401" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_635858815105500616" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635785181209273401" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_635858815105500616" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_635858815105500616" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_635858815105500616" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_635858815105510617" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_635858815105500616" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_635858815105510617" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_635858815105510617" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_635858815105510617" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_635858815105510617" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_635858815105510617" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_635858815105510617" xlink:to="us-gaap_SharesIssuedPricePerShare_635858815105510617" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_635858815105510617" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_635858815105510617" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_635858815105510617" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureDebtDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_635858824698576517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_635858824698576517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_635858824698576517" xlink:to="us-gaap_RelatedPartyTransactionDomain_635858824698576517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_NotePurchaseAgreementConvertiblePromissoryNotesMember" xlink:label="coll_NotePurchaseAgreementConvertiblePromissoryNotesMember_635858824698576517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_635858824698576517" xlink:to="coll_NotePurchaseAgreementConvertiblePromissoryNotesMember_635858824698576517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_635858824698576517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_635858824698576517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_635858824698576517" xlink:to="us-gaap_RelatedPartyDomain_635858824698576517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember_635858824698576517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_635858824698576517" xlink:to="us-gaap_InvestorMember_635858824698576517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_635858824698576517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_635858824698576517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_635858824698576517" xlink:to="us-gaap_DebtInstrumentNameDomain_635858824698576517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" xlink:label="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_635858824698576517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_635858824698576517" xlink:to="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_635858824698576517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermDebtOtherDisclosuresAbstract" xlink:label="us-gaap_ShortTermDebtOtherDisclosuresAbstract_635792138321334604" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_635858824698576517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtOtherDisclosuresAbstract_635792138321334604" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_635858824698576517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_635858824698576517" xlink:to="us-gaap_RelatedPartyTransactionAxis_635858824698576517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_635858824698576517" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_635858824698576517" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_635858824698576517" xlink:to="us-gaap_DebtInstrumentAxis_635858824698576517" xlink:title="presentation:  to " use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_635858824698576517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_635858824698576517" xlink:to="us-gaap_RelatedPartyTransactionLineItems_635858824698576517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_635858824698586517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_635858824698576517" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_635858824698586517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="us-gaap_RelatedPartyTransactionRate_635858824698586517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_635858824698576517" xlink:to="us-gaap_RelatedPartyTransactionRate_635858824698586517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureConvertibleBridgeNoteWithRelatedPartyDetailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_635858815105540620" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_635858815105540620" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_635858815105540620" xlink:to="us-gaap_RelatedPartyTransactionDomain_635858815105540620" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_NotePurchaseAgreementConvertiblePromissoryNotesMember" xlink:label="coll_NotePurchaseAgreementConvertiblePromissoryNotesMember_635858815105540620" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_635858815105540620" xlink:to="coll_NotePurchaseAgreementConvertiblePromissoryNotesMember_635858815105540620" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_635858815105540620" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_635858815105540620" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_635858815105540620" xlink:to="us-gaap_RelatedPartyDomain_635858815105540620" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember_635858815105540620" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_635858815105540620" xlink:to="us-gaap_InvestorMember_635858815105540620" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_635858815105540620" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_635858815105540620" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_635858815105540620" xlink:to="us-gaap_DebtInstrumentNameDomain_635858815105540620" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" xlink:label="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_635858815105540620" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_635858815105540620" xlink:to="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member_635858815105540620" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermDebtOtherDisclosuresAbstract" xlink:label="us-gaap_ShortTermDebtOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_635858815105540620" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtOtherDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_635858815105540620" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_635858815105540620" xlink:to="us-gaap_RelatedPartyTransactionAxis_635858815105540620" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_635858815105540620" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_635858815105540620" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_635858815105540620" xlink:to="us-gaap_DebtInstrumentAxis_635858815105540620" xlink:title="presentation:  to " use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_635858815105540620" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_635858815105540620" xlink:to="us-gaap_RelatedPartyTransactionLineItems_635858815105540620" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_635858815105540620" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_635858815105540620" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_635858815105540620" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="us-gaap_RelatedPartyTransactionRate_635858815105540620" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_635858815105540620" xlink:to="us-gaap_RelatedPartyTransactionRate_635858815105540620" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_635858815105540620" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_635858815105540620" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_635858815105540620" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails5">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_635858824698466517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698466517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_635858824698466517" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698466517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_635858824698466517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698466517" xlink:to="us-gaap_RestrictedStockMember_635858824698466517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_NonemployeeStockOptionsMember" xlink:label="coll_NonemployeeStockOptionsMember_635858824698466517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698466517" xlink:to="coll_NonemployeeStockOptionsMember_635858824698466517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698466517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698466517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698466517" xlink:to="us-gaap_AwardTypeAxis_635858824698466517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis_635858824698466517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698466517" xlink:to="us-gaap_TitleOfIndividualAxis_635858824698466517" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_635858824698466517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis_635858824698466517" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_635858824698466517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_NonemployeeMember" xlink:label="coll_NonemployeeMember_635858824698466517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_635858824698466517" xlink:to="coll_NonemployeeMember_635858824698466517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698466517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698466517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698466517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_635858824698466517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698466517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_635858824698466517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_635858824698466517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698466517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_635858824698466517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_635858824698696517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698696517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_635858824698696517" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698696517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_EmployeeAndNonemployeeStockOptionsMember" xlink:label="coll_EmployeeAndNonemployeeStockOptionsMember_635858824698696517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698696517" xlink:to="coll_EmployeeAndNonemployeeStockOptionsMember_635858824698696517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_635858824698696517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635858824698696517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_635858824698696517" xlink:to="us-gaap_RangeMember_635858824698696517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_635858824698696517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635858824698696517" xlink:to="us-gaap_MaximumMember_635858824698696517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_635858824698696517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635858824698696517" xlink:to="us-gaap_MinimumMember_635858824698696517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698696517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698696517" xlink:to="us-gaap_AwardTypeAxis_635858824698696517" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698696517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698696517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698696517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_635858824698696517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698696517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_635858824698696517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_635858824698706517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698696517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_635858824698706517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_635858824698706517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698696517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_635858824698706517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_635858824698706517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698696517" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_635858824698706517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate" xlink:label="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate_635858824698706517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698696517" xlink:to="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate_635858824698706517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_635858824698706517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698696517" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_635858824698706517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_635858824698696517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698696517" xlink:to="us-gaap_PlanNameAxis_635858824698696517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_635858824698696517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_635858824698696517" xlink:to="us-gaap_PlanNameDomain_635858824698696517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StockIncentivePlan2014Member" xlink:label="coll_StockIncentivePlan2014Member_635858824698696517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_635858824698696517" xlink:to="coll_StockIncentivePlan2014Member_635858824698696517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698696517" xlink:to="us-gaap_RangeAxis_635858824698696517" xlink:title="presentation:  to " use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635786944414449215" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635786944414449215" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698696517" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_635858824698706517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698706517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_635858824698706517" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698706517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_EmployeeAndNonemployeeStockOptionsMember" xlink:label="coll_EmployeeAndNonemployeeStockOptionsMember_635858824698706517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698706517" xlink:to="coll_EmployeeAndNonemployeeStockOptionsMember_635858824698706517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_635858824698706517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698706517" xlink:to="us-gaap_EmployeeStockOptionMember_635858824698706517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698706517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698706517" xlink:to="us-gaap_AwardTypeAxis_635858824698706517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698706517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698706517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698706517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635858824698706517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698706517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635858824698706517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_635858824698706517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635858824698706517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_635858824698706517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_635858824698716517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635858824698706517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_635858824698716517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_635858824698706517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635858824698706517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_635858824698706517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_635858824698706517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635858824698706517" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_635858824698706517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_635858824698716517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635858824698706517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_635858824698716517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_635858824698716517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635858824698706517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_635858824698716517" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_635858824698716517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635858824698706517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_635858824698716517" xlink:title="presentation:  to " use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification" xlink:label="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification_635858824698716517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635858824698706517" xlink:to="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification_635858824698716517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635858824698716517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698706517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635858824698716517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_635858824698716517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635858824698716517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_635858824698716517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6358588246987165171" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635858824698716517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6358588246987165171" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_635858824698716517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635858824698716517" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_635858824698716517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_635858824698716517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635858824698716517" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_635858824698716517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_635858824698716517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635858824698716517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_635858824698716517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_635858824698716517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635858824698716517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_635858824698716517" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_635858824698716517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635858824698716517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_635858824698716517" xlink:title="presentation:  to " use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice" xlink:label="coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice_635858824698716517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635858824698716517" xlink:to="coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice_635858824698716517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635858824698716517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698706517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635858824698716517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_635858824698716517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635858824698716517" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_635858824698716517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_635858824698716517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635858824698716517" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_635858824698716517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_635858824698726517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635858824698716517" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_635858824698726517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_635858824698726517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635858824698716517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_635858824698726517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_635858824698726517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635858824698716517" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_635858824698726517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_635858824698726517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635858824698716517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_635858824698726517" xlink:title="presentation:  to " use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_635858824698726517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635858824698716517" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_635858824698726517" xlink:title="presentation:  to " use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_635858824698726517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635858824698716517" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_635858824698726517" xlink:title="presentation:  to " use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue" xlink:label="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue_635858824698726517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635858824698716517" xlink:to="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue_635858824698726517" xlink:title="presentation:  to " use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding" xlink:label="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding_635858824698726517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_635858824698716517" xlink:to="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding_635858824698726517" xlink:title="presentation:  to " use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635786967613158358" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635786967613158358" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698706517" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails3">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_635858824698726517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698736517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_635858824698726517" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698736517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_635858824698736517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824698736517" xlink:to="us-gaap_RestrictedStockMember_635858824698736517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698726517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698726517" xlink:to="us-gaap_AwardTypeAxis_635858824698726517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698736517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698726517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698736517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635858824698736517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698736517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635858824698736517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_635858824698736517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635858824698736517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_635858824698736517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6358588246987365171" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635858824698736517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6358588246987365171" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_635858824698736517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635858824698736517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_635858824698736517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_635858824698736517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635858824698736517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_635858824698736517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification" xlink:label="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification_635858824698736517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635858824698736517" xlink:to="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification_635858824698736517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635858824698736517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698736517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635858824698736517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_635858824698736517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635858824698736517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_635858824698736517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6358588246987365171" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635858824698736517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6358588246987365171" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_635858824698736517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635858824698736517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_635858824698736517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_635858824698736517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635858824698736517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_635858824698736517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue" xlink:label="coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue_635858824698736517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635858824698736517" xlink:to="coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue_635858824698736517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_635858824698736517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698736517" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_635858824698736517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_635858824698736517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_635858824698736517" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_635858824698736517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_635858824698736517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_635858824698736517" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_635858824698736517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635787075984183851" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635787075984183851" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698726517" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_635858815105560622" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858815105570623" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_635858815105560622" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858815105570623" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_EmployeeAndNonemployeeStockOptionsMember" xlink:label="coll_EmployeeAndNonemployeeStockOptionsMember_635858815105570623" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858815105570623" xlink:to="coll_EmployeeAndNonemployeeStockOptionsMember_635858815105570623" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_635858815105570623" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635858815105570623" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_635858815105570623" xlink:to="us-gaap_RangeMember_635858815105570623" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_635858815105570623" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635858815105570623" xlink:to="us-gaap_MaximumMember_635858815105570623" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_635858815105570623" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635858815105570623" xlink:to="us-gaap_MinimumMember_635858815105570623" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858815105560622" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858815105560622" xlink:to="us-gaap_AwardTypeAxis_635858815105560622" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858815105570623" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858815105560622" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858815105570623" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_635858815105570623" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858815105570623" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_635858815105570623" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_635858815105570623" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858815105570623" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_635858815105570623" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_635858815105570623" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858815105570623" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_635858815105570623" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate" xlink:label="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate_635858815105570623" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858815105570623" xlink:to="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate_635858815105570623" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares" xlink:label="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares_635858815105570623" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858815105570623" xlink:to="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares_635858815105570623" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_635858815105560622" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858815105560622" xlink:to="us-gaap_PlanNameAxis_635858815105560622" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_635858815105560622" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_635858815105560622" xlink:to="us-gaap_PlanNameDomain_635858815105560622" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StockIncentivePlan2014Member" xlink:label="coll_StockIncentivePlan2014Member_635858815105560622" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_635858815105560622" xlink:to="coll_StockIncentivePlan2014Member_635858815105560622" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858815105560622" xlink:to="us-gaap_RangeAxis_635858815105570623" xlink:title="presentation:  to " use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858815105560622" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails2QuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_635858815105570623" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858815105570623" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_635858815105570623" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858815105570623" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_635858815105570623" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858815105570623" xlink:to="us-gaap_RestrictedStockMember_635858815105570623" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858815105570623" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858815105570623" xlink:to="us-gaap_AwardTypeAxis_635858815105570623" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858815105570623" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858815105570623" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858815105570623" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635858815105570623" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858815105570623" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635858815105570623" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_635858815105570623" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635858815105570623" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_635858815105570623" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_635858815105580624" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635858815105570623" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_635858815105580624" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_635858815105580624" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635858815105570623" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_635858815105580624" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_635858815105580624" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635858815105570623" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_635858815105580624" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber" xlink:label="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber_635858815105580624" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_635858815105570623" xlink:to="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber_635858815105580624" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635858815105580624" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858815105570623" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635858815105580624" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_635858815105580624" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635858815105580624" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_635858815105580624" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6358588151055806241" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635858815105580624" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6358588151055806241" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_635858815105580624" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635858815105580624" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_635858815105580624" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_635858815105580624" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_635858815105580624" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_635858815105580624" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858815105570623" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_635858824698496517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635858824698496517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_635858824698496517" xlink:to="us-gaap_RangeMember_635858824698496517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_635858824698496517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635858824698496517" xlink:to="us-gaap_MaximumMember_635858824698496517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable_635858824698496517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable_635858824698496517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_635858824698496517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_635858824698496517" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis_635858824698496517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_635858824698496517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis_635858824698496517" xlink:to="us-gaap_LossContingencyNatureDomain_635858824698496517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember" xlink:label="coll_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember_635858824698496517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain_635858824698496517" xlink:to="coll_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember_635858824698496517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_635858824698496517" xlink:to="us-gaap_RangeAxis_635858824698496517" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems_635858824698496517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_635858824698496517" xlink:to="us-gaap_LossContingenciesLineItems_635858824698496517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected" xlink:label="coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected_635858824698536517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_635858824698496517" xlink:to="coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected_635858824698536517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_635858824698536517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635858824698536517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_635858824698536517" xlink:to="us-gaap_RangeMember_635858824698536517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_635858824698536517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635858824698536517" xlink:to="us-gaap_MaximumMember_635858824698536517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_635858824698536517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_635858824698536517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_635858824698536517" xlink:to="us-gaap_DebtInstrumentNameDomain_635858824698536517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember" xlink:label="coll_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember_635858824698536517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_635858824698536517" xlink:to="coll_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember_635858824698536517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_635858824698536517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable_635858824698536517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_635858824698536517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_635858824698536517" xlink:to="us-gaap_OtherCommitmentsLineItems_635858824698536517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract_635858824698546517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_635858824698536517" xlink:to="us-gaap_LeasesOperatingAbstract_635858824698546517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm" xlink:label="coll_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm_635858824698546517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_635858824698546517" xlink:to="coll_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm_635858824698546517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635858824698546517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_635858824698536517" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635858824698546517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_635858824698546517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635858824698546517" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_635858824698546517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_635858824698546517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635858824698546517" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_635858824698546517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_635858824698546517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635858824698546517" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_635858824698546517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_635858824698546517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_635858824698546517" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_635858824698546517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseAbstract" xlink:label="us-gaap_OperatingLeasesRentExpenseAbstract_635858824698546517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_635858824698536517" xlink:to="us-gaap_OperatingLeasesRentExpenseAbstract_635858824698546517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_635858824698546517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesRentExpenseAbstract_635858824698546517" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_635858824698546517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GuaranteesAbstract" xlink:label="us-gaap_GuaranteesAbstract_635858824698546517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_635858824698536517" xlink:to="us-gaap_GuaranteesAbstract_635858824698546517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_635858824698546517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GuaranteesAbstract_635858824698546517" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_635858824698546517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueAndCreditsAbstract" xlink:label="us-gaap_DeferredRevenueAndCreditsAbstract_635858824698546517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_635858824698536517" xlink:to="us-gaap_DeferredRevenueAndCreditsAbstract_635858824698546517" xlink:title="presentation:  to " use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_IncentiveFromLessorGross" xlink:label="coll_IncentiveFromLessorGross_635858824698546517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueAndCreditsAbstract_635858824698546517" xlink:to="coll_IncentiveFromLessorGross_635858824698546517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ReimbursableIncentiveFromLessorGross" xlink:label="coll_ReimbursableIncentiveFromLessorGross_635858824698546517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueAndCreditsAbstract_635858824698546517" xlink:to="coll_ReimbursableIncentiveFromLessorGross_635858824698546517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_635858824698546517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueAndCreditsAbstract_635858824698546517" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_635858824698546517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_635858824698546517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueAndCreditsAbstract_635858824698546517" xlink:to="us-gaap_DebtInstrumentTerm_635858824698546517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_635858824698536517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_635858824698536517" xlink:to="us-gaap_InvestmentTypeAxis_635858824698536517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_635858824698536517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis_635858824698536517" xlink:to="us-gaap_InvestmentTypeCategorizationMember_635858824698536517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="us-gaap_StandbyLettersOfCreditMember_635858824698536517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_635858824698536517" xlink:to="us-gaap_StandbyLettersOfCreditMember_635858824698536517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_635858824698536517" xlink:to="us-gaap_DebtInstrumentAxis_635858824698536517" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_635858824698536517" xlink:to="us-gaap_RangeAxis_635858824698536517" xlink:title="presentation:  to " use="optional" order="3.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails5">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_635858824698746517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635858824698746517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_635858824698746517" xlink:to="us-gaap_RangeMember_635858824698746517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_635858824698746517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635858824698746517" xlink:to="us-gaap_MaximumMember_635858824698746517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_635858824698746517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635858824698746517" xlink:to="us-gaap_MinimumMember_635858824698746517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698746517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698746517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698746517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698746517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635858824698746517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635858824698746517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635858824698746517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_635858824698746517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635858824698746517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_635858824698746517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_635858824698746517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635858824698746517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_635858824698746517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_635858824698746517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635858824698746517" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_635858824698746517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_635858824698746517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635858824698746517" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_635858824698746517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698746517" xlink:to="us-gaap_RangeAxis_635858824698746517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635787756472507570" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635787756472507570" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635858824698746517" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_635858815105600626" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635858815105600626" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_635858815105600626" xlink:to="us-gaap_RangeMember_635858815105600626" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_635858815105600626" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635858815105600626" xlink:to="us-gaap_MaximumMember_635858815105600626" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_635785186856726711" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable_635858815105600626" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_635785186856726711" xlink:to="us-gaap_LossContingenciesTable_635858815105600626" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_635858815105600626" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_635858815105600626" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis_635858815105600626" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_635858815105600626" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis_635858815105600626" xlink:to="us-gaap_LossContingencyNatureDomain_635858815105600626" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember" xlink:label="coll_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember_635858815105600626" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain_635858815105600626" xlink:to="coll_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember_635858815105600626" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_635858815105600626" xlink:to="us-gaap_RangeAxis_635858815105600626" xlink:title="presentation:  to " use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems_635858815105600626" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_635858815105600626" xlink:to="us-gaap_LossContingenciesLineItems_635858815105600626" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected" xlink:label="coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected_635858815105610627" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_635858815105600626" xlink:to="coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected_635858815105610627" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:label="us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_635858815105610627" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_635858815105600626" xlink:to="us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_635858815105610627" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis_635858815105600626" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_635858815105600626" xlink:to="us-gaap_LitigationCaseAxis_635858815105600626" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain_635858815105600626" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseAxis_635858815105600626" xlink:to="us-gaap_LitigationCaseTypeDomain_635858815105600626" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" xlink:label="coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember_635858815105600626" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseTypeDomain_635858815105600626" xlink:to="coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember_635858815105600626" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" xlink:label="coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember_635858815105600626" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseTypeDomain_635858815105600626" xlink:to="coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember_635858815105600626" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails3">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_635858824698456517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_635858824698456517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_635858824698456517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_635858824698456517" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_635858824698456517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_635858824698456517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_635858824698456517" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_635858824698456517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_635858824698456517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_635858824698456517" xlink:to="us-gaap_MachineryAndEquipmentMember_635858824698456517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ComputerEquipmentAndOfficeEquipmentMember" xlink:label="coll_ComputerEquipmentAndOfficeEquipmentMember_635858824698456517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_635858824698456517" xlink:to="coll_ComputerEquipmentAndOfficeEquipmentMember_635858824698456517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_635858824698466517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_635858824698456517" xlink:to="us-gaap_FurnitureAndFixturesMember_635858824698466517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_635858824698466517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_635858824698456517" xlink:to="us-gaap_LeaseholdImprovementsMember_635858824698466517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_635858824698466517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_635858824698456517" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_635858824698466517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_635858824698466517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_635858824698466517" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_635858824698466517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosurePropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_635858824698486517" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_635858824698486517" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_635858824698486517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_635858824698486517" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_635858824698486517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_635858824698486517" xlink:to="us-gaap_MachineryAndEquipmentMember_635858824698486517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ComputerEquipmentAndOfficeEquipmentMember" xlink:label="coll_ComputerEquipmentAndOfficeEquipmentMember_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_635858824698486517" xlink:to="coll_ComputerEquipmentAndOfficeEquipmentMember_635858824698486517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_635858824698486517" xlink:to="us-gaap_FurnitureAndFixturesMember_635858824698486517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_635858824698486517" xlink:to="us-gaap_LeaseholdImprovementsMember_635858824698486517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_635858824698486517" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_635858824698486517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_635858824698486517" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_635858824698486517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_635858824698486517" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_635858824698486517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_635858824698496517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_635858824698486517" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_635858824698496517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_635858824698486517" xlink:title="presentation:  to " use="optional" order="1.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails3">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_635858824698476517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_635858824698476517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_635858824698476517" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_635858824698486517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_635858824698486517" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_635858824698486517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_EmployeeAndNonemployeeStockOptionsMember" xlink:label="coll_EmployeeAndNonemployeeStockOptionsMember_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_635858824698486517" xlink:to="coll_EmployeeAndNonemployeeStockOptionsMember_635858824698486517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_635858824698486517" xlink:to="us-gaap_WarrantMember_635858824698486517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_635858824698486517" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_635858824698486517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_635858824698486517" xlink:to="us-gaap_RestrictedStockMember_635858824698486517" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_635858824698476517" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_635858824698486517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_635858824698486517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_635858824698486517" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_635858824698486517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails2QuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_635785183845173401" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_635858815105520618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_635785183845173401" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_635858815105520618" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_635858815105520618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_635858815105520618" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_635858815105520618" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_635858815105520618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_635858815105520618" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_635858815105520618" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_EmployeeAndNonemployeeStockOptionsMember" xlink:label="coll_EmployeeAndNonemployeeStockOptionsMember_635858815105520618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_635858815105520618" xlink:to="coll_EmployeeAndNonemployeeStockOptionsMember_635858815105520618" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_635858815105520618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_635858815105520618" xlink:to="us-gaap_WarrantMember_635858815105520618" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_635858815105520618" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_635858815105520618" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_635858815105520618" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_635858815105530619" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_635858815105520618" xlink:to="us-gaap_RestrictedStockMember_635858815105530619" xlink:title="presentation:  to " use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_635858815105530619" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_635858815105520618" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_635858815105530619" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_635858815105530619" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_635858815105530619" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_635858815105530619" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails4">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_635858824698746517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_635858824698746517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_635858824698746517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_635858824698746517" xlink:to="us-gaap_IncomeStatementLocationAxis_635858824698746517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_635858824698746517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_635858824698746517" xlink:to="us-gaap_IncomeStatementLocationDomain_635858824698746517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_635858824698746517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_635858824698746517" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_635858824698746517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_635858824698746517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_635858824698746517" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_635858824698746517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_635858824698746517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_635858824698746517" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_635858824698746517" xlink:title="presentation:  to " use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_635858824698746517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_635858824698746517" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_635858824698746517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureIncomeTaxesDetails3">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_635858824698756517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_635858824698756517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_635858824698756517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_635858824698756517" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_635858824698756517" xlink:title="presentation:  to " use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_635858824698766517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_635858824698756517" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_635858824698766517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember_635858824698766517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain_635858824698766517" xlink:to="us-gaap_InternalRevenueServiceIRSMember_635858824698766517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_635858824698766517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_635858824698756517" xlink:to="us-gaap_IncomeTaxAuthorityAxis_635858824698766517" xlink:title="presentation:  to " use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_635858824698766517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_635858824698766517" xlink:to="us-gaap_IncomeTaxAuthorityDomain_635858824698766517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_635858824698766517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_635858824698766517" xlink:to="us-gaap_StateAndLocalJurisdictionMember_635858824698766517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_635858824698766517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_635858824698756517" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_635858824698766517" xlink:title="presentation:  to " use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_635858824698766517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_635858824698766517" xlink:to="us-gaap_OperatingLossCarryforwards_635858824698766517" xlink:title="presentation:  to " use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>coll-20160104_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementBalanceSheets" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementBalanceSheets" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementBalanceSheetsParenthetical" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementStatementsOfOperations" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementStatementsOfOperations" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementConvertibleRedeemablePreferredStock" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementConvertibleRedeemablePreferredStock" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementConvertibleRedeemablePreferredStockParenthetical" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementConvertibleRedeemablePreferredStockParenthetical" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementShareholdersDeficit" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementShareholdersDeficit" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlowsParenthetical" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementStatementsOfCashFlowsParenthetical" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNatureOfBusinessDetails2" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNatureOfBusinessDetails2" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails2" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails3" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails3" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails4" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails4" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails5" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails5" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails2" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNetLossPerCommonShareDetails2" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails3" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNetLossPerCommonShareDetails3" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosurePropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureCommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureCommitmentsAndContingenciesDetails2" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureDebtDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureDebtDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureDebtDetails2" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureDebtDetails2" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureWarrantsDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureWarrantsDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureEquityDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureEquityDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureEquityDetails2" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureEquityDetails2" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureEquityDetails3" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureEquityDetails3" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureStockBasedCompensationDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails2" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureStockBasedCompensationDetails2" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails3" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureStockBasedCompensationDetails3" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails4" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureStockBasedCompensationDetails4" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails5" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureStockBasedCompensationDetails5" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureIncomeTaxesDetails3" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureIncomeTaxesDetails3" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSubsequentEventsUnauditedDetails" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSubsequentEventsUnauditedDetails" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementBalanceSheetsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementBalanceSheetsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementBalanceSheetsParentheticalQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementBalanceSheetsParentheticalQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlowsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementStatementsOfCashFlowsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlowsParentheticalQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#StatementStatementsOfCashFlowsParentheticalQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetailsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2QuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails2QuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetailsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNetLossPerCommonShareDetailsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails2QuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureNetLossPerCommonShareDetails2QuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureFairValueOfFinancialInstrumentsDetailsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureFairValueOfFinancialInstrumentsDetailsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureConvertibleBridgeNoteWithRelatedPartyDetailsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureConvertibleBridgeNoteWithRelatedPartyDetailsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureConvertiblePreferredStockDetailsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureConvertiblePreferredStockDetailsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetailsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureStockBasedCompensationDetailsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails2QuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureStockBasedCompensationDetails2QuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetailsQuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureCommitmentsAndContingenciesDetailsQuarterEnd" />
  <link:roleRef roleURI="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetails2QuarterEnd" xlink:type="simple" xlink:href="coll-20160104.xsd#DisclosureCommitmentsAndContingenciesDetails2QuarterEnd" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858824697236517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_635858824697236517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" xlink:label="coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LoansPayableCurrent" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncentiveFromLessor" xlink:label="us-gaap_IncentiveFromLessor" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_IncentiveFromLessor" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermLoansPayable" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" use="optional" priority="1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockCarryingBasis" xlink:label="us-gaap_TreasuryStockCarryingBasis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockCarryingBasis" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" use="optional" priority="1" order="8.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" use="optional" priority="1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" use="optional" priority="1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" use="optional" priority="1" order="9.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_635858824697336517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_635858824697336517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProFormaMember" xlink:label="us-gaap_ProFormaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ProFormaMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="us-gaap_OtherExpensesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherExpensesAbstract" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" use="optional" priority="1" order="7.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementConvertibleRedeemablePreferredStock">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquitySharesIssued" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" xlink:label="coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" xlink:label="coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedAndOutstandingModificationShares" xlink:label="coll_TemporaryEquityStockIssuedAndOutstandingModificationShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" xlink:to="coll_TemporaryEquityStockIssuedAndOutstandingModificationShares" use="optional" priority="1" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementConvertibleRedeemablePreferredStockParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_635858824697386517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_635858824697386517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesCPreferredStockFinancing2013Member" xlink:label="coll_SeriesCPreferredStockFinancing2013Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="coll_SeriesCPreferredStockFinancing2013Member" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedIssuanceCosts" xlink:label="coll_TemporaryEquityStockIssuedIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="coll_TemporaryEquityStockIssuedIssuanceCosts" use="optional" priority="1" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementShareholdersDeficit">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_635858824697386517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_635858824697386517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="coll_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="coll_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified" xlink:label="coll_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="coll_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockIssuedAndOutstandingModificationShares" xlink:label="coll_CommonStockIssuedAndOutstandingModificationShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="coll_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified" xlink:to="coll_CommonStockIssuedAndOutstandingModificationShares" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" use="optional" priority="1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" use="optional" priority="1" order="8.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlowsParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" use="optional" priority="1" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNatureOfBusinessDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_635858824697416517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_635858824697416517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_635858824697416517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_635858824697416517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember" xlink:label="coll_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="coll_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_635858824697416517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_635858824697416517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_InvestorMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain_635858824697426517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain_635858824697426517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" xlink:label="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" use="optional" priority="1" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="FairValueDisclosureItemAmountsDomain" xlink:title="FairValueDisclosureItemAmountsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="FairValueDisclosureItemAmountsDomain" xlink:title="definition: FairValueByMeasurementBasisAxis to FairValueDisclosureItemAmountsDomain" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:title="definition: FairValueDisclosureItemAmountsDomain to CarryingReportedAmountFairValueDisclosureMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" use="optional" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails3">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_635858824697436517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_635858824697436517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ComputerEquipmentAndOfficeEquipmentMember" xlink:label="coll_ComputerEquipmentAndOfficeEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="coll_ComputerEquipmentAndOfficeEquipmentMember" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" use="optional" priority="1" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails4">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_635858824697446517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_635858824697446517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_DeferredOfferingCosts" use="optional" priority="1" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails5">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824697446517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858824697446517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_NonemployeeStockOptionsMember" xlink:label="coll_NonemployeeStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="coll_NonemployeeStockOptionsMember" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_635858824697446517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_635858824697446517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_NonemployeeMember" xlink:label="coll_NonemployeeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="coll_NonemployeeMember" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" use="optional" priority="1" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProFormaMember" xlink:label="us-gaap_ProFormaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ProFormaMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementScenarioAxis" use="optional" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_NetIncomeLoss" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityRedemptionValueModificationAdjustment" xlink:label="coll_TemporaryEquityRedemptionValueModificationAdjustment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="coll_TemporaryEquityRedemptionValueModificationAdjustment" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" xlink:label="coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" use="optional" priority="1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" use="optional" priority="1" order="8.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails3">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_635858824697466517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_635858824697466517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_EmployeeAndNonemployeeStockOptionsMember" xlink:label="coll_EmployeeAndNonemployeeStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="coll_EmployeeAndNonemployeeStockOptionsMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" use="optional" priority="1" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosurePropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ComputerEquipmentAndOfficeEquipmentMember" xlink:label="coll_ComputerEquipmentAndOfficeEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="coll_ComputerEquipmentAndOfficeEquipmentMember" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" use="optional" priority="1" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635858824697486517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_635858824697486517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_635858824697476517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain_635858824697476517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember" xlink:label="coll_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="coll_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember" use="optional" priority="1" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_RangeAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected" xlink:label="coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected" use="optional" priority="1" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_InvestmentTypeAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_635858824697486517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_635858824697486517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="us-gaap_StandbyLettersOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_StandbyLettersOfCreditMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_635858824697486517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_635858824697486517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember" xlink:label="coll_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="coll_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember" use="optional" priority="1" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_RangeAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LeasesOperatingAbstract" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm" xlink:label="coll_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="coll_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseAbstract" xlink:label="us-gaap_OperatingLeasesRentExpenseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseAbstract" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesRentExpenseAbstract" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GuaranteesAbstract" xlink:label="us-gaap_GuaranteesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_GuaranteesAbstract" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GuaranteesAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueAndCreditsAbstract" xlink:label="us-gaap_DeferredRevenueAndCreditsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredRevenueAndCreditsAbstract" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_IncentiveFromLessorGross" xlink:label="coll_IncentiveFromLessorGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueAndCreditsAbstract" xlink:to="coll_IncentiveFromLessorGross" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ReimbursableIncentiveFromLessorGross" xlink:label="coll_ReimbursableIncentiveFromLessorGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueAndCreditsAbstract" xlink:to="coll_ReimbursableIncentiveFromLessorGross" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueAndCreditsAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueAndCreditsAbstract" xlink:to="us-gaap_DebtInstrumentTerm" use="optional" priority="1" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureDebtDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_635858824697556517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_635858824697556517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" xlink:label="coll_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="coll_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xlink:label="coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xlink:label="coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SiliconValleyBankLoanAgreement28August2012Member" xlink:label="coll_SiliconValleyBankLoanAgreement28August2012Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="coll_SiliconValleyBankLoanAgreement28August2012Member" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xlink:label="coll_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="coll_SiliconValleyBankLoanAgreement28August2012Member" xlink:to="coll_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xlink:label="coll_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="coll_SiliconValleyBankLoanAgreement28August2012Member" xlink:to="coll_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_635858824697516517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_635858824697516517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableToBanksMember" xlink:label="us-gaap_NotesPayableToBanksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_NotesPayableToBanksMember" use="optional" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_635858824697556517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_635858824697556517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" use="optional" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" use="optional" priority="1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" xlink:label="coll_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="coll_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" use="optional" priority="1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod" xlink:label="coll_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="coll_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod" use="optional" priority="1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" use="optional" priority="1" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" use="optional" priority="1" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" use="optional" priority="1" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfFinancingCosts" use="optional" priority="1" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" use="optional" priority="1" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" use="optional" priority="1" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" use="optional" priority="1" order="16.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureDebtDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_NotePurchaseAgreementConvertiblePromissoryNotesMember" xlink:label="coll_NotePurchaseAgreementConvertiblePromissoryNotesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="coll_NotePurchaseAgreementConvertiblePromissoryNotesMember" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_InvestorMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" xlink:label="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" order="2.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="us-gaap_RelatedPartyTransactionRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionRate" use="optional" priority="1" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProFormaMember" xlink:label="us-gaap_ProFormaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ProFormaMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_635858824697616517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain_635858824697616517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember" xlink:label="coll_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="coll_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" xlink:label="coll_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="coll_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" xlink:label="coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" xlink:label="coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_PreferredStockWarrantsIssuedNovember2010Member" xlink:label="coll_PreferredStockWarrantsIssuedNovember2010Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="coll_PreferredStockWarrantsIssuedNovember2010Member" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesaPreferredStockWarrantMember" xlink:label="coll_SeriesaPreferredStockWarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="coll_SeriesaPreferredStockWarrantMember" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" use="optional" priority="1" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureEquityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember" xlink:label="coll_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="coll_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="2.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_EmployeeAndNonemployeeStockOptionsMember" xlink:label="coll_EmployeeAndNonemployeeStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="coll_EmployeeAndNonemployeeStockOptionsMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" use="optional" priority="1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" use="optional" priority="1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockVotingRightsNumber" xlink:label="coll_CommonStockVotingRightsNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="coll_CommonStockVotingRightsNumber" use="optional" priority="1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" use="optional" priority="1" order="10.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureEquityDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember" xlink:label="coll_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="coll_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StockPurchaseRightMember" xlink:label="coll_StockPurchaseRightMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="coll_StockPurchaseRightMember" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesCPreferredStockFinancing2013Member" xlink:label="coll_SeriesCPreferredStockFinancing2013Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="coll_SeriesCPreferredStockFinancing2013Member" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesCPreferredStockFinancing2013TrancheOneMember" xlink:label="coll_SeriesCPreferredStockFinancing2013TrancheOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="coll_SeriesCPreferredStockFinancing2013Member" xlink:to="coll_SeriesCPreferredStockFinancing2013TrancheOneMember" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesCPreferredStockFinancing2013TrancheTwoMember" xlink:label="coll_SeriesCPreferredStockFinancing2013TrancheTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="coll_SeriesCPreferredStockFinancing2013Member" xlink:to="coll_SeriesCPreferredStockFinancing2013TrancheTwoMember" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesBPreferredStockFinancingFebruary2012Member" xlink:label="coll_SeriesBPreferredStockFinancingFebruary2012Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="coll_SeriesBPreferredStockFinancingFebruary2012Member" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="3.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" use="optional" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" order="2.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" order="4.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RangeAxis" use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedIssuanceCosts" xlink:label="coll_TemporaryEquityStockIssuedIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="coll_TemporaryEquityStockIssuedIssuanceCosts" use="optional" priority="1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SaleOfStockNumberOfSharesAuthorizedToBeSold" xlink:label="coll_SaleOfStockNumberOfSharesAuthorizedToBeSold" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="coll_SaleOfStockNumberOfSharesAuthorizedToBeSold" use="optional" priority="1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SaleOfStockAuthorizedAmount" xlink:label="coll_SaleOfStockAuthorizedAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="coll_SaleOfStockAuthorizedAmount" use="optional" priority="1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SaleOfStockNumberOfTranches" xlink:label="coll_SaleOfStockNumberOfTranches" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="coll_SaleOfStockNumberOfTranches" use="optional" priority="1" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" use="optional" priority="1" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" use="optional" priority="1" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_SharePrice" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" use="optional" priority="1" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StockModificationAbstract" xlink:label="coll_StockModificationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="coll_StockModificationAbstract" use="optional" priority="1" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="coll_StockModificationAbstract" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" xlink:label="coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="coll_StockModificationAbstract" xlink:to="coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" use="optional" priority="1" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureEquityDetails3">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" xlink:label="coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember" xlink:label="coll_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="coll_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesCPreferredStockFinancing2013TrancheTwoMember" xlink:label="coll_SeriesCPreferredStockFinancing2013TrancheTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="coll_SeriesCPreferredStockFinancing2013TrancheTwoMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" order="4.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RangeAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementScenarioAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" use="optional" priority="1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StockModificationAbstract" xlink:label="coll_StockModificationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="coll_StockModificationAbstract" use="optional" priority="1" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="coll_StockModificationAbstract" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" xlink:label="coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="coll_StockModificationAbstract" xlink:to="coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold" xlink:label="coll_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="coll_StockModificationAbstract" xlink:to="coll_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityRightsToElectDirectorsNumberOfDirectors" xlink:label="coll_TemporaryEquityRightsToElectDirectorsNumberOfDirectors" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="coll_TemporaryEquityRightsToElectDirectorsNumberOfDirectors" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage" xlink:label="coll_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="coll_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityCumulativeAccretionOfDividends" xlink:label="coll_TemporaryEquityCumulativeAccretionOfDividends" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="coll_TemporaryEquityCumulativeAccretionOfDividends" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityConvertibleConversionPrice" xlink:label="coll_TemporaryEquityConvertibleConversionPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="coll_TemporaryEquityConvertibleConversionPrice" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityShareholderSharesOwned" xlink:label="coll_TemporaryEquityShareholderSharesOwned" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="coll_TemporaryEquityShareholderSharesOwned" use="optional" priority="1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" priority="1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio" xlink:label="coll_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="coll_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio" use="optional" priority="1" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare" xlink:label="coll_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="coll_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare" use="optional" priority="1" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage" xlink:label="coll_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="coll_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage" use="optional" priority="1" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio" xlink:label="coll_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="coll_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio" use="optional" priority="1" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments" xlink:label="coll_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="coll_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments" use="optional" priority="1" order="14.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_EmployeeAndNonemployeeStockOptionsMember" xlink:label="coll_EmployeeAndNonemployeeStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="coll_EmployeeAndNonemployeeStockOptionsMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_635858824697836517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_635858824697836517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StockIncentivePlan2014Member" xlink:label="coll_StockIncentivePlan2014Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="coll_StockIncentivePlan2014Member" use="optional" priority="1" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate" xlink:label="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" use="optional" priority="1" order="7.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_EmployeeAndNonemployeeStockOptionsMember" xlink:label="coll_EmployeeAndNonemployeeStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="coll_EmployeeAndNonemployeeStockOptionsMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification" xlink:label="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" use="optional" priority="1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice" xlink:label="coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" use="optional" priority="1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" use="optional" priority="1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" use="optional" priority="1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue" xlink:label="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue" use="optional" priority="1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding" xlink:label="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding" use="optional" priority="1" order="10.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails3">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification" xlink:label="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue" xlink:label="coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" use="optional" priority="1" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails4">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_635858824697946517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_635858824697946517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" use="optional" priority="1" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails5">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" use="optional" priority="1" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureIncomeTaxesDetails3">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_635858824697966517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_635858824697966517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_635858824697976517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_635858824697976517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" use="optional" priority="1" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSubsequentEventsUnauditedDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" xlink:label="coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember" xlink:label="coll_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="coll_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember" xlink:label="coll_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="coll_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_InvestorMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" xlink:label="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StockIncentivePlan2014Member" xlink:label="coll_StockIncentivePlan2014Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="coll_StockIncentivePlan2014Member" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain_635858824698006517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain_635858824698006517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" xlink:label="coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" xlink:label="coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain_635858824698136517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain_635858824698136517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" xlink:label="coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" xlink:label="coll_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" xlink:to="coll_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_AreaOfRealEstateProperty" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" order="2.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" order="3.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" use="optional" order="4.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="5.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LitigationCaseAxis" use="optional" order="6.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" order="7.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PlanNameAxis" use="optional" order="8.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" use="optional" order="9.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementScenarioAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_VestingAxis" use="optional" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_635858824698146517" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_635858824698146517" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" order="2.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" order="12.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RangeAxis" use="optional" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" priority="1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" use="optional" priority="1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:label="us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:to="us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" use="optional" priority="1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" use="optional" priority="1" order="5.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LeasesOperatingAbstract" use="optional" priority="1" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockholdersEquityNoteAbstract" use="optional" priority="1" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" use="optional" priority="1" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementBalanceSheetsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_635858815104870553" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_635858815104870553" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" xlink:label="coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LoansPayableCurrent" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncentiveFromLessor" xlink:label="us-gaap_IncentiveFromLessor" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_IncentiveFromLessor" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermLoansPayable" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" use="optional" priority="1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockCarryingBasis" xlink:label="us-gaap_TreasuryStockCarryingBasis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockCarryingBasis" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" use="optional" priority="1" order="8.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementBalanceSheetsParentheticalQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_635858815104920558" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_635858815104920558" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProFormaMember" xlink:label="us-gaap_ProFormaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ProFormaMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" use="optional" priority="1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" use="optional" priority="1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" use="optional" priority="1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" use="optional" priority="1" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" use="optional" priority="1" order="6.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlowsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockNoClassMember" xlink:label="coll_CommonStockNoClassMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="coll_CommonStockNoClassMember" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_635858815104940560" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain_635858815104940560" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" xlink:label="coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AmortizationOfIncentiveFromLessor" xlink:label="coll_AmortizationOfIncentiveFromLessor" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="coll_AmortizationOfIncentiveFromLessor" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositsOutstanding" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaturitiesOfSeniorDebt" xlink:label="us-gaap_MaturitiesOfSeniorDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_MaturitiesOfSeniorDebt" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLongtermLoansFromVendors" xlink:label="us-gaap_RepaymentsOfLongtermLoansFromVendors" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_RepaymentsOfLongtermLoansFromVendors" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseInRestrictedCash" xlink:label="us-gaap_IncreaseInRestrictedCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseInRestrictedCash" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInContinuingOperations" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" use="optional" priority="1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" xlink:label="coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_InterestPaid" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_IncomeTaxesPaid" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesReduction" xlink:label="us-gaap_NotesReduction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NotesReduction" use="optional" priority="1" order="6.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/StatementStatementsOfCashFlowsParentheticalQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_CommonStockNoClassMember" xlink:label="coll_CommonStockNoClassMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="coll_CommonStockNoClassMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" use="optional" priority="1" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_635858815105000566" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_635858815105000566" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" use="optional" priority="1" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2QuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" xlink:label="coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="us-gaap_ConversionOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="us-gaap_ConversionOfStockTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="us-gaap_ConversionOfStockTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConversionOfStockTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" use="optional" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConversionOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" use="optional" priority="1" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" xlink:label="coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_NetIncomeLoss" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" xlink:label="coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" use="optional" priority="1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityGainLossOnExtinguishment" xlink:label="coll_TemporaryEquityGainLossOnExtinguishment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="coll_TemporaryEquityGainLossOnExtinguishment" use="optional" priority="1" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails2QuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_635858815105030569" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_635858815105030569" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_EmployeeAndNonemployeeStockOptionsMember" xlink:label="coll_EmployeeAndNonemployeeStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="coll_EmployeeAndNonemployeeStockOptionsMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" use="optional" priority="1" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureFairValueOfFinancialInstrumentsDetailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_635858815105040570" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_635858815105040570" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_635858815105040570" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_635858815105040570" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635858815105040570" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635858815105040570" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_635858815105050571" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_635858815105050571" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" use="optional" priority="1" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureConvertibleBridgeNoteWithRelatedPartyDetailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_635858815105050571" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_635858815105050571" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_NotePurchaseAgreementConvertiblePromissoryNotesMember" xlink:label="coll_NotePurchaseAgreementConvertiblePromissoryNotesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="coll_NotePurchaseAgreementConvertiblePromissoryNotesMember" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_635858815105060572" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_635858815105060572" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_InvestorMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_635858815105060572" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_635858815105060572" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" xlink:label="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" order="2.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="us-gaap_RelatedPartyTransactionRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionRate" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" use="optional" priority="1" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureConvertiblePreferredStockDetailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" xlink:label="coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" xlink:label="coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" xlink:label="coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain_635858815105070573" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain_635858815105070573" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" xlink:label="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member" use="optional" priority="1" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RangeAxis" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635858815105080574" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_635858815105080574" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementScenarioAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" use="optional" priority="1" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" use="optional" priority="1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" priority="1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends" xlink:label="us-gaap_TemporaryEquityAccretionOfDividends" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityAccretionOfDividends" use="optional" priority="1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" xlink:label="coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue" use="optional" priority="1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_TemporaryEquityGainLossOnExtinguishment" xlink:label="coll_TemporaryEquityGainLossOnExtinguishment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="coll_TemporaryEquityGainLossOnExtinguishment" use="optional" priority="1" order="10.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858815105120578" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635858815105120578" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_EmployeeAndNonemployeeStockOptionsMember" xlink:label="coll_EmployeeAndNonemployeeStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="coll_EmployeeAndNonemployeeStockOptionsMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_635858815105120578" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_635858815105120578" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_StockIncentivePlan2014Member" xlink:label="coll_StockIncentivePlan2014Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="coll_StockIncentivePlan2014Member" use="optional" priority="1" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate" xlink:label="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate" use="optional" priority="1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares" xlink:label="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares" use="optional" priority="1" order="6.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails2QuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber" xlink:label="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber" use="optional" priority="1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" use="optional" priority="1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" use="optional" priority="1" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetailsQuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_635858815105280594" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain_635858815105280594" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember" xlink:label="coll_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="coll_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember" use="optional" priority="1" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_RangeAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LitigationCaseAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain_635858815105280594" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain_635858815105280594" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" xlink:label="coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" xlink:label="coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected" xlink:label="coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:label="us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" use="optional" priority="1" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetails2QuarterEnd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember" xlink:label="coll_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="coll_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" order="1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_StatementScenarioAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain_635858815105300596" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain_635858815105300596" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" xlink:label="coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="coll-20160104.xsd#coll_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" xlink:label="coll_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember" xlink:to="coll_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LeasesOperatingAbstract" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_AreaOfRealEstateProperty" use="optional" priority="1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" use="optional" priority="1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" use="optional" priority="1" order="3.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g603081.jpg
<DESCRIPTION>G603081.JPG
<TEXT>
begin 644 g603081.jpg
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M&=Z_P^1*F,I9^&5]9'W-FE)".P!\SS7,[EQ:+3.%(1T>0(,6?32Z]LF-&O\
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MS2@OU[KK?-2V<45#<JQJGZ*>"ZTHD-%4#8Z1SK)&&B"#;Y2DNY8GJ6[XBO\
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MUM95L>B!/2W"KM%7<-45DJ21MIJ@I(Y1641D 3-?4RQ/30NA!,;QLFQIP]/
M=^:"WS_TU;6_%G^4HG\R6G1/]"=L[-&Y$1SD1.B(Y41$^B)U^G;.W3'T?0?]
M#1_^-#_Z?(?EUQW](W#_ *ZL_P#)G_\ ?J0/3997>!]YGK>9MEBF;R?Y58Y9
M[!A,?%<SW!D&4 L[ZB YZ0(RQ1XQ7%H #$(/6&Q@HD1QE!%?Z@4.+&A18T2%
M'!$AQ0"CQ(L8(X\:-&"-HH\:. 36""  6,"$0V-8,3&L:UK6HB>9!R)P:\[L
M;O/;R'C=5(+'XW<@L/VAK:'/"QK<BU^"RI<_P\0WG:4!A6V,RWX^24UY6!L
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MOZ&.9'EP")98_/>-I(LM8YO %Z3(JSUU-I"O*FLNJTR2*ZW@0;2 =.B(>%8
M%+BF3HJIT( PW_)51%7HB]H>^?DJF-NJJ% 4*V,+!*D-^X:IU;():7$JO'(1
M'+T,.L,,OVR([TTB,OZA6+VDOX\ G1M%ZG#8HK9;<#QI7-5CV.:$D 1(C7->
MY[O&V(\"/55Z.<BN:UC7(QKDO*HQ&&(Y^?'']? ],P91Y(\Y53D']/\ ]^8Z
MZ_'-/%I+ 6_AJ)2?SVUDG:D;W@TLW!'O\ZGD+F=3('KZQV_I[D."8D:5X;+
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'[#[A_#K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g95987.jpg
<DESCRIPTION>G95987.JPG
<TEXT>
begin 644 g95987.jpg
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M3,("7;B&A:9$@/NO0'$6E2^I/IRXZ'6%!+Z0G6O-DTV2+O<<^LYYW'VK/N?
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M-OGD V]G=HHV#1R+"F@0ZN,MQ@14C5AW/HMML6BT>*8_59G7YK06&2Q,GO\
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M<]=(_P!?Z?Y^/_77EP_'9<Z4,=ZPNLG%*7 <?N=TMQ>I:NS3/-Q+W(_S3/\
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M8;>X'>U.,U>,VU],N\OH:MFHN5.SGG'JF)6-V,2\-F5?(/.2XZ Y+M4/*EV
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MP==3:7I99J\*RV!F-Y98SEU08KN)U5A%385N3-JD%J=$1,4Y\H'TMJ]1MQ:
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MZ^ 7(U<U6%+J"#R.7'.0">/(Y\\:@\S:*PRNSR:RK8<EU<G)XV=.-H85W&+
M"ZQQU"N EP)4KO4I/L$NI(!23J^/%G-G,?E['WN5?E4MBFVRN:?<:A?LV;"T
MCYQ90J=JLG1X<-E:YT6,_#=<6(CS[GCZ6@OVG#'M]\3Q/'L<A4- S/ET-3D&
M-3+.33+I85_3W$MZ:B2J3;I19+EQY+KC"&T5Z_5:5ZGKH6E#91*$XCTIKK'W
MK.[>0B+%<D26GE<LM*;M(D:_C3FB3]39<C2F^02GOB*!(X!UL2=(M794G39M
M!4VT*TKYM=B3$14:Y2VF?\NS-FB#(4EI1 C3(7R\N %A#WR#\8OMH>*T)QY=
M#EG"WHW5R:-FU3 N*K&=O:.;1UDF.^[ ;F0\@DP&Y<QIT?)V$J/&FJ;9;DM!
M,9"VW$L*<6I3.9I*0E(2D )2 E(    '   X  '@   #VTB<Z:::1&FFFD1I
MIII$?^_\-82M^/P\WPK^I/>7<K?W=S8O*+_<_=O*9^99S>0]X]TZ./:WUD(Z
M9<EJHI\HAU<!EU,9D?*0HK,9/"N&_K7W9M=-2*<*?)K_ %(<<<M9 GD@_P"Y
M@(D?AD_@XR<<@8L]TSVYKJZ[L[YB2G=W=%N[<F6S$9B;'F7Z,G3<SJHB*R['
MJ)DUZMA20Y)AQF'GGEK@J?PNOP9D@ =-^6^./??;>0GGWY*CF/)5SY*B>XGS
MSSK81TU/5E\67\O]RKX>#SABUYXC_P 37V1^%_\ @WM2H<UKIVS%J77OQY,2
M0UOQO*VZS(BN)>CO(6C,4J#K+S;;J%\]P<;;7SW)!U4O/?P\7POMT-P<EW5W
M VLW,RG<',<CJLNR?)[3?_>)R==Y/1M,,U%[/:;RQN$]95[49EN+),4+:0E2
M$D)=="\WVFG5D\Y9/U?SL?Q)Z, HQQ#RZ2OXKU?YF ?)OPRWP@LQR&\RO)=@
MLVM<AR6UEW=[:.[[;P,OV5K/>5(FS7T1,MCL)<E/K4Z\EEIII:SR6]?9_P##
M0?".F0J*LG[([CV53C!D''::TZB-[[.EI/FULN2TU-1/S:175S<MUAIV4U#C
M,MONI]1U"EDJ.?+34=66O>=<;=:K7EK7RCHPW[N.^?=-_/4P6W?X</X2UQG[
M&YT;I^R'$\SA.07ZVRP#=W<W F*F371VH\:755>)Y)4U<"7VM!QZ3'B(?DOK
M=??6XXZM1D%S\+O\&AY]V2]TX98[)>6I;LES?3>)3[BEGN65NG+^]7>H]RN3
M]2N"?8<;"&FI,LCC+(^2PX8.G#&KO])SSY=^_G->_P#U7?X- :<91TXY:VEP
M\K4UOIO"VZ2. "'4Y>'$\<>.%#C[>=5EG?A_OAMV^4XWFM]@N[^3Y1A^.-XA
MBEMEG43O)E2\=QEF JKC4M/$R'++*O@P8E>HQH;;$1)BI[7&%(>0VZG-7IJ%
M7E7YK!A@76.):+HVG#\SL^>^9@9RW\-C\)S._P M.8[-[E9$NH:L8]<[8]0F
M\ZY$=BWMY=]:M?,-9@T^\BPN)\RPE^NXZIV1(62KM[4IE7_5=O@S\ ?Z-^6
M   #?3>( )2.  !E_@ > -;"&FI,L@HRR#R%"'#!VXXN[WB>AY>A^5->[_5=
M?@S<\CIPRT>_@;Z;Q@?5QR2/VP\GP/)Y/]=<_P"J[?!F_P#LWY9_^NN\G_\
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M.VW<7=B'!I*:!@^.^M&:>9L,KQ2XW&EQE)*TE3:).:XY$*R&AVJ$=/822 >
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2:::1&FFFD1IIII$::::1/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g249773.jpg
<DESCRIPTION>G249773.JPG
<TEXT>
begin 644 g249773.jpg
M_]C_X  02D9)1@ ! 0$!A0&%  #__@ ^1$E32S$S,3I;,35:0TXQ+C$U6D-.
M-S0W,#$N3U544%5473(P-S0W7S%?4%)/1%5#5%]+7T9,3U<N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_\  "P@ N@)H 0$1 /_$ !X  0 ! P4!
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MN[5*[I;5ACGS4#P\/<()!(7\V*)%3N&2,RMW5*U<H=3BTF4W&^=#YM5\6S'
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M:ZN57MQ5#;F'3-3VO6-IX8QHBWKQ:6##Y_W.8Y9/PVENO@B]/.6TQPRE4X0
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M10?BENOTJ)]^[2C?P%J<(K6UBT8"#=Q$R/4A3G%"7#@51@-&<8!]"6JR25#
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MLD;J9XWX4][92<.M:..PW86>'>4.2>:@1O'"R8DT2RGRLXV%6*X9<N65/?\
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M;B;$Y"MSW73@U*VDMZAS4+:YHM$0I(:P04QV.6G%0-.4B)="XO+S%II DY:
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M'UF=VV>TO%"'J.O;DYR9OM1@3 ES(X)I ZY/UZ'3JRMV==W;+*PAUKW%,IA
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MQ*E4-AM[.WR:140"P9'(7S+,VG*.[O?3:$;8)^VRHCK2LMWN2;#BP<NEJ/\
M5HZ6>Y^C[R<<1^5.U9&+UYT6<G>-89U2Q.?W6H<3Q#>E$;B9[F9&&C3>1_\
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MH\S. $D$F&#S@(<YUYSE=,=T7!Y12@C?=MJ/(4%%'D'DV2V&DGD'EA-).)-
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M0&GN0^E+_17H\OWV;H_Y :>Y#Z4O]%>CR_?9NC_D!I[D/I2_T5Z/+]]FZ/\
MD!I[D/I2_P!%>CR_?9NC_D!I[D/I2_T5Z/+]]FZ/^0&GN0^E+_17H\OWV;H_
MY :LAN3@'2.;6J'M7<//J^V+OT+IV&ND\E#-#KIW'&RIR8V/A&N26/%/='-S
M0:\&)AF9;RG%<E1FJ0EEJ%!)0Q&@J87 IQOPM67;?:A=G^*[>*[?G*';N-SL
M6=53$X%.J'&0.^UW;G)D 1&J[C<RQDH;MLUD481;?HJN61IF<\W8](2X1]%%
M75=7M*U[#JHJB'1^OZXK^/ML6AD,BS:0TQ^.1]I("G0-;6@3AP60G(+QD0A"
MR8>I/,.5JSE"Q0H4&]]TTTTTTTTTTTTTTTTTTTTTTTTTTTUCXU;EZ\>3&@I)
M'[M*$]',)"/+EMQOUG 2.1FU>2@$YF.M<(P,Y1 [<B^7DYU$C)CY;989SX-O
M*JBS!Q27!?L(&E2J\,MM8*5@9C"@"HJYPJ A?1UR6BPH2"@N%209(K1C>74"
MDDH;(!NG0W@*(%9V$*-0Z3<S7BWDN#'[N!S_ '9P.9VX7\C['>W@1RO-\W7!
M/(\+P_8^\.=X'=7)2[O/E/ .:]PS3=?<(=$C<L3LMLEE.:9N5)PKJ,N9M4%E
MNA3 <F"N2.$%3*6T\L$D;\+DR\I,H;#$[T2XEIC8Z_ ;H/W3==YQC.(_=_5G
M&,^_MOO[&??QC/OXS7&,XS[_ +^,XQG'Y,^_JI2;D( L-R24PW0$>"%:C.5&
MWB]DI?#1(U"XX.#E->%E9.&2F, F3X'QUBH1*)(6<K4$$F53QN%@C(0:H6,=
MP' *RXA&%LH.[7D[.6M!*7%3PR&F K#SL&$1!U+0Y*+'AS6*HZWM_,KI9&$[
MM&K-S5=H0KQ'1Z[QX;@NHC^5VW7^NR9AGQ.!*^3"CK<\3ADW%?OG=P4.%&7?
M*V(X:\*\SV$]_3KO?$*92'E0L9K7.+8B) H6A;*.N-X..!&BK'.< M2=J@ZP
M][.4 JV2892&@M:=(C'&"%,);B;9M> DT&X;F:\;>\^8C]W&=U=^<SR6W"_G
M'B^#_C.Y[N_D*X4]Z<?Q22CNCNWFN_N\Z][DY_QK5GX5R&-PT$R)X#ACN#K9
M.],+,YH*[L!.[H-M E5W6/,!P%YXHZCE&6_+3E;AV*<Z].;.;)M:LS)7M>]Q
M,#8#E9"YBN,\:(MU-.$T[?KQ?21A9U5@I%6$Q[-7ZXA88:;6DA$W%)##C'=.
MX0E4U@5IK'@)LCX<;CX!E6-%W#<_%+/7IQ#SMYO;";)C<*;!/$!9FO.5,),S
M 'O*-06<(AP"MB0T)B@$[A8GV0<;]A#848:H9+:,"6IY46$5%7.Y&9-RH>$N
M! *0010881Q618+*H 1)L)SFQ3DW"=Y:35D+[IJO/T?N[V;[]_ESJ:;K]A#F
M46:G9+:+"8IY4.%M%7.VF8-PH9TN1#*7P1.861Q7M&+"H80ILIR713@W*=F=
MC4<?G<? ,*P(NX;GXIAZ!.$>-O-[938,<10D) AK,5YRI9)>9^R96*##@D-X
M44M&N,3@@DT$Q;6S<E7[LH:DR5@NHHQX4,B9()PVZWRUD%&/YT%(0B<5#E72
M4AH(('8;$)V4.AB0AB*0S$YY,0E5_.!L%5G<-!,"9PY8[AZWSNOD\XH*[LA)
M[W-J\E+WH+$!R%EX0[<B^7'O;*+NDILL(YSY0FJ;,'%(]OW,UXY=V<O'[N+[
MU[CY;G=N%_-W"\(/%CR/>'/UPF[KX'C;B_>_>7*]P]V6%WWR'BILSP4G&B^(
M4]$,RA&S6N26^D1]0B"YT=<;.<2"2E5P<WA=4[K!T9[(<G!:4;P]$.Y:(Z.F
M-T[*?BVXVLK#!&8)'N:KM<% (F/7>##B%J$1S6VZ_P!#DO#QB#B2<X%96Y F
M_)6+ 8^\0KL)\M&44NPZ829@4V[AJFG<? 'DU*2D8;G*$L3)U167+;S>K06
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M71'+7S>)["<OUD]S+G2>Z6B;EVW3Q#N':8?;,#FT"ESG%J$N] ^IV$3?/,R
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M"7N0@!JI&D"PW/@U<-B 2(S;S>Q2<&9"75QB#*I497@4R() ;>BV'@:PT@#
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M)Y: IPEX$(X3HW8*P/*Y+@[?X8Q/K(QX3Q[K5<'EO_/&K_Q',"9PI^!_XO\
MWW'%(6$)/#[7%$]-& =K+FAYCB*G$,/X/!ED9.YCE^!PG]H,XW.=S\IP>PMS
MQ.:\(6'E^QVN/WVT<+M]Y(N/4D2R+J@IQII&PGA5A2C2B)>6TT*@*W#2)&(C
M):H6#@J@OS(),(K(\'X=VO).1X<47'IBYQ##L%Y*EL9,P=@G@Y+D#0/BX4]W
M<ODO(%N>WQ^^&G@Y!U\7O-NX?:YU+Q=Q$SAZG( IY5'3Q&  86$E_:S<F ,
MWF%C!@M:+(PC+=6L8!!ZPB XH!!SD*Q-DW0<TAQ0L!,E4< +(0#P$;^U SD!
MI8#2QXP);C/9,+& P NKJ& 01ASD(@YSL\.(7^EL:_/G_P"86C\W_P"=JI-E
MD6( :8=)&$DL@!IAPS7MN+ 2 @*D1XS1#5A"6$D*)8(T0\A"7A(IR/(<$&Y!
M3F3>&%<3B2V-%\'C<7MR%I!PN7[QYCB=I=CL<#N=VXW:ZN%W8X=OL\DJX7+B
M81+.#\XD\>SA-Q>8SA];,X(X 741W&SA9U%<(+$]",XG9X>&ATR/LX;UF2>,
MZ:PU/D\*B61L@282H*G!T@:2LD"19> K,'8&M#DK*7,>?\*<&8#E/ED=\'8!
MEL78(W9F</",PL4JCN#"LJ<&@R_M6!EY1X>1*\&!RM[0,IL1U_RHP+&,D89'
M?)O8PV+LD<BB711($P:J3,"8)(S0&B/?&TD)8R.]N. S)JL& ")[B>^*$6<"
M+[H=.W@/=RS@<!DWAA7$XDMC1?!XW%[<A:0<+E^\>8XG:78[' [G=N-VNKA=
MV.';[/)*N%48ED5$$0L21AR$ CP#%A[;LA -,-64H"+.%><!$08@7%G!SG&2
MAHU8#,!$G.P"G.F4/ ,1(Y5&RS2S@A, 8_M0!%C*.Q@P P"6=H(PY ((@9#U
MX%CLBQC.,XQXY]&?T<D4VL&HK8OZTH3<VX=B\9D:J7#8[MRFOMMM36!94GE:
MJ*56A4A1G'SZP,R)&;<EN."$F42P>&NOF@QM@,>1-SM[)"F,3 (H I/'@B.[
M'!")[:PY-XAB$DOA8RKQDSB&N;:4#L8SVS'!" /6-6GP9Q G$,-X?#ED9,XW
M!X78D#0/B\QW=R_#[*W/;X_?#3P>SU\7O-O[':YU+Q:HF5QA1@C)$B8CL*<)
MA)\E/#:;@\*S#3E)DG(%0N+A5A]9,I\E]K!^'=KR5V\.*/CTI4XAA_!R3+(R
M;S&$V2.%(&<SC<YW/E)P>PM%Q>:\(6'E^'VN/WVT<+M]Y(N/S)IA%%@2QI)-
M'E(#A)PE"3O;6>$T2L#.8EP6(I6/ \J2Y Q#(P'.<G >6D1>!!<D.3]GAK#^
MT 'A5&^V9A-DL'?S3VAX6 ;#$F0!YSK'A2!Z9QI\AQG!X'5M$5VPKTF3MA<X
MAAO#X4LC)G&X/!X;^T#XO,]W<OP^RMSV^/WPT\'L]?%[S;^'VN=2\6H%+HL
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M3AG@<U-BV H< &B$%8?.IB:IP89)WL2[CQM\H3"@:S%(U%S9AJP\Q5XM87S
MSW 4J&O/&?ADXHCEHYU-A*S!"R-2*8RG)V1YD+OSE8LHRE'$ RG"H*N7%&'X
M4F%K*^B*D U.#W)3A0,![.,(C\*'EX48-%C)F#W5R-[7$7*A&QGN<MOGF*IO
M]U\'^XM2:.C*4;@ *;Z@JY"46?E266CKZ(I@ 4Y/;5.5  $,X A/RH9F=1DT
M.,&9/:FTWM<1"E$51YV^4)E0!9FD:BYLLU&>6J\6L+Y@![>**C0'@/RR<4)R
M(<%A(DA@18&F%#HMDG(,QYHY/:@V\T$UG-ZALH^H&Y0TG-:AK/05G"DAS:>Q
MF1(YE.;S4[&6-&:T&P&"FM9J810V\R%Q,:01(XXSY1U&:$HW(FT6:9JC(F;D
M.Z!9KJ'9$U=U&0(YL[MSEFZT/=QM5UB:@Y7)7)F5S!!I^&.(1W+=1H]N>WQN
MY'N^BJ<0]U]U=V\G6$'2]W]Q> ?<G(\!B+Y3N?Q65EW5R_#[N\74$Y/@^"$>
M[ME6ZD:89RFPAIJ.L&LAE*9R&<EN@,30E-)$>+A)3 2VEI6@H" IC*K2N2V@
MM($D#87 84!$$@,58<((E+MRV]HL) HZ*IM)A!AO"APFJ^#D818:<13#5A)@
MIB!A-ALQ!(/AOP3@&$6(;%,)L%8CK1R?.W[?*%:!IS6JDJB;#4A!"9*8WUK"
MT1B9,F)C"9,G3C3,A0B2$Z:$PQ.047D)91$2C!180@8&H*311M[H169@U52-
M0J3<%)D^#%%:0HXS!"-,2B2$X&8R"%@I*C3ITB8O&>P0F()(*"$HH  \/N<M
MO><9QFB:;SC.,XSCQ7P?JSC..K.,_P#D7OXSC.<9Q^?'O:E%M'4JY$+4KC4-
M7KTKD0N3."9;7\25)UZ=S+>"7$A:2>T#+5$KRI"_E+2CPF%JRWQX H"8%S6X
M/C%&W/;XLYKFZ*IM5SW/\[S%80<_G.]?"KO/FN*Q"YCO'PZF_/\ %[?.>&4J
MYCB>$+OSE8&A*, %P "F:H"!VPLPZA#7,."%RPXES0EPPX!PS8PMPN*LBPRE
MF%.#<*BYY,P'=L$I?,+Z5?MVV_NHW(UTHVGG$QX,>37<Q?6,(6#=#9$.?&/Y
MCB-0QF"7&/AEJV>-X&JR:)S'8T\$NR>*82++ER#V^4(:>I5&4C41BE:)V&L4
M#K6%C/5#?@3XM\$I.$R9,/$\@M:T .PC1#RX@L>>A69.Q,9'ARJW2BJ2?"U1
M+U3U6.Y2XY<H6E.=>Q%P+6'N>9KER.5 5LYP5!KAFR;$RN--P,:O,]FG,",\
M*GWGXY1MSV^+.:YNBJ;5<]S_ #O,5A!S^<[U\*N\^:XK$+F.\?#J;\_Q>WSG
MAE*N8XGA"[\Y)@HVE2RSBBZ@JXLI0:X'J"P5_$@EGGNRE[6.IYP L^ FG.:N
M32-4X&#QD:U2_O9ZG)AKJO&HH%6WR@U1YZQ92%0JE2M08H4J5%:0H]0I4JC\
MF'J#SC601AQQQYHSCC3!",-,&,P8A#%G.<3=E=P;$=Z,!?+&V^5]5&%4/F3]
M75BQ-37$&9YS7LUB$A-+.898THVXTU(%4K8T4HBKJ2<H9I(T8:9&P+591>#$
MV71M"4:>8C./IFJ#CF[*?* TVNH<88AY15'%R7DQC9A"3<LNAT16)^!D'!51
M:.*"^R<QM@TM&FVY[?4?*\I15.)>1Y#DN6K"#D<GW5X*]U\KPF(/+]V^ D(Y
M#@]CD_ V*\OP_!YHY.804I3;6%N V5+6;<!H T@:@H8%%4@6P# &%!8@-X4[
M27A$%F#6M=!:0IL%!;@P*%X1X)Q%6+""&1;<MO;;A!ANHFFT&&K#3ALPBJ^#
MI<-V&'$"PQX08(8B\(\,V*KK'#5A/P\-V*Z@F$?!\$([W;7M-#T>P%)2&*FZ
MJ9B4(VPU"2TUW#VXI&8R$01*S&)2T;,0!.-I35=6:=L&2$ D!%=P4I)DDN(Q
M\+=3XV]T)@Y.HQ2-18/2!:P)#L5K"^*E QD1!*RA3F=R=LD+.FKZ!)VL)8@X
M;R(1$"4F"2XTRA1<*;;IM]19291T73B3*#+>)#E-6$((RBRTYBF6K*3)3$#*
M;+;F"0?+?DGL91YAL4RFX68\T<G)&T92AR<2,ZH*N-2#)+3C2FU]$3$XB"0M
M0"B!$"9\E")* Q,@2R\AR  6=J"$.,-Z3!,9[G+;YYBJ;_=?!_N+4F71E*$I
MPHR:@JXI( DQ.!*77T1+3A(."Z@-("0%GP4$DT#Z]A,+P' !A>'4(@YPX*\'
M1JG;IM]6Y5Y6473BO*_+@)=E36$(/RMR[9E>77*O)K$/*G+EF=SC+AD[MY69
MF4KRIXN9"[\YS9V]T)DY0HS2-19/5A=0*SLUK"^*J ^$2]*]!4&=R=LX+PFL
M&>IW0)@A8<")O+R5>#BY*]!6U#M0]'OY2LA]INJGDE<-S-7$NU=P]Q*6&/9$
M[2O)BHM8S'@4#=DUHV8G<QG!&)>18DZ*5Y.+ET@"XT"W;EM[<L+\.-$TVOPZ
MX=L.>%M7P=5AQP_8GN'S"_![$9A9AYQ:EG8=<*.)AQQ8L[PLXWA?(N\IE?2E
M-N@7$#G4M9N('<#L!U"N@455A<P/X9J%] X!4-)F%H7D-E6*%V"IP:%Q#/9I
MA9@[$J?<+X=3MSV^K.:YNBJ<5<]S_.\S6$'/YSO7PJ[TYKBL0N8[R\.YOS_&
M[?.>&4JYCB>$+OSE850E&D&+#B*9J@DYQRHRO-*KJ'%F+N;52-<JYP8&8(E/
M,KIC+EBCCY'QE4ID:@SM'/CF-474'1CF;@]RIBIW \.#<!.75S#E9N,'K%3@
M?C!A[*8/&#EZY:N-QC/^\6+%2D?:.4&C'P)]O="(U!"M)2-0I524\E2E4IZT
MA1"A,I3FA.3J"#BF0)A)Y!P &DFEB"84: )@!!$'&<5PZ-I4PLDHRH*N,*3F
MMYZ<L=?Q(19![2I9%C4>2 3/D)1S8KC,<5-Y@,8&B4L#(>FR6:U(!IXQ/MSV
M^(^5Y2BJ;2\CR')<O6$'(Y/NKP5[LY7A,0>7[N\!81R'"[')^!L5Y?A^#S1R
M<BUT523&6E)9:>JQH*0G(5"(ILKV(MY:,]LS"LMIR4"1G)"G-;\UM7>4)I6
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MG>C7_P 4:_\ N;?]IT[T:_\ BC7_ -S;_M.G>C7_ ,4:_P#N;?\ :=.]&O\
MXHU_]S;_ +3IWHU_\4:_^YM_VG3O1K_XHU_]S;_M.G>C7_Q1K_[FW_:=.]&O
M_BC7_P!S;_M.G>C7_P 4:_\ N;?]IT[T:_\ BC7_ -S;_M.J=Y?F..L3O)Y
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MSXO=%WL!LR\:UJ@K<U7ZBHMG^WZ4SE+7.W)Z;R6YWW12F+7;8+O#YO;,:.(
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G;3QW7/YW;/\ 7Z5_>VGCNN?SNV?Z_2O[VT\=US^=VS_7Z5_>VO_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g119546.jpg
<DESCRIPTION>G119546.JPG
<TEXT>
begin 644 g119546.jpg
M_]C_X  02D9)1@ ! 0$!;P%O  #__@ _1$E32S$S,3I;,35:0TXQ+C$U6D-.
M-S0W,#$N3U544%5473(P-S0W7S%?1$5415)?1E!/7TM?4$A4+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M"=C9>.$J0])VJ;";CGK%1OU )BD]C$ #![<ZHTPBI%RNZ8,#MVZ2BA^\YD9
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M<?RK9V;#V4IV(=EZU(V-R$P2?11C@/A$9R%.E+,$SD "E<*,GADQ.!E2' %
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MQU $!$?J.!S"4!X 0/SYY#QSR(>./T'6).9<O=45$P%!4.#&$W@G0 \#TAR
M^ $/'W#CSH+3XDO +.5*J_6 14%PYAE!Y#CI$5G,?P!/I 2BH\;%$0*4H+HI
MB)"H%U8'6K UT")=-)1DL!7+)RV>M%P.;@JR"P*I'.'47R8Y0'@?(A](@//
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MLDD5Y:2(%*8IC >K14LW7$!^A%R8P@(<@/199%0<& I.% $HB !](B(CY'[
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MZ2,R8JFZB DNNP8N'"2R[)JHCD[S8[M(DZYB"I3&WW&,[7< OA?X6B[#74K
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M;*>X#&MSCF5)EKI7WS!L5RG!1A%IAF_336*9+U$<Z*[8': F<2*G$Z12 GT
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M7>94:1\C"OXI=TB8IHYK&N$8R5<,56ZA^%!7<)D39G<=+1;U)S*=T@B@4YP
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M#*F0,8I4A$W$2EE;/K0[: V25ERK-4WQEVR"+PRRJ"#1,XK&31 $?3\)&6*
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M7;(NVK4XE.BHD0>@@%'N>ZLNUB34.+8Q"/'\HW)'(*]HIUE4G!N4BI*J"1R
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M%6YZ@O'*K-CM%4DS+2BB_0+);O !$ER'#U"@IB<##K%\?*.+5&L'[&&?(OB
MX,[2BPD1%9%,XB KI&,811,4W6JH8% ZS"'4!1X#(+%.LZVR&76B9&3(S52*
MNW:)I"9FF90""Y<@JJB8[=!3PL= JA@ 1,)>!T&NG=!09^O3-::8CA$H5.9
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MSBD])XP<30)I2+L\:D$I8JTF=!NBV7,W:G7FVA"=*G:2D>"FX$"AM8TT]]-
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M)ETEEDCIE!-+JXZ@#,F]A8LVS*8E4VS!<$4!<O1 !<=P42""9G8H D0#+E(
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MR(CY^P_T#WUB+E0  PB(>//' \#]/[!]_P!_/''//W#'9!01Z_J'DP@'Z>
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M56,V!='L$;*&*0Y%A,11,+J5:U+3T<W&<A'4.1TT3.Z0!VDH*BG64JR)56Y
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M6/-,Q#V<:QH,UJRA#MCNYYZY5*HS9!(QB"W /%$73,A%&@F26444(Y(D)5
M-D>#:?/9;RM4:C "\:.7<BW=2+\Q /\ +H6/62?2LR)QZ 1!!LB9-!4"@+EP
MJW;) !E"&'9KG'&+S',@D[:'=/:S*',6.?.#&<.FSKI,HI'2*YAY4<]!#K(.
M3@'JT2CUF%PDH&LVV#;=97#V+8^XY"BR1^7<@P\8]L\?W.[^$XPR2;IC4D3
M(E*J@<P/9@"_RR)_1B90C BA[LV6MP]NA']?G6A7D9(HBBND(])R#[I+H*
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MTE1?S06(SAF8C)XDFC%^BZ&77ZA36$7M>QQ)J^-=JBEH!_:XF&GQ+,L80*W
MO1<_,K4H5X0WS0L0=-#JBVPD>.A6X34$4>#!VM:U9H"XP499ZO+,9R F6I'L
M9+1RY7#-XV4$P HDH7CR4Q3IJIG BJ*I#HK$(J0Y YW76+VP;C,S[<LJVIX]
M& F,)2SBNE:U&/=29[ ]1!NJ2SRL@1\8D0QLC-R9,:^ZBQ20D61!CIP!+V%V
MO9!Q_?ZID^IQ%UI<JC,0$RAWFKE+Z%452#T.63UN8159R#)8#-WK-8 5;K$,
M4>H@D4.&9Z:::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH
M&FFF@K[N9VW8ZW3XIG,5Y'8$69/RF>0,XBW25EZC9$6ZR4;9(1102]#QF990
MBZ J$2D6"SJ/<&*DX$Y>DUE?9]F?:CF&P53,<F0DC'M7C6FS<?'OE*G>J?\
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MI!L1NDW#Z<8M9Z1O-84@R-C'7M,05!@\;-WP.D%9(J",6[47,0I4%4UO3O!
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M,LZ=+FSRL.X3G5H)O9TRQC21:N9J-^6NW#- 32[!-S&I/!5*>/%P#HB2IR=
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MRJDOP=PGZ?E4!-P)0\:#9A)=N0.^18@HW1.5<[0Z;IP!T3E(H+=8ITCI_F%
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MGVE38.&2LBU:R"A99T@LT8_*XPR[UNW[($=&:IL4@*90G$L5:AU**MEAO<=
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MULLU,)?^,H. ,7V$.?&HXE]W5?(18M?J4Z^4 J@(K2JS.);B8 _).=%-1Z]
MJ@B'*0I)+E 2AT@<> "W_(![CQKQR'ZA_D-:TK#N1RE,G4*TE&-:0.HF8B4*
MQ:J+MRI]7Y8O)0CXZO< 0%P44@*8Y0% 42\IZBRZ[HKGCNM3ESO&8SU.HUUE
MZ^:L<\>K1D/&- ,DGWWCYS"]E/N+*IMT2";K6<K(-D4CJJIE,&X#D!]A ?[Z
M\ZT=U/XBB$UCMYEZB9HA\I4Y-9W%HN8QO&3;)>89E]4K$J$CH=NZAY0J92D5
M^:$;D1;K%5/P"B2AKG8\WK-;)&L929K17,?( !T9&O*.&IB)_6"G<BIX$G F
M24Z$N2NB]P"J+$ P"F0P7VTUB-0O56O3 \A6)="131$A7: %.@]8J* 82)O6
M2Y2.6PGZ#]LRA.TKT',BHH0HB&7:!IIIH&FFF@::::!IIIH&FFF@::::!III
MH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@:]2Z*3A%5!=(BZ"Z9T5D52$425
M24*)%$E4U $BB:A!$BB9P$IRF$I@$!$->W30=7CXFNV. VE3T/FR)K[EY@^T
MY ATW3A&/-(L,0VB17<*L'<L4A#J-*T$@4A8*3,14[5RZ^6.#"<K4Z]+;:[B
M[;,,&-PE(UQ+71/U43%,R(,5I)C&-$G"RK1LBBB1!)&. IU%#%2%8JB@E$RB
M@Z[FMPIU6R#5YVE7:!B[14[-'.(F>K\TT2?1DI'.B]*S9TV5 2F*/@Z9R]*J
M"Q$UT#IK)IJ%Z^6]#8 IB]]&WRGP[^UT>/DSOF\N8AGL_C]P(BBT!0[5,CI.
M/3;'!J$B G9KH)]N3[*ARF4#5[DK#&'<A-2U>.J[N/9?)4V"<N=8(^Q1<JNB
M4KB2AIB)[#MDB@[ BZ27=.*J270Z34$P\ZW<2?#3L4I6QOF2LFF@T%K(Z8,H
MR.(WF[8^8M)9VDRE9)24>&*1618LTWY$FB2Y&J;DB3Q0%#&2#8C3+7:K+:+[
M4KC&1<)%P?5&I6. ?/@EYU-Z9TV]:R(X5]'&JHMRB5V9 06*X\I"D)2AJ2J\
MP+'Q\=&QM6DY9"!KKMRS?FE&I6J4;"E*D0LB_?K>K4=.DP3."B2#M8YTU5%^
M0^HX5VQ/%1F/,^VFE12+QRW&DQ[ME871.%0F5':#@L%)=H@L6+ARR;E>)&3.
M'< 2IATB)0U>*07L4\]3DIZ16>*,VX)"\?N51].U03%-(@G5$W0DF4I0(4#%
M*/DH ;D-81&.)"6CDP1K<.Q?2[AG(RDHQ [EVW,1$K92-%\'0*S<1Z#]Y9$%
MU!3*+?M) )-59F(S.43N"3+8GEM5PO*/')89DM)$/$+NG$: QXR+-(2/F\:=
MZ"X,%U04;'4*!0,'OH/DS%+,:C-1V0C1TJM&GNI2$&"8+NTV\:YCGA5YR>:(
MHK*FBT79$7).\F4#'.4"@90>D9^C7-U0HS6X,;Y6'Y9IXFLC!.8XKR<0+))>
MH:N4XI0C0[=H)!(L!RG_ "R& IB=?@,GDU9"SR$=ZYG$1J)&36)(UB61&J9V
MJ)>V51TF4@>H=JE'K<JK=8F4^KCJ#6;NJ556"":L,W=HDA(TCETN_33 R+AN
M!0522[')#-@Z2)I=9!4-QT\  !R$-0&/<R?/*KDF^OF9XL';XD:4&H FF?H$
MG?BDDT_E[=9 12,LDOWURD,7J4 1 -9-=&;^X0JLA'VEW'KQ]M8%ME@;,6/S
M)DU.<47D?&1TTB1%Z[D0$$R*H-EFC(4B+&*4H><M>72IG8*'F[O%,X6$7$CA
MF_D#I_*WSY-)11))D8 .FY6[B0&!)(XK"8A $P\ %6W61"R%OLP(@G+1LE8P
M?U],Y3,SQC,&K5DNW$R8*&.=RLV4>%.JF50"K E_*7C06BHU&9UZKL(*"<S<
MNDXEWLI'DEI<7DM(2DHJ=4TC+KMTD4W;L3G("J1P$H)]#4OY::0%D^*<W/$I
M9>IV$"'FG$4I"3+N481II!9%^(N53<))&;LG0D4(GW&XIJD2*0!$#F.&H$QC
M8)(@N&RYG3%P1RJ]B^^04%!*80.9%F94"F4.F)"JE(B8RO'UII@ B.KF82V_
MY/W'6L6S1-T6*1=)J6&XR_J%(^+2'H5.*[HP"J_E%R_2UCD3&<G, "N+5N!U
MRA^,&8-LN;KG"4F$0 \>LH20N<YW13;UFK#X4?F "&$\B]7#T4.T,'4]=]2A
MR^E0=+)=CBC4FNXZJ4%2JHP)&P%>8)1\>U*/4;H)R=5==3@!5=.USJNG:P^5
M7"RA_ " !A^&<*4;!E22JE*C@1!4Z3N;F'( I+6*5(@1 \E*.?(G,!" DT:)
MB5HP;@5NT2(4#F/+F@JMN!P&E>V;FU5-N1"XMD>IRS3[:2-D01#GMJ";I(26
M33#I:.CF JY0!NX$1%)1/6%)$7:+.&SA%9LNU54;KMW"9TG""R1C)JHK(G %
M$CD.42*)J%*8AOI$ $/.^;50=Q^W@E\9NKA2VJ:-S;I">0CR=*:-G;)$_E .
M2IIS:1"E*V<&$I7B8"V<B93L*$#5,].(G#SR(CSQSX 1$/ \<>?WYXX 0U46
MY58TEEAO9PL-D8!7!EV@UQA(D;UJP!-,HU,'-CCQ;J*2#J(]+W(8Y'")6JKA
M<YP4ZP#5N'J*R#MPW<H+MEVZIT%VRY#).&RR)A(HBX2.4JB2Q#@8ITSE*<I@
M,40^D=5@RW,-J4YLMJ=1\O(,XVO*6%S'U^.<S<Y(D9MCBX1BHAKRXD)%;TPI
MH,D/S%1X%,"\\Z"0(7CI#QU<>_ZA[?I]O^G(\>W&I2B  W0'/\Q"A[#R(B(@
M/G^O/N/GG^X5G-+W1RVH[ZD,8)1K)S<$YMJ-O4F(M_'T9^T5=2BT2S8H+*&N
M#8QVB3>+DS),14%PFY4(HESJ5;(\R&C7R+8T:U.0M19>"*#>Z/I6/@1A5)9J
M6PJ>HA4'#X9)"$]6K$H='IU)$$4W)P2$1T$IP..JE'WR9R2VCCI72R5V$J4W
M+_,I4Z;RO5QZ[D(ADG%JO3P[)9L[?NE#/6<>@]=%4*B[<K)II@7/\;05R@D)
M].YWA.\.7]MGY>!<$KC"MA7JM(.$SP52.FQ66^;'@&Q5&YYUR=-W)&5[BZ8'
M* CQT8L(<&./CN?2///T (AY$ #R(<&$/J$ '@>1#C7Z0C;T;(L-/-KHQ:XY
M9U*9C9N@GKC1S(RUL=239>%M#:VJ+D>QS&+C$W#%>"3;J(/EW'JU%2"0  ,U
MKI\D_CB[ELC>D%QVF%5_ARK!+3REU65.P/\ BXUX0?%+!I%3EA2+70@>3FCA
M.>1_.(/$J)](^/ >"F]P\< (^...??P'_KJ#KY/WR.3J9L?$H2KAW>:W'6H<
M@2TG#)$ICLS@L\K4CQ:2AI.ZE*5L,!&/0!@[4]658P=!.9B;"'3U&-R8WD!'
MJZP+P)0 WVYZ0+SQR'/(!XXT'WF5)S]O!A*4>H!#G@1X_4!  ]C 'MS[<<Q>
MM1SL,AV#)Q[G>G2,E3(NL_P^5E2.:!%?(';^4/9H.N),R.4K=+$<&CI!Z+Q;
MUS1-!LF@14"F'TU"AT.@SUX/60583>3+5*Y%M#1Y8Y.5=24^Y;L8^0E8Z,F)
M%Z,9$I)HLT1:PC9K"M%U  J"*RX=?HR);+35X$92KT:5R/)%DX)B%7A)J$@)
M$S*2F6<=*2Q)&PN6L9Z.OQSES-O6HJ@^?(,56S BC@Q0T'P4J\1F2J56;U$1
M=EA8RU1A)=E$7& ?56TL6JJBJ)$)NNR1$Y"(>@=%0QVCLA502[:H )5"#K'X
M/&E(I;ZZW1I'.6S_ ";8QLMA;HRD@NM9+$PAV$$,F89)T_;0,6UCF3)DNVAF
M;5!XN0YD6Z;A-RYU(\@Y(=0P@<3&,;H*<1,853=7040Z_J#JXY#KX]RASXU&
MD;D&FY)J<;9Z)8&-D@8:8M-!E)".%?LL;;5)]\E/Q*X.$4%".&ZKM%(3E)VE
MU$EB-55B)"(!C+Z,QJUFYF8+2(BKS-C)'DGK=7C'-.2AHAL9I$*V$S_N'L*$
M4FJ9!!%9PDZ2:&.A'G*<2I&AG+%$B[##V6@6]F61@IZ,<14PU;OWK)*3A95J
M10#-9&+<-'[9)^R637;.&CI!PF0Y>3IG Y2Y#D6ITW*40O6[)'MK1#(3T-(+
MQS:0=D,6PU:69S<.DH>&?-7B;Z/EF[)U\O,L053@FDZ;K(+"D>P%(VRTC,N2
M6-@FLSVV"M=.QLWI$OC*+62-7I42OOG3JSIQ[Q4T?*3T5ZD( []J'>BVS)5N
MNU.D5)<0IM4F3:-M6.X]H04V<=:*,Q:HB=544VK.=AVC1+NJF464[2"*9.XN
MHHLH).M50ZAC&'M/ 8"E$3"  !CB(CX  ZC>1$? ?W'6IL=EF':W98:W&>Y
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M#P1,3=)""4I2E$5.0^:(@&D6F0$B=Q<P<*NE _-4X,( 4.GJ*DF " <)](F
M.DYC@'GGBI#U   0! 2C[%$0#D1$O/ ](' !Y,/  (>1Y$1'WE3$> X$0Y(
M=0]!N -R).H0!,H]75P<1 " (<@(!P/7,V?[_=\F5OB N<+9%A%5L>/+/?HB
MST0:(A!EQ?!U]&7&-FB64D>C))F9'8QZ"R\P_<MK&,@/I4^\[:](=C3M&*0
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M<O(MS!.E&Q!5AG;EF[<L!)RF1JJZCUG#-8Y$R$,(HK*HB!BB4PB40#*SD 0
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M[!.LTTR0[]2525/'N3(D."K%ZMZ=07J)6YF"9P3.5RB+HB!><EU^3*AY
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MJ;MB@8 $R7CU0AP #UCP0">1,'2?VY\R@F3[CP(")1,)A O)AX$3#^@'X#P
M?2/4/G[8]"E;-FS=@FLB+F-:M2NFY#$.X04<D,L0[EN)Q50!P43G1[Q2=TI3
M&3ZBE$=9&F'*@ 4H@ AW"J#] "'(@<@!P(@8@])@*)1Z XXY$1T'OZ"B'2/5
MQY-U@'/2("(^.>?IY$.1\@'/L/C7Y29-R+N')$42N7 $(X<%02!=9-'DZ17#
M@"=YR1#D113<**IHB(BD5,0 0^@H%XZN0'CG@0*'4(B(\>W(%+_RAP(]/ \
M)@#7TD 1 O@?^(!,/T@'6/)0'C@?81Y]R^/Y1X\AA43186#G'=BC5I\SUV5P
M5PF_M%BE(XGJU"K+BVB)"0<QC/ZR!V/3M4@;)_EH"FF82CEYBF$QC%*(=1>1
M* %,)^.GR F$I@\\]0B ?M^WW&*)> +TE\B)^GJ'J,(<B80   W!1\ /@?/
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M#&,(6&8-(N)BVB#".CF#=-JR9,VR94F[9JW2*5-%!%,I2)ID* % /N(B(AR
M!P''_OSY$?[CH("/L(!_;G_&O.F@IEG7;N$H1];L?M@)) "KJ6K*( 1*2YY,
ML[AP\$;OP/U*JL?I0><G,B*3CI36UU.P,B=4BJ:B2B*BB:J:Q125242,8BB*
MB9^#IJ)F 2G3, &*<HE$.KD WQ<!_P"_\?\ 3Q_354\^[=&60D'-GJ"+6,NZ
M9!4<)?2V8V9,I!Y1>&* %;R@\%!O*"4W64OIW8&3.59$-3;]3D3@'W'^H<%]
MP#CV]^!]N?O[>>)4.*9#JE #BF0ZG3Y$#&(7K*40#R/)B\> $>/' \:YN=C9
M&&E'<1,L'<9)QJYVKY@]0,@Z;.2!R=-9(P (#P(&*8O410AB*)G,F8IAX3H!
M0IBB82@<!(<2B " ' 0Y >."CQY 1Y\^?' Z"/\ .%3O\'C;<?:-M]P?6+.,
MOCQ8U!@OQ,68DF$_%Q:S5T8L:\>.6LA-I)N'/X23>MR-XB2(T8EX*X  H=\'
M*2WS2$GFL=SJN7'./D&D"-37S227"<3O?S5T$ZC7#V%,DNK$A$%2/+(DZHA%
MX+$[00557YW=1]2KL6[4DHZ$AF,DX3,1Q),HIBTD%R+"15R#A^@BFX<>H4*!
MENLYB*'*43 <0Y'GQ2(50#G!17@  14$14 H  D\B(]TI0Y O3QT@(E$ Y+H
M/>0P (B0.!,4/?@1Z1-P8O4/GD#!R4I? $-_-R :]H!SP7K'J, ^/\\CY\AQ
M^W'(>??1  ,'/TF+XZ#> 'P/(@8O@0X]@$ $HCX'4?Y8B;K,TN9CJ',MH:<5
M8/BD[K+U;A]U-%RILF"X2$>$6^47%(R,H)U@:@0_Y)N=!(P& O !P)5"F,/'
M(\%Y H& 0+P(%'D1$>1 1'D0$.-?@P!Y#ZA . +P!1 >.0,(>3  <@/(@ <#
MS_\ OAIN^*-O6W [)<685/CYO4Y2U7N>G8NQ9$GZCZJLQ1(%@A(MH1I!JRRC
M1&<EBN2KF7?2*P'91SU5J@*C@PMKS;',ZV_<MM8Q-FJ]5=O4K3=8J44EHYFW
M<MXQZK%3,A$$L,(V=%,NA"V4C(LQ&HG56(D@Y%)!PX0*BNH%IQ+X  ZN!Y\"
M' ?T P#X$!#[B/ ^/81'54-XVU6K[PL(6'"UIFI6L)2$K#6.OV:(01?NH"RU
MY1PI%22T8NJW1EV(IO'[)Y'KN6PJ(.151615(D8+;&#R!ND/?H'I+]QY#J$
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M$%3"V@6/! )LR  *'   !^@>W]OT#]@\:\Z#\E(4A0*0H%*4  "E
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M,Q[7D(=B!%W:G"\M)"D5-:1>FY$RAND.HK='J%)HB8QNTB =0F6.JH?/---
MTTTT#3330---- TTTT#337SNUE6[5RN@V5>K(H*JI,T#HIK.E$TS'(W1.X41
M;D56, )D,NJFD4Q@%10A.3 'T:U._%3_ /NWA?\ _$5P_P#R>+U.=J^(#B>D
M3\C5[95\BP,]%+'0?QTC!LT5D3D'@#%'UYB+(J^10<(F.W6* BFJ8/?7YO:W
M/X\W#0V/&5(0G6Z]6F)][(A,LDFA3H2D<R;H"W,DNOU'(JV.50I@)QR4Q3&
M!Z0U[A^O'MSTASQ[<A_3] ^X!]N.? >?'@1'[\<\>_GWX#]>/[?V<?;CV\\<
MAQ[^_/D0Y_;CVX]O?R/'CD>?/T^?T#QY\^/'G_'Z:"X6PP1'=#CWS_\ +LP"
M'L'_ -W),0_P''''CSKL;%]@_H'_ $UUA=L.2Z]B#--5R!:BO3PD(E,>J)'(
M%<O#F?1+QBB1%,ZB91'N.2F-UG3("8&$HB;@!VWI_$GP.<2IDCKRH<QB)D(G
M#-3G.<_ %(0A7HG,<3& H$ O4)A   =!L,TUA5 N*E[KC.RC6K#5VTB4JS!E
M9F[1G)KLU$R*(O#LF[IRJU26 WY:;L$' @'6*($,4PYKH&FFF@::::!IIIH&
MFFF@::::!IIIH&FFJY9LW)5S ZS52Z5.ZJ0KX2$962'C6;^$5<"0ICM%7!7H
M*,G)!$2@D^2;BMTB= 5$Q*80E7)O_P"CB_\ _P"";9_^02&NIREX12#@>.PD
M//(\<=LO/]/Z!SK>;;_B*8+L%4M$$U97--S,UV<B6RBT2U!(CF2BG;-N*HD?
M&,!.ZN03B4#&*3Z@ 0UHR3 2D3((AR5(A1$! ?J A0$0XY\"(>.!$!\<#SXT
M'L#SQR <<>./;[?MS_;V_N'.O ^/'W^H?/N/@?(<<@ #^@_XYT ?U'P'CSX'
MG@/Z_P!^1_Z:\#R(^/?CW#G@1'VX\^W[^PC[\:#M)[<@XP1B/V'_ .K^L^W_
M /+4M33K5?B?X@.$Z/C.BU"4:7!:2K55AH9^HUB6PMSO&#,B*_8,J](<R8G*
M($,<I!-_R\>1MSA3<[5\\O'*=&J=W-$L!.20LDI&LV,$T6*41*V!V9\8SIT<
M>"@W9IKJ$ W6H!"%.8H67TTTT#3330---- TTTT#3330--?.[65;M7*Z#95Z
MLB@JJDS0.BFLZ433,<C=$[A1%N158P F0RZJ:13& 5%"$Y,%%K/\03$M,GI"
ML6JKY'@I^*5%%]&2,"T0<(G#V'_[>)%$SAP=)9(QT54S%.FH8#%Y"NOQ3O#?
M%'_\3.^/U_++S[?I[\_;6H']?OYY]OW_ + (_J/V'5^=[&Y7'VX-O1BTA.;0
M5KJ\F9^G,,4VHF3>)\)G0,DLN4X < (<#=!@]P#CSJ@O/GWY#SP(<AS^W AP
M(^. \\\<_?0..?T]^>> X_;VX'GV'G[^W.K;[&__ -9K'0<^SB2\<<>/EKC_
M *?80_\ 7SJI ^ X_?@ #D1_Z@/@.?'/'[ZGC;5D> Q/F2J7RS@\-"P1WJCL
MD>@5P\/WV:J)")(F.F4PF.?D1$Q"E /)@$0 0[0)?8/Z!_TUYUKQ#XE.!Q$A
M"1E[5.<Q4R)I0S-10YS< 4A" _ZCF.(@!"E 1,(@!0$1XU=F@W ][K;*S?AN
MP5AO(_FL6%F;MF<JJS,FF=%XHR;N7)VB:_6()HN^RZX()SH%(9,Q@S73330-
M--- TTTT#3330---- $.=1-D7'-/FX:7EG<,W2E8Z)DWC619 +)QZANS7<HG
M<>F%-)Z!%DRFZ'J2Y1$/   CK@LTYXA\&L6\U:JK<)"MK 0BUBK[!G(1K!TH
M<Q2-I$!>)NV9C@!1(NJW!J?K H+=93 %4YKXCV!Y2&EH]%E="*OXU^Q2.>(:
M"0BKMFN@D93I?"8$P.H F$O4;CD0*(<<AJO<Y4H3LMSA[9C%:0:W%K9*E:?0
MW*QNVTG7K DXCIIN$-/R3I@@X>(J+B11D#(&0&+Z%5N*91-439YMTVH[+<AV
MS)6.8G,5FL\_$N*W$+7*6JKI&I5AZ\0=OH>')&E9>L<.S-&2#F7D^X\%DS!
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M!A:LBB5%TR9+$*]A*BIQU@1F18IDG\ND)BE5D3$%-NJG_L^>06'8@ <>---
MTTTT#3330---- TTTT#3330?%(QL?+L749*LFDC'/D#MGC%\W2=,W;=0.#HN
M6RY3HK)'#P8BA#%^_@?.M,^Z[8(]KX2>0<(,UGT&4J[Z;HB8BJ^B4P$Z[AW7
M1,/4\8(EY,,7X<-TP$$!63 "ANETT'4&4(9,YDU"'243,8BB2A#)J$,0W2=-
M1,P%.FH00X.0P 8H@)1#QKP !YZ1'_/( /[<C^__ /T-;]-U6QRNY@![=L?%
M85;(X$46<HB4&T#:C%()@)(IH)B#.54. %+*$(8%1,(.RB)A5#1M9Z-<J;:'
M5,LM<DXJT-'7HSPJS=0[M5PH8 ;^E*F4?6I.>HAFZK7N%5*HF)>KDPE#% ,'
M@///CSXX$?[<\^P^WMP(^P#JZ^U_9E<<[NVMCL!'54QFBJ/J9E5$4I.P=HP"
M9G7FZQ2B8%!$2JRJI?3-P*()=]42EU9W:K\/Y54T;D#.S(A4>EN_A,?"<XG/
MU="R+BU&*!.V4."C\E()Q/SP\.3H[9MO[5JV9-T&C-N@U:MDDT&[9LD1!!!%
M(H$31113 J:2292@4B9"E(4H    :##\?XZIN+ZVRJ='@F4%#,2%*5%JD4%G
M*P% #O'[D0[[YZJ/U*NG!S*&$> $I>"AF^FF@::::!IIIH&FFF@::J33=XF.
M[8RW7/5J_=*Z7:/=[74;NWF8^+,[MD?5JFVLP7.@HQLN]^;UF>=DL%1@?F)X
MF8=6^I6&)7C&Q$&CEW]F,]WN+KUA.O9]M;A+"E"F<3XPRO*GR_9J169:CM,H
M+3#&.K5Z9-[+($KU@CIF)&NJ*+.%(2>L2RD-4I:>>Q\DDU"U6FH1CMRVW>7)
MC92*SGB*2#,:JZ.)B,<BU)TMDM9J\6CGB-$00ECKVI9A(-G+"02A4WBD<];.
M6C\K9PW63)QD/NOVQ6&KWZ[06X/#$Q3\6*-T\D6B,R74'L#1S/7*S./&T2K>
M7490Z<F\;.&<4L\631E7C==I&J.G"*B10L#IJNLUN\VK5NEUO(M@W'80A:'<
M6+R4J=NE,HTQE7[)'1LB$1*/H.3<3!&THTB9431TPNS.L2(>IJMI,6BJ*Q4\
M;/O4V[,,SR6#K'DJG5&V!$8AEJ<XL]RJ$3&Y/+FDMN&HM,<"M.^NL[DRE2.W
M7.T9@T7=SE>:1CE\YDT4M!:[34/([A<$+Y(G,.HYDQ@IE:LQ3N<L.."7FM#=
M82(8,FDG(2$I6@DOFS)M'1DA'24B=PU(,?'24<_>%0:/VBRV*.=W^U1G%5&=
M<[D,&HP=^LTO3:--'RG2_E%PM,!(,HB=@JS)A,BQFY&%EI*-BY9&.7<!'24B
MP8/#HNGC9)4+"NFK9ZW7:/&Z#MJY2.@X;.4DUT%T5"B51%9%4ITU4E"B)3D.
M4Q3%$0$!#6/U*EU.APZ<!3:]%5J&27<N21T0T29MO4.UE'#A8Q$BAW%%%5#B
M)U!,8I>E,HE3(0I<,0SUA)UE5U@QMES&Z^9F3(\@[Q6E=*\?(#=HG&M9I556
MIED!FB&0A7S":71%F#AO#/V,LLDG'/&SE7C;WN4V\XNM491LDYSQ'0;G,)(N
M(VK7+(E2K4^[;.4W2K5T2*F)9F\*U>%8O"LG*J2:#U5JN@T4773.D 39IJN;
MO=_M688VB,POMQ>%&>*[!-/ZY!Y"<Y*J2%0E[!$@_-+0D;.JRA6+V5BD8J4=
M2D>W54=1S*-D'SU)!FS<+I^G+F[G;MA6";2UUR]CIG(3M"F\C46K?CJI-[+D
MJMPT0K+INJ"P?S+0EC2FBE;L()ZT6&-E)20CV+9XHN[1(8+)::AQ'<)@]3),
M5AA3+6.6N8YF';3C#%#FZ5Q+(JT<[BE9Q!8E1&2^=&,I#-GDLFD1H95:*8OI
M1!-2/9N'2?T9(SYA##LE5X;*^7<;8VE[LY6:U",O-UKM6?659NZ8,7 0S6:D
M&:S])N_EHB/<.$"&;-Y"7BF*RR;N28HKA+>FJZX<W*43-^2MQ./*0_A)-3;A
M?(3&-R>1]MKTO(EN[RMMK'.1CVKQCEQ-5IG"!(-(5N_L)&9IZ=8V=G&LRI5Q
MPX<XV]WL;:DLC-\91>6\?6.>9+9(3OBL!>Z8_9XG1Q76GMFMS[)W3/%=5..C
MD(V0CG$@];@S82T>_8R:S-9@\*@%KM-176<YX6N< _M52RWC6RUF+A&EFD[!
M!7>MRL+'5M_*V*#C["^DV<BLS:04A,5"U1D?+KK$CWSZMSK9HX65BGI4>$?;
ME]N\7DM;#4GG3$4=EEN\@XU;&S_(M3:7=.5LQX\E=B#UE>53E@F9T)>(4B(?
MTOS.01EHMPV:*-Y!FJL$WZ:::!IJK%+W<8UN>Y[.NU%)G8(3(>"*5CF_RTE-
MH1K>LVRMW^-"1=O*B_;R+EVN-#];6VUX)+L8GY:I;ZVLS&0:/E%V^*;=-\N)
MMRE8->:J@\JU*(_W((GG;Y8*)7SG@MM^2(+'TY>VT.%I=2[S'UJ;3["Z0EQ;
M-5(:#J[Z%_'3BKS-DK\7(A=+35>X_=IM>E:"7*<=N'PL\QN>PJU$EX0R74#U
M<]K02;+J5@DS\V!D:Q V>,W18,%1E%&CQHZ2:';NFZJG/1.XO 4[<;OCZ%S5
MBN5O.-64O(Y J3"_59S8*6PKQT$["\L\6E*&=PK:O*NFJ5A6?IHIP*SMHC,&
M8JND"*!,VFJ]L=VFU^2QXIEEAN%PP[QFE..ZPI>T,DU)2K!9F,>66<UL)@)7
MTAK"G%*)298,JAI56.7;OD6BC5P@JIBEEWN;7ZB>B2=CS5C*(Q]DBA6#(-/R
MX_R%2FF+IR(KUEJ=8<MHNWKSR;"2>K.[8@[3^7F<M&L?%3+F2<LBL3AH+7Z:
MB*8S_@ZO9"J>)9W+^-(?)][8-I2EX^DKO7&=QM4<]]=Z!] UY>1))RC61&+E
M C%FC=4DF,9)%8"Y,P=@EB<KN[VL0=;L=QEMQN#V-3I]J:T6TV5?*-+"#KUV
M>MEWK:GR\F69,S8VA5DV<O0KZZI98C-LY=*M"-VZRB86)TU#,CN+P%$VK'M&
MD\U8K8W'+,7&S>,*RZOM81F\@P\R"OR25IL>>3!Q8XZ<].X+!O(HCEO-';N"
M12CQ1!4I/MRMGG"F"F<)(9GRSCK%3&R/UHN =Y!N4!44)E^V1*Y=MHU2<?LB
MO#,FQRNGYT!.DP;&*X>J-T3%.(98>A4M2W(WU2KPA[FA'J12-E-'MQETV"AR
M*'0*[Z.Y[D*4%1$5BI=2)5 2,8@Y;J(K!G_!E4F+/7K/F+&%>GJ34'F0;G#3
M5\K$9)U&BQX0HO;C9V3R417@*PV+9*^92<E2-(WIFHL2N3 ^;]SF:/ES%F2Z
M07)6/<BTJZX^$LL8UUK%FAYJL)?(%G#>?(XFF#M9@U6@G+-VVFD'*Z2\2X:N
M4)!-NJ@J0H2)IJL#3>SL]D)!G%,-T6 'TG(VMG1H^/:9<HKAX]MTB5N>.@&C
M=*<,JO(2(/&@,")E,F].[:IM555'")#\W9MT6#<=0@V#+^4L9XABE[Q<Z+$O
M[[D['\8QF9.D2[V+ES-'Z=C69(K-$V2CZ:B7J[:9J*(*M[>Q@WK9RW2"PFFH
M;G-Q. ZS*7"#L.:L4PDSCVJ#>K[$RN0*JQDJ52P+$G"UVQBXE$W->KRA)Z%.
MA+RR;1BY++1PMEE?6(=>-2F[K:U"4*!RE,;B<*Q6.K2:73K=TD<EU%G7)]:O
MO4XVPMX>37EB-Y%S7I!4C*?:M3*N81SRC*I-#D.!0L3IK![)DW'-/H;G*5JO
M=0KV-FD4PG'%]F+'$1]/3AY86A8F3_$;EVG$G92QW[!.*73=G))JOF2+ 7"K
MMN16)5=V6!$H^/MXY7Q8.)Y#'\AD,F7OXKXV+2$XB/O$-CXQA4-9PE561K/,
MIPJ]A1CE*U&V!(*M*RK*RO&,4Y"R6FJU.MY>TAE1V.3'6YK J&/).U/:,PNZ
MF6:.%6=W.,;"]E:JA.#-?+U+#$L2F?RT0"_KHN/(=]((MFA#K%L>W<(.T$7+
M59)PV<))KH+H*$61616(51)5)5,QDU4E4S%4343,8BA#%.0QBF 1#W::@S/V
M;$L&52NSJ=-G[_-7#(U#Q=5JK7'U?BWLE9\A3B<'$"XE+1)Q,-'1K50RCJ0=
MN'0J)MT3%;MW"YTTC8+6MV=.0=WV'SA!O]M4WC>KU.\6-3+]EH+*FN*9=9>:
MK\+98'(\):I2FR;%&PP3VO3C%U(Q4[7Y=:(2E(A%G8JX^E@M;IJ.HW+V*9B,
M9347DJA2$3(V:(I3"2:6V"79.[E/-6#Z$J*#@CX4U+1+LY6,=1M?*899ZA(,
ME6[0Y'2(GQ2H;F=NN0+I)8XHV=<0V^_P\G+PTE2JWD6IS-J:RU?(Y//QYX&/
ME7$D=W ^B>DFT4FZAHE5D\0D/3+M%TTPG#34%W+<9B+&*5YD\L7ZAXOK%&LE
M;JCVTW3(-(BHM>:L]886F.CW")IX\C R2K%Z91M$6-G%2LDP;*6"-9NJZJWE
M%?UEC<-C3#^/:QE6RSL>OCRTVO&=::7)A,P(5=FPRE88F @KD^L;^49PB=-:
M%F6LU(S:;]5$(0#O697?4D10)RUZ'35L];KLWC=%TT=(J-W+9PD19!P@L42*
MHK)* 8BB2A!$IR'*)3%$0$! =0#([M=K\1C>N9AEMPF&8S%EODGD/5L@O\D5
M-I4+!+QOS+YK%0\ZO*$82$E#EA9I2:8MEE'4.C#2Z\FDT1C'RB'MGMU^V"KV
M2,IUCW$81@[5,QS28C*[*92I+&8>1$A *6J.E46#B:3<?+9*M(JST8_,0K22
MB4COV"SEN4QP"6JG3*I18A.!IU?BZW#I++N"1\2T3:-N^Y4,HNL8B8?6HH<P
M\F.)A*7I(40(4I0R;5<W>[W:NPQS 9>?;B\*,\6VF9>URN9!<Y,J*-0F[!&>
MO^:PD9/*2I8]Y+1!8J55F(]%8SN)0C)%Q)(M4&+I1+G+MN9V[8VG*Y6<A9TQ
M%1[#;X,UFJ\-;,BU. D9ZME!3BP1;63EFZKN#4,DJFWETBC'NEDE46KA99,Y
M"A.&FHE-GK"1,I%P@?+F-RYC-$#/EQ<:ZUTM^&%+'FES27X3&0":]*$04TOU
M^CZAB2'E *,>4SD.$K&Z#;==4KVXI^>\.6AKB^%3LF1GD#DJGRC*C5Q5J\>D
ML5K>LY=5I!0 M8^06&;D5D(PA8]^"CHIV3DJ03KIJO0;M=KXXQ#-(;A,-#B4
M9_\ "89&#(]4&G#:NKI_#'SX)3T/XD#R88'N_-@2 5Q9@@ JZD)'+F*G$1(6
M!#)= 6@HJ@1N5Y.:2N->4B8[%TPA-.HC([^1)(&9M*'*-JW87$=;EUB0#U""
MF56S]0D8],B$AZ:K;>=VVWZD+96@SY1HUBR'AW'%LRC;\35RXU=]DQO6J?52
MW&2,G5%)=!\FX-".(QTF5V5ND@A-0KQ\JU8R;1RK*D'D^BST# V%O:(!LRL,
MHRKC$CJ;B2+?BYXF(C2S]#U1,UM:N"+L7=?244DD'K5TW,WZT% *&?:: ("'
M(#R ^0$/80_7419RRPGA3'#Z^C5IF[.T[)C^H0]4@'L'&RDW8LE9!J^-ZVT2
MDK+(Q,%'MPG;9'KR#V2D&Z+6.2=+$!=<B3=8)=TU5.L[K*\C;)N@YOJDIMSN
M$/1?XG-TLFV?'Z]3L5!1M+&ES%AK][K%IF*Z<*K:)NJPENBYQ6"EH5Y=*>J5
MH]C[%'OE)NK^5,96RM,KE6<@TN?J<BI5$6-EB+-#OX-TO>FM??4I!"4;/%&9
MU[<SME6=UI %>].-K) K1I'*<NP,X#/M-0U [B<!VG(4UB6MYIQ7/90KDHYA
M)W'L1?JO(7.*FF+1V_?P[VMM91661E8YDP>NI..%J+R,0:KGD$6P)FXP6R;P
M< T;,DS@_(V1*EC:Y,8_&;R"+?;95JNWO#G*3VV1L%%4U&4F$)&7D6<C5!CY
M,H,DFZ4A/5UBW<.'DFDCH+/Z:KS:=TF#L<)VMWEW)^-,2QM;N,C3FTA><GX]
MC4IMU$UZH6"3<-FZ5D7>1;B.2N,<E)0,ZWC;)'-Q:S3Z);P$S"2<AQ6:-X>W
M# ]<&=OV7\<L'\CCV;R72ZF:]U!I:,CUN(B5Y1LO0HZ2FF1+"6P*)(1-<>-U
M@C9B:?Q\:T>J.G:28A9O6)2E#IDU8X6W2U9A9&S5TBR<'./&""\C&$<!^:5J
MX.43$\_4F(]0HG$QT1(8PCK"(/<'A.PY"#$$?E*@GR^2!9V1YBC\7P!LB1T4
M\B(Z>*N^J2<@>80[,/+Q<FX(+83HQLBPD5"@P?-7*WV7//&$\<W*GX[OV6L<
M4N^9!70;4>G6FYU^"LML7=/R1+1. A9)^VD),SV652B&/ID#@^EE4HMF*\@H
M1L8)8TU6[%6[+!.7;/-T"N9#J3?*%>E\DQLQBM_:JU_$6/9XPR!-X\G9]W5&
M<L[DVT(O(PZ4HS<KHD52A9F%=R*#(S])/7U0F[G:Q8ZI:KW [CL'2]*H\G'P
MUQML?E.DNJW6)27,8D.QG)I&:-'1SB:,4P0A'+A,)H0'Y49YP.@L/IJN$+NZ
MVTVY<L70L[8=O=F=X_E,G0U6K>4:*YF9NF1+=RNYGV::TZB@C#I&:J)/)9\J
MUCHL"J.91PS:(+KIY(7<7@]&\U3%,MEC&L-EJZ0L;.U[%SV_5(UXE&<K'N9-
MF>,@VTNLYE2.6<?*.6"T85TA*M(F3?Q1WC%BX<)A->FJQ36\/;NTC<L+5?*=
M&R38<*QKB2R'1L>7*JV2Y5Y)I+C .DY"&;3 *,E6LV1>(=B\.@DSE6SB,=J(
M/TC-M9S2,[8ZNP7))">C8.2HDQD)E8H6?F(1C,,8/'-[M&/)>\.(\LDJX9TA
M[8*=/I1MA>D;,U CGB#@[=ZR>MFX3)IK$5[_ $1K'LI9U<ZJVBY*KR=XCY)Q
M8(I&/?4R%:1K^8MK1XH[*V<5J*8S,0]DIQ)0T8Q:2D>X<N4D7C<ZD<7+<7BB
MG1E:GE[M3)*O6"&-<#S+*]TE)LTQV?'F0,CL<@L47T\U=VNN2T)CFP*1)Z@C
M-O'[)G*6%NW-6:W9Y>("==-4NH'Q ]J&1'M%;Q68Z)%M<J4C$EYQ7(6*Y5&'
M1R0SS(K:FE;B*BU7G3/I.?CY:J.:_/1R;?F/LSZ.K955IM8S$K00%,;(<ER>
M6(*RMY^O1U*NF;[[-Y]9,YZ:0D+-AV)S@7<SA:*C8TL.>,E+ .1HM3']]92B
M[-FKBG)%]CFDB^718-UL98;-,ZTB P1:HI+'UVN>WQMMZL!: \L;^'@\GSN+
MZUNTI]I@E+0ZK[E&O'9H;BH2^8_G9&%D69KM2V;649PB!T; PVZ:J7G#=!*8
MPNH8[Q]@_)>>[K#T V6[S 8]7JL4YJF-SS,G7XM^W<769@65KM]KEX&R,Z;0
M:\Y<3<V:MS!UU8M,(TTD%>DMI.3<D7=UD>_5[#V*):W;6MWN'GD=C0CR4<T&
MT[F<IT2WLI@'QXV%0N%G4@JL>3RI=F(ULEIO'TQ<8,:)99Q%]BVL[C\DI1MJ
MLV*L-T69PMM_K^"*-0,=96ME:99&?P.8,)92)?*AD&M5V%E<(H4$V%VRFW^*
MEH>W*U^Q622)>8\:T5\TF+8+[SF9;LHV;X?R&.&HF_4S$ULSM)OZ77Z_5\EW
MM.M-XN#?T6:L33)1XF%L]TJ./[I8/PV@2J7N:7B7<<XCJW;)F#@AC\2JQ3#2
M'>1&SO.*R5MPQ+[DJ41_;\)Q:TS@>GNH-C>[A*%<7\Y*S8(5U:JG\CH<FH:<
MMC>PH.6JD<6(LQ(0((H&,=W&),[8*LSS%-%S/D*(P'O#"5;6*T0M-F(R(RYN
M,VXV"M-+%FJHXE8X\M.4?ET$^7RW,M\=5U]D=D@$JP7L$S6)&2N>:Q_P\,GQ
M."-QN,2/<4.['E/:'MEP-5WL<E*PM79VG#SC+\Q.L4H]Q$R$E7,;0\ODAJQQ
MQ'$7F'\;!,4TW"#5XWZUY[4WN6*L7G+*UHQ';I/ = R[0:=*9[8/J1!5:E5C
M)F+<*6NNRLC6YVU-;W;HZ$G,GMQOU@A*XDA4V$TR32;39J_:1A?MLF]R3J:4
MXRKN$LL9E>4V&RYD._R4.MBNDMJI0<9YKR/B^;2*2RWJ/;SMC8JT.6/6X2-/
MZJSPT4,G*OH"6=C&F"&HG:+G9#)ERA)%FT>8^3R7N;S%4[PXS=,DA7DKG6/S
M8E7(DN&XVA,7<7;X-7,3BN6V>F;E/5"0J4,9Y'QDC+3#&*J.+9CV.9I(-<:8
MR91EDKMIV78TV;6RD(Y9D<44FC-Z,WOS9U8'[2-IL_(W[&EH89%=1EFJE:4I
MMR21J$(,._<*RY'=3GA_\3/!S3/J.&4"MW<$7*-4P5)Y!_'^,VCIAF2Z(01X
M*K)8A>VI#,LE!EDK36:Y,7AA3%:_#3TSPX,I!0UCGX?@X3?#DJ^9]VDU.%PC
M<\?89W%2.9I2NY O*=3>&R#1Z/B"7NM2DF41"6=Y9L9R=E>$B;5"1%UAD'\Q
M25%C.RQ$TF]AF(?FB;:<YT/=7$3U>80T'A9E9#6ZS2!<D+VVIWKIQ$GCEI*!
MAN^5&R7#'N>4GK.-;2.1\?9>@:I/5-H_?66*L4]:K!#JR'G?:E8<K'W! W:T
M9XEEN=V<.V1)XIU2N(G;UEF+OUC9SQ#1#PIBE:(R2M5;_P"\1-*NSBH,;WU7
M.LTN6]O%E R!'8VM45;(RR2NY:J;9V::C.+,V5F[MC*N9+KF0"JA* <^-W9+
M=7*8M-IIG>L[S)%A',:0B#ETE#S_ 'P6>2G<5KXYQ7;;-'90R9@"LR5?L1Z-
M675-QAEY?. L<J,)):YI'L)YZ%QG&6IE6SD%^TK\O$=AFO)2$BTC X++.W'<
M6EE&:N>."QTC6KCG^SW64BZKDMAB*ZMH"RX6P!CN/D)'(KO&EWL3"JLIG&=Q
M<WBC8[<5NS6HCRES"-G?%A7=:5@%OLYW80>!\@X8;X_PA=WVX7:'C3;I;I:^
M9(FY:F8@L^&,6VC$T>[2@W=+=6#(^-+BB^:9(@(U"0A+56+W-6$EA.[!Z>P-
M[<[0MX%ZS.TQY$9/Q+9Z@XR%5LC3M*R4X/56=7R"YQE=OPW96S"G1]BEKG4$
MSQ\A%3-:>6B.:M;)#I/7P'C'1V+!]'4IO8R?1,R[UDKICF;?XYP;?L!8JQ8W
M;V#$M2ISQ2_8I99-M60<C9'M%C;DQY%-CS1&SB;O<E!ULC$E/JE9@I?(]B%E
M*AQ$+M#S?!;@Y@71AMV)++NC_P#I6'N4WF688M*^Y5>P$X6D_P 'HZG$DIBW
M5B8@FU;J%E+D)I3G%$*D>>C2"U<4B8E/<#@K-CO)N9[=BVH8\R=';E=O50V[
M3K?)5Q=5ECB$*HXS&;\3?+DJI95;S0;&WRZJ]M%+B%X.?7FZC&$1</FD^I(5
M2O-X^*)?W=?9W?!> F^1Z9(;+MR^XE-^ID;&ZI&.3=O.7ZUB*:HPSD7?1K=F
MJ;*7>3RKFV5)])1=G0+"/JG-':+O +>:*W80RKB(KEDQ[=:SD>3SY7]OBN/#
M+UBPS#&RSV.DLO!95Y*MS<C"&I+#%Q)6Y.YL'I#BUA).,1:'F4TF"@<UM]PI
M8<2QN7X2;L"DLC<K_$S,!8$'IU+&ZA(C!.&\5A,SJRC)%!K:G\OCR7FG)6Y7
MK4IG;1<'!SJJHHZO;;L/W+Y.P[C_  5.8]VZT^*P)M!W9;5ZY<XVS3+W^)[K
M.&WMAB*KVF#@$:HF[Q=3IJ1BVT_E*MSLA;IQQ-+-E8U]+-X(LI.7CW9[^:1M
M%L,0RO=+F'%4^30]AL]U=W'&](9M(R9L8UTL?CZ!OMIK]CS9<(;MJ35FIN,8
M^9EH*(7A$ES*S]JK$%*Y>QW5S<_>K%"PF!\LK8HA[1DS&XY]02J:U83O^+&E
MA2M0*TQQ.HWEO2&MHJU@H3#(KZ&1K#^\Q1HU8S.#D8FQOP@+<%MJSR\NN<FV
M%*KC*7J6Y/;QA#"SR5M-Q?TYMAYQA">RX[7=_AF+JDZXN479ZWE0C.M-89Y$
M*0\Y71;39$(:01DFU:<IL,@S^2JGMKJ=!Q]8$(WXG6--R+RW/RW6,R4VK<-G
MIEG>[RSG'DAC]LV9IU2LH/ZY!YK/?7..K72TH" KSYQ<9?\ !4;9#)V_6Y0V
M'[1:L28=R'D="AXLQ?-W[+)VN/HZ$I%URA2:=>86-E\=KW5K9K"XA:A=:M=L
MB-Z8A)1M6@[5%)PCNTOD)1A%;2"<&Y-YYZSAQU&Z?I.8H?3ST\_3SSQ[^??0
M8!BNU6RZ4>*L5VH3O&=C>.[ W=T]]+)S;E@UBK+,P\._/($CXOK)8H2/C;,@
MV58-G,>A,I1SH@N6BQSR'H  'L'']--!J/S?L9SK>LJY_P DXWO-(I$MEC)>
M*6<?,O32SU^.!IO ,3M]W'5R4;-H](6]A&-32R%C)!N\<1ZU]H='7FG;".5E
M$=1O8/AK95D(ZZ0T')XJA89=UO1?4Z"5&86K9X_+N[W:CN%P]0YZ(CXAEZ6F
M/Z7M^E\?9%1CS.@@F4VT0B8ZRLQ71+NXU$^2\O06+Y_#%>F8V7?NLVY73Q'7
M5HPC,[>*G5,;Y(R8$C-BZ=ME$XD(C&4PQ$[%-Z\^9OHP@-!:G=.6P53@<,96
MRMD_%6:LO8BPMC.0I6=5<F'JD#)A=;F#>&VYY9PU V:UY#:Q$5#W2W(2^1"H
M5%JU@H@E%HJ;M%2<G)>0!E"P,XV=YTLF/J[MUL-&PC(X]PQ5MP4;7<CW*SVB
M<6W!J9BQ[DVB1=?OM2JL56+71H>R$R*K9,]2,=='<K+VR$C)&D.'JBXR$5.%
MCW^H)KV-ECC;[EK*+ZEFW 2%P)$RF-JVQA*OMLS99<'WZ8"5MMQBV3Z3EYZK
MR$Q1*R@<DE8H4BZKU6"78O4T<?RCNYL[')N*(ZCHVASB>4ST[8Y9OB##',8C
M3,:5G:!7-RHLD8^UOW=DG(&>C[ A.V65AJ\6]QS&+L=6KK5E(#7I=Z$!Q6*=
MV=*<86LEAQ_%Y$M$;NEE[]4*%DS)D1?KG$5N#VCYQICWY]N.KF*:ZR>S8R\I
M'-,1S60JG.R\&P.XKEHR <UHC$*58W"VTZ]0%I?Y$O[&D-YB\5[=W*3-2CY5
M:SQ>.K!N=R)B>U)T6IRSRL0WS.M-(G':SN[S1(Z)3L=[F9Z7;PIHZ30(V]$Q
M\1 M+KJ4QD?;5FJG3EOA*9:L(4,9;%$_<\SP%TREC3$:2$,TA;ZK#U.V5JQY
MDQ>_N-9NDU%)0U?N;&30FI T/:6]?^:=^(;-0]EF:ZCM3S-*DK^7:SMMDI>/
MLV(SL3;B[GC*CY'KF/H]%2[$D'5;*:]QM7L>4%F;2H5Z8:OWIQ?P31U)MPKY
M4=BF?Z9<V-<<EB[?CV]V_:1D2XS!<S6"KU:AOMNN-=N-)L%:5QM&4\MBOCX)
M7 7XJQ+8X:[5)@QE[0BA;HY@QK[Y2WY,39?G7&>*-MJE$;0L[>\*7+=++V6J
M4G)IL4.)Q+<CE";O)+35L@R%$L4:WLD(#AJA86,S5VB,Q$V.X-F,N5TBT93=
MVG&XH9';#=LW2-=M.,YBGL<@1MJJSA&I7*RTVW8ZM$Q3+-'(>AG@IMI]%-PK
MI6-=-I]*,EH]1JX.JS545:H8U5MXBEERM&TH^$,EPN/IO,N4-OD+F25D\?!7
M9'+&+$[PZDV"5496MW>DZG--<>69M!6]:$(BI-LBQDG&1K5PUEEPI2WV2;C:
M)+87B,91] A6S:-Q&.1K.3(L_9:(H6CY6G\FV2HY2Q%E6LW<<T,X4;-,EP??
MZ1(X=O51L:[%19W5J[7*VTCK![U\ [BLP7:N*XJ/!*TN8PUEO%%@3:WIMB.Q
MQ,_D'Y<:-F[?=X_'MSO]GQ*@VC$?F^.<?3],D'EF:14U)$L9$8]>JRGDO>9#
M8^W)5';>UQW9K7/3T;1YJ8?Q5@HT;,QT%?;-)59G8ZKC:PV"*R)E6KU!W&*R
M.4[%C>"GH['4&H+^4.Z<,95@PC3!6]NYV>!A5<I8.R#&)SE)S19Z?=8).GOV
M>4I3"-@EFMFKE2H49:G]SC'LO"MD)&ANYYBQCKFW;N5R+Q)WD,E*A"U.V'97
M@=MMB@.FIQ&9Y6Q;),@/6U>N;V)97)_M3PGMVI,A1;%D *=,.F#!_9L56TU0
ML)*I--XLS^NV)_"&$96))9W$.#<DH;?L]U^ZQ:=>R#G-6\2'RR>R?(Y5?LEY
MG%,!C*"5NEW+7J_$/IM9"MM%Y?\ "=:;Q#&/%DS!Q9)9I(V"6A.N?%1I5A:/
M8F/PW<;)DQ',>(\,,\?8SR9@3*Z;FPYOJMZM-(<.[]2<F/Z%"HQB>.K3'W]G
M,335_4%8\)5-*;KCV+F9#+;O\1^M8\@82(N&+)>H9XE;O<:0YPC>LK8.H8QZ
ME"K=+N-AM1,L6R^1F+Y6HN:ODO&LE6UXN;<V6:6O</&KU:*>Q5Q)5PXK+FR.
MUW''>>:O4F6.(J7R)L2PSM:ISE0#Q[>+G<:RN6I!=J[78P*JS"EM/QM!*08,
MDG!TEFSP2133T[<RW@VWS<#BF\2>2*-0L79H<6U]NCJ4A2;A?7%.C:U6\X[B
M);,E9M;>0<T6RH2,?)1,BWKF9ZFFS3DI)O!516NN9SY,LR<7OPOEVIYWQ72,
MNTA1PI6;U -IR.2=J1RKQD8ZBS1_%O5X=_+0KA[$2C1]%/'<)+R\&Z<LE7,/
M+R<8JU?+T\1^(M1BW//4$\QG>5JQ@?\ B$QG;+6)W&]TGE;1CN5;P84^>Q97
M;@XR3CN>R=*N2(803OL%"M<F-P2?-W,.UE:^I,AA=BV5W\D#DV?K[#%(WMUN
MEVJ[DH"MQ+=_4Z3?8_;5B3 -0)C654!I+O*-$J3V-;6;&8JEN;&AC^"9>01E
M?2RS<?MPOM2RD3<LQW39+@*#6)&S7?-N0)/'D7-#:GF-'-[P?M=P?7V45920
M,='62QV&.P-/V;(D_&MX5D1Q:6<!'IS:,>]G)3$,W[Z<S0Y\>8RA\'73%.99
MG<IM'I61:]*6##MPD*Y@7<)D"TP*.1:G/DL\A0IQ_+/\9WO'+R($LC.5&=8/
M)5>'7B7E2L4M8?:ONKO&9-IDIN-R;B&:JD]#2F<2&Q]25HFX3%FB,4W^ZU6*
M/4FS"PR"3F7LC6K%8H1DM+1J@6$CL[@T="KM'10X>\[;[N\V1XZP:R@*C;[]
MC2'P@[;1BETM5 ;&L.(+#5[&A)X^R16FZ4K2+M!O:\G,8ULTC!2E<96:/B$;
M;77U9<2C8M:HS;;OHI\8PRC29+&[_.+7 65,61"E^M,(M-P\AE;<_0,B%L=H
MLM/Q1 T*\9$J&+(JT2JEH#'<9!7/*#:LQULBYV/7LMVFI=I/Q)Z[?(A\RK.(
M9ZVY/0RU3\/M,=XYRQ@?)S-2?O\ CFX9)K;^4R12\AR5"@6#"*HME9W)G(2G
MS^MN8X'C6'GX>3@)&9SIIOAD+ 6BUND;=\GV[,$TTR3,Y"Q"WLF+8F9Q=7L/
MY/?8=O#^4MDQ<FE"LSM_D*.=P>/8JL6)VXNB*2TLHK 1;&2=,@J<\V?[@*X?
M$-YQOCY6 >T+&N7\*3V,6.Z!.-F[0YRSD''64IG<!:<MGP^^CK/9KU;ZM/*9
MIKRU*92UC4F4;##RSP[$:J\V+;;HBUXZJD%@:8I#>%K^$L4X5J$!=(J9L,C6
M[A((TY=A9HRMM+4T//,XBENH1@Q8K2=AL;YY'RK C]TUD&3MMKG-KN2YK,VW
M/".6;&W%I.Y(QA3;M*LS1:L(JS>V2%:RBS1S"K+.5HAVU,Y[#R,5<+*L'2:S
M5150R0F&>. ]^/(^X_KQ[:"J>[C'&2,A4O';K%4/6[);<;YXPYEI.M6FT+TR
M-L$7C^U$E9B*3LJ%?L_RR0<,#JG8*+0SENJX2*@L=N17OIU\M6VS.6?+3_$7
M,M;Q)6 1G]K<;7\51=GF,@,X^DX@W%P6>,E3%NN$A3JU&V*R6=_6:PUJ%9C*
MJVAH!*N*#*6*9<V4XUW9?K6)O2WQY"PQ0MP<EAC#-KNB>#F=;@;7EPKBBO:/
M3<AVH:?)H0SJF/[A$WFVQM4K-SKLUD"6K\4JVK:%CC46:4Z[C;2A70PZR;5M
MQ8Y7=UJN0F.'F)97X@&/][<IDR9NDA'V!"N1\=7&UAQC%X\9UF147N,9-UI)
M[&V1[8VU9DX%V43%931#LTJ^;<6>1KAN"^'I3&V.:(VJ>T#'&XBMV2YU9I=X
MR?2BY#%U4QG6WULH=OH5.?X)E+S.-P>3F,[9*3MPGK3&2<U#%DJA63VR5N5>
M-_T/B^4K-:&D7/*-@M]^W%1S"*CY'%M%LSJ$P?FF7QA.5[&E7L]UC7F;;Q'J
M-#.X*A4 \CD"P5EFSFIB(A9JR5^%ELO_ /IQHA?IR*+@7+I<45+<"VVRV_-Z
MZU+3K,+DZ6L5:J,"^;5(UF->IC&[RTW&L5N6R%&P9HNMRTL<91J$3"6:6A B
M3<)M5S--6_)V3L?Q$3.S\KGRGY/H3BKY1D,1Y;J4>SVO5[ \U-T7(#RNV6EP
M=E^9L9-K.UF^4Z]TR[8[D';19"+L3:+'4US6WC)=QVX[;L97AUCJ9N^,\G[7
M[]?%8V%0KM,>IX6RA5+Y,A 0D9#HQ99)NVKZ8Q(,8&M0C^PM22+"$J$>X;14
M7 L!\7+ TT>YO_PY.K5N-QKE7*^-W5;MV+KQ<,I5;##$LQ=$6^+JG<I._P"/
M;&\KYOQ)3:]D>'K[ZT10@RYB[48M:-+Z6^ETWS9C[!,_@2\P5[M,12IFV5I6
M]8C?72BQV0[)-5Z#FT*"TN/XIR33JR$6VDLKWK&#2SU7&C-^[^9R,@I5K@$$
M'!3."<X8TS-(Y\QS2Z)E1^O;,YM&V.9:^GQX5*OYG+@%\WNK.RN:59F#*QQD
MKAV0AK9&&CU%9:HV$'<7).)2,4@YV*<;_#]O57I.5:C:CXQL8WRQ; I$H$(\
M7B'$3M>G<;6&Z0BS*2KX+(046[KEA88LB7(/02BDX4D@I%.%WHHYK3?BIX(M
M$A<UW+!6/J,51;WD&@3D;D7#EQL.2X;'SYA'R+!MC6HWZ5OE'L-F-*Q3ZAP]
M^BH,\^QDFC>37KEB,I7DITP;N RMDC..0L;Y(PS8L)A4,/XJO;6N6:7HML=/
MWM]O&78-=Y'W+'EILL!(),&-&8QDW!*^B?5^>;.U$3S$'+0DY(A#=BV]YPQW
MN$G-R6.*?1<JKOYC-4 TQ?,WM2@)(U[,T5M>6&]-[&[J-DCF,['S^!9:&N$(
M$6Y<3]1L3&1C)89.&6K\YK;SWBG)V!=NFY':#6Z-C/,5OS9M&P]BXKE>J9%K
M,H:ZQ>.)3&L94,1U=6HSK7-N/HB3+ZW'5;K5TA9'!+QR^7RJ\A8&3:6M7;)+
M?$!Q/!F.,Q7+K&LV6$\S9@G)1RG6DX^OR6%;NYQ_-XGDUC6 #_Q-L%AA;DA5
MXILDO%O1I4\W>2K%\:,:/Z@9Y^(GF*@Q^84<:XY>6J+IV$/B2Y&<9#LK>F1Y
MZ-?=FMYH%0A:JG2(N['?7FII2%Q")/(HH!8K6M*5QZ+>"18V4J09C%;,<U1N
MX.5*]0C[%B1]NUG=WC&\/,M6"-:14C)O59N-JY,-QM=0D760:Y*F3K<3;7>0
M'./W=%;H+S-:>JE/2UOKO&P/(<S@O;IC6I2E0J,M@_:Q3<8/$*[+.ZS%SUXQ
M_EC:OE5K44I1E5)15ACF['P;;*U/S8P+Y_%H6-E*EJTP)WT>>75][CH]_@\6
MW;&F2L&9#2S%A*NN*S,)XOOB<_1LWP>9Y.B2SZ<KEW>Q=;:2KK"MYB;0BT6D
M;149:":@U83D+-M9D\E[<]W2N>Y2NM)3">2L11^1L/1&=\2/[\_HSIW>,</E
M:VUDW4C!U&RSTG1K%!N;C5#NZ[94TEW+&P-%F3I5XPG8V("IE<VS[D:W;Z3N
MC2HD+8LIU2\7Z2?88O.>GMLFY^NW+$51Q1'VD^8%:1'TF$R=6@JRC=HC&4=2
M)?XWF9"!D[0YL!DCH1M;=D^[" QQG:FX\K&!9R;W7[0\FX"LA0MU@H&/<#V^
MY92W9Y89*0T6G4+#.7?'L<CN@/38I&,1@9DKVE)2CJ-CHBQB2NVR=?$CPXSW
M&$P0NR*G%FRVSV_#?CW_ !<5R.:I R+-I5D,1?BXV9G->4L;A&EGOB=+" 2M
M1E0.4*NV<6I/%ZU\3_'$F_R3"V#'%I@+33H*IS5:HT;>L-7Z]VN0R!E:%PE1
M,?SU8H>0)MWB/)UER5;:1!)U3*2M=9Q1;6DXFY^/4K%Y;5<(GR%LYW(VG)>7
MHRM,J97<:W.K;B#+O)B_IVJFVF?S%A"ZT" FZUCBQX[GKG@W+Y+;8H@^3[OC
M_([#'ENIS.WF3HSV8R"M'5N0L4X9L*^]678NTU+!B+#L#1<VO7K@CQK&5O>7
M:<.I;?)>&JI5HI@PG8EO@Z&>7V770<2*L7=,H.))\+24F4B)<E?MYFX2&O&W
MNIQFUN_PEQO>6\N8TM>)I^6QPJ[M+>J[=YK,%4MM"RR2WI8]4HPOD&;"?L(N
M5I:.G(Z9I3JKA-)M >7@P-F2O9^Q14LL5F/F(>/M"$HDY@Y]-LG-5Z>KD]+5
M*U5R3%@Z?1CAY7K5 34*N^B'[^&DCL1D8=^^C735TL$P:KKNIHMZR%AQU"XU
MBX.=NL/D3!^08:"LEB6J4/.!BO-V/,F2<.YLJ$'93PRLG$5)^S8O1@I)).06
M:E<(%0.HLE8K30:Q,C;9,T[G[@CD;-M3Q92FM<I=7QG4L1L+B_R=&R]?F]R^
M!\W9DG\@6=[0ZE'+JOH;;[28"AU&)@7S-$Y[&ZLT\Z&>8,J[F.2L4;C7^5;A
M 4BJXU<XLR7N-VQ[A)[)%BN\HTFJ]$X9F, (7*@,\?L:PNXD+/+Q^$B2=5LH
MV,E< DZNRFFS)U&(#)["M19F2Z!0:1\_];(1YEK?C.LI.XR)CIMTFO>,FTZC
MH%&/E7\:S.U67L::$@X%T#EA'JNI%@@\?M&S)P&H/;>WNC+)^RK;XVIE3FJ_
MM@RGGR<D\G+1M]0RPM75<69ZII;%>*-,X_B4L*S5MM.08%O;G%FNLXAEB9>M
M[#C-2U5YU)3D%/>Y/;5G^TY-W:R6.*!AVY5G>!MCQCMC5LMMM[^MV+&(U]EN
M&C9ZV6>++5)O\>4&.1S+'3,32*])PM@D)^)DT%'[-M,)2L),%9WQI35A1)(X
M S+"T.?3SNRQ]>$BTRU.[_:-O#^U-[I68/'52M,S?4'=C8TVPR6,UW4,0;BE
M&*,G#6"?R5>;SD=8]^)G3,A,K["0^+Y^6R_4[#B&LP>)J)DG#&57MHE\Y!?C
M4>-<7?'=YG:-2Y.'1Q7D:2R8PN$O&J4.!J3R?,I.1DC!+2@<IBW9O<Z3N6K^
M7)Y[5;# U>V9OEHN5?.7+VY*MLAX)VF8FB)=4J\25%O/RCG!]T<6DR$@/2RF
M(\J3I\$@^0:PM<-HNX^(PSDO!M/HF%LAM=P6SRB;?+#:;O=Y"(A,56K'>*+9
MCMNDYK"=%E7]]QN^6GTK36V<,\@Y>(MSJP>O;-(^40F64CY;WU93HI(D)W;Q
MD/&$ ;;MO.RGE"?FU\?SEJQ?.;98" DXM2HP2ER8UW+,/9F\VVE:_*0;Y>O3
MB<Y7&LG)UMQ&W5E"SA*[Y,0U"$7=7%>9B)& R3=L;6QD\:L/7P:.-L*.]QEL
MR!(-(UX](-33P0A&Y/;A%F?23F/M%;@F;!:?E&T<8(;K6W/<! [P(>\13*MP
M6'VEVELA6]Z]O*-UKES-,XDD:(+ZOXELU)?63%.?RS[J-0G\H8[R76:)9J*T
MLA)6H24O>9.'8\_DC!><8[,^;).C4/#N8*+NC+AD+%(YNDG3R!PV?$D6G .H
MV0QDG'+KY1J#YJD:\5"'A+14GD9DR5G%95=E'2!9]+*MJF_C'6Z.X3U!CH,:
M?<&5(B<IP,&.0\59)6F\:S4L$$A-2+O$MPN3"F6.,F%F#"P4BUNH^;CU91BH
MP4F&Y)):.][;?#'*2-ELR^%<K%VZU]]F6%#<='I5F:J*DS@5K<E,@.).FQ<V
MOD2MTU66QW=:E3KW,U]&"MUNB(R*8^G;76B2-D"/K7LJMECQ;#8^C)*J5206
MS;OIR#/66.!=1\TCMTU:W70==GVQFT:Q6EK<R=9NITE:2KJL@57C)<S>1>'9
ML!<1]CS:1G"=?0U@R37H2NR=0NFV1BQ93>;9;,!96HX*RNKDF:>0XI8ZHT#
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M#8E7$E&G5)$9.R)D?)MC=1YB0R94)-.PY0L2,<NL5RW0C4(MNNU=+MW#IWK
MS'OGSR;&<QEC&ERC%(F$QGE/=7 -*52L4.JV[V\N+Q<8C;'9<L7O.V5,=0S/
M'.4:;0)&<GOX/KS^5G4C/ O"C7XJ+A6]OM!5MT^3+'N^C]O1)RHIT1T_#( 9
M"+"RISNB/L:1MF#:*S=GAD*HKF.L_,2Y=GITLP$TKA5W"HMZL6P&FIE@$J1&
MQ>BU[*(WV!R'DB'J[V^1.6+#BJ."@LJS9LI14-"PZEKD[<THJ&6T(ZP*5R G
M+=08O(;#']HG(L5)2N*1$S9X6=^;'NQ2MT3(6&[J[S9G*[PFW,+ZRP-CFW2]
M%7J6/:]D&J.*6_KCB1B:%$WB]LZ[654(.ER5^MMCGZ]$L&S()9Z+B6<25;=U
M.[#<I2<U96A,309AK6W:BXLN:\&Z=;>8:LY0D<DFL!U6N3[EF',U#N]"HS@T
M.WIU,L>*:7-O$KPG8%Y%[<E6"% )QEMWP9IJEWW*59"3QVYA=N5=S-:*U=IB
M!DRU[,[MBX@6Z=74<LG46W9#LT_$J3G=>\JCLY)1LZIHU^3K[\V1XVI!<'.&
MQS$V>[AD>\6RP9(AIS)&WYYM\<GJ%@BHA"I,5[(I:6.5*,5S7I)>OYJ@9$D:
MC!7LR[LK%C P34T4L$>F8W/S>T:B.Y&&F:W9;E296NRV )"%6@E*T]:,6.WG
M\2L:Y DCK#6YALI%V2MW"QUFT&4 TD#%Z@_KC^OS;!K(EKXTO%^K60*'C6ZY
MMQQN-D6N;,4R36884YI4KO4(W(6)L_3C9*4CJ5*DHZJ3UU14WN-W9".IHU3D
MWS>X1TLH$#<)JMK3=#FA[ABDVZVY1Q9GN)W-[)<IYKDZI4J6SA*KA^<H&+:Q
M8U'L=*05I6L\UBNPSTV\QI8BW.14LK?(SZ#+"3=?:*OZFT#:)0MN-$QRAB)M
M OK*JEA:%O\  U,))^Q<&<L<BO6#Z;&;,C%MA>+ME8UN2,4;>A*BF*@.2.SF
M Y8FRKL=H.2['8[NUO%]IMWG<R4K.36=C&N/+1'PEUI.$G>WYB1M3LB4.XTZ
M8AWF/)*1[S2SPDTZC+2X1M5=?PTG'1YF]0U]WFYA;,-XG&<,XBL90V:L^8$;
MU.R$V[QE729X@J>0Y2/NT#+*9N#</.Y0F'5*C\@!3G&*C5B5Q-,J?+*ZU32:
MY.6J]F;<IN[5V\5UA.YZ:Q=QSYM4VG;IXV\4"DQ5&5PY99W<KM@I%_H]230D
MEW%@QY98;)K_ *CW24D+(R*C(M7,Z^@YD(:,#9)&?#FH$;!C GS!FF6;.<?;
MLL8S#R9=8U<2<[5=WE[8Y2NR;]TSQQ'MV\C3\C,?Q+07L0RC$V23MQ7K$TL=
M;2CXMCEM,VMRC;>));E+<_.]-5\#4_#=?D?G+07F5[859P_M69[_ $J#K5>J
M%7N4'$K*8^I[FO\ ?.K7;)>T%&D/#+U^,0A_$.X/-C[=E,4O(UWA'&.[+E#,
M^(\;LZU"XWM.-K$^Q9&2L\RBH*^4NWO<N5'/%?@:S-N\YTS-E%K= ;RC>7B<
M7O\ HC:^XM.;6[+V37F;LDN6.=\<8OHV!,M81QM(8HL=1CI=]E&-RO!8XFG4
MS.V('SJYP4E:7-\?4O")*3'-(\]SJ$H>UMKDT<O8JOA]^XWX>]"W&VG)MDDL
MJ99QZEF?%]?Q3DZ,H?\ #)<\[ U%6S+UAQ"V&^XWNUKHCEFM:Y$TNSH\Y PU
MI*@Q"=C7)PD59+/X;:(RA+G*S#7-N:_X>2ERO&33X5^<U(E!0R5DAA,HW.RI
MRA*>&1%X65G;+9[RCC=]=76-F%XL+V8;5<&;&O1,+1&U;E-WP+8@K$?-R$O+
M[FLC[FDX*1Q)0L(HR>):-MOM+^!KE/@$L]Y'J-'NN0\FQB[2RVJ7L%C?FCX^
MJ7%"B8\*U07GX6.<I?$"W'P.,X3+K-W#%_A)AS%^1\P5>A1^")+'4I-7K(%U
M@F:F0<I73.;I%M3,ATRILY3'L!M<D,K7>N69:R-;'8K,1K6(*7"^UD^'Y39F
M)EZ;"9ISG1\97.HXTJV3\=565Q\2*R.YQ-6*W2ZO:I6?F<=R]TKUBDZ?3JC5
M;J-)L=<A[; UB'8.XEL(2:TE?PI0*' ?J8WG]3&$P_\ J(\?MK0H&X'=+6,C
M73#%5R'>KY)98WG;P&,-9XF&P9)W3%U%PQ6L76.O8LH</FW(..\:/U)!*XKR
M;GYW*24RTIM;LKVMU CARZL,#G;#>7N5DEL%Y M<M4*)1QI6$Y3*):2GAC,-
M 1ELE9DM.+I!UE#\+Y>E<PU2%R#'QM:5P':,%L\G4:*N\K8663+!8:_4W:2X
M;L=->"CR'/[B']P$0'^X"' \>.?;QKSH&H-SO@YAG"&IB 7&V8ZMN-;_ !63
ML<WZEEKCF=J5QC(.R50[U.)N,!::C.,96HW*UUF4BK#7Y)HI'SCAVR!C,LXN
M48SEIH*=8NV58ZQ=7+1 M[GDZX/+K7,U5ZU6>YS-;>V*9/GS+%US-?YQ=6%J
M<#%(2REQOLX6%(RB6L/$PI(Z*1B3I,B'-D[;:5BI(S0CPUBEV#>QKV-Q%2<@
MR4CY11WMLB-K+V+D"M8QHX/$O,:PR#A=%NY;.ALB[N03>)L3I1:-GM-!12%V
M(U(KBN.\@Y?S)EU[CUOC>&Q._O3G'2#_ !G4<;91Q[EI"MPSRH8ZJZDXK=+'
MBG'4=D.U6\;!<;+7*?#QZ<U&O%9>2EY04VI8Y5E9R7-)V\'4_N;KNZUZ4LG&
M B3(U:IM3H[",;E^3=9*@I$4^+6=QBBBDFH_5>K)S*2*J39"J6ZC-&2L?;@7
M==Q<M2:[9[)&;$J(E<K%7)"S/(Z#SKNUR;C6Y=<26QQ4:_/%UIDYD*BD9!J+
M:T+"XE7<G$B:,3@>Y[G]V<!$V>C1N0(^<F,'9<W"5&W9'KM)PHZR#;*OB''>
M$,D5N\V_#EVR!CR-F,:P;3*TM%Y[_@$4<FD(PI*^/*[ GLTFYC![VVG2F *7
M+8LR-B)R^L1:SDZ;R//6!TB]8EF6[S)]NEKG8"13I2,4:MV[:5F72,41PQ=G
M;L2().%':Q#N%/FCMNU'C0JWIW]D-^$L]7_<5&=UZP$5;QD<<E#.L'@!%$%2
MMM_XI6+Y8Q2[#]#TT3ZB4=^G<^LH"?=CEV6DU<SPN5J ]HT'N:VV;<6>WF)I
MJ!)&\UK.LO@V*7R4XL,Z]2R-$W61ALMR69\:P#%%E52XC@8IM<(B0D75@M,3
MQN--T-DQ9M+O;][::LV?8LVA8=R33)"V.R*N):W7ZU9MK1UI->2E4EYIE)3E
M0K,)#M4CI**2BRD8BLY?.R(E"X^:=F]7SCD. N=DR7E"/KL9/8VL\MC*/=U!
M]4I:QXGMC&X5.;@Y>ST^?O\ BN0=2$5%,+>MAVXT(+C#QK5"8 [\SJ3<^^Y[
M+,47O%L5B6:EKVG6HBD9=H;9U&3C",FE(K,[=5"SNEGK:%*D#YB=0%X<B+1&
M-$I!CYJ.FH=R^CG5,,?9>RS3+;;;>WS?1[%47'Q&;IMR4V^?(63N>6B\BYI:
MPJLD%N=3![BUR-18V:=903AHQL2CIX=@)!LZJJCH N[*!(7=IN9JU+JL+CB-
MF4H/!&W7 F19.3L9L (T3+<EE=6S>L3R#=LS9PQU?:Q1XX\,C1X:QXP@I.42
MR.>2^9OK$$:A0WX62R'\-*QO+'C2U4_<%E9[:V^<=OEWO5K>FP[23UFMX!A\
MW$K<KC"F4C"L;CR.G2N\I)PLM5Y.JOJ9;H!63-9HJ0D%5'*L^R>PBN2C6#L2
MN9LJ&SI%6R\VY]G^1B<.66X3Y\D05-K%NJTE2K3BR9P\VI2M>QMC*,A(2%QY
M%.H N-ZH\92QGY[,YLG[WIY6M.)T(RT4UC65K57\(;M[W69&RL9"0;QMGQ[A
MQ.Q5[O-6$O')N8IW)E1;V%HH!U7<>4Z+!S&N1*ZUD6 +MF%OG;</@3*=\BLD
M#CNF8+RA7+HUIL529-HGFYYF>-F*<M$0[EQ%.X&HO\2INJG(NTU;&K&3BT?:
M):Q/8Y.:=A-&+<53.+G#6#97VRV''L'C2C4V"A+4X93$ZI:X&7N;^V9"F; 2
M*8.G4Y=6TY (2;-$Y*^V4@4Q@8*NLS"S7KG:OA_4&_WNW6_(.4LO7".GX+*4
M#7JV^?T6+=T%KEL459M.N9-K]$BLRR#*J/$AD,70UMR'8X7';XS):&CU K%(
M+5J=#OYW%&L##&Z9,8A9I:"8;3HVZ*Q+@:T?XDL?:B$MM5>1K>>4=LJDSQ0J
MIEAK55!^9&BHV23&1,T0,X#&;MO+SA9;5;8^HY#F"8OSYC#>XWPQ<25#$-3B
MJ^;!=(M[^EW7$+(F2I/<+99^&?UUW&Y*?Y6Q[7*:^L $>4<*NP)"%L ;!F6Q
MZIR$\C><F96RQEK)J=^P9=3Y"LZN/H*44CMND_:[3BVA$@*%0:G3&5/866]W
M:Q3PQ]=:V:QS-JDUWUB!FSK\?"9/7]G]'@MNF1]L2ENO<KCJ_O<KJ-'#UQ6$
MK'2XK*]GF[B_@8!\RK#:.EHZNV*PRKR$_&\1:EG[58L/;SV>'!5DMKRKVZ7=
M0RLE9KD2^E[9"83B-HU6MTU,I;:X2LYM=YSI.-YR?NEVLM^S=3<GU8))6XR%
M6Q@IBO'\TQ?W^I3R+Y7)[UPXI\+L)V=7/+&3J#;,D92M\#.A/Y9S'7J77*U4
MF]<C:A2\99BR+C.O(NWYI"2E+%8Y^'JL9.V9^\49LF<NX7C8:,;,VYUW88QC
M78]7*+>F.1IW+N4LB69C.T*SI)SS'$]7KB$UCJIY7HU?-%U;&F,Z1"P<6-6R
M[/L9"'B6[9H\?1T3-J"$N>9=2W*3>S& &T,+UCO+>5\17A.0RVG-VFFFQU*/
MK+3LTY-=Y>MM$D6E[Q_;8EG%Q=]=J3=*L,+'QMWJASNVK:RN6$M,M)&YFF@C
MG$&,*]A3%F/,0U)S-/*QC.FUZCU]W8Y(TS8'4/6HQO%1[B<F#I(JRTLLV;)J
M2$FNF5P_=&5=N.I=50YI&TTT#5%<X[$:MG%SE:-?YES51L;9T6JTKES%5"?8
M[8UFW6JH(UUG'VE":G\=V&\UA_-1=/J,1=(^LVJ,@K;'5B,2D(Q-1[95K!>K
M304*S%L#HV7JK+T9;*66:M3+<^S&MD&K12V.YZ$N3+-N0;'D>RID8WS'UN0I
M%D@YBVV*,I>2<=IU7)$# 28,E[1).XBN/X7&J!L:E$KID*<R!EO)!Z!9=U\U
MN11P?#V&NO,=6";A)JIS>+Y>P3#ZF?Q38)Q,S3:Y:I_'T/D1O0I^U0321F8>
M01E;8ULFQK30:_*K\/#'-8BYVH_Q0R[)XW5I%OQW1L>K/*#&Q6.JK=73=:09
M,YV"H$7<<@N81@U0KU,?9@L605ZE!)]$:)II5Q.JR#E[9W6LS93K60;)DO);
M2!@;7C*^.,8LSTB0J;NXXCM49<*G.04]9:7/9&QH+^4@X!&[Q>*KM2HF\1L.
MFUFV1SR]H<3U1,SY\W4,<N9Q/1<H4JL4O&>\7:?M3JU-?XQCY\LA$;G:)MK+
M9KU:;"YF$)IU8J!/YPD;-0HN#5@H-ZK"H0=T;6**?]4=C%MW/Y;Q*$F[G7M6
MR'D''%5W 8O#*T]6"01BMV&ZO:OBN.R=<J[5)&*K+"J4VNY4_'F4V,2QBFKU
MGC]Q(1DA46#MZT2"U=?^'SC>)B+A3)3(F3K+B^<I%OQ]4L;/?X<PT3C:OV^3
M:2A5(&RU/'M?OEFF:0I'1C/&4QDBT71U1648R5CQ<32:DTK,N&]NB^+[G;<D
MVK,V5<V9!N5+I6/I2QY'+CN,0;5;'\O=)NOMXBM8QH./ZQ&2#F1OE@>V*5;Q
M0NIYXNW4<"BV81S-G3Q_DK<M#9-QCMS@]S6+;_+6#<6I3+IDQ#&L&&1:=C@N
MV2[YX/6;%4XARTQNCDF6L%7C$:I*1T<DP:XILC25L59?61DVE;%&K_=]N KM
M3I67&V4\.V<VXB*W%(0F*;)%1M.J&VB1Q#C;)MTA)JXWUHZ7L[B$I]AHD-BO
M/C^_F;1;3(MUBE8=QCJ/2)77@6MF/AT;?YJ[6F\+N\A-W-QW,T3=+.U]M9F9
MJFYN=%KC^&"F?)'<(Z3'%EPFIFPY O5-556"PY L4O/&D&J2R+%O\UY^'CBN
M[HV1@>^Y4@8J\16\6OWF-AWM)53LE<WLV"K6_*4.+J9I$H[AP@;92:O-4-_#
M+LI*-".7C9UU8HV0>-E*GU?=-G^1DJ)@F:S3'X^R+9MPZ&)[9.YAQEBV.R[1
MJ_=-K.2\YTJ%;,L876Y[:+GDBQS=*3?XXEZC8[!475#%S'W.ON[JP3;SV-5K
M)NY',N5X->O9OKU3L6+L-[\J=)Y+@*$TGH'+X;>=S&$:O4;9'46=DSU&);VI
M!"3@\D.XL9'T<W&V2,QG,UID^(ZB@V5WK:)C/(.8D,W3<I<D+:WEL(S!&D=)
MQ2$$+K B>=DJ:4S->$=/!1>EW"7;\0E"0 ST6-<]">-!B_"3S>BX!I>/WF*'
MT*]L*ZN'L'J8"K!9%ZR63=TQ5;'RQGLT#>-:F=6'KQM @#UH=@R KB3#Y;RX
M;BTU:06^'<[D:VUNYU2K"RJ-?=;1(F<HK);;HQHMQ-N5Q]AZ\6![-77)^>:I
MF>(?D5R?*5["A*/CUU&3DY2G[.20R)(R$A#53X2[JMX$]4]N$,WFW$K:]T\]
MN5LS2R8>H6%6CW&M'V_S4/"5:D5Z*W"9*I]&M%JOD?(GN-QF)VR/I9K&0-P9
MTBD-&#(]AKH7P4V.T<V4[!>DLB9/94JT7B;R?.89BWU1B*D[R%9(M5A/32-Z
MBJ@SSE'PLO)+*6]_1X[*K6G+W ZLF:("/<.8=:*(/X9&/HZ)CX66S;FZ?85V
M@LL>TE$A,/5!.D,ZK?,=91Q=;()M0,355B[R-C'(^+*?<8FY61I/.;9(L#1N
M16=NK8IP:=K]J^3+EF+;YBK)608>NP=RME61D+ PJ5B@K56C/DGKU@+^$G*Q
M.VF =1TP@S1F&Z439[&S8%?_ "U*>EP9C(.+ Z"IE2VG1\5<J#DN]YAR_EW(
MU OUOR&PLMVDJ>S9.9*WXI-AM6%0J%.IU9J%9J\33Q[[&(IL/7SR%I5>VNS/
M)^9DY!PO+F%,/5? ^/(S&=.=33R B9BYS39Q8'31Y*&=WF\V6_RY%G#%C&MC
M((S5ID4&!"-"'1CDVB"ZCA=-5RM*^F@::::!K",A4&&R574ZS/+2#>/3LE'M
M)5(Q9!!U\QH-XKE^ADA4<-G:8M%YJL1Z$@GV056CU'2*"S9=1-RCF^F@J#<]
ME.);WC!GB6<E+V6K,V&X"-!:-GF,;-+-=R,)?X&_%/*(0W6@HS99'G35I=FD
MW5CUD(T7QI5)%TB]B*+^'-7&$K.6U?<#G!QD.1C<-(0%RC(_!U,)0)G =DR/
M/8XGJ73*'ARLT-J8K++>1*K<:_-UR=JU[K%ID&%BAUUDHUS'[&]-!1:V;%*S
M?:TT@+OF;-=G?2%)W)T+(MGDI2D*3628#=#4F%4O"$@W"CA 4LE:3@JJ_P >
ML,9PM.AJ^M6&320C9QA)V)O,YQ*;,,+SV1;ID.?;6&:_B!@57;Y:Z8[E4$*7
M)UA^Q/!3]K!G'1[*:99&LU-2B*#-VYC.MEU:978&(9-60L1<*VQTT%5-OFU>
M.P+)24NIE7)N47ZE7A*+7SWG\!0[.M4VOKG<LF*</C"CX^A;-8GBWI1FK_=(
MZQ7>32CF33YVU9>M;/<+:[%Z220L$,_R;EZ3P?-S>8+0VVY'GJ_&8QB;'G9G
M<VV2'(2T%6(K)\] O7>1K]/5RD6N_3M,IMDM!IFN0K):IX[)3;OZ:"DU=V25
MU"R0]VR/F+,.9[Q5U<:LJA;;^OCEI+URI8NNC'(,34D2T;'=082;>SVZ*B)K
M(-CF63ZWVQS#Q"1IR.8QC-FC^;MLKI#ZCS\569*R*3X9AW!;C*X28F&"<6KE
M?/&*LRXSF(R75:P97):.V99GL"L>R:BG,,7#:*<KS#\C1RV?7;TT&O&J?#_@
MU*;!P^4,S9IR'8:GB2JXMQ989F?I:=@P*S@I3']P4E\<6:#H$)(V*X'O>+\<
MS;B\Y7)D"=FD<?5EC.&D6KNVDM$ST#:O"5.UQV1[5D7(&4<HM[XK?9.^VU&B
M1+^;<H8RL6)*_6G$-1*54JY&U"IU.U3JL%$0T4P<FL,I)V&9DI>1E) [BT^F
M@US./AKXN9)LDJ1D[+E %Y6)NA7U["*8TDYK(5"E\HY-RTTK[J=M..)Z4H<C
M6;%F3)T=5KOBES1KS%P-O=)'GW<U#U6<KUG$MN5&13;)$D+,)6F=AW")">09
M*'_&@IK)!'J*'C#**UTJ:QBBV4,:44, **RZB@G.>?=-!KYF/A^0-@J6.,?S
M6>,T2E$H-?KM0<U608X:D(^R5NE6]_9:5VW$ABAY(X\ML'#O4Z(\R)B)Y0;Q
M9*M'Q3R>FGEUA8*WQ6P4   X#]1'^YA$P_\ J.O.F@::::".[YB7%.4E:ZKD
MW&= R(K3Y8)ZIJWFEURW'J\Z4$@+-5U2P1<B,++%[" %D(T6SL!11#N\I)@7
MAG=+P;CVLC$.:9C&H5"=EZ57#Q(52L0U?E9MU/1L+0(=6-1C$8]V^&QNXIA6
M&BK<ZB$JNS2CBHKF2XUDNL;YB'<O892=J^1?Q.ENL/<662H/$4G8F<CMI9UE
MI*EIZ.6I#+ZM/:XODZ6U>8DG\/ML:)W)UD]Z]M$+1G+YVSRT>)(W;]F-U29=
MMGO$.4,@1I,H;0<JX:A7\N^RJ^Q)MLIVYBKS;_;W/,VB3>2F,TXL@G=AN=ZL
M:7XFD+=3).'J;.U6O^$K+U@;G6V%,,L[[*Y2:8FQHVR=.*,U9K(J%!JR-ZF%
M8UNU:QYY.X)Q!;!(J1[5DS;,CNI%91LW:-D43$2;(D3S*3K-9FGK*4F*]"2L
MC&,)B*CG\E#,7SYA&6))HA/QS%T[:JN6S&<08,D9AFV4(WDTF;5-\DN1NB!-
M&#7#.Y1Z^NC9[7<O,LTHO]\BEXO-;ILK )Y&K-JI>:(K"\?(9XD<RN8:[4>7
MD+?B:4PM0:12V5IQ1*T>&9R,+C1E6IX)><,K[=KICMF_CL9X^OLKB)U7=G$M
MG"E5*5EI:V9ABZ5D/)S?-S%L9W8$I.T9'EX!]CB=R<\7D4;'EJE5^7JTK)VF
M2E6L*^"_Z^+=M&1YAG$2&*<16^9V_BPHT$WF<95>47Q4E*52MS[*N5!25KRB
M=<CG-2D:ROZ*KJ(1I6/H6:A2*,O3MLQ+C_$-%K*)6U"H=:JE,D%KZR91=,@V
M,37)F'C%RJ6J-C(V*(C'SC*+*X12E6#9.6(V%1L@L)#BD;3[(X?O#>8G):IX
M2R%6-MD[O&F['+8UMV,;-DM.6II]IF*Z%1LAJ8(A\CUFVDPG$Y4K%U]!BE5-
MS(UB<E:Q;G6(X]DP4-5?BEL29&-1YV.R]A+<7EN)L6S9>M[:JY&M72=SQ5E1
MW<<V.K159)S%91LC7"^0IBGW#!,11,B63(CW\/U+'<I69?),7.1,@ULH;?G>
M.L&Y>?8\R_+XYQQ?YN#8Q%EQ?D"Q4. F[/6FC\65CB)2H3DY#+6"M***BPED
M31R\>Y;O$T'0E1>H%.3)RXWQR5K$L"4.FD902MB6@VA:K"%:PJUP2D4+6I%(
M!']B,5LZ,O*HV$S,B!II.4D$Y,717SHJVNK+&"-Q=PV\XDQK)3*4G3EKQL-C
M9_'M&@;+2,EUBF4W*.&7&=TK=E>-RF+>S5U>J0MS0L<?!4NI+KUQT\C.](D!
M9.1B!MAG-['<S/I259R T?LMW^,K-BB^T>@NEXZ%VH0$#0U%*0RS(\RG 4>A
MXE8P-<N>/\DX46H;FW6>>GW\]7:U:)"PQ-UC@V78<H6W/^&5?D,"T'&M7QG;
M2HWZL&QWC^"I,.X>S4&,0WN+"*CH&'!C.N()0(\LJLP;RI(X"L5#E:%! /&*
MML.!<.5X8&D8KH,<X?TZOTFX65.BU)I:,BQ-;C$HQH?(<U&P3%:WNG!2K/'H
MRWJ&ZS]X^<D;IF<J@.G2$P5N*B8BGU6VTC(C:>1P5M4K6"I^J8J?W6=PQ9(9
M,D+DEK%WM#-5)IF(KG6KN9[D2]V*V0KB(N^.5X2O)2U_"*7QPSY6W8\W(V;<
M%5;%$XGS71%9/)^^"#S*[QA%3$;<%J1;,1YYJ6"'A-TM\R8K$7"'M5D3Q+;L
M05FL4*.QQ@.?D*XWMP4I6AKO)4-TJN%<,KWR1RJOB;&JN3I>,4@Y;(RM!JZE
M\E(5>,1AE8:0MQX@;$^BU8=NA%JQ[B05:GC4$F"B0LT2(%^N=Q'BBTP:M;LN
M,L?6*N+5$: O 3E)K<O#+4056*YJ4K$OXMPR/4Q7C(U8:T9N,/W6#)3T/6T;
MF3T=PF),]-:-C^#A<9W5/%%>R=@&5SLI)81OE6>Y4K_\$\NU2<:W':<EF=VU
MODICK*;W#5QSE:,66%E6\RR"+N7C:ED%MCY5*Q6+R7$Y"H7PIMSY5PRC79S\
M"[BIFA04HZ-C:_U6LS%KL;NB5RHKH7VZ2^-8Y.+<- QA'3=[6L..*U(5N#FP
MJ[NOK0,(&S"'PSARO7N1RC 8HQO!Y,EHM*$ELAP]"K$9>I.%1:1;!"(D+8RB
M$+ ^BT6,'"LTF#B05:)M8B+; D",>S(C[)O#N(;->Z_E"QXMQW/Y,JB*#:K9
M#FJ-6I2\5INW,_.W;P%N?Q2\]#(H'E),R*4?(MBHGD7XI%(=ZY[NJUYA*P9'
MMUOC<6XDS3A_ %E/M#B\CTN<5L>.)FXWB$W$0UQR?.QWIK8>9%M 8<0F:%G.
M[0\B6/S&6<:LFEBR%'P!Y='EX3%-\KV3I*/?8HR,OFA#>@QLU'S57T7S'&M8
MV<L)>-E8RK&MK9[#0;+'T)@UC)87DL$D:N9.3RNZ3M3>I/VKG^)+4-GEOP_B
M/(=62HM^Q=CR[TE&2+,I4^X4>MV.K)RY'#MV64)7YJ*>1!)(CI^^<E?$:%=E
M7>O%@5 [EP93'K/MSV\W1U$2-RP5AVUOJY4_P) O;-BVDSKN#HPM7K,U.B%Y
M6 =K1M4,RD9!H->9&1AP;/GC<K,J3IP130WMZHV=,B[.-O4QMCH.<\<;BI#8
M/E5#)&:KW:Y5E%Y!O=MQ!',,2!*727GW3/,5ML=_787W%EX;/),N'*O'2\?+
M2-(<6#\+OK%U;;K<L@V&)CHZF9DIF$Y3*6UI[<Z&A29_;[2I!I4:_GR;R6,G
M29G+M\N,^XD_Q!C"A9XL2YF5,RVE&UYDP>WT\18K"8-CLO2-H>0GLQ1YC%&(
M,@!D"^S![A&K8<A+K79K)&)Z\RAWCK(L@6HRM;:VZI5PK"OP[Z[/6LJ5D@C7
M8!POZ<6!)0E,&X2G;#2[=-8?QA,6O&S2-C\=V:4QY5']AH3&)<$=13.ES+N&
M5DJNTC7*:;B/;P;EB@P73(LU(@J0#AIOMFWW<+ O,RP^ ,>Y#HCR0R1\1J>!
MS5W2](CK!-Y3Q!3%<*62%E_Q-7(R0<3+H7L'2K A+L4*==&[@KJ1J;V.<R"/
M*AA^\R-=N+VO4G,%0QBYN6UM8^/T]LKM+'1YB!?WU_D2>N>VBSYNL61LOP'R
M2S4ZFYP>UV6BE;1-UFJWRD)Y!DZ-/STN&]$!Y#GSY_4! ?\  \"']PTU639T
MQML9MTQ_'7:C36-YQBM=6:-0L%CLEFDF%;;Y!MB5+?F7M]@M5FK[.PTTL#9(
MK'TW8YR0Q=$RS'&R\F\&I@J-F] TTTT#33308[(U"J2\@26E:S7I.43/!*)R
M4A"QCU^0]8E',Y6SD>.6JKDIZ_-/'<O"&*J!HF4<N)"/%N[756/@]UP'@S)+
M?TF1,,XIOK3\0N;;Z:YXZIUH;_BIY%MX1W9NS.0S],; YAFC6)<S(E&1<1C9
M"/6<J,T4T2RUIH(X<8=Q([R!%Y9=8OQVYRG!QP0\+DIQ2:RM?XB(!J\9?*HN
MXJ19K$PC?1R,@T]"TDDFP-7[UL"0(.W":G$SNW_!%HD:S,67"V)K!+4IBM%T
MV4G,;TR6D:G&.7 NG$=6GLA".',$Q<.1]0LSBU&K=1?\XZ8J_7J7=-!&"6$L
M,HW]OE='$N,TLI- D0:9)2H543OS4LPDZ0EBM[B2)+8D2RB3UXE(]N2*+U-V
MZ3<BJFX6(?TS&"L)V&9I=CGL/XNF[#C?M_P\G9;']2DIBA=EZA))?@R3>0ZS
MVK]N0:M7R80:[$$WK9N[(!7*"2I)5TT'"3%:KMA+T3T#"S9/12D;T2\4PDR_
M+IQJ#&:8=+UNN'HI=D ,Y-KQV)!J -W::R/T:^A&%AVTK(SK>)C4)N79QL?+
M3"+!HE*R;"&/(JP[&0D4T2O'K.*4F)92-;.EE4&)Y21.U(D9ZY%7D]-!AR6/
M*"W="]0I%00>#<5\AB[1K4(FY&_.HA2ON;N+@C$%AM[B"65A5[+U_.U8A52-
M4?&9',@.*1N <%0UJF+U$87Q/%7:PS3JR3]PCL<TUE:9RQ/64Q&O)^7L#:%2
MEY*:=QUAGV#F4>/%GSAE-R[59=1&3?$7ES300PAMPV]-I6ASC;!.&VTUBR-C
MX7&,NWQA2$93',/$KNG47%4203@BNZC&QSE\]<,&-?6CVK)=VZ7:I(JN%CGE
M:*AXF!9$C82+CH>/(N]<D8Q3%K',R.9%ZYDI!P5JS210*N^D7CM^\5!,%'3U
MTX=+F47754/R.F@::::!IIIH&FFF@::::#&G%,J#M9\X=56MN5Y2P0ELDUEX
M*+65D;164XE*N61\HHT,=W/P"4!!)PLRX,I)12<-$D8.6Y8YF"'I=42DOB2A
M'E/J[HDVPL,7,E<UZ(7++1EM,T/:8Z3*JS.$@QLIV#$U@9NP6;31F;49-)T+
M='HRO301O2\.8DQO%1$%CS%V.J'"5^3DIJ!AJ;2*S5XJ$F)EBK&2\K$1\)%L
M6D;)2L<NNPDG[-)%V^9+*M'2RK=0R0_/&X1PU#V>X7:(Q+C.+N60F+V,OUMC
MJ'5&-FN\;(G34?Q]OGFL2E*V9B].BD=XTFG;YN[.DF=RFJ=,ABRAIH*QR6SG
M;8^B:=5&F&\:0..Z?8;)9PQ97\>4:*QE8Y2TU![2Y)6TTAO70@9C_P -=(.4
M5%&9%P?Q<4JJLJBQ20":X+'=!J["&BJU2*A7HNNUI2F5^-@ZS"1+""IZIVBB
ME5AF;!BW;Q=;4.P8G/!,4T(HQF30QF@F;(B3,=-!%+K!&$7MKJ5[>X>Q:[N]
M!C8Z&HMQ<X^J*]JI<1$).T(J*J=A5AS2]<CHU%^^2CV,.\9MF*;UVFT21*Z7
M!3Z+;A3#=_I[7'E[Q-C2Z4!B^3DV='ME$JMBI[611,\41?MJS,1+R%0>HJ2#
M]1)VBQ(X(=Z\$J@>J<=R3M-!\C!@QBF+.,C&;2.C8YHW81\>Q;(LV3%DS1(W
M:,V;1N1-NU:M6Z::#=N@FFB@BF1)(A$R%*'UZ::!IIIH&FFF@::::!IIIH&F
MFF@::::!IIIH&FFF@::::!IIIH&FFF@_/241ZA*7G]> Y]N/?CGV\?T\:"4H
MAP)2B' !P(!QP'D ]O8!]@]M--!YZ2\B/27D?<> Y'GCGD?OSP'O^@?IH)2B
M @)0$!#@0$ $!#]!_;]M--!XZ2\<=)>.>>. XY_7CCW_ 'T$I1XY*4>D."\@
M \!X\!X\!X#V_0---!YX ?< 'C@0\>PA[#_;[?IITEYZNDO5_P W <_Y]_N/
M^=--!XZ2^!Z2\A[> \>>?'CQY\^/OIT$YYZ2\^_/2'//Z\\<Z::!T$ ! "EX
M$0$0Z0X$0\@(AQQR @ A_37%3L#!V:'D:_8X:)L$#*M5&4I"3<<SE8B29J@'
M=:/XU^BX9O&RG =Q!PBHD?@.H@\!IIH.6 I0YX*4.1Y'@ #D>>>1_4>?//OS
MKP)"&YZB%-R @/)0'D!#@0'D/(" B @/@0'CVTTT'%0,#!UB%B:Y6H6)KU>@
MHQE#P<%!QS.)AH:(CFY&L?%146P1;L8Z-8MDTV[-BT01:MD$R(H)$3(4H<J!
M2A[%*'GGP !Y_7P'O^^FF@\])>1'I#D?(CP'(B(<"(C_ $  _IXUXZ"<<=!>
M/ \=(<<A[#QQQXX#C].---!^@  #@   #V / !_;3330---- TTTT#3330--
M-- TTTT#3330---- TTTT#3330---- TTTT#3330---- TTTT#3330---- T
LTTT#3330---- TTTT#3330---- TTTT#3330---- TTTT#3330----!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g556684.jpg
<DESCRIPTION>G556684.JPG
<TEXT>
begin 644 g556684.jpg
M_]C_X  02D9)1@ ! 0$!A0&%  #__@ _1$E32S$S,3I;,35:0TXQ+C$U6D-.
M-S0W,#$N3U544%5473(P-S0W7S%?4$A!4T5?1E!/7TM?4$A4+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M]O%I^'KKI_Q5F]G]"]/;BT&#"D6C$)Q:O5JS.^T87?\ L^WC^7KK^2,W\V8
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MKXRS#MX:#RSQ:S>=_$8*1:,0P9?K?383SS\_<S>(_C4)[!#]R'LYX?ZWTV%
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M53Q17:S>=_$8*1:,0I[];Y["?\=<S\KA/7_Z'Y\=>P,,?T/GL*!D G7-#<(
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MY::#OSRTW#ED//C@$<ARY^/>(<=>W(! ]>O///B.OM]V ,\\N_AN#OWY]PX
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M7TZOV8EB=751TJAS$P:!Z50A]L(CF(!IYVCVD=I'97V0-I<C99C,Z-N+)?*
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M5Q!1%6Y7'KK,=*)7&4;H:IC;DXW'3;5-J5;NR1X@BXIC^ZR8Z(.K.%MY'Z;
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MT"MECYD7>I80^J3S*)"Y/=<J,)5H2VQL>(D7%I G9FFIU.3B%O72WEXH\RW
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MZ-B329!0Y*$A-:4NLXM.JK3UC2)BHFB@*NC4;492!%)GVW1I:K3,1S .F92
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M9<I[&M$U+*AK$#&Y.C\X855514-#"L$Y8!1@B74('#(&_P P%0ETF5)S_/\
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M>EZ"I1FR:&=J8&Q R,;:A9V9J2DH6QK;4Q2- @1D4A02F2IR:::"BBZ:0
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M-^?;]'#!V#S#GKW\,OS<0-VX.L?''37W=1H(<P'GIAX, N&GJ[/;P[\&67<
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MV1,_U0;R@XZ!E"ME??R^+4D[M  >T!T#/6P&W9<?;1L6N:[G6FG4%3;/U:E
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M7**9#*-GBP-FWAZ>8ZX,R-JD%,KMZO98 :K2%+HFF?[LW"3G1Q&;)R R\X0
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M#S[P XCIKEV^O773=[L&>[Z-W;RT[-_'!V;\@WYY<>/?UC@'QSW;PTW^.K
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M4QE]$HE%%$KD]-%$ED5-%%,A>::***'E=311332M *:::0"FFD RII  #(
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MSCIZLL^.# &89[\MV>?#33J#U<< [A[!P:<_;V^/S8!W#X]VOKX;]V U()6
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M+#\>,_J]^#G@%U:[O&O@>6>&/CZ\+7/=ID(^O/Y]_C0'7GV (9Y=_?EQZM<
M;PY]FF?,.KD(8./;D&77J/CLP]?HY_1GGZL+GKK[N[+QQP!GJ #O'?ER#/JW
M9^WUX!'W\-=!XCRU[?H>[Q](X67OS[.SE^?GH!S\#Q]_#UX. <=P#OSX=7O
M.>F#E[1W:AE[\&OC@/5IJ'7SP#RS$ S"D!$ $:M*0 1RZ50Y"(4TY]*H0 1
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M3@$,LPW;\P'377,!XAKGGNR[L&?U9<?F#JUUP!TL@Z0@-6^JH   JJ_JA
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M22=N6,TOG,.17"AL?J8%<>*D:]?)X,O3RUFI:FE>2L8@4K@.IH0K037YMO\
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MN##R\=_T^W!@$.[AGEV?7XWX-0#77=GW[_G'@'MP_'@-<(-VO'ARSX>/8&F
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=TK_^?@P8 ^!F[I9>9,RZ.[TI7EO_ +_@P8,!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g740367.jpg
<DESCRIPTION>G740367.JPG
<TEXT>
begin 644 g740367.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!#1$E32S$S,3I;,35:0TXQ+C$U6D-.
M-S0W,#$N3U544%5473(P-S0W7S%?1$%)3%]!5D5?1E!/7TM?3$E.12Y%4%/_
MVP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0'_P  1" ', DD# 2(  A$! Q$!_\0 '@ ! 0 " @,! 0            @'
M"04* 0(&! /_Q !K$   !@(!  ('$ X&" (' @\! @,$!08 !P@)$1(3%R$Q
M6)<4%1DX.5%V>(&6L;2WTM35%A@V-T%45W%U=Y.UMM$B89&2F-@C,C,T<G2S
M\"2A)28U0G.RN"B&0T1&4E-B8V1F@H>(E<'3_\0 %0$! 0
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M,<#BW2NOJ]:IE1^S='+'/H2R/I%:38P\,\<-H2"<H5V1D%Y9N\=J! HE,'A
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MN;&,8#&,8#&,8#&,8#&,8#&,8#&,8#&,8'Y)#_V?(?\ (/?BJN=FO.LI(?\
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M\3#JP2,)VV(C"(LG,A6J]79.PMF48VG7;J.C6<:E:7H"G2G>+2K[^:G],QZ
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M*%'_ %'C[4RP^-;RF\H4?]1Y9&,"-C<3; 4IC#RMY3]10$1ZMA,!'J .L>H
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M'[7N8_C]# I[&,8'YW?^Z.O^76_Z1\G_ (F]_CGJ41$1'[%R>$1'_P#'WN4
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MX<MF^U;(3HOJE')GVE?"KY:^=&79EGGUX_(#&,9 QC& QC& QC& QC& QC&
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M#&,8#&,8#&,_FLJDBDHLLH1%%$AE555#%(FFDF43J'4.80*4A2%,8YC" %*
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M+!FM&U5F_39'D%$DG+YV@U0!1RJD3*/.<I"F.<Q2%* F,8P@!2E .LQC"(@
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M<HL5#NC6-FV:@>51X??WWY>'/ZZ;A\ANS<JQ1--8ATE2$434*8AR'*4Y#D.
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M]N_=2^!FRK?<U7A_#YQQ'?\ P_\ LYMG/9P-6^YJO?H.(_=S;.>P/'4']?\
M:/\ /)'D*;45><-2MZM7KZEK2XTWM!*S'B&)IY-%OLJB,T$B2PH"]*1%I)2#
M5( 6 4V[UT@00275(:N<FIYZ;^K>UNV#\J6M\"E<8Q@>!\'NE^$,CG@'Z4W4
M?Z,F?XBE,L8?![I?A#(YX!^E-U'^C)G^(I3 L?&,8$H;^^_+PY_73</D-V;E
M7Y*&_OOR\.?UTW#Y#=FY5^ SXF:I$"[G#7MC 08;'CJS,5V MCB.24E6C&2
MCGSK5=E.@NXB5)%NT=*QZK@J';$A.F9%0QE,^VQ@:"^*FU^DNM_+#>\->-2:
MIJCI>%A?LE?V*,M4%!0+6(20CJ')1RL;(V-*=D;/!@,DXA6\Z(DZCF=#7R D
M53<7.47:MJI,+!O=RO:+;$7HN+#;M65&ML3R3,2K $9&QFPVNQV<43^FEVQZ
M8KQT8R(J(BW[9V!/A=;^F:Y'!^#SLU+_  HG_(,J/ P/5= PM>D8N;E=A;HO
M,[%NTWI)"V[7MQF#IPCUB07U/KKZOT1VB!Q$_F92K^9^RZNI/J*4"SUS<XYZ
M'F>.?)FV26HM?.+7,ZZLUCE;26KQ:%G?3T'&&?1,NXL#=NE+'?Q[IFV5;.?-
M8*)BB0O6) [$;]R:N9'I4^0WZH+W^X7>!EC5U0K%"UY3JE38..KE:A:_&MXN
M&BFY&K)HFHW(X6%-(@!UJN7*RSITN<3K.G:Z[EPHHNLHH;[W.&KGW/0/Z&B_
MB*&<S@,F%]Z<&#]KW,?Q^AE/9,+[TX,'[7N8_C]# I[&,8'YW?\ NCK_ )=;
M_IFS5#Q-X?D>;AI?,J=G:S.L)OBK0=$Q5 D:<1V_K:U"V%:;U'WV.M3V0=II
MS3N2GG,<HQ;0K/S&R;-G+:4.Y[-,=KSO_='7_+K?],V3_P 3/2Y:E]BY/C[[
M UT[&Z++85P9[LA*_P BX*L5_?'*[D%R-N;1UJ(TW(D@MY\<T=$DUY&3C>[P
M4W'#6'L9%V]W-1,I$L;NF*]3N%=E*P52*D?KM.]&?8]835QCY'<D!9M8[GXS
MZ1TKN:KJ:W<L[6TO&DN/KWC>PV+I2[%N)PUTG::#)N0F8V6@K5*L7S9,8B<;
MMI"01';AC T]U+HR+56];<3X%?9&JC;%XF;HUSM"-O-7TP]IYMU16DM)7+0N
MJ(;;X!>I^1<6%I3+0V\^K-"NTHYF,8,;5JM%1SQ8A<<PG0J5&KT".UA"[FG5
M:U9]<<=]=[BDI"OI#.SB?'CE?9>7<;.T)-&3&-I[RX76X6&HRK%XE,,X6M*Q
MDJP.]L3!TO)[RL8'@H=B'5_68?[QA,/_ )CGG&,!C&,!C&,!DZ\M?2X;>]B+
MGXXRRBLG7EKZ7#;WL1<_'&6!EQQ]PR_L55_<ALC7HL/4VN"/M2]"_)U!993C
M[AE_8JK^Y#9&O18>IM<$?:EZ%^3J"P+W'P>Z7X0R ,O\?![I?A#( P*ET-]Y
MK6?L,@OBA<RT;P#^8?@S$NAOO-:S]AD%\4+F6C> ?S#\&!J?XL^JI=*A[$N#
M7R777-L.:GN+/JJ72H>Q+@U\EUUS:):((MHK<_6S2TW!%GX:3AC35;D/.JPQ
M)9-FLS&2@Y,$7 QTNR!87$<]!!86KI-)8$CB3L1#2)TA/,7E'J+D5)ZTU7N"
MNZ@H\9I^G6UNNMP3W[RNF)Z>LDI?&DXY6MNM[+6:M3B0K:NPI8N&>%F)%VH]
M>23])NS;MT7FY744J_G=4ZSFY267GI.8U]2Y60G'48I"N9E](UJ+>/)5Q#JD
M35B5Y%PLJ\6C5$R*,%%C-#D*9$2AUZND<KRU7W-7Z+"7OGA,.*/QLU["/GNM
M.D=TIQ>@I*/@D+PV1M=^B-BOXN?N-RGD8IU]E=^%DA&2TFI&0S(OGJ\%J/8(
MTAYE[C&I/,+U629=S&@>9)%:6)/+/VOV)0_F=ZK.)@"<RHZ1[!=26( $D3J"
M\* %6 ,#*&,8P&,8P(3HOJE')GVE?"KY:^=&79D)T7U2CDS[2OA5\M?.C+LR
MSSZ\?D!C&,@8QC 8QC 8QC ^&V- W.RU.0B*#>4]<V=RHS%A;%:RUMQ(\B3I
M-1T08)[(Q3=WYK;E4; 8[U(4!4[<4#F(!!B[BX7DW<[-=IK8'(R-LM:UMN"Z
MZW>51IIV%@36AE66D09M(J3B%J>.(A==65,=1!!F\(4&Y"E4'MAA#82/@]TO
MPAD?\0?]WY&>VIVW\4J.!8.,8P)FY3?<;0_UUZC_ (RCL_?R0N%RAZE"T;5[
ME)GM3;EB0HE+D5%$@^QE%5NZE;=>U$E$U@62I53CY69;HG2,@]FBP\2J=,\F
MCV7X>4P==.H8>ONS48?VW*.SZVKL:)LB^CN&,&8D)2DM[OJ2%</@.E!-#M;0
MDWNTC7&Q@$CE:1EZZSAW4XF<2N&T&1JU[%$5C+!E^/:J,F#)FJ[<OU&C1NV4
M?/3)F>/3H)$2,[=&2(DD9PX,45EA333(*AS"4A ZBAQ]E;6!Y 2[6JRC"$L;
MABNE#2TI&'F8Z/D#%ZF[IY%)O(\[]ND;OJ-2O6IE0[P+$\.<YC ANDZ(Y2UG
M:=CV1*;\U;+%NX4%E;XAKI&1CO-,/0TIELT;0[T^QW8QKU\WGGP+O%T7Y$E2
MMS)-RD(=,]R8Q@,G7ESZ6'?'ZK[=^ZE\HK)UY<^EAWQ^J^W?NI? S95ON:KW
MZ#B/W<VSGLX&K?<U7OT'$?NYMG/8#)J>>F_JWM;M@_*EK?*5R:GGIOZM[6[8
M/RI:WP*5QC&!X'P>Z7X0R.> ?I3=1_HR9_B*4RQA\'NE^$,CG@'Z4W4?Z,F?
MXBE,"Q\8Q@2AO[[\O#G]=-P^0W9N5?D$\A]PZK9;LXLM7FPZ@V<U3=-O&S-U
MIU@1: +W%]AL>RF$Q6[*.(+UZU:%.[!(AG+A) IA4.!<N&#G(>RQ+&=@)-C,
MP\DCYHCY.,<I/&+Q#LSI]M;.43&263[,AR=F0PAV13!X0' Y7&,8$N:W],UR
M/_1FI?X43RH\ES6_IFN1_P"C-2_PHGE1X#)JYD>E3Y#?J@O?[A=Y2N35S(]*
MGR&_5!>_W"[P,^5S[GH']#1?Q%#.9SAJY]ST#^AHOXBAG,X#)A?>G!@_:]S'
M\?H93V3"^].!!CU#U?:]S/?[$>K[OT.]U]7A_J\/]N!3V,8P/SN_]T=?\NM_
MTS9/_$STN6I?8N3X^^R@'?\ NCK_ )=;_IFR?^)GI<M2^Q<GQ]]@41C&,!C&
M,!C&,!C&,!C&,!DZ\M?2X;>]B+GXXRRBLG7EKZ7#;WL1<_'&6!EQQ]PR_L55
M_<ALC7HL/4VN"/M2]"_)U!993C[AE_8JK^Y#9&O18>IM<$?:EZ%^3J"P+W'P
M>Z7X0R ,O\?![I?A#( P*ET-]YK6?L,@OBA<RT;P#^8?@S$NAOO-:S]AD%\4
M+F6C> ?S#\&!J?XL^JI=*A[$N#7R777-H%MEE8"K6.<1,W*M#P,S*I&=%.9J
M"D=&.WJ8N"I""ID .@ K F(*"F!@)_2ZLU?\6?54NE0]B7!KY+KKFUU9%)PD
MH@NF19%9,Z2J2A2G3524*)%$U"& 2G(<AC%.4P"!BB(" @(X'6"T9S,XH71Z
MM8.7G)VC<K=>[ZX\Q&R+5#WWC1.'A]8; 0LU;M#/5.O;%'ZV56<ZY(SEGSV(
MK=E?RSY.2J3.SM7P&>R0AV5J)8(2V4BG6FM(%;5VR56NS\ V*W*T*WA9F'92
M44B5J0B9&Q4F#ENF#<A"%1 H)%(4"@4(WY#<V]$<-WYZ_NLT54J VKU-9T]"
MG23>Z7635EUIJ*<0;31%51<[#2@(9K%1R4=+0$%.QT@FZ>- ;L2Q"@K5GK&_
MT395.A[-KF0(^JSAHW2CTQAY:MNV""2)"MV+ZM6".AYZ 71;@EV,;+1,>Z10
M%(?,Y4S$$0R!C&0'R%Y@WK0G)#C7J9SJFK66A<B=E,-31<ZVVU"1.SV4](0,
MS8'=OC=7R<:B,[K^J)0AX^TOT)].51=RL4JR9*IJ"DH%^8R,>=W,*&X2Z!EM
MT/ZNXO,BVLNOJ[%T]E(HQCE\6[;(INOWDRN[5(L+6)K@W!I(R#@&ZH"H9DQ'
MM1WZ:A*6G]D46F0L7.WRY5*C1\L5L5H\MMDAJXR7=.&Q'/F1L[F7K)!PN4AA
M$$DE#*"4HG['JZQ )+HOJE')GVE?"KY:^=&79FNK3%ZI-_Z1?E#+T2X5:ZQ3
M3AOPLCG4G4K#$62/;2!-R<X7)V+AY#/'K9%X1NY;KF;**%6!%=%42=K5(8VQ
M7+//KQ^0&,8R!C&,!C&,!C&,#P/@]TOPAD?\0?\ =^1GMJ=M_%*CE@#X/=+\
M(9'O$0Y$VO(Y0YRD(3E/MPYSG,!2%(5G4C&,8PB %*4H"83"(   (B/4&!8>
M>!$ _P"^L?[ [_Y_6R>!Y,4"7NRFN]=M;%M2T,3-33YJ+%>;JO5V3I8J(/IR
M[R"T=4C%2,*A5HZ#EIN<253,DO%(]\X?QN.C)_9MN=N=A;/LC[5Z3DBT9J.M
MI)U.$? 1 B9T[K/Q2R5AMK%58#./.1PY;1)5"HF%-0R8]D&O_I7N3,U3-*U:
M+TPO$6*9L-RDVZ5O@W#NQA4KG0G5=>QE?:A6TY)HWN,FM++J1+6:,5 CJ(.T
M5:*NG"14MGVE*O$4S4>MZQ Q+Z"BHFFP"#6)E%CN)1D*D>BX<)RKA0 4<RAG
M2RZLBY4 %'#PZRJ@ <XY@_?E*J%'UKKROTZL0-8A&N[]2+H1<%%,HQD5P:X1
MQ5'0HM$4BJ/%0 !6>J=F[7-UG67.<QC#7X>#W3?".!YQC& QC& R0^;&Q=?U
M3CSN2O6>[U*N3TYJVV'A86<L43%2LN4S!PW*,9'OG:#I\!G!3(%%LDKUJ@*8
M?T@$ KS/EYZD4RTN&[NRU*LV%TT2%!JYG("(EW#9$QQ4%)NM(LW*J*0J")Q3
M2,4@G$3"7LA$<#Y_5EZI-ZJ<8YI5OK%O;1L;$,9!Q6)Z+GD&+SSJ:*^9'BL6
MZ=)MG7:SE.+=8Q%0*8!$@=>9(S@8"JUFJH+MJQ78*NMW2P.'*$%#QT.BX7 @
M)@LNE'-FR:RH$*4@**%,<"% O9=B !G/8#)J>>F_JWM;M@_*EK?*07(JHBJ1
M%44%CI*%27 A%114,0Q2*@FI_04%,X@<"'_HG['L3?T1'(U7XX[P6OS38P<J
MIM.PL:I*TMJ8--ZQ,U) S$Y%3[M$Z!D^I1P+^&8]K<"(&*D10G8]:@FP+/QG
MY6*+ENR:(/'8OW:+5NDZ?&02;&>.$T2$7="V0_T+<7"I3K"BC_HDA/VM/^@4
MN?JP/A-@[%K.LX="=M2LDE'+OD&!#Q<+*3BX+KB(D[-K$M7;DB0 41,L*7:R
M '?'K$ R.^C\V!"K:.U]J]Q'VJ'NE=@9=Y,1,_4Y^#!HD:?=*%*+N28MVBBI
MR/6YR(IK&5,0XF @@0PA?PAU][O^X(A_Y@(#@  /!U^Z8P_"(X'G&,8'RSJC
MTQZX<.WE3K+ITZ.*CERY@(A==PH(@(G7669'56.(@ B90YC"( (CW@SGV3)G
M'-46,>U;,6;8G:V[1F@BU;($ZQ-V"+= B:*1>R,(]BF0I>L1'JZQ'/U8P&,8
MP)<UOZ9KD?\ HS4O\*)Y4>2YK?TS7(_]&:E_A1/*CP&35S(]*GR&_5!>_P!P
MN\I7)JYD>E3Y#?J@O?[A=X&?*Y]ST#^AHOXBAG,YPU<^YZ!_0T7\10SF<#P8
M.R*8O6(=D AU@/4(=8=76 _@$/P#^ <D%WPNUP\L2EL5NVZ2V$[%Y%DE$MHS
M";E"*?/E))>,;F!MU),?-B@K$0 ! ABD #=1<K_&!^2/9DCF#*/35<+IL6C=
MFFL[6,X=+$;(D1*JY7, &774*0#++& #**"8XAUF'/UXQ@?G=_[HZ_Y=;_IF
MR?\ B9Z7+4OL7)\??9]AMW<NNM,0+68V/..X./F7*\3&K-*Y:;(=P_!FLY[2
M9M586;=-R]I3.;M[E!%N(@! 5%0Q2&G?@]N[6UZU+1]>UJ9E'5OJ=.([L$/(
MTV\5P\<CYZ*HCV3NS5N&8.% 4=H%%!JZ77ZCBH"8I$.<H7!C/ B  (CW@ !$
M1_J#PY&SOGIQO9;?-I9S8K>E9&^W6>@96QGU?L<FL8'=TS!0]DJ^JYW:IZR6
M@QERN$//PZ]5C5Y[L)AW*1,0FX3F9N#CI(+*QD3[NYZ:/TQ7=SSY3V;8J&A-
M7WW9^T'FO8)S-U2G(4FLN+"TIUEV"((TJ(V%<5TVD-5Z($P]MZSF1;RDE!1U
M=2=3"'PNO>;%LBV7*V(Y)ZMB==;"XH:=J?(JW0>M[B[V%"3>G[]3]C6R 5A9
M6=K=)>GM\)(:GV!1[)&JQGG2K-0;*9BI(8J=2:QX;$L9J";](ON>/L,?H^W\
M?Z;"<G=FFXXR^F*<PVG*R>NEJ=R8C]UR\?,;$N3BB1DW%/\ 3+#C[LXNRX^K
MU>=3GWS.LM*8Y#[)CJ0O!R_2@[-[G]WN%:XY0LI+<8M?;@V5S-K+[:X,E:+&
MZ-W+LG3%MK.HY!O47B5_LED4T[L_8]$<V9&EPKZGUR*AYUQ#66S@G!AN9QD8
M47E+9+7S,V+Q=E-;1D+6:[Q[UWR#H>RV=Y\_7=[K=ZO=MHG8OJDG6HY&I$;/
MZF\78E-8IYX^:F*X=HQG;$FX6?@,8Q@,G7EKZ7#;WL1<_'&645DZ\M?2X;>]
MB+GXXRP,N./N&7]BJO[D-D:]%AZFUP1]J7H7Y.H++*<?<,O[%5?W(;(UZ+#U
M-K@C[4O0OR=06!>X^#W2_"&0!E_CX/=+\(9 &!4NAOO-:S]AD%\4+F6C> ?S
M#\&8ET-]YK6?L,@OBA<RT;P#^8?@P-3_ !9]52Z5#V)<&ODNNN;0+:-H+5K&
M:D><?V9%@I8U4"S)O5JZ-C*P7-"%GDXURTD30YY(&Q)(&+E%X#,RQFZA50+U
MZO\ BSZJETJ'L2X-?)==<VB6B/F9:M6",KD^I5;!(PLHR@[,E',)A2OR[IDL
MC&S18F426CI,8QX=%YYWODCM'H(BV7#M:AA .OK)(=)=2+ALSD?L<O0M4+=U
M6TSKM3=M\L$'R)6?Z\HD4E>)BG,7MUL6T63*)K#67<W\8N53;Q:,RJ@Z=OFH
MB@@@GNNX_P!4J[:H--J1\77T[MO*NT'86S;+6S/O.RXVEQ2(5N$TS(^5,=&-
M%MU$BD2HMNP8&1!1(%>RZNM_S*X^\GVUIL,9R-YVW?:P\=..$7RGV/; X;<.
MZ]K"U0U>M9ZV_@G%.EHI\?8#NDCY];%JE3O+HT'"/TF*4=/DGGH/2=G#3;QM
M(ZBU:_93AK,S?:YHSQI9#Q18(]@;.:O%+H39H0@B2'-+)')(&BR")8X7 LRB
M((@(ADG-?/)+AO:.5FS*&?:]HUYW%]1;BU3O35K*N4>8C]V0=TURVD3NXYUL
MAS97D,6N3\I(&773AJM%RA(TJD6Y?NTESG#8-C U2\Z.C?L/._1CZEWO>URU
M[M9P-6C26?5%HV52M9/:Y6-RUK9R#.R:MC+H5C99=-A!*L8N:DWJKB&L!XVP
MLR]<0S:$V/Q>NZVVJ%8ITVU&Z,JQ$1D6V>WDP7*6>GC6*3()*4E;"1\\DI9T
M5(57DFZ.9VZ6.=18XF,.?=XP-?FK*_!5SI'N3K*OPL3!,UN&/"IRLUAXUE%M
ME7 [GYQHBX408H-TE%A2123%4Y!/VM,A.R[ A2AL#R$Z+ZI1R9]I7PJ^6OG1
MEV99Y]>/R QC&0,8Q@,8Q@,8SP8Q2E$QA I2@(B(B    '6(B(]0    B(B(
M   (B( &!\!M6Z,->ZZN-QD91"'1@H"1=MW[A 794Y,S=1&&129%_IOW+N65
M9-6D>F J/G"R;4@"*N:F>C'UMNJ^ZMY4P'+(BTY7[WNN71?TJ>E4W4JWL'G3
M".[XWDUH=)DHQ9R#M:) T.#YTBV*B:/1[0@V6*XV.1"]$Y+I,[$[@I&2I>N-
MGK/:-*+2SM& NUBIIW<0XL80C8R32:@8&QB_:P9Y<'C5>;ASS+)!,S)DX4^(
MX@]YOR,]M3MOP]\1_P#"5'OB/X1'\(_A' JN$@86MQK2&K\3'0L2P1309QL4
MS;L&+5%(A2)IHM6R::) *0I2@($[+J#OB.<MC&!,W*;[C:'^NO4?\91V4P'@
M]TWPCDS\ION-H?ZZ]1_QE'93 >#W3?".!YQC& QC& QC& QC CU>O_8(_!@,
M8Z^OU_= 0^'& QC& QC& QC& QC& SYNW6ZOT6OO[1:7XQD'&%3.]>E9OY 4
M2K*D03$&D6U>OE>R54(7J0;*B'7V1@ H"8/I,]%$TUB"FJ0BA#=7610I3E'J
M'K#K*<!*/4(=?? <#7KK;D-J,>1NZ9(;+($87%/5<96GBM,O2+66?-X)O&.$
M&[A:LD1+VA\J1LL=91)-$_6*IB$*8Y=AN?C"/8E$H@S:@)1 2B#9 ! 0'K 0
M$$P$! >_UAU#U]_/V8#)>Y/ZMW1N.ESNN]<WS7]+JUSJ4]5K<I:Z3.6F9,G-
M(^9 =03F+L\$T8G0:G6*)'K1\514Q#AV)2B4:AQ@8=T[![F@(E\PW!;:#;%T
M"QC:NKT2HS=33:,FC51!V652FK'8C/G#@Y6QT56QVB:)2+%,FH*A1)F+&8=V
M]N-MIZ)-.R-!V/<8EM'2TO*O:)!1TRE!QL*S6D'[N6!]-1)T4R-&ZRQ 0*Y.
MH"8E*3LQ*40S%C,&:0WO%;V@VUGKU$V55ZW)PD-8H";O-?80C&R1,ZAYJ8.H
M46LU*++ 9J9-PJ5RBU,FDLF/4)A,4N<\ /7U#U!UCU=X/!UCZW7D8S/([>,5
M?(K7Q>*\@[E[!#6ZQ0*Q=O5%%J_@Z9(5N.EG:QCQ!A9+F6ML(9LS5[-54JZW
M4;K;F[*SLG:U 'VT>F.\'WE>07X/_P"+>/W\Q_M' SO$.7K^)C'DK&#$23M@
MS<OX@[I%^,6]7;IJ.8\7J!2(NQ9K&.W%RD0B:_:^V$*4I@ .1 I0\  'Y@ /
M@SSC ]3@)B& /")3 'X.^("'AS5/5^!^Q;=N/:]FVSMBRQFDWW.:)Y85;1</
M'41]#VV>UI7]1R&IK%)79.,4NM?@V&QZ(C<9ZA"\44E[#5H1P$E$U]_-0D]M
M:Q@1)8N!VH)BJ;0U;#2ESIFBMUU'9%1V?H>N2D>IJV23V=&S3:=GZ5!3L5,K
M:AL))>=?6GLM5O*I796S+*35@K<K)'\V%Q_5> #YJPV6?8_(G8&U+/OAA6]=
M[^M,S3=;P#K:''JEZLV7K.KZ.!E7X)NWID:D\V=.[(F[M4U&%REM@.I)5J]A
MJG)%JC'8WC U61_1DJ)M#6Z=Y,;-L_(FLR&AQU+OV3I^N&TMKVN\:X_8\/K.
MK.J5%0S*KW&-FXK<6UVVVUI+S O?%[W(/8G["G$-51@?R2_175YY4"TV(Y$[
M@@V.QJ3L?77+*23C:"]FN4%8V]MBT[IV,M/O5ZZFGKZRR]QV#LF(B)ZE-TBU
MC7NPK#4HB-3<L:I/US:]C GB.XZ5J+Y/S')]I,RR=@EN/E-X[_8D1".3K3*M
M4K8MSV+&R[4R;<LB645>W1W%JH"X\[R1[)H*2!7 JJ&H?&,!C&,!DZ\M?2X;
M>]B+GXXRRBLG7EKZ7#;WL1<_'&6!EQQ]PR_L55_<ALC7HL/4VN"/M2]"_)U!
M993C[AE_8JK^Y#9&O18>IM<$?:EZ%^3J"P+W'P>Z7X0R ,O\?![I?A#( P*E
MT-]YK6?L,@OBA<RT;P#^8?@S$NAOO-:S]AD%\4+F6C> ?S#\&!J?XL^JI=*A
M[$N#7R777-KRBB:*9U55")))$,HHHH8I$TTR%$QSG.80*0A"@)C&,(%*4!$1
M  $<U0\6?54NE0]B7!KY+KKFSJZBW"GVH7<.>PM@K<\+B!3$Q5)I (EX*T20
M2"!P/))=FQ*)1 P&< )>^ 8'7_Z5M2#DMFSUFN>IW^]ZNKQ3A'O%JJT+CE8]
MV!LGD:EMQC*1%2MD[ Q4Y4[/2)MD2"%6HW95C48N(6F;@=\V>(-9%IO\HBT\
MXI%.7M,(PK5F7JU>6L5=BE$UHR!G5(=D>7A8Y9(3)JL(J1,Y8,U$S"0[=NF<
M@B40$>KO)<L^0>KJ-Q_AXMEJSH7=+NZ]JME24-Y;1D^5&PIVKJPD61+6]>XQ
M5YY8:UKJ*AVPM8X)2>N%2MJZANL8QL*<@<G:=@7*CR#AG:LBUEU745'.%)5D
MS4CV<FHNS15/(-&"KEXHR;/3'%RW:*.W1VR2I$3N%S$%4P<MC&,!C&,"$Z+Z
MI1R9]I7PJ^6OG1EV9"=%]4HY,^TKX5?+7SHR[,L\^O'Y 8QC(&,8P&:]-T<=
M-;*;HTGV+K9[5+9-^O![DSC]X[HC(Z5*G1[!.I()1T??6S**:HRK=!T@UAT8
M]NAVHJ**1$ [5FPO)HW)]^?BS[.[W\F-EP,^UR C:M Q-=B >%BX5BWCV(2,
MI)S3X&S9,$T@=2TR[?RL@MV(!VQT_>.72QNLZJQS"(CB/;D%,;<B'.M:-LAA
M5"$GHAIMEU!ND75Q8TIT@X=OZW%=H%0U=F+:@D6,\]W(MWD9$.7LC&E.[30
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MB& BI2&$I@#J'5KQ9]52Z5#V)<&ODNNN;8<#7/QPXE\#N <34=?TR,H<3L:
MI=8;/-E[,E6-JWI9H@LA%4AE9K+?[.=]:F\;+V5PR8E3:/8FHM9E[YEC(]@4
M>U$V+E$#% Q1 2B " @(" @(=8" @(@("'? 0$0'P]>==+I.(1W>>5\]JNK6
MFXZ51WCQ>K.@=Q[Z;\9(+;U-C*=>;Y9INKZ^1V ^N%?7J&Q[T[K\Y7:,SE8V
M3K[27EFDZ82R#5NF?<5Q)W%2]IZHK4?5(V?K2]*IVN62]1N$U&SUQB*W/T2#
MGZ#)S\G%/'S9ZXL54<M'QGOF@ZCA\E)$7ZG""H8%29XZPZ^KK#K'O@'6'6(>
MOU>'/.:BN>.\-I\>^2O"B3B-G[.J>N=O<B:MK38*_<U1L_'R(I$M!S+8E1NL
MS'(.+! [.V#<"19*';%'#2OQK9G)Q\R" KQBCL-N@B =76(!U]X.L0#K'U@S
MSD#=(&ANEAI.UW'1^[K5J_9<#!BWTW6ZK48JV!L#=3Y^4E0K%JA9!)PYLE2G
M5$RQ$S$Q@QJ\-$J2]P4D3(0JB YEV/O>6TAK:BV2\:JW-LJS33*%86*#T#JN
M?VO)15@/#MG$TX=Q%=-YH80J4GYJ00?*B*/>33[XF <#$]%]4HY,^TKX5?+7
MSHR[,U5<4MU--Z\_N5EJ9ZUW1JY.+XD\+H T'O+6,]JFSOCI;:YL2 RL7 V'
M_P 8_@C@_!HG+(_^&,_:O68"*K10<VJY9Y]>/R QC&0,8Q@,CSD[>*SKB]<>
M[M;I)*+K]7L6RIV5<&_TK@&,=JNSK+ T9D$7+YTIU%1:M&J:J[ERJBW2(955
M,IK#S1;RUTG+;ZZ2K2D<TESHU*I):CE9R9E(YY)LZM;:-+7O9J=9I0$E48U.
MQV>OL8PUO,Z8E/'0TE6GXG?=M1;)!M0T-';#E$++M79;V5CIC9RD4]@]:+.4
M5(?6-,B$WJ=9ATTT>V=NMDPS?FG+S("X42-,.DXEDF1C#(*N*"SU( %*4H>
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M]1[2KK;1<5+6+HZ.47+^VM7M4L-@C)'8/&3:%.I)*M JMMB11H6MWEK-R9)
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MA$&[6&B6S2*)!-6\8P0;0B:39%.';HM$4T8LB+,QFB1(],I694VIC-TRH@1
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M<Q%?F52 11UKO7B1C4O7J;8@F:L7,%%EL)F78$EY^6=%.[4J<
M      \ !U>  _ '@SS@2;RI "K<:P    Y6:@   .H  &UL    [P 'X
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MW(W9WNL.O_7@OP>'\ _V#ZV!:N,8P)7YK>EEVA^CXG]_Q65*G_LT_P#@+_\
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M=C_X@(PTB1-\9GV?^Q%V0JXE_P!H4![V<Q@>#> ?S#\&19P$]+ZM^NSDM_\
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M1$;8I",J\Q8S1]LB[-5;/2WWV30[:OV4X=A7L0]<W]\_SL=B'KF_OG^=GMC
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MT;-(1!=9;NH^U)$CDBZPRD?5#/3+Q2()G "+NO-1>U*J]DD02F$2CUCF>0(
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MZ@LMZR?<_.?H>4^(.,B'HL/4VN"/M2]"_)U!8%[CX/=+\(9 &7^/@]TOPAD
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M,%]@;"=QGG++0-:F';MN:8L$<[<]AT.^ =?5X \'@]S^KUL#JXPVJFW1??;
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MI5.0_+>>DJK9-D:V6</(+4''+C,D3S%*W_=U^K*3H=5BY:+1@:V@&4+8)V:
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MAD 8%2Z&^\UK/V&07Q0N9:-X!_,/P9B70WWFM9^PR"^*%S+1O /YA^# U/\
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M#&,8#&,8#&,8#&,8#&,8#&,8#&,8#&,8#&,8#&,8#&,8#&,8#&,8#&,8# @
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-'O\ ^B;?W5_I&!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g951646.jpg
<DESCRIPTION>G951646.JPG
<TEXT>
begin 644 g951646.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ _1$E32S$S,3I;,35:0TXQ+C$U6D-.
M-S0W,#$N3U544%5473(P-S0W7S%?0TQ)3DE#04Q?2U],24Y%+D504__; $,
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M2?\ R'I'\+,>'$Z6#UU)_P#(>D?PLQX<3I8/74G_ ,AZ1_"S'AQ.E@]=2?\
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MD_\ D/2/X68\.)TL'KJ3_P"0](_A9CPXG2P>NI/_ )#TC^%F/#B=+!ZZD_\
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M[_.,+[&QWB1>F.]_G&%]C8[Q(O3'>_SC"^QL=XD7ICO?YQA?8V.\2+TQWO\
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M@M<3QKDL@B $YZTI)VP"1U0'%%".=(PO-"!-)6I I. WN:]H&H3H5VP$GBT
MY.:=8'&,8QC&,8QC&,8QC&,8QC&,8QD!U]Y[;]^*?ZFK\RU)_*&=?"5!]28A
MG54EYCJ]^ ;5^[\<=O,'2W]%L$^K+;DR8WO6M;WO>M:UKKWO?BUK6O+O>_R:
MUD$0CE!QULAHM%_@UVUA)V2DU:]';KJU3-C/05L)M91R14JFBH2LLF/MFHZ6
M;($[PXC):%K&4:[H5ZEO*-4 S&J+@JF]H0UV72MDP:VJ[>SG%.S3FN)2RS.(
MNQ[0O/:W0IMD,?6+VI:8W.252WK0IU1FTJU.>F.T XH8 X38/GMH+XV/J:@R
M?,8S7KRYXLU%)I9%.3<FES+6*NJW2/2">NKO'VQ[C<YC,;>6Y:4UR5L4;3FN
M3WW(E,8(\>$2T]1I>G;#6QUV0UIT]KZ5N^N[^A"2>UL\[=&<\\Y$L2*R=H7M
MB=$_5M0SO[28,2AK<R"QE';(-V(!Z8XA8D-4)#R3ARWC&,8QC&,8QC&,8QC&
M,8QC&,9!-E^=?CI\,I]_A%,\S1R\Z<0^ \]_?=?9@O\ .;^(O_,;)\QC&0'8
M/GMH+XV/J:@R?,8RIO++C)6O)V-1B,3-_-B,I:W929 Y.@/0B=DJA:209(6I
M(TN1P$CXG=6IN")2CV6,]*8B2N9 R](C2SZVIJ7X<='G*=W/(I ^)E\B$CB<
M":WHPZ6.D=*/0ID<L7QIO;TFWE6%83H3C*'Y8 \MD;#C&IO$D2KBF]7LP9'M
MHDC0V/[ Y(GED>4*9S:75M4E+&]Q;UI03TBU&J($,E0F4$C 84:6+81!%K?B
MWUZUVF,8QC&,8QC&,8QC&,8QC&,8QD!U]Y[;]^*?ZFK\RU)_*&=?"5!]28AG
M54EYCJ]^ ;5^[\<=O,'2W]%L$^K+;DR9\;@804@6F*4YBM.6D4C/2DI!KS5)
M("#!&IRD18#3%AAQ>A% 2EEF#4#'HD !B'H.](R* 0RT!<[I];;5R%E'$SE5
M%^);&SFL= 7=0?)"OU;&\3*+.E1H&>LXK#[_ -5=3>E4$F1TN71-$YP]7-[3
M3/4ADL<;WLMDV(\*8[<42HE#&+FELLGCFQ3BT6V S:R$J9);,HI8BP9!JF'B
MW0(VMC(464?78F($F<U#(S/ST:4G>9@U-\R7R%(5]DI:)0BY&U XNTN]F6)P
M%;&V..^U]M;O:_K4/:M[U[+I31K7;L@@-#UK"P;UVWK\I8.NU&,9K4<XFBY&
M\NN4U16*H=W^J(O2E/1S46VZ+2&QHES\N73%)+61,#?<S9+FWL='-[\24-<
M(=)C3%"#8D>H+X7V]5_%^X;2X<R-Q;%*M1;Z])"+40DMHDTH6K4#4D;(=.7%
M$,K:27-QX=,",L*7V*3/ 5L<T- ITB(5V]YF\T6;BFV15$CCGMSG4Q4'*FQ@
M/<!,[8CCC.J2!?'9U= D*CB#3@'[0L:4I(;M6N[>J4C);VU8(<!\C.DD<:N8
MZ*EL%JEV<(I:4<1S]Q=9ZB<(Z4?'M'G)W"&QPTDSL 3=.$KN\YP6!5LY#:H9
M7%O2/C6^EN"/:%&7PF3QQ@DB=*K0IY RM3V0B< D 7HR79 G<"DJX"4]4F L
M3EJ DJ0IU*@C1P!Z)/-+[$P7>8QC&,8QC&,8QC&,8QC&,8R";+\Z_'3X93[_
M  BF>9HY>=.(? >>_ONOLP7^<W\1?^8V3YC>^K^S7DWOR[ZOR?V[\FM>/?BR
M@L6Z12EIA"9=9;-%;:%739/X/6-83A9$F=#%^2<TLFP%58P9IX[/*B6:2S\J
M03$@AO ZN HRT-"->E>Y"M:&4M>N16CIJY89><..F,+.6%E-DJF<!E+ [E)4
MTCA=@5S)W.%SV#R=&B6N*),_Q:3L[@UK!-[BY,[@64G>&!U=V%R;'59C5@[U
MW[J"\?I9^IJ#)\QC*,W!"I7/N:G%LTR*O*JNJGB=IV,X2G3:>*.IYDZ)4D6C
M[2-W[7M(6]E WIP)0;-"J,1C,/ 6(@)P@Y!S(XM5WR+KQ2JDBXF(2R#-+RZ1
M>Q ;)(&PIBT@USD@?3#"S K(FMVB)4.J<P.CD(TQ;LVG)EJ?>SH)Z.+E?![/
MKZ-T6)D;X;/JUA: DAL9R"2HW,8^TZ3(ELKCFTQ8 )SAK5B=2^-JP(%0U+F!
MV3&*R%I_<FSS&,8QC&,8QC&,8QC&,8QC&,8R Z^\]M^_%/\ 4U?F6I/Y0SKX
M2H/J3$,ZJDO,=7OP#:OW?E*KKY/@XH<$:6GX;&X[5"OD,;JF!LUG\J9NHAE*
MPIS?(<:XZ>9*0UK&Z2S=:2@8W#3!7<8=6%RESMVA&LE<.82GB4-5+N$',Z[[
M2O!)$H?TI/1W])>C4M:J6V#2M!T\93%J5[!$CRP,CU-(/,X[>]O1EU:XFX2E
MI#N/6='V8Z9%F%-C9-6)YZS3O05K_G_U\N_+Y?\ CX\_/\7JWY.K75O]/Z-]
M?E_W;_+^3.==75XO)_SU_P!OE_3D"6#Y[:"^-CZFH,GS&,C.O+-@%EK9_J$+
M].*R"3=SKN9G;:%S:(B51PE/M:@TI6HTP78E&6K++*7(S52+>]F%DG?Q1:R@
MO.?A$HLI.[7!1;(@2W((DLF2-R8X#:JFS/HDQ,K/9%)ZM(U-,^TG$2E"^J-I
ME3LR%J&?;HWJAIUN\EXT\$8JT0D<FY.1YHMZZYGI"LD[K-U:V<&1UL0&H5$>
MB*!>\JU9 S60M F+=')N*(+7'[/;2S5;*4#2F]$ZK2!67&5$.G<38I1'#R32
M@M;NW)E1",9J)0W!5M@AE[-:G%,C5J"4+DVC2KD&C-B1J"1:#O6'10-4<?&*
MIJ0(E!+&6O3J(A6+/+)&>O?9%MA3=WGMB%P=3!*'14B2*"]%D;,#L! DJ)&5
MV(4Z?4U>7R8QC&,8QC&,8QC&,8QC&,8R";+\Z_'3X93[_"*9YFCEYTXA\!Y[
M^^Z^S!=[ZN37Y=_]A?DUY?.-_P ^7Q:\N]ZUE,;>O7I.9).WA+Q-XM<6&VJX
MP\+6TJ7\Q.2$_K2<6D4W&%IU3E"JRJ.GK-4P>/+512PN..]E2%+('I($IV7P
M:.H3D07&X5(VE9-HU2I>[ IPBMK3;TBE&\P'V]-LXKUZ<S6<ES:'* 6\SLA+
M?-:XE*=:D$URHV),SXB*-6(I+"6AZ;532/6(GZ/F0+O9>\*XHB"<7Y.;=W"[
MDJ?Q5A\CBA\&D=N<:Y'/U-Q2<;I#DC;6C/-[H@5@)8*TS)M8VE0^+:IKB5V6
M)M,6+FV.; .&-%2RE85:SG/3DA,VOGD=>/(V01UO4IUZ*#@M>6[6QF"@=DI9
M29Y<8K"6J,-LD>$@1MSC*P/JAH/5- D"H_O95$DK-R,I^0%/$J6J'\5L;/;G
M>4/+LPMW5#VH6M,3$N5&MC'KK)ZMZ;4Y&Q!,."+8@F"UEIL9QOR?J_MWU=7Z
M.OR=?Y.O-//#YEY S;EU?EI'6XLD=3QB=2NN9(N5IQ@:+$6,0CBF!@C,8[K/
M;XPF@P5:<T3Z@-[/Q&(2=.6I ZG)-PV]:$'81=6];UU;UO6NK>M^+>MZWXMZ
MW^76^O6]>+?7K->-E@@?!)^B]DU]4L59ZNM2S-M/(.6)/9(3W#2'\HLF(.;$
MGTH,0LT*0OYK@J>&=.02T)3U00MR-.N<@&ZV%$'%*22E!!I9Q!Q8#23B3 FE
M&E&!T,LTHP&]@,+, ((RS [V$8!!$'>];UO/ZXQC&,8QC&,8QC&,8QC&,8QC
M(#K[SVW[\4_U-7YEJ3^4,Z^$J#ZDQ#.JI+S'5[\ VK]WY!QT5BDIX/184KC\
M2?RXU0""6,0YE7;=:C7'Y*R5:L&TR<B#.*%PT_N#,(\XTAM1D>R#F48H:$H]
M;<1A'HNZ%-==3QR6:WNSX_TA3:B=^,TG=0NW*W@9PUXI4R[OCH\T^M-/JR>\
M<1DS:8N"@LQ:L8XS+6],S@AQBEW4%)7Q"G*,]4)X!&$F@ <-.,99@0J"M%;,
M($(&]!.+T>6<1L96]Z&'1Q)I6Q!UHPLP'9 %YZ;"E=XTC8/,"HD$EY!1&(S'
MDKT73 TRF>7.Y7 C0T/R;O@5(W'<%9R]1*'27TR_6BXQF80Y_@/5%F"L%((Q
M85=I&M;*E>FW8WP FTJD+3RH@KU)'N7Q2A^9MT4G4TADBIU=GL^MXTSP"1)8
MXOD[XH6O$N%6\NE\QJU/)'=P<WA6BA25*].;@[H5JHR694]OZ_D93[6XPUS8
MVEL%;&FF2JG:.K$,C#N'M6NM"WMCHK>4&PZ,-$+3P@0^(G>M;$(PL.[3XS$+
M '-BX3*C*W(8E,] Q.0H@1)C5)+ ;(0IA[:P.QB,(E(4.U78=NV7V/7X@C,*
M*V,P&OGHV8AR%A\9MHNYHB"+MDELAYER(3XCTV39WFSJ=VF<N:I DT)NW%5"
MA$CVP*RNT@4G!7&-05;$8@5BV:XQE>>3''UAY%5NJB:Q6-@E;0K)DM<SA&$8
M'>$39K_VS0]H%!&P*0D". !,Z)BC ;5(1BV7LM60C4$2;6:2>-U?PY!:#DQO
M%A(X\V)9@[1LI42QN;^G3@*<%[>!82G/"2L-#V\79ID@1'&&B*2)BA%IR\YQ
MC&,8QC&,8QC&,8QC&,8R";+\Z_'3X93[_"*9YFCEYTXA\!Y[^^Z^S!?YS7Q%
M_P#"Q\\773A\;>CHXW\SS$BRO.BDK"37C WOD384KYR+>DFL*QK*L>>V;.RI
M<ZM#!Q)GR-B@C!I0B3K$@WU$4;*US@^E1)&2CAKF25[*N%VF_7#[BIII-CI[
M7[FZC/8T^()WU)$SF_O717N$V+I91H,F31L:3M(F$B2:U("6G:,M[U[*!5Y9
M?&0'8/GMH+XV/J:@R?,95CEUR69N,57#EJQG=']^D#@*,0]H0=M1)E+^I0J5
M83G5^VA7HV1"@1IU"W9IJ96L6G$%HVUO6'F#T5B?1]H8&CXL5Z? #9,K;W8Z
M1O+VYR]K"UO[K+G!^7&29:K[FT)M<20N.A(F]V:#U3:X-R-*<2H$9V\LJZ>1
MQ<$023ZKI[#ED38YT5((J\("HC)7!6T,4@6B2&&MK<Y.Z HY>T)SG$I+OV70
M [O:S @7(ADJ2"CB]=?1S6[?+](K4I>X6YN;4]6)FH#8S.0RF670K8S0-*&&
M-L<$)0M>8 A;40=L<H4JU>T^RB$P7R3A=0*6_:WC&,8QC&,8QC&,8QC&,8QC
M&,@.OO/;?OQ3_4U?F6I/Y0SKX2H/J3$,ZJDO,=7OP#:OW?E;)0=:J'@S GFJ
M9+4D:4L%-1YZFXKH8)\\1%VK=!6BLR7MA3I6K\U2R&/(46P.:"7(&:=[0%MR
ME&&$NRAP3J4&D/HT7[H=.(UP5E/Z:X_T-Q_F?(L,LXS5CR.XS<M7;EW0-MR!
MK*@,\FE2JWEPD2&R8%*VI*FA\R>5MG45"X_'6T:43Q8*,UZ1)'?U6*4R9<F4
M(U9!*M(J).3*DR@L!R=0G/+&2>0>49H19I1I8QE&EC"((P"$ >MZWO60="^,
M/'VNZS=J;A=0P2/5<^-P6=V@R!A3>UY<T%)0H4;2>A4=O[)K:T("D3*W=LTC
M8T9)"5F)0$$$@+DN"P2'UG%&>#P*/-<5B;"4>4U,3.F"E0I>[%BER7G]AK8C
M#UCDYK%KHZ."HP]>Z.:Q8Y.*E4N5*%!D86#Y[:"^-CZFH,GS(JL.Y()6SDRQ
MR1/K6@E\O8YP\02/.SBECP)DH@#*4_/[*UR-]$ABR9X(;3RW'N%S>$:KV&3N
M\@ 08QQV0+VS5TGZ<'A-.(Q/S:PL]A5RN!<<I[=TL1R-Q9FY- 9!%S"V1NJ]
M[($[A/F4^62@PY.:R5B9+T/L,C1OQ;UMGE\(72#8O1US(9G0L)LV?2"*,CUW
MM(3,;1T-43&T,%<)-!F.='IY2W/*\:N#F$L+ZVO![7)5*=4W-JU,>>,28PH\
MRP6MZWK6];UO6]:WK>M]>MZWX];UO7BWK>O)O.<8RHG+N-W?N-12TZ"?W?4V
MIUY5RE76Q*Q0"/6U%STQ),BB;RV%"T!R<@($PU$=[+0E!*D:LIM[6Z*D1Y5@
MZTFY5D0"'STED?(V7+8\V/VF"2MZEK?6<3@F <-N<T*LD@\E4D,V,H6QD@T<
M (%!8>UG S.,8QC&,8QC&,8QC&,8QC&039?G7XZ?#*??X13/,T<O.G$/@//?
MWW7V8+_.:^(O_,?Q_P#/_#-*_-ZEKHN'D>NGUDR+I/N+2&,05NKM/*.BFO\
MK2QHS+ZW)L">/43GEP5 =6^^2X949MU6IVU+#JCG+)&AHY(S,LD?S#5BQ5NF
MXM/T >^/=0@K2SEEPQ2/5]$8@EL1Y.,W*Y(IB<>;&-:XSM$K3H75CGZD]'M3
M-X^_MC1(622'N*![9VMQ)/1$_P G+E5Q]:G"Y&A59[ 8[<?WF 1JW6E 6Z.K
MI#Y5:B1K65Q#SFYJ;EJQWF<W+?&,J-0Z/$N\F=ESZQMJ5J&XO+:E52C +!A]
MHQ5NFL$>R'^-N9SHD(7%$+$9Z=R8G9<P2!E=6MS3(G9CD,<D#8YQ^21UZ0-[
MY'7]L<61Z;T+HA5)2HUL'SVT%\;'U-09/F,UY<]MG3Q3QOXW)P",+O.ZV8R3
ME@#H>C*]K<!4JEI9H.O0NTF!$@V9V(@;V62,/9ZUO81W^:VQN9FY TM"%(V-
M38C3H&UM0)B4:%O0)"@$(T2-(G 60E2I4X"R$Z<DL!910 @ '6M:UGWXRE]L
M4C/".3E)\B:B3-IBPH*BL;Q:UKH4T$O55N79JDCV#0B]^R3K$W#6U"1$#8U2
MP>FPHO02$I^PW/UY/+U^_OR>/_Y^7.<8QC&,8QC&,8QC&,8QC&,8R Z^\]M^
M_%/]35^9:D_E#.OA*@^I,0SJJ2\QU>_ -J_=^1Y$BXV;PO8"IB%X%$C.-R<N
M4!CZ0]<^BCHZT$%\"RHDR=8I5NPFO:O3:E3I%)ZA=L@DI.>8,)0_,MPNXYH^
M95STR5(RNF%JAZK2&VC8D4NWE_Q1X;4;4UGU;/HO3E+NM6L*:HV9:I/E;QQ[
M(31QD>=%-3JE2'OD^-$!T9VN/)?8,J&H(2*34B?NQ262H.3I=G 3]TGZ ,PI
M/V\S6RR.W&=B3HXP(@%=EVP>A!#O6]6+IRWY@5@9R\CD\HR*7;,*4HVJ;DK%
M/Q?8[!?CG>36ZZSZ.%T/*(B\.+Q(Y),*\50U%-'260E2B53BLWY.^):R@[P)
MJ9GFU7"F\7OD5QTA=M2.3UG*GM_7S!"Z+:JCUH0Z.MJ^,2][C"Z,NL,NE TV
MG"IQ%5K.HC]@0Z<L[0_QB8-[NS+6Y,)'K0ONELQB3WR'IJ-LTG8'60QT5L!?
MV)N=T"QX9-[A[6'7LLVISS%C=H0CR@@VK))T,1@0@V+?BRT&>?SIEF-QY;W?
MP!Z,QGD!)43Y(6C(K;Y%M3:V%[E"&A:)3('Y0^M,M4B4IHH-:ZB=61JV4T+%
M3R_B;="7IFQO<6E^BOEET&/#GW/; LE5EUQQ_F=&\?CJUINVFB,Q:F(TWV)&
MI"[3ADMNTSDB]>[V++U;"SM;)("EKHL*2:-L*7P]G0.TE;F^/Z]@BZ2JZX[)
M>:,ZAU-0F4\,8%QU>+;Z/LQG?XJ]\SJ=JPM3+!WG<S(_B:6=P9R6Q.Z27CL4
M[(GE)%W^,2AA$E89+%3HZ[>J+A5RQ;N:].H>0L)AJV,4[,S2-U2ZR!\;E4MF
M+8@2%HI4\O<7:BE*>&IVN:D/<6:4#@]K7QY(8CY$N:V!$Y-*53;[&,>7*M<F
M;^D/'0NNILKAH'^G%4G&PW#*$BA88^UZW.I:=+&I*E:DY)H%[.%U,-*?33M]
MF4#21*D#W8O(%NR[8YM[TW-[NTK4SBUNJ%(Y-K@B. H1KV]<06J1K4B@O8BE
M"54G-+/(.+$(!A0PC#OJWK/NQC&,8QC&,8QC&,8QC&,@FR_.OQT^&4^_PBF>
M9HY>=.(? >>_ONOLP7^<W\1?^8V>=?IGK+XM47TAO%&X[CY2\':3GL4K5BD;
M49?]6<K9WR-K5FK^?S601Z54.Z<<)DSQ-M8;4D+D\P2:I+;CRH1C&TR$<>,F
M2!2[Q%+?7HAN'MF\5>CZ20B$6A24@<IM6,8DE"V=!X3.$4,E6Y%5Z-[C-Y6K
M#)3J/25PF\SD\EV[35H">0X.<9C\92KWXMY4+DK/5>/\$.8<*M&YYI-(W$I9
M$H)R9Z,OD$T"KY/)CWZ]$''\B1[OE^(+E,O?G^46 U*)*.PS$[^ AYG5AL7:
M&<TY0M9DQ6W#@754ZKB"7;(IVTJ(NHO7EER1Y!1B%KBMIGB(P2T)\<MA:*0M
M_;CRFB4O[$W)IU*&0(@GLD@ESBTNA87I&YY(LL871NY$4XZJYC(GM"Z#MD2&
M-N2:+E,T=UN'-6^Q:#VJ.MK\=UZ*&$7LX]O(=!/'LH)0]:'EHLXWY/\ G^O_
M .77XO?S4O7MC\O)=T@M@PY2?&5=:5R>0@EC&6:%1#XK!7A"-PB#HRN&TH7K
M=I2%,J*.6AWH)2D6G9L<R$S"U-QY.8=)3S?D?!YDHF7PIG36[-[,LX5413BJ
MV(%(;&Y O$G0DE(N]U)$!#HMBCG73B% \NZM;&GV/OC2\&1A44W2%WBSHFC_
M *-_I/(SS498=7R!MF#[?T699*Z<MFAYA)54)N.4E*=W-(U0YQC[VX*ELA [
M/X3HI!M1I7(W0R.QM=)[)6QA^, RN6WG6];UUZWK>O?UX]9@EG@L$RO9D75)
MS$GL<<><@PL^3%FFL94@VG%['F. "M]>R@F__5[-"8F H[2-84<D">4/7'T<
M%CWHM?;HIZ_)"['2N!+&=]3QB? 5FV.@U*SERQU</9(1@D3C#%"D:8UI F$J
M+0GKP[;#4\>6-*4.U?&,8QC&,8QC&,8QC&,8QC&,@.OO/;?OQ3_4U?F6I/Y0
MSKX2H/J3$,ZJDO,=7OP#:OW?D"*2;H,X7UD91,8@L]F9-50D*RN;!ESO73-8
M486PD+8_19NLIFC\N45Y)U"=:6NC<G5Q&2LX') 6U/+>A0.AD@9=/71R<'UW
M''D.BEW'CH5&3HWUJZ&J(!9O(&S.:L;O<3O7BM_BK\_12"517$_LQ1-']_6Q
M%MVU267NM6((R8/4A6[D&RU$+=O2VK*4')%)291I*I-3G%D*=DA4A3GC+&$D
M[9 Q  >$DS83-DC$ )V@=@(0="WO5$Z\XI7Y74>F:)!S-F#[)).YL#^1(9#1
ME$A3FR4F8M4@G4@F+3&HW&U$V<[%C32FKMP4'/;*9$(D6F+KX<8<&]N5I;/T
M[4<>IJ+N,?8SE+@MD<RFUCS%]6A()5R6>V-)%\LF,@-2) %(6XMP>7$_:-K0
M%%HVQO*2(2>V]H$H.Q>P  #=U!B" (=BW;0A;"'6MB$*&M_9;WO6NO>Q=B'K
MWOQ[[$/7Y-=4^"WK0=[WY->/?Z.K?7U_IZO+U?EZNK/+?T?=7.5D=,'S$NL^
M@4J>NN+4E1<8JOC[G;FY6IXMN$HC<GLR3/$&9U0C8B<Q2]P>7=/(8/#7U8*F
M7>RPLL%0O,9'(%K/LJZ0[C%+KUM'CC[7W>8FMDADIT#>TY+2I?HA7"$DDZ4&
MV06F2E (:'H8$ F\2UQ4E%+UB"/DIUR Q'L"G87)J0KR>PAG@ED,NK(9VU/#
M@+Q3$X:U5+38.Z-D@9S)L)'M FE"93(FE$_/;$[IE,:>G,O9CFRJBM]ISS\=
M'O/2NCWYS<V>CH.IZSE9=M\BF3D9Q09&(@MQ1N=*6H,3?8\M4NBJ2>T2)UQ3
MPF@UQ7N2@]GDSL!.;%=LSY/S&5A,],FO'_\ /_G_ .?OXQC,5G$72S6&RF(K
M2&I0FDL?>&,TI\:2GUHWIS0'I #<F4XY,6ZHBC32SE#>)2F[J++V3I00(030
M:;.-#9<'1_*)2[<DGM\;J*=)2@KYN*8D:J=Q\J0F%E[:[6,/(6"6U] O8Q&%
M@V3M$8Y.S@M0MZJ/)=,2=P4[JV=X:9 UM[XQ.:!Y9G9(0O;'5K5D+VYQ0JBP
MFIEB%:E,-3JDIY0@F$GDF#+,!O6PBWG98QC&,8QC&,8QC&,8QC()LOSK\=/A
ME/O\(IGF:.7G3B'P'GO[[K[,%W_XFOB+_P QLT(])%,:'=N3AS[R$Y2],1T>
MD\8(&BJ-B3<)ZQMM]J2_(\URV5R]BES59U2\=+\C<W=_^M@4K8R/*Z$2VOS%
M#BT/<:1'NIRA5O%X:2AQE''>M=GQ.Y(VRQR*QJ&Q-TY!Q_<)N>P(]$HTS,1-
ME6#7JHLI\@3W-%R)<ZCCDK2M4L[48!U?8[&E#F!D1VDZM>/Q:\?BWXM>/7DZ
MM^_XO%X\YUK6M=6M=6M>+6M>36O>R [!\]M!?&Q]34&3YD:6E;M>4PQM4FLZ
M1$Q&+NTF9HCN3N21PW&V=WD(SD[,.5OR9*>UPYE<%Y1307)Y2J:(V4].#0T*
M79.X/#:0I\C[!SRYM3'DK.DG &%LMK1NU.D-<V9AYF6")VA'&:SX\V0:3)VO
MCM*4HH\F(=4C&W:6C16%%GE.\O3G&F0J LBZ6O8T[Y;3HVN"G,LOD;67-#G8
MC*M*5,<CY'P.%T^>):P)>#L@E<YD3^YSV%-LG4!C]@P::F!=H]&386XONX/&
MY7$%\0<9FPF.(H'*72#\-;"X\V+1/*+HNJME.N8E>-%I!G#0D:GB4PJ_J37
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M(9HQC%WF,8QG\SB2E!1A)Q8#2C0"+,+,"$99@!AV 8!@'K81@& 0@# +6PC
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MOFK#IF5+.M2CCEBD-BYS[-K3!7K4+"ODAK8/MR8Y0,96]!V@P>PX-9;&GDD
MEL?F+&I" 1;G'71(Z)@",!HS1*C:8P8T:D(=Z[8E6%D*2M]83"@BUO6LRQC&
M,8QC&,8QC&,8QC(#K[SVW[\4_P!35^9:D_E#.OA*@^I,0SJJ2\QU>_ -J_=^
M:SN8<X.C/!#C!$'3E6/@[7%QJ*JJVV>5R<J.IG&JX0[5=(WOV.9I?,@F0FK7
MVSW^/LE8L]JS$HUHB"N4! VE#ESK&>J&>CO35_1W*5/0-"]*=:/26P"45/,Y
MK-H;=5U5_P IK XZ.4:7P9%%YHCNV"("5<-B=AA?5D1)JR8B"%_4I44BA8RR
M8E*2E&_O>M;UU;\>M^77O_HW^CW]?ERLF^(5%BCEXQ<R-NJEJY#6@1==E!6R
MN3+E*BV4!<-"R3Z,*U;F<?!WZ-'UU '&+CB V=''7>',3PTI$KDF-4GR54-/
M0:D(AN&P-N/2HU;](Y=(7=S6'N\FF$UF+NI?Y?-9A(%FQ.$AE,E>EAZYT=5I
MFQ;UW.A1E(VQ"@0I<4L'SVT%\;'U-09JWH9L133IU>?;Z)$A4M]1\..)M7C!
MI,C$F)>9[+))<"[9I)2<TLU>8I1M[F:>L.3N1*D!1^R#RA(U1&QA2HX]6QR9
MC^RIJ6\79QP:9()-$T+P(*!L+GR%.V/2I8WC3"2/#LT)R4Z96%N6B4QDYQ3%
MO)!)JQ$ -K,8QC&,^!U2*5[8X(4;FK95:Q"K3)7AO);E"YJ4GIS"D[DB(=T3
MDU'*T!PP*TI3DWKD!AY)8%B-4FV:09IRL?H%NCQM.5L,\E4&G@9VVQ)Y9)#.
M8]94CB<UL*9/CR1(5=SSJ5QPQM>G6X!/(WE2HE214W(71,_JFAX8U[,SQ-OC
M^."Z,3FC1VA'\,.E=Y&Q]J1$Z U5?RZCD4Y6P/10/^XV%OSXG8)NS( ZUHL!
MJ-4L5E%^,(Q#UK>_P9R$Z;;CP$SOQ<)N.W-&*-9&NZ9AQ N)PK*?*2 [T':S
M=57*C/+<7#8=]F)L8'$ !#ZRR1Z#_&SN(YT[?#]D<B(QRIAG)+@M,]]B2>S\
MJ:)F\18-J]]0=A13^.()/$%*38M[T6N5+VTD00[,$$L&P[WL]I_DIQ\Y!-13
MU1MVU5;K8:G I[IKJ>QB7[**'KKUM4F9')8L1CUK>NS*6)B#0;_BC '>MZR;
M-"UO?5UZZ^KKZM^+?5_NWX_[,YQE*9?Q2=F2[&^_./$S2U9*W]_0&7/%E[>J
M=:_M9A-7%FO*US8DAZ<2":;3"4FHWQ(,O:A>(M0<8B4&+UBZY&W)O"X :1KD
M>G0Q*8O+;MJB-+QH2S@D#6!1[,[I$E+.& DQ3HK9 #A!+$/0Q!#O[L8QC&,8
MQC&,9!-E^=?CI\,I]_A%,\S1R\Z<0^ \]_?=?9@@M]CR:Z__ -#-:U^3QBL?
M6M=>_'U:Z]ZZ]]6^K7CZMYI#LN%=)[R5Y&O/-;C=QQZ*Q;6K$RR&C*S:.4B:
MTY;R<MFD(E/)JUS)I-M"*L+Q Z*;K3>#) YL,8:6U]V2D71XBVSG@YJ-96K>
M9QK?XK*>/-'2"#1<R#PUVJ6O5<8A)RPMQ-AC&.*M86V(FN)!RE,XCC"8 &(3
MBD5*T2_V/[L1JE*4\DX<V;%K6M[WU]6M]7DWU]?Z-=77OK_)U=?7^3&MZWKK
MU_Z?KUOQZWK\NM^/6_%O(#L(.QW908-;ZMBU;(=;][8H:AUK?Y??][-)7"]H
MI*QG_IHK@Y!KFDBK['Z1EUJ9/(G,\\1B RE8=#ZVB#@P."83@N0.S>_/8PLZ
MQ 3H"40S2Q;VT[5(R-XU"4%7G'6!(X)7J T";1G=SV^N.R#Y!*GH90"CWM^7
M$$)BU*LPHLLA.0G(3M[<B*(0-J5,D) 7DV8QC&,8QG&]:WXMZUO\OC]_W]>]
MO].5*Y/\$^(_,IETS<DJ&@%GF$%:+;)(ZM.F^=L&RPC[29'+!8S&R:,)A Q=
MM+"W/A)&S @V:0:$/8YIV+Z&OD[PTL!NN+HTN7"Y4"/+1KR^-W+TQ[EU>2%!
MM(H*41GOH0DUIF"5K/">84A3/;.Y;3']S*3WK1J<1X\BE738WEQ7?F&/=(=T
M>5M<=6G0 H)#<L%D95NTDX..SR@!<XM-&5E"T)VTX@6SMLTF>T+VF&862::+
ML!#%N?XW\H*.Y:5HV6U0D]:)["W(T]*):VG![K;'!*+L538\H-B$H;%Z?>PB
MV4HUHLXH9:A*:>G-+-%/W7UXQC&,8QC&,8QC&,9 =?>>V_?BG^IJ_,M2?RAG
M7PE0?4F(9U5)>8ZO?@&U?N_,1K2 0:U.*-=5W9<.C%@0*84O#F*60N:,+7)X
MK)65;%VP"QI?6!Z2K6IU;E(=:T<D7)3B!["$6P=F  @_9QXXE<8N)+ ]1?C'
M0-0T(PR5P(=I(VU- (W!R)&YI"C$Z-PD V) D4/:M"F.-2H#W0]6-"E,,3H]
MD$C&6*PV0=R5Y U_Q7HBT.0EHK]-T%JN*K),^'[4(D6S]@-3H&ML O=%")H;
MCGEZ7-K.0Y/:]N8VXU<!>].3<U)EBTC^?&NY5W(&EX1<*R% @9$[0'O;,RD6
M/5UMH5<<.6'@C\C:;"IF536N)*S2AJ F?FA=&Y,Z$;;UR<"DPE8$].5\UB;_
M .VNA.KRZ#;75_OU#$/O^+-971JFG3'GOTT]J&Z&<!3RJI^ED*O?= R=)Z1H
MYL;CT99PPDE"VD7R$83B0I>VI1B[':Q8E-3##*'$#C##R>37(^ZCH@^1Y! ;
MCED+J!J<=.R)N3C.0=4SEJ0MQT!8[E.2IU5I64\P]2T)D;BN[D <<!*8@VQ^
M3&,8QC&,9QO6MZZMZUO7O;UUZ_5O.F?XW'Y4U*V.3L;1(V5>7LE<SOS:B>6I
M85O6];*5-KD0J1'E[UO>M@-(&'>O%O75FL:XNA4Z-:XW53*#^-$8JN>'#[<G
ML/CXZ/\ 0DQ0J^OLM+4ZVKW*/-IJK0^H?;%S2L#L>NR& 7CZX,,Z-+GE1)IB
MOACTKEX%LB()06NIN:$0CG)Z&B(*UKJ;/;JH Q3UI0>+M83$(3UI)6_XIXAA
M[(7]M\GNFBX_;-!>G &EN6T8;P +43KA3=@XK*CR0>(2[5072F+<URLP&MC$
MWM#L6#9F]%E#UK8=[[Z/=.WPJ:G<B*<F&?D)P@F@]@(,8.6=$SFO6[N[>]!&
M0EFS0ADT,4D!%U]@M-=T9 RP[-WL .O>MHM37]1]\,A,CI2WJUMEC.3EJ0N=
M=3>.3%, HT.A V?MA<5QJ4?5O6A%*BB32Q=81@"+6]:B;DCQA(N1?'[)@4L7
MU=R!KU(837UEM0SM]K1B..6&125MNMB+>8BYJ#S^[$@R1FD=TJ!! K1J%S8N
MFEGDCI!:L:Y)?$D@[&\L,<1*+#DK<M-:(,F="2@%N*U"J?=I3DK8<HV':<*L
M)0^S,T465K6RB\D-$M1N21*X-ZI,N0KDQ"U$L2'E*4JM&J* >F5)E!(AE'IE
M!)@#2#RAC*-+&$98A!%K>_JQC&,8QC&,9!-E^=?CI\,I]_A%,\S1R\Z<0^ \
M]_?=?9@N]=?)KJW^6B_]W_F-^3>O'K?O;UX]?DS6_=?0@\>+EN266:EY%\[Z
M:@-ER!?*[?XO4)RMF]7<9;7D;^O4N<S=I-7C0G.<68VP5ZU8LG1$$DD22O[@
MN<G?9*-X=G-P5;>XU&(_"(JPPZ(L[?'8O$6!JC<88&A,6C:F)@8&Y.ULC.V(
MRM:*2MS6W(TJ%$E+#HLE,044'78ASS_)Y?/ U/>$422R7.$#?^G?3TE;[FMD
MTFDRYDH*97!6I;W!5C^O>ECU'(7*GYUCE<.20"].VM4/FRQA3D-["K[63L?Z
M.J1RQZK*[V=V4N;A Z\YB<JZOHQP<^Z#MFTU +7=6&-L[6YJC3CW>-PA^(E=
M>11<,TT)<:B+4VDG*$[<2H-[^^;3D596?!9S*ZV>G2$0-%:KR097:\,WG+ZQ
MIXRQ >W1- O8UD5BW'VD]PD"QF97:121Q;6=8ECK*]OA[>T*]$'1;%K>1/#^
MJ80D 6@.NSI";JY4SH^6KVZ,F6) ]VO*WQT6ULW/#J-_L)"PD-T;0R)R0-:-
MJ Z*=M38N?7.,33;)ZPM>3_?U[_7OK_3[^<XQC&,8QC&,^!S:FQZ;UK2[MZ)
MT:W),<C<6UQ2)US>O2* ;*/2K42HLY*K3G%[V6:0H*-*,!O81@V'>]9J%N7H
M3>)DJEZVW.-;G9O R^#^Z3P6CQ!ERNL4JY8=K?8ZDU;)MCKY];MCV(:Q$E9V
M,Y;H0PFKM;%H8:R-2CIP.C^<D^I*@BO2K<<6T\S:Y;$-IX!RQ:6(.QAVI3Q]
M_5Z12QX+V(LX*!&]S4QPT U.#;9VPLTBY=#=,_P+NN1IJX?K-=..=V]U&MSK
M1W*.+.]'6&RNA 0]M0*O;845$U9AIN]DH1MLG5Z<# [+3@V=_LM;4R%!"HHH
M].<4>2>4 X@XH83"CB3 A&6<28#8@&E& $$0#2Q"+&'>A!%O6^O/[8QC&,8Q
MC&,8QC(#K[SVW[\4_P!35^9:D_E#.OA*@^I,0SJJ2\QU>_ -J_=^..WF#I;^
MBV"?5EMR9,9'MGCL\N*&&5"VP)YF9;U&A :K)>9%'8NX1[4@;O;>F&_1=@E3
MJT/(XM[+;C:[VMOC>4_Z;M.S<<V"5;#&7%KC\T\;:Q7P-H UHB'ZS+<M99'H
MRF]CH3$G>XK&D5D/44@C5W.E]CHHRN<C5)T -ID8EZH2]Z$W-0G3;6BZJ3P>
M(L'(ZG90S1YK;9#)S+6%('A*FT6N=]ZB#4(/=Q_7L1V@B3DBUK?BUL&MZUK?
M7UZH.BDNJ UEQOYY<I;&<R6MKM?I+^8DK1]K 2<]R(3=+6V%1V.,R+:@]P<7
M=6*,JBD+>H6G 2$=O6"/2,A)BHK=M3EJ1RZZTB-GQ4)Y+/+FDES*0K#T![BT
MJ!;$4M:'3;:L7HR7-L5%FI%Z8E49V@\L0!=B+K#J3<8QC&,8QC&,9QO6A:ZM
MZUO7O;UK>OU;S'93#XG.&=5'IG&8_+F!<'L5K%*&9MD#,K!U;#L"EJ>$JU <
M'81"#O1B<6MZWO7DWO-7EL="'T;5H/"F6-7'U)1E@'G=TDV)QFE,IX_RM"JZ
M^R[J3=[ET:8^,_0^HS6UC J!L6M=D#>NO6XF'T=72(47HT[B#TKUKO3,F[ +
M;5_-^O(MR-CPTQ75VIO'8Z$N.V$VI@AT$K1R4M2H"7X^R$+7CU[=()9_3$-L
M/J>&<DN*5&V+%B[B:6='+>(MINCF]6N^O+$[-C"PQJBIZX(YHJEJ0W2J5E";
MT,A0-;4WO*APW&F@A?(DW;='YTHO>'ITIRN/C]TGDF8W0<F0M[7&>*RF>496
M@HG+7E*OCL.DK#(5\I5N;$FZT,YVZ((RB;I A=FX,5:%*4D@4GS_ /A ,!C\
MX?UC#(F6/P49I>V6(7]QIY65'.6PI.W)#%"5PD08:[QQ6N<C1*W%MV$L@.VK
MM8U"=+V@P:BZ\4Z=CHTW:LBY4[\LZ,+G;?#3'U_KEHFAY+F;($#84K<8W%E$
MT:8@%^..6&:1,RD0$Q;H/8NYMF]I-%J3Z/Z8'@A?,D9XA%[C9F60O@U!#<DE
M3C'$"(Y4E;CW0Y.-\;Y Z,R8?<:8XPO:Q8F 8,(20B[<:46.]Y]UT\F4-213
M:M;IE3Z1M2R)CYU%BCWA.$)0MG-A8G70EQ6@GD;[8G[8#>CB]Z%O0P]<B)5J
M1<04J1*"5:4\.ADJ4I@%*<X&_(,H\@1A)@?%O^, 8M>+RY]&Q@UXMB#K?O;W
MK6_U;ZMYSK>M^3>M_P"[>MYSC&,9!-E^=?CI\,I]_A%,\S1R\Z<0^ \]_?=?
M9@O\YOXB_P#,;)\QF!D596:9HES GKR#$,4_5."Z=,I$1CQ+3,UCL0%*ZJI8
MW%-P$<D4.28(4[@>]$KCEI =%*1FEZT'63L3"R1=F;([&F=KCT?94*9L9F-D
M;TC2SM+:C+"2D;VQL0$IT2!"E)"$I,D2$$IR"@A 46$.M:S5QTMTM)@/&FRY
MX?*)/#M0GCORCE)+[#7C<?D8%[55Z<30V(7LM.H6-9+\\FMS&Y*VSN5W V."
MP#6X-RP92PG6#T7_  #B*:14='D3W/&=MIKC1Q:LVWDI$D=1$F\@)K$2Y^X,
MT/4B. MKMN5[?$RV5-4?7!1GK&IP-:4;*OD+VM.]3.M=7]N_U[Z]YSC&,8QC
M&,8QC.-ZUO75O6MZ][>NO7]N5GY(\-N+O+R-;BG)&CJ]MQL 2(E"JE3$0;(F
M0(A;$(<;F"':*6QH[8Q;%VYB>T ]B\8MB\F:M4_1:\M.'1)BSHON<4KB$-2F
M#5D<3N7Z=3>=!G",,V>>WQ66@+)L>M$YVP%@")HVYF"'OLU*SL=C%O\ :#I?
M+?XQKDD5Z4SA3:7&8&U 46N1]+)'#D!Q8=Q['L7LDID$6)72Z"IA)]A/VW/*
M)]<$I?9B6A3=@,(-MU$<F./_ "?B!$\X]W%7EP10\LHP;K I0V/^D CNRV6G
M>4*4_;HQ+>H.^S0/:%O6E]74,@.3EK>MZZ];UO6_)O7CUO\ KQC&,8QC&,8Q
MD!U]Y[;]^*?ZFK\RU)_*&=?"5!]28AG54EYCJ]^ ;5^[\<=O,'2W]%L$^K+;
MDR8S')?+XO 8R]3*:O[3%HK'4!SF^2!]7)VUI:T!&M=L4K5JH99))>A" 6#0
MA=F:<8402 P\TLL?S0:=1"RXHT3>!R%KE44?BE!K4^,ZD*I"JVC6*6U>1V>M
M!,(6MKFC6M;HWJBR%[6YHEC:XIDJY*H3EU)YBVYNA5, N4V+N\N:*U8+EF$K
M:V%<PH7A'#&.#)5TKDC?J2N+2TN9T79RE#Z8Q"<DK@])D2A RZ6O)J!L7><C
MHO;)J&_^!]"</I\@D552![M&7V&S7J[,<=D#0_3BQK:FLB<66,-NG-&[1I&_
MH)$FAR23N*8EG<'H"M#IK,9]I5"CUD4W3L%HF ,U<UXU:;6%H":::<<,)[F]
M.RO81NC^^+M  )P>74\.CEBD00%AT$I(D)3(4R5,3*.,8QC&,8QC&,8QC.L5
MLK.O7M;HN:FU8YL@UAC,X*D*50N:3'!*)"O&VK#BAJ4 UJ(0D:P20TG:I*(2
M<_9A(M@V;F5H: K M+8@; N+BL=U^FY(G0Z7.KB9HYP<UFDA9/=3BN-UHU8N
M4=L5*C-:&><8+6MY]2A&E5%")5$%*21A&$12DL"@L01@$6,(@'A,!O0P"$ 6
MMAWH0!;#OK#O>MP[)^-G'>;[%N:4/3,NV/90A^V>K8(_;$(@@24D6Q.C J%L
M1*88TY0NOK+(&(H&PEBV'*P3'HG.C1G@=ADO!?B^I[("4O8F^H(G'Q[+1F#,
M(!LR.H6DSL-#,%LT'9=BHUV(5&C0@ $-<I!_!_NB;>PBVBXK)(>?O9.PJ8':
M-QQ$8.TG#-WL!+7/@I B. 8-,:9W-LS:3>DQ8BRP UK%67H%>+T#*V72W(CG
M]0H G@5DIZHY@3YI;B5A*CMR59II>4KVVF'HR=C1INVD#*TG%V1Q9ZD(3]?$
MX]$_S C:CMM,=-!SLC21.84)"UVTGKZ[TI9*95H],G/4O2!C4*@@+$:6I,4D
MFC<M=@6N$,@ 2M?'-N)'395RQ;5TITIT.NEP3*1 )BUW\2JCCIRA 8KTHT:.
M81M2;HY>5KLDYP#6]&0:B'LM$:C.**'O#:\=?X1LG>G5ED#=T?;RF;&I6N(?
MK#C4_BK8]*!*B1)6UM65C-9$8%Q&#MY"?2IG2MY",.U;BL&K[20;&5H]*#TL
M?&^?JJ^NKA=Q$DRY*C1KMOE?<@K*B<6-(>&[2YM[0^3>"N!)PD0P&)7/99(^
MS5&%$%Z3!*./U'=9]-=RFL&_5E'V56-0\9H?9$UIH;!?;E8+#=\,X\QZ8-I)
M;E!IXN@@$,>D$XLQY91MM=*)@J@ *S<YXV*+51+F5/& R+U.:\>OR;\OD_W^
M3^KR?DWXO'K7DSG()LOSK\=/AE/O\(IGF:.7G3B'P'GO[[K[,%_G-_$7_F-D
M^8QO>M>7?5_OQGG:_A)$H6-'#>%0EN#H:R]+49*.&7L8@;,;)>O8GEX!KL-Z
M$()R"*FIC=:WKL25!@^O0@AR_'1FR-KFM<V/,RJW6PZ12&>%&RF4IU*]1#)X
MO:F1*Q(E$(*=%JQ:TM\<;FXAI<F LU8UM;D89M ZJC%*M U[+<8QC&,8QC&,
M8QC&?.J1I5J=0D6)R%2562:G5)E!0#DZD@XL11Q"D@T(BE!)I8A%F%' &6,
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MZ>&_Z_'>^NWT^_W3PW_7YC$VBO(>/PV5OL<N,<DD#-'7AT8X\74L4&8^.R%
M>I0-( )E^E AN"HLI*$).PF[V;U%[[/L=;R0N 7>,LL8[[[ 8BP"&#O3P[^(
M(0=;$#QKNO\ BBWL/C][R[\N?OO?7;Z??[IX;_K\=[Z[?3[_ '3PW_7YA_M;
MY&>W[VM=]PWVL>T_V<]M/>FBO:O;![/>QWL!V?=O<O9^Q7_2?:__ +1U?Q^S
M[5_L\S#O?7;Z??[IX;_K\=[Z[?3[_=/#?]?GQ.4&O5(W+U22]-K%:9$L/2I
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M%_\ %O>?K(GE=\4C!'PR,3:X:LB$C)*0'FL$IL2'1Y[*)=0G";#C&EX>D3@
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M/8!Z][_C=>^O_P!X6^KK\O8^/^+_ /V]6<Z#H/7U=?C]\0A?_%O?5_5G./\
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MO=$(D#ZRJW!C=6QP5RAC(#K[SVW[\4_U-7YEJ3^4,Z^$J#ZDQ#.JI+S'5[\
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MVNPO*!910UE@KV26S.-%Q-P=W6+Q%SJ5M;F9+7\>DNI0[.<&M'0\7.STQ'H
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M/].V7>_]VO)KR:\6<^ZMX_\ I(:OV=(OL3'NK>/^_P#S(:OV=(_L7'NK>/\
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'ZMZZMY__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g966126.jpg
<DESCRIPTION>G966126.JPG
<TEXT>
begin 644 g966126.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ ]1$E32S$S,3I;,35:0TXQ+C$U6D-.
M-S0W,#$N3U544%5473(P-S0W7S%?4U534$5.1%]+7U1"3"Y%4%/_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1
M" #Y JP# 2(  A$! Q$!_\0 'P    4% 0$               8'" D! P0%
M"@(+_\0 ;1   00! P(# P4("@P("08/ 0(#! 4&!Q$2  @)$R$4(C$5%AE!
M40HC,C=88='6%U)Q=7:!D926HA@D)B@V0J&QLK.U\"4S-#4XDK3!&D1(5F1F
MAJ:V1E1B=WB"QN'Q)T-58V6$UV=R=*.W_\0 &0$! 0$! 0$
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MNQG!I4&M;35QJZ,(\:38SGD;QRZ7)+I6XL%/'B:ZZ]? ;_Z&.7?_ &A<^_\
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M8U8,*%>_B_R4A-?TLWT)WB:_DRV/P_\ /[3;]:OC_E^WH?0G>)K^3+8_#?\
MP^TV_6KX_F^/1$BV,>(=K[B6G^%:;5M=I>_CV Z!ZS]MM [/P^T=M1ICK]8P
M[74R/-E1<KAQ7KVUFPF7*ZWCU\-JF0IUB'7>2YP2NV(^(A5W>B'=AC^M6)XA
MD6H>IVDW9QI!I5BL? ,DDZ8V.*=JV<3+N##U!=AY[!NH$LXV\Q7P;2LM6WK&
MT82Y-9AQ@ZMW"^A/\37\F6Q_I]IM^M7^_P /W:_0G>)K^3+8?T_TU_6OHB;)
MJ'WMZZZL8WKYB^HTS$,N@]Q>KM!KAF\NUQ;>SI=0\7H7\2HK/ Y$6TC1L:@U
MN(/(Q:#52H5W$@T\6((0C6#'MZ]#I_W<ZS:8:9X7I;AT[&J^HTVU\@=RVG-_
M(QJ/-S'!=6(5=4U3]OC]T]*$3Y.MH%)6QK6JMJFU0ZPU(9A/P&;">W(=S]"=
MXFOY,MA_3_37]:^A]"=XFOY,MC]7_P OM-?K_P#:O_?Z]NB)DFM?<9J'KO38
MGB^6(QZFP_![75+(,8P_#JR744%;DFM692L]U.R(-V-I=V3]KE&126UE4BR<
MAU%57U=-3Q(4&&4O;VS[J=0I<+5!JGQ_3G";?6G3:@TBU1RC!\7GT%WE^GU
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M*=^O^2;ATHL)IC",Q[0U 7%5YAF1_OB7BTGS/>6.*N.'VS#?032X?;B<,?\
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M^NJ)=T/E*X;IX%I<)::L91;>[Y]&6!J'%-3JFJ\TJSC+].\\H?V-;]MV@R?
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M'\,;",9A]N-3D6<HSN#VU8=C6$X5D5IISBM#JJF@K8&<5&:XRUJ?BDJHMXV
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M,M+=(!=6VRMZ0MIM3A4I#:GWE-I(077"DK44M1?Q?9W_  -R?_8D[HB,%/\
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MCM6FT3&]LR5B7C\93UM%?B-E/5[NUT\TDU=T/TFL;3$9D[5;,<ZQC*9LG/\
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M:$O[J1\6]RJ\BNU"TUK[WR&&SD3NFM+,)FMELS9 QFW2[C1]M2B0E,5,+V6
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M.7!2?PE.D*)22 E*4E()^L^@W]+\X\?*0T0M?WSDHI*$;[[MIXDK40" GDD
M;^I/IUGAI'Y>7+ZV@\T_J,;_ #*BY?T@9@18,-ET07GW4'XM,AB,,;U4T[Q.
M0EY1ERSI7C.6HE,EHI;C(BY@S8QXH;?4'$R8S;,ETI#3ZUM'AUC6WW4?XLRJ
MM I=1]-ZBT\R*E=VYIM27) :6D3N5#?)E4058<7-DMP]JY*RJ EL-M@<]3J2
MIQ)5YKB$</.:"4DMN!P*\T$$+)44@ $E)^S;<G'<2R)(6&U$N* 03S6D?'B
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MQXGK%WQ;.^6.^PI,&/JVVSC+S24??<6324[U<MM8677BJ2;="9,E:GG $I=
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MW*5%I;.^XVV &RSK\6;NVR%*V,OK]!<[>C.>4_(S/1;'+&0LD*2>+[#S9XK
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M&.TW^P]0><Z[N75(^<V6>XUZ<$[ ;\G"H$G8-D^O433S3JD+2RVZT%+(3-6
M"OU)+B/-"U; [D*4VE*1ZH2!L>LK2U;P4R$J)\E)"@W&3NKT5Z[KV(+BOM"^
M+8_")(&YTJGW%NI9!*4'?FI* &D;>A(6 4D_ <4<4^N^Y&Y&?+0RGDA+BY):
M)4\[[I V!&RWB"I[U]4H!2DI&XV&P&K>4[()#0YH2G;;@H!23Z)V1Z;#;?\
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M;YB2R@%0*N8">:N1.^^Q(3M<9>94XT5NNNR$AQD\0-@V2G@^^HA&Y4E3:U*
M"22@\04J'6Y&GN?Q9+05AMXI@J2)'""W*V"2%;I4AYP*0LC<E+?NGW0K;8C(
M3@.=NJ<\O#L@"5O; -TA3)\MPE:TEYQQAG@0EL*0"/P1NI0 '4ZI_,"&R(89
M$2[1H9S(L.9PL3Y:ILU)AX,3N2+%KS&A;9;26$>WN.LI<4@)+?!"I">2U(4K
MD01Q<W0DJ5YP!VW3[HRD-I,IYU,E2FD+Y*96?+(D+04K4025%* VK=*^*4DI
M4G<$<;,^)*KY3T68PY$E,OI@R(4EA2)$26RTE82XUN&/.;<XH/ D-I)45J"Q
MOZ::=0HJ2@;..!U6ZTJ7N$\BDN^H'G.*6H[^8E*/=20%>D(S<2,VVO RMF&W
M9<ZG!+Y[ ,8)&H(WGN*]..;-I6TM]Y25.H2V@(47E>O-!&P\O@4GBH#=L>I!
MY &VP$\6G6E/MH:!1P?4I:GD$!/F+(.X6I1 0HI"$J'PXA)ZM,J4TMMMM@**
MQ(=>'F!/%*G 3Y;J24MA2DE(:4E)W0.2@>LI+'F"3PCEIM1;45*.Y6M)/ND)
M6I):W"4IWXI7R4-@D[F6!$!VDL[$C($VN"7BS)EME9VM(UF/LQ%X+3YI\QY8
M+JD!#*DC;=+9*T<@5 +&_(DD@E/%/UE0*4--ES<@L@EM "PU[XV6%A*E*4!\
M4%*%%)/HC<#?W#C2I:W4(<;#[+/-0<=CLMI="D)4PV72!NI92E8XE0"BM"DI
MY=4<6VAMU;"/*;!3Y 4I*E*Y\0I8X!*$GS5+(0H)V2CU/J.LW('G;-N?D<R5
M&+ Y.PW:_-H<ZD.ZNMR7D,J;;>XB4 76DJ*VGBV%*9.Z@"?+WYASB.&ZMALH
MCKP6UAM;3BG=B&N82L-\E!*5>Z4$$)*@=^9&_K\$GJQY94EA:^:5M\0DI('J
M$A*PX4[I<;64[@ <02D_ ]9<B2DMA:6W7G4@H<"7 ?>0 $!1=*>"2@@ A2PC
MBKT"?0!<-?P\_P"#D@D7((L"6N9 RS<R!=8PD!3KC:7RXXTCTC!*4@*W6I.W
M(@E?O)"T<B$[!0*0KH!Y*G'&SR*VT-IXJXAEQYQM1#05RYI0-BKFG<\4@;$$
M@T?6>0#<=;I/-+X"VMT$I06_,)XE)2$J&X5Q('$IV*2<)IM33:O)V#:5.+44
MNMJ""&U%*O,0EQ3B.7IY'HI) 5RXC8T '3( .+N ;-N8!@W)N/V:?%\^0;OB
M=BKGL7%.[>6TH<5(!1N0"I04."E)0GD "0%? <3L!;6\2VTMK@ZA*FTNK *0
M4$<E.H&^VZ00V$I)2">).Z3MA.(*& I]B0\EED$I<6 '7'3R<<+2-W0I)4>*
MG4E*4@%*00#U;9=+B8Z6VW0A!2&4$M!*GDM.^\I:=EAOUW<V1OR42=OKH#C*
M#> &;:7SFV:-#Y.WH0V?.-CF%DK*)*0I_DTPX&5-K<'F!"UAQ"QQ1N0KU2.:
MP6P/>&RMCUBM*26DNO2'#Y*UK>6E:E(6%KXMLME"T\7$%*5!L)V">?+<>O5(
MP<;W#JBV](0\MQY3B%$AD@)2"X"T@.!2E<B%#B/= !/&ZX^T4(\LB,2MQIE1
M0VIESBI*%>:E!*.*]@M+G!(2L$[^A"JQ%K/!!=A;(5$CQL(R-D%@(>XG:#(U
M8@%V>("PY:G$DOLONJ2XA7G!#H<\IM'_ !2UG8%LK!)7Z)*3R .VY-UMI7M#
M2E3'VY#B$^X 'BI0;')M]'X(]%<V4;!/$ C=1.V*9#CC*2E+CA+KCCRW/O2B
MA*EA#!3N"IE8;4M2/4*W 1MOR.0TXX^H(]I)4$%7GH0%-(44K22^C@%I< 4I
ME*B4MJ24K*DA()TS#* 9N<MK0QBP"T00,K,2-"PF#;N+,V:Q) V(0V]R"GE-
M%&SB#'#"N(*0?,605'X;I.P*D\E;CK$<66926V93*2GDKF(_FO\ %('O>0XM
M/%>Q]Y#J>12H+2?3EUD>T/N*6X&TLJ(<Y*00UYX;V\U1<*U!95M^"G98*]P!
MML<*4EP+*RAY[V@-DJY;*7Q 0=_-]0TG\!3@Y$@%7 ;'K0>-N\/&VW[+=(9@
M=-C,"7#0-;MWB\MY#:)CBT><%0Y1V4T"5.J0KT2@*/ %)4>:5%22-@G;XSG>
M.X6V\G\*B4I:0E7@O]BS" M0"5<J/)G!^%ZD^FQ! .QW^W:"5X..,2DA*$[Q
M9*5H)2Z4@LN$D*V""KR_5 X^JMO7ZNIRO'HCJD7WA1H9"E('@P=B@05( 40J
M@R?9;H20E*4) 4I*0 "H@$'CM#VJ/^7H/?<N^%2.'%!/#%#F[#BRR#C2/50<
M.K;2&E%""HN)1YAW5L"%JY A)" G;U*E!(&YWW.W5MY*G@ =U(Y)"DH/JM&W
MH"=T[?XOP!(!^)!/6*7U-M"(B,^X]P0VK9M89V6 5DK2"%>Z23L4^]N2#\.L
MMMIN.E6QV3QW4GW4IW V*MOVR@G8[J()&R0!Z"K#<+'-RV;B,GBZ]D[ N!(Y
MG?< [@GUVYJ ^"3O\-TH).WH>M2\ZESS0XD\&E$@A0*EE2>84AL$<TE02!L5
M!2 2#R"@<Z%);F)4AEMQ!"02DIW_  B00D@%*MCMOL #R'I\1U[<AI#"62E/
MWM"$#SD$I(;V]5!)0H*VW_!4D ^I!]=PN/?K'B@:BIJA+@;@."3&T7:?'&8#
MJVTN^T.MI=&P:#*5H2E)4 H<B?+*DIY$D_XWUGK8!"0D)]"$[;$@';C\/B/J
M^ ^L#Z_KZQVU+3'.RTOK*B@%"5<?582 M)4"E+8("OAQ2G?;TW-[D-RE13OZ
M[$^[O\>7N_F!]2#[WJ?=&W19J+DV$V:VVL;JX!L "=]OKVVW_=VV'\FW0;<'
M-7%:TJ:(]Y(V][8* 25;;[!0Y%&Y3ON-R#M<"0XKBREQP\ K9(YJV'X2N* 3
MP^'K\!OZD]> APJV*"5;[ <2%_8!L-R=]O0?'8[;>FW13W[O[S6^K9"2"EUU
MQ:U*/ D+4C8-IW25[$<]_J/U_7\.NSS[C=;0GNG[T5(45;]O>E0(( ^&J5^?
M0C??8G;?[1]FW7&!6K\I1:&RU*4VI0W*5)"]D*'QV)0"2K=/[I&XV[0/N-X(
M'=+WG[%!6.WO2H$I(W(_92OSL=OJ!.P)]3_%UPQ1!RM],LAXK7PX'3TPS3IE
MD.1E_JR^@[T3=1?Q?9W_  -R?_8D[HY=$W47\7V=_P #<G_V).Z\R^LDL[AF
M_-[5]<&BP[*#N@&IC9C,QU2WI//36\3Y#41'OR77M_+;CI]YY:@VGU4.OED3
M(.G+,>+$EA.+6"849,5-U4Y!B+@D",WYC;#EE$?C%3:M@I#:"$J43RV /7U4
M-8U*3V[ZI*2HI4G1G.%)4/0I4,"M2E0(]00=CZ=?/KNO8+J(S69% 8M&)#$9
M;+<F$S,882 TA3SS4Q*VU(=6L!Q7#<(',)"3T11A5&::C8.&%XMD2[RB2ITS
MJJU?:RFF2TMM:@XQ,B//SX"E!(W#C4((2LN;(V(Z=-I;WIX905;59F> RJ=<
M4N'Y>K'DY%222'?,\M_9:I]<"L^6ZAQ<IQ/#E\=ATKM]VP:.7,?G&J!B,YW=
M]RTQ*=*II D;??%K@LERN?4K_C%[1&W%E7_');'$MXRSL^U(JT.7&#V=%J=4
M$^1+KKAJ+C.8AIU*E-QF[)#BJZW>"6ME>VH+.^P1&4ZIP]$4P.C&NVENH^-P
M+V@S7!'GX\-*YU>G(X0?KT-#S5.S84EUBT\EMK8R.3,9E(25+>\M(Z:CW"=R
MD3-M2:7#L1R:NML0Q<"QL9%%.8D5=OE$E2VFU)=A.EF7%Q^$ RQLMUIJ=+?=
M2XI<="DP_P"4X9!K)\G',DKK/3/+YC3T2NK,KI34IE2O=!CQ[)Q(KI+3I^\J
MDU\E#*PK@[%:;*RE+,4RK(-.\H9K+6$[72:V0N+*C+0IE:!R_#*%;-\0@[E.
MP2H*2?>;4D@BZ7\#U0G0ZZIFQI9#L!QMPE"U<S%=3Y4ALK3[Q3P65[#<DH3L
M/0=.%@]QE95L369 +]FZGT>D%?EN-@>[Y6Y)(W!)'NG?8K'PZA5Q#7@T]&S(
M*)5JEP-(9B53"7Y:@Z!N0RE7);;227G1O^ E1&_P)-RGNO1#G&,(Z?:4*44F
M;(]C;;WY<SR=;45.I!X^6 -E'WM@.B)U>M>O;EGJ#9BGB*E6:0W#8:@,*?EK
M)XN+4D-#9MO<I3S7Y:4@$*4  >DOC2]1LA67<JR9>+5ZCN8S#XF7#C6Q/%;A
M6N-#4=MBE/FJ3\?>5MTV9/<;"")+M;!H6)\@J<DRW+N,EUY1/O./NMPR\O<'
MT1O[NPV 'H$8RWN)7[YL,\K*Q"2LJ9Q^.F7**?BE/ML];O'CL=UHCH]?@/B>
MB*5+"9.EC$X44#))#]Z'$?*+3MTW-NGUK;\UOSHSSB51FBDE25(899X$+23N
M I4\V[I]/]*HK6"M5D_);]N(F2B@+#-E+;85NVW)E.+_ +4AQ2L;I=DO-#?<
M@$^O7,/J=K7@,Z^K\EJWLFG9="4U%=O79Y;BSZU#J7%5UL8_LBQ$)Y%IR&MJ
M4R5\4++9XA&\W[@IJ;5M>'_*<2-8QV1-;EY!9VK@FH!0I$9;RD.B*Z=WDQY!
M?\AM2FT.JV2.MC#K+00^9@>SEKDN?2TN0"#IPEP0QS@/!!#Q&JZ)<@[W<R2J
M2FOR+!M+6)"RAMF)RR.\^^* *O(@>77M.GX^4I;B&UJ4I1(2>B+E>2ISF'%O
M-3=2<FU&BE"7H= ZXBHQUTN)YI,NOK0V+#<$!2'UNH22$E/QWB4T-JLUR2O?
MN\VLIU77K/FP6XCC4&44; !3:U,K5NI.Y"E[\DGT3\.EALUECDS#S3.$1V4%
M,=I=Y$=0A 'JE"7:\E(VWVV^!^L#K)#$AP6TM["T"X! ,Y1XW;EK">38ZKF%
M6KK:.! QVL;26(\2&PU$:2A*0@$,L! 2?4 $DKW]3L1ZIHWG$V5+:W>=E.JF
M1(\9(> 7+L)#@;A5S*5+2%29CX2VVWN2$AR0X$L,NN(;NB[K\;QY[(\QGS':
M(+>77R;FUDM763R$.%HU>*54!RM-V^V\A:)EBE+=73I0Z]:3VRVB,[CZ5Y,_
MJ-G%;'8P^M@P6;95E6)^7\K=D4K+@0RH+F_+48+FJ82EE<M#3;CAW3';::]S
MHQ9\DX@3PQQ  D/8'7G+:L5TM:6Y*QI+I!B\&ZBV,^135C8F^Q,E15/LGE3;
M%WSBZF&U$;FRWTB4M:_-;4A"6EK<" GF=]P5KG%*_C BU]=7OR(3THQ3)5+D
M-1GEN(B./'V>.J&ZORC+83%(E):2ETAI2D*.]1VXR,BTFJ86&W.0TXR=B"C)
M')F6Y1=3)D0(;=;%8,MM;%F%(K)P2M34!$3Y1CNJ;>47&(YZ1_)NT^XTY@6=
MO5LVUR8;3;UL_P"WO6YCUJ.9D2U)5-4I#D53PE%IB(IU3;;R  &SM%I..TRN
MHCV-U2!'#:RY-CM.'D"ZQ ;4ZE3H?5MYLF5);<)0$MI;BMH2G@D;:W4:VY9#
M$BP8K:X\2''*E%LDH3OY:^#B?0*"T..**=R72"YNA('1 T_PJ_=Q^GM($&6[
M%D*DI;EI866?:V TF>R7G Y_;#!*)+J OFJ(KS>!3ZAT%5I!+RR173'[.EI9
MBVRW/CV<I+2VPRH>>A/ND+2%)#B2D[+9?0I))*@DB:9;3<D:R1EC'6'IUO*J
MX=\W31BW&193\&R"G\]"@N0TV38XCDE]234R &9,5$+F%+A1N&Z8TRR[^T_;
M Y+1"M*B.I4J<EPSZG'[G)<<;?>$<*"7+C3:_:ARBZY]_-=7QIFZHR=GV5^A
M.(4=FB\M\[PUBP8CV$-F>F67Y*(=E[,J9%9:;<*4IDB'&+GF-J62RA*5#=7(
MPO46G*([R&LML+ITL.MH%512'V0M*2$$K<6PVXA!V4K9Q*2/@?K!%"SE&B.8
MZBZ)Y1'C7$J'/R73BQK:QMV.M;[MNUI_E6FJT.IF/'D,@JDX_P"<I3(<$B W
M(/-3B%(BC^YY\OG8QXH?;/@-D'H4W(=?-,D+A20MAQ%AC=_(BSX;B"G?VF.P
MX]S:6=]V' KW@KKJ:>PS%D5DR%*AZDY,)4)ZG>G6MO4XJPI+DEMYQ<=%:P\B
M&L.(,>/+;0EYJ.ZMA#JB00TWMA\/G3;'/%+[5.X/!X,'"&V>X[3S)[/$53)M
MJZWDQM7!-M*:T;7"\MO(H[I3<0)L69 =DA<Z$N/(6M"Z#!!)8BPL^3OZW4(,
M,!<22Q >6@WMDIRO%X0?[)S$75$E'[#6/(;2G=3GF#)\L)(2?3904 5 @@#W
MM_=ZBND/HD-J1)=#320"IIMQ*2[S!X!;Z=BE.XW4&U)Y>@*B-^I5_%ZE):[D
M<48;84Z\=',?45J0I$=M/SGRL)4[(V.RMP2AIL+<.Q]U*25")9L%;RWG?(?"
M5\O,4@-,<D@;$((6#P&Q"RIQSD-T%)W'456.^AF0V$)0D10G<>2SZ*2O<<FD
MK4VKW0G=3SNP()X\]SO;17J#/WN2VAAL'DX6DAQ6P(\MM"4E7+T')QP%(/HV
MWZ=&46,%*4.N^6DJ(^^J1N L^@.Q'F(22/=40!L#N1N>M#9N1I12N--X.* W
M:2DAJ2D>JE)7L5;_ ! 4V?>]220>B+1K=:*#]X9:0TM/%Y:UJ=+C>S@6@K"E
MN KV"@L -^NVPVZ@HI\';TH[I]0:AQA]==BUWD%Q5^>L.KE5-A(AWU:[YH("
M_:8-DVCS 02H*]04D)G:EUTV0UYB4N */%3:$*6VZ@I&WWPDI)2H >]MN5$$
MD@=1_=T.EK<'+Z35VM66A/H9.GV0UY:6VZ[,:;FV%%=!Q/-*SY+,NHD,N!I:
M4HKU)4OWFT$2>Q+=>3727@5ANRL''T,(Y+=##[AD<=N2RMW9PH2"I:G' G<J
M/'J6+3#%T8-BT",8S8R*V88?LE!*2Y'W2%,P&U_A)8@-*2V4#9*Y1>>/)2@>
MHK>V*I1D.I^+0GVRN-$<EW$H+Y*'L]8DNIY >A!DMQ@?7B!R3L=RD2]UTH/R
MWY:ME>7N&T$@^ZGT2/7ZE+ Y'T/IMOT1*'4PD(<"G%A4E0Y//O$%MA!&Y4HJ
M^&PW(3N-OW=NE#K\EQ"K8DMLT3V8V#K1:$F6YY-;')V/)A 3YBUA22"XA+22
MDJ 6K<$I%5-3LHO&\5K.1\MAN?=202$H0\5*:;=<&_!I*4EQ8WW5NAO8@[%R
M<''\<Q2(P):6G'DH!YO()6M03MR:8&WH#NK<@[#U4?7U(D3R+,(;2BJ5BK=<
MT?>YUSKB7$)()W*'1Q7L#N4I.Y]/3?<=%4655>0C+KY;$Z)R+:G6QL]%=!_X
MI]O9*T+1N>:%C=0W4DD>O3@[J/C^61O8$-L!UUQM*'%M(4=@5 HV!0O9Q*E
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MJ 1=37A-I*>SO&@H;'Y\ZCD[K*U'?)7?59.VRC]:?@GX#K;]S'XS7?WAI_\
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M5G6]O^&2M1M0\$FZAT];J]*TYK;ZBQO)\]Q7 GVB_D6*8??Y+CE1D<AJRAW
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MLD\]04H(+2]E(1R.RBF7N=E'BE)(V(2E) V'14=B/(1]]2$)4 H'S&PHCZB
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M77+$[+.2S22"3(S %EC"J%?Q.&1333)[(8=D[G[Z[?0EZ)NHOXOL[_@;D_\
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M:$NH6Z'D._VLE8W8W"4H=*%%+@05!(!Y%Y6W'=L,O*V:VSCN6,N2X'FW=_9
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MGW4+<4B,26VP&VV@A/#9*_+!+O%/)6^YZ4%RQA -Q7%QE.!A*A&2L)5Y#:4
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M/-7S)3MN%I!X A!W4GT, @2N'NM%L;)"?P$J!7^ E*%?%>QYA 2H\?4C;TZ
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M7V$;]9%4MN%+1,FMI6Q[4F:XA;ZTKE.QP5M-<>:D)#B^+3R]@II!*@3Q3R<
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M<PVMR8B(*GI+W&,T2V&M@$)*D(6C9)].(1NM9(4OB5;@$K22#UCD@+)V(40
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M.Y]3MLD"UZ?6=OL_.?LZ(C%7K2O=3C+3;J?=0MM 3N@I)*/0^ZH!*N2=O7T
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M@@V(/(@^+<^]4TU"326]WTWLLB!LEWF5$!&RBD;@%((W*B/0I3R!*3ZD[;?
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MU&?'^YG/&W;5';<[,FUAL>\__9 ]N! ^L(X'5'F=D\6P>2>)&_P )Z4G#H
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MN.J1*2G8EM(4?3<'CR/7H_<T'C7K"TGLU6E((4'/[(#MP\T^NY0V!JH"A V
M!)).Y3MMZ]..CYZ?U!0X5=A36T ]4P2W['^%!,IL .*2TEU:RE9;=(X+6D)"
M.16%I''BE0.WHI(((.Q&OA 1V5!82RE,E:R I*2LN**3R3Q/N>9S*%>GGD!?
M))Y;SRG[F@\;7EN.S502E+?$_P!D#VW'GN5A?)O]E-*2M(XG=2@GUW&Y&Q]J
M^YH_&S4E!3V7M J0Z7$N:^]MZB"EL^2DE&JVQ*G".6VX">0!!Z<='S4_J"HP
M\1B."HN0"6J<, <Q$1(B0UE! ^V7VU(;=#?GH"4K &Y1LI7%*=_4CDI2E [E
M.Z>()Y#7S.1,9MMPAD%+2'@YQ2XZ 4D(4>1*DD)W65%'$J2-^)ZGF8^YH/&V
M0$-N=EV[?HG8=P7;: WQ 'N!.J:%%!W.Q6X5GB2=CL#Y>^YG_&S=+9/92E*D
MNJ4AP=P/;< SQ]UEPMC5?B[Y:2I7 <?>"1OL2.G'1\U/Z@MTX>(" :*B Y$"
M[-.K,+DP(!=0&-NI1%L4OO.AUUIS9386I9*&G?4<1N01^$3MQV .Q]4]&OC<
MYM>8U+\*Z#42FV4/>#9V+27 ]!@R@2O&<D:"N<EA]84>/X 46_3X$J/26C[F
M9\;UE,ORNR_FMYE]M"O[(+ML!*UMN(2X0K50>I4H+"2H ;[*(]>IA_%>\#;Q
M0NY>S\/R1HUVT(S%G17PQ^TSM[U1=5J[HI0G&]7=-*>]C9MBG#(L_JU6_P C
M29L=(NJ5-A06"G.5=92D(6I.:JJ":7-)$NY!%ETJIKIIK-(J!/ QI<$MPB )
M R9R\Y7Y '=3\R=3Q<L(GJKENFHJD[DC8[@0]B3L/XQ^=6]&]3LRC++K=I#Y
MJ2K?E34BP1Z$I =KU$<0  4@<1N/791,S3GW,[XUBBX$]G&R5;<5C7WMQ2M/
M$C8IWU4V!.P)W2?7Z@/3JT[]S->-4ZIM:^S4+\D**4_L^]N'%2BDCDI/[*H!
M5]8^ )"=_0;=/PO]/_JN+8V9Q=VXR;!LQ<D _50X#57-]^2;& V3L2A./8X4
M [\MN*ZE0)23Z+*0H_'TW(ZJ-6\^.S:KF"E*.7O-8IB2'CS5R"/-71.((2-@
M=VU$^I/'TVF6/W-#XUI!']AJCU__ *^]N/\ _-7KPG[F?\:Y"4I3V:I5L4@E
M>OW;D5$?XRM_V53NKZ]O1)^ XCTZ?A?Z?_5&QS_F^-6V^X\M%#M^S%J(A2.&
M0(2&TA"=\:PP+ &_,*/S:&_(^OP"DGT"NE$P_N\[C=.O;3I]J[E>&FS:;8M1
MCS&.4[=DPT%!MB>S HFF9[#86X$-S6WTI"U@)"7' J4<_<T7C7G?^\T1O\=S
MK[VX['Z_JU6)_E'Q_-Z] _<T7C7#;;LT0=SM^/SMQ]/CZG_\ZWP_<W/KT_"_
MT_\ K[\?53\?_5RL:]M.Z/%1JTG?5W3XS,>LJ?4:EBV3Z5J=LSI+I%*L0XHJ
M49#,M>#AUN8HDEQ]/ON*.ZM]^D*U-U4U+UHS6RU$U8S>XS[-K2-6PIF0W:(#
M4LP:II3%?!:8JHE?!CQ(C2U)898BM);"B=B3N9G_ /P:+QKOR-$;_FU][<?^
M_5;H'[FA\:_ZNS5OXC??7WMQ]1\#\-53Z_ CX?#;]V@X8+@T Z@T@^(5/3U#
MA(K()!+AW[+9/F,_JH*&'BEYOFX?,!2 XHI"C\-UI2HJ]!Z[^A"=SL=QOUVE
M_<::RYW3=Z"R!LKMWTG((! 5OJED&Y 5[P&X]-]]]]_S=1)1_N:/QJ ZD/\
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MI\,/O>6X5JT6+ !!*4:AZ;A3NQ&WWQO+"60/7EL'%*25 $%1)V"/#0[Y&BM
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MW?VO]4_HZC9Z'1%)-[O[7^J?T=#W?VO]4_HZC9Z'1%)-[O[7^J?T=#W?VO\
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5,CK6])SD7_/$O_\ MA_]@B]$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g682449.jpg
<DESCRIPTION>G682449.JPG
<TEXT>
begin 644 g682449.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@ _1$E32S$S,3I;,35:0TXQ+C$U6D-.
M-S0W,#$N3U544%5473(P-S0W7S%?345!3E]#3TY?2U],24Y%+D504__; $,
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MOQ<G?V'D?W/CY0&7XN3O[#R/[GQ\H#+\7)W]AY']SX^4!E^+D[^P\C^Y\?*
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M''*W&^J50G9C>T]<H3@?*NR%<1BJ+8+1VS[#BZY6%0MI)&$5:1WV=D@S$",
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MLZ;FJ$1ZSRZN)G"RR0225'/:?;6':C0#-8&02W2+%1L\D0.4LB@F0QLD^CA
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MNH]T1)6Q^&K_ .8)E]B97^J./AJ_^8)E]B97^J./AJ_^8)E]B97^J./AJ_\
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M\V@T'C$CE$Q?62 R6A+Z)1)Z>:FS*M%(]DAD*^+6;C,K%2PY3KA*1A$C<:&
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M:C4$'9"]B:MHY\4)UB/L18K49$S$I($=R&5M7DQIXI7AXL!F,B!+.$&WQ J
MS/K3USK7KC8EM6LTD-ES2?W(RC(V<R@C3^\1)3%.(%I85 2*Q=*_@<;'639+
M%O+W,5^5"6,'4R<P@'&8Z](.LCGA I=#Y10/^03'[ 3?]0<?**!_R"8_8";_
M *@X^44#_D$Q^P$W_4''RB@?\@F/V F_Z@YC9*:"W,DC;]$9,-FHYL?U>*>P
MDSUREL\;LDVN/5[ L*J8543WT])+3?5/.,95RGKMKMG)/E% _P"03'[ 3?\
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M;HU<,BL@?8Q_L; !W;NX1EQ2:0BNP$>F72/L3V#KU&M95'65=:4.&E5LTY)
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M<8SC_ED)Q[LX\\>[VNYS[5G?JZE_YY"?VOX]JSOU=2_\\A/[7\>U9WZNI?\
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M^U_'M6=^KJ7_ )Y"?VOX]JSOU=2_\\A/[7\>U9WZNI?^>0G]K^/:L[]74O\
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MMP7[OQ[13GZOOZW!?N_'M%.?J^_K<%^[\>T,X^K[^MH7[OQ[0SGZOOZW!O\
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M.[485;$MS%Q>HE!SGK[5&T?MJ[9#V-NJ8R4E8-S77((X"A/MW/C \.%47C\
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M;#A%5=C2T=RVJBPK(CNTLA47D>2C!;=^> :CC&'S?83H29-LJ!S"+-\Y:/G
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M,!#=FV4577;;C^Y_9Q7I[URG_81.D;K[#[03V>SM5'7N)IS:T9 D>DPJ.JO
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MCCCCCCCCC_V?-SCRQY^?ECS^G_;^7\/T^6//YL<YXXXXXXXXX\L>_P!V/?\
M/_+_ #_3SC&,8^;&,?S8QC_9SGCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCG
MSR>/]7T;S6/364 H8/=2\IXHW0F23PP(CNI"1NZ^J^3S%5^<DCEBS<DMX= Q
M9IVJ](/LX"1UN8<;KJ-<E5,N:M]_K5O'J_V/\4N0=10H:N#E>^%E1UC4),:Z
MZ_U87DVEMGNT4^D$N A):O6)PM.V!=>68DQ*L3I"3QID1ESJ4C8Z+(F5"F^$
MI=Q_$%A_:8+' W86X;5@H3Q9NHM#L([(:_K#4%.NM78;IN8L2Y%SAN-5, 5U
MB\:O5F' 1::L7X\35KXHJ"*/GV5F:3:^W@@]H>UG:>-S&;]D+A;R"7,HH-CM
MX=?3U<2N+3_KOV@!6M9C2:A%%G-?PN,PV#F:\<P0/%ZOR5GYA-K#$Y_I+'"\
MJDN5]7"ZEE6GUH\(2SI<;F(#L-+?%Z[DV;V*F0L4V?RV!6)&"';^NC'QDF=!
M'Q4=&5VV 5U4D:U."W0>/1X5"0C+"R#<3G>Q73OLQXAW:^?>%M5TV[.6Y30V
MY/#CEEO]EC<5J*I6LF,WY4MUQ\2$9O7UA5+)1\%ELXBXTXRF4<;,QS,S%T9.
M[!QX&5V8R$7@EJ=G>TTKZ>>+\VNF;320S[K)&@=[]4[YK]%DG7KB;+7]:TFZ
MY#X=&\0>/6/1G82!%HS!*:LVC98[D#U^""QV8LEM1=HD#LU^MZ.N2SP"&=GF
M:0\VY%#7!A@AMZ:+$JNR05),T=LK.,[)-7V[ANGGUZW\!/7'K5/\//<\<<<<
M<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<XV
MUQMY>?I>[/G_  =MM?R^CG'GC^3/NYQG7&?/SSM[\>7NWWQ[O/S]V,;8QC/\
MN/+/E[O/RYQZ&OT[_/C/_.;YQYX]WEY>EY>7TZ^7HY_#C/.<:XQC./?G&<>7
MEMG.WNS^#^%G/N_D^;\G,'BE:0F#&)L;B()O'WEBR+67S%$6JY:C34MRP;C'
MLH6$)K8&(2 RR9,$I 6:-&[R0*#F#HRJ^>MM'/,XQKC&<9QG;W8\L>>^^?Y?
M?C.V<9S_ "Y\\X^;&?+F%S2NH98B4>;34"SDC&+2P'.0XTIE9P+2E<7<_&$8
M-.QF5<,2CJ-EM6YT!J4;O6XB1#Q,A8((&PPE^RS;CCCCCCCCCCCCCCCCCCCC
MCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
MCCCCCCCCCCCCCCCCCCCCCCCCCCCCE$[K\3SP\^N%C&ZAOCNAUNJ6T(T@)<2&
M SVUXM'96#2.BVIL/DL%?/='@_8D'?,BK--TFFJN.>LWNFF6[I!12GG<'Q]O
M#BZO=2Y5VDB'8.K.RV6YPG7];UM25BQN3R*Q[89AV9G2'?"ABI/$4$"QY42:
MF<R+CU1L8CS]HY0:FC92/Q\UU75O]T/^%5V,HJ VY).V=+]?)5)Q6N9;35V6
M-'HA8, E+/&B!P$_:$5&B9L4B\])2/RT5IL(DHA1L_0U9/?C 2.V===^VW67
MMS'#\KZP7U5%[Q^+F4H[(C-6S,--& $XX8)$FPTON'=J[,G3A@NF];HN/59<
MMO3W0WVQHILG4JJ_$CA#6M]I-V6W'P*9F+4[P0N#0FJHE;UN$Y=%.C%H2^N[
M)DHL=&829/.S2HF'K3S>)-1NY)(.1RQ"XDJ@8J0TEL=XC_3LKC7=E:CY1%R?
MZ]1\(YWK2V46DM4[7)%MNNIR$.EH+HA-(5;3L >#Q*>QE0G"WDA!EHZL=0-L
M]V&WZ0?Q&>H=@9QD-9A46C\FMMVJJ\FU8VQ78]M&:!E2,)O0:[(SN$1YDUGM
M-R=TR%V;5ZJ^+%AF[]BX-QAJU=H+[^17O[UW4B$D)1B8O'\W#SB:5$G6SR V
M9O8P^V8;76+3*QN25@)B3ZR1@X17KL/81HWI&]QB$#,AY"T?.$C8;1] G7'Q
M+H?9%=P&R+5/P>*JSOJYT.MM.J(5&+<D]ELK/[FC; ?1V*@\[1Q8388.7N8I
MN,K4="="4Q8[Q&>D[#:AAJ#!9O*XOQ,>J9R71H"'EIU_&93UKSVB'V4G"IDE
M!M($M8J57#0KPBO'TW+"?$)EJ_CVD&(M64H;R1JWB2XKVI+# Z]GZ=ORK;YB
MIN7UC(]SP^*S&8UU,1JX@R(D\*L*OR2@B90:8Q,LP9R.-RL"]T3^$!2HUN[<
MLG@PJ.U>BBPMZ\J\T\47I,_K1*XF=L%5*P4CVTVVFSBJ[=& DJX:MXZL;M7=
MT7@@_;:J(DK*@@R;V0@FM$84=6?1Z3%!AL(<8#O5!=]XG'#7;!O=NHR,AJ&[
M%/JE@JT!&S2PCU@0MCU5I_M03E_LP!"$CBSJ-0NQRY"4_$ ]\$'!0#9^B]<+
M%62+K/4_$+Z?KFQHEM<X9V-,!-SHZ>LA$G>50Y23HG;M!D;BV6H1:O$S^_77
M7-UI %9$F56KG.DC2:[MU$]=_P Y%X@O5Z'PDO/I9+9;& <;S)UY0VD-2VN&
MD<9!0B&PFQ)K-#D4(0Q"1LZ_A\%L>#2J23WXM4B8L3)AJBQ;+C=5NEY]@>UB
MD'G/6*DZA8QR:6MVZ+S?Y-#A=^\<5E&Z^K" ZV18-JR,A&ME2)\*/"/HR'B@
M*/NF2LPE,TC33:0Q\%L3D+",HUX@D2@,XOBGNUF&%;3KK],NN8 Q.HH"FQVJ
M9K%NW1 I'NOTZ:*H##IJN64@G\?D]62QO.7BD9B$U!-MEI\^#240[TG!KW=Z
MU.GR(W$\*-7CFB9WV8:I$ZYM /HZHZM#^L8FT_:."T+9-G3 (878);#&ZRD@
M?LC4=,BQ#X)) )$CU[SOCU6&2J00\Q:;<$2B\2G4Q./)!&9D" ,6571^+RJS
MPF\C+1YF$WG%;1Z:Q8E/:]3>[S>*X+Z,BX%L38%F(_L&_=3KZ\".2*4J/,S;
M:UA5&.*^*5O9#*VF5LGHKK/0L,=T^M%D[,P2?UWOFS4,I1G9LO6C=].D76T<
M9.R"%:>L?B>U%9_72A+<N@H*K646[& LF/L 06?FH+7HN96Y+*<KN03N7O8V
MFC6D6L&8Q=P BQJT5(FF_/(%ARN&NX4MAA,XKQ&.GQ>62"&(VLX'EHLW[ JF
MWLAKVT(O&&SSJN70"]@@2$PDD+%1<A**N<.$7LCBHXL[D7Q'OB0CQKT'C9_B
M4H3V?K>U81;DJJ7X_GQZE2THB<YK%  5C%FB+"C<58S)O7Q&'S%J!*AY))P!
MF-DXM@J@U'&Q4G FF+U<4_3<\IQU!\1,?>]/%>PLXE="Z4Z)A$<)3$E6\DF#
MR=TK=9:1Y"2#J_;U72,;F<B+6BKDC&P YHL&!2J=RL@N*&UF"V6 IG) /]^H
ML\M+K#'JT;LI3!;9M'L;45O[%0\Z!VK4DXHBA9A=*T8=UBY (R-"3J)1+X,2
MC9P4U,.@YZ-G(LS-#CHUXX[2=>)=U7B4-C\R"R>56$A*X_U0FT;&0:M++-$S
M-=]SK38U)1\_8()P_7X3'C<H</D""*/K#@AV+W $0[:3% 0<HCO?BH102RC=
MC6''B^(Q>=\5P'"576MW&9<*C]%ZB7<YQ,82]B#J7+EJP&$D'=I2^.A5:Y';
M$P: DFNY*,6[W+"/B&=0QT\%5U\K."ITP7Z_AFQ.-PBQI1!4%NU*+O?KL0)6
M9'HB2KH5'K@=,\AX/)W\I0CI>0NA\=T*:&R#9CO=/&?/W_\ O_[_ ,G,>EDM
MC$$CI673,^(B\8!M\.S!\Z_;C!(UOLLFWT5>/G6Z:"&JBZR*"?I[XRHNJDBG
MC91337,!?OT^I?\ &+I_[<A/O/(HT\1KK+O<RU7YL2(ZQM.")2C2U]I./Q!E
MI#L2V04@Z9'T?@F3"8C9(MZ_#W*6ZF5!7J\/TLZ;2O\ OT^I?\8NG_MR$^\\
MP2W>TY !,^E+.H/D[L:O^U5YR.I"DQQ("CG4 -CM)W#=#B113,=0?CY*]V1I
M<Y$50K]R+PW*EVCS9[O\6NQ;N'Y+XNO2P55\SM*,S*:SP9$ZR$VZR%Q^HK9'
MDYK!B]NM*(W-P+,GA(1K+VL<M5^QB4[R 5(KP%Z]8[RUL*3(L/A,Z[]^.J3>
M;R>!$K4; B\."66<D).1QN81R(#DZ7BL<G%PB%IJ;C[&*XE-5Q&6@#U@Q+);
M$CBK-T^3*#$7@"1M1&/H>(/U_)SRFJY _*28E%Q7;.Z"3%_))9@DG7]@U[3N
M]X&A]FAC448&H5HY@;V*GQ"II@T1(QV6CY:FMK%AQTJ-Q[MQV^FO3RQ*CEED
M0L$KTYG1I6OK#ND-F5FIK35GGV*C:HF4F@HI@Y;%(+;DXRPK$3+QS[1S'K%D
M,)CI8(JRF"<A#>NIWJ&TNZK*%]PPK>I['F]$7=V3ER\/$SN8U54U:4P9@; P
MSF=BZQO9CB4-4+&CK0NBVTU&MY-ZT"/<D,F(2[E^0$/$EZC"6.BQ*<R]N;R_
MNT.M TJ8NDA9S0_UUBL>G5P1M[6PNOWTR:R.)PF5QR7I@E1&I.1QDNU.15N;
M&^N<H^V/\1WIT2:O'[:V'&H]N6Z[B6)!U75IL6$FT[9+/&?7.00EX\A*#>;P
MJVRHTJ"B4[BNY:'NY"'+ 5S;<L/7:8]-YXE73H;7*]JDK&E3&%#DBVLD?+4C
M?"A&#F =G/:6*0^PX\UK-S(*^L%O; ]W7R==3$8&G+V4Z:"QT?>*N&V5I<@'
M;6B+-M0Q3,.ESXA/!#.Q7R31U$)D'"R!&GIP*K*WM(A+#(!A%Y<[JJQ3@B#V
M&QCQ<@]B<H?)"2J"#C1?"-;PO:?L+>TE[1N>K<!J4W!NK]A36BV:=I2&9@3U
M[WO6\?$E;!C<?*@QBPFK()%I(::5PA.C(BQG\AEPZ5.4XD&CH,:4DF;F/$7Z
ML0EQ,P]F6'K"S]7P>R9C9FNT8FQR,1U>C83%I[?,8&34'&B,9ETJI^.2X.5F
MD9BQ(L?'#E';GXN4R&/IB>T4\0OJCHSEZ^E@&W!*#3-6$2&(-JRM):P]""5;
M/+DT-AZYUAOMQ*(0_J8<0L4)/HP ,0Z111BZ(@#1/='9OS+D>Y?7PJ4'Q<)8
M&F96?MUMU]CX\M#K#'-%+J,4JR[!QN&%'B\420&:GZA*#9X&-.UVX$V%<9;A
MBSTSIL,UKQ0GB65#*^N?6"VKZ- ZJF-^5Y4,M.AQ+26'H1 "-SR_:MX)[33'
M8.HSB$7F5E:;0>&R.<N0;0T>UW995141<Y0M]3W8RJ+X<GVU9F3!K$>&1V0*
MOWT-F,="&XM+R$L%Q270V02($+"3B*2)Y!I3H+D$2?F!JV@K*RBR23MANZG+
MCCCCCCCCCCCCCCCCCCCCCE$KK\,/P\^Q]C&[>OCIAUNMNT)*B);R&?3VJ(M(
MI6;2!"VH0/@L:?,MWA#8:'8LA3-1THJJ@.9,V6F^&[5!-.CO=G]SV>'%VQZK
MF>M\#HBK^JYAI("4^K&U:.K6-Q\] ;((C!HEX;("QOQ-I-XR?&!A B80PP4;
M-#0L8-5&D $@# CPSV^KG[G@\*KKI1<!J.2=3*7[!RF,B]?:RY;MKJ/3"P9_
M*'GH+FSK]V12=IA1:SSTDP$3$[ZB(V(3;,$-GCSXP*D=G77?J1UEZCQR013K
M!0U44-'Y283D,B$5;"0T.8'3C=@D,:DRZ(=NWV?NFS%!-F@HXWWR@VQNDAZO
M"BF=J2Q[PTI2)5K9V3OP(4>5W8?B$6"ENTIYV*;%5^_969R N+4;J6P349H5
MB<G!106ZPY=*RL4V8#WJ0)YHY+.,?">%E( B=0MT>P I=M54#\,F"XU5I]UJ
MN=1\-*Q+ L.+$ME=+7RF,5M=W8+X;(FVJ!#2+-A[1<6L7647USX2/PG\S*-;
MP^37QOD$[#>)4$?K *TT%F]4O$6M4?<+P@*>DI\>',R=+2T2-^(/C$.:%S8>
MVRUD L;HNXU4R0+X>UT"5:$L9+L%3(?L#3DEM+4](X!U)&UO2EBUQ<]=1"O)
M_&R5,1JX$S8Z9NG%>PFPA-@KVH:^+)F&7%:1K>O'B4/981!_"UM2MX!"XI%N
MU8?4K#J'Z ]>G3YY1KY$%.Z^Z-3RU)0X!3<*+NAD3= ;L VP4C<P#@))'\L-
MP 9PJ^/1XE*(>9PL;X+NHZHXW6*'9)PS=1SK1+.O[4^PI>-X9)%&/:QIVUHR
M?,HF2EY$$DUK.<#AX*95V21-1>TXLDN*35@J"^<8NM7?1"#M1M42JZA]83R]
MJ@DI^;PR9U76YKKU5\7EAI<,XPXC=-0^QS#=<;HM' CE_K8$NL$Z4=HO,[GF
MHY=D*&5?;>%+)(S ^GT:A-ZUXI(.L]-S#KI+B=J=8P%O1"TZCF)>.GLOA,!D
M5CMD*WMJ)F(N.(Q&;)'I?'<;/#@V60:4@R+<8/R.V?#*E\SGTLMJ%7A706?%
M.S[B_P".C[.ZWL;AJ]"+R#J]475>9U;-J_=VC%,RW).,4I!YS')P .P(G$YR
MR720$$(H\> 7'56-X8-ESFU0%@M^S$1;CX"2'$:L%2;K9'I6X@@]7IA8W4N6
MP!F+UL('5V]628M/5[E=PH?5PA$@?6-0^6/Y3%<Q%*(XNP\)$_$1-7YK&YJO
MB3VN91<39A7,TZ\/KSZW1JG+P!U8TEU75!4EI7.3/U.B$FM1A+8K;<;8Q:%U
M_*)'-H>-@#FKCB<1:WRN_J>RL@YUQLR$2O2#77U0,GB-1S,G'FT@CCT%-H&K
M6UCU_/H8'>P]N6ADZC&P]RY0C1&*$8]+8U$9( =(( U01.%B?AZLI\AV.(W!
M.0\UDO<YW6L.[3(M(:6$1&5]:*QC<CC ;K;78S>>O9!7H$HSEDH=R2>JR:1R
MPD5F\])"D8ZN5B^(37^4],+(E9?HYUJL-6U;5UZQO%9;*.YZ 2NZ]A<SZ^JC
MY/#C74>=A$[,D<]FLLLH5'ZD&6;LSA R(RD#&Q]B.).(ES!2/N<YDWACR^5"
M>W=0O>SY@?UB[.3BU+F!5X&K1@A:=671;SX/+#Y1O<#^8D1<JK8!:HM>UXC7
MN]8QXFWD1)0)(9N?B3)L&WR SX>]AE;%$=EF-ZQ8!VR9]AZ]O,G+VE1$7M,F
M!,-ZY23JN9K1S5*UH-9/@/*ZRFLM-;2/:T59(!G[L&09.7<7CB,8?0M"_!\(
M1>K3E,%>Q>TF@=PTO#Z%[(([56U$$)I"JWO6W+BA!>M-\S@PUK.9[@KKFE9R
MXJ12FPXNPTC4R B(O(@"C<KD\U\)-.Q!AP%)[Z72#R2;^(I,RF8_6J0\NW5[
M_MG^ZR 5\3G1L>U=4V<>(&0KLH&-,)MJP0&' @MHL\RYN)1?6ZSJRH>>5[*K
M5KA:V)V,-MU[/HGKZ!Z\Q8*;=0U&)!9<)K45,)FZWDK-PV1E)8@7G9/X<;WW
M9!$XU&V@D,PJ?,?"V*6C)['M&>W+& -XS"K:"A2-HTO3B5<[2VP.N%W0'L16
MMTWE&B4^F#6U92&L>M8V*&B?C2/:!*X+6##!L@U3F#1[&)4C_A_DFMPP*]3]
MK#7,V9]EK:[06J.#5_L-C4QEUF]3Q?3UE'8:BM,'!"#@HG6(  ^P^,KSPQ))
M.Q<D'ZK!N0V:-JSP_P (JQ ,*CT3+=K@[U>OZ"Z74'6Y(3U^3')B!O0_M4CV
M5IB5RA@0N$QF3FSR+1M#;+8L7<:%F5\J2*,)Q)+74$K-3+PY9M$[**W17_8
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M>>08XZ6FPB2;RYI'BL?JP1\/#L(7KFEQA/O1(G5XU!U*[(=2MNPNE,C4YA,
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M+T[7?9EB0WO.BNS.L7F&(UU=F5?M2+<78^)D/%IQDK(Y)J3?5JYJ121)$YM
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M243QAH\60PY304QOKG.VR&W\'?TM,;Z8\\;8USMC?T=_1]',??$5H_CN,_\
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MG!^Z]&!^METAB-0,FG; 6EV&LOK/,Y.4ER$X-9ZZ%YGK%&G4,0O#GM2"H[9
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;_P"EC_V\\/P)_P"G_P"S;GZ\<<<<<<<<<__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g387315.jpg
<DESCRIPTION>G387315.JPG
<TEXT>
begin 644 g387315.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!!1$E32S$S,3I;,35:0TXQ+C$U6D-.
M-S0W,#$N3U544%5473(P-S0W7S%?0TU!6%]2051)3TY?2U]"05(N15!3_]L
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MEL6]1(S[MIWNV ^9;%O42,^[:=[M@/F6Q;U$C/NVG>[8#YEL6]1(S[MIWNV
M^9;%O42,^[:=[M@/F6Q;U$C/NVG>[8#YEL6]1(S[MIWNV ^9;%O42,^[:IWE
MC3O%PQ[)>1+"^FT,IW)DED/NRG P& 6K[W)%8JND@0]OLD@I+6RY<) -=]AP
MK@2 ;?:FX<0AWN;R9WU18&1YSU :>-'L803E2NOQXQ8=AKXM5-Z"-RF7PR26
MS)5.FX2CE:EVC9"YD%CM+)L;U1I*^P5!99E]PCO=L!\RV+>HD9]VT[W; ?,M
MBWJ)&?=M.]VP'S+8MZB1GW;3O=L!\RV+>HD9]VT[W; ?,MBWJ)&?=M.]VP'S
M+8MZB1GW;3O=L!\RV+>HD9]VT[W; ?,MBWJ)&?=M.]VP'S+8MZB1GW;7UHL"
MX0;CA4M^(L;(E E7D"<EA4=(-$DR\LR\H3"F^VX2[[R2K[K-N]&XNP1#;;;L
MJS2M!$ \8^,=@?TC^ /PC_56@W6@.P1\/]0B ?@VB ;+=OWMHAM^]MK7? ([
M-OA_Z>/8/B$0^^ #M#[^R@^+Y[?I"J%Z;_Y*$']\<L?M;G55UI2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*>+QUMW]G\ZW_ )@_ZTW]G\ZW_F#_ *TW
M]G\ZW_F#_K7&9=:-H %UNWA"?OA_^[9_35MK<AKK0W/73[MNM#]SRIXQ#GSR
MC5RG?V?SK?\ F#_K3?V?SK?^8/\ K3?V?SK?^8/^M:@(#XA ?ZAV_16M*4I2
ME*MW;J0YR-ATE*9)$Y=,H8^L.H'1T<F=(3*7N)KUB)YU>8-BK\Q.JMA5HE3I
M&G^.2!X9W^/+#C&EZ;UAJ1S2*D]PEU;PW1S)N2\?:O7)^09#EX8>BT%TDWY%
MRE 7&5FNFYIA(=1$K _,<FQ<U.B"*YHA.J2.,CO YLM5(WV0X1CL%*EV0H^]
M80>UZ.O7:>\FY)/RSI*S"ZSJ8J\BZGMT W1_3UFW'[@]R)?'6K$F%+]71>-8
MFCB:U6:PQ2_!M^FO%3<WO2!E:UBY7+YPM5*35617=0X7SY0]N3"U<?:XH^S)
M7QI(1W%CJB.IG*XL\T+#55ILH?HXU 0DM_=#[3',LZZT0 @LV[;:$4<!Y(F"
M#&:!.EP7DYX)^%.33N/-[IB8M,)BG*,T4')K;'')B%6!J$TV]"J&]+85>J3G
M7I#%2*Y.K45DY59QT=\M^E\,]K%.56<='?+?I?#/:Q3E5G'1WRWZ7PSVL4Y5
M9QT=\M^E\,]K%.56<='?+?I?#/:Q3E5G'1WRWZ7PSVL4Y59QT=\M^E\,]K%.
M56<='?+?I?#/:Q3E5G'1WRWZ7PSVL4Y59QT=\M^E\,]K%.56<='?+?I?#/:Q
M3E5G'1WRWZ7PSVL4Y59QT=\M^E\,]K%.56<='?+?I?#/:Q3E5G'1WRWZ7PSV
ML4Y59QT=\M^E\,]K%.56<='?+?I?#/:Q3E5G'1WRWZ7PSVL4Y59QT=\M^E\,
M]K%.56<='?+?I?#/:Q3E5G'1WRWZ7PSVL4Y59QT=\M^E\,]K%.56<='?+?I?
M#/:Q3E5G'1WRWZ7PSVL4Y59QT=\M^E\,]K%.56<='?+?I?#/:Q3E5G'1WRWZ
M7PSVL4Y59QT=\M^E\,]K%.56<='?+?I?#/:Q3E5G'1WRWZ7PSVL4Y59QT=\M
M^E\,]K%.56<='?+?I?#/:Q3E5G'1WRWZ7PSVL4Y59QT=\M^E\,]K%.56<='?
M+?I?#/:Q3E5G'1WRWZ7PSVL4Y59QT=\M^E\,]K%.56<='?+?I?#/:Q3E5G'1
MWRWZ7PSVL4Y59QT=\M^E\,]K%.56<='?+?I?#/:Q3E5G'1WRWZ7PSVL4Y59Q
MT=\M^E\,]K%.56<='?+?I?#/:Q3E5G'1WRWZ7PSVL4Y59QT=\M^E\,]K%.56
M<='?+?I?#/:Q4>]6V?<LP?2QJ1FD2Q#E>#2F(X*RM)8W,CE^&EA44?62$O3B
MU2,Q);D1[N4ELBU.2Y7I[69VN.M3#8#:MWW%[\%RW=G]U &RP1U?SK:-E@B/
MP2Q)X1&T!$?Y.OOCX?\ ^@K=\<_NG_2^G75+$G9U3XY_=/\ I?3KJEB3LZKE
M3[L_NG_&$PCJ\G%P I3W;V^'XA,LNWIUEP!?9?CBZR^T1 -]9?;=9<&VV^VZ
MT1 :!:8]UCW1'&>"L?0F":H9?&HJR)I-:ULZ*+8O.(2]T9U*WE:('KX$L6GW
M*')R6*;KU*H^^WA@)+NL3%$$E5X^.?W3_I?3KJEB3LZI\<_NG_2^G75+$G9U
M3XY_=/\ I?3KJEB3LZK*6W$76AJ;U$Z5Y[-<W(\GZAY4V9XDT903)%9AQC*;
M6%'"8 XIHW<D-?<?7&&(ESFO<+E ,RJV^UTM+[IFB7Q9->/Y59QT=\M^E\,]
MK%.56<='?+?I?#/:Q3E5G'1WRWZ7PSVL4Y59QT=\M^E\,]K%.56<='?+?I?#
M/:Q7V(<F3)6>)1^!LHMQ8%7F H6.N)+R1OMO*MM) $63E9W"&6F7&6B)0%!:
M28%YEMXEVWUAI5,,P8:QOGJ$*\<98C9<NA2]UCSVM8#W1\:DJITB;\W2F-+#
MSF!T:%IAK))6=I?VT+E0EI7AK;G$NP%:%,:5X7(VE# .6963-<@8_(D,@%EB
ML;>#C9#+F]MFT;@TF-F<.CF3H^T2!OCV5X]%Y2J7OK"QY*:I6UM;BZO)Z1*4
M#T[6+>RCVF7!<5RJ[YK8,=M+=DAY4R9>H>RE;R:A1.\V*CY$YD+#%U+F?$8O
M*9Z3%8X5/95&F%ID4XL96ZV5.;L":W;78?%\]OTA5"]-_P#)0@_OCEC]K<ZJ
MNM*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I41-T ^X6UD_FN9Y_9C):
M_+HL_@R_R9?ZEM;J5R$W6VG$7776V6@>3MNON"VT/W6P/#=<( 'SB%4OPY=:
M.-(H%MUMP@0\;0MNMN&W;)WT0WP6B(AM#PAMV;0\(>"JF4I6<_\ 8ROW"N5/
MSIYO^S3$U9&-*4I2E*H[G'/&,M.D,0S_ "P]+6"+N,VQ_CM(O0QV1R6^Z69/
MF3+ (4A4)(TU.RI C=)9(F=K/>W(I&PM(K;%+PYH$H";7#DS/6/<62&"PI\5
M.[OD#)BEV*@F/8@PN<JF<A0QR]M"62,MF:B3!;(?#RWAIOE4R?E#3%V0YV96
MQ4Z@]/S&V.7D(EJXP=-<NN6%F"3+3Y:B?)Y$VY<JCSX@A\JFF*>Y_*K"H;,E
MB(F/2F68U%T2ES%D:5IZEM4)W](0*Q7#IH1'9+#XOGM^D*H7IO\ Y*$']\<L
M?M;G55UI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*B)N@'W"VLG\US/
M/[,9+7Y=%G\&7^3+_4MK=2OA<VMM>D"EK>&]&Z-JRRTM6WN"<I6C5%VF6&VV
M'IC[;RC;;32RS+;;[1 #+++P#?6@(=<PQ6,1:Q25&8ZR1\M;>48L+96Q&VV*
MC"+;[";U%J0HJTV\JTTRTNZ\+ALM,O"T0"X=O?TI6<_]C*_<*Y4_.GF_[-,3
M5D8TI2E*4J .Z;Q67S;2-(8W!(=+)Y)SLOZ6']+&H6PN$B?535 M5&%\B2Q8
M2@;RC+N!9X?$G]Y/O.O)L-L0"C37'."I$C4PGUB85U$&ZL,VYBP^BS8GRM/M
M/VD.*Z-<AX\,E5L B,SQ7G_)DLS/C;.S>@$J'L^/)@US:(2>;%Y?2FQN6PU.
M_(XO8;DN&,**WDP1@/,,?RGI/PPNQ?*&4G2EKLW0C4Q.LM+X\K20J58LSK9J
MKNPZ?$YL:I-:Y))\E6:KHY=*XLUNCR_11?C2;%S5$SD$1A2_7KY0R.3\U=SV
MN5OL-5<:2'@]1U/'5+E:4G-"\U):5*&*1M(D*[?W,\3&PPZVT $@TJ[;<,4<
M!XWF"_&:!0ESIDYG)^%.32>(M[7B8Q,!B;*,T3G*;;W'&:Y6)JXTJ]<J"]5>
M58J4'6)"TJ*U.D3UDY*IQTB,M^B,,]D].2J<=(C+?HC#/9/3DJG'2(RWZ(PS
MV3TY*IQTB,M^B,,]D].2J<=(C+?HC#/9/3DJG'2(RWZ(PSV3TY*IQTB,M^B,
M,]D].2J<=(C+?HC#/9/3DJG'2(RWZ(PSV3TY*IQTB,M^B,,]D].2J<=(C+?H
MC#/9/3DJG'2(RWZ(PSV3TY*IQTB,M^B,,]D].2J<=(C+?HC#/9/3DJG'2(RW
MZ(PSV3TY*IQTB,M^B,,]D].2J<=(C+?HC#/9/3DJG'2(RWZ(PSV3TY*IQTB,
MM^B,,]D].2J<=(C+?HC#/9/3DJG'2(RWZ(PSV3TY*IQTB,M^B,,]D].2J<=(
MC+?HC#/9/3DJG'2(RWZ(PSV3TY*IQTB,M^B,,]D].2J<=(C+?HC#/9/3DJG'
M2(RWZ(PSV3TY*IQTB,M^B,,]D].2J<=(C+?HC#/9/3DJG'2(RWZ(PSV3TY*I
MQTB,M^B,,]D].2J<=(C+?HC#/9/3DJG'2(RWZ(PSV3TY*IQTB,M^B,,]D].2
MJ<=(C+?HC#/9/3DJG'2(RWZ(PSV3TY*IQTB,M^B,,]D].2J<=(C+?HC#/9/3
MDJG'2(RWZ(PSV3TY*IQTB,M^B,,]D].2J<=(C+?HC#/9/3DJG'2(RWZ(PSV3
MTY*IQTB,M^B,,]D].2J<=(C+?HC#/9/3DJG'2(RWZ(PSV3TY*IQTB,M^B,,]
MD].2J<=(C+?HC#/9/44]=F-IB@T3ZNUJK.V3WA,ETSYP4'M3@UXE+0N))&.)
M$::A6&-V,D#A8E5V67)U%Z%<B66E&7BF5$&A:9;^:-9^\+_)E_J!6ZE*4I2L
MUS['"A<CD>B7)ZQHRI.8.G+U.3)->UQE!C]4A/.+QSBTR]<:9*H1)' %1UAQ
M9!EA*XI&!28D;$EAPG&FY _)5..D1EOT1AGLGIR53CI$9;]$89[)Z<E4XZ1&
M6_1&&>R>G)5..D1EOT1AGLGIR53CI$9;]$89[)Z^Q#C.9)#Q-/SSE%Q+$J\L
M$ZQJQ)82%]UY5UIP"BQBD.X0NTNXNT!-$H;3C!O+NO NZRL(CL 1_ &VHIE:
MSL$KM0)&EIC?7N2YW)=7%-*,?1R*2!W<\<QIOCILA(R3DY4E0WM>/\92$.(L
M,+FDF7M[;.9:YIHO$>[+PF=4S;*L0"X-EP (#L'9< #_ $AM ?OA00 ?& #_
M %A^ 0$/T" #_6 #38 #M   1\8[/#X=FW].P/T!^"@^+Y[?I"J%Z;_Y*$']
M\<L?M;G55UI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*B)N@'W"VLG\
MUS//[,9+7Y=%G\&7^3+_ %+:W4I2E*5G/_8ROW"N5/SIYO\ LTQ-61C2E*4K
M2[9O;MNS9O1V[? &S9]_^C\/]%6/R)0G:]TT9H$SY'Q:M:7G4%)Y2_XMA#!B
M1"^LDM#3&_ LET^E:=N=\N/DQ?FX8@W=RQ<D5[8ECRQ))"&.!WX^M<IZZ\LW
M9+T[Z?0RIBRR'&OC=F/3=$7@B:M+N\H%$-RMJ%QAB.6V-2=G>V Q-)262=JU
MK Y+E*UK0."4HY>S.I.U-5.-9NKF=X3F.G^#8E8H\_+99J?TM8[S@^25.YG-
MD$Q=GK,#=C%(C8@1'I"G#)\L4JU"B/MQRDQ)'(PSODO?D]X&Q-LD=*,+ZV\O
M3O)>#I@_-D6MP'JIU0:MM+>,HVE9E*&:P1;II*S>;#<@R&17/BXJ0EY7*TTY
M75O3"6Q-Y$8)DF.DK>IL,9I*MDMTF2RR+PUK%ZETB9(NS@I2I;G60.B)H;K%
M*LS@TI%ZU><0FL-4& -A5EQ@7&7 (6@(@-16P#G7"K/C)"A=LM8X;5H2O)RF
MY(NFD>2J;4Z[*,T7(CKB#G"PRTM6B4)U::^ZT+3DIY*@L;BC2[[JS=\3@/GI
MQ;U[C/O*G?$X#YZ<6]>XS[RIWQ. ^>G%O7N,^\J=\3@/GIQ;U[C/O*G?$X#Y
MZ<6]>XS[RIWQ. ^>G%O7N,^\J=\3@/GIQ;U[C/O*G?$X#YZ<6]>XS[RIWQ.
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M ;;@ 0$ &T?" AX0'PA5!M.*5-?BEO&].1<(3#*]H#<27<(6AEN=;  1M'8
M?>#Q!5<^)(_)$WF"O8IQ)'Y(F\P5[%.)(_)$WF"O8IQ)'Y(F\P5[%.)(_)$W
MF"O8IQ)'Y(F\P5[%.)(_)$WF"O8IQ)'Y(F\P5[%.)(_)$WF"O8IQ)'Y(F\P5
M[%.)(_)$WF"O8IQ)'Y(F\P5[%.)(_)$WF"O8IQ)'Y(F\P5[%.)(_)$WF"O8I
MQ)'Y(F\P5[%.)(_)$WF"O8IQ)'Y(F\P5[%.)(_)$WF"O8IQ)'Y(F\P5[%.)(
M_)$WF"O8IQ)'Y(F\P5[%.)(_)$WF"O8IQ)'Y(F\P5[%.)(_)$WF"O8IQ)'Y(
MF\P5[%.)(_)$WF"O8IQ)'Y(F\P5[%.)(_)$WF"O8IQ)'Y(F\P5[%.)(_)$WF
M"O8IQ)'Y(F\P5[%.)(_)$WF"O8IQ)'Y(F\P5[%.)(_)$WF"O8IQ)'Y(F\P5[
M%.)(_)$WF"O8IQ)'Y(F\P5[%.)(_)$WF"O8IQ)'Y(F\P5[%.)(_)$WF"O8IQ
M)'Y(F\P5[%.)(_)$WF"O8IQ)'Y(F\P5[%.)(_)$WF"O8IQ)'Y(F\P5[%.)(_
M)$WF"O8J(VOY*ELT,:R+K4R>VX-+F>1 ;22[1 0QE)1 0$+0$! 0 0_ ( /C
M"OR[[/X,O\F7^I;6ZE*4I2LYK[&9((-T+94$TDHP>^GFP;3"[+QV!C3$^P-M
MUHCL#:.S\&T?PC61;Q)'Y(F\P5[%.)(_)$WF"O8IQ)'Y(F\P5[%.)(_)$WF"
MO8IQ)'Y(F\P5[%:@D26CMM3)P'9LV@26 [/P;0M\7@#]%6T,])-T!P%ER;Y.
MTAX<P9JNQSF=5'GV<XER?FE?ILR'C[(T;A<=QY;)85D,G&V38G,X%)HG$8W>
M[1&1-#!)(K)6I>X,C[(6J67MD3KCI"Q[J$9&W)&5-5"K'"#->:Y8U21SQQAU
M<]/F-<01",Q9KB,*QZTS.2MK+(,C2!.A0+9!-I^N8(RA>),_JVV.1MLC;&U&
M+)?J%*=(5<>J/*3DVC9;<<>9825:)E]I987&&76V6[\R^PNS?7!OC+[++=MU
MUH#\:E[9T;FW,JIT;DSN[EK#6IK/7)27%R*;K"S%YK>A-.L5KBT)9Q5ZR]*2
M=:DL,+O4"7;?:(ZDO+2H<UC*G<V\]X;DR18O:REJ8QQ0I%]Q]J%4L0V&W*DJ
M=;<F46HSSR2RE0D' 1>8)1F][$?%\]OTA5HN([H? <,(GO&+QI_UB2]RB4_R
M@A527&^G.5S2#NUZC)<M<;5$>E+>I+1/"0LM;8F/4)[ L*7$*TMW[HGOJ?B[
M4 PH-/ENHJ^!Y</C]T%13T,?I<>NBC,8(5Q*<ZQC''%IH.P2PFU3;8J8.%XT
M0:6=9=<(ECMC_A?=!X%F[)<=Q>S8$U>PMSDG=;B\ER?IWE,&@S=W'9U[R;W:
ME+BI,1-G&R6\Q&W<-8/'',](A+V&*+!KU.HG6[#--TU;(/(L,:GLB+72-))0
M4]87P;(\EQ=,F5N3FV6-B]]:%!29(^E&-9JE0U&6B>2A5(%5P[Q66 5/P_J(
M8,RXC<<PM$ S##VEN,E19D1R3CEUA>1E Q.PV]5<CAK@:8O4V.@%"#!=88 .
M]UY=I&]&\*BW ]TWQO/YC#88@TW:WV%9-9"PQQ&\2[2_,8]&F=1(%R9"0XR9
M[5*[D[(S(+U-I[NY*+;B6Y(6>H- ;"KJD/J4U3QG3$BB"V28QSQDFR9+7A"D
M)P?BEZRBJ:+V5,B5''R,AG.)N9DJRU;84V'J!NM6GDJBBP"XB[:TUZIXQJ=1
M2];&\8YXQM9#EK.A5DYPQ2]8O5.][TF6JB3XX0\''7/*5':BO*<STXVVH3SD
MQ1FVX^W9&V5[J%C2(R63QA7IIUSNJF+/S['U3E'M+,S>&-S/8')6V'KV)T(5
MVDNK0N-1WJ6EP)MM*<$)R944 6'6A4NLW9]8L%8P*RF]P7+4V;#5T>0!&,5X
M_=)Y/+;Y)>%B<^^*-IA:VQ*W#=OGE0-^];;0N$X!V52[3EK3AVI:5/T2CF'=
M2^.54?CULC/=<UX2D.,H^O3W.:5K!N:'=W/-(<'D#55JD6TJT#@0E'JQ'>%7
M /C<T;H/ L(Y+D6+WG FKV:.<;[D\8DN,-.\IG,&<>[#.@>2NXLI;E):)SXH
M2X%HW'@; XFYD*T)FTQ/>-5T[XV/][MWR/)]F3X/? [X:<G?)N[<M'$^'XOW
M'Y-.%[K_  EWWV_<7A>,<%^Z;[9X*H7A?=!X%F[)<=Q>S8$U>PMSDG=;B\ER
M?IWE,&@S=W'9U[R;W:E+BI,1-G&R6\Q&W<-8/'',](A+V&*+!KV6HW6G#M-,
MJ88E(\.ZE\C*I!'KI&0ZX4PE(<FQ] GM<U36+<[N[0>40WO(FI;E(-IMHG"A
M-(5@.\-M *D8)U#L&?,:N63F* 9A@K:V.[ZSFQO+..G7'\X4FL*-(L/5H8NY
MFFK%3<NL5V$M*VR\"W!24H)* +B;A&)T4W4+&DNDL8C"333KG:E,I?F*/I7*
M0Z69FSL;8>_N21L(7OKH>KN):FA":LL4NS@=;<4WH25*HT!L)N"I-ZD=3T;T
MRLT7>I'C7..2"94\+65*CPCBYYR>YM9R%NN<KUC\A9SB3&EL/+L%.E6GC<6>
MM&U-: 7CMKYM->J>,ZG44O6QO&.>,;60U:SH59.<,4O6+E3O>])EJHD^.$/!
MQUSRE1VHKRG,].-MJ(\Y*48 W'V[(\3S=-\;P"8S*&+]-VM]^60J0OT<6/$1
MTOS&0QIX41]<I0GN,9>TJNU.]LR^]-<>T.2>VTEQ2&$*"@"PVVI29@U$,&&L
M1MV87> 9AF#2XF14LN(XVQRZS3(R<9985>EN60UO-+7IK&L#0!_NO,$&BZPR
MT_?#8-4PT[:W89J1FKG!X[AC4]CM:UQI5)S7K-&#9'C2+J4R1R;&RYL0/KNH
M-3*WTTQT*4IVJRT#CD*5>JM'>)# KS^<=?T%P1DIWQB^8)U;3AR9D;*M.DF*
MM/DHGL'66/;<2Y$DMLH;%):-:I1%G G=""[ N0K;#$QNV^P1JNZ'4 PK]/EV
MHJR!Y<(C]L%6ST<?JL>NB?,8H4)*@Z]C#'%QHNPRPZU-=8E8.%XT>:839;<
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M[-G)EB7UR2O;^GD8V_YUH#YJ'#P\F6)OGS++1_R'#.RM1?-0X^/&6)?FS++
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M4I2E*4I2E*4I2E*B)N@'W"VLG\US//[,9+7Y=%G\&7^3+_4MK=2E*4I6<_\
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M@-]%YS&CL%IC&2!E /+PS=SV$C9(47<1+W*-7\<:RN$4\<:UV_*X"4]FYFY
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MX0\5;N_4U7\_F0?\4S^YJ=^IJOY_,@_XIG]S5R$ZT]5UQY%MV>\@#;<>1;<
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M !\( (B #X0#;6V](D,NNO,2)#+[AVW7F)$QE]P[ #;=?>5=?<.P #;=<([
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M_9XZW H46@ 6J#[0     XT   \   !<   !X   V '@"MEM]]EV_LOOLO\
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M'4?E:;SY7MTXZC\K3>?*]NHC:_E26_0QK(MM4I[KATN9Y  M.+N$1'&4E
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M]R>S?'*$[NI;P+.;U5BN]$\,ZE?[ITRMC!D:6]_><BP1I8W9K:WMK>7.8QM
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M]4DOBH:5:CM T]Q=I6R++GK!>/81&<:8VW>"0Y%=277&?%TN*-43/EF?X$:
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M\Q9 TH1O2W%\A:-]'.(SXPP9 Q=+;4N3M.\AS\3)6M,3CA4LL<HD0P91CJ&
MRES-1.2R+,2-.[L,<<1&/-=VNE*4J".IO%V3IGJ>T$9!A\$&60;"65<RRK*;
MB$BBC4<SL4]TYY(P\S"@9W]T0*Y&>,@G"):Y(T-H<78T:\^R]4MXLVJ;1,'W
M+[*;7BK$D1D.F+&JEYC^@3=(].\T"YSQ"L2+<CZA,H0B48)(4G"L"U^8DD=C
M3^E,<E91A$(-?RDB5'84H<C".YCVYQ9U,L5NLST_P]\DYVK'<I\P&O3C)<6.
M[RIA^E["^G_'^HLT756[&*A<5[GC&:)DC>:KLOR SOZ.Q>:6G<W9&CUE.@'/
MR!N7QMQTM)LRX#F>2]TS@$BTZQ'42P8+M9,8ZRM03%F+&N2R%C,_-\440D8P
MSN^/\LPIN5)LEPOX0)93C%ODJ]$YH%]0T.D'5<Q9QQJC>, QV>-N)]TX)U7-
M6IHK*4-4N;YITEVGO(6*BH&*6=/:G,'PVPNDEC%BL&=V+-9)ECR&1Q]2R]6[
M.;NTM<9'3<\-9S-I^P'C%@TUPA4^XEQ;"D[<Z1K(>(VU\32+&FZ4PO4T.,G9
M[D[H8DC\&<\5Q=CD^-56*DC6N,R$T/,?R@^-3 TPQ"Y5LE.A;4Y$G>1KR-.#
M-F7&1VL#= Y+,<18\SY'\32'+^'M;ZRUXBN1DCHZ*(E% <<5M+A(,5S;'N1'
M I>YQ6:S=YA2Q8:VLK3*),:EM"6H*4:)LTX+@&1WB41J3Z0&' >+='#B.-E6
M*\?2EGBT"CK.X(]0D[C89\F!49&,.1I<@R5D!Y7NQKH>[JF\U<G:42'R\\T1
M3"_5Y:O;]++3*]-^1I#I;R["EL1S<5@YCTF9<P!.7V=ORB98H@TF8S)L:YRN
M1+\I11\Q#<['R_(KI,(EE3BD+>S)*X4/FVA[4FY1IG:YIIG49XQA,YANH>/L
MH8%:=2C%B!P30_6QJX==0>-\LJ)$U2-'&'Z*&0)0.+\OQ9&N3Y-AMRU-(L7H
MI*:UJ$#A]9^A_4RIU*2J5O>FJ/+L;KXMNBN+7^R(9FBD:;,AP[4%AC3HS8NE
M-DQ=WAUS\LF>2+\*WP/)\AGSN#C#9P2TOT4;4D(16R5734G0-K *92&[+>"7
M'51B"7)=26")!C1VS-BC3AJ =L7Y>BVG=!!LOZD7W";ZTZ?LD2AM;L0R'!F2
MG[&(,V173$Z'%64&..K\G_#F-773=7^E+(F0H]HER%B@EG=\H:&L_P"/LWM<
M!>)&Y=RLGQIOQ=,L+9,@*":3%0YN"&5K8-D!Y>L?2N:+CRU<Q865),WIL2/C
MM)VN,>>M#V0-7VH?,.><M8(:TT"D^CM!H$Q]AO(<C@+O)SF/+N;(]D_-VH^>
M*H;*7N-QRW%@1B$K<,Q:&SI]G[D^1A]>[%\'=G)B%-1')6(LCX<TVZ=X=)W/
M#,3W2#3CJEE3]HCG,CE$742K7:YN$A+QQDG)LNBK*YF9 <9)J"PUE=4]:LF9
M">NOBLZM#)BU>5$V1H-:J[7Z(,B8>S]$(I$M/./-2&F^2X1TCX\8YG+I1%H0
MNTSY.TI9KG&8GC);]$-J-ZD[=E65RYBR\D,Q):HD3EFF$DM4[1ML1<6^5LL<
M'O<Z]9$BP>AQVP-$?@.;\+Z<==6%7+-ITV:$\>UHG9YR5$IQ R)&KC3NZ9!9
MFK)QD<<95F9SR,S-SACK(,D?"82@F[:\N$AL]J@TIZI7//LQU+-VD9AQG%5.
MIS0MJ$7Z<+\C895OV0H_B/3-E;3[DN+D&0^4%8N)G.))9-H)EG%ZB52A'%IB
M9B>,I>[<0>"VVUD\+(=R^RRX1?+3)=@J!.[?/=">Z>XDQW''1YQNY)L42_5S
MJ='->F_#!2AV5 6GCN&8XK=4)C\P@LBL$='18S0.]R9"R7 ^1V,](V;2M7+/
M*,QX 63=@0Y:QAJ8Q?J%[YAS:VK"SPT:6(C@*8XNDF'6.4)GV2S]E/C\R9(V
MX1Y._P"%YW!<F7N\[4)9'&U+,^WP;0V6@'X  /&(^(-GC':(_P!8^'\-:TI2
ME*4I2E*4KIG>.L#^*$7QD:'@6M98X-HNK8A<A;UQ8;VQ8B%:G/%(KL#P6*4_
M!'VAX+3 "NYI2E*4I2E*4I2E*4I7P.C4V/:!4U/+<A=6Q:7P2QN<D:9>A5%!
M?;?P:E&K*.3'E[^RR_>&E7V[ZVV[9MM 0YD2)&W)$R!O2ID*%&04F2(T9!25
M*F3DVA840G3D6%DD$E6 %I911=A=EH!;9;;: !7TTI2E*4I2E*4I2E*5#/4[
MJY;-/V2M-F'K$<.*F>IZ632*P:093G!F-,8)G6"QQ#)%$75R\B.2I0LR+-"G
M E#CB"HVD%\I%#)W!.J"R,G(''[HKJ^AC/ ,;O6ISX-:6\F3XQX2J,4SV=-B
MY:PJVJ>FX]*/,D0H&1$JCKJ^*8TE:)>L;V6/N:Z7QIL2J17O+:F5:8SU=Q.6
M91SOBN>61;&+YB[4V3IKQ]8YSI(N5YH?%6G'%VI)*=&&Y8T,!Y4HNB.0W$#X
M(V#(W E'#W=X(<EJ4%%B'IY#N@NE! \-L68,[8@>I%)L&92S_$'%;D)H:,9N
M$$Q1(;8;)'=\R@46ZQ^.M2&86N3,\+KBW$]C+B\S6+F\+HRK2FU':-4F'2+L
M1QN>9-Q/%\F99B\!>6:(M.0DLC:G!TR$WF&QQOBLG5M<=^$#9+'5"]MF-71Q
M9HVOR0#.KOCK%>O(6M2+ZHGJTTR3O(:#%$*SWB:69&=?A]:V0^.3I@>7MQ48
MK>@CN2D"%,WK3[5;G WL;FZ6M2<PQS83RS1<4A!1)IMDAJ^)0VMZI6A7J4*-
M0N;+E-S<L/2D&JT%RPGBRNY$I,+N/2"J3_N"@4YA?#DB)1V_+'>U]M*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*AKK(P:[ZA8DTXS?
M,*8 U'8.D"63(LOX7SRJ6M*>0W7IFH^!O\,?R(3.TS-)HH]I7%78N/;&]:C*
M6V.3"^-CXW(3AMHHMS$U-,.'WW$CADG'V94&=]SV6:#\N/>597.7:0X@1(,C
M9TEF/9K )2[1F0R3,K= X3J#=L=K44P78YDDO58AQ9+U3NVKG-\(8ZQRW0QJ
M-1Y!D&284KQ-(EK/NC&!=7\)9)ED&9-BR6XZQWHMBFC28L$WDR#%KP$:R(I;
M61?D]J5M;+,&%[<3RHTXJ63ACGPJF<!W-C4Q"XTW-Q\FP2[N3GIBW2_3G,"[
M7_("%"4.L34@KU XME<=-O@C@8?8T7FE1O(3,ZD%7M!5IKC'7.77W6HK>1/N
M9N>O@A/,.NLCQBN@6H&&[GO=D6:(Y/)4\UP;D+12WXSC[[?BM"9 "@G\=FK;
MB>-R3&ZYY?\ 'R['N0W.3O;HQO:%RXO=5[%NA'-<*S#A3(3HLQ+<V8]U[Z]=
M5DB*:Y+*3W97"M6L9RTQ15C:K5&/4*=7+XR;DQ)=*"ERQO:#$L=WC2\K[EA)
+:.[_ $I2E*4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g222982.jpg
<DESCRIPTION>G222982.JPG
<TEXT>
begin 644 g222982.jpg
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MD"2SZW7G,J=#8$)6*))&EDSCR=)+(^I/?8BW> \?E+,40XF&.L<1>,I_''Q
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M FT2>(1(%02B%*DJBG+_ +,N><SY-6EM2:X&>L[ ;ZLA\.F\211-1,H>W/"
MQT>GX^(.H7R/.QB/;Z_+RDQ;P!3H]*E2G;/)&88#-HE,5<S4G5%=U)'UBYQ9
MJZB#%$&]Q<Q $X.!#(A*2>/+/!:"2 ]88 Q2820$*<C9O@" A)+!K4FY5"]Z
M5N*^'0<5;^0=@\=ZE3-:7QY701L7:+GG#VI--,6I5=C3**3 JO(<V)2TJ<DB
M!,:&=O;B>I6[G4=;$)+4ZUHI2E5?'VZ7.KZTYG\M+1ES5'VFP)127+V:+;JB
M\OKU<ZFQ]1)Z]M:5P5--6)U;W92%M,%&K)>H^T.Q*!%,ZY\6=VUU'M&QC&,8
MWKKK>OIUTRH,HX8P"5L-^1];85Y(TO(><1Z>RM0U6H](5T8<XX:V&I&VO#PD
MCU%&!5MJ3%.#226J*5)=%I>^!.C;RTE4N?G9D&\M'5FL"#VF\1FQ&9M:(X%I
MGCF]2.NU3 V$+2]F($";1KE&9(J.5A4N;VB"O*?/ :+<D&E ]+P3)QEX#L-$
M0SCDWO%DSU_EM K+1>RAQV1.L7@4F>;<.,-D*9YAFCU@'-D90C 7'4ZQ6$X"
MC2IP6^$&O-2E6@IVF(_13#,&B.O\_E)$LG\NLQP.G4K73%U2N\M4E+G!H9%2
M_19B)A3&D:TU-(>_X$PTXTY0>>H-.WH69>'/(>0UYQR8Y9QED0'""]O1>O-2
M3-\F65*Y[9>--DW#R;L"/6%X5).WE(H$8V6G!#'2'-BA7-TC@4M3'QLS;2,P
M7L5SPKY!PZRZ>F*?CJYL08YV['+;EO(7=L5UD0O;.*%GT]R'AD-F Q-LNVX*
M6Q]>+5C24< ;0JY<D)&\*7:)I241PS^DXC\";KK)+V0Q4WXNA9"^,]R=I--.
M0"?8*E7AB+/=QEP.-++U &F4KBI4;(USW7!R!)%]R!1&US0UGOI+&.-)3D=?
MZ3X(\H(32M343R6X/7#R!JRV.#-;\6I'7-><AH%6J"C;'J^\.0\H=F2[U;;<
M<3*4T=8L3LZO9FU6/3SG8,UA;Q7XF%#$/+),53EV,MSC5R\6.UR5:X\9)U<D
MA%VQO$'G?6W(!LDM1FQ9_P".,(MRAGPUF\MV!9;%,HY8E US )95@XTXLY(W
MB+H6AX8'=X*ECYI/VT-XS\H:X6IP XH/"UE?NUXYW7R1*8VNJ)PLNJ:;ON%V
M.WU?:M<1^43,%;M!5DJI>=7M@/\ )T,BF]7PV3R=P3UVD>'0J51RN5"]GKSP
M;J'@T'#5+Q4]COW8-E< D\N?YK6QJ.J^1U8V38SFD:)LJB\[=I(GA5E1^1MH
M(E+:]0RHU*TK5>Y(DAK@C DS9%QGX[6M8*:U+5B%5\D.S"NVPF*C(58DXGMA
MTKR2GL])I9/.R$T/CL.?95?U-)ZDAGGBL98)9"UGBUJ2ML."F$SL$5:6Q.OB
M&XNSZO.S[H[2EZ1Q5F=+*M;L[>,=+\;N6-@Q^LFU9(^2E:1'E!';$E.A0X)4
MEJUTD2:U(*TOLEC44B[>4T.+RAAOA6Z+IF\$:S?C#;-P\?+5FL'[/R^:+O>R
M;;[,E'8<7MGD%7UB2V;,'#OEU [BE1L?);+QEE9(JNJ.!-,U:JUF*I=&K0LE
M.Y)V $00LB*/)54EP+C+=:?D?83+;7#NRK4DU>\ON4G+GCCRA.Y)I8OQO-C-
MRM%G[K]F<8FT6<AM%LN!KAT_#QADT(7U"XUR;#VTF=N$B5M*%F;-U:I3B7RJ
M\))ETXXM<DZE8IAV?W9LU(V$4G)>,D$D/'RY>)_*JR)J],]*1\V?3!M51GCV
M3+8M-ZL9K%^4P5Q06$/+?-)%)'.4)&5]DYPX]<T$""CY5?7&BP.55?2ZI>:G
M':Y:PXWR"LN,]@KUUX<B29M#>1-C5B]7)!JU;"^3M:H?$^4428+!=!P&4.:=
M[:& #>>XQ:/;$N57">5V;P6H.H*<9H_$K0XGS#A[>5+U^]S:2R.%'S'B!,H/
M-V"H'ZQI,-TESRPR%GBSA71-B2$:MW N6MDU?2%>DZY$=T/(B VMSBL3A"C'
M25DT[6W&?D]$>9-O/=F;AS=)#Y-3,&G">MJ3K]GC4QE*:8OK[8LR;ETMF:)Q
M+KINB44<26>3/CI(FQ,5#O%[C)*N.W(:WGF<\<6%OXA<KJPM.R5[<_K*]$P<
M#7B520^27'QP?VY\G+BW&T[R3*/-N.P152VKX*P7<@F"5_ IK]V@#E'J^UYQ
M"OB><*>4U?U@_0VX%O'I _\ $+@ ZKY2 3/<O%BIK?A-Q.56S.<GEZ:$H+*;
M8Q'>$LZ>0'JHXJ040FECT::%U=B"+"RRM[<G5J\;^:T-X1S:HD4?Y6:L_E!0
M\D7U&IO6T0*>)\TXWQ:^'%BB$YED#>GWCJYNT72P^/(IPIE\N@K;(90PM2:0
MH(>T/<35#Q=Y)<;N15+7B.@)C9?':5WIVE;V9QTB+C6ATEXL)>8]@4S(ZCL+
M<4D,U8HDN;'!NK^W4U@L<6D3DJJH/(E[;D#>M:E,TVDB;@UQ#Y/\;:TI%HO[
MB3([$KU_[,F8<,Y)1[2_U7*'*LK)1<@+>G;C'GY 5-S(F16?**MI]!6%UE+$
M]N;?%5M0QMMLEOCS>)M6)(@FO9A<M&OCSS!K+Y&S[:MR0]F!V4_&.O+0)>:W
M"LM"]^+LJG[I;ZALDLEDS,^MHHL2YURI1S>:EQX4D#$6]8VN3D],B<L-ZJYX
MRVZJY>RF/WWQ7MFSVINYXO\ SBX_\JB.0*2-T-!8M(X^!-'4LNKQLM5JLTJ]
MJJC+@]4$AKY)5DBKJ<Q0+4YR:4 B&W!*5;GG_1<)Y*J(Q55\<29K>5(MD7=+
M"C-P4^]H62[*'OM@?VI'$5];NS9.H79T;?G>/JW)8VRV #4H4"MDTTSX XP]
M"*U2VA:#YNU7*N-]C<OH=/>8;"KX-7QQ;GS$M6UE-+1A4@D/(%1/*YW:S8>_
M,\)E[[<_'4B"4U?U@0]V?&$-G5FB=9 I/@\@52Y)6Q5V9W,1%4GR%*HTHG+J
M'_L]E_<"4L_=9;&3XLEY&3V2LSY *H-=7-[%)%C)&H^V$19)/U#"9'!)&-M/
M7.Q*U9L@'Z\B^)W,3DZCY/RV-\3+ B15@=G_ -FE7</C4^E=(LLHE-F\3.9T
MSNZTZ]4H"+-7-[5)#H:[ +ARQ\=4\.>#2$X%\K8=.*,L<ZW[Q%Y43VV^TCLF
MMZ27H&BX7SLG[8A<&D#Y6#.BY&-7$6;#FO(N@GE8AECLW,CS*8F BNTSA,1H
M87)G,9#5N1*83IP>4_2<@.%5S7?R$>>0<3X^/Z>M[1[0'LKKD>*KF.X.W/B)
MIXGZGZ?D'R.E$2=9*-G:W*00^6P2KALR18NGTQ:*@2*B6%P:%K4:IV.]FQ35
METG&.6K-8T"75XGG/: <O[EK9I5*HXH2N546[9(IC"Y$VIXP\.Z-G(?"E:YP
M5,;AY+?6]P/5">&A(J4B&=LBQC&,8QC&,8QC&,;]&:WEW:C\:V_DX+C"HU-=
M/Q<R*K8^=:94/F&GL$UQ T:CIJH3J%]T26\F%L9S\!E&S%.PMDC4:1%F. )3
M?)[REM5KL9CJ.OF^BI17=Z,\4;9/>:(U_BMK54UJ"E,FEL+21D>ER7RTC,\5
M93%GA22QA&5X\2M&:-LSPKBW7*]ZO!;/%,CMJ.WJ_P 2D#[7=JN94UKR,*(<
MD+(;$D(C#DDVD841JLDET5%:V>(2Y.C$6866D+#NQQ))2<L!)!8"22@ **)*
M"$LHHLH&@%EEE@UH!8  "$   "$(0AT'6M:UK6?IC&:M>;=G\Z*-?9M;];W)
MP!I7B9#JZA2V5S/FFDM0O;'-AOTH02!6DD5>SN&,K5&UZ9? FIL0OVEKRZ2A
M0J3-6Q 4)4IU<.SHY>S+EQRKDSK*^6'9U<CRH'QZ=D"!MX++;54.<5.DMHPM
M0M6V.58DKEZ;3>ZEL*%-%QM:IN5:5H7\*Y.J(VC-3;V<8QC&,8QC..FOHU]V
ML=-?1K[M8Z:^C7W8Z:]'HUZ-]=>C7HW].OHWCNAZ]>FNOH]/377T>G7I]?HW
MZL=T/T:]>M^K7KUZM_QU\V_FSG6M:]6M:Z>KIG&M:UZM:U\_HUT]._7O^><]
M->OIZ?ISCIKITZ:Z=>O3IKIUWZ]_QQTUUZ]-=>G3KT]/3Z.OKZ8[H=>C0==/
M5TZ:]77KT^_>]_QWUQW0]-:[NNFNG3737373U=-?-T^;.<XUK6NO36M==]=]
M-:UUW].^GKWG02N)Q:>1>1PB;QMAF$-F#"[1:61.4-"!^C4GC3\@/:WR/2!C
M="%3:\,CPVJE+>Z-3@F4(5Z)0>E5$&D&C +\(7"H=7$3CL"KZ*1N#0>(,Z&/
M12'0]C;(S%HRPM9 4K:R1^/LJ5$TLS2WI@ 3HFYN2)TB4D 2R20!UK69-W0]
M.[W==W_\>FNGI]?H]6-ZUO6M;UK>M=.FMZUTUT]737S=/F^C'=#O6M;#K>M;
MZZUTUTUO7JWK7S;QTU]&ONQTUUZ]-=>G3KTUUZ>OIU]?3K\WJQO6MZZ;UK>O
MHWK6]>CU>O&]:WZ-ZUO6O3K6]:WTWKU;_EG/377KTUU^GY\XUK6M=-:UK73I
MTUK6M=/3Z/X>G?W[SGIKZ-9QH(=:UK6M:UKU:UK6M:^?T?1Z<YZ:UZM:UC&,
M8QC&,8QC&,9'4DMJMXC-X)6TDF3"SSVSM2#=?Q-<N+3O4LW%D(')]"T)C.Z$
MW:!(8 TSPQA.C-B\&3LTP(@!KO&)AR=N]OI:>1V,BXTLS79TI)NRK;A84L@F
MLMKUF/4-;/YJN;.8)*PJ'I00%W2*SM)Q;3GDFA4*D*8)3U"K'V3G%QCO5!?8
M%%F.D@03L^R01A\F"9WB)\P,>E,C(7K"E3)N0K$R)\/+<4S:ID!J,1R1*6J
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M1I8H5J#9)'F5+X](SU[4ARL[G!Q-21N,2MQOFOF=IE]MN]",1;\Z',+T==S
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M+(:X=Y5+)2^)SDJ<B).R-L$YU_X1T'9E;<P[@L6Z^//$2F[+LJJ#GE6X<?\
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M&,8QC&,8QC&,8RLM_P#+6G..R4":8/ACK,UQ8-L-<Q<H+Q-7H\_>@(P :RC
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M+?1,>I*T!/L(1MZ%MWU#NQ^M:UZL8QFGSM?N1?&V&4XQ\;+8Y!U)6-B7V_Q
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M$3<UYU8DL(Q*"-RQ_;WR5-Y3?($D>0'EJ !:Q'EK=CV:69M,6$9_[R?C$Z7
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M.=2MW3F?%)Y+'WHAZE.@/#C(GPK9C:A;U>NHSG!>E\(D(&@([B4$?*$4M)&
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MLBM>0X.9I#:A.<M.<@<!(6](-[,/1 2H2%*9$VD>4%(\VTR.3QJ%,QSQ(W5
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M3@,PHP)&B?'&TDD.AJ"E"E2F*NGTZ8QC&,8QC&,8REW/":%5)QMLBRFZ^?\
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M[N<]=6I2HDJA8M4D(T:0DU4J5JC@)TR9.F (\]0H/-& HD@@HL9IQI@PEEE
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M_6!^Y_\ ?L?K _<_^_8_6!^Y_P#?L?K _<_^_9QO=@:]?FA_+3_O?W:UO?\
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M]S_[]C]8'[G_ -^Q^L#]S_[]C]8'[G_W['ZP/W/_ +]C]8'[G_W['ZP/W/\
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M6M:UZM:UKT:UKYM:]&M>C7HSG]8'[G_W['ZP/W/_ +]C]8'[G_W['ZP/W/\
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MWC-($YAR)0B\8&M7IQ'"."I1)#"S=IR<?<)?SGY#(%;FE31_A53("C52Z63
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MYONA:,,DDA'IX>S#^H1;/+4* :(1&;%KO=Y G3"Z[WWABZ[WN8ADE&;+V86
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MK3B.)MSM>IS,UNS-@51?CU"),2F4#T(.A$(G&+-I[2<$6]]TH?=T 6]"%_\
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MSETCILRVY,,4<W9,Y/$?1M+0G4>!+3-@C0*7D3RI.5.RQ&WMZ)"T*E2Y>:6
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M#^RC[3^1#/+E'-)G&!482(T\#I+'/9X@[UKO+@JE) AEE:"4(&@ 4CV( =Z
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MM)#$_@R@$"DRDX4@V426$@'E/H1U)\&+<&=K28K1T_Q@=$#J]M2Q%VE'9MI
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-C&,8QC&,8QC&,8S_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g625784.jpg
<DESCRIPTION>G625784.JPG
<TEXT>
begin 644 g625784.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ ]1$E32S$S,3I;,35:0TXQ+C$U6D-.
M-S0W,#$N3U544%5473(P-S0W7S%?345!3E]105]+7T)!4BY%4%/_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_P  +" #] E@! 1$ _\0 'P !  $$ @,!
M          D&!P@*! 4! @,+_\0 8!    4# 0,$#08)!@L' @<  P0%!@<
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MOK4YFAV;7IJ%TZM24G^&AAN996'B1.8-U/,):78!"="FCD>TDS2@IC!B7*%
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MF![9%\\\@Q M>>E*4I2E*V9>33C94<FD9BJI66)1:@(SAD+#%%:Z@T"R.7N
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MT6,7#MC?.P X(U\+9;;8WRL%GG?&V5\;[+Y;-NR^S;LO7*I2E*4O?9;;]/\
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M<K_+'1C #D<R*M$R2DBN0^&(N(YLB1%3% I<D5[3PC.@71L<D+*53&G2+\Y
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M">KBD,&&F>7=SOD-.EEW*Y8!1+7=DE)!A$,I3W=!$!1#2W"Y$T1M-S$@IK!
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M2X)4H7#QM@""%AAC;9:JBI3ZZM,WX,BAJ/N3).;C*2D:09C*(Q&37B0S4 7
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MY*R&=*-F +J!E9N.YJ/-1/@8-4(,=IG$)^/$F3:8-BY%.NO#F"HN!@FE"D)
4[6MC:UK?5:VRW\UOJM_9S^&O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g394314.jpg
<DESCRIPTION>G394314.JPG
<TEXT>
begin 644 g394314.jpg
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M"_N@/S@_KQYA?W0'YP?UX\PO[H#\X/Z\>87]T!^<']>/,+^Z _.#^O'F%_=
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MN0LRHQ*<%0F,4M3RE6H#S$YX G$&&IQC)-#HPL0!Z[Y!CF/TZZMY<L4!8SI
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M[;I8.++54L3<F2-/\WF$>0U2INVS720/;,YC/<BIG;C'$8 Q&&IV1OA\-?W
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M3:H%"+C;*[?;<J2=L"@A*%Y)]W28C+:[GC&L<%+4<2\PJ1($;0N8G4<CKZE
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MLCJA5B1K"BE241VR%)19Y9@ W=[TX[_6LO\ PMR_W[(']42,,)'3HYIGE-P
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M]1&Y(L JPAQM\>:WXNQ=TANX>:SKR']"U"MF?N4F>Y O+6EI@.#@D@L:/3Z
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MR=!&$8#[D<!F%:,:!B!ZABBP%%@++ $L  A" L&M! 6$.M:"6 (=:T$ -:T
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MM#\1N_D*ZD_61X3IA$\]NG7J_8 V#%Z;>W$EP N$2U$C&$]X=XTQ[F39KOW
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M8]MJSX=2E7V#;UA.86>#5E#9).I:Y"\&QI&"+M*IX<QIRA&%;4+!ID@R4*4
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M6,ST:SPF&3"+UH^OL.62D9:DE[$M/>#V562 HLH3<G4&$A)*V2 PDT0# K#
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MUF%%K5[6U+D9FB3'C>B%:A;LX\P[1@P]DIAJU/N2Q111!19))8"22@ ****
M$LLLLL.@%EE@#K00   .@@"'6@A#K0=:UK6M9YM^O;=4YN%SXY])GCZX"W;_
M #/F;"KLI0C$,SWI4FRO0SPJ'H)&A#(:7AV9'65//<0='1"M7]&<$1+N7HS?
MI1-.0OCW3=8TA7:$#="JKA$<@T<(T222<8W1UM(0 7K=)RRBS7-U.*.=753X
M-#5N:Y6J-[F'#%O+&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9Q
ML.M]N^N_;>MZ[_:WKV;UK[6^WJ[Z^UO>OM[S#DYH*JK#6*W21Q9.)Y6:+](>
M6Y0J;'(T110"2C#S4AP"%1A919981*TZC[ L !=PAUK+-LZ@U4IKN,UU$I W
MH(['D)S8KCLUCK3.X[*V\:8"<A+)$#^A<4BP"?7I&] /;5:0>E9@=HP>4FV5
MIGN?H"<2+189G.'NH?@CMMEV)RADBX<R ZNE;NNT5L0U*B$.S<X5XA6$+-E*
MB=QR+,"]0 *@DLP)OHWBAU!JEZV_%63-D-XH\O#^2\<(T8)MH_F5'1II&80U
M)CU/N$AELF4N1X"-I$XR4IZ&SH0CT:$.AI4@-@#DAHE^Z!['I%T-AO4<X!WC
M0KRS+CFE]L>HT>[+K32U.<).H5;3+%"4:5"2<'>M^]^:3H0P]]$#/&#P#W(<
M9^H_PAY?$)0T!R/K::O:D!8_>2I>/>I8A AE^8,!]?S IBEW8K?<!AZ=I4H]
MB#ORU)@-A&*;FA:WZN_K[=^V];T+M\OAWVWV_DSG&,8QO6MZ[;UK>M^W6_7K
M?\F<:UK6NVM:UK7LUK7;6OY-9SD9>8K#R&E7'"S8SQ960YNNJ0-K6SQQPG$\
ME-8,Z-F7R!I(G1B&P87#)_)X7+#(&*2)8/*FF+N:B.3!2RONRM!;M]\1=.*9
MDROCL-J<([>4*L&N;,LFM+?@?(2ZI/R*GL(M2*O^M29@0W;*%[@JLF ;3KVE
MYK25(Q(43G!W=D/,9(^Z"<V1!DCE3.$:"OY+#QL,T4*W$F)F%/2&&OZZ)IO2
MIFR%A X2I,B,96\PGR!#5 5JRMIBQD#-\.CRM#E:'V;_ !A_IBS'EK('!\@L
M@B[*]M+$_P J;U# RJ7=7Z(G/5+@Z >C+V )JDP]2@TL*!I(0H4%^+9P21Z+
MWGT5C"2*[@<:AY(R3C&=N+*6J2"]EEJW,\8U3FK#H6M&; H7''#+\W7F:*\L
M(M:V'MJ/'-_G#17 :D7BZ[R?3$R, C&N&0QF$D43>R9:80,Y#$H6U*E*8"QQ
M."':AP<51R9ECK66H>7Y<B;TXACT:]#6-NG-_DQRXZO=QG,A\UG$Q<J0I6!D
M.J9[5T_!FAN9AN24X( A,;5 HN&+Q!D4F)T"EV2)YM(P)](I>6,SU'8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8SCPA[Z%O6M[U[-[]>]=_
M;VWOV=_P=LC[+^,%.S$U>H51TYH5.AYZAR.CSBI;"EYJHP1JH2MMWM2SG[4F
M#&,_8V[Q&#&(>]^/>Q9K/Y+]#'A%=#VIDT5X^4Y"W5<A3 7BC;2]UVX[>$8E
M&]2%H>H&O0)V5W5%&E 6GI6(&UR@@*Q<:I.$+>HJM? ;JJ\.7-N?^*/.MZ44
M<E %&LH#D(TR;E6*-;3A-$FU'W-?Z _[B#@<46%00RR&)O,63&>9I1(=&:*2
MW3(^>_4YKTQ#9L^K"CY9'ZH-9$DUH;CVW3:03/D4QR%X]SY=)(:HL!(@DM8S
MROFXQH<*^K,K4K;ITO')D$ADA1"Q@-8_1(U+A.;8WN(T*YL&O1)%@VYS*+(<
M4 E2<L\2)P()/4E$KDFS-IUA)2A064I+-+ >< .C!=AC&,8S#]WT\FNZ%DP\
MZP[<JXY')8U*F^7TK83I7$R2.,8<RW-,B-=6\I8B>8XZ> :"1Q.1M3U&I$V'
M&(W9J4AT2(JY:WK>+55%DL2B2584@*6.;LO7NKFO?)!() ^KSW:02:32!U/5
M.K](G]U5*7%V=G%2<H4J3MA#Y28I.G)L#DUK7P)S7U?_ *8[_I?'LSP'V;_&
M'^F+(H3-D>[*Y#5\0! J-@59D*I$K>R-%GM9LN(4>MJVL)'LLIU1*D[02H;C
M!A6D$!6#-) 0=K9DL?9KU[]FO7OV?R_@SR?=9M2/J;<VN.'2AH5LC*R6UJ[N
M-O\ (2\U+ ED2JB8\OCR<I:Q(EOC0*TA8(ZX,[Y,(^D>D),MDSU5$24*$JLM
M8H;M]' G@;2'3VHEJI6FVXU4H4'E/]C6(\D)M3&T9R8A3HETKDQZ?7DIP 3I
MRFZ/QY$+31%V).E:6X)FP*EJV;.,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC>M;]6_\ C[61@E7%*"R^4N\P<Y+.RWEX<A.9AR-V:B@H
MSP^7I*6@$-D-.3DMY9)!*$.SC!D%D%:\8A!V+<FB"MD$$DB--/$4467L\_8-
MG';  (-FF[  L&S3-Z\9FP  '8Q"V$ =;T'7ZXQC&,XWO6M=]_\ '\GMQK>M
MZ[ZS W)K^).:_BQW_2^/9=UI6(W5S#)(_FGI#'1K95CDW-1JDD"E6;M8F:TA
MVTXS FB0%.KDWE+5  [+) <$(A:$,&A1:XEBM%H<WH$JC4AW$YT2.8)9(N+*
M"D]W3] ..7BT-3H\!<C1G:,T/:?N(Y(D%X= .V/6MGJB]>^F.%LBGW':G&A=
M;_)1KA;VF&YLQS*IK:HK,7 2)XNR6"J4KBE;V\MQ"M1(WR*QTA6H;MHFI@D"
MEK5/QHFK/71GZ?#[Q#IN2W5?#B.9\R>5R\FSK[FCHM2/SHT[>5*N0-$ 3OZ8
MU2F7B0*'A6_3!S:C0MKW,'-4!$)0Q,$;V3N=QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC-8O5"E<L:H?Q#K]F<5K7![YZ@G%
M2D[P.1%*NSC3TFD,@?WN&."U$:0>WL-H2:)Q"K9'O9Y2=W89FXQI5H]*^')5
M%736D[NL7<^:S*7*EE8T%U!+;J:D$YQ1A:&-5Z95E(68\P*/;,++"&)UY:UC
M6/$(LVH]>Y468VM%#6<"9ICR%$E^CFY:]OH)W%*=CT4;V>HWZ#N,QF5H+G!D
M<G-]DB!](;X[6<6BNU![@U[;5(")S*9>]H -ZM$B:8O'=*U2^0*FF#<KYQDO
M7(-DK)%/X"\\L7B&'L%=TT]QN4*$TQ.71EU.;SET4;THM.4->74D]]E+BV/9
M+0W@1K_&[M/N/V1Z6.!M_P#[H;Y7"Y 0.F++7-Z5JLQXU:]DWA$HRW*:HG[@
M(3=):LJTZ:,IY<=/9 D@7ZK%FCIZ&!$IV\X!T5]VBRWJ;U0?N>AC1V;#[NY7
M#O\ Y3V..7R"P;J87Q_HAFK:XI6[*"'%$%Z-/GBZ=J&<AXVN<I44ZO*L5@[4
ME-KBD8F8M:WNOI=0SVRVQ&E;F[C5*4*!"F(1HD2.;TZE2)$B4H!"9*E3$3 L
MA.F3D%EDD$$E@)))  HH "P!#KZOA+M?[W29?3ZHOVSSH&N\I\\N\F8F_C[-
MS7.(+FYN?B!S6J20)5;LRH9 A 2>9,=%*@F-3BD/&80(02S#!$"WYA8]:[_X
M2[7^]TF7T^J+]L\?"7:_WNDR^GU1?MGCX2[7^]TF7T^J+]L\?"7:_P![I,OI
M]47[9YT4BO"?Q1O(='SCY-TR)2\QY@),)FU4*A"=)2^-\<92=ED3$0PEJ'=T
M1$&GBUHM.68)0=L)18Q:[WX2[7^]TF7T^J/]L\?"7:_WNDR^GU1?MGCX2[7^
M]TF7T^J+]L\?"7:_WNDR^GU1?MGCX2[7^]TF7T^J+]L\Z)HN^P'Q?)FQLX^3
M<Y9$'HB/OQ9DUJD@*5T4,3/(RB23#9B$"HL30_-A^SR=B+"8<,C>_-)-"'O?
MA+M?[W29?3ZHOVSQ\)=K_>Z3+Z?5%^V>/A+M?[W29?3ZHOVSQ\)=K_>Z3+Z?
M5%^V>=!(;RGT6(;5+WQ]FZ8EWD##&$ BIK5*K9KS)7(AI9TXPD3$6RBE"]02
M4:H'V*3@%LTW>@!%O7?_  EVOO\ \.LR^GU1_MGCX2[7^]TF7T^J+]L\?"7:
M_P![I,OI]47[9X^$NU_O=)E]/JB_;/&[,M?6M[WQUF7;6N^_^GU1^S7_ /F>
M6]'[TGLHV]Z9N/LW4;CLA<XL[>;-:J3>0],_D>Z"<OSY@#SR2O22? I*[E&^
M+?@W]CO+A^$NU_O=)E]/JB_;/'PEVO\ >Z3+Z?5%^V>/A+M?[W29?3ZHOVSQ
M\)=K_>Z3+Z?5%^V>= ]WE/HZHCJ5WX^S=.=*I 1&&0)<UJE1I2\J6UT=BDYH
MB9B+28H2%F<#=J#O"4$90"M[\9Q>M]_\)=K[_P##K,OI]4?[9X^$NU_O=)E]
M/JB_;/'PEVO][I,OI]47[9X^$NU_O=)E]/JB_;/'PEVOK_PZS+Z?5'^V>=!'
MKRGTI(<E+)Q]FZDEHD#]&%XC9K5*793S&G(]I>$X GS$.S2DZ].<44H!W*4
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MF; 2&.'<3G!VMI'U%DW3B?H4Q7?&#8RWV-)J4:+U@,_0SQ[A3":ZPA[ATB9
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0D[P\JPI3$TG<8QC&,8S_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g543307.jpg
<DESCRIPTION>G543307.JPG
<TEXT>
begin 644 g543307.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@!"1$E32S$S,3I;,35:0TXQ+C$U6D-.
M-S0W,#$N3U544%5473(P-S0W7S%?4D%424]37U)%3$%47TM?0D%2+D504__;
M $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_   L( 0H"&@$!$0#_Q  ?  $  00"
M P$             !P$&" D""P,%"@3_Q !G$   !0,! @<)!A$&"@@%!0 !
M @0%!@ #!P@1%Q(A,5=8E]4)$Q05%I66U-=!45)6I]88(C(S5&%Q<G>!D9*3
ML;+1TAD:(R=VM@HU-C<Y1U6AM+<D)B@X0D5&=$1S=;/P)31#9X?_V@ ( 0$
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MS3?U@[GEQ3UBP_MFOTES;AHY2G)EK&1R'*!B'+/8H8IBF !*8I@=Q Q3 ("
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M6(]YD:_5*>1\3^+$>\R-?JE/(^)_%B/>9&OU2N812+@  $<80     &=M
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MP+926PN73 -PX6R$M@<Q@MVR$X)"VU2E*YV_KMK_ .;:_P#N%J-</_YK,?\
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M02-EA;+'9,QVF99'F](UV[EA\;WNRYDMA=N7%EL4%NWX$0MPX6@3J>'>/QW
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MB$&P!#[H" ^\-=4O-B%MS:;$(4I"$FTR(0A0 I2$)*'<A"%*4 *4I2@!2E*
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MX\:D4.GD576':9"K61;8S=M$O6KEDXG ETAK9AM7;MBX '*)1&W>LGMWK-P
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M>EC4^-M@T42"?>XH.6W9/=./!MVN#=N&';L+;M&"Y<,.S:.PI"F-L !$=FP
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M[SVU^MT\L(G\9X]Y[:_6Z>6$3^,\>\]M?K=/+")_&>/>>VOUNJ^5\4^,T?\
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MFUI'/N:FHMG;U;@@3.+J?)VG5>1I1*%5FTM<3(TN1 4K2MR<]U49*F$+ZH+
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MWE"4EY98!F>LC'<4XMZ@QTIKET1(I-;&]8_HC%J^OHD<L[MO*CZ#;/\ Y?\
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MOXZ>&H_LM-^GM?QT\-1_9:;]/:_CK#O7\I3W='V<2V[]FX88XU;"DND.8?\
MK;'0Y"F$>40]SW:^5TW*/W1_75*4I2E*4I4FX3$"YGP^8P@!0RKC@1$1
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M4]LP"./XL(;0.40V@+6("&WE 0$!Y! 0KJO9I;MV9I-+-HA;=JS-)C9M6R%
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M)?S0_=3@$^"7\T/W4X!/@E_-#]U. 3X)?S0_=3@$^"7\T/W4X!/@E_-#]U.
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M;?I@XMH[ V\?NCQ![X\5.&39MX9=FW9MX0;-O+LV[>79Q[* <@AM Q1#WP,
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B0 VP!X^, ]P.0*YIQ$W"$PB(AP=@B(CRAM'E^W7Z:5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g321889.jpg
<DESCRIPTION>G321889.JPG
<TEXT>
begin 644 g321889.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@!!1$E32S$S,3I;,35:0TXQ+C$U6D-.
M-S0W,#$N3U544%5473(P-S0W7S%?055#7U9!3%5%4U]+7TQ)3D4N15!3_]L
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M _HZ<X/ ;Z!_1TYP> WT#^CIS@\!OH']'3G!X#?0/Z.G.#P&^@?T=.<'@-]
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MV+ T#MEP3CC!U:=$>1-!A5V";A!@C$1YWDG+R=BEBPT(W471@:^E,3,@C78
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M8^7I]YSM8:?8XN<JEBG(*3B;%!2L8Z82;DBK0RG4E$]WI!$0'CW??J!_@!S
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MXM\NZSZRTZ1. _'3BWR[K/K+3I$X#\=.+?+NL^LM.D3@/QTXM\NZSZRTZ1.
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M2WD^BI)IIE' O*"B()D*0!$1VA (\"@ <1 H (]\0 / &MD.@@ ]\ '^O5.
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MC)-(<30BCM>'$6.K<<\F9L'=J8^46VHX: ^*[G>K[0A1JQ&O8]8LF60]OO\
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MR)&K-!Y/6*6E)9=HQ8,CNQ9L&:"$AZ:::::::::UR<JX &V6V4I@ 2CG?92
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MNU7PFYW5U$CK.W;A040*FF5 G$NINAH&$KS!*+@8B-AHU  *BQBV+9@T3
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MN0<2S2+Q8Y@HUM,3".;\<GCHM[)C#-'SCJLN7J#B5!C)F8I]3,H<5RQ[P>)
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MM)C[E8VS1G8+8QRKA-G9IUFP3028M)B?;6%*7E&S)-JV39H/WCA)L1N@5 A
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MOLRXPC[5%TE>Y0ZEIF'Z<6SAV2JDBN$@L)@2:/%(])RVCEU#%$J:;]9L<QA
MH!Q$-0G/6;=%=;7)P-'J</C.KP\VLR&WVOJ$FZEV;1R=,KUBT,"Z;AG(()]<
M)(L8]3^:5(B>:;K<\Q)#L6W/&EQO*^0+?'OK'+N&D>V/'/Y)T-=3-'MDVR:J
M$0F8HE(J5,IEF:SM=@=03JG:F65644FUBQ91C-M'QS1LP8,D4VS-DS02;-&K
M=$H$10;MT"$1112( %333(4A"@ %  UVM-----------------?G3Y9G.F\&
M\NV&TK;!MHY1.:K3&RX=O^6=QVPO)F/<6W3L7<C:GEBPS7KQ93.9:H6=1N6J
M6F0D&\1),I*,ZP@'P-8R<>N"R;R)M9ROCZI9\:9M@N4PI[^<ON.T*N3E1=P%
M4SMD:8/V(S8N&N+++5X"O0["HIJ(&%Y6D!D9+W>!]).!13<)I%WN* )DS@'=
M$Q# 'Y1$H@'Y.^/?[WA[FM7?)Q4ZW5"P\I">[T>[U)"Y<I-F[*-*7MM,LM=0
MMU!L&.,*1D#=J<XF8MHE8X)](U>P-&<G"G=DZZC%DP$O56IEX<L^'\%W/:]4
MS;V,&[@;&YW8;E[1N.DH[&5)W&3]_P +Y'L\9/N\+/[+(;>44\I8CG\:X<@:
M%BN+M2P,F=:O4>PB7CJ'<N6PH;$=F]<S-4=L6%ZQN!LLW<,M05)91EJLEJ6C
MG5RE@:.GJ=?<WIY$)IQ;^_%JH0*%\D8\R[.0N",V];NWJ;@'B_;W(-Y9W%XL
M;04DVAYA;-^.21TH]C!F6C%QU67-U=Q% ^C#/D^IE4(*!9!F/$X'!8!)S3>L
M6G9]YI>&;*: <T.YVE./XO[S=<NP[/WCLIOF4^TW3L.S]X[*;YE/M-T[#L_>
M.RF^93[3=.P[/WCLIOF4^TW3L.S]X[*;YE/M-T[#L_>.RF^93[3=.P[/WCLI
MOF4^TW3L.S]X[*;YE/M-T[#L_>.RF^93[3=.P[/WCLIOF4^TW3L.S]X[*;YE
M/M-T[#L_>.RF^93[3=.P[/WCLIOF4^TW3L.S]X[*;YE/M-T[#L_>.RF^93[3
M=.P[/WCLIOF4^TW3L.S]X[*;YE/M-T[#L_>.RF^93[3=.P[/WCLIOF4^TW3L
M.S]X[*;YE/M-T[#L_>.RF^93[3=.P[/WCLIOF4^TW3L.S]X[*;YE/M-T[#L_
M>.RF^93[3=.P[/WCLIOF4^TW3L.S]X[*;YE/M-T[#L_>.RF^93[3=.P[/WCL
MIOF4^TW3L.S]X[*;YE/M-T[#L_>.RF^93[3=.P[/WCLIOF4^TW3L.S]X[*;Y
ME/M-T[#L_>.RF^93[3=.P[/WCLIOF4^TW3L.S]X[*;YE/M-T[#L_>.RF^93[
M3=.P[/WCLIOF4^TW7E3,7F.N1ZTM/[@\>0L8WX=7D)3$#=BT2$0$0*9=SE%-
M/GF H\Q,#"H<0X$*8>YJ(&>1LN6^"O#[$F8:IDF=I9(X3P3;"+J$)*FD5S)I
M]82,GD-)%<A4&[Y<!2*8ZHM032*8'"!U+IJ]5W7VPKV0N]]J%':2$4K'$K+>
MI-;*4I7)")KKN4&,S$G8NSHF4 BR-KD#HG.9,6Y2E+S?.H.UBTXT,FXJE_Q\
ME*)&$R<])X3]UIY/G%,02MY%UDL3,R<PPD,5BFUZJ7NK"J83&&7.PW/H=[-E
M,#_^2?VFZ=AV?O'93?,I]ING8=G[QV4WS*?:;IV'9^\=E-\RGVFZ=AV?O'93
M?,I]ING8=G[QV4WS*?:;IV'9^\=E-\RGVFZ=AV?O'93?,I]ING8=G[QV4WS*
M?:;IV'9^\=E-\RGVFZ=AV?O'93?,I]ING8=G[QV4WS*?:;IV'9^\=E-\RGVF
MZ=AV?O'93?,I]ING8=G[QV4WS*?:;IV'9^\=E-\RGVFZ=AV?O'93?,I]ING8
M=G[QV4WS*?:;IV'9^\=E-\RGVFZ^S:H9W3<MU'69J@Y;)N$#N6Z>&NMU'#8B
MQ#.&Z;CMDK=;J+H@=(B_45NH&."O45>9U,TX:U[;U-FV.\T(IY<3W+YYV39)
MJ42WCW^X';SF!AB9U(55F[4<1];RS$VUE.8GR-4XZ0>.%H-+(-8?2=97D),E
M2G8(DS+)/K-V5[(L=XXGF^>IC>7N4W^7LB,I'4G)>X#.4'DVEXX(_9^X]A#$
M5!QK%UG$%0GIB+ T1/W!O7Y2_N8MU*0?9.U@9B4B7>SO3@ =X._W1_*/AU3@
M'<[G>[W_ #^WPZKWN]J!<Z_AX=_OVQU^V:U/!/P"_P!DO[ URTTTTTTTTTTT
MTTTTTTTTTTTTTTTTTTTTTTTU ^:\O1.+&D=)J6B!;R#-P#EW2WATSR]HB5R&
M042BS(@J[BGK13_;6,@[0]QG*B"D?)*MD7 /F<*,<A[G,C5^KSF,V%(3AK%!
MIL7DR]<1ZKR"FXM9-"6EI)H=PJFP6DUQ4-&P:+.<&-8)$,_2,_< FWF&-PB>
MT4.)K&=)L^3I6/L:]E+( 9U#(MEU$U$$8Y$T<HQ6=,6S==REQ<)H]6(X,4$$
M4TD2$F2NU:N5&.)$UB#BH&-3YH@SBF+=DB8Y2@7JJI4"%%=8P '/77,HL<>Z
M<YA[NO>TTTTTTTTTTTTTTTTTTTTTTUHUY8NE;1:15L:;HM\]"H>?<*5;..#,
M9R5-W 9$M=>P?@JCY!LCJ"R#FB"Q-5X*T0^9<KH X:+I1MKK$O*J5J/4B*W,
M5"&;68]@][DZL;<DO=;Y:<W<E%/8XJ:%-E(NJYP8;8W5C@,,W]K.5R57@JO?
M\>*&9XXDK%#BFUM%?N$# -KO6'#8T>E8@@+/98.;W5B(%*)C#W"@(B/#\0!Q
M$> ?D[O .[X..L!*!R@F-I_%.]3,N1J_(X<I.R'->:<0Y(>VZ?KKXSYOA>GT
M^XREO;.(ATI%,6,\RN#)"'B59)V](H"";U=!XY49-(MH_*.6"XX_V\S*6%*6
MXR'N]S#)XRVQ5BE;G,;9=QUD2N5C'%CRG><M2N;,4P5JK4'0J76*3<D)<(&&
MNT\M/QL5",(MPYGD#M,S=L.X>K;HL/0V6:O%RU<%:PW^B6RGV [ ]AHV2<2W
MZR8MR=2)L8URZ9*OJM?*C/Q)'S546<PQ093;$ 8R3;7WSK^'AW^_;'7[9K4[
MD$.87NA^"7\8> -<N(>$/G#3B'A#YPTXAX0^<-.(>$/G#3B'A#YPTXAX0^<-
M.(>$/G#3B'A#YPTXAX0^<-.(>$/G#3B'A#YPTXAX0^<-.(>$/G#3B'A#YPTX
MAX0^<-.(>$/G#3B'A#YPTXAX0^<-.(>$/G#3B'A#YPTXAX0^<-.(>$/G#3B'
MA#YPTXAX0^<-.(>$/G#3B'A#YPTXAX0^<-.(>$/G#3B'A#YPTXAX0^<-.(>$
M/G#3B'A#YPTXAX0^<-1A/9GQE6[-$TZ5ML82S3,FSB6L.U,K(/$7S]4&[1.1
M*P3<%BP67,FD0TB=M[Y0@B $$3A"MJ6W17VX3%?JZ4/B6DP\TJU;VUT+65F)
M]BW6**#]B@<'8J).DBE7ZR3:1B9.J"S=RBAB+$U+DI@_&L[=&^0IZ ;R]L1;
MM$5GKQ=RJP='8LC,6SA>#464B3JMTC"=N(MAZBL5)8O%5(APN>L8_K%.="YK
MK=>. \+%0CEJF]<'9O481!-I&/WK90YDW,TW8I)QYYE3_;W3%-!J\6<)MFH(
MWMQ#PA\X:<0\(?.&G$/"'SAIQ#PA\X:<0\(?.&G$/"'SAIQ#PA\X:<0\(?.&
MG$/"'SAIQ#PA\X:<0\(?.&G$/"'SAIQ#PA\X:<0\(?.&G$/"'SAIQ#PA\X:<
M0\(?.&G$/"'SAIQ#PA\X:<0\(?.&G$/"'SAIQ#PA\X:<0\(?.&G$/"'SAJNO
MS;<NIRE>(<-,*EM#A\H0>-<\S5VPWD"QW*_;)KQO#I^,\.3R]Z;/;[!TM"I3
M>/[%>6;Z"2:(0<O(H3#&N/IZ0AFQYD8KC?G('Y:9Y=J&YJ7:[E:/N:/&7;&<
M<XL])V&H;!T:Z8]/FW2=>D:#V/0#ZYN!(K[I(6UZ#PJ*#OW':*HHMA1#]!9R
M\XARA_UBB7CX.<'#C_AQX\/QZU9;>,0;F=LM5Y1&TQ^(*5E&YYFWMY*W)84Q
MX?+D;4VMTH5[KN(*NG$V2VO:E.1M%N<<VHMAE48QW&S4$[='@8]:S1Z;^1D8
M2'X[8/=,?WK$VZK%N+ZE3[C0MY^6=T;O:U6+% 1D"SI.X/:Q%;9<IU.M6,"1
M= CLFR4[#L-PTV=D:(H$O?I.[P))URYL"MZDLW]A.W.U[9=OI:=D.6BYG)]]
MRWG[<'E%S +K.:XQR#N0S7><VV6MUMTX8Q:[Z!I[JZIU*,EEHR,5G$83W;4C
M(TTB+!O(6Y"*2G(S%D.N[E&",AF_'3=1Y"R;R&EFY>JRZ@J,)6.50?,%_P";
M O5VJR2O4S'(!P*<VO7+@2%$I1[8F<_P0[V:\A<.]_[9UR[0D+XQ,Y^>O(7K
MG3M"0OC$SGYZ\A>N=.T)"^,3.?GKR%ZYT[0D+XQ,Y^>O(7KG3M"0OC$SGYZ\
MA>N=.T)"^,3.?GKR%ZYT[0D+XQ,Y^>O(7KG3M"0OC$SGYZ\A>N=.T)"^,3.?
MGKR%ZYT[0D+XQ,Y^>O(7KG3M"0OC$SGYZ\A>N=.T)"^,3.?GKR%ZYT[0D+XQ
M,Y^>O(7KG3M"0OC$SGYZ\A>N=.T)"^,3.?GKR%ZYT[0D+XQ,Y^>O(7KG3M"0
MOC$SGYZ\A>N=.T)"^,3.?GKR%ZYT[0D+XQ,Y^>O(7KG3M"0OC$SGYZ\A>N=.
MT)"^,3.?GKR%ZYT[0D+XQ,Y^>O(7KG3M"0OC$SGYZ\A>N=.T)"^,3.?GKR%Z
MYT[0D+XQ,Y^>O(7KG3M"0OC$SGYZ\A>N=.T)"^,3.?GKR%ZYT[0D+XQ,Y^>O
M(7KG3M"0OC$SGYZ\A>N=.T)"^,3.?GKR%ZYU0V!H,A3&-D7.12E 3&,;-F00
M*4H!Q$QA&9X  !W1$>X <1$>&HN=0.-W"=P9T_*>:;Y:J?!NIIU4JSG:^O)1
MWU'G)I,VZI)A1J=PJZ K50B*CA9LLH0BJ JJ))*1[C'$>;KI9D;#=;'E+'V.
MQ0= %0<9ER"^LS_JB"Q6*BCE25Z_9&37,DJ[4=JQHJII"B2&)U45"3'&;/\
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ML6^0E9]6Z='; ?B6Q;Y"5GU;IT=L!^);%OD)6?5NG1VP'XEL6^0E9]6Z=';
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M6-.VK>/D[Y;_ $OAG^+&G;5O'R=\M_I?#/\ %C3MJWCY.^6_TOAG^+&@Y5O
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M)"8LMH8-D%EY9HR:MC&?2,D^@W2K&59,&#8#KK.&#]([)X)BIMV;H!2=KH"
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M<1Q14"-U6V/:37JJ=V0G$0-(/(E@VD))81$1,O(NW2YQ[IU##W=36   B(
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M%=-6[J*93S9D\:LGB3ADWR;W(^[7N7BSL<]R_=WMWXZ]R_=OKOW)ZZZK+_\
MY0ZP_P!LZWZEU3CUO_.<_F?]3G:] O2:YI?_ )B_P0\8W@UR^^;_ #%_K&T^
M^;_,7^L;3[YO\Q?ZQM/OF_S%_K&T^^;_ #%_K&T^^;_,7^L;3[YO\Q?ZQM/O
MF_S%_K&T^^;_ #%_K&UTI&2W%Q#)U)2K[;_&QS)$SAV_D'.0&;-JB3\)5PY<
M'3113#O<Y0Y0XB !Q$0#4.V2Z9^R%3&S*I0N(<AUN_'D:TM/U8EB>Q]?ZDL1
MH]5G6-L,@B1N("N!7"C-R#-1L*QFC@ZK(BMK47#F8:T+2O2M,QA= ?RDW*)6
MW(K.S3RT2YK<FX;1T:8$A6481TL561M$([$IDI!:7=$D$49-4>J9+E+N9( %
M(7!)"E "E*4N12E*4 X 4I0  *4H=PI0  *     !PU7[YO\Q?ZQM/OF_P Q
M?ZQM/OF_S%_K&T^^;_,7^L;3[YO\Q?ZQM/OF_P Q?ZQM/OF_S%_K&T^^;_,7
M^L;3[YO\Q?ZQM/OF_P Q?ZQM/OF_S%_K&T^^;_,7^L;3[YO\Q?ZQM/OF_P Q
M?ZQM/OF_S%_K&T^^;_,7^L;3[YO\Q?ZQM/OF_P Q?ZQM/OF_S%_K&T^^;_,7
M^L;3[YO\Q?ZQM<1-N9#B''!8B'? .V.8P?\ W0XC_P -:7^5@Y7C<#R9TCA6
M';XWV]9<ELJI7U>3BT+G?(22J2%0[% 8KOV*3=^Z!&>-8W!6BCI)J0QHIR5$
M5A*IU/7%AC[J&SWD.>E:X\V1L;E8W$2D-&J&$9'(E[LMCL1I)LBJPDF@1(N8
MB(3C5'#KW69QLTN+U%!C[G@1UURCG,PW(?=#6[=DU1Q#M&P+L.J<FH!!O^X.
M==62\LTC@8>N6U.E"2,HR,0H!P0E<3KF%00X+%*(&)9E@Y#'>CN,D&\GOLY2
MC)&X2'.IUP_Q95Y2X8OQXHH<0,HV091)74&BUYP<P56-&C'2A"E$%$!*4"YV
M;?.2)V][8E&;S%.TW9T6;8E2%"UY C<F98N";E(!_P!M0L.15K O'.CB(F,:
M$0B42F'@D@D4 *&QI)ON3023001P,B@B0B:*"2>1$T$4TR@5--%$@%22(0H
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MMT2-HE)5?89H(<0X=W_ 1 ?G#@.J<T.'#N]_CWQX\>]W^/'O=SO][N=[0
MX!^_YQ'NB(_C$>Z(]T=0-G7\/#O]^V.OVS6IX)^ 7^R7]@:Y::::::::@/,.
MX&KXG6:016;ZTWJ6026A:?#)J*/%RN554&J[Y9-)<6C9PL@LF@FB@\D'9DE
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M")MQ=R* !Q$34#$92@ ?C$PTP"A_B(:L&POEJES^RO>DUK/4^(G"?88!B3%
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M:[HY1[A5.J%X@;**D[26N-BIACZ\LJ69(@$!>N87P9'/3@4>)16DDZ&:3<G
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M;_=3F$JQ-G_(_P"\')S%T*J<5<<K(CBBK&$.;U%PX63KL[&&2-SP,HD-L:F
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M YZR,N8PD3%I76+)!4X\_J8%-&.;*Z JG!,P<YF"@%4'W@G)S#?(^\G?#;C
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):::::::::__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g557825.jpg
<DESCRIPTION>G557825.JPG
<TEXT>
begin 644 g557825.jpg
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MF*V/4"=N% PL$D-&/-U7/LQ(?LQ DH%G$XG;2^#'"W<[+[532]CL,AI2J$:
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M(0A"$(0A"$(0A"$(0A"$:,?Y5_\ NE,(W\Q=RO\ $=#C5+A"$(1/78LOWRC
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M;-*BW[54?!^1PA*>#A\6J:Z>Y5/$K:^Z%XRZ(^QG=:<_D)=:5ETMS/8JPUU
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M:R@$PB(A+* B(!%F;)XA++XCD!TN6RS_ $9_)#'N&[+3/.LD@I%3;2N6Q35
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M!S -?Z1_LSRR =8!P .8@ "(QRA"$(0AP\,4"4 X,_UB(Y9\68CD'U!D$!E
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M,I80A"$(0A"$(1PJ32R233SS2R22!MIIIA"66667Y4TTTPB !++* C,(B
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MIWQL_<J[6(EC8F;)8JDFMAGL\WEE]&F#>G!6.&9ND&*9>1)P$'*Q7I:)Q/\
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MKX/JX(K--, &,II@VH3;76/R?VR8-6O5J  U>8 C])Q':R#GK&GF(^?,)J0
M/Z0":;7_ +0\8Q&3&O//)@^Q7SR3323T\-E^1DFEF&6:09;1.Z:49)@$!E&6
M8 F 0$!"8,PUZX]"V-N:;]CFP%S[:;;?Z$^%*;;9CMMM-8MA[:;/ASFR#,<\
MQR#/@")J#--G6^5-\F>EEK'5F 9Y:]6?GRX?/'.2:8:M(!$1 2X3"&8Y#,(A
MF(AP"(\8ZXX2S3#)/G--JFI &L=0#6$! .(!#4(><-0ZH\FE\S_U3A^H)Y@
M/U   '$  $?I"$(0A"$(0A"/'JZIM6K]JJ3?^J4/DC^D,QR'A#/5%!$0&0 $
M0 :%28<A'7-\D=L/UYB(Y\.L>.,!]M'\^G+^4.8@K9.-Z.U?MM;W 1:!^,&W
MRVXUA58['?#I6C:"YWFSVF>.5T%LNMQH5:JBKSB12!)75TFK43E X8)SS41S
MWB(_"0ES':B&8RYCD([01SRX,\]?Z=<5#AG^J2KE]6528 ]0  !Q   &H(_*
M6:899\YIARI!,&8B.4V?"&O4/U\,?K,(A-3R$0SKC*.0Y9R@$V4HY<(!Y@X
DC\!GGVE,=M-F,]4!';#K )P  '7K  $0 !X(["$(0A"$?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g216412.jpg
<DESCRIPTION>G216412.JPG
<TEXT>
begin 644 g216412.jpg
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MZWWJ4.Q6C5)N=S)D9-B-+],W69)]-4C6X@5L-% 3BTN91<DEP1Y>6[%:*/\
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M/"DJQG"L9Q^/&<9SC./HSRRQ_N'V9M "T5X]MZPD&KS2@NMKY8,C:K%V%?\
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M$.@JO=Z!;9U7DO2ZP5/T6] [+4YYRMR),I8$^H0@X*;ES(L,BU"F2XS^5_\
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MI"TH4I+32\X2K.,8SJEN_CH^&#26 ,]7:"H6L68(2H,V=2(Q>R.5UMNN&3T
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M@P$Q\/9U>]ZL$1]>Y\8NPO2RU/3ZECX,]C*/-?EZ6;+<BS;-,+WD".#AY<>
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M(,5O#TJ80C#Y#T*+&:S['7Y$E#33+>?+"W%I3^/GEZ\8/QZ'36;5)ES+,BL
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MII>C!_N&+OB7"U>08(.%0)9JMSW=]PFJU^V:TK=;N5/KT\-*KE540IY8#\+
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MJ_K4E-:=2A#<F="L>P9$7&$N>BYB1\'7Z#+_ );@?FXXXXXXXXYQG/ECS_\
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MQ\99#R?4,OW3U+V0T[NM4N!1KA%=M O&4GZ">BS:KL2MOMI3F1'/4:PL#[)
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MB&VC+<63MVUQ,8RE.7*Z)R(U]%D*2YC$A5B3'4CS=].[''''''',?M-<B6P
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M0%3:B2LY2J""STG;=47$9,DP.B^RUA4,]:S_ -Y8KVD+R>QZ2)8=JO3XC%M
MR!X2@(76?#FZEUX+&3$%!M5QQL",EM]I#4:)8; TVEI$K4>AI&&LX3E367=-
MZW6IO*5YJ0KTL-9V+\P':O\ -EL3^XMP_P"G"?&JOYLM=_W%I_\ TX,Y\]>4
MR33&+<F7.9GOVB_VRY*<887'2PR>FMN0H:T+_CO1(,>,P^\GR0ZZE:T8PE6.
M2%QSY2)#$5AZ3*>:C1H[3C\B0^XAEEAEE"G'7GG7,I0VTTVE3CCBU)0A"5*5
MG"<9SC2!NC;FM/$N[>Z)Z@Z7V+K[;/6?2**WW$[=6>A7$%<:O<IU5LSL7K;H
M1,\#.(#"\4MLD4[LS8XSTI+,4+3*X,(KC.&D1I.[O.8T%AYUQ3,=EO#TF0\O
MU;#2?8IV1(>7GT&T8]BW7G5YPE.,*6M6$XSG&M"HYVGVB[6U3=062+E=2-0D
MK$SKN4:A):8NMPC5Z55R]SJHMJ9F:9RT<)3V*O?22HP-@,.F("B)$V8N?(V<
M8QY8QCZ,>7'''''''''',?L]4KET#2J]:@T Z&F>K4_ (,8>9RXTO#C+[6?-
M+L>5'<QAV/*CN-28[N,.,NMKQA7,/^)S>M*+\7T4<8V!*%R<.0A%GM^4E'1C
M\W#DB!"/E(TCUBAL-2VPT4DXE*T-M17R",>3F<EIUH1< 3!GXDL%=>R])ARP
MUF%NBB\"9">RQ*8=:SEQF0SAU&?@\Z"_(@S6O1>C/N-Y]D,;"ZHZ9OYM5R:!
MS]?;'\E98VAJ@S-US?FW%9SYN2S5;5%:/)SYY2J+9H)J&XC.6W8ZD9RG.D3Q
M0_">V%NS3FS+)4Z_IC:^YDB1SP/?3M-(:G[+PPXP\$(FQ%Q)ZB;@UGL$)DUH
M5/'MAK=7V"#$J2@L(COF(L9"ZJ^&N]WA\.K0@[7@NW]8;@*M=[L^QDZ,[(#]
MU];#1B%88H)$ QJ'M.>"6#61A^VQ!R)'W(7:FC6!$QE/J+"ML@XEG<T&\6C4
M]&2,']TM0[JZ+E23K,6#:]R5N/<>NY^4]AM2553M'J"3=]-3("VW6W6I%H-T
MV8IE27'1[.,^S930]CZ_VG6H%SUG=ZCL2H%4>L&6FBV0/;JZ0;SC&?3A&J_,
M(#I"?)6,_P##D*SCS]N,9\\8S/&?/YO/_'&<?MQCG/'''''''.,_-_BG]N.4
M7UW\W6/\\?9C]F[.:NO^T55C7=YT=I&FWC58S9,XQ:=M.5B43B[@-9II!C49
M.*]8Q=;TSTS[JGR!R)DC#E!YQN@UNICYP]J*?LLJ"7=KA??QK;^;VC?\-37_
M +'5;_AKP[A;?_J =_ 5AYB*]A2/XJL.QH[F,X\EL,K\VTYMR";E_/\ :2_N
M;NO_ ,,N5C\66S9IGAS]OK2VXXF0)TA=TP&6<Y;>F%C0E^L!(3$I+["X3T@T
M>'X;E-9<=:RGR:8>6I*,W&TO2D:VU!JS7C3:6F:'KBBTQEI"&6T--5:J" 2&
MT-Q\88;0C$#T4MLX]4C&,);\D83R3......5IWGVGUUH@[5:6:@VVV[%OH\O
M+HFO:%7W['9K/*%OPXK8]AAIQF,-61DRW$PR!>1#%(9&&)4J;'9&NY5#_P @
M&T^S?_K;MN0Q6-<O84Z&ZOZXM!!D)A"L^E&F[BV&&6-*WT['SZ#K=>K[PNE"
M9;+;R<G'T^OY9_3FDM::#J;U'U375U>L/F9Q]8M1H\;1@J2:BLS9+4BP$BDJ
M.F0F%'4N,P^W%]<ER1AG#[[[CDK\<<<<<<<@/>76#1/9*ND*ENO6U9V!6S#;
M,<V%L(V*0&FH;/L3$)PY3+S$C"4>3;$Q"&2L!.,*&$8+F$N8U#;3Z@=Y>GIL
M.OH#M79.T>N,:PZ\)3^GVZ=LF"&(L"JV/)55!TAV*,1+1L73%++)>C#3E=M:
M;6"+@X#=<8L5<$3)#3=\.OOB.:4W%>_D*V,(N?5GM-$9;5/ZU]C!\"DWPOYX
M]%PEJPZW/FT7=]76ZA[,.Q:KLEB2N*A#Y$>*6Y\'1L$QG&?FSY__ &S]&?HS
M].,^W'.>...<93A6,XSCY\>6?Z<?1GZ<?3C/GC/X\9Y4R[].M9F3\R^ZR(6;
MK[M&7E3TF^:8G1ZQDU)]++GI7.FN1I5#O+3KJLJE9L==E$'DY4ELDPO.'$U=
MN7;GL)UFV_1M4;JJH_=-2(PGBYK:FF];WY-HP"GHG"@&"U'B(*5J#96CL)4P
MO& 6(BT0!N9<'AQ<WX-&E[ =4[OU1N\*\>U;> =OAPW<QBD: ^XP9!3$J4A<
M"QUT@U#/UT@A:%I5!-C8,G'HYSAO*?+.95XXXXY N]?X^G?S[:Z_::Y.Z?Y/
M']3'^7E=CGX:,?VH0_U;W(\J7X/Z3?DL?^S%QY"OB^1J$_T8V2]L>5K>-7!]
MEUF13G;-!WCM"BX+QKV%R&E&:)UQ'%=Q63 <@MFP1AM1BL*D2!#;9<U5PBR%
MI"RUX;JJ(KH[UN^3)Z+(H2-=QVJK,ATZWZ]9G"&3)EI@C]PM\CQ+747B*D.3
M9-<+Q(K@B4^]"C18\!J(RBNVW>WVW*#OG96KX5HIZ:--/Z;AUO9I"ECY%6U-
M!LE;[2R;XLW805[.0K%,AW31-*UM'KFP!NM+ /M]N/SX*3X-0.(-MTSM&T7[
MIQ7-KEM?&&;1LGKZ!N5AHP=8^)-J92[ZP9/FA[^+>5KZTQJO,)2(LQF0]\=9
M:C9;9&RY^,Q53AJS'_NRUYC&<9QBC4_RSCS\L^5=&>W'GC&?+/E[//&,_3C&
M?9SHZ? V.MZ^""K:XXY8DR#LXJITA@HI+Y:Q%BJ&\34J6AUMJ/,8;;0VK+;"
M$XCMY]!I.,29QROO:[;]"T'UMW?N+9Y%\91:!K2VG#ST-M#Y.6W\428,$,$B
MN8RB;8; 5F0 ->'9]I$V2@0DXSE_&.::? W\),YX?=2D;^V/L0C(V9OG1FNH
M5YU++K0T4,U',B3Y5S>"KLJ"#LPX6&,DHPD^MZ .@QRD(BJ(IZ-AA2-DU_L!
M#MM=3.B->EGX>BZA*8B]A]E@YF$KM\QUEJ6UHNAEXN5I4J<PZQ(V;8A[N<"1
M"L5J-(01(R4IN^%"B:X(&  (V$'"AH$06)%#8S4,>-'06$1H<&%$82AF-%BQ
MVVV6&6DI0VVC"<8^?.?3XXXXXXXXXXXXYC=LJ@:Z@9M<.M2G!T[U"UY@D)PN
M:P_%?;E1)42>.?C2XTB+*9:?96V[A.'&TX<0XWE3:L5CL']9T:9Z4FZ;<F"9
M*GH;3N CENDBGY;",0TO?^J8QB2)B*>?P_(S@F32UEKS>DK:QS(*7=@5^"8.
M 5S?@Z)<D=,B$QTT24&$X64)FC"8Z>RS)B3H:W$)>;4E2/-6%M.N-J2O/LF0
M02QC9(>PB!AT1-;]5,%&H$4J-EM9^=N5 GLR(KZ,^><92ZRK&<>SRY4XWTJU
MO$20>T[8+KH"623)5/&:T+,+UR:<E)4AQNQZ>M<6PZR+PW$+<;D1FZZ/6^TX
MXVI_'I>>-&WB#>$5>U:,W$8T#K33P/9AD<(E3-D];"^S>JI.SC0]B%&3Z]O]
M?=8D">H=P*>#Q)SS$F *''QYEN,:'QW78[D5^&?#,V%WL\/[0PW7Y1CKONH!
M:KO9]@PM4;:V-MGKYN(I$M+(1B 9U1O_ ''79V@M@!S<<8F>/I!=^FS1\E3^
M$665@AC#.[6F>+/UD28$4SLF/V9T>V(8=CPQM>[<4]6MJ?8YSB<)<10][09A
M_0-_AJ?_ (,&77-E//3F5LR$0FTN^BG9>++BS8Z&7#$81841CM2QY,9*8(#Y
M\5]/ILR84Z&X_%EL.HSA;;T=YUM:?X259Q[>>AC/G[?;_CC./^6<8SSGCCCC
MG&?F_P 4_MQRB^N_FZQ_GC[,?LW9RA/CMJT3&U)HV?O6)H.6";V+:HL7.\>K
M&W>V+T"*_2G9AZ9K>AZIH5[8$W@@.&MU.)9M@MA:,'CVE9*;+.$AXVG639?N
M^Y&*1U./V.A6P'K^W1M6-N:[E+341\>5;T4]4RGU8#'VV4@UAJ2;*1H(J'#M
MDEY>("Y+#N6R.$3HM6.L_<#<^W.P5?I%C!+CUPW5;9)*5V91I],L55$5O2_4
M[8M1V=8!I"06)5U6R[5O"]UW-3(&B@T:@4'KP4I.L%#O10]<6QEI\OLQJP4_
M6S(V"+I6WEP;%,?!+#V%4IK5[C[0EF":F'&7!RU98F9-!A+2W$YS =FM^;F*
MH>+<J(4ZM@M=S4//M[K["];]'Q(D=#JW)!/:&YZ: B9=REZ*TW$C1\D)LAUV
M7&RWF,SZAYJ4IAU&S].,XQGS_P#F7G_#*U9Q_P N?KCCCCD![_WN,TE7A"8@
M>5=ME7HLBJZIU@'DL,'KY;9*?-N,RMW.<#*\':S@G;K/);R/K@9MV7)RMY<6
M._#>L.G-??LHW>G8?,79O91XV.MB[;"GGA5;U[)&IQ\1TK6HB&2AM1JA5V5+
MAMO%F)D^S272)4UA?QFY#1>#YOFXXXXXXXXXXXY5#L_TLZ_=O:^U7-XT8=<1
MS#L)V.D@E;CX]R!(2_&FU\@VZP6J)V*KTEP+/3R0"PP7_5O-D5X:2US7V?K?
M?KP]C$5&EK/9>^O5[+\?+6HM^6.-![(Z_@/..,YK^JNRLUWXIV.T-3AC >K]
M@1T$R0;6P-@[.6ZVXYBT>E_%&ZA[C)/4EZYV#4N\!ECJU-LG6O=5+LFONP==
MM]Q-/@00)6M9<&80M*9,Z+(D.6*@2+;4HH1AVRS3T2O-N$D;#\*PKS\LXSY>
MS/EGS\N<\<<<XRG&?G\_\%*Q^S..5QVIU9U3M$RU=/@9;7NU(2%8$[?U:4<I
M&QX*E9QGU<LT-;^#V8>K./1="V^ >#O(4XA<+^'E7(KQ<>VNA5^JV%4XO:76
MD-'\*_ZK&PZSN\7$2KVR;+J9^2W7+JXPC*4O2=?%1A&2AM<AFK*=5F/RP^IM
M[:HW>+DE-:7(98E#7/@YT+G$@7:JQ-QGT%C[54BS,&R5N>VYA3:HQD9$4I2%
M9:RXCR7F7/G^;CCD"[U_CZ=_/MKK]IKD[I_D\?U,?Y>5V.?AHQ_:A#_5O<CR
MI?@_I-^2Q_[,7'FM#QN-\HUK8^I6N+/V.7H#4NR;%:BNU5OA>MMKCF0=*N&H
M5A[0'H783K#V48V+;M6V$Y NPVK E:M8:#03YE^WEK1#IE;E[*_#M#Z?K_2S
MKV$T%L:)MO3HJC9@:^V1!HE8UE"M]>C'SC<<Q$HE+JM'J=:BO/XDLL#Z]4*V
M(RTPF3"#P69"64VR34JLE@O%37 *8Q^:LD<C)#C<1S)!QY,AR<58Q%PT2F./
MI2\N5-0_(6ZE+BG,K2E6/"VK_-EL3^XMP_Z<)\\2H29T/1]:EC&I#Y*+JL)(
M'LQ&<2)3TUBFQ'8C49C.,X>D.2$-H9:SCR<<RE&?XW,EUOFP*U]2%VMV8]9G
M*G7W+ X19;CS\F7!<9PCB:PRVTVU*3*4ZA]M+;?HNI5A2$J]+',TYPK/HI5G
MY_+&<^7Y,>?XN?R8]Q>^][[,>+CI7PM[SK #'Z_:X[H:ALUKG"R]A=,[9CU;
M5[6UZ2*NXV0-^*HM3";"EC+++'1'WX=C<JPJ-+=891(7S^@3NP5<+:CBZ2 N
M2%[![$GA>LJ9$ASYL!Z.F5*CE[?:""QSS,QRLU&K0B)6Q1<J^!$XRV 4_"HQ
M=;:YCZ^Z4 ]>]3575-<(SRX^MM3W'"I)N.Q*(D2Q&26)S,1(J41H$9Z;+>S"
M',84W!B89BY>D+:4^Y-'''''''''''''''',3N]<D6JKE ,(E*#2YV(BHI6%
M)DQ94"3%GQ9K,MMV*M#J\M.1DJ5'4K#,M.,Q9.<1W7>8G2ZW<-?4TU"DDD;"
M+L2")($PI#(&9-P[&9<:$D#$MV4W(E.SDOH07F(0EJ(N*PZWE$;T\^Q3+Q-L
MD0JY8*79Z!,!^JP09M+8],!U*VWW79(DV.FRQQ2#&0PK,B2A;&6,*;RZTC"\
M>67"C @]!9)!"8XP.DIPMB>+FQB$)]&<8SA34J(Z\PO&<9QG&4KS[/;SKG:W
M7[0*D@[*##V$+,1ZJ6(.C(1<7*;\LX]7('D&)$1Y'EG./16SG'E[,>7LY3ZZ
M]"M)'@Y412?N@U./,-OH)UBH2X1?5IKU^,X4U8=)WR!;-2F(CF%*2^SFIQ'7
M4J5C$E"LX5C2'W&\)3L;I_16UY/1.P$Z!8)T2"2=KW63<6U>LE:M$>"<&$3D
MBR]>X!FVZFF%60T:<_#(:DF:L..S&666X!2(Z\&F1IX>7:WQ"NA&D!]2[1Z:
M,=@:E:+C8+R-/6G>=O&;[B ;$P%^!YJAG?0:#J+8M8D)AKEU^K1-N5"PC'I4
M_#L%]4V-AS=?IGQ=>C>W2PZHF-HRM [*)*RW&UCV<KQ'15JE2/2PA$4&2N6(
M]#N;SB\^@RJC72S,R,^66'%X4G*MED>5&EL,R8K[,B/):;>CR&'$.L2&748<
M;=8>;4II]IQ"L+0XTM:%)SA259QG&>??CCG&?F_Q3^W'*+Z[^;K'^>/LQ^S=
MG-(/B_;DU;8.YK77#LSW&9Z^]:\:!CESHTOK;J1N)=<M5VKFTALFQBM5;CZ>
M;SOA*KW2HC2E'M5U%[>JDL:8(!*^$UU+#R++;V/Z<J;#"3J'4(\9Q@\%^YFL
MN#I<L7'BMSXC0B X.(9%J92S!<>92Q+1&0RWB$M>&6TM^J3A.7ICL)?7)2RW
MB0XTAE;^$)]<MEI2UMM+=\O34VVIQQ2$*5E*%..*3C"G%Y5!]R_G^TE_<W=?
M_AERK7>Z.#M.SN@6MRCL%TH=[E4B^U<8Z]Z))\KI2LVG9A(F.CMXR\_@+70Y
M3,_S4EAB"3=D/X6AO&$[&4>?H(\_G]%/GY_/Y^6//_GS]<<<9SC'S\JENWM5
M7=;$I>O-?5H_N[>K@M\@/U+KN,@L3%,^KS\&,; *)=0,H==R]EO&9)R4P3GX
M6EL,-G.KQE$2](]=[!-1#F_NS-<MC?9<S-)4V3*NX\1 CU2A#G(\@,$UD&#.
MOBZ_6"[;Z)QY]C#9<Y8&IOQPZ^S$B97L'XXXXXXXXXXXXXYQG&,_/C&?R_\
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M:&]*>N,5@,?KZ$ZV'/9#6B^6S91V [+G$ICS)&YW^+"V"6<R\^XZVWL*%#V
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MBOX9 AP.'6D#78))YB/AJ<EYZ]/'''''''''''''''''''''''''S_/SR#8
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MB&^ZEU&<W'7-'J77HMK<'61,6D4/4\RM5*NOQD$!X0+4*3($5J'$01^%+_\
M4X^!$CPY#BUR6_4)<R]EW*EY^&G:E PQ6KY@LN:3D:?UG3G!GG'4V'8'"DG7
M%*6A:I"9!11>*^XS(2WZ+,=AYOTTR,*37[Q'>PUNT1UWD@]/PX!SLIV&M(3K
MAUEK)!AN7$(;@VDF4+@V(M#=0ZV[5-:5MJP[,N#\F.\/9 524U.QZN4E*^CU
MQZK]4_#)ZX!GP=1HM7D:ZU76:KLW=,"EAH6Q=HR1#C;DDI:CHL>D_9R-DN)*
M7-#!I<J6W%EE(0D8U&BQXS3.5],)#>T1VQ.TQ-<9\[O.VSHH&*F1'E2:;JS7
MD^?5J-2).&4J1 *L.QS%BLT-EWVGCCV7_2<81G%WN...................
M............<9^;_%/[<<HOKOYNL?YX^S'[-V<H;XK59W9V"O%/U3KKK=O7
M<&D]65:QGNR]BU%W&H'4MXM6MGBD")&L&X)01/NNZXXZI!YFP[+K"=:]/:GN
MN6JM5[;>;*R^6K,#;98=5T'<O7PAIT\N>3UIL75C5&)K$OOU@@2IIZLQQ3N8
M+\!#$D$_-#O8]7F&AAX=EWT(_JEM(RGIUSK3J*K;;+;O%5M2=A&6SSDLF_-D
M/06S%N"ZZKMTL\$+YH$CK+<P>I==#;*7@Q([Q!BLM+2EA\K8'B]<^]&RI.AJ
MY:-WUVI.6VU:\ZQ=J[B%K0L=-E%+G90E:U[BJUOU86-(,RL%3;@T>K,-F5+B
MQ'7GX[*LL83RVND!A4/IW5XX]"C#K!'H-2S88,)R2["BV&0"@RST>$Y,RJ6J
M&R8D36XN9*E2/4);]=G*_/GQW7NO7_7^@$ME;**O"JT,EC("E0X3Y,E-(%YC
M<*! &#(N,R9\QYQ:W<LLX\VXL>5*<REB,ZM-'!6B]T]G=RZC[5[)(PM3UO6E
M@63U7H6S4QBUG&Z;,RC,L_>IKQZ+ K&QK6WAF?'CC8))RD-P0"/A#Y.#,;<V
M=XQY8\O_ #G^G/\ 3G\?''''''''''''''''''''''''''''''''(%WK_'T[
M^?;77[37)W3_ ">/ZF/\O*['/PT8_M0A_JWN1Y4OP?TF_)8_]F+CSW^U_2'K
M/W:KU4K?8[7LRX1Z*8('*::KE]V/JJ[5B:8&Y$'6 FP=2VZCWD>(L8S#4*R@
M&+ D'8F(@_!D=-<&CG(L]ZXUS1=0T*H:OUE50M(U]0:Z)J=.J5=A-CPM>KH.
M&U!%BAT1OSPU&BQFD(QE:G'G5^F_(=>D.NNKS7F [6\LZQV)C/S9HEP\_P G
MW.$_/D9Z"KR:-JYRPV(J*1BT1AUW(%59^ 0A@9-)KD&$DC+EJ0VPV)"AVUSI
M;SB8S"4ONX<2RC*L?S-Z2Z<;6[>>))/\9.L;4K-)Z5U?LD4O>O6MEF+B-.;'
MU5K;6;.K#VTZ*,;;DU>NT*WFQ!F152)V:'>M-:C*-R(<<<1@?#-Q^L3]R\1,
MQ.7LNFFM?=9M>F&9T2H)<+Q5[P,REN2JW'MQMS I3U?JP=(ZP3P5=8?%DRQD
M6\LX\S$;9YL_JE4K=&K8:H5 */KM9KT!D8&"BHZ(L ?"8QG"&6&48^=2LJ=>
M><RM^2^X[(D.NONN.+R#CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCG&?F_Q3^W
M'*+Z[^;K'^>/LQ^S=G.SV6\.+IGV^V%3-I=A=-1[[=:.,B (!!NZ['J(^R5:
M =S9H-+V;7*/;ZU6]O46$><E$H=(VD)M]6C/$S:&12(YTRQ/NXTTVPVVRRVA
MIII"6VFFTI0VVVA.$H0A"<82A"$XPE"$XPE"<82G&$XQC'TYK1[X[B':LV[T
MBJ\L 5LLSL/NR9UY'0 \Z' D0,7)=2LAFR3'9?GET/6ZY2RY0M&AIS/D1&E-
M15(6K*TW3W9N*K:+UK8-BVA[THXMEN($#1DN/%+5:2><Q*O4 ,*.V]*GF[&5
M7&'0(D9AUS'K7)+B41H[[J-?NDM-$.]-/SM?NF+L<Z3&FSZO6=#9%W_5%.UR
M^)<0T1LJA[I,<=N-GMD=]I_%FG2718T1(6"$QVW&9JD;2 04=6P@>NB&G6!0
M$4/##&7Y<N>^T/%PV8,)IZ>0?DSYKK<9AI#DN;)D2Y"DY>DONO+6M7J\<<<<
M<<<<<<<<<<<<<<<<<<<<<<<<<<<<@7>O\?3OY]M=?M-<G=/\GC^IC_+RNQS\
M-&/[4(?ZM[D>5+\'])OR6/\ V8N/+G\<J3V^VC=-75/7,JK&?N."VO:+-3V+
MLE->;L;NM*8O6VS+/$LK$.;&GA&'R]_J]%H#4T\-(C&573U28N24@<^Q!W8'
M?^[JST$UUM^10_B_9=_J6@V-P E IDCY+X>UH=;@[?,JK4Y],R3C7+1PS)4
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M9$J9)D3"$R5-ERI<E^3)E2'GWW5N.*5G)N...<9QC/LSCS]N,^WZ<9QG&?\
M#.,9Q_3CF.5*GU:A@HU9IE?$UBO0Y!.7$#!(3(\;'DFBT\Z6?9B1TI:;=(F2
M9 G,6E.,OS9LF0OS<=5G.2<<Q.YWRF:[#XL%ZM(*HA5SX(MLG8"<47#=)$WO
M4#Q[+TIQO#TV8[A28\9KTWG?0<4E&4MK4G!==]BM"[<F"QVK=R:SV)/.59=Y
M"PZ5= %EDEZ4C[FL_=<+9$392Y]8<1<JD\R>BI=%R(UGK\IB4Y',0'7Y$M=6
MK-ZK1RGW($+LU6LHR6&/U\Z/9(B2XJ>SEF9!(0);;C$F*^TOT7$.(RG&?+.,
MI<2E2< D7/1VCF:E0"5OU]K;[H+$&K50KAFR" 4NP6_8ALRH$+&QR<YN::M-
M^LL:P+'(5F49N%A9,K963*HGJQ+_ *:<_3Y>SRSZ*O+/I9QC'EGR\L^?GCVX
MS^S//+"'@ME&LF*\6'&Q4AR6RP1%S(\Z&Z\/FR!T]E$B,XXUEZ$0B2X,QGTO
M6Q9D:1%?0V^RZVCUN.8_:ZI6[S6S=/N (59JO9!DL,> &X3!$27%SFE,RX,^
M%)0XQ(COMJRE;;B<^WT5IRE:4JQ]*W6@=1#Q0%<&QA(F&N8\S$C87Z*I)&=)
M*$YLAUU;LB60*%)LTF4(RWGYQ(E,ED)TB1,DOO+]SCCCF(76@T_8HN %NU?'
MV,6+LM6N(Z&20XMJ%::0?@6JHGHWJG65LDZ[9!0TV(E(7A<,G B2VO)UAM2>
MI5=9:^HYJV6*H4^O5PY>9_QG;B@<9'@S#\[XQ-&5/D7F4I4]E9NRV4ZZWCT&
MG3MCL)MQM94Z5F3,ZXXXYB%TH5/V(,@!KK7Q]C&"[-5;D.ADFW'&85IH]@'V
MJHGHV&W&EM$Z[9!0TV)E)5Z<,G B2V_)UAM6,=I&F-8ZW/7"T4FH#:^>OI24
M8MA.(Y/=D&"1 V5L1"6]B;-E-,.SSIPJ6G8@M1&Y<^:[)D(<<PWE%9]=_-UC
M_/'V8_9NSEZ>..8*0UCKXK>PVSB-.KTW8%>@?%@6WR!D=P^.A8CGHC+$8@I/
MKDXB1+7:XD!Q65.CHEJM$6 Y&CV(TW.SKCCCCD6G]+:OM&PZ[M8]3QA/8%4A
M1AP"RR%S\31\*%-($H<9++4UJ ^U$(DYI"*F7#D9CSG4S&LHD,1W&92QCRQY
M8^;'LQQQQQS'C=3K5EFU@B?!"S$ZEV#[JZG+(0VI4BNV3XB.UCX\#NNIRJ"3
M^YZSV$-\+9REWXM,D8OI>JE.XSD/''("NG:/K]KN[0=<W?:]0K5W*2WH(VME
M9SS!,A-B5M%R(1(328JVY4D54'6K6898=6X'K3C9THF&+6F5F3*+L"F[,JHF
M[T*P#[54SB);@D\'6[)'3T02$P5+S'>RTC*O@Y$?-ANX4A*D/QW$9Q[,9SXU
MIUSJPK91>SK=5:I(LM('/9@7(U!A-RPHF#,0?SZ\I)]6U\7""<1!^)D@MV*#
M*,?'<',&>E4SGXU]N75>U9=Q'ZWOM8NDW7I<,!NL.N$V24BL%[%4 %_K\$NR
MQYKB.G*/:JU;0^58RT3KAT28A./09\=YS+C-IKE=? QCQH<'?M!MFM5ULG*:
M@Y,V"3!GDHP4>J2IM,DI*@BR,F+!;5F3*1#D8CMNK;RGGO\ S_-QQS S>K]>
MV.W KZ<IU?)W&M1L0@UCECF7"L.&V19,QHF9/EC,F- -1V30MB;B2T*,MI+C
M$1"7G*SGF,8QCRQCRQCV8QCYL8^CCCCCD1']"Z=M!.ZF;#KNL%RNQ6:4S="$
MT?ZZ58,:X>FR:$]->RYA29E/DD9TBN3XOP:<)?EOO0Y+;KF5\DP.'$UX2, @
M1D ,$"#H0@.(%1(X\8*%#8K4(<-'08C;46%!@PV&8L.)':;8C1V6F66T-H2G
M'H\<<<A6W==M+7J;<25IUZ"*D=@.Z_?N)!7P^)/L#^JIDPAKE^?,'3H<E3],
MGD)DVO/,NLNCI3ZI#2O6X0M.,;5 !ZJ$T)6:\/CB@->W%JL*&&1<*3&'BQ<8
MK"@0V,+4M>&HT5AII&5K6O*48RM:UY4K-CD_R>/ZF/\ +RNQS\-&/[4(?ZM[
MD>5+\'])OR6/_9BX\N?QQQQQQQQQQQQQQQQQQS"-DUR?;*%<:\(2-^.S%6L@
MH(\66^S C%2X$D(AR)4F)$FS(L=M4]7PA^%%?E)C*>0RTO+F4YT:9\*'LP-U
MEU6UQ5^PX&LP-%=)^H'5FYLURR[8J<*XV'KEV9Z];4N5R&IK7P"3!B[+TWIN
MUZ:7E];1V$'V1-&3YD^N0)$(ICV@?"E[UZS)Z]C[![TV6]46OWRFVFVU&)L_
M>T2>;<$ZHA4E^Q"KB5GDC8T[6+=70-L$5YY+M6NHXG9@EJR'FN0S:\T[B>&1
MO3LIO7L>6"7T17*_MK;'1?>^O+M.GV2-(I$?JC4-D5 _JYAVLO,6"OE?NQM0
M[:M).")#<)Z5;KDI:QQ4%Z1GM ?"Y[6-:[W'&-]P;:SN^_N]6&:=M49L_<Y8
M53XND>N^F:!LG!37EDG/TRRCMS;QU<9VO?PV0PXC;@U]/"7KA6KDR.O$+8)T
M:T?L#3(3LB6OSWP/Y>>X>_\ L-3:9F5F2YKRB[(+AF@5>F8;4J!$-6!ZOD=F
MV<:,]*(+L^P# ]V64)1B!>?>'CCCCCCCCCCCCCCG&?F_Q3^W'*+Z[^;K'^>/
MLQ^S=G+T\<<<<<<<<<<<<<<<<<<I;O7J\<VWVHZ6[_@V, ,K_5H]OP]8JJ1%
MSIA"_+W/I8EIZ+"ASV%H@!V0#)%1F8Z0B%U%VV6Q33(Y/G-YI8M'@3]F++1*
MQ5__ $X<C[!7M)4S4N;?'&[<1/DSJIK?NM3Y-G4W%V;#=4Z=LO9S5%PFQY$M
M^8B3UMI["B;[\D/+JMV97AH[R(=8?$,TY8NS92[;,[C:VV]2*GLXZ4V,TBN1
M-DB;=(KU>MH&?:;  6-H!"Y$]?CK34P8NPF=2L! YN(Z[7AH]N!=D>$7O;;6
MR>WNZJSOR%H:3W*T-=M=S-;C!5L6O5-GL_7#I[IFAEY!.HW8>$L\[1UEZS62
MSTX@)BB9.&M@X9!DP:ATB24F'='AD[&*W4<WJ'9Y&L:SL-RZ3JQ0Y9NQG06H
M8?4[L'J[L.9V?2C5J,%;6$NEO':WLVJG:_7I3P&XS]B!+D9C5(I7KT<OF[A.
M,XQ[<^>?/.?_ -V<Y\OR8\_+']&/FQSGCCCCCCCCCCCCCCD"[U_CZ=_/MKK]
MIKD[I_D\?U,?Y>5V.?AHQ_:A#_5O<B@*Z><H?6*PTT-%M9'7T63-,@'S&*Z^
MN$:U[8*LEZ(0G#Y,!U<4@3C+>94M*EL8<6TI>4^@J5?E8VW[C4_6A6_W+Q\K
M&V_<:GZT*W^Y>/E8VW[C4_6A6_W+Q\K&V_<:GZT*W^Y>/E8VW[C4_6A6_P!R
M\?*QMOW&I^M"M_N7CY6-M^XU/UH5O]R\?*QMOW&I^M"M_N7CY6-M^XU/UH5O
M]R\?*QMOW&I^M"M_N7CY6-M^XU/UH5O]R\?*QMOW&I^M"M_N7CY6-M^XU/UH
M5O\ <O'RL;;]QJ?K0K?[EX^5C;?N-3]:%;_<O'RL;;]QJ?K0K?[EX^5C;?N-
M3]:%;_<O'RL;;]QJ?K0K?[EX^5C;?N-3]:%;_<O'RL;;]QJ?K0K?[EX^5C;?
MN-3]:%;_ '+Q\K&V_<:GZT*W^Y>/E8VW[C$_6A6_W+Q\K&V_<:GZT*W^Y>/E
M8VW[C$_6A6_W+Q\K&V_<:GZT*W^Y>/E8VW[C4_6A6_W+Q\K&V_<:GZT*W^Y>
M/E8VW[C4_6A6_P!R\?*QMOW&I^M"M_N7CY6-M^XU/UH5O]R\?*QMOW&I^M"M
M_N7CY6-M^XU/UH5O]R\?*QMOW&I^M"M_N7CY6-M^XU/UH5O]R\?*QMOW&I^M
M"M_N7CY6-M^XU/UH5O\ <O'RL;;]QJ?K0K?[EX^5C;?N-3]:%;_<O'RL;;]Q
MJ?K0K?[EX^5C;><X\]&I\O-.<_\ O0K>?9C.,Y]GQ-CS]GXO/'G]./GY$H<)
M?*Y7-)S(58&FK70[YM>TV>I-6=F#B'!V$G8GP!N&?E"OBX@_ 5;1N):6VVDJ
M]&1EG*\-XPN6OE8VW[C4_6A6_P!R\?*QMOW&I^M"M_N7CY6-M^XU/UH5O]R\
M?*QMOW&I^M"M_N7CY6-M^XU/UH5O]R\?*QMOW&I^M"M_N7CY6-M^XU/UH5O]
MR\?*QMOW&I^M"M_N7CY6-M^XU/UH5O\ <O'RL;;]QJ?K0K?[EX^5C;?N-3]:
M%;_<O'RL;;]QJ?K0K?[EX^5C;?N-3]:%;_<O'RL;;]QJ?K0K?[EX^5C;?N-3
M]:%;_<O'RL;;]QJ?K0K?[EX^5C;?N-3]:%;_ '+Q\K&V_<:GZT*W^Y>/E8VW
M[C4_6A6_W+Q\K&V_<:GZT*W^Y>/E8VW[C4_6A6_W+Q\K&V_<:GZT*W^Y>/E8
MVW[C4_6A6_W+Q\K&V_<:GZT*W^Y>/E8VW[C4_6A6_P!R\?*QMOW&I^M"M_N7
MCY6-M^XU/UH5O]R\?*QMOW&I^M"M_N7CY6-M^XU/UH5O]R\?*QMOW&I^M"M_
MN7CY6-M^XU/UH5O]R\?*QMOW&I^M"M_N7CY6-M^XU/UH5O\ <O'RL;;]QJ?K
M0K?[EX^5C;?N-3]:%;_<O'RL;;]QJ?K0K?[EX^5C;?N-3]:%;_<O'RL;;]QJ
M?K0K?[EX^5C;?N-3]:%;_<O'RL;;]QJ?K0K?[EYA]H.;+OA77;)C6D2H!JSL
MFL7(P;DWL8;PP- ()J?:8&BPZ9<F5(=E,-,-IRA&,Y4MQUM",^E9/%SKF$8Q
LDCCSPGRS_P!T(?BQ_P#Z?(!-V4)DR7SB;YXR3GYQGX-+^;,IW./_ .AS_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g967111.jpg
<DESCRIPTION>G967111.JPG
<TEXT>
begin 644 g967111.jpg
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MO#US*(^N0$2N+F+A(B.<&3,B9=A&,&2QDC"4QDA5:MTE!3$Q"&$G>[HB0HB
MB4.G<]T/K_[C?;D9N--ZP>J;,5D:7"2Q]Q-V[+9HS2"DUXXQC2$+76<++!+*
MO -7V,1X5LPKS8&\(Q4>2+QHP1?R<BZ=9O!0<96H.&KD,@HVAX"*CH2*;*NW
MKY5"-BF:+!B@J^D'#M^]42:H))G=OG3EXX,457+A98YU#=KT#Z ]09P)"#TZ
ME*/0.@=2@/0/H#J'F#.>Z7H =TO0/F#H'0/\ _-CH'3IT#I]'0.GJSGH ?,'
M3&!#J'0?L_EG'0/\/\!$/Y9H5_M <)4[+QITO!S53J>T;*ZW\R4H^H;MQ@Y&
M<KX6Y2"6NKTG9IUCK[B_:J7LF&M&LZ0XL-]K5M7G1K#5[%J0LNR(M-L)N#=D
M1HV\O=D;UYISMC3FHGD'9;L:0\H/&C9?&/D46T0<%QZTVWA-CT79=TO5@0K$
M!6N-4?<:ZZF9U60FK=MR^2["+A8(S%Q/S[VBG*;9^K]BT'4] KFQ).CP_'OD
MAS#Y&O=13M1K&WI/3?'%SK:"+KK5,U;I2/093]SL.RB2=ADH-1G:T*Y4AK=6
MG:O.7-I9X:"=7\M]HW#?E#V="[%L<O0MC]I!/<)ZWJ-9TNM6#\=&O!U_O2G7
MT\+*12<\RV4[LU::[BDK?(F4E75,NKFI2*Y( D/\6[X@'O$*80Z=0(/3Z.H@
M/3*6: VM,0^F-;QB.F-OSB3&K,6R<O"QE(6BI$B)UTRO(]1]?8]X9HX OA$!
M=,6JXIF*91!,1[N3!Y:)ST";S]CZ^_$G'EHG/0)O/V/K[\2<>6B<] F\_8^O
MOQ)QY:)ST";S]CZ^_$G'EHG/0)O/V/K[\2<>6B<] F\_8^OOQ)QY:)ST";S]
MCZ^_$G'EHG/0)O/V/K[\2<>6B<] F\_8^OOQ)QY:)ST";S]CZ^_$G'EHG/0)
MO/V/K[\2<>6B<] F\_8^OOQ)QY:)ST";S]CZ^_$G'EHG/0)O/V/K[\2<>6B<
M] F\_8^OOQ)QY:)ST";S]CZ^_$G'EHG/0)O/V/K[\2<>6B<] F\_8^OOQ)QY
M:)ST";S]CZ^_$G'EHG/0)O/V/K[\2<>6B<] F\_8^OOQ)QY:)ST";S]CZ^_$
MG/G=[SD8]JY?/]';J8L6:"KIX]>Q^N&C-HV0(95=PZ=.-F)H-T$4RF45564(
MF0A1$Q@ ,PRP[JM=\U]+&UAKW;T1(V.!<EJ-]85_65JB6#IRF)&<R@W2V@+.
M401.!OR2*G # )@*=1+P1JB4OC="5Q5*T3U Y5V?;9GTM-.]J*-J UGR3[U@
MBWBY.,(XV<_^#>+SY(\BQ(^4D#R@N7,98324&J$42\:6UIM6,9L)G0N[)I5%
MNU([<.ZSK0J;UV@B0BKT60;&.V;F76 ZX(HE\&AX3P:0]PH9]R>X9=$ *EQ_
MW>D!2@4 3A->)@!2AT*7H39!0[I0\Q0Z="AY@ ,]OEHG/0)O/V/K[\2<>6><
M] >\_8^OOQ)QY9YST![S]CZ^_$G'EHG/0)O/V/K[\2<>6B<] F\_8^OO_,?*
M3Y@^D1\P?./FR&]F<TXC7-5M5N6U1>7\9KHD=-;+24L>I6KZGTM1V*4Q/N&3
M+8TPZ4D&31-PYB(!VA&K65TV/$QSTDBH@DI7[6':X:#W+L:VT[6M.V3:(6F:
MOE=ERLXRAX]*:595]V4;-\ J;N2;K.8FOQBK1=W(_&I)1_+/$X6%KTDH@Z=)
M]]J#M8./&^+O$Z]U51.0ELLTVE(KL$&^JR,&'@XJ-6EW1GDO)V5G&1X?%[=5
M9'X>Z; L<$VY.KE=NBKZJ5VFS386P(6D5;AQS3<-YB;-!'LLGJ%I"0\8LW<K
MM))Y*K2=@0;,6$8NB(/'+E^@5,O43=TQ1(/C+\Y^4X;$>5&L=FGR$E:U'V].
M$7N4W:Z=7$G=?-)$9&LD8V,F_A70BV\-(),26I5IX J)'<LU,J<R/7[6Y.=H
MZQO]@C=,\!F-CUXT621K5DO6V*W 3DXD#)%59\_AHV>62@TSOCKM469E7RY4
M$".E51.X%LCT._-V=J8[M;5'CAQJHD?1_%JO.7;S9!H^0LY;<=LZ\:(I,C39
M$;'&A&CHS0D0_!B5=VBDHNL*1EC-DO7MVP]IO<8W5!=5/&.HI-K06;#='A--
M5>V-Y+8JHHFDYNB*3-\F%$*VU3\,C%1D@+)WX8#N';AVDN@DT\KM4^<5^T[J
M:FGWAR"UUM"IA9%-H;*U_H738M=H+2<@1S6R(Q#S;$2M6$ZJP)\7G/&&;IV$
MRJSM^Q;G\$F2FFS^'7+/859M]?D9SD_8WZS)DTMMS<EUG0[3RIB!?-WA-=WM
MA5]B/JI6*?KR("6B-<6"Y1MVLDC8+*^;V9!MKJ*9QCZW5(X?ZCA]%W/1-UU'
MSCVI2]D3U5MUD;;0O]7DYJ/E:NBS4B8^'>UG9T.RA6#-PV(9_'Q8+,)%PF'A
MU7C5!EX*2=2\9^+>DJW>JGK_ ()[(:P>SH>/@-A,[!%5.Y%N$/%JKN&4=->-
MFV9@JS)!XY</BM42H(@^5%V! 631.E.>O6VMM3"L;6'"VVZ]5<L@CG;FEZST
M[6W;QB!D5/@CQY%7EL[=MQ5;H*F2<KJIG62(L<IE2@?)/3W%,)%[J6@-XIEZ
MB/=3A=>D)U'S"(D)L@I1$?I$!'Z_,&>?EFF_-_\ ,'O,>GS=8?7PB'^ CLGS
M?PSGRSSGH#WG['U]^)./+1.>@3>?L?7WXDX\M$YZ!-Y^Q]??B3CRT3GH$WG[
M'U]^)./+1.>@3>?L?7WXDX\M$YZ!-Y^Q]??B3CRT3GH$WG['U]^)./+1.>@3
M>?L?7WXDX\M$YZ!-Y^Q]??B3CRT3GH$WG['U]^)./+1.>@3>?L?7WXDX\M$Y
MZ!-Y^Q]??B3CRT3GH$WG['U]^)./+1.>@3>?L?7WXDX\M$YZ!-Y^Q]??B3CR
MT3GH$WG['U]^)./+1.>@3>?L?7WXDX\M$YZ!-Y^Q]??B3CRT3GH$WG['U]^)
M./+1.>@3>?L?7WXDY+T!*K3</'RKB&EZ^L^;E<*0L\DR1F(XQC& 6T@E'/Y-
MB1P7N]3%;/W270Q1!41$0#3OVJ\0PO,/3Z3OOAWSAY&:$A+G$;&J-L[/"Y.V
MFTJS?FM1M5,6AMF5*K[2U5M\8,6MGE7\#.ZZ=6>KO?AR;2\L:\I"-W,],O9@
M1+JK::7J%)XV<GN..@XF5G977\;S9O9;5R8M,U;)YU.6&0EH1:\[.M-6HD<=
M4&M:3VE=S;%>KKN6BU4KM<AH=U.7(W1QMTIR%2A$MNT9K;#5YE:XB+=%E['7
MI$E=OL2C!7VGO)2JS,%)2M%OT.V9QE[H<J[>TZZ,F$<WLT)*$CF/P?R:\;M)
M,MKH;L::_B&VR&J9_@DTBXE4F#-^K48W7REB954D@%09W)77T/%:^5N[6 2M
MZE!C6-)/-FK#5&*+-X_-_$O\PR"N,H .@M3]0 ?_ )&17SA]2N3KT#Z ]08Z
M!] >H,= ^@/4&.@?0'J#'0/H#U!CH'T!Z@QT#Z ]08Z!] >H,= ^@/4&.@?0
M'J#'0/H#U!CH'T!Z@QT#Z ]08Z!] >H,= ^@/4&.@?0'J#'0/H#U!CH'T!Z@
MQT#Z ]08Z!] >H,= ^@/4&>D%VQES-BJH"Y*D5<R *)BL5$YC$(J9(!\("1S
ME,4JG=[AC%,4#"(" 4MVQQLV/OS9;IOL_8Z+'CM%J1SN#UI2_AT;,6=XBU;F
M<FN\DHDF3N)R15SMSM5Y "LO %C6\*_\-(FMS5JK7:378>IU2'8P-<@&24=$
M1$<B"+-BS1ZB1)(G4QA$3F.JJJJ=19=911==159110W?]"_0'J#'0OS] Z?3
MT#.![H#TZ>HHCZQ ! /X],B/:>^]):1:H/-N[5U_KA-VW5=L4KC:8>">R#=
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M4V7#\W\2_P PR"^,O_(+4_\ T9%?R5R=<8QC&,8QC&,9'>V82\676]QK^MK
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M^.ZHE9CQA:DYO+.B343>GE#;3RUS9TB296]S!)5UPG)#-@_-_$O\PR"^,O\
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MO!V$;8UM;ZK7II6RCE"@U):V+MDZR[B@<;O@#ND*41Z] ('7Z>@@'7*9\?\
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MBS9H+.5DTC8WQGY8Z@W?2%W4)>)0TO5G01-@;;./5ZY<U/"JNS1,Y(,H8L;
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M '3)2.[=].8_8LERZIO-][.P ;#D$(0%^0FN:I2M?6@[%F@5B=A4*W%1T,=
MS5]'15@/-0\=MWQG _-_$O\ ,,@OC+_R"U/_ -&17\E<G7&,8QC&,KWOWD+
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MDX=)FWFCLFCER51%NR20M1C&,8QC&,8QC&,8QC&,8QC&,8$0 !$?F .H_P"
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MIS%V7FM*6J?0 02KFI-Z\@MP2[M8#&*#9OY.;+88P'!C%$"IN)-OU'I^4 "
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M0 Z?FSRSCH'T!Z@SG&,X[P>?H/7I\_3S]/\ 'IU_A]/YLCJ[;?U7K=%5Q?\
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M.@C_ /1,)@^L<SV)I-1@BE"(KD,Q$H@)548]N+CS?-U<*$47,/UBH(_GS)P
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M,VO?^#I_9C&,8QC&,8QC&,8$0#SB/0/I'/ 5" '>$?R0 1$WG[H  =1$3?\
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MG460)6 0;HGV@DT1I%,A$R:=U60B9"ID(77E0*4A"% A"$*6& I2$(4I2%*
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M8>@%*(B 9J-V=VR_8[4Z7-5-759ERIO9E%&S>F\8N-9-D/'+T!$B3=";<UV
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M9:URU/DYK?FXK7L-^ BH$/2JU4-4U5L90>\LV080,6Z<@VZ@!"BT4C#^#
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M?H?U;[O:C_L^/(7I/T/ZM]WM1_V?'D+TGZ']6^[VH_[/CR%Z3]#^K?=[4?\
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M@:KB (2!M709X:V' I# KX!L_E1-T .Z<.O7Q-P*[8/D,4RW*WM3VNBZXO\
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M4BZ+:1>)I'*#@_7X->\>M;ZXGW%H@&;]Q-.(%6L_"Y9T#LR,(O+MIQPP31\
M@GX)659MGG]\FH9)4AS(&2\.OX67E8&$7.*B\1%K*"  *BL<R4.(%#H4!.=
M3"!0\P (^8/,&?,>JUA4>\I78)0P!T 3P\:<0#Z.IFHCT\X^;/6-/J8_/6*\
M/^,)%C_-I@*?4P^:L5X/\(2+#^33/(*E5@^:MP ?X0L8'\FN JU7ZB 5V" 0
M_P#P:.#_ !Z#\% !Z?,/01Z>8!SR"L5GO= K\( A_P#@\> #_@;X+T$0_. "
M(A^?(RGN/^N+%L"L[%>LI5O)UEL[;E@XR:?1M-GCK]1:O+14VATX>>>Q)CK&
MC5W:'Y(K 5Z5Z1I'D9RRTA8A@4Y6,9'LRJ=T5 :L6J *"0! @J>"1+WQ* B!
M1-U$.H]!\XYV)2%(4"E "E#YBE_)*'Y_,4O0 _@ 9ST#Z_6/VXZ!]?\ W#]N
M< )3?-WOH\_?*/J-T'_ >G0?S8\PB(>?J'3KYS?G^OKTZ_5\X>;K\X9ST#Z_
M6/VXZ!]?K'[<X A2@!2AT  Z  =0  ^@ #H !]0  9ST#Z_6/VYP/0 ZCU_@
M)A'U!U$?\ P'00Z@(]/\3!ZP$>H"'YP'S@/F' =!#J'>Z?6)@]77IU#Z!#S#
M^8<YZ!]?K'[<= ^OUC]N.@?7ZQ^W'0/K]8_;G!A*7SCWOX=\W\1 O40#Z1'S
M!^<<#T .H][I]7?,/G^HO4?_ "\P><?-G(  AU 1Z#]9OMQT#Z_6/VXZ!]?K
M'[<= ^OUC]N.@?7ZQ^W'0/K]8_;@  ?/^5^?YQ,'S#T^8>@_;\X>;'0/K]8_
M;CH'U^L?MQT#Z_6/VXZ!]?K'[<= ^OUC]N.@=1#\KS=/SFZ>?Z!^8?F\_0?-
M^?YPSQZE[W=ZFZ__ ,?3_#O?\/7\_=Z]>GGZ=,\N@?7ZQ^W'0/K]8_;CH'U^
ML?MQT#Z_6/VXZ!]?K'[<  #_ />\P]/.)@_G\X?6'FSCS=1#S]0 !'SF_/\
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M%E/9CQ-N@*ZWG[C8;+ Z_@=@2E-FKW ZYA9MX\;4N MDOKRE2<I Q!DX=)_
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M<O=D0$56-F[-AX2EU3E=/V ME)6DV3FKR%*V&[UW8I375BM]1=MG:\1,VX\
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'8QC&,9__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g217011.jpg
<DESCRIPTION>G217011.JPG
<TEXT>
begin 644 g217011.jpg
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M>0J52);:]:I%B%0>D6I%4[BJ=2C5)CAIU"940<[ -3J"#P#).).  PHX BS
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ML?":I/QU#]W9?^'L?":I/QU#]W9?^'L?":I/QU#]W9?^'L?":I/QU#]W9?\
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M7BND[A. $Q63&N$*^VAN1%MJ!$WE#-,*0I$R,HP\>C#S"DI(""QG#"$&AG#
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MM\:=42H=R>Y1<GED(;HH5*M)%049T67S%0D4(IH6@&NTW*XDI3R<E(-9W(:
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ML><LT]D]E1\$E)=)FQR9T=F]T*6M94O4PT)+^XGL\99%QRQ2ORNQC&039?\
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M25J>S#2R'1Y1)PB5>^O:SEC#44AJN2OK<N'H,SCT;EB<QX<7-RCC^!8:VO\
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M>R7ER=Q-,9:SGSW(*9G*EMJ4ZK<5'8*BK;;:X1# 5<,W FU$[6#VT37HB2S
MS8'4;(W[APQPCEWL3[+M29-7_O<9'71QAK:ZVHDXSQ)>4K*''[=L-(<0OE=:
MF 4O?9RULC6O^[L"W2(1"?2U)O5]V&/W]*TID:T[IH=L>]J-25SBL=J8103#
M0\O=D@4/X/'H"84B;P[VE7;/AT ,VC1;:%:R3[*:N#VPR>-IVA!+'9[C+8$H
MK;@_5_&K^KI%[C_OW?E?Z"7MCM4_20ZL30]I(^:5U,ZA%MG[RN0)Z$BAI<5L
MF$[B:6V294-O#O>EQ=/:YA&)R]#$]-$)(":0"R^5.R-4Q.Q]\6?MCA%N$ =0
MK8CMM=M@FG, W47:7 $ITP.$F;Q;-$N8XI9%B6*C$0IT]4##3"G18@WQ-/\
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M'P\>[UD2T<%W'-&.K"UNY%EKSZR?8< N5F6';LL.F2-H=7-.-)KDB.WTZ!&
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M]BHN8J)U4S3:[6-I6.#DGB#XL6IAJ(T[Q9QEL35FU]/%LH@0$\;(S4UKJ_\
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MQC&,QEY*4Q85[((+!66PV.&U&HEZ19R$BJJ*O+Q(KEK!,69M=4;/*6N81L$
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MP-I)W=F\,"0-CIR I"2WHNLMB=&N*/RQS7O3"QV-%TA,P7-AS&]!*<$++(W
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M'1@5Q21/D?;9 -];JIR^(Y6W+0,L;JJX^1X#FEE5&.R>M[<74L_V%)&Z/73
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MA"UQ* 2X*X@^N;>J=(TI7DEEDKCV56A-6$@"2I&:5KL9?N,8QC&,8QC&,?\
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M-1L[D=3M=-;CQWK>7N0JP00]3/W_ -\%G7I/X/M$2Q0F&1U2S2=\9W)^72&
M,\HAS0KRLE'2EB8+341M+Q?M)?4$?Y0<>.)T[N]5,JS9V^*V?R*A%32IK0EP
M%2]J)@];J]PN&-L]RZ2@3(X<2AD#DWN<A/8W-G21>JZ32T[#MWBJGA5"696W
M'2X4=Z<CV6X'Q754A67OQ1H*D)%(%ZAJ@6WTV4U,NLR=3VAI/7"B6B:71X@+
MB>-]60=Y5J8WOB)=-%$Y4S6'IHH=TG,ZBTKX?1*)0"E;YH2Z54XD?,>>S&%1
M&OA32(2H%;Q2VZ[2U_+Y?:T1=I8IBD9BC<G>T]C.+6N O*_.>])1>\Z'1L;J
M'CE-H&PW5RZJ;BF7R)52VHIS#&JR(E82ESY71F/0_N\^22V$Q&%5)?U5L=SI
MV AD>[(C1KHP,9<1[SS93E'R\Y_G\;'.PV2OZ"GO(ETHNBUW)GD/N%RJO8>W
M5!3!9$V4,2U:NGC\T%RJ?S4JM[ 6PZN6#6ERYGA;XZ/CU&RE<8#(<+Z/Z81(
MA7<>:1M)H;[+M,^0\9N//)2?LUH4-"9"P\I;Z9ZV+<6B#\<%,F:K0G4"KN:6
MK%(W9LOC4<;6Z'".>-M:&7&PJ<:8Y$E?2WP^2\=V6;0R!6I&I?.J!F5@R N/
M)H'+I5Q]D#O<IW$^G&I:W/ZD$'FM@V/R4&ZQ>M8BM5I69^+KJ?N4C-1-\=4M
MKA4Y+TML6@-VR2@E]>IY2^1-KY,-Q;F1>E$AGSB_\4:DD5E2Z66'3T9?GM^I
M>J;#,A[RP0B=S ]&NT_+V$3W (^Q/S0O/BSCITGMOS-BK!7;%;2E3R3F],<:
MF4/$^M$5?IX)(;\Y+,%P7RRJ6>U)*\F2.'IZ^XV50IL>W$$S5Z9X)!WEH,0I
M)C82]&P+)9'TK<H<B4<0AO#VPI9>[.FY@&6M5I5MU&SL=4AX;RRM(G-'QZLY
MT<2V1YALT66C']P)Z9&<U[6J>[&YXB;0K:9%WBV8<?[@9N0M$TO?<=9GV.1^
M[:HKNVV)@E!"9+)61FL>(M$P;&F0)D:A6C3O3>B>"$KF2E5JDP%91NB%!Q79
M&*7<8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9P(/:UU=>]?
M)O6]=77K>M]>MZZ];UUAWK6]=>MZZ]:Z];U\6:T:#Z-1!QR;(I$H!S-YM'5A
M#D\J2-%3R"=4@NA(TTN#)SUX' ]#Q\:IHN-2/<K7R="M.F'?#;^F0*'!6O1E
M'H5,KLO /C\TL=:Q10BD[]#JKX:RG@O&XD]O:<QD-I&<HZ[;)H-RTW-3:XF3
M64M571)L>),A<&_1B1,JTG;DQZLP_4.Q+HL:A;&)@9K&N'D!>ZF&,5)0&!/E
MJR&N=N4'IVAK=KFZXM3C$D@570:/CB<KFM25N9;4C=V5SM&U&R'1YLED_4IF
M=M"ER6Y4\58URKCE;,SW8=GU<\U!;T9O6NIG5#G%$$@8[+A;1)FN*.RY%-H=
M.HI)FEG-E*UT%%I)''./.S@F0:>D"]"08C.Q4<.B;IP^0Q^9LUV<EHI/0PF^
MH/:%AQ^;P0,]O%+R2>8H_6C(IQ*W>L'9SALW6KH1%$#!,:(%4#Y$X;'V.MHV
MI:Z\8&&--<@Q[HW:IA59RZOH%:E_01VD]<<3JS;[2B<Y8&>QX8R<,&AM;:7-
MBJM-"PQ8L'=:)P>9Q'7V*OL)FZJ42QI>8ON*OJF/AF*A^(==T9!+:A^GJ560
M\7_,I)8-Z6%,PQ)AEUGS*50Z/U\Z/3FDJ.)UC#(R($)BD=CJ)) HG%$R8ELT
M[""?)%[J]KZ#1_1_\3..,U*L2G*J]Z$P(8G&-D/ IW9\DV2SNW<7=Z4M!,)O
M(6H(S]-Z0/=>D'=I8"Q )4E@./";8Y_1Z09WNM);DSNF_+"9(U:M@WC6%03:
M0P)X@U/6Q9D0E,)DLIKF5ZK=/>#:VIF2:RO<5K]TMQWK:&N#UW='HDC,9HT!
MDQ[<>A?H=;#G*NT=\<IV.#2/BM1'$2:L3+,JK2*)I67&TM[25*<[R0=,G2=K
M5MC4_+&F61B'.T7K"STH"S[,@$K7J796YY4JNC^H!S9T# ^$RY^:"N5%F\P'
MQ$ZOR4XJ9VQ:;'8\=>")7LAH3#5Q%B:;)6)HBQ-HVH]B]ZT)&!S4#8.M9C$=
MT-M'NU5KZFF5]<J9ZQ(^- ^(U:+9/.JZ"LINC$TYK2?,<8@S?'ZF88T[KVMT
MIVM6MVD5F,4^>+$C,511VTE$U:C5"<<U0'HVZHA]KI[KD=GWA;%A!MRN;P7.
M5D2"!GMKA8-64797'Z(*"F"'UO#F>-Q=LA]I2%Z0P"&)8W!V>:IVZ2,3$UG"
M>"'C\*CZ-2IJ>L:NIFR6C>SW#:3M&Z[=HBBI%*8<=3M/2V_T<]36$;'6YIK]
MGFLG)T=:%@*(@=94XFSG!290Y,\6<6YC,VVC[<ANC7JCD3.[AE[K:E\UNS<C
MZMA51<CZ\JN61!AB%XQ2N%4D'"0RU6_0"439A5-;3,)/%78%=R^&-TTB;J)@
MFS>_HDR<(;CA7 *"06Y'FSFFWKY-A;G=<OY'(N/ATMBR*G&6[9Z%89*YF6<Q
M0=HMF0MC@[.3I)4=:S2TI-53)*G-1(&F$IER1E$T42#]&3QJKR-R>+QOP@E(
MIER[C/,N2+%LL(<'5RGT'M\N[X'7^UJIE,$EI2"SHDM7$ZZ0@3$M!.UAQ;J-
MV=WIU<82BG0TT)&X*V5JONWD[+8/'./G)GB_#8^_3&LTB.(5!RH;D37/D;9J
M+U#'ANL]:R&Y&:R7#+!R.UW0T!A,]E\S;5![<9+<CZ-"KW%U0SF(V[>-9W6S
M7%'[LC]ZQ!;4ZR=L<E9N+\4XA.#(EC\QJ2450KA4HIJ)IT;U&'2N5R1+)W-T
ME,;,8%PD)2&KQ[HTN.\8C-EQYI<+1+56UQKF_&69RY;.=NTU7,-IS>S;+MNR
M@R%U:%IPKDM:P;5?Y?.9LK)5I5[LV18#:PM3<P)4 \YXE%F.#1:-PN,H2VR.
M1)@98PP-I.M:);V6/MB5H:416@Z#K1:1O1)TX-:"'6@EZZM:U\67#C&,8QC&
-,8QC&,8QC&,8QG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g1037036.jpg
<DESCRIPTION>G1037036.JPG
<TEXT>
begin 644 g1037036.jpg
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MTY7-SB,.B:= =F>S>;'WB71Y,8DQSBE(BB!GLV02=Z+R>YXCI#0WN:]%8Z1
MZ8L=HZ$[%L_0<32>IIG4%67,\2-EU<T-9!Q BY%Z5M@\*=FV86[%G2:6*M0K
MXJXJ6RKD=@-Z5!*XNV^FS7HU2SM^5P'2TZ:0PX%GI^Z:!SG'M#G6NH,Y"+'L
M$'.0Q/(<Y"+N'.<9R'.<=PYSCMG/UZK+II?<_P#3/_W:JA_^$^:>JPZ:/BR+
MU?VF7BR' ,B_J::@\60!%XP@R+X)=\@"/[/ ,YR' _L\8P+V\9Z6732[9_\
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M2:E_]BLE_O?>_P#-BKE&T7_M)T__ -%M>_\ 5%GY=3CCCCCCFV;^]Q_="?\
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MQG(B\&!QD1>1X#@P(1"!XL8SG'RG5IE7EO-CR3_-SAIC_)& ,\BH*\/E2#?
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M@XT=#[QJ:O+:C)Q1Q7H>PXBQRQ(G\N'PF&H?3")4>VJ>WM K;CDBHH6,#*.
M+&,XP[2SH*TW GY=/= =C-D.GS/5)OG&$=03YYE=1KC<=S,E/E72]T,PO1&F
MXQ@Q 5)26\)61%@;\@[ Y13K,>NAJTW+H_=%#:[]5&DSDIR%[=JJ5(Z=N]Q8
M% ,I#DS[7K^A+ATB//39SE4VL\;>\JAYS@UQ[9$9CGMW7^TRK6&%0694_<^K
MUO1 $=CZ+6>\ZY54VL3H,*B6Y:5%),-"X090TQM#@2@@LY0S'+22BBTZ,DL9
MIZ>=<<ZN'3XD2N*-!>QL6;Y)+H@JFJ"-KFV2&N29H;CTB1T"O4M3,YLI:MN5
MJ\$G%)W526I+3+5S>:K;D9ZL&1Q,I(6)R%28T!R=224H(.+SX@&DG%A-*,!G
MV=P&%C",.>WM"+&>;W''''''''''''''''''''''''''''''''''''''''''
M,</4]OC937^@&&3:P? -JF\BLR/PMRF]D5%<MYQ:%MSZRR3,?&HKBBDZF;+5
MDVL1)":V221;A-"X1\,#I5+EA2!N*+.LCTAMJ-G=FF+9PC:27Q^3SJF[CCE8
M'(8CK!:.ML>AKTEK*-O<[A1B>UGQ[>9E)XK-G-WCTH=&=2MB9*MI3.D1?I%%
M9.QN&,QF<=_9GW<\\F[C#,=8=V17=1=0D-<JMS03J$Q& V;6<Q$YSBQ=FHW#
MD^R$:(V/@3Q&@*Y7$8@"OE#)0DE03608ALCDSK!%;-&HZ]1!NQV_3:5@A>S6
MMU;U@O6+ZOL7HKZRW_;CB4G4C2S"Z':RBVN$W)*G$TOQ.%H7"QO5MJ)?)W90
MLD\S(B3:-X5F%QE%G&:VWGR8,T6<,12#_#+"QGD1;IGX3-4=]$D%M)HB5'9S
M)-RX>7$,T/D4W@&5Y'Q#SD)@<<BQKCL.[.]KQ/6?$51@8HGJ-45FXEX%ZLQP
M4.;JW1UMRU'MOFN$2=#E*L"-.HRKRJ&I2GXR6(H8<%3^XXXXXXXXYY@?V1-U
M2I[J3'ZEUVUHLU1 ;YF3JGLZ;2>/KVTMYAU<QPT\J-L"C"\A8E3'V;)PF>4)
M5)Q".B<6><9*\W=2319'.B[2&NU5Z'5#.J!?%5A';!L2.Y+6N60AP=.[/M*0
M8/#,%$R6#4+CB5T0D07F(EL.%ZPEE5-KF8<I7O;F^/#IEBXXXXXXYIG&!8[9
MQC./DSC&<?S9Y:RVJ-IN^8T=#KJJRO[8BQ^# C8;#B3%+FT'E@X 8:F(?4*[
M")3X/WBI%E.I*%@(RC0#Q@6/"3:_0%ZEC1L9:$YUNIRKJZKPJT9VMIY,P7Q%
M4&6.OE+\ZIHJ24D>LJER?"J+FIA+FMS\K@K*M0W'%9*+P#&7=7U2.I'TY)R3
M3._VL\?V5@;&B:R6G8'61.LB4C?F#"!$:)]*@TC**C<N.;2A&MSHE9_@1YFX
M(%033!EX)./R\:E=6'1#='*=JIR]XXEL P)85=0V-G-;VNWJS!>'*'X'R@Q(
M:^'E>SRIT262)#CQ!R%6+&>9&L"QGW9]OOSC/LSCO[NX<]LX[_?QCFO'''''
M''''''''''''''''''''''''''''''''''',/?6A+MITU]I>)4X?N@IDTVV:
MA<>71/1*W(]K[=DZ82Z^M%]7QXV]92,EDK:)I3V9))G,T]2G.FKBP-->DGI?
MA0)>CZ3HTPBVJ_@%]L-PQ+?&%R$5G1=<WL_4%VAB6V-L^A3ZX8RB%,4L*&F*
MVMJKHQ6G6%M\3-<5BQOD94E7F81DN1*(G,__ *?S>[EE:WUSHNH)'+9;6-50
MB#22<O4ED4H>(XQ)6]:YO,T>\2:8KO*%XSA$9+)($$BDQ;8%$G?WXHEX=B5C
MB24I!V58T53E+FR4^J*SA5?'S!6B5R0Z)Q]O9C7;T7A;AG1J3$A0!8:6/#DY
MA860C)+*PA<W+#,WH,."W!];2_\ L4DW][[U_FQ5R'FM6OF&*;Q_9/,M,6"G
M&KM*UL7#LLI1!;07'&-E<ANF'P*\9B[ST9> A1C;B,ILF&YRJ/!Y$LJ<O'''
M'''',>74AW]B&@U(E2D+,.Q+SLMU+K[6^D&L"I;(K8M-V&0B:&TAL;<"=!QM
MH5KD*N3KD@0&Y).1,+8:.1/[(E41?Z?/2V:8;&9KL)OY&H%LANYLTZD3RZWV
MQ(G%IVQ5S@TL V.I( C>4#JR-;/#47F[>Y*V A.A6K4A#6UC%&V%D#G,-#H3
M#:[CK?$(!$HS!XFT^=>BXQ#V%IC,>;?/59[@M\P9&1(A;$?G:]4I6JO-DI7G
M"M0>I-\9QI@Q5/WY9<B^("?.#X4%QP 16,IP/QHR ,2AV+&()[44LR9CL:7C
M'@ K,P%$H4A-2$G"."7Y6\"=6E5@P:E4$*2\XQG TYQ9P,XSC L9P(H0PYQG
M @YQVS[<9QGW9QWY'?\ TS[/\?..E5I5I.%")2G5D"&:6$],<4H)$,DP1)P,
M&%"&#(BC0#*,#@7B+, ( \!&'.,<CCCCCE#6'6<!MF-+(?8\39)C&UV.YS6]
MHBU919V # 6L1'9\*IM<4^!BRE<VX](X)19\:=24+V\QR[7]*;16X:27-#WJ
M'&9[)JZAKI^UNHAKNHK^X35[>0H7-;0U7 G4AD)BU0N$/S0V6JY$W%JCLG'-
MZC(O)BP[:]H]^*3>Q0G1/<MXL%TC&3"5W3VZFZ(\Z:HRVQ. PU@JN^VXEI7N
M)190CQ-K><7!!)$9'GSDT>: R<*>,0ZY,>J20H*VZF6KEVZ 3I0H"WIYQ)V-
MPLO761*@8$4)4P6U$&XX $RD\&<E>-L=&](3G.5;]V ,SF::L+>JRZXD@GE0
M6+"K.A;F (T,I@<F9Y4Q'Y$6 W)7I)E6+$Q2@L(P^62J!DJB!]RSR2S,9#BX
MO'''''''''''''''''''''''''''''''''''''',//6R;]>'#5&*#VJUND.S
M]&LUSL<EEE?1IMNEZ=LN+#7UE*8>4T,M%!Q*'*3S"6FM%9PWX5+6*K6V53AK
M>Y](FQ UI"UEK^A-4K-2U*7!$V_2B#:.O#U.H98,OJBM+*N:SXTT2&9URTJ4
M\1DCU<K2A4);BKJ,(H[&;A:X"YR& MLI$!L+7M\S;YG'F;.MQQRG9?\ V*2;
M^]]Z_P V*N0#T]N*PY3;]@T\ZK6@VN:JH/5Q;%4);66G>4KK,JQ9W9W/4NA8
MLC<$ZLS)^,E*0APD\@C D"' E0S<CW''''''(^;2[.U%IY1D]V"N^1E1R!0%
MI&M59!DHUW?W8_.4[%$HPWFFD^EI3)W,1#2QMV#"RS%1^5"P](W)5JQ/B!Z<
M&L-N[6W<?U;-\(V8VV7,&GS'2^@G89RIJUEHY?E2>S/QB%420$5BS-M7"< .
M2A&F<4R-S62%:F0/;ZC;(MFRL.VHE6F&TI\-4'K7(XO!+8VEE*%I2#RG@/<S
MRAFE!*1$=A!#D0\'*C0B)1E'& -\G1BJ]?3AYC=5L-D$]6!%DH3GA,:R1M,/
M.<8",]S7E@'D.,XSW"(I-@6/8$WOG/;8^ -N3G]TGT\!%6D['<R+5^ 2<P10
M^V!IUC\HR(\8LA[A-"#*P@>._@[8SS:1:P5RD?@.9H'!>S 0!3XC:]2,Y(8N
M\.2AKSUH1%+30"+_ '3"'Q ( JSDX.<%8 F!VZC7&L!&>4;4#TP&=^X3&*1N
MZ(0,^SV@"8H4 #VSC&<8P'M[ ^SL$.,=*\T9($S4X$1&U[!2GC2'EIVYY?1K
MFQ2(16 >:J#2RR528DX.,E9/)P(PC @C"$>"\A';RIJOO&/,SAZ.DR2"E'.(
ML 8'=M3OY:@9.!$J'+!8!FDM^#LX#@D28SRCD L"A3@L ",F75"W;(H<9$%_
MK!ZP' 18"J;'AN,,R 7;PYRF $L C@^TP7? 2Q>PO&/?EE^V,2YR$V#5\[A#
MX\>-ND:Q#D><?9!'@*X><X#G'<L(,X\61]A"R //O-CV\A]CC1RY1CQ![B9Y
M>T+/L1A^QQ@&2A9$((\9\IGQ8" /;OGO[_D-UOJ?'B=Z9L]"'&,",&E:T[F6
M (<]CQ>(DPK.0%]\>3SVQD[&>X<!Q[>6]7;4$)9JE0'1EP;8H2#"-XR[IAI9
M.D7'9 +*O+> XPLE,B#D.#$!F1JU91@E!8RC $ICK],UNUD_Y\+7-X\</XB5
M"\MO49S\F$[CA(=W^]X._P![EP"3R%)832#2CRAX^Q,), <6+&?CP,O(@9QG
M'QXSG';E 2"I*RE4QBEA2*"19YG,&4&J8G+%[.D/?V$XY.>E%E"YY+PK $)*
MD_!)1IAI2<PT1R<LH[L9B,^X]AS. L[*%9K W;(Z^NB!V(NAJ* VR1]9T0#$
MN4)Y-=/#8O;)(T!3>>K'(Y24:05YN$E6<SD"PX#Q3QOI4Z4[!IEVR73!ONWM
M"K4$X93/"_7Y_=VR&I9)@H+@>R610SXY%-/@R2J)SEK9'-FCRQ&9D]$2XI#,
M#%56-C>M#HKGS?9K6^']1JE&OV'W=J5@,/OAO:PY[Y<972*Y*4CD"U,D*$<J
M(BC0C1^/QB.D0^_E,S2U0ZO^ANWK@5$H)<J*"6R$[S-PH^[D8ZEMEN<\&X)$
MT@CLH.(0/[@ W.0#(BCP_##VSD8 =LXQDXP+&?9C/M^3.,XSV]W?MGMGM\F>
MW;/Q<UXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXYAXZP"^5SJC&6IJ5V17
M5'91-I0!XG$>J_=" Z7W6X5H[)WUE,=&:UY*C?7%H9(D].C)9C]$D3>PKK7C
M\*7P-NEK9Z9-3K[9]#^"W97L5VRC=SS^<6D-KO=@9X/8<_W\2[Z.<TB3'5\;
M:A2M@?$GD5-2065OJ=WE4+K>6MS78C8R/9**8)E8V=L>73.GSJTSVSK'-Q9D
MCJW*7=G C,=FM.N2GN+66X%C.0#<4)1HU2$"XD S48U9)(590!&)\F #G./I
MM>6EX\_]$N;>Y>BW%4T.7H]:E6^CW5%X//&Q=YJ:;YHXI/*E^=(5/DE:?RA?
MEB2_&#OU\O\ ;%)-C_\ #[W_ )L5<C)JS1$*@Z+%ULYSZ9+[JJRD,2PE>Y 4
MLR3$.KYJ:V_#&A"F+.0A5%"\LO"H5+ B/#C",*,CQ$BE[QQQQQRT-^W;!=;Z
M6LZ][+<<-<&JF%OLVD:G B\'FHF1$8H+;D #!!"H=GE;YJS,Z/&?&L=7!&E+
MQD9P<9\T>F*RQNO==<5V\VFC$5@FF6H#TC:Z]U?;Y1\+&BP]DR&9M?I%.+.P
MK3(<ND:BK8ZM6&UO?&Q*B7D*"(^E(7M IFOD'H\?;G&YN)L6J1FS.Y 7GR:I
MS+%DJ)LO?.0^67NN,EE*O!G'?!2<TL@S]X6J,,QDGE*+=<E\RQZ<L*<+U\N5
M'HQ*3FI(D*:$360:,1S,W)S2BS,X\F89A,N%Y$"<X>3LH3\B.\O))A86F,M"
M%C9$92!K;B<$)4Q7?P@#@61C&,0LY&:><8(9QYY@A&GG#,-,&(8\YYV_''''
M''-.V/DQ_-S7E)*X+$UTG2S%4QHCY&C2#1$.1A>1&8*'CPA&85G.2#E))>1D
M)U9Q0U*=.::028 HS(<<!ZJ^O)#C.'B&1U8+/?Q'9:TR=3GO\?G*0!"C&?DS
MY3OCV9Q[<<H [76#$&Y41IPET-48SD18XY)G @L LY[]_(+!*PYQC/;L' @X
M[8QCOCMS9_:ZN%DQGX-7*>Y%X_>(YFP)'/&<8S[ &.)63%7;.,]LC"6$7LQG
M'Q\9?=AF//A<85"YDG*QG(CXX^'LRL>/?WP0ZYR'(\X[^'!9..^>W;MWSRGV
M&S(Y <.GGE&R:M\/CJ>]OBIAB+<8W.KTJP66L=W)8QD(\N#BH 46$Y>H)/5'
M ++P,8L!QR%S3U&955T]=HYL_ 4*2O'&1KRX;=-7I'IQCR%E4N"G+.EF<<<,
MGO:%>D;AI"W-4C\"X"D!PBF%43V5<D/LKH-HSO>Q^*\J4K:S%QR8!C98+646
MRV,T^5(QYHI:+%B9[;+DOD,"+/(2J'-0@R8 'G" T.!%YQMBZ<W4GTH'AQZ<
MN]SC:M9-0<C0ZH;V!56!&RVY)V-)8(;;C847(8X69D1A"(@A)%TY&/)Y7.J@
M.1"#WD?ZVSC03RW0'JE:B7-H])CCP-Q5MM[2NN/662+ =PFJV>QX8E7K&TD\
M>0"*0Y2R3*0L7]?.9>0"SC,S3E\4OL)$$D]HZTH';$.6 *$7((#)VF3MY)AQ
M7E@I5XVM2>:UK@ _^F;W,I&N3BP(!Z8L81!Q=@(PCR+ 18%D&?"+MG&>V<XP
M+MGM[L^'.,]L^WMG&?=G&<_7''''''''''''''''''''''''''''''''/'-U
M6YIJNU=2TR07]!.CVIK"NFG7E!?D/W2RVNFY-[Q":%)$[M(*)62%*K:(?%Z<
MA#JE719JPJ:D4VEC+-$S]A2G&C-)S]=.11TSQQ"U4G3((UZ#62*=M)=D*=8R
MF8%8J;$-B#4:1W.BXQ1E3)RHCEBP\F-N1J0)QMA+F:8I+#@O(]GMG&>_N^/^
M+'M]OWOE^]SSH[*4W6K/L?/+MTG6PN#;$Z^Z][\MDTG\7>F']MS:_:FX:A5O
MU>Z]R-40ZI97<CK4C\Q([56!D!+XAJ]V9Z]K^"Y;!I)JT1:H.FF8@BNSFM,&
MIXY2?4<HZ(NJEL6RK0)<A;Y':SM9(T55V3,5("B?/+0L>.K+N52!_=0&R65)
MV/RKRI, QI, S<V\ZSALBCEB&1!IE7G++(P.V727YBOHM.!H.R0>FQB./^7,
MPX8C0B(_K'!/D@"$</!N?)P5Z=5C2V;239%C>Y4]/L9@3C24;A#,XGYRW19M
M)JE(2XH&1'DHOS),I<$0CE.,9,PJ/!YWD8S#1FF90.....:9SC'OSV_^7O\
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MD/):U29: ZZC!ES)HB39_F)_PL(@!K@=%//@+%6$V68QX\"WPG-P40U05 O
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MR6+K3:5#.,;0MBP"R9#0.,:?1KU"I,8B8GQ*2A$N6(_-O.% "T9A($II1@E
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M/]4WC.?]HO\ .-__ %WQ_-G/'VS?X"_SC<?;-_@+_.-Q]LW^ O\ .-Q]LW^
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M!(45'0-S"S'M1/DW%IF#KYU!-N[$D^MA%@P?6]-&K1V@W"T2L+$*56D![0;
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MQVQ[<9]F<?RXYQTB)&@3E)$*1,C2$X%@E*E(*3IR<"%D8L%$$A 47@0Q"&+
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M2B2BTH"0%@"'F)8+"D,I<YPBB,81S1Y9D4==Y<EC[0GD[HP-A@SFUC<9 2C
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M'2\6K^;(ZENV"S.J9%7*R\+L>(A#ZCL91E;/JFI9D>9\O1T/7$O7&'K'V*U
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M00%@"(8Q8"'.<6PI6\*KV)K2,W#2TR;+ K:8%N1D<EC*6M]'N86=X<(^YX*
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/''''''''''''''''/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g837120.jpg
<DESCRIPTION>G837120.JPG
<TEXT>
begin 644 g837120.jpg
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MT*U+>D<;4QX*$:HGL?9$YUMF2*4I76B\-0"("Y-X" B @*U+N @.P@(=FZ!
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M4XEAT$AITI,,C:@R2&Q=C,?[U%DHC:6T^]YO0"XW'6I;+$UIMRD;[4]MI(7
M7;;:$@0@D('<1AL5$1NO$1&/- B(C?=TB(H]Q]=08S9I]U<2'(KPZX1RG@V!
MXW4)6FQEBS[B:..+JW*2&XDEWO5N*B$OYB[MURM/6$F]N%6E$'%I;4A/:XF'
MX$F.EOA$U<4DB2W.&$'L5+&YD"S1[',7BK\[6FI3+;VQGDEN.6^YB<EY8WI4
M;F#@@[6/-LN%<BM$514)-&6G35P^/<]78D5->(4C+??$Y8Y93B*5Q9W"1M:R
MWLT:2QE\CC^*J0L-P&7+WE.B)M:2SKF^]S.O<.U1G^&F/A$=PWU!Z=]OI_\
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MSB3DJYZA<?>V-OD[>VSA D4N;%:X(]M_!,!'OY1/"X.T+Q],(3 ,AZXXWE2
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M76^OBB&_[ZH-H".XC=T>"ZZT/WA:( /[Z#: []_I\%UP"'[! 0&W?Z>+MO\
M3O3B6_\ M=_?^G>'T;= A=T /?$ Z!'I'<>FG%#IZ;ND-OZ=_H[WZW0/1WPV
M'O\ A&H@6:.XU;KB.UV79%R"9/3=/ :8B\?760RW&Z?&83<K)8F%6EQ6R<72
MBZ=V&.XNYTS-2=I'F,X-(([2A+E^-EH[?T@V#8 MONM#U6W '[^_5.);T?TN
MC</Z=_3OX?UOUMOHXV^WT;5R   -@WV_:(C^T;A'<1](COZ:!:   =([#N&X
MC<._[1$1_OJG%#<1WNZ>_P#KW[=/@#C;!^X V^BG$M$ #];H[P\>_C?LXW&X
MVWHWVZ Z.BG%#<!Z0VZ  +K@#H\-H" #^\!WH-EHCN._[.-<%H_VK0$+;O\
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MB.2665-3P\OS8ZXI7M*B,RE3&4BEW7L:=V=9/.ND36CC;57I=UI8V)TXY1R
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M$S5W9PS*<RV_L@VAV&9=SD*8+3;1L$6ZRPL;AM-NLO\ :K9_1'O_ -,SO_\
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MWW#QK+##X\_ -Y5O3:-CW:%P\2SLH\:^\.=F@G4#+B]LL:[LTNY*@;;EK/#
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M>V.*5>-N0*P+J:_J3FO]F._\WQZL\6]X?[5_^>ZN5*4I2E*4I2J"(!W_ /\
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MQ&ZXT;A&RT1$1M :RF7)7@FRTLK&TM*+L +;"RU<(++MM -@MMLLEUMEH
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M*66.CU)\A321O[KM]I2E*4J@@ AL( (#WP$-P]0U6E*4I2E*4I2E*H( (;"
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834TJ4I2E*4I2E*4I2E*4I2E*4I2E?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g570433.jpg
<DESCRIPTION>G570433.JPG
<TEXT>
begin 644 g570433.jpg
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MV1#/U-Y.@/:"?9$,_4WDZ ]H)]D0S]3>3H#V@GV1#/U-Y.@/:"?9$,_4WDZ
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M=B /4RZ8:(IG8@#U,NF&B*9V( ]3+IAHBF=B /4RZ8:(IG8@#U,NF&B*9V(
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MJ9=,-$4SL0!ZF73#1%,[$ >IETPT13.Q 'J9=,-$4SL0!ZF73"213,IRG(E
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M]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&?
MM<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q
M:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&?
M M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[
MQ:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&
M? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"
M[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^
M&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<
M"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]
M^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^&? M<"[Q:]^*(R&
M@YEXZ4A86<\S%^"0BU/Q!KLY_P#?^:7ACQT1_P!_C_S\?^V7XI(0A"$::_N=
MS\G<_4JCU?\ DZQ@2C )@FIK%!Z:I83\/DITU7[5,Y3DU:7E.4Y3JE.4Y3E.
M4Y?-.4Y3\,HF3GP+7 N\6O?AGP+7 N\6O?AGP+7 N\6O?AGP+7 N\6O?AGP+
M7 N\6O?AGP+7 N\6O?AGP+7 N\6O?AGP+7 N\6O?B$/*,(A7O)@PQ)-0U)*H
MEZY1V@P%@K;Q#.O6SJE55=Y1%!E0DAS@@+M!HDDXM2TJ-2)37@=\M,#M'B%(
M2%)L5C1MLS!8S\#V#FMEL4[<KVWR.+/8.0Q8GW-+C)_D)C:I?<Q3P4T25=F2
M:K0=Q*)BNLF60FS:"7#Z[77(IK+ 4A "U<'470_8!$F%X017S5-T%Y[?OE5P
MP(K<S.D(5G%VZ#J$E='/(<*9T!@)C758IYSL@S"BP'O9W;"C)44V;N+?#PD.
M4S+'C4"_?=F,!Q*(71496%NY"!Q'8@')7%XM3!*JKK1-6D$HJ,-K=DB-;HE5
M!V#%'-X,J#2Y*\*6ZRK3Y^LEC=$@+O-2SKTN@_+3XI\2S:M:SCELTRSJLZ3)
MAJG).'9H40AXU*V)TN3,>NC) ME=I01=6T2?$(1+#$Z+-KH\^-SL_J)!Y8#!
M#\@,4(LK+!]=%8XN C:[=,Z+=8L('$UT43GEG315>MUSIIG.4ISIIG*4Y^&<
MLL4FCB>V$3<+ ]1#1Q/;")N%@>HAHXGMA$W"P/40T<3VPB;A8'J(:.)[81-P
ML#U$-'$]L(FX6!ZB&CB>V$3<+ ]1#1Q/;")N%@>HAHXGMA$W"P/40T<3VPB;
MA8'J(:.)[81-PL#U$-'$]L(FX6!ZB&CB>V$3<+ ]1#1Q/;")N%@>HAHXGMA$
MW"P/40T<3VPB;A8'J(:.)[81-PL#U$-'$]L(FX6!ZB&CB>V$3<+ ]1#1Q/;"
M)N%@>HAHXGMA$W"P/40T<3VPB;A8'J(:.)[81-PL#U$-'$]L(FX6!ZB&CB>V
M$3<+ ]1#1Q/;")N%@>HAHXGMA$W"P/40T<3VPB;A8'J(:.)[81-PL#U$-'$]
ML(FX6!ZB&CB>V$3<+ ]1#1Q/;")N%@>HAHXGMA$W"P/40T<3VPB;A8'J(:.)
M[81-PL#U$-'$]L(FX6!ZB&CB>V$3<+ ]1#1Q/;")N%@>HAHXGMA$W"P/40T<
M3VPB;A8'J(:.)[81-PL#U$-'$]L(FX6!ZB&CB>V$3<+ ]1#1Q/;")N%@>HAH
MXGMA$W"P/40T<3VPB;A8'J(:.)[81-PL#U$-'$]L(FX6!ZB&CB>V$3<+ ]1#
M1Q/;")N%@>HAHXGMA$W"P/40T<3VPB;A8'J(:.)[81-PL#U$-'$]L(FX6!ZB
M&CB>V$3<+ ]1#1Q/;")N%@>HAHXGMA$W"P/40T<3VPB;A8'J(:.)[81-PL#U
M$41DG4_(O'3D1$\IYF+\,BP%*?WM=E_]#\'@CQX!_@'C\FOC_P!LOQ20A"$(
MTU_<[GY.Y^I5'JY<G<0D=[ -@HNWB8INW;F%##[7<N72X'<N5UUM8EZJZZZZ
M[,ZJJJJISJJJJG.=54YSG.<YSG$Q]'$]L(FX6!ZB&CB>V$3<+ ]1#1Q/;")N
M%@>HAHXGMA$W"P/40T<3VPB;A8'J(:.)[81-PL#U$-'$]L(FX6!ZB&CJ?E.4
MY$1-*<IRG*?-8++*<O#*<O\ D/'*?AE%C7ZPY$[WARTQ .2[C'.(0VJPR?=U
MBE<$22Z+B^[>D(O$IF$/2-6(%>)JZ)EG4DHY2(62=#&%4S4M+0!OD'RCJ@\#
M#ER/@9EB(Q\XN,4*<+Q=T0&;!7V6 9QM3:Q<I\ %=DV&YDFC4#BE<I]U0+3"
MM5(U%G 2Y< J%*G *NJQ/(A9LV0UFT'L6[=BQ8MV[-FS:HHM6K5JW3*W:M6K
M=$J:+=NBBFFBW;HIIHHIE3313*F4I2BHQF.G!_B8<-P&G8/$8TSL..UU-^^M
MD<BU: -SPJ+PIK,B%G88);G1(^3@(^ES"-4J<K.$^"/9TDPHSM&5= 6JX;=X
MCV,=E4&:,;ESTDKU(5EAB>3+28Q[_4:I\G4@A&':D3 FNU: K%-$2R""D<?*
M1(BCPB(U<&OI@V,09[:J 2O;"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"
M$(0A"$(0A"$(0A%"9_T<._,Q?[/=CQR!_P!_C_S\?^V7XI(0A"$::_N=S\G<
M_4JCUA^3I_J!8)?\)V'O_*I+1,N$(0A"$1YQ6HA9./A_<9%H0Y4Y(>GA>4V;
M]U$K:IM%F;I@*I20>N4>D7'MSM7V]4Z[0X11(DA70085CD@:* *H !T1C"^P
M<@,2V$4NQ1TXB,%R$NLF[6$UFL.+(/HW;C"\03Q-PJU/BA"SI*PK4-N@DLC'
MK>51KT$R]-TM<$[?APC&R<!KMTR3A$..+2X4QH.SQF $&9@1A<86*!($P"B
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M0_EJ8K_[?'!WHG[&A_+4Q7_V^.#O1/V-&>GD[W$7#H8<B]4N$J#57J*ZM%L
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M\EI_52*__7[A?_O-J,C<(0A"$(0A"$(0BA,_Z.'?F8O]GNQXY _[_'_GX_\
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M$? 1O;\,V56V"/@(WM^$PJJG*<N>"/PRR?T"-[?C%NZ/)7%[H.0NG'&O@9%
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MD4,F$M6[9;8# K/W4?)KL>IPKI!C!7/#;J=[%^V>.!6"@:P(; JE]F@FW<T
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MW^.?$*G'5=-2+A7 A1VF688=F+:>!*M97TJ -2,:KUFKU<L$RA6Z(*S@J(+
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MLQCRM+0);15LPJ26ZRY$:K91*0"K#2P0E]@[V,UP+XJ[B1? I"(]"WC)P.7
M93E"4]3=<L)9#S8!JW3P[."/!FM_F"NH(XYF 8XQ*R])V;8PGMBC\IK$J^T'
M##J[/,4M@+?FTQ1#@;58$@&MBW./)/XI43B7M*X)>4HQH4YC-JQM$B8OI6L-
M)4E+]!%'>O,R8G5NW<1(M+7A;E657<-1EUOZN-GF 7$VLN3BQE8;Q)(W2>>-
MWL;+WXI&[ BE_=%(TV3:ZQUE^,!,IH[5)8EQ8M-GUU/A;B%,KM2;."XH/Z;
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*M$VKF0V$(0C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g535411.jpg
<DESCRIPTION>G535411.JPG
<TEXT>
begin 644 g535411.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@ ^1$E32S$S,3I;,35:0TXQ+C$U6D-.
M-S0W,#$N3U544%5473(P-S0W7S%?6%1!35!:05]+7TQ)3D4N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_\  "P@!20(= 0$1 /_$ !\  0 " 04! 0$
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M%6R%U32QDB4!L="_IB6\,.E+B>I-$W72A\6 AP,01#P$.!B $0 "'@.,#$
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MTX_)@I#]!>/@Y^GS]!73C\F"D/T%YK\'/T^LF!-SHMISY4  E@,^QAI#R@
M (L  C]POB" !8QEA#C.,! ,0<8P$6<9T^#FZ?/T%=./R8*/_07CX.?I\_05
MTX_)@I#]!>/@YNGSGVZ*Z<?DP4?^@O-PNG3T_!B$,>B^G0QC%D0QBUBI 0A"
M%GOD0A9@V<B%G/KSG.<YSGUYSRA#K<Z9Z@5YG6<, U4UN@^'8VZ,NN(?1=71
MG#GY@54/F/I##)%4.%OF7GJSS3SG!F4_G:KR/@\N;XL]==2J]2JHC4(V3F.M
M?2]D]O6U:43J5^O+J7>ZL-=QV.,5?2UT86="&!1B9V,[N:S$<+9VIJBS44RL
M@53A*I3@* E6O*DMT)GR$R'4*=.$ ;-!VJ/8V'FQ!23INH[,1ZU!5%P6K\J!
M(\6O'XO)CYR((B<3)2F9$;&:<%O"A\LI+7'#NHXXY@JZ/[>4'_CS9_\ 1]9/
M,Z!]F/P8_DYKQQQQQQQQQQS89]SC]V7_ #@>5T=*3_B71O\ Q\;K?^-W8ODZ
MK"A;79$#FE?/9BLEFG,2DL.=S4!H2%Q37*61>PN!B,X8# E*RT;@<-,8( @@
M/"6(0<AQG'*]NG_"=H-9]9J'TZLNG43FXZV1>%T4V7Q'IK!PU)8U25BD21V+
MS] P>Z#-ML,\>:^;&LIZ@+U7Y;2BL'#DD!/G**^1E2J <+Z=EWUGK1JN&-Z_
M0HFX*-ZM$QV[L&,1B056SR>;4))-AMII5&$K+,C%K3&7)]@]>;"L2LN)R21L
MJ9%F.RB/Q]6,TQGR[]2K70G=BNX]2.8M7)$1MR$W9L2^/+HHL*G[&UMFE1VO
MU.IEM2@@M]U=)P)9:#W/P5^;+0J"UJ)&BM^O;12&,;B4)K6*6K'7Y)TM]KY<
M%"ACD6C58R&2[#==.9.EG'S"*'NL2BO40A]QL>O$F<O<NXGOSVN:7*8UZMG3
M$R''JF#,1\LWF.9S0R#,R.Q:8[/EN.N6T:34$N$6O5.QNOTKV(U_=-K45K/>
MP$3J*B[JHQIE\"E+_*4%--*6D':XFZQJ,898;!I9*&B(&D3A5$GQDKR.M\X]
M"=>KKH7I]SRD; J]JBEB&6/N])(M (O,(B]-QL>O;8&Z+8KM"D>D!S9&&CR;
M)9#4UJD1RD@AK&@/$,10<EI2ZWP=-+9MPI#7&&O-*Q$^9U9T#-B.G-(E:N:5
MNO #8J:QFB8M7N&]T,7B.6P8L5:3!P]U @E98$4E2@ TY6KW=*G_  G?3*V2
M>HS9D8;*,AQK?,:HZ&K$T(A3"LD[:DF>@]^OEA[)+5A!CCV)5+J^>QQB)OB8
ME0IF)F%;.K.;&<T*@[+4?Z>NPS/=R6?MM8Q^,X-ZT-[;C'3)FE,!3R)KUOM#
M2^Q-?F9U2C2.1+F9)$5BS4J3K8*4<6+S I:ZY4J'0_*4W#,9Z=6WQ.O-;B=-
M>&Q-LIJD1I9 9(>[[6KYS#M\JFU"V%B]N/$%@K<ZNY$4J>"V*&..5CQ9!=4=
M97UGMF18@SQAFKLN12R2=^KS1+;AOOQEN@=!0V,>8]4?>S<%J:I#8E>K!(*Q
MV8T*DM#1-/)QQ!S<#TZQ\N1W:'&T62)KW=<%E3/4@0+WUU2M'I*.JCII[VV#
M4UWM#E0D4KA\L#I^]-^HVJ!J;0II%!6BWM+-L7^VII4T!9ZU3K&:)54.$.&&
MND7%_4/RTMA+9R[&E&):Y2(+;/NJ])M@A;160HM6OGQO1)MEKYVKH'<J+;$%
MN)M4@V#K5[A1L+8J"><KVYQN2L6V4.59H%=@068T!(:V;V:1.S>]O#4TP-+E
M-TT-LASW@U_LZ>OCQL!%:WTQV@IQSV0MYNHK%J-5KVE=U)694CNDBE>0FM&;
MM6#57LJ2QV11R'M#@R+W!F,RL7KW%]?$U>)G38VJENELFJ^2:XH&3:.#4UJI
MJX&TW':Q7/XQ?D/U\VDJBX%<R@3$Z/J5CKBO7)K@DLG;>S6-&$%H-,\L!TA3
M,F01=.\2&6YY>='=FE%F;3E/NN$,NIT#:6WNSFJ-S6ELC*$-/+738^C9I7K/
M0ME4;%90V2E,]-Z>7JJ2F+@>0Z54YTJ83(D;R?*F=@C;;A.#=/[;\,EN>=/]
M36]5[Q.@=.>55;+::MS4MMM^EK&UMUXO"I)FY,M=*<?8URZ,14Z1QNOEU22T
M2R#3NFI6K3I'M;(6D931FBO-%]K,7'"D^Q%(P>T(E/XOH%8RZ851>S_3U2:K
M7CI[$XPV/<<14HQ25DD\FB#?+(N58]'%5ZN<V?W3/DBALX%'X4J5N[UZ(<8[
M8_?SG^'.<_+GY?E[?)C&.V.5I;/_ /*&],K_ -=C_0/'.67<<<C9LEL["=;F
MJ"$/#<]32Q[@FQ%:4K4D1$U9F=FSDUG=)(N0MIKXXM+"PQR*11C?)G/IQ)W5
MJBT+B+*X.KJO$I&V-KEB[9W=V-ZA575DTN6'. YQ:EHU-5#56]?O )><C>+1
MM2$U>9(E4D5,\=()@T*63V/+Y3*5[,VIBE#DSQM$0ID$B84:^<8<^+'?[XL?
MQ19#_P!O;OS7CE<G5U_Y-'=3_$%-/YM)RQD/LS^Z'_GBYNY$[<38N>ZQU*]V
MC!-=YQL3B),DGFLR8H=,*^@XH[ 8,S&2"6OACS83TUH'%Z UE&XC$3;2E#A)
M5Y*@@2IH1ICW$'Y6QN+751ZJ-&V#\P3848E3#4"N&0)2SD,-E2&77X]PV)5+
M6QK _K4"=@F<CFL^B\5<$KZN1H8PN4KU3\M2-S2N5%]HUTV(;+Y3VNRJ8ZJA
M-E4+;#O2MQ056YIWL$<FR",Q2=M2ID?TZ-L#)(C+Z_G<-F<5D&6=G4*FM]PA
M=6=G?FQW:44CN8MO#_@9MG_%G/\ _P!D'GF!NG-_R?.BO_4XU@_T'P7DR^.,
MYQC&<YSVQCUYSGV8Q\N>0C:=TF>8[63S6>M8(98J.EDC>"_[*C5JTPI!3,B=
MX>9-FB,R6G@3<^^7)6ZM*N.$-[LQUTKCJMV?Q-2=U,71^1DML;'?JS1*IWO8
M%EVGU\N#7 ZG=>#ML(;Z=<('.3K>HXR>E5:V :"X5(5B:%6^ML)RB\845-,E
MR12W*YI&CSY,:G].F,DSM>=EDUTR2Y*QDL.6UE=>O\BA[%:E<+'Q!*R6M+8T
M%:;%@$C8I:SI4C5(H_(6!S5MPE1*9&>WRR+RYB-3G)VM$[.TH>..>=OKU?=:
MK_X2\_YJF.9]ZGS-L/9:Z$1V*0792HXG4UCM-DQ;;756M=?=K)R6E<ZNF4,E
M\0>J!L@TRR6%O4*9<:E<5%>UW;2F3-34E+R!N X'(4LA>F&E;6^DYZB(VMF>
MW3S[\3XHDLZLFDVS7>QHDZ^XN!MX:ZF=2-T'K<R..C C;$Z\HURAC,Y+DCR3
ME6%4:1E499%QQS!5T?V\H/\ QYL_^CZR>9T#[,?@Q_)S7CCCCCCCCCCFPS[G
M'[LO^<#RNCI2?\2Z-_X^-UO_ !N[%\L:XXY$.V]L6V&7U!=5:XB"BU-AIM7;
M_<ZJ'AD".'1N 4M&9 WQ!=9=B3!:VO8VAL>IFZ(X9"F1CCLEDLLD 70:5J21
MZ.260-'YT7NK3UQ%29@>W=MJ6WJ]MUTH"R:<L.2QENET<N)I8F66!C#&<%R"
MWS]LDL+DD<G,(D41$N322)/R%48D:GM*^L#-G!NNZFG@X*=IMFLW,\42.GP2
M6^?1)::*#)A* *)E@M*\&CS%"!I%03I'@.64H290$Q<'))F _2EN*I5TGCD)
M1V?7BN9S!@(E<2B*:;1E1)Y1%U*%2YIY)'6$ET&ZOC >W(EB\EX:TBIN.1)5
M*LI0-.G.,!^L=MNK)>JF2&)V5 90NKI1E'8"*.S*./:J#+,!7BRCF*=L<E1L
M85>%K<A9(? (3?"WKL^'LC5>2B72G4#IZX;)W!BF'2'QBOM2954,><+M66E"
M'2MIR@MZKV2RFJ0MS^A5%LD?0-^'Q-'#4[J^*%BAV"+]K2^63$'21>MBM?XV
MTM+](KQI]@8WZ+(9PQO+U9L(:FIYA;FZL["VR]I<5[ZG1N,7<'R0L#,AD*,X
MYG6.KZSMR=::L<T1)_:W.SZV9)JP5L\V!"6BQ)6G/61>!.<K8$$TDB1*0N5*
ME3#%E;@2^/"=*F;'%0H.;D"DLDAO7'&""4C4C*C5<&WA<&O9+K77->J;9N@F
MCWC8UW@Y,SCL$<CZK:I,KA9 H29)RC$LWF;Q*D*II2Q\@YG8V/LA5SB8Q%,_
MQH3SEMLV/I[+=#<S">PRLY9,6BM%Y%=6%-8A&YZUNEM$B#!XLYQU8^ 6!DD@
M=D[E'65M3 /&_/S.ZMS%EQ.1'8!W85JU@"='5>*Q8(&RT[.=(5%>"E\>Q.2(
M^G+3&GOIT2RXXD!3,26M1F&NAC<%"46J3&&'A+4$B'A@[=K4L,\JVLD&P]//
M\ZN:2JHG7L;C%BQ"2N3X\)(6ZSX9>"&1Y6Y2)SHXTB.0J57DBG)8XLC:W95+
M7EO)/RJANZFG,B?*FVV:T<4]4^4]] ]!.XLL*K?R1:T\[$\,3.IH8?DHAM<#
MQXD.6[(2D*P>?4E49+P=I]MY'=OD.PCG&([AD:Z'V>LS6X+JGEC',6N=#KMG
MA;T">L3I'2_1I++(4LS390MN%;@J182# N5X5C.2)9@\<<K1V?\ ^4-Z97_K
ML?Z!XYRR[CCE8^ZNK#S:VS>F^Q?O/1S8^!T/&=IZQL:CI .$F+7)BV2AD#;D
M=@1)MLUS8J[>GB,N-:%PR0LTE?&HQ37UE2M>S'+W)J!'WJLN?='7<=9I13=7
M17;^8EVG#T>G,5>("L:J;F,(B\/H[;^-WL!'$[3LNM'.REQ=01LM J8T"IT2
ML]GR*I(4@D+'[F526,MWI;9T:QO:FU"X.BE[7HT*1*M>5A"%*K=U9"<LI2Z*
MDS8E1-J92XG@,6GIV]&D0D&GC*1IB$P"B@<CQRN3JZ_\FCNI_B"FG\VDY8R'
MV9_=#_SQ<W<A+O)7ZJ\*M<==GK6F2["U9=$4G;%/3X];<5JHF$.C6VMZZ &O
MRQUEL4EIS._R$PP)C[ <25XB1[,2XJHF]D*"4^(L7?K'M38&J-1ZRJRDEF63
MK+$-!KW9-D)G82("'8;935.Z(A8$[KR31Y4WGR]A,G2"J$JT5H/IAK6H=[.2
M*5B7)\9?@*)&:6T78L G6Z-[VHU8B<HVZV93VTT5X-T8WAS@%=P.CZCH& ,T
MJ<(PK=XT?-'AIJD^82,F.2.1LC6.1(61(].2AL6KE$]>8MO#_@9MG_%G/_\
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M\@E=DU9==FJI,RT-K(M9(>=2#M4[>]PR5,*2-J96V2AS(MN-/#8%R9VYM&V
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M^:6LU9ES2N115@/IYD_ONU_Y11?[?F,+M>F<VF[8 6Z-I@\UE8(L! O2#%G
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M ",&<ZUU)CN$8<"#GL*)X%CN'.,]A8P+'?L+&,]\8_3X++II_0 TU_)LJ/\
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M\.)R=$T-QK@*-R%XZ'9<.46#+^G;K_ (8^Z_*]I:8?))J12!_P!D)1Y$RB,
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M&E5 XQCV8Q"R\8Q^]YWQ\$5TT?H5T%^)9?\ 2^:"Z1'3/&$0!Z4T , PB ,
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MU_C=ELQ]@S<;DN=FQ.\OB$AD-<$E?$^>.\JAS3-'!O:G4+-E KEAI#TL-3M
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M%(B'6/N)+(-T>%B; A*\&F<N2'UQ(] 2RL;*=/;J2:\B\I@"IU?-;ED\B24
M<%#//S(X(\..3R""1F'C-3M9N<EDF> H0_"7FJ-I_95\D=K5:HCC4.&ML'=;
M.;8KB7/=W/[.O;88Y34AAQ*WIK75B6F:%J".G^GG9L6KBR&Q02I1*UI9:<U2
M'V"Q691.<LR:10N31^71];C(D3[%WIMD+,L+]H34SHT*EB$XL8/",(BS\XR$
M6,XSVSSLF!8SCOC/?'RX]?\ )WYKW[_+^_C./Y>.....................
M....................4&?LB2?5[$-,:[C]N,>D2RM;)V%C$/?I+OC']@I;
M5$+7IZ_L>5,+O'&'6$HBX")^XK8Z9'FN3,#_ !]%'F5U?1/*M2W+SD@^W?L?
MF4U[(]$G%%52C3)7 8A><\BD?4:*P.]H#2AI::-P%X7#6)MDPF7%(K $Y/:L
M4LE,I<GH#B 34C:74YL;4Z9)>+G'?&<>OUX[>K.<9]?R9QVSC/W\9QG'Q<P/
M+M9:-G2NV7"55^VN[A>$<KR*V:N/7/9:N1-%2KWYVK/)1Q#H4)A=8*\R5W?(
MS((WZ'?VM\.2O)#GAR;&Q4C[A5E2P2F8P;$X SFMK>M?GZ5O:YP<W202*3RV
M4N)KM)97+)0_K'*02>2OC@<(]P>7IQ6+#"P)D91A*!$B2)^I7/C&'VA,XQVS
MF\V?OGX\_P#Q?63CU_+ZO5RJ7J-HD^^]@HM*]='I T[7Z1WCJ!N.]K+!2/L<
M@9$.7R!X 8C9)@V-D@RY2($?5"<5+5Z&"F'DQ"B+7><F*AMU:W[("WYB+_?U
M+]-YRL1=$* <)56DCWK?HT6D6.X(=(II'79C@_B-"4I2%QZ*I#[$DJ=*I+$>
M4ZQ7*D*DA"H;U7K7B;3&V*,1UEAZ5N1Q1G8FAJC"5H$6-K2QUN;DR-C3-AA0
MS2QMY#40D*1#+,& :4!0@"$'.,Y[#QQQQQQRD#]D/CBYO2UN=F?G-R2ODEF=
M,,=:LK0E3+'&:6<9:$=<(E#2"5.0XP2\&-ZTQR4$9$K1-:)8J2E''%!*'TKI
M!=%O'3?F+W>#W=KO/IU:5'QR"S" '0MG9&"%OISPP3)_):9"D?7)>_DM;RWG
M,2,]6@;_ #I*6)P-+ :8$@N_+!8,9[X #&<>S. XQG'[_;GSFH49X\F')4QI
M@L8P(9B<DP><8QVQC(AEB%G&,>K&,YSVQZL>KE376!TAV9W\H"(:_P! 6K6M
M6191.DLIML,]*F&,RYHC*3"F%QM .(M[CCT8EE(P2%Y1.*8)*M2S,&23/"E/
M)-A/T\[EV'Z:-L4]TJ-\BF:1Q.>MPD6DFS,++>U4%DZKP*G1QU_?EK\B0N)3
MW'E E:>) 6$ <FI&:U,2HI5'7",.Y'I$R  \![=_#W",/A$(./5G L>K&<8S
MC.<8[XSCMGU]\>OGG\=_V-7TYGZPW6QWE5L*Y.3[/7.P7AC66LV'1AR<7F5*
M):Z,ZML%!_.#HXO6*U+>I;1+_+&LYQB(2WQBRHYDJ6=!'35L>U<TU7EFQ6BL
M^,+.,3/VJMV2Z'L85YHQ&A.6P9]5R".*$03,A\;6@ T(QE%@) $H.,9Y2KUF
M&SJI: T;4ZA^ZH$]MNIG^VBXO&'UGC6*'OM ^E064NQ2&93ZNG9.5.HD-L;E
MPC4KHL\Z.?RVQSRF%E,(9/=?V.EU/6]TDMX4QN1N!+9+9=ER>NCZ#37S94ED
MJ)T W,TA0RJ-Q25RU<N8VA^7N2QA.*BQSJW.$C'Y UI2.*@@T /9A@6,^S/X
M<>S./O9QGUXS][.,9YKQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQRI
MWJMRZZD-2QANU_=-AC'9GF872WT6C<6HFR=W62LUT4D#>B<J=A%Z.[>Q)V]P
MERR/-DWD#"4IG;?&5@A1A&<D/?%*7O/2Q<-@'?7!P=KZQL4<)PL!U,K!SW!B
M%+07:YUK=+'(LW)S[XCE"KW*"D2A#+$4K9V-8J.3S1="VV.FS5 G>L#&?93Q
MQS!5T?V\H/\ QYL_^CZR>4G;.K;"Z:EO=6#J=345?*TESU]K-56I3$K=7)\>
M)+/X]#CHX6R2-H*(:CV5F(EF2WI>T('-1A;'6-X>@*T@$V<#X?HSTE2V\VL$
M]V[VYB=%;6WO?5]V0]3QPGE*UV]**L&P$,T/:JK;O3$85.*%J3QUH:I4C;1N
M2Y"G:90UID1RDE.):J]&+:VMS,W(&AH0HVMJ:T25N;6UO3$HT#>WH4Y:5$A1
M)$X"R$J1(F)*3IDY( %$$%EE%@"  0X^WCCCCCCE NU>0[L]8C4S4<HL+G46
MA\6.W<OY,(S D"ZU'K)3!K[$G5(=DU(J4M9QZ26!1&D9,/:WE>+MY(&?*7UM
MCFVNZ,"YJ<$3FB&8I)"L;U298F&>C4G(UA85"4PT@1J980>E4EA'D1"DDX@T
M(#BC !^[OC.<XQGUX]O^_P ORX]N.^._MQS7CG&KF=I<SVU4Y-C>X*69;Z3:
M#UJ)*K.:W'S90B\_;C5!1@T*WS-6J2^=I1$J/-E*@CROD3C "KND74=AE;;_
M *+12Z:\D%3BLB(Q^0:VW>_.[>?75[O:I'G,H@S>("9-F)2MA>,#8&MN=%ZP
MV1.1)2?R;4I?8>GD=D>,]_7_ +_[_>XYQ3NQ,K^G+2/C0V/*4HX*@M,ZMZ-R
M(+/" 983@$K23R@&A 88#!H08'@ QAP+ 1"QF,VQVC^JNV%9.-27I2<&F,/6
MF&K$80LJ1D?8V\#(PG+D,2DK$4WOL9?R"PE@"YM*Y.8>07A&N L0#-2&5">X
MKJ8=(X)9U7K)CU--!63)@CZRD:DD>YU!18C^YA4AP7A/<<:94G@\W9#$QRTM
M*FRD0LD1;RC'3-L&G._&KV]L&,FNN]DM\C4-82RYC 7<OW/V?7;B(7DC6J>0
M1<;Z985!*G TH%^ *V%><49Z*>%Y8<CY,GCCCCCCCCCCCCCCCCCCCCCCCCCC
MCCCCCCCCCCCCE%NUF\R'IJ[3VO9%ZZ3;$6U75\1^MPU?M#JS3S=<CBS(H;$R
M6-UURN LMU893#C&::(Y!9%<J1'.,5E1%G/@4V$3U&7D9TS^GA/I]=%=6EL%
M*J*L/6B(WS<;G8E14O;K>D8;798 .#P2.*)E8\.0K%Z2OI9:DV8);8*J$IUJ
MH2)"]M[ZZJ3I%(GHT=@?-/$'U^O'J]OK^+/LS^#/Q9]F>:XSC/L_W^]^'[W,
M%71_;R@_\>;/_H^LGE;E/OE4=660[D5?M;K=5DXK333=*8TU4@'DQ\=37E1$
MXFG;766/[4I7$%())XG9Q2$'(,A;AL[F @A.%20K4J;#]==3-<=2F&11C7"H
M(;3[!+7LB1R-JAB)0A1O#XF;4[00YK"SU:K(U9;8E3H@F!$#'D"2PY#G(<9Y
M(GCCCCCCD6]B]U=5-3@H2=A[YK&J'1Y8'R2QZ.S"7,[/)90TQW <.AD98EBH
MEP>C<*#"6U,4C*&)4Z*4S>1D:HX)?/-)K#:@S.G!O5U#3;8/B&SO4:V6DS7#
M00!2VRFQ6-$P2,,,JG7E"C(R)SC+\FB GT]S$C-2/\8C3TUR%L+P[$M(%$LM
M"=(NJK1%0N?N(NJMJ*2R23+W<-&6_$AV@C2F *PG%)1.$?<E9,*<)(>,U2Y-
M+(I4'+PHV]T?L8=CU"0GJ-=2WK4QO>JU@*8NGM)S:8U@<EB#^ZJX5JV]P?RB
M@N#JZP?E.,(F%V5+1*%+*8A&JFYYY3ZVV,$PA,<<CYC;3JA]1BB[3HZ'R?5U
MBIQQ7NHG1;#D;T7<2'8-.:K TAB$3E+&U"-9#B/+>4&V1XM?-DCRK8'!:1EF
M%Z)>K$X_UC-(UT D$HE<[?*ZFT09/2,GI6;1)_9+83.P EE&1EB8%R%*DE;N
M-P'E"F$RN TPPA$X+AMC<4J4)I]4K==:[!UM&K8JB2HY3"I2BPJ0.*;N6>E4
M%Y\FO:'A$9_5#0^M"K!B%W9UP2EC>L*,*-!D/DS#,4;@:7Z_;RU4*IM@8F<_
M,25V12.-R!C=%$;G$&DC<8$::1P>8-V/2D:=\$A&C4J$8LE+4)IJ1:0H*\G@
MN" NKG3,4ZGQ'3B7JF-OBS36K:P9ME]DIHC0['"*2/3?4J]U=G$3>H\]@AR1
M-AT6J1O2^RE)47'Y5>IP RYO&<9QWQGO_P"6?CQG'MQG'QXSZ\9]6>:\<TSC
M&?5G'?\ ^_'LSCY,X^+./7C/LY4WN/TE*=V(G -C*-E\HTZW29L&*H]LQ1PO
M0KJ]+,BP,2&V(BC4-[)9C(OQW3NN7+S1^6)L@3JWA>WDX:S8Q0SJ?[':-RMF
MI/K#5<DA[&XK26* [^TLS.KWK;8J@8\$(2[(:$"#+G4<J6A+&:M+&WIT(CQC
M.#&69E*]+FWPQ271:=1QFE\+D;%+8I(D!#JP26-.R!\8'ML4A\2=P:'AL4*F
M]R1'!]9:I&H.)'Z\8'WQG&.P]\9]F<9XXXXXXXXXXXXXXXXXXXXXXXXXXXXX
MXXXXXXXY6]U,=[)1H94,(G<&I%GO2:6#8Q->1R*RR\X9KG$S%_N4DDK"@%9$
MV;WE*YSB2ACWN:K"KHXQO4ULV8N21CCJ#.25B@GX.EIOA*^H-1]AVW,8!3]:
M.L.NM]J\N*4SL3'MG&)*A:X)7<O3*'RR8K'HTP@E*G,U-PYQI*@ NC@"B&J1
M$-LF2O+2BLF6DG*$:I.G6'-Z@],>20O3%ICE"(XTH8"E9!2PA2D--3#$$\LM
M2G/3F#+" \DXK(RQ><Z7V9;]'6QN-K:SRS:"$-DPV"Z7[=&GJWK,4VD8U49M
M1?:?7F\+XI>T1SB;2"NPV9(X]*H4.MG11"O>@EA#784-CD=Q.2D;;:%HO*9,
M>\;FU&Z2B032'ZZ[?R&K*JD$I<G5_?R($^4E1ETYACC*7T]<]RH-;R^V97!6
MEY>'1T= 1UE969P7*%30,T>7+B?G0ZQJ/CQD.D29I37.Q*R9L:IC&8VN4"KN
MQ#,MJ9,3(C94%8 8Q$B&IC1"#(R3<X6^ 1 SL'].6DZ JFO[VF&N]Q'WE$M@
MMK[ZNM]F:@UE58;)PZRL<3E\#1+FA"A-7-T&?8HO8TRMT"<O4B+.5!/-1*$A
MAEAO'''''''/$I^R>H$_6MN'J!!82KC"F4&4!:CBL;WB81V+%,C,EG3<X8?9
M,YR)P;&N/L2LI O3M;DZ+""G5R1*FQN"I6E^2SG3]CP:,66^0N-W3L WJ4]5
MT?9=DOFN4(5G(E+.\VG+1Q]#-+;!A*-0F=$T=!&T+%''00S0FOJ,1S<>45&@
MY5>O;&,8QVQZL?[_ .^<_'QVQW[_ !_ASV_@]F,Y^/.,=\_'SAW*.L#RL9G!
MW9&AT7QU>8ZQ]:XMJ):K8G0U&H;C')F4JB#3VMP,;U:M"-:A&G4B1J5"41N2
M#C"Q0XW:T,I[=NOC(Y,T^(S/&@H\^ VHT(2CY%$G,PH!?A5I_+HPR>-+ EED
MO$8=56$ZHC&#VY4TNY"-T31*B/1WC=/1YF!KGMKM'1$Z2-Z$,BD46F*)SA\S
MD!*8HI?(GZL'-*"/^->:6'&&Y*M+3)T)*5'D1XR,J3.QX:.L+1N ^CI-K+NK
M&TYX2PII&W.%"6JI1DB\>,A<&\S,#&J& ."_*JA*,",%@1@# Y%G/F"M2N]+
M)3N;-F?8[1*Z*Y!+%\P]^QI:+ZN"Q+YCMKRYR<)<^VU&_++C(]*&AJPL&Y,\
M6Q'G-@=HWGW2D*G$DA&VG>AO0/?#3J@J"8Z5M7J1E74]0I=(,LDYV(A[S2TU
M9:^ 8 Z,PZ3*Y60,$@5PUM*&@'*75\.<'0L0"\E)$B5$A3VRMNR^O;W!'2SF
M*[:K?J^98\?*W68,,]C#VPH(ZF395G.RE<U.:L)24!&._<0?*",$$@)8E L%
M9[755L5U=T"CEG55+&J:P:6(<+V.0-!AN4ZHH(Q$J"#TZDHA<WN*!268C<VE
MR3)'-K6E'(G!(F4E#*#D3CG59M!H;9,5?(-8,5CTVADF0&M<BBLK9V]_CSXW
M'=O*H79G=$ZI O3"S@(O)*2# @,"$P'A, $>/*7U)-:+?Z+E/RO:'IG[-SRB
MJ>EU@Q:-3G560MK):E8,;]/'8:9)+Z@(L)#)2X0<4K2$IGII.1K3%36<,M$^
MD)TB5IYP/0CZP>P.RNQ5GU3N_L[$'4IX@$:.I!AE,=JVM%$@G1<I5D2)KCBZ
M.QZ+"?GHQ@4-Y@(^>J6*U!0,J&I$:82K$'U]X%@6.^,]_BS\6<9^3.,^O&?O
M9QC/->..................................4S=::Z+6J:F:*;JBL]SJ
MZ13S8%J;#WB%Z../4%M(Y+$8)-+$2'P&@25S:TY,8'B+-L@DDX=%Z15$&) :
MOCAIC\)(F4<_T7726O6LEEN<WELOF\C<-D;#=721SG1)CZ=<C<5[[%J\?W-4
MOUX9%"SQG+G5T7N:FR'E:J?I\O7K5[@>8%(G&*VIV:D#XU.3*Z$>=-KN@6M;
M@FR8<3A0A<$QJ-61Y9,82H*\LG.-+\H0<4<#Q>,HP!F CQ'V/ZBZ\QRM9#4J
M>O"GJ$RR-QB(21/-Y+,[%D3W&X0F\VA#2XSN?R.2SQ2F@^,B4PC(Y-Y:'N0S
M':-FMCJ::M'E.M:N@M11O,3K]B QLYSP^R-P$:O=7MX?)+*'52^263R:22!>
M[224RB0NZQ2Y/DDD;LZ/;LL-$>N7'BP#PPVZE;+?<EU\11?6!PB[+>\HFP(U
M7TAF3VLCS#&5C]7]AM;W)375 TO2E*Y,475/CE'Q@;S@8D"=K$<(HD S0TY_
ML8"O]DH7KK8<BDBZ'N6J]IR5XD%7)BI.ZK)W%[3A$A4UQ8A2N.',1+:ECDQ1
ML3<Y@7DR)8I&Y,!:TUO*,?50RO4IQQQQQQ[/;RLG;#JS:D:>V%FMK+?9*]OK
M9'GJ1385?M"24%U^6WM@W%G9Y.'#FC&1(Y7D'F[0T)_+G-P3T3G)LLC.N2+C
MO.-7'3QW;ZK<BN+J6RL4*K/%_K$B[7B%6*Z+RW$VDF1?AHK]I2Y86]U#$&$F
M-)<N@'UP2J5<N=\*'A&RE-LC+?!^LO3+7 S4[72O*,/F[S8"J((5F5K^ZY\D
MFPO=UQ[LO;(VWY\0V>)-:U6H31QI./5*$B# <J5)J@TW.)2<<<<<<Q\95%;'
M62FN(V#Q<=I(XN="DL_$SH\RM/%%"T+B<P%/62O/ -@U@?+93A,QC'B,+"+!
M)QI0^*L2B:5MQN7--I5+6MBMKDE.1+D4V@T9DY"A,>6(DTHS#NV*S.PBQ"#@
M03 C!W\0!!%C L>3S>SHQ4EHVT;";4PVVD\)U.;:PE3Z@I9Z0N4@G\7O9Q5(
MD541.J)&I6@3/4'F$R6HF1\99>-7(&MC4* HW5P,2(7A@RCTC*ZO.<ZH1BZ=
M%=UH8QV,^C4'[ ZO6O#6Z25^Q6(T.2]F-+,]%K5DRB*5Y;6]"<S2HAN+/EK.
M:@7&+0^;EM[=:=C?O:Z@<>;[IZ-SQ"P),"RMNG5M:"YJ\P0'/@PX.,6P<7+(
MRB[XR89A>L/4 !G. I<B#@.9AT/O;J7LI@E/4-XP>0OIF0 ,AS@XYBTZ3*!8
M[C3'PR4%M$AR:2+N6;E,A4DX'CL$X>,XSF6V!8SZN_K^3/?&?P]L]L]OO]N8
MLN.CZ?V$A2FN+QK2%6Q UCBUNZF(SZ/-\FCYSHR*L+6AP&V.1)R?*QM58\NC
M48!@T@S(L@%CQ"QF#5A=&OIDV+!I# UNFM(Q9'(2D_>0UU#F^OYPR+D.3C&U
MWC<RC!:!]9')N/.$H(&E592*# @+<D:]+C*?,'\UMU5>EM^WTJ_/?5%TP9\Y
MS[SMAN9+9N;4T;),/$%) )UDHQ%;K<U(_-2R6QT*7.R@L@+<R1-D)P8OY8[I
M=U+=3]ZD"U%3\[,:+0CP#03JA+(0#@MWP-:C\('),_U^\& <525N/&$A2^1\
M;RQ -$$HUP)49$G!/S&<9QWQG&<9]F<>O&?W^.......................
M..........4M];V14_%]=ZK?[S4;+-T#C5S#DQ3CJS:-J5):*F8H*LL9KA,/
MC,@J.&2N0/TNL-^?2(7 X2[N5?Q%^E;LB622P6- RC3./<.C$A=VK5R6M\D@
MUT5W+@W"Z.$RB%Y[6N.YTRB\C=JZK-<;$5-XO$=BKJM<8BV&-<>FD'5M1P:T
ML9#,800\.V&<TTFW3CCF!;PRGPZ49E7DG"0-U(,J\J,@PGPCQ6]F^=Y4Y,_:
M\)L)O*^<9-_:L$>4\K^U^+G(Z\P>B:ZIV%176AGKYCI%(B7+X(AJPYI4P,2%
M\=E[TO71Y6QJ5C6L3.3RO<5YRM(K4%GJU!XO*YS]J'-/''''&<XQC.<Y[8QZ
M\YS[,8^7/(%;2]0>C]=FEZC[(]-UP7\)^3P.&:\UZZIGVQI%8SJB1K&:..;2
MU^?+(PC$0XH5KHZ.B8OS9"8(M$0M=1DH!_SE.I_:6Q+OM]M>S[$2AJ3V%B;.
M".<QR+G-*2&-#FDBK&M21MGRWDDEKDD:0&-K28L.5N2QP5-QJMQ=7D\P;BJ_
MIZ:U@(*UWH@I,2E3)BJ9JPM.F1)TZ1$G(! H\$HA(E2 *2IDI1> @3ITQ1:<
MDH("R2P%A"'&;.........1IVFU"U]W1K]KJ[9&#J+"@;/*F^:HH\"7S6))<
M25J0.;:W.*HZ%2&/*G#S)*\.&$R1P/4HB5!X5I:<*PA.>55/:'0FJ"MALUN]
M,V<RO1G:.#>='QN9MDOG$^K^>(CO":=![8BTU>I28Y1-Q.))+,$A I2I0B-.
M<HS)0A3IB+AXW+76M*:@KWL_/:M8)NAC$,:K/F:%R+@]9K+&7I$#:ZYC)\P<
M$QR%H>I.::1&F]Q5X<#PJ4J0)65 PD8Q!>V@^H6ROE5]ITA"G:1&^,XF<,*,
M4.GB=29C BEA,QB1C0]G'%9[&$Y7*5Q/?L+)0PYSC,2_L$]P]?L>7TTWCF"R
M.(_!A#2VV3<&W83A*7^V8;6V<)B2Y?'4G?'DBL(D.3 !SC(U6<X$+/ 23J/[
M+ZKM)JS>K2Z1Q^.)1!2!NG7:5,MAU@XN:O(D[*E6MKXXMSQ#_33A@I"E]-.H
MS<'J2P!2F#P$H><= .I35^\C"[-^&TJM+AC9QIC[5[B]E.IJID.//]%R2)/
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M&,A[)13>N1G#5*LAQD(5[@:2#(^XS2^POM<+W3<EDS2.B@_44Z0+I;L**2J
MN,IJE/!]FXRD3FX[*')J95J4B6QOPAS@T!J5W2N9'KR >!A\7*Y(K2?3#0R(
M;CH)U#=D>E?;:I1XA5I(Y#-FNK,K G"- W2>I+Q$9%5B?*G. 90I9N6C++\0
M2TP_;F<\=V ZV&O+:4[2*IM8.J=3Z,.5/OFZN3MOJ*Z%[;]S@Y1!G,2Z#/SM
M@OPJ,((DE. H%Y0L"O(AA$#.52]=;1N628BM;X<K(TDN/RI*-96>X, >:B4
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MLF?8;';DLZ-1ITE,9(;%+\RDHF&72,M4VIWE*L:SCAJ6,E,8!8F-+R0>=D&
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M=3I1V8-,G9]R:XCR]2'&<M]C()A69Y O $>2SSYQ&V5M ,/B\.<!<!AR,(P
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M^(/C 'Q8[ZC4IR_*>4.+!Y((QFY&,(?)@ ' QC'WSCP "#.!B&+L' ,X'G.
MYQG,=;$VA@-:WEK/0KPURERDNU2NUD5<R)C1LRV&H%-0UTJLZ1%RAS.?4KDB
M])1M(=F/#:F9Y(7JP#+4GH"09.%((3JV!(5J1."(*9 8:2N4"5$8(1&D8QDX
MM8;DSR:4PG @Y. >(L16!!R9@/BQW_;*Q($Q.2)20$U6$P:4H1H F*0%!",T
M1 !"P,X)8!@&9DO L  , Q]@B#G(I8E/.4)R5!!IZ00 *R2S2QFIAFEX-* H
M+"+(R!&%9P:6$T(!&%YP8# @9P+D399N/!VFR;1J> P*U;VFE&QYBD-V-U,L
M48?PU;F4MF)#%XR_&269Q 3[8D@B>!S%NJ^!ER^PO<J:SNZN.)"Y;"BY)G:I
M[;K>\ZVA-P5),66>5K8L=;I5#)<PJ!'M;XQNA7E4JDKRI9*I*H+$$U*X-C@F
M2.K2XIEC6ZHD3DB5I2,A>4!_Z8?B^/V]^_;M\N,^$7KQZOM1>OU9[?B6L2&G
M*""E!)AZ/)851)9@!FIA&EA-*"H+"+(R1&E"":4$T(!&%"P8# @9\7/QPYHA
MHL+TZ@A4E,QCR!R=0G&2I$,?DB0$*!' 2CR>?D*<H0CP%"/$$L1@<]^T?-6=
MHJ]VUH>#[!P-OE$7B,^=)HRM#-82)I8Y:E=(+8<MK1X0.;:UO3\WDK39##'<
M2)*D=UQIR+*<8O HR<G)D9E2G"8 G)Q6#3!9 65D8<&#%@ C<X #.<"'G!81
M&?:XS^UA$/[@(A8V%K$AIZA,6I(,4),%Y5$ .+&<FP<#)A.5!019,)P<6'(R
M?*A!Y4&,C+\0<9SB)CYN77S9-9G%&>&6C.6>L[3@-)6?8D&CS$_0JO;4L4,*
M4,\/D10I6BFIIK2UV1 GN9R%@ACY$82T2A$JDT@;Q(GLIIEKA2GR;Y#RQ7EL
MX,S@K(P8-S@GR?E1>3[^/PE^5*R,7A[!P:5G.<8-+\6PM<C.\Y\DJ(-\S-R0
MKP6: S*4\( &")4X"+/D#0EF ,$6=X!A , Q!P 019ZP58,*.G*JM"9*U&SU
M#$D,[6Q0I2$QY20YT>W*.-LB5) 8$).UN+ZS.[6A4G9 %8L:G(I-@WS!7DGD
M7>2-[7'7&2%>4=D:%N5KR"6@:-4I=1)B3#"D+4(Y6E0J5[@<6%"WE&KDY*A<
M<2G$H*\>1AQ1K!L+"]L->J:V4KINDC3!;PKN,V9$VR8(F]NE*%AE;>6Y-J9_
M0-3H]-R)V*3F!"M2HG9Q3D'>(LM8?@/CSG?CCCCCCCCCCCCCCCCCCCCCCCCC
MCCCCCCF#=B-:J,VPK1?3NQ%;L-J5JYNK&^+8G(LN): UWC:\#HQN #VI<VN!
M"IN7%A/(,3K"LY[C*,\H2886*O"0=%/2^$P2T"].*O@FI5\3VLI?5+#?\>8Y
M1.Y! XU8B9,R3L;&Q/\ /$B8#H]Q/TDQI'5*X(%[0:O"XICS,IQ)5$"]2/V,
MGK=3,TD3MLS+8?N%!W2*%M##!Y/4SW7AT0D:9T1J4TE9Y''[;<CQ%&-):YG<
MF90@,)6@-;E1:I(8VY KE=M)TF:FK35)?%^GI04,A4VAVT6J>X*BI&M]6-#1
ML&]:L6S%YY[U[](IJ_+VYL.E,4:7=HBYSNM11E-*\LICVH;&\]>[I,U[P.<V
MW#Z>VY-:5IKE=A<VL346\HM"X]840!7$O!;TP@R]GKZ%-*!\=D@EKM[J%:%2
M\2IL=\0!F(;<*QRMR*,"4&J'<71FW8HQ;&1/6#5";E1_8_HVNE6Q]%6;0R-Y
M&-S6BVWVR9 ?9!JF0MZQJM%_3REM>&:>/8EBJ2/S2YI4DD&[H" *,C[.:X;0
M3%VZF""MZ.GMBHME]1=[*_9";)KUIC5HUE9UFTW7$0K>+5#>S-,C8A>=$WK(
MVU"E:ZSG+:7*M9G&&/+D&?HJ_&T,2[ILLU:V@K.RKED\"UXNI5K>;:W3@M:R
M*MK9!73Q)[D9(=JA>-3[(/$0K>T3Y#"+(LF'6N[Z[3>QFF<-.7:U"ZT"Y,BJ
M925B;CQ=3V9TNO!#1MFTHQZO;)W=35C=*?8:D=/H;-'2 67,M<=F978]RSLI
MNL5K:U\=BE9N,TK^4TK'8"_1T2YEK!@J+-'HWX_S9O!);8]XJWMR?ZB:@,$,
MJ>=26;1#:?IRVI,H2TI&13(HG$J*OJI;.M-<\YP^A8?.8M&HB]"&A;7QQ/=G
M(DEM80NAZ@KO7G+M'K4>=BIG//L;98N;G[KHQ"\!20]O0FY7:32?36'UG=KC
MD1S[E<&IYY:C0YM5EU@(@LZQD!:(R0P60QLI)A/AB,Z#7>ZQ&E8=-=4IFO8:
MYU@ZY5/J(N^-#$X15J;+OV5;)YH37Z-@%(U3"I9PURB.%73:F0G-%7GI&1O<
MS8BO:V@*#L;9J7N= (5)U\!H:V27.3Z%=']VV$86=9 @3'8B]=;[]FLKWHAJ
M]UL-X=XO/=@993+PV1[,ILOTC&[< C25\X2U]CQIZ8O*SIK'/8UFCG%OUAVD
ML[3^>QW?X2K7FQ4E9N<XJ'8#9!'6KK4MF2*B8=[D8-6E>#3L]]1"(1J/EJ2:
M*<K;-?W841S-G5'%8\P#5G:2M*,:PO\ I/:$V,STF>C=K;8$!6*,''J[,UPO
MZ9"V#P?'H)9S0[V1[UM</41FKG4B&2L+7?,;;UM5NKB,A=*F@GLE+:-[;([H
MI24ET1,8VDJS:#K+,U732:,M7MWO(1+:%A@4TU1L=FC#=(3T$2JYKFI$E<$3
M16C8I*A,G M0MD4)4+BS5,M-$M8]IB88=*8$"X-)=BBJBH^F]B7?96J:7M6J
M['GU/HI,G?9!5]<4Q,*N+LI>XO$@<G$.U<YG*Z33*#KHW$G%K?W=&Y*8/C.W
MM)[QS8'4VOF#:_RA\L9VW U2L:ME[0F@Z*=WAJ]'*TU,;=R:^I(=BNCU#&=7
M;3S4ECIE,#G &>/62K;(VQR0#O%W5K4BYA!J)=":;:+2;7BMMA:VBC;:W4=M
M IQO(5?HGW7ARV4U7D<,KUQ=:[KIL9X[4,0=KT?5+W'ZJAC-(/<8D<ECR^I8
MV!P6L+#@V :YVXWU=4#_ ";1O:UWG:V;:74SM_&;&'3RN (9/18IZN>-CX;2
M=*+XFW[=M#5+'43:=:=M2EW2R1BG-?3*>16P\T^ZLL:_;5[6+;ZO(EH$3(*8
MM9XGE,N39 9?55]0!@F58CK:/]0NP9/'9A +FB,P'(-7+?HNG L%BM#B6:^U
M->M5-L0I8R&.66F)A;9I=,W7>WH?< Y7?=;;'Q?8>L8-<M0W;;DM7TRU4%L*
M"8V\GG4/L"$KH*RFV%>BUZ3HL3"./EEN*)\HXB0S:!K#2EDA&RGYIIB'67HW
M?74(<GBHK0NN&;6["$;;TU)ZBC1$N>7%\>J=JNKI30LS"<XMB> O<=D]:)W"
M$R67K6JL5T+E9:U7-6IS99*U-E8:+IM7S0>MVH[.AU_5W!=>ND7L:>[01&!+
M(XC@.R].;.[8K[GL302&/3TZ,A3F[5:\.S?8T1F,@]"QE(FJU'7Q;P7#+VL(
M$?G(+7'#EU&Y!&H.1$UVNVSR&JMX-C8@N5IR9I6>P^JKPS1.&-"V-)TYGF+/
M>LA=*LE;^PJ5Y!3=*->[8\:->99;\J*@U#-:=NW73B=Q8O4.ZXQU!JUKH5:;
M,W6ML]OB<3W?C8-N:[N>W&^M)8W6#E/;LBV<K".SY/'YM.6^'+Z71SJ0U,D>
MHRVRU8U#S&[:\WE%]B$UU0W7RR';IR/^[M>6$^Z6-<-;VN0I4Y^G\KK-YO)+
MKVZC:2TE<-VS[Y!YK):LRF2N:R611UV$%$EYB-N=%4;];]-]BX/1-45IL)J/
M:LNH_P"PNWFI. 4ND3QN02&E-FYKMY8]H5?,LLK?)7=O@KE9E./\*8ZZOTI?
MY6GGN"+$SW(H&AE 71ZYV-:,;AQ></,ZL:K)O9UY1O;SH7V IO)H4)5ZN9?8
M]573E?=0.UX8ZN3TV.+<AD;>U6_'[!'Y@QNUMLCWEN VRUL=D0<3FZ?NO5PQ
MO9)=++ZK?8QBONI'#:F)6#=KHLI=CUVV!K^XKF5SVM7N./L,8#+4O)4<Q(X<
MZ1UALY:V*]>US;-8X ;2G<6=CDW ;D:\W$+8>=[!:3UYL'K]NR9;5-QY',(F
M:2\Z<;L5>@1P0EY=]M8<J='*"(D%>1%7.88&PG9GA5],!L18<ULY3E$.+LIF
M FO3/99COQ7:%>TW,(382[K-[?VK&[</2H3!Q;5.[=%Y?6#/,5*@Y[4K2*FD
M6QA]>2"15R0C$N<G.,))<\PCPLR5Q!'BV]']J+&T[!&(%K5;L&MTKIFH->]N
M8>:X)43EL9NW'[YUY?8'8#?*PRM$VVK)(7[B=C[/,V2.D+AA;&+;9XZ"4*7Y
M_?6!@EKM#H-:T0N_;B0:1ZS)(>QV'TZ=?8E4[[ R:W@0'&<P+;>Z[9V0I,MQ
MD:].ZQ6>7I4MBI(NB<'YD,B;^N?CDLM>D#<RN D_P-.OLV89K0%GM.J&V<KT
MXL.V=GY=;>L=J,-,E3>$W7;-,5/!*IN-3K36Q$9@4+K1H=8?:L?6,K>M7BCM
MAVBZ7ZJ0L9$C6OY5I_27K6QJ;Z:^E%2VY!GZMK*K+7BNX#-(3)LM GEA?HFT
M 9UB=4)C=7IN$ T28*E*(MP,.$E.)RL)2*LG)2K$....................
M...............:"]F?P9_DYQQ']CF_O?RYYN.^Y)_Z.9_-XYIG^N*?P9_S
MB^!?<*/W!7_^O-QWW";]P+^;QS]#OZV3^$/^;S\L_=9_PP/Y,\VX^/\ <F_^
M?-X/:/\ Z-G^0/-!_P!C)O\ " _D'S8+[@S_   /\XOG[D_W/^&,_FL\W)?_
M ,]_AA_^7- ^U7^#/\@^?F#V)/P?^?-F/ZV;_P!*Q_G8YJ'^N)_PF_SPN?03
M_75/[L/\F>?FK^Z*_#C_ #P\VJ_N%7_1L_\ GRD'I,_\<#K??_U$T?\ H'KW
MEX)7W2O]UG^07/S_ /T,/[H/^?CFIG]:)_PHOY1\T']V;_A ?RYY^Q7]D*/_
M *G\G/S,_LH'[H/^;GF@?NP_X<7_ )<V8^X4?X3'\X/GT_'C_HV?Y0\_#/\
E8I'^$#_G"Y]9']:!^#/\N>?KQQQQQQQQQQQQQQQQQQQQQQS_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g681689.jpg
<DESCRIPTION>G681689.JPG
<TEXT>
begin 644 g681689.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@!!1$E32S$S,3I;,35:0TXQ+C$U6D-.
M-S0W,#$N3U544%5473(P-S0W7S%?1U)!4$A?1$E34%]+7TQ)3D4N15!3_]L
M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  "P@!'P*D 0$1 /_$ !\  0 " @(#
M 0$            '" 8) 04" P0*"__$ &P0   & 0(! PT(# H&!P4$"P$"
M P0%!@< "!$)$E<3%!87&"$Q46&1E]76%5166)66T=(9(BA!9Y*3I]?8X^<*
M(S)2<8&8F=/4)#>'H;&V&C,Y0GBW\"4F.'>R)T-&P30U1W)V>82&E+7Q_]H
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M@+HGIGR4'^)IW,N NB>F?)0?XFG<RX"Z)Z9\E!_B:=S+@+HGIGR4'^)IW,N
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MQ,I&0<KF+>#&S,T)RP\3(<IKOK92<L9,>!PC(]SN72>2 D'[4P,D%^:;B4>
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M$0*/#[OL9NWCI!WN_P!X_O\ /UC]/L9NWCI!WN_WC^_S]8_3[&;MXZ0=[O\
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M88MSUK(XUE;WMNJ55B+6U6!Q'*&4B)679G%)!]%.7:8G;-9*+<+I/6],:WN
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M;..#"C VYLU6K4ZHFL2'E7PH+=3FT! ? (#_ $#Q\(<0\X" _P!'?TYQ1#B
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MF4Y6WLEGPKU:PF: "8D@A#-5JNHB:(*\6+&& \S/MY0RAF((&<"]026ZY%8
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M9TK$G<R" RJKY12DN_AQ6<5;G+GO/QS&S$UL>1L&,<+<LHPI<K'+53)S*L6
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M<NHX\DTA)>7/+OXF.@XU],OV+932+&;\Y? TNJYQC,;;DV6#=H.\C<MN@I&
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M[O,$1B9ND=EK"6Z;N7M>.;SLPN66) -O./,?\I+DS"&XJYTC<_?<P;)+Y!Y
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MI^IJEX\Q1,#[=# 10G$>8<G-,3C]J(:$Y5/9.F4I"3^="D+PYI2[)M[@%+P
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MM("(N]1Q!/V5_C^J6!FQ8,738\)!M(UG8FJ5QCXUG<14GCV;\'@U >0?]=N
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M)GV55FQ56,@D\=S.%LZY@EX"_P 4-B<6*/F'!ZL]C48HSJ"D9!8K])IL5*'
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MZ[<!?[6/^36&I\TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTX_\
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M$2[-2E3T>-J,!+_^_(7Y   . >,1_K$1$?'X1$1U 60RE/FS 13E*8HAED!
MP 8! :8R*(" @(<!*82CXP$0'O".IUZR9^]&WY!+ZFG63/WHV_()?4TZR9^]
M&WY!+ZFG63/WHV_()?4TZR9^]&WY!+ZFG63/WHV_()?4TZR9^]&WY!+ZFG63
M/WHV_()?4TZR9^]&WY!+ZFG63/WHV_()?4TZR9^]&WY!+ZFG63/WHV_()?4T
MZR9^]&WY!+ZFG63/WHV_()?4TZR9^]&WY!+ZFG63/WHV_()?4TZR9^]&WY!+
MZFG63/WHV_()?4TZR9^]&WY!+ZFG63/WHV_()?4TZR9^]&WY!+ZFG63/WHV_
M()?4TZR9^]&WY!+ZFG63/WHV_()?4TZR9^]&WY!+ZFG63/WHV_()?4TZR9^]
M&WY!+ZFG63/WHV_()?4TZR9^]&WY!+ZFG63/WHV_()?4TZR9^]&WY!+ZFG63
M/WHV_()?4TZR9^]&WY!+ZFG63/WHV_()?4TZR9^]&WY!+ZFG63/WHV_()?4T
MZS9^]6WY!+ZNNN%W70DB0PN(8)=1 [E.+%9B$BHV3X=4<$8B<'1D2<XH'5!$
M2%$0YQ@XAKH[V>?BZA/R%'KD98+6UCU%8.'>]1;MGST#I@":JIE&P"!$A56*
MD+EOU<Z94.N$15ZH6EI<*;E<Q  Y4O#2C5M<0,>L0R34Z@I&XG*FI$PBC>/,
M;O@03R\[**E#@!T3<WFZN1CK',%C:G0U,BCN9%G#I."D>2PHKO%U7;M=ZX.;
MJ:2:""77#A0$&K9)-!LB!$B%$0,<^;]9M/!UJVX<>/#J"7A\''^3X>'>TZR9
M^]&WY!+ZFG63/WHV_()?4TZR9^]&WY!+ZFG63/WHV_()?4TZR9^]&WY!+ZFG
M63/WHV_()?4TZR9^]&WY!+ZFG63/WHV_()?4TZR9^]&WY!+ZFG63/WHV_()?
M4TZR9^]&WY!+ZFG63/WHV_()?4TZR9^]&WY!+ZFG63/WHV_()?4TZR9^]&WY
M!+ZFG63/WHV_()?4TZR9^]&WY!+ZFG63/WHV_()?4TZR9^]&WY!+ZFG63/WH
MV_()?4TZR9^]&WY!+ZFG63/WHV_()?4TZR9^]&WY!+ZFG63/WHV_()?4TZR9
M^]&WY!+ZFG63/WHV_()?4TZR9^]&WY!+ZFG63/WHV_()?4TZR9^]&WY!+ZFG
M63/WHV_()?4TZR9^]&WY!+ZFG63/WHV_()?4TZR9^]&WY!+ZFO(K5J0P'(V;
ME,4>)3%13*8H^,! H" ^4!U[]5_89>M4WN+L.&H7'3=[1Z5CRI6^XY9<W)NU
M1CK3='UI3A,>1=*+7G,C+S:<17$+-*2IYN.AH^$G(K^.7E%R1RF==G?6F3D\
M<S$41@I-U9]:J7-)2:+M&Q,ZZ[AX^XQKEF=!JZB9>O.[%7W2;?G2#.6AY8C]
MF](YCY>/8R-K'+%<:E4309;7:*[636:?C:K7 L$Y%PHS]GF5>H1%<A0DW;49
M6>E5OXF-AX\'$B^5_BVK94_>UUUFR/CZERM7@;A>:?59N\2 Q%*A[)9H2#E;
M?+ LS;FBZO'RCYH\L$B5:08)"RB47;D%7K-(4NJ.VY%>)3)&/(2WP./IF]TV
M)OEI;N'E8I,G9X-A;K&T:%='=NH&MNWR4U,-VI63PSA>.9.4D2M70G, -E^I
MYKJ \@_Z[<!?[6/^36&I\TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTUTTY8H
M&LL5).Q3,7!QZ7\M[+/FT>U > B!06=*)$,<W#@4A!,<P]XI1'O:]T--1-BB
MV<U!23*7B9%'J[&1CW";IFZ1YQB=4072,9-0H'(<AA*/VIR&(8 ,40"L&8*C
MN3N]Q<0E)ML/3,;G8L3$E6KP[.:5<&2YLDB\.T;+S1UBK]4,U28.(UD=H*(*
MO.N!5*'V8CVL5?&=B:W>2L$W<+JV*]ZG*OS@T9(JR#95F[639%4=.W2ZC9==
M'JTG)O1 %#*$335YIBVFTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTUI
M'W]9FR%@#/3NW;4]U.UW%><Y;&M%;Y0V[[R:=DJ3PMD^IA-W)''.3(:^8915
MR1BZ^U\C*]5)Q(-HRY5:Y0:<;'3M8:/ZM"3)<YY.N<R_N%O]IW';F-T>U;,6
M6Z=37.+ZM@W9HWM*&',#U>YSL38+'9YU_EH29HN60<J.*+5VB-GLL%2ZI%UN
MGK1-'KZYY2SR[S;_ *U%\K9#1#UER=\T[B8UY,0'*M;$?<*5<Q[1S)0ONODY
MS'RPQ+]9%1U&>Z<>(LI S)5 7C0>MG(J(B*8T+W:E-,Y,_A&,CF@2'CL><F+
M@$F"'<THH1:J8U6P5N@O[JP44_$7$5(K[EZS(2IYB$!*3-<:+3UPX2-=@ER4
MTM$_G.0Y-_ED<K9D5DV^^RKYYV%EHDB8RY+I6[]6-M^P6R;6V]3,@HL\AW3W
M,V0K@_CV\4Y00?6Z[7HSDB3J?L(N?V6H"<4B"KS05YH=5 @B) 5_^] @F$1Y
MA5.>4O$1^U .^(=_59\U/K+'96P*ZJ4!'V:9*XRD1.)D[ -9:*-C4QH+A<98
M(>=$BB/-)U-#W/,"XG'G+(E((FRCLQS]T)TWTU_NRT[,<_="=-]-?[LM.S'/
MW0G3?37^[+3LQS]T)TWTU_NRT[,<_="=-]-?[LM.S'/W0G3?37^[+3LQS]T)
MTWTU_NRT[,<_="=-]-?[LM.S'/W0G3?37^[+3LQS]T)TWTU_NRT[,<_="=-]
M-?[LM.S'/W0G3?37^[+3LQS]T)TWTU_NRT[,<_="=-]-?[LM.S'/W0G3?37^
M[+3LQS]T)TWTU_NRT[,<_="=-]-?[LM.S'/W0G3?37^[+3LQS]T)TWTU_NRT
M[,<_="=-]-?[LM.S'/W0G3?37^[+3LQS]T)TWTU_NRT[,<_="=-]-?[LM.S'
M/W0G3?37^[+3LQS]T)TWTU_NRT[,<_="=-]-?[LM.S'/W0G3?37^[+3LQS]T
M)TWTU_NRT[,<_="=-]-?[LM.S+/O0G3?37^[+3LRS[T)TWO^#_[;/#^;+7J7
MO.=VJ*KESABD-VZ!!4677S>1)%$A0XF.JJIC,J:9 #OB8YBE .^(AJ/H?<A;
M[!: ID#2L735D%LY=%CHK.IGQ3ILP [M--\WQ:>.5<MDQ%99JD[46(B1102\
MU-02Y+:YS<S.U^1B*YCFFTV8?)I(M;,&5DIL\27KA([E=&,6QRV1<KJ-BK-T
M>J*@5%18K@ ,9(I1J4WVQYMF)I>:RC!IY%<%5_T7_P"VQ2*ZJD \>#IR]Q[,
M/FQ1$3 5K%+LDTR\ !<>^4+<UEYF&G0,;6:U@*D14'$-^MH]@CFY50B"1E%%
ME!%1?&RJZJJRZJJZZRRBBJRRJBBAS',(Z[WLQS]T)TWTU_NRT[,<_="=-]-?
M[LM.S'/W0G3?37^[+3LQS]T)TWTU_NRT[,<_="=-]-?[LM.S'/W0G3?37^[+
M3LQS]T)TWTU_NRT[,<_="=-]-?[LM.S'/W0G3?37^[+3LQS]T)TWTU_NRT[,
M<_="=-]-?[LM.S'/W0G3?37^[+3LQS]T)TWTU_NRT[,<_="=-]-?[LM.S'/W
M0G3?37^[+3LQS]T)TWTU_NRT[,<_="=-]-?[LM.S'/W0G3?37^[+3LQS]T)T
MWTU_NRT[,<_="=-]-?[LM.S'/W0G3?37^[+3LQS]T)TWTU_NRT[,<_="=-]-
M?[LM.S'/W0G3?37^[+3LQS]T)TWTU_NRT[,<_="=-]-?[LM.S'/W0G3?37^[
M+3LQS]T)TWTU_NRT[,<_="=-]-?[LM.S'/W0G3?37^[+3LQS]T)TWTU_NRT[
M,<_="=-]-?[LM.S'/W0G3?37^[+3LQS]T)TWTU_NRT[,<_="=-]-?[LM.S'/
MW0G3?37^[+3LQS]T)TWTU_NRT[,<_="=-]-?[LM.S'/W0G3?37^[+7:P=IS.
M\EXYK/8GJT+#+N2IR,LSRQ[M.F#82'$7"$5VOXSK]0#@0@-_=!IS@.)^K!S.
M::8=:]-P&]V3P!F64QS';(MY>X$IZ-2[<KD;;+BRH7BKIJSLC<XL*E9)6RY(
MQ\X0LT*G7"R81[5.701AK#'.5'+51X#<V)[>,FY1W/;GV6:GNS3.6U;'6-,-
M7G&ZURW,1^-JCE3,%AO-RQ_/Q59K="HF0,ASC3'./&]-FYUQ9+Y(0QG=FMR#
M"EPRS8;5)J;-]19E#">*\T%I1,I4B#NY,<WF"R;123R*[DE5R'5U#JUF[PA$
MG"!6-IKJJJRT%-IA[H1"RRRL>NW465,?HLF[;,%YEL,!:LGXQJMTGJXW;L&+
M^:9*+"ZB&=CB+BRK]@;(KH,[96&-Q@(*WL:M:VTW7&=LAHJRM8M*;8-GR?-G
MVW8,N>2X3+]IQG5YO(M><5I['V5^S457/(TEQ,.Z)+2K %RP\_-4![89]]C^
M:L$=*2U$?3<N]J#V%=23M96;]0'D'_7;@+_:Q_R:PU/FFFFFFFFFFFFFFFFF
MFFFFFFFFFFF@CP[^JOYGS?7,=2,7+Q^0(=Y(Q!EVD[C1)=N^<3\>[50!59NL
MQ;NEZ_9(@4^N(Q>560B'K<SN-D$T3N6[]IS@2R7_ "?$5:[S<X9G68B&5B$X
M] \6O)WBRIIF935CLQFJ1DXB-8.2J)0, U!J_5< I*R9R-S,V1NFR=MLLF6;
MT_E+-E290H*@,3QM.CVIPZQ%)LW0>($*NZ&&_CUDE'82"\8]>B=<4C% J"9A
ME?&^!\98K4*\JM?*$R#=1JI8)1=63FU$%1#JJ1':_!)FDJ!2 JC'-V2*A2%*
M=,Q0 -3#IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIK@1 /"(!_2.O4L
MX1;I'6<*IH(IE$ZBJQRHI)D !$3'44$A"E  $1$3  !WQ[VH.N&Y_;O006"V
MYJQG#KH"8JK!2X0SN4*<O$#$]R8UT]DC*!P$.ID:F.(]X"\=:"-Y'+N5%&W#
MC_;8O=XIE2K6Z)9LBN*4P=)6R0K<NJW3A*[&2LD53L)?F:@O*R4@UCYB<:+D
MCVC:&1*X<NK/XIY?#:-;:7&R5[@\KTZY(E(RLD*QH2LY#DE4FS9==U!2;295
M.XAW8."*M"/TV\BU$5&;I)0S<KMS9W?MNTW/[?9*H57 FV.#M49<8YRK.[K<
MW75[ ;6,$.$S/ 3-E.(Q1"9&SJ^.'6S8Y5 I5(QTH639IRN7:^*4BI'QYR=%
M!W%7R8CMXFX+? 3<8_OM,R_CZO8JQ;2Z5C_:O3HR-S1',$+3AB)@7UDMEE66
M2QV*#VZ9!OU\FI*+L31!J]A6R9VCW;KIK7/N\WS92VOO+M(UG8IN+S_C'&=#
M"\9!S!0KMMKHM-@C)L9&8?UR-C<TYGQ[=;E,1<*T9/7BM-JTW&J/IJ.K<<]D
M+*5]%,^WNV^67C=P=5VU8KVZ7K..1TJMC>XYT9T_+.VZL+;;J_DZ4.QA)+(M
M:R/ENI7VR-F<>QFY^7/B^H746D5',@*160L=>8O]@/\ 5P\/_'P_U^'4!Y!_
MUVX"_P!K'_)K'4]\0\8><-.(>,/.&G$/&'G#3B'C#SAIQ#QAYPTXAXP\X:<0
M\8><-.(>,/.&G$/&'G#3B'C#SAIQ#QAYPTXAXP\X:<0\8><-.(>,/.&G$/&'
MG#3B'C#SAIQ#QAYPTXAXP\X:<0\8><-.(>,/.&G$/&'G#3B'C#SAIQ#QAYPT
MXAXP\X:<0\8><-.(>,/.&HXN^7<;XY(;LPMT3$N0*4Q(SJXO)E4#EYZ8HP[$
MKF2.4X<!*IUL5(0,!A4 H\=1WBS<I5,NW&3J]6@;,5I'1*LGV0OVC5&/4,@Y
M;-CM5DD7+A=BLJ+DIV978D5<%36 R*)DP TE91HHY)I4M3RV*4K R@LQ&5B#
M_P"DIE:NT7)VZJ754.N6;LB9F[MOU=$%4CB GX )35]K&R_&%>FH*6<O)6PH
M1*+E5[%S?6BK&;EU#IBS>OD&Z:"!6,>!53DB$T!1>KG35D7+I-$4%9>H6(&>
M.UX!: GG:";2OMH.UL2-&R4;<G$<S(UBK [9%4,2+L+(" DK),CG4DF',827
M7)6S%9K,O$/&'G#3B'C#SAIQ#QAYPTXAXP\X:<0\8><-.(>,/.&G$/&'G#3B
M'C#SAIQ#QAYPTXAXP\X:<0\8><-.(>,/.&G$/&'G#3B'C#SAIQ#QAYPTXAXP
M\X:<0\8><-.(>,/.&G$/&'G#3B'C#SAIQ#QAYPTXAXP\X:<0\8><-.(>,/.&
MG$/&'G#3B'C#SAIQ#QAYPTXAXP\X:<0\8><-.(>,/.&G$/&'G#3B'C#SAIQ#
MQAYPTXAXP\X:<0\8><-.(>,/.&@F /'_ $\!X=[R^ /ZQ -1?;LW8=H1%CW7
M*6/JJ* <5$IVX0$<Y#Q@5HX?E=G-Q$/M"(&-W_!JK-OY3#9W4BG F3U+4X3Y
MP"WIU9L4T4PEX=XDBK'L(8>=Q^U'W2 GWQ, <!& WW*RUF?==8X<V]9@R8X4
M_BVYNH-(Y)54P\TO-1KC>[/@*)A+PYZ"1N!N E*8. _".Y7E+\D JEC[:= X
M]9KE,9&4O@.TG#5(1X@H92V6&GHB8I! 3<Z!5#O&'J(\.9JJF7<Y;C*FBN;<
M?RD&V_;]UN?FN:E5KK!R%Y1*H!A%-"IXSK2]J<G*!1 A"2BQS&'@501'6M3(
MV\'9@ZEU8R4S_O+WD6I10B36.HU0)2X26<*&$3IM)',=BLUI.W,?@4AF%!76
M6YQC$0((  =W3JAO#S"= -L_)5NZI$/#&ZQO&Y^VW>63,CP ".UF5JE<#TI0
M0$1./6M2GFYC?Q9$G( //TM9:KUVJ.6,I5;)$9&1>0:]D:Z0]VC:VPZA765J
M8S[U"<;5]%BV38IP:4@1<D2#%,C,6 (&: +<4Q'ZJ*W<*1\D8C9V<ONN8.)6
M;H0XA%Q?$/\ J=?T1<G[Q]H>%;0>D9EW3;<<371*/8RJE2R9G+&%!M*<5)@H
M>.DC0-JM41+DCY J"QF3P6@-G8(J"@JH"9^$)X#LO)UY%W$SF0=K66=N-XSB
M\QM9F]WC=OF6:):O=2G2MNI;Z5MUZIV.+#)0BDR%DCZY'-;Y-1;>PNTW*L(:
M8D&A0:L[_::J1NIJMCR>XP5A^-K\K)4NYYMJ=IS#,HQ!GD%$XUPN5QEXL/-2
M!A!NW[8&1:GCJADC51YTO"S=E*!3MF3PNJ-;L<)4#=!N JHXZVPY,Q?O*VZ[
ME=O-QIN]9YA1O2XDF.:Y,4ZU94?0FX2/5!GEC%URP^O>\%V'"LE-/Y68MDPW
M8R] BH6(9WF+W-E 0#@/C'Q=X!$1 .]WOM0X!WO%JL6:JVWMF5L"PSJ3L40B
MHXRDX%[5[!*5B7*9"FM.8FG+0SAJ^(W.*G%=N58$5^:0%B' @%UE/:$A>D3.
M?IKR%ZYT[0D+TB9S]->0O7.G:$A>D3.?IKR%ZYT[0D+TB9S]->0O7.G:$A>D
M3.?IKR%ZYT[0D+TB9S]->0O7.G:$A>D3.?IKR%ZYT[0D+TB9S]->0O7.G:$A
M>D3.?IKR%ZYT[0D+TB9S]->0O7.G:$A>D3.?IKR%ZYT[0D+TB9S]->0O7.G:
M$A>D3.?IKR%ZYT[0D+TB9S]->0O7.G:$A>D3.?IKR%ZYT[0D+TB9S]->0O7.
MG:$A>D3.?IKR%ZYT[0D+TB9S]->0O7.G:$A>D3.?IKR%ZYT[0D+TB9S]->0O
M7.G:$A>D3.?IKR%ZYU\,GA>JPT>]EI;*.:8V,CFRSQ^_>YRO[=HS:H$%19PY
M75FBIHHI$ 3J*',!2% 3&$ #7R+XFH[;J_7&7LO(]:PXV!QU7/=X3%"" 5 ]
MV5>=/ "<7Q25#W0,(-1%,_!4>:/#J9VA8SK-90N4[F?+\=6':3)=G,JYSR"=
MF^3D4@78=8"C+JJ/CO$!ZLU2:IK*KI )TR"4IA"J<]EBDNI$83%:VYC(LL<Q
MTT.=F7)<8U6. CS5$&+.0DIY=(0#G *S".+P'B94H=_5QH+"+.3A(>1D[AG>
M%D9"+8/9"&6SA?UU8IZZ:I+.HU58DP!%CLESJ-C*E*4%!3$W-+QYH8Z_V;X=
MEGLE(3!KS+OI7F&=OI"]SZ\DHL4I2'<GEP7)+N'*Q"E(HJ\?N1(0I2-P0(4I
M0RB,VW5&$9(QL-<<QQ$>W+S4&,9E^],&B0<  >8@UE4D^</ .<<2B<PAQ,81
MU]_:$A>D3.?IKR%ZYT[0D+TB9S]->0O7.G:$A>D3.?IKR%ZYT[0D+TB9S]->
M0O7.G:$A>D3.?IKR%ZYT[0D+TB9S]->0O7.G:$A>D3.?IKR%ZYT[0D+TB9S]
M->0O7.G:$A>D3.?IKR%ZYT[0D+TB9S]->0O7.G:$A>D3.?IKR%ZYT[0D+TB9
MS]->0O7.G:$A>D3.?IKR%ZYT[0D+TB9S]->0O7.G:$A>D3.?IKR%ZYT[0D+T
MB9S]->0O7.G:$A>D3.?IKR%ZYT[0D+TB9S]->0O7.G:$A>D3.?IKR%ZYT[0D
M+TB9S]->0O7.G:$A>D3.?IKR%ZYT[0D+TB9S]->0O7.G:$A>D3.?IKR%ZYT[
M0D+TB9S]->0O7.G:$A>D3.?IKR%ZYT[0D+TB9S]->0O7.G:$A>D3.?IKR%ZY
MT[0D+TB9S]->0O7.G:$A>D3.?IKR%ZYT[0D+TB9S]->0O7.G:$A>D3.?IKR%
MZYT[0D+TB9S]->0O7.L5>X]QG&VN&HLAFW*;*YV*/?2L%576X*Z-[#,1L88"
MOWT9$*V KYZU:"(]76;HG*0$U3<1*BL*>4]H:$X<0R)G,0\9<UY#-_PF1UB-
MFHF*J4B+BXYWR15$  1%:R;CK3!I   )OY<G9FH> !'@'$> #WN]JL5MW%;)
MZ=U8C_=;E*9<(\X!:T[,&7+D<YB\.)"N*\L_8%'O\ %5XF01 0YW>'5:9W?O
MM\5<C'XU;[SLD2(F$B"3/*MMB$7!_ 4")C:9:: HB @/&#!0  1!,1#AKK@R
MWO-R*4I,2;8-PD"W<<T&TS?LYYD,F!3 /!7C.2>.HDP=[CQ*HX(7AP$#B(:[
MN%VZ\J?<')G4QF\V*VB@E_T%[EF;ECMR"''@FWAF]M5.< $2B"\\)C"0/MP$
M1,;/)7D[\F3T>I-[C=\-_D8IJF12532>R<?!MD"@'5 &4M]N/#-T_" +*P*9
M1 .>9/G#P"J5V8\B?MWZ]0R+N0+DBP-4S$<Q54OTG?IPKL@E%4@QV$H4&[)?
MB(E.$L\323^V*<X' Q@I\??QL26L@1&S+8YN?SW;#&.BS61LEBAT5'!#&*V4
M090ILJ6HB J& QQ6@HAP4H@504E *)948ARZ6X)-NCBC$#_9_3#\PC5S=<NV
M)E(M&RB@]3!1E>K-99](4T_Y:;3&$<80 QBII'.0I9@9\C-O8SDV2)O)Y2G)
MECBQ(D#FEX^>W";BE4CGZHX;"]L\U6:V?@ B0JZN/G@&,/.%,Q"@0UH<=<@3
MR>%&:%3FZ=D3)DB(I'6E;KDJ<9F55(3@H/N3124V"ZFJ?^,,FM'N!X\"BH8I
M> WFQOL6V_8<CPBL20]HQE'@4""A1;G/5I10H% @=</HMPWD71N:' 3NG:YS
M=\3&$1$1DX,!PH!P#(F=/Z\V9#$?.,T(_P"_79PV%82%EF$N2XY7E%&#@')6
M4]E&XSD2[,!#DZE)1<C)+LY!N('$QD'2:B8G*0XASB%$)7!@R . -&W_ /CH
M?X>M:O*11>)\286OFY5QA+:58LEI*8QI+_+FZVD-I;%..:FZN)8).\Y;GHNN
M3=P2Q[CMI:IN4.PB7$,W7?R#=I)V2J0SN1LL32KDW<EW)UO8M>*LDI\F74LA
MP.W[(+BV8CV581NE%S7C^6@,K8SCCK9CE;!-29H#']KBIF#L.-!D4RQV7HQV
MPN-( D57G4C.?H+TUXF,4O 3"4/$)A /Z>''3[0#!_)YP\1#P<X>]WQ#[X]X
M.^/B#R:\M0'D'_7;@+_:Q_R:PU/FFFFFFFFFFFFFFFFFFFG$ \(\-/\ UY]4
MMR5O)I-<D)VKURLRUUEHEQ)Q<KU<J<7 (*L3JM) JZJR3U\[:H*D62<*%C",
MU"%/P<BF8##6W&[A_*6II+90KTK!XA/7&,LE78]<QZ]&5)>TN5:X>;9O%%[
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MIA =0'+<KKA]TL+3'&*,P9!>#P!--O&0L6DJ<>(%*!&TG/292F.)"\1B^?\
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MU1XSD,>-ZI0Y2J*P<D6WN[9^D!!4%TDUB@(%5(50H&#@8"J% Y ,'$>!@*8
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MFAXS?CG^MIS0\9OQS_6TYH>,WXY_K:<T/&;\<_UM.:'C-^.?ZVG-#QF_'/\
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M)3\_J8\_51I'^$#P%V?JQ>V391N0SBZ,8R31<Z246W54$1!$XLZ)$Y2D2D4
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M@:6(7-9D[1 "Q=5!.40G?:OL=E-O^X>P92J5OP"UP(XQ?-4_&5&Q3MSK6/\
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M#)UYQ(6P_$IC%,4 K$?+%$W$I@  -Q-P^UX\2\8&L/*Q[284ZB<=)WVTG+Q
MON'2G#,B@AQ$>8I:'U>#@(!WC"4 X"!N/,$#:C97E7VL\J9#&.V#,MY.81!
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M^5_[L9CRO(9REE%.JKKS%IN=237.)Q,)EG+./L%B5,8O-(<XV,J@B43 <HB
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MC&\V)I:K94HZ<FF3%*.26>G=F;*-&ZRR[=-W'IN4V#WK=1PN*!G;=<4RK*$
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MT^Y;)KD_$SA0[^I1I5U3)$ ZG/L$7>7P 9RFDN '>JG$J1$E5%#$(L2>Z?R
M/)R595-5_1<CW0R9RG$MHRO9VR2O-6%42JH4X*DB8A@$$3E A>>D4IC#U?BL
M-FZMR37)T4\4C1>TO%3]1$H%*M:V,Q>5C"!$T^>H>Y3,Z"AS D4YC&+Q%83K
M]Y550YK0U7;)MQHHI&I6 \+U$Z)@,D>M8MHT*HF8#JJE,1:/@D%BB51=8Y1!
M3B4RJ@EX<\0&:&[-JT1(W:()-4$BD(FBV3(V1(1,A4R%(D@":92D(4I"E H
M4A2E  *4 "&\_;=<.[H<=NL4YRIZ=XHCN7A9Y:$4F;!!F]UZ\[Z^AWR4G6Y2
M(ED%6;D1.!47I$E2F.DNFHF82ZHJ?D3N31.0Q#[<>>0Y3$.0V5\T"4Q#@)3%
M,';![X&*(@(>(=;3&#%K&,FD<Q1!NR8-6[)H@4QS%1;-$2-VZ0&4,8Y@313(
M0!.8QA O$QA,(B/UZ:::::::::::::::::::::::::::::::::X$0 !$1X
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M81C;;M$$Q]5&V2#WU[<RPC0EI.KFG+#Q->6#G&<F.HRO96"X";F"!T$P1$0
M2 '#O9EW-^*/>%Q]+&6_;K3N;\4>\+CZ6,M^W6G<WXH]X7'TL9;]NM.YOQ1[
MPN/I8RW[=:=S?BCWA<?2QEOVZT[F_%'O"X^EC+?MUIW-^*/>%Q]+&6_;K3N;
M\4>\+CZ6,M^W6G<WXH]X7'TL9;]NM.YOQ1[PN/I8RW[=:=S?BCWA<?2QEOVZ
MT[F_%'O"X^EC+?MUIW-^*/>%Q]+&6_;K3N;\4>\+CZ6,M^W6L%K6VJN$M>15
M+"VN*E97F8 U"2[;V3U.MXE.H0J4V3J;>[%<M^J6DLNKS'ICJGY_54A!L=$I
M<Z[F_%'O"X^EC+?MUIW-^*/>%Q]+&6_;K3N;\4>\+CZ6,M^W6G<WXH]X7'TL
M9;]NM.YOQ1[PN/I8RW[=:=S?BCWA<?2QEOVZT[F_%'O"X^EC+?MUIW-^*/>%
MQ]+&6_;K3N;\4>\+CZ6,M^W6G<WXH]X7'TL9;]NM.YOQ1[PN/I8RW[=:=S?B
MCWA<?2QEOVZT[F_%'O"X^EC+?MUIW-^*/>%Q]+&6_;K6%/\ ;56!R'6%V3:X
MEH:=1N:5B;]M[*!>JVE66I9JFKU ]V%\IU&,2MQ>JMSE;(]5YKHIE%F@ES7N
M;\4>\+CZ6,M^W6G<WXH]X7'TL9;]NM.YOQ1[PN/I8RW[=:=S?BCWA<?2QEOV
MZT[F_%'O"X^EC+?MUIW-^*/>%Q]+&6_;K3N;\4>\+CZ6,M^W6G<WXH]X7'TL
M9;]NM.YOQ1[PN/I8RW[=:=S?BCWA<?2QEOVZT[F_%'O"X^EC+?MUIW-^*/>%
MQ]+&6_;K3N;\4>\+CZ6,M^W6G<WXH]X7'TL9;]NM8O9< 1,.XILSC="TM9N'
MR+0Y215=91R"\;#565C9JVM)=C/VY_&2"2L&#LAV"[1<SL!ZDBF*PD$+.!X
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)333333337__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g594336.jpg
<DESCRIPTION>G594336.JPG
<TEXT>
begin 644 g594336.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ \1$E32S$S,3I;,35:0TXQ+C$U6D-.
M-S0W,#$N3U544%5473(P-S0W7S%?4$M?2$%07TM?0D%2+D504__; $,  0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_   L( 04"I@$!$0#_Q  ?  $  @$$ P$
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M)CB&*L-WN\4;L;'=6VMM;K&JB6W>YK6E:V\=I*E>*M;;:UI^:M:4K_-02(
M A*?_P"0Z)^MN"O\YF()M
M              !^8X<*)Q0T?/FBY$B2+YS9PX;SXBQ4H5+8K\YDR9,9KK,.
M N7P8\F;-FRWV8\6*R_)DNMLMNK2J##U]Z'92*O$]&>L#3/(12/&?GD%]F&3
M-\<NC$SV*6,8BF9XN2]%<)RU';%AO/@*]W#U<*=<:SX2]AB[-FQV76 CR2F'
M+#:PO".76BO!N9CRHE55$0Y8:Q%EA#/YTI<15##6EAI+6T-4+&4Q:15,N354
MA1+YR2B3+&<5^*G"I_\ Y#HGZVX*_P YF()M
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M!W)F7PZCKJS</M0#N3,OAU'75FX?:@'<F9?#J.NK-P^U .Y,R^'4==6;A]J
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M4$)S_P#R'1/UMP5_G,Q!-H
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M/\),_2E/3]1<%?NUT# J     "^O!9?I*-"7]J.*?WU4=JS9_$M_JV_X4&X
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M=!F.W&LHBPWCU+K4IR7UK>F+I%.4;,=:9;:69KRMN'-6E_Y')DI9=6F"P
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MXQ6XGB%QI.-G)B/F<*^WEA65L:H],QPI>4RN5,SVDE)N%D M=2\TGY\EV2P
M$)3_ /R'1/UMP5_G,Q!-H
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M,MQP7I !"4__ ,AT3];<%?YS,03:
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M3/TI3T_47!7[M= P*@     OKP67Z2C0E_:CBG]]5':LV?Q+?ZMO^%!N
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MU >#L/=,WQV##EFH#P=A[IF^.P8<LU >#L/=,WQV##EFH#P=A[IF^.P8<LU
M>#L/=,WQV##EFH#P=A[IF^.P8<LU >#L/=,WQV##EFH#P=A[IF^.P8<LU >#
ML/=,WQV##EFH#P=A[IF^.P8<LU >#L/=,WQV##EFH#P=A[IF^.P8<LU >#L/
M=,WQV##EFH#P=A[IF^.P8<LU >#L/=,WQV##EFH#P=A[IF^.P8<LU >#L/=,
MWQV##EFH#P=A[IF^.P8<LU >#L/=,WQV##EFH#P=A[IF^.P8<LU >#L/=,WQ
MV##EFH#P=A[IF^.P8<LU >#L/=,WQV##EFH#P=A[IF^.P8<LU >#L/=,WQV#
M#EFH#P=A[IF^.P8<LU >#L/=,WQV##EFH#P=A[IF^.P8<LU >#L/=,WQV##E
MFH#P=A[IF^.P8<LU >#L/=,WQV##EFH#P=A[IF^.P8<LU >#L/=,WQV##EFH
M#P=A[IF^.P8<LU >#L/=,WQV##EFH#P=A[IF^.P8<LU >#L/=,WQV##EFH#P
M=A[IF^.P8<LU >#L/=,WQV##EFH#P=A[IF^.P8<LU >#L/=,WQV##EFH#P=A
M[IF^.P8<LU >#L/=,WQV##EFH#P=A[IF^.P8<LU >#L/=,WQV##EFH#P=A[I
MF^.P8<LU >#L/=,WQV##EFH#P=A[IF^.P8<LU >#L/=,WQV##EFH#P=A[IF^
M.P8<LU >#L/=,WQV##EFH#P=A[IF^.P8Z^+^$5Y''DX3=XW.LHB$EC8?!M,N
M!OJ!]33*8:)3C_)WXS2FF))JN2^_\M6_'<3MMQVTQTIERW5OK3!B     "]'
M!B7*-G",:'[DC$2SJMNIN+:IV!2,9RB?E-T6?^U8SIHJ6.F2Y>ZO'3)EP$S.
M6RGQVX;_ ,P[0&PYJ ]S;_\ %V'OXM/^.3X[U/\ F&-W+-0'@[#W3-\=@PY9
MJ \'8>Z9OCL&'+-0'@[#W3-\=@PY9J \'8>Z9OCL&'+-0'@[#W3-\=@PY9J
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MG^$F?I2GI^HN"OW:Z!@5     !?7@LOTE&A+^U'%/[ZJ.U9L_B6_U;?\*#<
M   ,=VH;06=U4RFJ*,SZH-2./38:;S:2[M)$2R 9AB.7<K$"RR6="Q*3]CHH
MB3@[$9SEU!/)YH[2I,:\?9,:10VLHBX>4#%V&U\'Z?H-TUL<E&NG^)8\AMB$
MKZ9L36CAHHK12LQW\C9BS*:B71R97(JK1NW';>HK:OD.K"CGK<8/GC&?)?DN
MF( $)3__ "'1/UMP5_G,Q!-H
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M2:;GR&+#9RS(K9SF6_(" "$I_P#Y#HGZVX*_SF8@FT
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M=^G/0..G?IST#CIWZ<] XZ=^G/0..G?IST'7-?PDS]*4]/U%P5^[70,"H
M  +Z\%E^DHT)?VHXI_?51VK%E:>XM^.G\6W^>G>H-W'3OTYZ!QT[].>@<=._
M3GH''3OTYZ!QT[].>@<=._3GH''3OTYZ#&_PIZ>[CFEDTHLQE,]XJ#*D)D28
M9-NN$77J)-,BZ+\JG(3;=K.B9D**<YEQ[9'VW&BT4-9)54"+'Q.T\^G$A.)L
MMU80S\8<%BV8L3%/6.Z]/^FU1A. )%U )COC-^.J+Y&A=YS1>?CIO7O0_6-Y
M:*(SX2(YCMWY%)C16?N:+#:IY!P'B;1:/<U(R.MU95W&J7H;?7%K&CJSAO2$
MA25+$! +%SBZMW)Y+.;M2$4H;-$2AI64JX:$DTN:.DRV8[GP8\YLMANOSX_G
M5D:*I_U7-.:Y</:-]0D?ZBZR_H3GU02IFPQ DM-SQ%HOU1->8FGI"B6C7F9]
MFUY8)-RV67FM.AS$FNBO"8'I[K'E(MQ1;:6SLF&A>*W^A23KSU OAN*;)3M5
MVJ\G(T:,U>3<R,Y2481KI]A73ZWG0Z$,WEJ?;JU(:C%:X\\#>52Q)<36VIMZ
MYPIZ.O&E%"29IU,LD^KHJ*N8) ?B'@K(D))?O>13C=PH%,N>7&F6M6:83[84
M5&BN6N.XS9?)W3Y%0T0(W92.7#CSX3//ZQ M<=?]N,T^56'3_P!E(\XJ?]%
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M00G/_P#(=$_6W!7^<S$$V@
M ZYG^$F?I2GI^HN"OW:Z!@5     !?7@LOTE&A+^U'%/[ZJ.U9L_B6_U;?\
M"@W    "F3UT Z7)%U'4U:O-BK"MJ#),E&CEL283D&0FPX6*RD:]8S]PV(9:
M+G0/>E17.+RH<<*FC4*K2[?GQ%E-1,)Y$@3+3E&L+M.*E1YJK:5'^I9WR;03
MJO1^24_),REL[=1+$$G:D*4A.!S+*43RDL=F4TF%%*Q,R*-3"GC)XCY]0SFI
M;&GNJ<5:_'Q4K6GQVW4K\7Q?%2M..OBXJ5X_YN,*5I7XZ?\ 7_U_GI_/2OYJ
MT^.G'00G/_\ (=$_6W!7^<S$$V@
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M5^[70,"H     +Z\%E^DHT)?VHXI_?51VK-G\2W^K;_A0;@       0E/_\
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M/<J3N4KV=*\&2<U)?C)P&4JTZG7+".5>3-2L#B1L:BG9U=NFU9.*J:8;,X%
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M-/LEKTINQ+(I[53DU.PHQ-RN-4R)MN:PP<QX3%<-QFA;$6+%[7?G_,
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M>$$1YG?ZXY6@JV1B=T *&1JR)G;F9LN4XF/=J&UVW([4]Z(.92Q++ PDKD5
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M'?89<19F++LM49$Q1)B9*LHSKCC$PZLT9H:DUE\[A4$=P8CA69M*.N]A:MG
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FW$/$48#+CMF%\":2IES'UC TL;I=BR=4%]YK[A5S-IK#80 '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g865624.jpg
<DESCRIPTION>G865624.JPG
<TEXT>
begin 644 g865624.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ _1$E32S$S,3I;,35:0TXQ+C$U6D-.
M-S0W,#$N3U544%5473(P-S0W7S%?345!3E]$4E5'7TM?0D%2+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MGDHIAUQ_<+;6'!>K1!S9!VDV_>(YKV,.30MH):P]X0=DH9Q*C<KLBQ8<NJ$
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MI!=SG]SZ::8S]KX.WVO@S0X130YLWMD'REW>TD5Y*>?CG5),RG//\.>?;^&
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MMRY3?JIGV08HQ.?_ %DM _\ X)[E_P#UQH" O,T9<=7+K]*&C+CJY=?I1RA
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M1#*T8A!..O4.OE^',5C>;(Z"*QO$L>CJ1"&22Z A1H$"X()*V0X<"9+<J"F
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M#0H[VGDR\T! ^O6O8Z^WBZGSU#7K7L=?;Q=3YZB>-"CO:>3+S0T*.]IY,O-
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MK!<0DU\Z&!*^KFY.E%#=5J4)U'8LWK()5%*450@2IDL6*<*< 4VH10HZ) X
MR$B!-R8(P@^<MNDJ?DZ54R]1B>4ZAN +1 G#Q4$92>G=TT,I$Y9;*2DP'!QY
MC68F]5)6 H"6+M0TRJI !97A<Y68#!D/AM8MMUXLG-1#8)1.+M?J,^5RI4@
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MV6:.H?3V,L"J@AIV2MW0]O\ 7==$@?6^G9TJK]R4KKM7SV[??).C?7X"?(1
M>KY[=OODG1OK\-7SV[??).C?7X"?(1 >KY[=OODG1OK\-7SV[??).C?7X"?(
M1 >KY[=OODG1OK\-7SV[??).C?7X"?(1 >KY[=OODG1OK\-7SV[??).C?7X"
M?(1 >KY[=OODG1OK\-7SV[??).C?7X"?(1 >KY[=OODG1OK\-7SV[??).C?7
MX"?(H;]D4?N!23^L4U7_  E=Q;1J^>W;[Y)T;Z_%)&7V2SC$N!DH%JQT?;D6
MU/\ MA9H*?:.0)S0%5E2XG9&=?%8F\(KZA*FN76]5,K=SJF>J>>B4!TRH0A
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M.C?7X_:P@7HMUSJO/OU>C0G*5O56C[6:J<Z9RKTJ!TY]J4JJ='N3TL\^W3*
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M>>&G1WU/*EYX#E"..G1WU/*EYX:='?4\J7G@.4(XZ='?4\J7GAIT=]3RI>>
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M6"D6F])$WC@*J\]="K)DT>*5*D:B%%AZ1II&'HA.5&ITGDN9UC*B&P1W#HT
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M=*<IU3G.87*:4N*KD5^C#2EQ5<BOT8@?@RLGX%T[Q*_I##@RLGX%T[Q*_I#
M3QI2XJN17Z,-*7%5R*_1B!^#*R?@73O$K^D,.#*R?@73O$K^D,!/&E+BJY%?
MHPTI<57(K]&('X,K)^!=.\2OZ0PX,K)^!=.\2OZ0P$\:4N*KD5^C#2EQ5<BO
MT8@?@RLGX%T[Q*_I##@RLGX%T[Q*_I# 3QI2XJN17Z,-*7%5R*_1B!^#*R?@
M73O$K^D,.#*R?@73O$K^D,!/&E+BJY%?HPTI<57(K]&('X,K)^!=.\2OZ0PX
M,K)^!=.\2OZ0P$\:4N*KD5^C#2EQ5<BOT8@?@RLGX%T[Q*_I##@RLGX%T[Q*
M_I# 3QI2XJN17Z,-*7%5R*_1B!^#*R?@73O$K^D,.#*R?@73O$K^D,!/&E+B
MJY%?HPTI<57(K]&('X,K)^!=.\2OZ0PX,K)^!=.\2OZ0P$\:4N*KD5^C#2EQ
M5<BOT8@?@RLGX%T[Q*_I##@RLGX%T[Q*_I# 3QI2XJN17Z,-*7%5R*_1B!^#
M*R?@73O$K^D,.#*R?@73O$K^D,!/&E+BJY%?HPTI<57(K]&('X,K)^!=.\2O
MZ0Q^UC#8S >N=RRC::*YT3HG5[8%;5]+5.FJ<LU:@JEVYT4SSYL_:[4\TYYP
M]-B+>M-89D-><V\W*W<,V4"R0B-L(MGTE=5KHK4T41K8(PU"?3);3;'J<2FB
M.1DHC"Q4(L6BM)D!V:BAI>5%8P59U]2^4'9I1O$3H.RB5VEQIJDL/<U@IEXG
M["'.D,KL1:W>]#L\SZR1Y[=LK<$LJEJS2]*#HNK 5%I //TL-!"3<H5-PX!R
M+CS+#PWPY*0"FVR2[I'EU0HF9>3JK$VIL'(4CNT*8#.I8%N(Y#$YZO&T/TU:
MZH+)1Z*+KBA-QERE/6;H<$:CKU-6V !@&N=)]G,+E^RC:LRN<-!WA5<Z2-8K
M* NSC'(G!&A4X]%#3*)]C=:)E'4B#9#JN2M7J4*S M[/GCCF)TZBR'J(>;%I
ML:!V$I3E5*4Y=R<I3E_!/MRCS'B4I4RE3+N2E*4N[/M2EFEVY]N?W^W%93W9
M0I#(;%3=PRA5RB&V+&U3[2*G$&\#CE"@'I1(F&()4&Z08-HR86 NEB:(5FY!
MJ0F XR6;AJ H2*3+1J,*"\N5RF7H:PF LVA%/99E$E]?79*O#%.)H-AQ5&4F
M6>32*2:V6&%3B@U4E#%5M6%>@<HKJAM%UTL.<2:(.6YN("E'AQ !%&90M*5$
M(%A!P$7;L/,B\J 7S,T&A"TO"69B!8TP%6 00+9EFTK@D4)N6@]BW3.J4JKE
MVY11*<Y2G5VY0$0-5^WC$1_2V4?H9:>)MC5UL7);P,M'_O"%XC+%H:ZI2(!W
M+RI(;5L6'I:!K@M0@+7<,*:;]BD4&$!JKMJ=5$A%B]9G/JEJY33,FM5LMHB%
MWP3G.<!GT(P'6JV6T1"[X)SG.&M5LMHB%WP3G.<!GT<:JJ:*:JZIRIIHIG55
M5/N2IIE.<YS^Y*4ISG&!ZU6RVB(7?!.<YQ^(ATFTN![]%#A(:NNNS=HHHI5R
M=JJKKJHJE3133293JJJJJG*FFF4ISG5.4I=V ]C)PT7.6>2C+,T^W+]6K_NH
M:PD7X1EG^NK_ +J-,I3JE*6><Y=J7PSCSGGQS^6<!N9K"1?A&6?ZZO\ NHKF
MRB"M39I=P)=8G( 3U'*284J;O4[WU$[U3A]3TM.FC-35U*OZ;ZFG1^FG3GEG
MDW//CG\LXTEQKSGU7!+VY_7)L(?P_P#Q.? 7167"1?4K7^$99^QT?^VK[V7_
M ,J/TUA(OPC+/]=7_=1I?9G/J5KMS_8Z/AGWLH_3//CG\LX#<S6$B_",L_UU
M?]U'N"A2$9]7?H*#,*85AJ;==^D/757.U3=G73;JKSTTYI5SMUREFS_4SC1O
M//CG\LXEIJ50FTT).[BC4)(0T#+ &@'6=FY>54"J[-P55>H#5& D/3?KM4W+
M=5VFU.J=NFNF=>;2ISAM+",!UJMEM$0N^"<YSAK5;+:(A=\$YSG 9]",!UJM
MEM$0N^"<YSAK5;+:(A=\$YSG 9]",!UJMEM$0N^"<YSAK5;+:(A=\$YSG 9]
M",!UJMEM$0N^"<YSAK5;+:(A=\$YSG 9]",!UJMEM$0N^"<YSAK5;+:(A=\$
MYSG 5?9?7ZSIE!_ZO"A_XTGH^.5>_9;O^DK_ -J<?8%R\CA((WR/^4! %2U2
M)D.OX>E!18!EZE)!HN]74>)VFFBT&"C[MZY5.JJ4I4T43G.<Y2E*<YRE/X_5
MW]EN_P"DK_VIQTV&56\<)VGM]]GYPA"+ID(0@$(0@/IG^PR?K9#X?UW7)_0V
MQ$=NF.GA[#C6B/3F31>T$H%4FR,9<QKN,)MA#@]*BL3<#W&>8VW1?HL#Q8>[
M59KN6;M%-VFB=%5=NY335.JBN5/;1UJMEM$0N^"<YSCBM/75NO3E&T<,^A&
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M<I3E.4Y2G+X_5W]EN_Z2O_:G'V-<OK]9TR@_]7A0_P#&D]'QRKW[+=_TE?\
MM3CIL,JMXX3M/;[[/SA"$73(0A (0A ?2I]AQHM'J/)HO:-4"539X,MXUW&#
M6Q9P1%1H)MA[;/,;<HL47QX01=ILT7+UVNFU37*BFNY<JIIE577.KMHZJFRV
M=H7<].<V1U5/89/ULA\/Z[KD_H;8B.W3'%:>NK=>G*-HX8#JJ;+9VA=STYS9
M#54V6SM"[GISFR,^A'AK =539;.T+N>G.;(:JFRV=H7<].<V1GT(# =539;.
MT+N>G.;(:JFRV=H7<].<V1GT(# =539;.T+N>G.;(:JFRV=H7<].<V1GT(#
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MX9WP:T.D6DC2:40R\337TV"$X&J"Z>$IK:&?J I2Y*8J$\%R!%!4%J&#QD[
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M-$\;#"(Z!SI$.+9N3K &Q>-!7*Y43LW+@>NL/<O6*J+M8;%PB"M=!YL$?/\
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MA=Q-THUP+A94A722#,D:S5CAH@_<":7#J1M++M'I.UQ CC9-%CH*)+J,I=(
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M=]S50G[234[@7;YH4"ZZUDI$L'")I0*.J<S4[3X( 3&8D46@08:Q_18PCX6
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@"$ A"$ A"$ A"$ A"$ A"$ A"$ A"$ A"$ A"$!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g1011221.jpg
<DESCRIPTION>G1011221.JPG
<TEXT>
begin 644 g1011221.jpg
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M ?P+"_GX_-->FQ^I9H#^!87\_+#>.!7E^::]-C]2S0'\"POY^/S37IL?J6:
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M:]\Z&IW1]->VG;>@ZF[ 7'N@<LU7K]/TOI/9<Z^[WI[M.GZNVG!U<>L??YS
M)FGTZ41ZY:*O$,4,TN<0-)CKZ3F/T^GW*X1<)*1P] '&<XQCSG.,8_'/RQR
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M-AB;$OJ#5WMB$F]1Q(-4GWBSV+:%+SC%>;GU:%6:$0&'RNQ#HFI#XYB5]OJ
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MI/>-3"*#,$@*8 6$/=TNLL.T76K$]I"0LF@5[9%G/GSPT\#HS@?34^(*W&X
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M;<I77FT:3UV>N5A[+:$!;ZU?K"U6VKZSO]O%';A,IDFNTB'8OB0NP3E#F!;
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M*OGYS]V5*SC_ $3G/LX_QQC@<I\^/GCQX\XQC]F,YPG]Z?&<X^[/R^[G/''
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MXT]-L<K0Q=CQ-CQ4-16)>#*IN)+,9MN.T][;;*$-I2G ;#XXXX#CCC@....
MXXXX#CCC@:$UT0V?)W5V(@VULLC7@V?J].J%S!\:,+=B2Z*B1<LAYS,=M\BE
M-E]XD@J5(D*B2L8CM>Y;QA&=]\T3KV3M)W<W8*/;T$DZYBS]9XU(N3%@-#G(
M;U(0Y=,BY,9I,R7A-G]YB;D@ZZMB1[+4;W;'A.=[<!QQQP&<8S\L_P#/_;./
MNS]<9Y7'VJ:M73ZJV?LKUQ$!YDLC;*Y%V#H0\68INH]EV39MRK]+CW\C<EQ)
M<+1]E$%S<$Q<-GJA2:>1KL<P]L %*G9A6P+8YSKRPD6>&$ IL; ,!RT.0.*"
MBD..0&DA\QI3$N#/@RVWHLR'*86MF1&D-.,O-+4VXA2%9QD*JM$^I8>LY;8N
MO-P]<MZ,;)U?(JGY12=.:-VE<ZAENYC")* *F)<@2B%<M(50J;'*"Y4\I *#
M'@5KKQ:<&/LHBR+_ .N.J?\ R [D?_2MM7_\7R3NN=6ZUT_66:9JFA4_6]28
ME2IS-:HU=%58&W-FK2N9,2,"Q8<3XJ2I*,OR,M9>=PA"5KREM&$YYXQ^W]^?
M_?@0F_ZXZI_\@.Y'_P!*VU?_ ,7Q_P!<=4_^0'<C_P"E;:O_ .+Y-GQC]O[\
M_P#OQXQ^W]^?_?@0F_ZXZI_\@.Y'_P!*VU?_ ,7R,F[_ %-3E?NM(UCJO1>V
M@5GLU6M]_)V??6@=]!:M JU+G QD^&&K]%J9V[V<LY*.LSC,X2/>'TRN1'S1
M*.4>DCQ4FW3QC]O[\_\ OS7&R].ZHW.'AU[;FMJ-LT&.)1S \1?*N&M8Z"6B
M^<,$8<0U#F,QIK:<J;Q(82VZII:VEJ4VI2,A$'K[ZE/6G=NJ:)L4S;%:JG6R
MOM%9H78E?O5-&P93<B1!F_9%IO%.J0NQ 7Y<1Z2!/1DQD&!#T*>J'#=?<B,R
M4KG9WK=<"B E3W_I.SF5X3E(FO[6H1<IGVL8SC&1L"P/S\*\*3Y3F-A6/./.
M/GS<T8?!A0XXZ'$CQ!\2,U"B0(S3<>%&AL-)88B1XC*41F8K#"$,LQVVDLML
MI2VA&$8PGFI;;USZ_P!^2^F\:0U'</BL*P^JRZWIQIQWV_'M94]/#//94K"4
MXRKWGG/C'S^6.!N3"DJQA2<^TE6,92I/G*58SCSC.,X\XSC./GC.,YQG'SQQ
ME2<9\95C&?'GQG.,9\?3SXSXSXY"I?IW]0HKJGZEJN7JI]65*2O1NR=KZ'0A
MQ2,H]YB+IV\TF$K.,9SGV'8KK*\Y5AQIQ*UI5\^.FMA"NK?H7<3N%4/=X3B
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M->[ULJM]H]JTL[V.=[8:JUPUNSJO3SMTHM?UL'U)L_84/($(V/BU"6#GD*O
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M,>,8T=VRQC'W8Q@IU_QC&/PQC'RQC[L?+' FWQQQP'''' Z"SPF" (C%F%B
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M$!!5KU(NL[]EF4UECL([;1P"!:I];1U$[3J,0ZT5)30XP[(A8U#[UH9/*C2
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M=#&M=@U8]"C.3:K>*XP*)D:R<C)=(B94J/ +@S,66,G%!,X<3&D1T^2R\AS
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M/9CO1&9JF&U3&HLAQEU^,W)RG+[<=]UAAUYE+F&G'&6G%HRIM"DA!PAZC'7
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MYX'"<>SCQ^U2O]5*RK/^F,Y\8_9SGCC@.:GNVM'=E128&Z'''J9/Q)C.5@'
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M6ZC-OU5T'[8ZOVE;]NT.\5JW:[WZ*OVF4T1K9(RTC 1H(7(48+<&Z]9+$-^
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M)[;T>S4VC5]JY! :=41]C.7T);@@P9"B-2@YR$P5<@#G:_*Q=NSP_L-:+%(
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MG58/?@^I*V*,UK-+.ZQ,$&V(==%A)9>&/]"/C_G_ #Z?_P _CGG'C_']^?\
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M5)_M9_L^/[/U^G[/IP/)1J[N)WBV%H/JH$N.]=BZE$;"J_>S7&.P;W7#L9V
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M+=&36\_8;,#1=6"40X%A5Z]*BC)!5K)VZC&<^]QCSGQ[*,^/.?'GV5Y\^/\
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MUXDM)PI6$YRGRG"LXQGY_?CSXSS^SN<X<:QC.<8RK&,X\Y\9Q\_EG'W_ .O
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M#;[#&#Y92P0H+PZ9[R[.R). "NU79G.X+6 E;KVFL$*_[1 +T<+AOX<;AO\
M2LSUJ'3WZG\4D VJ1IL=MB,7B1K4S)0PQ8(SL,A:9,I:OB/3QC.?*?GG_P#5
M7CZ_=A+GC'^&/&/E^S'/B]XOSG]-?_BL)_M9_L^<_H_7Z?L^G \DL'O9O*N=
M?Z\?V1VDVC7YN;+ZF6B->02-#WX1+0[L-[+2@W3;?=RV'K;4EZE7P#J/4+3+
MDG7%ZG2R.S:@9"7)JN['(N+6BYG:L77E]]/325&V=LG:_84)M8CUBHTK?>DF
MWK%=96RR^Q:?)K>\(L,4"EJR IVUA8ZT'QA.J$H(0 *E#[F >'C3K3>:]B+C
M;P78&FC0=JL@8<08H:9\ 4<)CH4Y+KFR/>IF18DIEB3ASX:/[S#S:\+]PS[7
MGW2/9G=2(<0?2ZLQ BQH3"PXJ2IF(PU&:5)GLMSITA3;*4(R_-FR9,R6[G&7
M),J0_(>4MUUQ:@\U>[=V=F]6GT/!#310S/\ 4*]+2HWOO)HRD3J2$[5:5L6Q
M[?3-R:ZV;44NVZM#;9I6@U\BG;ULUU)@T9VN66MMK_).:'F5Q.?]<^R/96X;
M3N](VO=K[CJ33_4C]1/3]SV4[8KK7[;3]3URO4,WTY$JV0*5$NB=9G;6<V/%
M";(7:6H9(A6JG1W31D-,?'<]'"E*PRC.%*QG+V,9SYSYSCVE?+.?/GQ^SZ<_
M.%K]V_GVU></9QC/M9\XQYQ\L9\_+'[,?+@>9W76PN^FQ]ZV#1^Y[EN".6E>
MC1M"^N4BN3)E=;>[*PNRE[JNJS4J;7A@9<+<%PT9$I9*R5!L@SA6",TA&!1X
MS^9[L A.].V'7[JD(UGJ_:W8.BRJ5_V:_6.SP=5=?MIDI5.^PJVTD+)'5K\L
M1!TK&V-*%,X$)UV/E/Q!H-TABKUT)#S*E(]LF%*^)PGVL^S[G&?9\Y\>?/U\
M?3S^WZ\^9QQS&<>%KQ_4)S\E*Q\_:^OU^O[?KP/.^6[)[XE->IP*!]CKK0 =
M#TWZ<FS-4["G4V_[6:JI#8E3^*["IJHNJ4R^6]L7;88@&%M4FD5<VC4A6W/7
MEH('GYE..3=]*W<F=[5#L'L?/8<SN :?WD4EZ]UG8GK@BP]=M.Y#08VO]?6%
MC8M3JMZ,'2$J):2TZ]DLV,-;$(C1@MJ//5XL0>DAW#/' - JA $9*A9Z-C"&
MT3A)&8.F(;<IEX4XVF3#>9>2AQ2$*6G"\)4I"<JQG*<>,LZJRY1O6@^RF9,@
MO8R@RL1B=@)O.3S9&-#K(R9$CSBLI3L^6Q%EERLJ,U(?<;8DDR#[24NS9*G0
@DUQQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g408147.jpg
<DESCRIPTION>G408147.JPG
<TEXT>
begin 644 g408147.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@!#1$E32S$S,3I;,35:0TXQ+C$U6D-.
M-S0W,#$N3U544%5473(P-S0W7S%?345!3E]$4E5'7TQ)2U]+7T)!4BY%4%/_
MVP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0'_P  1" $S E # 2(  A$! Q$!_\0 'P !  (" @,! 0            <)
M!@@*"P$" P0%_\0 :1    4# 0$&#0X)"00( @L   0%!@<! @,("1$6%U>7
MU!(3%!4A,59AD96GT=4*&!DH.5AG<7>QMK?3US,V05%4<WB6UB(W.%)VDIFR
MN"-RD](D)RE&4WF!F"5')C(T-4)#1(*$H<'_Q  7 0$! 0$
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M+K;[:5H$G@         A* /Q'6_E;G7ZYGV)M$)0!^(ZW\K<Z_7,^Q-H
M
M                                                    P8Q)\;%'
MT2B\U(#)+24IIN=:38],.M!POA01BN+)F-*Y%I9%"U?-IA;#BR93!_ GY"N'
M%CORY,MN.R^ZT,Y 88@2-'[K<#H:;7?+/<;I9!G 2>C;07,B+"^T#AJE]Q4H
MZ$9./&5%OF3-N+)<7+JY8GES6X[^EV75LOI;F8"$H _$=;^5N=?KF?8FT0E
M'XCK?RMSK]<S[$V@
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MRCBR&3J:B&2I>_(+"J=KM;G>_-WA7$X?=:X?_P#+LU(_ZGM*PL=
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M^48?O@#\1UOY6YU^N9]B;0$!^V;^ ORC![9OX"_*,)\ ! ?MF_@+\HP>V;^
MORC"?  0'[9OX"_*,'MF_@+\HPGP $!^V;^ ORC![9OX"_*,)\ ! ?MF_@+\
MHP>V;^ ORC"?  0'[9OX"_*,'MF_@+\HPGP $!^V;^ ORC![9OX"_*,)\ !
M?MF_@+\HP>V;^ ORC"?  0'[9OX"_*,'MF_@+\HPGP $!^V;^ ORC![9OX"_
M*,)\ ! ?MF_@+\HP>V;^ ORC"?  0'[9OX"_*,'MF_@+\HPGP $!^V;^ ORC
M![9OX"_*,-6)LVG$40Y.CWT\)4&:Q9YD2-&VP7/(6/37ID?,SH3+)2<46U!D
ME'"NMW)B*DE-<3F\JGBQ/H+_ /HY7)NY>FV9<6/ /99&_P"\%VK7^'_+?VX#
M>;VS?P%^481S+$22C.C!7XLEYF:;9#CIUXBF!S,QT$Y&4FZOEB)XLIE"JPFW
M7V8% KA4290[:5-4R%ZFBI?-=BNOP8ZVZO\ LLC?]X+M6O\ #_EO[</99&_[
MP7:M?X?\M_;@-WRI;4L3+8"N"D&TPEL.$OCZ9EDO/DZ7@Q68L?3,^?)ESYLG
M066TOS9\N7-ENW;\N2_)===7[[FIJO;I!=>48:,^RR-_W@NU:_P_Y;^W#V61
MO^\%VK7^'_+?VX#>7<U-?F@KL4W*=B1NU^;XNQ3L=KL!N:FNUN05N=O<W)&[
M?Y__ .J> :->RR-_W@NU:_P_Y;^W#V61O^\%VK7^'_+?VX#>7H=3.YN;D%;G
M9IN;DC;FY7L5IN=^G8J%::F:UI6M(*K6G:K6DC5K3=[>Y7\F[WAHU[+(W_>"
M[5K_  _Y;^W#V61O^\%VK7^'_+?VX#>;VS?P%^48/;-_ 7Y1AHS[+(W_ '@N
MU:_P_P"6_MP]ED;_ +P7:M?X?\M_;@-YO;-_ 7Y1@]LW\!?E&&C/LLC?]X+M
M6O\ #_EO[</99&_[P7:M?X?\M_;@-YO;-_ 7Y1@]LW\!?E&&C/LLC?\ >"[5
MK_#_ );^W$[:6M?\9ZJ)+D:'D>*M2L,R7&+(8TCN!F:DX-<L)+QMDR*O/%LM
M9R(2<YC&0TL)1U<83J3KC>#%9@QF4HQBIDOR69+<8:U+_#][*E$O1<$'7_V/
M741TG<W\=9^H?7/:8>J^F[O_ $[JOHNHNI^@_P!GT/573>QTD6"^V;^ ORC#
M5YP^ZUP__P"79J1_U/:5A8Z @/VS?P%^48/;-_ 7Y1A/@ (#]LW\!?E&#VS?
MP%^483X " _;-_ 7Y1@]LW\!?E&$^  @/VS?P%^48/;-_ 7Y1A/@ (#]LW\!
M?E&#VS?P%^483X " _;-_ 7Y1@]LW\!?E&$^  @/VS?P%^48/;-_ 7Y1A/@
M(#]LW\!?E&#VS?P%^483X " _;-_ 7Y1@]LW\!?E&$^  @/VS?P%^48/;-_
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M,5] MY      $)0!^(ZW\K<Z_7,^Q-HA* /Q'6_E;G7ZYGV)M
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M=%<3A]UKA_\ \NS4C_J>TK"QT
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MMY0FCZ8#ATA/C@BWE":/I@!*@"*^'2$^."+>4)H^F X=(3XX(MY0FCZ8 2H
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M+>4)H^F X=(3XX(MY0FCZ8 2H BOATA/C@BWE":/I@.'2$^."+>4)H^F $J
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M?TT]EC\O>I7_ $/3X+'17%JT_II[+'Y>]2O^AZ?!8Z
M       KBGCW2_9]?()M!/GTABQT5Q3Q[I?L^OD$V@GSZ0P%CH
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MSA]*\ O?%$'J<[W-IN_+7.'TKP"]\
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M#;%P8I\V_/N.6T&_9\7/I VP'3'9OPN7]9?_ )JCYCZ9OPN7]9?_ )JCY@
M     #L^_46GN8,Y?MOR+]2D!#K!!V??J+3W,&<OVWY%^I2 @'+]
M     5#[=SW++4_^KB3Z[HZ'747=NOQU^<=BOMW/<LM3_P"KB3Z[HZ'747=N
MOQU^<!X         !S\?4YWN;3=^6N</I7@%[XH@]3G>YM-WY:YP^E> 7O@
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MO7_U[=?CK\X[%;;N4W-EEJ?[?X.)/RUK_P#.Z.OSU'74W=NOQU^<!X
M   !SI/4_<S18Q-G<WD1X/MN-Y6I,LU&*IRF?MP&[<&=S%<V#-=AZ&ZZW'FQ
MY+;\=]:4MOMK7H:UK;=2V[?US4!<;#,\:T^S%2GJ<ZG_ &;3=[?\]<X?EK3_
M +U8/S5%[^Y3O^&OG 07ZYJ N-AF>-:?9AZYJ N-AF>-:?9B=-RG?\-?.&Y3
MO^&OG 07ZYJ N-AF>-:?9AZYJ N-AF>-:?9B=-RG?\-?.&Y3O^&OG 07ZYJ
MN-AF>-:?9AZYJ N-AF>-:?9B=-RG?\-?.&Y3O^&OG 07ZYJ N-AF>-:?9AZY
MJ N-AF>-:?9B=-RG?\-?.&Y3O^&OG 07ZYJ N-AF>-:?9AZYJ N-AF>-:?9B
M=-RG?\-?.&Y3O^&OG 07ZYJ N-AF>-:?9BOA GV&+=JG+;@K)32HC9MGMIV)
M8E&JICH6R'"FIW4]<9*V7=#T53&&P\4R9,5+>CMQ9\>7H>EUK?2WO<IW_#7S
MBN)O4_[6N7^W[G9IN_+7WSVJCO@-J?7-0%QL,SQK3[,/7-0%QL,SQK3[,3IN
M4[_AKYPW*=_PU\X""_7-0%QL,SQK3[,/7-0%QL,SQK3[,3IN4[_AKYPW*=_P
MU\X""_7-0%QL,SQK3[,/7-0%QL,SQK3[,3IN4[_AKYPW*=_PU\X""_7-0%QL
M,SQK3[,?<KJ1@DX9+$RLIL_.:.&2Y,K@QJE+LF<T;S8RY;!CMZ73HLF;/EQX
ML=N[V;[Z4_*)MW*=_P -?.&Y3O\ AKYP%7&UKUA21H@TZ,^:XZ>T&1K;9,K;
M:[U?6I-J36Z861&HMM!^=(+N[UOK1>TEH!A;=Y5J)3=72:,51:KV8FA*ZR3J
MN$RBCJMH,VEDUZI=>DWQ(],K5;L>H+(BLHQX:)1\]D1XH:T7T[Q/*TVR2HO5
M](;4=2TA-Z6Y.X%,S<<+"9AY#R[U,RLG(KH-J20>VGVM[DD-O:<F,7BYQ:Q4
M%XN6=&@W4_!H6,0P5GMQ6YVC(*E<WTW).QXFR+VZ8S)A<ZME<>,^OG\J>FD$
M@E=>9SYR_P MDB6U%X=/;[R:D".L/"M9YQ=QB.S^NM:B53U#*,:YFDP,9*Y;
M3(7R9V:V$ BZRKK2T%*LS]7JV(CG=QDJ0P.$F2+A:>      (2@#\1UOY6YU
M^N9]B;1"4 ?B.M_*W.OUS/L3:    (HGC^9*7ODT>_T;4AQG;>U3XJ?,.3%/
M'\R4O?)H]_HVI#C.V]JGQ4^8!Y   :KSA_2 T/?*E/G^EF21M0-3IGAJ=W_*
ML72 PI?BEEHL1*:\OM9N.R$W.^E,RNN^/EZ.71E77 ES$RRYM+RI"^9-H9 F
MB)YE+4,6'(<4%;!T>&[;"WHJ6V]%6E;NAIT5:4K;2MVY3HJTI6M:TI6[=K2E
M:UK2E:4K6ZM-VH>0  %P&S,_$R5?[9(GT<Q"S@5C[,S\3)5_MDB?1S$+.
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M^9*7ODT>_P!&U(<9VWM4^*GS#DQ3Q_,E+WR:/?Z-J0XSMO:I\5/F >0
M    7 ;,S\3)5_MDB?1S$+.!6/LS/Q,E7^V2)]',0LX           !3YM^?
M<<MH-^SXN?2!MBX,4^;?GW'+:#?L^+GT@;8#ICLWX7+^LO\ \U1\Q],WX7+^
MLO\ \U1\P       !V??J+3W,&<OVWY%^I2 AU@@[/OU%I[F#.7[;\B_4I 0
M#E^@            *A]NY[EEJ?\ U<2?7='0ZZB[MU^.OSCL5]NY[EEJ?_5Q
M)]=T=#KJ+NW7XZ_. \          Y^/J<[W-IN_+7.'TKP"]\40>ISO<VF[\
MM<X?2O +WP           <=3U456M-E:YZTK6E>'S3[V:5W/^^1D<BL<=/U4
M7[E8Y_E\T^_3(R"<?+>WS'6V]'?_ %KO[U?.'1W_ -:[^]7SCU &+VZ._P#K
M7?WJ^<.CO_K7?WJ^<>H /;H[_P"M=_>KYPZ._P#K7?WJ^<>H /KCOOZ9C_E7
M?_7M_P#Q5_K4[X[378#5K79 Z(:UK6M:QTZMVM:[M:_];$A?EJ.K(Q_A,?\
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M8;;LN#H^FX[:WVVTK033M4^*@Y,4\?S)2]\FCW^C:D.,[;VJ?%3Y@'D
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M %<2?7='0ZZB[MU^.OSCL5]NY[EEJ?\ U<2?7='0ZZB[MU^.OS@/
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M654K+?E2U,@<MJ34#-E,9FRVZ^W)2^RTO!+G?3V_BZ0!!7KD(H_3WCR3RW_
MH>N0BC]/>/)/+?\  H-4Z@(*]<A%'Z>\>2>6_P"!1\LVI>'RN.[.<6G*0*X[
ML5,QU1C.44X@5MRYL>"S*</G667)DB],N7';D,F\^$OAI=T>;+992MU GH
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M"7O@:;-I"INDCIH/:<6U+2$GNC5WH.C";%MZ1NUT+$PD;5";:#C5X5DQIO\
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M9FG'9S/:7TB3Y<D$PZ"S?UIQVM*+?QQ@\G18Z%QZ'(^SH**W4@Q))E5<<YO
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M1E'DUS2AJR!+$E,Y(Q)1=?P+3Y*N=[&SJ4N.==::$K/Y[JK/;K<..(UDMW$
M                            .WVP ! Y/3/I_(R,JR\1B!AD9(7%XJY5
MQTDD F3.+CK3\&-.(/%;+%K,2<KO4BGX<! F\E$F9<Y4D7+%,"MC+E\&/'5M
MKWT<:4HG8VG[/&.G:'8_,R#K]V?['>9MGL%NMXXX6>?UDHC],-L\;2R)8S5'
MH\W*NN0L1PY<6 BJJ.4R2M+W68:8@ +,R6DO34G'F"LD83CXHK1<4Q)C$4\"
M"7QGT$AA==SZL*VFJ?[=1PW/N^K[RVJUY_I[YLQ/'/7(Y<&%4QXOBT&:*K#3
MN.UTK0-E-/XB[TUZ9C$8M0U<Y4J0WAP@OI&5J&4S+::1'>^*5=CB1;[>M2LO
M7Y5(X3RF<N7)> !_;<.C+2:[WX^Y0=.G.'7#(LH,.R+)'>JNPF\?<K[CS$GE
M$FUINQ6,$<AM>2:HZ<G(N3$I9#.3,B)Y!&S9;TPD5*8IF8,>LJ,6]C:C";B<
MV$# =4#]""=COIT]153-YY34CQK/DS'5%343F7(8/**@8,G366M+L^>_H;>A
M  S4             &(.9@,EYJ+15W8UD-Q*C <%'8R%!73RYTVU'/:0-I5'
M @9\UEUZ6L42E!12^N!2N(U5-45 A7)U(>-8<P $?Y-->GTPL-!Q7PM&5B\P
M$-V-AB+!=F(1119;=?F3/E?*&U#94EAS-Y*>F0QER.TBDWE"SCOK9<LXSMV+
M%6S%B&CC2BCO&*) 1].D-I#W@EGUCJ&'6DQ^VTQ=BYA7U.=*9S&4B*?@,MMM
MIU5%2N14=+O+D4*]34KT7"0N4#E<X '[E+27IF4F,SXP,P7&5D>,!85G"QV<
M2:B8F-]HJZWA5RZ^9;B<FX2F!'QN0HXG"1<Q,C;@).,@O+9!<+GR:LH8#%?F
MUK@"$VSH#UY2NWXN921(;CTYNY+77010B> ZJD\S::[&RVG<-N/J',8O8Z"B
MLJX[<5ZMWH)1%L=4=8RV(A: !8@CZ7=.Z)B;N%-AM@8*LQZ+LB-,WD;Y,VIM
MU_.5#S-=<>B0K'+3"H1=*@U3&9I9%W <L4\32R5:Y<SB0-Q.ICB9HJTBHKNB
MM^HNFN%$5YP6VS+-AMSH\=ME+6HR:9TZHJ5[<91X@GE\S?1BJDLK*DEIZ?=@
M+(JBL*QY(QD32D=S9P /FZM$VD%ZL1A1:[=,\(N&.(M<YA[QLQU6.&N;:[#=
M9G.=,'EMIHV1.J1032KD5E;KS:FX2^!:QJJG@5L1S H&\>:1V5 \-QT\W7(+
M%C=IM5Z/LVMJ;M<2*E822@MJ3E6,3A<Z@8NQ[F+$=="[B++#G-%<>#.XU,DG
M'5O(>,)I#(6  ET             $$N_3/ #[>V.27C$3%<;WP9D QD7U5"*
MF3"F9:>6AMI&E\O=;U"Y#32-W=5-0TX"JD8;)FW'G0\A#+CQWV@ 8G.,,Q"7
M8;ZD*D6QZ9>S-4G7J&:SE46:WE1409U;\:'6VC2VFYU)/-T+R GME-)-C"Z+
M;>NM6QAWN9#-Z)ES$<FA^RT34/61LXL;KU0-=GS2K:JW+(:_J'P/)G-8RWY6
M5R2]@CP@;<K1)I!-J5HG,V/V6AIQ=/12)5/P-I*,$\& Z7H:J !8#;I'TQ8B
M,9)F""(P+)L*HMS>BU/*M)**D6:W[E1,5[T!,*%\&(OD0\JX@HCBSI![&;3C
M#F1TMRYBV1=(%5#%\L6CO2G@E-6G.S3M#E9?65\\[5.1<L?MO.ZC+K.M3*PE
M%T55,Z?DS8G&K,K+>UEI<P=*5%E"K:FJIHX6LQX[0 /U-G23IE:*(WFRW(,C
M5+06>\6W(C33<383\N!LOEGD+TIF.I!J8Q9LJ0M,A(NJC,@Z0R8,K-1=Q';%
M4I-I0K3^1?HHTAU7HL<]--,)VN"#%AQN*'EC''+8QGXV6WFX\CP=:BT,^-.M
MO1C#A>=]7JK5*5LL.O3H7=FLN<=MJG0 #:,
+           ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g743713.jpg
<DESCRIPTION>G743713.JPG
<TEXT>
begin 644 g743713.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@ ^1$E32S$S,3I;,35:0TXQ+C$U6D-.
M-S0W,#$N3U544%5473(P-S0W7S%?3$E+7U9!4U]+7TQ)3D4N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_\  "P@!9@)H 0$1 /_$ !\  0 " @(# 0$
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MR%) )-)+*.9^2<!+G2 Z_O2X[U+?BO?6AT(:-,A/RP_);SF0SD(5!+9@;B=
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MHU@UQ&RR70W9J0IH0R+B0VA\ISCZL/D2[IY#%%9'6APBC>/+_KT25?/9.*K
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MC%.-C=&C@8S&[-M8^/PCG3\$T^Z^$[Y3Y@M,M?V!9?.](6";RL#%B\J7G%4
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M;?P],;AZ2.[..H[BP_"3<FC)^ .#[CY=YV#2<)"A8B#P )55\"]NBXVHR!F
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M>>>>>>>>>>>>>>>>>>>>>>>>>>>@CI*WG]&5-+6+'1PL^6CB #AG#H\*7@,
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MQ_KC/[9Q_EGW/GGGGGGGJ6]']%FM0=%<"U(-QHT]'.IK[M*K3]Y,M))>8B8
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M8)KPYN R\K'.(XIJ&_Z5.8]L0ATTYCUW;*3%#."38D4,O^90RT\-2#&5>4Q
M2\H^,NQ1WG^X)Z<(^ K!FX /Y1OHOEWY%-<P&<Z\_*X+DWH,SE=U7Z]6R[Y>
M.@^4[J+'CQ=LLHVH.TB;<CTJZ<--OF,XVQC.,_7&?_+^/VSC.,_OC.,_7&<9
MQC.,XSC.,9Q[GU5KSN2KJ[N_C:OCBOOU8:WO<=A M/%7Y,.2/],C 8YUMRT2
M FS(S"FDO _G->A)8%_CQ7165=9(\13[76"?2>^MJ<?QCZ?V\\\\\\\\\\\\
M]2RA^:2NJ>L.Z;]F9X>D1OJ8IYZG1"&C,RGYV/-J@H>$JF;1)/QC%O'??R<S
M&+2,7^4O'Z?Y8HGE[NV>?;;ZW3\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
M]J,ZWI/LJM;A-^H>+=N4WD_8P_1 O<)'T^26@+SX36E*&[F9<PXH7CVA&(1=
M.[PA(:E)Y JCHX0,7<P<%4:0D\V_&X:"]G!?4_4_3UCR4J2V[\8MS4(-#)+&
MD,YP/?QE>9#!V@K(C.0^,-%B6,CHL?@G4&@;K:ZL5'4J^DFT?G*:,<@NJKMO
M]QMMKIKG;;.-==<9SG.<XQC&,8^N<YSGZ8QC&,9SG.<XQC&,YSG&,>J?4?=O
M&U]"UKG--=-TE9051:"CJXC 1L(?EQ6M6B+.8DEG9D1(N\0\$S1CH"9D%7;U
M[HV381SIYNKJVTPKM+]77-65V0,I/UD6L"F/A990>GTD$9"-EQZ;TCHZ9_)R
M$?FV480#TFX@IB'GF+*;BV"[^!F8:=9)N(>5CWKFBGQL_JS]5?)1^M_T]^HO
M^LKMW[W]+?FGY+^3?T'YF_27W?YS_P!__,_TA^0_J+[7_<_U'^;?E7_A/X'V
MSWSSSSSSSSSSSSSSS.,9QG&<?7&?VSC/\9Q_;/J.=*\-!=W&$5>E:FA7S1UN
M(0_Y(&=,U(E&IE+N!07_ !S:NKE#Y5)0,Z#I=:0UPL\K"T&$DWB=EWLM7,]7
M9BJW+&E=TNF$9/5?B+Y7:AKFO9Z\FKZI14^:?CYWB;L9J41R\>N(A)45;;2%
M56H2-LN$E.:[ED&ALY=YSBH#:Y64>J1M/*F+'/\ @NUP?COH\KG#?G&QGS40
MXCZO-G^7DNT(<[?<0/&'2!2YWS^+MMG&(ZI<]7!.[,E>@!R/V RI=U>H]B2M
M';3C.,_OC_U_^;./\\?SC/JK7F!4.4W?QL46D:?INSZWN.P2/G =_4D=#?KZ
MQICG:VPXO@?R=XR<NRO\KITAL$J_*HMS'NF.(/\ /EG"K*+<M%[4X_C'T_MY
MYYYYYYYYYYY[7KS/!77'=O?)+,'K6PT:F(#3E=:B7),M.;A#N*C>9QV/L/:M
MD9!=2(09('J;Y$JQ HMTE";#G>1U4D,J*9V%>>>>>>>>>>>>>>>>>>>>>>>>
M>>>>>>>>>>>K=UK26W0M$%]7:PX>58E'P?.J MC[/M:TLA$)-!\U5K.RORUC
M*O<U_8.@_D4+/L0I"UUB)1=64%2^)3?"LS4/EJN.H)^_V=JVQRIS;Q=7E<5R
M45N/"M.V=%6_95NNR"4&7+%R3D@O453BH;488T@G;T6"\($1%,E$JWFG>@8T
MA58R?VF^AOH05$SVDK0 #FPYBJ!*P0R:KZ=L(<)H$-(QAB=MLB6[T<*25A)P
MT$1+;S&C""D'4>\W1E7C3\(W5?;-M??G"Z^A>DJUY5[(Y3MFXG?2O/7.EX_%
MV9ZWI.C(D-V@WYP+.H0F0O>BKPS5L *B$[,4=7%>#QS/F<,+C4C,TS8K)P6Q
MZ6J&J\EL:IPC1&_E4^54^U>9CZ@!N8^%4K0EDVCUU'-K?%8'HXVGL:I,6SQP
M](H2C)VMWY"SC459':!E@=)5DYRXB\9[#XC2NMCN-^0(VJ$CFBZN"WY';B(Q
MHB(9$WE)62UF:4YP?S&5'-C[9,D630A7EH^&BI35%K PK2.@1]JR&HV'9H;=
M_////////////////8'9U75U=("559;00+V/7!Q$.($O!S2$8$0N20[G.NRL
M?,0TF@X9/4,*:)KH_>I95:NDD7;51!TBBMIJ N/FBYN::S,ZET!2WY'/C:,X
M!Z.'O+9S-2)OU[0H<OOHI]>?S\EDLRW2X (Z(H20S5=@$<9T: .XEC*4_<)[
M*18G7+'SX&[J@8:1K;F^P+N4Z"JNQ'$X(\5=HS69-N16S( C7=4BY,ZT93K"
M(FJZ[ZJ2&:N=I:'+X@;F[Z%8.5,<#0[98Y8@BVOAT1SD47%T%PA;T%.P$;!\
MKWI9MJ&$;*9D_P S(X8XY<NRC(^/&OP3)RRS(M"&S8F8=_FSE@T_)F$A^'<*
MO_PK5>X^/VQC']L8]SYYYYYYYYYYYZBO/711_9_8?R!482(#J87S.7<V0E=+
M1D:X:SJ[.U^>H&SRC),_4D72$HNF223A.*W;,8S5G%X2:JINU-<NM[U>>>>>
M>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>K+V$]M5ASP?J4T5S0 :KZCL?O88O7^
M+7,*Z$9(JA&%A'X16>\?+H'1L' C@AGQ(>=0T^U<SS%DNY%B])ML*S.O/AWM
M6RNB;VJ $K_^KMI5 *\;-%.N;?LNI2BMQ$5ZTA7%710B) !.4@@!@U/R^/=6
MW,W6.B+";"Q+,0%NV3H6E'4I#RVZ;V%V)6]>V\%$5;6L"A]EUX7Q^8HJ!3X:
MAC /)8S99%SF/GAL@9R$/+,_Q#=NXPW?,UT]7""*^FNJR*>^OS#%5UH%!&*T
M$:_#!FO/R]W$Y!H(8A8L2WC)!OLTD&"P\S9)13AK(-MU$)!%PU5T?HJ*)O,+
MZ;[8R *PKFI1O<3K &%*^&<NW<EM!!L#&CD7M(/M4M7L@HSBFS9%5^X30035
M=JZ[N%$FS9#97"+=#1*@7QNN29V6_)0N7Q,)"3N?DIMI)2.'9]Z3Q6D4VH/F
M-L,NTYB1'Q=VH^E1=&&EIJ/VA448*;?2, S?3;*,;SLGLZ\\\\\\\\\\\\\\
M\\\]QG&,XSC.,9QG^<9Q]<9_UQGVJ;NKXJZJZN:GQQ7$JA15^GD5 ,34SB(I
MV_ +N2"UTWP.TZ&KR&F!A4VFP*1;LI6I;P$R (Z6H4BC(8BINWAC:-6AY/\
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MM]DT%-M.^U21PEA+5-/"/V?IJGKKKA/&O\XQC7&/LXU_SQC&/I_P^GO;]/\
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MY^;N(]I^3,)'[APK(?A6B]Q\?MC&/[8Q[GSSSSWCG37.?KGZ_P"F-ML:Y_\
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ML4;>X58-DI=;]+CT@@-?6><.E=/P_P!B.V188T2Q,UM4I3]]A<A7-WU=7UO
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MO0RQ2R H*XN=:!M8E$60Z[U@;8ZF8@SZIH&/B)8AAGLS&J_U4JEH4S^JS%E
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M $%Q59EL4C<Z0@P#P0^DR(!%ZDK&$=L!P"AN8JSZ* K8/J<V4A(W\EB9OKR
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M3"0D[GY*;:24CAV?>D\5I%-J#YC;#+M.8D1\7=J/I471AI::C]H5%&"FWTC
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MVRDD"-X6'6FHPX&P1\_OPO9"Q0I)ZQ=F1=5F<5(MGKX=>%"CX1W9M_T<4O\
M(?Q+T!+Z"]7]*U;)G>SK=FI5Q)/9KBXF;E/.,;(25.6:W#K2C%L;9^SE-\(H
M;?;QMICZ[:[8Q<S[>O\ GG[/US],?:QG3.<_VQC;&/K_ .7U]Y>>>>>>>>]+
MA31)'=53/V4TL?>J;?3.?LII9PHIMG&,9SG[.FNV?IC&<Y^GTQC.<XQG\SD#
M0UP6?\-A,("M760K9]6_(K9_4250$022@IL?@U<?+*4]7I1,(-'44/R<HXL"
MD<)$]>Z(,72!3(OX",C_ +Y^\_#I7RYZASHU[D^0;M@*""20K GY[Y<H:BFY
M"W?5VK=Y?2+&\K+-I6-;&\;$RP^.,R2XQVKHTIFX/6+6(HHU5;[N64(XVV[S
MXL)XV*%/D&(+'KO6ICF5^0ZQG))76I9"G.!9[CG?EY%-I^K1YNUAIS9XS2:R
MN[IB@GJEO(;-%OM.FZ^^VUOSSSSSSSSSSSSSSSSSSSU5KS%^?9N[^-9JV2/$
M/:H?<=A2_,D1F9=QOZILR0YUMP?,XO$<@U70G_P-*RUC3GX!ZNS1:XC,RJ:R
MCEBBV6M1C^,?3^/ICZ>Y\\\\\\\\\\\]KUYG!KB'^WODE+SB*+6=6GYIRP[I
M.1F7KA<:EXP;YG'1\^4#FBCU=%BV9'"#UG.:-VC'5Q,Z++JZ.%-LK[;"O///
M////////Y_GVHWY9N'770E!V';7/$.8A?;X."XA:ON:B25>N;X?UZX(XAS9M
M2LB&/(!".L.+*Z^R8M0ZL[-G, F+#>0$PQD0N>2;&$7JRX1K+O(6Z.E9;C&F
MZ%IRF(;GIJ&V[(69SMWMQ_3UL60B5#>M7RJ'/MW2SLMWOT.#H8N6L:PP#8N$
M-HHU1"RVVK+G8X==06Y'_P!KY_\ =P__ )57G_M?/_NX?_RJO/\ VOG_ -W#
M_P#E5>?^U\_^[A__ "JO/_:^?_=P_P#Y57J6]\X^7_//JOYCCF;->_U+J7-U
M?[+G^V3_ %E_HA^NHK^I?Y#^@_\ ];'Y%F)^XQ8>*8__ %N9K/)E@#^LSE/'
MH+^.HQ[@$#6\G')_/-.6GR"@'5 U&(:1Z5Z\J&H=[GUDK 4LZ8Y>_P!J/FX\
M(]()[!.0Y*T!B#?-:CCC"/;RHV6S5D2MFPS#:>S[(Z[@$E5;+^+?I)-%';&-
MGU*79R!<;+;3.S?'WJ3&;N^I2Q?3'W^VFVB0MNXQNW7VU1V;:8=;>3+Y.*PC
MT=UK/YP[[IC5)/"KA4UX9Z'*HUII]$-E,NB2D!"WQ=)-OJJILY<?G66Z6C5P
MIE7.F6^7'VP?RV?'!,/LQ<AU]3X!*Z[:I[Q-RRTI1,NFKO\ 9QJ@M%75#@#]
M%S]O.Z.S99#1;1RW>-M]-7#%XFA;"O.C>?K=3U6JB\J=LY#;7.^BU>6>#&J6
M^F-<[YWUW&IZ3UVUQIC.WVL?M]G&=L_M^_ID^WC.?I]-_K_Q3WQC^_\ .=?I
M_P#'_A_/NMF)*&C(U](3KZ-81#)LHYD7LHZ:M(YHT3Q]55WSEXHFT0;:8^F5
M%7*FB.O[9WVQ^WN8E[$2D<QD81U'R$4[;).(Y]&.&SN/<-%-?JBLQ=--U&JS
M;?3]TE&JFR.VO_[/;./1A;_/-"]!0J8Y>]+53<\"CA3[B(M2OA.P&#;93&<;
M*-&Y7$RNK-;&<_:T7:?<+)[XUW34UVUQG%+=_BYJD)W;N>6[TZTXT79[*KM(
M.B+Y()VJ4G&VVVZ6,<_= M+NHAFTTSG5/9G!5[!:;H:80T41QC7?7WI"/RJU
M)^&U'K;Y)[%@&N5E%HVX $ZY+M-VAIC.=$E[,J!S=M724@IKC&,*)4 ',=E]
MLYVU;(Y_[/T(?(+9-=JMV?4_ G7U+H_;<?CK"JH5@.RJ?0;M_M_60TF.9I8P
MN)A&[8TVW_%%M#"JB*.=%';=MC[S"<^TGWGQKT5))C]-]*5 :&.VVZ:]=HF<
M7"VE&J)_MNA-543JP=D0CG3/UPHUEQ5DXTVQG79/&=<XQ:"8GX0>8[RD]+1L
M)&I;IIJ/YA\UBF2:BN^$TM%'<@JV;I[J[YQHEKNKKLKM_A3QMG]O=FDJDNDF
MLBIHJDKIJHFHGMC?11/?7&VF^F^N<Z[Z;ZYQMIOKG.N^N<;:YSKG&<^SSSSW
M'TQ]/I_./^/[_P#S^OO#;&-=-OIC.?VS^V<YSG;/_NYSGZYS]K_=_GZ_3/TU
MSC/T^FKGXR/N?U!\D_X<[=62E_UF5U?0N>KBSAPNI_17F_[X?V5"XF#'ON@5
M?[P";)(QJ4HW;#"+<F<R12E-2CW:5YYYYYYYYYYYYYYYYYYYZH/0/-\W<5^<
M.V]&$L7#1O*EWV5:A!#O6;YR]+(\XYDN>BFD5$.&N<-6#QC+6:PGG"\CC+96
M/BW35''XQ=OG%O<?MC&/[8Q[GSSSSSSSSSSSU"N<^@;$LGLWY#Z4)W$0J#\X
MF',L-6B#*)092C9E:/.8_917K-22:FRTPJJ3R+E5@HXT2RQ99T9)XW3TQMF^
MOGGGGGGGGGGGG\_S[C&,8S]<8_?^/K_G]/\ +'^F/\L?QCW/GGGGF<8S^V?_
M %_^;./\L_SC/N,:XUQ],?7_ %SG.V?\_P"<[9SG/\Y^GUS^W^7F<8S^V<8S
MC^V<8S_\_>.$],8^FNN-<?\ V/\ !_\ \_3WPR,1%S#)>.EH]G*Q[I-1)RQD
MVR,@S7253W2536:O=%T%4U$M]T]]%$]M=D]]]-L9TVVQFJ!Q\?/"-F++N[!X
MRY8,G[G9?=:3(N?ZIDI;91SLXW65Q+*BGYGHLHJZ<+[+)N]5?Q"RCC[?WV?O
M,0VW^);AF%<*O0"N;#IEYOKG5)6@NE>GJ(0:XSEQG&&D74]QB<(AKKEVZQKI
MK%Y2UU=.D\)_8<KX4UW]^?&89M6E$$ _<GR$]&<]B%P+D=Y40I9P#U@4-6VX
M?,Q]96<.53UB$V,-71"5=8;MO,&-5DJ9?(2$%,[%P6.2I97PQ'(\_'3R'\BM
M/C%Z3-,W,,\\T8;W4],*/YYZRXSK[,TWA%@$1BS UVK?ENYZ+%^;H2S['CR$
MJB:H@8G#]BCON=&(L/'!J30.=AB)9\M ;JOO,TMP5>[=+?7&BX9?5]<ZS3E/
M[]'395(<-:0OR%14^XPJOALL>X3UWWU0_&;_ ''WKSE'M#JL5;*KVS\7_3S9
M)'/T6E*)M+E6^X?&,:J;**-X]2Z*OL1VEKC&F--&]>[NU=OMZ:-/M81PX9^5
M#FZ ;:*VT#]=T(KG.^%OZR<1]6#L,URE]UA79R<0-4%==ZHI[*YQLZ2+U6F=
M$E%]7&S;[M962 /Y)_CZLUPW9!G:',,M-.-]4DAU:ZZ_A"W553ZXU15%"&<A
MR=LOM]G./N%HI-;'T_?3'UQ]91M?GCE?K ;:M[EINDN@AM1NII%N3D'#+*;-
M4U<9Q^(A)B1CY9Q&+Z;9SN@^AY!HY04QA1!=-377;'X:_P#I5?QEE]05OS 3
M\L39-'<MMB,D&RKG\OZ?."(='KBEMV:H<5U55UZ6K-MTM)$1_/H>9A:E8)-A
M6,@LSTI LH9S)3+?].'_ $>:G>@:-^)SE\)Z,,XTQ+%HLG*A'$4=1%FLABJ"
MXD?3M9B3<['Y>?@)]M$CCI)=CI!3DI#P$?(-!:.=Y;06B2.['SSSSW@I_N;?
MY?MG]_\ W?\ [7_\/^]^W[_M^V,Y^F/:N/C(^Y_4'R3_ (<$=5LE_P!9E=7T
M$7J LW<(*?T5YO\ OB#9(+EIP>^Z.E_O#ULJC)*RCAL3HN"9M&E*LU%LMI7G
MGGGGGGGGGGGGGGGGGGJ!]5A-NDO4OQJ$8!&%3T"K_I.XI^[WL$\7;P<0$RO&
M71 F-NS)ND\;I/X9Q9<Z&Q\>@Y;OTTB)U$.M$$ED$W2%^\?QC_3'N?//////
M/////57I_HH4L[HSKFC(<,=P1)S.0TK"%Y4MO%;-3AQ:]/Q-GPCIEHS1TD4]
M1^'DD8)?$NJLILNAMLRRFSSIIBU'GGGGGGGGGGGGGGGGGGGGGGGGGN,XQMCZ
M9QC./[9QC./VS]<?MG^V?W_U\QC&N,8UQC&,?QC&,8QC_3&/V]S[C.NNV/IM
MKC;']LXQG'_+/N/L:_3&,8SKC'\8TVVTQ_\ Z9U]&UA4Q4-M,<Q=J5;7-EQF
MVFR>T=8(,+&K';3;&-=M-FI-$RB.VNVN,:[:YTSC.N,8SCZ8Q]*;3/Q+?')*
M2&TO$\CU-6TQNIJMM-T8PF>>IW"VNVRF%TYNB9JN9-)?[S;[S*R3K13*FB2F
M=L[HH[)T6OCXVK4I3J?G/JGEJ4ZIO 5JT2.@*>I64[8E)JP!34I)@0JQ+UD1
M=H.;7$W@$?,0Q6N[M!&YS5A3N.*#I$"F6[Z(D!Z0V(?'?0%B<\T%+P-H1(8%
M%5BW;>U[*T]6DLM/UI1+"[+,G; CZ?")Y6&&TYQ@*(2WXB=F(\:'H.3-I<K>
M#D,P'UHQ+U[?///55[4ZBB..N<SB]I(9?'$G#2 *& P%&/4HU^=VC;1^,U35
MH>E(*-WV\:UGCXR@&DQ+MXR7<PD#^:S2$/*J1^L>XQ'GSIHE-+LZ+Y;N&&&(
M:Z>=(*GSZ4F IQ)Z 1[5EYQ!4X#RL<9DCE<BAW<,4U[88,4Q;]S)MT7 ]$D3
M65T1*=8."A?XUF$Y&%'R3M",GT,97'R66^YWGM(AA!:JQTA1/,\C!16(V,56
M9ZY&(%W&"VS["GXF8VA<S,AHE(2#I+3:!YYYYYYYYYYYYYYYYYYYZB_3U]6!
M5G3'QUU>)N(E(5Z1Z(MJN+,2?Q2#Y^Y&1#D*_;CADH1\HIHK#O=#2O1U9R\;
MZ*J.(U-[';ZZHNU%-+SX_?&/],>Y\\\\\\\\\\\]4VFHCFEETIV))U5)X=W[
M,D='J=2Q^'Y,YVBIYC340RJ%/9E+):#\=^,JG2,=XT%5%6[K&_XF8SI+;*Z8
MMEYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYZB/R0<UF?4_*Y#7]9*0N
MMIB5CT3>U8M21\M&#LV=<ZW8!W9!B4Y(()+[1T8;Y"'(:O+;HJI0VT\E,*I[
MIL-L>C>A.<"TXZP[:ZON^N-1,1Z0J6@.:06FCS<5GR!:I:@A[.E3B6M"*&9H
MO"<YL(XN<G@6 TV("#3]$"<?(RBK98H7AF,-UCR-V=QB1=%C?$T!P6,<ZVA>
M,]>8-7)$)W"%/@/>?K6LQ*9$(L=JAHQ!VD<I,U\]G&7Y0U0PLX(5_OF^'/WF
MRN34^?\ S$6O4]:6?(@G!]7/[$ Q0V>UJ?M.JF!R .B:%9RZX:8,<HMMF9,-
MJN]HF<:[MF^R$BU<)Y13QC&OO3%6)\Q,G;YO5*E?\)QL<'5[6QXUM!\TZIT
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MG&^NV,XUSC.,1T"6)\Q)J47"-NZ_X2#4*HL.. XXB)FG5+:%M%F_K4!L+<W
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M26(0=2PJ_D6Z#9O(/Q>:Q(C[U\W;H-WCF-5<H(I)*ZIZV2\]QGZ_3/T_?/\
MECZ_3ZY_RQ]?\O\ EG_3U5BSI>0JLL)(VY*;L80KF/>.51^\A-CFV*R>0"#%
M%YM(&Z(,V=V'4[IC_P![_/'AF!)5[&(-]'2=DO4U%M6M5^ZOD05HJLZI*^:V
MH+=+FP;!Y3?3)IK+?J2K1CGWH/I6L:):V&VG!280;$DV>N3IY'4VPC9G$=-+
MPQ6:N5WXV 2\9+1%>/R='E>_[<]X"PV%/.7_ (Y+MJ:C[K:R+>5=6#9TA/0U
M7%M_E0:1(S<8/A*%$"=T"#B&'Y. *W-@3@F<13]\,MY4:?LMUFF^%--=]<XV
MUVQ]==M<XSKMKG]]=]=M<YQG7?7Z;ZYQG/\ AVQ^_O/SWCOG?&NV=-==M\8S
MG37;;.FNVWTS]G&V^-=\ZZYS],;;8TWSKCZ[8TVSC&N:;M.Q8$*V3C^H (JY
M<D,/F45@M/EXV<H66D))]F-B\0?0@RHX (S2;D-F[& B;6S5!M+/';9FB':N
MUTD-ZCB?R G=J?)05\C!-B\U  553E^T+:GN< Z!%^J;:C!H?=."ZQJ G)IP
M&TP7UW&E;II!Y?#:-B.6,4*E)#,*LVTM"(L\2H/Y.3VRFO$E\%@T$QO,7R)W
MU;E"T;',$)=I8==.1^&MPHH(T,R!W,O(8T;WN,4:6NI8?AA@>P!2ID!,&$V2
M-(V>D)3==C.-M<;8_C;&-L?Z9_?'N?/8F=2A7"")!+@XJT-RR.C5W<&)/B5
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MK@?FR&I3B)'!XS/ID#:VNS0A]7M:$15-%@C+YE8A24FF&8><D]4M?537LY\
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M*Z44ZA+>N$4S:/MBPJLB*6L1O%G4_&U]8-<#R<]@=A3BN&2J(D3R \L2SJT
M6RS!P90J<DZC8L@:PJFT7FK4K\-7&,B#.*S01NV)!)/D[3B>='(^^[)5;$?/
M$+,3D[7(5-.YB6E91UBH7Q).I5H[1?-MH:(E7P]+(SX^X5B]Y5,/C/YI/17I
M(-*_ZHS$1UJTIME?2KFU"C:9-F]$C<")5_\ :GOO,S$,NC!#,,S('D*\8NRS
M9INY(5W[IV]6<5M[\^/![9,43'5$09H17+=G4/QX6#=DS_5*-$GNE<<67'!&
MK63"7<RXBXD1,(<.;E#4=W&D6CB;+9ID^G-_NV^)%A9XV^.+GJS1J2A3]2RB
M:5)KV ^DCPP?'SQD56/:]51D3$U6_L#,(T8#)"*5LU'1A8/J_(ZC5\1,#<3/
M)B2\VBO)NO29_&_15B%D*=FI7>\^91PC=%;2Y(YNHN;R9A5-^#P0/V+590LP
MW9Z+@KW:N B>B(R&3@WL 3P69R+DT'4P08EK4T538ESU3-742!N"-T$5""C%
M>"*A:0/RDBU&Q&+;0T&A*3\EG+R27:1S-LUT44PFDDW01;-D&[5%%!.$X+AB
MA BCXCG^K(THI\#'+;E;P&E*P+906(8*Q9FSYJW'\HSF]?QBCF,<%D_(MW Q
M+(20R]$U- A_$NQ/3,3O,]04B 4D$/ ,*C%,1<R4G9V4O)51%_*%YU:!3+FU
MB%Q&MHV:LW<N7E4]+R\HFU8,8I+9YEA&1D?%-VK!"$*NX8IJF8)[75<2-C#=
M#.';UU'\XMSAZYI492DY!:6DA\0@'C1<D%P!Y(NG:O\ 2N'+FU7,V3MS!1H8
MR'5<P_N%N#.>I$0[% )^')R8,[MF28@Z+'9\QFGK DF2ZOX:K)F0'LI*-7(0
MLH C(J/M-1=Q'I,$QF%D&::4NV5D'$<"_P 9M!"FYU-L3?I!_8ME#?/@T96]
M/=%V7.6;-_[,1?+'%23"A!(RB[)"9AI^;E_S#9G#H1DQ#2<J,/HK8<EI:+?9
MH-?'[0(G8];V_$(F2-G5E.="%\28Z$^&KR;.NIM8G6\CDLBX^+9#L\1F6!\>
MPCLI#-X@7T@HY$1B(-!-=)Q">GP_<@QL'0D.';WK6;SG<0GZO#2RJ^A;4K<Y
M(:6*R]4\)J1LPQ$)V*G+(JV7+%UIO$ 4.7CZ&?+N%QR8AE'+C=3*KG^*WE&[
MI6YG$\TM$3'.B@D!";WKRL;9,*]KRT4*I;#T769&0#0^Z23CC(*&Q:!$(\D%
MG8\]E1"*BQTHUGXZ&A4XZS?1_,59=3TO(4';&2YW74M)A4K+-8 QFQR>DG5?
M$T(9BV794P7R0;X9E8W SKK;1_HO*.XQ).36=LW#YLZBJR.!*(MA[TS(&ZEA
M23SK^C0SG*^U6A[*Q&#"I09L9LH4<:)1*#-(8749V/8+64F1E.*EI) QF-7+
MS/V(W,=B%G?&7S-;SHS>GB=D2J]@U-05)%FR-D3<=B2KWF:PE;8IV*2PQ30_
M+7HY8[E\5NYJ+RREB%W(OV$^[D(1SM%X[>T?CDYRN3?JK<_1L*6QV=#5&.WZ
MFWL&9B4R6"H_=7:NHN$TB]&OZ+;1.KEZF]R)_E*TYH_>?G*KW=;[>O(M\<O.
M8=T&9=$0.;292]BD+JP+ JE.W3G3G(SN&0AF8]*7<0<^(R:-7/+6EHABW2E2
M/4?192$DDD2N8;<I;M)MOC5/_%]S91Y;2!8#RMW_ %YC9VU!\VC9!=YT1B-(
MAER0\1"%%?!H_*O5V[\'C&4'&)!\$:J%VHFU8QT3$N$H*&@XJ,Q9M\0_'T<(
M 8)"L;7@!<%YYNKE#$?"6^8L%B[GF^910B-JQ.I--QF5)(= K4_4X[(*/6I!
M#26-V>)AU .'<*XS]/XR.1EX(F&B,+*#6#/>4 /C*RXDQL@[FHNS:4K)N2M0
M- [C,3;6,FS@43,BK(_8>K1H70BLVLO$2+%=C$*QTS<Q\J ?+ G(C B8718;
MN768XD3>^KD/+ML1Q$0NCMN+BWZS/962E6XH),WSUL/0+3+9DV5?RDJ\U?3T
MQ+RSY_LC4TM<-ZW5*Q4P0$?2-3B5(W# D4XZF0$NK(&;ES48&' 2\3VA6S9@
MA8)ZDX<-4TWDJD83:,NN^15:IM*OC?Q)<HCU V/S,Y?WX95%8L!! F(*Q^B;
M5L-_7U3"\Q%3PY3E2$!?/2TS6M:1$G"12J<(-.FS]^WC(N/F9F2CX>(:L)2G
M/CQY^G.E=NI\.[<@;"G=05Q:HZ(7+8 A4M^3M6L6L=615>U2#LO' MEDP(T8
ML6T')RT2EHNRCXR+G&LS$1<='MHMCOB3Y/B70JHP<W<UC@&2ZM6KZ ;7B>-(
M0&@>SF$BC>@6,LV;U!9F*3,S+/2R$;.'3R6&B/+1Q&S6L7%QD2SRXY^,;F6T
M0<V%[*ULTS*SB<ITH<7>[LTA@;]'2KGAJ_:4.6AML!?Z7(!@NJM.8G-Q\J88
M_4,JL0DBQE)%"A#,9=VRI&EQ6AJ]BJ\%)(S(4&2CA_+F%D&9!8UCFI _RGM*
M%1T>%3Q_/E!%);(H)JO7SC"#1BU80\2SC82,C8UI6%Q\;G-;@(DZ7_!&Z/,L
MR3OBV5Y3;&C]#GUZ^E2)8PEH'8.T;?G+6LY<M77GI6EF!2TIF06<.XQT *#S
MU[#.,LNWA"A>@HRT8RRVIS*)VA*4C,+.8JPB09E0%]SJ0HE]2*4],P+AC)U+
MN,&"2I5JL$.HIR]GW\K(O5UE91]A?!HNCK!MKL(3N6\::KH8%^0&EF"O+-DM
M;*VL2T+16N(8"X(ML$BC$@,19U,S80,-.#3H+UF31V1S\C@FQ(0S.%CT9/M
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M0;;R*+I5,A<L$DW:U\^*NS:K[NH=C?=1QYE 0NY;8%?3XG84,T@C4-.JR*9
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MIL'D$U"ACB#18$JK=C8^N^58I6M8P6ZC+D>TS369=$<M85Y5C5/X;:8<1;2
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&+_GGO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g261394.jpg
<DESCRIPTION>G261394.JPG
<TEXT>
begin 644 g261394.jpg
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MCJ7_ (OJA/YP3?ZHF/+QU+_Q?5"?S@F_U1,>7CJ7_B^J$_G!-_JB8\O'4O\
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M5Q_Y77AQXY(WK5)T2VXR4^W>/"JK#4JZNY_XR)4D2CMG)J)IM+/&UPAT@=4
MXL_.$0>V=QEP5,<Y.N.G P0*U*C=S+ -=*/XX7IR/Y+\?:@+C"9$KB%O<GC;
M$,EHI'+#'1<FD<*K[RRW%JIF!MC,:<& $X0E/3T^:AC08MLK5)$JU,8C6)B%
M24T.@&IE))2@@P(1:$$)A)P!E#UH00BUH8!:T(.MZUVZUO-?*NBT:,FW(0!D
M>8QA*MEH 4$;0W#"4#=.569L!81)MZ #9AAAFPAUK6QC&+_="%O<T^*$4_!J
M/_ K9_9<>*$4_!J/_ K9_9<>*$4_!J/_  *V?V7'BA%/P:C_ ,"MG]EQXH13
M\&H_\"MG]EQXH13\&H_\"MG]EQXH13\&H_\  K9_9<>*$4_!J/\ P*V?V7'B
MA%/P:C_P*V?V7'BA%/P:C_P*V?V7'BA%/P:C_P "MG]EQXH13\&H_P# K9_9
M<>*$4_!J/_ K9_9<>*$4_!J/_ K9_9<>*$4_!J/_  *V?V7'BA%/P:C_ ,"M
MG]EQXH13\&H_\"MG]ERNOJV1J/(^FOS2/2,3,E/!0<Q$ Y.U("#0"+\!- ()
MA2< P[ 86 P.]"UL(P!&'L$$.]6:!]K?_.'_ *XL]L8QC&,8QC&,8QC&,8QG
MH9_>S/\ F"_U=Y71P%_X1>I7_P!8M.?_ +8>)V6-8RIL$]FG(WJ<<A.,4MFL
M_KZE.+7&/CC94>A=?3B5U8\W!/\ D9)+G0OD_?9Q W2,3AQB%9LU:-T/C\4:
MI"DC'C8_/KY)DKZ[HXP&-V(TU!UU:U^W0ISLF7VRI9GJ9"+FT^<T[U,%:!VF
MD@>VAC?'=,40%S4PYI<D,-3KC2"5:I"PHSEI0%IA_;*7;K^/^+6]_P#9GG&>
MHO:U_P X'^N'*YND5_Q:/"O^0*%_]VKRQO&5\]1RR+'8J0'3U$6&Y53R Y!;
MD,&K"SFB%R6PEE5>PT8<Y5(K/51.*L$A=%K<QE-S3%"58D84:*33N,&'B.$(
MM$JT^>>94BY*<4NE]R/BK],JD?KFY@\<ZOO2$L$B?8H<R2E<X3F <@J(F"()
MR)4<"-6O$W2*'I'1*@?2%+,E[QIM-7*4BCD^H_R%M?C^\3A34UA2>+O]J27I
MJ<>D\G4NPI%#Z"1\K^4]G5%8EVMD&?@.<-0R=%#6-L2,+D\-1[*5*"V)<O;G
M,@3HVO-D%=T DJ^QFF31^Y+M>6+5=OL/=*VLJW9I:[&_O@GR(+T-D%*;%?9&
M_M4K9D+,XL:TME<4T>6))4I.$RH5P=*5>RF,T+ZIO_%I\_\ _P"#7DG_ $1R
MO-WF'_>1H_\ =;=_]$1G(*2C#DYY)1XTQII)I92DL(!F)S#"Q  < !FA%B&4
M(6C A&'8-B#K0M;#VZRI.L*JF!?-NW:.4\C^33M&:;XQ\%[4CJM[N64NBAVG
MLDN#E$WV0[R=O4*-L;VBLIGIN*,\GC:AMU&DC>:Y@C+0PG+>_ MPT+7W?E^[
M[7M_;\VOMZ]K/;M\_9Y_S;[/S^UC*U>H_P#WW@=_UD7%?_6G^63$_P!Z*_Z,
M'^KK/TQC&,A*JOX<<B/Y6VC^AFI\FW&,8QC&,8QC&,8RN3JZ_P#%H\U/Y II
M_P!VDRQD/M;_ .</_7%GMC&,8QC&,8QC&,8QC&,]#/[V9_S!?ZN\KHX"_P#"
M+U*_^L6G/_VP\3LL:QFO-G\7*=MBQ(A<$@9G]BMN#1]XAT?M"NIQ-:OGNH/(
M%B5R>($]26 /T><)3!%CLB2/@8=*1O4>02),GD;4WH'XH+EFH=\\*;<FECI%
M]264]5_5:"'UK&TL+9[WO& E[5-7V3IUJ.RMLA1XT2]\L!PM.GW!PERYP4RM
MY75\Y.+NY%.04"MQ@L7"SJ%OK'/0R3D+'$4O>VFEUD,D+!>M_>QT?GE..%B+
MGE[=H]J+,Y3HPWRQ/T:KFW(P6Y 9B6+V5ED7;D<@C4#;FRYZ/%+R&%E)=4:-
MN="FEN+<6]O=5KZWH%Y:,@"M$A>W% U.#RC2J F$)75>V-RUQ3EEK%:!(H.,
M3E\QGJ+VM?\ .!_KARN;I%?\6CPK_D"A?_=J\L;QD=G57"5%J-]TG-S@98C5
M!72MFYV%(I)MM1PU[?&J2O#61%?9?Q2+4.CVQ,BY>]!8]/RO;,U)CW,:)N2)
MB8&0<$>+C5 +0K)LKE:BB%P7&X<AIFD)L"RQ.8+V<Y8CGJFWH=(CY@=(:VL$
M,Y;T,R222NG.*K$$H2$OB':=QT8>9DAW$#CZ[5U:]6S.!ALZ)WF0!-;X;9?I
M)9[W8*9,E+1M*1_DTV=GE_\  8R4249#&YM<6Y!"%H/92()F1U&8N'FU747!
MZET68P*IU(7).SE1U%(+,LRP;9E#?'2AI3=,:&361)),]IFX\]"B5.00+O"7
MQ:B1+GU2YK$20\B8\9H7U3?^+3Y__P#P:\D_Z(Y7F[S#_O(T?^ZV[_Z(C.6R
M"57'VO4ME65>,?;'A%<=F5PR5E(Y-N?3XA Y1:'>-2N#LVH^7(%$89"(T[S2
M4.;8YL,=1/")=(WQP+5&JW!0(VK5AX(<ZXFQ,B9LY#^,3T='8W$YHHF7)3DD
MZI'-L'3W%Z-3=U:3%K.\C1R=7;]7W=9;$ZF(.Y-\IR=M>B#F%UE,6S9_CAQN
MY0U=;, G%EV:WSJ.!XZUW5=ILBRW;9E9:VX*\@T79E5_0]GE#"F8R7JSEY$@
MCUA1LY.RI5+>SP^QT[DHG3I.$#K9#E:O4?\ [[P._P"LBXK_ .M/\LF)_O17
M_1@_U=9I#RFYJ'4 \(*]J_C;R(Y=78ZLQ#^56''V)LIZ6+,2]2O1,\@M&TY^
M_P -JJLVA]7-3JD8$S[*#Y7(MM3LJCT4=F]H=%B/!N-7/F6VK,FBL.1?"_E!
MPHL23%G>)6[H:X),*KGSB0E6N)\7BES4]+IK#TTW(:&Y8[@A<Y!") ]($R\^
M)I9(%I=_ +&_;]K&,A*JOX<<B/Y6VC^AFI\FW&,8QC&,8QC&,8RN3JZ_\6CS
M4_D"FG_=I,RWG[R!GG&VL*LG$'D\"B!,FY/\=J>FLAL>-JY''F.!W1:3-7,D
MD)1:260[V-=HRF? /S<XKW)4T!,0C3.C8H3*-GIH"XO]1E=(N.,OO/D2GBX8
MHHY2R^BN,%HP%O%!(GS&KC84:VK[GK]CLV9":H6PS%."8-X'N2V1X@/C?7;M
M9S%*DT(D;(03F0.K1Q355;Y7VD-I/<1:8+#["L$MJKU4HD56,4ZNV5<=(Z&:
M1HUS(=5"U3<,#G,7.+A94O2$-T3=9MX<.!&-<F<N9*YX0R)679L7D1EKS9>X
M<QF/B17\!9J;;F%?$K..XH1._BHB;)ULS)02B/3!IVZ25GLN2F11G2.LA#$A
MA#'X_P"-A_$1#JP<9I.T$R)W9+BKF-+:>G=O-,ALB!(XZVN^ZHN&)\?K:K=!
MI-)G5?NQZVNB=PZOGQ&J1)(B^.DA2.,$F<OCB1U>F_\ 5JZJ5!R030TPV"7E
M.9V]2SD+ $E=P^&Q9[>A3OC9"XK8\VBQ$K)GQ=3NAK] IK&I37\B8K&=87+D
M#EX*GDR1W1.#6EWJIVUH;>U2UC=E=K5;C K=K^'69"UZ]O4M*]7%9S'V^2L"
MA<U+0@6-BTQL<DVUC<L !4A4]]2J !-*%K)(QC&,8QC&,8QC&>AG][,_Y@O]
M7>5T<!?^$7J5_P#6+3G_ .V'B=EC.]]FM[[.W[FO-KMW]K7G\WG]KSY7F7SQ
MBC4SR2TY0QS4=8J^89G!VKT4.B?C2]2BRVJR#:6=9@[B(6%;;8TX74U2: LY
MI)O@:9"RH'A<8I72,M T? +J?<?R:X=;!61JWV];$8=RBG]G5NIAC6?9=61#
MAG8+?6'(MXE3"V2IP:W<,$E[LVH42.OG^;+INF5>R$#(D:-.J-(Y*QN<T:K^
M5Q64N#?+SZ;-BM -CV4P0TR02\RT>9%L1ZO>/[4XMB95M7'430F1.ZV9E'#V
M:E#.H<89H9P2$2W\ZVZBM5W!8D7IEFA5UUU.YU-[YI5 YV% 6$J/1"^J 95L
MEF]6R)4R3E[3N<B(A*0ZQ6!WC!K]64FC*4] EL1/*@FQXG)N$5PW'R<X+4G=
MTR?H:RV_<-9-LW.<(K#5C?!V%Z>AG&-Z%)%'B42-U4LB31!*=P+4RLUS6D&J
MS4K@VJ!)1)9JXNWRU<F*)@-SM;2KCPY2E>F^01Q;LP9\9G$)E#Y +#B^SSB4
MQJPN-SR+21D3N!B5()Q3("5VTJ;:CO!<^"]K7_.!_KARN;I%?\6CPK_D"A?_
M ':O-AK4NE:P7C0O'>+IM^.%SMMISQQ?3""EB.(5;2J:&DS!ZVD$;K2EW>)?
M9=;PUD(5 TB)#(7=[.VI,8R&QPKXX[=4EK;J4.=N43//!39@KOGG<JB>1"L4
MC?7]AP7A+R G<$L5C@+:EE;@[[G<2@2>!NZEE=4:%ID^W90*+2J1.3;(DC3(
MCEUBN)<;N"H./\Y:[R@%UWW7EIVQ4=:RBH'GQBFE<UE'I!*R)8C$PKWQJ;T-
MAQ^(RMPKY&\N3<\+#(ZX-DJ;8@\&-[>MSZ'=3_CQ+F%VD)K#;L11@JSBU<D*
M*F4%2M:JU()S(EY=;4.XP$I%(G4(UDEM(P-<+VF7&1!R9) ).Z+TX86O;94L
MY1?S;9[%B+F"GF>:M,W8^4"_C7*&F60LO;NQ2.J#U4UOPMI:"G-:DF (_5<2
MEIT=?(ZM<H^_O+G&3&5>YD+BN^1(/K#<;R8>BGJBN.1Z:).5!U+RJ0O)]9,P
M4YW&VU7A)'E%PC!J<;/2L=:/J](W6'&%Q*6R=%' >X)!YW&][>0[&<?+FM*P
M>37.2L)FY1%1"./-FU1"ZV(88JN9I 8V6#0E>7*Z*)B]JY0\I'Y>WN<V4,38
M:TL<73A:D!!ZU*M7G&J YY5-TKGV\[\X[2D'?I;3K;5]C-+X6BTWD2:J+QW.
MRH4L-3 WM,%[CLIK*Q(4]B0;$D7$Q]ED B6U2_*&I#$G5-_XM/G_ /\ P:\D
M_P"B.5YN\P_[R-'_ +K;O_HB,Y7>]:UO>_-K6M[WO\FO;RI/E[S9LN(U#S<L
M.D%;(Q$<.9[4%4*79\C?CB&9V!)5M)S*SD:1I I2FE-D6KRWH_&&DY&%6X*)
MRMD!IB!82PM:)RE-]ZEM4L %C6;4'))UL1+R2GG%0JHF&M65UL)?;T,H==R:
M;6M&%/-]Q#V%L"DTJ28P:1JI:E;%079&TR0R,/21\;VB<J%OI1/;+O>CY,F7
M%3RC5=:OQJY6S[9=R"M;NBJV65T]*V\(S$J!_;7!BG5?R=$A-.1F/,%.>D^D
M!3X%F:]J,K5ZC_\ ?>!W_61<5_\ 6G^63$_WHK_HP?ZNLZ_'6%I"81543RI)
MYH=7.$MSL;7%+Q#BITP6UIE<JFTN.U+G0Y_10%>@4>RD@6-I+BND$@6O+"VH
M&"-(4.M+5^T92CE^B*XS:0$<E0SQ;U@GE,B<*94LFNL+7;3 ITF7 3628K4T
MBWMJM:D71'6@-FY*X:"G5)I*0B+_ '^M%##?IC&0E57\..1'\K;1_0S4^3;C
M&,8QC&,8QC&,96]U?5!"3ID\W5BHXI,D1<>9XL5J3QA*(2I$B4A0J5*#1["
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M *2=1_2O'[J;TT_?_P##7_23J/Z5X_=3>FG[_P#X:_Z2=1_2O'[J;TT_?_\
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M=7)<H(2($"(@Y4K4FEDD%#&+6LW$9NJ1TUB6AJ*-Y^<-RS"VQO", ^251Z$
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M LGN0U_!R+^HST,863O9G^U#7_N!?_PY%][O_P#H97?P+:FQ18G4IT>W(3M
MZB\\V#OJ-,9W.S.,?$X9FP]V4+N=C%^^'O79L0O.+MWY\L3]@63W(:_@Y%_4
M8]@63W(:_@Y%_497YS YFQ/C1:''VBXY"ZBE-P\B'MS0PQAMRT@\?X@N2M2M
MJ:_8ICL575-C1Y\LZ0NSRG30:K#=,KW-$[;(U#.O$H:2D+@:^9L3EW/&0\)H
M%#*B=U];1E#(K:<Y1:94'M5G(<8[I^)=JTI!RJM;NXX&W*'>&QR43R-V2WM\
M5DTB5LKN@+6,NBG3,^2M]RV@)Y2+>WT-"9K6UI7#4M+N[\=93)&+*!(K<DZR
M.)UU95@?#'1-8J"MT*;4ZM ARFD)<FZO$LBD,81R045=$N]S],3)O6MZ:&KL
MWKM\S>BWK?Y=;[QY];]O6_MZ\^>?8%D]R&OX.1?U&/8-F!L P-+8$8#"Q!$%
MO1A$$03 ["((M$ZV$6MZUO6];UO6]=NMZWE=/20:&H_IJ<*AGMK></5 PS6A
M&HDI@M:%I:9O7=#*%OLV,8Q[UV^<0A"WVB%O>[%O8%D]R&OX.1?U&/8%D]R&
MOX.1?U&<:\D11@:7-\=F]K2M;,WK75R4Z:25'@S>W)35JU1WA*C/4G=Y2D&F
MZ)3DFGF[!WLDL9@@@W7QP]YSP/E/3MF<AU$3J",TK%)&%BB3Y"[4*M*:N2D)
MYA*J)6I6QE5P*14O<J,Q?$VXZFW'<LDAS]*$K2B6*];;5CS'-?=0M=;L%J(^
MN>+Z51=-EQ7ES9;M3<AFK*@,A-<</[J44=+@N4O9H@_MZZP9K-5D4CT/C:-O
MW'@OKP^>&S QEBHW5XL4IB<US>]059=L$:R#83;]=0JSXB-S:&Q*Y[C4\C;;
M*&0+DD3B6$I'(MN=$Y;@D+5* I5@#TX3S=%Z,%)?L"R>Y#7\'(OZC'L"R>Y#
M7\'(OZC-#NJ2S-!/36Y^F%-;<68'AMR1$$9:%( 81!J65#"((@$Z%K81!T(.
M];[="UK>NS>M;UNXQ,3*)E:-[:&S>_8IMUV[;T>]^9"GUKS[(WOS:UK6ON:\
MVO-G*^P+)[D-?P<B_J,TWYN<H8=PVI]?9 JT*LR2%JV';9 6L]I85)\?5SJ%
M0V5S-U>5;:X%-$5@Q<W:5[PN\ 6*5KBN88NTI%3Y(VP@7(<U^359\+*$>KNF
M3-#Q)T\@C<08RI8O4PR$BD<I=PMJ!3/+":X/.P5O!FI*6X/DMGKI&'-IC+(V
M*UBP@W?>2S)JI=V56-54!GLNA-?1E^F,9;9(K9H'-&FVH8F(=RO#6PV,64AB
M\40S5E7M1R%R02!%'VU&O(6!&D*,3Z+4GR=[ LGN0U_!R+^HRM_J+-Z!$=P0
MVD1)$NQ]2/BKL6TZ8@C8MA\H8 [%LHL&][" TT.M[[=Z"88'79H8M;LR)_O1
M7_1@_P!764_=7YGHZ'TS%K<E/'KBS:ENN=GUY54"DO(6RF/C'[$E2)2ZN;LF
M;.7)9C5+:8<"(\Q/2R,K&IZ$:]R0AMBK2TN3X_MR8=?G [J(SM7R@AE+PZ2I
M9-3KU1M56+=,2M#EJ7R]=ZVM*R>7\UX:-$&XKW\TD*UM@U^U25@13^0/%H2R
M=+I+#7"-(HRE@<@+?0.EZDBXZ3N=VZZR6P[[D,NHKQNK*Q8CQZ,@%>M#;$YM
M5JA@?X\,5EM#8FF\FB95A1IHM J//O?70F9H4A I2?#"-1$<35[T[*UKZV:[
MFB23/*^N*.MF_P"^Z%IT]K:DK#65Q<G/&ORJR4I[2;"OD#2F\H=HBKN.+T*8
MN$F6A+N^N4A)20DF'V&=FNSL]K7M>;S?F[.SL_R9"55Z_P#QQR(]O_A;:/M[
M]#-4?ER;>S7Y?S[^7'9K\OY]_+CLU^7\^_EQV:_+^??RX[-?E_/OY<=FOR_G
MW\N.S7Y?S[^7'9K\OY]_+CLU^7\^_EQV:_+^??RX[-?E_/OY<=FOR_GW\N.S
M7Y?S[^7'9K\OY]_+CLU^7\^_EQV:_+^??RX[-?E_/OY<KDZNFO\ U:7-3V_^
M *:>WO?^#2?=WDK\R*+L*^XI33+7:^&MRZN>4G':^7DR:*I E2.#%1=HLUD+
M(^UB8&5Y. [R0;(4SI5RPH*!K"I&O.)7]Z"C,U 2=/FWC)>A=W"75LF:1\_>
M4W+9S$B.EJMS(A?(?BS;7')OBR(D^/(4JN51@^TMR=6L4*T3.Y)F(#0F-1C<
M-K$4#D=-;F6".<5XLXV1QT?&_C7&.G&E9C$PK9AA 7W@U:SBZRH+@TL[*X!L
M9+:E?J&QTC3K8#D<*I9:VO,6AL<1M\]DMA;RP'3;Y.G\8[SXBN-B<>CJ_;T%
MFH^+]I&1"9++==4=A<AV;D:V,-ZF:3(44;:HF\,X(6^J*U>)&?:P L5C/Z2.
MOD;U&GNT"Y8SR#F->1*'UY)H7#GV1/,?07),TSA*6=X98(>(HRP 4N-*ROAK
M=.75-M:SPZ224XHF([4E23:9P=T:1.364HZ9MXP^J^77&"EIU4<2XJSRU*AO
MSB!6SZ58+JHX^3R#6O5UU6-6JO:5&0F#2%HV- WJ4,S+'51KI53G,I'IK+E+
M:XI6QE^"<=.CEG.;OG%E/EAT4X-K^P\_X(U*$Y]CQPPF#<PZRJEFA(2:\:HP
MHA4;DE:RZM]-$S?T3@^2&VV$TF?221ZEAWBP@Y.6=-B]7R(R=A0RZH2%KOQI
MZ85)-ZA0KF^DY3[P&OY[NF2NRK1,3$<%DL,A^.8&%,3W2QA/2%.+H%86I,3$
M1QQBXWW%;<FFUB(6FL(RV<>^HQU0;TIX^>,D]\8+'FMQ NBIH WS-C.C3)IL
MI-T9;:=YDYRR*2*4+;$CC9"VYE:FDD"USW(K?T_N6B2LXS"%,THUVD$@M&0V
MIR>L)RD%J%6#R(L.T:9M*K9_9 ITRPQDD-7IH2HDM>DUA3L%$ACZFG87OCVZ
MSY@KPX\#K,TLZ?4YL_IP<:N*,NL")PV_N,3+Q1EE;VC$&E\E%?L-Z\07"&OM
M;R!5'G@<6?)1!W9TA2=NES2,V-.ZYA>W?V&4,;J4VJTTPW;6_,V[:&D45\*X
M_5K9!I%:+$+&U2*;SF%R5WC-GP.;S,M18KO5D<EM9E/T8C,AA\)DL5KZ2S.M
M7V1MUF-;HMDD38TA57J3C#R.HSD#Q-J-L9Z>GK\L,ZRTM:G1X5W"NK2/PSEC
M9]<6E"$%B3!RATL>1S@#C(),TB97D_>["98I(DB26>R:E:[IYRC/2@GL(>8%
M%H!:C? *TC7$]+Q+LU_CLBG8S>2L!CW#H/'.O5UM<>'%(IJ=HM"LY\,F=0^]
MH5,4%@@JYC;Z#>BGJ,+1NC7CD#Z<'+Y"B4#FTNXW:7*&/I)(PHHPX6JK1$.?
M34N75D2(T;B[P]&:J06P@2@(9B=-",^*JW4:1Q,?$[#IUDF6M/3/LA'J\X++
MX+POMRM797R$,J:93.*3]EOV813DQ:6[*E];VK/(\U#6U=J'A=WMC0VM2#T=
M,[ 71NII<\M42<8.YH)/8WPVIVU*%H=@K*X+5?KAE#)([ 5MLGE,B=IW)VR$
M/LY?WROX/([/D+2Q2FVWR 0Y>SQ%RMB7,C5+;"5-1DED:33JM4'';3=NOR_F
MW\F.W7Y?S;^3';K\OYM_)CMU^7\V_DQVZ_+^;?R8[=?E_-OY,]#-Z[V9[?\
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M/;B=!V:6 H]4@*=%_=! ;W6B#E"0"[S!-[V/1)II?<CV6+18M[+%W.O39>]
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MUB]5I68>?X&U:0-R?NQ;[>])$:<D/M *!KS9OAXHQ_\ Q#7^=+O[7CQ1C_\
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M4BT2IS8C(IR;K:S;"G,?LITNROT+>F4M\4CDIET661M:KE3/5*"'LSPA5/\
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M & LD+=#+=A+W!)&XQ)P2-4G;VM]3>#GKF!R7MKPA1.R3>@*$*E8U.*8M06
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MO6ISXB2 2(Y4 +J2%.?7;?EX]6CI;\8!W/6O(VJ>>'#UY30\N!6SR$B;TEY
M5.DES\W-D932A"DD,<568@=CEA4>VYN+R[.R!6:!Q/;65N2]Y'\'24Z^UN\E
MN3CO5?-V=\9*HKYRK-V6P-[*:5-6&/-I$2B*)&B,%R*66 \LRDURCRZ1J2&D
MPI*I6'H"A)56S"A)E';38I&P2AM3/,:>FF0M"P.QI75B<4;PVJ0:WL.Q$+VT
M]4D.#H6MZ[2SA:[=;U]K><OW8/;[H/9[7;W6O;^Y[>>=;UOVMZW_ !;UO_LS
MSC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,HTZZ'('BE6M#5K5G*KD_R
M7X9QVS[?A#O'.0O'2MK&?'V,/=<FN\T1I$MCQ2 S-GASWMR96Q40W WJ<N"4
M/LC&6A<V-TA<F;%^AK:M 6TAY0/7'GJ"<T>H?%FA[J-B=[-Y;H)0E0P]]]@I
MH]&1"LSI7!:[7;%X$ZI7"<(28^:2G4&1A:%T5E.99*2_/&,A*JOX<<B/Y6VC
M^AFI\FW&,8QGJ,6@!$(6]!"'6][$+?8$.M:[=B%O?FT$.NW8M[\V@ZWO?FUE
M-G%6 R3D9U$N1W.>2S(4EJ2NXRS\<N+D1 !:6V1<Y&6:IM&= V8;I.N=Y,!2
M7MN< %@"D99@Y-X$X1[-5*;?6%@9HPV$LT?;4K0TICEAR9N0E]Y1IAKUJAQ5
M!3$!WWM.28L5J#@IR EIR>^;+(***" L/,8QC&,8SU$$(P[",(1!%K81!%K6
MPB"+78(.];[=;"+7F%K?FWKMUO6]9IUSPHJO.0/$ZTZCG[2U+8X]-31IM0K6
M!VD"<N1-CVVJ8D6WL$=.2NJMT&]@1(F0MM%W],YJ4BHDDP28(,IIXE=+SB3
M[-D%&<@>G%$3G.TX00:3)337BU:Q;(\P(B5+BK,72N2RI;$)&YOA!*9>[,DA
M(4)'94UM+8U,K<NVM=MEGOH$\,H\YJW[C!/>4G"B4J=:&G7<9^0\[CC46868
M T.CHK)ULH;%"(!P0&>"%B2E ,T'8!%Z[>VE#K%?NG731KND1$=5>Z;5K6=S
M^2L<<5KF=@J^WF=Z;8CMU4))3/XRH.-G\9,;2-[1HW4T@U \!VX%)=B..,#F
MO0-ZQ++XP7%57/KF9*7R86))J^W13[>,M6N\33^!M+\BE$:(G2L V&(.3JO4
MLRPA#(U[2B=N\:$C5C5@VG'W/"#R5)19Z<TLXDXL!I1I0PF%F%&!T,LPL8-[
M ,LP&]#+,!L0!AWH0!"#O6]_KC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&5'=:6[[@H+A^US6D[5>:2EB^]:BB+A:$0XT)>6UBQ*+29Q=T;XYUM23FH2
MLTDE9 "TXC3W<WO**+>,WL=K3\H:1:U_Z'7("YKX3<FU%O<Q[YY>CC"RGB(^
MY7AP&9> IL$*=4EE"=&V,PMC='!//B7M0VIE;M*E)256W'-Z%D[H\DHH*>_#
MNM=O9]O^+?9_%V]G9K?Y.WM[//V8[K6]]G;Y_D]OLW[6]Z^WK6^W7V^S/.0E
M57\..1'\K;1_0S4^3;C&,8ROGJF\DVWB?P,Y%7,K.4B<FN%^+45:V]>4W.T@
MF$Y<T,1CS UJS4RL2=6Y*W<03%)"4]4C1%K%J8O9R8&PR%P'J)VI;B=3D5E"
M$ENGCM%TTZL9(2$W04<\GNM2F0LX1&[[LPB,&N1$21&" 7L3>P).TL&^T.;B
M8QC&,8QC'MX[/M_^/_'Y<UDO_BU#+]5,$A726>0*>Q!(N212<P"3KF-U:2UQ
MY*LXDY($8F]P3C5IR3AA,))5]@=EE+B"QBUD2N5<V#6M1KC;]F%><G6B%35*
M\MA5DUZQDOSA"E+:%BTQMBIQ&ZHE=HJ7=>$Z+&FI%ALD5;)A9BD!S^4[-46P
M>"<(^<, M2GY[3M$.<9<Y$L3+:,6UVV1"?1$EC*.9"GV0;3I&1Y1SD1H%*D3
M]"A)_$H)X8R1(%BU(X*U.BZWC/U#.DN?N2\'7^5<Z^$S:,Y2_<*K6D'A5X50
MQ [I0>/CQ9!J<]8_MK>6 [P2%G(5"G8!%I4\2DKF>:_I=KZPZZ_3/GT+;I+*
M>1<?H^3B4K6F3U/=Z-U@MGP:1M(BBG=@D\<-0K %GHCSM$@<$"M8UK1 ."E5
M;/3+$R6QNA^0M*<G:_2VI05DQ>U:]6.KPQII9$5HUS0:[Q]7X"\M^C324Y@5
M3<K["5)8R@[ +8=Z[H(@BW,N,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&5
MF]6APD+/P_?WMAM-CK(IJF43&](WSEFZ<&@VBWNOLK'FZJ&CE,PLK\_U5(9+
M*GF..;&<T(B!S)='RZ]='B/Q^5O#XWX%TPT_.U6\74_\V6V"5,O*A7&N P[C
M1&[V4\AIA!'*NX+(V>:7'9,[TD1,">0WX(^.+$;%$DWL.0WP<*YT5NDO42-W
M<<:YU1E557,'@=R(;G7E6QM;]RI@M56Q9,%M9S>Z0889:D;=::K*B;#XYK+%
M;(X?#;?O680)0HM5GJN22&!2DDA[>):B2*T!;7J-QIY!6\Y.73MY+.\\D[E9
MW-OJ(\YN.UY5RJ?7U;%DU/0=+S,.@,.988L6*FJ)F<<]<8ZT3(7)M9VYV\)<
M[!42!8)7/Y,I<.QA(GS<>8ESW[$/;YM"06=[$QQOVZ/2S9AI1/>T"#OR?:DP
M'?>^C!WXON22S1]O[SLWJ-7%S"1S"]5&JJN=5[)6>UK.\HX)M0H;] J>M4'@
MCF5[+ \%6C\"\,+)[H?=(%:)1W6O".X!+GEU'Z';V]76_GK'EU'Z';V]76_G
MK'EU'Z';V]76_GK'EU'Z';V]76_GK'EU'Z';V]76_GK/@=.0B!J;'%T=ZGNU
M TMJ!8X.:U97G<)$;<B3&JERI2+;R+L3ITI1QQW[T6]E@%K0![WH.^JK?'**
M%<E^=G&_B@*T9.AX\'WO 9P*AWG;K(CI; H>L7R.OZT:VX_8B4<HG\MTG-0L
M#P?MS3UTXFQQ(^%M32D9UO:W!>H^YU_YG;V[=Z[K?970NSM%^^WV=KUV]G;O
M?9^3/;RZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?S
MUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZ
MC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M[>KK?SUCRZC]#M
M[>KK?SUG"NUI,KZI9%CQ1%U.:B..NGQB,6UIH_36\!1*V\MT2 ,>MEEKB4:Y
M80G5=QLY.%0:(@19@N[UK5<M65#<#^GGFZ4Y(5[:B%Q;W-%:5;0O<:F03T'>
MRPA6*0.YR)RT:E+TEV>L1C7%%:"$A8 &A%CF^PN8U>U*SH7NRX9<4.95[B4S
M)'5[KI9I(>YFD&J"D@SDC@IT4<<2G.,+$<$DLT18@%BV9K0,ZNO6UZ?7);GE
MR/J^^>&_&%W>XHOIA.T3V5%EP2#+9;+BY:\N+.].!JE\3&2X>HBM:T2.1C4.
M!H4:<IJ&I !$407(/3LY(<N>C)0J:H>>7!NV63C#J92F7@Y'U9I!9"BM'.:N
M92A>DM6*L#DX@*C(W$ !H)(A<&PY F. BVU/RT>M@[&E-\Z*>Y#P5JLVBVJP
M[8@#V#>VZ4PF*)GA!LP&@[-1N!!;X!Q8W0CN@^$,[ZB;'9/K81'(@ $$0I5\
MNH_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0
M[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>WJ
MZW\]8\NH_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>WJZW\]
M8\NH_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>WJZW\]8\NH
M_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>
MWJZW\]8\NH_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>WJZW
M\]8\NH_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>WJZW\]8\
MNH_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0
M[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>WJZW\]8\NH_0[>WJ
MZW\]8\NH_0[>WJZW\]9GL(G>YK[)=L.G<3]C?!/X:QS;!X?X5X1_O;VK5GA7
M@W@__E7][[SWY/\ [KOO[W/<JGZP\GK&&\4&B2SJ07C&9NU7-7YO'9UXY4#$
MN4%P$\@3T4I2Q $4HRP8I,(#/N^QLZ:!=FR6MR%,4SZ6K&!_C\S(C3HGU/Z'
M#RNL)^Y<6W9$SZA5J\@Y<*BV:Q[2YY\;V?B<!SB$;2VJ;740HBDXXK71^-PB
M+JW>;.DE5M*G13C*I4,\PD!VSAFV]*N+E;NMH.UHR-TLJ7J7&9Q&QT,%F5I3
MF551%)_!F5*QQF5PFM'MY61>(+&PM&0\D-K&C2QPN9 #/BF0N;A!( \7%N'-
M"0ZX=W:R1(\N7)7RQ9='$"MY=%\/A$YN(1 K?GL$AZM0:QQ&9VAW@7CJ_LR9
M.J=!.<F-)TC/FLU-D6T6]:WKLWK6];]O6_/K?^3(1JL(=SCD1VZUO_SMM&_/
MK6_/Y&:H\^39W /O0_HZ^3'< ^]#^CKY,=P#[T/Z.ODQW /O0_HZ^3'< ^]#
M^CKY,UAONP8H\!D/&1K7^$V_;U/6EXI,1:15M$22*(O;<E62!X)(-21Y$N6F
M&)T2E=V!4C3*=%AWL -&]#SI!]-SFE9W+:A^3+7$&>3U5QNY=,<2N"Q%UHQU
M9O;[3BI GG0HQMP7FN]@-[1L:1$B>&0"E$XF: F0FB G-[Q_1@" .@AUL >W
M0=:WYM>WK6>>X!]Z']'7R8[@'WH?T=?)CN ?>A_1U\F.X!]Z']'7R8[@'WH?
MT=?)CN ?>A_1U\F.X!]Z']'7R8[@'WH?T=?)CN ?>A_1U\F.X!]Z']'7R8[@
M'WH?T=?)CN ?>A_1U\F.X!]Z']'7R8[@'WH?T=?)CN ?>A_1U\F<%)HK&YFQ
M.<8E;$U2*//*82-T9GA"G7MR].+>M][4I5 !E&=R+6C"A]SHPDT(#B1EF@ ,
M.A2>G#.)CF:U\:GN9RUXFSHN>6/C=)'HAR@)#(F3;#(GA$]*DY3E $K0K/;E
M!$E<W96G>%VTD*/3.+D_(G)KE.@N0U1V6!WJE58#C([09E+P@FD:LJ,C@LE=
M%JHX\UZ2-<*=B2RMQIO$>>U(F)(8['-C0D()=3W 0]NSA7U?71R;8C/77DOT
MP[35<"^2Q^C%CTQ1!'I3QHN099WA862TJ@TG6L3>D5&ZT7[)1EF,0HMC.6^*
MJMR-\/*JLN'^Z..8O$6QG_CER<X/U!N]:QTTM-@+8G>#ZBBSRO<FA"^-DACR
M%+"I8!"S2!C<VQX1(C) O5)2UG>%FD:D!B!+VB^(=YG\GN+]!<AEL82PY9<]
M40JQU<52.ACXECZF5,J9T/:4[P<WM9SD2B,.$24L-;D1AX Z&-.4+>PYL9W
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M7EI4KF=P(>%NVG28XV[XI]/;C%4[@FT3+A5RW3ZQ3AZ'X:KL:T!#G\P,<3#
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M:HAO&_CJU$S231%.=O12PZ'GO8SMQXAR4'FM)+>".HCPLS6WI4_8A* $!8
M#H  AUH  AT$( :U^\ $(>P(0@#V #K79K00ZUK6M:S],8QC&,8QC&,8QC&,
M\;UK>NS>NW6_M?\ C\GF_BS1>8<-HX]67); AD>A-;J0MS48D(:$K@I9[3?D
MRU,^')+;B9!K?'C8$4O1I25$<:$?LJ_.X02YT>=*V=F;MXG;5STG:+I-N''-
M&H"HM$[+84S$E'.E!+U5%H)'!$B.6A8I<6E:C&A:SOANM,#RH"TN;:ZMR)R+
M6QV0A0(\JW;I'R5Z$3Z!@FPK!Y4]))R="4\4GA!2J57=P>3N:LLE$R2TDO0S
MYC3*/8RDB)8GTC3(]&:$U%L3WLN+R_L+5+;U8WM7\9M2GIS&[%KR8-Y;G&Y;
M%7,AT:'-*/S#" \G?=IUB0S0DSBV+2DSFU+2SD+FC2+"32 2/C&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC*L^<W39>>3<W:+SX]\O^0' _D:WQ5#7\AM2B%Z-P
MC]G5ZTN+H[L$9N"KWI4BCDZ%"G%]D*N!R U<V/<4\8WU,!6M;5@$B66>"'!]
MIX:16=G/EZ7)REO.W7UHD5T\BKYDVI%/ILMCS48V12.-J-+OV(A==PIM7N)<
M*@K/WY&QZ?7=28M7*',P_-\NZUK?9Y^W^+?9Y_:UW79W/;^3M]O>M>WO7;XT
M+6]]G;Y_/KVM]G;KV]:WV=F_M^UO[6_O=]GMD)55_#CD1_*VT?T,U/DVXQC(
MJ%4U=.=JH+VVV^'S]MAJF!MCWIS5JD:-@,<E"Y44B;@J!MA2\:DU4F.<"20K
M-IS3T8S.]B&'*9..8-\J>N-S*OD__;2!<#Z4@O#ZN5>_WB5/9]@G'SJW5"3N
M#1EG.33H#K''(0=:-*(5I"E 2QA*#N_#&,8QC&,8QC&,8QC&,9'=G5-75S19
M7"[.B;5+XXK%HT2%R*,T8F4!UL(%C<O2F)W%J7 !L18%S:K2JM%#,*V;LHPP
M L%NJ2)J:IA0:RU ^VQ%V1N:HJXU]&2$3FJ!!!I=,[H<>VO&EGLXTM;(7LMP
M:Q$+CG!,+9:L.DFUJLBA&-<4)+64GDO*KH6W'&HN>[K=2"\.G1;"]2VTE/%N
MR] 4"CS,J5E+J=F QZTD;5Z%8GBPU.](&:8Q^/D',:O>?BIUD:&N&;?8^<E8
MU)>#O+MKV4A>Z'Y"][C*5\<NPP(CZOL5P+;HQ.FE8(L VKNQLSNYA4%>Q+<[
M)]:6FW!A&$7G"+6_-V_Y/M"\_P#R=_:%[6]>?6]ZQHP&]]FA@WO?M:T+6][_
M ,G;GMC&,8QC&,8QC&,8QC&,8QC&,8QC&,94UUJ&BO';@E.-VA;_ !]J:)H)
M-&U"I/RKD5F1WCO::I80],:.J;5%3TLB=D.C&^FO&Y UMD:%)-:E,5871^A$
MSC#6]1]9JOT*+0=[I!R-G<FY@<3^1TE:8GQ<J@^ON$Q-FK*-J..U5"YY&8E)
M'.86RPQJ3S:WK5:RS?'=VVQH4R!A@<+94VA-:%I2H=C.6G$EEF7++C7:E1+9
MJV\J6GD755MSB[C)?*D396?$.O3M(+8IAQ(0C+AY5<WA'TJZKX[59S?H^6V!
M,WZX58%ZV 223-.BO&*QK#->.FQR$7.SX?R1Y:]2;J$4UR6;CA/?A3]3L12<
MUPD5U(6HY0,Q+&>-HN.M)H:]1+.\)X3MF<3FPA-J:RX+YV4'YT7,[(L=$# Z
MRA<E)+,)8&0UH(='$8S2BQ$HS7YT9FD!A83!'BVM<TA?>BC-!,$;LLHS4^MK
M)F":8WP<315GKC%MHM:A2F3.E2A.:C@U-6:4*%>)59J8@Q480F)< #;3EZ/2
M1<E -6!:%4D32]Y59Q[W>V_A>F?K8QY59Q[W>V_A>F?K8QY59Q[W>V_A>F?K
M8R$>1W(6PH+25B/[=1EK,;QM@/96!Y/.KYU3-<@D@P,+,X*4D0L!_D&B4:U>
M6HT>A:5>BE!:?1^B23!'%U3\HNI ^]&GC3Q<A3SQ5EL_>)^;.6UR62:SXA#$
M)<G:D37,7YQ0CCP;.='(A2[RL1&TKHWQ@92))H>CCUIIY":'?[G$Y(NDUXX\
MF#2*2G,RL9QY53&R[:L-@D<".+FLNN!M(E9)@T,OD<1=&@F-M*5&QIT@#Y"G
M4ZT8Y[7HCUIC:3V*/*K./>[VW\+TS];&/*K./>[VW\+TS];&/*K./>[VW\+T
MS];&/*K./>[VW\+TS];&/*K./>[VW\+TS];&/*K./>[VW\+TS];&/*K./>[V
MW\+TS];&/*K./>[VW\+TS];&/*K./>[VW\+TS];&/*K./>[VW\+TS];&/*K.
M/>[VW\+TS];&/*K./>[VW\+TS];&/*K./>[VW\+TS];&/*K./>[VW\+TS];&
M/*K./>[VW\+TS];&/*K./>[VW\+TS];&/*K./>[VW\+TS];&/*K./>[VW\+T
MS];&/*K./>[VW\+TS];&/*K./>[VW\+TS];&/*K./>[VW\+TS];&/*K./>[V
MW\+TS];&/*K./>[VW\+TS];&-VI.-_\ L[VW\+TS];&1TSIVJ/SQZL]BX?3=
MHL"1-6V5^E;:;2*)U=VX2PEP,)7FI[6++4F'K$Z8]2K,*VL5"3)M*#S0)R0@
MT<YK0-RY& =H[R<Z<K7?O'!(2D#'#MJHZKOB$+5+<7I\?F!=#I3('=I&!;H_
M:;Q46LQFTI",2]Q'L1I0*W$O&GJ \9*=>;-Z8O)7D=N@4L6F#LFX]\Y6RM9E
M'XO'V-O>?98^NITOFX+"AZIE4(G%QCS>MCC6@5*TR$Q6L=41@M*J)^+/5QZC
ML-Y.5 Y7KR.Y16)5M?6'"WN[JU1-4:D,A?H )20%Q8@QXE@:1N[G)$RL@+*V
M(7-(I?S30#8CS@]R9KN!T7US>"'(E9IFKB:')93HP*<<,LJ3U/3TOTI%K>O!
MRV>T+*BH5AW=:V#O;<K6B[OL!V=H@ZW8PEN"6KDY"Q#0-I+4:HDM0F6(G^DE
MB-20:'0RCDRQ+;9J5028 6A@-)-,+&'>A!%O6^W/H\JLX][O;?PO3/UL8\JL
MX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL
M8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO
M3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O
M;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JL
MX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL
M8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO
M3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O
M;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL8\JLX][O;?PO3/UL9FT.
ME;Y)O9#V9KN70+P+P;P?QI60M7[*=_[_ -]\!\499*.]^!]Z+\(]D/ NZ\))
M\&\([D_O.;Y4/UKV",NW#5$\R'D1'^,"V"7A4DZAUI.?&5OYA2,F9L3@[E,\
M8KGCNO1.7E%G,N)7KF-,WD(%84<<425Q="PL"9X-+ULZ"THW,XOR/?W#F"9R
M@?S76JF]RCLAZ<\)Z;MA5(C2-\\.;29+6T):6])8++.-KECC%I]M<\H2C&1]
MCJ%<2J;G1$19Q,NGEP]L&Z%7(.:4PVR.W%\GB$P<)6Y2NPS0N,@@(&HJ&K7&
M/!F (FX%1PID:RFIN6,)[4F*1@+TA$ 9H3):C_&.B(K:;C=+!7#*W6,XJY6Y
MB>BCW8Q"VO4]"SAG\DCL74.)T2BLLL$,?9=6#+8PQ-$EG>FQ'J6.KQWK?=3S
MD)55_#CD1_*VT?T,U/DVXQE?DOY*JVB_';CV@LAMVD6JF^1OMDELB=8?3#8X
M.29"973Z:G;SHH%Y?'-2V-D.E$F G1QTI^3-\N2O3]IB]GZHO[HFI&+<F77I
MO<>V]WD">[[=Y2N,'K]O;-MIK$BKY^8V8%SSJ2IE"0]R,\265"PJF3:12C1^
M%*G 3F!604$HNSKIM],RI>FA";-A=43ZR9^DM.9M<S>'"QS8H-6A4,\>(CB!
M$V BD;CB8"82,G:A2-42H/-5&[V 1)0-%99-C&,8QC&,8QC&,8QC&,8QC>M;
M]O\ _P"?EU]S?Y<XYW;DKLTN;4M1D.*)R;UK>K0*AC G6I5J8U,H2*# A,&
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M_=%/3R>5I;3;RB].+[OH8"%1-\TM*&QI3*1AWO03)-"/'9D*)&,)A92A6>C
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M,VP,U/S0.MUUL,:<1@@Q*6J9QQ<-BRMQ3Z0.:5VIHUF,(V;%A[NHZDRFP4?
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M@Q1OMZU_#NP?M[[/1UK,1@-@<AK#AL;F[3#Z71MLG:D[NC2K9[.AJR"%/=;
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M-B%.0$-?;4Z4)SHBO&I$:4$H1:A-HD8QA/T#+/#N2_X,4;\>[!^KK'AW)?\
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MD'4;ZE,GK\85E&*8#P*8V]\8CR%L ?[P::UMA?/U<57-QJEF5N+=2C[QL:)
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M.+$Q:R8^$KH==%=W+!VZLDPAQH)()0Q&VV-P6OIVO8=44PA3)D90G'9J+0>
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C8)8\N+\[OSPZ-4-6(5#'63:I]@6=^E:U:]29SWAQC&,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6802703696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COLLEGIUM PHARMACEUTICAL, INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001267565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6805992336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 105,460<span></span>
</td>
<td class="nump">$ 1,634<span></span>
</td>
<td class="nump">$ 4,178<span></span>
</td>
<td class="nump">$ 7,551<span></span>
</td>
<td class="nump">$ 11,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Refundable PDUFA fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">866<span></span>
</td>
<td class="nump">527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">106,326<span></span>
</td>
<td class="nump">4,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">627<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">107,050<span></span>
</td>
<td class="nump">5,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,237<span></span>
</td>
<td class="nump">2,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,681<span></span>
</td>
<td class="nump">1,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent', window );">Current portion of deferred rent and lease note payable</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Current portion of term loan payable</a></td>
<td class="nump">2,667<span></span>
</td>
<td class="nump">1,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Convertible bridge notes with related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,600<span></span>
</td>
<td class="nump">10,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncentiveFromLessor', window );">Lease incentive obligation</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Term loan payable, long-term</a></td>
<td class="nump">4,813<span></span>
</td>
<td class="nump">6,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 13,489<span></span>
</td>
<td class="nump">$ 17,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (See note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; authorized shares - 72,000,000 at December 31, 2013, December 31, 2014 and at December 31, 2014 pro forma (unaudited); issued and outstanding shares - 962,960 at December 31, 2013, 1,006,219 at December 31, 2014; and 7,559,035 at December 31, 2014 pro forma (unaudited)</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">213,027<span></span>
</td>
<td class="nump">12,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(119,483)<span></span>
</td>
<td class="num">(101,753)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCarryingBasis', window );">Treasury stock</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity (deficit)</a></td>
<td class="nump">93,561<span></span>
</td>
<td class="num">(89,348)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,225)<span></span>
</td>
<td class="num">(61,404)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible redeemable preferred stock and shareholders' equity (deficit)</a></td>
<td class="nump">$ 107,050<span></span>
</td>
<td class="nump">5,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible redeemable preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,277<span></span>
</td>
<td class="nump">23,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible redeemable preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,376<span></span>
</td>
<td class="nump">$ 47,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible redeemable preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the combined amount of cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date and the current portion of the net carrying amount of the reimbursable incentive or inducement received by a lessee from a lessor, in order to motivate the lessee to enter the lease agreement, which incentive or inducement is to be repaid over the lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 12<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveFromLessor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the deferred credit for an incentive or inducement received by a lessee from a lessor, in order to motivate the lessee to enter the lease agreement, which incentive or inducement is to be recognized as a reduction of rental expense over the lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Lease Incentive<br> -URI http://asc.fasb.org/extlink&amp;oid=6516590<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 55<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6584307&amp;loc=d3e41620-112719<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e40010-112707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveFromLessor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 25<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 8<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCarryingBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost basis for treasury stock acquired for purposes other than retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCarryingBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6805601008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
<th class="th"><div>Feb. 29, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible redeemable preferred stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,481,000<span></span>
</td>
<td class="nump">54,481,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">72,000,000<span></span>
</td>
<td class="nump">72,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="nump">20,687,829<span></span>
</td>
<td class="nump">1,006,219<span></span>
</td>
<td class="nump">962,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="nump">1,006,219<span></span>
</td>
<td class="nump">1,006,219<span></span>
</td>
<td class="nump">962,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible redeemable preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible redeemable preferred stock, authorized shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,498,419<span></span>
</td>
<td class="nump">18,498,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible redeemable preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,232,334<span></span>
</td>
<td class="nump">9,232,334<span></span>
</td>
<td class="nump">18,464,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible redeemable preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,232,334<span></span>
</td>
<td class="nump">9,232,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible redeemable preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible redeemable preferred stock, authorized shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,324,237<span></span>
</td>
<td class="nump">27,324,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible redeemable preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,324,237<span></span>
</td>
<td class="nump">27,324,237<span></span>
</td>
<td class="nump">27,324,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible redeemable preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,324,237<span></span>
</td>
<td class="nump">27,324,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible redeemable preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible redeemable preferred stock, authorized shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,658,344<span></span>
</td>
<td class="nump">8,658,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible redeemable preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,658,008<span></span>
</td>
<td class="nump">8,658,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible redeemable preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,658,008<span></span>
</td>
<td class="nump">8,658,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27011957&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 28<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 28<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 28<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6806770704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 6,444,000<span></span>
</td>
<td class="nump">$ 12,652,000<span></span>
</td>
<td class="nump">$ 12,652,000<span></span>
</td>
<td class="nump">$ 14,157,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">11,027,000<span></span>
</td>
<td class="nump">1,686,000<span></span>
</td>
<td class="nump">1,686,000<span></span>
</td>
<td class="nump">1,885,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">17,471,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,338,000<span></span>
</td>
<td class="nump">16,042,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(17,471,000)<span></span>
</td>
<td class="num">(14,338,000)<span></span>
</td>
<td class="num">(14,338,000)<span></span>
</td>
<td class="num">(16,042,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="nump">259,000<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">155,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,730,000)<span></span>
</td>
<td class="num">$ (14,448,000)<span></span>
</td>
<td class="num">$ (14,448,000)<span></span>
</td>
<td class="num">$ (16,197,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.94)<span></span>
</td>
<td class="num">$ (18.26)<span></span>
</td>
<td class="num">$ (18.26)<span></span>
</td>
<td class="num">$ (4.06)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares used in net loss per share-basic and diluted (in shares)</a></td>
<td class="nump">11,179,756<span></span>
</td>
<td class="nump">926,597<span></span>
</td>
<td class="nump">926,597<span></span>
</td>
<td class="nump">1,697,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ProFormaMember', window );">Pro Forma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share - basic and diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares used in net loss per share-basic and diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,471,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ProFormaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ProFormaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790162416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE REDEEMABLE PREFERRED STOCK<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (decrease) in convertible redeemable preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue', window );">Accruals of dividends and accretion to redemption value</a></td>
<td class="nump">$ 2,926<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (decrease) in convertible redeemable preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at beginning of year</a></td>
<td class="nump">$ 23,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Balance at beginning of year (in shares) | shares</a></td>
<td class="nump">18,464,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue', window );">Accruals of dividends and accretion to redemption value</a></td>
<td class="nump">$ 970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue', window );">Performance Adjustment of Series A</a></td>
<td class="num">$ (12,239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityStockIssuedAndOutstandingModificationShares', window );">Performance Adjustment of Series A (in shares) | shares</a></td>
<td class="num">(9,232,340)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at end of year</a></td>
<td class="nump">$ 12,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Balance at end of year (in shares) | shares</a></td>
<td class="nump">9,232,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (decrease) in convertible redeemable preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at beginning of year</a></td>
<td class="nump">$ 47,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Balance at beginning of year (in shares) | shares</a></td>
<td class="nump">27,324,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue', window );">Accruals of dividends and accretion to redemption value</a></td>
<td class="nump">$ 1,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at end of year</a></td>
<td class="nump">$ 49,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Balance at end of year (in shares) | shares</a></td>
<td class="nump">27,324,237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (decrease) in convertible redeemable preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of new Series C convertible redeemable preferred stock, net of issuance costs of $45</a></td>
<td class="nump">$ 12,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of new Series C convertible redeemable preferred stock (in shares) | shares</a></td>
<td class="nump">8,658,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue', window );">Accruals of dividends and accretion to redemption value</a></td>
<td class="nump">$ 120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at end of year</a></td>
<td class="nump">$ 12,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Balance at end of year (in shares) | shares</a></td>
<td class="nump">8,658,008<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the combined value of accretion of temporary equity during the period due to unpaid dividends and accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of decrease to temporary equity to its redemption value during the period for a modification of shares issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityStockIssuedAndOutstandingModificationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in the number of shares of issued and outstanding temporary equity during the period as a result of a modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityStockIssuedAndOutstandingModificationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 28<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6769882832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE REDEEMABLE PREFERRED STOCK (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C convertible redeemable preferred stock | Series C Preferred Stock financing 2013</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to temporary equity resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=coll_SeriesCPreferredStockFinancing2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=coll_SeriesCPreferredStockFinancing2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6805398560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SHAREHOLDERS' DEFICIT - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Treasury Stock, at cost</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of year at Dec. 31, 2012</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (61,414)<span></span>
</td>
<td class="num">$ (61,404)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of year (in shares) at Dec. 31, 2012</a></td>
<td class="nump">1,924,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in stockholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock', window );">Accruals of dividends and accretion to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,925)<span></span>
</td>
<td class="num">(2,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified', window );">Performance Adjustment of Series A</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">12,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_CommonStockIssuedAndOutstandingModificationShares', window );">Performance Adjustment of Series A (in shares)</a></td>
<td class="num">(962,962)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="nump">1,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,197)<span></span>
</td>
<td class="num">(16,197)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of year at Dec. 31, 2013</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">12,313<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(80,536)<span></span>
</td>
<td class="num">(68,225)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of year (in shares) at Dec. 31, 2013</a></td>
<td class="nump">962,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in stockholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock', window );">Accruals of dividends and accretion to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,300)<span></span>
</td>
<td class="num">(3,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock awards to employees (in shares)</a></td>
<td class="nump">10,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="nump">32,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,917)<span></span>
</td>
<td class="num">(14,448)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of year at Dec. 31, 2014</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 12,407<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (101,753)<span></span>
</td>
<td class="num">$ (89,348)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of year (in shares) at Dec. 31, 2014</a></td>
<td class="nump">1,006,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in stockholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17,730)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of year at Sep. 30, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease (increase) in additional paid in capital (APIC) and adjustment to retained earnings for the increase in carrying amount of redeemable preferred stock that is classified as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_AdjustmentsToAdditionalPaidInCapitalAndRetainedEarningsIncreaseInCarryingAmountOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) for the decrease in carrying amount of redeemable preferred stock that is classified as temporary equity and common stock and the (decrease) in common stock value as a result of a share modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_CommonStockIssuedAndOutstandingModificationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in the number of shares of issued and outstanding common stock during the period as a result of a modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_CommonStockIssuedAndOutstandingModificationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790345760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,448)<span></span>
</td>
<td class="num">$ (16,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_AmortizationOfIncentiveFromLessor', window );">Lease incentive</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Non cash interest expense</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Accrual of back end fees related to note payable</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">183<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositsOutstanding', window );">Refundable PDUFA fee</a></td>
<td class="num">(2,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">990<span></span>
</td>
<td class="num">(822)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">943<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(17,947)<span></span>
</td>
<td class="num">(16,530)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from issuance of convertible bridge note</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Proceeds from notes payable, net of original note payoff</a></td>
<td class="nump">7,056<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaturitiesOfSeniorDebt', window );">Repayment of term note borrowings</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongtermLoansFromVendors', window );">Repayment of lease note payable</a></td>
<td class="num">(62)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of common stock options</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">12,038<span></span>
</td>
<td class="nump">12,351<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInContinuingOperations', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(5,917)<span></span>
</td>
<td class="num">(4,385)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">7,551<span></span>
</td>
<td class="nump">11,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">1,634<span></span>
</td>
<td class="nump">7,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue', window );">Accruals of dividends and accretion to redemption value</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">2,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified', window );">Performance Adjustment to Series A and common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReduction', window );">Repayment of term note with proceeds of note payable</a></td>
<td class="nump">944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) for the decrease in carrying amount of redeemable preferred stock that is classified as temporary equity and common stock and the (decrease) in common stock value as a result of a share modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_AdjustmentsToAdditionalPaidInCapitalDecreaseInCarryingAmountOfRedeemablePreferredStockAndCommonStockValueOfStockModified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_AmortizationOfIncentiveFromLessor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amortization of the deferred credit for an incentive or inducement received by a lessee from a lessor, in order to motivate the lessee to enter the lease agreement, amortized over the term of the lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_AmortizationOfIncentiveFromLessor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the combined value of accretion of temporary equity during the period due to unpaid dividends and accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in monies given as security or collateral for items acquired or borrowed on a temporary basis. Deposits may also be paid as initial payment of the cost of acquisition or for the right to enter into a contract or agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of long-term borrowing, with the highest claim on the assets of the entity in case of bankruptcy or liquidation, as it matures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of notes retired (or transferred to another entity) in noncash investing or financing transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongtermLoansFromVendors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflows under financing arrangements with vendors (seller-financed debt), which had a maturity date at inception of more than one year (or more than one operating cycle, if longer); such debt may have arisen from purchases of property, plant and equipment or other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongtermLoansFromVendors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6766796112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789488128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>NATURE OF BUSINESS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF BUSINESS</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>1. NATURE OF BUSINESS</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Collegium Pharmaceutical,&#160;Inc. (the "Company") was incorporated in Delaware in April 2002 and then reincorporated in Virginia in July 2014. The Company has its principal operations in Canton, Massachusetts. The Company is a specialty pharmaceutical company developing and planning to commercialize next-generation abuse-deterrent products that incorporate the Company's patented DETERx&#174; platform technology for the treatment of chronic pain and other diseases. The Company's lead product candidate, Xtampza&#8482; ER, or Xtampza, is an abuse-deterrent, extended-release, oral formulation of oxycodone, a widely prescribed opioid medication. Xtampza has received Fast Track status from the U.S. Food and Drug Administration ("FDA"). The Company's new drug application ("NDA") filing for Xtampza was accepted by the FDA on February&#160;10, 2015. On February&#160;25, 2015, the FDA set a Prescription Drug User Fee Act, or PDUFA, goal date of October&#160;12, 2015 for completion of its review of the Xtampza NDA. On November&#160;6, 2015, the FDA granted tentative approval to the Xtampza NDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. With a tentative approval, the FDA has determined that Xtampza meets the required quality, safety and efficacy standards for approval but that it is subject to an automatic stay of up to 30&#160;months as a result of patent litigation filed by Purdue Pharma, L.P (Purdue) in March 2015.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company's operations are subject to certain risks and uncertainties. The principal risks include negative outcome of clinical trials, inability or delay in completing clinical trials or obtaining regulatory approvals, changing market conditions for products being developed by the Company, the need to retain key personnel and protect intellectual property, patent infringement litigation and the availability of additional capital financing on terms acceptable to the Company.</font></p>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>1. NATURE OF BUSINESS</b></font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Organization</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Collegium Pharmaceutical,&#160;Inc. (the "Company") was incorporated in Delaware in April 2002 and then reincorporated in Virginia in July 2014. The Company has its principal operations in Canton, Massachusetts. The Company is a specialty pharmaceutical company developing and planning to commercialize next-generation abuse-deterrent products that incorporate the Company's patented DETERx&#174; platform technology for the treatment of chronic pain and other diseases. The Company's lead product candidate, Xtampza&#8482; ER, or Xtampza, is an abuse-deterrent, extended-release, oral formulation of oxycodone, a widely prescribed opioid medication. Xtampza has received Fast Track status from the U.S. Food and Drug Administration ("FDA"). The Company's new drug application ("NDA") filing for Xtampza was accepted by the FDA on February&#160;10, 2015.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company's operations are subject to certain risks and uncertainties. The risks include negative outcome of clinical trials, inability or delay in completing clinical trials or obtaining regulatory approvals, changing market conditions for products being developed by the Company, the need to retain key personnel and protect intellectual property, patent infringement litigation and the availability of additional capital financing on terms acceptable to the Company.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Basis of Accounting</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The financial statements include the accounts of the Company and are prepared in conformity with accounting principles generally accepted in the United States of America.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Liquidity</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company has experienced net losses and negative cash flows from operating activities since its inception, and as of December&#160;31, 2013 and December&#160;31, 2014, had a deficit accumulated of $80,536 and $101,753, respectively. The Company expects to continue to incur net losses in the foreseeable future. A successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company's cost structure.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">On March&#160;6, 2015, the Company received aggregate consideration of $50,000 from the issuance of Series&#160;D preferred stock, comprised of $45,000 in cash and $5,000 in convertible notes from related parties.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company expects to continue to incur losses for the foreseeable future. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic partners or from other sources. The Company believes that it will have sufficient cash to fund operations and future growth initiatives through December&#160;31, 2015; however, there can be no assurance that the Company will be successful in achieving its projections, reducing costs, or raising additional funds with terms acceptable to the Company. If the Company is unable to obtain financing or increase profitability, the related lack of liquidity will have a material adverse effect on the Company's operations and future prospects.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780286192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Basis of presentation</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial reporting and as required by Regulation&#160;S-X, Rule&#160;10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the interim periods ended September&#160;30, 2015 and 2014 are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The condensed interim financial statements should be read in conjunction with the audited financial statements and notes as of and for the year ended December&#160;31, 2014.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Initial Public Offering</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In May 2015, the Company closed an initial public offering ("IPO") of its common stock, which resulted in the sale of 6,670,000 shares of its common stock at a public offering price of $12.00 per share, including 870,000 shares of common stock upon the exercise by the underwriters of their option to purchase additional shares at the public offering price. The Company received proceeds from the IPO of approximately $72,029, after deducting underwriting discounts, commissions and expenses payable by the Company.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In connection with preparing for the IPO, the Company's Board of Directors and shareholders approved a one-for-6.9 reverse stock split of the Company's common stock. The reverse stock split became effective in April 2015. All share and per share amounts in the condensed interim financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. In connection with the closing of the IPO, all of the Company's outstanding convertible preferred stock automatically converted to common stock in May 2015, resulting in an additional 12,591,456 shares of common stock of the Company becoming outstanding. The significant increase in common stock outstanding in May 2015 is expected to impact the year-over-year comparability of the Company's net loss per share calculations in future periods.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Subsequent Events</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Through November&#160;12, 2015, the Company has concluded that no subsequent events have occurred that require disclosure, except as described in Note&#160;9.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Critical Accounting Policies</b></font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2"><i><!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->Earnings (Loss) per Common Share</i></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Earnings (loss) per common share is calculated using the two-class method, which is an earnings allocation formula that determines earnings (loss) per share for the holders of the Company's common shares and participating securities. All series of preferred stock contain participation rights in any dividend paid by the Company and are deemed to be participating securities. Earnings available to common shareholders and participating convertible redeemable preferred shares is allocated first to the preferred stock based upon the distribution criteria in the Company's Articles of Incorporation then the remainder to the common shareholders. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods that have a net loss.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Diluted earnings per share is computed using the more dilutive of (a)&#160;the two-class method, or (b)&#160;the if-converted method. The Company allocates earnings first to preferred shareholders based on dividend rights and then to common and preferred shareholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted earnings (loss) gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants, convertible redeemable preferred stock and the potential issuance of stock upon the conversion of the Company's convertible notes. Common stock equivalent shares are excluded from the computation of diluted earnings (loss) per share if their effect is antidilutive.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Recent Accounting Pronouncements</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In May 2014, the Financial Accounting Standards Board ("FASB"), issued Accounting Standards Update ("ASU"), No.&#160;2014-09, which amends the guidance for accounting for revenue from contracts with customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification ("ASC"), Topic 605, Revenue Recognition, and creates a new Topic 606, Revenue from Contracts with Customers. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain practical expedients permitted; or retrospectively with the cumulative effect of initially adopting the ASU recognized at the date of initial application. On August&#160;12, 2015, the FASB issued ASU No.&#160;2015-14, which defers the effective date of ASU No.&#160;2014-09 by one year to December&#160;15, 2017 for annual reporting periods beginning after that date, including interim periods within those periods. The FASB also approved permitting early adoption of the standard, but not before the original effective date of December&#160;15, 2016. The Company has not yet determined which adoption method it will utilize or the effect that the adoption of this guidance will have on its financial statements.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In July 2015, the FASB issued ASU No.&#160;2015-11, which amends existing guidance for measurement of inventory. Current inventory guidance requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. The amendments do not apply to inventory that is measured using last-in, first-out (LIFO) or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out or average cost. An entity should measure all inventory to which the amendments apply at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The amendments in the ASU No.&#160;2015-11 more closely align the measurement of inventory pursuant to GAAP with the measurement of inventory pursuant to International Financial Reporting Standards. The amendments are effective for fiscal years beginning after December&#160;15, 2016, and interim periods within fiscal years beginning after December&#160;15, 2017. The amendments should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company does not expect the adoption of this guidance to have a material impact on its condensed financial statements.</font></p>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Use of Estimates</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The preparation of the Company's financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company's financial statements and accompanying notes. The most significant estimates in the Company's financial statements relate to the valuation of equity awards, fair value estimates of warrants, estimated useful lives of fixed assets, asset retirement obligations and accruals related to clinical trials. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company's actual results may differ from these estimates under different assumptions or conditions.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Unaudited Pro Forma Net Loss per Share Information</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Unaudited pro forma net loss per share applicable to common shareholders is computed using the weighted-average number of common shares outstanding after giving effect to the conversion of all the outstanding convertible redeemable preferred stock into shares of common stock as if such conversion had occurred at the beginning of the period presented, or the date of original issuance, if later, and excludes the gain on extinguishment of preferred stock and the accretion of dividends.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Fair Value Measurements</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Disclosures of fair value information about financial instruments are required, whether or not recognized in the balance sheet, for financial instruments with respect to which it is practicable to estimate that value. The carrying amounts reported in the Company's financial statements for cash and cash equivalents, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these accounts.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Fair Value Measurements and Disclosures describes the fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, as follows:</font></p>
<p style="FONT-FAMILY: arial;"><font size="2"><b>Level&#160;1</b></font><font size="2">&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. The Company's Level&#160;1 assets and liabilities consist of money market investments.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2"><b>Level&#160;2</b></font><font size="2">&#160;&#160;&#160;&#160;Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level&#160;2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security. The Company does not have Level&#160;2 assets or liabilities.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2"><b>Level&#160;3</b></font><font size="2">&#160;&#160;&#160;&#160;Pricing inputs are unobservable for the assets or liabilities, that is, inputs that reflect the reporting entity's own assumptions about the assumptions market participants would use in pricing the assets. Level&#160;3 includes private investments that are supported by little or no market activity. The Company does not have Level&#160;3 assets or liabilities.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Transfers are calculated on values as of the transfer date. There were no transfers between Levels&#160;1, 2 and 3 during the years ended December&#160;31, 2013 and 2014.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Concentration of Credit Risk</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the financial institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Cash and Cash Equivalents</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Cash and cash equivalents include cash in readily available checking and savings accounts and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company's cash equivalents, which consist of money market funds, are measured at fair value on a recurring basis. As of December&#160;31, 2013 and 2014, the carrying amount of cash and cash equivalents was $7,551 and $1,634, respectively, which approximates fair value and was determined based upon Level&#160;1 inputs. Money market funds are valued using quoted market prices with no valuation adjustments applied. Accordingly, these securities are categorized as Level&#160;1.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Property and Equipment</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Property and equipment are recorded at historical cost. Maintenance and repair costs are expensed as incurred. Costs which materially improve or extend the lives of existing assets are capitalized. The Company provides for depreciation and amortization using the straight-line method over the estimated useful lives of the assets, which are as follows:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table style="text-align:left;TEXT-ALIGN: left;" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" width="40%" align="center"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="40%" align="center"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;" valign="bottom">
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Asset Category</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Estimated Useful Life</b></font></th></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;" valign="top">
<td style="FONT-FAMILY: arial;" align="center"><font size="2">Machinery and equipment</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="center"><font size="2">5&#160;years</font></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;" valign="top">
<td style="FONT-FAMILY: arial;" align="center"><font size="2">Computers and office equipment</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="center"><font size="2">5&#160;years</font></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;" valign="top">
<td style="FONT-FAMILY: arial;" align="center"><font size="2">Furniture and fixtures</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="center"><font size="2">7&#160;years</font></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;" valign="top">
<td style="FONT-FAMILY: arial;" align="center"><font size="2">Leasehold improvements</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="center"><font size="2">5&#160;years</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">Upon retirement or sale, the cost of assets disposed and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recorded in the statements of operations.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Impairment of Long-Lived Assets</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Long-lived assets consist of property and equipment. When impairment indicators exist, the Company's management evaluates long-lived assets for potential impairment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. While the Company's current and historical operating losses and negative cash flows are indicators of impairment, management believes that future cash flows to be received support the carrying value of its long-lived assets and, accordingly, has not recognized any impairment losses since inception.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Impairment losses, if any, are recognized in earnings. An impairment loss would be recognized in an amount equal to the excess of the carrying amount over the undiscounted expected future cash flows.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Initial Public Offering Costs</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company defers direct incremental costs attributable to the initial public offering ("IPO") of its common stock. These costs represent legal, accounting and other direct costs related to the Company's efforts to raise capital through a public sale of its common stock. Future costs will be deferred until the completion of the IPO, at which time they will be reclassified to additional paid-in capital as a reduction of the IPO proceeds. If the Company terminates its plan for an IPO or delays such plan for more than 90&#160;days, any costs deferred will be expensed immediately. As of December&#160;31, 2014, IPO costs were $233 and are included in prepaid expenses and other assets in the balance sheet.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Restricted Cash</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Restricted cash represents cash held in a depository account at a financial institution to collateralize a conditional stand-by letter of credit related to the Company's Canton, Massachusetts facility lease agreement. Restricted cash is reported as non-current unless the restrictions are expected to be released in the next twelve months.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Deferred Rent</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis for the facilities the Company occupies. The Company's lease for its facility provides for fixed increases in minimum annual rental payments and for additional rent in the form of maintenance and operating costs during the lease term. The total amount of rental payments due over the lease term is being charged to rent expense ratably over the life of the lease.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Convertible Redeemable Preferred Stock</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company classifies convertible redeemable preferred stock that is redeemable outside of the Company's control outside of permanent equity. The Company recorded such redeemable preferred stock at fair value upon issuance, net of any issuance costs or discounts, and the carrying value is being increased by periodic accretion to its redemption value at each balance sheet date as if the redeemable preferred stock was redeemable at that date. In the absence of retained earnings these accretion charges are recorded against additional paid-in capital, if any, and then to accumulated deficit.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Research and Development Costs</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Research and development costs are charged to expense as incurred and consist of costs incurred to further the Company's research and development activities including salaries and employee related costs, costs associated with market research and design, costs associated with conducting preclinical, clinical and regulatory activities including fees paid to third-party professional consultants and service providers, costs incurred under clinical trial agreements, costs for laboratory supplies and laboratory equipment, costs to acquire, develop and manufacture preclinical study and clinical trial materials, facilities, depreciation and other expenses including allocated expenses for rent and maintenance of facilities. Government grants are recognized as a reduction of the qualifying cost being reimbursed.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Patent Costs</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Costs related to filing and pursuing patent applications are recorded as general and administrative expense as incurred since the recoverability of such expenditures is uncertain.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Stock-Based Compensation</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company accounts for grants of stock options and restricted stock to employees based on their grant date fair value and recognizes compensation expense over their vesting period. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the fair value of the underlying common stock as determined by management or the value of the services provided, whichever is more readily determinable.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Stock-based compensation expense represents the cost of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of estimated forfeitures. The expense is adjusted for actual forfeitures at year end. Stock-based compensation expense recognized in the financial statements is based on awards that are ultimately expected to vest.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">For stock option grants with performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable or the performance condition has been achieved. For stock option grants with both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company accounts for stock options and restricted stock awards to non-employees using the fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic revaluation over their vesting terms. There were no non-employee grants in 2013 and 2014.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Income Taxes</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company accounts for income taxes under the liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the years in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future, in excess of its net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company records uncertain tax positions on the basis of a two-step process whereby (i)&#160;management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii)&#160;for those tax positions that meet the more likely than not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50&#160;percent likely to be realized upon ultimate settlement with the related tax authority. The Company will recognize interest and penalties related to uncertain tax positions within income tax expense. Any accrued interest and penalties will be included within the related tax liability. As of December&#160;31, 2013 and 2014, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company's statements of operations.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Net loss per Common Share</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Basic net loss per common share is calculated by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock options, warrants, redeemable convertible preferred stock and unvested restricted stock are considered potentially dilutive securities. Because the Company has reported a net loss for the twelve months ended December&#160;31, 2013 and 2014, diluted net loss per common share is the same as basic net loss per common share for those periods.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Diluted earnings per share is computed using the more dilutive of (i)&#160;the two-class method, or (ii)&#160;the if-converted method. The Company allocates earnings first to preferred shareholders based on dividend rights and then to common and preferred shareholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted earnings (loss) gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants, convertible redeemable preferred stock and the potential issuance of stock upon the conversion of the Company's convertible notes. Common stock equivalent shares are excluded from the computation of diluted earnings (loss) per share if their effect is antidilutive.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Recently Issued Accounting Pronouncements</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In July 2013, the Financial Accounting Standards Board ("FASB") issued ASU No.&#160;2013-11,</font> <font size="2"><i>Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exist.</i></font> <font size="2">ASU&#160;2013-11 amends the presentation requirements of ASC&#160;740 and requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, similar tax loss, or a tax credit carryforward. To the extent the tax benefit is not available at the reporting date under the governing tax law or if the entity does not intend to use the deferred tax asset for such purpose, the unrecognized tax benefit should be presented as a liability and not combined with deferred tax assets. This ASU is effective for annual periods, and interim periods within those years, beginning after December&#160;15, 2013, which is fiscal 2014 for the Company. The amendments are to be applied to all unrecognized tax benefits that exist as of the effective date and may be applied retrospectively to each prior reporting period presented. The adoption of ASU&#160;2013-11 did not have a material impact on the Company's financial position or results of operations.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In May 2014, the FASB issued ASU No.&#160;2014-09,</font> <font size="2"><i>Revenue from Contracts with Customers.</i></font> <font size="2">This ASU is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This ASU is effective for annual reporting periods beginning after December&#160;15, 2016 and early adoption is not permitted. Accordingly, the Company will adopt this ASU on January&#160;1, 2017. Management does not believe the adoption of this ASU will have a material impact on the Company's financial condition, results of operations or cash flows.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In June 2014, the FASB issued ASU No.&#160;2014-12,</font> <font size="2"><i>Compensation&#160;&#8212; Stock Compensation (Topic&#160;718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period</i></font><font size="2">. ASU&#160;2014-12 applies to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. That is the case when an employee is eligible to retire or otherwise terminate employment before the end of the period in which a performance target (for example, an initial public offering or a profitability target) could be achieved and still be eligible to vest in the award if and when the performance target is achieved. The standard is required to be adopted by public business entities in annual periods beginning on or after December&#160;15, 2015 and interim periods within those annual periods. The Company plans to implement this standard in the first quarter of fiscal year 2016 and is currently evaluating the potential impact of this new guidance on its financial statements.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In August 2014, the FASB issued ASU No.&#160;2014-15,</font> <font size="2"><i>Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern.</i></font> <font size="2">ASU&#160;2014-15 requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU&#160;2014-15 is effective for annual periods ending after December&#160;15, 2016 and earlier application is permitted. The adoption of ASU&#160;2014-15 is not expected to have a material effect on the Company's financial statements or disclosures.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In November 2014, the FASB issued ASU No.&#160;2014-16,</font> <font size="2"><i>Derivatives and Hedging (Topic&#160;815)&#160;&#8212; Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share is More Akin to Debt or to Equity</i></font><font size="2">. This ASU was issued to clarify how current U.S. generally accepted accounting principles should be interpreted in evaluating the economic characteristics and risk of a host contract in a hybrid financial instrument that is issued in the form of a share. In addition, this ASU was issued to clarify that in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (that is, the relative strength of the debt-like or equity-like terms and features given the facts and circumstances) when considering how to weight those terms and features. The effects of initially adopting this ASU should be applied on a modified retrospective basis to existing hybrid financial instruments issued in a form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods. This ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2015. Early adoption in an interim period is permitted. The Company is currently evaluating the impact of the adoption of this ASU on its financial statements.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6770349552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER COMMON SHARE</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>3. NET LOSS PER COMMON SHARE</b></font></p>
<div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="56"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="73"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Nine months ended<br />
September&#160;30,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2015</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Net loss</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(14,448</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(17,730</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Extinguishment of preferred stock&#160;&#8212; see note&#160;7</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">31,806</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Accretion of prior preferred stock&#160;&#8212; see note&#160;7</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(2,469</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(23,327</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Accretion and dividends of Series&#160;D preferred stock</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(1,245</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Loss attributable to common shareholders&#160;&#8212; basic and diluted</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(16,917</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(10,496</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Weighted-average number of common shares used in net loss per share&#160;&#8212; basic and diluted</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">926,597</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">11,179,756</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Net loss per share&#160;&#8212; basic and diluted</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(18.26</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(0.94</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">The following potentially dilutive securities, which represent all outstanding potentially dilutive securities, were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in common stock equivalent shares):</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="59"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="59"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Nine months ended<br />
September&#160;30,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2015</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding stock options</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">311,365</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,356,246</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Warrants</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">18,810</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">2,445</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Redeemable convertible preferred stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6,552,820</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested restricted stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">28,536</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">153,589</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>3. NET LOSS PER COMMON SHARE</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. Stock options, warrants, convertible preferred stock and unvested restricted stock are considered to be potentially dilutive securities and are only included in the calculation of diluted net loss per share when their effect is dilutive. For the twelve months ended December&#160;31, 2013 and December&#160;31, 2014, these securities were anti-dilutive due to the net losses in those periods and, therefore, the number of shares used to compute basic and diluted earnings per share are the same for of those periods.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The following table presents the computations of basic and dilutive net loss per share:</font></p>
<div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="67"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="56"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Years Ended December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Net loss</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(16,197</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(17,917</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Performance Adjustment of Series&#160;A</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">12,239</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Accruals of dividends and accretion to redemption value of preferred stock</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(2,925</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(3,300</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Loss attributable to common shareholders&#160;&#8212; basic and diluted</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(6,883</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(21,217</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Weighted-average shares used in computing basic and diluted net loss per common share</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">1,697,044</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">933,997</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Basic and diluted net loss per common share</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(4.06</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(22.72</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares):</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="59"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="59"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Years Ended December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Stock Options</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">229,791</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">281,029</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Warrants</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">4,170</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">18,809</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Redeemable convertible preferred stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6,552,820</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6,552,820</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested restricted stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">55,298</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">15,387</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6795310560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2014</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>4. PREPAID EXPENSES AND OTHER CURRENT ASSETS</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Prepaid expenses and other current assets consisted of the following:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="42"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="42"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>As of December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Other current assets</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">253</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Initial public offering costs</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">233</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Employee advances</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">21</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">33</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Prepaid expenses</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">33</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">8</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Prepaid development costs</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">656</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Prepaid expenses and other current assets</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">710</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">527</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6795333520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2014</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>5. PROPERTY AND EQUIPMENT</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Property and equipment consisted of the following:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="42"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="42"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>As of December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Machinery and equipment</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">741</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">741</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Computers and office equipment</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">26</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">26</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Furniture and fixtures</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">36</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">44</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Leasehold improvements</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">606</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">606</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Total property and equipment</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,409</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,417</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Less: accumulated deprecation</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(716</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(903</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Property and equipment, net</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">693</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">514</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">Depreciation expense related to property and equipment amounted to $169 and $187 for the years ended December&#160;31, 2013 and 2014, respectively.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6769772384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>5. ACCRUED EXPENSES</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Accrued expenses consisted of the following:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="68"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="70"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>December&#160;31,<br />
2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>September&#160;30,<br />
2015</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued compensation</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">635</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,169</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued development costs</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">970</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">597</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued marketing</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">685</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued audit and legal</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">249</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">109</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued interest</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">71</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">31</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued other</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">31</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">90</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Total accrued expenses</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,956</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">2,681</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>6. ACCRUED EXPENSES</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Accrued expenses consisted of the following:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="42"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="42"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>As of December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued development costs</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">520</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">970</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued compensation</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">449</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">635</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued audit and legal</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">12</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">249</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued interest</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">71</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued other</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">32</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">31</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Total accrued expenses</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,013</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,956</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6770013200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>9. COMMITMENTS AND CONTINGENCIES</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company's NDA filing for Xtampza is a 505(b)(2) application, which allows the Company to reference data from an approved drug listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the "Orange Book"), in this case OxyContin OP. In connection with the 505(b)(2) process, the Company certified to the FDA and notified Purdue Pharma,&#160;L.P. ("Purdue"), as the holder of the NDA and any other Orange Book-listed patent owners, that the Company does not infringe any of the patents listed for OxyContin OP in the Orange Book. Under the Hatch-Waxman Act of 1984 (the "Hatch-Waxman Act"), Purdue can elect to sue the Company for infringement, and if they do, receive a stay of up to 30&#160;months before the FDA can issue a final approval for Xtampza, unless the stay is earlier terminated. On March&#160;24, 2015, Purdue sued the Company in the District of Delaware asserting infringement of four patents. On March&#160;26, 2015, Purdue filed a second suit against the Company in the District of Massachusetts asserting infringement of the same four patents. On July&#160;23, 2015, Purdue voluntarily dismissed the Massachusetts suit. On August&#160;6, 2015, the Delaware court dismissed the suit in Delaware and issued a memorandum opinion finding the Delaware court lacks personal jurisdiction over the Company Following the dismissal in Delaware, on August&#160;6, 2015, the Company filed a complaint in the Southern District of New York asserting an action to obtain patent certainty, and requesting that the New York court find that Xtampza will not infringe any valid patent claim of the patents asserted by Purdue in the Delaware action. Also on August&#160;6, 2015, Purdue sued the Company in the District of Massachusetts asserting the same claims as the prior suit. On August&#160;7, 2015, Purdue filed a motion in the Delaware court requesting reconsideration of the August&#160;6, 2015 order that dismissed the case. In the motion requesting reconsideration, Purdue asked that the Delaware court find that it does have personal jurisdiction over the Company and then transfer the case to the District of Massachusetts. On October&#160;7, 2015, the Delaware court transferred the case to the District of Massachusetts. On November&#160;9, 2015, the Company filed a motion for summary judgment, for which it requested expedited hearing in Massachusetts. At this time the Company is unable to provide meaningful quantification of how this litigation may impact its future financial condition, results of operations, or cash flows.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In March 2015, the Company amended its lease to include an additional 9,660 square feet of space for a total of 19,335 square feet. In addition, the lease term was extended and now terminates on the date that is 5&#160;years following August 2015 which is the date that the landlord delivered the expansion space with certain improvements substantially completed. At the Company's election, the lease term may be extended for an additional 5-year term.</font></p>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>7. COMMITMENTS AND CONTINGENCIES</b></font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Legal Proceedings</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">From time to time the Company may face legal claims or actions in the normal course of business. The Company is not currently a party to any litigation and, accordingly, does not have any amounts recorded for any litigation related matters.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company's NDA filing for Xtampza is a 505(b)(2) application, which allows the Company to reference data from an approved drug listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the "Orange Book"), in this case OxyContin OP. In connection with the 505(b)(2) process, the Company certified to the FDA and notified Purdue Pharma,&#160;L.P. ("Purdue"), as the holder of the NDA and any other Orange Book-listed patent owners, that the Company does not infringe any of the patents listed for OxyContin OP in the Orange Book. Under the Hatch-Waxman Act of 1984 (the "Hatch-Waxman Act"), Purdue can elect to sue the Company for infringement, and if they do, receive a stay of up to 30&#160;months before the FDA can issue a final approval for Xtampza, unless the stay is earlier terminated. Purdue has not yet brought such litigation, but it is possible that they will do so. At this time the Company is unable to provide meaningful quantification of how this potential litigation may impact its future financial condition, results of operations, or cash flows.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Operating Leases</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company leases its office and research facility under a non-cancellable operating lease, which expires in December 2017. Terms of the agreement provide for an initial two-month rent-free period and future rent escalation, and provide that in addition to minimum lease rental payments, the Company is responsible for a pro-rata share of operating expenses and taxes. Aggregate minimum annual lease commitments of the Company under its non-cancellable operating lease as of December&#160;31, 2014 are as follows:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="31"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" nowrap="nowrap" align="left">
<div style="MARGIN-BOTTOM: 0pt; WIDTH: 95pt; BORDER-BOTTOM: #000000 1pt solid;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Year Ending December&#160;31, <!-- COMMAND=ADD_SCROPPEDRULE,95pt --></b></font></div></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">2015</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">106</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">2016</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">111</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">2017</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">116</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Total minimum lease payments</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">333</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">Rent expense under the operating lease agreement amounted to approximately $69 for the years ended December&#160;31, 2013 and 2014, respectively. In addition, the Company maintained a stand-by letter of credit in connection with the Canton facility lease of $80 at December&#160;31, 2013 and December&#160;31, 2014. This amount is classified as restricted cash in the balance sheets.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">As an inducement to enter into its Canton facility lease, the lessor agreed to provide the Company with an improvement allowance of up to $174 towards leasehold improvements. In addition the lessor provided the Company with a reimbursable allowance of $164 which is to be amortized and repaid by the Company at an 8% interest rate over the initial term of 36&#160;months. Amounts provided by the lessor related to tenant improvements are considered inducements to enter into the lease. The Company has recorded these costs in the balance sheet as leasehold improvements, with the corresponding liabilities as deferred lease incentive and lease note payable. These liabilities are amortized on a straight-line basis over the term of the lease.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6795305664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2014</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>8. DEBT</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">On August&#160;28, 2012, the Company entered into a loan agreement ("Original Term Loan") with Silicon Valley Bank ("SVB") to borrow up to a maximum amount of $1,000. In August 2012, October 2012 and February 2013, the Company borrowed $250, $250 and $500, respectively. The Original Term Loan bore interest at a rate per annum of 2.25% above the prime rate fixed at the time of advance of the Original Term Loan (5.50%). The Original Term Loan provided for interest-only payments for the first 12&#160;months based on the date of each borrowing, and, thereafter, 36&#160;monthly payments of principal and interest. In connection with the Original Term Loan, the Company granted SVB a warrant to purchase 23,810 shares of common stock at an exercise price of $0.07 per share (See Note&#160;9).</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In January 2014, the Original Term Loan was amended ("Amendment No.&#160;1") to provide for the following; borrowings of up to $6,000, repayment in full of the Original Term Loan balance outstanding, and an adjustment of the variable interest rate from 2.25% above the prime rate to 1.75% above the prime rate. In February 2014, the Company borrowed $2,000. The proceeds from the initial borrowing were used to pay down the Original Term Loan balance outstanding resulting in the Company receiving $1,056. Borrowings under Amendment No.&#160;1 bore interest at a rate of 5.0%. Amendment No.&#160;1 provided for interest-only payments for the first 12&#160;months based on the date of each borrowing, and thereafter, 36&#160;monthly payments of principal and interest. In connection with Amendment No.&#160;1, the Company granted to SVB a warrant to purchase 14,430 shares of common stock with an exercise price of $0.05 per share (See Note&#160;9).</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In August 2014 the Original Term Loan was further amended ("Amendment No.&#160;2") to provide for total borrowings of up to $8,000. In August 2014 and September 2014 the Company drew down $3,000 and $3,000, respectively. Pursuant to Amendment No.&#160;2, interest-only payments are to be made for the first 12&#160;months based on the date of each borrowing; thereafter, 36&#160;monthly payments of principal and interest are to be made. Borrowings under Amendment 2 bear interest at the rate of 5.0%. The warrant agreement contains a performance clause that the Company met, resulting in additional financing extended and issuance of a warrant to purchase 86,580 additional shares of common stock with an exercise price of $0.05 per share (See Note&#160;9).</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In September 2014, the Original Term Loan was further amended ("Amendment No.&#160;3") to extend the loan draw period through the earlier to occur of September&#160;30, 2014 and an Event of Default.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company capitalized deferred financing costs of approximately $38 in entering into the Original Term Loan, of which approximately $16 was repaid at the time of Amendment No.&#160;1 with the remaining approximately $22 being amortized to interest expense over the term of the debt. The balance of deferred financing costs was approximately $15 and $7 at December&#160;31, 2013 and December&#160;31, 2014 respectively. The total outstanding amount of the loans was $958 and $8,000 at December&#160;31, 2013 and December&#160;31, 2014 respectively. Interest expense on these notes payable totaled $62 and $208 or the years ended December&#160;31, 2013 and December&#160;31, 2014.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In November and December of 2014 the Company entered into a Note Purchase Agreement (the "Bridge Notes") allowing for the issuance of $5,000 of convertible promissory notes to a group of investors (the "Holders") bearing interest at a rate per annum of 6.0%. The Holders are related parties of the Company. All notes become due and payable at the earlier to occur of a qualified financing, a deemed liquidation event and November 2015.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">As of December&#160;31, 2014, future payments under the Company's debt agreements are as follows:</font></p>
<div style="WIDTH: 75%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 12%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="49"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">2015</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">6,194</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">2016</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">2,667</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">2017</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">2,667</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">2018</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">1,479</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Balance as of December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">13,007</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789629200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2014</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_WarrantsDisclosureTextBlock', window );">WARRANTS</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>9. WARRANTS</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In November 2010, the Company issued to Comerica Bank a warrant to purchase 33,746 shares of a series of then outstanding preferred stock with an exercise price of $1.778 per share through October&#160;28, 2017. In February 2012, all outstanding shares of Preferred Stock were converted to shares of Series&#160;A Preferred Stock. As such the warrant was amended to be exercisable into 33,746 shares of Series&#160;A Preferred Stock. In December 2013, a Performance Adjustment (See Note&#160;10) occurred, pursuant to which the Series&#160;A Preferred Stock and common stock were subject to modification such that every two shares of issued and outstanding Series&#160;A Preferred Stock and common stock became one share of each class respectively, resulting in the warrant being adjusted to represent the right to purchase 16,873 shares of Series&#160;A Preferred Stock. The shares of Series&#160;A Preferred Stock have certain mandatorily redeemable features resulting in the warrant being recorded as a liability and re-measured at each period at fair value. The fair value of the warrant was</font> <font size="2"><i>de minimis</i></font> <font size="2">at December&#160;31, 2013 and December&#160;31, 2014.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In connection with the issuance of the Original Term Loan (See Note&#160;8), in August 2012, the Company issued to SVB a warrant to purchase 3,450 shares of common stock with an exercise price of $0.48 per share through August&#160;27, 2022.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">This Performance Adjustment resulted in the number of common shares issuable upon exercise of the warrant being adjusted to 1,725.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In connection with the execution of Amendment No.&#160;1 to the Original Term Loan in January 2014, the Company issued an additional warrant to the lending financial institution. In January 2014, the Company issued a warrant to purchase 2,091 shares of common stock with an exercise price of $0.35 per share through January&#160;31, 2024. The warrant agreement provides for additional warrant shares to be issued and immediately exercisable upon additional borrowings by the Company. Additional borrowings are contingent upon meeting certain performance measures for the Company's lead product candidate. The Company met the performance measures and in August 2014 additional financing was extended. Based on the terms of the warrant agreement an additional 12,548 shares were granted. The fair value of these warrants was</font> <font size="2"><i>de&#160;minimis</i></font> <font size="2">at December&#160;31, 2013 and December&#160;31, 2014.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_WarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about warrants or rights issued, which may include the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_WarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789631664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2014</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock', window );">EQUITY</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>10. EQUITY</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">As of December&#160;31, 2013, the authorized capital stock of the Company included 72,000,000 shares of common stock, par value $0.001 per share, 962,960 of which were issued and outstanding. As of December&#160;31, 2013, 54,481,000 shares of preferred stock were authorized, designated as Series&#160;A, Series&#160;B and Series&#160;C Preferred Stock of which 9,232,334, 27,324,237 and 8,658,008 were issued and outstanding, respectively.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">As of December&#160;31, 2014, the authorized capital stock of the Company included 72,000,000 shares of common stock, par value $0.001 per share, 1,006,219 of which were issued and outstanding. As of December&#160;31, 2014, 54,481,000 shares of preferred stock were authorized, designated as Series&#160;A, Series&#160;B and Series&#160;C Preferred Stock of which 9,232,334, 27,324,237 and 8,658,008 were issued and outstanding, respectively.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Common Stock</b></font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2"><i><!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->General</i></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The voting, dividend and liquidation rights of the holders of shares of common stock are subject to and qualified by the rights, powers and preferences of the holders of shares of preferred stock. Common stock has the characteristics described herein.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2"><i><!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->Voting</i></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The holders of shares of common stock are entitled to one vote for each share of common stock held, may act by written consent in lieu of shareholder's meetings in accordance with the Company's articles of incorporation, and shall be entitled to notice of shareholder's meetings.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2"><i><!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->Dividends</i></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company shall not declare, pay or set aside any dividends on shares of common stock (other than dividends on shares of common stock payable in shares of common stock) unless in addition to obtaining any consents required by law and/or the Company's articles of incorporation, the holders of Series&#160;A, Series&#160;B and Series&#160;C Preferred Stock then outstanding receive a dividend payment as specified in the Company's articles of incorporation.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2"><i><!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->Liquidation</i></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">After payment of all preferential amounts required to be paid to the holders of shares of Preferred Stock, the remaining assets of the Company available for distribution to the shareholders shall be distributed among the holders of shares of Preferred Stock and common stock pro rata based on the number of shares held by each such holder, treating for this purpose all such securities as if they had been converted to common stock pursuant to the terms of the Company's articles of incorporation immediately prior to such dissolution, liquidation or winding up or deemed liquidation event of the Company.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2"><i><!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->Reserved for future issuance</i></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company has reserved for future issuance the following number of shares of common stock:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="96"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>As of<br />
December&#160;31, 2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Conversion of Series&#160;A Preferred</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">18,498,419</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Conversion of Series&#160;B Preferred</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">27,324,237</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Conversion of Series&#160;C Preferred</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">8,658,344</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Options to purchase common stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">3,412,685</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Total</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">57,893,685</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Convertible Redeemable Preferred Stock</b></font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Series&#160;A, B and Series&#160;C Redeemable Convertible Preferred Stock</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In February 2012, the Company exchanged all previously outstanding preferred stock into 18,464,674 shares of Series&#160;A Preferred Stock ("Series&#160;A"), par value $0.001. On the same date, the Company issued 27,324,237 shares of Series&#160;B Preferred Stock ("Series&#160;B"), par value $0.001 for $0.84 per share, which resulted in gross proceeds of $20,050. Closing costs associated with the issuance of the Series&#160;B amounted to $147. These costs were recorded as a reduction of the carrying amount of the Series&#160;B and are being accreted to the carrying value of the applicable preferred stock. During 2013, the Company issued 8,658,008 shares of Series&#160;C Preferred Stock ("Series&#160;C") in exchange for $12,000 in a series of tranches. Costs incurred in connection with the issuance of Series&#160;C amounted to $45 and have been recorded as a reduction to the carrying amount of Series&#160;C and were accreted to the carrying value of the applicable preferred stock. In accordance with the terms of the Series&#160;C Preferred Stock Purchase Agreement, the Company authorized the sale and issuance of up to 8,658,008 shares of Series&#160;C for total gross proceeds of $12,000. Closing costs associated with the issuance of Series&#160;C amounted to $45. The Series&#160;C financing was structured to close in two tranches. The Company determined the right of the investors to purchase shares of Series&#160;C in a future tranche met the definition of a freestanding financial instrument and was recognized as a liability at fair value. The Company adjusted the carrying value of the tranche obligations to its estimated fair value at each reporting date and upon closing of the second tranche in December 2013. Increases or decreases in the fair value of the tranche obligations were recorded as other expense, net, in the statements of operations.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The first tranche closed in August and September 2013 and resulted in the issuance of 2,886,004 shares of Series&#160;C for gross cash proceeds of $4,000. Upon the first tranche closing, the Company recognized a liability of $266 for the fair value of the future tranche obligations. The fair value of the freestanding instrument tranche obligations was determined using Black-Scholes option-pricing models on the date of the issuance using the following assumptions: fair value of Series&#160;C of $1.30, expected life of 0.35 to 0.43&#160;years and expected volatility of 53% to 60%.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The liability related to the tranche obligations was remeasured at fair value up to the date of the closing of the second tranche in December 2013. Upon the closing of the second tranche, the Company derecognized the tranche obligation, which resulted in a net increase in the proceeds allocated to the Series&#160;C shares of $345. The fair value of the freestanding instrument tranche obligations was determined using Black-Scholes option-pricing models on the date of the issuance using the following assumptions: fair value of Series&#160;C of $1.27, expected life of 0.16&#160;years and expected volatility of 52%.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The valuation of the tranche obligation liability was determined to be a Level&#160;3 valuation based upon the use of unobservable inputs. A roll-forward of the recurring fair value measurements of the tranche liability categorized with Level&#160;3 inputs are as follows:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="35"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Balance&#160;&#8212; December&#160;31, 2012</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Tranche liability upon issuance</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">266</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Change in fair value</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">79</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Tranche liability upon close of tranche</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(345</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Balance&#160;&#8212; December&#160;31, 2013</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">The closing of the second tranche of Series&#160;C in December 2013 triggered the Performance Adjustment (described below) of the outstanding shares of Series&#160;A and common stock to which the Series&#160;A and common stock were subject to modification in which every two shares of issued and outstanding Series&#160;A and common shares became one share of each class respectively. In connection with the Performance Adjustment, the Company adjusted the carrying value of the outstanding shares of Series&#160;A to its redemption amount by recording a decrease of $12,239.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">As of December&#160;31, 2014, the holders of Series&#160;A, Series&#160;B and Series&#160;C Preferred Stock had rights, preferences, privileges and restrictions as follows:</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2"><i><!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->Voting</i></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The holders of shares of Preferred Stock are entitled to the number of votes equal to the number of whole shares of common stock into which the shares of the applicable series of Preferred Stock held by such holder are convertible as of the record date. Except as provided by law or otherwise, the holders of shares of Preferred Stock vote together with the holders of shares of common stock as a single class. The holders of record of Series&#160;A exclusively and as a separate class are entitled to elect two directors of the Company. The holders of record of Series&#160;B and Series&#160;C exclusively and as a separate class are entitled to elect one director, respectively, of the Company. The Company cannot amend, alter or repeal the preferences, special rights or other powers of the Series&#160;A, Series&#160;B or Series&#160;C without the written consent or affirmative vote of not less than 66% of the then outstanding shares of the respective class.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2"><i><!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->Dividends</i></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">From and after the issuance of any shares of Series&#160;A, Series&#160;B and Series&#160;C cumulative non-compounding stock, dividends will accrue at a rate of 4.5%, 8.0% and 8.0% per annum respectively per share. In the event a dividend is declared on common stock, Series&#160;A, Series&#160;B and Series&#160;C will receive a dividend equal to the equivalent number of common shares multiplied by the dividend payable on each class of stock. The Company has recorded cumulative accrued dividends for Series&#160;A, Series&#160;B and Series&#160;C of $2,371, $5,307 and $1,114, respectively, as of December&#160;31, 2013 and 2014.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2"><i><!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->Conversion</i></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Each share of Series&#160;A, Series&#160;B and Series&#160;C is convertible at the option of the holder at any time into such number of fully paid and nonassessable shares of common stock as is determined by dividing the original issue price of each Series by its conversion price of $8.46, $5.80 and $9.59 per share, respectively.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Conversion is mandatory for all Series upon an IPO with gross proceeds in excess of $50,000 and a price per share of at least $20.70.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2"><i><!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->Special Mandatory Conversion</i></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Any holder of at least 1,000,000 shares of Preferred Stock who does not participate in a Qualified Financing by purchasing such holder's applicable portion of the shares of each Preferred Stock, within the time period specified by the Company, are automatically converted into shares of Common Stock at the applicable Conversion Price to that series of Preferred Stock concurrently with the Qualified Financing. A Qualified Financing is a financing or series of financings after the issuance date of the Series&#160;C involving the sale of additional shares of common stock (including pursuant to the conversion of debt) with gross proceeds of more than $1,000.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2"><i><!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->Liquidation Rights</i></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the affairs of the Company or a Deemed Liquidation Event, the holders of Series&#160;B are entitled to be paid out an amount per share equal to two times the Series&#160;B original issue price of $5.80 plus unpaid accrued dividends. The holders of Series&#160;A and Series&#160;C are entitled to be paid out an amount per share equal to one times the original issue price of $8.46 and $9.59, respectively, plus any unpaid accrued dividends. After the payment of all preferential amounts required to be paid to the holders of the Preferred Stock, all the remaining assets of the Company shall be distributed among the holders of the common and Preferred Stock pro rata based on the number of shares held.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2"><i><!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->Participation</i></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In the event of liquidation, payment to the holders of Series&#160;C shall precede payment to the holders of Series&#160;B, which shall precede payment to the holders of Series&#160;A. Holders of Series&#160;C shall be paid at their Original Issuance Price plus any unpaid accrued dividends. In the event that the amount to be distributed to the shareholders is in excess of the Series&#160;A, Series&#160;B and Series&#160;C liquidation preferences, the preferred holders shall participate on an as-converted basis with the common stock holders in the distribution of the remaining assets.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2"><i><!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->Redemption</i></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company shall require a redemption of Series&#160;A, Series&#160;B and Series&#160;C in the event of a deemed liquidation event, including (i)&#160;merger or consolidation, (ii)&#160;sale or transfer of substantially all of the Company's assets or (iii)&#160;sale or exchange or transfer by the Company's shareholders of a majority of the voting power of the Company unless the requisite holders (as defined in the Company's articles of incorporation) elect otherwise.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">There is an optional redemption feature on or after August&#160;27, 2019 for all series of Preferred Stock, upon a vote of at least 60% of the holders of the Preferred Stock voting as a single class. The payment is equal to the original issuance price for Series&#160;A and Series&#160;C and two (2)&#160;times the original issuance price for Series&#160;B, plus unpaid accrued dividends on the date of the redemption. Optional redemption shall be paid in three installments.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2"><i><!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->Protective Provision</i></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">At any time when there are shares of Series&#160;B and Series&#160;C outstanding the Company will not engage in certain activities (including enter into a liquidating event) without written consent of a majority of the Series&#160;B and Series&#160;C holders.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2"><i><!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->Performance Adjustment</i></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company's articles of incorporation provided that if the Company raised additional capital in excess of $4,000 after the initial closing of the Series&#160;C financing, that such additional financing would trigger a one-time modification of the Series&#160;A and common stock shares (the "Performance Adjustment"), such that every two shares of issued and outstanding Series&#160;A and common stock became one share of each class, respectively. The Performance Adjustment occurred in December 2013.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Combined disclosure for securities with redemption features that are outside the control of the issuer and shareholders' equity which may include, for temporary equity, a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable; and for stockholders' equity, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityAndStockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6784095280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK BASED COMPENSATION</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>8. STOCK-BASED COMPENSATION</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In July 2014, the Company adopted the 2014 Stock Incentive Plan (the "Plan"), under which 525,700 shares of common stock are authorized for issuance to employees, officers, directors, consultants and advisors of the Company. In connection with the Company's reincorporation into Virginia in July 2014, each outstanding option to purchase shares of common stock under the Company's 2012 Stock Incentive Plan and 2002 Stock Plan, was automatically terminated and replaced with an option to purchase shares of common stock under the Plan having the same vesting terms and exercise price as the option that was replaced. The Plan provides for granting of both Internal Revenue Service qualified incentive stock options ("ISOs") and non-qualified options ("NQs"), restricted stock awards ("RSAs") and restricted stock units ("RSUs"). Stock options generally vest over a four year period of service; however, certain options contain performance conditions. The options generally have a ten year contractual life and, upon termination, vested options are generally exercisable between one and three months following the termination date, while unvested options are forfeited immediately.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In April 2015, the Plan was amended to increase the maximum number of shares of common stock that may be issued to 2,700,000 shares. In addition, an "evergreen provision" was added to the Plan that allows for an annual increase in the number of shares of common stock available for issuance under the Plan. The annual increase will be added on the first day of each fiscal year beginning with the fiscal year ending December&#160;31, 2016, and on each anniversary thereof until the expiration of the Plan equal to 4% of the outstanding shares of our common stock on December&#160;31st&#160;of the immediately preceding fiscal year (or such lesser number of shares of common stock as determined by the board of directors).</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Restricted common stock</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">A summary of the Company's restricted stock activity for the nine months ended September&#160;30, 2015 and related information is as follows:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="53"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="82"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Shares</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted average<br />
purchase price<br />
per share</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">15,387</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.69</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Granted</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">194,694</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">5.73</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Vested</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(128,955</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">5.13</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested at September&#160;30, 2015<sup>(1)</sup></font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">81,126</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">5.73</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --><!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<hr style="COLOR: #000000;" align="left" size="1" width="26%" noshade="noshade" /></div>
<div style="POSITION: relative; PADDING-BOTTOM: 0pt; TEXT-ALIGN: left; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<dl compact="compact">
<dt style="MARGIN-BOTTOM: -9pt; FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><font style="FONT-SIZE: 6pt; POSITION: relative; TOP: -2pt; add_sup: 2pt;">(1)</font></font></dt>
<dd style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">Excludes 72,463 shares of unvested restricted stock remaining from the early exercise of stock options as of September&#160;30, 2015.</font></dd></dl></div>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Stock options</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">A summary of the Company's stock option activity and related information follows:</font></p>
<div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="59"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="65"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="54"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="49"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Shares</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted-<br />
average<br />
exercise price<br />
per share</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted-<br />
average<br />
remaining<br />
contractual<br />
term<br />
(years)</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Aggregate<br />
Intrinsic<br />
Value</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">281,029</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">0.69</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Granted</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">1,197,452</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">10.47</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Exercised</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(121,729</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">3.89</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Cancelled</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(506</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">2.06</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding at September&#160;30, 2015</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">1,356,246</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">9.04</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">9.2</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">17,722</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Exercisable at September&#160;30, 2015</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">208,438</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">2.65</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">7.9</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">4,056</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Vested and expected to vest at September&#160;30, 2015</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">1,341,543</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">9.13</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">9.2</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">18,595</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">The fair value of each stock option is estimated on the grant date using the Black-Scholes option-pricing model using the following assumptions:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="28"></td>
<td style="FONT-FAMILY: arial;" width="24"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="28"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Nine months<br />
ended<br />
September&#160;30,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2015</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Risk-free interest rate</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.8</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.7</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Dividend yield</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Volatility</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">77</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">77</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Expected term (years)</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6.25</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6.21</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>11. STOCK-BASED COMPENSATION</b></font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Restricted Stock Awards and Stock Options</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In July 2014, the Company adopted the 2014 Stock Incentive Plan (the "Plan"), under which 525,700 shares of common stock are authorized for issuance to employees, officers, directors, consultants and advisors of the Company. As of December&#160;31, 2014, 281,029 of the shares of common stock authorized for issuance pursuant to the Plan were outstanding. In connection with the Company's reincorporation into Virginia in July 2014, each outstanding option to purchase shares of common stock under the 2012 Stock Incentive Plan and 2002 Stock Plan, was automatically terminated and replaced with an option to purchase shares of common stock under the Plan having the same vesting terms and exercise price as the option that was replaced. The Plan provides for granting of both Internal Revenue Service qualified incentive stock options ("ISOs") and non-qualified options ("NQs"), restricted stock awards ("RSAs") and restricted stock units ("RSUs"). Stock options generally vest over a four year period of service; however, certain options contain performance conditions. The options generally have a ten year contractual life and, upon termination, vested options are generally exercisable between one and three months following the termination date, while unvested options are forfeited immediately.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In determining the exercise prices for options granted, the board of directors considered the fair value of the common stock as of the measurement date. The fair value of the common stock was determined by the board of directors based on a variety of factors, including valuations prepared by third parties, Company's financial position, the status of development efforts within the Company, the composition and ability of the current scientific and management teams, the current climate in the marketplace, the illiquid nature of the Company's common stock, arm's length sales of the Company's preferred stock, the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event, among others.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In connection with the Performance Adjustment which occurred on December&#160;4, 2013 (See Note&#160;10) the Company adjusted previously granted and then outstanding options such that for each option exercised, the option holder would receive one share of common stock for every two shares of common stock underlying the grant.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Stock option activity under the Plan is summarized as follows:</font></p>
<div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="53"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="47"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="55"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="47"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Number<br />
of Options</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted-<br />
Average<br />
Exercise<br />
Price</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted-<br />
Average<br />
Remaining<br />
Contractual<br />
Term<br />
(in years)</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Aggregate<br />
Intrinsic<br />
Value</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding at December&#160;31, 2012</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">323,488</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.73</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6.94</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">8</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Granted</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">146,730</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.48</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Exercised</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(1,077</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.62</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Cancelled</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(9,559</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">2.76</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Modification</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(229,791</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.17</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding at December&#160;31, 2013</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">229,791</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.17</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">7.02</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">117</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Granted</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">89,641</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.28</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Exercised</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(32,390</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">2.21</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Cancelled</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(6,013</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">4.42</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">281,029</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.69</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">7.49</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,505</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Vested and expected to vest at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">247,139</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.83</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">4.31</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,293</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Exercisable at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">121,304</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.38</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">4.31</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">570</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">As of December&#160;31, 2013 and 2014, the unrecognized compensation cost related to outstanding options was $40 and $215, respectively, and is expected to be recognized as expense over approximately 1.1&#160;years and 1.0&#160;years, respectively.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">As of December&#160;31, 2014, the weighted average fair value of vested options was $1.93.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Additional information about the Company's stock option activity is as follows:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="35"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="35"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>As of<br />
December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Weighted-average grant date fair value per share of employee option grants</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">0.28</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">0.76</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">Restricted stock awards under the Plan are summarized as follows:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="51"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="82"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Number of<br />
Shares</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted-Average<br />
Grant Date<br />
Fair Value</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested at December&#160;31, 2012</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">203,342</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.62</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Vesting of restricted stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(89,308</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.55</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Performance Adjustment</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(58,736</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.62</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested at December&#160;31, 2013</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">55,298</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.69</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Grant of restricted stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">10,869</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.24</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Vesting of restricted stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(50,780</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.62</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">15,387</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.69</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">As of December&#160;31, 2013 and 2014, the unrecognized compensation cost related to restricted stock awards was $73 and $26, respectively, and is expected to be recognized as expense over approximately 1.2&#160;years and 0.2&#160;years, respectively.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Stock-Based Compensation Expense</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company granted stock options to employees for the years ended December&#160;31, 2013 and 2014. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the fair value of the award. Stock options and restricted stock issued to non-board member, non-employees are accounted for using the fair value approach and are subject to periodic revaluation over their vesting terms.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Stock-based compensation for all stock options and restricted stock awards are reported within:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="28"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="28"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Years Ended December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Research and development</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">24</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">12</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">General and administrative</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">38</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">10</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Total stock-based compensation expense</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">62</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">22</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="97" align="center"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="39"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="4" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Years Ended December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Risk-free interest rate</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="center"><font size="2">1.09%&#160;&#8211; 1.22%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.80</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Expected volatility</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="center"><font size="2">87.8%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">77.1</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Expected term (in years)</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="center"><font size="2">6.25</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6.25</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Expected dividend yield</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="center"><font size="2">0.0%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.0</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2"><b><i>Risk-free Interest Rate.</i></b></font><font size="2">&#160;&#160;&#160;&#160;The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the stock option grants.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2"><b><i>Expected Volatility.</i></b></font><font size="2">&#160;&#160;&#160;&#160;Due to the Company's limited operating history and lack of company-specific historical or implied volatility, the expected volatility assumption is based on historical volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology and medical device industries.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2"><b><i>Expected Term.</i></b></font><font size="2">&#160;&#160;&#160;&#160;The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, through December&#160;31, 2014 it determined the expected life assumption using the simplified method, which is an average of the contractual term of the option and its vesting period. In 2013, some of the stock option grants were in-the-money, based on the retrospective fair value determinations, so the Company determined the expected life using a risk-adjusted method, which adjusts the average of the contractual term of the option and its vesting period for risk, thereby reducing the expected life.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2"><b><i>Expected Dividend Yield.</i></b></font><font size="2">&#160;&#160;&#160;&#160;The expected dividend yield assumption is based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6795336960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2014</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>12. INCOME TAXES</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">For the years ended December&#160;31, 2014 and 2013, the Company did not record a current or deferred income tax expense or (benefit) due to current and historical losses incurred by the Company. The Company's losses before income taxes consist solely of domestic losses.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">A reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="42"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="42"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>As of December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Federal income tax (benefit) at statutory rate</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">34.00</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">34.00</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">(Increase) decrease income tax (benefit) resulting from:</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Expiration of state net operating losses</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(12.11</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.00</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Permanent items</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(0.01</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(0.17</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Research and experimental credits</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">4.19</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">3.74</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Change in valuation allowance</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(26.07</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(37.57</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Income tax expense (benefit)</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.00</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.00</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company's deferred tax assets and liabilities are comprised of the following:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="53"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="53"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>As of December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Deferred tax assets:</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Net operating loss carryforwards</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">21,392</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">28,419</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Depreciation and amortization</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">36</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Research Credits</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">2,400</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">3,070</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Deferred tax assets before valuation allowance</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">23,792</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">31,525</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Valuation allowance</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(23,788</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(31,525</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;">&#160;</p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">4</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Deferred tax liabilities:</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Depreciation and amortization</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(4</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;">&#160;</p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(4</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Net deferred tax assets</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. As of December&#160;31, 2014 and 2013, based on the Company's history of operating losses, the Company has concluded that it is not more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December&#160;31, 2014 and 2013. The valuation allowance increased $7,737 during the year ended December&#160;31, 2014, due primarily to net operating losses generated. The valuation allowance increased by $5,081 during the year ended December&#160;31, 2013, due primarily to net operating losses generated.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">As of December&#160;31, 2014 and 2013, the Company had U.S. federal net operating loss carryforwards of $78,276 and $60,380, respectively, which may be available to offset future income tax liabilities and expire at various dates through 2034. As of December&#160;31, 2014 and 2013, the Company also had U.S. state net operating loss carryforwards of $34,184 and $16,354, respectively, which may be available to offset future income tax liabilities and expire at various dates through 2034.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Utilization of the NOL and research and development credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that have occurred or that could occur in the future, as required by Section&#160;382 and Section&#160;383 of the Internal Revenue Code of 1986, as amended (the "Code"), as well as similar state and foreign provisions. These ownership changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an "ownership change" as defined by Section&#160;382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50&#160;percentage points of the outstanding stock of a company by certain shareholders. The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since its formation. The Company has not recorded net operating losses that, as a result of these restrictions, will expire unused.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company files income tax returns in the United States and Massachusetts. The federal and Massachusetts income tax returns are generally subject to tax examinations for the tax years ended December&#160;31, 2011 through December&#160;31, 2013. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax authorities to the extent utilized in a future period.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789587872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFITS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2014</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract', window );"><strong>EMPLOYEE BENEFITS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">EMPLOYEE BENEFITS</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>13. EMPLOYEE BENEFITS</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company has a retirement savings plan, which is qualified under section&#160;401(k) of the Code, for its employees. The plan allows eligible employees to defer, at the employee's discretion, pretax compensation up to the Internal Revenue Service annual limits. Employees become eligible to participate after completing 3&#160;months of service. The Company is not required to contribute to this plan. Total expense for contributions made by the Company was $31 for the year ended December&#160;31, 2013 and $35 for the year ended December&#160;31, 2014.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49170332&amp;loc=SL14450702-114947<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e2410-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39675-114964<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6414199&amp;loc=d3e39622-114963<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789649664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2014</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>14. SUBSEQUENT EVENTS</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company has completed an evaluation of all subsequent events through April&#160;27, 2015, the date these financial statements are available to be issued. The Company has concluded that no subsequent event has occurred that requires disclosure, except as noted below:</font></p>
<dl compact="compact">
<dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: arial;"><font size="2">(a)</font></dt>
<dd style="FONT-FAMILY: arial;"><font size="2">In March 2015, the Company sold 41,666,667 shares of Series&#160;D convertible preferred stock for aggregate consideration of $50,000, comprised of $45,000 in cash and conversion of $5,000 in convertible notes with related parties. The convertible notes converted into 4,166,667 shares of Series&#160;D convertible preferred stock. The accrued interest on the convertible notes was waived. In this financing, the mandatory conversion for all series of preferred stock was modified so as to occur upon an initial public offering with gross proceeds in excess of $50,000.<br />
<br /></font></dd>
<dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: arial;"><font size="2">(b)</font></dt>
<dd style="FONT-FAMILY: arial;"><font size="2">On March&#160;24, 2015, Purdue sued the Company in the District of Delaware asserting infringement of four patents. On March&#160;26, 2015, Purdue filed a second suit against the Company in the District of Massachusetts asserting infringement of the same four patents.<br />
<br /></font></dd>
<dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: arial;"><font size="2">(c)</font></dt>
<dd style="FONT-FAMILY: arial;"><font size="2">In March 2015, the Company granted a total of 638,095 stock options under the Plan to employees. The stock options were granted at fair market value on the date of grant, vest over approximately four years and expire ten years from the date of grant.<br />
<br /></font></dd>
<dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: arial;"><font size="2">(d)</font></dt>
<dd style="FONT-FAMILY: arial;"><font size="2">In March 2015, the Plan was amended to increase the maximum number authorized for issuance pursuant to the Plan to 1,087,005 shares.<br />
<br /></font></dd>
<dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: arial;"><font size="2">(e)</font></dt>
<dd style="FONT-FAMILY: arial;"><font size="2">In March 2015, the Company amended its lease to include an additional 9,660 square feet of space for a total of 19,335 square feet. In addition, the lease term was extended and now terminates on the date that is 5&#160;years following the date, which has not yet been determined, on which the landlord delivers the expansion space with certain improvements substantially completed. At the Company's election, the lease term may be extended for an additional 5-year term.</font></dd></dl>
<dl compact="compact">
<dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: arial;"><font size="2">(f)</font></dt>
<dd style="FONT-FAMILY: arial;"><font size="2">In April 2015, the Company granted 194,694 shares of restricted stock to an employee. Pursuant to the grant, 97,347 shares vested upon grant, while the remaining 97,347 shares of restricted stock vest in monthly installments over a three-year period commencing as of the date of grant.<br />
<br /></font></dd>
<dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: arial;"><font size="2">(g)</font></dt>
<dd style="FONT-FAMILY: arial;"><font size="2">In April 2015, the Company's board of directors and shareholders approved a one-for-6.9 reverse split of the Company's common stock. All common stock share and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse split of our common stock, including reclassifying an amount equal to the reduction in par value to additional paid-in capital.</font></dd></dl>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6805519120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Use of Estimates</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The preparation of the Company's financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company's financial statements and accompanying notes. The most significant estimates in the Company's financial statements relate to the valuation of equity awards, fair value estimates of warrants, estimated useful lives of fixed assets, asset retirement obligations and accruals related to clinical trials. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company's actual results may differ from these estimates under different assumptions or conditions.</font></p>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock', window );">Unaudited Pro Forma Balance Sheet and Net Loss per Share Information</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Unaudited Pro Forma Net Loss per Share Information</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Unaudited pro forma net loss per share applicable to common shareholders is computed using the weighted-average number of common shares outstanding after giving effect to the conversion of all the outstanding convertible redeemable preferred stock into shares of common stock as if such conversion had occurred at the beginning of the period presented, or the date of original issuance, if later, and excludes the gain on extinguishment of preferred stock and the accretion of dividends.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Fair Value Measurements</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Disclosures of fair value information about financial instruments are required, whether or not recognized in the balance sheet, for financial instruments with respect to which it is practicable to estimate that value. The carrying amounts reported in the Company's financial statements for cash and cash equivalents, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these accounts.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Fair Value Measurements and Disclosures describes the fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, as follows:</font></p>
<p style="FONT-FAMILY: arial;"><font size="2"><b>Level&#160;1</b></font><font size="2">&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. The Company's Level&#160;1 assets and liabilities consist of money market investments.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2"><b>Level&#160;2</b></font><font size="2">&#160;&#160;&#160;&#160;Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level&#160;2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security. The Company does not have Level&#160;2 assets or liabilities.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2"><b>Level&#160;3</b></font><font size="2">&#160;&#160;&#160;&#160;Pricing inputs are unobservable for the assets or liabilities, that is, inputs that reflect the reporting entity's own assumptions about the assumptions market participants would use in pricing the assets. Level&#160;3 includes private investments that are supported by little or no market activity. The Company does not have Level&#160;3 assets or liabilities.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Transfers are calculated on values as of the transfer date. There were no transfers between Levels&#160;1, 2 and 3 during the years ended December&#160;31, 2013 and 2014.</font></p>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Concentration of Credit Risk</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the financial institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.</font></p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Cash and Cash Equivalents</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Cash and cash equivalents include cash in readily available checking and savings accounts and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company's cash equivalents, which consist of money market funds, are measured at fair value on a recurring basis. As of December&#160;31, 2013 and 2014, the carrying amount of cash and cash equivalents was $7,551 and $1,634, respectively, which approximates fair value and was determined based upon Level&#160;1 inputs. Money market funds are valued using quoted market prices with no valuation adjustments applied. Accordingly, these securities are categorized as Level&#160;1.</font></p>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Property and Equipment</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Property and equipment are recorded at historical cost. Maintenance and repair costs are expensed as incurred. Costs which materially improve or extend the lives of existing assets are capitalized. The Company provides for depreciation and amortization using the straight-line method over the estimated useful lives of the assets, which are as follows:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" width="40%" align="center"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="40%" align="center"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Asset Category</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Estimated Useful Life</b></font></th></tr>
<tr style="padding:0;" valign="top">
<td style="FONT-FAMILY: arial;" align="center"><font size="2">Machinery and equipment</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="center"><font size="2">5&#160;years</font></td></tr>
<tr style="padding:0;" valign="top">
<td style="FONT-FAMILY: arial;" align="center"><font size="2">Computers and office equipment</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="center"><font size="2">5&#160;years</font></td></tr>
<tr style="padding:0;" valign="top">
<td style="FONT-FAMILY: arial;" align="center"><font size="2">Furniture and fixtures</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="center"><font size="2">7&#160;years</font></td></tr>
<tr style="padding:0;" valign="top">
<td style="FONT-FAMILY: arial;" align="center"><font size="2">Leasehold improvements</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="center"><font size="2">5&#160;years</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">Upon retirement or sale, the cost of assets disposed and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recorded in the statements of operations.</font></p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Impairment of Long Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Impairment of Long-Lived Assets</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Long-lived assets consist of property and equipment. When impairment indicators exist, the Company's management evaluates long-lived assets for potential impairment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. While the Company's current and historical operating losses and negative cash flows are indicators of impairment, management believes that future cash flows to be received support the carrying value of its long-lived assets and, accordingly, has not recognized any impairment losses since inception.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Impairment losses, if any, are recognized in earnings. An impairment loss would be recognized in an amount equal to the excess of the carrying amount over the undiscounted expected future cash flows.</font></p>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_InitialPublicOfferingCostsPolicyPolicyTextBlock', window );">Initial Public Offering Costs</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Initial Public Offering</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In May 2015, the Company closed an initial public offering ("IPO") of its common stock, which resulted in the sale of 6,670,000 shares of its common stock at a public offering price of $12.00 per share, including 870,000 shares of common stock upon the exercise by the underwriters of their option to purchase additional shares at the public offering price. The Company received proceeds from the IPO of approximately $72,029, after deducting underwriting discounts, commissions and expenses payable by the Company.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In connection with preparing for the IPO, the Company's Board of Directors and shareholders approved a one-for-6.9 reverse stock split of the Company's common stock. The reverse stock split became effective in April 2015. All share and per share amounts in the condensed interim financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. In connection with the closing of the IPO, all of the Company's outstanding convertible preferred stock automatically converted to common stock in May 2015, resulting in an additional 12,591,456 shares of common stock of the Company becoming outstanding. The significant increase in common stock outstanding in May 2015 is expected to impact the year-over-year comparability of the Company's net loss per share calculations in future periods.</font></p>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Initial Public Offering Costs</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company defers direct incremental costs attributable to the initial public offering ("IPO") of its common stock. These costs represent legal, accounting and other direct costs related to the Company's efforts to raise capital through a public sale of its common stock. Future costs will be deferred until the completion of the IPO, at which time they will be reclassified to additional paid-in capital as a reduction of the IPO proceeds. If the Company terminates its plan for an IPO or delays such plan for more than 90&#160;days, any costs deferred will be expensed immediately. As of December&#160;31, 2014, IPO costs were $233 and are included in prepaid expenses and other assets in the balance sheet.</font></p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Restricted Cash</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Restricted cash represents cash held in a depository account at a financial institution to collateralize a conditional stand-by letter of credit related to the Company's Canton, Massachusetts facility lease agreement. Restricted cash is reported as non-current unless the restrictions are expected to be released in the next twelve months.</font></p>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasePolicyTextBlock', window );">Deferred Rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Deferred Rent</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis for the facilities the Company occupies. The Company's lease for its facility provides for fixed increases in minimum annual rental payments and for additional rent in the form of maintenance and operating costs during the lease term. The total amount of rental payments due over the lease term is being charged to rent expense ratably over the life of the lease.</font></p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock', window );">Convertible Redeemable Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Convertible Redeemable Preferred Stock</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company classifies convertible redeemable preferred stock that is redeemable outside of the Company's control outside of permanent equity. The Company recorded such redeemable preferred stock at fair value upon issuance, net of any issuance costs or discounts, and the carrying value is being increased by periodic accretion to its redemption value at each balance sheet date as if the redeemable preferred stock was redeemable at that date. In the absence of retained earnings these accretion charges are recorded against additional paid-in capital, if any, and then to accumulated deficit.</font></p>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Research and Development Costs</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Research and development costs are charged to expense as incurred and consist of costs incurred to further the Company's research and development activities including salaries and employee related costs, costs associated with market research and design, costs associated with conducting preclinical, clinical and regulatory activities including fees paid to third-party professional consultants and service providers, costs incurred under clinical trial agreements, costs for laboratory supplies and laboratory equipment, costs to acquire, develop and manufacture preclinical study and clinical trial materials, facilities, depreciation and other expenses including allocated expenses for rent and maintenance of facilities. Government grants are recognized as a reduction of the qualifying cost being reimbursed.</font></p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_PatentCostsIncurredPolicyPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Patent Costs</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Costs related to filing and pursuing patent applications are recorded as general and administrative expense as incurred since the recoverability of such expenditures is uncertain.</font></p>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Stock-Based Compensation</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company accounts for grants of stock options and restricted stock to employees based on their grant date fair value and recognizes compensation expense over their vesting period. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the fair value of the underlying common stock as determined by management or the value of the services provided, whichever is more readily determinable.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Stock-based compensation expense represents the cost of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of estimated forfeitures. The expense is adjusted for actual forfeitures at year end. Stock-based compensation expense recognized in the financial statements is based on awards that are ultimately expected to vest.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">For stock option grants with performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable or the performance condition has been achieved. For stock option grants with both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company accounts for stock options and restricted stock awards to non-employees using the fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic revaluation over their vesting terms. There were no non-employee grants in 2013 and 2014.</font></p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Income Taxes</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company accounts for income taxes under the liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the years in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future, in excess of its net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company records uncertain tax positions on the basis of a two-step process whereby (i)&#160;management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii)&#160;for those tax positions that meet the more likely than not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50&#160;percent likely to be realized upon ultimate settlement with the related tax authority. The Company will recognize interest and penalties related to uncertain tax positions within income tax expense. Any accrued interest and penalties will be included within the related tax liability. As of December&#160;31, 2013 and 2014, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company's statements of operations.</font></p>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per Common Share</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2"><i>Earnings (Loss) per Common Share</i></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Earnings (loss) per common share is calculated using the two-class method, which is an earnings allocation formula that determines earnings (loss) per share for the holders of the Company's common shares and participating securities. All series of preferred stock contain participation rights in any dividend paid by the Company and are deemed to be participating securities. Earnings available to common shareholders and participating convertible redeemable preferred shares is allocated first to the preferred stock based upon the distribution criteria in the Company's Articles of Incorporation then the remainder to the common shareholders. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods that have a net loss.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Diluted earnings per share is computed using the more dilutive of (a)&#160;the two-class method, or (b)&#160;the if-converted method. The Company allocates earnings first to preferred shareholders based on dividend rights and then to common and preferred shareholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted earnings (loss) gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants, convertible redeemable preferred stock and the potential issuance of stock upon the conversion of the Company's convertible notes. Common stock equivalent shares are excluded from the computation of diluted earnings (loss) per share if their effect is antidilutive.</font></p>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Net loss per Common Share</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Basic net loss per common share is calculated by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock options, warrants, redeemable convertible preferred stock and unvested restricted stock are considered potentially dilutive securities. Because the Company has reported a net loss for the twelve months ended December&#160;31, 2013 and 2014, diluted net loss per common share is the same as basic net loss per common share for those periods.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Diluted earnings per share is computed using the more dilutive of (i)&#160;the two-class method, or (ii)&#160;the if-converted method. The Company allocates earnings first to preferred shareholders based on dividend rights and then to common and preferred shareholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted earnings (loss) gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants, convertible redeemable preferred stock and the potential issuance of stock upon the conversion of the Company's convertible notes. Common stock equivalent shares are excluded from the computation of diluted earnings (loss) per share if their effect is antidilutive.</font></p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Recent Accounting Pronouncements</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In May 2014, the Financial Accounting Standards Board ("FASB"), issued Accounting Standards Update ("ASU"), No.&#160;2014-09, which amends the guidance for accounting for revenue from contracts with customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification ("ASC"), Topic 605, Revenue Recognition, and creates a new Topic 606, Revenue from Contracts with Customers. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain practical expedients permitted; or retrospectively with the cumulative effect of initially adopting the ASU recognized at the date of initial application. On August&#160;12, 2015, the FASB issued ASU No.&#160;2015-14, which defers the effective date of ASU No.&#160;2014-09 by one year to December&#160;15, 2017 for annual reporting periods beginning after that date, including interim periods within those periods. The FASB also approved permitting early adoption of the standard, but not before the original effective date of December&#160;15, 2016. The Company has not yet determined which adoption method it will utilize or the effect that the adoption of this guidance will have on its financial statements.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In July 2015, the FASB issued ASU No.&#160;2015-11, which amends existing guidance for measurement of inventory. Current inventory guidance requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. The amendments do not apply to inventory that is measured using last-in, first-out (LIFO) or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out or average cost. An entity should measure all inventory to which the amendments apply at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The amendments in the ASU No.&#160;2015-11 more closely align the measurement of inventory pursuant to GAAP with the measurement of inventory pursuant to International Financial Reporting Standards. The amendments are effective for fiscal years beginning after December&#160;15, 2016, and interim periods within fiscal years beginning after December&#160;15, 2017. The amendments should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company does not expect the adoption of this guidance to have a material impact on its condensed financial statements.</font></p>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Recently Issued Accounting Pronouncements</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In July 2013, the Financial Accounting Standards Board ("FASB") issued ASU No.&#160;2013-11,</font> <font size="2"><i>Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exist.</i></font> <font size="2">ASU&#160;2013-11 amends the presentation requirements of ASC&#160;740 and requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, similar tax loss, or a tax credit carryforward. To the extent the tax benefit is not available at the reporting date under the governing tax law or if the entity does not intend to use the deferred tax asset for such purpose, the unrecognized tax benefit should be presented as a liability and not combined with deferred tax assets. This ASU is effective for annual periods, and interim periods within those years, beginning after December&#160;15, 2013, which is fiscal 2014 for the Company. The amendments are to be applied to all unrecognized tax benefits that exist as of the effective date and may be applied retrospectively to each prior reporting period presented. The adoption of ASU&#160;2013-11 did not have a material impact on the Company's financial position or results of operations.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In May 2014, the FASB issued ASU No.&#160;2014-09,</font> <font size="2"><i>Revenue from Contracts with Customers.</i></font> <font size="2">This ASU is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This ASU is effective for annual reporting periods beginning after December&#160;15, 2016 and early adoption is not permitted. Accordingly, the Company will adopt this ASU on January&#160;1, 2017. Management does not believe the adoption of this ASU will have a material impact on the Company's financial condition, results of operations or cash flows.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In June 2014, the FASB issued ASU No.&#160;2014-12,</font> <font size="2"><i>Compensation&#160;&#8212; Stock Compensation (Topic&#160;718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period</i></font><font size="2">. ASU&#160;2014-12 applies to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. That is the case when an employee is eligible to retire or otherwise terminate employment before the end of the period in which a performance target (for example, an initial public offering or a profitability target) could be achieved and still be eligible to vest in the award if and when the performance target is achieved. The standard is required to be adopted by public business entities in annual periods beginning on or after December&#160;15, 2015 and interim periods within those annual periods. The Company plans to implement this standard in the first quarter of fiscal year 2016 and is currently evaluating the potential impact of this new guidance on its financial statements.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In August 2014, the FASB issued ASU No.&#160;2014-15,</font> <font size="2"><i>Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern.</i></font> <font size="2">ASU&#160;2014-15 requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU&#160;2014-15 is effective for annual periods ending after December&#160;15, 2016 and earlier application is permitted. The adoption of ASU&#160;2014-15 is not expected to have a material effect on the Company's financial statements or disclosures.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In November 2014, the FASB issued ASU No.&#160;2014-16,</font> <font size="2"><i>Derivatives and Hedging (Topic&#160;815)&#160;&#8212; Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share is More Akin to Debt or to Equity</i></font><font size="2">. This ASU was issued to clarify how current U.S. generally accepted accounting principles should be interpreted in evaluating the economic characteristics and risk of a host contract in a hybrid financial instrument that is issued in the form of a share. In addition, this ASU was issued to clarify that in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (that is, the relative strength of the debt-like or equity-like terms and features given the facts and circumstances) when considering how to weight those terms and features. The effects of initially adopting this ASU should be applied on a modified retrospective basis to existing hybrid financial instruments issued in a form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods. This ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2015. Early adoption in an interim period is permitted. The Company is currently evaluating the impact of the adoption of this ASU on its financial statements.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pro forma balance sheet and net income (loss) per share information with respect to assumed conversion of all outstanding shares of convertible redeemable preferred stock into shares of common stock and methodology for calculation of pro form weighted-average number of common shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_ConvertibleRedeemablePreferredStockProFormaBalanceSheetAndNetIncomeLossPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_InitialPublicOfferingCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal, accounting and other direct costs incurred related to efforts to raise capital through a public sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_InitialPublicOfferingCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_PatentCostsIncurredPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs incurred related to filing and pursuing patent applications.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_PatentCostsIncurredPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued which is not included within permanent equity. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityRedeemablePreferredStockIssuePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 203<br> -Paragraph 02-03<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51676700&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51676700&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements (both lessor and lessee). This disclosure may address (1) lease classification (that is, operating versus capital), (2) how the term of a lease is determined (for example, the circumstances in which a renewal option is considered part of the lease term), (3) how rental revenue or expense is recognized for a lease that contains rent escalations, (4) an entity's accounting treatment for deferred rent, including that which arises from lease incentives, rent abatements, rent holidays, or tenant allowances (5) an entity's accounting treatment for contingent rental payments and (6) an entity's policy for reviewing, at least annually, the residual values of sales-type and direct-finance leases. The disclosure also may indicate how the entity accounts for its capital leases, leveraged leases or sale-leaseback transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453394&amp;loc=d3e39740-112701<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6482485&amp;loc=d3e14754-158437<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6456037&amp;loc=d3e48589-112741<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789469536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2014</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of estimated useful lives of property and equipment</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" width="40%" align="center"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="40%" align="center"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Asset Category</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Estimated Useful Life</b></font></th></tr>
<tr style="padding:0;" valign="top">
<td style="FONT-FAMILY: arial;" align="center"><font size="2">Machinery and equipment</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="center"><font size="2">5&#160;years</font></td></tr>
<tr style="padding:0;" valign="top">
<td style="FONT-FAMILY: arial;" align="center"><font size="2">Computers and office equipment</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="center"><font size="2">5&#160;years</font></td></tr>
<tr style="padding:0;" valign="top">
<td style="FONT-FAMILY: arial;" align="center"><font size="2">Furniture and fixtures</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="center"><font size="2">7&#160;years</font></td></tr>
<tr style="padding:0;" valign="top">
<td style="FONT-FAMILY: arial;" align="center"><font size="2">Leasehold improvements</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="center"><font size="2">5&#160;years</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6630486064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computations of basic and diluted net loss per share</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;">&#160;</p>
<div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="56"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="73"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Nine months ended<br />
September&#160;30,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2015</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Net loss</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(14,448</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(17,730</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Extinguishment of preferred stock&#160;&#8212; see note&#160;7</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">31,806</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Accretion of prior preferred stock&#160;&#8212; see note&#160;7</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(2,469</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(23,327</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Accretion and dividends of Series&#160;D preferred stock</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(1,245</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Loss attributable to common shareholders&#160;&#8212; basic and diluted</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(16,917</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(10,496</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Weighted-average number of common shares used in net loss per share&#160;&#8212; basic and diluted</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">926,597</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">11,179,756</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Net loss per share&#160;&#8212; basic and diluted</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(18.26</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(0.94</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="67"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="56"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Years Ended December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Net loss</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(16,197</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(17,917</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Performance Adjustment of Series&#160;A</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">12,239</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Accruals of dividends and accretion to redemption value of preferred stock</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(2,925</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(3,300</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Loss attributable to common shareholders&#160;&#8212; basic and diluted</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(6,883</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(21,217</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Weighted-average shares used in computing basic and diluted net loss per common share</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">1,697,044</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">933,997</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Basic and diluted net loss per common share</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(4.06</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(22.72</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="59"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="59"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Nine months ended<br />
September&#160;30,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2015</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding stock options</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">311,365</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,356,246</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Warrants</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">18,810</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">2,445</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Redeemable convertible preferred stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6,552,820</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested restricted stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">28,536</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">153,589</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="59"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="59"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Years Ended December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Stock Options</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">229,791</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">281,029</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Warrants</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">4,170</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">18,809</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Redeemable convertible preferred stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6,552,820</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6,552,820</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested restricted stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">55,298</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">15,387</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6785562832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2014</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of components of prepaid expenses and other current assets</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="42"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="42"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>As of December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Other current assets</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">253</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Initial public offering costs</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">233</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Employee advances</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">21</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">33</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Prepaid expenses</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">33</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">8</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Prepaid development costs</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">656</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Prepaid expenses and other current assets</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">710</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">527</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6795260896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2014</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of components of property and equipment</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="42"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="42"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>As of December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Machinery and equipment</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">741</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">741</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Computers and office equipment</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">26</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">26</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Furniture and fixtures</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">36</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">44</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Leasehold improvements</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">606</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">606</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Total property and equipment</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,409</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,417</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Less: accumulated deprecation</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(716</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(903</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Property and equipment, net</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">693</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">514</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789858880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of components of accrued expenses</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="68"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="70"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>December&#160;31,<br />
2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>September&#160;30,<br />
2015</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued compensation</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">635</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,169</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued development costs</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">970</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">597</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued marketing</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">685</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued audit and legal</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">249</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">109</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued interest</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">71</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">31</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued other</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">31</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">90</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Total accrued expenses</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,956</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">2,681</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="42"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="42"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>As of December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued development costs</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">520</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">970</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued compensation</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">449</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">635</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued audit and legal</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">12</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">249</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued interest</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">71</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued other</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">32</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">31</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Total accrued expenses</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,013</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,956</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6584042256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2014</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of aggregate minimum annual lease commitments under non-cancellable operating lease</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;"><font size="2">Aggregate minimum annual lease commitments of the Company under its non-cancellable operating lease as of December&#160;31, 2014 are as follows:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="31"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" nowrap="nowrap" align="left">
<div style="MARGIN-BOTTOM: 0pt; WIDTH: 95pt; BORDER-BOTTOM: #000000 1pt solid;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Year Ending December&#160;31, <!-- COMMAND=ADD_SCROPPEDRULE,95pt --></b></font></div></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">2015</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">106</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">2016</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">111</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">2017</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">116</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Total minimum lease payments</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">333</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789536480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2014</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of future payments under debt agreements</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;"><font size="2">As of December&#160;31, 2014, future payments under the Company's debt agreements are as follows:</font></p>
<div style="WIDTH: 75%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 12%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="49"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">2015</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">6,194</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">2016</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">2,667</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">2017</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">2,667</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">2018</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">1,479</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Balance as of December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">13,007</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6805994368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2014</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock', window );">Schedule of shares of common stock reserved for future issuance</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="96"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>As of<br />
December&#160;31, 2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Conversion of Series&#160;A Preferred</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">18,498,419</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Conversion of Series&#160;B Preferred</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">27,324,237</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Conversion of Series&#160;C Preferred</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">8,658,344</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Options to purchase common stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">3,412,685</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Total</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">57,893,685</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of roll-forward of recurring fair value measurements of tranche liability categorized with Level 3 inputs</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="35"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Balance&#160;&#8212; December&#160;31, 2012</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Tranche liability upon issuance</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">266</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Change in fair value</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">79</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Tranche liability upon close of tranche</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(345</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Balance&#160;&#8212; December&#160;31, 2013</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790854544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="59"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="65"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="54"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="49"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Shares</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted-<br />
average<br />
exercise price<br />
per share</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted-<br />
average<br />
remaining<br />
contractual<br />
term<br />
(years)</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Aggregate<br />
Intrinsic<br />
Value</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">281,029</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">0.69</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Granted</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">1,197,452</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">10.47</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Exercised</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(121,729</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">3.89</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Cancelled</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(506</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">2.06</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding at September&#160;30, 2015</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">1,356,246</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">9.04</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">9.2</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">17,722</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Exercisable at September&#160;30, 2015</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">208,438</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">2.65</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">7.9</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">4,056</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Vested and expected to vest at September&#160;30, 2015</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">1,341,543</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">9.13</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">9.2</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">18,595</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="53"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="47"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="55"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="47"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Number<br />
of Options</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted-<br />
Average<br />
Exercise<br />
Price</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted-<br />
Average<br />
Remaining<br />
Contractual<br />
Term<br />
(in years)</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Aggregate<br />
Intrinsic<br />
Value</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding at December&#160;31, 2012</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">323,488</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.73</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6.94</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">8</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Granted</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">146,730</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.48</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Exercised</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(1,077</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.62</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Cancelled</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(9,559</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">2.76</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Modification</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(229,791</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.17</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding at December&#160;31, 2013</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">229,791</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.17</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">7.02</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">117</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Granted</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">89,641</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.28</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Exercised</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(32,390</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">2.21</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Cancelled</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(6,013</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">4.42</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">281,029</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.69</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">7.49</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,505</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Vested and expected to vest at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">247,139</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.83</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">4.31</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,293</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Exercisable at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">121,304</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.38</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">4.31</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">570</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Schedule of additional information about stock option activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="35"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="35"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>As of<br />
December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Weighted-average grant date fair value per share of employee option grants</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">0.28</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">0.76</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of restricted stock awards</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="53"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="82"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Shares</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted average<br />
purchase price<br />
per share</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">15,387</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.69</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Granted</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">194,694</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">5.73</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Vested</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(128,955</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">5.13</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested at September&#160;30, 2015<sup>(1)</sup></font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">81,126</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">5.73</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --><!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<hr style="COLOR: #000000;" align="left" size="1" width="26%" noshade="noshade" /></div>
<div style="POSITION: relative; PADDING-BOTTOM: 0pt; TEXT-ALIGN: left; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<dl compact="compact">
<dt style="MARGIN-BOTTOM: -9pt; FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><font style="FONT-SIZE: 6pt; POSITION: relative; TOP: -2pt; add_sup: 2pt;">(1)</font></font></dt>
<dd style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">Excludes 72,463 shares of unvested restricted stock remaining from the early exercise of stock options as of September&#160;30, 2015.</font></dd></dl></div>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="51"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="82"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Number of<br />
Shares</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted-Average<br />
Grant Date<br />
Fair Value</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested at December&#160;31, 2012</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">203,342</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.62</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Vesting of restricted stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(89,308</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.55</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Performance Adjustment</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(58,736</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.62</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested at December&#160;31, 2013</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">55,298</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.69</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Grant of restricted stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">10,869</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.24</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Vesting of restricted stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(50,780</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.62</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">15,387</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.69</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation for all stock options and restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="28"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="28"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Years Ended December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Research and development</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">24</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">12</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">General and administrative</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">38</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">10</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Total stock-based compensation expense</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">62</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">22</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used in Black-Scholes option-pricing model</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="28"></td>
<td style="FONT-FAMILY: arial;" width="24"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="28"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Nine months<br />
ended<br />
September&#160;30,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2015</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Risk-free interest rate</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.8</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.7</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Dividend yield</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Volatility</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">77</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">77</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Expected term (years)</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6.25</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6.21</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="97" align="center"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="39"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="4" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Years Ended December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Risk-free interest rate</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="center"><font size="2">1.09%&#160;&#8211; 1.22%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.80</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Expected volatility</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="center"><font size="2">87.8%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">77.1</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Expected term (in years)</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="center"><font size="2">6.25</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6.25</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Expected dividend yield</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="center"><font size="2">0.0%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.0</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6779192576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2014</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of income tax expense (benefit) at statutory federal income tax rate to income taxes</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="42"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="42"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>As of December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Federal income tax (benefit) at statutory rate</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">34.00</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">34.00</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">(Increase) decrease income tax (benefit) resulting from:</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Expiration of state net operating losses</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(12.11</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.00</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Permanent items</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(0.01</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(0.17</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Research and experimental credits</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">4.19</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">3.74</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Change in valuation allowance</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(26.07</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(37.57</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Income tax expense (benefit)</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.00</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.00</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of deferred tax assets and liabilities</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="53"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="53"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>As of December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Deferred tax assets:</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Net operating loss carryforwards</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">21,392</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">28,419</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Depreciation and amortization</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">36</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Research Credits</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">2,400</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">3,070</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Deferred tax assets before valuation allowance</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">23,792</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">31,525</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Valuation allowance</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(23,788</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(31,525</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;">&#160;</p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">4</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Deferred tax liabilities:</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Depreciation and amortization</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(4</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;">&#160;</p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(4</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Net deferred tax assets</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6630664368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NATURE OF BUSINESS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficitAbstract', window );"><strong>Deficit accumulated</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Deficit accumulated</a></td>
<td class="nump">$ 119,483<span></span>
</td>
<td class="nump">$ 101,753<span></span>
</td>
<td class="nump">$ 80,536<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6805963120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 06, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Principal amount converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member', window );">6.0% Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Principal amount converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Cash consideration from issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events | Private Placement | Investors | Series D convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Aggregate consideration</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Cash consideration from issuance of preferred stock</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events | Conversion of convertible notes into convertible preferred stock | Investors | 6.0% Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Principal amount converted</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=coll_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=coll_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6805693552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Asset transfers out of Level 1 into Level 2</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Asset transfers out of Level 2 into Level 1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Asset transfers into (out of) Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset', window );">Financial instruments with off balance sheet risk of loss, assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountLiability', window );">Financial instruments with off balance sheet risk of loss, liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789805072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,634<span></span>
</td>
<td class="nump">$ 7,551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6803283008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2014</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimate Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=coll_ComputerEquipmentAndOfficeEquipmentMember', window );">Computers and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimate Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimate Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimate Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=coll_ComputerEquipmentAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=coll_ComputerEquipmentAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6791310784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 4)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred IPO costs</a></td>
<td class="nump">$ 233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred IPO costs</a></td>
<td class="nump">$ 233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6806769552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 5) - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">1,197,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="nump">194,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=coll_NonemployeeStockOptionsMember', window );">Non-employee stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock | Non-employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=coll_NonemployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=coll_NonemployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=coll_NonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=coll_NonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789805072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.94)<span></span>
</td>
<td class="num">$ (18.26)<span></span>
</td>
<td class="num">$ (18.26)<span></span>
</td>
<td class="num">$ (4.06)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790921024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE (Details 2) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,730)<span></span>
</td>
<td class="num">$ (14,448)<span></span>
</td>
<td class="num">$ (14,448)<span></span>
</td>
<td class="num">$ (16,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment', window );">Accruals of dividends and accretion to redemption value of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,300)<span></span>
</td>
<td class="num">(2,925)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted', window );">Loss attributable to common stockholders - basic and diluted</a></td>
<td class="num">$ (10,496)<span></span>
</td>
<td class="num">$ (16,917)<span></span>
</td>
<td class="num">$ (21,217)<span></span>
</td>
<td class="num">$ (6,883)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used in computing basic and diluted net loss per common share (in shares)</a></td>
<td class="nump">11,179,756<span></span>
</td>
<td class="nump">926,597<span></span>
</td>
<td class="nump">926,597<span></span>
</td>
<td class="nump">1,697,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.94)<span></span>
</td>
<td class="num">$ (18.26)<span></span>
</td>
<td class="num">$ (18.26)<span></span>
</td>
<td class="num">$ (4.06)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityRedemptionValueModificationAdjustment', window );">Performance Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ProFormaMember', window );">Pro Forma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used in computing basic and diluted net loss per common share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,471,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that basic and dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the combined amount of accretion of temporary equity during the period due to cash, stock, and in-kind dividends and decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityRedemptionValueModificationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income to adjust temporary equity to its redemption value due to a modification of the number of issued and outstanding shares of temporary equity outstanding during the period, as defined by the entity's articles of incorporation. This item is an increase (decrease) to net income necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityRedemptionValueModificationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ProFormaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ProFormaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6791126416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE (Details 3) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=coll_EmployeeAndNonemployeeStockOptionsMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding excluded from the computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">1,356,246<span></span>
</td>
<td class="nump">311,365<span></span>
</td>
<td class="nump">281,029<span></span>
</td>
<td class="nump">229,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding excluded from the computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">2,445<span></span>
</td>
<td class="nump">18,810<span></span>
</td>
<td class="nump">18,809<span></span>
</td>
<td class="nump">4,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding excluded from the computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,552,820<span></span>
</td>
<td class="nump">6,552,820<span></span>
</td>
<td class="nump">6,552,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding excluded from the computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">153,589<span></span>
</td>
<td class="nump">28,536<span></span>
</td>
<td class="nump">15,387<span></span>
</td>
<td class="nump">55,298<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=coll_EmployeeAndNonemployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=coll_EmployeeAndNonemployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6791187952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Initial public offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromEmployeesCurrent', window );">Employee advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_PrepaidDevelopmentCosts', window );">Prepaid development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">656<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 866<span></span>
</td>
<td class="nump">$ 527<span></span>
</td>
<td class="nump">$ 710<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_PrepaidDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs of product development that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_PrepaidDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromEmployeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from an Entity employee, not to include stockholders or officers, which are usually due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromEmployeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 8<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51662447&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790702848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,417<span></span>
</td>
<td class="nump">$ 1,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated deprecation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(903)<span></span>
</td>
<td class="num">(716)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 627<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="nump">693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">741<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=coll_ComputerEquipmentAndOfficeEquipmentMember', window );">Computers and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 606<span></span>
</td>
<td class="nump">$ 606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=coll_ComputerEquipmentAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=coll_ComputerEquipmentAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790620800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued development costs</a></td>
<td class="nump">$ 597<span></span>
</td>
<td class="nump">$ 970<span></span>
</td>
<td class="nump">$ 520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">635<span></span>
</td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued audit and legal</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 2,681<span></span>
</td>
<td class="nump">$ 1,956<span></span>
</td>
<td class="nump">$ 1,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6787504128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=coll_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember', window );">Hatch-Waxman Act of 1984 election to sue for patent infringement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected', window );">Stay period before FDA can issue a final approval if patent litigation is elected</a></td>
<td class="text">30 months<span></span>
</td>
<td class="text">30 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the stay period before the Federal Drug Administration (FDA) can issue final approval if patent infringement litigation is elected.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=coll_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=coll_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6802686800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm', window );">Rent-free term</a></td>
<td class="text">2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Aggregate minimum annual lease commitments under non cancellable operating lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2015</a></td>
<td class="nump">$ 106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2016</a></td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2017</a></td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseAbstract', window );"><strong>Rent expense under operating lease agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteesAbstract', window );"><strong>Guarantees</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAndCreditsAbstract', window );"><strong>Lease inducements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_IncentiveFromLessorGross', window );">Leasehold improvement allowance</a></td>
<td class="nump">174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=coll_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember', window );">Canton facility lease reimbursable allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAndCreditsAbstract', window );"><strong>Lease inducements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_ReimbursableIncentiveFromLessorGross', window );">Reimbursable improvement allowance</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_StandbyLettersOfCreditMember', window );">Stand-by letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteesAbstract', window );"><strong>Guarantees</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_IncentiveFromLessorGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross deferred credit for an incentive or inducement received by a lessee from a lessor, before considering accumulated amortization, in order to motivate the lessee to enter the lease agreement, which incentive or inducement is to be recognized as a reduction of rental expense over the lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_IncentiveFromLessorGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rent-free portion of the term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_LesseeLeasingArrangementsOperatingLeasesRentFreeTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_ReimbursableIncentiveFromLessorGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross reimbursable incentive or inducement received by a lessee from a lessor, before amortization, in order to motivate the lessee to enter the lease agreement, which incentive or inducement is to be repaid over the lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_ReimbursableIncentiveFromLessorGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAndCreditsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAndCreditsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=coll_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=coll_CantonFacilityOperatingLeaseObligationReimbursableTenantAllowanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6807657840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 28, 2012</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Aug. 31, 2014</div></th>
<th class="th"><div>Feb. 28, 2014</div></th>
<th class="th"><div>Jan. 31, 2014</div></th>
<th class="th"><div>Feb. 28, 2013</div></th>
<th class="th"><div>Oct. 31, 2012</div></th>
<th class="th"><div>Aug. 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Loan and Security Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Proceeds from notes payable, net of original note payoff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,056<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=coll_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member', window );">Common stock warrant, Silicon Valley Bank, Original Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Loan and Security Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Common stock that may be purchased upon exercise of warrant (in shares)</a></td>
<td class="nump">23,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share)</a></td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member', window );">Common stock warrant, Silicon Valley Bank, Term Loan, Amendment No. 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Loan and Security Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Common stock that may be purchased upon exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member', window );">Common stock warrant, Silicon Valley Bank, Term Loan, Amendment No. 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Loan and Security Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Common stock that may be purchased upon exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Term loan | Silicon Valley Bank loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Loan and Security Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_DebtInstrumentPeriodicPaymentInterestOnlyPeriod', window );">Initial period of interest only payments</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod', window );">Subsequent period of principal and interest payments</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Deferred financing costs</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Financing costs repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding amount of loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Term loan | Silicon Valley Bank loan agreement | Prime</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Loan and Security Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate margin (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Interest rate (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Term loan | Silicon Valley Bank loan agreement, Amendment No. 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Loan and Security Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Proceeds from notes payable, net of original note payoff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_DebtInstrumentPeriodicPaymentInterestOnlyPeriod', window );">Initial period of interest only payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod', window );">Subsequent period of principal and interest payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Term loan | Silicon Valley Bank loan agreement, Amendment No. 1 | Prime</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Loan and Security Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Variable rate basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Term loan | Silicon Valley Bank loan agreement Amendment No. 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Loan and Security Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_DebtInstrumentPeriodicPaymentInterestOnlyPeriod', window );">Initial period of interest only payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod', window );">Subsequent period of principal and interest payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Term loan | Silicon Valley Bank loan agreement Amendment No. 2 | Prime</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Loan and Security Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time after the end of the interest only period to maturity of each borrowing, the required periodic payments include both interest and principal payments, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_DebtInstrumentPeriodicPaymentInterestAndPrincipalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_DebtInstrumentPeriodicPaymentInterestOnlyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time from the date of each borrowing the required periodic payments are applied to interest only, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_DebtInstrumentPeriodicPaymentInterestOnlyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 20<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 16<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the amount as of the balance sheet date of capitalized costs associated with the issuance of debt instruments (for example, legal, accounting, underwriting, printing, and registration costs) that will be charged against earnings over the life of the debt instruments to which such costs pertain. Such amount is before the consideration of accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the carrying amount (net of accumulated amortization) as of the balance sheet date of capitalized costs associated with the issuance of debt instruments (for example, legal, accounting, underwriting, printing, and registration costs) that will be charged against earnings over the life of the debt instruments to which such costs pertain.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=coll_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=coll_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=coll_SiliconValleyBankLoanAgreement28August2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=coll_SiliconValleyBankLoanAgreement28August2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=coll_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=coll_SiliconValleyBankLoanAgreementAmendmentNumber1January2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=coll_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=coll_SiliconValleyBankLoanAgreementAmendmentNumber2August2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6784250096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details 2) - Bridge Notes Purchase Agreement - Investors - 6.0% Convertible promissory notes<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related party transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amount issued</a></td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Stated interest rate</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=coll_NotePurchaseAgreementConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=coll_NotePurchaseAgreementConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6753036832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT (Details 3)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_MaturitiesOfDebtAbstract', window );"><strong>Future payments under debt agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">2015</a></td>
<td class="nump">$ 6,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2016</a></td>
<td class="nump">2,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2017</a></td>
<td class="nump">2,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2018</a></td>
<td class="nump">1,479<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Total</a></td>
<td class="nump">$ 13,007<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_MaturitiesOfDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_MaturitiesOfDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6791825600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2015</div></th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2014 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2014 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2014 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 28, 2012 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2010 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Performance adjustment ratio</a></td>
<td class="nump">0.144927536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Performance adjustment ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Performance adjustment ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=coll_PreferredStockWarrantsIssuedNovember2010Member', window );">Preferred stock warrant issued November 2010</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Stock that may be purchased upon exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=coll_SeriesaPreferredStockWarrantMember', window );">Series A preferred stock warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Stock that may be purchased upon exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=coll_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member', window );">Common stock warrant, Silicon Valley Bank, Original Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Stock that may be purchased upon exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member', window );">Common stock warrant, Silicon Valley Bank, Term Loan, Amendment No. 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Stock that may be purchased upon exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member', window );">Common stock warrant, Silicon Valley Bank, Term Loan, Amendment No. 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Stock that may be purchased upon exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=coll_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember', window );">Conversion of preferred stock warrant into Series A Preferred Stock warrant | Series A preferred stock warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Stock that may be purchased upon exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ProFormaMember', window );">Pro Forma | Common stock warrant, Silicon Valley Bank, Original Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Stock that may be purchased upon exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ProFormaMember', window );">Pro Forma | Common stock warrant, Silicon Valley Bank, Term Loan, Amendment No. 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Stock that may be purchased upon exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ProFormaMember', window );">Pro Forma | Common stock warrant, Silicon Valley Bank, Term Loan, Amendment No. 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Stock that may be purchased upon exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Stock Split<br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=coll_PreferredStockWarrantsIssuedNovember2010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=coll_PreferredStockWarrantsIssuedNovember2010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=coll_SeriesaPreferredStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=coll_SeriesaPreferredStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=coll_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=coll_CommonStockWarrantSiliconValleyBankLoanAgreement28August2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber1January2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=coll_CommonStockWarrantSiliconValleyBankLoanAgreementAmendmentNumber2August2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=coll_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=coll_ConversionOfStockPreferredStockWarrantIntoSeriesaPreferredStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ProFormaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ProFormaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6791512784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Authorized common stock (in shares)</a></td>
<td class="nump">72,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">72,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value of common stock (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">1,006,219<span></span>
</td>
<td class="nump">20,687,829<span></span>
</td>
<td class="nump">962,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">1,006,219<span></span>
</td>
<td class="nump">1,006,219<span></span>
</td>
<td class="nump">962,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Authorized preferred stock (in shares)</a></td>
<td class="nump">54,481,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,481,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_CommonStockVotingRightsNumber', window );">Number of votes each share of common stock held is entitled | Vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">57,893,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=coll_EmployeeAndNonemployeeStockOptionsMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">3,412,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Authorized preferred stock (in shares)</a></td>
<td class="nump">18,498,419<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,498,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">9,232,334<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,232,334<span></span>
</td>
<td class="nump">18,464,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">9,232,334<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,232,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible redeemable preferred stock | Conversion of convertible redeemable preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">18,498,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Authorized preferred stock (in shares)</a></td>
<td class="nump">27,324,237<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,324,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">27,324,237<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,324,237<span></span>
</td>
<td class="nump">27,324,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">27,324,237<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,324,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible redeemable preferred stock | Conversion of convertible redeemable preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">27,324,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Authorized preferred stock (in shares)</a></td>
<td class="nump">8,658,344<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,658,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">8,658,008<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,658,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">8,658,008<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,658,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C convertible redeemable preferred stock | Conversion of convertible redeemable preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">8,658,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_CommonStockVotingRightsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of votes a share of common stock is entitled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_CommonStockVotingRightsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 28<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 28<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 28<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=coll_EmployeeAndNonemployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=coll_EmployeeAndNonemployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=coll_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=coll_ConversionOfConvertibleRedeemablePreferredStockIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6802945680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Details 2)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2015</div></th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2013 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_StockModificationAbstract', window );"><strong>Performance Adjustment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Performance adjustment ratio</a></td>
<td class="nump">0.144927536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_StockModificationAbstract', window );"><strong>Performance Adjustment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Performance adjustment ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible redeemable preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_StockModificationAbstract', window );"><strong>Performance Adjustment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Performance adjustment ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue', window );">Performance Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible redeemable preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,658,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible redeemable preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=coll_SeriesBPreferredStockFinancingFebruary2012Member', window );">Series B Preferred Stock financing February 2012 | Series B convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,324,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issue price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityStockIssuedIssuanceCosts', window );">Closing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=coll_SeriesCPreferredStockFinancing2013Member', window );">Series C Preferred Stock financing 2013 | Series C convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,658,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityStockIssuedIssuanceCosts', window );">Closing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_SaleOfStockNumberOfTranches', window );">Number of tranches into which financing was structured | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=coll_SeriesCPreferredStockFinancing2013Member', window );">Series C Preferred Stock financing 2013 | Series C convertible redeemable preferred stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_SaleOfStockNumberOfSharesAuthorizedToBeSold', window );">Shares authorized for sale and issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,658,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_SaleOfStockAuthorizedAmount', window );">Amount authorized for sale and issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=coll_SeriesCPreferredStockFinancing2013Member', window );">Series C Preferred Stock financing 2013 | Series C convertible redeemable preferred stock | Stock purchase right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Stock purchase right liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=coll_SeriesCPreferredStockFinancing2013TrancheOneMember', window );">Series C Preferred Stock financing 2013, first tranche | Series C convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,886,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=coll_SeriesCPreferredStockFinancing2013TrancheTwoMember', window );">Series C Preferred Stock financing 2013, second tranche | Series C convertible redeemable preferred stock | Stock purchase right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract', window );"><strong>Fair value assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="nump">$ 1.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Roll forward of the recurring fair value measurements of the tranche liability categorized with Level 3 inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Tranche liability upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales', window );">Tranche liability upon close of tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=coll_SeriesCPreferredStockFinancing2013TrancheTwoMember', window );">Series C Preferred Stock financing 2013, second tranche | Series C convertible redeemable preferred stock | Stock purchase right | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract', window );"><strong>Fair value assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=coll_SeriesCPreferredStockFinancing2013TrancheTwoMember', window );">Series C Preferred Stock financing 2013, second tranche | Series C convertible redeemable preferred stock | Stock purchase right | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract', window );"><strong>Fair value assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 months 5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=coll_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember', window );">Conversion of preferred stock into Series A Preferred Stock | Series A convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in exchange for previously outstanding stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,464,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_SaleOfStockAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Authorized amount of consideration that can be received in exchange for shares of stock issued or sold pursuant to a stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_SaleOfStockAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_SaleOfStockNumberOfSharesAuthorizedToBeSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be issued or sold pursuant to a stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_SaleOfStockNumberOfSharesAuthorizedToBeSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_SaleOfStockNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of tranches in which shares may be issued or sold pursuant to a stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_SaleOfStockNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_StockModificationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_StockModificationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of decrease to temporary equity to its redemption value during the period for a modification of shares issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to temporary equity resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Stock Split<br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27011957&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=coll_SeriesBPreferredStockFinancingFebruary2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=coll_SeriesBPreferredStockFinancingFebruary2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=coll_SeriesCPreferredStockFinancing2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=coll_SeriesCPreferredStockFinancing2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=coll_StockPurchaseRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=coll_StockPurchaseRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=coll_SeriesCPreferredStockFinancing2013TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=coll_SeriesCPreferredStockFinancing2013TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=coll_SeriesCPreferredStockFinancing2013TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=coll_SeriesCPreferredStockFinancing2013TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=coll_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=coll_ConversionOfStockPreferredStockIntoSeriesaPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6807528144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Details 3)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2015</div></th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 28, 2015</div></th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>director </div>
<div>installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_StockModificationAbstract', window );"><strong>Performance Adjustment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Performance adjustment ratio</a></td>
<td class="nump">0.144927536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_StockModificationAbstract', window );"><strong>Performance Adjustment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Performance adjustment ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments', window );">Optional redemption feature, number of installment payments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage', window );">Affirmative vote of outstanding shares for optional redemption (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock | Mandatory conversion, initial public offering | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issue price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock | Automatic conversion concurrently with Qualified Financing | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityShareholderSharesOwned', window );">Shares owned by a shareholder (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityRightsToElectDirectorsNumberOfDirectors', window );">Number of directors holders of record are entitled to elect | director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityCumulativeAccretionOfDividends', window );">Cumulative accrued dividends | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,371<span></span>
</td>
<td class="nump">$ 2,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityConvertibleConversionPrice', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio', window );">Liquidation rights, ratio applied to original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare', window );">Liquidation rights, original issue price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_StockModificationAbstract', window );"><strong>Performance Adjustment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Performance adjustment ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue', window );">Performance Adjustment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible redeemable preferred stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage', window );">Written consent or affirmative vote of outstanding shares to amend, alter or repeal the preferences, special rights or other powers (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityRightsToElectDirectorsNumberOfDirectors', window );">Number of directors holders of record are entitled to elect | director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityCumulativeAccretionOfDividends', window );">Cumulative accrued dividends | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityConvertibleConversionPrice', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio', window );">Liquidation rights, ratio applied to original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare', window );">Liquidation rights, original issue price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio', window );">Optional redemption feature, ratio applied to original price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible redeemable preferred stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage', window );">Written consent or affirmative vote of outstanding shares to amend, alter or repeal the preferences, special rights or other powers (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityRightsToElectDirectorsNumberOfDirectors', window );">Number of directors holders of record are entitled to elect | director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityCumulativeAccretionOfDividends', window );">Cumulative accrued dividends | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityConvertibleConversionPrice', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio', window );">Liquidation rights, ratio applied to original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare', window );">Liquidation rights, original issue price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C convertible redeemable preferred stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage', window );">Written consent or affirmative vote of outstanding shares to amend, alter or repeal the preferences, special rights or other powers (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C convertible redeemable preferred stock | Series C Preferred Stock financing 2013, second tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_StockModificationAbstract', window );"><strong>Performance Adjustment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold', window );">Threshold of additional capital raised to trigger Performance Adjustment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The threshold of cash received on a stock transaction to trigger a modification of issued and outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_StockIssuedAndOutstandingModificationSaleOfStockConsiderationReceivedOnTransactionThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_StockModificationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_StockModificationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the required percentage of written consent or affirmative vote of all shares outstanding of securities classified as temporary equity to amend, alter or repeal the preferences, special rights or other powers of such securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityChangeInFeaturesWrittenConsentOrAffirmativeVoteOfOutstandingSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share conversion price of stock classified as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityCumulativeAccretionOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative value of accretion of temporary equity due to unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityCumulativeAccretionOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the original issue price per share of stock classified as temporary equity that has liquidation preference in the event of any voluntary or involuntary liquidation, dissolution or winding-up of the affairs of the entity or a Deemed Liquidation Event, as defined in the agreement to the financial instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityLiquidationRightsOriginalIssuePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the original issue price of stock classified as temporary equity that has liquidation preference in the event of any voluntary or involuntary liquidation, dissolution or winding-up of the affairs of the entity or a Deemed Liquidation Event, as defined in the agreement to the financial instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityLiquidationRightsPerShareIssuePriceRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the required percentage of affirmative vote of all shares outstanding of securities classified as temporary equity to exercise for the holders to exercise the optional redemption feature on or after the date specified in the agreement to the financial instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityOptionalRedemptionFeatureAffirmativeVoteOfOutstandingSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of installments in which an optional redemption of stock classified as temporary equity is to be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityOptionalRedemptionFeatureNumberOfInstallmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the original issue price of stock classified as temporary equity in an optional redemption, as defined in the agreement to the financial instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityOptionalRedemptionFeaturePerShareIssuePriceRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityRightsToElectDirectorsNumberOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of directors the holders of record of securities classified as temporary equity are entitled to elect.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityRightsToElectDirectorsNumberOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityShareholderSharesOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of the entity's securities classified as temporary equity that are owned by a shareholder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityShareholderSharesOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of decrease to temporary equity to its redemption value during the period for a modification of shares issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityStockIssuedAndOutstandingModificationAdjustmentToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Stock Split<br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=coll_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=coll_ConvertibleFinancialInstrumentAutomaticConversionProvisionCompletionOfQualifiedFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=coll_SeriesCPreferredStockFinancing2013TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=coll_SeriesCPreferredStockFinancing2013TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6805621232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 04, 2013</div></th>
<th class="th">
<div>Apr. 30, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2014 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares of common stock authorized for issuance outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,356,246<span></span>
</td>
<td class="nump">281,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Performance adjustment ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.144927536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=coll_EmployeeAndNonemployeeStockOptionsMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares of common stock authorized for issuance outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,791<span></span>
</td>
<td class="nump">323,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Performance adjustment ratio</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=coll_EmployeeAndNonemployeeStockOptionsMember', window );">Stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate', window );">Period following termination date vested options are exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=coll_EmployeeAndNonemployeeStockOptionsMember', window );">Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate', window );">Period following termination date vested options are exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=coll_StockIncentivePlan2014Member', window );">2014 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares of common stock authorized for issuance outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period after the date the vested equity-based award expires during which an employee continues to have the right to exercise an award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Stock Split<br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=coll_EmployeeAndNonemployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=coll_EmployeeAndNonemployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=coll_StockIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=coll_StockIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790187952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details 2) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock option activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of year (in shares)</a></td>
<td class="nump">281,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,197,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(121,729)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled (in shares)</a></td>
<td class="num">(506)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">1,356,246<span></span>
</td>
<td class="nump">281,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">208,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and expected to vest at end of period (in shares)</a></td>
<td class="nump">1,341,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year (in dollars per share)</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">10.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">3.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share)</a></td>
<td class="nump">2.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">9.04<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share)</a></td>
<td class="nump">2.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and expected to vest at end of period (in dollars per share)</a></td>
<td class="nump">$ 9.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock option activity, additional information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period, Weighted-average remaining contractual term</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of period, Weighted-average remaining contractual term</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at end of period, weighted-average remaining contractual term</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at end of period, Aggregate intrinsic value</a></td>
<td class="nump">$ 17,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at end of period, Aggregate intrinsic value</a></td>
<td class="nump">4,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and expected to vest at end of period, Aggregate intrinsic value</a></td>
<td class="nump">$ 18,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=coll_EmployeeAndNonemployeeStockOptionsMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock option activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of year (in shares)</a></td>
<td class="nump">281,029<span></span>
</td>
<td class="nump">229,791<span></span>
</td>
<td class="nump">323,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,641<span></span>
</td>
<td class="nump">146,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,390)<span></span>
</td>
<td class="num">(1,077)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,013)<span></span>
</td>
<td class="num">(9,559)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification', window );">Modification (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(229,791)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,029<span></span>
</td>
<td class="nump">229,791<span></span>
</td>
<td class="nump">323,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and expected to vest at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year (in dollars per share)</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
<td class="nump">$ 1.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.28<span></span>
</td>
<td class="nump">0.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.21<span></span>
</td>
<td class="nump">0.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.42<span></span>
</td>
<td class="nump">2.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice', window );">Modification (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.69<span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
<td class="nump">$ 1.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and expected to vest at end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock option activity, additional information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period, Weighted-average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 5 months 27 days<span></span>
</td>
<td class="text">7 years 7 days<span></span>
</td>
<td class="text">6 years 11 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of period, Weighted-average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 3 months 22 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at end of period, weighted-average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 3 months 22 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at end of period, Aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,505<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at end of period, Aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and expected to vest at end of period, Aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which unrecognized compensation cost is expected to be recognized as expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue', window );">Weighted average fair value of vested options (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock option activity, additional information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding', window );">Weighted-average grant date fair value per share of employee option grants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to a modification during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average fair value for outstanding stock options that are fully vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could acquire or could have acquired the underlying shares with respect to a change in shares reserved for issuance attributable to a modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodModificationWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price (at which grantees can acquire the shares reserved for issuance) for exercisable stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=coll_EmployeeAndNonemployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=coll_EmployeeAndNonemployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6806452336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details 3) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted stock awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of year (in shares)</a></td>
<td class="nump">15,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">194,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(128,955)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of year (in shares)</a></td>
<td class="nump">81,126<span></span>
</td>
<td class="nump">15,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at beginning of year (in dollars per share)</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">5.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at end of year (in dollars per share)</a></td>
<td class="nump">$ 5.73<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted stock awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of year (in shares)</a></td>
<td class="nump">15,387<span></span>
</td>
<td class="nump">55,298<span></span>
</td>
<td class="nump">203,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,780)<span></span>
</td>
<td class="num">(89,308)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification', window );">Performance Adjustment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,736)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of year (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,387<span></span>
</td>
<td class="nump">55,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at beginning of year (in dollars per share)</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.62<span></span>
</td>
<td class="nump">0.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue', window );">Performance Adjustment (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at end of year (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Unrecognized compensation cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which unrecognized compensation cost is expected to be recognized as expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The addition or reduction in the number of equity-based payment instruments, excluding stock (or unit) options, attributable to a modification during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherIncreasesDecreasesInPeriodModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of of equity-based award plans other than stock (unit) option plans with respect to a change in nonvested shares attributable to a modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790473280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details 4) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6791198176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details 5)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">77.10%<span></span>
</td>
<td class="nump">87.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 2 months 16 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.09%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.22%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section D<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789804832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax (benefit) at statutory rate (as a percent)</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent', window );">Expiration of state net operating losses (as a percent)</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="num">(12.11%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent items (as a percent)</a></td>
<td class="num">(0.17%)<span></span>
</td>
<td class="num">(0.01%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and experimental credits (as a percent)</a></td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">4.19%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance (as a percent)</a></td>
<td class="num">(37.57%)<span></span>
</td>
<td class="num">(26.07%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax expense (benefit) (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense for the expiration of state net operating losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxesExpirationOfStateNetOperatingLossesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6791523920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 28,419<span></span>
</td>
<td class="nump">$ 21,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research Credits</a></td>
<td class="nump">3,070<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">31,525<span></span>
</td>
<td class="nump">23,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(31,525)<span></span>
</td>
<td class="num">(23,788)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets net of valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceAbstract', window );"><strong>Valuation allowance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax asset valuation allowance increase</a></td>
<td class="nump">$ 7,737<span></span>
</td>
<td class="nump">$ 5,081<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Liability<br> -URI http://asc.fasb.org/extlink&amp;oid=6510232<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 15<br> -Subparagraph b(2)<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6785464000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details 3) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Net operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Available net operating loss carryforwards as of the end of the year</a></td>
<td class="nump">$ 34,184<span></span>
</td>
<td class="nump">$ 16,354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">U.S. federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Net operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Available net operating loss carryforwards as of the end of the year</a></td>
<td class="nump">$ 78,276<span></span>
</td>
<td class="nump">$ 60,380<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6805630592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFITS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract', window );"><strong>EMPLOYEE BENEFITS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan', window );">Requisite service period of employees to be eligible to participate in the 401(k) plan</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Total expense for contributions made to 401(k) plan</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period that the employee is required to perform services from the date of employment, or anniversary thereof, in order to be eligible to participate in the defined contribution plan, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_DefinedContributionPlanRequisiteServicePeriodForEligibilityToParticipateInPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the cost recognized during the period for defined contribution plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6809698768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 26, 2015 </div>
<div>patent</div>
</th>
<th class="th">
<div>Mar. 24, 2015 </div>
<div>patent</div>
</th>
<th class="th">
<div>Mar. 06, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2014 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Principal amount converted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,197,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Common stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.144927536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember', window );">Office and research facility operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Term of lease extension option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember', window );">Office and research facility operating lease | Delivery of expansion space with substantial completion of certain improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=coll_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember', window );">Amendment to office and research facility operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=coll_StockIncentivePlan2014Member', window );">2014 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember', window );">Purdue Pharma, L. P. patent infringement suit, District of Delaware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Number of patents asserted to have been infringed | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember', window );">Purdue Pharma, L. P., patent infringement suit, District of Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Number of patents asserted to have been infringed | patent</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock | Mandatory conversion, initial public offering | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Cash consideration from issuance of preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member', window );">6.0% Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Principal amount converted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Common stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events | Office and research facility operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Term of lease extension option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events | Office and research facility operating lease | Delivery of expansion space with substantial completion of certain improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events | Amendment to office and research facility operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events | 2014 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,087,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events | Employee stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">638,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Period from grant date to expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events | Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events | Restricted stock | Vested upon grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events | Restricted stock | Vesting in monthly installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events | Purdue Pharma, L. P. patent infringement suit, District of Delaware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Number of patents asserted to have been infringed | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events | Purdue Pharma, L. P., patent infringement suit, District of Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Number of patents asserted to have been infringed | patent</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events | Private Placement | Investors | Series D convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Aggregate consideration | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Cash consideration from issuance of preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events | Conversion of convertible notes into convertible preferred stock | Investors | 6.0% Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Principal amount converted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events | Conversion of convertible notes into convertible preferred stock | Investors | 6.0% Convertible promissory notes | Series D convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares of stock into which debt was converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,166,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of another entity's patents that the entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPatentsAllegedlyInfringedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Stock Split<br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=coll_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=coll_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=coll_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=coll_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=coll_StockIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=coll_StockIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=coll_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=coll_ConversionOfConvertiblePromissoryNotesIntoRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6791602832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 105,460<span></span>
</td>
<td class="nump">$ 1,634<span></span>
</td>
<td class="nump">$ 4,178<span></span>
</td>
<td class="nump">$ 7,551<span></span>
</td>
<td class="nump">$ 11,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Refundable PDUFA fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">866<span></span>
</td>
<td class="nump">527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">106,326<span></span>
</td>
<td class="nump">4,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">627<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">107,050<span></span>
</td>
<td class="nump">5,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,237<span></span>
</td>
<td class="nump">2,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,681<span></span>
</td>
<td class="nump">1,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent', window );">Current portion of deferred rent and lease note payable</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Current portion of term loan payable</a></td>
<td class="nump">2,667<span></span>
</td>
<td class="nump">1,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Convertible bridge notes with related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,600<span></span>
</td>
<td class="nump">10,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncentiveFromLessor', window );">Lease incentive obligation</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Term loan payable, long-term</a></td>
<td class="nump">4,813<span></span>
</td>
<td class="nump">6,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 13,489<span></span>
</td>
<td class="nump">$ 17,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (See Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">213,027<span></span>
</td>
<td class="nump">12,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(119,483)<span></span>
</td>
<td class="num">(101,753)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCarryingBasis', window );">Treasury stock</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity (deficit)</a></td>
<td class="nump">93,561<span></span>
</td>
<td class="num">(89,348)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,225)<span></span>
</td>
<td class="num">(61,404)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible redeemable preferred stock and shareholders' equity (deficit)</a></td>
<td class="nump">$ 107,050<span></span>
</td>
<td class="nump">5,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible redeemable preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,277<span></span>
</td>
<td class="nump">23,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible redeemable preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,376<span></span>
</td>
<td class="nump">$ 47,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible redeemable preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the combined amount of cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date and the current portion of the net carrying amount of the reimbursable incentive or inducement received by a lessee from a lessor, in order to motivate the lessee to enter the lease agreement, which incentive or inducement is to be repaid over the lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_DeferredRentCreditAndReimbursableIncentiveFromLessorNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 12<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveFromLessor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the deferred credit for an incentive or inducement received by a lessee from a lessor, in order to motivate the lessee to enter the lease agreement, which incentive or inducement is to be recognized as a reduction of rental expense over the lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Lease Incentive<br> -URI http://asc.fasb.org/extlink&amp;oid=6516590<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 55<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6584307&amp;loc=d3e41620-112719<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e40010-112707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveFromLessor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 25<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 8<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCarryingBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost basis for treasury stock acquired for purposes other than retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCarryingBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6806314496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible redeemable preferred stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,481,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">72,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="nump">20,687,829<span></span>
</td>
<td class="nump">1,006,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="nump">1,006,219<span></span>
</td>
<td class="nump">1,006,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible redeemable preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible redeemable preferred stock, authorized shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,498,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible redeemable preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,232,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible redeemable preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,232,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible redeemable preferred stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible redeemable preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible redeemable preferred stock, authorized shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,324,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible redeemable preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,324,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible redeemable preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,324,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible redeemable preferred stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 51,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible redeemable preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible redeemable preferred stock, authorized shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,658,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible redeemable preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,658,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible redeemable preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,658,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible redeemable preferred stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible redeemable preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible redeemable preferred stock, authorized shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible redeemable preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible redeemable preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible redeemable preferred stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27011957&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 28<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 28<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 28<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6805966080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 6,444,000<span></span>
</td>
<td class="nump">$ 12,652,000<span></span>
</td>
<td class="nump">$ 12,652,000<span></span>
</td>
<td class="nump">$ 14,157,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">11,027,000<span></span>
</td>
<td class="nump">1,686,000<span></span>
</td>
<td class="nump">1,686,000<span></span>
</td>
<td class="nump">1,885,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">17,471,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,338,000<span></span>
</td>
<td class="nump">16,042,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(17,471,000)<span></span>
</td>
<td class="num">(14,338,000)<span></span>
</td>
<td class="num">(14,338,000)<span></span>
</td>
<td class="num">(16,042,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment</a></td>
<td class="num">(91,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="nump">259,000<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">155,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,730,000)<span></span>
</td>
<td class="num">$ (14,448,000)<span></span>
</td>
<td class="num">$ (14,448,000)<span></span>
</td>
<td class="num">$ (16,197,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.94)<span></span>
</td>
<td class="num">$ (18.26)<span></span>
</td>
<td class="num">$ (18.26)<span></span>
</td>
<td class="num">$ (4.06)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares used in net loss per share-basic and diluted (in shares)</a></td>
<td class="nump">11,179,756<span></span>
</td>
<td class="nump">926,597<span></span>
</td>
<td class="nump">926,597<span></span>
</td>
<td class="nump">1,697,044<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6806183824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,730,000)<span></span>
</td>
<td class="num">$ (14,448,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="nump">141,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_AmortizationOfIncentiveFromLessor', window );">Lease incentive</a></td>
<td class="num">(25,000)<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,217,000<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Non cash interest expense</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Accrual of back end fees related to note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(338,000)<span></span>
</td>
<td class="num">(139,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositsOutstanding', window );">Refundable PDUFA fee</a></td>
<td class="nump">2,335,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">962,000<span></span>
</td>
<td class="nump">1,563,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">815,000<span></span>
</td>
<td class="nump">2,518,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(12,628,000)<span></span>
</td>
<td class="num">(10,380,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(175,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(175,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaturitiesOfSeniorDebt', window );">(Repayment of) borrowing from term note</a></td>
<td class="num">(619,000)<span></span>
</td>
<td class="nump">7,044,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongtermLoansFromVendors', window );">Repayment of lease note payable</a></td>
<td class="num">(44,000)<span></span>
</td>
<td class="num">(46,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseInRestrictedCash', window );">Restricted cash</a></td>
<td class="num">(16,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">472,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">116,629,000<span></span>
</td>
<td class="nump">7,007,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInContinuingOperations', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">103,826,000<span></span>
</td>
<td class="num">(3,373,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">1,634,000<span></span>
</td>
<td class="nump">7,551,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">105,460,000<span></span>
</td>
<td class="nump">4,178,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue', window );">Accruals of dividends and accretion to redemption value</a></td>
<td class="nump">24,572,000<span></span>
</td>
<td class="nump">2,469,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of bridge note to preferred stock</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="nump">260,000<span></span>
</td>
<td class="nump">46,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReduction', window );">Repayment of term note with proceeds of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 944,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coll_CommonStockNoClassMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from issuance of stock, net of issuance costs</a></td>
<td class="nump">72,029,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from issuance of stock, net of issuance costs</a></td>
<td class="nump">44,807,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue', window );">Accruals of dividends and accretion to redemption value</a></td>
<td class="nump">24,572,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember', window );">Conversion of redeemable convertible preferred stock into common stock | Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Preferred stock conversion to common stock</a></td>
<td class="nump">$ 120,302,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_AmortizationOfIncentiveFromLessor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amortization of the deferred credit for an incentive or inducement received by a lessee from a lessor, in order to motivate the lessee to enter the lease agreement, amortized over the term of the lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_AmortizationOfIncentiveFromLessor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the combined value of accretion of temporary equity during the period due to unpaid dividends and accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in monies given as security or collateral for items acquired or borrowed on a temporary basis. Deposits may also be paid as initial payment of the cost of acquisition or for the right to enter into a contract or agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of long-term borrowing, with the highest claim on the assets of the entity in case of bankruptcy or liquidation, as it matures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of notes retired (or transferred to another entity) in noncash investing or financing transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongtermLoansFromVendors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflows under financing arrangements with vendors (seller-financed debt), which had a maturity date at inception of more than one year (or more than one operating cycle, if longer); such debt may have arisen from purchases of property, plant and equipment or other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongtermLoansFromVendors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coll_CommonStockNoClassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coll_CommonStockNoClassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6770957008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coll_CommonStockNoClassMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 2,408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 193<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coll_CommonStockNoClassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coll_CommonStockNoClassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789519920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>NATURE OF BUSINESS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF BUSINESS</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>1. NATURE OF BUSINESS</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Collegium Pharmaceutical,&#160;Inc. (the "Company") was incorporated in Delaware in April 2002 and then reincorporated in Virginia in July 2014. The Company has its principal operations in Canton, Massachusetts. The Company is a specialty pharmaceutical company developing and planning to commercialize next-generation abuse-deterrent products that incorporate the Company's patented DETERx&#174; platform technology for the treatment of chronic pain and other diseases. The Company's lead product candidate, Xtampza&#8482; ER, or Xtampza, is an abuse-deterrent, extended-release, oral formulation of oxycodone, a widely prescribed opioid medication. Xtampza has received Fast Track status from the U.S. Food and Drug Administration ("FDA"). The Company's new drug application ("NDA") filing for Xtampza was accepted by the FDA on February&#160;10, 2015. On February&#160;25, 2015, the FDA set a Prescription Drug User Fee Act, or PDUFA, goal date of October&#160;12, 2015 for completion of its review of the Xtampza NDA. On November&#160;6, 2015, the FDA granted tentative approval to the Xtampza NDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. With a tentative approval, the FDA has determined that Xtampza meets the required quality, safety and efficacy standards for approval but that it is subject to an automatic stay of up to 30&#160;months as a result of patent litigation filed by Purdue Pharma, L.P (Purdue) in March 2015.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company's operations are subject to certain risks and uncertainties. The principal risks include negative outcome of clinical trials, inability or delay in completing clinical trials or obtaining regulatory approvals, changing market conditions for products being developed by the Company, the need to retain key personnel and protect intellectual property, patent infringement litigation and the availability of additional capital financing on terms acceptable to the Company.</font></p>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>1. NATURE OF BUSINESS</b></font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Organization</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Collegium Pharmaceutical,&#160;Inc. (the "Company") was incorporated in Delaware in April 2002 and then reincorporated in Virginia in July 2014. The Company has its principal operations in Canton, Massachusetts. The Company is a specialty pharmaceutical company developing and planning to commercialize next-generation abuse-deterrent products that incorporate the Company's patented DETERx&#174; platform technology for the treatment of chronic pain and other diseases. The Company's lead product candidate, Xtampza&#8482; ER, or Xtampza, is an abuse-deterrent, extended-release, oral formulation of oxycodone, a widely prescribed opioid medication. Xtampza has received Fast Track status from the U.S. Food and Drug Administration ("FDA"). The Company's new drug application ("NDA") filing for Xtampza was accepted by the FDA on February&#160;10, 2015.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company's operations are subject to certain risks and uncertainties. The risks include negative outcome of clinical trials, inability or delay in completing clinical trials or obtaining regulatory approvals, changing market conditions for products being developed by the Company, the need to retain key personnel and protect intellectual property, patent infringement litigation and the availability of additional capital financing on terms acceptable to the Company.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Basis of Accounting</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The financial statements include the accounts of the Company and are prepared in conformity with accounting principles generally accepted in the United States of America.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Liquidity</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company has experienced net losses and negative cash flows from operating activities since its inception, and as of December&#160;31, 2013 and December&#160;31, 2014, had a deficit accumulated of $80,536 and $101,753, respectively. The Company expects to continue to incur net losses in the foreseeable future. A successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company's cost structure.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">On March&#160;6, 2015, the Company received aggregate consideration of $50,000 from the issuance of Series&#160;D preferred stock, comprised of $45,000 in cash and $5,000 in convertible notes from related parties.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company expects to continue to incur losses for the foreseeable future. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic partners or from other sources. The Company believes that it will have sufficient cash to fund operations and future growth initiatives through December&#160;31, 2015; however, there can be no assurance that the Company will be successful in achieving its projections, reducing costs, or raising additional funds with terms acceptable to the Company. If the Company is unable to obtain financing or increase profitability, the related lack of liquidity will have a material adverse effect on the Company's operations and future prospects.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789557488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Basis of presentation</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial reporting and as required by Regulation&#160;S-X, Rule&#160;10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the interim periods ended September&#160;30, 2015 and 2014 are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The condensed interim financial statements should be read in conjunction with the audited financial statements and notes as of and for the year ended December&#160;31, 2014.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Initial Public Offering</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In May 2015, the Company closed an initial public offering ("IPO") of its common stock, which resulted in the sale of 6,670,000 shares of its common stock at a public offering price of $12.00 per share, including 870,000 shares of common stock upon the exercise by the underwriters of their option to purchase additional shares at the public offering price. The Company received proceeds from the IPO of approximately $72,029, after deducting underwriting discounts, commissions and expenses payable by the Company.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In connection with preparing for the IPO, the Company's Board of Directors and shareholders approved a one-for-6.9 reverse stock split of the Company's common stock. The reverse stock split became effective in April 2015. All share and per share amounts in the condensed interim financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. In connection with the closing of the IPO, all of the Company's outstanding convertible preferred stock automatically converted to common stock in May 2015, resulting in an additional 12,591,456 shares of common stock of the Company becoming outstanding. The significant increase in common stock outstanding in May 2015 is expected to impact the year-over-year comparability of the Company's net loss per share calculations in future periods.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Subsequent Events</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Through November&#160;12, 2015, the Company has concluded that no subsequent events have occurred that require disclosure, except as described in Note&#160;9.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Critical Accounting Policies</b></font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2"><i><!-- COMMAND=STYLE_ADDED,"margin-left:9.0pt;text-indent:-9.0pt;" -->Earnings (Loss) per Common Share</i></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Earnings (loss) per common share is calculated using the two-class method, which is an earnings allocation formula that determines earnings (loss) per share for the holders of the Company's common shares and participating securities. All series of preferred stock contain participation rights in any dividend paid by the Company and are deemed to be participating securities. Earnings available to common shareholders and participating convertible redeemable preferred shares is allocated first to the preferred stock based upon the distribution criteria in the Company's Articles of Incorporation then the remainder to the common shareholders. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods that have a net loss.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Diluted earnings per share is computed using the more dilutive of (a)&#160;the two-class method, or (b)&#160;the if-converted method. The Company allocates earnings first to preferred shareholders based on dividend rights and then to common and preferred shareholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted earnings (loss) gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants, convertible redeemable preferred stock and the potential issuance of stock upon the conversion of the Company's convertible notes. Common stock equivalent shares are excluded from the computation of diluted earnings (loss) per share if their effect is antidilutive.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Recent Accounting Pronouncements</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In May 2014, the Financial Accounting Standards Board ("FASB"), issued Accounting Standards Update ("ASU"), No.&#160;2014-09, which amends the guidance for accounting for revenue from contracts with customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification ("ASC"), Topic 605, Revenue Recognition, and creates a new Topic 606, Revenue from Contracts with Customers. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain practical expedients permitted; or retrospectively with the cumulative effect of initially adopting the ASU recognized at the date of initial application. On August&#160;12, 2015, the FASB issued ASU No.&#160;2015-14, which defers the effective date of ASU No.&#160;2014-09 by one year to December&#160;15, 2017 for annual reporting periods beginning after that date, including interim periods within those periods. The FASB also approved permitting early adoption of the standard, but not before the original effective date of December&#160;15, 2016. The Company has not yet determined which adoption method it will utilize or the effect that the adoption of this guidance will have on its financial statements.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In July 2015, the FASB issued ASU No.&#160;2015-11, which amends existing guidance for measurement of inventory. Current inventory guidance requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. The amendments do not apply to inventory that is measured using last-in, first-out (LIFO) or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out or average cost. An entity should measure all inventory to which the amendments apply at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The amendments in the ASU No.&#160;2015-11 more closely align the measurement of inventory pursuant to GAAP with the measurement of inventory pursuant to International Financial Reporting Standards. The amendments are effective for fiscal years beginning after December&#160;15, 2016, and interim periods within fiscal years beginning after December&#160;15, 2017. The amendments should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company does not expect the adoption of this guidance to have a material impact on its condensed financial statements.</font></p>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Use of Estimates</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The preparation of the Company's financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company's financial statements and accompanying notes. The most significant estimates in the Company's financial statements relate to the valuation of equity awards, fair value estimates of warrants, estimated useful lives of fixed assets, asset retirement obligations and accruals related to clinical trials. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company's actual results may differ from these estimates under different assumptions or conditions.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Unaudited Pro Forma Net Loss per Share Information</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Unaudited pro forma net loss per share applicable to common shareholders is computed using the weighted-average number of common shares outstanding after giving effect to the conversion of all the outstanding convertible redeemable preferred stock into shares of common stock as if such conversion had occurred at the beginning of the period presented, or the date of original issuance, if later, and excludes the gain on extinguishment of preferred stock and the accretion of dividends.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Fair Value Measurements</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Disclosures of fair value information about financial instruments are required, whether or not recognized in the balance sheet, for financial instruments with respect to which it is practicable to estimate that value. The carrying amounts reported in the Company's financial statements for cash and cash equivalents, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these accounts.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Fair Value Measurements and Disclosures describes the fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, as follows:</font></p>
<p style="FONT-FAMILY: arial;"><font size="2"><b>Level&#160;1</b></font><font size="2">&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. The Company's Level&#160;1 assets and liabilities consist of money market investments.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2"><b>Level&#160;2</b></font><font size="2">&#160;&#160;&#160;&#160;Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level&#160;2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security. The Company does not have Level&#160;2 assets or liabilities.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2"><b>Level&#160;3</b></font><font size="2">&#160;&#160;&#160;&#160;Pricing inputs are unobservable for the assets or liabilities, that is, inputs that reflect the reporting entity's own assumptions about the assumptions market participants would use in pricing the assets. Level&#160;3 includes private investments that are supported by little or no market activity. The Company does not have Level&#160;3 assets or liabilities.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Transfers are calculated on values as of the transfer date. There were no transfers between Levels&#160;1, 2 and 3 during the years ended December&#160;31, 2013 and 2014.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Concentration of Credit Risk</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the financial institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Cash and Cash Equivalents</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Cash and cash equivalents include cash in readily available checking and savings accounts and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company's cash equivalents, which consist of money market funds, are measured at fair value on a recurring basis. As of December&#160;31, 2013 and 2014, the carrying amount of cash and cash equivalents was $7,551 and $1,634, respectively, which approximates fair value and was determined based upon Level&#160;1 inputs. Money market funds are valued using quoted market prices with no valuation adjustments applied. Accordingly, these securities are categorized as Level&#160;1.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Property and Equipment</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Property and equipment are recorded at historical cost. Maintenance and repair costs are expensed as incurred. Costs which materially improve or extend the lives of existing assets are capitalized. The Company provides for depreciation and amortization using the straight-line method over the estimated useful lives of the assets, which are as follows:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table style="text-align:left;TEXT-ALIGN: left;" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" width="40%" align="center"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="40%" align="center"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;" valign="bottom">
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Asset Category</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Estimated Useful Life</b></font></th></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;" valign="top">
<td style="FONT-FAMILY: arial;" align="center"><font size="2">Machinery and equipment</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="center"><font size="2">5&#160;years</font></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;" valign="top">
<td style="FONT-FAMILY: arial;" align="center"><font size="2">Computers and office equipment</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="center"><font size="2">5&#160;years</font></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;" valign="top">
<td style="FONT-FAMILY: arial;" align="center"><font size="2">Furniture and fixtures</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="center"><font size="2">7&#160;years</font></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-TOP: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px;" valign="top">
<td style="FONT-FAMILY: arial;" align="center"><font size="2">Leasehold improvements</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="center"><font size="2">5&#160;years</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">Upon retirement or sale, the cost of assets disposed and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recorded in the statements of operations.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Impairment of Long-Lived Assets</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Long-lived assets consist of property and equipment. When impairment indicators exist, the Company's management evaluates long-lived assets for potential impairment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. While the Company's current and historical operating losses and negative cash flows are indicators of impairment, management believes that future cash flows to be received support the carrying value of its long-lived assets and, accordingly, has not recognized any impairment losses since inception.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Impairment losses, if any, are recognized in earnings. An impairment loss would be recognized in an amount equal to the excess of the carrying amount over the undiscounted expected future cash flows.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Initial Public Offering Costs</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company defers direct incremental costs attributable to the initial public offering ("IPO") of its common stock. These costs represent legal, accounting and other direct costs related to the Company's efforts to raise capital through a public sale of its common stock. Future costs will be deferred until the completion of the IPO, at which time they will be reclassified to additional paid-in capital as a reduction of the IPO proceeds. If the Company terminates its plan for an IPO or delays such plan for more than 90&#160;days, any costs deferred will be expensed immediately. As of December&#160;31, 2014, IPO costs were $233 and are included in prepaid expenses and other assets in the balance sheet.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Restricted Cash</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Restricted cash represents cash held in a depository account at a financial institution to collateralize a conditional stand-by letter of credit related to the Company's Canton, Massachusetts facility lease agreement. Restricted cash is reported as non-current unless the restrictions are expected to be released in the next twelve months.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Deferred Rent</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis for the facilities the Company occupies. The Company's lease for its facility provides for fixed increases in minimum annual rental payments and for additional rent in the form of maintenance and operating costs during the lease term. The total amount of rental payments due over the lease term is being charged to rent expense ratably over the life of the lease.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Convertible Redeemable Preferred Stock</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company classifies convertible redeemable preferred stock that is redeemable outside of the Company's control outside of permanent equity. The Company recorded such redeemable preferred stock at fair value upon issuance, net of any issuance costs or discounts, and the carrying value is being increased by periodic accretion to its redemption value at each balance sheet date as if the redeemable preferred stock was redeemable at that date. In the absence of retained earnings these accretion charges are recorded against additional paid-in capital, if any, and then to accumulated deficit.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Research and Development Costs</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Research and development costs are charged to expense as incurred and consist of costs incurred to further the Company's research and development activities including salaries and employee related costs, costs associated with market research and design, costs associated with conducting preclinical, clinical and regulatory activities including fees paid to third-party professional consultants and service providers, costs incurred under clinical trial agreements, costs for laboratory supplies and laboratory equipment, costs to acquire, develop and manufacture preclinical study and clinical trial materials, facilities, depreciation and other expenses including allocated expenses for rent and maintenance of facilities. Government grants are recognized as a reduction of the qualifying cost being reimbursed.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Patent Costs</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Costs related to filing and pursuing patent applications are recorded as general and administrative expense as incurred since the recoverability of such expenditures is uncertain.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Stock-Based Compensation</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company accounts for grants of stock options and restricted stock to employees based on their grant date fair value and recognizes compensation expense over their vesting period. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the fair value of the underlying common stock as determined by management or the value of the services provided, whichever is more readily determinable.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Stock-based compensation expense represents the cost of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of estimated forfeitures. The expense is adjusted for actual forfeitures at year end. Stock-based compensation expense recognized in the financial statements is based on awards that are ultimately expected to vest.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">For stock option grants with performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable or the performance condition has been achieved. For stock option grants with both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company accounts for stock options and restricted stock awards to non-employees using the fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic revaluation over their vesting terms. There were no non-employee grants in 2013 and 2014.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Income Taxes</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company accounts for income taxes under the liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the years in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future, in excess of its net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company records uncertain tax positions on the basis of a two-step process whereby (i)&#160;management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii)&#160;for those tax positions that meet the more likely than not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50&#160;percent likely to be realized upon ultimate settlement with the related tax authority. The Company will recognize interest and penalties related to uncertain tax positions within income tax expense. Any accrued interest and penalties will be included within the related tax liability. As of December&#160;31, 2013 and 2014, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company's statements of operations.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Net loss per Common Share</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Basic net loss per common share is calculated by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock options, warrants, redeemable convertible preferred stock and unvested restricted stock are considered potentially dilutive securities. Because the Company has reported a net loss for the twelve months ended December&#160;31, 2013 and 2014, diluted net loss per common share is the same as basic net loss per common share for those periods.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Diluted earnings per share is computed using the more dilutive of (i)&#160;the two-class method, or (ii)&#160;the if-converted method. The Company allocates earnings first to preferred shareholders based on dividend rights and then to common and preferred shareholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted earnings (loss) gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants, convertible redeemable preferred stock and the potential issuance of stock upon the conversion of the Company's convertible notes. Common stock equivalent shares are excluded from the computation of diluted earnings (loss) per share if their effect is antidilutive.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Recently Issued Accounting Pronouncements</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In July 2013, the Financial Accounting Standards Board ("FASB") issued ASU No.&#160;2013-11,</font> <font size="2"><i>Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exist.</i></font> <font size="2">ASU&#160;2013-11 amends the presentation requirements of ASC&#160;740 and requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, similar tax loss, or a tax credit carryforward. To the extent the tax benefit is not available at the reporting date under the governing tax law or if the entity does not intend to use the deferred tax asset for such purpose, the unrecognized tax benefit should be presented as a liability and not combined with deferred tax assets. This ASU is effective for annual periods, and interim periods within those years, beginning after December&#160;15, 2013, which is fiscal 2014 for the Company. The amendments are to be applied to all unrecognized tax benefits that exist as of the effective date and may be applied retrospectively to each prior reporting period presented. The adoption of ASU&#160;2013-11 did not have a material impact on the Company's financial position or results of operations.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In May 2014, the FASB issued ASU No.&#160;2014-09,</font> <font size="2"><i>Revenue from Contracts with Customers.</i></font> <font size="2">This ASU is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This ASU is effective for annual reporting periods beginning after December&#160;15, 2016 and early adoption is not permitted. Accordingly, the Company will adopt this ASU on January&#160;1, 2017. Management does not believe the adoption of this ASU will have a material impact on the Company's financial condition, results of operations or cash flows.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In June 2014, the FASB issued ASU No.&#160;2014-12,</font> <font size="2"><i>Compensation&#160;&#8212; Stock Compensation (Topic&#160;718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period</i></font><font size="2">. ASU&#160;2014-12 applies to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. That is the case when an employee is eligible to retire or otherwise terminate employment before the end of the period in which a performance target (for example, an initial public offering or a profitability target) could be achieved and still be eligible to vest in the award if and when the performance target is achieved. The standard is required to be adopted by public business entities in annual periods beginning on or after December&#160;15, 2015 and interim periods within those annual periods. The Company plans to implement this standard in the first quarter of fiscal year 2016 and is currently evaluating the potential impact of this new guidance on its financial statements.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In August 2014, the FASB issued ASU No.&#160;2014-15,</font> <font size="2"><i>Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern.</i></font> <font size="2">ASU&#160;2014-15 requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU&#160;2014-15 is effective for annual periods ending after December&#160;15, 2016 and earlier application is permitted. The adoption of ASU&#160;2014-15 is not expected to have a material effect on the Company's financial statements or disclosures.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In November 2014, the FASB issued ASU No.&#160;2014-16,</font> <font size="2"><i>Derivatives and Hedging (Topic&#160;815)&#160;&#8212; Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share is More Akin to Debt or to Equity</i></font><font size="2">. This ASU was issued to clarify how current U.S. generally accepted accounting principles should be interpreted in evaluating the economic characteristics and risk of a host contract in a hybrid financial instrument that is issued in the form of a share. In addition, this ASU was issued to clarify that in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (that is, the relative strength of the debt-like or equity-like terms and features given the facts and circumstances) when considering how to weight those terms and features. The effects of initially adopting this ASU should be applied on a modified retrospective basis to existing hybrid financial instruments issued in a form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods. This ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2015. Early adoption in an interim period is permitted. The Company is currently evaluating the impact of the adoption of this ASU on its financial statements.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789561088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER COMMON SHARE</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>3. NET LOSS PER COMMON SHARE</b></font></p>
<div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="56"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="73"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Nine months ended<br />
September&#160;30,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2015</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Net loss</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(14,448</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(17,730</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Extinguishment of preferred stock&#160;&#8212; see note&#160;7</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">31,806</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Accretion of prior preferred stock&#160;&#8212; see note&#160;7</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(2,469</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(23,327</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Accretion and dividends of Series&#160;D preferred stock</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(1,245</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Loss attributable to common shareholders&#160;&#8212; basic and diluted</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(16,917</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(10,496</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Weighted-average number of common shares used in net loss per share&#160;&#8212; basic and diluted</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">926,597</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">11,179,756</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Net loss per share&#160;&#8212; basic and diluted</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(18.26</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(0.94</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">The following potentially dilutive securities, which represent all outstanding potentially dilutive securities, were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in common stock equivalent shares):</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="59"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="59"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Nine months ended<br />
September&#160;30,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2015</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding stock options</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">311,365</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,356,246</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Warrants</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">18,810</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">2,445</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Redeemable convertible preferred stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6,552,820</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested restricted stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">28,536</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">153,589</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>3. NET LOSS PER COMMON SHARE</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. Stock options, warrants, convertible preferred stock and unvested restricted stock are considered to be potentially dilutive securities and are only included in the calculation of diluted net loss per share when their effect is dilutive. For the twelve months ended December&#160;31, 2013 and December&#160;31, 2014, these securities were anti-dilutive due to the net losses in those periods and, therefore, the number of shares used to compute basic and diluted earnings per share are the same for of those periods.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The following table presents the computations of basic and dilutive net loss per share:</font></p>
<div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="67"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="56"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Years Ended December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Net loss</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(16,197</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(17,917</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Performance Adjustment of Series&#160;A</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">12,239</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Accruals of dividends and accretion to redemption value of preferred stock</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(2,925</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(3,300</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Loss attributable to common shareholders&#160;&#8212; basic and diluted</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(6,883</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(21,217</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Weighted-average shares used in computing basic and diluted net loss per common share</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">1,697,044</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">933,997</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Basic and diluted net loss per common share</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(4.06</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(22.72</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares):</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="59"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="59"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Years Ended December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Stock Options</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">229,791</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">281,029</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Warrants</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">4,170</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">18,809</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Redeemable convertible preferred stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6,552,820</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6,552,820</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested restricted stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">55,298</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">15,387</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6775947648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>4. FAIR VALUE OF FINANCIAL INSTRUMENTS</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy is now established that prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Level&#160;1 inputs&#160;&#160;&#160;&#160;Quoted prices in active markets for identical assets or liabilities</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Level&#160;2 inputs&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Level&#160;3 inputs&#160;&#160;&#160;&#160;Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The following tables present the Company's financial instruments carried at fair value using the lowest level input applicable to each financial instrument at December&#160;31, 2014 and September&#160;30, 2015.</font></p>
<div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="56"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="67"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="51"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="61"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" nowrap="nowrap" align="left">
<div style="MARGIN-BOTTOM: 0pt; WIDTH: 40pt; BORDER-BOTTOM: #000000 1pt solid;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Description <!-- COMMAND=ADD_SCROPPEDRULE,40pt --></b></font></div></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Total</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Quoted Prices<br />
in active<br />
markets<br />
(Level&#160;1)</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Significant<br />
other<br />
observable<br />
inputs<br />
(Level&#160;2)</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Significant<br />
unobservable<br />
inputs<br />
(Level&#160;3)</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2"><b>December&#160;31, 2014</b></font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Money market funds, included in cash equivalents</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">457</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">457</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; MARGIN-TOP: 12pt; TEXT-INDENT: -9pt;"><font size="2"><b>September&#160;30, 2015</b></font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2"><br />
&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2"><br />
&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2"><br />
&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2"><br />
&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Money market funds, included in cash equivalents</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">104,911</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">104,911</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">The Company's cash equivalents are comprised of money market funds that are measured on a recurring basis based on quoted market prices.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6795311936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>5. ACCRUED EXPENSES</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Accrued expenses consisted of the following:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="68"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="70"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>December&#160;31,<br />
2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>September&#160;30,<br />
2015</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued compensation</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">635</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,169</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued development costs</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">970</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">597</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued marketing</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">685</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued audit and legal</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">249</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">109</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued interest</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">71</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">31</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued other</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">31</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">90</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Total accrued expenses</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,956</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">2,681</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>6. ACCRUED EXPENSES</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Accrued expenses consisted of the following:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="42"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="42"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>As of December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued development costs</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">520</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">970</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued compensation</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">449</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">635</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued audit and legal</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">12</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">249</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued interest</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">71</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued other</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">32</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">31</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Total accrued expenses</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,013</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,956</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6787373632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Bridge Note with Related Party<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtOtherDisclosuresAbstract', window );"><strong>Convertible Bridge Note with Related Party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">Convertible Bridge Note with Related Party</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>6. CONVERTIBLE BRIDGE NOTE WITH RELATED PARTY</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In November and December 2014, the Company entered into a Note Purchase Agreement (the "Bridge Notes") allowing for the issuance of $5,000 of convertible promissory notes to a group of investors (the "Holders") bearing interest at a rate per annum of 6.0%. The Holders are related parties of the Company. In connection with the Series&#160;D convertible preferred stock financing (see note&#160;7), the Bridge Notes converted into Series&#160;D convertible preferred stock. Upon the conversion, the Company recognized a gain on extinguishment of $91.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789610960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>7. CONVERTIBLE PREFERRED STOCK</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In March 2015, the Company issued and sold an aggregate of 41,666,667 shares of Series&#160;D convertible preferred stock for aggregate consideration of $50,000, comprised of $45,000 in cash and conversion of $5,000 in Bridge Notes. The accrued interest on the convertible notes was waived.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Concurrently with the issuance of the Series&#160;D Preferred Stock, the Company amended and restated its Articles of Incorporation (the "Amended Articles"). The Company made certain amendments to the terms of the Series&#160;A, Series&#160;B, and Series&#160;C Preferred Stock (together, the "Prior Preferred Stock"). Prior to the adoption of the Amended Articles, the Series&#160;A, Series&#160;B, and Series&#160;C Preferred Stock accrued dividends at a rate of 4.5%, 8.0% and 8.0% per annum, respectively, per share. All accrued and unpaid dividends on the Prior Preferred Stock were automatically cancelled and forfeited and the Prior Preferred Stock no longer accrued dividends. Prior to the cancellation and forfeiture of accrued dividends, the Prior Preferred Stock had accrued dividends of $622 during 2015. The holders of outstanding shares of Prior Preferred Stock were entitled to receive dividends, when, as and if declared by the Board of Directors. The mandatory conversion for all series of Prior Preferred Stock was modified so as to occur upon an initial public offering with gross proceeds in excess of $50,000. The amendments to the Prior Preferred Stock were treated as an extinguishment which resulted in a gain on extinguishment of $31,806. The gain on extinguishment was added to net loss to arrive at income available to common shareholders in the calculation of earnings per share. During the nine months ended September&#160;30, 2015, total accrued dividends and accretion for preferred stock was $24,572.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In connection with the closing of the IPO, all of the Company's outstanding convertible preferred stock automatically converted to common stock in May 2015, resulting in an additional 12,591,456 shares of common stock of the Company becoming outstanding.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6807708592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK BASED COMPENSATION</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>8. STOCK-BASED COMPENSATION</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In July 2014, the Company adopted the 2014 Stock Incentive Plan (the "Plan"), under which 525,700 shares of common stock are authorized for issuance to employees, officers, directors, consultants and advisors of the Company. In connection with the Company's reincorporation into Virginia in July 2014, each outstanding option to purchase shares of common stock under the Company's 2012 Stock Incentive Plan and 2002 Stock Plan, was automatically terminated and replaced with an option to purchase shares of common stock under the Plan having the same vesting terms and exercise price as the option that was replaced. The Plan provides for granting of both Internal Revenue Service qualified incentive stock options ("ISOs") and non-qualified options ("NQs"), restricted stock awards ("RSAs") and restricted stock units ("RSUs"). Stock options generally vest over a four year period of service; however, certain options contain performance conditions. The options generally have a ten year contractual life and, upon termination, vested options are generally exercisable between one and three months following the termination date, while unvested options are forfeited immediately.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In April 2015, the Plan was amended to increase the maximum number of shares of common stock that may be issued to 2,700,000 shares. In addition, an "evergreen provision" was added to the Plan that allows for an annual increase in the number of shares of common stock available for issuance under the Plan. The annual increase will be added on the first day of each fiscal year beginning with the fiscal year ending December&#160;31, 2016, and on each anniversary thereof until the expiration of the Plan equal to 4% of the outstanding shares of our common stock on December&#160;31st&#160;of the immediately preceding fiscal year (or such lesser number of shares of common stock as determined by the board of directors).</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Restricted common stock</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">A summary of the Company's restricted stock activity for the nine months ended September&#160;30, 2015 and related information is as follows:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="53"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="82"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Shares</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted average<br />
purchase price<br />
per share</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">15,387</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.69</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Granted</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">194,694</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">5.73</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Vested</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(128,955</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">5.13</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested at September&#160;30, 2015<sup>(1)</sup></font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">81,126</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">5.73</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --><!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<hr style="COLOR: #000000;" align="left" size="1" width="26%" noshade="noshade" /></div>
<div style="POSITION: relative; PADDING-BOTTOM: 0pt; TEXT-ALIGN: left; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<dl compact="compact">
<dt style="MARGIN-BOTTOM: -9pt; FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><font style="FONT-SIZE: 6pt; POSITION: relative; TOP: -2pt; add_sup: 2pt;">(1)</font></font></dt>
<dd style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">Excludes 72,463 shares of unvested restricted stock remaining from the early exercise of stock options as of September&#160;30, 2015.</font></dd></dl></div>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Stock options</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">A summary of the Company's stock option activity and related information follows:</font></p>
<div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="59"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="65"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="54"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="49"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Shares</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted-<br />
average<br />
exercise price<br />
per share</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted-<br />
average<br />
remaining<br />
contractual<br />
term<br />
(years)</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Aggregate<br />
Intrinsic<br />
Value</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">281,029</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">0.69</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Granted</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">1,197,452</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">10.47</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Exercised</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(121,729</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">3.89</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Cancelled</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(506</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">2.06</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding at September&#160;30, 2015</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">1,356,246</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">9.04</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">9.2</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">17,722</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Exercisable at September&#160;30, 2015</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">208,438</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">2.65</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">7.9</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">4,056</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Vested and expected to vest at September&#160;30, 2015</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">1,341,543</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">9.13</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">9.2</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">18,595</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">The fair value of each stock option is estimated on the grant date using the Black-Scholes option-pricing model using the following assumptions:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="28"></td>
<td style="FONT-FAMILY: arial;" width="24"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="28"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Nine months<br />
ended<br />
September&#160;30,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2015</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Risk-free interest rate</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.8</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.7</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Dividend yield</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Volatility</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">77</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">77</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Expected term (years)</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6.25</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6.21</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>11. STOCK-BASED COMPENSATION</b></font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Restricted Stock Awards and Stock Options</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In July 2014, the Company adopted the 2014 Stock Incentive Plan (the "Plan"), under which 525,700 shares of common stock are authorized for issuance to employees, officers, directors, consultants and advisors of the Company. As of December&#160;31, 2014, 281,029 of the shares of common stock authorized for issuance pursuant to the Plan were outstanding. In connection with the Company's reincorporation into Virginia in July 2014, each outstanding option to purchase shares of common stock under the 2012 Stock Incentive Plan and 2002 Stock Plan, was automatically terminated and replaced with an option to purchase shares of common stock under the Plan having the same vesting terms and exercise price as the option that was replaced. The Plan provides for granting of both Internal Revenue Service qualified incentive stock options ("ISOs") and non-qualified options ("NQs"), restricted stock awards ("RSAs") and restricted stock units ("RSUs"). Stock options generally vest over a four year period of service; however, certain options contain performance conditions. The options generally have a ten year contractual life and, upon termination, vested options are generally exercisable between one and three months following the termination date, while unvested options are forfeited immediately.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In determining the exercise prices for options granted, the board of directors considered the fair value of the common stock as of the measurement date. The fair value of the common stock was determined by the board of directors based on a variety of factors, including valuations prepared by third parties, Company's financial position, the status of development efforts within the Company, the composition and ability of the current scientific and management teams, the current climate in the marketplace, the illiquid nature of the Company's common stock, arm's length sales of the Company's preferred stock, the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event, among others.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In connection with the Performance Adjustment which occurred on December&#160;4, 2013 (See Note&#160;10) the Company adjusted previously granted and then outstanding options such that for each option exercised, the option holder would receive one share of common stock for every two shares of common stock underlying the grant.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Stock option activity under the Plan is summarized as follows:</font></p>
<div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="53"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="47"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="55"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="47"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Number<br />
of Options</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted-<br />
Average<br />
Exercise<br />
Price</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted-<br />
Average<br />
Remaining<br />
Contractual<br />
Term<br />
(in years)</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Aggregate<br />
Intrinsic<br />
Value</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding at December&#160;31, 2012</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">323,488</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.73</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6.94</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">8</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Granted</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">146,730</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.48</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Exercised</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(1,077</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.62</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Cancelled</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(9,559</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">2.76</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Modification</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(229,791</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.17</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding at December&#160;31, 2013</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">229,791</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.17</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">7.02</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">117</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Granted</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">89,641</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.28</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Exercised</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(32,390</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">2.21</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Cancelled</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(6,013</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">4.42</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">281,029</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.69</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">7.49</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,505</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Vested and expected to vest at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">247,139</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.83</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">4.31</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,293</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Exercisable at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">121,304</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.38</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">4.31</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">570</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">As of December&#160;31, 2013 and 2014, the unrecognized compensation cost related to outstanding options was $40 and $215, respectively, and is expected to be recognized as expense over approximately 1.1&#160;years and 1.0&#160;years, respectively.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">As of December&#160;31, 2014, the weighted average fair value of vested options was $1.93.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Additional information about the Company's stock option activity is as follows:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="35"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="35"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>As of<br />
December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Weighted-average grant date fair value per share of employee option grants</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">0.28</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">0.76</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">Restricted stock awards under the Plan are summarized as follows:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="51"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="82"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Number of<br />
Shares</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted-Average<br />
Grant Date<br />
Fair Value</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested at December&#160;31, 2012</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">203,342</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.62</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Vesting of restricted stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(89,308</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.55</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Performance Adjustment</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(58,736</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.62</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested at December&#160;31, 2013</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">55,298</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.69</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Grant of restricted stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">10,869</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.24</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Vesting of restricted stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(50,780</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.62</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">15,387</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.69</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">As of December&#160;31, 2013 and 2014, the unrecognized compensation cost related to restricted stock awards was $73 and $26, respectively, and is expected to be recognized as expense over approximately 1.2&#160;years and 0.2&#160;years, respectively.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Stock-Based Compensation Expense</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company granted stock options to employees for the years ended December&#160;31, 2013 and 2014. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the fair value of the award. Stock options and restricted stock issued to non-board member, non-employees are accounted for using the fair value approach and are subject to periodic revaluation over their vesting terms.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Stock-based compensation for all stock options and restricted stock awards are reported within:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="28"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="28"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Years Ended December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Research and development</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">24</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">12</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">General and administrative</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">38</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">10</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Total stock-based compensation expense</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">62</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">22</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="97" align="center"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="39"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="4" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Years Ended December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Risk-free interest rate</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="center"><font size="2">1.09%&#160;&#8211; 1.22%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.80</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Expected volatility</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="center"><font size="2">87.8%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">77.1</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Expected term (in years)</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="center"><font size="2">6.25</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6.25</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Expected dividend yield</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="center"><font size="2">0.0%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.0</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2"><b><i>Risk-free Interest Rate.</i></b></font><font size="2">&#160;&#160;&#160;&#160;The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the stock option grants.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2"><b><i>Expected Volatility.</i></b></font><font size="2">&#160;&#160;&#160;&#160;Due to the Company's limited operating history and lack of company-specific historical or implied volatility, the expected volatility assumption is based on historical volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology and medical device industries.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2"><b><i>Expected Term.</i></b></font><font size="2">&#160;&#160;&#160;&#160;The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, through December&#160;31, 2014 it determined the expected life assumption using the simplified method, which is an average of the contractual term of the option and its vesting period. In 2013, some of the stock option grants were in-the-money, based on the retrospective fair value determinations, so the Company determined the expected life using a risk-adjusted method, which adjusts the average of the contractual term of the option and its vesting period for risk, thereby reducing the expected life.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2"><b><i>Expected Dividend Yield.</i></b></font><font size="2">&#160;&#160;&#160;&#160;The expected dividend yield assumption is based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6791844272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>9. COMMITMENTS AND CONTINGENCIES</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company's NDA filing for Xtampza is a 505(b)(2) application, which allows the Company to reference data from an approved drug listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the "Orange Book"), in this case OxyContin OP. In connection with the 505(b)(2) process, the Company certified to the FDA and notified Purdue Pharma,&#160;L.P. ("Purdue"), as the holder of the NDA and any other Orange Book-listed patent owners, that the Company does not infringe any of the patents listed for OxyContin OP in the Orange Book. Under the Hatch-Waxman Act of 1984 (the "Hatch-Waxman Act"), Purdue can elect to sue the Company for infringement, and if they do, receive a stay of up to 30&#160;months before the FDA can issue a final approval for Xtampza, unless the stay is earlier terminated. On March&#160;24, 2015, Purdue sued the Company in the District of Delaware asserting infringement of four patents. On March&#160;26, 2015, Purdue filed a second suit against the Company in the District of Massachusetts asserting infringement of the same four patents. On July&#160;23, 2015, Purdue voluntarily dismissed the Massachusetts suit. On August&#160;6, 2015, the Delaware court dismissed the suit in Delaware and issued a memorandum opinion finding the Delaware court lacks personal jurisdiction over the Company Following the dismissal in Delaware, on August&#160;6, 2015, the Company filed a complaint in the Southern District of New York asserting an action to obtain patent certainty, and requesting that the New York court find that Xtampza will not infringe any valid patent claim of the patents asserted by Purdue in the Delaware action. Also on August&#160;6, 2015, Purdue sued the Company in the District of Massachusetts asserting the same claims as the prior suit. On August&#160;7, 2015, Purdue filed a motion in the Delaware court requesting reconsideration of the August&#160;6, 2015 order that dismissed the case. In the motion requesting reconsideration, Purdue asked that the Delaware court find that it does have personal jurisdiction over the Company and then transfer the case to the District of Massachusetts. On October&#160;7, 2015, the Delaware court transferred the case to the District of Massachusetts. On November&#160;9, 2015, the Company filed a motion for summary judgment, for which it requested expedited hearing in Massachusetts. At this time the Company is unable to provide meaningful quantification of how this litigation may impact its future financial condition, results of operations, or cash flows.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In March 2015, the Company amended its lease to include an additional 9,660 square feet of space for a total of 19,335 square feet. In addition, the lease term was extended and now terminates on the date that is 5&#160;years following August 2015 which is the date that the landlord delivered the expansion space with certain improvements substantially completed. At the Company's election, the lease term may be extended for an additional 5-year term.</font></p>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>7. COMMITMENTS AND CONTINGENCIES</b></font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Legal Proceedings</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">From time to time the Company may face legal claims or actions in the normal course of business. The Company is not currently a party to any litigation and, accordingly, does not have any amounts recorded for any litigation related matters.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company's NDA filing for Xtampza is a 505(b)(2) application, which allows the Company to reference data from an approved drug listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the "Orange Book"), in this case OxyContin OP. In connection with the 505(b)(2) process, the Company certified to the FDA and notified Purdue Pharma,&#160;L.P. ("Purdue"), as the holder of the NDA and any other Orange Book-listed patent owners, that the Company does not infringe any of the patents listed for OxyContin OP in the Orange Book. Under the Hatch-Waxman Act of 1984 (the "Hatch-Waxman Act"), Purdue can elect to sue the Company for infringement, and if they do, receive a stay of up to 30&#160;months before the FDA can issue a final approval for Xtampza, unless the stay is earlier terminated. Purdue has not yet brought such litigation, but it is possible that they will do so. At this time the Company is unable to provide meaningful quantification of how this potential litigation may impact its future financial condition, results of operations, or cash flows.</font></p>
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b><!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->Operating Leases</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company leases its office and research facility under a non-cancellable operating lease, which expires in December 2017. Terms of the agreement provide for an initial two-month rent-free period and future rent escalation, and provide that in addition to minimum lease rental payments, the Company is responsible for a pro-rata share of operating expenses and taxes. Aggregate minimum annual lease commitments of the Company under its non-cancellable operating lease as of December&#160;31, 2014 are as follows:</font></p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;"><font size="2"><!-- COMMAND=ADD_TABLEWIDTH,"100%" --></font></p>
<!-- User-specified TAGGED TABLE -->
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="31"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" nowrap="nowrap" align="left">
<div style="MARGIN-BOTTOM: 0pt; WIDTH: 95pt; BORDER-BOTTOM: #000000 1pt solid;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Year Ending December&#160;31, <!-- COMMAND=ADD_SCROPPEDRULE,95pt --></b></font></div></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">2015</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">106</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">2016</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">111</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">2017</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">116</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Total minimum lease payments</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">333</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
<p style="FONT-FAMILY: arial;"><font size="2">Rent expense under the operating lease agreement amounted to approximately $69 for the years ended December&#160;31, 2013 and 2014, respectively. In addition, the Company maintained a stand-by letter of credit in connection with the Canton facility lease of $80 at December&#160;31, 2013 and December&#160;31, 2014. This amount is classified as restricted cash in the balance sheets.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">As an inducement to enter into its Canton facility lease, the lessor agreed to provide the Company with an improvement allowance of up to $174 towards leasehold improvements. In addition the lessor provided the Company with a reimbursable allowance of $164 which is to be amortized and repaid by the Company at an 8% interest rate over the initial term of 36&#160;months. Amounts provided by the lessor related to tenant improvements are considered inducements to enter into the lease. The Company has recorded these costs in the balance sheet as leasehold improvements, with the corresponding liabilities as deferred lease incentive and lease note payable. These liabilities are amortized on a straight-line basis over the term of the lease.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790211984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Basis of presentation</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial reporting and as required by Regulation&#160;S-X, Rule&#160;10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the interim periods ended September&#160;30, 2015 and 2014 are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The condensed interim financial statements should be read in conjunction with the audited financial statements and notes as of and for the year ended December&#160;31, 2014.</font></p>
</div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_InitialPublicOfferingCostsPolicyPolicyTextBlock', window );">Initial Public Offering</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Initial Public Offering</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In May 2015, the Company closed an initial public offering ("IPO") of its common stock, which resulted in the sale of 6,670,000 shares of its common stock at a public offering price of $12.00 per share, including 870,000 shares of common stock upon the exercise by the underwriters of their option to purchase additional shares at the public offering price. The Company received proceeds from the IPO of approximately $72,029, after deducting underwriting discounts, commissions and expenses payable by the Company.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In connection with preparing for the IPO, the Company's Board of Directors and shareholders approved a one-for-6.9 reverse stock split of the Company's common stock. The reverse stock split became effective in April 2015. All share and per share amounts in the condensed interim financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. In connection with the closing of the IPO, all of the Company's outstanding convertible preferred stock automatically converted to common stock in May 2015, resulting in an additional 12,591,456 shares of common stock of the Company becoming outstanding. The significant increase in common stock outstanding in May 2015 is expected to impact the year-over-year comparability of the Company's net loss per share calculations in future periods.</font></p>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Initial Public Offering Costs</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company defers direct incremental costs attributable to the initial public offering ("IPO") of its common stock. These costs represent legal, accounting and other direct costs related to the Company's efforts to raise capital through a public sale of its common stock. Future costs will be deferred until the completion of the IPO, at which time they will be reclassified to additional paid-in capital as a reduction of the IPO proceeds. If the Company terminates its plan for an IPO or delays such plan for more than 90&#160;days, any costs deferred will be expensed immediately. As of December&#160;31, 2014, IPO costs were $233 and are included in prepaid expenses and other assets in the balance sheet.</font></p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Subsequent Events</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Through November&#160;12, 2015, the Company has concluded that no subsequent events have occurred that require disclosure, except as described in Note&#160;9.</font></p>
</div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) per Common Share</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2"><i>Earnings (Loss) per Common Share</i></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Earnings (loss) per common share is calculated using the two-class method, which is an earnings allocation formula that determines earnings (loss) per share for the holders of the Company's common shares and participating securities. All series of preferred stock contain participation rights in any dividend paid by the Company and are deemed to be participating securities. Earnings available to common shareholders and participating convertible redeemable preferred shares is allocated first to the preferred stock based upon the distribution criteria in the Company's Articles of Incorporation then the remainder to the common shareholders. The participating securities do not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods that have a net loss.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Diluted earnings per share is computed using the more dilutive of (a)&#160;the two-class method, or (b)&#160;the if-converted method. The Company allocates earnings first to preferred shareholders based on dividend rights and then to common and preferred shareholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted earnings (loss) gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants, convertible redeemable preferred stock and the potential issuance of stock upon the conversion of the Company's convertible notes. Common stock equivalent shares are excluded from the computation of diluted earnings (loss) per share if their effect is antidilutive.</font></p>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Net loss per Common Share</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Basic net loss per common share is calculated by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock options, warrants, redeemable convertible preferred stock and unvested restricted stock are considered potentially dilutive securities. Because the Company has reported a net loss for the twelve months ended December&#160;31, 2013 and 2014, diluted net loss per common share is the same as basic net loss per common share for those periods.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">Diluted earnings per share is computed using the more dilutive of (i)&#160;the two-class method, or (ii)&#160;the if-converted method. The Company allocates earnings first to preferred shareholders based on dividend rights and then to common and preferred shareholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted earnings (loss) gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants, convertible redeemable preferred stock and the potential issuance of stock upon the conversion of the Company's convertible notes. Common stock equivalent shares are excluded from the computation of diluted earnings (loss) per share if their effect is antidilutive.</font></p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Recent Accounting Pronouncements</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In May 2014, the Financial Accounting Standards Board ("FASB"), issued Accounting Standards Update ("ASU"), No.&#160;2014-09, which amends the guidance for accounting for revenue from contracts with customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification ("ASC"), Topic 605, Revenue Recognition, and creates a new Topic 606, Revenue from Contracts with Customers. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain practical expedients permitted; or retrospectively with the cumulative effect of initially adopting the ASU recognized at the date of initial application. On August&#160;12, 2015, the FASB issued ASU No.&#160;2015-14, which defers the effective date of ASU No.&#160;2014-09 by one year to December&#160;15, 2017 for annual reporting periods beginning after that date, including interim periods within those periods. The FASB also approved permitting early adoption of the standard, but not before the original effective date of December&#160;15, 2016. The Company has not yet determined which adoption method it will utilize or the effect that the adoption of this guidance will have on its financial statements.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In July 2015, the FASB issued ASU No.&#160;2015-11, which amends existing guidance for measurement of inventory. Current inventory guidance requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. The amendments do not apply to inventory that is measured using last-in, first-out (LIFO) or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out or average cost. An entity should measure all inventory to which the amendments apply at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The amendments in the ASU No.&#160;2015-11 more closely align the measurement of inventory pursuant to GAAP with the measurement of inventory pursuant to International Financial Reporting Standards. The amendments are effective for fiscal years beginning after December&#160;15, 2016, and interim periods within fiscal years beginning after December&#160;15, 2017. The amendments should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company does not expect the adoption of this guidance to have a material impact on its condensed financial statements.</font></p>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;"><font size="2"><b>Recently Issued Accounting Pronouncements</b></font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In July 2013, the Financial Accounting Standards Board ("FASB") issued ASU No.&#160;2013-11,</font> <font size="2"><i>Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exist.</i></font> <font size="2">ASU&#160;2013-11 amends the presentation requirements of ASC&#160;740 and requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, similar tax loss, or a tax credit carryforward. To the extent the tax benefit is not available at the reporting date under the governing tax law or if the entity does not intend to use the deferred tax asset for such purpose, the unrecognized tax benefit should be presented as a liability and not combined with deferred tax assets. This ASU is effective for annual periods, and interim periods within those years, beginning after December&#160;15, 2013, which is fiscal 2014 for the Company. The amendments are to be applied to all unrecognized tax benefits that exist as of the effective date and may be applied retrospectively to each prior reporting period presented. The adoption of ASU&#160;2013-11 did not have a material impact on the Company's financial position or results of operations.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In May 2014, the FASB issued ASU No.&#160;2014-09,</font> <font size="2"><i>Revenue from Contracts with Customers.</i></font> <font size="2">This ASU is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This ASU is effective for annual reporting periods beginning after December&#160;15, 2016 and early adoption is not permitted. Accordingly, the Company will adopt this ASU on January&#160;1, 2017. Management does not believe the adoption of this ASU will have a material impact on the Company's financial condition, results of operations or cash flows.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In June 2014, the FASB issued ASU No.&#160;2014-12,</font> <font size="2"><i>Compensation&#160;&#8212; Stock Compensation (Topic&#160;718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period</i></font><font size="2">. ASU&#160;2014-12 applies to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. That is the case when an employee is eligible to retire or otherwise terminate employment before the end of the period in which a performance target (for example, an initial public offering or a profitability target) could be achieved and still be eligible to vest in the award if and when the performance target is achieved. The standard is required to be adopted by public business entities in annual periods beginning on or after December&#160;15, 2015 and interim periods within those annual periods. The Company plans to implement this standard in the first quarter of fiscal year 2016 and is currently evaluating the potential impact of this new guidance on its financial statements.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In August 2014, the FASB issued ASU No.&#160;2014-15,</font> <font size="2"><i>Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern.</i></font> <font size="2">ASU&#160;2014-15 requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU&#160;2014-15 is effective for annual periods ending after December&#160;15, 2016 and earlier application is permitted. The adoption of ASU&#160;2014-15 is not expected to have a material effect on the Company's financial statements or disclosures.</font></p>
<p style="FONT-FAMILY: arial;"><font size="2">In November 2014, the FASB issued ASU No.&#160;2014-16,</font> <font size="2"><i>Derivatives and Hedging (Topic&#160;815)&#160;&#8212; Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share is More Akin to Debt or to Equity</i></font><font size="2">. This ASU was issued to clarify how current U.S. generally accepted accounting principles should be interpreted in evaluating the economic characteristics and risk of a host contract in a hybrid financial instrument that is issued in the form of a share. In addition, this ASU was issued to clarify that in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (that is, the relative strength of the debt-like or equity-like terms and features given the facts and circumstances) when considering how to weight those terms and features. The effects of initially adopting this ASU should be applied on a modified retrospective basis to existing hybrid financial instruments issued in a form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods. This ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2015. Early adoption in an interim period is permitted. The Company is currently evaluating the impact of the adoption of this ASU on its financial statements.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_InitialPublicOfferingCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal, accounting and other direct costs incurred related to efforts to raise capital through a public sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_InitialPublicOfferingCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789520928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computations of basic and diluted net loss per share</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt;">&#160;</p>
<div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="56"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="73"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Nine months ended<br />
September&#160;30,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2015</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Net loss</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(14,448</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(17,730</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Extinguishment of preferred stock&#160;&#8212; see note&#160;7</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">31,806</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Accretion of prior preferred stock&#160;&#8212; see note&#160;7</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(2,469</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(23,327</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Accretion and dividends of Series&#160;D preferred stock</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(1,245</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Loss attributable to common shareholders&#160;&#8212; basic and diluted</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(16,917</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(10,496</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Weighted-average number of common shares used in net loss per share&#160;&#8212; basic and diluted</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">926,597</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">11,179,756</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Net loss per share&#160;&#8212; basic and diluted</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(18.26</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(0.94</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="67"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="56"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Years Ended December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Net loss</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(16,197</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(17,917</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Performance Adjustment of Series&#160;A</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">12,239</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Accruals of dividends and accretion to redemption value of preferred stock</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(2,925</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(3,300</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Loss attributable to common shareholders&#160;&#8212; basic and diluted</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(6,883</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(21,217</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Weighted-average shares used in computing basic and diluted net loss per common share</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">1,697,044</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">933,997</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Basic and diluted net loss per common share</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(4.06</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(22.72</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="59"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="59"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Nine months ended<br />
September&#160;30,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2015</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding stock options</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">311,365</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,356,246</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Warrants</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">18,810</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">2,445</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Redeemable convertible preferred stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6,552,820</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested restricted stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">28,536</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">153,589</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="59"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="59"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Years Ended December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Stock Options</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">229,791</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">281,029</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Warrants</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">4,170</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">18,809</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Redeemable convertible preferred stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6,552,820</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6,552,820</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested restricted stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">55,298</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">15,387</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790964112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of financial instruments measured at fair value by level within fair value hierarchy</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="56"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="67"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="51"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="61"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" nowrap="nowrap" align="left">
<div style="MARGIN-BOTTOM: 0pt; WIDTH: 40pt; BORDER-BOTTOM: #000000 1pt solid;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Description <!-- COMMAND=ADD_SCROPPEDRULE,40pt --></b></font></div></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Total</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Quoted Prices<br />
in active<br />
markets<br />
(Level&#160;1)</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Significant<br />
other<br />
observable<br />
inputs<br />
(Level&#160;2)</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Significant<br />
unobservable<br />
inputs<br />
(Level&#160;3)</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2"><b>December&#160;31, 2014</b></font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Money market funds, included in cash equivalents</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">457</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">457</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; MARGIN-TOP: 12pt; TEXT-INDENT: -9pt;"><font size="2"><b>September&#160;30, 2015</b></font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2"><br />
&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2"><br />
&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2"><br />
&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2"><br />
&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Money market funds, included in cash equivalents</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">104,911</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">104,911</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6795975056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of components of accrued expenses</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="68"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="70"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>December&#160;31,<br />
2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>September&#160;30,<br />
2015</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued compensation</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">635</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,169</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued development costs</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">970</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">597</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued marketing</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">685</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued audit and legal</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">249</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">109</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued interest</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">71</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">31</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued other</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">31</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">90</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Total accrued expenses</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,956</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">2,681</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="42"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="42"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>As of December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued development costs</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">520</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">970</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued compensation</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">449</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">635</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued audit and legal</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">12</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">249</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued interest</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">71</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Accrued other</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">32</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">31</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Total accrued expenses</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,013</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,956</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780556848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of restricted stock awards</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="53"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="82"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Shares</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted average<br />
purchase price<br />
per share</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">15,387</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.69</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Granted</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">194,694</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">5.73</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Vested</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(128,955</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">5.13</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested at September&#160;30, 2015<sup>(1)</sup></font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">81,126</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">5.73</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --><!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<hr style="COLOR: #000000;" align="left" size="1" width="26%" noshade="noshade" /></div>
<div style="POSITION: relative; PADDING-BOTTOM: 0pt; TEXT-ALIGN: left; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<dl compact="compact">
<dt style="MARGIN-BOTTOM: -9pt; FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><font style="FONT-SIZE: 6pt; POSITION: relative; TOP: -2pt; add_sup: 2pt;">(1)</font></font></dt>
<dd style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">Excludes 72,463 shares of unvested restricted stock remaining from the early exercise of stock options as of September&#160;30, 2015.</font></dd></dl></div>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="51"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="82"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Number of<br />
Shares</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted-Average<br />
Grant Date<br />
Fair Value</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested at December&#160;31, 2012</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">203,342</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.62</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Vesting of restricted stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(89,308</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.55</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Performance Adjustment</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(58,736</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.62</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested at December&#160;31, 2013</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">55,298</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.69</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Grant of restricted stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">10,869</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.24</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Vesting of restricted stock</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(50,780</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.62</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Unvested at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">15,387</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.69</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="59"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="65"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="54"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="49"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Shares</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted-<br />
average<br />
exercise price<br />
per share</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted-<br />
average<br />
remaining<br />
contractual<br />
term<br />
(years)</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Aggregate<br />
Intrinsic<br />
Value</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">281,029</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">0.69</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Granted</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">1,197,452</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">10.47</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Exercised</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(121,729</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">3.89</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Cancelled</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">(506</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">2.06</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding at September&#160;30, 2015</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">1,356,246</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">9.04</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">9.2</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">17,722</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Exercisable at September&#160;30, 2015</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">208,438</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">2.65</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">7.9</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">4,056</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="bottom">
<td style="FONT-FAMILY: arial;">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Vested and expected to vest at September&#160;30, 2015</font></p></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">1,341,543</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">9.13</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">9.2</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" align="right"><font size="2">18,595</font></td>
<td style="FONT-FAMILY: arial;"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="bottom">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;">&#8203;</td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 80%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 10%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="53"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="47"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="55"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="47"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Number<br />
of Options</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted-<br />
Average<br />
Exercise<br />
Price</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Weighted-<br />
Average<br />
Remaining<br />
Contractual<br />
Term<br />
(in years)</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Aggregate<br />
Intrinsic<br />
Value</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding at December&#160;31, 2012</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">323,488</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.73</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6.94</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">8</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Granted</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">146,730</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.48</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Exercised</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(1,077</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.62</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Cancelled</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(9,559</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">2.76</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Modification</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(229,791</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.17</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding at December&#160;31, 2013</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">229,791</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.17</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">7.02</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">117</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Granted</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">89,641</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.28</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Exercised</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(32,390</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">2.21</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt;"><font size="2">Cancelled</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">(6,013</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">)</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">4.42</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Outstanding at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">281,029</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.69</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">7.49</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,505</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom" align="right">&#8203;</td>
<td style="FONT-SIZE: 0.75pt; FONT-FAMILY: arial; LINE-HEIGHT: 0.75pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#ffffff" valign="top">
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom"><font size="2"><!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" --><!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" --></font>&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid; LINE-HEIGHT: 0pt;" valign="bottom" align="right">&#8203; <!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" --></td>
<td style="FONT-SIZE: 1.5pt; FONT-FAMILY: arial; LINE-HEIGHT: 0pt;" valign="bottom">&#8203;</td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Vested and expected to vest at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">247,139</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.83</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">4.31</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1,293</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Exercisable at December&#160;31, 2014</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">121,304</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.38</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">4.31</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2"><!-- -->$</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">570</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used in Black-Scholes option-pricing model</a></td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="28"></td>
<td style="FONT-FAMILY: arial;" width="24"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="28"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="5" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Nine months<br />
ended<br />
September&#160;30,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2015</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Risk-free interest rate</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.8</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.7</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Dividend yield</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">&#8212;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Volatility</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">77</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">77</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Expected term (years)</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6.25</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6.21</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
<td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div style="WIDTH: 70%; POSITION: relative; PADDING-BOTTOM: 0pt; PADDING-TOP: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 15%; PADDING-RIGHT: 0pt;">
<p style="FONT-FAMILY: arial;">&#160;</p>
<div align="center">
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="text-align:left;">

<tr style="padding:0;"><!-- TABLE COLUMN WIDTHS SET -->
<td style="FONT-FAMILY: arial;" align="left"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="97" align="center"></td>
<td style="FONT-FAMILY: arial;" width="12"></td>
<td style="FONT-FAMILY: arial;" width="7" align="right"></td>
<td style="FONT-FAMILY: arial;" width="39"></td>
<td style="FONT-FAMILY: arial;" width="12"></td><!-- TABLE COLUMN WIDTHS END --></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font size="2">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="4" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>Years Ended December&#160;31,</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" valign="bottom">
<th style="FONT-FAMILY: arial;" align="left"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font><br /></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2013</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th>
<th style="FONT-FAMILY: arial; BORDER-BOTTOM: #000000 1pt solid;" colspan="2" align="center"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;"><b>2014</b></font></th>
<th style="FONT-FAMILY: arial;"><font style="FONT-SIZE: 8pt; LINE-HEIGHT: 9pt;">&#160;</font></th></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Risk-free interest rate</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="center"><font size="2">1.09%&#160;&#8211; 1.22%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">1.80</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Expected volatility</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="center"><font size="2">87.8%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">77.1</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr>
<tr style="padding:0;" bgcolor="#CCEEFF" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Expected term (in years)</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="center"><font size="2">6.25</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">6.25</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td></tr>
<tr style="padding:0;" bgcolor="white" valign="top">
<td style="FONT-FAMILY: arial;" valign="bottom">
<p style="FONT-FAMILY: arial; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt;"><font size="2">Expected dividend yield</font></p></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="center"><font size="2">0.0%</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">&#160;</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom" align="right"><font size="2">0.0</font></td>
<td style="FONT-FAMILY: arial;" valign="bottom"><font size="2">%</font></td></tr></table></div>
<!-- end of user-specified TAGGED TABLE --></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6750416000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>NATURE OF BUSINESS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation', window );">Maximum period automatic stay in effect</a></td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficitAbstract', window );"><strong>Deficit accumulated</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Deficit accumulated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,483<span></span>
</td>
<td class="nump">$ 101,753<span></span>
</td>
<td class="nump">$ 80,536<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum period of time a product has automatic stay as a result of patent litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_MaximumPeriodAutomaticStayInEffectAsResultOfPatentLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790636000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from the offering, after deducting underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock sold (in shares)</a></td>
<td class="nump">6,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from the offering, after deducting underwriting discounts and commissions</a></td>
<td class="nump">$ 72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters over-allotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock sold (in shares)</a></td>
<td class="nump">870,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789858528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 2)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May. 31, 2015 </div>
<div>shares</div>
</th>
<th class="th"><div>Apr. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Common stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.144927536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember', window );">Conversion of redeemable convertible preferred stock into common stock | Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares of common stock into which convertible preferred stock was converted</a></td>
<td class="nump">12,591,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Stock Split<br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6791068560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17,730)<span></span>
</td>
<td class="num">$ (14,448)<span></span>
</td>
<td class="num">$ (14,448)<span></span>
</td>
<td class="num">$ (16,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityGainLossOnExtinguishment', window );">Extinguishment of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment', window );">Accretion and dividends of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,300)<span></span>
</td>
<td class="num">(2,925)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted', window );">Loss attributable to common stockholders - basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,496)<span></span>
</td>
<td class="num">$ (16,917)<span></span>
</td>
<td class="num">$ (21,217)<span></span>
</td>
<td class="num">$ (6,883)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares used in net loss per share-basic and diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,179,756<span></span>
</td>
<td class="nump">926,597<span></span>
</td>
<td class="nump">926,597<span></span>
</td>
<td class="nump">1,697,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share - basic and diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.94)<span></span>
</td>
<td class="num">$ (18.26)<span></span>
</td>
<td class="num">$ (18.26)<span></span>
</td>
<td class="num">$ (4.06)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember', window );">Series A, Series B and Series C convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityGainLossOnExtinguishment', window );">Extinguishment of preferred stock</a></td>
<td class="nump">$ 31,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment', window );">Accretion and dividends of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (23,327)<span></span>
</td>
<td class="num">$ (2,469)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment', window );">Accretion and dividends of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that basic and dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the combined amount of accretion of temporary equity during the period due to cash, stock, and in-kind dividends and decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityDividendsAdjustmentAndAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityGainLossOnExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) due to an amendment to the dividend terms of temporary equity which is accounted for as an extinguishment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityGainLossOnExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6807685712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Details 2) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=coll_EmployeeAndNonemployeeStockOptionsMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding excluded from the computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">1,356,246<span></span>
</td>
<td class="nump">311,365<span></span>
</td>
<td class="nump">281,029<span></span>
</td>
<td class="nump">229,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding excluded from the computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">2,445<span></span>
</td>
<td class="nump">18,810<span></span>
</td>
<td class="nump">18,809<span></span>
</td>
<td class="nump">4,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding excluded from the computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,552,820<span></span>
</td>
<td class="nump">6,552,820<span></span>
</td>
<td class="nump">6,552,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding excluded from the computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">153,589<span></span>
</td>
<td class="nump">28,536<span></span>
</td>
<td class="nump">15,387<span></span>
</td>
<td class="nump">55,298<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=coll_EmployeeAndNonemployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=coll_EmployeeAndNonemployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6775113840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details) - Measured at fair value - Recurring - Money market funds - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 104,911<span></span>
</td>
<td class="nump">$ 457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 104,911<span></span>
</td>
<td class="nump">$ 457<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6806048608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 1,169<span></span>
</td>
<td class="nump">$ 635<span></span>
</td>
<td class="nump">$ 449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued development costs</a></td>
<td class="nump">597<span></span>
</td>
<td class="nump">970<span></span>
</td>
<td class="nump">520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued marketing</a></td>
<td class="nump">685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued audit and legal</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 2,681<span></span>
</td>
<td class="nump">$ 1,956<span></span>
</td>
<td class="nump">$ 1,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790779504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Bridge Note with Related Party (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related party transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member', window );">6.0% Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related party transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=coll_NotePurchaseAgreementConvertiblePromissoryNotesMember', window );">Bridge Notes Purchase Agreement | Investors | 6.0% Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related party transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amount issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=coll_NotePurchaseAgreementConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=coll_NotePurchaseAgreementConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6806237056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Feb. 28, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Principal amount converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue', window );">Accruals of dividends and accretion to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,572,000<span></span>
</td>
<td class="nump">$ 2,469,000<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="nump">$ 2,926,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityGainLossOnExtinguishment', window );">Gain on extinguishment for amendment to dividend terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,806,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member', window );">6.0% Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Principal amount converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Cash consideration from issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue', window );">Accruals of dividends and accretion to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,572,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue', window );">Accruals of dividends and accretion to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 504,000<span></span>
</td>
<td class="nump">970,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue', window );">Accruals of dividends and accretion to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,836,000<span></span>
</td>
<td class="nump">1,836,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue', window );">Accruals of dividends and accretion to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 960,000<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember', window );">Series A, Series B and Series C convertible redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionOfDividends', window );">Accrued dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 622,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_TemporaryEquityGainLossOnExtinguishment', window );">Gain on extinguishment for amendment to dividend terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,806,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember', window );">Series A, Series B and Series C convertible redeemable preferred stock | Mandatory conversion, initial public offering | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock | Conversion of redeemable convertible preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares of common stock into which convertible preferred stock was converted</a></td>
<td class="nump">12,591,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock | Mandatory conversion, initial public offering | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the combined value of accretion of temporary equity during the period due to unpaid dividends and accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityAccretionOfDividendsAndAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_TemporaryEquityGainLossOnExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) due to an amendment to the dividend terms of temporary equity which is accounted for as an extinguishment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_TemporaryEquityGainLossOnExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity during the period due to unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=coll_ConvertiblePromissoryNotes6.0PercentDueNovember2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=coll_SeriesSeriesBAndSeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=coll_ConvertibleFinancialInstrumentMandatoryConversionCompletionOfInitialPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=coll_ConversionOfStockRedeemableConvertiblePreferredStockIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789564672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Jul. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=coll_EmployeeAndNonemployeeStockOptionsMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=coll_EmployeeAndNonemployeeStockOptionsMember', window );">Stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate', window );">Period following termination date vested options are exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=coll_EmployeeAndNonemployeeStockOptionsMember', window );">Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate', window );">Period following termination date vested options are exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=coll_StockIncentivePlan2014Member', window );">2014 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock authorized for issuance (in shares)</a></td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares', window );">Increase in number of authorized shares on the first day of each fiscal year, as a percentage of outstanding common stock (as a percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the additional shares that may be authorized for issuance annually under an established share-based compensation plan, expressed as a percentage of the entity's outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedAsPercentageOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period after the date the vested equity-based award expires during which an employee continues to have the right to exercise an award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodAfterExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=coll_EmployeeAndNonemployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=coll_EmployeeAndNonemployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=coll_StockIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=coll_StockIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6794206960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted stock awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of year (in shares)</a></td>
<td class="nump">15,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">194,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(128,955)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of year (in shares)</a></td>
<td class="nump">81,126<span></span>
</td>
<td class="nump">15,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-average purchase price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at beginning of year (in dollars per share)</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">5.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at end of year (in dollars per share)</a></td>
<td class="nump">$ 5.73<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted stock awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of year (in shares)</a></td>
<td class="nump">15,387<span></span>
</td>
<td class="nump">55,298<span></span>
</td>
<td class="nump">203,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,780)<span></span>
</td>
<td class="num">(89,308)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of year (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,387<span></span>
</td>
<td class="nump">55,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber', window );">Unvested remaining from the early exercise of stock options (in shares)</a></td>
<td class="nump">72,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-average purchase price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at beginning of year (in dollars per share)</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.62<span></span>
</td>
<td class="nump">0.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at end of year (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, issued in connection with the early exercise of stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedEarlyExerciseOfStockOptionsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6794145152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Details 3)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock option activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of year (in shares) | shares</a></td>
<td class="nump">281,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,197,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(121,729)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(506)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares) | shares</a></td>
<td class="nump">1,356,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares) | shares</a></td>
<td class="nump">208,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and expected to vest at end of period (in shares) | shares</a></td>
<td class="nump">1,341,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">10.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">3.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">2.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">9.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">2.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and expected to vest at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock option activity, additional information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period, Weighted-average remaining contractual term</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of period, Weighted-average remaining contractual term</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at end of period, weighted-average remaining contractual term</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at end of period, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 17,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at end of period, Aggregate Intrinsic Value | $</a></td>
<td class="nump">4,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and expected to vest at end of period, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 18,595<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price (at which grantees can acquire the shares reserved for issuance) for exercisable stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789463728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Details 4)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">77.10%<span></span>
</td>
<td class="nump">87.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 2 months 16 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section D<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6805975616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - patent<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 26, 2015</div></th>
<th class="th"><div>Mar. 24, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember', window );">Purdue Pharma, L. P. patent infringement suit, District of Delaware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Number of patents asserted to have been infringed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember', window );">Purdue Pharma, L. P., patent infringement suit, District of Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Number of patents asserted to have been infringed</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=coll_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember', window );">Hatch-Waxman Act of 1984 election to sue for patent infringement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected', window );">Stay period before FDA can issue a final approval if patent litigation is elected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">30 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the stay period before the Federal Drug Administration (FDA) can issue final approval if patent infringement litigation is elected.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">coll_LossContingencyStayPeriodBeforeFinalFederalDrugAdministrationApprovalCanBeIssuedIfPatentInfringementLitigationElected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>coll_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of another entity's patents that the entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPatentsAllegedlyInfringedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfDelawareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=coll_PurduePharmaLimitedPartnershipPatentInfringementDistrictOfMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=coll_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=coll_HatchWaxmanActOf1984AvailableElectionToSueForPatentInfringementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6787503648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 2)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2015 </div>
<div>ft&#178;</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember', window );">Office and research facility operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square of feet of space</a></td>
<td class="nump">19,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Term of lease extension option</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=coll_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember', window );">Amendment to office and research facility operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square of feet of space</a></td>
<td class="nump">9,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=coll_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember', window );">Delivery of expansion space with substantial completion of certain improvements | Office and research facility operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Lease term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=coll_OfficeAndResearchFacilityOperatingLeaseAsAmendedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=coll_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=coll_AmendmentToOfficeAndResearchFacilityOperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=coll_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=coll_DeliveryOfExpansionSpaceWithSubstantialCompletionOfCertainImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>142
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MZ@(  &X[   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%V\N.VC
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M.%5M;I\/_TN[C?JSI/GK:.W+#U!+ P04    "  5-B1()0M)?L0$  #1%0
M$    &1O8U!R;W!S+V%P<"YX;6R]6,MRXC@4_145F\DLTA!"\TBEJ3)&-*[!
MC[%-TEFJC0BJ&)NR!)/,U\^5#02"I 06PTK(YTCW<:ZLZ_N,-^Z"(E_10C#*
MT>LRS?@=3/ZH+818W=7K/%G0)>'? )+!TWE>+(F O\5S/9_/64*'>;)>TDS4
MFXU&NTY?!<UF=':]VB]:Z]_+7:S5*F4)$2S/^BY+BISG<X'P:T+3^_I'0,F
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M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
M6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<
M_N\-L,+$CN'MB[\!4$L#!!0    ( !4V)$C[$.\A@0(   (.   -    >&PO
M<W1Y;&5S+GAM;,U76VO;,!3^*T(=(X41VQE)VM4VC$)@T)5"\["W(L=R(M#%
MD^4LZ:^?+HYO+$W:W=P7'7\ZYSN?=$[<X[!0>XH?-Q@KL&.4%Q'<*)5_\KQB
MM<$,%6.18ZYW,B$94OI1KKTBEQBEA0EBU)OX_LQCB' 8A[QD"Z8*L!(E5Q&<
MUQ!P\;<BQ1%\&KW_7@IU\PZX]>+#Q87_='G3QT=VXQ("Q_$EC6 PFT+O?-*Q
M[Q\G-IL]\MDKR5_B[E'/CU#74MR?9ASUH![1U<M$+8)>X/4I!9W<W>"Y?^)F
M[O 6TR/U;._]JJ;SP)![5?/$829XTT,3Z( X+)[!%E'M;]U7@@H)E&Y2K<(B
M'#'L/&X1)8DD!LP0(W3OX(D!;%]7?HQP(6UNEZ&?9^PWF>0ZB>"A).>G2QIV
MNYCC$4J[Q]- '.9(*2SY0C^ RE[N<WTX+CAV(JW?">^U1/M@,FT%V$7G381,
ML:PS!_  Q2'%F=(!DJPW9E4B-]*%4H)I(R5H+3BBAO(041F:=H4I?31OD6]9
MAWN7 >=C:NQ#8%0<3'T1E=FT@;U4K\WFN-NTTS?Q@EU6)]#1*,_I_C,E:\ZP
M$^N@A:B>3M$'1^CC$!U8P49(\JS]32.L-( E!%LL%5FUD1\2Y4N\4U4'>[OL
MF,*W'OEO:OKSM]:HT2WXKZ_GOR9OU\;^#&%/SQFEN"]9@N7"OIU?+^SC?*C*
MS#_]P4J;#5?:@ MZ-5QIUX.5-A_NNV/ EQ;\IC2O&D):DTYGSJE1D)2$*L(/
M&I"93.^-;MH909H91W.FNV:\L;L*)?J#K)-%DZ4X0R55#V0KE-V,8&/?&?G!
MK/9:UA01;.RO."4ELQ\!7O/5%_\$4$L#!!0    ( !4V)$B(W/X_!0<  -4=
M   /    >&PO=V]R:V)O;VLN>&ULE=E;<]HX& ;@OZ+A9K,7W8#Q,=-TQH#2
M>!8,:SMI<^F ")H:F[%-T_;7KV22YG7X<)JK $$O.CR29?EC=?%8E-_NB^(;
M^['-\NJBO.QMZGIW<7Y>+3=BFU;_%#N1J_^MBW*;UNIM^7!>K-=R*2;%<K\5
M>7UN]/OV>2FRM)9%7FWDKNH]I55_DE;M2I&NJHT0]38[A&U3F?<^?:PNUC(3
MMZ*L5#!+=[LPW8K+WH^LQ[*TJOE*UF)UV3/5V^)1M#XH][O17F;ZC=6W>N<Z
M[+FIBY(MBY4XA"4;67UY^D>/K<0ZW6=UHBK[_+N7O8%A&H9]R-!?NY7BL<)
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M%6U:>!.>[!DCXL\)*!^.?NC?)]Z;:ZW,!"IR-/NJAD$K&]YZ BY'_SD\G,+
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MQ,K2E, QJU(JET.IFN2-F>#>4J64KW@63 ,M!$Q#LT$C$;H9F:E2!*0/2*
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MUX@8AJP.9/, ;AZ&5O[ $_Y=[PL)W;\BJ'1LZ1:6P$39T(L1R"X"W$4,S>[
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M M11 !V%QO@/2'S7D?_@^\3P;46E<Y3FF*&.&73,#<<,#$TW+/V?X1J2$<7
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M@Y1="$)\WS<&Q.80IB&VP/U<, % @D(V!$<60]!B:%NDAL46H<- R,?,]@B
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M6&WB@>K!]:,=3%$!.SEG18Z71<W'U%Z9HL$G$MB[&J#BC%UN,!\%\%'LF26
MC\SB>D?&?!3 1WM1;03LYD+'FY9@] E"G\WA231_3Z9436"-OL2!8<'D$T"^
M4 UCHKW8)?NS$Y72-,?QI*GU=O5;U0TG%[.[]].L%QY.9*S[&WK:WLZD/L.L
M5Y?\:/[*F^.Y:KW7NNOJ<CR5.=1U9WJ+P9=^6$XFW]\O"G/HAI])_[NYG4S=
M+KKZ\G'0=C_M6_\/4$L#!!0    ( !4V)$C4[DH,L0$  /(#   8    >&PO
M=V]R:W-H965T<R]S:&5E=#DN>&UL;5/;;IPP$/T5BP^(P<!&7;%(V511^U I
MRD/[[(4!K/A";+.D?U]?6$(37NR9\3DS9^QQ-2O]:@8 B]X%E^:4#-:.1XQ-
M,X"@YDZ-(-U)I[2@UKFZQV;40-M $AR3-#U@09E,ZBK$GG5=J<ER)N%9(S,)
M0?7?,W UGY(LN05>6#]8'\!UA5=>RP1(PY1$&KI3\I =SZ5'!,!O!K/9V,AK
MORCUZIV?[2E)O03@T%B?@;KM"H_ N4_D"K\M.3]*>N+6OF5_"MTZ]1=JX%'Q
M/ZRU@Q.;)JB%CD[<OJCY!RPM!(6-XB:LJ)F,5>)&29"@[W%G,NQS/"D/"VV?
M0!8"60DD"H^%@LSOU-*ZTFI&.E[M2/T+9D?B+J+QP=!W.'-"C8M>ZZS(*GSU
MB1;,.6+(!G/(5PAVZ=<:9*_&F7SA?TOW^?FNQCSPBPV_S/;YQ2Z_"/S\OQ[)
M?H)R-T'Y14!6Y)\N*6+N T8&3%%^JH$WCR) ]V'V#&K4),.D;Z+K>#^0\*@?
M\+H::0^_J.Z9-.BBK!N-\("=4A:<DO3.21G<!UP=#IWUYKVS=9S)Z%@UWG[8
M^LWK?U!+ P04    "  5-B1(4BD*L+@!  !,!   &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q]5-MRVR 0_16&#PBZV6D]LF9B=S+I0V<R>6B?L;22
MF'!1 5GIWQ>0K"BVDA<!RSF'LRRK?%#ZU;0 %KT)+LT>M]9V.T),V8*@YDYU
M(-U.K;2@UBUU0TRG@5:!)#A)HFA+!&42%WF(/>LB5[WE3,*S1J87@NI_!^!J
MV.,87P(OK&FM#Y B)S.O8@*D84HB#?4>/\2[8^81 ?";P6 6<^2]GY1Z]8N?
MU1Y'W@)P**U7H&XXPQ$X]T+NX+^3YON1GKB<7]0?0[;._8D:."K^AU6V=68C
MC"JH:<_MBQJ>8$IAXP5+Q4WXHK(W5HD+!2-!W\:1R3 .T\[WB;9.2"9",A.^
M15\2THF07A'(Z"SD]8-:6N1:#4B/M>BH+WF\2]W-E3X8+BKLN<R,BYZ+.,MR
M<O9"$^8P8I(EYB/B>(O8IC.$. .SBV3-Q2&YX2=7)]PBXOOU$]+5/-/ 3S_)
M\X- MBJ0!8'LRXM:PVRN$EG#;*^,D$7U!.@FO&J#2M7+T$.+Z-PX#TFH_CN\
MR#O:P"^J&R8-.BGKWE"H=*V4!6<ENMM@U+K6GA<<:NNG]VZNQ]<^+JSJ+KT[
M_T"*_U!+ P04    "  5-B1(GT+'2[D!  !,!   &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q]5-MNXR 0_17$!Q3?VK218ZG):K7[L%+5A_:9V&,;
ME8L7<-S]^P)V7#?Q]L7 <,[A#,,X'Y1^,RV 1>^"2[/#K;7=EA!3MB"HN5$=
M2+=3*RVH=4O=$--IH%4@"4Z2*+HC@C*)BSS$GG21J]YR)N%)(],+0?6_/7 U
M['",SX%GUK36!TB1DYE7,0'2,"61AGJ''^/M(?.( 'AA,)C%''GO1Z7>_.)W
MM<.1MP <2NL5J!M.< #.O9 [^.^D^7FD)R[G9_6?(5OG_D@-'!1_995MG=D(
MHPIJVG/[K(9?,*5PZP5+Q4WXHK(W5HDS!2-!W\>1R3 .XTZ63K1U0C(1DIEP
M'WU+2"=">D$@H[.0UP]J:9%K-2 ]UJ*CON3Q-G4W5_I@N*BPYS(S+GHJXFR3
MDY,7FC#[$9,L,5\1AVO$73I#B#,PNTC67.R3*WYR<<(U(MZLGY"NYID&?OJ?
M/+\(9*L"61#(OKVH-<S]12)KF(<+(V11/0&Z":_:H%+U,O30(CHWSF,2JO\)
M+_*.-O"'ZH9)@X[*NC<4*ETK9<%9B6YN,6I=:\\+#K7UTXV;Z_&UCPNKNG/O
MSC^0X@-02P,$%     @ %38D2//B416X 0  3 0  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL?51=;]L@%/TKB!]0;)RD4^18:C)-V\.DJ@_;,[&O
M;50^/,!Q]^\'V''=Q.N+@<LYAW.Y7.>#-J^V!7#H30IE#[AUKML38LL6)+,/
MN@/E=VIM)'-^:1IB.P.LBB0I"$V2'9&,*USD,?9LBESW3G %SP;97DIF_AY!
MZ.& 4WP-O/"F=2% BIS,O(I+4)9KA0S4!_R4[D^;@(B 7QP&NYBCX/VL]6M8
M_*@.. D60$#I@@+SPP5.($00\@?_F33?CPS$Y?RJ_BUFZ]V?F863%K]YY5IO
M-L&H@IKUPKWHX3M,*6R#8*F%C5]4]M9I>:5@)-G;.'(5QV'<H;N)MDZ@$X'.
MA"_)IX1L(F0W!#(ZBWE]98X5N=$#,F,M.A9*GNXS?W-E",:+BGL^,^NCER+=
M)CFY!*$)<QPQ=(GYB#C=(W;9#"'>P.R"KKDXTCL^O3GA'I$^KI^0K>:917[V
MGSP_"&Q6!3918//I1:UA;J]J#4-OC)!%]228)KYJBTK=J]A#B^C<.$\T5O\=
M7N0=:^ G,PU7%IVU\V\H5KK6VH&WDCQL,6I]:\\+ ;4+TT<_-^-K'Q=.=]?>
MG7\@Q3]02P,$%     @ %38D2,E^3!NA 0  LP,  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL?5/!;MP@$/T5Q <$V^M-JI774C95U!XJ13FT9]8>
MVRC .(#7Z=\7L-?KMFXO,#/,>_.&@6)$\V8[ $<^E-3V2#OG^@-CMNI <7N'
M/6A_TJ!1W'G7M,SV!G@=04JR+$GNF>)"T[*(L1=3%C@X*32\&&('I;CY>0*)
MXY&F]!IX%6WG0H"5!5MPM5"@K4!-##1'^I@>3GG(B G?!8QV99.@_8SX%IRO
M]9$F00)(J%Q@X'Z[P!-(&8A\X?>9\U8R -?VE?TY=NO5G[F%)Y0_1.TZ+S:A
MI(:&#]*]XO@%YA;V@;!":>-*JL$Z5%<()8I_3+O0<1^GDSR;8=N ; 9D"^!3
M$H5/A:+,S]SQLC X$C-=;<_#!--#YB^B"L'8=SSS0JV/7LITORO8)1#-.:<I
M)UOEW-]2F*=?:F1;-4[97_CT81N_V]2XB_C=/S3^1I!O$N21(/]ODULY^1]%
MV.I6%9@V/AY+*AQT?*JKZ/(^'^,8V2V]+'K>PC=N6J$M.:/SLXT3:! =>"G)
MW9Z2SO^@Q9'0N& ^>-M,CVIR'/;7+[+\T_(74$L#!!0    ( !4V)$BU/.BF
MH@$  +,#   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;'U3VV[<(!#]
M%<0'!%]V-]7*:RF;*FH?*D5Y:)]9>VRC ., 7J=_7\!>QVW=OL#,,.?,&0:*
M$<VK[0 <>5=2VQ/MG.N/C-FJ \7M'?:@_4F#1G'G7=,RVQO@=00IR;(D.3#%
MA:9E$6//IBQP<%)H>#;$#DIQ\_,,$L<33>DM\"+:SH4 *PNVX&JA0%N!FAAH
M3O0A/9YW(2,F?!<PVI5-@O8+XFMPOM8GF@0)(*%R@8'[[0J/(&4@\H7?9LZ/
MD@&XMF_L3[%;K_["+3RB_"%JUWFQ"24U-'R0[@7'+S"WL ^$%4H;5U(-UJ&Z
M02A1_'W:A8[[.)UD^0S;!F0S(%L GY(H?"H497[FCI>%P9&8Z6I['B:8'C-_
M$54(QK[CF1=J??1:IOM]P:Z!:,XY3SG9*N>0+RG,TR\ULJT:Y^PO?'J_C<\W
M->81G_]#XV\$NTV"7238_;?)K9S#'T78ZE85F#8^'DLJ''1\JJOH\CX?LCB5
MC_2RZ'D+W[AIA;;D@L[/-DZ@073@I21W>THZ_X,61T+C@GGO;3,]JLEQV-^^
MR/)/RU]02P,$%     @ %38D2 5:G(:Y 0  3 0  !D   !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL?53;;N,@$/T5Q <47Y*F&SF6FJRJ]F&EJ@_=9V*/
M;50N+N"X^_<%[+ANXNV+@>&<PQF&<=8K_68: (L^!)=FAQMKVRTAIFA 4'.C
M6I!NIU):4.N6NB:FU4#+0!*<)%%T2P1E$N=9B#WK/%.=Y4S"LT:F$X+J?WO@
MJM_A&)\#+ZQNK ^0/",3KV0"I&%*(@W5#M_'V\/*(P+@E4%O9G/DO1^5>O.+
MIW*'(V\!.!36*U WG.  G'LA=_#[J/EUI"?.YV?UAY"M<W^D!@Z*_V6E;9S9
M"*,2*MIQ^Z+Z1QA36'O!0G$3OJCHC%7B3,%(T(]A9#*,_;BS&6G+A&0D)!/A
M+OJ1D(Z$]() !F<AK]_4TCS3JD=ZJ$5+?<GC;>INKO#!<%%ASV5F7/24Q^M-
M1DY>:,3L!TPRQWQ''*X1M^D$(<[ Y")9<K%/KOC)Q0G7B'BS?$*ZF&<:^.E_
M\OPFL%H46 6!U8\7M82YNTAD"?/KP@B954^ KL.K-JA0G0P]-(M.C7.?A.I_
MP?.LI37\H;IFTJ"CLNX-A4I72EEP5J*;-4:-:^UIP:&R?KIQ<SV\]F%A57ON
MW>D'DG\"4$L#!!0    ( !4V)$@^P78JN $  $P$   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$V+GAM;'U4VV[C(!#]%<0'%%_2=!4YEII4J_9AI:H/N\_$
M'MNHX/$"CKM_OX =UTVLOA@8SCF<81AG ^IWTP!8\J%D:_:TL;;;,6:*!A0W
M=]A!ZW8JU(I;M]0U,YT&7@:2DBR)HBU37+0TST+L5><9]E:*%EXU,;U27/\[
M@,1A3V-Z";R)NK$^P/*,S;Q2*&B-P)9HJ/;T,=X=-QX1 +\%#&8Q)][["?'=
M+U[*/8V\!9!06*_ W7"&(TCIA=S!?R?-SR,]<3F_J/\,V3KW)V[@B/*/*&WC
MS$:4E%#Q7MHW')YA2N'>"Q8H3?B2HC<6U85"B>(?XRC:, [C3AI/M'5",A&2
MF? C^I:03H3TBL!&9R&O)VYYGFD<B!YKT7%?\GB7NILK?#!<5-ASF1D7/>?Q
M-LK8V0M-F,.(29:8KXCC+6*;SA#F#,PNDC47A^2&GUR=<(N(']9/2%?S3 ,_
M_9)GO"ZP6178!('-MQ>UAKE.9 US?5=L43T%N@ZOVI "^S;TT"(Z-\YC$JK_
M"<^SCM?PB^M:M(:<T+HW%"I=(5IP5J*[>TH:U]KS0D)E_?3!S?7XVL>%Q>[2
MN_,/)/\/4$L#!!0    ( !4V)$A7330KH0$  +(#   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$W+GAM;'U3P6[<(!#]%<0'!-OKW50KKZ5LJJ@]5(IR:,^L
M/;91@'$ K]._+^"UX[9N+S SO'GSAH%B1/-J.P!'WI74]D0[Y_HC8[;J0'%[
MASUH?]*@4=QYU[3,]@9X'9.49%F2')CB0M.RB+%G4Q8X."DT/!MB!Z6X^7D&
MB>.)IG0.O(BV<R' RH(M>;50H*U 30PT)_J0'L]Y0$3 =P&C7=DD:+\@O@;G
M:WVB29  $BH7&+C?KO (4@8B7_CMQOE1,B2N[9G]*7;KU5^XA4>4/T3M.B\V
MH:2&A@_2O>#X!6XM[ -AA=+&E52#=:CF%$H4?Y]VH>,^3B=SUC8^N^&S!?\I
MB;JG.E'E9^YX61@<B9ENMN=A@.DQ\_=0A6!L.YYYG=9'KV5ZR MV#40WS'G"
M9"O,8;= F*=?:F1;-<[97_GI_7;^;E/C+N;O_J'Q-X)\DR"/!/E_F]S"[/\H
MPE:WJL"T\>U84N&@XTM=19?G^9#%J7S RZ+G+7SCIA7:D@LZ/]LX@0;1@9>2
MW.TIZ?P'6AP)C0OFO;?-]*8FQV$__Y#EFY:_ %!+ P04    "  5-B1(5J//
M,*$!  "R P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q]4\%NW" 0
M_17$!P3;N]FT*Z^E;*(H/52*<FC/K#VV48!Q *^3OP]@K^.T;B\P,[QY\X:!
M?$#S8EL 1]Z4U/9 6^>Z/6.V;$%Q>X4=:']2HU'<>=<TS'8&>!63E&19DNR8
MXD+3(H^Q)U/DV#LI-#P98GNEN'D_@L3A0%-Z"3R+IG4AP(J<S7F54*"M0$T,
MU =ZF^Z/VX"(@%\"!KNP2=!^0GP)SH_J0),@ 224+C!POYWA#J0,1+[PZ\3Y
M63(D+NT+^T/LUJL_<0MW*'^+RK5>;$))!37OI7O&X1&F%JX#88G2QI64O76H
M+BF4*/XV[D+'?1A/OD]9Z_ALPF<S_EL2=8]UHLI[[GB1&QR(&6^VXV& Z3[S
M]U"&8&P[GGF=UD?/1;K;Y>P<B";,<<1D"\QN,T.8IY]K9&LUCME?^>G->OYF
M5>,FYF_^H?$+P7:58!L)MO]M<@WSITJVN%4%IHEOQY(2>QU?ZB(Z/\_;+$[E
M$U[D'6_@)S>-T):<T/G9Q@G4B Z\E.3JFI+6?Z#9D5"[8-YXVXQO:G0<=I<?
M,G_3X@-02P,$%     @ %38D2"I1.PBB 0  L@,  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL?5/!;MP@$/T5Q <$V[O9359>2]E457NH%.60G%E[
M;*, XP)>IW\?P%[';=U>8&9X\^8- _F YLVV (Z\*ZGMD;;.=0?&;-F"XO8&
M.]#^I$:CN/.N:9CM#/ J)BG)LB39,<6%ID4>8T^FR+%W4FAX,L3V2G'SZP02
MAR--Z37P+)K6A0 K<C;G54*!M@(U,5 ?Z4-Z.&T#(@)>! QV89.@_8SX%ISO
MU9$F00)(*%U@X'Z[P"-(&8A\X9\3YV?)D+BTK^Q?8[=>_9E;>$3Y*BK7>K$)
M)174O)?N&8=O,+5P&PA+E#:NI.RM0W5-H43Q]W$7.N[#>+*?LM;QV83/9OQ=
M$G6/=:+*+]SQ(C<X$#/>;,?# --#YN^A#,'8=CSS.JV/7HIT=Y>S2R":,*<1
MDRTPN\T,89Y^KI&MU3AE?^6G^_7\S:K&3<S?_$/C;P3;58)M)-C^M\DUS/T?
M1=CB5A68)KX=2TKL=7RIB^C\/!^R.)5/>)%WO($?W#1"6W)&YV<;)U C.O!2
MDIM;2EK_@69'0NV"N?>V&=_4Z#CLKC]D_J;%!U!+ P04    "  5-B1(6RSO
M#;<!  !,!   &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q]5-MNXR 0
M_17$!Q0;ITT5.9::K*KV8:6J#[O/Q![;J&!<P''W[POX4C?Q]L7 <,[A#,,X
M[95^,S6 11]2-&:/:VO;'2$FKT$R<Z-::-Q.J;1DUBUU14RK@16!) 6A471'
M).,-SM(0>]%9JCHK> ,O&IE.2J;_'4"H?H]C/ 5>>55;'R!92F9>P24TAJL&
M:2CW^"'>'3<>$0!_./1F,4?>^TFI-[]X+O8X\A9 0&Z] G/#&8X@A!=R![^/
MFE]'>N)R/JD_AFR=^Q,S<%3B+R]L[<Q&&!50LD[85]4_P9C"K1?,E3#AB_+.
M6"4G"D:2?0PC;\+8#SMTHJT3Z$B@,^$^^I&0C(3D@D &9R&O7\RR+-6J1WJH
M1<M\R>-=XFXN]\%P46'/969<])S%VR@E9R\T8@X#ABXQWQ'':\1=,D.(,S"[
MH&LN#O2*3R].N$;$V_43DM4\D\!/_I/G-X'-JL F"&Q^O*@US.55K6'HA1&R
MJ)X$7857;5"NNB;TT"(Z-\X##=7_@F=IRRKXS73%&X-.RKHW%"I=*F7!68EN
M;C&J76O/"P&E]=.MF^OAM0\+J]JI=^<?2/8)4$L#!!0    ( !4V)$BTT *X
MH0$  +,#   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;'U3VV[<(!#]
M%>0/"+XE&ZV\EK*IHN2A4I2']IFUQS8*, [@=?KW >SUNJW;%Y@9YIPYPT Q
MHGXW'8 EGU(H<X@Z:_L]I:;J0#)S@STH=]*@ELPZ5[?4]!I8'4!2T#2.[ZAD
M7$5E$6*ONBQPL((K>-7$#%(R_>L( L=#E$27P!MO.^L#M"SH@JNY!&4X*J*A
M.40/R?Z8^XR0\(/#:%8V\=I/B._>>:D/4>PE@(#*>@;FMC,\@A">R!7^F#FO
M)3UP;5_8GT*W3OV)&7A$\9/7MG-BXXC4T+!!V#<<GV%NX=835BA,6$DU&(OR
M HF(9)_3SE78Q_DDFV';@'0&I O@/@["IT)!YC=F65EH'(F>KK9G?H+)/G47
M4?E@Z#N<.:'&1<]ELLL*>O9$<\YQRDE7.7?7%.KHEQKI5HUC^A<^V6WCLTV-
M6<!G_]#X&T&^29 '@OR_36[EY'\4H:M;E:#;\'@,J7!0X:FNHLO[?$C#5*[I
M9=&S%KXSW7)ER FMFVV80(-HP4F);VXCTKD?M#@"&NO-G;/U]*@FQV)_^2++
M/RV_ %!+ P04    "  5-B1(PG&I$:$!  "S P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q]4]MNW" 0_17$!P3;>XM67DO91%7[4"G*0_O,VF,;
M!1@'\#K]^P+V.D[K]@5FACEGSC"0#VA>;0O@R+N2VIYHZUQW9,R6+2AN[[ #
M[4]J-(H[[YJ&V<X KR)(298ER9XI+C0M\AA[-D6.O9-"P[,AME>*FU]GD#B<
M:$IO@1?1M"X$6)&S&5<)!=H*U,1 ?:(/Z?&\#1DQX8> P2YL$K1?$%^#\ZTZ
MT21(  FE"PS<;U=X!"D#D2_\-G%^E S I7UC_Q*[]>HOW,(CRI^B<JT7FU!2
M0<U[Z5YP^ I3"[M 6**T<25E;QVJ&X02Q=_'7>BX#]/)_01;!V03()L!]TD4
M/A:*,I^XXT5N<"!FO-J.APFFQ\Q?1!F"L>]XYH5:'[T6Z6&7LVL@FG+.8TZV
MR-EOYA3FZ><:V5J-<_87/CVLXS>K&C<1O_F'QD\$VU6";238_K?)M9S]'T78
MXE85F"8^'DM*['5\JHOH_#X?LCB5C_0B[W@#W[EIA+;D@L[/-DZ@1G3@I21W
M.TI:_X-F1T+M@GGPMAD?U>@X[&Y?9/ZGQ6]02P,$%     @ %38D2)2%BL"B
M 0  LP,  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL?5/!;MP@$/T5
MQ <$V[O)KE9>2]E457.(%.70GEE[;*, XP)>IW]?P%['2=Q>8&:8]^8- _F
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M4;O.BTTHJ:'A@W3/.'Z'N87;0%BAM'$EU6 =JBN$$L5?IUWHN(_3R3Z=8=N
M; 9D"^ ^B<*G0E'F5^YX61@<B9FNMN=A@NDA\Q=1A6#L.YYYH=9'+V66WA7L
M$HCFG-.4DZUR]KLEA7GZI4:V5>.4?<*O2KS#[S8U[B)^M\;G_R'(-PGR2)"_
M:_+^0Y-;.5\^%&&K6U5@VOAX+*EPT/&IKJ++^WS(XE3>TLNBYRW\Y*85VI(S
M.C_;.($&T8&7DMS<4M+Y'[0X$AH7S#MOF^E138[#_OI%EG]:_@-02P,$%
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MH/.SC1.H$!UX*>G=-B&-_T&3(Z%RP=Q[VPR/:G <MK<O,OW3_ -02P,$%
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MK0OF@[?-_*AFQ^%P^R+K/ZW^ E!+ P04    "  5-B1(:L&_$[P!  !,!
M&0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q]5-MNXR 0_17$!Q3?DE:1
M8ZG)JMI]6*GJ0_M,[+&-"L8%''?_OH =QW7<?3$PG',XPS!.>ZG>=0U@T*?@
MC=[CVIAV1XC.:Q!4W\D6&KM32B6HL4M5$=TJH(4G"4ZB(-@205F#L]3'GE66
MRLYPUL"S0KH3@JI_!^"RW^,07P(OK*J-"Y L)1.O8 (:S62#%)1[_!CNCHE#
M>, K@U[/YLAY/TGY[A9_BCT.G 7@D!NG0.UPAB-P[H3LP1^CYO5(1YS/+^I/
M/EOK_D0U'"5_8X6IK=D HP)*VG'S(OO?,*:P<8*YY-I_4=YI(\6%@I&@G\/(
M&C_VPTX2C[1U0C02HHGP$/R7$(^$>$$@@S.?UR]J:)8JV2,UU**EKN3A+K8W
ME[N@ORB_9S/3-GK.HCA.R=D)C9C#@(EFF/ [XGB+V%Y%B#4PN8C67!RB&WZT
M..$6$=ZOGQ"OYAE[?CSG;WX02%8%$B^0?+NH9'%1:YC-(I$US'9AA,RJ)T!5
M_E5KE,NN\3TTBTZ-\QCYZE_A6=K2"OY25;%&HY,T]@WY2I=2&K!6@KL-1K5M
M[6G!H31N>F_G:GCMP\+(]M*[TP\D^P)02P,$%     @ %38D2'?5_+2C 0
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M+W-H965T,S$N>&UL;5/!;MP@$/T5Y \(-NO=5"NOI6RJJ#U4BG)HSZP]ME&
M<0"OT[\O8*_CI+[ S/#>FQD&BA'-J^T ''E74MM3TCG7'RFU50>*VSOL0?N3
M!HWBSKNFI;8WP.M(4I*R-#U0Q85.RB+&GDU9X."DT/!LB!V4XN;O&22.IR1+
M;H$7T78N!&A9T(57"P7:"M3$0'-*'K+C.0^("/@M8+0KFX3:+XBOP?E9GY(T
ME  2*A<4N-^N\ A2!B&?^&W6_$@9B&O[IOX4N_757[B%1Y1_1.TZ7VR:D!H:
M/DCW@N,/F%O8!\$*I8TKJ0;K4-TH"5'\?=J%COLXG>S3F;9-8#.!+81OD4"G
M1+',[]SQLC X$C-=;<_#!+,C\Q=1A6#L.Y[Y0JV/7DN6IP6]!J$9<YXP;(4Y
M[!8(]?)+#K:5X\S^XV?WV_S=9HV[R-^M^8=\6R#?%,BC0/ZIR>Q+DUL8]B4)
M7=VJ M/&QV-)A8..3W457=[G XM3^8"71<];^,5-*[0E%W1^MG$"#:(#7TIZ
MMT](YW_0XDAH7##OO6VF1S4Y#OO;%UG^:?D/4$L#!!0    ( !4V)$BR.OH0
MK@$  !@$   9    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;&U4P6[C(!#]
M%>0/*([CI%7D6&I:K78/*U4][)Z)/;91@7$!Q]V_7\".X\UR,3"\]^8-,"Y&
MU!^F [#D2PIECDEG;7^@U%0=2&8>L ?E=AK4DEFWU"TUO096!Y(4-$O3/96,
MJZ0L0NQ-EP4.5G %;YJ804JF_YQ X'A,-LDU\,[;SOH +0NZ\&HN01F.BFAH
MCLGSYG#:>40 _.(PFM6<>.]GQ ^_^%$?D]1;  &5]0K,#1=X 2&\D$O\.6O>
M4GKB>GY5_Q:J=>[/S, +BM^\MITSFR:DAH8-PK[C^!WF$H+#"H4)7U(-QJ*\
M4A(BV=<T<A7&<=IY2F=:G)#-A.R.0*=$P>8KLZPL-(Y$3T?;,W^#FT/F#J+R
MP5!WV'-&C8M>RBS?%O3BA6;,:<)D*\S^!J%.?LF1Q7*<LO_XF\<X?QOUN W\
M[9J_?XH+Y%&!/ CD_Q29WQ49P^SB27;1)+N(P/XN20QS?Q1T=742=!M>J"$5
M#BKTPRJZ-,%S%J[^!B^+GK7PD^F6*T/.:-T#"M?<(%IP5M('YZ5S;;HL!#36
M3Q_=7$\O=UI8[*]]N/P,RK]02P,$%     @ %38D2$A<C+KY 0  * 8  !D
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M<W*U#;J#<GNF,F6BERK)BI)<K-",V4V8Y 83WR/VCX@\72#$&%A<))B+7?+
M3[P,CXAXC6=(T3I3QT_O^!$ND*$"F1/([@[JBW=0"&85>85@F!@WLD*-K! !
M_[0PS"<7DJ-)<D0@\ZK%,"O/"(;)<2-KU,@:$5A[23!,@2<IT"0%(N#?+8+)
M_;O%,/[=DIN7R4$VKF.IH!;GWO7'F^C2%)\3][(_X%4YT 9^4METO0H.0IO^
MX%[Q20@-QDKT9/X"K6G;RX+!2=OIVLSEU,FFA1;#M2\O'X?J'U!+ P04
M"  5-B1(-\%+>:T!   8!   &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6QU5-UNVR 4?A7D!R@.3M(I<BPUG:KM8E+5B^V:V,<V*OBX@./N[0?8<=V4
MW00X?'_'0/(1]:MI 2QY5[(SQZ2UMC]0:LH6%#=WV$/G=FK4BENWU TUO09>
M!9*2E*7IGBHNNJ3(0^U9%SD.5HH.GC4Q@U)<_SV!Q/&8;))KX44TK?4%6N1T
MX55"06<$=D1#?4P>-H?3SB,"X+> T:SFQ&<_([[ZQ<_JF*0^ D@HK5?@;KC
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MY@AW!^U1",V,(GXRSDMS%X\3SH[:#E,SEOWMU$^T:*^7[7CCY[\!4$L#!!0
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MYWF!H9)ZFJHY'QO6N)"LN[3?^1M0_ =02P,$%     @ %38D2">1-$.H 0
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M\SWH)*4!ZR5^L#]392^1<<'A9-QT9>=J:*O#PLCV=DN,5U7^%U!+ P04
M"  5-B1(?N)QEZ(!   =!   &0   'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6R-5,M.XS 4_14K'X!3ITV'*HU$08A9C(18S*S=Y*:Q\"/8;@-_CQ]IIH 7
MW<2^U^><>ZX?J4:E7TT/8-&[X-)LL][:88.Q:7H0U-RH :1;Z906U+I0'[ 9
M-- VD 3'),]++"B365V%W+.N*W6TG$EXUL@<A:#Z8P=<C=MLD9T3+^S06Y_
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MS76\OC&P:C@_QOF/4'\"4$L#!!0    ( !4V)$AQZYRO50(   4(   9
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MFX9[9$Q2I=!]4:6:JYD\;$IZE'JY4&O>3:EN(UES';K#Y$_^ 5!+ P04
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M)0X+ F>IIVLUYUV7Z!:2-;>>-S3>Y#]02P,$%     @ %38D2*?K2ESL @
M\@H  !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULE59-DZ(P$/TK%/>5
M?  !"ZT:Q:W=PU9-S6'GS&A4:H"X$,?9?[])0(303KD>)(3WNOLUG::3BZC?
MFR/GTODLBZI9N$<I3W//:[9'7F;-3)QXI9[L15UF4MW6!Z\YU3S;&5)9> 2A
MT"NSO'*7B=E[KI>).,LBK_AS[33GLLSJORM>B,O"Q>YUXR4_'*7>\):)U_-V
M><FK)A>54_/]PGW"\PT.-,0@?N?\T@S6C@[^38AW??-SMW"1CH$7?"NUB4Q=
M/OB:%X6VI#S_Z8S>?&KB<'VU_MW(5>&_90U?B^(UW\FCBA:YSH[OLW,A7\3E
M!^\TF BWHFC,O[,]-U*45XKKE-EG>\TK<[VT3R+4T6 "Z0BD)_1^8 +M"/1&
M\+\D^!W!OQ'"+PE!1P@L#UZKW60NS62V3&IQ<>KV=9\R755X'JAWL]6;YE68
M9RIWC=K]6%(4)=Z'-M1A5BV&##!XC$BGB)#V$$\%T$=!H"A69,(G8P_K*0);
M8:8 A(TA&P 2PW%2,%O4\.DH6W<,^* !WQCP!P88M;+=0IB!5 ;R#3-&D940
M".;[OIV4QV ;"!;BF,': E!;,-%&L15UVF+"H1]*D87: "@2DP .)@2#"8%@
MK*I=A8!HY,>AE6D(%L9V;:4 C& R*4$ %D;1G=/"0&T,T&:=EQ6;I!!CS&(6
MV.JFP)B$06RK>PRV =R&,4.^#^N+0'W15!^R'*U:3#Q,(YK%-![]+*D !T<S
M8F4D?0RV 6#^#(6PT!@4&D^$#@[FB*\_=E#W1H\W)'SG X"!:K)ZTJ8##:L6
M$T+O>0*;_!,FT^9W)UT8;K_X/_HOAALPGG;@R>%).]"PC)G/,$5WCBF&&R(&
M.J)=R&D'&M41F47V@?$&'_22UP<S2C7.5IPKJ3,RV.W'M2>B!P)K?X7G:PSL
MIWJ\,P/$S?PR.64'_BNK#WG5.&]"JC'$# M[(217T:.9BOZH!M#^IN![J9=,
MK>MV)&MOI#A=)\Q^S%W^ U!+ P04    "  5-B1(8<02P*("  "\"0  &0
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MW?;Z/4Y?$C#;W 8P&\!BB."7AG@VQ/]K@+,!&H9@6HHN1(T$*@M&1X]-/V]
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M8@TQB)\5NXK)V-/)OW+^IB??]RL_U#FPFNVDIJ#J\<XVK*XUDU+^/9!^:NK
MZ?C&_M64J])_I8)M>/VKVLN3RC;TO3T[T$LM7_CU&QMJ2#3ACM?"_'J[BY"\
MN87X7D,_^F?5FN>U?Y.'0Q@>0(8 ,@9 ^C @&@*BSX#X84 \!,160-"78C9B
M2R4MBXY?O:[_>F>J#PDL8[75.[UH=M:\4ULAU.I[&<6D"-XUT8!9]Q@RP:31
M" D4_:A!,(TUF<5#=B^Q02"+>\AV#B%X$A%::&3"H[M"'57$*$%L".([@MC:
M*0R3X"()*I(@6:8X08H2I(8@-01MOTLA)%::/2B;@"!TJ&2H2H:II);*' 0
MN$J.JN28BG5RUG,0@*.6!:JR0+Z9+;*8B421X_#H6P;S68A\V=Q!X; J()DN
M;*_"+-74PFP&3(9C[E-!'?T$9%Y-$CHH<#]"-*N&V-L^8*;%Y*%=S+\QVP$S
M+7B1.;+%S0^(LQ/'80;<VH!X.W%<88";&U(DB\C>M/D5 %GLT,'M#1FBXZ+
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M)'"1XZFNXA*4Y5HA _4A>USMC]N B(!7#H.=Q2AX/VG]'B9_JD-&@@404+K
MP/QPAB<0(A!YX7\CY[=D*)S'%_9?L5OO_L0L/&GQQBO7>K,D0Q74K!?N10^_
M86PA.BRUL/&+RMXZ+2\E&9+L(XU<Q7%(*_=D+%LNH&,!G0IH,IZ$HLV?S+$B
M-WI )FUMQ\()KO;4;T09DK'ON.:-6I\]%^N'78[/@6C$'!.&7F'N)PSV_),(
M71(YTO\(Z$SDBF"]Z'(="=97#AZ6"3:+!)M(L)D1; BY:3-A=A&C(F9+9J K
ME>VBRG9!976CLH2A-R)X=GH23!,OJ46E[E5\$K/L] X>:3S];WB1=ZR!O\PT
M7%ETTL[?H7C2M=8.O!5RY[VT_J5.$P&U"^'.QR9=WC1QNKL\Q>E_4'P!4$L#
M!!0    ( !4V)$CNZ@=WS0$  -8$   9    >&PO=V]R:W-H965T<R]S:&5E
M=#4R+GAM;'64VVZ<,!"&7P7Q +$Y+(05B]1-%;47E:)<M-=>&!84&Q/;NZ1O
M7Q]82HCW!MOC?_YO?,#EQ,6;[ !4\,'H( ]AI]2X1TC6'3 B'_@(@YYIN6!$
MZ:$X(SD*((U-8A3%&&>(D7X(J]+&7D15\HNB_0 O(I 7QHCX>P3*IT,8A;?
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M_4W.MXVZ9/*ZZOK1[J81AW-[W??XB_]02P,$%     @ %38D2+-YU#;R P
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M1]W*UGWD.X&^$^#;1$9BU0F%2)@];1V$(TLIM)0"2P9AGE)[B'")_@\+(F4
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MA@-D8F86=1L9%@3NI>48'([ ,4]B+PH-7PY'&"_.@2/'#)@N;N\Q[I7%X'
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M2!"%_PKB?4S?RFU'!"E 1KL/*XWF8??9 2>@P9BQG3#[[]>7#L'5IYEH\Q#
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M^"'Y-462QIQ_:R"3)K8Z5%-CCFA4>K!=NM)^Z?&E'7W*=&NDD\(&EE=CXF@
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M3J[607-09D]5)E3T6B19EGM7+;1@RAD3;C!IM$(\);_F"*$<9?B%'^P>4U0
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M<PD[(UAQ*NW7J\Y2<7:E^!XC[]/8]78<IY7T?J:Y"=%,B!9"F/R7$,^$>$-
MDS-;UW>B2)$+/GIB.HN!F",/]['N7&62ME%V35<F=?92I%&:HXL1FC$/$R9:
M84+\&5(Z(/<+!&D'BXW(:2.R_.23#>P6B)T"L16(UP)AYA9(G *)PT&V:<2$
MP1;36TR<A%FRZ<4M*DSC7>(VLW.:V3G,_*.?J5,@_7H[L%, ?Z$=^*90G$5X
M<WO*6U0:Q%FP,8-6%W8@)_A)Q*GKI7?D2M]]>T,;SA5HQ>!.MZ?53](24&B4
MF6(]%]-?.@6*#]<W9WGXB@]02P,$%     @ %38D2& 9:)?3 0  I@0  !D
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M.UG(D(C0PP$,<7'!PP$,<?GGU?_!"8W6ELCJ&+@"J'$"-87"!11Q':8L4!R
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MJ4=2&J"FPQI.:[#(:8":#FLXG#,ZA)MP"K?1X3%<;(0$JXL&H&EB$]+HR!"
MIHE-"*8, -(A&T3*\24I&X"0H>CP6-T00EJ#?<8 A R%$#HE!0@9 B'4]!F
MD*%V(;_'-2%"*%1 CZ'H >NH ?08@AZ8+J#'4/N/W^.:D!Z4+CK IKH?L)H;
M0(ZYH/LQ@!Q#E&_:^X)H;4)R)-/M'_!F 3R6XL(K%M=.:&)';0$^EL#'[V37
M-CR!^Z23M8 R2QQB&[!A6D"9#0_@X%A:@) E$/([V;43FM;)6@":)2I"C3(&
MH-GP_ UG#"BRU/X3^QD3YV^,FKR+P3>XQ^0E_3LI7_:':O98U'61=]_8/A=%
MG39&FU9X/MNER?9\D:7/=?NV78/*_O< _45='-]_WG#^C<7J?U!+ P04
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M7INV*M]#EHLR_WG]/IZ&[\OUGT2-87( C@%X"P#S88 > _1G \P88#X;8,<
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MZG.EY+XK*O( &$N"0F:EOUYVQYZJ]5)?FCPKU5/EU9>BD-7?C<KU=>5S_^/
M<W8\->9 L%X&M[I]5JBRSG3I5>JP\K_PQVW(3*1+_,K4M;[;]@S\B]:O9N?'
M?N4SPZ!RM6O,$+)]>5-;E>=FI';F/\.@_^<TA??;'Z-_ZY;;XK_(6FUU_CO;
M-Z>6EOG>7AWD)6^>]?6[&M80FP%W.J^[_][N4C>Z^"CQO4*^]Z]9V;U>^W?2
M<"BC"V H@%L!CV8+PJ$@M J"GJQ;UU?9R/6RTE>OZC^,LS2?.7\,VS.W,P>[
M$]6]UZZL;H^^K9.4+X,W,]"0V?09N,O .+'%"9[>(D$+<*, D@*Z^NBN/HZL
M*?I(TD7*(1()SABC)PK)B4(\46RMMH^(NXG8 V/6.=FZ4B.6B&2),$MBL41H
MT6;!W9_%@Y,I6,$14DPBQ1@IM9!B-!&P1*0"%A81#K;L"? %#9200 D&$A90
MXIRGYW'G1CPIR9,BGDC0]8*L%W@]%N=&?.KZ<Z5&+ N29>%LNLT"G3/[NL,)
M+J*%B*9.JW$JI2&&8!)F:X@Y:8C( D((PVB"9D**'-,@*7(W#8[,T]!RY-B.
M20HV3A]*YW!PA$,J)JX93@N4$P:=4 RGM<<)[]D],&1<3>",C7EHYW%">G8?
M<"PS='8),:8A1!!.?!-RVG@<*P]W G89PL$1!PXM/(Z-AULA=>/@B .']B?'
M B5Z0;A[ 4=B#APF8&B!<L*@$]<>T-H#K#W4"T/&U0O.V)B'%A]@\:%> +?X
MB(A(8A%&$^*#B;M"0GQV*P"^+T0T.&)H&)OXY@;:?(#-ASIAR,S2X,@\#6U1
MP!;%C3"$YAJ!B/"0\ZD/BE8H8(5".C4$K3T@[O10)R2?ZP17;,Q#>P^P]W G
MN+TW&QEST,(#0GBH!X2;8RXRYJ!=!]AU^.IWWR[.1L;/;[0Q0^)&$5WW0VCN
MNI^-]"#!W3/T61[53UD=L[+V7G33/HYW#\T'K1O5#L<>V@XX*;F_[>3JT)C-
MM-VN^A\.^IU&GS]^![G]&+/^!U!+ P04    "  5-B1(>Y3_KB0#   J#0
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M5;M:M7ZL*%YX'[J?#EFW"!X@Z)G8V@0->L13\?LD,)3$&EMZ(X>-3:#(2 )
MV#.2 $@,YQF Q0H:?3#T26 ] ?6DT9.A/C2*W2*L0<HN!"&^[QL%L3F$:8@M
M<#L53 "0H) -P2>+(6@QM"U2PV*+T&$@Y&-F>P1 &E';XD0N ;@H"D<-4M @
MM0T:PVQ-[3B,,&0G#H D""([<P"D/L&CJ3,P=6:G;KQ$:V8%^@;GOH%(,/GM
M9#*!R"]]1J#/R'Y-1U[S&-3'5IV8D>DZMC(-]$ RBV1C"-G8=AJ6V!BCHZ71
MRR,TW_O ^ T,=QWT]"!B-!YJ9&E!=AVMM059D7 8VX4$.+"2$[D$XL+QJ0"!
MZ]8+PK9#JY;8FE?5*\4"8+2 J)K]@7=J.IJ *$7Q^,R.X-4/!;9;8KIMF7@8
MS)_%0?ST,WT#(A3-,#5-3^,2B",SGXZXA==J9"_6S%RL.^9YM"$6LY":%FTR
M5LMPS$R+T[@$BDS5(R7F?L0;; 0+7IV:+7CM[,6UE'J.'+3VV_P7K#>21OL:
MS3<(:-_JSX)FX_GH?K6XI"?^*ZU.65D[.R'5]K799!Z%D%SE[\_46GQ6'R[]
M1<Z/4I\R=5ZU6_GV0HK+_<ND_SQ:_0=02P,$%     @ %38D2 [3G6=N!
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M-Q0J72EEP5F)[]81:EQK3PL.E?73>S?7PVL?%E:UE]Z=?B#Y7U!+ P04
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M<+;C2(V&Q^[Z0>9?6OP"4$L#!!0    ( !4V)$AIIZ 8N@$  $P$   9
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MT[V;Z^&U#PNKVEOO3C^0_#]02P,$%     @ %38D2(2IF3J@ 0  L0,  !D
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MT/F7C?VO$1UX*<G5-26M_S^+(:%VX?C%G\TT4I/AL+]\D.67%A]02P,$%
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M_-F,(S4:#KO+!YE_:?X!4$L#!!0    ( !4V)$A?=][8N@$  $P$   9
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M3^_<7 ^O?5A8U4Z]._] \D]02P,$%     @ %38D2+S=P#.\ 0  3 0  !D
M  !X;"]W;W)K<VAE971S+W-H965T.# N>&UL?53;;N,@$/T5Q <47])D&SF6
MFJQ6NP\K57W8/A-[;*-R\0*.V[\O8,=U':LO!H9S#F<8QEFO]*MI "QZ$UR:
M VZL;?>$F*(!0<V=:D&ZG4II0:U;ZIJ85@,M TEPDD31E@C*),ZS$'O2>:8Z
MRYF$)XU,)P35[T?@JC_@&%\#SZQNK ^0/",3KV0"I&%*(@W5 3_&^]/&(P+@
M'X/>S.;(>S\K]>H7?\H#CKP%X%!8KT#=<($3<.Z%W,'_1\W/(SUQ/K^J_PK9
M.O=G:N"D^ LK;>/,1AB54-&.VV?5_X8QA7LO6"ANPA<5G;%*7"D8"?HVC$R&
ML1]VTGBDK1.2D9!,A!_1MX1T)*0+ AF<A;Q^4DOS3*L>Z:$6+?4EC_>IN[G"
M!\-%A3V7F7'12[Y]V&7DXH5&S'' )#-,_!5QND5LTPE"G(')1;+FXIC<\)/%
M";>(>+=^0KJ:9QKXZ9R_C=<%-JL"FR"P^2(0+2YJ#;-,9 VSO"LRJYX 78=7
M;5"A.AEZ:!:=&N<Q"=7_A.=92VOX2W7-I$%G9=T;"I6NE++@K$1W]Q@UKK6G
M!8?*^NG.S?7PVH>%5>VU=Z<?2/X!4$L#!!0    ( !4V)$ASB;@L @(  "@&
M   9    >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;'U5VX[;(!#]%<L?L/B>
MBQQ+ZU15^U!IM0_M,W$FMK5@7"#Q]N\+V/%Z,=F7 ,,Y9PZ#F>0#XV^B 9#>
M.R6=./B-E/T>(5$U0+%X8CUT:N?".,52+7F-1,\!GPV)$A0%088H;CN_R$WL
MA1<YNTK2=O#"/7&E%/-_)1 V'/S0OP=>V[J1.H"*',V\<TNA$RWK/ Z7@_\<
M[H];C3" WRT,8C'WM/<38V]Z\?-\\ -M 0A44BM@-=S@"(1H(97X[Z3YD5(3
ME_.[^G=S6N7^A 4<&?G3GF6CS :^=X8+OA+YRH8?,!TAU8(5(\+\>M552$;O
M%-^C^'T<V\Z,P[B3)A/-38@F0C03ML&7A'@BQ!8!C<[,N;YAB8N<L\'CXUWT
M6%]YN(]5Y2H=-(4R>^ID0D5O1;;;YNBFA29,.6*B!2;\C#BN$5D\0Y R,+N(
M7"[*:,6/K QK1+AQ9XB=YXP-/U[RDP<"B5,@,0+)IT+MK$*M,9L@<"=)G4E2
MAX!5ZW*-"7>I52T7)G,;R9Q&,H<1ZTI*%^;!K6^<238.@<1*LL9$H?UMN# /
MC&R=1K8.(U9)RS4F"NVRNS!VV='B95+@M>E8PJO8M3/]<1&=F^)S9%[V![S(
M>US#+\SKMA/>B4G5'\PKOC F05D)GM0GT*BV/2\(7*2>;M2<CYUL7$C6W_OR
M_.=0_ =02P,$%     @ %38D2!)TO^W, 0  U00  !D   !X;"]W;W)K<VAE
M971S+W-H965T.#(N>&ULC53;CILP$/T5BP]8<PE)%1&D3:JJ?:BTVH?VV8$!
MK/6%VB9L_[ZV(2PEKM07;(_/.7-FL%V,4KWI#L"@=\Z$/D6=,?T18UUUP(E^
MDCT(N]-(Q8FQ2]5BW2L@M2=QAM,XWF-.J(C*PL=>5%G(P3 JX$4A/7!.U.\S
M,#F>HB2Z!UYIVQD7P&6!%UY-.0A-I4 *FE/TG!PON4-XP \*HU[-D?-^E?+-
M+;[5IRAV%H!!99P"L<,-+L"8$[*)?\V:'RD=<3V_JW_QU5KW5Z+A(ME/6IO.
MFHTC5$-#!F9>Y?@5YA*\PTHR[;^H&K21_$Z)$"?OTTB%'\=IYU,\T\*$=":D
M_TO(9D*V(>#)F:_K,S&D+)0<D9K^14_<+T^.F>U<Y8*^47[/5J9M]%8>XGV!
M;TYHQIPG3+K")'\C+H^(?;9 L#6PN$A#+L[I S_=9'A$)(=PABQ89^;YV9J?
MQV&!75!@YP5V:XOII@WG$&9;2 CSCU[E02-Y0&"W,1+"Y!LC(<Q^8P2OCA$'
MU?KKI5$E!^$O\RJZW.#GU!_##WA9]*2%[T2U5&ATE<8>9G_D&BD-6"OQD_72
MV3=F63!HC)L>[%Q-UVY:&-G?'Y'E)2O_ %!+ P04    "  5-B1(?$1TP:$!
M  "Q P  &0   'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6QM4\%NXR 0_17$
M!Q3'29MLY%AJ6E7M8:6JA]TSL<<V*C NX+C[]PO8<=W4%V"&>6_>#$/6HWFW
M#8 CGTIJ>Z"-<^V>,5LTH+B]P1:TOZG0*.Z\:6IF6P.\C" E69HD=TQQH6F>
M1=^KR3/LG!0:7@VQG5+<_#N"Q/Y 5_3B>!-UXX*#Y1F;<*50H*U 30Q4!WJ_
MVA\W(2(&_!'0V]F9!.TGQ/=@O)0'F@0)(*%P@8'[[0P/(&4@\HD_1LZOE $X
M/U_8GV*U7OV)6WA ^5>4KO%B$TI*J'@GW1OVSS"6<!L("Y0VKJ3HK$-U@5"B
M^.>P"QWW?KC9)2-L&9".@/0*P(9$4>8C=SS/#/;$#*UM>7C!U3[UC2B",]8=
M[[Q0Z[WG?)ML,W8.1&/,<8A)9S&K*8)Y]BE%NI3BF/Z I\OP]:+"=82O9_"[
MW:]E@LTBP282;+Z5N+LJ<2GF.@F;]52!J>/H6%)@I^.@SKS3=-ZG\4V^PO.L
MY37\YJ86VI(3.O^RL?\5H@,O);FYI:3Q_V<R)%0N'+?^;(:1&@R'[>6#3+\T
M_P]02P,$%     @ %38D2&MG%1^] 0  3 0  !D   !X;"]W;W)K<VAE971S
M+W-H965T.#0N>&UL?53;CILP$/T5BP]8 R9)%1&D3:JJ?:BTVH?VV8$!K/6%
MVB9L_[ZV(2PEM"_8'I]S?,;C(1^4?C,M@$7O@DMSBEIKNR/&IFQ!4/.D.I!N
MIU9:4.N6NL&FTT"K0!(<IW&\QX(R&15YB+WH(E>]Y4S"BT:F%X+JWV?@:CA%
M270/O+*FM3Z BQS/O(H)D(8IB334I^@Y.5XRCPB 'PP&LY@C[_VJU)M??*M.
M4>PM (?2>@7JAAM<@',OY [^-6E^'.F)R_E=_4O(UKF_4@,7Q7^RRK;.;!RA
M"FK:<_NJAJ\PI;#S@J7B)GQ1V1NKQ)T2(4'?QY'), [C3D8FVC8AG0CI3/@4
M_Y= )@)9$?#H+.3UF5I:Y%H-2(^UZ*@O>7(D[N9*'PP7%?9<9L9%;\4AB7-\
M\T(3YCQBT@4F^1MQ>43LR0S!SL#L(MUR<4X?^.GJA$=$<M@^@6SF20*?+/F[
M?PADFP)9$,B6%DFVNJ@MS&Z5R!9FOS*"%]43H)OPJ@TJ52]##RVB<^,\IZ'Z
M'_ B[V@#WZENF#3HJJQ[0Z'2M5(6G)7X:1>AUK7VO.!06S\]N+D>7_NXL*J[
M]^[\ RG^ %!+ P04    "  5-B1(DUB :]P!  !>!0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970X-2YX;6R-5,N.W" 0_!7D#UC\GF3DL;0S490<(JWVD)P9
MN_W0@G$ CS=_'\ >K\-PR,5 4U54@[N+F8LWV0$H],[H($]!I]1XQ%A6'3 B
MG_@(@]YIN&!$Z:5HL1P%D-J2&,5Q&.:8D7X(RL+&7D19\$G1?H 7@>3$&!%_
MSD#Y? JBX!YX[=M.F0 N"[SQZI[!('L^( '-*7B.CI?<("S@9P^SW,V1\7[E
M_,TLOM>G(#06@$*EC +1PPTN0*D1T@?_7C4_CC3$_?RN_M5FJ]U?B80+I[_Z
M6G7:;!B@&AHR4?7*YV^PII 9P8I3:;^HFJ3B[$X)$"/OR]@/=IR7G4_A2O,3
MXI40_R\A60F)0\"+,YO7%Z)(60@^([&\Q4C,DT?'1-]<98+VHNR>SDSJZ*T\
M1%&!;T9HQ9P73+S#.(C+(R)/-@C6!C87L<_%.7[@Q\X)CXCHX#\A\>:96'[R
M#S_T"Z1>@=0*I'N+6>I<E ^3.8GX,+G?2.8UDCT*I)\=(QY,%CI&?)C(;R3W
M&LD] JX1#R9WC?@PKA&\^Y\9B-;6N405GP;;57;1K94\Q[8>/N!E,9(6?A#1
M]H-$5ZYT5=E_O^%<@;82/NE+Z72SVQ84&F6F!ST72_TO"\7'>S?;6FKY%U!+
M P04    "  5-B1(41'GT ("  "F!0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970X-BYX;6R-5-MNHS 0_17$!]1<#*0106HN5?=AI:H/N\\.F014&[.V$[I_
MO[8AA 2KVA?L&9]S9CP>)N^X^)05@/*^&&WDRJ^4:I<(R;("1N03;Z'1)T<N
M&%':%"<D6P'D8$F,HB@(4L1(W?A%;GWOHLCY6=&Z@7?AR3-C1/Q= ^7=R@_]
MJ^.C/E7*.%"1HY%WJ!DTLN:-)^"X\E_"Y2XU" OX54,G)WO/Y+[G_-,8/PXK
M/S I (52&06BEPML@%(CI /_&31O(0UQNK^JO]K;ZNSW1,*&T]_U054ZV<#W
M#G D9ZH^>/<&PQ42(UAR*NW7*\]2<7:E^!XC7_U:-W;M^I,$#S0W(1H(T4@8
MX[@)\4"(;X3O(^"!@/^7D R$Y(& ^KO;RFV)(D4N>.>)_K5;8IHJ7";Z;4KC
MM$]ASW3MI/9>BBR,<G0Q0@-FW6.B"08'Z8A!6G\,$KF"K*.90)2%]T$V#LP]
M8CM'A-D]9.> /+L3C9W5B"T_GO(Q=@M@IP"V OBNG/%#.>>8&(?N((DS2#++
M,DH7;H'4*9#.,I@*]._18S*+:?I2A,]X\7"9K0,6A%GR -O-88L@B1^;"$VZ
MEH$XV7DAO9*?&SN=)MYQ)+U$MNMO\")OR0E^$G&J&^GMN=+_CNWP(^<*=#+!
MDRY@I8?F:% X*K/-]%[T<Z0W%&^O4W$<S<4_4$L#!!0    ( !4V)$@K=AVD
M)P(  -,&   9    >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;(U5VX[;(!#]
M%<L?L!@<WR+'4I*J:A\JK?:A?28.CJT%XP*)MW]?P([CC8DV>0@PG#-GAC%#
MWG/Q+FM"E/?!:"LW?JU4MP9 EC5A6+[PCK1ZI^*"8:67X@1D)P@^6A*C  5!
M#!AN6K_(K>U5%#D_*]JTY%5X\LP8%O]VA/)^XT/_:GAK3K4R!E#D8.(=&T9:
MV?#6$Z3:^%NXWD-D(!;QNR&]G,T]$_R!\W>S^'G<^(&)@5!2*N,"Z^%"]H12
MXTDK_QV=WC0-<3Z_>O]NT]7A'[ D>T[_-$=5ZV@#WSN2"I^I>N/]#S+F$!F'
M):?2_GOE62K.KA3?8_AC&)O6COVPDP8CS4U (P%-A$G'30A'0G@CQ#;3(3*;
MUS>L<)$+WGMB*$:'3<WA.M0G5QJC/2B[IS.3VGHI$KC*P<4X&C&[ 8-FF%40
M?\;LEY@XG"! AS#%@5QQ[-""G\#H3F.)@9E;(W3F&EI^..-GR,U?.?DKRU]]
MBO'^' 9,8C'M$"/,HL@M$SEE(H=,XG80.QW$3^>9./F)(X#T[IL8,/$LSSA.
M OUS"Z5.H=0AE-T)I<L#?9!,YM3(OB[:+EMH).AA*J8KN"Y2L!1"CUP\N(OP
MZ<)!YRW:0O1$Z4;0O':IJW1@UD,8$2?;6Z57\G-K6_G,.O7OK6W?X 8O\@Z?
MR"\L3DTKO0-7NI/9?E-QKH@.)WC1WWNM7YAI04FES#31<S'TW&&A>'=]0J9W
MK/@/4$L#!!0    ( !4V)$AT.1M4]@$  !<%   9    >&PO=V]R:W-H965T
M<R]S:&5E=#@X+GAM;(U476^;,!3]*X@?$(,QT$8$J<DT;0^3JCYLSPY</E0;
M,]N$[M_/-H32A$Y[P?;EG'/OL7V=C4*^J@9 >V^<=>K@-UKW>X14T0"G:B=Z
MZ,R?2DA.M5G*&JE> BT=B3.$@R!!G+:=GV<N]BSS3 R:M1T\2T\-G%/YYPA,
MC <_]*^!E[9NM V@/$,+KVPY=*H5G2>A.OA/X?Z46H0#_&QA5*NY9VL_"_%J
M%]_+@Q_8$H!!H:T"-<,%3L"8%3*)?\^:[RDM<3V_JG]U;DWU9ZK@)-BOMM2-
M*3;PO1(J.C#](L9O,%N(K6 AF')?KQB4%OQ*\3U.WZ:Q[=PX3G\>@IFV3< S
M 2\$_&]"-!.BA1 2YW2JS/GZ0C7-,RE&3TYGT5-[Y.$^,CM7V*#;*/?/.%,F
M>LE3'&;H8H5FS''"X!6&!,F"049_28*WDASQG4"*\<<DIWL,"=+M)-&FD\@)
M1!^21-L"9%. . &R$DC(;943QEX, ^H<*-B%A#SB-(X^V9-X,UM\G^WADW*3
M38'D__VFFP+I704I)C='/V&2E=T0QX\AB6^]HM6%XR!KUXC**\30:7NLJ^C2
MZT_87MB;^-&\ 5/+OLOD64]K^$%EW7;*.PMMVL%=VDH(#:;.8&>VLS&OU+)@
M4&D[3<U<3HT[+;3HK\_0\A;F?P%02P,$%     @ %38D2/KM4W0) P  ^@L
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M1,]%VWO;A>+U_2GIW[/L'U!+ P04    "  5-B1((@6FV@0$  #X$P  &0
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M,(C8^M:L4!"W6MDGH'$PN&@)5*T]^VN"J9;#CFEPPQ412_=ZH+BX*11WZ+*
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M*YO[LC^8ZA]J?7P_9[L<]LW_ U!+ P04    "  5-B1(BN'F48 "  "%"0
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M=3.:^^O F*3*B_^BMGU2/5$_*>A!ZF&BQKSM$MJ)9/6UZ>D[K^P?4$L#!!0
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MH@#>4'^[@]20:]3E; X%)A1ZZ:O)(J@SYJ1&HII<KJWA*8PH"$^D(JW;OBM
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MR#'7#YC%\8YY%69(T;4;)?--I5O"UEM[-M7()9WUC-UI))$Z0FQLQ!7>F*U
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ME.C<,<T8$O0$>UBV;-,SKE 7\3IBI3G6RE8YPAA3W&''95J6&@UN(1BSJ9B
M;/."94?"96%_/M?[,R#C&<'+"4"9C-G]=3?+K/XQG_L#C:;G#[20'%URR^Q(
MX+[^27.G7:JE"+;.0Z"-_3A;EZ@3'FZYR_KIRFS#;E]W64G'VRZ6["370BR7
MF+_\U\W\E@6)3VPHW%&*!LC-I.Z W3,7C"=P(LF&BE=JTP V*W7&:AK9,L_0
M/8YHV'_#%H*^73 LC3)*\%N(D2!=S[%R0)QEE!7 Y?J[IT.G+?G0(C0:6T4)
M':A[K143DIIZ2E_VE<6X.TZGTWY28RYECNAJ=#0479,B&\9F),&?CL :,X\V
M$HT"<$9,-V)@=,G 6^&N>'!625Z;.RSHPL-Z>X>H3[&<^&*0\#T:%P98P$U$
M;%=0')3VX-R!&''[>4E!_^/ 21'VH1%,6\JI#P0M8NLN6'EL+%AJ0]R:!736
M;/;D@#L-(_!EK-$?/J71OR7?+A%GV212'/P&E\CVE+!'1FC2%A04">)^L,U>
MHHW4%RH+<NDO6<(X>YCJLWJTA-T$DPY;LC!!:O<K 77@O0F^HTZ09898L@UL
MTU]-F%]-F%]-F-U-&%F%[>1]3=C?:P[L^)O'O<.EKUTI#<KTC*1V: Y;4/XR
M,M*GXO^2TM(RMX4@']-+Y.86-!R&,G6XR5S)F3'(-,8P%ESW:6I.\4O*:$#8
M<.?7E7>>24O>H*Y&447=/HF@T+H2K)<G$B%4SH,;[(.CX&JKN8<+HBZKLTQA
M$&R2NR;UJNRASG:"\LP2*X)83N/31#<QJJ?:=8PJ6PX03UF"HWZ[L?PHZ$#+
M2#DGM[#06Y32$;XT3P#98+%V5<5V>-YW @+:OO.2[MK(IV@T-,$0(T88\<W8
ML3E)!OWI"\K='PP&^!^8$]=P$(I/,=Q%5T8U&HT:+SSE.?QDD:I]U7!CC8Y>
M;! @[/+^:GK\TP(!34TN[O7%;HA.P/>B72@QW'N,[PZOO3KJ8S7*C@DRDD,L
M]9LH%GT# <+6B$#B6T#RN2L373,$>G*U,>AI3JCI*A)<ZWQ5TZMKO AX''/+
MYNQN:4LKHUMZP"DO!%X-#L?P_QD0<-$:-@N.Q$Y (4Q;QG6HNER>;L=]-9B.
MC0+-E6#<5TC4<XFA2M:8,R6H9N?H.^^2KP@"5BU+Q[1R3D0?31V _HDH?6["
M\FE9AVT1@(##ZU ACS*^_*G5T;$Y+;S91,VIFVO39Z.-.)"(VH\A];2,;2B)
M*Q(;"8 "#<P94WA!K?<4_HW_1HG.TJA56W_$<(/^2#I[ [BMURWW&Q#;%&_.
M7C<"SD>]!/]LW"3#([IDP_#>TPYS* 8KJ1<E:L>.%>V!OBI-VU"X)>_@YY?[
MO%>7L" X.>P(NP#]X76V^A&>O_P3@F(@X6$WSP>Y"%C3])6%@T/Z>C5(^_U^
M5& 'LU/G _Z+MO5M?EU1_;*'Z'#X?S0(3/_5<-)/Z7\Y9#KI]V/6=T7:8[P:
M_(2%^,+J5R)]3!-"249[/^P-)]]A;=L7A8Y#S8B>DU[C4JN.?\8Z#4Z&T&-K
M&79OTIOTO]OOG):[33=:O0?3.R"#PDDCUSZ"ZB1AMU3CM&C+"N7,V/RT7T#7
MJ<D?I+**U%UI.P)G]6-1E,!MZTPZS9/F4L(3HYIEF!W0">RTY(P2F]46?\,1
MI1QW):UR<>'7O)IA 2+UHB-JZO?ZAR:)<>\2U*D/>!6/][FH7(K@?2E<RZZC
M,T.]*GLO3[1@AJKD!DS75IL+(JJ_\[M;&Q$P12I/B>T^2OLN[GW;31O*LTRV
M5BK6ET5!E ]@]WC!@K2LFTS=+70+<QOT#CM^I1VS]V[<>>_X$E_1Z]RJQZ>G
MJ=1P&\/YKIJ5>H]MY-$XWGT?$M^%+424$T,,?T#&,IGVP$9TQ\%J5W2>G5<?
M-G;2ZW_7:[SPC[B4/_.=C);0?AGA++KO(Y8,C3KOHVI"[3=RLNU&FK+J;?=1
M.V!TW<MAR[TD';[U.AZU")TQ;:-/4W$S<HZ+*G]@2GTUPO=9QHST9ELI<X&-
M#&0+HWFF723C@6R6F>4LSZ>@WWT[]42SV'I]AO!45@57!^<47AYD"4I/7J/
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MCG.0@JWUG2*]S@=,9,,(BO7WT9S=EG/<$;-37$>$17%#SY!'&6B_WQN/))F
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M YL*%G3?PW2]F+I*"T0RZ>-[F/N&-O]]61B5,J@%T98YF3K?<$6:86:S5IJ
M3B@(\:4%P8+#I5AOYK3I#&.$M<1K:MK<,EE\WQ*^/DMN!8-<+OA3;815%R0U
MN*'\4IIZM,W1 4^UR@0DH52!T7&+99OJ/$ (3%F."^_9K-"K'0YW4RS8LG86
M:@Y$MW*^O<\K\H!>KMGQ"K3W'C8JF]W!I]:*@J#RI?%SVX?#W#O#H-C&RIQG
MR;EV\8=MGHE!IZ,.=0=!#<.N:4T7#*DA:\&O"*]I&HWM\#*)([AWT$GJ)#3Q
MC7KMRJ[$OR4-"=W2U('1F0J*&\F,BR;(6<$D2M;!<ASWL!CHX@EL-%M[?_'N
MXU_.SI+79Q_.WIXWV]GB;C4>:M F$MRZD%S!FI)H0?WC[%UU9OJT5 Z]U\)K
MQOW!WH_[EMVDG.>,X.<:;1,W-$7JN8 N7Q2WA%OF(W(4;[G!2)WV/I:?T.0L
M:@3]9\@6^ _8P2"ZY.&>M^R_EX[HLW;C2@-F-R/RQ7G8$:Z8%_:"UW6DJ:,^
M)S:\?X7>=@^H0TY.)BZ:9\'[BZ2\)C\UNR%NRLH_2O=EF0'_#GUC'*$>#8*H
M[]:@[ZO19)>'F\W\+C^_OCS[X^>S#U?)V9_.6MHE8S"Y\5"#O@QO7B5Y@,/,
MW7BN:]@KRN?\(D$"Z2G*!:,,SR%%HQ1[9K;8ZE"CP*Y5YUQ):),I1[;6JFS,
M)90/])2<*Q,E\&[2AW('5HI=O04+^/L7>]D^2O'WI$CX-3B(&9!HR7B03J=3
M;(O=1+EX$_4R#[O$4.!8<_Y<HK#;6X&O2T-'S*OQ1)M_D+N9$1$LQ-@K_X 9
MG+N54[)GU-R<][7Y; 0#!QKY-RU3ZF %A<2%#<7*;IDB:HP9J%"*_534(9A%
M;N !S<J;X"^-_H#P9<:TP#^55#Z@?=D56%!A-3@6AVI?7KG2VQW !GO)WO4^
M-NL1FADK[5]L*E3G.;_!<AO>AS<%JPAL72TP48!"5GDEJMH-3B-7&#!*\$?^
M1N%3/]PT&@YU"5*I&#>[WA38@31#W):G9A%J#=U3(0<[EFN$<]J;;;TZ+@E8
MNJ3 AZ:CH[1_/(GR**),,9LW(V[/X'';.-7U%. <;XW]A^@W]&QJJR>"A!]7
M21&8C%KL4/O:T^![L/QYZ_*?6S+_K.HC:IS</SH$.IRXDOF]?.LYZ#Q0WB]X
M%J6V_TS"#K7'</G[20V:!!9/Y#F=/@&<\-WS)SDX3D<@L\RC4>D^SD!&PY"A
M[:$KA30/OLPH!"QBKUJ=3/0 @@(05_2!8)JBMC_F:[8!?!@TQ4]ZU1$V;[X@
MY&K0(I"?:! 2["E"/Z)%$@M0BZ98HLTJ,BL$\'+BDA"10E<BP5ZU;8$X!]PN
M*$*!W_X)6W'X=._%WLU^&R)#?+NT/-QS[$9*$C4+=7>JAXPCH"RY'\>'Z6CL
M6+\D$A+3E >XT(8]LEJ8';[4-CI=.VP9CRK9XC$ E.HV83%+/V?PHHZD-J#[
MVVT[!$?14A5#.K[%2B->\(78%*(BP:$<3'O'F# &OP+KN5\4<<>^J$ $: !D
M4A,HB2L]7"ZMHCAN"S7:-EQKS&H3"&AGTZ@$Y%VJ-4[-7.:6W.A<<R)'VUA&
M#.-@"X&JG!"5BAMN\.4 ,@.4,]\1#,O(7$,YI#%/R!A=/R#UA7"N6K36]^]/
M/OTE^?@VN3S_X</YV_/3$U!.3TY//W[^<'7^X8?DXN.[\]/SL\MD[Z($*0WB
M?C_^R&>N_S_3[,BG?F<+IV)@=>/J:ZML,F?BE,F"NSED/^8F(Y,!VWT&&_,N
M^.!L+=LE.8!Z_"XBF%IG94HG!<:0;Y2RJN4?1/E.D>7<)]= O2.XU\#I:U?$
M5X0=QP_AF9-ZQC)WB<FX-M[HU[S;QUD%5;()3 K<4<R[$HO?9+GX0> Q[7V>
MFO)NT%5N-F@C?E$ X*^4T<L[2O_?FLJV:8ZLM@)BKA.39CQ; "O#A ?@6_!3
M:(-<4Y^N[O,.\\0X1$Y1+$+'\U:. +6H%UK*\%P "8R1(O_")C;'?VJX2-<+
MBS@S*ZK99HE2:!9W=-/X6AUT-&N=+7K85K<EH5-CB+J!<<=Y/NJ01*'%(6ZG
M!]7VF'AZ&@1?AZ-5MK:T<3U7&; =/(.+JL1<F&66:(.9RSO4/7#V&+U\1RHY
M#$. &\#RG1-OEV]N_T+B7T'(6OH[.?\6^HIP;X^!;9K-1HBK+BG%9Y\UTEV[
MT/.MIY4=&L#."=4P8.BA':BPOO9E:VXAO".(ZC;+-,+]CDM4BQNNSS/C89#'
MV=DNIJG 15K&R.+;R:4T$:^&RNX&NF6*8^%EK%+A?0(40ZH)%2^C$88,;U/4
M=VJ3Q.M13LF])V5_NA.UWB+/^1/QG/>FD=..CZ$5)?R8N9#G8,W"G;:&AYI4
MPOZGU/FT8;/4#2W9)IKM*3>CQIN11MDC]KMB_E.0PG<LXACU/6;Q>2K66\Q<
MR#16C)I\UEZ*[<;ZR4GF/!?X'[Y]!')I3NJO75L(QYGS*$7%VVDX;%'9UAY^
MS[D-DK3U(EL5#*KU 2G=085O[0H*L"=(Q]'B9.SQ:O>H1O7%70$W&DRN1YM4
M@%G6"PQ%"4@H-OFB9BS>%)$6AP^EMMG1XG'3CTRI>8' M;93F4!]BBU!^?*H
ME/ "S.S2H$T1-QT;(+-33?)OFY*9'N4F*]BJ%DN+9)(2C!R40M/!(JY;9[MU
MCHF2,PR$886/,P(\K+$YV5CHZ/PZM!E-(*2PU2I_5&N?FY4*-"U_8YC\,5@8
M3DV#DJHE$*8^=5]SB[0;G!=T%=EF6 @$O_Z+KUYH#7+4=2')L>H9G95555XK
MY@==2W/ L@+8OLQ/78SRVBZ,CY,8;GAD@4VPR&\Y[]WFZ@9=JUR>O**%<V_U
MJ)(IS-/6>76<H;:RNY"B#-/2+FBNIX[MUL^D:NZGP:%(:J;1H07Z%Z8,!%,^
MK )5PY=(VK_*)KM8 ?%'BIAO& I0RTG\['JF09\<!O8"8S0!?RB.<.K-O;!&
M['Q5K-<,VKTJ=7"MS7QZGT>==T50OR5G+UO,-@O%.A(&Z&UD!Q'N$"6JG%UF
MJ]+]Z%,5WS&OPO "7;M1G$>S0[%:+#1/2T)2\586Y^Y1D<ISGM4>(*&$4]_/
M?;G.]0:Z>*;98E1O@G3):"!)$N 4=>4P/B\(G^@28>%9HBL$'48H*BBUC=BI
M1&?9X4'M3T-Y7:PE?A2XF)MO:32L+5KMS8TYP7*[C&V!@E8Y&R%F>&,CSH\O
MW'=+D2S!%OH=T[R5T)/A@#PTF[1SQ2H-L4C&[1I2]YU+^@\7NTW;*6]N#@+]
MB*<(D\ -:9*G'BO]QYD_UIT?3$Z[*,/Y5>F' OTXV;RP]3[)["Z?_<@.EKD+
MY89'967<S<;U.]$=496!>LZ"&G*+;C5!-+%,RJ$UJ<J]1&7(@:L8B!V2('6+
MJ]O!.[%=NO4B_*9NT?7XH+L$."V.^Q-U= DF_!K??U5,UMTJC5MZU7=>:2DJ
M3B>3@:2DI=-11T::44OKH!)U-6_ \_C6LZKC:*O9]XV-H'T0<<\6I$A\E6,L
M^.E8X4:8Q$A7PRYMI=HR1VLG\UWVM^E-FSDEK'%?P)0&-B. F'@+*,EJMZ>2
MX,^Y^[.FU',K\[7UH6 5..Q.1J4W=*<%@@PW&G_T%6BKFF>N)2K88PQ_U\1!
M. :6#^+*YW8:Z'YGY5J=2/G7HEZ;ICB\.>2ZY"Q<>_L"G+'YUB1N4X0&@@<=
M 0<+@@^DRBM7B+S%O>45$T=\4<GJ";F\3ODH'YVW<YY\YD^]*V[R%^^SV1T,
M7,7'(!&6%Z?LN!#_.(/QM3SV=E.M"K*G*+.O^+HF"^E0?GZ'L0YTAX2A$PWC
M4*MNZYNK"$Q)8:"8/<@)S(N:19 :0NJO T;)+0&Q&BS8?**H);GR'1L+V"KW
MCM?,./8L5.SG*4S+03%QC3GKD\+;_%CG2Z1,=4N\0Q2F=QC:3NAD&D*E^?B!
M?9S_LJ"_R%X8YGG?>IMZR9_1V5CX+Z.],LO(PTBT'0=&C#+@78>+QLA(X4[-
M,M_'+GIVN.8>WC SQ&E)P@@Q7>O!U$F*^T&&7.(MH800^KRA &RQ62L: +'O
M&\Y3<A3/,LJGA5%2#FH8YEK[?J(=$L*^@1NK(2\CY-K+Y1K9@D%U@YEP1BG+
M[H#03>"V,NW6TR3/S'S( 5OD=&ABBH0+<\7P%/UMG# !]V564MA,2,7+6#W&
MI^US*E>854/YE.?Q(RG3@30@#'U:P!'0;5BWDA+;:-?Q.QT1J;#)5>-(E<D&
M].,J2AN[VKS?DBYRP>DB'S5=A$3-K@]3>/ZQ)8Q+K=?GV])2]EZ>7WQ\N:]G
M& ;O6"8P5S.\2YH:3M/I8=S4,OX&MZ6-!_4][@9#K+,S33U]O/"H\?$06TWK
M=WR-]Z.>1%YA=Q[?@JE0M,4 4[39E%'LE=;IAF+:70N7R^.D G8615$39(&\
M.APBWE<JSO<YASFQ#$EGB_]0$B)TVN6RJ&L76G(Q._5JQO6R+9A\'(VD,D[Q
MD<#<8F;]6J/8;[X]BLU1Z5UBV5<V:FQ>DRX\'(U CE;8R#O'P'<(>V- B/4V
M2A,KEMV12<X50U]<OBY_[M X2:O&*G^N:'A\%;9'Q[O0&J.^3T0:K:WCNL(_
MC1A)1P]8$]&2V)#A5G$Q@5G(8)A.C@?I>#+MX@'A5#F1EY9D 2,HQ<OX&6RS
MCO!K9IUFCC':DPF_H^9Y@"+@0(!KEQC]#R%&_3ZVQ/W4VZ:.BR#;^YG"(O0
MYN2'8[\R+UE+J]G&D5QW#=;@3+]!1&BQ#7_4H7RPP]B%8M0=41K/MWO%!<JC
M/"<!=D6@+FQPYIJ:J0/<21451\VYO17IRU:;)/"[:D7?O$1SN[UKB2^#0I<*
M2$G^:"HHY?86//?NZZ?U''J1_0!.=, -#>G8)*[AHBAM7M*Y2+B@_%ADCX)Q
MZG[V-3?'?>P%0_"NC[)\MVQ=@K-P ^SB3N1!'%@V$KV]KX:CD8/$*C2)FGS>
M.8%?!#DF?/"B%+:%'!N4;F#_T!OVQ,\6)9!T+8,W0_]&OQ_74X@[D/!^F#I9
M16EU)C+K6E#XF(QU*DY:>;4!V<4!NN;S]5K"[N+%[*+K4V!!F+T7)L?>9#-F
M&IS0EV%'(C:%XI45)EQ*NO3J0"V&H,VFB<VT(.K ]+C 51L6Y5\Q9I@OOJC3
MKG$BKM3\4XM[)OC1 QPP7#(;F#[-SD$:N# !K4P:7];&*"?U7*\-?<P!C:RH
MS,NZ/1@2034=V=%" JMZM3##X+XE1,C[KG4K[C@";PPG ZGX($)&B#1,MI7:
MDHI9;+ 2NKB>/51L0/,<2T:[64;>*&_KR=WU,1.?\,DKX(Q9;U_&,T!'NK-1
M3+8H MKD- +(H=M< !'-!F-WY6L,5+B7$>I'CI ^U!:8<;K!)Y\:$K4__;:W
M0@^U\MXZV3$=17-^S2,H[8MY*SKW"C3 A7W@W@&9<&Y9PQ9@OP2QXRVS"'W/
M9,#X-)55[OJSNR1M/G[D]]XPT-L1V>#N0(/B=8=0Z/-64(-9\TX(N)&XE]<,
MDAV&.N:,Y*8]1[<LCOLFN)\S@2;@.*&TG,ZN:[KW1*@8U$);64QUGT$A$V7*
MK"-GKI0>= M<XQ90>' 4T(%C#S3!HE7F^(+?-Z;@M]46W_YTTHFTZ'W,YNKI
MK3/>9JW+4><<O^=^A9=N-M7ZKM&&LK-LV;2[]68(*$]9Y<K9%<U0I1>-F>J4
MZ[I$=V@NC3HD;!"-AYIVUQLH.L7L1=>J)$:F/D627?&W>$XLH%MF?).3$:S-
MZ8MJ?H 1>.+5-SE9S*3EALU=I$Y/&7KE5N4VE%,-PVQ-+XC=\Y0.D5'B!4X1
MO6(+W3_S=^<]U?>(!BD?*]53T<#I!M,U2>WWFR(ES$0#X90T[D"9K3.7YM (
M%;#.Y=0POX%8@#G+U$U%/Q*8FCH=K32BY+.92Q7X :7!BJA) .<BUUN[LLNE
MHX\JT(1157FQO-Y46+W<B/90#5#[O;._R?\:9>L&YBK6!E6X$*WQ&Y)CZ74B
MSU1<-Y*D!?FT[6ZR=U*5%,R]]$8?20%Z:5YP!*/ 1%:I^V@FJQ-@ZFOBV*>F
MI'77YP)1Y"(2KDL-5ZD^#2P;P E;&)NBZL#QYL_(T=?M8*\M8+B*:6BG_;\
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M%3/7:FLJX6KN6ZXWW5=A8?N3Q]36,NHNLXDT?D$.G]8FPSQ9I)JV[TQ\%2@
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MXYXCL" .NPKK=H!U9X3?3$Y!G."'V?2.0%/X .V%[0,Z8T^DG1B_^YSRC_B
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M_W0TB7YKE=PX<2$F'O YJA1^G"XR UIZR:4N3RF[:3,98^/U="D?I&5PHV1
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MS_.^T?85XS=]%&3NVLF38[O+ZZAH-D"M>H\W4MPH:!(+6NT(1'6CU=T;RJI
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MROOX9)N."Z[A._2\Q'XM1T[5.//4-U&W]\OUBI#W$O)BOJ)^N6/#U96ZU^[
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MSZ<IXK-MPQ+O!J<C\6EP=DU(\>].ST&8G [.Q.GY^&ITS9OSRJ@%/$?#)8B
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M#RUVK:$0=K/\=SD:OAN.1L!P%)* ]/M(EAG<Y]GQR:1#9,,-)CL0'INZ </
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ME/*/O7)BULZ99G_<;)[^_+]02P$"% ,4    "  5-B1(. 1QM8 "  #>.0
M$P              @ $     6T-O;G1E;G1?5'EP97-=+GAM;%!+ 0(4 Q0
M   ( !4V)$A(=07NQ0   "L"   +              "  ;$"  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( !4V)$@T5K@[Z@(  &X[   :              "
M 9\#  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( !4V
M)$@E"TE^Q 0  -$5   0              "  <$&  !D;V-0<F]P<R]A<' N
M>&UL4$L! A0#%     @ %38D2*/&.JT_ 0  :0,  !$              ( !
MLPL  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ %38D2)E<G",0!@
MG"<  !,              ( !(0T  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    "  5-B1(^Q#O(8$"   "#@  #0              @ %B$P  >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( !4V)$B(W/X_!0<  -4=   /
M      "  0X6  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  5-B1(<FS%
M5_T!  #_!0  &               @ % '0  >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ %38D2$?GK#NO!   !1@  !@
M ( !<Q\  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( !4V
M)$A:S88730,  $<1   8              "  5@D  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    "  5-B1(T.W!8U@#  " #@  &
M        @ ';)P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ %38D2 RJ?V7T @  . P  !@              ( !:2L  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( !4V)$A*!X[PK@$  .\#   8
M              "  9,N  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    "  5-B1(6I/L'*@#  #\$   &               @ %W,   >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ %38D2*-ZX8(;!
M^1,  !@              ( !530  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( !4V)$C4[DH,L0$  /(#   8              "  :8X
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  5-B1(4BD*
ML+@!  !,!   &0              @ &-.@  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( !4V)$B?0L=+N0$  $P$   9
M  "  7P\  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
M%38D2//B416X 0  3 0  !D              ( !;#X  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    "  5-B1(R7Y,&Z$!  "S P  &0
M            @ %;0   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( !4V)$BU/.BFH@$  +,#   9              "  3-"  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ %38D2 5:G(:Y 0
M3 0  !D              ( !#$0  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    "  5-B1(/L%V*K@!  !,!   &0              @ '\
M10  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( !4V)$A7
M330KH0$  +(#   9              "  >M'  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ %38D2%:CSS"A 0  L@,  !D
M     ( !PTD  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !4V)$B4A8K H@$  +,#   9              "
M 1)3  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ %38D
M2-63;4:@ @  "0L  !D              ( !ZU0  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    "  5-B1(&AL.:*8!  "S P  &0
M        @ '"5P  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( !4V)$B;8I7BRP$  -4$   9              "  9]9  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ %38D2*;0^+NE 0  LP,
M !D              ( !H5L  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    "  5-B1(2OE>':4!  "S P  &0              @ %]70
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( !4V)$AJP;\3
MO $  $P$   9              "  5E?  !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ %38D2'?5_+2C 0  LP,  !D
M ( !3&$  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  5
M-B1(6G>$=*0!  "S P  &0              @ $F8P  >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( !4V)$BR.OH0K@$  !@$   9
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M970S-BYX;6Q02P$"% ,4    "  5-B1(";=X 0("   /!@  &0
M    @ $_;P  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M !4V)$@GD31#J $  /(#   9              "  7AQ  !X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @ %38D2,29JY4# @  M@8  !D
M             ( !5W,  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    "  5-B1(?N)QEZ(!   =!   &0              @ &1=0  >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( !4V)$AQZYRO50(
M  4(   9              "  6IW  !X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @ %38D2#+2?0P$ @  A 4  !D              ( !
M]GD  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  5-B1(
MI^M*7.P"  #R"@  &0              @ $Q?   >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;%!+ 0(4 Q0    ( !4V)$AAQ!+ H@(  +P)   9
M      "  51_  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%
M  @ %38D2'3,S08% @  8P8  !D              ( !+8(  'AL+W=O<FMS
M:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  5-B1(1.AH=6H"  !["0
M&0              @ %IA   >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+
M 0(4 Q0    ( !4V)$@+E&24,0(  &('   9              "  0J'  !X
M;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ %38D2,[H"+_&
M 0  C00  !D              ( !<HD  'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6Q02P$"% ,4    "  5-B1(UTEO=MP"  #&"P  &0
M@ %OBP  >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( !4V
M)$CF@G,(8P0  *D8   9              "  8*.  !X;"]W;W)K<VAE971S
M+W-H965T-3 N>&UL4$L! A0#%     @ %38D2"81K+.Z 0  &P0  !D
M         ( !'),  'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
M    "  5-B1([NH'=\T!  #6!   &0              @ $-E0  >&PO=V]R
M:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( !4V)$A)D2Y_?P,  .\/
M   9              "  1&7  !X;"]W;W)K<VAE971S+W-H965T-3,N>&UL
M4$L! A0#%     @ %38D2+-YU#;R P  P!0  !D              ( !QYH
M 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  5-B1(J QA
MB0L%  !%'   &0              @ 'PG@  >&PO=V]R:W-H965T<R]S:&5E
M=#4U+GAM;%!+ 0(4 Q0    ( !4V)$@3 W[QN00   0:   9
M  "  3*D  !X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @
M%38D2.3UV-K< @  +PP  !D              ( !(JD  'AL+W=O<FMS:&5E
M=',O<VAE970U-RYX;6Q02P$"% ,4    "  5-B1(8;J6Q74%  !/'0  &0
M            @ $UK   >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4
M Q0    ( !4V)$@-T/4/A ,  -(/   9              "  >&Q  !X;"]W
M;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ %38D2&4G%<D1 @
M5@8  !D              ( !G+4  'AL+W=O<FMS:&5E=',O<VAE970V,"YX
M;6Q02P$"% ,4    "  5-B1(A0Q%C'("  !,"0  &0              @ 'D
MMP  >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( !4V)$@=
MV*>5&P(  / &   9              "  8VZ  !X;"]W;W)K<VAE971S+W-H
M965T-C(N>&UL4$L! A0#%     @ %38D2#"U"]Y[ @  F @  !D
M     ( !W[P  'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !4V)$B. ?0W;@,  )@1   9              "
M 5#.  !X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ %38D
M2'N4_ZXD P  *@T  !D              ( !]=$  'AL+W=O<FMS:&5E=',O
M<VAE970V.2YX;6Q02P$"% ,4    "  5-B1(#M.=9VX$  ! %@  &0
M        @ %0U0  >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0
M   ( !4V)$CINU+XU0$  -L$   9              "  ?79  !X;"]W;W)K
M<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ %38D2'2*TCR\ 0  3 0
M !D              ( ! =P  'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q0
M2P$"% ,4    "  5-B1(G,YMSKP!  !,!   &0              @ 'TW0
M>&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( !4V)$A0 ;60
MNP$  $P$   9              "  >??  !X;"]W;W)K<VAE971S+W-H965T
M-S0N>&UL4$L! A0#%     @ %38D2#ME']&B 0  L0,  !D
M ( !V>$  'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    "  5
M-B1(::>@&+H!  !,!   &0              @ &RXP  >&PO=V]R:W-H965T
M<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( !4V)$B$J9DZH $  +$#   9
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M970X,2YX;6Q02P$"% ,4    "  5-B1($G2_[<P!  #5!   &0
M    @ %O[P  >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    (
M !4V)$A\1'3!H0$  +$#   9              "  7+Q  !X;"]W;W)K<VAE
M971S+W-H965T.#,N>&UL4$L! A0#%     @ %38D2&MG%1^] 0  3 0  !D
M             ( !2O,  'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q02P$"
M% ,4    "  5-B1(DUB :]P!  !>!0  &0              @ $^]0  >&PO
M=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( !4V)$A1$>?0 @(
M *8%   9              "  5'W  !X;"]W;W)K<VAE971S+W-H965T.#8N
M>&UL4$L! A0#%     @ %38D2"MV':0G @  TP8  !D              ( !
MBOD  'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q02P$"% ,4    "  5-B1(
M=#D;5/8!   7!0  &0              @ 'H^P  >&PO=V]R:W-H965T<R]S
M:&5E=#@X+GAM;%!+ 0(4 Q0    ( !4V)$CZ[5-T"0,  /H+   9
M      "  17^  !X;"]W;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#%
M  @ %38D2&Z;DWND @  O D  !D              ( !50$! 'AL+W=O<FMS
M:&5E=',O<VAE970Y,"YX;6Q02P$"% ,4    "  5-B1(]?)",*X!   ]!
M&0              @ $P! $ >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+
M 0(4 Q0    ( !4V)$A/68/200(  ,<'   9              "  14& 0!X
M;"]W;W)K<VAE971S+W-H965T.3(N>&UL4$L! A0#%     @ %38D2-*3L*(B
M @  VP8  !D              ( !C0@! 'AL+W=O<FMS:&5E=',O<VAE970Y
M,RYX;6Q02P$"% ,4    "  5-B1((@6FV@0$  #X$P  &0
M@ 'F"@$ >&PO=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    ( !4V
M)$B*X>91@ (  (4)   9              "  2$/ 0!X;"]W;W)K<VAE971S
M+W-H965T.34N>&UL4$L! A0#%     @ %38D2-V\>99' P  # X  !D
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M=#$P,"YX;6Q02P$"% ,4    "  5-B1(JS+7/S.:   3@P( %
M    @ %I'P$ >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P4&     &T ;0#N'0
&SKD!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.1.900</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>229</ContextCount>
  <ElementCount>303</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>78</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100100 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/StatementBalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100105 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100200 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/StatementStatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100300 - Statement - CONVERTIBLE REDEEMABLE PREFERRED STOCK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/StatementConvertibleRedeemablePreferredStock</Role>
      <ShortName>CONVERTIBLE REDEEMABLE PREFERRED STOCK</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100305 - Statement - CONVERTIBLE REDEEMABLE PREFERRED STOCK (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/StatementConvertibleRedeemablePreferredStockParenthetical</Role>
      <ShortName>CONVERTIBLE REDEEMABLE PREFERRED STOCK (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100400 - Statement - SHAREHOLDERS' DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/StatementShareholdersDeficit</Role>
      <ShortName>SHAREHOLDERS' DEFICIT</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100500 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100505 - Statement - STATEMENTS OF CASH FLOWS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/StatementStatementsOfCashFlowsParenthetical</Role>
      <ShortName>STATEMENTS OF CASH FLOWS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>110101 - Disclosure - NATURE OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureNatureOfBusiness</Role>
      <ShortName>NATURE OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>110201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>110301 - Disclosure - NET LOSS PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShare</Role>
      <ShortName>NET LOSS PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>110401 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>110501 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>110601 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>110701 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>110801 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureDebt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>110901 - Disclosure - WARRANTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureWarrants</Role>
      <ShortName>WARRANTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>111001 - Disclosure - EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureEquity</Role>
      <ShortName>EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>111101 - Disclosure - STOCK BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>STOCK BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>111201 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>111301 - Disclosure - EMPLOYEE BENEFITS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureEmployeeBenefits</Role>
      <ShortName>EMPLOYEE BENEFITS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>111401 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>120202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>130203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>130303 - Disclosure - NET LOSS PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareTables</Role>
      <ShortName>NET LOSS PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>130403 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>130503 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130603 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>130703 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>130803 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureDebtTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureDebt</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>131003 - Disclosure - EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureEquityTables</Role>
      <ShortName>EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>131103 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>131203 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>140101 - Disclosure - NATURE OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureNatureOfBusinessDetails</Role>
      <ShortName>NATURE OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureNatureOfBusiness</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>140102 - Disclosure - NATURE OF BUSINESS (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureNatureOfBusinessDetails2</Role>
      <ShortName>NATURE OF BUSINESS (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureNatureOfBusiness</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>140201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>140202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>140203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails3</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>140204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails4</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>140205 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails5</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>140301 - Disclosure - NET LOSS PER COMMON SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails</Role>
      <ShortName>NET LOSS PER COMMON SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>140302 - Disclosure - NET LOSS PER COMMON SHARE (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails2</Role>
      <ShortName>NET LOSS PER COMMON SHARE (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>140303 - Disclosure - NET LOSS PER COMMON SHARE (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails3</Role>
      <ShortName>NET LOSS PER COMMON SHARE (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>140401 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>140501 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosurePropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>140601 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>140701 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>140702 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetails2</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>140801 - Disclosure - DEBT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureDebtDetails</Role>
      <ShortName>DEBT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureDebtTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>140802 - Disclosure - DEBT (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureDebtDetails2</Role>
      <ShortName>DEBT (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureDebtTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>140803 - Disclosure - DEBT (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureDebtDetails3</Role>
      <ShortName>DEBT (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureDebtTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>140901 - Disclosure - WARRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureWarrantsDetails</Role>
      <ShortName>WARRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureWarrants</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>141001 - Disclosure - EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureEquityDetails</Role>
      <ShortName>EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureEquityTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>141002 - Disclosure - EQUITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureEquityDetails2</Role>
      <ShortName>EQUITY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureEquityTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>141003 - Disclosure - EQUITY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureEquityDetails3</Role>
      <ShortName>EQUITY (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureEquityTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>141101 - Disclosure - STOCK-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>141102 - Disclosure - STOCK-BASED COMPENSATION (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails2</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>141103 - Disclosure - STOCK-BASED COMPENSATION (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails3</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>141104 - Disclosure - STOCK-BASED COMPENSATION (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails4</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>141105 - Disclosure - STOCK-BASED COMPENSATION (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails5</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>141201 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>141202 - Disclosure - INCOME TAXES (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureIncomeTaxesDetails2</Role>
      <ShortName>INCOME TAXES (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>141203 - Disclosure - INCOME TAXES (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureIncomeTaxesDetails3</Role>
      <ShortName>INCOME TAXES (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>141301 - Disclosure - EMPLOYEE BENEFITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureEmployeeBenefitsDetails</Role>
      <ShortName>EMPLOYEE BENEFITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureEmployeeBenefits</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>141401 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureSubsequentEventsUnauditedDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.collegiumpharma.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>200100 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/StatementBalanceSheetsQuarterEnd</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>200105 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/StatementBalanceSheetsParentheticalQuarterEnd</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>200200 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/StatementStatementsOfOperationsQuarterEnd</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>200300 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/StatementStatementsOfCashFlowsQuarterEnd</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>200305 - Statement - STATEMENTS OF CASH FLOWS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/StatementStatementsOfCashFlowsParentheticalQuarterEnd</Role>
      <ShortName>STATEMENTS OF CASH FLOWS (Parenthetical)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>210101 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureNatureOfBusinessQuarterEnd</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>210201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesQuarterEnd</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>210301 - Disclosure - Net Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareQuarterEnd</Role>
      <ShortName>Net Loss per Common Share</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>210401 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureFairValueOfFinancialInstrumentsQuarterEnd</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>210501 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureAccruedExpensesQuarterEnd</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>210601 - Disclosure - Convertible Bridge Note with Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureConvertibleBridgeNoteWithRelatedPartyQuarterEnd</Role>
      <ShortName>Convertible Bridge Note with Related Party</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>210701 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureConvertiblePreferredStockQuarterEnd</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>210801 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationQuarterEnd</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>210901 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesQuarterEnd</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>220202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesQuarterEnd</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>230303 - Disclosure - Net Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareTablesQuarterEnd</Role>
      <ShortName>Net Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>230403 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureFairValueOfFinancialInstrumentsTablesQuarterEnd</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>230503 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureAccruedExpensesTablesQuarterEnd</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>230803 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationTablesQuarterEnd</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>240101 - Disclosure - Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureNatureOfBusinessDetailsQuarterEnd</Role>
      <ShortName>Nature of Business (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>240201 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailsQuarterEnd</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>240202 - Disclosure - Summary of Significant Accounting Policies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2QuarterEnd</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 2)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>240301 - Disclosure - Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetailsQuarterEnd</Role>
      <ShortName>Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>240302 - Disclosure - Net Loss Per Common Share (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureNetLossPerCommonShareDetails2QuarterEnd</Role>
      <ShortName>Net Loss Per Common Share (Details 2)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>240401 - Disclosure - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureFairValueOfFinancialInstrumentsDetailsQuarterEnd</Role>
      <ShortName>Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>240501 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureAccruedExpensesDetailsQuarterEnd</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>240601 - Disclosure - Convertible Bridge Note with Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureConvertibleBridgeNoteWithRelatedPartyDetailsQuarterEnd</Role>
      <ShortName>Convertible Bridge Note with Related Party (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>240701 - Disclosure - Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureConvertiblePreferredStockDetailsQuarterEnd</Role>
      <ShortName>Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>240801 - Disclosure - Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetailsQuarterEnd</Role>
      <ShortName>Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>240802 - Disclosure - Stock-based Compensation (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails2QuarterEnd</Role>
      <ShortName>Stock-based Compensation (Details 2)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>240803 - Disclosure - Stock-based Compensation (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails3QuarterEnd</Role>
      <ShortName>Stock-based Compensation (Details 3)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>240804 - Disclosure - Stock-based Compensation (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureStockBasedCompensationDetails4QuarterEnd</Role>
      <ShortName>Stock-based Compensation (Details 4)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>240901 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetailsQuarterEnd</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="coll-20160104.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>240902 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.collegiumpharma.com/role/DisclosureCommitmentsAndContingenciesDetails2QuarterEnd</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>coll-20160104.xml</File>
    <File>coll-20160104.xsd</File>
    <File>coll-20160104_cal.xml</File>
    <File>coll-20160104_def.xml</File>
    <File>coll-20160104_lab.xml</File>
    <File>coll-20160104_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>148
<FILENAME>0001047469-16-009501-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001047469-16-009501-xbrl.zip
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M,-[<B4@(Q*K)-SOG!D9NM2BP6PGFZS4EF.^B*Z?PU?QVG8[!-7\<M:O/:Q&
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M'0BZ#58(Y90TD2"O@!_<J%Q6#C1E3&(B V%*M3^]W$[JOFO[MSX$/S OC%!
M^@P/!-8K]Q+;/)Q7HX!#Q,0S%VW[H3)S.]9Z?^@)BXWC<8SY]#FW-2WJ\,>+
M#":?3(^SF<D[3C.0REHB(@E-7@A$;"Y4H9"V&:$)BL);&W&*4CVRNZ=Z;NV-
ME@\]9P><D+]^CF.P=_[R=MG+[WTVK@0RAO9;?A#\%M]C>7.>?OMQ;8=Y+^\+
M4"[^44PN<X0[L<.\85O?WWL3RSS0XO[1_9/[7>K%:H]CU>/8_3D.XY\S)-*:
MY4\4!YR/4Q+->SA1(TMS%TL2B8EH<6";*F(/QNL]TKY&MV7"WWIAD*DX',?E
M$RN;)WOG%@$OP(!P[Q32)$ F$L&F> T1D-G*)ON1A$/K0?&7048;:-:!J-(H
M34DN478I(1XE1P:#>=*.YND/V!'3Z;![78_XD1-5TFXT;<)6RA?GYIEE<Y"H
M2#Q)B-2IBXA+:_*\!9'[7&@4#(37;3('&^8)/E?8[E\OR$>J:[C2#Q&[/6M^
M'PW #&6CN)Q=.:-4Q#H@EEL-N3 1.0Q&AH"7#@9'S53S%C/M.;9I0B5MQ\1E
MMJQAY\=J#%BU_!QD_/=P! ZI_#Y+WJZG$_ JP(KL\JI=/OBO:9DSO-?@C<8?
M(,FK'O!WB$#R3MK[H1],P0N^']Z.UZIM>864%,9I-O6.$R(AS28>::L]3H(X
MTG+TVXL7A^53(K-D8_?&V)W*4S5>HWXV(QG'AG'D69YEK'U FMOL7KW6>90B
MI^W:/WO962Z^E+L4GAD7=RHHF4 U.?&2>B6E0U;P/%Y3\-P5*9'P$N=18P2+
M]NVOO9PLCN?%+N6D8N)C(T$&H5X*0:-(B<U5X@H9CC4*-'GEM)#.NXV1X%V-
MW;8'N&ROK.A0$2/_*/<:,!J+&<5@X:4,.;6W%))\15&>H09IOPC,=@@8>\9V
M#2S9%@/+!Q4W4N4IAO18>IE'C('B.DB.40J&0,*L>'";=N_VR]\ZPO#1\_?7
M"_%1[#?34RH1KP2XR8RNI(U'1FF# L;21@J:+)OK#0ZNN"?%V'6**YM\<T?%
MO4/GF=4=-8/EW 'Q5K@XXZ^CR6PS^O;S7+'X:33Y1YQDQ_]MF&'AZ\,;:MN.
MS AC%' XM[)S#F)CJ<'(6H$#U3;_\^AJJQV,(.++AQY[H=;>YT)%I>#_6B+*
M,*BQTQ@Y;C&2 INJX2Z8HV(*(>J938;B,5H:#,M]:CC7UN$\)%JAY*R6*5'L
M2'-!0JMYR;N8#$6I488\W\E0+DEE\MANKG,UM10"Z<0((D)[S5QT0G<8$;GO
MR5!D&\".3YD,M3M#>7>GV9=6P2;K.N6]2MYEQ##@H' Z8V(Q1*DUC'IB\9HA
M1FW*OY\,J7^O!?9@%#OXQ J1,O1&C,B'D#*R3<8G=+FSBW+IDQ*0W3]^&N0V
M)E80P?1>H%)/:& %F$2NK(9X0>0:.N)";GFT*"@<!/<R*M*\Y]9B^O<.!E9L
M8Q3/S@96'(&US#NEEF&/E,6Y)\MZL);<@].SS/L0&36/1Z78@K54K+>6,Q@C
MBID3.6^2L@I,'#+&0Z@((8I/4IMH6TX7V!ZG5B:."6JV,3/T.5E+0@QX.1D1
M<[EL,M>(:"O![D4>+7Q"HFBN&N\<3O;6\M&Z/T/X?3<JYW_*U]51Q3-H"*]V
MNV(NMXP661]R:*FQ3,3'M 20M9M!'C__>D$_$OIV#Z:PD1R'!OJ7AD3*+<NM
MG."G;.Y?5"3C! $OK+ )%&K?PU4VS;K<CRH=PZR4#M;0&^,TE3;/:. 9O(&!
M)JF %#>,6\Z473/_O6'?>.LLW)17TP.,,SJ:X6>_5P;DODI:3+FPAJ#(3>Z@
MY0E44@,WP5QJCJV0MKF4]! J*;#2>YETLTRMP_"H@TI*R1DAX-(((1CQQ!4D
MX50B<'A21Q-5%,WQ_V%5<E^C"#O2]3@"%JT5)]$YX*11N5<G(">30@%#I**=
MX9S+;00LW78P?[T@_SCQZ&7C\!D=+!%2Y*(UDYV;<O GZ5&0QKJ(2<*)'X+J
M)SM*QDCIDK4$$1X<F"8CD#4F(>H)$%<E(I=.F?<GQOL:#/.8VY[?'@%76_2Y
M,FO%:'V.5[885G SLZZ=Z:R'I";)W#MPY-B@0&,FO%7(VJKUCV=X8**X>R0
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M4 C".Q6XU?SQTR6/G*[J09<&I'J,L-ID9#16HNRN(&:/&9(=H@4(R8ST-HI
M'M^X=^1$-6(U4MB:K%IN@%X\(&.!F)QZ("OQN:")IZ YL1#X/5>R$O%48:U,
M[Y?K,MIP/JS;Y-KVKC4,Y)8J1*0%"@>(#2SS$$+%:#P3@H"YV,JNQI%0N[O?
M6XO&3*E8)_3K*?]4?A%1@:I@Y$.>R6F!52YABF3 D87 !.$=#IV/']GP^/BU
M&/=T7A;?0!L'^:\S\U9C%).,JMQ0SZF#'Q9"2TV!Q#%/P03%$F[-]GL3$M(,
M/74QHP/+)3XM7NGUS7\/BW]/8RT<:YQG=5&.KHKQ>%3>5)27K_ <0OSM-'[*
M,+8921L>MHK?$ =V/DGB)H,CC*UO>D1%G+3^<>\A,>@^J6O-P\>O;^J?K(QT
MR=5JHW++LRR:!K(MB]9&(=DD4W-BY K'6^&<[<K.=FMK N:)#8J Z@M-=)X_
MFZ?,BPRHSH,73"85.EB"7L*V*V$M 4S>/@A@\A0Y7:D3(1+^4>L$]2')6Y;:
M.ANJ5U\CI59ZXQ3UR$%8@;AF%!GM) H\>B8C<=0W(THU2BE=C)VM?J5F 4VS
M^D(M!+5V]3(?LOC,&&3;#0]\@,UG37=9WZRBN>12U<X?-E-[E3-W@P'?V.MB
M8@>SBS-^=OD]YD+<=]-<WW,[2[ ^4H 1+:C,/LL LY)$.FJ"E,-*>8Z9U\VG
M-:WZOQ_/H9K^+I3Z/L=J*]\FGM#Z*AXI-.-+;.I(^JUQSN(8%!,2"99K$7,+
MC\/:HH UM=8*KDGSA+WGPKG7G3A'%:.<,G4,K'-1)T(8 6-F,^MD=;AOD"%)
M"JIB%+QET\Z)LJZS<320^9OML:X)T^SNW#(#9A:3;!IRPA->W_QF_>7RM34M
MC#K0Y#C*[8^(&\:0#58B2*BMBPP'8UO6)#:-QWD ?*U&AODE6YJ;LY6#8D+!
M!M5X]E2B[XR'X.:<CQ8H[S($%Y$,:08!,6@AY<[*('%SWM:JJW_+/-R0;F^'
M:ZJ>,Q\OTXR55%B(692W%O&0&\(93RA(SBGFRF#: ;BF*]AP4Z XO_@A^DJM
MV"D0V#MG$Q$61<W!20D)D:%."E%MF=8L<(L[Q!?W8O>G$G@W6<#\$6N3@78\
M9DQQN5\>+U7 W7TXGG\ZKF\B! /L@(@_0X1"V"\P<I2 XB2/E=5,V]0:7.W
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M-^]K5[>&".5R5!;_LQ3(24C7-86,7:I\?&XIR)80*+*0N%!),]NRV6"7Q'H
MAO6!U;8@S2P)J=GUZ( 6D&\Y%_(43B4SOIQ!T?GHE:)Z7??A@<F"L7Z ++.5
MMB!)S6/6[%$P)CIG\A8W)*,^6J2]C\@;II0VU-+4LG;MV.A26^Y3 @(N1))>
M,!1X+E5/*N9L/<(J'4M2.*=XW'E \! V[O+A":$KQ6+["0BH,3)*@E&@&08W
M>8,TS2 !$@(%" <,70-G?SA*,;Q^3V]/ 0'S21NA.5(Q5W\PK#-T64)@Q?/8
M+"7DFL:CXY6OG0<$1A K;7! LUQP2WA&.><8):VH8EQ"4- )5VSG1#MD0. ,
M-8I8DL$,\K#5# E/F87HR24,1MZLFS^]5V(]A.Z]_8B 8F.$81*1RK#G1@E+
MP68Y@B$B-UHDMX>H<B=T>5I($'V D)\&"+(CV''.%:3 CH+6*8^9 WEA>PB5
M=D*8+<4$R48K&0%92; X'HQ"AD FEZ>V.!)EY%;O/";HN&VO-#E 3"!3M-KX
MA PV>?P;Q)@V(Z)&EO-@>">;'C^J<">4RLV^AXX)E,^0'D0@HG),(#)N9G9R
M5)*H$]9>KAD1=KSRM?.8@$HK<=! LSST!,QYQK>6N;*/B: \<9*V+-'9$]$.
M&1,(+YEEH)%>YV-]F0V8HQK^4Q,1O0@Q["$F>.K8B.W'!(8KS0*8*UJ-8*?.
M(A-(1)*HA%6,GODC$*)ENAC**&,/;9X\+23 "G([Y3W$!L)E)!&5QZ1*Y)7R
MEG''G>T ^'9,=+D7$3S%VS&@0# .XB6<IR\IYI#FF"(G(M81;+D7[4[VF["9
MGJVW\]Q3'T'+M,BM4LEG!'M([C!C-NC (^FP;["O(@BE#NKME(B:<!LAFLKC
M,C38;F=RH7*@H*'!61D[Q.A[(-I!,V"0J6!AE6#$(*%1@N:AN1D8/@2;*Z?X
MFMZFO1+K -XN>JM($LACJ2',M!G2@6@DC/<X@\* _AT;7?;A[?*\5QN!+@GG
MJE0)2[,I[VLZPW32T4.J>9IT:>?M+G.AP/O;D_?Q'V4QF<0\77(<,QSDXXH<
MF$TX06J,P-]D)30<Z>!!$XF@((A$8WM<10Y=3B;NRAKD&D^Z19+NG7%2>JFY
MJUI$P=5X@K04N;0.&$DC9!"FN4;[L(QKMW_TG!GGA" V,(L(R2C-V("RI>C!
MC!$2O*&8VN:CO<,RKENQY&$9UQ07YV;QVS]OJ *61-A(LP%TN4LEHPT;CCT2
M.*9DF'1BS52'QW;];K,FQ,CU!8R=:;)!+Q;59?4:S&)IXBT307(!V8/+#;^"
ML5RZ!=:*0IP7.1.&;0=<<?=U(N:5,&ND>2TAUA.OMJ,[P\N^G6->!4?5E^_G
M%<*H1*R.*.)<!DRC@:PL*12Y#5Y(&I7LT.AVI-3L0)D.Y+W]RN(F54UVC;94
M2!6(1$%%BCBA#M(U;3),JY<&/K6AV9'B@U"V;F=)2T*NH<%Z*LZ^]G7TVR#Z
MR=NBA)^C<GQ;E'OWAUKB:SG3N2^72LAYN8\,B*@(\IHXFS37O.V UCV1L2I1
M#O.%K*5D2SJL]A/5GWQK;#_GIN&&<$!3*Z05&-EL+7E(/D]&LRC%Q"S/=71=
M,.'V+(#X5;W>I\W"=^*TF3.&<Z'!:3M(8AS)0[I!#IE,TG*EB3#M:EZW1,).
M=1M$SY'(C\!K2YL;#S**/=-Y0QGR;,.8 5UFUGEE0I0MVTWV3\D5/R->Z77[
MIWOSVECP7,N E%8&5+L22T/@!W>)*A^5QB=/S0-Y;2 >!$ .DMZ8CX1";@@(
M*0/*$$Z,-@R[N$>OW26MI;ORVFN[-!ZDIK+2:A%#!HL%]TV81X[&A"#:](R&
MY)QJ!?9_/-3L2HLMQD+""P/$<Q"BDPJ(UR+C!$61YC">!>)ILV@>2NV/)A;B
M1E)PXQH1)W*I:LB4JTIYJ%7"VQC6A.*'HMP1QD(>"V)24(AIG8<D.8J<(PPQ
M%303%+*:-2Y\1[%0IQ,\@==W NTY%'**Y*ZR@)C/\T\L!Y/(E$)!\#S[Q$1)
M]IMR/_Y43[_BZ[;C]A4*!2<DV#^"J,(6<<$U@KP&HDOEG1169P=^\M0\4"AD
ML,6&!Y^!"_+F$$1!+D=&DGIP-R*D1)HK9G?CO+ML%!_/!H:.F%D%P0^0TF<$
M.H:L4N"$K"&.!H+CF@; 0PGHBM->$P;MP6F#RX;XD%7'3QAQ1N2LOX02+"SD
MWDFF_68YW4XJ,!='X+7!""9(72**-H#08<R0L1Y2Q3R'2-!<D]NNV.8!=-W=
MM*+2O1P[U%!,6J%8@=]F D=09!% ,&VN.JTFRP5CG(H)PLL./F</1%W33K<U
M#+<Y@,+\!=> 3$5PTQXGCG0%8!1DR.#8 B5("E.TWI,U-:C'((D5?F5-G3>L
M>)OXE"D022&^1E2H#-4"*FR3=TA)2R!,],JT+# \D/:RC8WDK8BQ$ZNH?,B5
M]0I%P@-$C>">'3<8/'.2TA"(:]16T-I/>E_W"?3EE%'NJ4.LJC3CPB%'4T2$
M46I!IFU<,[MX1_3ME"L:M1>OLW)A,V)6':C$\&3SL!@19 :2</D$'".60L*>
M6&S7%.\= TDWHXBUHL0^D-JH,XKRO+N1VW(YY^#8@43(":R324[JV+Q-=/PT
M?BJ1GDC^6?Q0B^VE9HQ[C4)2#'%M0)H)1/DNY"H9I9GA';8R]T#JANI+_A12
MSPA2HVJ[;RU@%7-E$]B?<C[!P,?B>PSGPQHT]-=+>$)&%JL9$0V)N[$)*$1
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M3-YF58B 6DBCC-*\Y7'>[DB_3&[&"96ZMB'8>?7+Q+O3UMG$HF86?AI5 R"
M$7E%XZ\C>$K]\[Q=\6DT^4><S&<=_<_<B<[75,/^8X8F#.$PU1RB8\X4RC!2
M2%CFF9.2!_GX!O6MB_K/OU*RO%^S%W*M@!DWCIJZKU5NC5;-9R7E'L+WPTE9
M0(SA*RVJP1Y+XR+U.$^WT;FABUID-):("NH)Y(G.X_;]IWM@BU#+L-V[HU$#
M+YY@X6K/F9UPU,_(M!)!01Q-")BB9 32QD!\I6QPRE#M><OZU'V9(D()PWR%
M"=LDSLYHO^)7;J>)K9RO0PPK$G4<24X]X@139'+=45161Y4!D$QS:GD47IGI
MG7!F$^FVRZ]:'+"LD[7S$X.-S'$MQKE1B0@(;C/.@+;>)N.U-;[Y8.] 9@N<
MB;AOMW9!HYVQ8M5LY:X/F4*>LFDS"US% @D1%(?X21"CVG;1[,ML40V:;';"
M@UV8K?7A\!JS14+R.D),2[C'&13<5&>W*)*88=HI,*QY?_<(S!9^)7?#F?V9
MK5D2 ]3(<UGS[/FOH_RGF@D]^_:MC-\@$5UGUEC&QP;%0D)GL^9EGM6207:X
MQBH$ PK6[E!I7V:-&K95L_9H&NZ;E:O6T%J+*>,,$1ERJXR%D,%F>%S+ Z6.
M*;IFRL[AK"%7A&U1Y]K2;-^<:F<[O30T" ]<B^##N#,,?I,4$8@TG/)!X=@*
M:^ PME.S??+Q89.ZE4VA\\EE+-\/?1GA@O';./_E_7!VQE_?2J\5<T81C1+
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ML[2^>G,2O8\A<__0K]QQ3,DC%#.@3Y. %,0D]GB8%@DQ)+O%2B]X+%IIIB&
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M<>7)_H9Q4S6J @_$'722SGJ&ZW+#U-VAZ>@V,Y@^9 -3-VUF6:8U=+SA\)]
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M1,9KR]HZ$%VC1/MK-<SQJOTVNYH#>7!0AS7@'*I[V&5P8:OV_S "!II+5"+
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M!546(Y@@EET)\8X% <0:0%Q86E(^%M6MUQHH,:?$<IHE=TM5*.H0NC,]%@6
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MXP!XDMQ39C'>8"*G7/%\(8ZN?"AP6:@!=X/)- P:&Z=.D^/5#XLFLM9@^7#
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M;I;#(.OJ12H6 O<$9A7@@H)A1Z!=">2QHZ7QA"]12>*B/XAT^%V?Q!&'!=:
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M^ASBML(-<Z^*%14<E6#4?BDT)87O4!;>:S? 7*#;]R68-<)%MXJ[[(W_.P_
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M<L\;=GF_5O[9 THF+$S__L9>J1:TED>!>.#[* D#?9HG_,U/W2,\/*O1M_+
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M3S@)8GI>.RHIZ?2X[0Q\UX)I[,%^":90'\(F6^_ST8A[=K?OF.X6Z#0MJ_<
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M2G J(.4@H/_?'-[];R*MJ!O:?QN=?^:#&.1?QIR'2Z2.Q1@&RJB!&&@$IQT
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M9W* HU;FL@E=UEFKH>]_./F+&AH5 ?#&727,CU@\<@Q_^(.1HAR=SR@8QMY
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MS96CMXMR02; %<[3EC3]A/M&X(4%0;UG(+P=;FA6CD<SQI=<B1C%HY&R;+X
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M_S-Z^^;]Z9=?WOS$90L7_^7KZ%-^HD!7PO,,2\[EK98\6LG7C-]1B^N>6E+
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M@[Z!C.8+#AW,E;T0%W4L1=6"6^8<+TH)^5HW6AWDK7K@"+K":U>+\Z1GHJ)
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ML86%)=2#GY@7&C9U7 ($>R3812U USX,7WJ'9 DLA54HGUF%4'^9?L(&UZ7
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MIBCHJZ",%$43)&;(4FJ83H0P*2#QL1T ]\&ACRU0-,F*PNJ![LJZ$H$65,J
M5:\D<[4W%E,G 5L-X2E8:_@OYF"X9AHF]:+83H%2UI]U>Y0W%MAFITEES2(?
MH$:49"J4F$Z*($D&2YT4H9;AF"1N:,0H3JX31V"EMT<)^)2^K<*WK%C? T0H
MA1M*LY1OI@$65<=^BK!7)OK\.' +N1?Y<1#9_4[DCBA1%KF2G*[.\DB<LM0W
MB$.PO-.B>,5N&PEXQ&:4$"=@V[MB7R50/;KIC-WE938O5UF,*++#V'2-%*\8
M7 8!2NACNWM$/?B53T"VMGB1WKWSZEE;!^A(7B%]%N,&USE[;FRR.,#I92Y#
M4L!KC7C[ON^'0 =$D^;6K(;?H>3!92Y!@:R&I+9=QPZ98QH.P<O(!#1Q2!VL
MW4AMCSF![;E;*SFQS"5TCW[TZ>8#%6Y$?]1@V:D?1A3B/QLA:,P8G(\H2 S?
M]Q@-T<_;WC$(NFOO6UHG;]V'*&/1F! SM8S4PIKDV$*,:XC/G3 UL:(IL9SM
M10F!TX&%7(D7H_P!JV84W&81QRL9R,BBH&&(P/!RT;C%-(J,U,3N9_"<$G-W
M[NE#RUQ)U)+L.)Z5,--&A E,* +OC9B'.0PBJR!(;!IM+7UEF=W4ST-GEO<@
MKA)[0EUB.DYL>!"B2>2EU$QXB43L>L2G=&LWF%:W3*QG9?VW->H'E=N)-(4(
MAL0&.$"@/*,@@+5CVV<26HP%#OQY:\D,/^P P_8MK8.[H#3O2O7*46)AF\0H
MZXS195L0N)YM@QO!+#@6;@QA<^C1R,!KB-C%1O.!O9Z#3D3'P]M@Q7UIZ8?3
M&C3RF.^ O?;0.7<M3%$3#_/4+/"ME('KM#5+U]%6ZY>X+EO=!H1:HLFT S.*
M00G[#&G"F:LQB(K!?"M)?&99X<#.IR$[9G>SO@\N=& NNX7AD,(N61[&K1;(
MGQND.#47U ,E5N0%<-"2@3@H0TCJ0,JM6^%2]_2\R+"GK3_R12SF)2L/[CH+
M70K>;>A@*S6X*"&E!C4]*P+E!\=\:[G!L'VXAB^W2V9[UDNK>CK-DJP%<>71
MP 9MSH*$(?@&3HD$0Q0F/O&=P(O#[3D$P$LKZ%P#/;S6GH;#E;Y!X#$@ 2?
MH3?I0H1BIBDX_F!M YM0/]S:==;_S][;-[>-(_O"_T_5? =>GYU[DBK1R_>7
MS)FM<F(GZWL3V]=V9O8\_VR! &CS#$5J22J)]],_W0 I41+U9DNR9&/JG(TL
MD0"ZT>AN -V_QO#;J<JPR_R!VT* 6C[44=ORB$4 5K;\ N99%IX0!E& )Y\F
MGK9'L$6DAN]04%"<;DS:)B=B_NB>>FE"+.+Y 0P$H0CP$]BE2!SM^KX/&S!S
M=<VP+ '0VI-+$\Y\&K+0TBTO!J5ANPZX3:)P<6CXIF6$_AKNW3*B6Y4M-G%I
M(AH: 1U.<JR=#1)&;D!MG<=8UA)'0YB)82ZA8\5F:,#6;E,4>FZKOLF<D:UW
MX8/A"WZ,J)*FL, "X(1Y>N03TXA<US?IZC=Y2T'>IKSO#5WXD)@YEH%'JP$:
M)H*>D0>;.L9!#=H>L]?9.R]-FC9G$G(V>N'C@]X+7% 2 9[#,A,QFL$HV3&Q
MP3?G4<@V1XO51<EJ]ST;3ZKR#9O$%E@K*\+ 988@%ICS:C*0>9>$H#Q7=]Z7
MP6*:,Y=V6TBJ6GHGYD6&'YG<TCD&;(.RL!!OR,"C7#, [4AMOC'=B$U,">YC
M[L0<T!(1;A9#V\7J#!PT1>1A]7/#,CQPE\QP]4.')4,.C:E+FC7NQ (SCGTG
M<F&?BZEI#FQT Q80].A@T)%/?7?U.[$EXPPLS^P89_>=V"J71HS:E@\C!2_1
M T<!=@YZZ 48=P 2X9@&AA&N?FFT>/1/NC0BD<-L+#W"D-6."WT1-_;T&+:I
M7@ &/W*ZMZ2=)_CKE.C8R:41;-L<&\\Q0PMAS3!*F]AQJ!/+=D./69P8W>MS
M1?)V=VE$&+$-,\:D.<Q?M_%NU0P#/2*&!ZN!^?:<K)!'41)Z5N@MHN/Q=T91
M',9>[ 2Z)ZB)0/:(C67M/=@6X"DEIVO<XSV9D$=<&06>%S!N43#PN#6+*+J+
M""K$#<N-0C?TY]2W>92SLLZ5D7281[#TG:?FC/A>& 7 >HZWCPZ6D/ M5P>K
M$'$:\9CY&]O#3*?%SA_?>GF81A"[D6&:NNL''&ON@ PYAJ=SEP %-B'^BG7H
M5Z#!LD&1/ST/<^*$R0[-V,:[><ZQPI?AQWI$O4#W&:$!X6[LKX@E_N@Y:(]K
M$QFD(?-#"BX0$R6?0"-A)5:T)39LG@B-"=^84%FFO6Q"'IU!NFIJ);=MRT$$
M:9\@7EL8.NBO4)URP[>=D+K.'+OR&'J=*:.RN]1*RJP8;0O,+^*#TA"\,0]\
M&8,PO)8U0V_%$F6KK;,@6$SGTM3*\0LMU;+"SH5YH6_%& AON^ FD"C4 T<2
M"UXF<R.;K7YP^-CUN,J0UTPE=4T#<[MMS+<$-]0*8'N"Q+FQ2<T@#*EOKAZ3
MO719KI]*ND:4@ EZD1)FZ9YO!7@*!4X<[C M'B'8=<R<S6T'G*DPRC6C!!Z7
M(!N&OD'#P- -BH=K>. ;<8[0Y ;A0!-W^,8(?,8$65A2W YA'\<,##3P+03(
M=AS=YAZ+"+5=DV],)#>2(+LPYB.D#K$"C 8TL:J28X1Z9,,<!LPP;,L-B;TB
M@/DJKN!4[,K2F(].]\^W2.!B<@PXWN #6F"^0L^$#1^')66YL,+6"!Q:6BW=
MG334&XB9B$+*3$Q0P_1 ':T0GD93H"LT0LMV$!%X:\<7FXN9(#;(1L!BG5L8
MNR*1]2P;EH'-7#N$*5DC\&"99O;,8!X9ZX=,,!HR+^:F;L=8> #\5MSXN+H5
M^Z9)@LB-XM7CV9<)D#T==?"DB G'\?W0CFRLV0/F,&)8'2X(= J6D+D&Y199
M/7%[V3F_,Q5NLS1@8M4H C.BKN\[>$P>^S@!!J:?1XAI&T6(>>2PC6U^[*DJ
M"=N*(C ]%]'*39W&(9H\7]1/Y7K,/-^AIN<$]L:TD@@_>UH4P<)L/ANV #&U
M;3UTL*0G^BR!@R=L8>29I@MJ=HU$N*4+9%OI?";Q7.*%6$ (4Z5B3.<S8ZRP
MY[H.[%4C:TY%V\=8-L<(I^A8/9UOM9@.FU OPKL)T$] 3@@^9,18B.XCGG+:
M,?<V1HX73L_*-F,Z',.S(I.YNLM"/,&E#A@7@^F>92&>.O>"%0M6K').OON8
M#M#-'-8_TTGLBCMG1X\<L)L^<8EANQSL_<;(T\&3FP)MVF1(1P@]Q=R)]9!8
M://M&)<4>#*F8\?,B%P2;TPQZ%Y@32$5+0WI6#4OEI@QC3Q*==/&=&4_]/7
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M15I<@S[4B3HTA58SAAR2.$T2L@N;+AA"-4ND'C(2 P2V@C8'*;#[CF<(D8<
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M_'2/S8-5#RI[?HJ7*GM^<DS[D22L<J&5Q"B)>69\J$,#MV^?7"VX/,1WR^%
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MLI#YS>J<9>*65/(8@;"26K/!%YPD$=8OR2@T!P,MJV(HE0,E8)UGE/"P;*B
MED%!R 4O^2AU%A6,!8W%";WO;!N;G!\^)+32@I/BXX7,.M <F$6>K (9'/-"
MY=RHG)N])D/EW*B<&Y5S\T(CVU7.C<JY>1W3HW)N7LA\J9R;_8RH4CDW>]3=
MH8;8'T!WBK6*M8?7W:&R=EU;J,*@#D$:%SH&*C5$,58Q]I"C<Q2#]\PJ[L<.
M4>7<['=W+R-P_@"Z4XQ6C%:,WC]&KVM6U6;S$&1SCSU+E1:BF'N8S-V_/9%B
M\(O)N7ERRL9_EC.F3,1_4_BY2$0^0XPU6Z>,X3A0O$X=$'D/1"N:Q!Y,ADA:
M*1%U''H3*RU"/Q9'\RY()^I*")K,'?I$DJS\G&.6R&5V]J."$0V3\AXCD"_C
M4QY5X_PA%GFV$WN&'D8.U1W+9WK$(Z8SD\'WU'.L.&[E#S&8GSY)R]^.='NE
M;")MF"7R@:3,'<OT]:\WIT=_"TW#,,:T+1WP%'T\XP5)3S)VPC#WHZP*$=E\
M]F/ ,XPZ;ZBSN 4D<4>/7,\#ZDRBDS@R=>H3CU$6A1$WMT"=:1J6/TG@XA%/
MDG>>@?SQ6_*#EU<D8:UD+^K'OD=-W>%NI#N,,#VT+:Z;!C.BR/%8&+A;(,>9
M(&5J=#-#+V!)\%,N_SW/3BC-A["NKLB#S#L8$0,"1PP:ZLSFL>YXW (9M C,
M36PB(3SF]C8DS[.FR5D\XA4(+(:<?6ZE<8UH="/'-WD(E'G4TIW XR!_U-"Y
M%1/7MUR+!=N0OP :7$KCU*"7D7G*!WF95&6[3.J(3LI(0%QFZX%!0#K=B.NA
MX?BZZ1BQ9=/(,!C; IVZ9=O+*.T8]S)2KPH^ ,D^K8NRU6L4UNXEAH#);,XQ
M[8[)@L!F'#Z@CJ&!J9, %(T7NU;L4\?Q7&,+M-MVL(3R5<CH9L5Y=CTJ*?4!
M[>.(6)O9D4,BJD<FP713TP,-%#DZ]QB+ PZ6P_*WH5"]3EJGQSE-3<6Q-)94
M6#7Y%WF6#S@JW^SN@K<,(0'YA44*1$6X5 EHV2"P(K <0*YA!"YSMJ&.="'
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M/4K>7?V_/GG!GSH0?<?0W9.\7]8KV%QN-- TU_*!97F6WQT#94H@[YHM!HK
MDT*&0B3$#EQ0RDX([!R$,7$YMZ4+7DW,O5T50?B+8W]P_7UH@L]'<4\<; !X
M5Y2IS%; +=4\%R S6:E&&''24X=)AX%&2&)P!'W/<0A+A$OLD%,6^C:/TO @
MCD=@TSWP\%2$OS!]!\MN&$)>E1GO:(^4.WXDA$\<3SK$#ZE'XL!-"0T<FZ:1
M&SC".["+X1Y]T65XBB[[7:*^__^^+*JJ);SD*4]X(DGBI:!&I&>3. 7ZA*X-
MX;P-CK<]'@>]V-MVXM /W/U1? 3-_:KKR_6J6K$<<[X3=9G;,8^1"S&F$Q,G
M"2"J84E(8A8+PAP>!3$3B4.C7=5UC'Z;NT=M_1D8[I?$VOW6 J.=Q@*_>I&A
M]"//=8/8)P($'QP3+DD41HQ(</EB+H+([3DF_QS*[P_Q'75']8Q4U7II1WV>
M>'XB;!J0B-LA\?W()2RU71)'$&5[@1LE?G)@?>X=1?$.VF6OA-CS(CR9P=FR
M B%$Y4[J""(AU &%P\ ?=[@@;A134/6,.>EXRG%_*^#81_XNWOG^R#"D?U&N
M4#A.9+(:.8"3>"SE:>R01 0!Q-1.2B(&S@>H!S<*)?5B*GY_!W#Z&W_VQL;?
M\^?3$[UW8AU?7OS'Z?7M&>XV_'A]=O+^U+JXO#VU?CZ[_<FZ/CV?WYZ>6%?S
MZ]M?U+[#EKK0Y32PMX-TEEL7Q:^JYESU:SV17'_ VMZ9M;J7%C(.RQ\M5>PJ
M!59&%A:#UR 2O5J7_!XXQYK?0=2&O&.]QG=>_5AFXDZJAZI7;RRV6!2?0'%:
M:5&J03.(^5@.LE.DUG?!#(MMX3=896"L589'>Y9E\0!/%>6CE>,HEIKUKBS6
M2WPTR[&=;%%69L*?BH60)<Z52$ :IFHJ.!G\J\HXK:7",E\_X CTR/[^R+J%
ME\V[0"RICT@!EDL&<,"L\&"'"$<6$ R@S,%>X%;,IVQUK_Y^ ^(AJW:KZF2
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M>XX6K%2F9!)8O(*_*FMV4 6)^H$!4RHY08E=YVPM,I1$X"N $,QF+<]L 5.
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M0P)!3 D6NX^K2 1CMDA(++&_4N!Y)$Y\#Y1A['B1PWQ*Q]L<O Q7QW<&N+;
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M) 8S">&!S8(@B*,D/81?"'YR.(40$_&91)O+^@335-J YY#Z?D+!;\2VF0R
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M6=T84=%8?Y<7*Y4WPE52L,)WO5'*[MI@V;J%9W70)!!T& !D/&+8K$%-^Y8
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M 1WG%]IH0;9@EW/J\D156XRO"0HHJ'(T,3+>J#C%64(%.79ZBS4U/)..EF
M :N[0[^AR''?J\<G3I>>^<"6Z4G$E:0T 5A,^*84#U+ ,AC>IYP>LN 3>';O
M4*B^LPG',4NQG]\WFY#T#D5Q?F(HI)$T];STA++-W',XBL_1P'SD36UL#U[;
M5O*1H!'8=G[D.]S&&;5P:IJF_8+%QPVFNB0V;MD.Y<E\)3A)W0J9JG4(^^Y[
MJ$@VZQO(_KOU7U;&:_VB&]=[0;MXMM<KDZH)ML2ICV1?7?]@0.CVD,OX:;."
MC(T#< KDE)/$=L13N',0-ZZ%X=,-@=LPH?IXNJ%07]0K]GOKM=1V%>TGJ:#&
M]8Q?V[O3VAZRAN[IW G6O(2K,@JS-K3UO90F0-6O4UJ=A^4[;.T,9C'LI$=6
MW"HOP_S]]L#LQ2[? R'FQO5 ^I'!_?5J48=2;H[OY"QJ+#]PY+ 5GO,^IGCM
MPVP%D@RSA)P[V-L/!BPZ?WIBJR^2>3*]#D/JQF]HJRJHJ3X,<> ._QXMHR'M
M^"V<>8A/SFDTX [.]#F,3N_C>:"PZ]\_-IQ+$<B%G/O@RC&.P6=VUS#$K<S$
M'!-F#*S@VDDQEC$_BQHZ<2QH"=^?\$ :Q]FA;W6#7UT;+=,BTN$4NF]79E-5
M;YXN.)Z>R=M><>WX\4X>_TM=OIDMAMY)AL_YJM#8>%FHYH650 G><\_]*3'W
MX'0]=VT[[-]0;0%P6*UG435U?H4JO<_-]GO]V(29?4>GMFDD-U7.U2#T]I4-
MS&R>W:0C5;@)9\E,]ST%P95IPEY,OA(VD:1Q6XB0F@L."2092:DT?P?;Z+BH
M%,A<JRZYL6HHUW)PG*)X"Q@SJ!,$\A84=@S&R,(9RXF?*;H&1;..J*VW+*6I
M7?N(%V^ S4(Y9L'/W82YED[2M*F&UR+0OSQXH#^C0?9D$<_ G/8D#2*G;5KS
M3H[J'I*?9^'K$8.CT7>$LP5><,Y,[S0AO8*,QMJ;Y6_UAC4/]D@'HSUJI71#
M=Q,E7%Q4R\7B5:MPXOSY]LEZL8!%CJ37(C>$5I39/./FS1)]AM@UF'\%&WUS
MM\]F"WIP3Q.]>[89U7G3/4 .]YQPO ?A)DPR\1WQ99+#JXMJW(B-6)F?H4*X
M=HPL_16/37F,K[./_Z9S-'9%"6F2H=TS"8\?24\G:1R"C^25;;R-GSQVN.(1
M[Z(96'X^>1>_AN.9[BBX7N9XI<R)'5A%S#<]"^I_S<[_S-8O_P]02P,$%
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M ),T7I1S@"2'+LJQ?3E//X//<?[G55BY]G#'+.S+B/Y"5+9%JM>$$QNC>I#
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M2T.,X%.G27HA/ET7?U-_CA$V  *E\3P#?G)1D"2;:R"'ON6OI$74X!6_?2%
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MWXP3K->'52\1L>5HWAP2F%C>KH,MQWC$,1YQC$>$??"="WQ:FR1)#8=(DB"
M>)Z="WQ6FR1)#8=(DB  >2YB)X3$U8-Y",NN(V$5!B?NA<0%=]C'>(FR% ;%
ML<-/B'4!9QVV:WN2:7C"WARP*R?KF= 'NRZ%F7P-X>;>[I+V9IQF IIE=Q#4
ML'*G3]G_XL0- M&//#V#E-Y6E^4@9ALP0MHV#M/NC#/YA:C_L%8^SUXIXR))
M%0@0C=/[!:+\!2?L\YAMAAWEG4I1^)2-I/ATO2^S28>=X=J#"_U9@$*MS=?/
MI^P;BT)E+LU*O0 ?Q)2\6*Z":(WY]V^C$&_^E2G_-/NT(IVH>5W;+N<>Q\#.
MEC3O#8@3=L&LS7HBGJ3)@IFQ_\355WR,:MC> Y@:7$H0\(\0]]+/$)W2S#KR
M_T!!BF>89H#TY,EK.DBB' SX\\ #5<Q#4TQ'W[:T@Z25 8!_4/1 \FF:Q D*
M?1(^F;)5JN(L9244X)\'?6!K<D017>>'KX;+G+:6*^QI@8!_#52(0#E+*FLX
M35R-V;+I2YX]DJ:?,?75G*:O[LS9\7N>A9G\CRAA0N1A4WF$G?AD0%D!.A<F
M&."_O[F7_PRM2(*"7)?N<(SI,_8O(WJ9)BG%?&[@[V/IC1'3=J#SVP):S=<T
M(<6-V7OA: P<L^Z4' /'QL"Q,7!L#!P; \?<#1SK/:?:F'*LX:(ZIAP#-/K'
ME&-CO.@8+]I?AB9I!J'&.9FT+=JV)[K+PJ2%ZDIT:/=YEVQC&%,3#3;#Y -C
M\^QN]GE%P@)I6=NS0ITT!5(0X,?[??H8$Y\@NKY'NTA'U8Y#7MX>AKTD?.HN
M/<RDCE$TJ&A_]&LI*FU[#2 -,PF(]M^7)$2A1\(G5OZC+HN)25W;L83&FE=)
M:6*"K<>(L\:<<7S> D]#W(:]PU8L\=A(4VM0>0C45B(A RD??D4=D%IHY;A)
M+0"U-5)/)5)>XD>ZR46GR/58OPU79]LZ&,%;;./]O?'^WBN]OR<XH'$#:0_W
M]]P KMB['-L5S;KINP5QZVX@=? )I#M^MTOAU2C\WD5&"N*+>]]NJ'8FGO*8
ML53"OL?E0%T..AORB>(->B'+=*GL\$H9RX:]0$&*/5X1%F*$S0WK,&V?E\L
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M9MWESL7TL_<>#A$S1DW,JG)9BVD%<C%^A/$*>\S\QKXZ[Y.\/" #2T1$.;^
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MC1?6QPOKXX7U\<*ZDR0Y=&$]%_B\-DF2&@Z1)$$@)LFV%T'X"K7:B"N7=<V
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MUW%.JW# W]M[P,M51!%=\ZRGR7KB>703R[1=0F2$&M5TA4XC, 9D?NGV4,%
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M#2C!Z^:$8_-S_C_^U,.__7]02P,$%     @ %38D2"$W/_JKYP  2MD. !4
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M-Z:']TO.:D-!&^>QP2PVSOG=,(CK3/;WA.59+%J"GN+HU7Q:[..'%>L 1R0
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MOKIU'&$Q0V5=9C "'M< 4EE0W*D@BBX(+_Q2\22A4:I5[6,*F?0HZS3$%I]
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MKH<#J5=K<!^5:@BNJFX=&M=14CGDDPI"BN1QVL-MH+@++J8!DGAL XYLBDE
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MG\9;N!*9@V0%J^'%%0_OGZLBUV(/P>J+E_BK*-I[X<KW ZC@A8<'**W2:YK
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M(03A,1X\D4Z7_7C^SJRZF;.Y<=DUS2G88-<T+W?8-87_D$(;R4.#!_I(I9"
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MM<)E>N@O;.AS*I:8!O\!'7V.U%MUR0^5AU/5^#]J19R9$U-LZEBO0;2^KT6
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MOH:;5-6ZJ OY#,\)+^":5[2;5.X'LN8?+FX)!':925/-&#3\5XO*ND@Z1D%
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M,-W*D\ ,G0@H*S7'&U"%$E!!Q(RC:482]HALO>0AB,@K+R4>7+P-Q]$XL/#
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M%3CA3:)A&.R=%2N\LP>D]L0I$M?;MBW8*R!!I8(U/""/.@\H&@>,<H29^ 5
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M@G*&+"#G@ED]A\\(!U(@#EOLF1KT[\=)\^5)D9)T5^1%E/#S!],?X3X7H/U
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MI;XFXF(PE7LX!#D5)O *(K3=)"Z3UUVSJ9_PQ"" Y) C19(X02%O Q(_"AT
MHD"@UXV ZG:U/]B? SG(!]*Q8_1K40"0=X4%-Z,\B9])H&#$&-8F<9:=KR,^
ML89_VE-OA\T7#?V6I(\YS=[8"E7^,]C9SV4.*P?-_$SH:+/:;?B?=^EF<Y%F
M[.QH&7FZ]C>D8'?^<(+7]?- 2@<.FPG@#V?>>PMJ]6?R<$\GI.NKRFBD[^V$
M=/R1K\PCJ5V&DNN<Q^&8-&<*_=F\ADT KH9(3MOKD0M81<(#]:GZ-QNL%2^4
M[/?#?(J$APHU@FQ'W%7YWV8N^9V4V9L^IUG\KY)'^#1T5?'\A<2\&/C!!.XP
M/S]VCZ&4TTX0.G"!7["AST Y^-7!E&6&DY^8#AT57^'N6^PB>ER0*W#2][@C
MU<T<"G8#YPW9X7[,Y4_?_-*IEV"UTH>MDV:.7O?54&!3^*(/=]3?QN@UAN6)
M2@.'P_1M0BH>E(X Q*+0EWV_T/G +*PO&0! &,<J&#T&>JXQY":M:?Q9@:G_
M#O7D0^))1^5JS:"8.6\OMM_J@SE:JZM@:X4N>LQIVXG/X"J79N$GMR0[189T
MKG=VI0@V(O4P4L8F%(63+,R'1>>90.T9"92#%38?&7X&24)I(ZQTT0Y(U(MR
M "JJY#!2P8]#2:L<I(*Q)\-@&QJ0$O]^=BZPI3P0.*BC3 TB$T7G4'+/Y"*'
M=ICBK]N:2\<*&A-&%J@&1<1_CXN7T710WI\/ZD\>\0\>VV,NK^7?O+OQHJ![
M%"_H88WXV_&3"D[CS#@#PZ=TZH!/-(]?)N6CI3RC-U#<R4GWT.7K8#[K=Q1*
M2M;#CUG'OD*,7.<Y'*N-LX>PZ,QI?LCT3]7)TS\WKXM^A" . .>"TH&7-^V'
MKK^6X^:K-,\OD]5FMZ;KR^0\RI)23+J9X5Q^44L@D-\ J-7@^810)L&:ZYIU
M(:UP4$JU;D\(<TQ^8JY_)HWSDN=)X_X8V-TD=)'YWIPU9O=^&-P18*$&;74
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M 7A!:0&R'>$)J83)U_J_X7U*#0+*.)X-\&6DZ1YE;L;86H^6<),?911*\>8
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M8]@ZMUP->YD'-2+A[G!>\9DB QQ>ZI> 82$+=R1NXM0>8GRT_0$)WQZ9$Q.
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M+*-K_G;H+'Z+US19WT4%O:4EYI,B>AX"WT2E20<@%;M -&B590* >5)$',3
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MCMR7PZW(,:+&E'A[BN'Q[C4%U\0=41W7<E$W8=)IA2-^K3Q,B BFJ"MX2YE
MHZ+;O?IX&(,!HN ,$O-P9N-H&C9&/$GWL$B.!Q:F!%FKN(,&[EDU&D<3H?'I
M8T!#NG)0J1)>UJRF*HS?T$K4=-ETI.8F5B2M<Y1EQ]XFA,[0B"[[UE-,AS/5
M)$.,/MS46#-5G@5Q\R1QD5-[Z!W<( @-6:;Y7J >'L$;4[LQJ3L/KKF(W)+"
MP4MIOC[P+9W"Y^PI,361I^<#T3S<;,W*/3Z^7[W0]6[3?)KSFB:TVMOBL-[>
M6N')E)U#Y^72\UFZC>($3,PC#2TS=S0<1=6H3:ZXN>MH2CCM]??5347.RQXY
M5VN,*]%@>7F,!$ @R>!CH.<:1#-Q<]^?%9JZU;)RU?I1(\J8FWN:X9'S;SE]
MVFVNXB?!=EY0#1TY=S7<Q-6X38[(N>=H0CAU]'7!5(D2)AMH* F0H \E*7P,
M]%R#:!YR'OBS0A,CY_.\B+?L.)>C1XXI"?<UO9'P7=F]HJ_M1M?K7]6Y;H7X
MD7T[<NR:DX-V+[7@?P;Q-=OX2:?2AR3[S7[A(]P+07"G"R&4S^H%/A!@!-C_
MH"O70"F($E/TU%/%XY+_>JR.0<U;0[N@'F)YZ!#[2))1!A+^0E^_7;"8&$SU
M&MJ Z]EAU[1]EI1CX$X!=["5!>Q8@T V<C$'2SJY'Z=VRSQHP^51(Z\(L.,<
M? #G:<R!-QFOF^A[9/U-.9Q;WT;EF$8X@2X7:'E\+& 90C*/MLPLL*N*A9'X
MHKY&^,50R@]Y!Z7Z1ZI]0LA=B4Q[0O,F?5H1V;'TJI2*1()!<,Y#%B5YM&([
M E9'K>4W3YUK"C(":@I82JN)AGE@&_%X3>\0%APZ.X.8Z=PZ(;4">Y_>N1Y.
M.$&!(XPS,]1-T)\+>\Z(&.(7!82=XQG9%NF^=WJ>"V( C@=8"([\!5/6>DD-
MN2-,:^O;X(:\M5/?"CTY.8<Q00[H5VU@2"?1#:#@'?3: 9=45@U\]-I=V@XG
MX#<<G(TU50$07'4O[V-=$ !'<K,"8XZRPGBH)]+]4!@QJQG"'2)>27:#@(JK
M:?,*Z5-^:&N<D.<5:!<(K;(J/*Y"V?\!W.VZ*)$!!:KD%"YS4.H5<-<'@'J+
MG%>.G&(OY7G+'7RTF-'J51 [/D@:=U=>A)%J5U+-IY6DB]CHML$)B]8.C .!
MZZDFQYA D&'0ZU9=! @P )!WA80Y"++U,PD2_*NC@F,B3LH&T+P@V=$@P8P&
M&XW0&##__-Z] Y^04BBJ^5&HZ")(%"UTPIYB?\:1(S(S?%D7[GR6"A:ZJ-)#
MRES=8[SM3S!FNS"R VVOTK*Q[$2PWVFR3K-QI,%5VAB#J%A&%[Q5MG$%\J2*
M*("!1>]@=[Y#9G7:,)>LCK*K97U'F $<TBG=->'I.X<2L*SY:P6FA#ZS@%<5
M-D"7=JBJ1H"U'(/5AD8Y;0]S9^NACA5,TCH(INJ1H'-:/KB79;(^HV]TD_(/
M6LZ_O](D'P\* ;(M)2ME+0,(T Y;$E:[4,6)2G/1W.9?XW4$2"WA.SX@/9P:
M=83)<W4'"^1QHL[31'Q4!-I!R'HO<CS(D'*E1B=,DI1\& '6@! FTO)T<)L<
MDB?H PB]_CY,EF(B#>:C!S@08-&C_- A  S-Q[3 SQH@%@Z1=2W0,X6!@_A@
M0=&^:@\Y$Q[N:T!XN-%P%T/]-CGDX=;1Q-"I];4%;;@;;)I@ Q9<0D 9Z+F&
MU7S4W/%GA:\1-7<1=IKFOH]R<86A*02]U_1)T$46KPJZ/HURUDKV'[9-QENT
M89,@XJNR"MK:U)[2+4S9!J7UK[!. C8M4$;O=,.+O39A$KR*YW]T9!5W0EFF
MAX#1%!,KB%WO#??86<JN(6X"@.4U#NKH![I-$(':M\&FR>NR4W991D=G4YHK
M E-@5]%IX(];Z#:]]?Q-C^6.F5'J$H7P"=EKA!W% LB 8U8*-W/UF4 W:VX9
MN,5 7ST>:O"W*N4^ KPF)H"^@0#H7K63DD)F1.*8>]8H_&)1,WSG(Y%&%_!A
M[6>DZC(!RO7[%,W4OXY8T&2O(;%.MZOS$'80FM[#6LH*9Q>@HAQKT/5YE"5Q
M\IPO5ZO==L=7$)[1IW@5CXM0J$++6WH%2Y!#6V3+:  _*M1KU1>-#&F$R$\=
M,5++_>P[+L (2,W[R/B1.\8.^EH\D$,;&#$FK?\DT?[N,8)&2K,01=? ,3ME
M4I=F0>ZL8//I3XLNV:RKRT<)&_&IDS#%@%/U\K$L+Z*5><H>*H)3]U[1<30-
M6^@ZE7?\V015:P::VLG71L7[^,88- 81* &<N?I,L$,>,QFYQ<#?@=8$&!";
M7"-T#01#^I+I(Y60A,R1)AA4GG%)&C2%)%01D&\HDTC*CI.B73F--%LW.R5%
MX$R21&DAR*V'W-5 $@M@0ND^VM";)SZ]=9HF>;RF6<0__J8K&K_1]4TBW^1U
MDF[]0 QUK<)A4COMR-#4I3QFS"PMF#C[F(\KG)">"FET2/EW,#N^3D-1:M6Y
M-GTU'Q11"=O<,Q(FZZ,B5Y2NZT^5BQ<&T2>:E1QX0J*GLN5D3=>[4CQY)KND
M-/<MB_D_UG&^JC8I9B_N5^EV&^>Y_QV*YL2L))<8VY@1MT93:6\T>TSQD*N>
M5S.U-4 NV[XX*E'!&#:O&#:A_./I]L[*_SKG6=$IGILSMA%" 70=;6EO_V7A
MMJ]PA7&I(U7 "DY-B]"*&KD?4.S)U*ORY:8N7P@38_\*;\]/ Q"(X@H&'+B:
M8_BX*D14[FQPQ'?QZA;"1XT:?8&@4/3'NRN:1%F<_I;DKW05/\5T+:9;G5S#
MLG(YN^C0^;?D5(5Y10A(M1;-+=*Y%PK\M5V9@I\Z]"&ZZ7M<0E1ZF0 "3G_U
MS9,CQ8&,]%3R'KGNI1S>,CI>KE;9CJZOXN@QWI1#7)H_L(V6V&>V_"O;$?F9
M*K9L"%>T#!'3%MKRI8$_5>R S2P:659-U-*D(TZ^<H5P/I6> )IT>G=.[IV9
M8(=,U49N,?!7D?D>@:MT^YHFS5: 48U'6GU5['OB81;D2:G?Q$ (N2 IXG6\
MV17Q&[VGJUW&FWK^?;79K>F:[3EW6O;UKN 3)S=/S4NC6YK=OT09Y;])GB\0
MC8]S"HIQ+ ) _*5HN0FG32#^P'#5SW$=BV1ODC0VJZG0CE6FU+ZI+PT3;KG.
MB^$D0\R($-$6?L2Y<7$$U*<OEY$=H%,@?AV$_(M#H4+3<A[+G4-*#'*H@!TP
M#A@2.O0XUM!T-93!;-Z<,3H<&KVF13DNBJ/-YIVTT9KOHY7VHG6U]\&'4ERC
MO/F-QL\OY1^_1&\TBYY+"\QI*;(K\B)*UF53?@2M#7AG@&$ )<X9?:)91M</
MT?=EGM,B7R83IOTF61D5*X96D&AO4MNQR@Y3YQ#>,K/9HZ9&E92ZI%+F*YH.
M8QYQ&@H%9&(#9TM;/D#M*&&;MP$=W</4F\?/2?P4KZ*D&,Q0KAOD%R7RHSWR
M-WO3'QOFVL1H;"V [#?,SI^C/%ZQC3"K(@N8_299&64_0RM(1#&I[5C9S]0Y
MA!_,;/;883P2/B%<O=HEMBZ\P\U_TW H( 8;0%O:\@%K1_G/O WH^!:]E>L.
M)A];=#?#2K9.>)/F.7DM8X /*3\VNK5IS]A:J&GO\WLY<-VFR>FF+'_4;^T,
M]6&I3J3OD@WD[76:WH1N)P>^P!HLI9V0QW=2Z1*N?$(N$S:'P3YG>?B65A?)
M%UJ\I.O0WI&9X@]* EH(3[820M _/=$5F[4J^SG=TK),9R?GWE'VQ,L:G2<%
M:,$[V=28"B:8PF*%R;\"C2"FM #$%>:&^[31Z)/* )\/8B9(WT;(Q?!TC(KH
MPA;Q& :]X=Y5@3RM(6X"8%@J9WV@LV_GJE!@$T3U.C;RTR--Z!/;8"<J2%X6
MUKN2QM_)$V4?DFVZ&NQT=E*DG4OA3"CY#A5]C3W)9 @Y=_NZ2=\IO:?96[RB
M38U U^P=48D@WO+EAK>%ORYBO^DYB?]%UV5)$:=K?AR-IAC']S'.TI@^L&@,
M_W>CY774IH'X#M%COQ*H#9/:<C6(^.61V29=XR=D;YXI[AV0RD-UM%)P0PD'
MT2,B16=!ZM33\5"H?DSCQH\K*L6O"MW\_L HU70<A>QU#FH-<C#F*+C<,2UT
M&/<QHMG5 -!!*SV$]6B5 ?N8O8[C5<<B>4HS$FTVE0!)7ZOW,.SU2S8XHX!$
MWZ)L'<X(\6#C5S^VQ/<70-5TL2MV&?T2)_%VM[VC21%M;J-W=K!G?I%F-Z]\
MGYOD^8J6OQ2ZR _!YJ@:LK*)Q)4(OPNKRK%K"H3Z;#ST2*XR1&I+I#)%&EN<
MZEIKI#(7<(&"@6T!F>&%#*IE_X'CJ*"P;9'C"!H6"M'S<\:/]B#;.HRB)-F5
M8;1ARM4^@D453WR[09*DR2\KMG_;9L,C*6TCC&O\B"8]WMP@)X"4_R4JZH\1
M;IZNTN3Y@6;;,_I8 +.[F?HHD4/5D:C'K+58Z1GL%<(C0&,]PMCKL'\QK5]*
M;MP2IA=P=C7$EB#T)Z%SJI%9,>HH$QHXQP/K,+\]537B:U,45DELS< :E9F/
M\JL?#:3:5 0W$T#6N<U8#5*\WY80*I;)FIV4^LKZ5?W2$J8VRC(Z-:3(A;4.
M*ZMHO4$"5&-DT=P_(5R"3SJU,J&]E .B0Q""1K@R50X@W.XH/WSB-BJ;V=DH
M,__\WKNCC+T)-D:!:&0#*2HGM!LK1,U<0^+5Q&(OI]:W";_?W7(XYTMZ^[<#
MB^LIR!,$^70 6UD*(/PEL]-9V?3GJIKZ_+Z7J0>P2_8J04T)2'9'-&%M%XDZ
MD'X?%IW8-P=",;9>>K0C>S=-NO88 74%:YN$&PV-C+ P+R HW'!"MQXLD?%=
MP&^JUZ)+MN SKLE7/WUE:Q!(71"#3CD+_HO<DA6H'=-9"F >1$\G]<;ZM:D3
MTA@+>+;,&LI@1C(.#SRSGH/$T:R;57-<1@N?F=MMMU'VWJY0J1>@D*C6^(%_
M%4X<]'A0>;A;)W2;_WNTV54%1I[OMM4UXYQL;UR1GVV,H].0_2_%S]M6;3)C
M)0M7TGS>&T6,$GIKF71,'T1V1P@*)=.A!9T;%P&%GO-JP+)I<\7@\/W=:(_)
MJ!-B.Q:;<5*&5[3ZXY=2K7PV>5U3_/*:Q2NV+&6;KNGF1^A-@:)C4(50?+!&
M?WX';#@BE1R7!6-)+**1M0$M80L<@")_I-=/I3Q?LMT^^(X>H<W"27M6%& :
M& #D_<&>9C'-E[=9O4T>;UO_N/8&]GK)!O8J23O8Z]M@"7NE P7L%7J+ZB99
MDO9V<ZYB)>$;]8".30UZ /Y 76$!MW#2^)D$"E[2-+ H^Z8L9(J8#0U*,4JW
M?)3PVJ*%SXL<!TADA81:PS,]?@;3HU*R1X\228204+8!@QYE#G21(-9KXN!S
MT/2H[MC4H ?@#]05%AS0H]S/)%!TZ/'S =&C/4B4]"C5\$R/IV!Z5$KVZ%$B
MB1 2RC9@T*/,@2X2Q'I-')P&38_JCDT->@#^0%UAP0$]ROU, D6''D\/B![M
M0:*D1ZF&9WH\ ].C4K)'CQ))A)!0M@&#'F4.=)$@UFOBX"QH>E1W;&K0 _ '
MZ@H+#NA1[F<2*#KT>'9 ]&@/$B4]2C7\T6/[SJ"[2O AO7DLHCCY-4W7[+".
M>@>,?/F8%UFT*H;,:66D(=6)1NQBS*KEEE0\U;<B(*>97'3?J?=6[7Z+BY=V
M-ZIJ/YKK-*'MA:^-#=\4;X? % </*-WK <^XZ61Z$["!S9.09,>ECXQ768Z:
M;"R ]-5=8R=-3R*A4?KI"R&%H\@S5OH8V(9$44^E1_^G <:(L-L$,:#H7K6H
M@TYVQ*DC%Z:]K>+$9O/R0^YW+;<-A0/CK@[URK[5X?_S.\W9KC/51G-_!C&>
MG6DE3TXU[2#P['ZE"TZ>W"+3V)[H2,K_W;& \@.^D_H[OMIPO?=LB#1B&0,:
M\D&),!<.@HFS&=*B1</F"3B6@IM(>?T1*9/0XQ0'AU<2L/U(BO?+I!R2[?BH
M[:9XH=G#2Y34*W]_+4T4^652_4JL<F&B6]M2PMBM'_J;^'0\E2#FK77 EJ:-
MP"A=*I^DXY1PKZ0HW>Z_)JH\L\\:#KJZF1JR]GQN1Q9S.S\(RC"KIMYH]I@Z
MJ:>F--L_>[ ZC%\I.>&G,JYS9C3_^4=@SP5:;^ [C.#^%,)0:4JC PCM3W]:
MW T/SGC^$>O^,.P-C4<_F/M[_2GNLOH2E]\\BPIZ$<49^^!S].UD:.V:>3@(
M:-=!Y ?P\SV, 27DY_A/+/I6>AR2GI"F>:1N7R5"6 L):R+?$R/(]WL^^6?V
MM&A*C<&U[C@(\D"'S[#?=0!<.1R K]/-)LIR]E*D*M _2'U^R$SE>30/:M\1
M#@&NV9+ZO/SAUSO1IRQS^W5>PH_\!IJ!),\GU!)\W%P?:6/8BAE+Z-9U^2=W
M?JP91Q:X,V04-6?,[OTPF,.L-JV6D9PG:Q_5J:CE = (JRY_JZ^0J" T6;--
MK]YIE'V$*>!P G[V$E'@_T""WNB53Q7T]T64%2&$O:\W/^-V],+^D3['2<+6
MVOT(?A_!/_<;(('_8Q[_W:6;S46:,:7Y!X$"Y_.-!'O.0^=WP9,*?DS8;[-7
M:N\VQ>?HL-V /"=?69M(W:A@/G^>-=3GS"9RJO'3A ,BG#"^N9C>]%"8APTH
M1XN*(G;']TG%'RK\_0TG!XTXYK(RG$5%YDV:KP0]W#?EYD\U^'(UU 5$!@WT
M4]I^[$5#$_AESL07VE*A#\5]A_@2)MS5049-5+ZZ^3@+A0Z=G?P5ZU-6!AT@
M0QWD&R/8SPJ<HT#OF7XPU<$PE;<75:"F?>C)!J\ON::T+J IB(.:M9[RK ]_
M8B*@%VU&;0UYNB+ K8G#Z+0@DV\ ;_<^+I$>VOM!X]]V,(S*YCT:^?9DY=<2
M1R^E?\).3J;[D<0/6CLD6@MX(D3]6O.PJ<UH>L3C%Y[3?]WAD-NG#KG]>-5T
M/,P6[L3)H)5'.(?R.W\0L^_K*7;K?-9CZ#;05"5^.J'.4XQ:ZR.C#!HQX\Q"
MY?GX]_64A.P,645)%G,[/PC* ([(_UJ11D*?RZ3G9=6!H-G^V:/97_UC;/47
M2ES//L =NS_Z^BZ<5;D3VS5SA7BX:]0F/M_#J#%#7:EKVDJ/5>I'7[4[E7]F
M3XNAK=_]H 1Y(.^XIORJ V#*047^<1;%'0]->2[O#V"?OT?]4W@</87OKW'&
MA>43N)AVN_4WCEW[](#Y^Q#J7Z3F:%@9Q0M*_=D:#6?^$Q7QJ3.PN<).&"&%
M7S&AM6J&V&(5RVF:\ 6$NVA#-O%3"&.IP"-#521@V0\D.APL+$%KUQSQ\>E/
MB^HOPN!9G:U#UFSRH4C9.>*U](^8@2/)'2(.;V*\K>N7>;[;5B."9;+^0HN7
MM!P^IL_OS?)NK"EO<X^VD]DF'OW,PI@_$T\3T$8-=3!A8N ?HVCO?.;0<4BB
M9$TZ+@__$X@),6D_<S*9"&;T&SH=A#'=:MA>K[P@7/H?=8)[EU?O?XH72CYO
MHM4?O]RO7LJGEY.42_#/ ]CGQ]MT7:*AK,+6M'RPVSBA7.>)<<8;YXSTB5^A
MV]=-^DYIO9-9;897<H>ZH5G@A($]B6KF^3BJP+*^I6S_O;/X+5[39'U7CCE<
MUH J?RXJ0+&_< A?]3P"JOXDS9R)XX7>W55^?!J7.R2-1\)<'A&+*\/0#8<#
M(G\VKV''?[CEGK2U'HF E7IMO*Z;>'V/Z69-?HK*81Q[,;XJK1[J:_& XW>.
M"DSF]_!>3ZM^W4,YMOBSJ/!RZLCV!3; D9\7#. GX.D5-Z1]#MX[Z-W.4E4Q
M5P&0L=O0LG^W81K&[MT%&LQAO%R'-=-'5/=*)#:+Q=<-LEWU@OB0Y^#C$/M%
M/<AAJ+$8R*M\6$.]1..G033^"$%,V,T(G^.: OX]W91F-G'Q/M<DL-BCRVG@
MH<?P)H+$SR3 J>!10V>> QKXGV7@LO=YK!/"DI!T.Z6DY($9_8;.!N%/# O:
MZY46^*=2[94?\>H6E3[P%7S,!K)GGF&+_4;MIV[4'O];G!""&'G;.3//QS&0
MNHOS/RXR2B^3,O72O' ]C%+Y<S&($OL+AX!5SR.@ 92DF3,QKM"[R\$3<TB8
M1]*X/+:QDS(.W9 X(/1G\QHV 80[9I*VUB,3\$.9R^N_/+& C9N S7X$K%-H
MS@^RP(,VX$&3M+T^P_:3-&R/=_042A3/,'*2^3V\<=-5G-#+@FYSK('1R*#M
MR*=CT ])CGZ1I[%+MQT.N&UOWG[T0;XR:X2;.]2O,\= MN<P67#@F?4<(F%4
M]_WFN(P55I_?L^\+ZRA8=>S\P+T*'PYZ^O"R[_5N^TBSFR=^-U_NBI<TB_]%
MT4ZZT-FWS<UR^WYX2/=[/65N1;,<D)/4&\:L8F6<?6-=F2=[^P?*=]H8L:<_
M8!@Z\Q)6,(91(RA;-V-4_N_F&X^<!559/VS+>*RV+(A:(?*49B0NQY]1B?\C
M./;!8\QA5R J/X'%72"3>,KVS1EYG_ZT^!)]C[>[+4G:M%8%UH_8<XM ]T@Z
MO,% O3/T<KV.V1_1YBS.5YLTW['?AKP=G(DOVT$"S)<?KC1Y#IX&#\ F.B!.
MD&>,045[#LC>%>GX.OR=WHS"S9Y_)T3W+![#C?$PQB3@EGH*]G:VL]E-K;P6
MO\7%^PF)]I$;)V7%M#WD*=  PQ5[V +U>7B[>MPTBUMIMHKSZ''#WM)F<9+'
M*_X:%VU7#[ CVUT] ([\?'P,?@*>=O6 M,_!%\=ZMZA%4\?/"6D]!7- FMO0
MLO^4V32,W;L+-)C#V-4#UDP?45WMZM'>)5%!V,YGZ1-;[,4/-5P^/V?\-.,?
M8>H2GC,"+=10#633#UA#O03K)WBPQFVPOOT(5FR S@BT@YT2[ORL:LH;>1I8
M:A]IZE=@W^M4D/3W^IWB%37+W4S/V)N[44GE( #B=!(D:#- NCATYB6L: QJ
M,E;<NAG#4C>L.()7TAXCS-&\JM#/,=0?@Y.*ZSOT-HM'[#"S5_Q:1>TU%,Z$
M/)M@ZAI-8V>A564;W-5 C5M2^VWN4L(]'PUU@V+5!:$;D,3,O@^!*D(MNK1M
M]LX9H )MG6XV49:S2U6Q=CRU6I ![[ZNTWD_AC?G@]]X1[=1G,3)<^?L<-2#
M,NQ;@/^N'=Z"4%X&F#ZS8-[.&S1\EG<&X/;,6#6VC2"=5ASR"1X(,>_BA<5$
MXO'8CD.CGU#7$QBU/R@>TJ] &)W!F[5TLNK0R0&?@G#@=.)^%8-)2PYVQO(B
MS9YH7/#5K,GZ_/MKG'$+^65RRT,!>:X2[ ]IEA+@S^ND _AY^)V9A#33W?R"
MWCMJ7=EQ1Z(R+70<LI/7*Y<!L/XL88@V'V$:^;-Y#3O^@<7?7RL&2/A"K+6[
M"4=8>SU2 2OM3MD7R)L-/:)7OB$&K*.I0Y#?XRVX9GQQC-*6N0JU@-\<H3S'
MP L\;R^D[5HV?V%XY"^P<3ACOB0U^\ON#TMD0;T8M_\E@3+:N+X]MC?FQ\0P
MODKDL-^Y6_SR7TO!HOV9OV9ICK8AM]X#4JDK]."5]Q6_V6]9*FZ8.VH6^4,M
M(2L'W6J1.SELQE:%#!H/Z^/2H9_0HC.H6DO6OEG#E-5%_/(QS?KY"BQ'98O$
M4W#!%<C^GYH6SAM>G_ZTJ.^2YQ]AA@VT.0!S)#7_8&C#;YY%!6V/'WI@BS<>
MZ/?B<_F;_G Z.IC8%B?C"..V!$2[$Y]C2&,3\Y\P%W^;MLSQ>&<T.\Y%"&M1
M]RC6K[Q5A#6+\'8=^):F.,3A*!O9\5@0+3I<-@MX+#?EEP1*:WQ+UM4+7>]*
M5DF?)/NPDN@QW17UL1+I:W6IWKOU!_^$PC^S#$\GM.E@*^R;79$74;*.D^?^
M=E#(U;/6#U)EK/#C-4]H?[_?BE;5/'>T+O>*6HEVW(2X^ZO3J$*C;6@ ._<6
M9A@'5<JI6^DAGED)UKEY8/N^'GB .JJ9E/X"#=*PIO?5[?01II_@81K>CJ^'
M'J9N7@DH_1W#L,7)=J]2^_C#E" VF)3^WF"&)3-L]SKVYFX8<@S;O<J#Q 5;
M.MSN-?AH-!M=5,GZ/''X,:"XA3.&IFY$<3Q+%'Q$F?LA@W3+5]^19C1$J+!V
M7T19,6>LS38\:/T-8^V1/L<)WQ.EC+AW&F4_X@T'=>Z1$UB\_27,>;-.Z^:,
MM+\8GW2?=@+S1PRB(-$]IHYAW'V7;C87:<9NNAM\"YS@C\![3D*A1\$O#V8L
MWF_;+/S8=>EJ5$Z^,B^D=G/@J\XT0>2"1^7!ZM95@"$;ZNO 81/GCEWI\=@_
M@@T#;#/!YAC*EQDWVS'TBE_@!+SOA.&S":8$\K8I#K0-[EY='/4F-Z:QZH+:
M9]^XYJBH(N1W)1ZWGH&W0O]>Y=CVG0D]Z-T7>(:[QH09^$&_NM&VW'_H0U_S
M_ A_7\#V!<YC'_"Q\>V3Z[ELPP;,.PSL-> 0V%[PQ YB<-AOMW?2[S;'VY"1
M?%T^YOQDC>.9=#>-]KF3BIQQ_#7CP'@GU$E^D^:'1$!L[-DR17/Z$FV8XI4S
M15MS_B *GX / +H'>WBH_.?*#IKZ)"I*_;0 Z?#022WP>GJ?Q3-#J$MG;[B[
M0_NFM&?&RO18#P^UB7FTT_[LB<=C.PZ-?H(Z/'1J^X/B(?UG[!_F\-!#I1-'
MAX=.;,G!SJO^3G/V$_D)!'15_OF0LDN=,U3;+\6=;BMDW0ZD65:+=GB=]+!^
M?G[G7&V:[V[F8WJK4.O<JAG-<56\(:1(^>43TFG,T6Z^8D\.:',M6#SEO36'
MR59!S=3:_8H :8N5Q1VRH1VR>2LO?YS=GHZ!<!S-\5JUYT!))ZS=INQ^1XBT
M\VDZ[1S5[E5'03MNUCA9M>>(1^=.-LTR=3O;V#N(37U,GT[H(^L9-N0"-\+3
MN/D8-O$R#MH9<X7#+;^.C#0.;( [RYYA!LTPJB./9YN5\&/?VVA4NC_9,56!
M,WX#C=.8V2K&@#^#Q'F2H5>7WKZOMFR:ITKTJ+_)1N*.&9/7[%]P?V!&.[#2
MU^,GX-:-,R^3C^U3T>.B(F_5M>'GYH>SMM_XI\N6A_U95'\'U3"D+P$P&^9U
MA2[^$_;[W0#J[W&WC!>QF:'4[L?Z"8(##D);2NR,'\-KWI&P9%"?-R#_K$.@
M2_-57]\^RL<1'X/H''U*@=O <&?O<]DHBO_/0]F^\AG<EC1P'6WI6<I^H^F<
MO(4+Z$S[)!=N9YLL?K7C6?%I+;.8$)KBL*J"R6=E%9R3SW497 OVRN#Z?YE]
M4CH@S -A+LC7RDGHV[S8! Y\;L<^/%TZ"BY(YYWHG=K >:.5%6'G_]S%Q7L=
M<S\"# MDL\#E ,N3NDQKYFSSR^26U_>8BPF<.+<N::8Y]\2C-D_*5QDTL<TN
M*'=24T 3B#ET!K'U3>*$W XV&#C,%_UNXAHA(2#PBI\F'!"[!%*_36YZ*#3#
M:[[ZPH&^93\J'D O&:<VXG"+R5]+R<)+)6GN&:N,-/'LE^7-GY'G M*HP0YI
MW: =N*5CY?CCU(T3HA@O64RF$ _^#X5(PJH5#=L=!*.P*I%+'VN->" Q[ZHZ
M-&M!:*4AGQ0M?\'JA=XD] N%?XVNTE279F)-%XRH:J.3TDCBT)B(A'84+P2K
MUWR5 BDUR-=*)\S7#TKHZ+@!@+L)^G.A;XY\*O6+ L/.<J/=:XF]9\9_'P-F
M9BE$9B'@%/#P+9V8 D::X!30T70<A*,VNDX!78<VL;>W TT!I<;!I( Q= QB
M4X:["?ISH6_F%-#WBP+#)@6P!:/EB&:;)L7+YKW\,R^BS887S1\#=),30L]"
M8 FA&M<LD_5E^7R3(GZC;+E$?IMNXM4[*#& +"@3A,:"@U %M=E%PM Y-HU8
MM3WI]&8S:<G7D+>J?,5@3BIE\K7^[P/]7I#/)3#_"#*YP."GB7<3#%O8F1O)
M,R0?O7]42+-D=%^46/QE7!5]3'0:926M);_92?JN4?HJ$&V"'?M%&O ]5_<U
M5##OA%33MYHW*KC]@<]?X-<%[6S^111GU7:U[*.JG'%/N#/[VIY3L44@T];Y
M99[OZ)JWYI9F_)J($U1R78H0R]DC5.4?@4 DYC6P%6I5])*3ZMY)??IO>;MZ
MJQT ;I5]F8(?._0INNE\,[:"[3PN]3,!!_P<K:<GFK&1?'6N:[!$9@D(%<W)
MY!V!PF@[>D@*DWJ9 HE/?UKPR\>.!\4^YS)YSUFP<[:9,/L)[O>R7N\^ K8%
M_C"R7-^L#L)=Z3JK]4X6#0&IHHY)M<]2]VAP>] L554["9PG:QTS#3T8="=+
M3I^C4KIDH?T>!N\TR@+;^->P?Y69:""'W,=&F:?JX_LBR@J37H;DG;Y\MY<?
MZ7.<\)THCJ.O55EF(.<QNZ19P39J.*./Q4WQ0K.S.%]MTGQ7-G+YF/.]'$89
MQT"GS4(@'4O,&[3+-EO!7*F" 6)A<9HFY="@B!\WE'S.XO4S)==I0<FWN'@A
M=W03%7P%<E:\^PX0$TRDD[IL2@^$$5CLI0E_9Z**I)&0*'0Z0GBQ,O*,&!Q=
MV\!HV*LL^/5?V&9$A-TA7P-Z_:3L.C'"95VL%G70T<A3J5(7ICW.ZKZ#I#QC
M!$@K09FP/R:+GY/X*5Y%2;%<K=)=PM9^\'=$,<VES&:DU# =4,DN((Q:9LF$
M4%^*.(&96'3DR%Z0-)(A,:<9--)I'3>I'V8 %O:T,-RI+<;XR_;?OGQ9WOV#
MW%R0^\M?KR\O+D^7UP]D>7IZ\]OUP^7UK^3VYNKR]/+\_I@Q)N-NL+(_+F=C
MSL?W*UJPG'[S=)K1=5R(U_T"1!O>5HK:!16@%98<K?:@B!J5XJ*^2^K;Y.:)
M5 *AK,V%=&]JT@T&3]49)'#K6IVC:=BH%BV5]W\IX;'A$FS":\5%C@44,HK4
MJ/@DQH+M#G95NMC\?[LLSM?QBJV.DG$C1'I/CVIIVW" M,6:)#5.E+&@U%UP
M ;Y')1<A79EPV!+4X:EAKY@]9)<XP69.K:_)@*GYL_"]4@49$G+&U&GY)4WV
MR<?I)LI+-N=+<9??XUQ$ERJY+E&*Y>RAK_*/0(X2\QJ4"[46_ JK"?@U\I5=
M#8$ E5V8@I\V].'YQW6UJRM;,ITF[,LF%;95LD-\BV5Q,*YJ!Q+.)2X 6!=J
M-IOG[B^'!7EESXYA#P "2,,__*_BA%Z6?THQ/Q(8 KTC@(/ND4<D2'?M G"\
M%U^TU\A7=I7PRZ% =]Q!8[S*.E$NAMR5^*7GV+Q)G[8%)KMZB!VI*B5'@OYI
MYN;I-,I?+C;I-^F*$X#HD'J$HCC(5;0"B8[$'@ @%BDN3F^NS\ZO[\_/R/W#
M\N'\R_GUPSV;PC]=WO^-7%S=_-WW;#VD>\=XUX,!HA "_B_B)$I6<;2Y3?.8
M?Y.GC0.MRC@>%"I8<:%M%5I\J#R!XD1N8/%Y>;6\/CTG]W\[/W\()S;T72Z*
M$2A03!1#B!D^4'Q)-^NR'J@*:'W0Z'7&4:/2P0H;?;O0XD;I"A0X"@N+?GZY
M_]OR[OQO-U=GYW?W_T;.SB\N3R\?@@DG !A$\03&D)&F_XBZ7]$DRN)4-<<A
MDAE&3%\&)T)$?I$B8F :$ $]C47SK["F+(0=-4:SHC^5DO[1^L#.()3!M'=S
MB,_Z)@XP>YZ0$-G8!$"Q$NU.0? KH:"PWP]C^(GZ22SB$7!#SAZ!3B;0 F\L
M8 D^F4=;  KLJD X$E]TK_T;:<Y$*XHL?MP5K"?9P;2W41; O(JTUU+]<]8^
M-N3^-9P@2XMHHYH@$YHWZ6@V0?; O%0?9[4=3JL._VE-G^)57/C^9FM2'TOG
MSD2"V/T\X1L]]7>88A=&??U)]B7F0?:NY)L\H2!V[_[%O'=U7V"*G1CU[U_4
MWV >9"__Q>!I!51:2"<PP+,6SJ8J7,]/3)R44,Q$P$N1<NA6JWDOG$UF) RG
M(6:'!O)K/:6;*1CAK_F4]<M_'@,<P 5-5R$@4F3?_H&)420L)<>^,'(4B%J"
M39(#'R9!T%,5DR7_Z#)<:A1VM2(>%-" J006$_SJ_>LF+JH/9O,X3>[8MIY_
M!D6)7ET9-RIU!Y&D;ZV+V%)Z-8TVA3%Y_)W42T"YW@G9:Q*N&F), H"EB5(P
M-*<:F16@CLL@@',\I%:?YV^W)?ZJK4]S)D6RCXA%<%VE-S,O'HTFF?0?($]Q
MCXC(3W]:W-+L*<VVU13&^O_?Y05_%_(Q40F=X-*;\5OO5-LPGNW8]J35\7K5
MQEG7]!N_-7Y';:+4K6T 2O8!"FX90AT#\:6)0+V)JF:I-Q$FE61[T&VS%V,I
M7DGX/A/&#!SIM*Z;U!,S0 N_ H&YM,48JS;87YS8>[NMA[$GH%-0J<H+D/(<
MP')02L"<6D/KT["0+7/CAX&6HD8 *8=9&=S1O,CB54'77(P?N?5KEN9&E8+6
M"*1R4!AQ%Y7:ECNL+%2^)X:JW"2H\MBKUS,HW, )X28"#FX]_F#!#L6QG2D/
M:)ZOF%$W 1O6PV(GVP.XRE 1$\W96TNZ?=VD[Y3F!Y*PG&-Z2JVD-!9F@N,W
MZY/GF\/EUR;)36D DM@D!MS1@++%#A.:S._$J!>;DY['2)995GJIEO0^OI.N
MW&WTSB_7^:PV>D(:LSD[E;7R'3 EJ)$(HP,(FJ>;F1G3P+3VUPK5"7UFN^!.
M3&SR!F#"FR6T]A\'DJF<P7)*AI(:FAN:J&<637./"LQ/>V#RC?>Z\P!I)?SA
M\3IABD!J*+1JZG=V?*/A>P2QCKIF&NJXB%MQNYQ41B-7QD$YL* <R'/9X-\@
M2&"ABSPEFHPTW6-JC@&WP*,EN%CUL7Q^SGBA5%)\DL=KFH5P,+1#()E5&6/=
M((G:8M2KUP<0^(SC WU[W1$[VHA780U"^)5(K=J.:L,<RP+P!0I@ZY%L.$"=
M+5L@#F*5]K1#A8^'S EI!CJ6G3'E[!YS^L\=VWWQ3;75H4:L22!2,;OPTWBW
M3 =RZXH8DBDM]G<(OQ72?HBZ7DRA3QSX )WT.BZWJIR8=W]U.,SG^_/__NW\
M^H&<_\[V #KT3I<1G4(\%#X3'UN@DA$S&<[6\RJ_J!P&.8Y J"%@KS .'E!V
MF0S!JD,&YNI?EVP%.T9 HM/M:LKN^"[A++H8QE A'!70;Y%THU>-F)BDT#9X
MU7A'I2K@QJXRI<"SK6K_5E@?ZX2#@3(_X>V]^E_I<9@F.A*02W10$:]L%R[\
M9:[@L2"V,,KD^4EU"N8[^5K_-YRC,(U@(8T@")J,--UCRF5UH/!H":Y!]7 >
M7O6 "B%8=2'7#8:BH;0,I6)7H>*8<J?1K(I:0SI66-N74O";<:;SSL<^(ECI
M9P(.PI_KF=3Y0+8+DN&$V^$J1,2\AK(UKL(K*IL!MLD5*0@F>H+8,U?563+L
M*O;/A72L/[26_D3;C*NE))AMI5!A._"-B]R]<3AX&YTQ?MFM,'8?U_2?%,;B
MCM;(A@3FLW0;Q8D>SGTY.: ;.6Q(]_VC@[HU;P3K6DL&[.IV>- >]*4*W,)N
MUTJ[Z7R7 ^^!EPDH$ VPCPT'L#JS+^^5[.)U'&7O-UFU<<P76KRDZ\ODC>8%
MI??1AM8GFWQ^'PLW8K+Z%-MTAU+Q3%L'(O:OM"=NQ!:IHQS-T6(O0-*LV2.O
M,D@:T1/";.Y/3F;?SHG4&OEP:G_T0$A= M AG@)@NDZ#):,4I=R(@T9R2(0B
M\8_%#F/SD% ?:BWZ$1G*.$7=@X+@47>V5CHL6%\I5COJA54 OT)< Z=OB0.H
M7X%702I4.\EJF)+"6A0)Z&QU+,C  5-Q"!'T<8[&U52L\!%/C1"^KOR80*$8
MZJB5O-'E ]V^IEG9LG/5B1P:J?K'2J6L8*_Q;4>)<N-R?,MT%NV-INP.93-Y
M7?>EP&<->W0N>AN5W50^C+N]VB*:[29;Q.R4E8RN*=WR U=>RSBE6=;L:'38
M&)!0FT(Z&$Y;K3+*OL2Y>3J+W^(U3=;#.M! 0\)U0@W42%"T"9<#Q8[@@2'2
M'W'C"6GE6"702H85)"H<2 -&#QX#/=<0<DJL,G]66.)?NI?7V2>UZ^.&#9!S
M)9JA\.]IE&7O<?*\W*:[I.@>2?:05@>2J=D8KB_F9H@^9IC!VXO*VR"WX,@#
M6!-P>J-%*K63(,_"G0XO6>P:(W2RE7EQZC(Y +TC O9 *_59\ G+-# [,V,4
M^PSA:2W Q&F@)Q![P:5X7[9)=F;&)?[IQ]/:@(G,H,].]H)/\<G+D^R$4J^?
MQ?EJD^:[3'8,*5A>7(^+Y#%C4]X>U'I;Z 8<; +M7G%RVU8D]\%5)(H.ET62
M%B-@K5"BY"HN_[/F&^Q5?463$3Q-5,2Q(E'!#!=EJU C1N8)'#1B X)Q:$>0
M["6#"B(U&&1Q!(&0B:)S(+D<0LH=VB$*/E \(9L.TEZ/'FFP8:)4-13N+FNN
MFZPLM@M:[=9V2S.^I;.:OG5:8@:7:V'&GJYMJ#RN< 8./*D- 9N7LFPM:R5=
M[9O)=M&LCHD(*M2T$)%%&Q!;AKIS(,PEP2M]6D/-A.9?2PB^<>"QC?+7Z683
M93DI1^W5IOF>]\QWC4(8[:NT0V'^:N?^Y:YX2;/X7Z-]E8'28J8?2V/&GZPM
MJ,PN< (.LY&N@,DK&;(7"BINI-TMBQ<-/H Z+E'BDIV%OB;#Q82-HU:K/K/D
MN& $HUN1EE,HX1Y^"_$V'4R?_K38_VL(H' .NT%'#NAUB4@KK 1=[:H-2<Y]
M255B;B3Q8Z3?!@<)N75@&!"UGCP15P(!QL"@6]7X%V( (.\*">Z3;L?/)$B8
M)-NX.KTBV$0[ 2HF"7:OX0PNCE<PC'Q-@XQT54+@Z70*/@S2Z%[#&3Z<KR08
M>9N&$,WJ@"/$">CM_U##&4[^PWV!WO$T#2/_\:?%[: :KQ/,\:'C/Z8\U[ *
M\9M=D1=1LB[#&%*-"\15)7E/'#\L!*UQ4)SWO1A&15=97J9WI (,#5&GJ^-#
M#A.HDE.PN*_?A\ZFH\:DDD_W:N&6\U9H,BGL!VIN$37#W-G0G06F/HV3=!<[
M86=J.P 95/X#M6 2]X1#H&U,2!+\#,?YVK0:MQ"P/D!ZDD%1P7 X)TQ;84X:
MT)//GSX0_#JM31 .JYYH,LRSJ_U!%%C(3#SH>@:8NBUXP$U !FI9&+&_^!17
M^D22DDKO2[ERB';*< NJPA-:,-VXL;-*\R)G5_ZO__A_/BS<8647U)2_4HRU
M_N;I,N$;$^RBC6 _1:5,4TR)9>S"6.77LAR2F%9$GU!CP2^S6-C?"&('176?
MI:!'#'EBX0#W[W'Q<D<W/ GG+_'K0WJ>E+_@7;CS^T1M&=AUVKAA &LK<H!H
MG1J$CL96'50WO:!B.J2K1!Y24JD%LO/X5$S)@]$(E!-MS E-W*' !-]H&&4#
M@!X8BP\.1EGY;V[%7T;):)3OLJIH:SZ _ASEXWI(*]CD"86@7=QI6V#)_BK[
MBB"2JRV:>]6$3V?C'7[?<[#H.S2%/WKPDW0$ 2#+_K4"0<+G,%1K<]2.IJ"!
ML6>+AQ#VKT'I?QD%*A7"8+O^B>8BFA.>5R^4P$-UWR<BH[6&@>"MY0<<1KY6
MUWUG>D4WB5$K[$N%'':/XI:!$OM&7=LCI#I!106?Z#K,SH5PT5[2&PG]EI0-
MVK 5_;^6U=]5FN<WR1G-XK>R/GP;O?,#2M>_6"MM!6M@6^Q(2^]$CG*=[F(O
M0)@$^8G)_$S2A'3$_*(?VN&I8:^8/627.$&NU2#>)D.&+]QY*54I*>'R%,7-
M!\;I$UFW8F031X_QIAS2'1=V)(P*T/+'KGDY]#[/BWA;HF9$IL*;#7<.;MJ%
M@-"3)3,.;2I0W1==E/]FB&VOG)#;=!.OWLG7^K_!G)<NZ:)4_6"5SPFQ(U&K
M.(%I:(\R6AKVZ2'UFXQ81D+>>(2]KN03=LO-)OW&7@%+MMG3"]8_425H!5%]
M"^QX1VE?CEB%VJ*]1]J;P1S# NC0%/[HP4_2$010&4OC9@H6&)/MT1 UMX\!
M A*24RL$1'AG]9*8A^C[,L]I4=7!ETFU/ZJ6!F'J4G+4J2/'"ZRUV$2J]6H2
M4AIC(M(](8T2*;4(5SLAE\F*S9E0\M,9K?[Z^:0^*R"TN 2"3!&M1C"=:F16
ML#JF?(!S/-2R]-!"M"@A&C$9/@8?9(QR?%YA]:-!%)QF]&8\)I\L9NLP[\JZ
M7[ 83W:[31[#VY;Q)O9F2_XCJZHP&0@OFBN$70IBM9VT4U+=@]0\ER!0*%Q!
M)Q<0(!%EL9'<(QX: :O9!.)#1 :Q DC104)4*A:5S="5R(E::-ZD3ZNQV+'T
MJC0OB@3]<0[-"W;FA"#IC>\T+-.]8X?)L0]+7ND95("O([>H_Q%&5A,\]53Q
MN.2_WC>DQ!E,=*\/*QRR$_E!@18D6_4D]_ *@\R$/3"$F"HQN>HFW'0TL@SL
M+YZ$#K;'9$EG*..-'/X>95F4%,+%;\)[]>\8W+-"G="/'3D,3<K!UI=<U/\,
M9%V;N =2Y8-3/0>\;D(EA[%E8'\Q<J@O>'[?:=)3$E(8R?@FA7R9K._BYY<B
MOT[+XEAWP)BA5I](]%H8V(6V#85\ ,ZT,-?:6/Q]>7>WO'ZX#P+^X+X?!H8A
M: QUPPDD^<YL$%%9R.!ML@5I!7)P0'=B4RJV68"4%TAU/YP-V$!]*P\)W<9K
MGO#@H@20.YH&#%8@5!\JO):_\86]Q,R83"@K-/&0H2XJI"K^J)&RYM#U\HUF
MT3.]WK&JY^:);]+5:2/[2&A5-OXLWNR*T>;R=D8:.IUHQ"ZPK%IN2<%3?2MB
M<)K)1:-':D52:;*%C.-=-$_X=Y(K3O&U!<_1:P>_% <,*'WK <RX^6-Z$[!1
MS0>EM>8O48WKI,7U*MUNTV8K1K++2_#'"=]?J"Q;.Z>3_?+8@GU=&0YG"T>_
MP)>ENLG&?( ?=ZLMBT:@P_^3 /X#M)<Q\+KC4[ICD/<BH1LL/^ _A X2!"QK
MP)RN_OTY??N_US1FY=]_L#]8U?<?G:JOO/2_EUN:K,O_+RXVT7#T*[Q7_[S!
M/:M@%?JQJZ:&)N7QU)=<M/\D[-]^$2U^_JGRL:F>PDR0.MUE&?,9YZMH\P\:
M9><EL*-BV/<ZL?J7R,6L,*?S;@<_A74Y$J5*B_H.J6X1=H^<LWJ[O.L7HMI.
M3*$/'/C\9L+P6;K:;=L65)LC7I37ANL_M'+USU+(6<%8Z]\.QRKS<B#+M1;-
MK0;*U4W"[_I%LKXG4_!#ASY#+V!FX:2'\DA*".2.%"*,1[XQ0=PU#H7P7F<$
M8,[%P<%WW'L2\,JZ62,[,W!OFX/:!&6$4F8 VH$,"F2%?G$ .S2MAVM?8P_6
MFF;#J!G4/38"JJICE9(S@_2A-"O!9O?6 )+5+10D=KW@ +"VJ,<=%]S#C?TS
M#(SUGOP(6H)^$0G,!*1JO\G3TFT6;2Z3-?W^7_1]T.-*F?HG2&2L,*;T:P<V
MF6DYZL0:BWJ;T_HZX3=(><<O$M4]EH(>,.1YS0M2/@/(W^'J#K>#*_3AJU3
MP#*@12C 5OO1HEREWD*^FI"M]X<+[:0[ P0,PP&.&KC:O(%2363<T=<T8U/K
M]T54C$9>$-%^<$A$,<)"V0J4@)!YT(:"6+$-@GJ2K+U/*H$@P*_NVR'L(4B
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M.5VO<:A1GDT6.VN?9:DJQ'=F<B&^?'U(RH$,'H'W#<4?Q",^6:S;.G05_S+
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MX=75T<4QA/=Z^C83!6Z,9J)H)GK> =AD(G*'U0<SEDQ/J1N@N$*>#L5?:,B
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MQ[J]VT2;CBWYYJ_]8\O>)+SQ(X+%YJ&9NC<&N>V!RUMV,R)'IV5V[8422&7
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M*NP&UI8M+\AG#P7/G#!E,\M)2DMF5$-(8H2!0JLI!Q0A9^K[NL*N5)U/,1@
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M./:&EBL2.N$ZBW]GMX2B*$'>7<+.#&>(;EV\U.)$S^A[^J=]B*@/9 1XA!!
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MA#O& %./I3MT[VOV>?P.C)V75^?'5\>7U^>7EZ=G1\>03'C5@6-Y8YC:(RD
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MK2R0C^-I9V&/!B9E6%TLK[H33"UK"R,*O##&<=(#,;HA?@SH1AD]\>N1%=K
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M;)#/],R<8:NNO+O"8": 2@P(I!56&(,R@Y_F@((Z#;D+3>AO$D.' QA]SYI
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MB[N6^&B;L=67F?5"_:L'$K(_MI]6E_L84'5H%9[MY-;5,=4R_W?,-H6A$<I
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M &-*.\9=2WRT,3U4A8OW?R8X7C\&=!%+4IFF=\#>/IQ@$TK8A;E;?#]1:1)
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MU1<FK+J&"-'!-6/@IJGT$)-%Q5*P^[L Q+J>=G6=I*\6,+6CFK.'!K>.(,N
M^\WY@9?)LA(#A3: 45 O52)#E&5;Q&\XJ$="OLU@D%!+E&4VP;CB9A5[JB$4
MF:K90@AO.Y0L&=PM:O_%S6!9OJYQUQ(?+3O]5^9B5K)C(^QHDL0?)&0Q<-VH
MYWT'J!*T"DH=Z)?BIVV>ARI3T_]C>8@X6&2'0)6O7&KZQ*@"[;+2LAW8U[E2
M-3_?]_EY_V.%P[1Q?5D3'>./N&^1C\8D<.DN-;)A4?IL)LH8-)FS8[X=UUCJ
MJ%(J<[-/6@KWWEAKS Y NP8$0>+X7P\L[;N(DX@RTF7<6-!=7NZ9HZRA7M5H
M-I=19X#P7%&9%*[8@O"AML><%6=Q^29C!%&((\U3BGJ$0F5V2M6Q.!0XB(JG
M1*(59!D36N"MLBP1X3%@YA!_(D8P;7/&3P*I:@];[O5")*HT0@"!!096*$E!
M:<<W9A3G!^T=6'JXTFJNL.:%'7JN\(GYR<)]9XF-R<(M6(IZ>2L$W*U+%@;V
M<"0LB/60."S/)<N@9FAN%1A(MTJ>5&Z5!OS"7=''W*I^<0<KM\KH _5VR_6
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M'*,W6I](%!5F5W6UK;PQ3#U0$F)>+22(;>Y30)#\S?K9B3=^W/;7ZXJ57'P
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M+3(P,38P,3 T+GAM;%!+ 0(4 Q0    ( !4V)$BHL_$9/A<  '8F 0 1
M          "  7ZI 0!C;VQL+3(P,38P,3 T+GAS9%!+ 0(4 Q0    ( !4V
M)$AA$5;S_@\  #W[   5              "  >O  0!C;VQL+3(P,38P,3 T
M7V-A;"YX;6Q02P$"% ,4    "  5-B1(_YZ5>/14  ";N 8 %0
M    @ $<T0$ 8V]L;"TR,#$V,#$P-%]D968N>&UL4$L! A0#%     @ %38D
M2"$W/_JKYP  2MD. !4              ( !0R8" &-O;&PM,C Q-C Q,#1?
M;&%B+GAM;%!+ 0(4 Q0    ( !4V)$BU8TDRD'T  *XH"P 5
M  "  2$. P!C;VQL+3(P,38P,3 T7W!R92YX;6Q02P4&      8 !@"* 0
&Y(L#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
